<SEC-DOCUMENT>0001388658-22-000020.txt : 20220228
<SEC-HEADER>0001388658-22-000020.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228080324
ACCESSION NUMBER:		0001388658-22-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iRhythm Technologies, Inc.
		CENTRAL INDEX KEY:			0001388658
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				208149544
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37918
		FILM NUMBER:		22683977

	BUSINESS ADDRESS:	
		STREET 1:		699 8TH STREET
		STREET 2:		SUITE 600
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		415-632-5700

	MAIL ADDRESS:	
		STREET 1:		699 8TH STREET
		STREET 2:		SUITE 600
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies, Inc.
		DATE OF NAME CHANGE:	20110429

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies Inc
		DATE OF NAME CHANGE:	20070201
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>irtc-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f,d:4a303ab734354a4f8fadd28a70ce663e--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:irtc="http://www.irhythmtech.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>irtc-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml8zLTEtMS0xLTI0NTQz_42cbe345-c3b6-49f3-8691-90ed5782ea4b">false</ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml81LTEtMS0xLTI0NTQz_d6163968-dd2c-42a1-99d3-b6b65d468fb6">2021</ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml82LTEtMS0xLTI0NTQz_2f2fdf87-1417-4610-8831-8e8f26ac26a9">FY</ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml85LTEtMS0xLTI0NTQz_d0822755-bf0f-4783-bb7a-eb545405023d">0001388658</ix:nonNumeric><ix:nonNumeric contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMC0xLTEtMjU3Njc_6a589db0-786c-44fa-92b8-d954be45f1b9">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="irtc-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d690f4bdf3453780103c6489d41661_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic3c55699c69d45888a86b4cc7ec1c790_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0124649f48144c50ba45fea5ba1d4440_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632162ae05734a44b80f1fdf5560120e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3f70e09ee54d849d92393b3efb75fc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifacca0dbed9549a594071a1cd185cd79_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia05eac998f1044e4967c9890b0d2a65e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40721ab01cb74086a6725dda65e33834_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i432949efa6c64c78b50dceeab40e000b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b02c96d685b4c76b557a50fb39ac9f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i704ac771209d404fabd6c01f42ca5256_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd0dc96bbc744424acc7449cb5f9e134_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe09ccc9143a4642b389d469b06bd919_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2201df0cbe746b8a0639b3748578218_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia897aa3797f647999451688e21df6eeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib239f55d6fa744e4b1ae93b2be580360_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a97f947148a4da3ae69e61dd1e1f636_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1767edc2ad274e82aaee985c123834f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0664e61690104fa2bf238691cd944c77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide789f0109144f18a87971e164951119_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd2b799a58640109328cde5026037c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d9a9c176034c01bafbe635f0ba6f6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad3589afc968435cb10d5cb10bf4738a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fea2d8c84be4bf68ebf457a8a6c2b3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie425bc192eea43c4998ce9d1e84e53a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa6df92e00f41ecb73a3d3d2c300e65_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b094e744ff4732b19b6fd8fa91c517_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a474771fc24576ab925990fae0b21d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c8908741ec4840961679280bd8d5d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie322229942454b178e796984276627cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-10</xbrli:startDate><xbrli:endDate>2019-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1486d77445c34613a8e3383fbbdb5025_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-21</xbrli:startDate><xbrli:endDate>2020-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e80ace037a44aa1bc75148d38174bb5_I20200821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b979f3794644df876abe57a7d76980_I20220110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:ProductAndServicesZioXTServiceCode93243Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3706f468116148dbabf8b4fb4c6f96e7_I20220110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:ProductAndServicesZioXTServiceCode93247Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ed4074ebd54c72b7c475f8882ba2ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3ebc6891a9455e9c6fb6ea48899e99_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61d7a2d6f1774f9cb8ba5206eeae226e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb7f500e8934bd2b96bfe5eda7af356_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9db8564ddc2f47cfb7aaa008517d05ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0624798b12fa464ca5bea6b9c12f361b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50fcb4b97216498585c183117c671309_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c78456bd4045eab249ad061311ce9e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00144f28bbd4b3b8d6872c91909a2d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325e1cd03bd94e598819e2c8159b85ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60332e77ea34183a58d2508319463aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id814a6da95c1480a914c87a5028a3a5b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0e1acdecce4bc3890820a3d9e96ee2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af04eb3c79a43ebbb272cec9b11188a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6ac2500f824b45a5cffbbccaa42236_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50f5215d1174ad28382c2494c5399c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a7ea2b4b2b4143afc1c82e0fa1f8dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a1fb6ef69b842c6bc4f8e224841fd0e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id16459be997449c3b7b484cc95d1339e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie651d17a114348fdb3edf9a8b0b5827c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f360678d4246b89d728c59cd20976d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a7c57c18f549c5852ef8cd95cdc265_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifddd05d06ccf4b7d89a49501aaf7f236_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id929e42695a1425db8d875f569956607_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7fcae5bab84669835f080a9618b3be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efc11c28170439fb0e0ade90d22cd61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3848c1d4a184a1eb78ecfae9590242e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d649d197bda45e596f9af06665706a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad8d5012263e4befa279cf0bd28d07fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment_security"><xbrli:measure>irtc:investment_security</xbrli:measure></xbrli:unit><xbrli:context id="i544774a11590471697b6d8b7df26516c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3915c703cd486c8d2ddb5c86644b14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1386205dcb64400c8549d89adf0e66c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad512d72fba24e88bc963667bb17d917_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc05c01347a43d4839f5af04b73fb66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90655704d594a51bf0f84615c1aac60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3286b0953db143438a81b1243412ad19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661ccccd2342454cadb45ffd6ac1cdf8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8141234416514b26856b026454673afd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b9d94fd49d43a1a73305efd5b103fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e6fab54d734357843ce9f2f235a342_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d2ad0e7093a4f1d983b41003553428a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7a85404cf446fba9e007019f906e7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2cd6a7df09a4e08a91ace7c629e1a29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e65c8c9f154d91b116d7c006a7f126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia000fc56e55e41559e67dd102c2dbf14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i117f9b88ed88410697d8af034364839b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ead7a95130417d9939c1641c99b464_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf07b6a8c12148a5b3ef09aaeed1bb3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7ed4e30c8343c989fb2a52999238d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8bc8f58f314b7dbda7fa3d301c42fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da38639ddac4da59033ac85cd253110_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3ea2f79999340578304ad9bf5ee9000_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d61d9f2150452f8914338857d1ec28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5831875e85f74ca397d08ba1b12b77b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e1c45b9cf14077ba98cd181deae320_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8e3f6dd8127416aa1c4b2182d28bf1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id359b2cae0f94347aea71e824f7d93b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63032f4fbea4c8cb31c3a1f550699f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i105f7310b335489e8b39cfa28972fa27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i436d569dcf544ec4b7f8f38f9ca866f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f57aaa377ac4100b7afae26cd7bc6ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6218693389e54b8a90202c61bf65dc84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd2ccd64143145f6bc932f06c1f08a5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8350a688f64d4a83b788ae9b0d39c23b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d6cbcfa7d0c4b59951bd7970942f9cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c0eeaf2a7e4830a84e5a3e15aaccca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0754b2aa6645d49d7942e54354b1f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2335277db35e4da9bc6053ad827c6b6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabe8b8dfb0134468b31a854434788716_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b53675a3ce4bbf8c3f060474b55387_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60805415d1e4c0bb61070f850509317_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28ab4afd0d0c40b89860d2c5c5281a69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:RawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57913d02322c4309a6e6b2296ed4ae43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:RawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fdff6e9039430eba2e53b4f1ac3997_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i599e4ae97436440ebb5518c8ed6cd48a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:FinishedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1a81becd2e4d4d9eab5264496e678a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9b27deda984a24813a7638b456e4b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cdcfe3d98f64ac28d89432c71dc7330_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e29bf199ddb4f14a081a37d488b00d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d87a54ba7c9421f9e5c705844818d32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d4a41e7e284759a1cdb699a6d54241_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c8e622beead4bf5bdede9b59f014923_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9c5185f80148638094fa6bbf5f7ceb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8d067edb8c4d64bdd24a8de4d79690_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51fe3bdc1dc34b259a371515f18bdb86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0786295f5443bd811598620bb82a9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6c6807592d254ff88a10a57aea41b8c5_D20181004-20181004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-04</xbrli:startDate><xbrli:endDate>2018-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="optiontoextend"><xbrli:measure>irtc:optionToExtend</xbrli:measure></xbrli:unit><xbrli:context id="i295d5c0437d34174bf44c52749a0ac5a_I20091029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:LincolnshireLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fde8b0fa6ab4dfe86bf892cb5232e3d_I20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:CypressLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473a9e8ce4c04091aa983711246e3313_D20210318-20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i247ed5aae14d46398ee4c08aefa80fc9_I20210318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc473ee2e3f047b9becb2198e94c3342_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:DeerfieldLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8d51dc95ba423b813f74a49801e062_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i583c6b3e405b4a20a3da03740a2eb9f3_I20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3ae94beacb488f8fa3638f2d2170e4_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658ecfa8506846dc82b0e01ee90a18e1_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bd3de617d2f41cbbeb04e8d26d24912_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:PharmakonLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634d244c801140b8ab07eeabd8d14ef6_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e385fae9c694ac58ec7814ba00a5b71_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e808628b6a4613b5438a4e78004a62_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79eb7c2fe0da4198aa7a5eea32e35ebd_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a67f248e25942c7be0ace4b0a88b4e1_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id79b2be320cb4762a45bd10e6a3c51f4_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ec1526aa3b646a98a400738b384e12d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18aaaa80c4654a52a50440835da85723_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba739cc6baef49ae98b4d255720f346f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbbed17d9fc4fb0935e56255354c327_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83d09b0b4814982af13362f56c4531a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a2d071786e4b82beeb20f9e6115f40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86359793df1b40e2af06185a48d324e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9466bdc61cfa44fda7e517775eb15b05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae8319ea0074645a500405f0e3d6579_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:GrantUnderFutureStockPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6546f2892d4749599e08c50b5624c54d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:GrantUnderFutureStockPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i330f02be0068413f808f4f28a9e5df09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b76829668ea4e88ae1e21924f45a625_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d4bd0b270848488c2997023ea615dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id412c2fe707d4befae3144ed0cfbb2d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee82ee8a6ae43a08349bfe55fba2da0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i731d5a16540847ed99546bb8519fea22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:OtherStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25aed7f0402b404688f5892cc0328e06_I20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb6e1927b5a42bdb8c43f08b9014d6a_I20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b57f096a6b04e42bb623131e05c164d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8afaf349a043cc9d3265230b6be88c_I20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-30</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofpurchaseperiod"><xbrli:measure>irtc:numberOfPurchasePeriod</xbrli:measure></xbrli:unit><xbrli:context id="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedcc9216016246979e44e071acb39f72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65041d451358415cbfcfe6fed3a436d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6a3e4be968456eb56ea5292deeb1ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f36de2be3c245f5ae385981bc73b6e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95dab85175994185bd642051f38f6586_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759c278fc6f747e3ba280896f23d9bbc_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0400993af6a41d99753781144b0a14e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad41d5498b1410b8ada5b20ae638221_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a4c3b7811b486b8f1f6dab487979c1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8555106470244294838f2dcfdde58a82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc42661c3194491383dc17aab6af6e5c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:MarketConditionAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ec867e77104c7c880eca8b43778fb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3077a0d7299d4f5aabbf2184ffe9be97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibac55be5040a4d65a2fa2138c70bc7f7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51c63a57313342ee870d007775314912_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i036e8e19c0244562aa901632c01f81c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a9f2820af84e70bfdad6b84dbcdbbb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f92497acfec4d779bc015e79d7a07a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a2b1da44734fbd961217ea3df13e21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9032a6810bae4fa187e1e649dd2ad127_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65aa22d39afd4fdeb7a543c352ccd14b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad223dfee47d4235be238a5c63906545_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9db1a2a402414e83610b8705c23f4a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-19</xbrli:startDate><xbrli:endDate>2020-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>irtc:employee</xbrli:measure></xbrli:unit><xbrli:context id="ia53dfea28b67446ea357092412155f6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e8a36476e6e476ba97c7dbc8c1d08f6_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i285f97c5349f42d09fbf05bf4afa82fd_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d4090f1770461094499a8926219715_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf36d99211d4d7bb644f4a40a5aa345_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4171790573c447c9bd09afc513f59f75_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db5399825c5480b91e101758d1f1cbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fd28149e2f14307ab0e6573f2a75749_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd15311b9e074984b42d19b85d262583_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2ac6ed88094e85ad351dfffe1b0bcc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccce65a61f0b4298b073d981b57911fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:ConsultingAndProfessionalServicesAgreementCPSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f49daad3c3e4a63954ae45aeab81118_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:ConsultingAndProfessionalServicesAgreementCPSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef8252f0e0e4c2080743e4f89a810c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i869c663a60864d6dafba82faf152398d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9215b3bc96c4411aa73e32bdd167b66d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec01902a609c42cca84e32a7417ad2c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb08d6c4a54f49048409724c6ec35971_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab020b110c64525bd57c35617d3162e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001388658</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4a303ab734354a4f8fadd28a70ce663e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xODk_d3616d36-845c-4a0b-b062-7f6a63ad6f0a">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark&#160;One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6MjJkNDkwYmZlMjYxNGEzNmIyNDUzZWU3MWQ0NGRhM2UvdGFibGVyYW5nZToyMmQ0OTBiZmUyNjE0YTM2YjI0NTNlZTcxZDQ0ZGEzZV8wLTAtMS0xLTI0NTQz_d35c13d5-2dd7-4b20-bd81-041bb12fcbf1">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY_8efe950d-0060-4736-ac28-398d265b24d9"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY_60479ff1-4100-40a3-9c6f-490776331cc8">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6N2YyMGFlNTJhZmVmNDAyYjk2MTkwYzc0MGZiYTY4YWYvdGFibGVyYW5nZTo3ZjIwYWU1MmFmZWY0MDJiOTYxOTBjNzQwZmJhNjhhZl8wLTAtMS0xLTI0NTQz_b0e7fd8b-21b8-4c17-a047-bbafa42e2c08">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjg_7e5ce145-f31f-4f82-b3a7-96acf6c533f6">001-37918</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80NzY_c2d61352-0ea3-4eef-ae4c-3fe9f3743447">iRhythm Technologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8wLTAtMS0xLTI0NTQz_0fbf414d-5402-4887-9fc9-4ec189f17abe">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8wLTEtMS0xLTI0NTQz_bad507a5-6ad4-42d9-bfc1-3f37a41e6075">20-8149544</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfNQ_b9486175-0a65-476f-915f-54cda4698b88">699 8th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfOQ_b01bd4cb-d5c6-4d99-ae84-5e0e26733c82">Suite 600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfMTI_d13f9bde-d088-4867-9c4e-96211482fee2">San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfMTY_9f012bd6-d968-43ff-8cba-752608c7b339">California</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTEtMS0xLTI0NTQzL3RleHRyZWdpb246OGMwOGYxMTkyNmIwNGUzOTkyMGM1ZDQyMDhmZmJmZWFfNQ_327d1cf9-f131-459c-8f65-3a1dba291db8">94103</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV82OTQ_6a56015b-b6eb-4fb5-bcdb-d73d45bfca02">415</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV82OTg_51c0a41f-c0dc-4b59-8d53-f53725290b75">632-5700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: Common Stock, Par Value $.001 Per Share, Common Stock traded on the NASDAQ Stock Market</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xMTM5_3303e0ff-9949-4c8d-b5ba-e18376b2add8">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;Yes&#160;&#9744;&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xMjcy_3facbd44-22e2-45ce-b4cd-bdb39f44fab9">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xNjIz_3036f4e7-c67e-44c3-9556-a229b0add894">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit and post such files).&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xOTUx_0fb71b2a-818c-49ca-8f7d-73580fcd740f">Yes</ix:nonNumeric>&#160;&#9746;&#160;No&#160;&#9744;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (&#167;229.405) is not contained herein, and will not be contained, to the best of Registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#9744;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.562%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8wLTAtMS0xLTI0NTQz_71da41fc-ed5a-4182-be08-5cbd5a3c0cd9">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Small&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8xLTMtMS0xLTI0NTQz_f3b03c91-aa30-4bf3-9063-f7e900848ecc">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8yLTEtMS0xLTI0NTQz_a12a8c91-8433-42ac-994d-17f5d86b10d1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8yNzQ4Nzc5MDczNDkz_c2240c73-2fcf-45b7-a679-04a461d7adf0">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;<ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY5_d0f783ce-8c1b-41f3-bef3-700bfe793cd0">&#9744;</ix:nonNumeric>&#160;No&#160;&#9746;</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="i93d690f4bdf3453780103c6489d41661_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjA5_9b0e647e-4ca6-4e3a-9ae3-c5292dee7c7b">1.9</ix:nonFraction>&#160;billion.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s Common Stock outstanding as of February&#160;18, 2022 was <ix:nonFraction unitRef="shares" contextRef="ic3c55699c69d45888a86b4cc7ec1c790_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjg4_e6d8eddf-2944-40d6-a0f7-49d9e92de658">29,513,264</ix:nonFraction>.</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDEw_923b27f0-f68b-4748-b3d9-89cc06755952" escape="true">Portions of the information called for by Part III of this Form 10-K is hereby incorporated by reference from the definitive Proxy Statements for our annual meeting of stockholders, which will be filed with the Securities and Exchange Commission not later than 120 days after <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDA1_8efe950d-0060-4736-ac28-398d265b24d9"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDA1_60479ff1-4100-40a3-9c6f-490776331cc8">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric>.</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTAtMS0xLTI0NTQz_037d4a6b-0838-496c-83a0-9ae6f1febd11">Common Stock, Par Value $.001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTEtMS0xLTI0NTQz_d9f731c6-f534-45d0-b896-180ee98a00e5">IRTC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTItMS0xLTI0NTQz_4f1cbde7-a2d9-4aed-abbb-02cd3f48971a">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_19">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_22">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_25">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_28">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_31">64</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_34">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_37">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_40">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_43">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_58">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_58">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_58">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_61">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_61">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_61">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_130">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_130">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_130">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_133">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_133">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_133">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_136">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_136">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_136">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_1583">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_1583">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_136">115</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_139">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_142">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_142">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_142">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_145">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_145">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_145">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_148">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_148">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_148">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_151">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_151">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_151">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_154">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_154">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_154">116</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_157">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_160">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_160">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_160">117</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">the impact of the COVID-19 pandemic on our operations and financial results;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">plans to conduct further clinical studies; </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to modify our current products, or develop new products, to address additional indications;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the expected growth of our business and our organization;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding government and third-party payor coverage and reimbursement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts in international geographies;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding revenue, cost of revenue, cost of service per device, operating expenses, including research and development expense, sales and marketing expense and general and administrative expenses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">worsening economic conditions, including inflation, in the United States or internationally;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain and maintain intellectual property protection for our products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to identify and develop new and planned products and acquire new products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our financial performance; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors or our industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report on Form 10-K may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the SEC as exhibits to the Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. Our goal is to be the leading provider of ambulatory electrocardiogram (&#8220;ECG&#8221;) monitoring for patients at risk for arrhythmias. We have created a full portfolio of ambulatory cardiac monitoring services on a unique platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. We believe that the Zio service allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies and avoid multiple indeterminate tests. Early detection of heart rhythm disorders, such as atrial fibrillation (&#8220;AF&#8221;) and other clinically relevant arrhythmias, allows for appropriate medical intervention and helps avoid more serious downstream medical events, including stroke. Since receiving clearance from the Food and Drug Administration (&#8220;FDA&#8221;) in 2009, we have provided the Zio service to over four million patients and have collected over one billion hours of curated heartbeat data, creating what we believe to be the world&#8217;s largest repository of ambulatory ECG patient data. This data provides us with a competitive advantage by informing our proprietary deep-learned algorithms, which may enable operating efficiencies, gross margin improvement and business scalability. We believe the Zio service is well aligned with the goals of the U.S. healthcare system: improving population health, enhancing the patient care experience, reducing per-capita cost, and improving the clinician experience.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the Centers for Disease Control and Prevention, approximately 11&#160;million patients in the United States have a heart rhythm disorder, or arrhythmia. The most common sustained type of arrhythmia is AF. The American Heart Association (&#8220;AHA&#8221;), estimates that as many as six million people in the United States have AF with at least one-third of these patients being asymptomatic at the time of their diagnosis. Individuals with AF are five times more likely to suffer a stroke; however, the National Stroke Association (&#8220;NSA&#8221;) estimates that up to 80% of strokes suffered by people with AF are preventable with early detection and proper treatment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ambulatory cardiac monitoring market is well-established with an estimated 5.6&#160;million diagnostic tests performed annually in the United States, which we believe to be an existing $2.0 billion market opportunity for our Zio service. Traditional ambulatory cardiac monitoring tools used by physicians for diagnosing patients with suspected arrhythmias, such as Holter and cardiac event monitors, are constrained by one or more of the following: short prescribed monitoring times, non-continuous data collection and reporting, cumbersome equipment and low patient compliance. As an example of these traditional constraints, patients often remove these traditional monitors when sleeping, showering or exercising, leading to failure to capture critical data. These limitations contribute to incomplete diagnoses and repeat testing, which in turn result in suboptimal patient care and higher costs to the health system.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the Zio service provides a comprehensive solution that addresses all of these limitations and offers a clear value proposition to patients, providers, and payors by providing an easy-to-use, clinically proven, cost-effective platform solution. Our Zio service is prescribed by physicians for both identifying arrhythmias as well as for identifying risk factors which may be associated with a previously-identified arrhythmia. It improves physician management and diagnosis of arrhythmias by providing a patient-friendly wearable biosensor, curating and analyzing voluminous uninterrupted continuous ECG data, and ultimately creating a concise report that is used by the physician to make a diagnosis that can be integrated into a patient&#8217;s electronic health record. We believe our Zio service can continue taking significant market share from the existing ambulatory cardiac monitoring market and expanding the market for new clinical use cases and indications. We believe the Zio service has the potential to supplant traditional technology and become the primary monitoring option for patients who are candidates for ambulatory cardiac monitoring due to its ability to detect more arrhythmias with a high degree of clinical accuracy, which allows for earlier changes in clinical patient management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio service consists of:</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37pt">wearable patch-based biosensors, Zio XT and Zio AT monitors, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days. Zio AT offers the option of timely transmission of data during the prescribed wear period;</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37pt">cloud-based analysis of the recorded cardiac rhythms using our proprietary, deep-learned algorithms;</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37pt">a final quality assessment review of the data by our certified cardiographic technicians;</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37pt">a scalable digital platform that includes an easy-to-read Zio report, which is a curated summary of findings that includes high-quality and clinically-actionable information which is sent directly to a patient&#8217;s physician and can be integrated into a patient&#8217;s electronic health record; and</span></div><div style="margin-top:6pt;padding-left:76.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:37pt">a proprietary cloud-based digital information system, ZioSuite, that allows clinicians to connect via a web browser or mobile application for convenient online report interpretation and streamlined clinical workflows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to both the Zio AT monitor, and the Zio XT monitor herein as our Zio monitor(s), unless otherwise specified.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed a body of clinical evidence which we interpret to show, among other advantages, that the Zio service helps reduce healthcare costs and improves arrhythmia detection, characterization and diagnosis by prescribing physicians. These improvements have the potential to change clinical management of patients. Our clinical evidence is helping to drive physician adoption. We interpreted one study of the Zio service, published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The American Journal of Cardiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in August 2013, to show that among 16,142 consecutive Zio service patients in whom an arrhythmia was detected, over 50% of symptomatic arrhythmias detected by the Zio service occurred more than 48 hours into the wear period. Although this study did not directly compare the Zio service to Holter monitoring performance, it should be noted that 48 hours is outside of the typical wear period for Holter monitors. Furthermore, an internal analysis of 500,000 consecutive Zio records concluded that the first incidence of certain critical arrhythmias, specifically ventricular tachycardia, pause, AV block and atrial fibrillation, occurred beyond 7 days in 22%, 18%, 16%, and 13% of patients, respectively. Based upon our review of another prospective comparative study against Holter monitor, published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The American Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January 2014, we concluded that the Zio service detected 96 arrhythmia events compared to 61 arrhythmia events detected by the Holter monitor (P&#160;&lt; 0.001), providing a 57% improvement in diagnostic yield, which is the percentage of patients in whom an arrhythmia was detected during the monitoring period. In summary, we interpreted the clinical results to show that the Zio service is preferred by patients and allows for significantly longer continuous monitoring, improved clinical accuracy, increased detection of arrhythmias by physicians, and meaningful changes in clinical management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over four million patients have utilized the Zio service since its commercialization, we have achieved both policy coverage and, where applicable, contracts with the majority of payors in the United States, including the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) and other government agencies. Over 95% of patients in the U.S. are able to access reimbursed Zio services through our third-party payor contracts, our independent diagnostic testing facilities ("IDTF") participation status with CMS, and self-pay programs when excluding state Medicaid programs. We have designed a comprehensive strategy to allow us to compete favorably in the ambulatory cardiac monitoring market, which includes capturing market share from existing monitoring devices in the United States and international markets as well as expanding the market through new indications. We expect to drive sales and margin growth in our business by expanding our sales organization, securing additional contracts with commercial payors, maintaining technology leadership through research and development, and continuing to build clinical evidence supporting the benefits of the Zio service.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collected over one billion&#160;hours of curated heartbeat data, creating what we believe to be the world&#8217;s largest repository of annotated, continuous ambulatory ECG recordings with contextual patient information. This extensive database, along with our proprietary analytic platform, differentiates the Zio service and gives us a competitive advantage. We will continue to seek opportunities to capitalize on our product design, proprietary analytic capabilities and data repository to capture additional opportunities in the digital healthcare market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a vertically-integrated company headquartered in San Francisco, California, and we have additional commercial operations and facilities in Lincolnshire, Illinois, Houston, Texas, and the United Kingdom. We manufacture our devices in Cypress, California. Our revenue was $322.8 million and $265.2 million for the years ended December&#160;31, 2021 and 2020, respectively and we incurred a net loss of $101.4 million and $43.8 million for those same periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Opportunity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Every year, millions of patients experience symptoms potentially associated with cardiac arrhythmias, a condition in which the electrical impulses that coordinate heartbeats do not occur properly, causing the heart to beat too quickly, too slowly or irregularly. Examples of arrhythmias include supra ventricular arrhythmias, which are fast heart rates that originate from the upper chambers of the heart, atrial tachycardia, atrial flutter and AF. The symptoms of arrhythmias include palpitations or a skipped heartbeat, rapid heartbeat, shortness of breath, dizziness, light-headedness, fainting spells, vertigo, anxiety and fatigue or no symptoms at all. Early detection is essential in order to obtain early treatment and help avoid more serious medical conditions, such as stroke, and additional medical costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Atrial Fibrillation and Stroke</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In patients with AF, the upper chambers of the heart beat irregularly and blood does not flow properly to the lower chambers of the heart. The AHA estimates that AF affects as many as six million patients in the United States and 33.5&#160;million patients worldwide. The NSA estimates that one-third of AF patients are asymptomatic and still undiagnosed. More than 750,000 hospitalizations occur each year because of AF, and the condition contributes to an estimated 130,000 deaths each year. Since AF is more common among people over the age of 60, these numbers are expected to increase as the U.S. population ages.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, AF is the leading risk factor for stroke because AF can cause blood to collect in the heart and potentially form a clot, which can travel to the brain potentially resulting in an ischemic stroke. While individuals with AF are approximately five times more likely to suffer a stroke, the NSA estimates that up to 80% of strokes in people with AF can be prevented through early detection and proper treatment. According to the AHA, stroke costs the United States an estimated $34 billion each year in healthcare costs and lost productivity, and is a leading cause of serious long-term disability. The AHA estimates that ischemic strokes represent 87% of all strokes in the United States and that between 15% and 20% of the estimated 690,000 ischemic strokes are attributable to AF.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Zio service is prescribed by physicians primarily for symptomatic patients. However, we believe that high-risk asymptomatic patients represent an additional market opportunity for the Zio service. Monitoring high-risk asymptomatic patients may lead to increased diagnoses and earlier treatment and potentially avoid more severe downstream conditions, because, as the Framingham Study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stroke</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in September 1995 demonstrated, 18% of AF-related strokes present with asymptomatic AF that is only detected at the time of stroke.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early detection of AF is critical in optimizing patient care, delivering earlier treatment to help avoid further adverse clinical events, managing symptoms caused by AF, and reducing the total public health burden of treating stroke. The AHA and American Stroke Association (&#8220;ASA&#8221;) have published treatment guidelines for patients diagnosed with AF to manage heart rhythm and rate and prevent stroke. These early treatments include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">medications such as oral anticoagulants</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">treatment with anti-arrhythmic drugs</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">interventions such as cardiac ablation therapy to help control heart rhythm and rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Atrial fibrillation burden, the amount of time a patient spends in AF during a monitoring period, has been identified in the clinical community as an important measure for determining appropriate and effective therapeutic interventions to manage patients with AF and assessing stroke risk. The calculated AF burden is only as good as the data available for analysis during the monitoring period. Since the most common type of AF occurs intermittently, long-term continuous patch-based monitoring, such as the Zio service, more accurately measures AF burden because every heartbeat is recorded without interruption during the entire monitoring period. A study to determine the correlation between AF burden, as measured by the Zio service, and the risk of stroke in patients was published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">JAMA Cardiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2018. Using this data in combination with electronic health record data from 1,965 patients at two large integrated health care delivery systems, the researchers concluded that an increase in the burden of AF is independently associated with a higher risk of ischemic stroke and arterial thromboembolism (&#8220;TE&#8221;) in patients who are not taking anticoagulant medication. An AF burden of 11.4% or higher was associated with more than three-fold increased risk for stroke or TE event after adjusting for either CHA2DS2-VASc or ATRIA scores, two tools physicians use to assess stroke risk.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Heart Block post Transcatheter Aortic Valve Replacement ("TAVR")</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TAVR is now the preferred strategy for aortic valve replacement in most patients with severe symptomatic aortic stenosis. Due to the less invasive strategy, TAVR provides treatment for patients who would have been declined surgical replacement. According to the American College of Cardiology ("ACC"), it is estimated 100,000 patients undergo TAVR procedure annually in the United States, and expected to increase with over 250,000 procedures conducted worldwide by 2025. One out of ten patients experiences injury to the conduction system during TAVR resulting in high-degree atrioventricular block (&#8220;HAVB&#8221;) necessitating permanent pacemaker implantation. While most HAVB occurs within 48 hours of TAVR, there is a growing number of patients developing HAVB after initial TAVR hospitalization due to the trend for early discharge post-TAVR.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Well-established risk factors can be used to identify and advise high-risk patients and guide management. As the population of patients at increased risk for late presentation of HAVB grows, development of algorithms for mobile outpatient cardiac telemetry monitoring post-TAVR, particularly in the first 2 weeks after discharge, may be needed to reduce the risk of adverse events.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ambulatory Cardiac Monitoring Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrhythmia symptoms are generally monitored either in a physician&#8217;s office or healthcare facility or remotely with the use of ambulatory cardiac monitoring devices. Typically, physicians will administer a resting ECG in their offices to record and analyze the electrical impulses of patients&#8217; hearts. If physicians determine that patients require monitoring for a longer period of time to generate a diagnosis, they have historically prescribed an ambulatory cardiac monitoring device such as a Holter monitor. If the diagnosis is not definitive following the first monitoring period, physicians may prescribe a repeat Holter monitoring period, or alternatively, prescribe event monitors, mobile cardiac telemetry or implantable loop recorders. Physicians use frequency and acuity of symptoms to determine which monitoring device to prescribe. Some physicians own their own ambulatory cardiac monitoring devices and provide ambulatory monitoring services directly to their patients, while others outsource these services to third-party providers.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holter Monitors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holter monitors are non-invasive, ambulatory, battery-operated monitoring products that continuously record the ECG data of a patient, during a typical prescribed wear period of 24 to 48 hours. A Holter monitor consists of a recorder, electrodes that are attached to the patient&#8217;s chest and wires, or electrode leads, connecting the electrodes to the recorder. After the prescribed wear period, the data recorded by the device is delivered by hand, mail or internet for processing and analysis by the physician&#8217;s office or a third-party provider. Holter monitors are typically prescribed for patients who experience daily symptoms. For patients with suspected arrhythmias, Holter monitors have a relatively low diagnostic yield of approximately 24% due to a limited prescribed wear period of typically no more than 48 hours and low patient compliance, likely resulting from bulky equipment and cumbersome electrode leads. The low diagnostic yield is also attributable to missing data, because patients typically remove the electrodes and disconnect their Holter monitors in order to shower, sleep and exercise.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cardiac Event Monitors and Mobile Cardiac Telemetry</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac event monitoring is another type of non-invasive, ambulatory monitoring. Event monitoring differs from Holter monitoring in that the monitor is prescribed and worn for a longer period of time, up to 30 days, and the data recorded during the wear period are symptom driven. Event monitors generally record several minutes of activity at a time and then start over, a process referred to as memory loop recording. There are many types of event recorders available with a range of features including patient-triggered or auto-detected symptom recording, and manual data transmission or auto-send. Typically, physicians prescribe event monitors for patients with lower acuity symptoms. Mobile cardiac telemetry ("MCT"), is another form of event monitor that usually uses wireless technology, such as a cell phone network, to transmit event data during the wear period for both patient-triggered and auto-detected events to a monitoring facility where the ECG data is analyzed and the facility determines if physicians should be notified of significant events. Typically, physicians prescribe MCT for patients with higher acuity symptoms such as syncope, or fainting, that require more timely notification and actions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Event and mobile cardiac monitors have several limitations, including limited data storage, the lack of trend data, and poor patient compliance due to electrode replacement, bulky equipment and the fact the patient must both activate and transmit events in some cases. Additionally, MCT technology has unique limitations including the need for patients to keep the transmitter close at all times and frequently change the battery or recharge the device to ensure timely transmissions as well as notifications sent to physicians of non-actionable events. These limitations can severely impact a physician&#8217;s ability to provide </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a timely diagnosis and result in a lower diagnostic yield. More recently, there have been new MCT products introduced to the market that include patch-based or combined recorder-transmitter features to try and address some of these limitations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Implantable Loop Recorders</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A separate segment of ambulatory cardiac monitoring consists of implantable diagnostic products such as implantable loop recorders, also known as insertable cardiac monitors. Implantable loop recorders are implanted underneath a patient&#8217;s skin during a hospital-based, minimally-invasive procedure. These devices remain implanted in a patient for up to three years, capturing data in a looping manner for patient-triggered or automatically-detected events. Limitations of this monitoring option include the semi-permanent nature of the implant, infection risks during insertion and removal, non-continuous data collection, under- or over-sensing which may exhaust the memory of the loop recorder, risk of missing events due to the looping nature of the recording, and the high cost of the device.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Traditional Ambulatory Cardiac Monitors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Limitations of the various types of traditional ambulatory cardiac monitors can include the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">short prescribed monitoring periods leading to low diagnostic yield;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">non-continuous and interrupted data collection, resulting in an incomplete picture of a patient&#8217;s arrhythmia experience;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">bulky monitoring equipment with dangling electrode leads causing discomfort and low patient compliance;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the need to use multiple, often times costly, diagnostic options that would not be necessary if initial tests had produced a higher diagnostic yield;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the generation of excessive and uncurated data for the physician to analyze; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">over notification of non-actionable events.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a significant opportunity for a disruptive arrhythmia monitoring solution that offers a portfolio of ambulatory cardiac monitoring services on a single platform that is cost effective and provides certainty in a single test obtained through uninterrupted continuous monitoring, combined with patient-friendly design, to enhance compliance and simplify the monitoring experience while maximizing diagnostic yield.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Solution</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an uninterrupted, long-term continuous ambulatory cardiac monitoring platform known as the Zio service that provides continuous ambulatory cardiac monitoring through both the Zio XT monitor and Zio AT monitor. The Zio service combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor with a proprietary cloud-based data analytic platform to help physicians monitor patients and diagnose arrhythmias with a high degree of accuracy and confidence. Since commercialization, over four million patients have utilized the Zio service, and we have collected over one billion hours of heartbeats, creating what we believe to be the world&#8217;s largest repository of curated ambulatory ECG patient data.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While wearing either the Zio XT or Zio AT monitor, patients have the ability to mark when symptoms occur by pressing a trigger button on the device, and separately recording contextual data like activities and circumstances in a written symptom diary or digitally via the myZio application. This allows physicians to match symptoms and activity with ECG data. Following the wear period, the monitor is returned and data are uploaded to our secure cloud and run through our proprietary, deep-learned algorithms. A concise report of preliminary findings is prepared by our certified cardiographic technicians and made available on our proprietary cloud-based portal, ZioSuite, that allows clinicians to connect via a web browser or mobile application. Zio AT offers the additional capability of actionable transmissions during the wear period to assist physicians in diagnosing and treating the small percentage of the population requiring more timely action. During the Zio AT wear period, physicians will receive notifications if there are significant events that meet pre-determined arrhythmia detection criteria.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="irtc-20211231_g1.jpg" alt="irtc-20211231_g1.jpg" style="height:461px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the Zio service is a disruptive option for ambulatory cardiac monitoring. The Zio service addresses patient compliance, continuously monitors patients without requiring patient maintenance for up to 14 consecutive days and produces easy-to-read, comprehensive digital reports that provide the information physicians need to make accurate and timely clinical decisions. Clinical studies have shown that our innovative digital healthcare solution improves physicians&#8217; abilities to detect arrhythmias by increasing diagnostic yield, and potentially allows them to change the course of treatment. Our proprietary deep-learned algorithms give us a competitive advantage due to the depth and breadth of ECG data available from the over one billion hours of curated and annotated ECG data collected to date. Additionally, we believe we have the first mover advantage in the long-term continuous market, particularly related to our efforts to secure both policy coverage and, where applicable, contracts with the majority of payors in the United States, including CMS and other government agencies. Over 95% of patients in the U.S. are able to access reimbursed Zio services through our third-party payor contracts, our IDTF participation status with CMS, and self-pay programs when excluding state Medicaid programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively working to make the Zio service the standard of care for patients who require ambulatory cardiac monitoring. Our solution helps reduce healthcare costs and improves arrhythmia detection, characterization and diagnosis by providing simple, seamless integration of heart rhythm data from patient to cloud to physician. We believe we offer a high value, low cost, disruptive solution to a market ready for innovative technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value to Patients</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We designed the Zio monitor specifically to address patient compliance issues common to other ambulatory cardiac monitors. Our wire-free wearable biosensor is easy to apply, comfortable, lightweight and unobtrusive. The Zio monitor requires no patient management or manipulation during the wear period because no battery changes, patch changes, adhesive changes or lead wire / electrode management is required. Patients wear it discreetly during activities of daily life including exercising and showering for up to 14 consecutive days. For a small percentage of patients, an additional Zio AT monitor is provided for longer monitoring prescriptions. We interpreted a clinical study by Barrett et al published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The American Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in January 2014, or the Barrett Study, to confirm that the Zio service is a patient-friendly monitoring option, and the study noted that 94% of patients found the Zio monitor comfortable to wear. The Zio monitor allows patients to mark when a symptom occurs by pressing a button on the Zio monitor and logging the surrounding circumstances into a written or digital symptom diary, thus allowing physicians to link symptoms with the ECG data. Additionally, patients have access to our professional 24/7 customer service team and dedicated financial counselors to address any product, service, enrollment or billing questions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value to Providers</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Providers, such as physicians, receive high-quality, easy-to-read, actionable digital reports that help them diagnose patients and streamline clinical workflow. The Zio service has been shown in multiple peer-reviewed published clinical studies to detect more arrhythmias compared to Holter monitoring during their respective prescribed wear periods confirming the Zio service's added benefit of higher diagnostic yield beyond 48 hours of wear time. We analyze and generate patient reports at our CMS-certified IDTFs staffed with our certified cardiographic technicians who specialize in advanced arrhythmia interpretation to help ensure high accuracy and quality of reports before delivering them to the prescribing physician. Due to high patient compliance, the reports include up to 14 days of non-interrupted data correlated with patient-triggered and diary symptom events. Physicians can use this continuous correlated data to more conclusively diagnose arrhythmias.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accurate detection and higher diagnostic yield allow physicians to more quickly prescribe the appropriate treatment options for patients, while minimizing the need for repeat testing. From our review, we determined that in 28% of cases observed in a clinical study by Rosenberg et al published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pacing and Clinical Electrophysiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in March 2013, or the Rosenberg Study, the physician changed the patient&#8217;s clinical management after prescribing the Zio service as compared to a Holter monitor.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><img src="irtc-20211231_g2.jpg" alt="irtc-20211231_g2.jpg" style="height:227px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Zio service allows clinical staff to focus on more value-added activities by not requiring electrode changes or battery recharging during use, device cleaning and maintenance following use, and by reducing physician and hospital staff time needed to review and curate ECG data. Our 24/7 customer service team provides troubleshooting for patient-related issues, removing this burden from the physician practice.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value to Payors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><img src="irtc-20211231_g3.jpg" alt="irtc-20211231_g3.jpg" style="height:339px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph above compares the costs of monitoring to the diagnostic yield of various ambulatory cardiac monitors in the United States. The analysis, completed by Decision Drivers Analytics and commissioned by us, uses cost data from the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) published diagnostic yields, and our internal database, and demonstrates that the Zio service has a diagnostic yield on par with much more expensive devices but superior to less expensive options. This implies that it is the most cost-effective modality among its peer group, optimizing the cost, time, and reliability of reaching a timely diagnosis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who use traditional Holter monitors often do not receive a diagnosis after one monitoring period. A retrospective, longitudinal study conducted by Arnold et al published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Health Economics and Outcomes Research</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in February 2015, evaluated the clinical consequences and costs of CMS patients who had no previous evidence of a cardiac arrhythmia and were undergoing their first Holter monitoring test. Our review of data from this study indicates that there was no diagnosis reached for 70% of patients after an initial Holter test. The Zio service has been shown to have a low cost per diagnosis compared to existing monitoring modalities due to its high diagnostic yield.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the Zio service is the best test for most patients requiring ambulatory cardiac monitoring because it allows physicians to identify a timely course of treatment and avoids healthcare costs associated with additional monitoring. The Zio monitor is patient friendly and allows significantly longer and more continuous monitoring, resulting in improved clinical accuracy and a potentially meaningful change in clinical management. Better diagnostic yield results in decreased costs due to fewer additional tests. We believe that the Zio service could reduce the need for multiple consecutive tests because it offers certainty in a single test.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early detection of arrhythmias allows physicians to assess a patient&#8217;s risk factors and decide on the best treatment course for avoiding potentially more severe downstream conditions. Specifically, the early detection of AF allows physicians to consider strategies to mitigate the risk of stroke. According to multiple studies, preventative treatments, such as oral anticoagulants, have been shown to reduce stroke rates by 80%, thereby potentially avoiding the patient effects of stroke and the high costs associated with post-stroke management.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technology Platform</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Zio service is built on a proven technology platform that is designed to integrate seamlessly across the health system to provide long-term continuous ambulatory cardiac monitoring.  It consists of (1) a patient-friendly, patch-based biosensor that maximizes patient comfort and compliance, (2) a deep-learned neural network algorithm that provides accurate analytics and clinical results, (3) skilled clinical and operational staff who utilize proprietary software to ensure quality in clinical results and are available 24/7 to support physician and patient needs, and (4) a cloud-based portal, ZioSuite, through which physicians can access and interpret the Zio reports via a web browser or mobile application. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The platform typically collects approximately 1.5 million heartbeats of data for each patient during a single application of up to 14 consecutive days.  Our Zio service delivers a curated, concise, and clinically actionable report to the prescribing physician.  Through the Zio AT offering, physicians can access the additional capability of timely transmissions during the wear period.  During the wear period, physicians will receive notifications and reports if there are significant events that meet pre-determined arrhythmia detection criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Zio XT and AT monitors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio monitor is a single-use, wire-free, wearable patch-based biosensor that records a patient&#8217;s heartbeats and ECG data. The Zio monitor was specifically designed with the patient and physician in mind. The Zio monitor includes the following features:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">patented clear, flexible, lightweight, wire-free design;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unobtrusive and inconspicuous profile;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">proprietary adhesive backing designed to keep the Zio monitor securely in place for the duration of the prescribed wear period;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">water-resistant functionality, allowing patients to shower, sleep, and perform normal daily activities, including moderate exercise;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">hydrogel electrodes and a compliant mechanical design to deliver a clear ECG with minimal artifact from movement;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">large symptom button, or patient trigger, that is easy to find and press;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indicated single application wear period of up to 14 days (for longer monitoring prescriptions, additional Zio AT monitors will be provided); and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sufficient battery power for the entire wear period, without the need to recharge or replace batteries.</span></div><div style="margin-top:6pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><img src="irtc-20211231_g4.jpg" alt="irtc-20211231_g4.jpg" style="height:323px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symptoms can be logged through a paper symptom log or through the myZio App (iOS and Android).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio XT service monitors continuously for up to 14 days, delivering a comprehensive report after return and analysis. The Zio AT service delivers the same comprehensive final report, but also provides physicians with actionable notifications during the wear period. These timely alerts are provided via a Bluetooth capability in the Zio AT monitor that sends data to a wireless gateway. The wireless gateway, slightly larger than a smart phone, is provided to the patient at the time of monitor application and will collect and transmit data from the monitor to the cloud via a long term evolution ("LTE&#8221;) protocol.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment and Initiation of the Zio service</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a physician determines a patient is a candidate for the Zio service, the patient is enrolled through our online portal, ZioSuite. The wire-free Zio monitor is applied to the patient&#8217;s chest by the clinical staff, and monitoring is initiated. There is also an option for physicians to enroll patients remotely. With this option, the physician enrolls the patient and the patient receives the Zio monitor in the mail along with a detailed set of self-application instructions. Additionally, the Zio service can be ordered directly through the physicians&#8217; electronic health record system through the use of the Company's Electronic Health Record (&#8220;EHR&#8221;) integration service.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio monitor is worn continuously by the patient for up to 14 days without the need for patient maintenance. The Zio monitor can be worn in the shower, while sleeping, and during moderate exercise. During the wear period, the device continuously records and stores ECG data. The Zio monitor features a patient trigger button for marking any symptoms during the wear period; the patient is instructed to push the button when a symptom occurs and make a corresponding entry into the written or digital symptom diary. At the end of the prescribed wear period, the patient removes the device and places it and the written diary (if applicable) into a pre-paid postal box, which ships to one of our clinical centers.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Analysis and Assessment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At one of our clinical centers, the returned device is validated with patient identifiers that are compliant with the Health Insurance Portability and Accountability Act of 1996, (&#8220;HIPAA&#8221;), and up to 14 days of heartbeat data is uploaded to be processed through our cloud-based, FDA-cleared proprietary deep-learned algorithms for highly accurate ECG analysis. When complete, a preliminary curated report is created. Our process can take the equivalent of 30,000 pages of ECG strips and distill it into an actionable summary report of about 10 to 15 pages, summarizing the key findings and providing supporting details on clinically relevant events and metrics during the wear period. Our certified cardiographic technicians play a critical role in report curation by providing a quality review of the data before the final Zio report is electronically delivered to the patient&#8217;s physician for final interpretation and diagnosis.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final Zio Report and the ZioSuite Web Portal</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final Zio report, which is curated for both Zio XT and Zio AT patients, provides information in a concise format for review and interpretation by the patient&#8217;s physician. Data provided includes total analysis time, AF burden, AF duration, comprehensive symptom/rhythm correlation, detailed findings per day, and arrhythmia type. If pre-determined physician notification criteria for symptoms are met, the prescribing physician is notified by phone of the serious findings prior to the Zio report being made available electronically. The Zio report is delivered through our secure, HIPAA compliant web portal, ZioSuite. ZioSuite is an easy to use, intuitive, and comprehensive portal for clinicians that streamlines clinical workflows to enable cardiac care. By enabling streamlined workflows, ZioSuite reduces administrative burden and helps to create more time for patient management. Physicians can open the Zio report and add their interpretation into the report file. These reports can be uploaded into the patients&#8217; electronic medical record for storage and are available for use by the patient&#8217;s other physicians. Excerpts of these reports are included below to highlight the key features.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="irtc-20211231_g5.jpg" alt="irtc-20211231_g5.jpg" style="height:347px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZioSuite Web portal via desktop or mobile application</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:54.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Up to 14-days continuous recording and storage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="irtc-20211231_g6.jpg" alt="irtc-20211231_g6.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:377px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 20,000 minutes<br/>of continuous ECG<br/>data, equivalent to<br/>approximately 1.5<br/>million heartbeats.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Easy-to-read summary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="irtc-20211231_g7.jpg" alt="irtc-20211231_g7.jpg" style="height:182px;margin-bottom:5pt;vertical-align:text-bottom;width:362px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preliminary findings<br/>based on both the<br/>proprietary algorithms<br/>and certified cardiographic<br/>technicians.<br/>Final interpretation by<br/>a patient&#8217;s physician.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive symptom/rhythm correlation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:54.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="irtc-20211231_g8.jpg" alt="irtc-20211231_g8.jpg" style="height:164px;margin-bottom:5pt;vertical-align:text-bottom;width:374px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient-triggered and<br/>symptom logged events<br/>mapped to arrhythmia.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AF Burden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="irtc-20211231_g9.jpg" alt="irtc-20211231_g9.jpg" style="height:137px;margin-bottom:5pt;vertical-align:text-bottom;width:374px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total AF during<br/>wear period and<br/>daily AF burden.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AF Duration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><img src="irtc-20211231_g10.jpg" alt="irtc-20211231_g10.jpg" style="height:161px;margin-bottom:5pt;vertical-align:text-bottom;width:365px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of AF<br/>episodes categorized<br/>by duration.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reporting Events During the Wear Period with Zio AT</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio service with Zio AT includes a wireless gateway that provides connectivity between the Zio AT monitor and our monitoring center which enables symptomatic and asymptomatic data transmission during the prescribed wear period. The Zio AT monitor, in conjunction with the wireless gateway and the unique Zio arrhythmia detection algorithm, has arrhythmia auto-detection capabilities that produce actionable event data for physician review. The definition of an actionable arrhythmia event is customized by the physician to meet his or her needs, with the intent to reduce the number of over-notifications of data that do not require more timely medical action. Additionally, patients have the option of pressing a trigger button which marks the continuous record and initiates a wireless transfer of a 90-second ECG strip to our monitoring center. In addition to the final Zio report, physicians receive daily symptomatic and auto-detected arrhythmia event reports.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><img src="irtc-20211231_g11.jpg" alt="irtc-20211231_g11.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:444px"/></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ECG strip of auto-detected actionable arrhythmia event from Zio AT Transmission Report</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zio AT improves the speed and accuracy of diagnosis relative to traditional mobile cardiac telemetry (&#8220;MCT&#8221;) devices and services. The patient-friendly design of the Zio monitor enables 98% patient compliance over prescribed wear times. We believe a comparative review of published literature with our clinical data indicates that the Zio AT solution is able to detect critical arrhythmias up to five days sooner than the leading competitor. Further analysis indicates that Zio AT achieves a higher diagnostic yield in half the time of leading competitive MCT services (83% diagnostic yield in just 14 days vs. 61% of a competitive service over a 30 day prescription period.) To date, 99.6% of interpreting physicians have agreed with the findings of the final Zio AT  patient report, which we believe demonstrates efficiency and time-savings gains for interpreting physicians.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Collaboration with Verily</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 3, 2019, we entered into a Development Collaboration Agreement (the &#8220;Development Agreement&#8221;) with Verily Life Sciences LLC (an Alphabet Company and referred to as &#8220;Verily&#8221;). Pursuant to the terms of the Development Agreement, the parties will develop certain next-generation AF screening, detection, or monitoring products, which involve combining Verily and our technology platforms and capabilities. The solution combines a long-term, patient-compliant, non-invasive, low-cost Zio Watch with a diagnostic-grade, AI-based approach to AF detection and burden to address an unmet AF monitoring need by leveraging the Zio service infrastructure. Under the terms of the Development Agreement, we paid Verily an upfront fee of $5.0 million in cash. In addition, we agreed to pay Verily up to an aggregate of $12.75 million in additional milestone payments upon achievement of various development and regulatory milestones over the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Development Agreement, which payments will be made in cash directly to Verily. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2021, we have achieved milestones and related payment obligations totaling, $11.0 million, including a $3.0 million obligation incurred during our most recent quarter. We have agreed to make additional payments up to an aggregate of $1.75 million, subject to the achievement of certain development and regulatory milestones including provision of the Zio Watch and completion of market evaluation scheduled to begin between late 2022 and early 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Development Agreement provides each party with certain licenses to use certain intellectual property of the other party for development activities in the field of AF screening, detection, or monitoring. Ownership of developed intellectual property will be allocated to the parties depending on the subject matter of the underlying developed intellectual property, and, for certain subject matter, shall be jointly owned.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Agreement, the parties agreed not to collaborate with certain parties to develop or commercialize products on a disease management platform for certain AF patients, and the parties agreed to certain exclusivity provisions on development and commercialization of products for certain AF patients, subject to exceptions, including contractual rights and rights with respect to pre-existing product offerings.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to be the leading ambulatory cardiac monitoring option for patients at risk for arrhythmias. The key elements of our strategy include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Further penetrating the existing ambulatory cardiac monitoring market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to expand our market penetration by targeting the large existing ambulatory cardiac monitoring market in the United States and driving broader awareness of its advantages. We will leverage our platform of products, Zio XT and Zio AT, as a way of meeting the ambulatory cardiac monitoring needs of targeted large integrated delivery networks (&#8220;IDN&#8221;). We will continue to position the Zio service as providing certainty in a single test due to high patient compliance and superior quality of uninterrupted data.&#160;&#160;Zio XT will be positioned as the workhorse service while Zio AT is appropriate for the smaller percentage of the population that requires timely notification. Marketing and education throughout the medical community are key to bringing awareness and communicating the strong clinical evidence backing the Zio service. In addition, we expect to continue developing and publishing clinical evidence to demonstrate the advantages of the Zio service. Also, within existing accounts, we will continue to introduce our Zio service beyond cardiology and electrophysiology into other departments, including neurology, emergency rooms and primary care offices. To enable this broader adoption within a hospital system, we have successfully interfaced the Zio ordering and report posting processes into a number of large health systems&#8217; EHR systems. This seamless integration of Zio workflow processes into those already used within the IDN has proven to be a key factor in spurring growth within existing and new accounts and is an important part of our ongoing market penetration strategy.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Pursuing international expansion opportunities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our initial commercial focus is the U.S. market, we have initiated efforts that will allow for future expansion into international geographies. We have an initial presence in the United Kingdom with efforts underway to pursue national reimbursement. In September 2020, we were named a winner of the Artificial Intelligence in Health and Care Award run by the Accelerated Access Collaborate as part of the NHS AI Lab. This funding will bring the Zio service to selected NHS sites over a 3-year program measuring clinical, pathway and economic outcomes. We also received positive guidance from the National Institute for Health and Care Excellence ("NICE") in December 2020 for the adoption of the Zio XT service which may facilitate for future support of the Zio service through the MedTech Funding Mandate. We are also conducting diligence and prioritizing other geographies based on market size, regulatory pathway and reimbursement opportunity. We estimate the total addressable market in our initial selected countries of the U.K. and Japan, where we have started regulatory and reimbursement efforts is at least five million existing ambulatory monitoring tests annually. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Expanding indications and clinical use cases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to continue expanding indications and clinical use cases for the Zio service in untapped patient populations at risk for arrhythmias through our clinical and market development efforts. We believe these additional indications and clinical use cases represent a significant opportunity for us. This market development initiative includes expanding use for our Zio service into the following patient populations:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">patients at high risk for asymptomatic (silent) AF, estimated to be at least ten&#160;million patients at any given time;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">ongoing management of paroxysmal atrial fibrillation patients, estimated to be one million at any given time;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">post-ischemic stroke patients, with an annual incidence of 690,000 patients;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">post-cardiac catheter ablation patients, estimated to be 200,000 annual procedures; and</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">post-transcatheter aortic valve patients, estimated to be 100,000 annual procedures</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a significant near-term opportunity for us to expand the Zio service into adjacent markets such as silent AF. Initial efforts to proactively monitor this asymptomatic population with Zio XT, including end-to-end care pathway pilots, are planned in 2022. </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe there is potential to increase the core symptomatic total addressable market by moving further upstream in the care pathway to the primary care physician call point. We believe that nearly eight million patients with palpitations in the United States visit their primary care physicians annually and that we can educate these  primary care physicians on the benefits of the Zio service for this patient population.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Advancing our product portfolio and core technology offering.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to invest in building a unique, innovative product portfolio and digital platform that addresses unmet needs in the ambulatory cardiac monitoring market. We will continue to invest in research and development efforts to further differentiate our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biosensor, data analytics and reporting, information system and digital platform. In 2021, we received FDA clearance for our third-generation biosensor, the Zio Monitor and second-generation deep-learned ECG detection algorithm.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Expanding our footprint in digital healthcare.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe that we have collected the world&#8217;s largest repository of ECG data from ambulatory patients, and we will continue to look for ways to utilize our proprietary data to create value-driving opportunities in digital healthcare, such as expansion of indications for the Zio service, new clinical insights, new therapeutic discoveries, payor and provider decision support, as well as internal operating improvements, We will also pursue development of our analytical engine for ambulatory consumer and other medical data, including the curation of third-party biosensor data in existing and new indications.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement and Revenue from the Zio service</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive revenue for the Zio service primarily from third-party payors, which include commercial payors and government agencies, such as CMS and the military. In addition, a small percentage of institutions, which are typically hospitals or private physician practices, purchase the Zio service from us directly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors require us to identify the service for which we are seeking reimbursement by using a Current Procedural Terminology (&#8220;CPT&#8221;) code set maintained by the AMA. For the year ended December 31, 2021, we received 82% of our revenue through third-party payors. As we continue to contract with more commercial insurers and the patient population ages and becomes eligible for CMS programs, we believe more of our revenue will convert to third-party payor billing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical centers, where we conduct the analysis of ECG data captured by the Zio XT monitor and the Zio AT monitor, are CMS-certified IDTFs that qualify us as a provider and allow us to bill CMS directly for the Zio service. We meet CMS requirements, including having an independent medical director for oversight and certified cardiographic technicians for quality assurance of our Zio reports.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Results and Studies</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio service has been the subject of over 35 peer-reviewed publications on its effectiveness to date. This body of clinical evidence is driving clinical adoption and clinical use case expansion. The following sections summarize a few of the key clinical studies which have been driving adoption of the Zio service. In our discussion of the results of these publications, we have indicated changes in percentage terms, regardless of sample size, and the statistical significance is demonstrated by the relevant p-values, all of which are less than 0.05, which is the commonly accepted threshold for statistical significance. This follows the convention used by the authors of the study as well as standard clinical practice.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefit of 14-Day Continuous Monitoring</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A retrospective study by Turakhia et al, published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The American Journal of Cardiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in August 2013, analyzed data from 26,751 patients using the Zio service for the first time between January&#160;1, 2011 and December&#160;31, 2011. While there was not a direct comparison of the Zio service to Holter monitoring performance, we interpreted results from the study to show that among the 16,142 patients with detected, clinically relevant arrhythmias, over 50% of the first-diagnosed symptomatic arrhythmias occurred after 48 hours of monitoring, suggesting that these arrhythmias could have been missed by traditional Holter monitoring during the typical maximum prescribed monitoring time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diagnostic Yield and Monitoring Preference</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Barrett study, a prospective head-to-head study comparing the detection of arrhythmias between a 24-hour Holter monitor, which has a typical prescribed wear period of 24-48 hours, and the 14-day Zio service, a total of 146 patients referred for evaluation of cardiac arrhythmias between April 2012 and July 2012 underwent simultaneous ambulatory ECG recording with both devices. The purpose of the Barrett study was to determine the number of arrhythmia events and the percentage of patients in whom an arrhythmia was detected, known as &#8220;diagnostic yield,&#8221; during the comparative prescribed wear periods. Our interpretation of the results of the Barrett study are that over the total wear period of each device, the Zio service detected 96 arrhythmia events compared with 61 arrhythmia events by the Holter monitor (P &lt; 0.001) providing a 57% improvement in diagnostic yield. An increase in diagnostic yield provides increased data for the prescribing physician to use when making a diagnosis. In addition, we interpreted survey results to show that 94% of patients found the Zio XT monitor comfortable to wear, whereas only 52% patients found the Holter monitor comfortable to wear. Of the 102 physicians surveyed, from our review, we concluded that 90% thought a definitive diagnosis was achieved using data from the Zio service, as opposed to 64% using data from the 24-hour Holter monitor. This clinical trial, however, was a single center study with a relatively small sample size which did not compare the Zio service with any product except the Holter monitor.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A prospective, randomized study by Eysenck et al, published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Journal of Interventional Cardiac Electrophysiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in February 2019, compared the accuracy of AF burden detection across four different categories of external cardiac monitors (&#8220;ECMs&#8221;) to implanted pacemakers (&#8220;PPM&#8221;), the &#8216;gold standard&#8217; of rhythm monitoring. The study enrolled 21 patients previously implanted with a PPM, each acting as their own control subject, who wore every ECM, including Zio XT, for two weeks in randomized order. Zio XT had an R-squared assessment of fit value of 0.99 compared to the PPM. Zio XT was the only monitor to detect 100% of clinically relevant AF, outperforming the other ECM monitors in the study.</span></div><div style="text-align:center"><img src="irtc-20211231_g12.jpg" alt="irtc-20211231_g12.jpg" style="height:366px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changing Clinical Management for AF</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Rosenberg Study, a prospective single center study of 74 patients undergoing management of AF, patients received both the Zio XT monitor and a 24-hour Holter monitor simultaneously to determine the pattern of AF, to document a response to therapy and to potentially diagnose other arrhythmias. From our review, we concluded that the Zio service identified AF events in 24% more patients (18 patients)&#160;than Holter monitors (P &lt; 0.0001) and the diagnosed pattern of AF was changed in 28% of patients (21 patients)&#160;after Zio service monitoring.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our review of the study, we concluded that 28% of patients (21 patients)&#160;had a change in their clinical management. The most common changes included a change in antiarrhythmic medication, initiation or discontinuation of anticoagulation medication, recommendation of pacemaker placement, atrioventricular junction ablation, pulmonary vein isolation procedure and cardioversion. This clinical trial, however, was also a single center study with a relatively small sample size which did not compare the Zio service with any product except the Holter monitor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AF Burden as a Predictor of Stroke Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The KP-RHYTHM Study, a retrospective study of 1,965 Kaiser Permanente patients with paroxysmal AF who were monitored with the Zio service between October 2011 and October 2016, examined the independent association between AF burden, which is the amount of time that a patient spends in AF during the monitoring period as measured by the Zio service, and the risk of ischemic stroke. The findings were derived by linking detailed clinical outcome data from Kaiser Permanente&#8217;s electronic medical records with our database of analyzed ECG recordings. We interpreted the study results to show that an AF burden of more than 11% of the total time their heart rhythm was monitored was found to be associated with a three-fold increase in stroke risk, independent of other known risk factors in patients who were not taking medication to prevent blood clots. We concluded that these results suggest that information on AF burden, which is measured by the Zio service, may help patients and providers better evaluate treatment options for reducing risk of stroke. This clinical study was limited to Kaiser Permanente&#8217;s patients from the Northern and Southern California regions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring of Asymptomatic AF in High Risk Patients</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the Zio service is prescribed by physicians primarily for symptomatic patients. However, the NSA estimates that one-third of the AF population suffers from asymptomatic, or silent, AF. We see a future opportunity in proactively monitoring the approximately ten million patients who are at high risk of asymptomatic AF to identify those with the illness.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STUDY-AF was a single-center, single-arm prospective study by Turakhia et al published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Cardiology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2015 that enrolled 75 high-risk but previously undiagnosed AF patients from May 2012 to August 2013. Patients were 55 years of age or older and considered high risk with two or more of the following risk factors: coronary disease, heart failure, hypertension, diabetes or sleep apnea, but had no prior documented AF or history of blood clots causing blockage in blood vessels. We interpreted the results to show that long-term continuous monitoring with the Zio service identified 11% of patients with previously undiagnosed AF or atrial tachycardia, a rapid heartbeat where electrical signals initiate abnormally in the upper chamber of the heart. We concluded from our review that in patients with AF, 75% of patients experienced the longest AF episode after the first 48 hours of monitoring and there was also a high prevalence of asymptomatic atrial tachycardia and frequent supraventricular ectopic complexes identified, which may be relevant to development of AF or stroke. This clinical trial, however, was also a single center study with a relatively small sample size.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mHealth Screening to Prevent Strokes, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mSToPS study</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, led by researchers at the Scripps Research Translational Institute (&#8220;SRTI&#8221;) and in collaboration with Aetna Inc., Healthagen LLC, Janssen Research and Development, LLC and Johnson &amp; Johnson, utilized a web-based platform to remotely recruit from 5,214 eligible patients from the Aetna Commercial Fully Insured and Medicare Advantage programs. Women over the age of 65 and men over 55 with certain risk factors were selected to participate based on information derived from claims data that placed them at a potentially increased risk of undiagnosed asymptomatic AF. Three peer-reviewed articles were published on the mSToPS study between 2018 and 2021. The study design was published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Medical Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in July 2018. The one-year results were published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Heart Rhythm O2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December 2020. We interpreted the results to show that at one-year, AF was newly diagnosed in 6.6 percent of patients who were actively monitored by the Zio service versus 2.4 percent in the observational control group receiving routine care. In addition to this primary endpoint to evaluate the difference in new AF diagnoses, active monitoring in an asymptomatic, moderate-risk population with the Zio service was associated with an increase in cardiology outpatient visits but also significantly lower rates of emergency department visits and hospitalizations over the one year following monitoring. We concluded that these results suggest active monitoring with the Zio service can significantly reduce high-cost healthcare resource utilization and shift toward appropriate care settings at one year. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-year follow-up intended to assess whether screening asymptomatic individuals for AF and other arrhythmias with the Zio service can improve clinical outcomes. The three-year study results were published in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PLOS One</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in October 2021. Over the course of the study:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">AF was newly diagnosed in 11.4% of those actively monitored with the Zio service versus only 7.7% of the control group (a statistically significant 48% improvement).</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">Active monitoring with the Zio service led to a statistically significant reduction in the combined primary endpoint of cardiac event (death, stroke, systemic emboli or myocardial infarction) versus clinical care. The study found the incidence rate of a cardiac event was 3.6 per 100 person-years in people diagnosed with AF who underwent active monitoring, compared to the control group incidence rate of 4.5 per 100 person-years.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">Active monitoring with the Zio service also led to fewer hospitalizations for bleeding, the primary safety endpoint for the study (incidence rate of 0.32 per 100 person-years versus 0.71 per 100 person-years).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">An additional finding showed a clinical event was common in the four weeks surrounding a clinical diagnosis of AF not detected by screening. Cumulatively, 42.9% of participants in the control group were hospitalized in the four weeks surrounding the AF diagnosis; however, for those diagnosed utilizing data provided by the Zio service, only one person experienced a negative clinical outcome in the period surrounding his or her diagnosis.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="irtc-20211231_g13.jpg" alt="irtc-20211231_g13.jpg" style="height:257px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded the mSToPS study found that active screening for AF, as part of a prospective, pragmatic, direct-to-participant and nationwide study, was associated with a significant improvement in clinical outcomes and safety at three years relative to routine care.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An additional study examining early detection of AF using the Zio service in high risk patients is the Home-based Screening for Early Detection of AF, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCREEN-AF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Medical Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;JAMA&#8221;) in February 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This randomized control trial recruited 856 participants 75 years or older with hypertension and no known AF from 48 primary care clinics across Canada and Germany between 2015 and 2019. The intervention group included ambulatory screening for AF for two weeks with the Zio service utilized at baseline and again at three months, in addition to standard care for six months. We interpreted the results to show AF was newly diagnosed in the screening group in 5.3% of subjects at six months compared to 0.5% in the standard of care control group. A secondary outcome showed oral anticoagulation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OAC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) therapy was prescribed for 75% of participants who had screen-detected AF. We concluded that proactive screening and monitoring using the Zio service could increase AF detection by 10-fold over standard of care potentially prompting anticoagulation use.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we announced our participation in a randomized, controlled study, GUARD-AF (Reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals), sponsored by the Bristol-Myers Squibb-Pfizer Alliance. The study seeks to determine if earlier detection of AF through screening in previously undiagnosed men and women ultimately impacts the rate of stroke, compared to usual standard medical care. The screening arm will utilize the Zio XT service. The GUARD-AF study population (n=52,000) will include men and women at least 70 years of age visiting their primary care physician for usual follow-up care. The primary outcome measures will be stroke and bleeding events leading to hospitalization. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial will identify outcome events using insurance claims from a healthcare claims database which, although subject to certain limitations, is expected to provide evidence on health outcomes associated with AF detection intervention that may help inform future guidelines.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities are focused on:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Improvements and extensions to existing products and services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are continuously working to improve the Zio service to increase patient comfort, product quality, operational scalability and security.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Advancing our technology offering.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our product pipeline includes patch-based solutions that combine continuous monitoring for extended periods with accelerated notification of significant events through mobile transmission capabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Customer workflow optimization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have initiatives that aim to increase customer productivity by optimizing workflow through easier patient enrollment, report access and interpretation, and integration of Zio reports directly into electronic health records.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Data analytics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are focused on improving and enhancing our backend deep-learned analytic platform, building on our core competency in data analytics.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Developing clinical evidence.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are involved in clinical studies to further support the benefits of the Zio service and expand indications for use.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Continuing to solidify our footprint in digital healthcare.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Using our repository of ambulatory ECG patient data, we will continue to look for ways to create value-driving opportunities in digital healthcare, such as expansion of indications for the Zio service, new therapeutic discoveries, development of an analytical engine for ambulatory consumer and other medical data and payor and provider decision support.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities consist of software development, algorithm and product development, regulatory affairs, and clinical research. Our research and development expense was $38.7 million, $41.3 million and $37.3 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our ambulatory cardiac monitoring solution in the United States through a direct sales organization comprised of sales management, field billing specialists, quota-carrying sales representatives, and a customer experience team.  Our sales representatives focus on initial introduction into new accounts, penetration across a sales region, driving adoption within existing accounts and conveying our message of clinical and economic value to service line managers, hospital administrators, and other clinical departments. We continue to optimize the structure of our U.S. sales organization to expand the current customer account base and increase utilization of our Zio service. In addition, we will continue exploring sales and marketing expansion opportunities in international geographies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our Zio service to a variety of physician specialties including general cardiologists, electrophysiologists, neurologists, primary care physicians and other physician specialists who diagnose and manage care for patients with arrhythmias. We have found success focusing on IDNs, in which large networks of facilities and providers work together to offer a continuum of care to a specific geographic area or market. Focusing on sales to IDNs gives us the opportunity to conduct a holistic sale for health systems interested in making value-based purchasing decisions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive and fragmented industry, subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations and other factors. Large competitors in the ambulatory cardiac market include companies that sell standard Holter monitors including GE Healthcare, Philips Healthcare, Mortara Instrument, Inc., Spacelabs Healthcare Inc. and Welch Allyn Holdings, Inc. (acquired by Hill-Rom Holdings, Inc.). Additional competitors, such as BioTelemetry, Inc. (acquired by Royal Philips), Preventice Solutions, Inc. (acquired by Boston Scientific, Inc.) and Bardy Diagnostics, Inc. (acquired by Hill-Rom Holdings, Inc. which was recently acquired by Baxter International, Inc.) offer ambulatory cardiac monitoring services and also function as service providers. Recently, there has been increased acquisition activity and consolidation in our industry. Many of our competitors have substantially greater financial, manufacturing, marketing and technical resources than we do. Furthermore, many of our competitors have well-established brands, widespread distribution channels, broader product offerings and an established customer base.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These competitors have also developed patch-based cardiac monitors that have received FDA and foreign regulatory clearances. We are also aware of some small start-up companies entering the patch-based cardiac monitoring market. Large medical device companies may continue to acquire or form alliances with these smaller companies in order to diversify their product offering and participate in the digital health space.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future competition could come from manufacturers of wearable fitness products or large information technology companies focused on improving healthcare. For example, Apple Inc. has added capabilities on its watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic AF. These competitors and potential competitors may introduce new products and services that more directly compete with our Zio service.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the principal competitive factors in our market include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">ease of use, comfort and unobtrusiveness of the device for the patient;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">quality and clinical validation of the deep-learned algorithms used to detect arrhythmias;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">concise and comprehensive reports supporting efficient physician interpretation;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">ease of use of service workflow for physicians and supporting clinicians;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">digital tools for data management including mobile app, website tools and EHR integration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">contracted rates with third-party payors;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">government reimbursement rates associated with our products and services;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">quality of clinical data and publications in peer-reviewed journals;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">size, experience, knowledge and training of sales and marketing teams;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">availability and reliability of sales representatives and customer support services;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">workflow protocols for solution implementation in existing care pathways;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">reputation of existing device manufacturers and service providers; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">relationships with physicians, hospitals, administrators, and other third-party payors.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect our proprietary rights, we rely on a combination of trademark, copyright, patent, trade secret and other intellectual property laws, employment, confidentiality and invention assignment agreements and protective contractual provisions with our employees, contractors, consultants, suppliers, partners and other third parties. In addition, we have entered into exclusive and non-exclusive licenses in the ordinary course of business relating to a wide array of technologies or other intellectual property rights or assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent portfolio includes numerous issued and pending patent applications in the U.S. and other parts of the world, which in the aggregate, we believe to be of material importance in the operation of our business. U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest application was filed. In some cases, the patent term may be extended.  As of December 31, 2021 we owned, or retained an exclusive license to, twenty-three issued patents from the U.S. Patent Office, eight issued patents from the Japanese Patent Office, two issued patents from the Australian Patent Office, four issued patents from the Canadian Patent Office, five issued patents from the European Patent Offices, three issued patents from the Korean Patent Office, and one issued patent from the Chinese Patent Office. Our U.S. issued patents as of December 31, 2021 are set to expire over a range of years, from November 2028, with respect to some of our earlier patents, to February 2041, subject to any extensions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had twenty-six pending patent applications globally, including twelve in the United States, three in the European Patent Office, four in Japan, three Patent Cooperation Treaty (&#8220;PCT&#8221;) international applications, and one in each of Australia, Korea, China and India.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our trademark portfolio contained a U.S. trademark registration for the mark My ZIO, ZIO and a pending U.S. application for Zio AT.&#160;It also contained registered trademarks for the mark IRHYTHM in Australia and the European Union and pending applications for that mark in Australia, Austria, Canada, China, Denmark, Finland, France, Germany, Japan, Norway, Sweden, Switzerland, United Kingdom and United States.&#160;It further contained pending applications for the mark ZIO in Australia, Canada, China, Japan, Norway and Switzerland and a registered trademark for ZIO in the European Union.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and patent applications seek to protect aspects of our core technologies and our product concepts for continuous cardiac monitoring. We believe that our patent position provides us with sufficient rights to protect our current and proposed commercial products. However, our patent applications may not result in issued patents, and any patents that have been issued or might be issued may not protect our intellectual property rights. We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive position. We seek to protect our proprietary information and other intellectual property by generally requiring our employees, consultants, contractors, suppliers, outside scientific collaborators and other advisors to execute non-disclosure and assignment of invention agreements on commencement of their employment or engagement. Agreements with our employees also forbid them from bringing the proprietary rights of third parties to us. We also generally require confidentiality or material transfer agreements from third parties that receive our confidential data or materials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our ambulatory cardiac monitors, Zio XT and Zio AT, in our leased facilities in Cypress, California. This 17,558 square foot facility provides space for our assembly and production operations, including packaging, storage and shipping. We believe our manufacturing facilities will be sufficient to meet our manufacturing needs for at least the next year, but plan to move into a new, larger facility during 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing operations are subject to regulatory requirements of the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) for medical devices sold in the United States, set forth at 21 CFR part 820, the Medical Devices Directive 93/42/EEC (&#8220;MDD&#8221;) and the Medical Device Regulations 2017/745 of the European Parliament and of the Council (&#8220;MDR&#8221;), which is required for doing business in the European Union (&#8220;EU&#8221;), and the UK Medical Device Regulations 2002 (as amended) (&#8220;UK MDR&#8221;). We are also subject to applicable requirements relating to the environment, waste management and health and safety matters, including measures relating to the release, use, storage, treatment, transportation, discharge, disposal, sale, labeling, collection, recycling, treatment and remediation of hazardous substances. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure or the failure of our suppliers to maintain compliance with either the QSR, MDR, MDD, or UK MDR requirements could result in the shutdown of our manufacturing operations, recall of our products, and various enforcement actions such as warning letters or loss of clearance or certification, which would harm our business. In the event that one of our suppliers fails to maintain compliance with our or governmental quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality control management programs have earned us a number of quality-related designations. Our manufacturing facilities, have received EN ISO 13485:2016 certification. The NSAI most recently conducted an ISO 13485 surveillance audit in 2021 and a renewed ISO certification was received in August 2021. We have been an FDA-registered medical device manufacturer since 2008 and have been a California-licensed medical device manufacturer since 2009. The most recent FDA inspection of our manufacturing facility occurred in October 2021, and no FDA Form 483 observations resulted. The FDA also performed a Remote Regulatory Assessment (&#8220;RRA&#8221;) of our design facilities in San Francisco, California, which concluded in May 2021. Unlike on-site inspections, the FDA does not issue formal 483 observations at the conclusion of RRAs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Circuit board components of the Zio XT and Zio AT monitors are provided by contract electronic manufacturers, Cal-Comp USA, and Veris Manufacturing, Inc. We have manufacturing service agreements with both providers that allow either party to terminate the agreement with 90&#160;days prior written notice. There are a number of additional critical components and sub-assemblies sourced by other vendors. The vendors for these materials are qualified through stringent evaluation and testing of their performance. We implement a strict no-change policy with our contract manufacturers to ensure that no components are changed without our approval. Our production group in Cypress, California performs inspection, assembly, testing and product release.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Order quantities and lead times for components purchased from suppliers are based on our forecasts derived from historical demand and anticipated future demand. Lead times for components may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components and subassemblies. To date, we have not experienced unmanageable delays in obtaining any of our components or subassemblies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has significantly impacted the global economy and has contributed to cost increases, supply constraints and increasing inflationary pressures. We continuously monitor the effects of inflationary factors and supply chain constraints, such as increases in the cost of our components and increasing labor costs due to high wage inflation and challenging labor market conditions. Competitive and regulatory conditions may restrict our ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Food&#160;&amp; Drug Administration (FDA)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio XT and Zio AT monitors are considered medical devices subject to extensive and ongoing regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and its implementing regulations, as well as other federal and state regulatory bodies in the United States. The laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, packaging, labeling, storage, recordkeeping and reporting, clearance or approval, marketing, distribution, promotion, import and export, and post-marketing surveillance and associated regulatory reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the medical device market to ensure the safety and efficacy of these products. The FDA allows for two primary pathways for a medical device to gain approval for commercialization: a successful premarket approval (&#8220;PMA&#8221;), application or 510(k) clearance pursuant to Section&#160;510(k) of the FD&amp;C Act. A novel product must go through the more rigorous PMA process if it cannot receive authorization through a 510(k) clearance. FDA has established three different classes of medical devices that indicate the level of risk associated with using a device and the consequent degree of regulatory controls needed to govern its safety and efficacy. Most Class I devices are exempt from 510(k) requirements. Most Class II devices, including the Zio XT and Zio AT monitors, and the Zio ECG Utilization Service System (&#8220;ZEUS System&#8221;), require 510(k) clearance from the FDA in order to be marketed in the United States. A 510(k) submission must demonstrate that the device is substantially equivalent to a device legally in commercial distribution in the United States: (1)&#160;before May&#160;28, 1976; or (2)&#160;to another device that has been cleared through the 510(k) process and determined by FDA to be substantially equivalent. To be substantially equivalent, the proposed device must have the same intended use as the predicate device and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. In some instances, data from human clinical trials must also be submitted in support of a 510(k) submission. If so, this data must be collected in a manner that conforms with specific requirements in federal regulations. Most Class III devices are high-risk devices that pose a significant risk of illness or injury or devices found not to be substantially equivalent to Class I and II predicate devices through the 510(k) process and require PMA. The PMA process for Class III devices is more involved and includes the submission of clinical data to support claims made for the device.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio XT and Zio AT monitors maintain FDA 510(k) clearance as Class II devices, with the Zio monitor receiving a new 510(k) clearance in May 2021. In addition, the ZEUS System's most recent update received FDA 510(k) clearance in May 2021 as a Class II Software as a Medical Device. The ZEUS System is the combination of proprietary algorithms and software tools that our certified cardiac technicians utilize to curate the ECG data and create the Zio Report electronically. Significant modifications made to the ZEUS System since its original clearance have been regularly evaluated by the FDA.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pervasive and Continuing Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is placed on the market, numerous regulatory requirements continue to apply. These include:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the FDA&#8217;s QSR, which requires manufacturers, including their suppliers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the product lifecycle, including the manufacturing process;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">labeling regulations and FDA prohibitions against the promotion of products for un-cleared, unapproved or off-label uses;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">medical device reporting (&#8220;MDR&#8221;) regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">medical device recalls, which require that manufacturers report to the FDA any recall of a medical device, provided the recall was initiated to either reduce a risk to health posed by the device, or to remedy a violation of the FD&amp;C Act caused by the device that may present a risk to health; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device receives 510(k) clearance or PMA approval, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, performance or functionality may require a new clearance or approval. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with the determination not to seek a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new 510(k) clearance or PMA, the FDA may retroactively require a new 510(k) clearance or premarket approval. The FDA could also require a manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance or premarket approval is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines, penalties, and other enforcement actions, such as warning letters.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered our facilities with the FDA as a medical device manufacturer and have obtained a manufacturing license from the California Department of Public Health, or CDPH. The FDA and CDPH have broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA and the Food and Drug Branch of CDPH to determine our compliance with the QSR and other regulations, and these inspections may include the manufacturing facilities of our suppliers. Additionally, the EU Notified Body regularly inspects our manufacturing, design and operational facilities to ensure ongoing ISO 13485 compliance and periodically reviews technical design files in accordance with the Medical Device Regulations in order to maintain our CE mark or issue CE mark for new or updated devices.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">repair, replacement, refunds, recall or seizure of our products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">operating restrictions, partial suspension or total shutdown of production;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">refusing our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">withdrawing 510(k) clearance or premarket approvals that have already been granted; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">criminal prosecution</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">European Union and United Kingdom</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Zio XT monitor is currently regulated in the European Union as a medical device per the European Union Directive 93/42/EEC, also known as the Medical Device Directive (&#8220;MDD&#8221;). The MDD sets out the basic regulatory framework for medical devices in the European Union. In May 2021, the MDR, a more comprehensive regulatory framework, replaced the MDD.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The system of regulating medical devices operates by way of a certification for each medical device. Each certified device is marked with the CE mark which shows that the device has a certificate of conformance. There are national bodies known as Competent Authorities in each member state which oversee the implementation of the MDD and MDR within their jurisdiction. The means for achieving the requirements for the CE mark vary according to the nature of the device. Devices are classified in accordance with their perceived risks, similarly to the U.S. system. The class of a product determines the conformity assessment required before the CE mark can be placed on a product. Conformity assessments for our products are carried out as required. Each member state can appoint Notified Bodies within its jurisdiction. If a Notified Body of one member state has issued a CE mark, the device can be sold throughout the European Union without further conformance tests being required in other member states. The CE mark is contingent upon continued compliance with the applicable regulations and the quality system requirements of the ISO 13485 standard. Our current CE mark for Zio XT is issued by the National Standards Authority of Ireland, or NSAI under the MDD. We will need to pursue CE mark under the new MDR.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to United Kingdom&#8217;s departure from the European Union, the UK Medicines &amp; Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) has issued new requirements associated with the UK Conformity Assessed (&#8220;UKCA&#8221;) mark. The UKCA marking is a new UK product marking that is used for goods being placed on the market in Great Britain. It covers most goods which previously required the CE marking. The UKCA requirement became effective on January 1, 2021. However, to allow businesses time to adjust to the new requirements, we will still be able to use the CE marking until 2023.  Additionally, MHRA has indicated that additional new or modified regulations are planned in the future beyond those outlined in UK MDR 2002.  We will need to pursue UKCA marking under this new requirement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Insurance Portability and Accountability Act</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), established comprehensive federal protection for the privacy and security of health information. Under HIPAA, the Department of Health and Human Services (&#8220;HHS&#8221;), has issued regulations to protect the privacy and security of protected health information used or disclosed by Covered Entities, including healthcare providers, such as us. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. The privacy regulations protect medical records and other protected health information by limiting their use and release, giving patients the right to access their medical records and limiting most disclosures of health information to the minimum amount necessary to accomplish an intended purpose. The HIPAA security standards require the adoption of administrative, physical, and technical safeguards and the adoption of written security policies and procedures. HIPAA requires Covered Entities to execute Business Associate Agreements with individuals and organizations, or Business Associates, who provide services to Covered Entities and who need access to protected health information. We are a Covered Entity and a provider under HIPAA and subject to HIPAA regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, Congress enacted Subtitle D of the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). HITECH amends HIPAA and, among other things, creates new targets for enforcement, imposes new penalties for noncompliance and establishes new breach notification requirements for Covered Entities and Business Associates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under HITECH&#8217;s breach notification requirements, Covered Entities must report breaches of protected health information that has not been encrypted or otherwise secured in accordance with guidance from HHS. Required breach notices must be made as soon as is reasonably practicable, but no later than 60 days following discovery of the breach. Reports must be made to affected individuals and to HHS, and in some cases, they must be reported through local and national media, depending on the size of the breach. We are subject to audit under HHS&#8217;s HITECH-mandated audit program. We may also be audited in connection with a privacy complaint. We are subject to prosecution and/or administrative enforcement and increased civil and criminal penalties for non-compliance, including a new, four-tiered system of monetary penalties adopted under HITECH. We are also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH. To mitigate the risk of penalties under the HITECH breach notification provisions, we must ensure that breaches of protected health information are promptly detected and reported within the company, so that we can make all required notifications on a timely basis. However, even if we make required reports on a timely basis, we may still be subject to penalties for the underlying breach.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the federal privacy regulations, there are a number of state privacy laws, such as the California Consumer Privacy Act (&#8220;CCPA&#8221;) and the California Privacy Rights Act ("CPRA&#8221;), that apply to us. The compliance requirements of these laws, including additional breach reporting requirements, and the penalties for violation vary widely, and new privacy and security laws in this area are evolving. Requirements of these laws and penalties for violations vary widely. These new legislative and regulatory developments may impact our privacy and security strategy and our web-based and mobile assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our operations are found to be in violation of HIPAA, HITECH, or their implementing regulations, we may be subject to penalties, including civil and criminal penalties, fines, and exclusion from participation in federal or state healthcare programs, and the curtailment or restructuring of our operations. HITECH increased the civil and criminal penalties that may be imposed against Covered Entities, their Business Associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal, State and Foreign Fraud and Abuse Laws</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the significant federal funding involved in CMS programs such as Medicare and Medicaid, Congress and the states have enacted, and actively enforce, a number of laws to eliminate fraud and abuse in federal healthcare programs. Our business is subject to compliance with these laws. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, which we refer to collectively as the Affordable Care Act, was enacted in the United States. The Affordable Care Act expands the government&#8217;s investigative and enforcement authority and increases the penalties for fraud and abuse, including amendments to both the Anti-Kickback Statute and the False Claims Act, to make it easier to bring suit under these statutes. The Affordable Care Act also allocates additional resources and tools for the government to police healthcare fraud, with expanded subpoena power for HHS, additional funding to investigate fraud and abuse across the healthcare system and expanded use of recovery audit contractors for enforcement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback Statute</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including, for example, gifts, certain discounts, the furnishing of free supplies, equipment or services, credit arrangements, payment of cash and waivers of payments. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered businesses, the statute has been violated. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. In addition, some kickback allegations have been claimed to violate the federal False Claims Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are otherwise lawful in businesses outside of the healthcare industry. Recognizing that the Anti- Kickback Statute is broad and may technically prohibit many innocuous or beneficial arrangements, Congress authorized the Office of Inspector General (&#8220;OIG&#8221;) of the HHS to issue a series of regulations known as &#8220;safe harbors.&#8221; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities such as OIG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have adopted laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to referral of recipients for healthcare products or services reimbursed by any source, not only CMS programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government officials have focused their enforcement efforts on the marketing of healthcare services and products, among other activities, and recently have brought cases against companies, and certain individual sales, marketing and executive personnel, for allegedly offering unlawful inducements to potential or existing customers in an attempt to procure their business.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal False Claims Act</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another development affecting the healthcare industry is the increased use of the federal False Claims Act (&#8220;FCA&#8221;) and in particular, action brought pursuant to the FCA&#8217;s &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; provisions. The FCA imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provisions of the FCA allow a private individual to bring actions on behalf of the federal government alleging that the defendant has violated the FCA and to share in any monetary recovery. As a result, in recent years, the number of suits brought against healthcare providers by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the FCA, and many of these state laws apply where a claim is submitted to any third-party payor and not only a federal healthcare program.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an entity is determined to have violated the FCA, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties of between approximately $12,000 and $24,000 for each separate instance of false claim. As part of any settlement, the government will usually require the entity to enter into a corporate integrity agreement, which imposes certain compliance, certification and reporting obligations. There are many potential bases for liability under the FCA. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The federal government has used the FCA to assert liability on the basis of inadequate care, kickbacks and other improper referrals, and improper use of CMS billing numbers, in addition to the more predictable allegations of misrepresentations with respect to the services rendered. In addition, the federal government has prosecuted companies under the FCA in connection with off-label promotion of products. Activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products and services and the sale and marketing of our products and services may be subject to scrutiny under these laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unaware of any current matters, we are unable to predict whether we will be subject to actions under the FCA or a similar state law, or the impact of such actions. However, the costs of defending such claims, as well as any sanctions imposed, could significantly affect our financial performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Payments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Payment Sunshine Act, known as &#8220;Open Payments&#8221; and enacted as part of the Affordable Care Act, requires all pharmaceutical and medical device manufacturers of products covered by Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to HHS: (i)&#160;payments and transfers of value to teaching hospitals and licensed physicians, (ii)&#160;physician ownership in the manufacturer, and (iii)&#160;research payments. The payments required to be reported include the cost of meals provided to a physician, travel reimbursements and other transfers of value, including those provided as part of contracted services such as speaker programs, advisory boards, consultation services and clinical trial services. The statute requires the federal government to make reported information available to the public. Failure to comply with the reporting requirements can result in significant civil monetary penalties ranging from $1,000 to $10,000 for each payment or other transfer of value that is not reported (up to a maximum per annual report of $150,000) and from $10,000 to $100,000 for each knowing failure to report (up to a maximum per annual report of $1.0 million). We are subject to Open Payments and the information we disclose may lead to greater scrutiny, which may result in modifications to established practices and additional costs. Additionally, similar reporting requirements have also been enacted on the state level domestically, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Laws</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, various countries have adopted anti-bribery laws providing for severe consequences in the form of criminal penalties and significant fines for individuals or companies committing a bribery offense. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, in the United Kingdom, under the U.K. Bribery Act 2010, a bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce or reward another individual to improperly perform certain functions or activities, including any function of a public nature. Bribery of foreign public officials also falls within the scope of the U.K. Bribery Act 2010. An individual found in violation of the U.K. Bribery Act 2010, faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited fine, as can commercial organizations for failure to prevent bribery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also international privacy laws, such as the General Data Protection Regulation (&#8220;GDPR&#8221;), that impose restrictions on the access, use, and disclosure of health information. All of these laws may impact our business. Our failure to comply with these privacy laws or significant changes in the laws, or judicial rulings interpreting these laws, may impact our ability to obtain required patient information and therefore could significantly impact our business and our future business plans.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Centers for Medicare and Medicaid Services (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program administered by CMS through fiscal intermediaries and carriers. Available to individuals age 65 or over, and certain other individuals, the Medicare program provides, among other things, healthcare benefits that cover, within prescribed limits, the major costs of most medically necessary care for such individuals, subject to certain deductibles and copayments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has established guidelines for the coverage and reimbursement of certain products, supplies and services. In general, in order to be reimbursed by Medicare, a healthcare product or service furnished to a Medicare beneficiary must be reasonable and necessary for the diagnosis or treatment of an illness or injury, or to improve the functioning of a malformed body part. The methodology for determining coverage status and the amount of Medicare reimbursement varies based upon, among other factors, the setting in which a Medicare beneficiary received healthcare products and services. Any changes in federal legislation, regulations and policy affecting Medicare coverage and reimbursement relative to our Zio service could have a material effect on our performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS also administers the Medicaid program, a cooperative federal/state program that provides medical assistance benefits to qualifying low income and medically needy persons. State participation in Medicaid is optional, and each state is given discretion in developing and administering its own Medicaid program, subject to certain federal requirements pertaining to payment levels, eligibility criteria and minimum categories of services. The coverage, method and level of reimbursement varies from state to state and is subject to each state&#8217;s budget restraints. Changes to the coverage, method or level of reimbursement for our Zio service may affect future revenue negatively if reimbursement amounts are decreased or discontinued.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All CMS programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, interpretations of policy, intermediary determinations, and government funding restrictions, all of which may materially increase or decrease the rate of program payments to healthcare facilities and other healthcare providers, including those paid for our Zio service.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in Illinois, California and Texas are enrolled as independent diagnostic testing facilities (&#8220;IDTFs&#8221;) defined by CMS as entities independent of a hospital or physician&#8217;s office in which diagnostic tests are performed by licensed or certified non-physician personnel under appropriate physician supervision. CMS has set certain performance standards that every IDTF must meet in order to obtain or maintain its billing privileges.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States Healthcare Reform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Changes in healthcare policy could increase our costs, decrease our revenue and impact sales of and reimbursement for our current and future products and services. The Affordable Care Act (&#8220;ACA&#8221;) substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. The ACA contains a number of provisions that impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in federal healthcare programs and reimbursement changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is uncertain how modification or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions, will impact us and the medical device industry as a whole. Any changes to, or repeal of, the ACA may have a material adverse effect on our results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective as of January 1, 2022, the U.S. federal No Surprises Act, prohibits providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to limited exceptions. Further, the No Surprises Act requires providers to send an insured patient&#8217;s health plan a good faith estimate of expected charges, including billing and diagnostic codes, prior to when the patient is scheduled to receive the item or service.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what other health care programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Human Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have approximately 1,700 employees globally. None of our employees are represented by a collective bargaining agreement, and we believe our employee relations are good. Although the COVID-19 pandemic has disrupted how and where we work, our employees have demonstrated ongoing resilience. During 2021, employees continued to effectively navigate strict safety protocols for those working onsite, primarily in manufacturing, and the majority of our employees were not required to be onsite and worked from home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity &amp; Inclusion</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in the richness and quality of a working environment that is informed by people from all walks of life and strive to create a genuinely inclusive environment. We are proud that, overall, our workforce is more than 60% female and greater than 50% of employees are ethnically diverse. To further build on our commitment to diversity, equity and inclusion, we have formed a Diversity Council of representatives from across our company that is working to coordinate efforts as we define our corporate strategy. In addition, we have an active Employee Resource Group (&#8220;ERG&#8221;) with plans to increase the number of ERGs to reflect the diversity of our workforce, and we are building external partnerships to expand the diversity of our talent outreach. We value our differences, recognizing that from those differences comes our strengths, and we are committed to continuing to build a culture of diversity, equity, and inclusion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health &amp; Safety</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to maintaining a healthy, safe, and secure work environment that protects our employees from harm. We comply with applicable health, safety, and environmental laws as well as related company policies and procedures, and provide necessary training as appropriate by role and location.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Rewards</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer an attractive mix of compensation and benefit plans to support our employees and their families&#8217; physical, mental, and financial well-being. We believe that we employ a fair and merit-based total compensation system, and we evaluate our compensation programs to ensure our employees are compensated fairly for the important work they do, and that we reward outstanding performance. We are also committed to achieving internal pay equity. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our employees competitive benefits that follow local standards and support physical, mental and financial wellness. In support of employee wellness, we provide a variety of benefits options, resources, programs, online tools and regular webinars. We generally offer to full time employees globally health benefits, retirement plan, paid time off and family leave, an Employee Stock Purchase Plan (&#8220;ESPP&#8221;), and an employee assistance program that is available to employees and their families with a variety of support services.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important that all employees have an opportunity to have an ownership interest in our company, and there are several programs that provide the ability to own our stock. Generally, more than 75% of our employees participates in at least one of our stock programs. During their tenure with our company, all employees have an opportunity to receive an equity award, either upon hire and/or during an annual review process to recognize those with significant impact on achieving our goals. Another program offered to all employees, whether part or full time, is the ability to participate in our ESPP. Participants in the ESPP may purchase our stock at a 15% discount to market price. We believe our discounted stock purchase program helps to build an ownership mentality amongst participating employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Workforce Development</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth and success of our employees is a top priority, as it impacts our overall company performance. We are investing heavily to build in-house tools and resources to support managers and employees on the road to success and ongoing growth. Our core competencies are the foundation for programs and tools being developed to identify top talent, prepare future managers and leaders, and provide equal access to growth opportunities.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer a variety of training opportunities, whether focused on building vocational or management and leadership skills. We use tools like Linkedin Learning to expand readiness of content and options for skill building. Despite the ongoing challenges of COVID-19, we continued to facilitate sessions around our core competencies, interview skills and coaching practices, and we rolled out a toolbox on our intranet with resources for employees and managers across the employee lifecycle. </span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_19"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes thereto, before making a decision to invest in our common stock. The realization of any of the following risks could materially and adversely affect our business, financial condition, operating results and prospects. In that event, the price of our common stock could decline, and you could lose part or all of your investment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary of Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company, as more fully described below. The principal factors and uncertainties that make investing in our company risky include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">changes in public health insurance coverage and CMS reimbursement rates for the Zio service could affect the adoption and profitability of our Zio service; </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">if third-party commercial payors do not provide any or adequate reimbursement, rescind or modify their reimbursement policies or delay payments for our products, including as a result of the CMS and Medicare Administrative Contractor (&#8220;MAC&#8221;) reimbursement rates, including Novitas Solutions' reimbursement rates for our Zio XT service, or if we are unable to successfully negotiate reimbursement contracts, our commercial success could be compromised;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the COVID-19 pandemic and efforts to reduce its spread have adversely impacted, and is expected to continue to materially and adversely impact, our business and operations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">we have a history of net losses, which we expect to continue, and we may not be able to achieve or sustain profitability in the future;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">our business is dependent upon physicians adopting our Zio service and if we fail to obtain broad adoption, our business would be adversely affected;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">we plan to introduce new products and services and our business will be harmed if we are not successful in selling these new products and services to our existing customers and new customers;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the market for ambulatory cardiac monitoring solutions is highly competitive. If our competitors are able to develop or market monitoring products and services that are more effective, or gain greater acceptance in the marketplace, than any products and services we develop, our commercial opportunities will be reduced or eliminated;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">we have recently experienced management turnover, which creates uncertainties and could harm our business;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to provide the Zio service; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">changes in the regulatory environment may constrain or require us to restructure our operations, which may harm our revenue and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The COVID-19 pandemic and efforts to reduce its spread have adversely impacted, and is expected to continue to materially and adversely impact, our business and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had, and is expected to continue to have, an adverse impact on our operations, particularly as a result of preventive and precautionary measures that we, other businesses, and governments are taking. The spread of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 in the United States has resulted in travel restrictions impacting all areas of our business, most notably our sales representatives. Many hospitals have also limited access for non-patients, including our sales professionals, which has negatively impacted our access to physicians and their patients. New hospital sanitization and social distancing protocols, as well as increased competition for resources within hospitals that have dedicated certain resources to COVID patients, have impacted and may continue to impact our business and operations. We have also noted staffing shortage at providers in certain regions in the United States and we believe that the status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could materially impact our revenue in future periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we anticipate that an increase in the unemployment rate due to the impact of COVID-19 would decrease the number of potential patients with access to health insurance, which may result in fewer diagnostic procedures. As hospitals cancel and defer diagnostic and elective procedures, it reduces their revenue and impacts their financial results, which could result in pricing pressure on our services as they seek cost savings. Prolonged restrictions relating to COVID-19 could adversely affect our revenue, results of operations, cash flows, and financial position. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we saw recovery of patient registrations for the Zio service in 2021, we expect these challenges of the COVID-19 pandemic to continue to impact the volume of Zio services provided for the duration of the pandemic, but its extent cannot be quantified at this time. Our customers&#8217; patients are also experiencing the economic impact of the current pandemic. Even an important diagnostic procedure like the Zio service may be less of a priority than other items for those patients who have lost their jobs, are furloughed, have reduced work hours or are worried about the continuation of their medical insurance. Such economic effects on patients may delay or disrupt our ability to both provision our service and collect co-payments or out-of-pocket costs, which would have an adverse effect on our revenue and cash flow. Patients may also be reluctant to visit their physicians or hospitals due to fear of contracting COVID-19. Physicians are not performing as many diagnostic tests for their patients and the facilities where these tests are performed may not be open, adequately staffed or open the entire day. Even where physicians continue to treat symptomatic patients, treatment of asymptomatic patients is being deferred in many cases. The reduction in diagnostic testing and physician visits, the increase in deferred treatment, and changes in patient behaviors are translating into fewer Zio services being prescribed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Governmental mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, our personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For the employees who continue to support essential operations, including those at its manufacturing facilities, we have instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of our employees. While we have continued to deliver our Zio service by operating with remote employees and essential employees on site, an extended implementation of these governmental mandates could further impact our ability to effectively provide our Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other measures at our facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminished. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing operations may be impacted as a result of employees assuming additional roles and responsibilities within our organization and we would have fewer resources available to run our operations, which could negatively impact our business operations and revenue as a result. We may also encounter voluntary departures of key employees due to any of the foregoing actions that we undertake. If key personnel or large groups of our employees contract the virus, that may also impact our business and operations. For example, an outbreak in our manufacturing facility could cause us to have to shut down our manufacturing operations, which would in turn present risk to the ongoing supply of devices required to continue our business operations. In the meantime, we have taken steps to support our employees, including providing the ability for the majority of employees to work remotely and implementing policies to enhance employee safety, including appropriate social distancing techniques, for those employees required to work in our facilities. We are also assessing our business continuity plans in the context of this pandemic.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, due to COVID-19, we have experienced delays in receiving Zio XT monitors back from patients, with some patients not returning the device at all. As a result, the increased prevalence of COVID-19 could result in negative changes to historical expectations around device return timelines and loss rates, both of which would negatively impact our finances. Finally, we anticipate that the COVID-19 pandemic may impact clinical and regulatory matters. COVID-19 is delaying enrollment in new clinical trials across the medical device industry and may affect any new trials we decide to pursue. Regulatory clearances may take extended duration of time as agencies focus on COVID-19-related priorities which, in turn, would delay our introduction of new products and services. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 pandemic has also created global supply chain shortages and delays, particularly for some electronic components, such as those contained in our PCBAs. We have experienced longer lead times, sometimes in excess of 52 weeks, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and increased broker fees during the COVID-19 pandemic, which has increased our cost of revenue. We have also had to increase our inventory levels as a result of these potential shortages. If we are unable to secure our typical supply of components on a timely basis, it may affect our ability to provide the Zio service on a timely basis, which would affect our cash flows and ability to operate on a timely basis.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these occurrences may significantly harm our business, financial condition, cash flows and prospects. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on our liquidity, capital resources, operations and business and those of the third parties on which we rely, and could worsen over time. The extent to which the COVID-19 pandemic impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. We do not yet know the full extent of potential delays or impacts on our business, financial condition, cash flows and results of operations. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to raise additional capital, which could negatively impact our short-term and long-term liquidity and our ability to operate on a timely basis, or at all. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The COVID-19 pandemic has caused extreme volatility and disruptions in the global capital and credit markets. A severe or prolonged economic downturn, could result in a variety of risks to our business, including driving hospitals to tighten budgets and curtail spending, which would negatively impact our sales and business. In addition, higher unemployment or reductions in employer-provided benefits plans could result in fewer commercially insured patients, which could negatively impact our revenue and business as a result. A weak or declining economy could also strain our third party manufacturers or suppliers, possibly resulting in supply disruptions, or cause our customers to delay making payments for our Zio service. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the economic climate and financial market conditions could adversely affect our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, which we expect to continue, and we may not be able to achieve or sustain profitability in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception in September 2006. The losses and accumulated deficit were primarily due to the substantial investments we made to develop and improve our technology and products and improve our business and the Zio service through research and development efforts and infrastructure improvements. Over the next several years, we expect to continue to devote substantially all of our resources to increase adoption of and reimbursement for our Zio service, which includes Zio XT and Zio AT, and to develop additional arrhythmia detection and management products and services. These efforts may prove more expensive than we currently anticipate and we may not succeed in increasing our revenue sufficiently to offset these higher expenses or at all. Accordingly, we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability. Our failure to achieve and sustain profitability in the future could cause the market price of our common stock to decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is dependent upon physicians adopting our Zio service and if we fail to obtain broad adoption, our business would be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to bring awareness to the Zio brand and educate physicians regarding the benefits of our Zio service over existing products and services, such as Holter monitors and event monitors, and to persuade them to prescribe the Zio service as the diagnostic product for their patients. We do not know if the Zio service will be successful over the long term and market acceptance may be hindered if physicians are not presented with compelling data demonstrating the efficacy of our service compared to alternative technologies. Any studies we, or third parties which we sponsor, may conduct comparing our Zio service with alternative technologies will be expensive, time consuming and may not yield positive results. Additionally, adoption will be directly influenced by a number of financial factors, including the ability of providers to obtain sufficient reimbursement from third-party commercial payors, and the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), for the professional services they provide in applying the Zio monitor and analyzing the Zio report. The efficacy, safety, performance and cost-effectiveness of our Zio service, on a stand-alone basis and relative to competing services, will determine the availability and level of reimbursement received by us and providers. Some payors do not have pricing contracts with us setting forth the Zio service reimbursement rates for us and providers. Physicians may be reluctant to prescribe the Zio service to patients covered by such non-contracted insurance policies because of the uncertainty surrounding reimbursement rates and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the administrative burden of interfacing with patients to answer their questions and support their efforts to obtain adequate reimbursement for the Zio service. If physicians do not adopt and prescribe our Zio service, our revenue will not increase and our financial condition will suffer as a result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to keep up with demand for the Zio service, our revenue could be impaired, market acceptance for the Zio service could be harmed and physicians may instead prescribe our competitors&#8217; products and services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for the Zio service increases, we may encounter production or service delays or shortfalls. Such production or service delays or shortfalls may be caused by many factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">while we intend to continue to expand our manufacturing capacity, our production processes may have to change to accommodate this growth, potentially involving significant capital expenditures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">key components of the Zio monitors are provided by a single supplier or limited number of suppliers, and we do not maintain large inventory levels of these components; if we experience a shortage or quality issues in any of these components, we would need to identify and qualify new supply sources, which could increase our expenses and result in manufacturing delays;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">global demand and supply factors concerning commodity components common to all electronic circuits, including Zio monitors, could result in shortages that manifest as extended lead times for circuit boards, which could limit our ability to sustain and/or grow our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">shelter-in-place orders in effect in California and elsewhere due to the COVID-19 outbreak;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may experience a delay in completing validation and verification testing for new production processes and/or equipment at our manufacturing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we are subject to state, federal and international regulations, including the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;), the EU&#8217;s Medical Device Directive (&#8220;MDD&#8221;) and, as of May 2021, the EU&#8217;s Medical Device Regulation (&#8220;MDR&#8221;), and the developing regulations by Medicines &amp; Healthcare Regulatory Agency (&#8220;MHRA&#8221;) post Brexit in the United Kingdom for both the manufacture of the Zio monitor and the provision of the Zio service, noncompliance with which could cause an interruption in our manufacturing and services; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">to increase our manufacturing output significantly and scale our services, we will have to attract and retain qualified employees for our operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">in response to unexpectedly rapid growth of our business, clinical operations capacity may not meet demand while new resources are being recruited and trained, which could delay the return of Zio reports to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to successfully manufacture our Zio monitors in sufficient quantities, or provide the Zio service in a timely manner, would materially harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our manufacturing facilities and processes and those of our third-party suppliers are subject to unannounced FDA, state and Notified Body regulatory inspections for compliance with the QSR, MDD, MDR, UK MDR requirements. Developing and maintaining a compliant quality system is time consuming and investment intensive. Failure to maintain compliance with, or not fully complying with the requirements of the FDA and state regulators could result in enforcement actions against us or our third-party suppliers, which could include the issuance of warning letters, adverse publicity, seizures, prohibitions on product sales, recalls and civil and criminal penalties, any one of which could significantly impact our manufacturing supply and provision of services and impair our financial results. Failure to maintain compliance with, or not fully complying with the requirements of, MDD, MDR, and UK MDR could result in similar disruptions in these markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party vendors to manufacture some of our components, which could make us vulnerable to supply shortages and price fluctuations that could harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on third-party vendors for components and sub-assemblies used in our Zio monitors. Our reliance on third-party vendors subjects us to a number of risks, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to obtain adequate supply in a timely manner or on commercially reasonable terms;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption of supply resulting from modifications to, or discontinuation of, a supplier&#8217;s operations, including those caused by pandemics such as COVID-19;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">production delays related to the evaluation and testing of products from alternative suppliers and corresponding regulatory qualifications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability of the manufacturer or supplier to comply with the QSR, state regulatory authorities, and in some cases the Notified Body audits;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">miscommunication of design specifications due to errors/omissions by either the vendor or our company, resulting delayed delivery of acceptable product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s failure to consistently produce quality components;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an outbreak of disease or similar public health threat, such as the existing threat of coronavirus, particularly as it may impact our supply chain;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">price fluctuations due to a lack of long-term supply arrangements with our suppliers for key components;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to control the quality of products manufactured by third parties; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in delivery by our suppliers due to changes in demand from us or their other customers; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in obtaining required materials and components that are in short supply within the time frames we require, at an affordable cost, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant delay or interruption in the supply of components or sub-assemblies, or our inability to obtain substitute components, sub-assemblies or materials from alternate sources at acceptable prices and in a timely manner could impair our ability to meet the demand for our Zio service and harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue relies substantially on our Zio service, which is currently our only offering. If the Zio service or future product offerings fail to gain, or lose, market acceptance, our business will suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current revenue is dependent on prescriptions of the Zio service, and we expect that sales of the Zio service will account for substantially all of our revenue for the foreseeable future. We are in various stages of research and development for other diagnostic solutions and new indications for our technology and the Zio service; however, there can be no assurance that we will be able to successfully develop and commercialize any new products or services. Any new products may not be accepted by physicians or may merely replace revenue generated by our Zio service and not generate additional revenue. If we have difficulty launching new products, our reputation may be harmed and our financial results adversely affected. In order to substantially increase our revenue, we will need to target physicians other than cardiologists, such as emergency room doctors, primary care physicians and other physicians with whom we have had little contact and may require a different type of selling effort. If we are unable to increase prescriptions of the Zio service, expand reimbursement for the Zio service, or successfully develop and commercialize new products and services, our revenue and our ability to achieve and sustain profitability would be impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual results may fluctuate significantly and may not fully reflect the underlying performance of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual results of operations, including our revenue, profitability and cash flow, may vary significantly in the future and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. Fluctuation in quarterly and annual results may decrease the value of our common stock. Factors that may cause fluctuations in our quarterly and annual results include, without limitation:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">market awareness and acceptance of the Zio service;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to get payors under contract at acceptable reimbursement rates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of reimbursement for the Zio service at acceptable rates through government programs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to attract new customers and improve our business with existing customers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">results of our clinical trials and publication of studies by us, competitors or third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing and success of new product introductions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in our pricing policies or those of our competitors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">general economic, industry and market conditions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the COVID-19 pandemic on our operations and financial results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the regulatory environment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">expenses or loss of sales associated with unforeseen product quality issues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">timing of physician prescriptions and demand for our Zio service;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seasonality factors, such as patient and physician vacation schedules, severe weather conditions and insurance deductibles, that hamper or otherwise restrict when a patient seeking diagnostic services such as the Zio service visits the prescribing physician;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the hiring, training and retention of key employees, including our ability to expand our sales team and clinical operations team;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation or other claims against us for intellectual property infringement or otherwise;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain additional financing as necessary; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advances and trends in new technologies and industry standards.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our quarterly results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have noticed seasonality in the use of our Zio service which, along with other factors such as severe weather, may cause quarterly fluctuations in our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the summer months and the holiday season, we have observed that the use of our Zio service decreases, which reduces our revenue during those periods. We believe that the decrease in demand may result from physicians or their patients taking vacations. Severe weather conditions or natural disasters also may hamper or otherwise restrict when patients seeking diagnostic services, such as the Zio service, visit prescribing physicians. Similarly, we generally experience some effects of seasonality due to the renewal of insurance deductibles at the beginning of the calendar year. These factors may cause our results of operations to vary from quarter to quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement by CMS is highly regulated and subject to change; our failure to comply with applicable regulations could result in decreased revenue and may subject us to penalties or have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, we received approximately 14% of our revenue from reimbursement for our Zio service by CMS. Under CMS guidelines for participation in the Medicare program CMS designates us as an independent diagnostic treatment facility (&#8220;IDTF&#8221;). CMS imposes extensive and detailed requirements on IDTFs, including but not limited to, rules that govern how we structure our relationships with physicians, how and when we submit reimbursement claims, how we operate our monitoring facilities and how and where we provide our monitoring solutions. Our failure to comply with applicable CMS rules could result in a discontinuation of our reimbursement under the CMS payment programs, our being required to return funds already paid to us, civil monetary penalties, criminal penalties and/or exclusion from the CMS programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in public health insurance coverage and CMS reimbursement rates for the Zio service could affect the adoption and profitability of our Zio service.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for our Zio service, which would significantly harm our business. Government and other third-party payors require us to report the service for which we are seeking reimbursement by using a Current Procedural Terminology (&#8220;CPT&#8221;) code-set maintained by the American Medical Association (&#8220;AMA&#8221;). For Zio XT, we had historically utilized temporary CPT codes (or Category III CPT codes), used for newly introduced technologies specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and CMS. On October 25, 2019, the AMA&#8217;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, CMS published its Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;2022 Final Rule&#8221;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for our Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#8220;MAC&#8221; or &#8220;MACs&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#8220;NCD&#8221;) by CMS, or at the local level through a local coverage determination (&#8220;LCD&#8221;), by one or more of the regional MACs who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#8220;IDTF&#8221;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas Solutions in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas Solutions and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We remain engaged with all of the MACs and are working with other industry participants to submit additional cost data on long-term continuous electrocardiogram (&#8220;ECG&#8221;) monitoring for consideration to establish appropriate local rates. We cannot provide certainty at this time on the potential outcome of the discussions with the MACs or on the timing of any action to be taken.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#8220;NCD&#8221;) by CMS, or at the local level through a local coverage determination (&#8220;LCD&#8221;), by one or more of the regional MACs who are private contractors who establish and write LCD policies and process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. If Novitas Solutions were to change, limit or cease to cover the Zio service by altering the existing LCD, it would negatively impact our revenue from CMS. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, we are and will continue to be subject to changes in the level of Medicare coverage for our products, and unfavorable coverage determinations at the national or local level could adversely affect our business and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, we will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if we are unsuccessful in improving the Medicare rates, we believe that commercial rates may begin to be more negatively impacted. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the CPT code changes that took effect January 1, 2021, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement rate and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual and may lead to higher write-offs of doubtful accounts for those periods and negatively impact our results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Controls imposed by CMS and commercial third-party payors designed to reduce costs, commonly referred to as &#8220;utilization review&#8221;, may affect our operations. Federal law contains numerous provisions designed to ensure that services rendered to CMS patients meet professionally recognized standards and are medically necessary, appropriate for the specific patient and cost-effective. These provisions include a requirement that a sampling of CMS patients must be reviewed by quality improvement organizations, which review the appropriateness of product prescriptions, the quality of care provided, and the appropriateness of reimbursement costs. Quality improvement organizations may deny payment for services or assess fines and also have the authority to recommend to the U.S. Department of Health and Human Services, that a provider which is in substantial noncompliance with the standards of the quality improvement organization be excluded from participation in the Medicare program. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordability Reconciliation Act (the &#8220;Affordable Care Act&#8221;), potentially expands the use of prepayment review by Medicare contractors by eliminating statutory restrictions on their use, and, as a result, efforts to impose more stringent cost controls are expected to continue. Utilization review is also a requirement of most non-governmental managed care organizations and other third-party payors. To date these controls have not had a significant effect on our operations, but significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material, adverse effect on our business, financial position and results of operations in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each state&#8217;s Medicaid program has its own coverage determinations related to our services, and some state Medicaid programs do not provide their recipients with coverage for our Zio service. Even if our Zio service is covered by a state Medicaid program, we must be recognized as a Medicaid provider by the state in which the Medicaid recipient receiving the services resides in order for us to be reimbursed by a state&#8217;s Medicaid program. Even if we are recognized as a provider in a state, Medicare&#8217;s rate for our Zio service may be low, and the Medicaid reimbursement amounts are sometimes as low, or lower, than the Medicare reimbursement rate. In addition, and as noted above, each state&#8217;s Medicaid program has its own coverage determinations related to our Zio service, and many state Medicaid programs do not provide their recipients with coverage for our Zio service. As a result of all of these factors, our Zio service is not reimbursed or only reimbursed at a very low dollar amount by many state Medicaid programs. In some cases, a state Medicaid program&#8217;s reimbursement rate for our Zio service might be zero dollars. Additionally, certain states may require Medicaid recipients to pay for part of the Zio Service, and since the recipients of Medicaid are low income individuals, we are often unable to collect any amounts directly from individual recipients of the Zio service covered by Medicaid. Low or zero dollar Medicaid reimbursement rates for our Zio service would have an adverse effect on our business, gross margins and revenues. Most of the Zio services we provide are reimbursed through Medicare or private third party payors and not Medicaid, but if that were to change in the future, or the percentage of Zio services provided to Medicaid recipients were to increase, our gross margins would be adversely affected as a result.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, healthcare reform legislation or regulation may be proposed or enacted in the future that may adversely affect such policies and amounts. Changes in the healthcare industry directed at controlling healthcare costs or perceived over-utilization of ambulatory cardiac monitoring products and services could reduce the volume of Zio services prescribed by physicians. If more healthcare cost controls are broadly instituted throughout the healthcare industry, the volume of cardiac monitoring solutions prescribed could decrease, resulting in pricing pressure and declining demand for our Zio service. We cannot predict whether and to what extent existing coverage and reimbursement will continue to be available. If physicians, hospitals and clinics are unable to obtain adequate coverage and government reimbursement of the Zio service, they are significantly less likely to use the Zio service and our business and operating results would be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any changes to, or repeal of, the Affordable Care Act or its implementing regulations may have a material adverse effect on our results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party commercial payors do not provide any or adequate reimbursement, including as a result of the CMS and MAC reimbursement rates for our Zio XT service, rescind or modify their reimbursement policies or delay payments for our products, including the Zio service, or if we are unable to successfully negotiate reimbursement contracts, our commercial success could be compromised.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenue from third-party private commercial payors, such as medical insurance companies. These commercial payors may reimburse our products, including the Zio service, at inadequate rates, suspend or discontinue reimbursement at any time, impose requirements that may result in a greater number of denied claims, or require or increase co-payments from patients. The recent actions taken by CMS and MACs to reduce the reimbursement rates for use of the Zio XT service by Medicare patients could influence the price that commercial payors are willing to pay for our Zio service. Contracts with commercial payors, which set forth the Zio XT service reimbursement rates for us and prescribing physicians, could be terminated or payors could seek to renegotiate such contracts at any time to try to obtain pricing at reduced amounts at or near the Novitas Solutions reimbursement rates. Some payors do not have contracts with us and others that are already in the process of negotiating contracts may look to negotiate lower reimbursement rates for the Zio XT service in response to actions taken by Novitas Solutions. Any such actions could have a significant and adverse effect on our revenue and the revenue of physicians who prescribe our Zio service. Physicians may not prescribe our Zio service unless payors reimburse a substantial portion of the submitted costs, including the physician&#8217;s, hospital&#8217;s or clinic&#8217;s charges related to the application of certain products, including the Zio monitor and the interpretation of results which may inform a diagnosis. Additionally, certain payors may require that physicians prescribe another arrhythmia diagnostic monitoring option prior to prescribing the Zio service. There is significant uncertainty concerning third-party reimbursement of any new product or service until a contracted rate is established. Reimbursement by a commercial payor may depend on a number of factors, including, but not limited to, a payor&#8217;s determination that the prescribed service is:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">not experimental or investigational;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">appropriate for the specific patient;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">cost effective;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">supported by peer-reviewed publications; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">accepted and used by physicians within their provider network.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each payor makes its own decision as to whether to establish a policy concerning reimbursement or enter into a contract with us to set the price of reimbursement, seeking reimbursement on a payor-by-payor basis is a time consuming and costly process to which we dedicate substantial resources. If we do not dedicate sufficient resources to establishing contracts with third-party commercial payors, or continue to validate the clinical value of Zio services through studies and physician adoption, the amount that we are reimbursed for our products may decline, our revenue may become less predictable, and we will need to expend more efforts on a claim-by-claim basis to obtain reimbursement for our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our revenue is derived from third-party commercial payors who have pricing contracts with us, which means that the payor has agreed to a defined reimbursement rate for our services. These contracts provide a high degree of certainty to us, physicians, clinics and hospitals with respect to the rate at which our services will be reimbursed. These contracts also impose a number of obligations regarding billing and other matters, and our noncompliance with a material term of such contracts may result in termination of the contract and loss of any associated revenue. We expect to continue to dedicate resources to maintaining compliance with these contracted payors, to ensure payors acknowledge and are aware of the clinical and economic value of our services and the interest on the part of physicians, clinics and hospitals who use our services and participate in their provider networks; however, we can provide no assurance that we will retain any given contractual payor relationship. A loss of these pricing contracts can increase the uncertainty of reimbursement of claims from third-party payors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our revenue is derived from third-party commercial payors without such contracts in place. Without a contracted rate, reimbursement claims for our products are often denied upon submission, and we or our billing partner, XIFIN, Inc. (&#8220;XIFIN&#8221;), must appeal the denial. The appeals process is time-consuming and expensive, and may not result in full or any payment. In cases where there is no contracted rate for reimbursement it may be more difficult for us to acquire new accounts with physicians, clinics and hospitals. In addition, in the absence of a contracted rate, there is typically a greater out-of-network, co-insurance or co-payment requirement which may result in payment delays or decreased likelihood of full collection. In some cases involving non-contracted insurance companies, we may not be able to collect any amount or only a portion of the invoiced amount for our services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to dedicate resources to establishing pricing contracts with non-contracted insurance companies; however, we can provide no assurance that we will be successful in obtaining such pricing contracts or that such pricing contracts will contain reimbursement for our services at rates that are favorable to us. If we fail to establish these contracts, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be able to recognize revenue only based on an estimated average collection rate per historical cash collections. In addition, XIFIN may need to expend significant resources obtaining reimbursement on a claim-by-claim basis and in adjudicating claims which are denied altogether or not reimbursed at acceptable rates. We currently pay XIFIN a percentage of the amounts it collects on our behalf and this percentage may increase in the future if it needs to expend more resources in adjudicating such claims. We sometimes informally engage physicians, hospitals and clinics to help establish contracts with third-party payors who insure their patients. We cannot provide any assurance that such physicians, hospitals and clinics will continue to help us establish contracts in the future. If we fail to establish contracts with more third-party payors it may adversely affect our ability to increase our revenue. In addition, a failure to enter into contracts could affect a physician&#8217;s willingness to prescribe our services because of the administrative work involved in interacting with patients to answer their questions and help them obtain reimbursement for our services. If physicians are unwilling to prescribe our services due to the lack of certainty and administrative work involved with patients covered by non-contracted insurance companies, or patients covered by non-contracted insurance companies are unwilling to risk that their insurance may charge additional out-of-pocket fees, our revenue could decline or fail to increase.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our continued rapid growth could strain our personnel resources and infrastructure, and if we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced rapid growth in our headcount and in our operations. Any growth that we experience in the future will provide challenges to our organization, requiring us to expand our sales personnel, manufacturing, clinical, customer care and billing operations and general and administrative infrastructure. In addition to the need to scale our operational and service capacity, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. Rapid expansion in personnel could mean that less experienced people manufacture our Zio monitors, market, sell and support our Zio service, and analyze the data to produce Zio reports, which could result in inefficiencies and unanticipated costs, reduced quality in either our Zio reports or manufactured devices, and disruptions to our service operations. Additionally, rapid expansion could require us to rely on overtime to increase capacity that could, in turn, result in greater employee attrition and a loss in productivity during the process of recruiting and training additional resources and add to our operating expenses. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to gain greater efficiency, we may expand the automated portion of our Zio service and require productivity improvements from our certified cardiographic technicians. Such improvements could compromise the quality of our Zio reports. In addition, rapid and significant growth may strain our administrative and operational infrastructure. Our ability to manage our business and growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to support demand for the Zio service or any of our future products or services, our business could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As demand for the Zio service or any of our future products or services increases, we will need to continue to scale our manufacturing capacity and algorithm processing technology, expand customer service, billing and systems processes and enhance our internal quality assurance program. We will also need additional certified cardiographic technicians and other personnel to process higher volumes of data. We cannot assure you that, with any increases in scale, required improvements will be successfully implemented, quality assurance will be maintained, or that appropriate personnel will be available to facilitate growth of our business. Failure to implement necessary procedures, transition to new processes or hire the necessary personnel could result in higher costs of processing data or inability to meet increased demand. There can be no assurance that we will be able to perform our data analysis on a timely basis at a level consistent with demand, quality standards and physician expectations. If we encounter difficulty meeting market demand, quality standards or physician expectations, our reputation could be harmed and our future prospects and business could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to introduce new products and services and our business will be harmed if we are not successful in selling these new products and services to our existing customers and new customers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received FDA clearance for our Zio AT ECG Monitoring System, (&#8220;Zio AT&#8221;), which is designed to provide timely transmission of data during the wear period. However, we do not yet know whether Zio AT or any other new products and services will be well received and broadly adopted by physicians and their patients or whether sales will be sufficient for us to offset the costs of development, implementation, support, operation, sales and marketing. Although we have performed extensive testing of our new products and services, their broad-based implementation may require more support than we anticipate, which would further increase our expenses. Additionally, new products and services may subject us to additional risks of product performance, customer complaints and litigation. If sales of our new products and services are lower than we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect, or if we expend additional resources to fix unforeseen problems and develop modifications, our operating margins are likely to decrease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on single suppliers for some of the materials used in our products, and if any of those suppliers are unable or unwilling to produce these materials or supply them in the quantities that we need at the quality we require, we may not be able to find replacements or transition to alternative suppliers before our business is materially impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on single suppliers for the supply of our adhesive sub-assembly, disposable plastic housings, instruments and other materials that we use to manufacture and label our Zio monitors. These components and materials are critical and, in some cases, there are relatively few alternative sources of supply. We have not qualified additional suppliers for some of these components and materials and we do not carry a significant inventory of these items. While we believe that alternative sources of supply may be available, we cannot be certain whether they will be available if and when we need them and that any alternative suppliers would be able to provide the quantity and quality of components and materials that we would need to manufacture our Zio monitors if our existing suppliers were unable to satisfy our supply requirements. To utilize other supply sources, we would need to identify and qualify new suppliers to our quality standards, which could result in manufacturing delays and increase our expenses. Any supply interruption, such as those that we have experienced during the COVID-19 pandemic, could limit our ability to manufacture our products and could therefore harm our business, financial condition and results of operations. If our current suppliers and any alternative suppliers do not provide us with the materials we need to manufacture our products or perform our services, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in our Zio service could occur. Any such interruption may significantly affect our future revenue and harm our relations and reputation with physicians, hospitals, clinics and patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our manufacturing facility becomes damaged or inoperable, or if we are required to vacate the facility, we may be unable to manufacture and ship our Zio monitors, or we may experience delays in production or an increase in costs which could adversely affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently manufacture and assemble the Zio monitors in only one location. Our products are comprised of components sourced from a variety of contract manufacturers, with final assembly completed at our facility in Cypress, California. Our facility and equipment, or those of our suppliers, could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, terrorism, pandemic outbreaks, flooding and power outages. Any of these may render it difficult or impossible for us to manufacture new products, ship assembled products, and/or receive returned units for some period of time. If our Cypress facility is inoperable for even a short period of time, the inability to manufacture, ship and receive our Zio monitors, and the interruption in research and development of any future products, may result in harm to our reputation, increased costs, the loss of orders and lower revenue. Furthermore, it could be costly and time consuming to repair or replace our facilities and the equipment we use to perform our research and development work and manufacture our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to increase our sales and marketing capabilities and develop broad brand awareness in a cost effective manner, our growth will be impeded and our business may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to expand and optimize our sales and marketing infrastructure in order to increase our prescribing physician base and our business. Identifying and recruiting qualified personnel and training them in the application of the Zio service, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in revenue. In particular, if we are unable to hire, develop and retain talented sales personnel or if new sales personnel are unable to achieve desired productivity levels in a reasonable period of time, we may not be able to realize the expected benefits of this investment or increase our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our customer base and achieve broader market acceptance of our products will depend, to a significant extent, on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. Our business may be harmed if our marketing efforts and expenditures do not generate a corresponding increase in revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe that developing and maintaining broad awareness of our brand in a cost effective manner is critical to achieving broad acceptance of the Zio service and penetrating new accounts. Brand promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of the Zio service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing for our Zio service is complex, and we must dedicate substantial time and resources to the billing process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for IDTF services is complex, time consuming and expensive. Depending on the billing arrangement and applicable law, we bill several types of payors, including CMS, third-party commercial payors, institutions and patients, which may have different billing requirements procedures or expectations. We also must bill patient co-payments, co-insurance and deductibles. We face risk in our collection efforts, including potential write-offs of doubtful accounts and long collection cycles, which could adversely affect our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several factors make the billing and collection process uncertain, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">differences between the submitted price for our Zio service and the reimbursement rates of payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with complex federal and state regulations related to billing CMS;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">differences in coverage among payors and the effect of patient co-payments, co-insurance and deductibles;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">differences in information and billing requirements among payors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">incorrect or missing patient history, indications or billing information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the CPT code changes that took effect January 1, 2021, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual and may lead to higher write-offs of doubtful accounts for those periods and negatively impact our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees and undertake internal review procedures to evaluate compliance with applicable laws, regulations and internal policies. Payors also conduct audits to evaluate claims, which may add further cost and uncertainty to the billing process. These billing complexities, and the related uncertainty in obtaining payment for our Zio service, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The operation of our call centers and monitoring facilities is subject to rules and regulations governing IDTFs; failure to comply with these rules could prevent us from receiving reimbursement from CMS and some commercial payors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be a participating provider in the Medicare program, and to be reimbursed by CMS under the program, we established an independent diagnostic treatment facility (or &#8220;IDTF&#8221;). An IDTF is a &#8220;provider-type&#8221; designation under Medicare, defined by CMS as an entity(ies) independent of a hospital or physician&#8217;s office in which diagnostic tests are performed by licensed or certified nonphysician personnel under appropriate physician supervision. Our IDTFs are staffed by certified cardiographic technicians, who are overseen by a medical director who reviews the accuracy of the data we curate and from which we prepare reports. The existence of an IDTF allows us to bill a government payor for the Zio service through one or more MACs, such as Novitas Solutions, Noridian Healthcare Solutions and Palmetto GBA. MACs are companies that operate on behalf of the federal government to process Medicare claims for reimbursement and allow us to obtain reimbursement for our Zio service at CMS defined rates. Certification as an IDTF requires that we follow strict regulations governing how the center operates, such as requirements regarding the experience and certifications of the certified cardiographic technicians. In addition, many commercial payors require our IDTFs to maintain accreditation and certification with the Joint Commission of American Hospitals. To do so we must demonstrate a specified quality standard and are subject to routine inspection and audits. These rules and regulations vary from location to location and are subject to change. If they change, we may have to change the operating procedures at our IDTFs, which could increase our costs significantly. If we fail to obtain and maintain IDTF certification, our Zio service may no longer be reimbursed by CMS and some commercial payors, which would have a material adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the year ended December 31, 2021, we recognized approximately eight percent of our revenue from non-contracted third-party payors, and as a result, our quarterly operating results are difficult to predict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited visibility as to when we will receive payment for our Zio service with non-contracted payors and we or XIFIN must appeal any negative payment decisions, which often delay collections further. Additionally, a portion of the revenue from non-contracted payors is received from patient co-pays, which we may not receive for several months following delivery of service or at all. For revenue related to non-contracted payors, we estimate an average collection rate based on factors including historical cash collections. Subsequent adjustments, if applicable, are recorded as an adjustment to revenue. Fluctuations in revenue may make it difficult for us, research analysts and investors to accurately forecast our revenue and operating results or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to assess our actual performance. If our revenue or operating results fall below expectations, the price of our common stock would likely decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a third-party billing company, XIFIN, to transmit and pursue claims with payors. A delay in transmitting or pursuing claims could have an adverse effect on our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we manage the overall processing of claims, we rely on XIFIN to transmit substantially all of our claims to payors, and pursue most claim denials. If claims for our Zio service are not submitted to payors on a timely basis, not properly adjudicated upon a denial, or if we are required to switch to a different claims processor, we may experience delays in our ability to process receipt of payments from payors, which would have an adverse effect on our revenue and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for ambulatory cardiac monitoring solutions is highly competitive. If our competitors are able to develop or market monitoring products and services that are more effective, or gain greater acceptance in the marketplace, than any products and services we develop, our commercial opportunities will be reduced or eliminated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for ambulatory cardiac monitoring products and services is evolving rapidly and becoming increasingly competitive. Our Zio service competes with a variety of products and services that provide alternatives for ambulatory cardiac monitoring, including Holter monitors and mobile cardiac telemetry monitors. Our industry is highly fragmented and characterized by a small number of large manufacturers and a large number of smaller regional service providers. These third parties compete with us in marketing to payors and prescribing physicians, recruiting and retaining qualified personnel, acquiring technology and developing products and services that compete with the Zio service. Our ability to compete effectively depends on our ability to distinguish our company and the Zio service from our competitors and their products, and includes such factors as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">safety and efficacy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">acute and long term outcomes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ease of use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">price;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">physician, hospital and clinic acceptance; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">third-party reimbursement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations and other factors. Large competitors in the ambulatory cardiac market include companies that sell standard Holter monitors including GE Healthcare, Philips Healthcare, Mortara Instrument, Inc., Spacelabs Healthcare Inc. and Welch Allyn Holdings, Inc. (acquired by Hill-Rom Holdings, Inc.). Additional competitors, such as BioTelemetry, Inc. (acquired by Royal Philips), Preventice Solutions, Inc. (acquired by Boston Scientific, Inc.) and Bardy Diagnostics, Inc. (acquired by Hill-Rom Holdings, Inc. which was recently acquired by Baxter International, Inc.) offer ambulatory cardiac monitoring services and also function as service providers. These companies have also developed other patch-based cardiac monitors that have received FDA and foreign regulatory clearances. There are also several small start-up companies trying to compete in the patch-based cardiac monitoring space, as well as several entering the patch-based cardiac monitoring market. Large medical device companies may continue to acquire or form alliances with these smaller companies in order to diversify their product offering and participate in the digital health space.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have seen a trend in the market for large medical device companies to acquire, invest in or form alliances with these smaller companies in order to diversify their product offerings and participate in the digital health space. Future competition could come from makers of wearable fitness products or large information technology companies focused on improving healthcare. For example, Apple Inc. has added capabilities on its watch platform to measure non-continuous ECG and to alert users to the potential presence of irregular heartbeats suggestive of asymptomatic AF. These competitors and potential competitors may introduce new products and services that more directly compete with our Zio service. Recently, there has been increased acquisition activity and consolidation in our industry. Many of our competitors and potential competitors have significantly greater financial and other resources than we do and have well-established reputations, broader product offerings, and worldwide distribution channels that are significantly larger and more effective than ours. If our competitors and potential competitors are better able to develop new ambulatory cardiac monitoring solutions than us, or develop more effective or less expensive cardiac monitoring solutions, they may render our current Zio service obsolete or non-competitive. Competitors may also be able to deploy larger or more effective sales and marketing resources than we currently have. Competition with these companies could result in price cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to compete depends on our ability to innovate successfully.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for medical devices, including the ambulatory cardiac monitoring segment, is competitive, dynamic, and marked by rapid and substantial technological development and product innovation. While there are barriers that would challenge new entrants or existing competitors from developing products that compete directly with ours, these barriers can be overcome. Demand for the Zio service and future related products or services could be diminished by equivalent or superior products and technologies offered by competitors. If we are unable to innovate successfully, our products and services could become obsolete and our revenue would decline as our customers purchase our competitors&#8217; products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, we must continue to develop new product offerings and enhancements to the Zio service. We can provide no assurance that we will be successful in fully recognizing the strategic value of our ECG database, expanding the indications for our Zio service, developing new products or commercializing them in ways that achieve market acceptance. In addition, if we develop new products, sales of those products may reduce revenue generated from our existing products. Maintaining adequate research and development personnel and resources to meet the demands of the market is essential. If we are unable to develop new products, applications or features or improve our algorithms due to constraints, such as insufficient cash resources, high employee turnover, inability to hire personnel with sufficient technical skills or a lack of other research and development resources, we may not be able to maintain our competitive position compared to other companies. Furthermore, many of our competitors devote a considerably greater amount of funds to their research and development programs than we do, and those that do not may be acquired by larger companies that would allocate greater resources to research and development programs. Our failure or inability to devote adequate research and development resources or compete effectively with the research and development programs of our competitors could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into a development agreement with a third party that may not result in the development of commercially viable products or the generation of significant future revenues.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a development agreement with Verily Life Sciences LLC (an Alphabet Company, referred to as &#8220;Verily&#8221;) to develop certain next-generation AF screening, detection, or monitoring products, which involve combining Verily and our technology platforms and capabilities (the &#8220;Development Agreement&#8221;). As part of the Development Agreement, we paid Verily an up-front fee of $5.0 million in cash, and $4.0 million in milestone payments during the year ended December 31, 2020 with an additional $4.0 million in milestone payments made in January of 2021. Through December 31, 2021, we have achieved milestones and related payment obligations totaling $11.0 million, including a $3.0 million obligation incurred during our most recent quarter. We have agreed to make additional payments up to an aggregate of $1.75 million, subject to the achievement of certain development and regulatory milestones. The success of our collaboration with Verily is highly dependent on the efforts provided to the collaboration by Verily and us and the skill sets of our respective employees. Support of these development efforts requires significant resources, including research and development, manufacturing, quality assurance, and clinical and regulatory personnel. Even if our development and clinical trial efforts succeed, the FDA may not clear the developed products or may require additional product testing and clinical trials before clearing the developed products, which would result in product launch delays and additional expense. If cleared by the FDA, the developed products may not be accepted in the marketplace, and there is no assurance that adequate reimbursement will be available, or that an alternative payment model can be developed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the initial term and scope of the Development Agreement, and in order to commercialize any developed products with Verily, we will need to enter into a commercialization agreement. There is no guarantee that we will be able to enter into such an agreement on commercially reasonable terms or at all. If we are unable to reach agreement with Verily on terms, the up-front fee and regulatory and development milestone payments and our internal development costs would not be recovered and the licenses to use Verily&#8217;s technology will expire.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This collaboration may not result in the development of products that achieve commercial success and could be terminated prior to developing any products. In the event of any termination or expiration of the Development Agreement, we may be required to devote additional resources to product development and we may face increased competition, including from Verily. Verily may use the experience and insights it develops in the course of the collaboration with us to initiate or accelerate their development of products that compete with our products, which may create competitive disadvantages for us. Accordingly, we cannot provide assurance that our collaboration with Verily or any other third party will result in the successful development of commercially viable products or result in significant additional future revenues for our company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing clinical acceptance of the Zio service depends upon maintaining strong working relationships with physicians.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, marketing, and sale of the Zio service depends upon our ability to maintain strong working relationships with physicians and other key opinion leaders. We rely on these professionals&#8217; knowledge and experience for the development, marketing and sale of our products. Among other things, physicians assist us in clinical trials and product development matters and provide public presentations at trade conferences regarding the Zio service. If we cannot maintain our strong working relationships with these professionals and continue to receive their advice and input, the development and marketing of the Zio service could suffer, which could harm our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry&#8217;s relationship with physicians is under increasing scrutiny by the Health and Human Services Office of the Inspector General, (&#8220;OIG&#8221;), the Department of Justice (&#8220;DOJ&#8221;), state attorneys general, and other foreign and domestic government agencies. Our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general or other government agencies, could significantly harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $21.4 million outstanding under our term loan provided by of our loan agreement with Silicon Valley Bank (&#8220;SVB&#8221;). We must make significant annual debt payments under the loan agreement which will divert resources from other activities. Our debt with SVB is collateralized by substantially all of our assets and contains customary financial and operating covenants limiting our ability to, among other things, dispose of assets, undergo a change in control, merge or consolidate, enter into certain transactions with affiliates, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The covenants in the loan agreement, as well as in any future financing agreements into which we may enter, may restrict our ability to finance our operations and engage in, expand or otherwise pursue our business activities and strategies. Our ability to comply with these covenants may be affected by events beyond our control and future breaches of any of these covenants could result in a default under the loan agreement. If not waived, future defaults could cause all of the outstanding indebtedness under the loan agreement to become immediately due and payable and terminate commitments to extend further credit. If we do not have or are unable to generate sufficient cash available to repay our debt obligations when they become due and payable, either upon maturity or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our ability to operate and continue our business as a going concern.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates. Our policy is to manage interest costs using the mix of fixed- and floating-rate debt, which we cannot guarantee will mitigate the risk of interest rate fluctuation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience inflationary pressures, caused by the COVID-19 pandemic or as a result of general macroeconomic factors, which could increase our manufacturing costs and operating expenses and have a material adverse impact on our  results of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously monitor the effects of inflationary factors, such as increases in our cost of goods sold and selling and operating expenses, which may adversely affect our results of operations. Specifically, may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages that we pay our employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict our ability to fully recover these costs through price increases.  As a result, it may be difficult to fully offset the impact of persistent inflation. Our inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have recently experienced management turnover, which creates uncertainties and could harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant changes in our executive leadership in the past twenty four months. In September 2021, we announced the appointment of Quentin S. Blackford as our President and Chief Executive Officer, effective October 4, 2021. In June 2021, our former Chief Executive Officer, Michael J. Coyle, announced he was resigning and our Chief Financial Officer, Douglas J. Devine, assumed the position of Interim Chief Executive Officer. In December 2020, our prior Chief Executive Officer, Kevin M. King, announced his retirement as our Chief Executive Officer. In June 2020, our Chief Financial Officer, Matthew C. Garrett, announced that he was resigning for personal reasons and in March 2020, our Chief Operating Officer, Karim Karti, resigned. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to strategic or operating goals, which can often times occur with the appointment of new executives, can create uncertainty, may negatively impact our ability to execute quickly and effectively, and may ultimately be unsuccessful. In addition, executive leadership transition periods are often difficult as the new executives gain detailed knowledge of our operations, and friction can result from changes in strategy and management style. Management turnover inherently causes some loss of institutional knowledge, which can negatively affect strategy and execution. If we do not integrate new executives successfully, we may be unable to manage and grow our business, and our financial condition and profitability may suffer as a result. In addition, to the extent we experience additional management turnover, competition for top management is high and it may take months to find a candidate that meets our requirements. If we are unable to attract and retain qualified management personnel, our business could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends largely on the continued services of key members of our executive management team and others in key management positions. For example, the services of Quentin S. Blackford, our President and Chief Executive Officer, and Douglas J. Devine, our Chief Financial Officer and Chief Operating Officer, are essential to formulating and executing on corporate strategy and to ensuring the continued operations and integrity of financial reporting within our company. In addition, the services provided by David A. Vort, our Executive Vice President of Sales, are critical to the growth that we have experienced in the sales of our Zio service. The services of Patrick Murphy, our General Counsel, are critical for managing our legal and compliance functions. The services of Mark Day, our Executive Vice President of Research and Development are critical for managing our research and development programs. Our employees may terminate their employment with us at any time. If we lose one or more key employees, we may experience difficulties in competing effectively, developing our technologies and implementing our business strategy. We do not currently maintain key person life insurance policies on these or any of our employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our research and development programs and clinical operations depend on our ability to attract and retain highly skilled engineers and certified cardiographic technicians. We may not be able to attract or retain qualified engineers and certified cardiographic technicians in the future due to the competition for qualified personnel. We have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies with which we compete for experienced personnel have greater resources than us. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees, particularly in the San Francisco Bay Area, often consider the value of the stock awards they receive in connection with their employment. If the perceived value of our stock awards declines, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to market, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes international expansion. Doing business internationally involves a number of risks, including:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">multiple, conflicting and changing laws and regulations such as tax laws, privacy laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining and sustaining regulatory approvals, certifications, and regulatory compliance where required for the sale of our products and services in various countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to maintain data and the processing of that data on servers located within such countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">logistics and regulations associated with shipping and returning our Zio monitors following use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limits on our ability to penetrate international markets if we are required to process the Zio service locally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the effect of local and regional financial pressures on demand and payment for our products and services and exposure to foreign currency exchange rate fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of disease, boycotts, curtailment of trade and other market restrictions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the United States Foreign Corrupt Practices Act of 1977 (&#8220;FCPA&#8221;), U.K. Bribery Act of 2010 and comparable laws and regulations in other countries; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance risks associated with General Data Protection Regulation (&#8220;GDPR&#8221;) enacted to protect the privacy of all individuals in the European Union and addresses export of the data outside of the European Union.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with business partners in new international markets may subject us to an increased risk of litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our business internationally, if we cannot successfully manage the unique challenges presented by international markets and our relationships with new business partners within those markets, our expansion activities may be adversely affected and we may become subject to an increased risk of litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in disputes relating to our products, contracts and business relationships. Such disputes include litigation against persons whom we believe have infringed on our intellectual property, infringement litigation filed against us, litigation against a competitor or litigation filed against us by distributors or service providers resulting from a breach of contract or other claim. Any of these disputes may result in substantial costs to us, judgments, settlements and diversion of our management&#8217;s attention, which could adversely affect our business, financial condition or operating results. There is also a risk of adverse judgments, as the outcome of litigation in foreign jurisdictions can be inherently uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be adversely affected by violations of the FCPA, and similar worldwide anti-bribery laws which could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from corruptly providing any benefits to government officials for the purpose of obtaining or retaining business. We are in the process of designing and implementing policies and procedures intended to help ensure compliance with these laws. In the future, we may operate in parts of the world that have experienced governmental corruption to some degree. We cannot assure you that our internal control policies and procedures will protect us from improper acts committed by our employees or agents. Violations of these laws, or allegations of such violations, could disrupt our business and have a material adverse effect on our business and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the DOJ or other governmental agencies could impose a broad range of civil and criminal sanctions under the FCPA and other laws and regulations including, but not limited to, injunctive relief, disgorgement, fines, penalties, modifications to business practices including the termination or modification of existing business relationships, the imposition of compliance programs and the retention of a monitor to oversee compliance with the FCPA. The imposition of any of these sanctions or remedial measures could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our proprietary data analytics engine may not operate properly, which could damage our reputation, give rise to claims against us or divert application of our resources from other purposes, any of which could harm our business and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ECG data that is gathered through our Zio monitors is curated by algorithms that are part of our Zio service and a Zio report is delivered to the prescribing physician for diagnosis. The continuous development, maintenance and operation of our deep-learned backend data analytics engine is expensive and complex, and may involve unforeseen difficulties including material performance problems, undetected defects or errors. We may encounter technical obstacles, and it is possible that we may discover additional problems that prevent our proprietary algorithms from operating properly. We may also attempt to develop new capabilities and incorporate new technologies, including artificial intelligence, which could impact our data analytics platform&#8217;s performance. If our data analytics platform does not function reliably or fails to meet physician or payor expectations in terms of performance, physicians may stop prescribing the Zio service and payors could attempt to cancel their contracts with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any unforeseen difficulties we encounter in our existing or new software, cloud-based applications, telecommunication service providers, and analytics services, and any failure by us to identify and address them could result in loss of revenue or market share, diversion of development resources, injury to our reputation and increased service and maintenance costs. Correction of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defects or errors could prove to be impossible or impracticable. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision of the Zio service is dependent upon third-party vendors who are subject to disruptions, which could directly or indirectly harm our business and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis we perform to create the diagnostic report for the Zio service is dependent upon a recording made by each device, which requires the physical return of the Zio monitor to one of our clinical centers. We predominantly rely on the U.S. Postal Service (&#8220;USPS&#8221;) to perform this delivery service. Delivery of the Zio monitor to one of our clinical centers may be subject to disruption by natural disasters such as earthquake or flooding, labor disagreements or errors on behalf of USPS staff, operational and funding reductions negatively impacting USPS service capabilities, structural issues timely processing in some geographies, or other disruption to the USPS delivery infrastructure. Further, for the Zio AT monitor, we rely on the provision of cellular communication services for the timely transmission of patient information and reportable events. Once received, all data from both Zio XT and AT monitors is processed, curated and reported on through cloud-computing resources. The reliability of these communication and cloud services is also subject to natural disasters, labor disruptions, human error, and infrastructure failure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these disruptions may render it difficult or temporarily impossible for us to provide some or all of the Zio service, adversely affecting our operating results, causing significant distraction for management, and negatively impacting our business reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or patients, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party billing and collections provider, XIFIN, collect, process, and store sensitive data, including legally-protected personally identifiable health information about patients in the United States and in the United Kingdom. This personally identifiable information may include, among other information, names, addresses, phone numbers, email addresses, insurance account information, age, gender, and heart rate data. We also process and store, and use additional third parties to process and store, sensitive intellectual property and other proprietary business information, including that of our customers, payors and collaborative partners. Our patient information is encrypted but not de-identified. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data center systems and cloud-based computing center systems. These applications and data encompass a wide variety of business critical information, including research and development information, commercial information and business and financial information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent on information technology networks and systems, including the internet and services hosted by Amazon Web Services and other third party service providers, to securely process, transmit and store this critical information. Security breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, can create system disruptions, shutdowns, or unauthorized disclosure or modifications of confidential information involving patient health information to become publicly available. The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information, including executing Business Associates Agreements with applicable vendors. Although we take measures to protect sensitive information from unauthorized access or disclosure, cyber-attacks are becoming more sophisticated and frequent, and our information technology and infrastructure, and that of XIFIN and other third parties we utilize to process or store data, may be vulnerable to viruses and worms, phishing attacks, denial-of-service attacks, physical or electronic break-ins, attacks by hackers, breaches due to employee error, malfeasance, or misuse, or similar disruptions from unauthorized tampering. We have in the past been subject to cyber-attacks and data breaches and expect that we will be subject to additional cyber-attacks in the future and may experience future data breaches. While we have implemented data privacy and security measures that we believe are compliant with applicable privacy laws and regulations, some confidential and protected health information, is transmitted to us by third parties, who may not implement adequate security and privacy measures. Further, if third party service providers that process or store data on our behalf experience security breaches or violate applicable laws, agreements, or our policies, such events may also put our information at risk and could in turn have an adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including protected health information, could harm our reputation, compel us to comply with disparate state breach notification laws, require us to verify the correctness of database contents and otherwise subject us to liability under laws that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in a timely manner, the market perception of the effectiveness of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security measures could be harmed, our operations could be disrupted, our brand could be adversely affected, demand for our products and services may decrease, we may be unable to provide the Zio service, we may lose sales and customers, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. We may be required to expend significant capital and financial resources to invest in security measures, protect against such threats or to alleviate problems caused by breaches in security. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm. Although we have invested in our systems and the protection of our data to reduce the risk of an intrusion or interruption, and we monitor our systems on an ongoing basis for any current or potential threats, we can give no assurances that these measures and efforts will prevent all intrusions, interruptions, or breakdowns.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because techniques used to obtain unauthorized access or to sabotage systems change frequently and generally are not recognized until launched, we may be unable to anticipate these techniques or to implement adequate preventive measures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that patients or physicians authorize or enable third parties to access their data on our systems, we cannot ensure the complete integrity or security of such data in our systems as we would not control that access. Third parties may also attempt to fraudulently induce our employees, or patients or physicians who use our technology, into disclosing sensitive information such as user names, passwords or other information. Third parties may also otherwise compromise our security measures in order to gain unauthorized access to the information we store. This could result in significant legal and financial exposure, a loss in confidence in the security of our service, interruptions or malfunctions in our service, and, ultimately, harm to our future business prospects and revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such breach or interruption of our systems, or those of XIFIN or any of our third party information technology partners, could compromise our networks or data security processes and sensitive information could be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption in access, improper access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of patient information, such as the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), the General Data Protection Regulation, and the European Union Data Protection Directive, and regulatory penalties. Regardless of the merits of any such claim or proceeding, defending it could be costly and divert management&#8217;s attention from leading our business. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to perform our services, bill payors or patients, process claims and appeals, provide customer assistance services, conduct research and development activities, collect, process and prepare company financial information, provide information about our current and future solutions and engage in other patient and clinician education and outreach efforts. Any such breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our business and competitive position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to or acquisition of our user data, we may also have obligations to notify users about the incident and we may need to provide some form of remedy for the individuals affected by the incident. A growing number of legislative and regulatory bodies have adopted consumer notification requirements in the event of unauthorized access to or acquisition of certain types of personal data. Such breach notification laws continue to evolve and may be inconsistent from one jurisdiction to another. Complying with these obligations could cause us to incur substantial costs and could increase negative publicity surrounding any incident that compromises user data. In addition, the interpretation and application of consumer, health-related and data protection laws, rules and regulations in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws, rules and regulations may be interpreted and applied in a manner that is inconsistent with our practices or those of our distributors and partners. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business. In addition, California recently enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which became effective on January 1, 2020, and will, among other things, require new disclosures to California consumers and afford such consumers new abilities to opt out of certain sales of personal information. It remains unclear how various provisions of the CCPA will be interpreted and enforced. The effects of the CCPA are potentially significant and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply with this legislation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use, misuse or off-label use of the Zio service may result in injuries that lead to product liability suits, which could be costly to our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use, misuse or off-label use of the Zio service may in the future result in outcomes and complications potentially leading to product liability claims. For example, we are aware that physicians have prescribed the Zio service off-label for pediatric patients. We have also received and may in the future receive product liability or other claims with respect to the Zio service, including claims related to skin irritation and alleged burns. In addition, if the Zio monitor is defectively designed, manufactured or labeled, contains defective components or is misused, we may become subject to costly litigation initiated by physicians, or the hospitals and clinics where physicians prescribing our Zio service work, or their patients. Product liability claims are especially prevalent in the medical device industry and could harm our reputation, divert management&#8217;s attention from our core business, be expensive to defend and may result in sizable damage awards against us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance, we may not have sufficient insurance coverage for future product liability claims. We may not be able to obtain insurance in amounts or scope sufficient to provide us with adequate coverage against all potential liabilities. Any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation, significantly increase our expenses, and reduce product sales. Product liability claims in excess of our insurance coverage would be paid out of cash reserves, harming our financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not increase at similar rates, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our forecasts relating to, among other things, the expected growth in the ambulatory cardiac monitoring solutions market may prove to be inaccurate.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth is subject to many factors, including whether the market for first-line ambulatory cardiac monitoring solutions continues to improve, the rate of market acceptance of the Zio service as compared to the products of our competitors and our success in implementing our business strategies, each of which is subject to many risks and uncertainties. If our Zio service works as anticipated to provide a correct first-line diagnosis, it may lead to a decrease in the amount of ambulatory cardiac monitoring prescriptions each year in the United States. This outcome would result if our Zio service is proven to produce the right diagnosis the first time, thereby reducing the need for additional testing. Accordingly, our forecasts of market opportunity should not be taken as indicative of our future growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other companies or technologies, or enter into joint ventures or other strategic alliances, which could divert our management&#8217;s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our ambulatory cardiac monitoring solutions portfolio, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment. In addition, any of these transactions could be material to our financial condition and operating results and expose us to many risks, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disruption in our relationships with existing strategic partners or suppliers as a result of such a transaction;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unanticipated liabilities related to acquired companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">retention of key employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">increases in our expenses and reductions in our cash available for operations and other uses; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible write-offs or impairment charges relating to acquired businesses; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">possible compliance, regulatory, or product issues.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the growth of our operations has been largely organic, and we have limited experience in acquiring other businesses or technologies or entering into joint ventures or strategic alliances. Acquisitions, joint ventures or strategic alliances could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business, joint venture or strategic alliance fails to materialize or fails to meet our expectations, our operating results, business and financial condition may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation of commercial payors could result in payors eliminating coverage or reducing reimbursement rates for our Zio service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When payors combine their operations, the combined company may elect to reimburse our Zio service at the lowest rate paid by any of the participants in the consolidation or use its increased size to negotiate reduced rates. If one of the payors participating in the consolidation does not reimburse for the Zio service at all, the combined company may elect not to reimburse for the Zio service, which would adversely impact our operating results. While attempts by Aetna Inc. to acquire Humana Inc. and Anthem Inc. to acquire Cigna Corp. have been largely abandoned due to antitrust challenges by the DOJ, it is possible that these or other payor consolidations may occur in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryovers may be limited.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of $464.3 million and $279.1 million, respectively, which if not utilized will begin to expire in 2027 for federal purposes and have begun expiring for state purposes. We may use these NOLs to offset against taxable income for U.S. federal and state income tax purposes. However, Section 382 of the Internal Revenue Code, as amended, may limit the NOLs we may use in any year for U.S. federal income tax purposes in the event of certain changes in ownership of our company. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. Future issuances or sales of our stock, including certain transactions involving our stock that are outside of our control, could cause an &#8220;ownership change.&#8221; If an &#8220;ownership change&#8221; has occurred in the past or occurs in the future, Section 382 would impose an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused. Any limitation on using NOLs could, depending on the extent of such limitation and the NOLs previously used, result in our retaining less cash after payment of U.S. federal and state income taxes during any year in which we have taxable income, rather than losses, than we would be entitled to retain if such NOLs were available as an offset against such income for U.S. federal and state income tax reporting purposes, which could adversely impact our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting which could, if not remediated, result in material misstatements in our financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act. As disclosed in Item 9A of this Annual Report on Form 10-K, we identified a material weakness in our internal control over financial reporting. A material weakness is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As a result of this material weakness, we concluded that our internal control over financial reporting was not effective based on criteria set forth by the Committee of Sponsoring Organization of the Treadway Commission in Internal Control-An Integrated Framework (2013).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To implement remedial measures as disclosed in Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 26, 2021, we committed additional resources, hired additional staff, and provided additional management oversight. If our remedial measures are insufficient to address the material weaknesses, or if additional material weaknesses or significant deficiencies in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate the material weakness that continues to exist and if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to provide the Zio service.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that U.S. and foreign patents and pending patent applications or trademarks controlled by third parties, especially those held by our competitors, may be alleged to cover our products or services, or that we may be accused of misappropriating third parties&#8217; trade secrets. Additionally, our products include hardware and software components that we purchase from vendors, and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products and services or to use product names. Moreover, in recent years, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; have purchased patents or otherwise obtained rights to other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. The defense of these matters can be time-consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand, and cause us to incur significant expenses or make substantial payments to satisfy judgments or settle claims. Vendors from which we purchase hardware or software may not indemnify or defend us in the event that such hardware or software is accused of infringing a third-party&#8217;s patent or trademark or of misappropriating a third-party&#8217;s trade secrets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if such patents, trademarks, or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling our products, license fees, damages and the payment of attorney&#8217;s fees and court costs. In addition, if we are found to have willfully infringed third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device and services area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses on satisfactory terms, if at all. If we do not obtain necessary licenses, we may not be able to redesign our Zio monitors or our Zio service to avoid infringement and our product development efforts may be negatively affected as a result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) may be necessary to determine priority with respect to our patents, patent applications, trademarks or trademark applications. We may also become involved in other proceedings, such as reexamination, inter partes review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent us from manufacturing the Zio monitors and selling the Zio service or using product names, which would have a significant adverse impact on our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, we may need to commence proceedings against others to enforce our patents or trademarks, to protect our trade secrets or know how, or to determine the enforceability, scope and validity of the proprietary rights of others. These proceedings would result in substantial expense to us and significant diversion of effort by our technical and management personnel. We may not prevail in any lawsuits that we initiate, a scenario that could also result in the invalidation of our asserted patents, and the damages or other remedies awarded, if any, may not be commercially meaningful. We may not be able to stop a competitor from marketing and selling products that are the same or similar to our products and services or from using product or service names that are the same or similar to ours, and our business may be harmed as a result.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use certain open source software in the infrastructure supporting the Zio service. Licensees of open source software may be required to make public and use certain source code, to license proprietary software for free or to make certain derivative works available to others. As a result, we may face claims from companies that incorporate open source software into their products or from open source licensors, claiming ownership of, or demanding release of, the source code, the open source software or derivative works that were developed using such software, or otherwise seeking to enforce the terms of the applicable open source license. These claims could result in litigation and could require us to cease offering the Zio service unless and until we can re-engineer it to avoid infringement. This re-engineering process could require significant additional research and development resources, and we may not be able to complete it successfully. While we monitor and control the use of open source software in the Zio service and in any third party software that is incorporated into the Zio service, and we try to ensure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that no open source software is used in such a way as to require us to disclose the source code underlying the Zio service, there can be no guarantee that such use could not inadvertently occur. These risks could be difficult to eliminate or manage, and, if not addressed, could harm our business, intellectual property protection, financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights may not provide adequate protection, which may permit third parties to compete against us more effectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to remain competitive, we must develop and maintain protection of the proprietary aspects of our technologies. We rely on a combination of patents, copyrights, trademarks, trade secret laws and confidentiality and invention assignment agreements with employees and third parties to protect our intellectual property rights. As of December 31, 2021, we owned, or retained exclusive license to, twenty-three issued U.S. patents, the earliest of which will expire in 2028. As of December 31, 2021, we also owned, or retained an exclusive license to, eight issued patents from the Japanese Patent Office, two issued patents from the Australian Patent Office, four issued patents from the Canadian Patent Office, five issued patents from the European Patent Office, three issued patents from the Korean Patent Office, and one issued patent from the Chinese Patent Office. The earliest expiration date of these international patents is 2027. As of December 31, 2021, we had twenty-six pending patent applications globally, including twelve in the United States, three in the European Patent Office, four in Japan, three Patent Cooperation Treaty (&#8220;PCT&#8221;) international applications, and one in each of Australia, Korea, China and India. Our patents and patent applications are directed to covering key aspects of the design, manufacture and use of the Zio monitor and the Zio service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on our ability to obtain and maintain patent protection for our proprietary products and processes. The process of applying for and obtaining a patent is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. In addition, the issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. Our patent applications may not result in issued patents and our patents may not be sufficiently broad to protect our technology. Issued international patents may carry a requirement to &#8220;work&#8221; a patent in the applicable geography; failure to do so could lead to loss of the patent or the requirement to accept licensing terms, both of which would be favorable to our competitors. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own products and practicing our own technology. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid or unenforceable; competitors may then be able to market products and use manufacturing and analytical processes that are substantially similar to ours. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Litigation is time-consuming and expensive and would divert our resources.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets and other proprietary information, our business and competitive position may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely heavily on trade secrets as well as invention assignment and confidentiality provisions that we have in contracts with our employees, consultants, collaborators and others to protect our algorithms and other aspects of our Zio service. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by consultants, vendors or former or current employees, despite the existence generally of these confidentiality agreements and other contractual restrictions. These agreements may not provide meaningful protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurance that employees, consultants, vendors and clients have executed such agreements or have not breached or will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be adequate. In addition, the laws of many foreign countries will not protect our intellectual property rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited abroad, which could affect our ability to expand to international markets or require costly efforts to protect our technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also employ individuals who were previously or are concurrently employed at research institutions or other medical device companies, including our competitors or potential competitors. We may be subject to claims that these employees, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former or concurrent employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our products, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our intellectual property protection is incomplete, we are exposed to a greater risk of direct competition. A third party could, without authorization, copy or otherwise obtain and use our products or technology, or develop similar technology. Our competitors could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our Zio service, brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our products and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information. Any of the foregoing could materially and adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets, and agreement terms that address non-competition are difficult to enforce in many jurisdictions, and might not be enforceable in certain cases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trademarks, service marks, trade names and brand names, such as our registered trademark &#8220;ZIO,&#8221; to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and in proceedings before comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands. Further, we cannot assure you that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. Additionally, we are aware of at least one third party that has registered the &#8220;IRHYTHM&#8221; mark in the European Union in connection with computer software for controlling and managing patient medical information, heart rate monitors, and heart rate monitors to be worn during moderate exercise, among other uses. We and the third party are involved in adversary proceedings before the Trademark Office in the European Union, and those proceedings could impact our ability to obtain a European Union trade mark registration for the &#8220;IRHYTHM&#8221; mark, although we already own many national registrations for IRHYTHM in Europe.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (&#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO, administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. Under the new post grant provisions of the Leahy-Smith Act, the USPTO introduced procedures that provide additional administrative pathways for third parties to challenge issued patents. Inter partes review (&#8220;IPR&#8221;) is one of these procedures. The number of IPR challenges filed is increasing, and in many cases, the USPTO is canceling or significantly narrowing issued patent claims. Accordingly, even if a patent is granted by the USPTO, there is risk that it may not withstand an IPR challenge. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent case law has increased uncertainty regarding the availability of patent protection for certain technologies and the costs associated with obtaining patent protection for those technologies. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In particular, the 2014 decision by the U.S. Supreme Court in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alice Corp. v. CLS Bank International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has increased the difficulty of obtaining new software patents and enforcing existing software patents. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the regulatory environment may constrain or require us to restructure our operations, which may harm our revenue and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare laws and regulations change frequently and may change significantly in the future. We may not be able to adapt our operations to address every new regulation, and new regulations may adversely affect our business. We cannot assure you that a review of our business by courts or regulatory authorities would not result in a determination that adversely affects our revenue and operating results, or that the healthcare regulatory environment will not change in a way that restricts our operations. In addition, there is risk that the U.S. Congress may implement changes in laws and regulations governing healthcare service providers, including measures to control costs, or reductions in reimbursement levels, which may adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payors, such as CMS, as well as insurers, have increased their efforts to control the cost, utilization and delivery of healthcare services. From time to time, the U.S. Congress has considered and implemented changes in the CMS fee schedules in conjunction with budgetary legislation. Further reductions of reimbursement by CMS for services or changes in policy regarding coverage of tests or other requirements for payment, such as prior authorization or a physician or qualified practitioner&#8217;s signature on test requisitions, may be implemented from time to time. Reductions in the reimbursement rates and changes in payment policies of other third-party payors may occur as well. Similar changes in the past have resulted in reduced payments as well as added costs and have added more complex regulatory and administrative requirements. For example, on January 29, 2021, Novitas Solutions, a MAC that we, physicians and hospitals rely on to process Medicare reimbursement claims related to our Zio service recently published reimbursement rates that were considerably lower than those than expected. On January 10, 2022, Novitas Solutions published rates for 2022 that were retroactive to the January 1, 2022 and replaced the rates that it had published in 2021. These revised rates were higher that the rates posted in 2021, but continue to be significantly below the historical Medicare rates for our Zio XT service. Further changes in federal, state, local and third-party payor </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations or policies may have a material adverse impact on our business. Actions by agencies regulating insurance or changes in other laws, regulations, or policies may also have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with healthcare and other governmental regulations, we could face substantial penalties and our business, results of operations and financial condition could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products and services we offer are highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely in the future. Our arrangements with physicians, hospitals and clinics may expose us to broadly applicable fraud and abuse and other laws and regulations that may restrict the financial arrangements and relationships through which we market, sell and distribute our products and services. Our employees, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements. Federal and state healthcare laws and regulations that may affect our ability to conduct business, include, without limitation:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws and regulations regarding billing and claims payment applicable to our Zio service and regulatory agencies enforcing those laws and regulations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the CMS programs;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FCPA, the U.K. Bribery Act of 2010, and other local anti-corruption laws that apply to our international activities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, or Open Payments, created under the Affordable Care Act, and its implementing regulations, which requires manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services, information related to payments or other transfers of value made to licensed physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; HIPAA also created criminal liability for knowingly and willfully falsifying or concealing a material fact or making a materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the GDPR, which replaces the 1995 Data Protection Directive known as Directive 95/46/EC;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician self-referral prohibition, commonly known as the Stark Law;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s Code of Federal Regulations, including but not limited to, 21 CFR Parts 820, 803, 806, and 801 that outlines requirements for medical device design, manufacturing, labeling, distribution, and post-market surveillance requirements; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the European Union&#8217;s Medical Device Directives and Medical Device Regulations (&#8220;MDR&#8221;) that outline requirements for medical device CE marking; and </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Affordable Care Act was enacted in 2010. The Affordable Care Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our activities could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. We may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments, with potential liability under the federal False Claims Act including mandatory treble damages and significant per-claim penalties, which were increased to $11,665 to $23,331 per false claim in 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have adopted policies and procedures designed to comply with these laws and regulations and conduct internal reviews of our compliance with these laws, our compliance is also subject to governmental review. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. The risk of our being found in violation of these or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant criminal, civil, and administrative penalties, damages, fines, imprisonment, for individuals, exclusion from participation in government programs, such as Medicare and Medicaid, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain and maintain necessary regulatory clearances or approvals for the Zio monitors and Zio service, or if clearances or approvals for future products and indications are delayed or not issued, our commercial operations would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Zio monitors, including the associated software and algorithm, and the Zio service are subject to extensive regulation by the FDA in the United States, by the Competent Authorities in the European Union and the United Kingdom. Such regulations are wide ranging and govern, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product design, development, manufacture, and release;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">laboratory, preclinical and clinical testing, labeling, packaging, storage and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">premarketing clearance or approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">service operations</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">record keeping;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product marketing, promotion and advertising, sales and distribution; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">post-market surveillance, including reporting of deaths or serious injuries and certain categories of field correction and removals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before a new medical device or service, or a new intended use for an existing product or service, can be marketed in the United States, a company must first submit and receive either 510(k) clearance or premarketing approval from the FDA, unless an exemption applies. Either process can be expensive, lengthy and unpredictable. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Although we have obtained 510(k) clearance to market the Zio monitors and the Zio service (Software as a Medical Device elements), our clearance can be revoked if safety, efficacy, or significant regulatory compliance problems develop.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to file various reports with the FDA, and European or U.K. regulators, including reports required by the medical device reporting regulations that require that we report to the regulatory authorities if our Zio service may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serious injury if the malfunction were to recur. If these reports are not filed in a timely manner, regulators may impose sanctions and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we initiate a correction or removal for our Zio service to reduce a risk to health posed by the Zio service, we would be required to submit a publicly available Correction and Removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall which could lead to increased scrutiny by the FDA, other international regulatory agencies and our customers regarding the quality and safety of our Zio service. Furthermore, the submission of these reports are public and could be used by competitors against us and cause physicians to delay or cancel prescriptions, which could harm our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we assess a potential quality issue or complaint as not requiring either field action or notification, respectively, regulators may review documentation of that decision during a subsequent audit. If regulators disagree with our decision, or take issue with either our investigation process or the resulting documentation, regulatory agencies may impose sanctions and we may be subject to regulatory enforcement actions, including warning letters, all of which could harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the Federal Trade Commission (&#8220;FTC&#8221;) also regulate the advertising and promotion of our products and services to ensure that the claims we make are consistent with our regulatory clearances, that there is adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading. If the FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Similar to the FDA and FTC, the European Union under the Medical Device Regulations has similar requirements and enforcement action regarding promotional material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and state and international authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">repair, replacement, refunds, recall or seizure of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">operating restrictions, partial suspension or total shutdown of either production, distribution or service operation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">denial of our requests for regulatory clearance or premarket approval of new products or services, new intended uses or modifications to existing products or services;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of regulatory clearance or premarket approvals that have already been granted; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">criminal prosecution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, our business and financial condition could be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material modifications to the Zio monitors, labelling of the Zio monitors, or Zio service may require new 510(k) clearances, CE Mark or other premarket approvals or may require us to recall or cease marketing our products and services until clearances are obtained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Material modifications to the intended use or technological characteristics of the Zio monitors or Zio service will require new 510(k) clearances, premarket approvals or CE Mark certification, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Based on FDA published guidelines, the FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new clearance or approval; however, the FDA can review a manufacturer&#8217;s decision. Any modification to an FDA cleared device or service that would significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new 510(k) clearance or possibly a premarket approval. We may not be able to obtain additional 510(k) clearances or premarket approvals for new products or for modifications to, or additional indications for, the Zio monitors or Zio service in a timely fashion, or at all. Delays in obtaining required future clearances would harm our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. We have made modifications to the Zio monitors and Zio service in the past that we believe do not require additional clearances or approvals, and we may make additional modifications in the future. If the FDA or a Notified Body disagrees and requires new clearances or approvals for any of these modifications, we may be required to recall and to stop selling or marketing the Zio monitors and Zio service as modified, which could harm our operating results and require us to redesign our products or services. In these circumstances, we may be subject to significant enforcement actions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our suppliers fail to comply with the FDA&#8217;s QSR or the European Union&#8217;s Medical Device Directive and Medical Device Regulations, or United Kingdom&#8217;s Medical Device Regulations, our manufacturing or distribution operations could be delayed or shut down and our revenue could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and design processes and those of our third-party suppliers are required to comply with the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) and the EU&#8217;s Medical Device Directive (&#8220;MDD&#8221;), through May 2021, after which time compliance with the MDR transitional provisions will be required until full transition to MDR compliance is achieved. Additionally, the UK will require the UKCA marking per new policies released by MHRA. All of these regulations cover procedures and documentation requirements for the design, testing, production, control, quality assurance, labeling, packaging, storage, shipping, and post-market surveillance of Zio monitors and associated software. We are also subject to similar state requirements and licenses, and to ongoing ISO 13485:2016 compliance in all operations to maintain our CE Mark. In addition, we must engage in extensive recordkeeping and reporting and must make available our facilities and records for periodic unannounced inspections by governmental agencies, including the FDA, state authorities, Notified Bodies and comparable agencies in other countries. If we perform poorly in a regulatory inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse regulatory inspection could result in, among other things, a shutdown of our manufacturing or product distribution operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our device, operating restrictions, warning letters, and criminal prosecutions, any of which would cause our business to suffer. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our product and cause our revenue to decline.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are registered with the FDA as a medical device specifications developer and manufacturer. The FDA has broad post-market and regulatory enforcement powers. We are subject to announced or unannounced inspections by the FDA and the Food and Drug Branch of the California Department of Public Health (&#8220;CDPH&#8221;) to determine our compliance with the QSR and other regulations at both our design and manufacturing facilities, and these inspections may include the manufacturing facilities of our suppliers. The most recent FDA inspection of our manufacturing facility occurred in October 2021 and no FDA Form 483 observations were issued. The FDA also performed a Remote Regulatory Assessment (&#8220;RRA&#8221;) of our design facilities in San Francisco, California, which concluded in May 2021. Unlike on-site inspections, the FDA does not issue formal 483 observations at the conclusion of RRAs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also registered with the EU as a medical device developer, manufacturer, distributor, and service operator through the National Standard Authority of Ireland (&#8220;NSAI&#8221;) our European Notified Body. Most recently, the NSAI completed an ISO 13485 surveillance audit of our design, manufacturing and service operations in May 2021 and a renewal of our ISO 13485 certification was issued in August 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can provide no assurance that we will continue to remain in compliance with the QSR or MDD, MDR, or UK MDR. If the FDA, CDPH, NSAI, or other EU or UK Notified Bodies inspect any of our facilities and discover compliance problems, we may have to cease manufacturing and product distribution until we can take the appropriate remedial steps to correct the audit findings. Taking corrective action may be expensive, time consuming and a distraction for management and if we experience a delay at our manufacturing facility we may be unable to produce Zio monitors, which would harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zio monitors may in the future be subject to product recalls that could harm our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar governmental authorities in other countries have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or device defects. A government mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors, design issues, labeling issues, or various regulatory compliance topics. Recalls of Zio monitors and associated software would divert managerial attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations. A recall announcement would also negatively affect our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent the Zio service&#8217;s commercial success.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that could harm our future revenues and profitability and the demand for the Zio service. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs. We face uncertainties that might result from modifications or repeal of any of the provisions of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Affordable Care Act, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the Affordable Care Act are likely to have an impact on our results of operations, and may have a material adverse effect on our results of operations. We cannot predict what other health care programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to set a price that we believe is fair for our Zio service;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to generate revenue and achieve or maintain profitability; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the availability of capital.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with environmental laws and regulations could be expensive, and failure to comply with these laws and regulations could subject us to significant liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing operations may involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Exposure to United Kingdom political developments, including the outcome of its withdrawal from membership in the European Union, could be costly and difficult to comply with and could seriously harm our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based a significant portion of our non-U.S. operations in the United Kingdom. In June 2016, a referendum was held in the U.K. which resulted in a majority voting in favor of the U.K. withdrawing from the E.U. (commonly referred to as "Brexit"). Pursuant to legislation approved by the U.K. Parliament and the E.U. Parliament in January 2020, the U.K. withdrew from the E.U. with effect from 11 p.m. (GMT) on January 31, 2020 on the terms of a withdrawal agreement agreed between the U.K. and the E.U. in October 2019. On December 24, 2020, the U.K. and E.U. agreed to a trade deal (the &#8220;Trade and Cooperation Agreement&#8221;) which was ratified by the U.K. on December 30, 2020. The Trade and Cooperation Agreement is subject to formal approval by the European Parliament and the Council of the European Union before it comes into effect and has been applied provisionally since January 1, 2021. There are still a number of areas of uncertainty in connection with the future of the U.K. and its relationship with the E.U. and the application and interpretation of the Trade and Cooperation Agreement, and Brexit related matters may take several years to be clarified and resolved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, because a significant proportion of the regulatory framework in the U.K. is currently derived from E.U. directives and regulations, Brexit could result in material changes to the regulatory regime applicable to many of our current operations. Although the Trade and Cooperation Agreement offers U.K. and E.U. companies preferential access to each other&#8217;s markets, ensuring imported goods will be free of tariffs and quotas, economic relations between the U.K. and the E.U. will now be on more restricted terms than existed previously. Therefore, at this time, we cannot predict the impact that the Trade and Cooperation Agreement and any future agreements contemplated under the terms of the Trade and Cooperation Agreement will have on our future business efforts to commercialize our Zio service in the U.K. and E.U. Accordingly, it is possible that new terms of the Trade and Cooperation Agreement may adversely affect our operations and financial results. We are currently in the process of evaluating our own risks and uncertainties to ascertain what financial, trade, regulatory and legal implications the Trade and Cooperation Agreement could have on our operations in the U.K. and otherwise. Finally, uncertainty surrounding Brexit has contributed to recent fluctuations in the U.K. economy as a whole which could experience future disruptions. As a result, Brexit could cause financial and capital markets within and outside the U.K. or the E.U. to constrict, thereby negatively impacting our ability to finance our U. K. operations which could also have an adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of securities could negatively affect our stock price and dilute the ownership interest of our existing investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected future capital requirements may depend on many factors, including expanding our customer base, the expansion of our salesforce, and the timing and extent of spending on the development of our technology to increase our product offerings. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Additionally, new investors could gain rights, preferences and privileges senior to those of existing holders of our common stock. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales or issuances of a substantial amount of securities, or the perception that such sales could occur, may cause a decline in the price of our common stock. Future resales of our common stock by our existing stockholders could cause the market price of our common stock to decline. In addition, the shares of common stock subject to outstanding options and restricted stock units under our 2016 Equity Incentive Plan and our 2016 Employee Stock Purchase Plan and the shares reserved for future issuance under both such plans may become eligible for sale in the public markets in the future, subject to certain legal and control limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may sell shares or other securities in any offering at a price per share that is less than the price per share paid by existing investors, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by existing investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may fluctuate substantially, and you could lose all or part of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may continue to fluctuate substantially in response to, among other things, the risk factors described in this Annual Report on Form 10-K and other factors, many of which are beyond our control, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in analysts&#8217; estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; estimates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the impact or anticipated impact of the COVID-19 pandemic on us;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">periodic fluctuations in our revenue, due in part to the way in which we recognize revenue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors, including deteriorating market conditions due to investor concerns regarding inflation and potential hostilities between Russia and Ukraine;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">changes in reimbursement coverage and rates by current or potential payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">changes in CPT codes or the establishment of new CPT codes applicable to the Zio service;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in operating performance and stock market valuations of other technology companies generally, or those in the medical device industry in particular;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">actual or anticipated changes in regulatory oversight of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the loss of key personnel, including changes in our board of directors and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">legislation or regulation affecting our market;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">lawsuits threatened or filed against us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the announcement of new products or product enhancements by us or our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements related to patents issued to us or our competitors and to litigation; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments in our industry.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our stock price, volume of shares traded, and changes in our market valuations may make our stock less attractive to certain investors. Stockholders may file securities class action litigation following periods of market volatility. Securities litigation, like the current action we are subject to in the District Court for the Northern District of California, could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business, results of operations, financial condition, reputation and cash flows. These factors may materially and adversely affect the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our stock, our stock price and trading volume could decline. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd Frank Act, the listing requirements of The NASDAQ Stock Market and other applicable securities laws, rules and regulations. Compliance with these laws, rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, our management and other personnel divert attention from operational and other business matters to devote substantial time to these public company requirements. In particular, we incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404. We continue to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. We cannot predict or estimate the amount of additional costs we will incur in order to remain compliant with our public company reporting requirements or the timing of such costs. Additional compensation costs and any future equity awards will increase our compensation expense, which will increase our general and administrative expense and could adversely affect our profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, it is more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified executive officers and members of our board of directors, particularly to serve on our audit committee and compensation committee. In addition, compliance with applicable rules and regulations for public companies is generally more expensive than it is for private companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of disclosure of information in this filing and in other filings required of a public company, our business and financial condition is more visible, which could be advantageous to our competitors and other third parties and could result in threatened or actual litigation. If such claims are successful, our business and operating results could be harmed, and even if the claims are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business and operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws, and Delaware law, could discourage a change in control of our company or a change in our management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and bylaws contain provisions that might enable our management to resist a takeover. These provisions include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a classified board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders&#8217; notice;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">allowing stockholders to remove directors only for cause;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a requirement that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limiting the forum to Delaware for certain litigation against us; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president (in the absence of a chief executive officer).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees to us or to our stockholders, (iii) any action asserting a claim against the company or any director or officer of the company arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or bylaws, or (v) any action asserting a claim against us governed by the internal affairs doctrine, in each such case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Our investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Our bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. The enforceability of similar exclusive federal forum provisions in other companies&#8217; organizational documents has been challenged in legal proceedings, and while the Delaware Supreme Court has ruled that this type of exclusive federal forum provision is facially valid under Delaware law, there is uncertainty as to whether other courts would enforce such provisions. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. In addition, our loan agreement with Silicon Valley Bank limits our ability to, among other things, pay dividends or make other distributions or payments on account of our common stock, subject to certain exceptions. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you sell our common stock thereafter.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_22"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_25"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease 117,560 square feet for our corporate headquarters located in San Francisco, California under a   twelve-year lease term, which will expire on August 31, 2031. We also lease 44,616 square feet in Deerfield, Illinois, for our corporate office under a lease agreement which will expire on June 30, 2033. The Deerfield, Illinios lease commenced in January 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease 41,500 square feet for our clinical center in Lincolnshire, Illinois under a lease agreement that expires in July 2022. We also lease 20,276 square feet in Houston, Texas for another clinical center under a lease agreement that expires in October 2027.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease 17,558 square feet for our manufacturing and distribution facilities in Cypress, California under an agreement that expires in September 2022. We also lease 66,983 square feet in Cypress, California for our office and warehouse facilities under a lease agreement which will expire in April 2032. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these facilities are sufficient to meet our current and anticipated future needs.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_28"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we are involved in claims and legal proceedings or investigations, that arise in the ordinary course of business. Such matters could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business.  These matters are subject to many uncertainties and outcomes that are not predictable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that we and our former Chief Executive Officer, Kevin M. King, violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On August 2, 2021, the lead plaintiff filed an amended complaint, and filed a further amended complaint on September 24, 2021. The amended complaint names as defendants, in addition to us and Mr. King, our former Chief Executive Officer, Michael J. Coyle, and current Chief Financial Officer, Douglas J. Devine. The purported class in the amended complaint includes all persons who purchased or acquired our common stock between August 4, 2020 and July 13, 2021, and seeks unspecified damages purportedly sustained by the class.  On October 27, 2021, we filed a motion to dismiss the amended complaint. The motion to dismiss was fully briefed and the Court held a hearing on the motion on February 4, 2022, after which the Court took the matter under submission.  The Court has not yet issued a ruling. We believe the class action to be without merit and plan to vigorously defend ourselves.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 26, 2021, we received a grand jury subpoena from the U.S. Attorney&#8217;s Office for the Northern District of California requesting information related to communications with the Food and Drug Administration and our products. On September 14, 2021, we received a second subpoena requesting additional information. We are cooperating fully and are providing the requested information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Common Stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2022 there were 22 holders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and, accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any filing of iRhythm Technologies, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the total stockholder return of an investment of $100 in cash at market close on December 31, 2016, through December&#160;31, 2021 for (i)&#160;our common stock, (ii)&#160;the NASDAQ Composite Index (U.S.) and (iii)&#160;the NASDAQ Biotechnology Index. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-top:12pt;text-align:center"><img src="irtc-20211231_g14.jpg" alt="irtc-20211231_g14.jpg" style="height:437px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:22.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iRhythm Technologies, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Biotechnology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_40"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved].</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data responsive to Item 6 have not been presented in accordance with amendments to Item 301 of Regulation S-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_43"></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in Item 8 of Part II of this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this Annual Report on Form 10-K entitled &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overvie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">w</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) are to provide users of our consolidated financial statements with the following</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a narrative explanation of the financial statements from the perspective of management that includes our financial condition, results of operations, cash flows, liquidity and certain other factors that may affect future results; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a discussion on matters that are reasonably likely to have a material impact on future operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. Our goal is to be the leading provider of ambulatory electrocardiogram (&#8220;ECG&#8221;) monitoring for patients at risk for arrhythmias. We have created a full portfolio of ambulatory cardiac monitoring services on a unique platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The Zio service consists of:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">wearable patch-based biosensors, Zio XT and Zio AT monitors, which continuously record and store ECG data from every patient heartbeat for up to 14 consecutive days; Zio AT offers the option of timely, detection based transmission of data during the prescribed wear period;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cloud-based analysis of the recorded cardiac rhythms using our proprietary, deep-learned algorithms;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a final quality assessment review of the data by our certified cardiographic technicians; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">an easy-to-read Zio report, a curated summary of findings that includes high quality and clinically-actionable information which is sent directly to a patient&#8217;s physician through ZioSuite and can be integrated into a patient&#8217;s electronic health record.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We receive revenue for the Zio service primarily from third-party payors, which include commercial payors and government agencies, such as CMS, Veterans Administration, and the military. In addition, a small percentage of institutions, which are typically hospitals or private physician practices, purchase the Zio service from us directly. Our revenue in the third-party commercial payor category is primarily contracted, which means we have entered into pricing contracts with these payors. Third-party contracted payors accounted for approximately 60%, 51% and 47% of our revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Approximately 14%, 27% and 27% of our total revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively, is received from Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), which is under established reimbursement codes. Healthcare institutions, which are typically hospitals or private physician practices accounted for approximately 18%, 16% and 20% of our revenue for the years ended December&#160;31, 2021, 2020, and 2019 respectively. Non-contracted third-party payors and self-pay accounted for 8%, 6%, and 5% of our total revenue for the years ended December&#160;31, 2021, 2020, and 2019, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on a third-party billing partner, XIFIN, Inc., to submit patient claims and collect from commercial payors, certain government agencies, and patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our Zio service was cleared by the U.S. Food and Drug Administration (&#8220;FDA&#8221;), we have provided the Zio service to over four million patients and have collected over one billion hours of curated heartbeat data. We believe the Zio service is well-positioned to penetrate an already-established $1.8 billion U.S. ambulatory cardiac monitoring market by offering a user-friendly device to patients, actionable information to physicians and value to payors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our ambulatory cardiac monitoring solution in the United States through a direct sales organization comprised of sales management, field billing specialists, quota-carrying sales representatives, and a customer service team. Our sales representatives focus on initial introduction into new customers, penetration across a sales region, driving adoption within existing accounts and conveying our message of clinical and economic value to service line managers and hospital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrators and other clinical departments. In addition, we will continue exploring sales and marketing expansion opportunities in international geographies.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in mid-March 2020, we experienced decreasing levels in the Zio service patient registrations which impacted our revenues during the years ended December&#160;31, 2021 and 2020. This decrease in revenue is due to a variety of challenges associated with the COVID-19 pandemic in the United States, including, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reduction in physician prescriptions for our Zio service due to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">a reduction in diagnostic testing outside of those tests related to severe respiratory distress;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">reduction in the hours of most physicians&#8217; offices;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">physicians and hospitals prioritizing the treatment of critically ill patients; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">patient reluctance to visit physicians or hospitals for fear of contracting COVID-19;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancellation and reduction of physician attendance at professional medical society meetings and trade shows and our decision not to attend them;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">travel restrictions and changing hospital policies that have limited access of our sales professionals to hospitals where the Zio services are prescribed and where patients have historically been enrolled; </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving Zio XT back from patients with some patients not returning the device at all; and patients who have lost jobs, been furloughed, have reduced work hours or are worried about the continuation of medical insurance being unable to afford the Zio service.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, our personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where our headquarters are located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. We are also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the we have instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While we have continued to deliver the Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other measures at our facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminished.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, we have adapted our service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second half of fiscal year 2020, we saw recovery of patient registrations for the Zio service to pre-COVID levels of the first quarter of 2020. During the six months ended June 30, 2021, we experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, we experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions of the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could materially impact the volume of our patient registrations in future periods. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are taking a variety of measures to promote the safety and security of our employees and customers. Our response to COVID-19 is focused on:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Protecting and supporting the health and well-being of our employees, our communities and our customers by limiting the transmission of COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Following recommendations from federal and local government and healthcare agencies, we transitioned employees to a remote work environment beginning in early March 2020. For a small number of our employees who continue to support essential operations at our facilities, we have instituted social distancing and other measures to ensure the safety of our employees. We rapidly implemented business continuity protocols and have been able to transition to a remote operating environment while continuing to deliver our Zio service. We will continue to follow local and national guidelines to determine the appropriate time to resume in-office functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:12.53pt">Delivering uninterrupted patient care for both Zio XT and Zio AT and supporting efforts to monitor COVID-19 patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of COVID-19, we have adapted our service to meet the immediate needs of our physician customers and patients. Our digital service platform enables physician ordering, results reporting, data curation and patient support independent of location, across virtual or in-office care models. As an example, we have significantly increased the utilization of our &#8220;Home Enrollment&#8221; service. This service allows patients to receive and wear the single-use Zio monitor without going to a healthcare facility. Physicians can prescribe the Zio service for their patients, either in-office or through a virtual care setting, and we ship the Zio monitor directly to the patient&#8217;s residence. We pay for the costs of shipping the Zio monitor, which represents additional expense for us. We also guide patients through the patch application process and inform them of instructions for wear. Home enrollment also eliminates clinical staff exposure to patients, as well as application, cleaning or reusing traditional Holter and event monitors that may have been exposed to viruses or other pathogens. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:12.53pt">Adjusting our operating plan as appropriate to ensure continued financial strength.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We continue to maintain a strong cash position and have taken initiatives to adjust our operating plan to ensure we maintain appropriate liquidity during these uncertain times. In addition, we raised $206.8 million in proceeds from a follow-on public offering in August 2020 to fund growth initiatives and for working capital and other general corporate purposes.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The majority of our revenue is derived from provision of our Zio service to customers in the United States. We earn revenue from the provision of our Zio service primarily from contracted third-party payors, CMS and healthcare institutions. In addition, a small percentage of institutions, which are typically hospitals or private physician practices, purchase the Zio service from us directly, and a very small percentage of commercial non-contracted payors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue on an accrual basis based on estimates of the amount that will ultimately be realized, which is the difference between the amount submitted for payment and the amount received. These estimates require significant judgment by management. In determining the amount to accrue for a delivered report, and Zio service provided, we consider factors such as claim payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to seasonality similar to other companies in our field, as vacations by physicians and patients tend to affect enrollment in the Zio service more during the summer months and during the end of calendar year holidays compared to other times of the year. Revenue may be impacted by the outcome of adjudications with contracted and non-contracted payors, as well as changes in the CMS reimbursement rates. Clinical capacity limitations may also restrict our ability to complete the performance obligations to achieve revenue recognition. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue and Gross Margin</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes direct labor, material costs, equipment and infrastructure expenses, device scrap and loss, amortization of internal-use software, allocated overhead, and shipping and handling. Direct labor includes payroll and personnel-related costs including stock-based compensation involved in manufacturing, clinical data curation, and customer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service. Material costs include both the disposable materials costs of the Zio monitors and amortization of the re-usable printed circuit board assemblies (&#8220;PCBAs&#8221;). Each Zio XT monitor includes a PCBA, and each Zio AT monitor includes a PCBA and gateway board, the cost of which is amortized over the anticipated number of uses of the board. We expect cost of revenue to increase in absolute dollars as our revenue increases due to increased direct labor, direct materials, and variable spending, partially offset by economies of scale in relation to fixed costs such as overhead, depreciation and amortization, and facilities costs.  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, including increased contracting with third-party payors and institutional providers. We have in the past been able to increase our pricing as third-party payors become more familiar with the benefits of the Zio service and move to contracted pricing arrangements. We expect to continue to decrease the cost of revenue per device by obtaining volume purchase discounts for our material costs, implementing scan-time algorithm and process improvements, automating manufacturing assembly and packaging, and software-driven and other workflow enhancements to reduce labor costs.  These decreases may be offset by increases to materials and electronics components pricing, labor rates, shipping rates, depreciation and amortization of investments, and increases in the general level of inflation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin for the year ended December 31, 2021 was negatively impacted due to the decrease in reimbursement rates from Novitas Solutions, increased costs associated with capacity constraints, and COVID-related labor costs, offset by volume benefits, with limited impact of higher Zio AT volumes, and improved payor adjudications. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although a large majority of our commercial customers have renewed their contracts for the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if we are unsuccessful in improving the Medicare rates, we believe that commercial rates may begin to be more negatively impacted, which would have a negative impact on our gross margins.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as they are incurred. Research and development expenses include payroll and personnel-related costs, including stock-based compensation, consulting services, clinical studies, laboratory supplies and allocated facility overhead costs. We expect our research and development costs to increase in absolute dollars as we hire additional personnel to develop new product and service offerings, product enhancements and clinical evidence.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and marketing expenses consist of payroll and personnel-related costs, including stock-based compensation, sales commissions, travel expenses, consulting, public relations costs, direct marketing, tradeshow and promotional expenses and allocated facility overhead costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses consist primarily of payroll and personnel-related costs for executive, finance, legal and administrative personnel, including stock-based compensation. Other significant expenses include professional fees for legal and accounting services, consulting fees, recruiting fees, bad debt expense, third-party patient claims processing fees and travel expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is attributable to borrowings under our loan agreements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information on our loan agreements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income which consists of interest received on our cash equivalents and investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021, and 2020</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,943)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,994)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,601)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,531)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue increased $57.7 million, or 22%, to $322.8 million during the year ended December&#160;31, 2021 from $265.2 million during the year ended December&#160;31, 2020. The increase in revenue was primarily attributable to the increase in volume of the Zio services as a result of increased demand from our customers, partially offset by a decrease in revenue recognized from CMS, based on the updated 2021 published rates. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue and Gross Margin</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased $39.0 million, or 55%, to $109.3 million during the year ended December&#160;31, 2021 from $70.3 million during the year ended December&#160;31, 2020. The increase in cost of revenue was primarily due to increased Zio service volume, increase in costs resulting from capacity limitations associated with clinical operations, as well as costs incurred to support a larger cost structure in 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin for the year ended December&#160;31, 2021 decreased to 66%, compared to 73% for the year ended December&#160;31, 2020. The decrease in gross margin is primarily due to the updated reimbursement rates announced by Novitas Solutions in April 2021 with an effective date of January 1, 2021, increased costs associated with capacity constraints, with limited impact of higher Zio AT volumes and COVID-related labor costs, offset by volume benefits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased $2.7 million, or 6%, to $38.7 million during the year ended December&#160;31, 2021 from $41.3 million during the year ended December&#160;31, 2020. The decrease was primarily attributable to a $4.0 million decrease of Verily milestone expense offset by a $1.7 million increase in payroll and employee stock-based compensation.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $77.6 million, or 39%, to $274.8 million during the year ended December&#160;31, 2021 from $197.2 million during the year ended December&#160;31, 2020. The increase was primarily attributable to a $64.6 million increase in payroll and employee stock-based compensation as a result of increased headcount and executive hires to support the growth in our operations, a $5.1 million increase in facilities and rent due to increased facility maintenance costs, and an increase of $4.5 million in professional services fees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, the our Board of Directors approved a decision to pursue reducing our leased space for our headquarters in San Francisco, California. We expect these decisions will result in an impairment of the right of use asset lease and we are assessing the impact to our Consolidated Financial Statements for the quarter ending March 31, 2022.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $0.4 million to $1.2 million during the year ended December&#160;31, 2021 from $1.5 million during the year ended December&#160;31, 2020 due to principal re-payments on the SVB Loan starting in November 2020.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, decreased $1.5 million to $0.1 million for the year ended December&#160;31, 2021, compared to $1.6 million for year ended December&#160;31, 2020. The decrease in other income is primarily due to a decrease in interest income and value added tax reclaims.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Year Ended December 31 2020, and 2019</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.359%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,755)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,601)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,503)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,902&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,830)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue increased $50.6 million, or 24%, to $265.2 million during the year ended December 31, 2020 from $214.6 million during the year ended December 31, 2019. The increase in revenue was primarily attributable to the increase in volume of the Zio services as a result of increased in demand from our customers.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue and Gross Margin</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased $17.8 million, or 34%, to $70.3 million during the year ended December 31, 2020 from $52.5 million during the year ended December 31, 2019. The increase in cost of revenue was primarily due to increased Zio service volume and costs incurred to support a larger cost structure in 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gross margin for the year ended December 31, 2020 decreased to 73%, compared to 76% for the year ended December 31, 2019. The decrease in gross margin was primarily driven by product mix, as well as fixed costs that we continue to incur, partially offset by increased volume.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $4.0 million, or 11%, to $41.3 million during the year ended December 31, 2020 from $37.3 million during the year ended December 31, 2019. The increase was primarily attributable to a $8.3 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million increase in payroll and employee stock-based compensation as a result of increased headcount and an increase of $1.0 million in Verily milestone expense. This was partially offset by $4.7 million increase in capitalization of internal use software.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $17.7 million, or 10%, to $197.2 million during the year ended December 31, 2020 from $179.5 million during the year ended December 31, 2019. The increase was primarily attributable to a $29.5 million increase in payroll and employee stock-based compensation as a result of increased headcount to support the growth in our operations, a $2.9 million increase in facilities and rent due to expansion of the San Francisco headquarters and increased facility related costs, partially offset by decrease of $8.9 million in travel, entertainment and office meals as a result of the COVID-19 pandemic and a decrease of $4.4 million in professional services fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of selling, general, and administrative incremental spend can be directly attributed to our continued focus on salesforce expansion and its support infrastructure to support our growth strategy.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased $0.1 million to $1.5 million during the year ended December 31, 2020 from $1.6 million during the year ended December 31, 2019 due to principal payments on the SVB Loan starting in November 2020 and a decrease in the interest rate in 2020.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, decreased $0.3 million to $1.6 million for the year ended December 31, 2020, compared to $1.9 million for year ended December 31, 2019. The decrease in other income is primarily due to a decrease in amortization of investments, partially offset by an increase in interest income, and prior year value added tax reclaims.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_52"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Expenditures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously reviewing our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe we will have adequate liquidity over the next twelve months to operate our business and to meet our cash requirements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and cash equivalents of $127.6 million, short-term investments of $111.6 million, and an accumulated deficit of $406.0 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected future capital requirements may depend on many factors including expanding our customer base, the expansion of our salesforce, and the timing and extent of spending on the development of our technology to increase our product offerings. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,753)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,759)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,863)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,264&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,391)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,274)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,577)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,934&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,166&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Used in Operating Activities</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, cash used in operating activities was $37.8 million which consisted of a net loss of $101.4 million, adjusted by non-cash charges of $109.8 million and a net change of $46.2 million in our net operating assets and liabilities. The non-cash charges are primarily comprised of stock-based compensation expense of $54.5 million, as well as depreciation and amortization expense of $9.8 million and a change in allowance for doubtful accounts and contractual allowance of $37.1 million and amortization of right of use assets of $6.8 million. The change in our net operating assets and liabilities compared to December&#160;31, 2020 was primarily due to an increase of $53.6 million in the change in accounts receivable as a result of the CPT code changes that took effect January 1, 2021. The number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods. We believe we have adequate balance sheet liquidity to manage through these delays.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities increased $7.9 million primarily due to increased compensation and benefit accruals as a result of increased head count, and an increase in accounts payable of $6.1 million, primarily due to milestone achievements on our collaboration with Verily, partially offset by an increase of $5.0 million in inventory.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, cash used in operating activities was $13.8 million which consisted of a net loss of $43.8 million, adjusted by non-cash charges of $86.3 million and a net change of $56.2 million in our net operating assets and liabilities. The non-cash charges are primarily comprised of stock-based compensation expense of $41.5 million, as well as depreciation and amortization expense of $6.9 million and a change in allowance for doubtful accounts and contractual allowance of $31.4 million and amortization of right of use assets of $6.0 million. The change in our net operating assets and liabilities compared to December 31, 2019 was primarily due to an increase of $38.0 million in the change in accounts receivable as a result of the increase in our revenue, an increase of $6.1 million in other assets, primarily related to an increase in PCBA boards due to increased sales, a decrease of $4.8 million in operating lease liability and a decrease of $3.9 million in accounts payable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019 cash used in operating activities was $21.9 million, which consisted of a net loss of $54.6 million, adjusted by non-cash charges of $62.4 million and a net change of $29.7 million in our net operating assets and liabilities. The non-cash charges are primarily comprised of stock-based compensation expense of $26.2 million,  as well as depreciation and amortization expense of $3.4 million and a change in allowance for doubtful accounts and contractual allowance of $24.6 million. The change in our net operating assets and liabilities compared to December 31, 2018 was primarily due to an increase of $28.7 million in the change in accounts receivable as a result of the increase in our revenue, and an increase of $6.0 million in accrued liabilities, primarily related to increased accrued payroll and related compensation accruals.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash From Investing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the year ended December&#160;31, 2021 was $105.3 million, which consisted primarily of $122.2 million in purchases of available for sale investments partially offset by $28.1 million of capital expenditures to purchase property and equipment and $255.5 million in cash received from the maturities of available for sale investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the year ended December 31, 2020 was $132.4 million, which consisted primarily of $277.5 million in purchases of available for sale investments, $13.6 million of capital expenditures to purchase property and equipment, partially offset by $144.1 million cash received from the maturities of available for sale investments and $14.5 million in cash received from sales of available for sale investments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the year ended December 31, 2019 was $89.3 million, which consisted primarily of $165.9&#160;million in purchases of available for sale investments and $20.5 million of capital expenditures to purchase property and equipment, partially offset by $95.6 million in cash received from the maturities of available for sale investments and $1.5 million in cash received from sales of available for sale investments.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash From Financing Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, cash used in financing activities was $28.6 million, primarily due to $25.9 million in tax withholding upon the vesting of RSUs and $11.7 million in repayment of long term debt. This was partially offset by $8.9 million in proceeds from the issuance of common stock in connection with employee option exercises and our Employee Stock Purchase Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, cash provided by financing activities was $214.3 million, primarily due to $206.0 million from the issuance of common stock in a public offering, net of discounts and issuance costs and $20.2 million in proceeds from the issuance of common stock in connection with employee option exercises and our Employee Stock Purchase Plan. This amount was partially offset by $10.0 million in tax withholding upon the vesting of RSUs and $1.9 million in re-payment of long term debt.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, cash provided by financing activities was $111.6 million, primarily due to $107.4 million from the issuance of common stock in a public offering, net of discounts and issuance costs and $9.5 million in proceeds from the issuance of common stock in connection with employee option exercises and our Employee Stock Purchase Plan. This was partially offset by $5.3 million in tax withholding upon the vesting of RSUs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bank Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into the Third Amended and Restated Loan and Security Agreement with SVB (&#8220;Third Amended and Restated SVB Loan Agreement&#8221;). This Agreement amends and restates the Second Amended and Restated Loan and Security Agreement between the Company and SVB dated December 4, 2015, as amended by the First Loan Modification Agreement between the Company and SVB dated August 22, 2016.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Amended and Restated SVB Loan Agreement, we obtained a term loan (&#8220;SVB Term Loan&#8221;) for $35.0 million. Total proceeds from the SVB Term Loan were used to pay off the loan agreement with Biopharma Secured Investments III Holdings Cayman LP (&#8220;Pharmakon&#8221;), totaling $35.8 million. We made interest-only payments through October 31, 2020, followed by 36 monthly payments of principal plus interest on the SVB Term Loan. Interest charged on the SVB Term Loan will be the greater of (a) a floating rate based on the &#8220;Prime Rate&#8221; published by The Wall Street Journal minus 0.75%, or (b) 4.25%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Third Amended and Restated SVB Loan Agreement, we may borrow, repay, and reborrow under a revolving credit line, but not in excess of the maximum loan amount of $25.0 million, which includes an $11.0 million standby letter of credit sublimit availability. In October 2018, a $6.9 million standby letter of credit was obtained in connection with a lease for our San Francisco headquarters. Any principal amount outstanding under the Third Amended and Restated SVB Loan Agreement revolving credit line shall bear interest at an amount that is the greater of (a) a floating rate per annum equal to the rate published by The Wall Street Journal as the &#8220;Prime Rate&#8221; or (b) 5.00%. We may borrow up to 75% of eligible accounts receivable, up to the maximum of $25.0 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended and Restated Loan Agreement requires us to maintain a minimum consolidated liquidity ratio or minimum adjusted Earnings Before Interest, Tax, Depreciation, and Amortization during the term of the loan facility. In addition, the SVB Loan Agreement contains customary affirmative and negative covenants and events of default. We were in compliance with loan covenants as of December&#160;31, 2021. The obligations under the Third Amended and Restated Loan Agreement are collateralized by substantially all of our assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires our management to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these judgments and estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All policies described below have not significantly changed over the last fiscal year. In addition, the policies below are critical because they require management to make difficult, subjective and complex judgments about matters that are inherently uncertain and it is likely that materially different amounts would be reported under different conditions or using different assumptions.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Zio XT monitor, a wearable patch-based biosensor, continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days. The Zio XT monitor is returned to our monitoring facility and the heartbeat data is curated and analyzed by our proprietary algorithms and reviewed by our certified cardiac technicians. The final step in the Zio service is the delivery of an electronic Zio Report to the prescribing physician with a summary of findings. Our Zio XT service is generally billable when the Zio Report is issued to the physician.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what our Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating the small percentage of the population requiring more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for contract revenue with a customer when there is a legally enforceable contract between us and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Our revenue is measured based on consideration specified in the contract with each customer. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, like a hospital or clinic, will pay us for some or all of the service on the patient&#8217;s behalf. Separate contractual arrangements exist between us and many third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered and should be considered in determining collectability and the transaction price for services provided to a patient covered by that third-party payor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue on an accrual basis based on estimates of the amount that will ultimately be realized, which is the difference between the amount submitted for payment and the amount received. Revenue recognition is subject to uncertainty because these estimates require significant judgment by management. In determining the amount to accrue for a delivered report, we consider factors such as claim payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and us, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Contracted third-party payors &#8211; We have contracts with negotiated prices for services provided for patients with commercial healthcare insurance carriers</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) &#8211; We have received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant Current Procedural Terminology (&#8220;CPT&#8221;) code rate for the services rendered to the patient covered by CMS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-contracted third-party payors: Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used for determining revenue recognition is based on factors including an average of our historical collection experience for our non-contracted services. This rate is reviewed at least quarterly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Healthcare institutions &#8211; Healthcare institutions are typically hospitals or physician practices in which we have negotiated amounts for its monitoring services, including certain governmental agencies such as the Veteran&#8217;s Administration and Department of Defense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition. We account for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, we have concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the healthcare institutions, we have historical experience of collecting substantially all of the negotiated contractual rates and determined at contract inception that these customers, and or their related third-party payor that pays us on their behalf, have the intention and ability to pay the promised consideration. As such, we have not provided an implicit price concession but, rather, have chosen to accept the risk of default, and adjustments to the transaction price are recorded as bad debt expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracted and CMS portfolios, we are providing an implicit price concession because, while we have a contract with the underlying payor, we expect to accept a lower amount of consideration when claims are adjudicated and allowable claims are determined by the commercial payor. The implicit price concession is recorded as variable consideration to the transaction price and recorded as an adjustment to revenue as a contractual allowance. Historical cash collection indicates that it is probable that substantially all of the contracted claim amount will be received. We provide for estimates of uncollectible patient accounts receivable, based upon historical experience, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For non-contracted portfolios, we are providing an implicit price concession because we do not have a contract with the underlying payor, the result of which requires us to estimate transaction price based on historical cash collections utilizing the expected value method. Subsequent adjustments to the transaction price are recorded as an adjustment to revenue and not as bad debt expense.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts and Contractual Allowance</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for doubtful accounts and contractual allowance is subject to uncertainty because we establish an allowance for doubtful accounts for estimated uncollectible receivables based on our historical collections, review of specific outstanding claims, consideration of relevant qualitative factors and an established allowance percentage by aging category, all of which are inherently uncertain. We write off outstanding accounts against the allowance for doubtful accounts when they are deemed to be uncollectible. Increases and decreases in the allowance for doubtful accounts are included as a component of general and administrative expenses. We record reductions in revenue for estimated uncollectible amounts as contractual allowances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review and update our estimates for the allowance for doubtful accounts and the contractual allowance periodically to reflect our experience regarding historical collections. If we were to make different judgments or utilize different estimates in the allowance for doubtful accounts and the contractual allowance, differences in both the amount of reported general and administrative expenses and revenue could result.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Usage of the Printed Circuit Board Assembly</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a printed circuit board assembly (&#8220;PCBA&#8221;) in each Zio XT and Zio AT wearable device and a gateway board in Zio AT device.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These boards are reused numerous times in multiple patients. Each time the PCBA and gateway board is used in a wearable Zio XT and Zio AT monitor, a portion of the cost of the PCBA and gateway board is recorded as a cost of revenue. Estimated usage of PCBAs is subject to uncertainty because we base our estimates of how many times a PCBA and gateway board can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. These estimates can be subjective, complex, and inherently uncertain. We periodically evaluate the use estimate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs related to stock option grants, restricted stock unit grants (&#8220;RSUs&#8221;), and shares under the employee stock purchase plan (&#8220;ESPP&#8221;), and market condition awards based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense for options and shares under the ESPP, using the Black-Scholes option pricing model. We estimate the grant date fair value, and the resulting stock-based compensation expense for market condition awards using the Monte-Carlo option pricing model. The RSU grant date fair value is based on the closing price on the date of the grant. The grant date fair value of stock-based awards is expensed on a straight-line basis over the period during which the employee is required to provide service in exchange for the award (generally the vesting period).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our stock-based awards using the Black-Scholes and Monte-Carlo option-pricing models, which requires the input of highly subjective assumptions. Our assumptions are as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected term represents the period that the stock-based awards are expected to be outstanding. We use the simplified method to determine the expected term, which is calculated as the average of the time to vesting and the contractual life of the options.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Expected volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected volatility is derived from the average implied volatility of our common stock</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our common stock has been publicly traded for a limited time, in some cases expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term for employees&#8217; options and the remaining contractual life for nonemployees&#8217; options.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Risk-free interest rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The risk-free interest rate is based on the U.S. Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Dividend yield.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions used in the Black-Scholes and Monte-Carlo option-pricing model, we also estimate a forfeiture rate to calculate the stock-based compensation for our equity awards. We will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for our stock-based compensation calculations on a prospective basis.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize compensation expense related to RSUs based on the grant date fair value on a straight-line basis over the period during which the employee is required to provide service in exchange for the award (generally the vesting period). Where there is a minimum performance condition required to vest in RSUs, we perform a probability assessment to estimate the number of shares that are probable to vest.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense related to the ESPP based on the estimated fair value on the date of grant, net of estimated forfeitures. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is subject to uncertainty due to management estimates used in monte-carlo and black scholes valuations, as well as probability assessments performed to estimated numbers of shares probable to vest where awards have minimum performance conditions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded stock-based compensation expense of $54.5 million, $41.5 million, and $26.2 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. We expect to continue to grant RSUs and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's material cash requirements include the following contractual and other obligations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Debt interest and principal payments - In October 2018, we entered into the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank, Pursuant to which we obtained a term loan (&#8220;SVB Term Loan&#8221;) for $35.0 million. We made interest-only payments through October 31, 2020, and began making monthly payments of principal plus interest in November 2020.</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating leases - We lease our facilities under non-cancelable operating leases that have remaining lease terms of up to 9.75 years. As of December 31, 2021, we had fixed lease payment obligations of $136.5 million, with $12.6 million payable within 12 months.</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase obligations - Purchase obligations represent an estimate of open purchase orders and contractual obligations, in the ordinary course of business for which we have not received the goods or services. As of December 31, 2021, we had $53.5 million of such purchase obligations.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_58"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities and foreign currency exchange rate sensitivity.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and investments of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$239.1 million as of December&#160;31, 2021; which consisted of bank deposits, money market funds and U.S. government securities, corporate notes, and commercial paper. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  For the years ended December&#160;31, 2021 and 2020 we had total outstanding debt of $21.4&#160;million and $33.0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spectively, which is net of debt issuance costs. The Third Amended and Restated SVB Loan Agreement Note carries a variable interest rate based on the &#8220;Prime Rate&#8221; published by The Wall Street Journal. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Sensitivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars, particularly in British Pound Sterling. As of December&#160;31, 2021, we do not consider this risk to be material. We do not utilize any forward foreign exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_64">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_64">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_67">Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_67">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_67">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_70">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_70">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_73">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_73">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_76">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_76">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_79">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_82">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4a303ab734354a4f8fadd28a70ce663e_82">88</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of iRhythm Technologies, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of iRhythm Technologies, Inc. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, of comprehensive loss, of stockholders' equity and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the COSO because a material weakness in internal control over financial reporting existed as of that date related to an ineffective control environment commensurate with the Company's financial reporting requirements, due to an insufficient number of professionals with an appropriate level of accounting and internal control knowledge, training and experience.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness referred to above is described in Management&#8217;s Annual Report on Internal Control Over Financial Reporting appearing under Item 9A. We considered this material weakness in determining the nature, timing, and extent of audit tests applied in our audit of the 2021 consolidated financial statements, and our opinion regarding the effectiveness of the Company&#8217;s internal control over financial reporting does not affect our opinion on those consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in management's report referred to above. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Contractual Allowance &#8211; Contracted Third-Party Payors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 2 to the consolidated financial statements, a large portion of the Company&#8217;s transactions are covered by third-party payors with whom there is a contractual agreement or established amount the third-party payor will pay (contracted third-party payors). These contracts impose a number of obligations regarding billing and other matters, and the Company&#8217;s noncompliance with a material term of such contracts may result in a denial of the claim. The number of claims from the first half of 2021 which had differences between the submitted price and reimbursement, and the overall denials, increased significantly compared to the Company&#8217;s historical experience as a result of the Current Procedural Terminology (CPT) code transition issues with certain payors. The Company recognizes revenue from contracted third-party payors, net of contractual allowances. As of December 31, 2021, the Company&#8217;s contractual allowance balance was $31.3 million, a significant portion of which relates to revenue from services provided to patients where contracted third-party payors pay for the service on the patient's behalf. As disclosed by management, management accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price and records as an adjustment to revenue as a contractual allowance. The contractual allowance requires judgment by management and is based on historical collections, review of specific outstanding claims and consideration of relevant qualitative factors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the contractual allowance for contracted third-party payors is a critical audit matter are the significant judgment by management when developing the estimate of the contractual allowance; this in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to the contractual allowance based on historical collections, review of specific outstanding claims and consideration of relevant qualitative factors.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the contractual allowance for contracted third party payors, including controls over the historical collections, review of specific outstanding claims and consideration of relevant qualitative factors. These procedures also included, among others (i) testing management&#8217;s process for developing the estimate of the contractual allowance; (ii) testing the completeness and accuracy of the underlying data used in the estimate; (iii) testing, on a sample basis, the accuracy of revenue transactions and collections from the historical billing and collection data used in management&#8217;s analysis; (iv) performing a retrospective comparison of actual collections subsequent to year-end to evaluate the reasonableness of certain of the estimates; and (v) evaluating the reasonableness of adjustments made by management to contractual allowances. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ PricewaterhouseCoopers LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022 </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2009.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value and share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNC0xLTEtMS0yNDU0Mw_d3011d38-6eae-4361-9b0a-72cbcf89956b">127,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNC0zLTEtMS0yNDU0Mw_892a1fcf-f96c-435c-a7ce-7be06534a181">88,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNS0xLTEtMS0yNDU0Mw_5474335c-38aa-40ab-8b51-f9035cf26e5a">111,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNS0zLTEtMS0yNDU0Mw_ba93a8e9-7b8e-4306-a76d-4461bce7f68a">246,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNi0xLTEtMS0yNDU0Mw_4f2aec39-9c0e-45f2-b37f-d829311d84d7">46,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNi0zLTEtMS0yNDU0Mw_5ac07c17-f5f7-462b-b321-a6ee273ca834">29,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNy0xLTEtMS0yNDU0Mw_b5dc0f9b-59de-416e-893d-6d33ccf2f4bd">10,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNy0zLTEtMS0yNDU0Mw_e461b279-47ae-4912-ae64-8cbbca0a3eb0">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOC0xLTEtMS0yNDU0Mw_6ed566e4-2ab2-4a79-af60-d0725290eb22">9,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOC0zLTEtMS0yNDU0Mw_89482823-ef8e-4b8b-9806-9dcadad118d8">7,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOS0xLTEtMS0yNDU0Mw_fe18c287-beff-4ce2-af19-3403eaa37aca">305,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOS0zLTEtMS0yNDU0Mw_5411c893-2864-4443-9923-5f667155fae2">377,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTEtMS0xLTEtMjQ1NDM_06ce8b5c-2994-48f5-af81-32bad0841c70">55,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTEtMy0xLTEtMjQ1NDM_8473fe6e-4bbe-48a2-976d-5d4ae2bdff94">34,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTItMS0xLTEtMjQ1NDM_da0731e1-bf25-45ae-914a-94cf9a904861">84,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTItMy0xLTEtMjQ1NDM_c5ee2b4c-f16a-4f1f-91ae-02c09d9c65eb">84,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTMtMS0xLTEtMjQ1NDM_4437f575-ea21-42f8-9950-165aea4e3684">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTMtMy0xLTEtMjQ1NDM_b7079b6c-5820-4e6b-a1f0-a8650837fdf5">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTQtMS0xLTEtMjQ1NDM_86a1a15b-934b-44e8-a18e-e85a4ba7315e">16,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTQtMy0xLTEtMjQ1NDM_14e0706d-6813-4dc1-9fab-5490df05ac78">14,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTUtMS0xLTEtMjQ1NDM_030c7a9d-6ae2-4d7c-b775-5be9ab3aab2c">462,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTUtMy0xLTEtMjQ1NDM_5a6e2271-f72d-48e8-a63c-c9e8a6781a62">511,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTgtMS0xLTEtMjQ1NDM_37d41b2a-d5cc-408c-bbad-4cddc48af224">10,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTgtMy0xLTEtMjQ1NDM_5531b771-bb10-406f-b9af-a3f873a38234">4,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTktMS0xLTEtMjQ1NDM_b50713c6-fb81-4a3e-b31c-94bdf9d4b697">51,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTktMy0xLTEtMjQ1NDM_3fb7407f-c928-4f3a-8816-f479769f9cb0">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjAtMS0xLTEtMjQ1NDM_dac837f9-65cf-4757-abb0-02ec8c90902d">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjAtMy0xLTEtMjQ1NDM_e958088b-2088-497a-ba9d-4ad8d30f584c">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjEtMS0xLTEtMjQ1NDM_22e01986-b301-4c7c-804e-3fdb46854892">11,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjEtMy0xLTEtMjQ1NDM_46b54724-5795-4569-9564-7527bc36ef6a">11,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjMtMS0xLTEtMjQ1NDM_81a8a04d-3159-4e38-a4e2-89b0553c71b4">11,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjMtMy0xLTEtMjQ1NDM_f1b5784b-6571-4ad9-b1f6-da030ea82a86">8,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjQtMS0xLTEtMjQ1NDM_4d978133-0df6-4c41-b2a3-99785e7458e0">87,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjQtMy0xLTEtMjQ1NDM_2060e7d9-815a-4cec-862b-6ba62c36417b">65,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, noncurrent portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjUtMS0xLTEtMjQ1NDM_d5fe705a-63af-47fa-806b-e23745a81f2a">9,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjUtMy0xLTEtMjQ1NDM_7fb1c57e-6a56-4a4b-91c0-d578b9b9a63b">21,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjYtMS0xLTEtMjQ1NDM_d22ec7d3-3eb4-4cf5-87ca-4ab1201ffc02">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjYtMy0xLTEtMjQ1NDM_4353b100-7d33-40f9-8904-51dbba39bd71">1,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, noncurrent portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjctMS0xLTEtMjQ1NDM_a94d4266-b676-49e0-aff8-cdd0ef76ca50">85,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjctMy0xLTEtMjQ1NDM_4c4d0386-294e-4bab-a263-f409f1c83913">81,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjgtMS0xLTEtMjQ1NDM_56396521-32c7-48ca-b339-791f8e4c42f2">183,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjgtMy0xLTEtMjQ1NDM_58c389ae-ef58-4baa-862e-0370e90639d1">170,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjktMS0xLTEtMjQ1NDM_ceda72a7-fa96-40d7-b324-bfcd0a516203"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjktMy0xLTEtMjQ1NDM_cfcc330d-bde4-4798-ac16-0ac032a62d96"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8yMw_4901a43d-0816-4b00-989b-71820f855a60"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8yMw_fdd5208e-9308-4510-950d-a0516a51a37e">0.001</ix:nonFraction></ix:nonFraction> par value &#8211; <ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8zOA_14d06339-e22b-4adb-94e1-4b768f443091"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8zOA_5dacd7db-6ec2-4e1f-92f4-ea8469315c35">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; and <ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_5624fbef-c24f-4dac-9cd5-7c490f8dfe48"><ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_5e2bdbc2-ec39-4fca-b5c0-8d77a287057e"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_637af92b-0b50-4fd2-855d-cb94f2a78820"><ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_c0245536-10b8-4394-b547-026977284fcf">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMS0xLTEtMjQ1NDM_59e71f8d-6e96-4dab-8a2a-9649f1fef5eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMy0xLTEtMjQ1NDM_d0c8af5b-32df-432b-8c17-109fc832ee1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8yMA_6a3a29b9-95b5-478b-bdb5-c823360ea4df"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8yMA_78bef688-729f-4619-af6b-ac92617d745b">0.001</ix:nonFraction></ix:nonFraction> par value &#8211; <ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8zNQ_2178a188-2ef2-48da-8271-538b94af3729"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8zNQ_22061c44-a0f4-49ae-8ec3-7016f62b16fc">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83MA_2f7dc360-3c97-4c01-9888-2febd0a80f90"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83MA_80f84952-cec9-459d-bcf3-209780963d27">29,493,726</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83Nw_4a0f7988-ce6b-4e84-b025-1bd17ac78db9"><ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83Nw_bb977a0d-1482-4d34-a64b-f4aef4650810">29,019,350</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMS0xLTEtMjQ1NDM_03d9ad8d-e8ce-41a2-94aa-3fa67a347592">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMy0xLTEtMjQ1NDM_aaf7871b-29af-4c5c-91f0-8ddf84a9d80c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzMtMS0xLTEtMjQ1NDM_b1f21914-b81a-4fbe-88b8-bc5abdef316c">685,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzMtMy0xLTEtMjQ1NDM_16fa8572-042a-409e-a7f0-0634c9f5a550">646,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzQtMS0xLTEtMjQ1NDM_25ece597-4c05-4a82-9c19-2b79033737a7">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzQtMy0xLTEtMjQ1NDM_dbb4b8ef-98da-450b-b256-d622b51f906b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzUtMS0xLTEtMjQ1NDM_f48fbde7-bec8-47d7-9b34-e23764714f3f">406,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzUtMy0xLTEtMjQ1NDM_c65b84b7-41e3-4a36-aecf-8d4001c5c62f">304,684</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzYtMS0xLTEtMjQ1NDM_764c0b62-b61e-4c9e-b912-b0cdb46d51dd">279,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzYtMy0xLTEtMjQ1NDM_05dde8f1-7dbb-4490-8b5b-b6c1fd659d7c">341,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzctMS0xLTEtMjQ1NDM_9f01d01b-60bf-4cb4-a782-4cab60029cb9">462,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzctMy0xLTEtMjQ1NDM_caabc679-99a2-448d-a8c8-97dcdf57eef8">511,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi0xLTEtMS0yNDU0Mw_f4281882-414b-46d2-80c2-5e771383b31d">322,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi0zLTEtMS0yNDU0Mw_07d10df1-717c-4a7b-9acd-34697991fb07">265,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi01LTEtMS0yNDU0Mw_0c195268-223e-4569-87cc-e10dad229626">214,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy0xLTEtMS0yNDU0Mw_880d8e9f-1f9c-4057-91a7-1322802152bc">109,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy0zLTEtMS0yNDU0Mw_35991370-b642-47d5-a931-9d0d95262e7f">70,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy01LTEtMS0yNDU0Mw_be63dc3e-b18e-4c60-8303-e64983ff7fc7">52,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC0xLTEtMS0yNDU0Mw_792a1c4a-95f9-467a-b63c-17bb991f342b">213,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC0zLTEtMS0yNDU0Mw_4e7eb357-0d3a-479c-94e9-59eccb5110ef">194,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC01LTEtMS0yNDU0Mw_c8780522-716c-4ac1-8b60-ef4f60a111e0">162,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi0xLTEtMS0yNDU0Mw_2b72bf56-4693-451b-8b46-7f08e5918ace">38,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi0zLTEtMS0yNDU0Mw_390283de-e17f-40b1-90cd-66b6218523d2">41,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi01LTEtMS0yNDU0Mw_90311890-1a83-43c1-8585-c8bdc6d3470e">37,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy0xLTEtMS0yNDU0Mw_70c680b7-5fa4-4b37-ab86-31335da00ba3">274,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy0zLTEtMS0yNDU0Mw_a9540a7b-3756-46d5-a782-0009cf806043">197,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy01LTEtMS0yNDU0Mw_ea28b06d-3fb6-48a5-bb03-7200e4ac4f92">179,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC0xLTEtMS0yNDU0Mw_88ff82a8-0040-48fc-855b-c2fbd60e78fc">313,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC0zLTEtMS0yNDU0Mw_2f938365-4f29-475e-a2fb-bb0097e16cdd">238,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC01LTEtMS0yNDU0Mw_e3dc2558-8d0a-46e3-b9d7-7ef557827455">216,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS0xLTEtMS0yNDU0Mw_5d34a89c-c790-45a2-992e-830bd5856d16">99,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS0zLTEtMS0yNDU0Mw_a5ccc253-9889-41f8-82b7-32b293d57e43">43,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS01LTEtMS0yNDU0Mw_d7d854ff-e41a-401e-bb5b-e3a11a40651b">54,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtMS0xLTEtMjQ1NDM_da8b1bbd-5bee-4815-a0df-c32cf024d065">1,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtMy0xLTEtMjQ1NDM_c58ec4de-7e61-4202-a6f6-f0c3388023f0">1,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtNS0xLTEtMjQ1NDM_e4e6b45d-da34-407c-a0c5-aa4dd5a40abf">1,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtMS0xLTEtMjQ1NDM_d17cce2f-b1eb-46ed-8bb7-052ebcba4fe4">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtMy0xLTEtMjQ1NDM_78015c44-9a9d-4331-be1a-52f87c9274d0">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtNS0xLTEtMjQ1NDM_16d32d08-7755-4a90-aa51-680c513132d0">1,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtMS0xLTEtMjQ1NDM_86bb5835-f2c0-4c19-86cc-360298d19789">100,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtMy0xLTEtMjQ1NDM_04049352-f2c0-4137-a4a0-20e825e7e617">43,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtNS0xLTEtMjQ1NDM_04bce399-e751-4c29-b92f-22d9e7f5afab">54,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtMS0xLTEtMjQ1NDM_f852a198-0c6b-4022-864b-d61b4f368aaf">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtMy0xLTEtMjQ1NDM_2019d7b5-e66b-4fb4-b358-608c58d50837">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtNS0xLTEtMjQ1NDM_e7fb0f07-c146-4715-b1cd-481d02281cbe">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtMS0xLTEtMjQ1NDM_f183b407-914d-40b1-91c5-2f7951467f21">101,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtMy0xLTEtMjQ1NDM_e3890031-4d46-44d0-a837-024c35674312">43,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtNS0xLTEtMjQ1NDM_03aab695-e087-49ff-bf26-53d8e8e75d60">54,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMS0xLTEtMjQ1NDM_15b9f241-2a26-4318-b165-34d7e7577a3a"><ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMS0xLTEtMjQ1NDM_f9f421cb-4a42-4222-966b-5e0503c9db34">3.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMy0xLTEtMjQ1NDM_83575b64-809c-4d48-a94c-dfc6da0655b3"><ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMy0xLTEtMjQ1NDM_a8d02354-882c-4b79-a32a-863c5063e5a2">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtNS0xLTEtMjQ1NDM_804e2cf9-9984-44a7-913e-45bf891d108c"><ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtNS0xLTEtMjQ1NDM_e4589b7c-8d77-4009-935c-c6d4d5f29714">2.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMS0xLTEtMjQ1NDM_62dd7a7d-7a27-427c-9f47-a9b717c05296"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMS0xLTEtMjQ1NDM_899ad9de-2b86-4429-9569-f7be5d287aef">29,331,010</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMy0xLTEtMjQ1NDM_89751266-dd28-4568-8224-4824de1cd470"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMy0xLTEtMjQ1NDM_fc898e8d-fbfb-468e-8361-3431f84945e8">27,754,404</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctNS0xLTEtMjQ1NDM_0d820e02-1d86-4c81-90cd-13a67ba1dbab"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctNS0xLTEtMjQ1NDM_68e7de61-ec54-43cf-a2ba-354071c70f86">25,265,918</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi0xLTEtMS0yNDU0Mw_4f5ceb20-ea8a-4c7e-8726-e31570279e90">101,361</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi0zLTEtMS0yNDU0Mw_77abc9a0-00f8-4033-bed7-53a3ee370fa9">43,830</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi01LTEtMS0yNDU0Mw_24b9c155-89e1-4169-bd88-c3055ee63996">54,568</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in unrealized gains (losses) on available-for-sale securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC0xLTEtMS0yNDU0Mw_1691d640-11ef-4464-8eac-a6e4a2fd3512">72</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC0zLTEtMS0yNDU0Mw_8b76e03e-d496-42bb-a630-e2e9b286c27d">71</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC01LTEtMS0yNDU0Mw_e208cc02-7d18-4d57-8d03-ae88d1912c17">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS0xLTEtMS0yNDU0Mw_e5140111-a973-4205-8b10-d1ff4ef3ca82">101,433</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS0zLTEtMS0yNDU0Mw_ba73cb29-c995-4c2c-9c38-66ca39fe22ac">43,901</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS01LTEtMS0yNDU0Mw_0d0525d0-05ff-4c49-b18d-e888df16d97b">54,470</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.435%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i632162ae05734a44b80f1fdf5560120e_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0yLTEtMS0yNDU0Mw_87cb711b-3685-4073-91b0-f21f5953c540">24,368,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632162ae05734a44b80f1fdf5560120e_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS00LTEtMS0yNDU0Mw_2a129f15-4daf-4751-800d-6d2da5f44882">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3f70e09ee54d849d92393b3efb75fc_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS02LTEtMS0yNDU0Mw_f4158115-5a57-4cbf-bdc1-0688f022588f">257,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifacca0dbed9549a594071a1cd185cd79_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS04LTEtMS0yNDU0Mw_390412b1-ebcf-4fba-b32a-b7bb63ad2b41">205,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-205825000</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia05eac998f1044e4967c9890b0d2a65e_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0xMC0xLTEtMjQ1NDM_fe47e757-68cc-42ab-b009-0328e3abade4">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0xMi0xLTEtMjQ1NDM_996e9ace-5c62-42db-a7f2-efd8dfcfafc3">52,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock  in connection with employee equity incentive plans, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMi0xLTEtMjQ1NDM_a8379018-8d96-4679-b9e7-647c026503fb">734,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtNi0xLTEtMjQ1NDM_917b43b4-0ea5-46ec-954b-0c247c329564">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMTItMS0xLTI0NTQz_cc7daa69-d072-4f88-8856-40c17ecf2e90">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Warrants exercised</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231" decimals="INF" name="irtc:CommonStockSharesIssuedFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMi0xLTEtMjUwNTY_1cb53be2-7f39-4569-878f-d9b6945190f0">4,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with follow-on public offering, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMi0xLTEtMjUwNTY_63d03fe5-804b-4c0d-891a-919cbed9d94c">1,575,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNC0xLTEtMjUwNTY_891ed095-61a3-49a7-a9a5-64fee7e8e44f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNi0xLTEtMjUwNTY_f3a1e250-1753-48e8-805a-6e0e16a2520c">107,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMTItMS0xLTI1MDU2_35da8cf3-cc56-4ba6-bf0b-0ea0f0dbd58a">107,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Tax withholding upon vesting of restricted stock awards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNi0xLTEtMjQ1NDM_6ed9025c-de6e-460c-95bf-51e270bf22ac">5,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMTItMS0xLTI0NTQz_1b8d9723-0c28-4704-8028-7419d4068bff">5,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Stock-based compensation expense</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTMtNi0xLTEtMjQ1NDM_5cc9a0ab-c96f-42a7-8548-756b60d7219d">26,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTMtMTItMS0xLTI0NTQz_d6f0072c-d0ab-4b74-ad5b-1a1ab14e02e5">26,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i432949efa6c64c78b50dceeab40e000b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTQtOC0xLTEtMjQ1NDM_dbdad204-c16e-471c-8c0d-a55d80863fcc">54,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTQtMTItMS0xLTI0NTQz_dc9025a9-b7da-4471-8d94-6fa9c15fb842">54,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net change in unrealized loss on investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b02c96d685b4c76b557a50fb39ac9f2_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTUtMTAtMS0xLTI0NTQz_d73ced8e-45b0-4fbd-9c6d-30aaa7821ad7">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTUtMTItMS0xLTI0NTQz_4c95e01b-1f77-4c3b-9494-6f1318b5eb8a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i704ac771209d404fabd6c01f42ca5256_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMi0xLTEtMjQ1NDM_5bb66e3f-b35b-4032-b69c-e32a343b82e5">26,682,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i704ac771209d404fabd6c01f42ca5256_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtNC0xLTEtMjQ1NDM_626f9a01-6bb1-4bef-85b9-dd36b5e31231">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd0dc96bbc744424acc7449cb5f9e134_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtNi0xLTEtMjQ1NDM_4af68a3d-beaf-4ff3-bdcf-7553277df214">395,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe09ccc9143a4642b389d469b06bd919_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtOC0xLTEtMjQ1NDM_a55acd94-9278-44fa-b0ee-85ec42f014c0">260,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2201df0cbe746b8a0639b3748578218_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMTAtMS0xLTI0NTQz_d26eab77-dfd9-4171-b628-fd9187e0bfdd">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMTItMS0xLTI0NTQz_4a242c92-da0a-4245-b4cf-6b2232e0b59d">135,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with employee equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMi0xLTEtMjQ1NDM_1ec06124-70d4-40fa-976c-25ef4006a258">1,079,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctNi0xLTEtMjQ1NDM_3de57fd8-ea3b-4f6c-8e80-23faf6ed946b">20,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMTItMS0xLTI0NTQz_2aa2983b-de14-44a2-adb6-bb5f0f6c9e56"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMTItMS0xLTI0NTQz_5abb257c-36b7-4273-975f-0b9b83d11d33">20,244</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Issuance of common stock in connection with follow-on public offering, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktMi0xLTEtMjQ1NDM_28875863-92e2-4381-8226-931cd168ac9b">1,257,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktNC0xLTEtMjQ1NDM_4e2259e1-131b-4cb2-81c4-c05c9ed763f1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktNi0xLTEtMjQ1NDM_923125c0-d581-4845-8b4f-16395072f387">206,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktMTItMS0xLTI0NTQz_9368e97e-daec-47d6-bb46-fd1c7c2a3ed2">206,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding upon vesting of restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjAtNi0xLTEtMjQ1NDM_4a0c6ab2-31c8-44c9-b63f-0db7115f0310">10,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjAtMTItMS0xLTI0NTQz_c2c376eb-4f45-494d-a13b-eeb6df55603f">10,009</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjEtNi0xLTEtMjQ1NDM_2c18b353-972e-4234-9325-04ef27d58a01">34,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjEtMTItMS0xLTI0NTQz_e9a8a210-8837-472b-a9d3-cafb4b158be9">34,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMC0xLTEtMjU3Njc_6a589db0-786c-44fa-92b8-d954be45f1b9">Accounting Standards Codification 326 cumulative effect adjustment upon adoption</span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib239f55d6fa744e4b1ae93b2be580360_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItOC0xLTEtMjUwNTY_118b1523-ad77-4ccb-a5f3-67971de703ee">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a97f947148a4da3ae69e61dd1e1f636_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMTItMS0xLTI1MDU2_976971b1-8188-4827-a4a8-d3ea0992f0cc">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1767edc2ad274e82aaee985c123834f4_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItOC0xLTEtMjQ1NDM_9d6c84cf-d02c-4b40-bcb1-e3858c760181">43,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMTItMS0xLTI0NTQz_656cb971-61a3-4027-86f5-3d95d2324376">43,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net change in unrealized loss on investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0664e61690104fa2bf238691cd944c77_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjMtMTAtMS0xLTI0NTQz_53ffbe73-7fe9-4aeb-bebf-6c6dc2e7ed0b">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjMtMTItMS0xLTI0NTQz_9fc07a93-0079-4c00-9f04-81ae42aba591">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide789f0109144f18a87971e164951119_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMi0xLTEtMjQ1NDM_5ee228f6-3698-44ba-9a50-42b6582f1745">29,019,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide789f0109144f18a87971e164951119_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtNC0xLTEtMjQ1NDM_7512dc3e-fd43-4259-840d-60ec0ba9a2e6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd2b799a58640109328cde5026037c6_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtNi0xLTEtMjQ1NDM_27a9f264-f32b-49b2-b846-c411ab4dfd35">646,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61d9a9c176034c01bafbe635f0ba6f6a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtOC0xLTEtMjQ1NDM_4147a97e-0cef-4c82-9c23-eaac2378c646">304,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3589afc968435cb10d5cb10bf4738a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMTAtMS0xLTI0NTQz_cd50538e-0edc-4df4-bc1a-3a8f594f6965">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMTItMS0xLTI0NTQz_aa14aeaa-c923-4a2b-9a01-b87f8c4b54f2">341,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with employee equity incentive plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fea2d8c84be4bf68ebf457a8a6c2b3f_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtMi0xLTEtMjQ1NDM_d459284c-dd1e-4fcc-bb7c-60c31700f712">474,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtNi0xLTEtMjQ1NDM_9bcd2809-62b0-4935-817a-496b008d840f">8,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtMTItMS0xLTI0NTQz_fac78723-4c6c-4f71-b46e-4ee906b22baf">8,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding upon vesting of restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjctNi0xLTEtMjQ1NDM_2f5230c2-e762-49e4-81fe-82438d1476af">25,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjctMTItMS0xLTI0NTQz_d897fdf2-16f7-421c-958b-a6195001dc3b">25,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjgtNi0xLTEtMjQ1NDM_2e640453-e0f0-4ac6-8a1a-6ad479d5c6b6">56,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjgtMTItMS0xLTI0NTQz_13fd9c15-331f-4afe-96ad-1f5d71668740">56,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie425bc192eea43c4998ce9d1e84e53a4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzAtOC0xLTEtMjQ1NDM_294a6968-d3bc-4e08-b454-30aa59bcd6d5">101,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzAtMTItMS0xLTI0NTQz_c43b54f4-33a1-445a-9c46-393a366f40a1">101,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in unrealized loss on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fa6df92e00f41ecb73a3d3d2c300e65_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzEtMTAtMS0xLTI0NTQz_e9e79756-b8da-4906-98f1-f92833e1238d">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzEtMTItMS0xLTI0NTQz_d1a0d140-cc1a-42ef-93d3-37cb236628e9">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08b094e744ff4732b19b6fd8fa91c517_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMi0xLTEtMjQ1NDM_cf44f272-03b6-4ce9-b8d3-baf3bce8332b">29,493,726</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b094e744ff4732b19b6fd8fa91c517_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItNC0xLTEtMjQ1NDM_29e7d03f-5aea-4b33-8b34-2a81ee8988f3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a474771fc24576ab925990fae0b21d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItNi0xLTEtMjQ1NDM_278ac426-a1b7-40d5-9486-f9e2d39609e5">685,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81c8908741ec4840961679280bd8d5d3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItOC0xLTEtMjQ1NDM_70f623f0-605b-4376-a0e6-15413ab1d774">406,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie322229942454b178e796984276627cd_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMTAtMS0xLTI0NTQz_8f3c9aea-a22f-4baf-9cd5-830fcaa04380">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMTItMS0xLTI0NTQz_31536131-31e3-451e-99c3-a44cdb2b0002">279,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy0xLTEtMS0yNDU0Mw_8e14c783-3843-4997-860f-37d75bc6fe39">101,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy0zLTEtMS0yNDU0Mw_2aadc314-d90d-4873-b722-f470b1b10227">43,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy01LTEtMS0yNDU0Mw_e1eaae2f-ef0a-4c3c-9a50-8b3cc05bd067">54,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS0xLTEtMS0yNDU0Mw_34b32dc5-a2ec-4ca8-9248-6ba3c557c03e">9,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS0zLTEtMS0yNDU0Mw_8fd7a538-c958-4a75-bf40-385ecce241f7">6,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS01LTEtMS0yNDU0Mw_81ee14ec-e36d-4580-9f85-9fc9adcc3271">3,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi0xLTEtMS0yNDU0Mw_42d8609e-d21e-4162-af3c-927aae59e3cd">54,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi0zLTEtMS0yNDU0Mw_fbb1d295-0f6d-4add-b4bd-5114f69ab40a">41,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi01LTEtMS0yNDU0Mw_f76da336-ead9-44ce-8bb6-a1b2bd6c202a">26,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy0xLTEtMS0yNDU0Mw_9af54dda-487a-40d6-8aeb-6910d77d762e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy0zLTEtMS0yNDU0Mw_5808702d-dbe9-41dc-ae6f-5e0795199b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy01LTEtMS0yNDU0Mw_1f6059dd-da93-4319-8c1b-93c2c92af4a3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discounts on investments, net of premium amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC0xLTEtMS0yNDU0Mw_f88c8e2e-786f-474c-82d5-1f7bbd0bee90">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC0zLTEtMS0yNDU0Mw_ab2b9d0d-1ca9-4b30-acf3-5bf4bac04980">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC01LTEtMS0yNDU0Mw_f7e4b7a5-d71e-4219-9a6d-456b7671b04e">884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for bad debt and contractual allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:ProvisionForBadDebtAndContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtMS0xLTEtMjQ1NDM_ee2f933c-c19c-4c9c-ba22-e06f910545b2">37,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:ProvisionForBadDebtAndContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtMy0xLTEtMjQ1NDM_2ea8201f-d73e-4e5b-8b3d-8ca2cd70eeb3">31,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:ProvisionForBadDebtAndContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtNS0xLTEtMjQ1NDM_96d812be-f510-4eb6-a4d4-a94362d8eac4">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:OperatingLeaseRightOfUseAssetsAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtMS0xLTEtMjQ1NDM_3792a153-1c9f-4270-b264-d33f56f59c4f">6,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:OperatingLeaseRightOfUseAssetsAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtMy0xLTEtMjQ1NDM_5124839e-7ebe-4042-a215-3e15ac02b76c">6,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:OperatingLeaseRightOfUseAssetsAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtNS0xLTEtMjQ1NDM_3205e3ff-0551-40c1-8c42-d47365315bcc">8,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtMS0xLTEtMjQ1NDM_304864e9-bb67-4311-b8b1-0facd4d8a861">53,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtMy0xLTEtMjQ1NDM_1541221e-705c-402f-b1e4-1214bf04a82d">37,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtNS0xLTEtMjQ1NDM_1b87e5de-5e4b-4f6c-b586-f551b9b29135">28,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctMS0xLTEtMjQ1NDM_f1165e69-18d0-448f-aab4-94a143773826">4,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctMy0xLTEtMjQ1NDM_28817909-1ff4-4f33-aeb5-68374fceef38">1,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctNS0xLTEtMjQ1NDM_f7787f2b-3598-4bfc-b0ed-8b06c746f375">1,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtMS0xLTEtMjQ1NDM_2364a498-baf2-40a6-a9a0-41a4149b9f14">2,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtMy0xLTEtMjQ1NDM_def2e3e7-8ad6-46e0-a229-372140da1240">3,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtNS0xLTEtMjQ1NDM_8125257e-faf4-4276-a785-7d1f3483072e">696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktMS0xLTEtMjQ1NDM_b9f618f6-3273-44cf-b251-543584e35d07">1,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktMy0xLTEtMjQ1NDM_3e8bf22a-ce76-4f3c-aac7-55eee9a70a2d">6,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktNS0xLTEtMjQ1NDM_b1f2ce0c-3a22-4a14-ac9c-534ce959d083">4,732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtMS0xLTEtMjQ1NDM_dcf091b6-cb31-4763-a7c8-8d37e70c0599">6,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtMy0xLTEtMjQ1NDM_a158dcf9-2990-4d94-8eac-c31bd76c0b0c">3,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtNS0xLTEtMjQ1NDM_777b9b1c-dcbe-4578-8069-084edfd43b04">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtMS0xLTEtMjQ1NDM_87038775-681a-4b61-868c-70a5966753a0">7,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtMy0xLTEtMjQ1NDM_5c1b934e-bcd2-479d-ae6f-cc4481933b77">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtNS0xLTEtMjQ1NDM_7725ac91-ab07-427f-a05e-c8b272875680">6,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtMS0xLTEtMjQ1NDM_2bb50f09-a69f-4777-84dd-dee2b76a2496">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtMy0xLTEtMjQ1NDM_410ca1e2-16bc-4536-9b9e-6c4ac54b7f9f">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtNS0xLTEtMjQ1NDM_48cc666c-13fa-4775-8d02-5ba5635fc2ce">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtMS0xLTEtMjQ1NDM_dd7659c0-8a96-4918-b6ca-dc5f1c06ac9b">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="irtc:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtMy0xLTEtMjQ1NDM_fe4b1646-b462-4119-8e8b-f909729934bb">4,819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="irtc:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtNS0xLTEtMjQ1NDM_910000db-4e70-4542-aefc-afbaade7ae06">5,241</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtMS0xLTEtMjQ1NDM_6bedb807-c9f8-44a2-b920-84c1911ac978">37,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtMy0xLTEtMjQ1NDM_e5bcae75-b9d6-4e79-a32e-2005bdabf461">13,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtNS0xLTEtMjQ1NDM_c3457e1c-d678-47bf-99f9-7a55fbc36c7d">21,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctMS0xLTEtMjQ1NDM_51234ae4-0d87-42f5-a2e6-7c7dfad3c534">28,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctMy0xLTEtMjQ1NDM_9101771f-8e5d-4e1d-8c07-b3a6ef3e78a8">13,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctNS0xLTEtMjQ1NDM_3d9e6ee2-29d0-460e-9bfa-b39ff4ea07c4">20,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtMS0xLTEtMjQ1NDM_4da9dd5f-7571-450c-9285-76c7af2899d9">122,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtMy0xLTEtMjQ1NDM_e925b568-9dbf-42da-b271-9562409232ff">277,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtNS0xLTEtMjQ1NDM_0c865b6b-115b-4609-b161-ba876196e022">165,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktMS0xLTEtMjQ1NDM_559e1e98-902e-4173-9c0c-d839d31f30e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktMy0xLTEtMjQ1NDM_67e5f314-4a37-4aed-b254-22f8e2d7369f">14,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktNS0xLTEtMjQ1NDM_f537ce2f-365b-4e50-b2ca-8b19581a1827">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of available-for-sale investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtMS0xLTEtMjQ1NDM_3dead6a5-f7b5-4893-ae71-723c250579ce">255,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtMy0xLTEtMjQ1NDM_b547d68b-4758-4d8f-9d4a-b92d62dced1b">144,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtNS0xLTEtMjQ1NDM_ef4b0b28-28b2-447e-9034-61830d2151a0">95,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtMS0xLTEtMjQ1NDM_e17e42c5-8c1d-46af-9260-6c52bfc386f9">105,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtMy0xLTEtMjQ1NDM_6862917a-ee62-4954-845b-4a4e2cbfac43">132,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtNS0xLTEtMjQ1NDM_b4a23542-ca1a-456f-af4d-0a58ac597de7">89,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with follow-on public offering, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtMS0xLTEtMjQ1NDM_62c1c2e5-323c-49b3-a14f-10da35517fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtMy0xLTEtMjQ1NDM_4b782d95-0bf4-4880-83c1-b1d1a0b23ba3">206,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtNS0xLTEtMjQ1NDM_7ba316f9-f7ac-4c5e-b069-a6877420aa39">107,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in connection with employee <br/>equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtMS0xLTEtMjQ1NDM_a0d93c4c-9027-484a-b641-39273f39e056">8,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtMy0xLTEtMjQ1NDM_364c1783-e2d1-4c0c-8e54-8efc6c983847">20,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtNS0xLTEtMjQ1NDM_18b873a3-4645-4adb-b30b-0b39ef3f6fd5">9,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding upon vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtMS0xLTEtMjQ1NDM_34edca93-c116-4890-8866-a67a893abda0">25,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtMy0xLTEtMjQ1NDM_dd0b8a87-0a9b-4644-8e91-dbcdb70ed013">10,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtNS0xLTEtMjQ1NDM_2e5ffad6-2844-4fc3-a3d6-8fdb9e5cd8c2">5,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctMS0xLTEtMjQ1NDM_768c5586-b4bd-41a6-a592-ab88ff8f0913">11,667</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctMy0xLTEtMjQ1NDM_10432393-90a9-48ff-ba83-50aa03ae83d6">1,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctNS0xLTEtMjQ1NDM_7c46117e-85aa-48e3-a3ac-fa58da9eb2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtMS0xLTEtMjQ1NDM_7d94cbea-cea9-4f6b-afac-bb46a6e429cd">28,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtMy0xLTEtMjQ1NDM_f57146db-7e7f-420c-9191-b0a18201aa03">214,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtNS0xLTEtMjQ1NDM_803f4956-1619-444a-b356-bba67fa47012">111,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtMS0xLTEtMjQ1NDM_720696df-c4dc-4f2f-aed2-a53815dd290e">38,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtMy0xLTEtMjQ1NDM_7707e6c6-bb36-48d2-a871-c170c350f696">68,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtNS0xLTEtMjQ1NDM_2ba06211-4a69-4453-9c6e-b66a3f4adf1f">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItMS0xLTEtMjQ1NDM_a69fa9c2-bfce-4240-b54a-57a508253388">88,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItMy0xLTEtMjQ1NDM_2b37f637-fb14-4699-96de-950e621335d5">20,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItNS0xLTEtMjQ1NDM_f1fd96a8-39d3-4f7e-acbc-1c86de428ba4">20,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of&#160;&#160;year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtMS0xLTEtMjQ1NDM_a9dac06e-d8d4-4c55-b895-e266f43c45b0">127,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtMy0xLTEtMjQ1NDM_7209eadc-5fc5-4fc8-b1b4-9f450ec9fb03">88,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtNS0xLTEtMjQ1NDM_d8d53480-e46c-42a3-9e54-cfd77934a220">20,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtMS0xLTEtMjQ1NDM_728a7050-d18e-4602-9010-34aaa0b76015">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtMy0xLTEtMjQ1NDM_0269ae0c-7edb-44b1-9503-b37f457a6437">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtNS0xLTEtMjQ1NDM_7cde4549-5f38-4fdd-8245-2a4aa235bcee">1,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctMS0xLTEtMjQ1NDM_dd088202-79c8-4c73-88f5-73f12ea83f8e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctMy0xLTEtMjQ1NDM_207df3d6-8a44-4e8c-a5be-93d0e24a4dc8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctNS0xLTEtMjQ1NDM_73353609-2c09-4ab2-8e5f-bb1cb314a98b">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred offering costs included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:StockIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtMS0xLTEtMjQ1NDM_911616f3-4083-4e13-98fe-ac7cab6d3f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:StockIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtMy0xLTEtMjQ1NDM_5ddd15b3-4dea-4ceb-9036-93761903b1c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtNS0xLTEtMjQ1NDM_47d9b97e-11fc-4c71-8456-3c07666a4da3">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktMS0xLTEtMjQ1NDM_ecf3aa5a-1685-4bf9-ab43-1d08b1cd0c7c">6,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktMy0xLTEtMjQ1NDM_c822057c-fbb5-43dc-b3d9-60e41f35c83d">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktNS0xLTEtMjQ1NDM_28612ebd-701d-43df-9c23-2155bd85445f">88,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized stock-based compensation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtMS0xLTEtMjQ1NDM_37501099-23a7-4d68-9ff9-cb621f941b5c">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtMy0xLTEtMjQ1NDM_1e8a0276-1fba-4a87-a5ea-e82f09f13a93">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtNS0xLTEtMjQ1NDM_516abb96-81cb-4ac1-8812-0473cfa639e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRHYTHM TECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMzUxOA_3ae59437-ffcc-47ec-8233-aa97566e7d11" continuedAt="ie2c82202bdd94994b17debec6e5a7ebc" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="ie2c82202bdd94994b17debec6e5a7ebc"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iRhythm Technologies, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in September 2006. The Company is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. The Company began commercial operations in the United States in 2009 following clearance by the U.S. Food and Drug Administration.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is headquartered in San Francisco, California, which also serves as a clinical center. The Company has additional clinical centers in Lincolnshire, Illinois and Houston, Texas and a manufacturing facility in Cypress, California. In March 2016, the Company formed a wholly-owned subsidiary in the United Kingdom. Additionally, in June 2021, the Company formed a wholly-owned subsidiary in Singapore. The Company manages its operations as a single operating segment. Substantially all of the Company&#8217;s assets are maintained in the United States. The Company derives substantially all of its revenue from the provision of services to customers in the United States.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 10, 2019, the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTEzOA_4374321e-8403-43e8-9b96-8680960bd762">1,575,342</ix:nonFraction> shares (the "2019 Shares") of common stock, in a public offering at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1486d77445c34613a8e3383fbbdb5025_I20190910" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTIyMA_b51cf04a-5190-41a7-9d7b-f493adabe364">73.00</ix:nonFraction> per share. The 2019 Shares included the full exercise of the underwriters&#8217; option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i1486d77445c34613a8e3383fbbdb5025_I20190910" decimals="INF" name="irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTMzMQ_c982f4f3-0156-45f5-9c75-fa30f8b64b57">205,479</ix:nonFraction> shares of common stock. Total proceeds received from the offering were $<ix:nonFraction unitRef="usd" contextRef="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTQwNQ_bfc4f3e5-e78b-42cb-a530-e9666e3b746b">107.3</ix:nonFraction>&#160;million, after deducting discounts and issuance costs.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company issued and sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTUyMA_5c877827-9cf7-4235-9187-8d66492b9268">1,257,142</ix:nonFraction> shares (the "Shares") of common stock, in a public offering at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e80ace037a44aa1bc75148d38174bb5_I20200821" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTU5Nw_37dc0c94-1822-46b4-9f4c-b6e534cdc857">175.00</ix:nonFraction> per share. The Shares included the full exercise of the underwriters&#8217; option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i4e80ace037a44aa1bc75148d38174bb5_I20200821" decimals="INF" name="irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTcwMw_a7693c38-c9cd-4806-ba3b-4a0bbdd4db51">163,975</ix:nonFraction> shares of common stock. Total proceeds received from the offering were $<ix:nonFraction unitRef="usd" contextRef="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTc3Nw_d6d3685a-dea9-4dca-96d2-be9c01dd1b1b">206.8</ix:nonFraction> million, after deducting discounts and issuance costs.</span></div></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTc_72f98496-a636-479b-b4b2-e1263227eabb" continuedAt="idf5228afee254cb4a449977b9fc75db3" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="idf5228afee254cb4a449977b9fc75db3" continuedAt="ia6ae4c2c4c224fbca06f8cd1fac3faa2"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTg_303fb8c0-5b43-4880-93e5-e1ea36942bf3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of iRhythm Technologies, Inc. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The financial statements of the Company&#8217;s subsidiary use the U.S. dollar as the functional currency. For all non-functional currency balances, the remeasurement of such balances to functional currency results in a foreign exchange transaction gain or loss, which is recorded in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:RiskAndUncertaintiesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTE_75bcf2ab-6957-4071-a25a-71d4b95716aa" continuedAt="ic1270dce99ca47849ec6af7c69437215" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, the Company has experienced significant business disruptions, restrictions on its ability to travel, reduction in access to customers due to diverted resources at hospitals, slower response times from payors who are also facing business interruptions, and shortened business hours as governments institute prolonged shelter-in-place and/or self-quarantine mandates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, Company personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where the Company's headquarters is located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. The Company is also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the Company has instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While the Company has continued to deliver its Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="ia6ae4c2c4c224fbca06f8cd1fac3faa2" continuedAt="i27cf9ea246b843f593818378d32ad821"><ix:continuation id="ic1270dce99ca47849ec6af7c69437215" continuedAt="i22244e70ed294d7487e1fb85d7d31676"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">measures at the Company's facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminishe</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, the Company has adapted its service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended June 30, 2021, the Company experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, the Company experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions within the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could meaningfully impact the volume of our patient registrations in future periods.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is continuously reviewing its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. The Company believes it will have adequate liquidity over the next 12 months to operate its business and to meet its cash requirements. As of December 31, 2021, the Company is in compliance with its debt covenants. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on liquidity, capital resources, supply chain, operations and business and those of the third parties on which the Company relies, and could worsen over time. The extent to which the COVID-19 pandemic impacts the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the COVID-19 pandemic or treat its impact, among others. The full extent of potential delays or impacts on the business, financial condition, cash flows and results of operations remains unknown. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing the Company&#8217;s ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact short-term and long-term liquidity and the ability to operate on a timely basis, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for the Zio service, which would significantly harm the Company. Government and other third-party payors require the Company to report the service for which it is seeking reimbursement by using a Current Procedural Terminology (&#8220;CPT&#8221;), code-set maintained by the American Medical Association (&#8220;AMA&#8221;). For Zio XT, the Company had historically utilized temporary CPT codes (or Category III CPT codes) used for newly introduced technologies and specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and Centers for Medicare and Medicaid (&#8220;CMS&#8221;). On October 25, 2019, the AMA&#8217;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. In November 2021, CMS published the Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;2022 Final Rule&#8221;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Company&#8217;s Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#8220;MAC&#8221; or &#8220;MACs&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#8220;NCD&#8221;) by CMS, or at the local level through a local coverage determination (&#8220;LCD&#8221;), by one or more of the regional Medicare Administrative Contractors (&#8220;MACs&#8221;) who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i27cf9ea246b843f593818378d32ad821" continuedAt="i69d233e9a9004afe88565e3ca2ebb828"><ix:continuation id="i22244e70ed294d7487e1fb85d7d31676" continuedAt="i48e3b0cb20ce4f98aa27ce8bf2954132"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#8220;IDTF&#8221;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $<ix:nonFraction unitRef="usd" contextRef="i64b979f3794644df876abe57a7d76980_I20220110" decimals="INF" name="irtc:CostReimbursementRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNzE0NjgyNTY2NDgxNg_25ad3b28-01a4-423f-b250-2a7f083b90ea">223</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3706f468116148dbabf8b4fb4c6f96e7_I20220110" decimals="INF" name="irtc:CostReimbursementRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNzE0NjgyNTY2NDgyMg_755788d0-ed8e-47e2-b8f3-3eac43a24a6c">233</ix:nonFraction>, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the published Medicare reimbursement rates are not adequate to support our cost structure, or we are unable to reduce our overall cost structure, the Company may be unable to provide the Zio service or would experience a significant loss of revenue, either of which would have a material adverse effect on our cash flows, results of operations, and financial condition.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, the Company will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if the Company is unsuccessful in improving the Medicare rates, the Company believes that commercial rates may begin to be more negatively impacted next year. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTM_2289c83d-4b12-47eb-8221-5457677613f4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (&#8220;PCBAs&#8221;), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjY_f3cd9ee8-d1a5-4019-bdb1-6cff7563904a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTQ_38998a43-203c-4857-8c92-e5ecd7735689" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDM_229d9da7-f42d-427e-9a8f-a894956f590a" continuedAt="i9268196db37f407aa3731efd812d9259" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are carried at fair value based upon quoted market prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically assesses its portfolio of debt investments for impairment. For debt securities in an unrealized loss position, this assessment first takes into account the intent to sell, or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value through interest and other, net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i69d233e9a9004afe88565e3ca2ebb828" continuedAt="ic6f95dfe043a48a2b3d059ff48684aad"><ix:continuation id="i9268196db37f407aa3731efd812d9259"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses on available-for-sale debt securities are recognized in other income, net in the condensed consolidated statements of operations, and any remaining unrealized losses, net of taxes, are reported as a component of accumulated other comprehensive loss. The Company did not recognize any credit losses on its available-for-sale securities during the year ended December 31, 2021 and there were no impairment charges for unrealized losses in the periods presented. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of available-for-sale securities sold is based on the specific-identification method and realized gains and losses are included in earnings. Amortization of premiums and accretion of discounts are reported as a component of other income, net.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjE_d133852a-fdf5-4079-9576-24e84f642a68" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable includes amounts due to the Company from healthcare institutions, third-party payors, and government payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts and contractual allowances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on its assessment of the collectability of customer accounts and recognizes the provision as a component of selling, general and administrative expenses. The Company records a provision for contractual allowances based on the estimated differences between contracted amounts and expected collection rates. Such provisions are based on the Company's historical experience and are reported as a reduction of revenue.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews the allowances by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to administrative delays with payors and a combination of negotiations with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, inherent uncertainty caused by the longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDg_c5210890-5e39-4fc9-adb5-7dcbe62f6595" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for doubtful accounts (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi0xLTEtMS0yNDU0Mw_bac8b67d-7664-46c4-a096-d9425243ba63">12,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi0zLTEtMS0yNDU0Mw_245274c7-b4f4-4799-8763-562f7ccf12ee">9,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi01LTEtMS0yNDU0Mw_a6053a19-b9e1-4c94-a527-2eba6af545f2">7,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: adoption of ASC 326</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ed4074ebd54c72b7c475f8882ba2ad_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy0xLTEtMS0yNDU0Mw_3b21e8ba-770c-493b-9b5c-6cdb79b1b000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3ebc6891a9455e9c6fb6ea48899e99_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy0zLTEtMS0yNDU0Mw_81d1d692-518d-46a4-8f43-02b8c3c45b38">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61d7a2d6f1774f9cb8ba5206eeae226e_I20181231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy01LTEtMS0yNDU0Mw_a4cac223-29d1-4c1b-9bd2-3fadd0b84013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: provision for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC0xLTEtMS0yNDU0Mw_f71e7bae-fe57-4e46-aab9-cc489a24e25b">9,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC0zLTEtMS0yNDU0Mw_119c62c6-f4c8-4fc1-a87e-ad988e3f378a">10,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC01LTEtMS0yNDU0Mw_6f6643bc-7381-42fe-be08-0e99ccb83b69">9,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: write-offs, net of recoveries and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS0xLTEtMS0yNDU0Mw_ca89e0f1-bead-4366-b7d2-5a6defff3929">8,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS0zLTEtMS0yNDU0Mw_4a2b0345-23c9-4ced-a17b-8ad9ff57e171">7,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS01LTEtMS0yNDU0Mw_763556ce-0ce2-4440-a407-606231d82643">7,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi0xLTEtMS0yNDU0Mw_e3094ca8-301d-490f-815f-5326e80a054d">14,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi0zLTEtMS0yNDU0Mw_c01482eb-7b8c-4dba-af10-ea123356783a">12,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi01LTEtMS0yNDU0Mw_0ead9ebf-2a7d-43f9-8418-5d0b00578cfe">9,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="ic6f95dfe043a48a2b3d059ff48684aad" continuedAt="i41d3fc1c35cf40faaa216aecb6ac5493"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ScheduleOfChangeInContractualAllowanceTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjc_787f8565-052d-4d91-aaf5-e4d859d6d6d3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the contractual allowance (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi0xLTEtMS0yNDU0Mw_d2254b9d-014e-4d7c-80d0-642a3105113d">21,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi0zLTEtMS0yNDU0Mw_383101c4-f354-41ac-8051-bb59ae16baa2">15,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi01LTEtMS0yNDU0Mw_69127478-1174-43c6-8e70-6073e8329014">9,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: allowance for contractual adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:AccountsReceivableAllowanceForContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy0xLTEtMS0yNDU0Mw_ed5cae31-8fc4-486c-8a46-339bfe151b82">27,459</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:AccountsReceivableAllowanceForContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy0zLTEtMS0yNDU0Mw_892fa86d-fdf5-43f7-b445-618bfab71666">20,916</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:AccountsReceivableAllowanceForContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy01LTEtMS0yNDU0Mw_16030ca2-d298-40cc-a4c0-99b53aaa3c6b">15,518</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: contractual adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:AccountsReceivableContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC0xLTEtMS0yNDU0Mw_4ac0e89e-f980-4328-b649-f830f657c775">17,466</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:AccountsReceivableContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC0zLTEtMS0yNDU0Mw_f4bfe4a1-8d9f-4891-b74e-87f6c950e7d4">15,068</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:AccountsReceivableContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC01LTEtMS0yNDU0Mw_d3680579-64e7-4044-8f00-f6aea58b1943">9,290</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS0xLTEtMS0yNDU0Mw_37a089fe-6c35-44ba-bd01-ebc789c9cea2">31,274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS0zLTEtMS0yNDU0Mw_6bbbd1ba-47b4-4f1a-9118-31fadd1e76f5">21,281</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="irtc:AccountsReceivableForContractualAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS01LTEtMS0yNDU0Mw_3c92830d-df98-4ca9-aa7a-ad997242fc33">15,433</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjI_d4c9bbda-18fc-4095-a19f-c7d0182406ce" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company&#8217;s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), accounted for approximately <ix:nonFraction unitRef="number" contextRef="idfb7f500e8934bd2b96bfe5eda7af356_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNjA_d8979cd3-eb5d-49d6-8bb3-548438b609d7">14</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9db8564ddc2f47cfb7aaa008517d05ab_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNjQ_277cfd3a-04f6-4128-ae61-80e37b9e882e">27</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0624798b12fa464ca5bea6b9c12f361b_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNzE_8b20de65-7207-4a08-8303-60c54b872d2b">27</ix:nonFraction>% of the Company&#8217;s revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. CMS accounted for <ix:nonFraction unitRef="number" contextRef="i50fcb4b97216498585c183117c671309_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkzNjY_011f4db4-ca9c-4155-a03f-8bb85e17de84">8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i39c78456bd4045eab249ad061311ce9e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkzNzM_d097caf0-9f29-47ab-b00f-33745612c8cc">20</ix:nonFraction>% of accounts receivable as of December&#160;31, 2021 and 2020, respectively.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:InflationaryRiskPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzg0ODI5MDc5OTU1OA_67223237-8bb3-4bd5-9196-fb4f08c7e8ea" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inflationary Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously monitors the effects of inflationary factors, such as increases in cost of goods sold and selling and operating expenses, which may adversely affect its results of operations. Specifically, the Company may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages paid to its employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict the Company's ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. The Company's inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjM_1f01e6ef-88f4-4f30-9542-d615094f4738" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio monitor and the adhesive that binds the Zio monitor to a patient&#8217;s body. These components and materials are critical, and there could be a considerable delay in finding alternative sources of supply. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A global semiconductor supply shortage is having wide-ranging effects across multiple industries. The supply shortage has impacted multiple suppliers that provide the printed circuit board assemblies to the Company. The semiconductor supply shortage may have an impact on the Company until global supply is sufficient for global demand.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i48e3b0cb20ce4f98aa27ce8bf2954132"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Supply Chain Constraints</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economies worldwide have also seen other indirect COVID-19 pandemic related disruptions including supply chain impacts, material inflation, and labor constraints in certain markets and geographies. Such economic disruption has had an adverse effect on the Company's business environment as increased lead times and component shortages have resulted in higher inventory costs. While the Company has increased inventory safety stock levels to help mitigate the delays and disruptions in supply, the Company cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not further impact its supply chain.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i41d3fc1c35cf40faaa216aecb6ac5493" continuedAt="if26f617fe5984a06acc64a03c8d4a9d3"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTU_5a0ea879-7c33-404c-894e-32ebcd63dad4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory owned by the Company is valued at cost, on the first in, first out (&#8220;FIFO&#8221;) basis, or the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand. The Company also records market value based write-downs on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzU_1ba4b108-cc7c-4415-aae8-e836bb94d21c" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d">three</span> to <ix:nonNumeric contextRef="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNjM_7e4e8988-da37-461b-88b0-140b0f6ce149">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTI_111a9199-579a-4a60-8dc4-8cd5a6e41d7a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal-Use Software</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs related to internal-use software during the application development stage. Costs related to planning and post implementation activities are expensed as incurred. Capitalized internal-use software is amortized, and recognized as cost of revenue, on a straight-line basis over the estimated useful life, which is up to <ix:nonNumeric contextRef="ia00144f28bbd4b3b8d6872c91909a2d2_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjE2NjM_02a08bef-6151-42f0-84d5-f3bc639b4446">five years</ix:nonNumeric>. The Company evaluates the useful lives of these assets on an annual basis, and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Capitalized internal-use software costs are classified as a component of property and equipment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTY_f01a33d5-4f28-4bbb-a9b5-be80f8beeed4" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible net assets acquired in business combinations. Goodwill is tested for impairment on an annual basis and at any other time if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Such events or circumstances may include significant adverse changes in the general business climate, among other things. The impairment test is performed by determining the enterprise fair value of the Company, which is primarily based on the Company&#8217;s market capitalization. If the Company&#8217;s carrying value, as a one reporting unit entity, is less than its fair value, then the fair value is allocated to all of its assets and liabilities (including any unrecognized intangible assets) as if the fair value was the purchase price to acquire the Company. The excess of the fair value over the amounts assigned to the Company&#8217;s assets and liabilities is the implied fair value of the goodwill. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. The Company did not record any charges related to goodwill impairment in any of the periods presented in these consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDk_4749c17c-ddae-4715-a371-d749d524e691" continuedAt="ia22c1b3d1f4d443fb64b62758232c09a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company annually reviews long-lived assets for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. To date, there have been <ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDA_7094b5e9-af53-4d7a-8dfb-3956ef4e4022">no</ix:nonFraction> such impairments of long-lived assets.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia22c1b3d1f4d443fb64b62758232c09a">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects this decision will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</ix:continuation> Refer to Note 13. Subsequent Events for further details.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="if26f617fe5984a06acc64a03c8d4a9d3" continuedAt="i5a8eb2bfb09f4acdad5c295bbc168721"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:OtherAssetsPolicyPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzY_6f8b81c3-c6e9-4b86-a6f5-0fd8e611df9a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses Printed Circuit Board Assemblies (&#8220;PCBAs&#8221;), in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the ZIO AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT or Zio AT monitor, or a wireless gateway is used with a Zio AT monitor a portion of the cost of the PCBA and/or gateway is recorded as a cost of revenue. The PCBAs are recorded as other assets and were $<ix:nonFraction unitRef="usd" contextRef="i325e1cd03bd94e598819e2c8159b85ab_I20211231" decimals="-5" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjQ1Njg_4d6124eb-f239-4aed-9526-773da4ebaff4">13.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id60332e77ea34183a58d2508319463aa_I20201231" decimals="-5" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjQ1NzU_b83bf943-dee0-4611-a3f6-d963e2847e98">12.6</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. The Company has based its estimates of how many times a PCBA can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. The Company periodically evaluates the use estimate.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDQ_603c3ec5-d6e6-47c0-852c-c496389348ce" continuedAt="i6a8bd98a426f412389ad05d032119197" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6a8bd98a426f412389ad05d032119197">Comprehensive loss represents all changes in stockholders&#8217; equity during the period from non-owner sources. The Company&#8217;s unrealized gains and losses on available-for-sale securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDE_ed29c64f-40f7-4ca9-8b3f-1dd1d935adda" continuedAt="i952085caba4e41da95853576e3b8ce03" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s revenue is generated primarily from the provision of its cardiac rhythm monitoring service, the Zio XT service. The Zio XT is a cardiac rhythm monitoring service that has a patient wear period of up to 14 days and is billable when the monitoring reports are delivered to the healthcare provider, which is also when the service is complete and the Company recognizes revenue. The time from when the patient has the Zio XT device applied to the time the report is posted is generally around 25 days. The Company has concluded that the Zio XT service is one performance obligation on the basis that the customer cannot benefit from each component of the service on its own or together with other resources that are readily available to the customer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what the Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating patients that require more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria. The Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report with two performance obligations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes as revenue the amount of consideration to which it expects to be entitled in exchange for performing the service. The consideration the Company is entitled to varies by portfolio, as further defined below, and includes estimates that require significant judgment by management. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, will pay the Company for some or all of the service on the patient&#8217;s behalf. Separate contractual arrangements exist between the Company and third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A small portion of the Company&#8217;s transactions are covered by third-party payors with whom there is neither a contractual agreement nor an established amount that the third-party payor will pay. In determining the collectability and transaction price for its service, the Company considers factors such as insurance claims which are adjudicated as allowable under the applicable policy and payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments. Certain of these factors are forms of variable consideration which are only included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Contracted third-party payors &#8211; The Company has contracts with negotiated prices for services provided to patients with commercial healthcare insurance coverage.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CMS &#8211; The Company has received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant CPT code rates for the services rendered to the patient covered by CMS.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-contracted third-party payors &#8211; Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i5a8eb2bfb09f4acdad5c295bbc168721" continuedAt="id2e027e9a9764dc49ca3718b05d09b62"><ix:continuation id="i952085caba4e41da95853576e3b8ce03"><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for determining revenue recognition is based on factors including an average of the Company&#8217;s historical collection experience for its non-contracted services. This rate is reviewed at least quarterly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Healthcare institutions &#8211; Healthcare institutions are typically hospitals or physician practices in which the Company has negotiated amounts for its monitoring services, including certain governmental agencies such as the Veterans Administration and Department of Defense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition whereby services provided under each of the above payor types form a separate portfolio. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, the Company has concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For contracted and CMS portfolios, the Company recognizes revenue, net of contractual allowances, and recognizes an allowance for doubtful accounts for uncollectible patient accounts receivable. The transaction price is determined based on negotiated rates, and the Company has historical experience of collecting substantially all of these contracted rates. These contracts also impose a number of obligations regarding billing and other matters, and the Company&#8217;s noncompliance with a material term of such contracts may result in a denial of the claim. The Company accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price recognized as revenue. The Company estimates the denied claims which require management judgment. The estimated denied claims are based on historical information and judgement includes the historical period utilized. The Company monitors the estimated denied claims against the latest available information, and subsequent changes to the estimated denied claims are recorded as an adjustment to revenue in the periods during which such changes occur. Delays in claims submissions could lead to an increase in denials if we miss the payors&#8217; filing deadlines and could result in a reduction in the Company&#8217;s receipt of payments. Historical cash collection indicates that it is probable that substantially all of the transaction price, less the estimate of denied claims, will be received. Contracted payors may require that we bill patient co-payments and deductibles and from time to time we may not be able to collect such amounts due to credit risk. The Company provides for estimates of uncollectible patient accounts receivable, based upon historical experience where judgment includes the historical period utilized, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to a combination of negotiations with payors and administrative delays with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021. For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For non-contracted portfolios, the Company is providing an implicit price concession due to the lack of a contracted rate with the underlying payor, the result of which requires the Company to estimate the transaction price based on historical cash collections utilizing the expected value method. All subsequent adjustments to the transaction price are recorded as an adjustment to revenue.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For healthcare institutions, the transaction price is determined based on negotiated rates, and the Company has historical experience collecting substantially all of these contracted rates. Historical cash collection indicates that it is probable that substantially all of the transaction price will be received. As such, the Company is not providing an implicit price concession but, rather, has chosen to accept the risk of default, and any subsequent uncollected amounts are recorded as bad debt expense.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="id2e027e9a9764dc49ca3718b05d09b62" continuedAt="ie29c22fec46448ee8601ff63aec2bf2f"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with customers by payor type. The Company believes these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzM_f99b203d-1e98-4a52-a0cf-39923e420da5" continuedAt="id6be737e7332419dafd4ef21364e3185" escape="true">Disaggregated revenue by payor type and major service line for the years ended December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="id6be737e7332419dafd4ef21364e3185"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracted third-party payors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id814a6da95c1480a914c87a5028a3a5b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi0xLTEtMS0yNDU0Mw_657df917-76a7-4339-b953-8f9563bd3e51">193,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0e1acdecce4bc3890820a3d9e96ee2_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi0zLTEtMS0yNDU0Mw_1e08295d-7c38-4193-bc65-42cc88a1cd66">135,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af04eb3c79a43ebbb272cec9b11188a_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi01LTEtMS0yNDU0Mw_52235a13-d815-4792-9fb1-8869fb284096">101,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contracted third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6ac2500f824b45a5cffbbccaa42236_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy0xLTEtMS0yNDU0Mw_21e34388-d2d9-41a1-aeb8-0774e9eca7e5">26,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f5215d1174ad28382c2494c5399c6_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy0zLTEtMS0yNDU0Mw_8eb7ab5c-9a3e-4af3-8b05-f9e8205e8c88">15,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7a7ea2b4b2b4143afc1c82e0fa1f8dd_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy01LTEtMS0yNDU0Mw_2e220715-eed1-431c-8d77-b028b9c54d13">10,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1fb6ef69b842c6bc4f8e224841fd0e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC0xLTEtMS0yNDU0Mw_bd36f020-0fd9-402a-8fa1-52e445c39c5e">44,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16459be997449c3b7b484cc95d1339e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC0zLTEtMS0yNDU0Mw_666b16a8-6d61-40f0-8862-33256d22bcd0">72,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie651d17a114348fdb3edf9a8b0b5827c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC01LTEtMS0yNDU0Mw_8e3dc698-7696-4576-a6bd-053ff73e07bb">58,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare institutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f360678d4246b89d728c59cd20976d_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS0xLTEtMS0yNDU0Mw_0499721f-e91d-461a-95a2-a096d961c889">57,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a7c57c18f549c5852ef8cd95cdc265_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS0zLTEtMS0yNDU0Mw_00c8a476-b753-4516-b434-1e1d844bd339">41,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifddd05d06ccf4b7d89a49501aaf7f236_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS01LTEtMS0yNDU0Mw_1acf76f8-c6d9-4fc5-a355-c706178d1f50">43,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi0xLTEtMS0yNDU0Mw_c70b5b8b-9a4f-456e-8e3a-9dc1b67d21f0">322,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi0zLTEtMS0yNDU0Mw_b8316ae8-7f01-4d2e-a143-4444021190f3">265,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi01LTEtMS0yNDU0Mw_f732e586-d418-4a1c-a476-caa2ffc5c55d">214,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ContractLiabilityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzc_4fe65234-349e-41e9-93e5-018969bb3cc5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires an entity to present a revenue contract as a contract liability when the Company has an obligation to transfer goods or services to a customer for which the Company has received consideration from the customer, or an amount of consideration from the customer is due and unconditional (whichever is earlier).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s customers pay the Company directly for the Zio XT service upon shipment of devices. Such advance payments are contract liabilities and are recorded as deferred revenue on the Consolidated Balance Sheets and revenue is recognized when reports are delivered to the healthcare provider. During the year ended December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzQxOTg_2e769647-bd4f-449a-9b4c-e4191231eaaf">0.9</ix:nonFraction> million relating to the contract liability balance at the beginning of 2021 was recognized as revenue. Total revenue recognized during the year ended December 30, 2020 that was included in the contract liability balance at the beginning of 2020 was $<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzg0ODI5MDc4MTQ3Mg_ab6a81f4-959e-460e-8360-b659419993dd">1.2</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ContractCostPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDU_ec809914-ffd0-499e-8576-4cf25db8bcf6" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 340, the incremental costs of obtaining a contract with a customer are recognized as an asset. Incremental costs of obtaining a contract are those costs that an entity incurs to obtain a contract with a customer that it would not have incurred if the contract had not been obtained.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current commission programs are considered incremental. However, as a practical expedient, ASC 340 permits the Company to immediately expense contract acquisition costs, as the asset that would have resulted from capitalizing these costs will be amortized in one year or less.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDY_544fa264-2802-4682-9239-95840e260b5c" continuedAt="i2624927b1b5d4d7dabcfe28bc5d846ec" escape="true">Cost of Revenue</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2624927b1b5d4d7dabcfe28bc5d846ec">Cost of revenue includes direct labor, material costs, overhead, data analysis, customer care, equipment and infrastructure expenses, amortization of internal-use software, and shipping and handling. Direct labor includes payroll and personnel-related costs involved in manufacturing. Material costs include both the disposable costs of the device and amortization of the PCBAs. Each time the PCBA is used in a wearable Zio XT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue.</ix:continuation> </span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjU_91f00c8a-03d7-4a33-8c90-b8d4195324a9" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are expensed as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, laboratory supplies, consulting costs and overhead charges.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="ie29c22fec46448ee8601ff63aec2bf2f" continuedAt="ie433e435de6b4a18844630d3859370fa"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTk_e8d05bc9-9765-404c-90b2-a392f2389670" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been <ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjA_31a23e33-72d8-41d1-9c1f-1b006441a18d">no</ix:nonFraction> interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognize taxes on Global Intangible Low-Taxed Income as a current period expense when incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDc_baf12aab-be7e-4de8-a325-141de1e295da" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. The fair value of market condition awards is determined using the Monte-Carlo option pricing model and the fair value of stock options is determined using the Black-Scholes option pricing model. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For restricted stock, the compensation cost for these awards is based on the closing price of the Company&#8217;s common stock on the date of grant, and recognized as compensation expense on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant, net of estimated forfeitures. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzg_9864195d-2261-4bfb-9f82-4ed0c5caa62b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Common Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effect of potentially dilutive securities are anti-dilutive.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzk_7eed2632-782f-43ff-accd-032235d6b593" continuedAt="i19589bb1b7cb41f4b482494eaefa049b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Identifying a lease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both of the following terms:</span></div><div style="text-align:justify;text-indent:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to obtain substantially all of the economic benefits from use of the identified asset; and</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to direct the use of the identified asset.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Discount rate for leases</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in the lease is not readily determinable for our operating leases, the Company generally uses an incremental borrowing rate based on information available at the commencement date such as a synthetic credit rating and current cost of borrowing to determine the present value of future lease payments.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie433e435de6b4a18844630d3859370fa"><ix:continuation id="i19589bb1b7cb41f4b482494eaefa049b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease term</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term is generally the minimum noncancellable period of each lease. The Company does not include option periods in determining the right-of-use asset and operating lease liability at inception unless it is reasonably certain that the Company will exercise the option at inception or when a triggering event occurs. As of December&#160;31, 2021, no renewal options were included in the determination of lease terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease Modification</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The San Francisco Lease is in the same building with the same landlord as the lease for the Company&#8217;s prior headquarters in San Francisco (&#8220;existing lease&#8221;). Upon the commencement of the San Francisco Lease, the existing lease which had an original expiration date of February 2020, was modified to expire in September 2019 and accordingly the right-of-use asset and lease liability was remeasured as of the modification date.</span></div></ix:continuation></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzUx_53cf92d5-03a3-49a5-9458-558bac8b8b18" continuedAt="id3a54b442a5d413abb94f73d892ef4e5" escape="true">Cash Equivalents and Investments</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="id3a54b442a5d413abb94f73d892ef4e5" continuedAt="i45eb7998810140b2b785668ac0dd0881"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ1_845424fa-7fa9-4667-ba32-56d07ce0c455" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of cash equivalents and available-for-sale investments at December&#160;31, 2021 and 2020, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929e42695a1425db8d875f569956607_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy0xLTEtMS0yNDU0Mw_3c85d9fe-2ff6-4a87-ae4d-51fa10040102">110,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929e42695a1425db8d875f569956607_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy0zLTEtMS0yNDU0Mw_daaf3dfd-c08f-42ae-be4e-32113eb3b5c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929e42695a1425db8d875f569956607_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy01LTEtMS0yNDU0Mw_68ae8f30-50ff-414d-9e9f-bfd467fc8a93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id929e42695a1425db8d875f569956607_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy03LTEtMS0yNDU0Mw_bafb603e-30fc-43f2-95f6-6f08408f5f63">110,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC0xLTEtMS0yNDU0Mw_bb618a77-1e6e-4353-a49f-61997f6c505a">50,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC0zLTEtMS0yNDU0Mw_ebbb2e33-8467-4640-b817-dfdba9b3d5fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC01LTEtMS0yNDU0Mw_dbc79a26-259a-4f1f-92e4-90d742004e24">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC03LTEtMS0yNDU0Mw_9f35dd7a-dec0-49f7-a961-0f28bf3f8b96">50,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS0xLTEtMS0yNDU0Mw_0b466a97-f2d4-4cf2-a2e5-46466833a639">31,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS0zLTEtMS0yNDU0Mw_2e5c1538-20ea-4041-a74b-05b16b0bef6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS01LTEtMS0yNDU0Mw_76fbb5cb-0d4a-41ca-9088-17331537df79">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS03LTEtMS0yNDU0Mw_4d7e056c-79d9-4c25-96e8-09e4d6e0678c">31,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi0xLTEtMS0yNDU0Mw_81932603-653a-4298-9a12-627eb820cb12">29,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi0zLTEtMS0yNDU0Mw_9ef89860-187c-4883-ab60-80c12f88ff08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi01LTEtMS0yNDU0Mw_daedc7e7-b1fb-4308-ac51-42d13379b2e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi03LTEtMS0yNDU0Mw_380f2515-685b-4477-b48e-c03e46809968">29,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total  cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy0xLTEtMS0yNDU0Mw_28c5cc51-35f3-40d8-b1b4-3402d178fbcf">221,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy0zLTEtMS0yNDU0Mw_e3fee90c-9706-42b2-b5d2-c8f10371222f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy01LTEtMS0yNDU0Mw_965e8ce7-01e2-41e5-81a2-c367bc339c5a">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy03LTEtMS0yNDU0Mw_c54adc34-ed75-4fc4-bfa3-eb38effc4c67">221,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfOS03LTEtMS0yNDU0Mw_3e31b97e-03c9-4024-8a1b-0211b1146985">110,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMTAtNy0xLTEtMjQ1NDM_d1d5f0d8-d1db-46b4-911d-9cbb1b95b24d">111,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMTItNy0xLTEtMjQ1NDM_46d4482b-0046-4778-bf78-6c4b33e99fac">221,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy0xLTEtMS0yNDU0Mw_e82a1734-7ea0-49e7-8ea9-5ff4b66673ae">59,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy0zLTEtMS0yNDU0Mw_e209bf3c-10be-4911-82be-284917313a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy01LTEtMS0yNDU0Mw_3a3392a0-f8ed-4145-bb75-f8091ac0ffc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy03LTEtMS0yNDU0Mw_c30cc7b8-b87a-4e42-aa2d-5a7c68f97f3e">59,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC0xLTEtMS0yNDU0Mw_06ae8286-95c0-4e8d-b488-c934688a056c">190,663</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC0zLTEtMS0yNDU0Mw_ad9a2026-bb36-4bce-84be-f9bf3eb817a9">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC01LTEtMS0yNDU0Mw_60fd78de-e2e3-4a6e-9bc0-45e79a70abff">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC03LTEtMS0yNDU0Mw_12b02f20-4090-4f25-9a35-f55103c84c0f">190,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d649d197bda45e596f9af06665706a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS0xLTEtMS0yNDU0Mw_1cd56063-6ebe-4247-8f7f-bc9478dfffec">26,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d649d197bda45e596f9af06665706a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS0zLTEtMS0yNDU0Mw_89cffb4f-f17b-4cda-9c7d-8844e76aabfd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d649d197bda45e596f9af06665706a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS01LTEtMS0yNDU0Mw_2535db2b-29e5-4c5a-8c59-508837fb2855">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d649d197bda45e596f9af06665706a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS03LTEtMS0yNDU0Mw_ec691f06-3cc8-44f9-9ac1-a98c328420d0">26,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi0xLTEtMS0yNDU0Mw_0a1835eb-9e6e-4eb1-b18a-ba8a76a59fd3">29,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi0zLTEtMS0yNDU0Mw_9856c60d-aae2-43da-80fb-b4fdf5e52bec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi01LTEtMS0yNDU0Mw_3f547893-738d-446f-a960-9b3f4d11b110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi03LTEtMS0yNDU0Mw_51d0980a-a3cb-4030-ad78-db0a3240f10f">29,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy0xLTEtMS0yNDU0Mw_0ddb1769-5a09-4afa-a849-00d19e0bea1b">306,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy0zLTEtMS0yNDU0Mw_d2944f22-935e-4864-b095-ea4713baca24">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy01LTEtMS0yNDU0Mw_ad71b492-a9fd-4df9-be8d-5a9f24ebcf58">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy03LTEtMS0yNDU0Mw_db5a9453-b3df-4654-b4f1-50474957e6b7">306,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfOS03LTEtMS0yNDU0Mw_f5a74b5f-454d-495a-9cf1-95a77153c6dc">59,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMTAtNy0xLTEtMjQ1NDM_bb74413b-1327-47df-8706-2884e82a2433">246,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMTItNy0xLTEtMjQ1NDM_dba48f22-9d00-46db-9bad-54f02c18815a">306,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i45eb7998810140b2b785668ac0dd0881"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ3_07f22e93-ff4f-4617-b5a5-c09e2ee643b1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company's cash equivalents, short-term and long-term marketable securities classified by maturity (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMi0xLTEtMS0yNDU0Mw_593ae3aa-a7c1-4eda-8b09-a29fef9a6693">221,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMi0zLTEtMS0yNDU0Mw_21441f9c-1992-4752-980a-487bc20e6d05">306,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through three years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMy0xLTEtMS0yNDU0Mw_5a7ab45a-c054-4aba-80aa-c4f24535af1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMy0zLTEtMS0yNDU0Mw_849fc700-a90b-4e7c-9ff4-0485083a70b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfNC0xLTEtMS0yNDU0Mw_2805d19b-eeec-4e65-ba7a-c20ff7c582e6">221,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfNC0zLTEtMS0yNDU0Mw_cf308c40-5eef-48b8-ba06-4e5c34351c30">306,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ5_c3717ed2-5017-469d-bb68-bedb10cfabb5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company's available-for-sale securities that were in an unrealized loss position as of&#160; December&#160;31, 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0xLTEtMS0yNDU0Mw_c49f6b9a-0d83-470c-8cdc-818aee351156">50,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0zLTEtMS0yNDU0Mw_ef5efaa3-d3b5-4f0c-9244-7d256301c03a">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy01LTEtMS0yNDU0Mw_fed013ec-dbba-421b-8597-30625789488b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy03LTEtMS0yNDU0Mw_283e675c-17b2-484d-bfef-735d581440fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy05LTEtMS0yNDU0Mw_ff512c34-ec97-4b67-9196-aae677835c64">50,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0xMS0xLTEtMjQ1NDM_ca00098e-4f83-4d12-958d-e820b8b37ce5">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0xLTEtMS0yNDU0Mw_1a7fe0e8-7494-4c69-9cfe-b20dfcd66b09">31,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0zLTEtMS0yNDU0Mw_8d357171-aee6-426e-a415-3b98461fb228">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC01LTEtMS0yNDU0Mw_c3c8813b-5a1c-4810-8f1c-8eff37168996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC03LTEtMS0yNDU0Mw_999e8839-52f9-40be-8db4-b9cbbb32e44c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC05LTEtMS0yNDU0Mw_d1ab28c5-35ce-4c27-972c-9a2942b88388">31,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0xMS0xLTEtMjQ1NDM_9372cb69-9dd0-4080-ad43-361056b25755">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0xLTEtMS0yNDU0Mw_c40b6a96-6c63-4a2d-bdb6-cff0651c7370">81,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0zLTEtMS0yNDU0Mw_b92e7d4d-1ce8-4f40-80c4-172fe3c548bd">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS01LTEtMS0yNDU0Mw_8a012527-2572-4565-b64e-0f934fd45ee2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS03LTEtMS0yNDU0Mw_aeed5e1b-3784-4633-bbed-5e5c21bc8099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS05LTEtMS0yNDU0Mw_fad887d1-a552-49d9-981c-b7e055cc3a59">81,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0xMS0xLTEtMjQ1NDM_d8ac0252-fbbd-4c36-9c4f-f553d8115f10">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses as of December&#160;31, 2021 were not material. Available-for-sale securities held as of December&#160;31, 2021 had a weighted average maturity of <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:AvailableForSaleDebtSecuritiesMaturityPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjAx_e0c8cd9e-eaff-4bb5-b79f-85a2d9e846b5">95</ix:nonNumeric> days. At December&#160;31, 2021, <ix:nonFraction unitRef="investment_security" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjEy_29ba57ef-2e4c-4ee9-8969-8c1e5bcfd910">13</ix:nonFraction> investments were in an unrealized loss position and <ix:nonFraction unitRef="investment_security" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjY3_0ec0f862-ea93-49ad-9da6-d43f55c895fb">no</ix:nonFraction> investments have been in an unrealized loss position for more than one year.</span></div></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMzA1Ng_79e75bed-7dc7-4e71-9e08-6e8bd3f335a8" continuedAt="i64fc9ad40c294084a144fd19096b9897" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i64fc9ad40c294084a144fd19096b9897" continuedAt="iae1cf7c38ae74be5919723b44ebcc8f7"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The corporate notes, commercial paper and government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s outstanding interest-bearing obligations is estimated using the net present value of the future payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company&#8217;s outstanding interest-bearing obligations at December&#160;31, 2021 wer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $<ix:nonFraction unitRef="usd" contextRef="i544774a11590471697b6d8b7df26516c_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjYzNg_946becb9-01f8-4f2f-93a8-aa93ce5fe554">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d3915c703cd486c8d2ddb5c86644b14_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjY0Mw_0b5e65b5-d601-4b60-8858-8da2a18a8728">21.7</ix:nonFraction> million, r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">espectively. The carrying amount and the estimated fair value of the Company&#8217;s outstanding interest-bearing obligations at December&#160;31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i1386205dcb64400c8549d89adf0e66c7_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjc3OQ_c029ce7b-f002-4b82-8aed-e8acb7a7cd05">33.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iad512d72fba24e88bc963667bb17d917_I20201231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjc4Ng_7bbb2dca-da19-445f-9a6b-89c75fd97936">33.9</ix:nonFraction> million, respectively.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no transfers between levels of the fair value hierarchy of its assets measured at fair value.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="iae1cf7c38ae74be5919723b44ebcc8f7"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMzA1Nw_b7741dfb-27bf-4274-a0b2-177c016b1611" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc05c01347a43d4839f5af04b73fb66_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy0xLTEtMS0yNDU0Mw_f56a4f2a-0e7b-4700-9c50-a11f6ba1bd27">110,137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia90655704d594a51bf0f84615c1aac60_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy0zLTEtMS0yNDU0Mw_1058ee38-5af7-4b36-927a-b5abb451f64a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3286b0953db143438a81b1243412ad19_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy01LTEtMS0yNDU0Mw_07c84fbf-2d05-44fd-b706-c88561acf11a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661ccccd2342454cadb45ffd6ac1cdf8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy03LTEtMS0yNDU0Mw_78a8ee39-02f2-4e82-b1a6-474f88a78526">110,137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8141234416514b26856b026454673afd_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC0xLTEtMS0yNDU0Mw_35c0bf18-182b-4814-93b6-bbdc31f03f56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b9d94fd49d43a1a73305efd5b103fb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC0zLTEtMS0yNDU0Mw_1ec8e6f1-7f73-46b9-8b46-ff5c48672da9">50,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e6fab54d734357843ce9f2f235a342_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC01LTEtMS0yNDU0Mw_96aa4d63-ff61-4ffd-8bcc-cecbff4cf370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d2ad0e7093a4f1d983b41003553428a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC03LTEtMS0yNDU0Mw_a0e1b6e9-b3a0-4b40-99eb-1ed13434aad4">50,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7a85404cf446fba9e007019f906e7a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS0xLTEtMS0yNDU0Mw_86339a6a-dec4-433b-9890-4611427891a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cd6a7df09a4e08a91ace7c629e1a29_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS0zLTEtMS0yNDU0Mw_c9592d1c-802d-454f-b526-b4a46c77fbfd">31,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e65c8c9f154d91b116d7c006a7f126_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS01LTEtMS0yNDU0Mw_e6886e68-b735-47c1-bfad-18abb776ea10">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia000fc56e55e41559e67dd102c2dbf14_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS03LTEtMS0yNDU0Mw_ee1c3a42-a77f-4e42-aac9-4393b5eccbd5">31,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117f9b88ed88410697d8af034364839b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi0xLTEtMS0yNDU0Mw_41d2eb2c-41ef-4928-895c-ac70a47a2fc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ead7a95130417d9939c1641c99b464_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi0zLTEtMS0yNDU0Mw_229243e3-5ff6-40c2-9e07-e738945e51f2">29,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf07b6a8c12148a5b3ef09aaeed1bb3f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi01LTEtMS0yNDU0Mw_f098f6ed-50ca-4427-9cd4-f60002941674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7ed4e30c8343c989fb2a52999238d4_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi03LTEtMS0yNDU0Mw_6fa08b1c-0670-4001-95f6-5c74eca41d3e">29,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8bc8f58f314b7dbda7fa3d301c42fe_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy0xLTEtMS0yNDU0Mw_dbc53b43-a771-48dd-8b06-7e187c140bb7">110,137</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6da38639ddac4da59033ac85cd253110_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy0zLTEtMS0yNDU0Mw_e2163283-1b1a-45f9-b72d-4fea9a777119">111,569</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3ea2f79999340578304ad9bf5ee9000_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy01LTEtMS0yNDU0Mw_5834017a-bbef-4b9c-b988-09f9eecb3cc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy03LTEtMS0yNDU0Mw_2255a78b-7a01-4b06-99eb-ce981e5a7724">221,706</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d61d9f2150452f8914338857d1ec28_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy0xLTEtMS0yNDU0Mw_84bfe91d-d95d-41bf-a3f3-1d619d879ed0">59,823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5831875e85f74ca397d08ba1b12b77b5_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy0zLTEtMS0yNDU0Mw_6f461cb1-9c03-4312-83f9-94ab51ef28d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e1c45b9cf14077ba98cd181deae320_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy01LTEtMS0yNDU0Mw_9120341d-887b-4425-9f7e-0fd2352de5bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e3f6dd8127416aa1c4b2182d28bf1a_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy03LTEtMS0yNDU0Mw_7d8c236b-8081-40b3-8a0a-f75fa4c11c27">59,823</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id359b2cae0f94347aea71e824f7d93b6_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC0xLTEtMS0yNDU0Mw_75ada976-ce54-45dc-ae16-1f9b40daf33c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic63032f4fbea4c8cb31c3a1f550699f5_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC0zLTEtMS0yNDU0Mw_e3cd1610-0821-4a55-955b-0be1c7c82b0d">190,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105f7310b335489e8b39cfa28972fa27_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC01LTEtMS0yNDU0Mw_d463724d-854e-47ae-82d5-63632d7f9f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i436d569dcf544ec4b7f8f38f9ca866f1_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC03LTEtMS0yNDU0Mw_a0fcb80f-b62b-4c22-8819-35820bbbe499">190,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f57aaa377ac4100b7afae26cd7bc6ef_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS0xLTEtMS0yNDU0Mw_a5b084d8-258d-483e-95b9-bb0e8a12eb0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6218693389e54b8a90202c61bf65dc84_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS0zLTEtMS0yNDU0Mw_420426de-fee6-4cac-bb0b-300d7e04cd57">26,423</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd2ccd64143145f6bc932f06c1f08a5a_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS01LTEtMS0yNDU0Mw_a40ba746-47e5-48bd-ac1e-eecf9a7f870c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8350a688f64d4a83b788ae9b0d39c23b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS03LTEtMS0yNDU0Mw_e9d8e705-29ef-4040-8644-ef054d2fdfb8">26,423</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6cbcfa7d0c4b59951bd7970942f9cc_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi0xLTEtMS0yNDU0Mw_911e753d-f287-4d4c-9324-ae1a134fadab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c0eeaf2a7e4830a84e5a3e15aaccca_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi0zLTEtMS0yNDU0Mw_8c926599-2627-4208-b4bd-49dc2538db27">29,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0754b2aa6645d49d7942e54354b1f1_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi01LTEtMS0yNDU0Mw_4abb6c83-7e1d-4190-ab59-d2ab70e92a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2335277db35e4da9bc6053ad827c6b6c_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi03LTEtMS0yNDU0Mw_862fb0e4-27e9-45bd-8c23-60a15e25fc7a">29,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe8b8dfb0134468b31a854434788716_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy0xLTEtMS0yNDU0Mw_7301e3e8-3126-4476-a1c7-fdf7da59fe93">59,823</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b53675a3ce4bbf8c3f060474b55387_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy0zLTEtMS0yNDU0Mw_1ad7910d-ea51-4fcf-a3c6-96b227250d84">246,589</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60805415d1e4c0bb61070f850509317_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy01LTEtMS0yNDU0Mw_09417782-3a4e-440e-af45-6b0b02cafd7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy03LTEtMS0yNDU0Mw_130e948f-54a3-443d-9dff-fff4310dfd8f">306,412</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_97"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA4MA_fbf47c8e-4cb5-4dd0-8457-b61c863c2c15" continuedAt="ie8971bd7596543d0b0cb4a55c4fb580b" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ie8971bd7596543d0b0cb4a55c4fb580b" continuedAt="i75a84f497f3c4df3a351b74f91107e9b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Other Assets</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA4Mg_8b638389-83b1-419b-8b6f-8221a0be5b49" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab4afd0d0c40b89860d2c5c5281a69_I20211231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMi0xLTEtMS0yNDU0Mw_9d4d3674-2326-4e56-b848-0e38c2eda749">5,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57913d02322c4309a6e6b2296ed4ae43_I20201231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMi0zLTEtMS0yNDU0Mw_9b95d77a-0477-4802-b179-003ab4f51c2a">2,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fdff6e9039430eba2e53b4f1ac3997_I20211231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMy0xLTEtMS0yNDU0Mw_4b0e23d4-0b2b-4d52-84c2-bae9c9e36b89">5,167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599e4ae97436440ebb5518c8ed6cd48a_I20201231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMy0zLTEtMS0yNDU0Mw_fe4003ab-2444-448d-bbe8-2913e25c89be">2,844</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfNC0xLTEtMS0yNDU0Mw_9463db1f-885a-4124-a851-3c3315f3b8b3">10,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:InventoryAndPrintedCircuitBoardAssemblies" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfNC0zLTEtMS0yNDU0Mw_db7bed3d-c526-496a-ad1b-22b5dced42bf">5,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses PCBAs in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the Zio AT monitor. The PCBAs are used numerous times and have useful lives beyond <ix:nonNumeric contextRef="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231" name="irtc:OtherAssetsUsefulLives" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzE0NjgyNTU4MTY0NQ_f370e60d-6639-4e36-aae4-194bbfe721b0">one year</ix:nonNumeric>. Each time a PCBA is used in a wearable Zio XT monitor or Zio AT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue. Each time a wireless gateway is used with a Zio AT monitor, a portion of the gateway is recorded as a cost of revenue. PCBAs which are recorded as other assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">were $<ix:nonFraction unitRef="usd" contextRef="i325e1cd03bd94e598819e2c8159b85ab_I20211231" decimals="-5" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNjc3_4d6124eb-f239-4aed-9526-773da4ebaff4">13.9</ix:nonFraction> million a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nd $<ix:nonFraction unitRef="usd" contextRef="id60332e77ea34183a58d2508319463aa_I20201231" decimals="-5" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNjg0_7bc9f128-03d9-4b64-a217-f8c723e3540c">12.6</ix:nonFraction> million as of December&#160;31, 2021, and December&#160;31, 2020, respectively. The amortization wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s $<ix:nonFraction unitRef="usd" contextRef="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzQw_12d941bb-dc2f-4318-8353-d24cff35934a">4.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2b1a81becd2e4d4d9eab5264496e678a_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzQ3_bc3e7d29-37a7-4c6a-b21f-75881904c627">3.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the years ending December&#160;31, 2021 and 2020 respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i75a84f497f3c4df3a351b74f91107e9b"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA3OA_f1845966-d3c2-43c0-a73a-4d887be6c7d2" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9b27deda984a24813a7638b456e4b6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMi0xLTEtMS0yNDU0Mw_1dc2d58c-929a-4d91-a397-14fff9539c43">5,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cdcfe3d98f64ac28d89432c71dc7330_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMi0zLTEtMS0yNDU0Mw_721ffcd1-280c-4245-b5eb-958e7bbb1c20">4,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e29bf199ddb4f14a081a37d488b00d4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMy0xLTEtMS0yNDU0Mw_3adecb7b-009d-4dde-9f94-b11f9cbe6ebe">2,353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d87a54ba7c9421f9e5c705844818d32_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMy0zLTEtMS0yNDU0Mw_23ccb8dd-7acc-4307-9873-d0ddd5b4ac47">2,005</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4a41e7e284759a1cdb699a6d54241_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNC0xLTEtMS0yNDU0Mw_f07a164b-fc54-4447-9e21-34b36fde48c7">4,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8e622beead4bf5bdede9b59f014923_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNC0zLTEtMS0yNDU0Mw_faaaee51-e8ae-4073-9d7e-059fa2ce480a">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9c5185f80148638094fa6bbf5f7ceb_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNS0xLTEtMS0yNDU0Mw_6de2bd37-3a3c-4d7d-9db2-84c51c5ba07b">20,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8d067edb8c4d64bdd24a8de4d79690_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNS0zLTEtMS0yNDU0Mw_320e9953-0e57-4cdc-903b-9997227bd165">9,215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51fe3bdc1dc34b259a371515f18bdb86_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNi0xLTEtMS0yNDU0Mw_ec7c96b0-c48f-41bb-bec5-4425e0f183b6">46,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0786295f5443bd811598620bb82a9a_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNi0zLTEtMS0yNDU0Mw_7a60acf4-d812-4bdb-9fd3-3e068de533f6">28,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNy0xLTEtMS0yNDU0Mw_c6195463-9818-413b-9393-306431a25560">78,648</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNy0zLTEtMS0yNDU0Mw_10299b75-2e73-4623-ae0a-c42755b85f46">48,097</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOC0xLTEtMS0yNDU0Mw_835e23a3-1377-4345-a876-6da7218072e0">22,704</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOC0zLTEtMS0yNDU0Mw_ccabdf8b-ead8-40f9-bd11-7ae26a8911be">13,850</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOS0xLTEtMS0yNDU0Mw_c225617b-3e20-476f-be9e-d607bc95e623">55,944</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOS0zLTEtMS0yNDU0Mw_78f8ba6f-1841-4e88-90d5-321682d983f4">34,247</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfOTY5_d16f653a-5fff-428f-a1a1-8a22a890775a">9.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfOTc2_64852c32-7869-44b2-817b-0c1f5b644380">6.9</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA3OQ_c301ad60-3a9a-46fe-b85a-eb5538de4a88" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMi0xLTEtMS0yNDU0Mw_953cf99e-7350-4b38-9254-992e39db82f2">7,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccruedVacationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMi0zLTEtMS0yNDU0Mw_cc558ff1-a71d-4347-83a2-ad62821499f5">6,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMy0xLTEtMS0yNDU0Mw_785b3ddd-2c5c-49e1-a4f5-25c5f813af72">34,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMy0zLTEtMS0yNDU0Mw_5e768952-819a-43e3-bb2a-2c85287768ed">19,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued ESPP Contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:AccruedEmployeeStockPurchasePlanContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNC0xLTEtMS0yNDU0Mw_00522415-fb92-47db-a1b3-02be8959ca2b">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:AccruedEmployeeStockPurchasePlanContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNC0zLTEtMS0yNDU0Mw_2db8b9d6-f2d7-4f85-814b-ff06bf5cfbae">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNS0xLTEtMS0yNDU0Mw_e255aced-f3fe-4bb6-aa41-75793f072f6e">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNS0zLTEtMS0yNDU0Mw_f5c17c8f-2e8a-422f-a9c7-cd012b3f31fd">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNi0xLTEtMS0yNDU0Mw_a1801399-3175-4a24-8d8d-8d163ee5f861">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNi0zLTEtMS0yNDU0Mw_87bddee0-a037-498a-8c83-d16ef892e972">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:ClaimsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNy0xLTEtMS0yNDU0Mw_64b758c4-2b2b-497f-b315-cd5dfedb6f6e">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:ClaimsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNy0zLTEtMS0yNDU0Mw_5973d694-6aa8-4757-b242-07942870f485">4,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOC0xLTEtMS0yNDU0Mw_f53e312b-1321-4a0f-8374-dcc4f62e98bd">3,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOC0zLTEtMS0yNDU0Mw_9258262c-23cb-4f44-a162-c36d4f89ad79">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOS0xLTEtMS0yNDU0Mw_73a75038-dd81-4262-b15a-4a527b515c85">51,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOS0zLTEtMS0yNDU0Mw_16af4a2c-d494-4d89-b2e1-36c45472678b">40,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcwODQ_bd59dfad-c4bc-4f97-9658-ddd36adcb8a8" continuedAt="ic79bdae7933e451f8cbab161e48a5757" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ic79bdae7933e451f8cbab161e48a5757" continuedAt="i41fa0e90137f4619b055adb753c17ad7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Arrangements</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office, manufacturing, and clinical centers under non-cancelable operating leases which expire on various dates through</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2031.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> These leases generally contain scheduled rent increases or escalation clauses and renewal options. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease right-of-use assets also include any lease payments made to the lessor at or before the commencement date as well as variable lease payments which are based on a consumer price index. The Company is also subject to variable lease payments related to janitorial services and electricity which are not included in the operating lease right-of-use asset as they are based on actual usage. The Company recognizes operating lease expense on a straight-line basis over the lease period. The total operating lease cost recognized during the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwNTM_ef2a4d5d-3b4b-4409-bbaf-ee9c4b77161c">13.5</ix:nonFraction>&#160;million which primarily consisted of lease payments and common area maintenance costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for operating leases during the year ended December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzExOTU_b34f19db-ced0-48b7-a5a7-75659ec16581">12.2</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 4, 2018, the Company entered into an office lease (&#8220;San Francisco Lease&#8221;) to rent approximately <ix:nonFraction unitRef="sqft" contextRef="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004" decimals="0" name="irtc:OperatingLeaseRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTgzNzU_29d4caaf-4042-4d28-a39c-490351e0476f">117,560</ix:nonFraction> rentable square feet in San Francisco, California, which became the Company&#8217;s new headquarters in October 2019. The term of the San Francisco Lease began on May 13, 2019, and expires on August 31, 2031. The Company is entitled to <ix:nonFraction unitRef="optiontoextend" contextRef="i6c6807592d254ff88a10a57aea41b8c5_D20181004-20181004" decimals="INF" name="irtc:LesseeOperatingSubleaseNumberOfOptionToExtend" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTgzODg_3de17b25-98dc-41fa-84be-5b85e9b24930">one</ix:nonFraction> option to extend the San Francisco Lease for a <ix:nonNumeric contextRef="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MDg_f5bfb2ca-5d0b-4f6c-b8a0-29d7fd1cd799">five-year</ix:nonNumeric> term, subject to certain requirements. </span></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i41fa0e90137f4619b055adb753c17ad7" continuedAt="id0713515dcd34714b55530cc2c760654"><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2009, the Company entered into a lease for a clinic (&#8220;Lincolnshire Lease&#8221;) to rent approximately <ix:nonFraction unitRef="sqft" contextRef="i295d5c0437d34174bf44c52749a0ac5a_I20091029" decimals="0" name="irtc:OperatingLeaseRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MTA_8a2350e4-9fec-4c18-a2c1-8263ff0f7dca">41,500</ix:nonFraction> rentable square feet in Lincolnshire, Illinois, which became the Company&#8217;s clinic facilities. The term of the Lincolnshire Lease began </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on November 1, 2009,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and expires on July 31, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 18, 2021, the Company entered into an office/industrial lease (&#8220;Cypress Lease&#8221;) to rent approximately <ix:nonFraction unitRef="sqft" contextRef="i0fde8b0fa6ab4dfe86bf892cb5232e3d_I20210318" decimals="0" name="irtc:OperatingLeaseRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MjA_15891356-338d-45f2-af85-bb7181857e32">68,933</ix:nonFraction> rentable square feet in Cypress, California, which became the Company&#8217;s new office and warehouse facilities. The term of the Cypress Lease began on October 25, 2021, and expires on April 30, 2032. The Company is entitled to <ix:nonFraction unitRef="optiontoextend" contextRef="i473a9e8ce4c04091aa983711246e3313_D20210318-20210318" decimals="INF" name="irtc:LesseeOperatingSubleaseNumberOfOptionToExtend" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MzI_f6a8f2ec-e1da-4c08-81bf-7cb699b8f0d0">one</ix:nonFraction> option to extend the Cypress Lease for a <ix:nonNumeric contextRef="i247ed5aae14d46398ee4c08aefa80fc9_I20210318" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0NDg_59095d3a-255d-4623-85cc-94e101346bdb">five-year</ix:nonNumeric> term, subject to certain requirements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects these decisions will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcwODY_82f61f9b-4c8b-4d39-aed6-027d3ffefcac" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzEtMS0xLTEtMjQ1NDM_03991fa6-275d-43cc-8341-5e0bbd02b069">12,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzItMS0xLTEtMjQ1NDM_27cc6fe2-23b1-407f-9e51-a12413ade7c1">12,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzMtMS0xLTEtMjQ1NDM_efff57bb-0b1f-494d-ac95-785e5b3660aa">13,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzQtMS0xLTEtMjQ1NDM_d7bc35e1-7f74-4d34-a5bf-39224e7ac9d3">13,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzUtMS0xLTEtMjQ1NDM_8fc15c90-56fe-43a0-93c9-8f58ac127c45">14,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzYtMS0xLTEtMjQ1NDM_266d83e6-0dfc-48fa-b4c3-88c775f11385">69,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzctMS0xLTEtMjQ1NDM_f626c95a-0d59-464b-aa89-377e603489fa">136,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzgtMS0xLTEtMjQ1NDM_75793723-cc75-4619-b47c-b12e9ccb09bf">40,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzktMS0xLTEtMjQ1NDM_a5a8c8a7-5a23-4b6a-8c87-1ff7966b7a95">96,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average remaining lease term of the Company's operating leases as of December&#160;31, 2021 was <ix:nonNumeric contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzIzMjM_990537e6-2eb2-425a-8384-572dd9fb2216">9.62</ix:nonNumeric> years. The weighted average discount rate of the Company's operating leases was <ix:nonFraction unitRef="number" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzI0MDY_519c6912-be02-451f-ab8d-7e896df7d320">7.27</ix:nonFraction>% as of December&#160;31, 2021.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a lease for <ix:nonFraction unitRef="sqft" contextRef="ibc473ee2e3f047b9becb2198e94c3342_I20211231" decimals="0" name="irtc:OperatingLeaseRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTE5NTM_bba44f7f-b770-45bc-be1d-dc9da4d29d96">44,616</ix:nonFraction> rentable square feet in Deerfield Illinois ("Deerfield Lease"). The Deerfield Lease commenced in January 2022, and will be recorded as a right of use asset to the Company's financial statements in the first quarter of 2022. The Company is currently assessing the impact to its consolidated financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in claims and legal proceedings or investigations, that arise in the ordinary course of business. Such matters could have an adverse impact on its reputation, business and the financial condition and divert the attention of its management from the operation of its business.  These matters are subject to many uncertainties and outcomes that are not predictable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that the Company and its former Chief Executive Officer, Kevin M. King, violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On August 2, 2021, the lead plaintiff filed an amended complaint, and filed a further amended complaint on September 24, 2021. The amended complaint names as defendants, in addition to the Company and Mr. King, the Company's former Chief Executive Officer, Michael J. Coyle, and current Chief Financial Officer, Douglas J. Devine. The purported class in the amended complaint includes all persons who purchased or acquired the Company's common stock between August 4, 2020 and July 13, 2021, and seeks unspecified damages purportedly sustained by the class. On October 27, 2021, the Company filed a motion to dismiss the amended complaint. The motion to dismiss was fully briefed and the Court held a hearing on the motion on February 4, 2022, after which the Court took the matter under submission.  The Court has not yet issued a ruling. The Company believes the class action to be without merit and plans to vigorously defend itself.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company received a grand jury subpoena from the U.S. Attorney&#8217;s Office for the Northern District of California requesting information related to communications with the Food and Drug Administration and the Company&#8217;s products. On October 14, 2021, the Company received a second subpoena requesting additional information. The Company is cooperating fully and is providing the requested information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id0713515dcd34714b55530cc2c760654"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development Agreement</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 3, 2019, the Company entered into a Development Collaboration Agreement (the &#8220;Development Agreement&#8221;) with Verily Life Sciences LLC (&#8220;Verily&#8221;). The Development Agreement, which is over a <ix:nonNumeric contextRef="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903" name="irtc:CollaborationAgreementRemainingTermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzM2NTY_307fec08-d067-4e75-9063-2ca5e9ee78af">24</ix:nonNumeric> month term, involves joint development and production of intellectual property between the Company and Verily. Each participant has primary responsibility for certain aspects of development and approval, with all processes to be performed at each respective party&#8217;s own cost. Costs incurred by the Company in connection with the Development Agreement will be expensed as research and development expense in accordance with ASC 730, Research and Development.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company and Verily will develop certain next-generation atrial fibrillation (&#8220;AF&#8221;) screening, detection, or monitoring products pursuant to the Development Agreement, which products will involve combining Verily and the Company's technology platforms and capabilities. Under the terms of the Development Agreement, the Company paid Verily an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i3d8d51dc95ba423b813f74a49801e062_I20191231" decimals="-5" name="irtc:CollaborationAgreementUpfrontFeePayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ0Nzk_e1e449e7-df44-4960-ae78-f11a7cc922c0">5.0</ix:nonFraction>&#160;million in 2019. In addition, the Company has agreed to make additional payments to Verily up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i583c6b3e405b4a20a3da03740a2eb9f3_I20190903" decimals="-4" name="irtc:CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ1ODc_c4877aa0-8441-4e29-bec9-1cf4c605ce12">12.75</ix:nonFraction>&#160;million in milestone payments upon achievement of various development and regulatory milestones over the <ix:nonNumeric contextRef="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903" name="irtc:CollaborationAgreementRemainingTermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ2ODc_af8b91a8-8dcc-41a3-a0fc-136c370347c9">24</ix:nonNumeric> months of the Development Agreement, which payments will be made in cash to Verily. </span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones tied to payments totaling $<ix:nonFraction unitRef="usd" contextRef="i7f3ae94beacb488f8fa3638f2d2170e4_I20220225" decimals="-5" name="irtc:CollaborationAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ1ODA_7da11135-e1e5-4b9f-b7ef-f0b4db50703a">11.0</ix:nonFraction>&#160;million to date, $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-5" name="irtc:CollaborationAgreementMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ1OTU_13efa50c-81c1-4424-9b3f-7957230e5221">3.0</ix:nonFraction>&#160;million of which is associated with a milestone achieved during the quarter ended December 31, 2021 and is included in Accounts Payable on December 31, 2021. We have agreed to make additional payments over the term of the Development Agreement up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-4" name="irtc:CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ2MjM_4eaec0e0-9fb4-41a5-a81a-e6fbd50c8c20">1.75</ix:nonFraction>&#160;million, subject to the achievement of certain development and regulatory milestones including provision Zio Watch and completion of market evaluation scheduled to begin between late 2022 and early 2023. </span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Development Agreement provides each party with licenses to use certain intellectual property of the other party for development activities in the field of AF screening, detection, or monitoring. Ownership of developed intellectual property will be allocated to the Company or Verily depending on the subject matter of the underlying developed intellectual property, and, for certain subject matter, shall be jointly owned.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements pursuant to which it agrees to indemnify customers, vendors, lessors, business partners, and other parties with respect to certain matters, including losses arising out of the breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims made by third parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by applicable law. The Company currently has directors&#8217; and officers&#8217; insurance. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions, and believes that the estimated fair value of these indemnification obligations is not material and it has not accrued any amounts for these obligations.</span></div></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_103"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzM0MjI_9c7997a8-bfce-4cb0-8ddc-41563775561e" continuedAt="icb29c4d2f0a448a9b4d5ae07fd08849b" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="icb29c4d2f0a448a9b4d5ae07fd08849b" continuedAt="icef2e5903c104fbd840a84e7bbb6592b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bank Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, the Company entered into the Third Amended and Restated Loan and Security Agreement with SVB (&#8220;Third Amended and Restated SVB Loan Agreement&#8221;). This Agreement amends and restates the Second Amended and Restated Loan and Security Agreement between the Company and SVB dated December 4, 2015, as amended by the First Loan Modification Agreement between the Company and SVB dated August 22, 2016.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Amended and Restated SVB Loan Agreement, the Company obtained a term loan (&#8220;SVB Term Loan&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i658ecfa8506846dc82b0e01ee90a18e1_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzEyNTU_a1c0c479-60ad-44ed-9b17-bc0ce19b73bc">35.0</ix:nonFraction> million. Total proceeds from the SVB Term Loan were used to pay off the loan agreement with Biopharma Secured Investments III Holdings Cayman LP (&#8220;Pharmakon&#8221;), totaling $<ix:nonFraction unitRef="usd" contextRef="i8bd3de617d2f41cbbeb04e8d26d24912_D20181001-20181031" decimals="-5" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE0MTk_2f575713-0b01-447e-959b-66c9f91a1587">35.8</ix:nonFraction> million. The Company made interest-only payments through October 31, 2020. Beginning in November 2020, the Company began monthly payments of principal plus interest, which will continue through October 31, 2023. Interest charged on the SVB Term Loan will be the greater of (a) a floating rate based on the &#8220;Prime Rate&#8221; published by The Wall Street Journal minus <ix:nonFraction unitRef="number" contextRef="i634d244c801140b8ab07eeabd8d14ef6_D20181001-20181031" decimals="INF" name="irtc:DebtInstrumentBasisSpreadDeductionOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3MjA_75d3c365-0fab-42bc-948e-86f879267739">0.75</ix:nonFraction>%, or (b) <ix:nonFraction unitRef="number" contextRef="i0e385fae9c694ac58ec7814ba00a5b71_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3MzE_80b3a3e2-411a-42f3-8067-5a4d77b70c1a">4.25</ix:nonFraction>%. The weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3NzQ_f25e8bbd-650c-49fa-9a23-6e1353d6d2d7">4.25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3ODE_be501e36-72f8-46f2-827a-de0366575a1c">4.25</ix:nonFraction>% for the years ended December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="icef2e5903c104fbd840a84e7bbb6592b"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Third Amended and Restated SVB Loan Agreement, the Company may borrow, repay, and reborrow under a revolving credit line, but not in excess of the maximum loan amount of $<ix:nonFraction unitRef="usd" contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIwMTE_cdb12f8c-2756-4b45-bb8d-b10cfc418134">25.0</ix:nonFraction> million, which includes an $<ix:nonFraction unitRef="usd" contextRef="i91e808628b6a4613b5438a4e78004a62_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIwMzM_14745437-e051-4d86-bbce-dce95a8e38a2">11.0</ix:nonFraction> million standby letter of credit sublimit availability. In October 2018, a $<ix:nonFraction unitRef="usd" contextRef="i79eb7c2fe0da4198aa7a5eea32e35ebd_D20181001-20181031" decimals="INF" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIxMDM_82c99ecd-4f16-445a-a645-30804c948758">6.9</ix:nonFraction> million standby letter of credit was obtained in connection with a lease for the Company&#8217;s San Francisco headquarters. Any principal amount outstanding under the Third Amended and Restated SVB Loan Agreement revolving credit line shall bear interest at an amount that is the greater of (a) a floating rate per annum equal to the rate published by The Wall Street Journal as the &#8220;Prime Rate&#8221; or (b) <ix:nonFraction unitRef="number" contextRef="i1a67f248e25942c7be0ace4b0a88b4e1_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI0OTY_eb57583b-cfdc-422e-8276-80e3b2562d6d">5.00</ix:nonFraction>%. The Company may borrow up to <ix:nonFraction unitRef="number" contextRef="id79b2be320cb4762a45bd10e6a3c51f4_D20181001-20181031" decimals="INF" name="irtc:PercentageOfEligibleAccountsReceivableForBorrowings" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI1Mjk_72acaeed-9521-4919-b21d-c032929d2232">75</ix:nonFraction>% of eligible accounts receivable, up to the maximum of $<ix:nonFraction unitRef="usd" contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI1ODY_0818498d-10de-460a-b550-53513bba6a40">25.0</ix:nonFraction> million. As of December 31, 2021, the Company was eligible to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i9ec1526aa3b646a98a400738b384e12d_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE2NDkyNjc0NDY1Mjc_a5ba14e9-18b0-4439-9b00-c194adeadd4f">13.8</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI0NzM5MDExNjI5ODM2_438e9ad9-954b-48ce-a7e6-b696d7438c44">no</ix:nonFraction> amount was outstanding under the revolving credit line. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended and Restated Loan Agreement requires the Company to maintain a minimum consolidated liquidity ratio or minimum adjusted Earnings Before Interest, Tax, Depreciation, and Amortization during the term of the loan facility. In addition, the SVB Loan Agreement contains customary affirmative and negative covenants and events of default. The Company was in compliance with loan covenants as of December&#160;31, 2021. The obligations under the Third Amended and Restated Loan Agreement are collateralized by substantially all assets of the Company.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future minimum payments</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzM0MjE_eb7622c4-353f-4fd6-b424-f73a4d5c248c" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank at December&#160;31, 2021 are as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEtMS0xLTEtMjQ1NDM_f2bb5745-551f-4577-b7c0-1f83b0b7d023">12,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzItMS0xLTEtMjQ1NDM_dd0f259c-0797-40a5-b10a-5b4fb27fbcc3">9,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzQtMS0xLTEtMjQ1NDM_5decfd44-945c-41f2-9be8-6aa26bd8fb64">22,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="irtc:DebtInstrumentInterestPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzUtMS0xLTEtMjQ1NDM_61887c8f-9cf6-42a4-af82-58a6e37fd9de">883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt Issuance Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzYtMS0xLTEtMjQ1NDM_b0cc74f9-7f82-444d-91d4-a40c3f84a635">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Carrying Value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18aaaa80c4654a52a50440835da85723_I20211231" decimals="-3" name="irtc:LongTermDebtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzctMS0xLTEtMjQ1NDM_6db26f7e-5b98-4024-8694-461e7b53624c">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEwLTEtMS0xLTI0NTQz_22e01986-b301-4c7c-804e-3fdb46854892">11,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzExLTEtMS0xLTI0NTQz_d5fe705a-63af-47fa-806b-e23745a81f2a">9,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEyLTEtMS0xLTI0NTQz_b93e53e8-5349-426e-af43-1e4cfe2319a9">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzk_cad6f7ce-3646-43d7-9de9-645ef6434f3f" continuedAt="i4b7386e41bb144d7aea8007ea701466b" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:continuation id="i4b7386e41bb144d7aea8007ea701466b" continuedAt="if096dc9396ba4da7b335a191602bbd4f"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODA_9d7b5dd8-6fe5-41f3-9239-4811ed21b22e" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents components of the Company&#8217;s provision for income taxes as for the period presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtMS0xLTEtMjQ1NDM_e3e297de-3e22-40a6-b334-383f2ed449f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtMy0xLTEtMjQ1NDM_ae27c3e7-9171-4507-a45a-efe690b5e23e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtNS0xLTEtMjQ1NDM_f3db1410-0056-4988-a7da-a85c97df073c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtMS0xLTEtMjQ1NDM_10331f30-f112-4c15-9260-6e32b640bdc7">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtMy0xLTEtMjQ1NDM_0805e962-f173-44f2-9184-8d38fc6f4531">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtNS0xLTEtMjQ1NDM_d0e1b2f8-95ff-4baf-8073-be87a8e874cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtMS0xLTEtMjQ1NDM_c911c167-43ad-4812-9f9a-0b407ee352fc">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtMy0xLTEtMjQ1NDM_a7fe6f0f-3a58-474a-b9a5-e469248b2a18">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtNS0xLTEtMjQ1NDM_933a557b-81fc-46ef-90c4-d62a3388a071">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtMS0xLTEtMjQ1NDM_9470fd51-c866-4c67-8f37-2ab445275ee1">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtMy0xLTEtMjQ1NDM_b33525d5-f95a-444b-ad93-f91aee7d98b1">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtNS0xLTEtMjQ1NDM_f485c9fb-a097-401e-bf0c-7947dc260ea3">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktMS0xLTEtMjQ1NDM_b0bdce7d-eae5-42f0-b38a-5ac9b7c5ba61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktMy0xLTEtMjQ1NDM_75ee4560-4c11-4cf4-a718-acd9a42df640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktNS0xLTEtMjQ1NDM_c321ee66-9188-4c1f-a2ec-f4a6e2ecd839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTEtMS0xLTI0NTQz_d8b2fc1c-619b-479a-8ff1-bd05bd919fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTMtMS0xLTI0NTQz_eb6b80b5-9148-4377-90d6-ae7177e01b4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTUtMS0xLTI0NTQz_41e61f2b-8153-4c3d-b24d-cb95cd4f1df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTEtMS0xLTI0NTQz_9312be7f-970f-4a4a-94da-36ad58c0e8cd">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTMtMS0xLTI0NTQz_53bde6e6-a6cc-41b2-8f77-c506b1f71395">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTUtMS0xLTI0NTQz_05086ed2-30ad-40f7-a30c-bb0dc66ea3d4">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTEtMS0xLTI0NTQz_c832866c-c581-48ea-a76c-1fb59acfe87f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTMtMS0xLTI0NTQz_fdab7194-8034-453e-a373-c377349d19b2">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTUtMS0xLTI0NTQz_4055d2af-d53d-4688-8c0a-77b15ca927f5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTEtMS0xLTI0NTQz_2be5b63f-aed4-4ecd-a864-54b3d51a1303">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTMtMS0xLTI0NTQz_904aec3f-62fa-4d5d-a13b-a3c4de8c43a9">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTUtMS0xLTI0NTQz_4e128fc6-7abd-4777-9214-a69a12eb184f">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODM_4c694d17-7337-4972-b0e8-f9f3c56eb464" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company&#8217;s tax expense for the period presented (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItMS0xLTEtMjQ1NDM_6c71239f-c2c3-400a-a8e3-2da3415b4dd8">21,198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItMy0xLTEtMjQ1NDM_d8cf3630-3d6a-4dd9-93ef-a4bca32bfa5e">9,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItNS0xLTEtMjQ1NDM_7c391034-8a0d-40ab-9af9-37e238c05edd">11,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMS0xLTEtMzEzNDk_3cb94ca7-a8e9-4058-926f-9152430c114b">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMy0xLTEtMzEzNTU_bbceb6a0-0552-45ee-82c4-582506830bb5">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtNS0xLTEtMzEzNjI_deb41881-7666-4f60-ac66-ed6dd7e14861">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMS0xLTEtMjQ1NDM_eb77d503-002f-4f39-83c0-a9fb10d5e853">7,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMy0xLTEtMjQ1NDM_8cb7e360-1d98-4bc1-80d1-2886ce330818">20,762</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtNS0xLTEtMjQ1NDM_e58731e4-cdd2-4a71-be41-d9c59bca00ae">5,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and Entertainment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtMS0xLTEtMjQ1NDM_94cbb2d9-e8a3-4341-b7cd-19ebac3539b8">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtMy0xLTEtMjQ1NDM_6ca626e9-37e2-4eac-bb4a-223818fe94bb">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtNS0xLTEtMjQ1NDM_4ee26ecd-7a8d-4117-bd3a-f26f1722aa47">409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation - officers compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtMS0xLTEtMjQ1NDM_daf65bca-2a05-431a-8969-86f2145492db">4,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtMy0xLTEtMjQ1NDM_08829c82-221a-44ad-a928-e340e5523beb">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtNS0xLTEtMjQ1NDM_6bcfa8e3-95a8-434a-a206-4b98feab2630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctMS0xLTEtMzMzMDQ_ae0a9c19-4a1e-4a53-822e-c6bbaa7f3103">347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctMy0xLTEtMzMyOTg_49f78e15-f52b-4440-b660-8d76b7df3e12">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctNS0xLTEtMzMyOTE_497e1cd0-0541-4b69-93aa-f21d60d0e025">614</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtMS0xLTEtMjQ1NDM_5d31dbe6-26ef-4d94-8679-2f3e0f09b3d2">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtMy0xLTEtMjQ1NDM_e94aeea6-8b0b-42ac-9485-81fd2582856e">1,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtNS0xLTEtMjQ1NDM_24c8a422-f6db-41ff-ad0c-e7fd692735d2">1,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMS0xLTEtMzEzOTI_68d383ca-c850-4cf4-bff9-10d009d11f7e">30</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMy0xLTEtMzE0MDA_e2bb04a0-89fb-4430-88aa-4b15aeb186c2">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtNS0xLTEtMzE0MDY_ae7ea84d-34b2-4e6e-93cf-c8308b20a634">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMS0xLTEtMjQ1NDM_21f71290-426a-4afd-b57e-0abca9b1ac01">24,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMy0xLTEtMjQ1NDM_1733b7df-8bd0-4837-9364-6edecc237bf6">30,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtNS0xLTEtMjQ1NDM_aba224be-6c28-44ca-b437-30b15b914fb1">17,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktMS0xLTEtMjQ1NDM_579c8af9-bd26-4124-832c-7caabb882158">367</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktMy0xLTEtMjQ1NDM_198abdbf-a784-4e60-9ce2-684a1b300c88">229</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktNS0xLTEtMjQ1NDM_d4739a59-9412-4c8e-86f0-8a8ab4d19918">65</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="if096dc9396ba4da7b335a191602bbd4f" continuedAt="i1caf86f403804dfb9e2c9e91efd2dd2a"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODQ_71cbda83-eed7-42e8-862c-3241ba208b30" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzMtMS0xLTEtMjQ1NDM_ace85dad-2aa0-48a7-ac97-efcd148a8b95">114,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzMtMy0xLTEtMjQ1NDM_d0bc3fa0-8552-4ef3-a65b-3be156afe349">91,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzQtMS0xLTEtMjQ1NDM_9079ecbb-9d4a-4c21-a416-bf5abc65fe18">9,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzQtMy0xLTEtMjQ1NDM_396a7b97-3e3d-4287-8517-beb2b8db8a40">7,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzUtMS0xLTEtMjQ1NDM_77f1ce29-104e-4b10-bb42-2496f0934d0d">9,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzUtMy0xLTEtMjQ1NDM_28b79f5f-1dd9-4ba9-868a-8736cc82dcc2">8,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:DeferredTaxAssetsValuationAllowancesAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzYtMS0xLTEtMjQ1NDM_d0644ef6-0c41-43d5-9a2f-9d8a0780d746">20,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:DeferredTaxAssetsValuationAllowancesAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzYtMy0xLTEtMjQ1NDM_0ca70ce7-d95f-4c75-808e-94b638cbc050">14,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="irtc:DeferredTaxAssetsLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzctMS0xLTEtMjQ1NDM_fa96f047-7701-4a5a-b906-901d198c37f0">23,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="irtc:DeferredTaxAssetsLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzctMy0xLTEtMjQ1NDM_a6f1194d-d0f2-43dc-8dbc-44dcc488e9dc">22,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzgtMS0xLTEtMjQ1NDM_b63f23f3-dad7-4f0f-ba73-1880265ffd94">178,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzgtMy0xLTEtMjQ1NDM_55cde727-196e-4a47-8b72-0afe585a50a0">144,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzktMS0xLTEtMjQ1NDM_8e4d980e-2969-4365-84e0-335f92e856c8">154,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzktMy0xLTEtMjQ1NDM_f24c3cc2-dc80-4d14-9c2d-3fe38023c1bd">123,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEwLTEtMS0xLTI0NTQz_58fa98b9-f954-43ed-a929-9c6e81015b27">23,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEwLTMtMS0xLTI0NTQz_deaab83e-98c1-44ef-8eca-653b6cc54fe8">20,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEzLTEtMS0xLTI0NTQz_fde82471-35da-4b30-b3bd-40257a18ce75">3,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEzLTMtMS0xLTI0NTQz_2a232a85-9847-4c71-b0f2-c939cb93fc69">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE0LTEtMS0xLTI0NTQz_900ab478-5d74-4978-9b6b-9b691ab4c613">20,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE0LTMtMS0xLTI0NTQz_a56f7f02-334a-4663-a67d-80a02347aacf">20,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE1LTEtMS0xLTI0NTQz_c98d2df2-0123-428d-ad1b-6e1b84920795">23,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE1LTMtMS0xLTI0NTQz_5e01766f-f244-4d48-b1e9-20f632a48af5">20,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE2LTEtMS0xLTI0NTQz_00239295-1d79-4e38-9cb6-617fab981be8">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE2LTMtMS0xLTI0NTQz_f8a2b0db-5c6b-4086-ab03-aebcda5ca533">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company has provided a full valuation allowance against its U.S. deferred tax assets, and, therefore, <ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="irtc:OperatingLossCarryforwardsTaxBenefitRecognized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzg1Nw_c1a74d4a-6ada-48b4-bb17-a671b0d0ec68">no</ix:nonFraction> benefit has been recognized for the net operating loss carryforwards and other deferred tax assets. The U.S. valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzEwMDI_92ebad8d-d8f5-4ceb-8045-a9adcd157be5">30.9</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzEwMDk_7b44c55c-f6c3-497d-b8be-2f953ef7f9f0">35.4</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. The current year change in the U.S. valuation allowance is primarily related to the increase in net operating loss carryforwards generated during the year. The Company recorded an immaterial deferred tax asset related to the Company&#8217;s foreign operations in the United Kingdom.</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzc_63b28a67-9d21-4f5a-a071-5bd8086d9e74" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance for deferred tax assets consisted of the following activity for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMS0xLTEtMzMxNjI_1ecc31d3-8282-4e4b-bf79-6f21c817aed5">123,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMy0xLTEtMzMxNjI_1c985d6b-7653-4159-ab91-a219dddab3cc">30,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNS0xLTEtMzMxNjI_873fa6cf-281a-4945-8863-e6434b72ca2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNy0xLTEtMzMxNjI_3db7b875-e877-4458-b27a-31017cef7511">154,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItMS0xLTEtMzMxNjc_f8107a82-19dd-4b7a-b137-685629b948f7">88,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItMy0xLTEtMzMxNjc_891b8d9c-f560-4ea7-8460-7414c8865b98">35,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItNS0xLTEtMzMxNjc_846d11dd-0e21-4a6f-8036-f8b833f2bd45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItNy0xLTEtMzMxNjc_43720d80-d413-4bbc-84ff-7ca5bd16ba2a">123,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMS0xLTEtMjQ1NDM_fedd085f-72cb-424f-8b4c-a0c92bb3a4d8">66,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMy0xLTEtMjQ1NDM_77f4316c-1564-4563-8582-a140a29a0df6">21,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="irtc:ValuationAllowanceDeferredTaxAssetDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNS0xLTEtMjQ1NDM_6814ade5-1e82-4b45-a3aa-12470be11d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNy0xLTEtMjQ1NDM_12d7346a-3c21-499f-ae05-36ae6b9c98c0">88,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE1MTA_d9b73c1d-fc75-4a29-9016-b2ba8098b8c4">464.3</ix:nonFraction> million of federal and $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE1Mjg_9c7b9e2d-6f26-4855-8c3c-66299a97b371">279.1</ix:nonFraction> million of state net operating loss carryforwards available to offset future taxable income which expires in varying amounts beginning in 2027 and   2020 respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had research tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="iba739cc6baef49ae98b4d255720f346f_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE3Njk_972a5298-5bd7-4664-933c-f129270553bb">7.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i3fbbed17d9fc4fb0935e56255354c327_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE3ODU_6b578998-d69d-4cad-9d4a-4c84778c049c">6.1</ix:nonFraction> million available to reduce future taxable income, if any, for both federal and state purposes, respectively. The federal tax credit carryforwards expire beginning in 2028 and the state tax credits can be carried forward indefinitely.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code, and similar state provisions, limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its net operating loss carryforwards and tax credits could be limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2019, the Company adopted ASC 740-10 (formerly known as FIN 48), Accounting for Income Taxes, guidance that addresses the recognition, measurement, and disclosure of uncertain tax positions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i1caf86f403804dfb9e2c9e91efd2dd2a"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzg_754268c1-bcb8-4b79-93dc-8ad4de3e86d0" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefit amount is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItMS0xLTEtMjQ1NDM_fcf804a2-0d77-4cfe-b24a-7bfa12fbbe30">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItMy0xLTEtMjQ1NDM_28a79264-50e0-4757-a766-02b2a98f359d">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItNS0xLTEtMjQ1NDM_24a847cd-a278-4e1e-b416-a5b6cba48c5e">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtMS0xLTEtMjQ1NDM_b5aad57a-a7bc-4ef3-bc62-1d760dd77718">772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtMy0xLTEtMjQ1NDM_2bcc4b19-6ad8-4716-824c-e92789e58510">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtNS0xLTEtMjQ1NDM_f9ab9821-3c8a-4c2a-8755-08d772c9650c">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtMS0xLTEtMjQ1NDM_b27b1da5-0b14-4d77-ab89-c8f6e09f9ae3">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtMy0xLTEtMjQ1NDM_1929a843-dadb-4f76-b2d8-44bc96252221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtNS0xLTEtMjQ1NDM_d72f07a2-24a4-478b-8bb2-74aeba52d6a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtMS0xLTEtMjQ1NDM_68e35cb3-2e59-4b9c-b8a1-cb05662753e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtMy0xLTEtMjQ1NDM_48811e9e-63ae-4dd8-9c25-e4d6a361fda9">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtNS0xLTEtMjQ1NDM_ebc550c4-2974-43c3-a177-952d7c78f99d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtMS0xLTEtMjQ1NDM_703d6e27-3314-410c-94c7-18fa275fdd27">3,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtMy0xLTEtMjQ1NDM_a731804b-7c58-4222-99b4-9b66e6ae204b">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtNS0xLTEtMjQ1NDM_d624c42a-9faf-4965-8ac5-6911b2d7f4e4">1,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total amount of gross unrecognized tax benefits was $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNjA_413c3204-9bee-46ca-8724-e26a558b64f4">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNjQ_9523eef3-b270-45f8-8e9e-7644e90bf122">2.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNzI_674a521a-9b5d-4d5b-ac83-86f264196e9c">1.8</ix:nonFraction> million as of December&#160;31, 2021, 2020, and 2019 respectively. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rate. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. Management determined that <ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_397d6955-57ee-4f94-8d6a-f23e0bf934b5"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_3d308603-505c-43e9-9ad0-17aa4835b860"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_ad1c9245-4b00-4dda-b754-544b2df398b5">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrual for interest or penalties was required as of December&#160;31, 2021, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company files income tax returns in the U.S. and UK jurisdictions. All of the Company's tax years are open to examination by the US federal and state tax authorities. The UK is open to examination for tax years starting 2017 and forward. The Company currently has no federal, state or foreign tax examinations in progress, nor has it had any federal or state examinations since inception.</span></div></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_109"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2NQ_27f56340-7d33-46d7-8caa-6b11fe478860" continuedAt="i1744379ee7c14030a897e85166a894a9" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i1744379ee7c14030a897e85166a894a9"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s amended and restated certificate of incorporation dated October 25, 2016, as amended, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzE3NA_7145dd55-ae0c-48de-bf1c-a779ff79e09e">100,000,000</ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzIyMA_4485a893-6268-4221-8f32-cbbccedb49cf">0.001</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzIzNw_dfe8b184-052b-49eb-a78b-568c71ba36f4">5,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzI4Ng_7c5fb6c6-1681-4446-a5e1-28d10d6807b4">0.001</ix:nonFraction> per share. The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the board of directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. <ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:DividendsCommonStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2Ng_6c5ebc33-c335-4b6e-ae2d-282241480144">No</ix:nonFraction> dividends were declared through December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2Nw_e1795968-cc9d-4356-88b8-e05ed82ad079" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib83d09b0b4814982af13362f56c4531a_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzItMS0xLTEtMjQ1NDM_f91a693a-0c2e-49b1-9076-529d1d13f35e">504,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5a2d071786e4b82beeb20f9e6115f40_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzItMy0xLTEtMjQ1NDM_01f05ffb-d637-45dc-9431-a2ee807a79a0">609,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86359793df1b40e2af06185a48d324e7_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzMtMS0xLTEtMjQ1NDM_295fd920-d88e-4f61-93a5-8f8ef4d78aa1">1,649,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzMtMy0xLTEtMjQ1NDM_010d7a13-71f8-4655-87d3-f999877ff9b0">1,114,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under future stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ae8319ea0074645a500405f0e3d6579_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzQtMS0xLTEtMjQ1NDM_72a6e666-d714-46f2-aac0-23eb202d1e19">9,011,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6546f2892d4749599e08c50b5624c54d_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzQtMy0xLTEtMjQ1NDM_78416896-71b4-497f-9b0a-11b172af606d">8,016,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzUtMS0xLTEtMjQ1NDM_2061cae8-3348-4a7a-84c1-56ad14bd1ae6">11,164,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzUtMy0xLTEtMjQ1NDM_7f7fd846-bf0d-4a06-bf3e-74f12a4976b9">9,740,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_112"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NjY_c4f31426-f898-4aae-9f89-ff41b62d3351" continuedAt="i02d4744c93b14848a1fc2b7e64515ac8" escape="true">Stock Incentive Plans</ix:nonNumeric></span></div><ix:continuation id="i02d4744c93b14848a1fc2b7e64515ac8" continuedAt="ia34fc5e17fd048919d50d08b603c7e55"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2006 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2006, the Company adopted the 2006 Equity Incentive Plan, as amended, (the &#8220;2006 Plan&#8221;). The Plan provided for the granting of stock options to employees and non-employees of the Company. Options granted under the Plan were either incentive stock options or nonqualified stock options. Incentive stock options (&#8220;ISO&#8221;) were granted only to employees (including officers and directors who are also employees). Nonqualified stock options (&#8220;NSO&#8221;) may be granted to employees and non-employees. The board of directors had the authority to determine to whom options will be granted, the number of options, the term and the exercise price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options under the Plan were granted for periods of up to <ix:nonNumeric contextRef="i330f02be0068413f808f4f28a9e5df09_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzc0Mg_606ed9a8-ce0b-4808-b760-f96e9ffcbaa8">ten years</ix:nonNumeric> and at the fair value of the shares on the date of grant as determined by the board of directors. In general, options become exercisable at a rate of <ix:nonFraction unitRef="number" contextRef="i9b76829668ea4e88ae1e21924f45a625_D20210101-20211231" decimals="2" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzg5NQ_c6a0b4e9-a9bd-49c6-91f8-3ae147d3691d">25</ix:nonFraction>% after the first anniversary of the grant and then monthly vesting for an additional <ix:nonNumeric contextRef="i67d4bd0b270848488c2997023ea615dd_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzk4Mg_fe6eebc9-4c3b-4938-8b38-b8a860b5af23">three years</ix:nonNumeric> from date of grant. The term for options is no longer than <ix:nonNumeric contextRef="id412c2fe707d4befae3144ed0cfbb2d5_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzEwNDQ_01a38d01-67da-4c12-8e49-641fbd6465fb">five years</ix:nonNumeric> for ISOs for which the grantee owns greater than <ix:nonFraction unitRef="number" contextRef="ieee82ee8a6ae43a08349bfe55fba2da0_D20210101-20211231" decimals="INF" name="irtc:PercentageOfVotingPowerOfAllClassesOfStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzEwOTY_b8a20135-6c8a-43bf-8b43-0250d3dd7f1a">10</ix:nonFraction>% of the voting power of all classes of stock and no longer than <ix:nonNumeric contextRef="i731d5a16540847ed99546bb8519fea22_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzExNjI_20a69fbb-166e-4e90-8381-eada9a895f6f">ten years</ix:nonNumeric> for all other options. The Company issues new shares upon the exercise of options.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="ia34fc5e17fd048919d50d08b603c7e55" continuedAt="i0ddc17b7780a46259f9f2007801f02ef"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company adopted the 2016 Equity Incentive Plan, (the &#8220;2016 Plan&#8221;). The 2016 Plan was subsequently approved by the Company&#8217;s stockholders and became effective on October 19, 2016, immediately before the effective date of the IPO. Following the effectiveness of the 2016 Plan, <ix:nonFraction unitRef="shares" contextRef="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzE_8ef19d86-a3f4-43e8-a837-6da7a9fdf7d2">no</ix:nonFraction> additional options will be granted under the 2006 Plan.&#160;In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2006 Plan are subsequently forfeited or terminated for any reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2016 Plan. The remaining shares available for grant under the 2006 Plan became available for issuance under the 2016 Plan upon the closing of the IPO. On the first day of each year, the 2016 Plan authorizes an annual increase of the least of <ix:nonFraction unitRef="shares" contextRef="i25aed7f0402b404688f5892cc0328e06_I20161031" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIyMDM_e1e33912-d20f-4077-9e3d-96805ca76d2d">3,865,000</ix:nonFraction> shares, <ix:nonFraction unitRef="number" contextRef="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIyMTQ_17dbb7b7-8b52-490d-9c90-76eb9e35e5ff">5</ix:nonFraction>% of outstanding shares on the last day of the immediately preceding fiscal year or an amount as determined by the Company's Board of Directors. As of December&#160;31, 2021, the Company has reserved <ix:nonFraction unitRef="shares" contextRef="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIzOTU_02c144c1-d2cb-403e-9699-be0233d515f9">7,159,947</ix:nonFraction> shares of common stock for issuance under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2016 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2016 Plan at an exercise price of not less than <ix:nonFraction unitRef="number" contextRef="iffb6e1927b5a42bdb8c43f08b9014d6a_I20161031" decimals="INF" name="irtc:PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzI5MTA_47f75de2-f0da-4d4d-a498-39c2edb133e1">100</ix:nonFraction>% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed <ix:nonNumeric contextRef="i0b57f096a6b04e42bb623131e05c164d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzI_30864230-1d26-483a-8a4e-1bd86839060d">ten years</ix:nonNumeric> from the date of grant.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company&#8217;s Board of Directors and stockholders approved the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). Under the ESPP, the Company initially reserved <ix:nonFraction unitRef="shares" contextRef="iea8afaf349a043cc9d3265230b6be88c_I20161031" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM0MjI_36e9f5af-d8af-4363-97aa-2f696c08d119">483,031</ix:nonFraction> shares of common stock for issuance as of its effective date of October 19, 2019. On the first day of each calendar year, the number of shares reserved increases by the least of <ix:nonFraction unitRef="shares" contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031" decimals="INF" name="irtc:IncreaseInCommonStockReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM2MDI_1de56ef2-721d-4fd8-a57c-9616c103e22a">966,062</ix:nonFraction> shares, <ix:nonFraction unitRef="number" contextRef="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM2MTM_5801ba21-f312-4863-992a-0c1207737939">1.5</ix:nonFraction>% of the shares of the Company&#8217;s common stock outstanding on the last day of the immediately preceding fiscal year, or an amount as determined by the Company&#8217;s Board of Directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="iea8afaf349a043cc9d3265230b6be88c_I20161031" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM5Mjg_dde3813a-2888-47cc-878f-d9b02ef1b038">15</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP provides for <ix:nonNumeric contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031" name="irtc:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQwMTg_b4e02f8c-a16c-4f75-b12d-6b3126184ee3">12</ix:nonNumeric> month offering periods that each contain <ix:nonFraction unitRef="numberofpurchaseperiod" contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031" decimals="INF" name="irtc:EmployeeStockPurchasePlanNumberOfPurchasePeriods" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0ODA_37841148-4ebd-411c-b069-ad34a4e67f66">two</ix:nonFraction> <ix:nonNumeric contextRef="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031" name="irtc:EmployeeStockPurchasePlanPurchasePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQwNjY_fb8497aa-761b-4e00-a225-a778f1835aca">6</ix:nonNumeric> month purchase periods. At the end of each purchase period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQxNzA_272e0479-c580-4929-b30f-f3d5de5bfc9d">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the purchase period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQzNDI_cb7ce005-fa40-49cd-8555-779aa64dbd46">515,231</ix:nonFraction> shares of common stock have been issued to employees participating in the ESPP and <ix:nonFraction unitRef="shares" contextRef="iedcc9216016246979e44e071acb39f72_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ0Mjg_3455ddd2-5b11-4e99-805a-5d07c7879f82">1,851,538</ix:nonFraction> shares were available for issuance under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2021: expected term of <ix:nonNumeric contextRef="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2MTI_abf7d1ef-4147-4397-be28-ff734f6ffebb">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2MTc_0400b67b-2435-4d3e-af82-43ba47b0cdbc">1</ix:nonNumeric> year, volatility of <ix:nonFraction unitRef="number" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NDA_bfa26c7a-1632-499c-a658-65109ed58e7a">93.99</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NDU_968158c0-fba8-4035-8d06-3fcb0dc26888">106.96</ix:nonFraction>%, risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NzY_dc9d27b3-264e-47d1-8a2b-5753cf6bce66">0.04</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2ODE_b6b9ca4f-50b0-4a97-af52-772514f4d49f">0.18</ix:nonFraction>% and expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ3MTU_0a2892c5-046d-44e7-a6a4-5b730145db4d">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2020: expected term of <ix:nonNumeric contextRef="i65041d451358415cbfcfe6fed3a436d8_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4NDk_1c75a32e-1419-44c0-b6a5-366679ab12f2">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i1f6a3e4be968456eb56ea5292deeb1ac_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4NTQ_cfb6cca6-5197-4600-8a72-42c58d722ce4">1</ix:nonNumeric> year, volatility of <ix:nonFraction unitRef="number" contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4Nzc_66e9bcbb-7aea-44f1-9264-56ff5591d344">68.72</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4ODI_9246130a-ed50-499b-a4da-3007f27ae61b">75.78</ix:nonFraction>%, risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5MTM_4cf4eaf3-2537-4d27-ae15-3565e533c442">0.11</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5MTg_8087889d-a367-45dc-a00d-1f6aede8dc81">0.18</ix:nonFraction>% and expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5NTI_d9872d65-8db3-41d4-b20e-990579c7edf7">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2019: expected term of <ix:nonNumeric contextRef="i3f36de2be3c245f5ae385981bc73b6e3_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUwODY_9098d0f6-6265-42db-af92-a5d5b6a2691d">0.5</ix:nonNumeric> &#8211; <ix:nonNumeric contextRef="i95dab85175994185bd642051f38f6586_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUwOTE_f903d1fe-86e0-4b60-a3fe-9c490ff693d4">1</ix:nonNumeric> year, volatility of <ix:nonFraction unitRef="number" contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxMTQ_df1502c2-d5f3-464e-acf7-094ee80ef475">43.61</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxMTk_90ec61fb-210a-456e-b586-6bb7e6b6a314">48.05</ix:nonFraction>%, risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxNTA_d3ab3c04-5103-44bb-a02c-b8bb0de24d49">1.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxNTU_e3baf279-b133-4000-a1f1-c48f4b555097">2.35</ix:nonFraction>% and expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxODk_f7c274cd-16a4-4408-b6d5-457bd53cadc9">zero</ix:nonFraction>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i0ddc17b7780a46259f9f2007801f02ef" continuedAt="i1ca9583db9f741c79abfdd775774b5ee"><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plan Activity</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0Njk_6d0ba85e-a4d5-4f02-bdde-521bf2c81bd1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of share-based awards available for grant under the 2016 Equity Incentive Plan is as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i759c278fc6f747e3ba280896f23d9bbc_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEtMS0xLTEtMjQ1NDM_67af97bc-f32b-4df7-b76f-3087149f481d">4,717,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzItMS0xLTEtMjQ1NDM_7fcbebbc-b2fb-4013-acb3-1441b254cde7">1,218,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231" decimals="INF" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzMtMS0xLTEtMjQ1NDM_cef554ce-1c7f-4f83-9807-c04d70787170">649,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzQtMS0xLTEtMjQ1NDM_738afdc4-4a32-442f-aaa4-d0e903cbe931">181,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzUtMS0xLTEtMjQ1NDM_79076c5f-6860-4eef-bc72-f125bb0a2fda">60,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0400993af6a41d99753781144b0a14e_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzYtMS0xLTEtMjQ1NDM_2081df03-4ddd-4538-988a-037ad1f1a715">5,528,132</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzctMS0xLTEtMjQ1NDM_0e27376d-1402-4650-b000-eddebac7632c">1,333,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231" decimals="INF" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzgtMS0xLTEtMjQ1NDM_e90bc550-ef80-4edc-8ab2-58b48540a4f1">595,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzktMS0xLTEtMjQ1NDM_21c51c3f-04f0-464f-8407-a3ec2383ff80">156,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEwLTEtMS0xLTI0NTQz_95f6cb71-d367-4401-bd47-f1c20cfd1efe">82,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibad41d5498b1410b8ada5b20ae638221_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzExLTEtMS0xLTI0NTQz_fc023353-675e-41a9-8455-096c5aac7558">6,505,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEyLTEtMS0xLTI0NTQz_16ecd045-ab9b-4e04-b5cf-428b802e5ca0">1,450,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231" decimals="INF" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEzLTEtMS0xLTI0NTQz_62f99aa7-376c-4077-b008-a8c3f1cc07d2">1,289,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE0LTEtMS0xLTI0NTQz_4423866f-1bc5-4cd6-ac09-ff5bdd4e811f">356,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE1LTEtMS0xLTI0NTQz_55cd91ef-c5b1-4d55-a31d-eaabf094a2e9">135,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE2LTEtMS0xLTI0NTQz_2173a9c7-ef48-4737-a3ab-dfcb7709cf19">7,159,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUzNTg_a2021286-8e9a-4773-9a74-e76810f5ad64">1,009,457</ix:nonFraction> restricted stock units ("RSUs") were granted, <ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU0MDc_d06cb5b4-ab6d-4a44-b7d9-144bead0f351">285,331</ix:nonFraction> RSUs vested, and <ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU0Mjc_259cd632-9918-4195-83b6-4558f8635072">200,019</ix:nonFraction> RSUs were forfeited.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NjU_09ffc194-e31f-4ff0-8a9c-96472d4fe457" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock option activity under the 2006 and 2016 Equity Incentive Plans:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItMS0xLTEtMjQ1NDM_0d443ed7-ba80-45d7-a461-04ca00428587">2,094,137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItMy0xLTEtMjQ1NDM_24088597-0e61-4e6c-a392-3499312b2e55">23.20</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0a4c3b7811b486b8f1f6dab487979c1_D20180101-20181231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItNS0xLTEtMjQ1NDM_68d25725-6f15-4eb4-b402-821f3291bddb">7.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40721ab01cb74086a6725dda65e33834_I20181231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItNy0xLTEtMjQ1NDM_9c0edfd2-3c9a-4600-8a75-fe0cb8fa4697">97,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzMtMS0xLTEtMjQ1NDM_eea1c9a8-7eb0-4659-8228-c5781d39aea0">20,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzMtMy0xLTEtMjQ1NDM_de223932-db2c-4527-8611-f089ca72ee47">82.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzQtMS0xLTEtMjQ1NDM_70ddfce3-eb14-4d76-bc03-e4b828eb32e7">540,307</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzQtMy0xLTEtMjQ1NDM_6f64338f-969c-46fd-b947-2783ab093538">9.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzUtMS0xLTEtMjQ1NDM_5f2b5d99-ce51-40d8-9f01-df89bbbd02d3">70,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzUtMy0xLTEtMjQ1NDM_68eace4b-7f1c-4629-ba65-5bfc862b56dc">54.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtMS0xLTEtMjQ1NDM_222e24f1-f7af-4514-a522-1c344c2efaeb">1,503,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtMy0xLTEtMjQ1NDM_b31589e0-440d-4ad8-a352-6b99d0885b7b">27.40</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtNS0xLTEtMjQ1NDM_a430f5ea-7cb4-4360-b4a4-cdd7a9db6fa7">6.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia897aa3797f647999451688e21df6eeb_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtNy0xLTEtMjQ1NDM_42f31dfc-f739-4962-ad44-8b48b851aa5a">62,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzctMS0xLTEtMjQ1NDM_ef34db71-45dc-48cc-b87b-73c484bd9c42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzctMy0xLTEtMjQ1NDM_acab836b-f9aa-4c01-9de0-720f7d3f8e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzgtMS0xLTEtMjQ1NDM_b7fa20e3-5589-4340-bafe-54ef53a126cb">868,614</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzgtMy0xLTEtMjQ1NDM_1763c34d-59ff-4ebd-8582-ba19bf0c72ae">17.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzktMS0xLTEtMjQ1NDM_d3df4184-064c-4d51-b96b-1bc485579962">24,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzktMy0xLTEtMjQ1NDM_50d8ba8a-0478-4951-8830-d2cb00ba6f67">66.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTEtMS0xLTI0NTQz_aa241b3f-46e3-43de-9fa0-b674a3467d43">609,881</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTMtMS0xLTI0NTQz_061c7736-55c4-4a8d-bad1-7b81017ffce5">40.18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTUtMS0xLTI0NTQz_08205f40-4d72-4240-a25f-9313354f29a3">6.24</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTctMS0xLTI0NTQz_e21ca695-c9f3-452c-a224-cd78a74c317f">120,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzExLTEtMS0xLTI0NTQz_2010562d-b40b-40a1-98dc-483978fdaa82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzExLTMtMS0xLTI0NTQz_5e04e105-c518-4d0e-83fa-8ff0b6275df2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEyLTEtMS0xLTI0NTQz_d9895834-56d0-4a9e-8164-c8c7282f499a">90,939</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEyLTMtMS0xLTI0NTQz_d7d38a9f-7da3-40cc-9150-6bfa5d5cbe31">31.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEzLTEtMS0xLTI0NTQz_1acbc58e-7a52-40b7-9ca7-733ba1d4bfa2">14,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEzLTMtMS0xLTI0NTQz_fca17d09-3b10-4353-90ad-a8e31adf44ab">68.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTEtMS0xLTI0NTQz_32080317-eccc-4a5e-98a6-7f489b7c0c68">504,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTMtMS0xLTI0NTQz_cb6b181a-5cd1-49d1-9e98-19a07f657a0c">40.97</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTUtMS0xLTI0NTQz_3d8de7ad-d8a2-4ac6-8d74-67d6480ad0f3">5.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTctMS0xLTI0NTQz_225bcae8-673c-4fa5-9cd7-599adfea2402">38,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercisable &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTEtMS0xLTI0NTQz_c9f33c1a-3259-42ef-979e-38d71dc4bef0">483,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTMtMS0xLTI0NTQz_9ac55f26-15e8-4a6f-84fd-4d695f48e1b3">39.61</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTUtMS0xLTI0NTQz_8dc2a2bd-ffde-4084-87e7-234d8c10144c">5.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTctMS0xLTI0NTQz_6e5d5b5a-a121-4749-b210-d0c53b6e5a0b">37,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options vested and expected to vest &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTEtMS0xLTI0NTQz_46be7b9d-c90e-4b36-80bc-1b9e2903d075">503,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTMtMS0xLTI0NTQz_986f6f0a-9cdd-4ac1-b006-3035cfbf9156">40.95</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTUtMS0xLTI0NTQz_4a704c50-6e8a-49de-b939-21dd78234663">5.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTctMS0xLTI0NTQz_0c7249e3-2963-404a-bebd-0d0763030da7">38,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company granted options with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU5MTU_adfbeea0-6dee-4ae5-b2a9-37a73596bb5b">38.29</ix:nonFraction> per share. The Company did <ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzY_6888fd81-3080-4995-a68a-9246620a49de"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzY_6f7ccee0-9d97-4a72-8c96-b848f2ebe7d3">no</ix:nonFraction></ix:nonFraction>t grant any options during the year ended December 31, 2020 or during the year ended December 31, 2021 . </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i1ca9583db9f741c79abfdd775774b5ee"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwNzg_6b68402e-fb40-4809-ac5b-26e3ef458172">10.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwODI_d22cc013-3c6d-4520-8599-fd679b0b4bbc">109.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwODk_db21b086-a3e8-40f3-9b08-595c653319db">36.9</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The total estimated grant date fair value of options vested during the period was $<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMjM_9e6dbba3-8492-4bd1-af19-5c32b0269100">2.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMjc_ae78f177-2aae-4bb9-8108-f34bfe61d5ff">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMzQ_ff9cd903-316b-4422-b51b-95d1ae9066eb">7.8</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzA_42d01f2d-0877-42b3-aef5-5a46c5899a89" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-vested restricted stock units (&#8220;RSUs&#8221;) is based on the Company&#8217;s closing stock price on the date of grant.&#160;A summary for the year ended&#160;December&#160;31, 2021, is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vesting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8555106470244294838f2dcfdde58a82_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtMS0xLTEtMjQ1NDM_191fa0a4-cea9-4d2f-acbe-a949412cc7b1">886,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8555106470244294838f2dcfdde58a82_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtMy0xLTEtMjQ1NDM_2e56c78f-0999-4add-bbee-350f81885077">77.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc42661c3194491383dc17aab6af6e5c_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtNS0xLTEtMjQ1NDM_9c204189-3581-4d41-ad9a-bad600657861">1.39</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8555106470244294838f2dcfdde58a82_I20191231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtNy0xLTEtMjQ1NDM_005e8cd2-00c8-4d9b-93c4-a2c2595eaefd">60,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzItMS0xLTEtMjQ1NDM_212cafc1-b701-45f9-8253-57ef597b1746">595,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzItMy0xLTEtMjQ1NDM_dff51337-40ec-4a87-b08b-4a8aa48567ea">104.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzMtMS0xLTEtMjQ1NDM_ea60a475-6225-44d9-9cc6-4e54dd9a4893">235,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzMtMy0xLTEtMjQ1NDM_62090536-8f19-4b4b-ab9c-2fdb8f4ce255">69.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzQtMS0xLTEtMjQ1NDM_e9feb84f-d523-4647-930b-8918480af947">131,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzQtMy0xLTEtMjQ1NDM_238d2ed7-688d-408b-abc0-ef8edebd64cf">59.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtMS0xLTEtMjQ1NDM_9a342b39-20d0-4f20-84e7-809666faa1cf">1,114,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtMy0xLTEtMjQ1NDM_fd99110e-3c62-4a32-9aa1-95a1c73486f3">94.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtNS0xLTEtMjQ1NDM_817aa320-b5d8-4ca1-a6ef-e9b128f07a63">1.38</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtNy0xLTEtMjQ1NDM_93e2e957-74b1-45e2-a639-4670eb72d27a">264,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzYtMS0xLTEtMjQ1NDM_0d111969-8ef9-4a95-aea8-df552cf31250">1,289,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzYtMy0xLTEtMjQ1NDM_207d68f2-4e04-4f29-a110-2804e6d42763">98.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzctMS0xLTEtMjQ1NDM_be22b5f1-c0c8-4a90-86a3-3219ab92072a">412,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzctMy0xLTEtMjQ1NDM_433f9d1c-01f7-48de-9ec6-18662ccd73e4">104.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzgtMS0xLTEtMjQ1NDM_1fb36e90-a515-4665-856d-796a8e5bf7fd">342,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzgtMy0xLTEtMjQ1NDM_ea2b5cad-f4f8-4582-82e3-36020a48c3c5">113.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86359793df1b40e2af06185a48d324e7_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktMS0xLTEtMjQ1NDM_804d1673-8b38-4d3b-81c5-cfeaeae341b3">1,649,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86359793df1b40e2af06185a48d324e7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktMy0xLTEtMjQ1NDM_842f1285-b027-4543-bd6f-836bd92f7384">91.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktNS0xLTEtMjQ1NDM_bb529367-60c7-4d01-90ed-91e2bbbc9e1a">1.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86359793df1b40e2af06185a48d324e7_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktNy0xLTEtMjQ1NDM_6aa3d419-7fd0-48db-88f6-bcda6b42cd8c">194,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_115"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTE_8ed1f08b-5dc9-4b30-9d5e-f18dbfe6b512" continuedAt="i70e420012e664df39a97b20b2c2d9387" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i70e420012e664df39a97b20b2c2d9387" continuedAt="i14ab3376e0d54f2b9554a166baab6d28"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Options Valuation</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTI_d6f9ac06-d732-44bb-a4e4-3f1b8f52e668" continuedAt="i5f32821afd8144f5b8ad548e8b544c12" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee and director stock options was estimated at the date of grant using the Black-Scholes option pricing model with the weighted average assumptions below.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzItMy0xLTEtMjQ1NDM_8c47f7a5-6dc0-4010-ba0b-b021742bab3f">6.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzMtMy0xLTEtMjQ1NDM_a21dbd18-2b04-4c15-b5c0-c83400d0c947">45.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzQtMy0xLTEtMjQ1NDM_4485aede-0e30-4fef-a761-5f624c3f0ad1">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzUtMy0xLTEtMjQ1NDM_c0d2cf91-e674-408f-975d-3907d7e431dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant stock options during the years ended December 31, 2021 and  December 31, 2020. </span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU Valuation</span></div><ix:continuation id="i5f32821afd8144f5b8ad548e8b544c12"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of market based RSUs was estimated at the date of grant using the Monte-Carlo option pricing model with the assumptions below. Additional details on the Company's market based RSUs are included below. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzItMS0xLTEtMjQ1NDM_6445b11d-f87c-48b0-9cf9-ea537738c0ca">0.74</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzMtMS0xLTEtMjQ1NDM_a86f5c29-0ebd-435a-b815-6a693997b011">63.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzQtMS0xLTEtMjQ1NDM_77bec192-5d2b-4085-9aaa-649c246656d8">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzUtMS0xLTEtMjQ1NDM_ab2f8141-451e-4f07-8a0d-55fd80b204f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s Board of Directors determined the fair value of each share of underlying common stock based on the closing price of the Company&#8217;s common stock as reported on the date of grant.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i14ab3376e0d54f2b9554a166baab6d28" continuedAt="i0d757dfcc04c4fff95a227f3aa369c83"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the share-based awards are expected to be outstanding. As the Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants the Company has elected to use the &#8220;simplified method&#8221; as prescribed by authoritative guidance to compute expected term.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded companies in a similar industry on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to expected term of the option award.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzI0ODY_8937f7a5-81f4-4197-bbb0-867293adbcc7">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company&#8217;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company&#8217;s stock-based compensation calculations on a prospective basis.</span></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTQ_9941c3a6-344c-4ef5-b74e-bed426288756" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ec867e77104c7c880eca8b43778fb5_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItMS0xLTEtMjQ1NDM_edff33da-1953-4143-a9e1-8b731aa5436e">1,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3077a0d7299d4f5aabbf2184ffe9be97_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItMy0xLTEtMjQ1NDM_4fd7521f-751a-4e7c-a824-bac61e192b7c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibac55be5040a4d65a2fa2138c70bc7f7_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItNS0xLTEtMjQ1NDM_33163f38-7111-4c90-8966-a6fd0bf101a4">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c63a57313342ee870d007775314912_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtMS0xLTEtMjQ1NDM_ee09969b-1bc3-4a04-b7bb-008e342cc976">5,565</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036e8e19c0244562aa901632c01f81c0_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtMy0xLTEtMjQ1NDM_f9d028c6-1624-4399-b3b8-4439f4fa5eb6">7,727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a9f2820af84e70bfdad6b84dbcdbbb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtNS0xLTEtMjQ1NDM_39f7d7bd-d453-429f-95b7-fd0a34921dab">4,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f92497acfec4d779bc015e79d7a07a4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtMS0xLTEtMjQ1NDM_56adff12-d936-4ef8-b3f4-1f3b12cb5520">47,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57a2b1da44734fbd961217ea3df13e21_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtMy0xLTEtMjQ1NDM_ce581589-f759-42b7-befa-b0c0e44624cf">33,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9032a6810bae4fa187e1e649dd2ad127_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtNS0xLTEtMjQ1NDM_d0aadbeb-aafe-408e-ba19-4d7cd3bfdb44">21,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtMS0xLTEtMjQ1NDM_1925f56d-a10e-43ca-8f96-c0efdd886a6f">54,527</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtMy0xLTEtMjQ1NDM_2809770d-4923-43e7-8659-9a7482428624">41,515</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtNS0xLTEtMjQ1NDM_8841f8e2-be25-44fa-bd4e-1472083d9f64">26,241</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was total unamortized compensation costs of $<ix:nonFraction unitRef="usd" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMxMzk_182abb4f-8841-4b50-a805-5675802011d7">0.8</ix:nonFraction> million, net of estimated forfeitures, related to unvested stock options, which the Company expects to recognize over a period of approximately <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMyNzg_0d4e917b-b9b1-498c-aee1-00bc6f506ab6">0.4</ix:nonNumeric> years and $<ix:nonFraction unitRef="usd" contextRef="i86359793df1b40e2af06185a48d324e7_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMyODI_6bf22711-d8da-4df4-bd66-0a0bd8044645">113.5</ix:nonFraction> million, net of estimated forfeitures, related to unrecognized RSU expense, which the Company expects to recognize over a period of <ix:nonNumeric contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0MDk_cc313f86-50b3-49b2-8411-83e9a8bf2e56">2.4</ix:nonNumeric> years, and $<ix:nonFraction unitRef="usd" contextRef="i65aa22d39afd4fdeb7a543c352ccd14b_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0MTc_1bf3e0cf-f19d-4653-b34e-334cde0f1052">3.1</ix:nonFraction> million unrecognized ESPP expense, which the Company will recognize over <ix:nonNumeric contextRef="iad223dfee47d4235be238a5c63906545_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0ODU_7d096fbc-49f5-4782-baca-d2889a88c0a0">0.9</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance based RSUs (&#8220;PRSU&#8221;) and Market-based RSUs</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants PRSUs to key executives of the Company. PRSUs can be earned in accordance with the performance equity program for each respective grant</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2019 Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the company granted PRSU's (&#8220;2019 awards&#8221;) to be earned based on the compound annual growth rate (&#8220;CAGR&#8221;) of fiscal year 2020's revenue compared to fiscal year 2018's revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the impact of the COVID-19 pandemic, management determined that the Company&#8217;s achievement of its performance targets described above, was not probable in the first quarter of fiscal year 2020. PRSU expense of $<ix:nonFraction unitRef="usd" contextRef="i9f9db1a2a402414e83610b8705c23f4a_D20200101-20200331" decimals="-5" name="irtc:ShareBasedPaymentArrangementReversalOfPriorExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQxMjE_50fe15ff-c052-40b7-93a7-179dbc34b004">4.8</ix:nonFraction>&#160;million recognized in fiscal year 2019 related to the 2019 awards was reversed in the first quarter of fiscal year 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, the Company modified the terms of the 2019 awards to vest based on the Company&#8217;s average stock price for the 60 days preceding January 1, 2021. The modification impacted all active recipients of the 2019 awards, a total of <ix:nonFraction unitRef="employee" contextRef="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ0Mzc_c0ca3dd4-392d-4b4e-9735-b3b42a6787f8">ten</ix:nonFraction> recipients. The total incremental compensation cost resulting from the modification of $<ix:nonFraction unitRef="usd" contextRef="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ1Mjc_038716fe-ca62-4d70-a56b-d38b3d4463ca">13.6</ix:nonFraction>&#160;million was recognized ratably through March 31, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia53dfea28b67446ea357092412155f6a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ2MDM_bc503cf3-cbcb-41d1-9c39-a1c0bf3a51b9">2.2</ix:nonFraction>&#160;million of compensation cost for the year ended December&#160;31, 2021 in connection with the 2019 awards.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><ix:continuation id="i0d757dfcc04c4fff95a227f3aa369c83" continuedAt="i6dd60df1c50c4545acb22b9dde8812f7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">February 2020 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the company granted PRSU's (&#8220;February 2020 awards&#8221;) for fiscal year 2022's annual unit volume CAGR compared to fiscal year 2019's annual unit volume CAGR, measuring a minimum performance threshold of <ix:nonFraction unitRef="number" contextRef="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229" decimals="INF" name="irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5MjQ_dcaefb6f-a5d9-45a0-ab3f-ff797d5269e1">19.7</ix:nonFraction>% to earn <ix:nonFraction unitRef="number" contextRef="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229" decimals="INF" name="irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5MzU_05c7d56f-dc65-4ca5-9243-945e4b3119c0">50</ix:nonFraction>% of target, and a maximum threshold of <ix:nonFraction unitRef="number" contextRef="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229" decimals="INF" name="irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5NzY_34541cd9-8433-4b03-9e33-0438824925d0">29</ix:nonFraction>% achieved to earn <ix:nonFraction unitRef="number" contextRef="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229" decimals="INF" name="irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5OTY_772d701c-821f-4d0c-845b-3955f65deca1">200</ix:nonFraction>% of target. A total of <ix:nonFraction unitRef="shares" contextRef="i0e8a36476e6e476ba97c7dbc8c1d08f6_D20200201-20200229" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzUwMjE_89876ea7-f89e-40ce-b710-76a20f924488">133,834</ix:nonFraction> PRSU shares were granted with grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="i285f97c5349f42d09fbf05bf4afa82fd_I20200229" decimals="-5" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzUwNzk_c940deaf-6743-475d-870c-8447b409821a">11.0</ix:nonFraction>&#160;million. The 2020 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that vested was recognized ratably through March 31, 2021. During the year ended December 31, 2021, the Company determined that it was probable that the February 2020 Awards would vest and recognized $<ix:nonFraction unitRef="usd" contextRef="i48d4090f1770461094499a8926219715_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzU0MTI_758c4c0b-707e-4dbf-ae1d-ba12392b6650">0.8</ix:nonFraction>&#160;million of compensation cost in connection with the February 2020 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">January 2021 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company granted PRSUs (&#8220;January 2021 awards&#8221;) for fiscal year 2021's annual consolidated revenue compared to fiscal year 2020's annual consolidated revenue, measuring a performance threshold of <ix:nonFraction unitRef="number" contextRef="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131" decimals="INF" name="irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MjU3_c1baca8b-bb81-4ff8-8d87-d2cb32f4aa8d">10.0</ix:nonFraction>% to earn <ix:nonFraction unitRef="number" contextRef="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131" decimals="INF" name="irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MjY5_22307bc7-1ce3-420a-8c42-d8a7f9eedcad">100</ix:nonFraction>% of target. A total of <ix:nonFraction unitRef="shares" contextRef="i7bf36d99211d4d7bb644f4a40a5aa345_D20210101-20210131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2Mjk1_54d77880-20f6-45bc-ab4c-35d36fcdd621">53,862</ix:nonFraction> PRSU shares were granted with a grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="i4171790573c447c9bd09afc513f59f75_I20210131" decimals="-5" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MzU2_2aecb5fe-8684-4e1a-9586-d04dd60d1942">13.9</ix:nonFraction>&#160;million. The January 2021 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2022. During the year ended December 31, 2021, the Company determined that it was probable that the January 2021 Awards would vest and recognized $<ix:nonFraction unitRef="usd" contextRef="i1db5399825c5480b91e101758d1f1cbb_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI4MjQ0_cf867ee6-5d61-4136-b695-427c962783a6">9.9</ix:nonFraction>&#160;million of compensation cost in connection with the January 2021 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2021 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company granted PRSU's (&#8220;February 2021 awards&#8221;) for fiscal year 2023's annual unit volume Compound Annual Growth Rate (&#8220;CAGR&#8221;) compared to fiscal year 2020's annual unit volume CAGR, measuring a minimum performance threshold of <ix:nonFraction unitRef="number" contextRef="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228" decimals="INF" name="irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MDY2_db58885f-17eb-4e5a-bb7f-1a491d44eafc">19.7</ix:nonFraction>% to earn <ix:nonFraction unitRef="number" contextRef="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228" decimals="INF" name="irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MDc4_2b6a2e8f-b563-44f1-9a91-9d70f4977e46">50</ix:nonFraction>% of target, and a maximum threshold of <ix:nonFraction unitRef="number" contextRef="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228" decimals="INF" name="irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTIw_824fff12-bc74-434e-9486-1d5f2b6fffb8">29</ix:nonFraction>% achieved to earn <ix:nonFraction unitRef="number" contextRef="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228" decimals="INF" name="irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTQx_6f8125f6-65bc-47c8-9d1e-9b8ef8b59c0a">200</ix:nonFraction>% of target. A total of <ix:nonFraction unitRef="shares" contextRef="i7fd28149e2f14307ab0e6573f2a75749_D20210201-20210228" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTY3_c13f3aa2-15e0-461e-92a2-137bd4409fb2">112,872</ix:nonFraction> PRSU shares were granted with grant date fair value of $<ix:nonFraction unitRef="usd" contextRef="ibd15311b9e074984b42d19b85d262583_I20210228" decimals="-5" name="irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MjI2_7dc23f04-de7f-41d9-91f3-fc75c04c600d">17.3</ix:nonFraction>&#160;million. The February 2021 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2024. During the year ended December 31, 2021, the Company determined that it was probable that the February 2021 Awards would vest and recognized $<ix:nonFraction unitRef="usd" contextRef="i7a2ac6ed88094e85ad351dfffe1b0bcc_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI4Nzk1_d0dfc07f-bb55-409d-b13f-a1b0de55ebbe">2.4</ix:nonFraction>&#160;million of compensation cost in connection with the February 2021 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non employee Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, the Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) resigned and entered into a Consulting and Professional Services Agreement (&#8220;CPSA&#8221;) with the Company to provide consulting services through July 2, 2021. Pursuant to the original terms of the awards, the CFO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in 2020 as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended  December 31, 2020, was $<ix:nonFraction unitRef="usd" contextRef="iccce65a61f0b4298b073d981b57911fe_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEwOTk1MTE2Mzg3NjY_74f69af4-2adc-478f-a94e-df07c77c9103">1.8</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6dd60df1c50c4545acb22b9dde8812f7">On January 12, 2021, the Company's Chief Executive Officer (&#8220;CEO&#8221;) resigned and entered into a CPSA with the Company. Pursuant to the original terms of the awards, the CEO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant or a member of the Company's Board of Directors. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in the three months ended March 31, 2021, as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i2f49daad3c3e4a63954ae45aeab81118_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzE2NDkyNjc0NTM1NDM_50390e22-72be-4f24-a75f-9820feaa3736">5.4</ix:nonFraction> million.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1NA_448778f3-8215-452a-9d05-34895a74a67f" continuedAt="ib1321b848d544c94b77f8a579ee7e1ec" escape="true">Net Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="ib1321b848d544c94b77f8a579ee7e1ec"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company had net losses for the years ended December&#160;31, 2021, 2020 and 2019, all potential common shares were determined to be anti-dilutive. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1NQ_f4944831-474d-4d42-9bad-c48aea138278" continuedAt="i4cd0a21d9fe448d9b8231c2890743d12" escape="true">The following table sets forth the computation of the basic and diluted net loss per share during the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except share and per share data):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i4cd0a21d9fe448d9b8231c2890743d12"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtMS0xLTEtMjQ1NDM_3e561a4b-1acc-4f77-ac44-9d49e782f9ed">101,361</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtMy0xLTEtMjQ1NDM_d994fb03-c923-4aee-8ea4-f4914793456b">43,830</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtNS0xLTEtMjQ1NDM_c4eec405-6bcb-44ff-ad71-d2e8e904cf3c">54,568</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMS0xLTEtMjQ1NDM_82cf8126-f371-4478-a8f1-aeedf6f9f3bc"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMS0xLTEtMjQ1NDM_8f73d7e3-623b-4920-95ec-ec08e7025f90">29,331,010</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMy0xLTEtMjQ1NDM_91b9029d-4146-4fa2-81e4-8921fd155068"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMy0xLTEtMjQ1NDM_e35c3d88-9320-42f8-8360-6fba76fc40bb">27,754,404</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtNS0xLTEtMjQ1NDM_3b0bf428-5a9f-4a27-9ece-fed9e318c5a8"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtNS0xLTEtMjQ1NDM_789c6930-50ef-4ca5-931e-95beb18b0f5e">25,265,918</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMS0xLTEtMjQ1NDM_1956a634-8f6a-4bdf-99da-103851856319"><ix:nonFraction unitRef="usdPerShare" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMS0xLTEtMjQ1NDM_eb7449c3-a72b-4777-b91b-525c1660332d">3.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMy0xLTEtMjQ1NDM_469d06ef-4dbd-4d81-8398-c8d8ada93bf0"><ix:nonFraction unitRef="usdPerShare" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMy0xLTEtMjQ1NDM_6d7a4ad8-71f0-457a-b6f4-c99cab895424">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtNS0xLTEtMjQ1NDM_09a1e904-2199-4b6c-99a6-4b05a3128c14"><ix:nonFraction unitRef="usdPerShare" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtNS0xLTEtMjQ1NDM_88d4acba-4c13-422d-bd92-35111e0d44b1">2.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1Ng_31cd3a74-f2e0-4492-b231-faadef6443f0" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per common share for the years ended December&#160;31, 2021, 2020 and 2019 because their inclusion would be anti-dilutive:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibef8252f0e0e4c2080743e4f89a810c7_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItMS0xLTEtMjQ1NDM_1282ecef-6e6d-4587-a2e4-037dd5c4b6d8">504,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i869c663a60864d6dafba82faf152398d_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItMy0xLTEtMjQ1NDM_3316f03f-05cf-4618-bf88-bc1cdb3bf47e">609,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9215b3bc96c4411aa73e32bdd167b66d_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItNS0xLTEtMjQ1NDM_f99d1820-c5fe-47e6-8ac6-c1974b40c74a">1,503,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec01902a609c42cca84e32a7417ad2c3_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtMS0xLTEtMjQ1NDM_b465d0ff-5f76-4f5f-8bed-74af353f1742">1,649,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb08d6c4a54f49048409724c6ec35971_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtMy0xLTEtMjQ1NDM_ebbf8d14-4c74-4c7b-87e6-3e7db2024894">1,114,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icab020b110c64525bd57c35617d3162e_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtNS0xLTEtMjQ1NDM_d5005095-ac77-4091-9849-646a62073198">886,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtMS0xLTEtMjQ1NDM_e1f556f1-4676-41ef-9398-ae1f6f810d09">2,153,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtMy0xLTEtMjQ1NDM_367d4d55-52b7-43a2-84a5-f0f3fb403c47">1,724,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtNS0xLTEtMjQ1NDM_a3634736-e5ab-4a9d-b099-24ab5476d31a">2,389,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_127"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzI1Mjg4NzY3NDQ2NDQ2_1783bf3b-d826-4a46-97fa-2b126f6a19ce" continuedAt="i1ef85c8182d3452c81edcec0b0ea02fa" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1ef85c8182d3452c81edcec0b0ea02fa"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novitas Announcement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, CMS published its Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;Final Rule&#8221;). In the Final Rule, CMS did not finalize national pricing for the extended external ECG patch, medical magnetic tape recorder (SD339) supply, and ruled to contractor pricing for CPT codes 93241, 93243, 93245 and 93247. The Company has been working with Medicare Administrative Contractors (MACs&#8221;) to establish pricing for these codes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 10, 2022, Novitas Solutions, the MAC which covers the region where the Company's Independent Diagnostic Testing Facility in Houston, Texas where almost all Medicare services for Zio XT are processed, published reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $<ix:nonFraction unitRef="usd" contextRef="i64b979f3794644df876abe57a7d76980_I20220110" decimals="0" name="irtc:CostReimbursementRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE4MTQ_531c979e-04e6-4d22-baa4-49dd7ad45fdd">223</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3706f468116148dbabf8b4fb4c6f96e7_I20220110" decimals="0" name="irtc:CostReimbursementRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE4MjA_437741e2-dc44-4a9c-b224-7686d7bc9965">233</ix:nonFraction>, respectively. These updated rates are retroactive to January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a lease for <ix:nonFraction unitRef="sqft" contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231" decimals="0" name="irtc:OperatingLeaseRentableArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE3Nzg_51a52348-0cf6-4df5-97f7-0ebb6dc17e63">44,616</ix:nonFraction> rentable square feet in Deerfield Illinois (</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deerfield Lease&#8221;). The Deerfield lease commenced in January 2022, the Company will recognize a related right of use asset and obligation in its Consolidated Financial Statements for the quarter ending March 31, 2022. The amount of such asset and obligation has not yet been determined. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company plans to consolidate operations and will begin marketing the excess space for sublease by the end of the first quarter of 2022. Depending on the outcome of marketing the sublease, the Company believes these decisions could result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</span></div></ix:continuation><div id="i4a303ab734354a4f8fadd28a70ce663e_130"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:9.35pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (&#8220;CEO&#8221;) (principal executive officer) and Chief Financial Officer (&#8220;CFO&#8221;) (principal financial officer), as appropriate to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As required by Rule 13a-15(b) under the Exchange Act, our management, including our CEO and CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our CEO and our CFO have concluded that as of December 31, 2021 our disclosure controls and procedures were not effective at the reasonable assurance level because of the material weakness in internal controls previously disclosed and discussed below. Notwithstanding the material weakness, our management, including our CEO and CFO, has concluded that our consolidated financial statements, included in the 2021 Annual Report on Form 10-K, fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented in conformity with generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In light of the material weakness described below, the Company performed additional analysis and other post-closing procedures to determine its consolidated financial statements are prepared in accordance with generally accepted accounting principles. Accordingly, management concluded that the financial statements included in this report fairly present in all material respects the Company&#8217;s financial condition, results of operations and cash flows for the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Exchange Act. Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 using the criteria described in </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Internal Control&#8212;Integrated Framework</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not design or maintain an effective control environment commensurate with our financial reporting requirements. Given the rapid growth in the size and complexity of the business, we failed to maintain a sufficient number of professionals with an appropriate level of accounting and internal control knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. This material weakness contributed to additional material weaknesses, previously disclosed and remediated. In aggregate, these material weaknesses (including the previously remediated material weaknesses) resulted in the misstatement of our revenues, revenue reserves, bad debt expense, property and equipment, research and development expense and related financial disclosures, and in the revision of the Company&#8217;s consolidated financial statements for the years ended December 31, 2017, December 31, 2018, and each interim period therein as well as the quarters ended March 31, 2019, June 30, 2019, and September 30, 2019. Additionally, this material weakness could result in a misstatement of account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.  Because of these deficiencies, and in spite of our remediation progress, described below, we concluded that the Company's internal control over financial reporting was not effective as of December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Remediation Plan Activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As it relates to the material weakness that exists as of December 31, 2021, we performed the following actions:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Increased the depth and experience of our Finance organization by increasing the number of management and staff members, expanding our technical experience in accounting, auditing and reporting matters, and performing internal controls training for management and staff members.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Hired two Internal Audit Directors (one with broad Finance experience and one with relevant control experience over information technology environments). These individuals are focused on the development, maintenance and monitoring of our overall control environment and system of key internal controls over financial reporting.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Hired several IT compliance experts including a Sr. Director of Cybersecurity with 20+ years of experience in cybersecurity, a Healthcare IT Compliance director with 15 years&#8217; experience in technology risk management compliance and assurance experience, and a senior IT compliance analyst with 20 years&#8217; experience in information security, IT governance and IT asset management.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These investments in resources have significantly improved the stability of our accounting organization and our IT compliance expertise. While significant progress has been made in response to the material weakness in the control environment, key remediation plan activities include additional training programs, automation efforts, and hiring of additional resources in support of certain control activities in the IT Compliance area.  Additionally, time is needed to demonstrate sustainability as it relates to our internal control over financial reporting and improvements made to our complement of resources, including demonstrating sustained operating effectiveness of our internal controls. </span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no changes in internal control over financial reporting during the quarter ended December 31, 2021, other than as described above, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Inherent Limitations on Effectiveness of Controls</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting can also be circumvented by collusion or improper management override of the controls. Projections of any evaluation of controls effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or deterioration in the degree of compliance with policies or procedures.</span></div><div><span><br/></span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_136"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_1583"></div><div style="margin-top:18pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_142"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_145"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_148"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_151"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_154"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODU_66e6dbbd-208b-4ff6-b6b9-02a6aa00793d">PricewaterhouseCoopers LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODY_c781b396-ac4c-4b26-a54e-88a1ab932701">San Jose, CA</ix:nonNumeric>, PCAOB ID: <ix:nonNumeric contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODg_e7f05b92-a719-415a-b268-69199922ae0d">238</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2022 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i4a303ab734354a4f8fadd28a70ce663e_160"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">List the following documents filed as a part of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-41.27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">All financial statements;</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-44.04pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Those financial statement schedules required to be filed by Item 8 of this form, and by paragraph (b) below. All financial statement schedules are omitted because they are not applicable or the amounts are immaterial or the required information is presented in the consolidated financial statements and notes thereto in Part II, Item 8 above.</span></div><div style="margin-top:6pt;padding-left:108pt;text-align:justify;text-indent:-46.81pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:36pt">Those exhibits required by Item 601 of Regulation S-K (&#167; 229.601 of this chapter) and by paragraph (b) below. Identify in the list each management contract or compensatory plan or arrangement required to be filed as an exhibit to this form pursuant to Item 15(b) of this report.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Registrants shall file, as exhibits to this form, the exhibits required by Item 601 of Regulation S-K (&#167; 229.601 of this chapter).</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Registrants shall file, as financial statement schedules to this form, the financial statements required by Regulation S-X (17 CFR 210) which are excluded from the annual report to shareholders by Rule 14a-3(b) including (1) separate financial statements of subsidiaries not consolidated and fifty percent or less owned persons; (2) separate financial statements of affiliates whose securities are pledged as collateral; and (3) schedules.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Index</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516747730/d271825dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 26, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516747730/d271825dex32.htm">Amended and Restated Bylaws of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 26, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex41.htm">Specimen Common Stock Certificate of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex42.htm">Amended and Restated Investors&#8217; Rights Agreement dated May&#160;16, 2014 by and among the Registrant and certain stockholders.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1388658/000138865820000034/exhibit43.htm">Description of the Registrant's securities registered pursuant to section 12 of the securities exchange act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1388658/000138865820000034/exhibit44.htm">First amendment to third amended and restated loan and security agreement. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex48.htm">Warrant to Purchase Stock issued to Life Science Loans, LLC dated as of June 3, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex101.htm">Form of Indemnification Agreement for directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex102.htm">2006 Stock Plan, as amended, and Form of Option Agreement thereunder.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex103.htm">2016 Equity Incentive Plan and related form agreements.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex104.htm">2016 Employee Stock Purchase Plan and related form agreements.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex105.htm">Executive Incentive Compensation Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex106.htm">Manufacturing Services Agreement dated March 1, 2009 between the Registrant and Jabil Circuit, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex107.htm">Memorandum of Understanding dated February 16, 2015 between the Registrant and Jabil Circuit, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex108.htm">Warland Business Park Lease dated April 20, 2015 between the Registrant and Warland Investments Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex109.htm">Office Lease dated April 30, 2008 between the Registrant and 650&#160;Townsend Associates, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1010.htm">First Amendment to Lease dated February 26, 2010 between the Registrant and 650 Townsend Associates, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1011.htm">Second Amendment to Lease dated December 19, 2011 between the Registrant and 650 Townsend Associates, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1012.htm">Third Amendment to Lease dated January 8, 2014 between the Registrant and Big Dog Holdings, LLC, as successor in interest to 650 Townsend Associates LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1013.htm">Fourth Amendment to Lease dated April 22, 2015 between the Registrant and Big Dog Holdings, LLC, as successor in interest to 650 Townsend Associates LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1014.htm">Fifth Amendment to Lease dated November 20, 2015 between the Registrant and Big Dog Holdings, LLC, as successor in interest to 650 Townsend Associates LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1015.htm">Sixth Amendment to Lease dated August 10, 2016 between the Registrant and Big Dog Holdings, LLC, as successor in interest to 650 Townsend Associates LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex1016.htm">Sublease dated October 29, 2009 between the Registrant and Freedomroads, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex1017.htm">First Amendment to Sublease dated June 1, 2010 between the Registrant and Freedomroads, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1018.htm">Second Amendment to Sublease dated September 24, 2013 between the Registrant, Freedomroads, LLC and FRHP Lincolnshire, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1019.htm">Sublease dated April 15, 2014 between the Registrant and Lone Star R.S. Platou, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1020.htm">Services Agreement dated December 24, 2013 between the Registrant and XIFIN, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex1021.htm">Second Amended and Restated Loan and Security Agreement dated December 4, 2015 between the Registrant and Silicon Valley Bank.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1022.htm">Loan Agreement dated December 4, 2015 between the Registrant and Biopharma Secured Investments III Holdings Cayman LP.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1023.htm">Guaranty and Security Agreement dated December 4, 2015 by the Registrant and each other grantor from time to time party thereto in favor of Biopharma Secured Investments III Holdings Cayman LP.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex1024.htm">Note Purchase Agreement dated November 16, 2012, as amended, by and between the Registrant and California HealthCare Foundation, exhibits related thereto and related Promissory Note.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1025.htm">Employment Letter to Kevin M. King dated July 23, 2012 between the Registrant and Kevin M. King.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1026.htm">Employment Letter to David A. Vort dated November 22, 2013 between the Registrant and David A. Vort.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1027.htm">Employment Letter to Derrick Sung dated March 24, 2015 between the Registrant and Derrick Sung.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1028.htm">Employment Letter to Matthew C. Garrett dated December 2, 2012 between the Registrant and Matthew C. Garrett.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459017023798/irtc-ex1029_147.htm">Form of Change of Control and Severance Agreement to be effective upon the closing of the offering.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 14, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex1030.htm">Office Lease (Suite 500) dated August 9, 2016 between the Registrant and Big Dog Holdings, LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516733933/d941976dex1031.htm">Note and Warrant Purchase Agreement dated November 1, 2012, by and among the Registrant and the persons and entities listed on the Schedule of Investors attached thereto as Exhibit A and exhibits related thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 7, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459017015766/irtc-ex1032_76.htm">Office Lease dated May 1, 2017 between the Registrant and Radler Limited Partnership.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459018019164/irtc-ex1033_95.htm">Employment Letter to Karim Karti dated June 12, 2018 between the Registrant and Karim Karti.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 3, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459018019164/irtc-ex1034_154.htm">First Amendment to Lease dated June 5, 2018 between the Registrant and Warland Investments Company.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 3, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459019005924/irtc-ex1035_1041.htm">Office Lease dated October 4, 2018 between the Registrant and Big Dog Holdings LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000156459018025406/irtc-ex101_26.htm">Third Amended and Restated Loan and Security Agreement, dated as of October 23, 2018, between Silicon Valley Bank, a California corporation, and iRhythm Technologies, Inc., a Delaware corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 29, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000138865819000020/irtc-20190930xex101.htm">2016 Employee Stock Purchase Plan, as amended February 26, 2019, and related form agreements.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 23, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000138865819000020/irtc-20190930xex102.htm">Employment Letter to Mark Day dated September 3, 2007 between the Registrant and Mark Day.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 23, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.39&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000138865819000020/irtc-20190930xex103.htm">Development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 23, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1388658/000138865820000175/executivechangeincontr.htm">Executive Change in Control and Severance Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1388658/000138865820000236/a11formofunderwritinga.htm">Underwriting Agreement by and among iRhythm Technologies, Inc. and J.P. Morgan Securities LLC and Morgan Stanley &amp; Co. LLC as representatives of the several underwriters named therein, dated August 18, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 21, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1388658/000138865821000070/irtc-20210331xex1042.htm">Multi-Tenant Office/Industrial Lease by and between iRhythm Technologies, Inc. and Katella/Holder Street LLC dated March 18, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 5, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.43&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="firstamendmenttodevelopmen.htm">First amendment to development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.44&#177;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="secondamendmenttodevelopme.htm">Second amendment to development collaboration agreement by and among Verily Life Sciences LLC, Verily Ireland Limited, and iRhythm Technologies, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-37918</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 25, 2022</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1388658/000119312516718525/d941976dex211.htm">List of Subsidiaries of Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-213773</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 23, 2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="irtc-20211231xex231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="irtc-20211231xex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="irtc-20211231xex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="irtc-20211231xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:31.5pt">The certifications attached as Exhibit 31.1, 31.2 and 32.1 that accompany this Annual Report on Form 10-K, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of iRhythm Technologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicates management contract or compensatory plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#177;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and have been filed<br/>&#160;&#160;&#160;&#160;separately with the Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4a303ab734354a4f8fadd28a70ce663e_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4a303ab734354a4f8fadd28a70ce663e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iRhythm Technologies, Inc. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Quentin S. Blackford</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quentin S. Blackford<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:26.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Quentin S. Blackford</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quentin S. Blackford</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Douglas J. Devine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Operating Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas J. Devine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Bruce G. Bodaken</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce G. Bodaken</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Ralph Snyderman M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ralph Snyderman M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;C. Noel Bairey Merz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C. Noel Bairey Merz, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Mark J. Rubash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark J. Rubash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Karen Ling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Ling</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Renee Budig</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee Budig</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Kevin M. King</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin M. King</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Abhijit Y. Talwalkar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abhijit Y. Talwalkar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>2
<FILENAME>firstamendmenttodevelopmen.htm
<DESCRIPTION>EX-10.43
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7ae5f2266feb4a618fed9f7e5d1a4377_1"></div><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDMENT NO. 1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TO DEVELOPMENT COLLABORATION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This amendment to the Development and Collaboration Agreement (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into by Verily Life Sciences LLC whose principal place of business is at 269 East Grand Avenue, South San Francisco, California 94080 USA (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VLS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson&#8217;s Quay, Dublin 2, Ireland (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; and together with VLS, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 699 8</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street, Suite 600, San Francisco, CA 94103 (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IRTC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Amendment is effective from the date of last signature below (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).<br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INTRODUCTION</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRTC and Verily are parties to that certain Development Collaboration Agreement with an effective date of September 3, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The parties wish to amend the Agreement to &#91;***&#93;, pursuant to the Development Plan or Amended Development Plan (as defined below). <br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AGREED TERMS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Definitions.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms used but not defined in this Amendment have the meanings given to them in the Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">Amendments.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From the Amendment Effective Date, the Agreement is amended as follows&#58; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">&#91;***&#93; of the Agreement is deleted and replaced with the following&#58;  <br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;&#91;***&#93;&#8221; means any Intellectual Property Rights (a) Controlled by &#91;***&#93; or its Affiliates prior to the Effective Date, or (b) that come under the Control of &#91;***&#93; or its Affiliates during the Term other than in the course of performing activities pursuant to the Development Plan contemplated by this Agreement, &#91;***&#93; and, in each case ((a) and (b)), that are necessary or useful for the Development, Manufacture, or Commercialization of the &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The following is added after the second sentence of Section 3.6&#58; <br><br>The terms of the Phase 1b Agreement and any follow-on agreement between the Parties &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> To the extent that &#91;***&#93; shall be subject to the negotiation and execution of a subsequent agreement by the Parties.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The following is added at the end of Section 6.1&#58; <br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Parties agree that, in any transfer of the &#91;***&#93; will not transfer any source code making up the &#91;***&#93; and will not transfer any documentation of architecture, design or other technical specifications concerning the software library included therein, to &#91;***&#93;, except for information reasonably required for quality assurance purposes in connection with the performance of the Development Plan or the Amended Development Plan. &#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shall not reverse engineer, disassemble, or decompile any prototypes, software, samples, or other tangible objects that embody the &#91;***&#93;, nor develop any improvements to, or derive any derivatives from, the &#91;***&#93;. As between the Parties, &#91;***&#93; will own and retain all rights, title and interest in and to the &#91;***&#93;. Any ideas, suggestions, guidance or other information disclosed by &#91;***&#93; and any intellectual property rights relating to the foregoing shall be collectively deemed &#8220;Feedback.&#8221;  &#91;***&#93; agrees to grant and hereby grants to &#91;***&#93; a nonexclusive, perpetual, irrevocable, royalty free, worldwide license (with the right to grant and authorize sublicenses) to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display, perform and otherwise exploit such Feedback without restriction.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The last sentence of Section 6.5 &#91;***&#93; is hereby deleted and replaced in its entirety with the following&#58;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The rights granted under this Section 6.5 (AF Algorithm Licenses) do not include any rights or licenses to the &#91;***&#93;.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">&#91;***&#93;&#8217;s representations and warranties in &#91;***&#93; are true as of the Amendment Effective Date with respect to the &#91;***&#93;.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.67pt">General</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The Parties agree to review the Development Plan and propose updates as necessary to effect the changes reflected in this Amendment to the JSC and the Parties. The Parties will consider any such proposed updates in good faith and adopt an updated Development Plan, if required to reflect the terms of this Amendment (any such Development Plan, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amended Development Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The Agreement remains in full force and effect except as modified by this Amendment, and the Milestone Payments already achieved or paid under the Agreement are non-refundable and will not be impacted by this Amendment. If the Agreement and this Amendment conflict, this Amendment governs to the extent of the conflict.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:1.34pt">The Agreement&#8217;s governing law and dispute resolution provisions also apply to this Amendment.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:4.5pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:75.6pt;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div><div><font><br></font></div></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signed by the parties&#8217; authorized representatives on the dates below.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:48.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VERILY LIFE SCIENCES LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">iRHYTHM TECHNOLOGIES, INC.<br></font><font style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Andrew Conrad</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Doug Devine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Andrew Conrad</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Doug Devine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; 4&#47;26&#47;2021</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  4&#47;26&#47;2021</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.44
<SEQUENCE>3
<FILENAME>secondamendmenttodevelopme.htm
<DESCRIPTION>EX-10.44
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7a7f82739acd4cd285242a87a8682365_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT COLLABORATION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT AND COLLABORATION AGREEMENT  (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) is entered into by Verily Life Sciences LLC whose principal place of business is at 269 East Grand Avenue, South San Francisco, California 94080 USA (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VLS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson&#8217;s Quay, Dublin 2, Ireland (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIL</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; and together with VLS, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Verily</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 699 8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street, Suite 600, San Francisco, CA 94103 (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IRTC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Amendment is effective from the date of last signature below (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amendment Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INTRODUCTION</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRTC and Verily are parties to that certain Development Collaboration Agreement with an effective date of September 3, 2019, amended by Amendment No.1 to Development Collaboration Agreement dated April 26, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) which has recently expired, and which the Parties now wish to revive.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to reviving the Agreement,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> t</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">he parties wish to amend the Agreement to (i) reflect the Parties&#8217; intent to &#91;***&#93;, (ii) extend the Term to allow for &#91;***&#93;, and (iii) define Verily&#8217;s support for the &#91;***&#93; validation of the &#91;***&#93;.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AGREED TERMS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.42pt">Definitions.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms used but not defined in this Amendment have the meanings given to them in the Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.42pt">Amendments.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">From the Amendment Effective Date, the Agreement is amended as follows&#58; </font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.42pt">The Agreement is hereby revived as of the Amendment Effective Date pursuant to the same terms and conditions except as otherwise stated herein.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.42pt">Section 10.1 of the Agreement is hereby deleted and replaced with the following&#58;  &#8220;10.1 Term. This Agreement will commence on the Effective Date and, unless terminated earlier in accordance with this Section 10 (Term and Termination), will remain in full force and effect until the date that is &#91;***&#93;.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.42pt">The Parties agree that activities undertaken under the Agreement prior to the Amendment Effective Date are governed by the terms of the Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.42pt">Section 4.4(c) of the Agreement is amended to add the following sentence to the end of Section 4.4(c)&#58;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verily will &#91;***&#93;. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">          5.&#160;&#160;&#160;&#160;Milestone 6 in Table 5.2 of the Agreement shall be deleted and replaced with the following&#58; &#91;***&#93;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-11.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6. &#160;&#160;&#160;&#160;The Parties agree that Verily will provide &#91;***&#93;.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:line-through"> </font></div><div style="padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">           7.&#160;&#160;&#160;&#160; The Parties agree that Milestone 4 has been achieved. Therefore, Section 10.5 of the Agreement is deleted and replaced with the following&#58;  </font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:63pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination for Failure to initiate &#91;***&#93;. Either Party will have the right to terminate this Agreement if &#91;***&#93; is not achieved within &#91;***&#93; of the Amendment Effective Date. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8. &#160;&#160;&#160;&#160;At the JSC&#8217;s option, Verily will provide &#91;***&#93;.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:10.42pt">General</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:2.84pt">The Agreement remains in full force and effect except as modified by this Amendment, and the Milestone Payments already achieved or paid under the Agreement are non-refundable and will not be impacted by this Amendment. If the Agreement and this Amendment conflict, this Amendment governs to the extent of the conflict.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:2.84pt">The Agreement&#8217;s governing law and dispute resolution provisions also apply to this Amendment.  </font></div><div><font><br></font></div><div style="text-indent:4.5pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed***</font></div></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signed by the parties&#8217; authorized representatives on the dates below.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.871%"><tr><td style="width:1.0%"></td><td style="width:48.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VERILY LIFE SCIENCES LLC</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">iRHYTHM TECHNOLOGIES, INC.<br></font><font style="font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Andrew Conrad</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Quentin Blackford</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Andrew Conrad</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Quentin Blackford</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; CEO</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; 1&#47;24&#47;2022</font></td><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; 1&#47;7&#47;2022</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.275%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VERILY IRELAND LIMITED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Liz Cunningham</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Liz Cunningham</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; director</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  1&#47;24&#47;2022</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>irtc-20211231xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8b78a9a6ebd3417d92eef6269320b69d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of iRhythm Technologies, Inc. of our report dated February 28, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in iRhythm Technologies, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2021</font><font style="color:#000000;font-family:'Georgia',serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.625%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">San Jose, California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 28, 2021</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>irtc-20211231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i973402621f1f4022b7d6045c0b2dacd0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Quentin S. Blackford, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of iRhythm Technologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Quentin S. Blackford,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quentin S. Blackford,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>irtc-20211231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2e2b44773ceb4ae3843a9b867ef2768c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Exchange Act Rules 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Douglas J. Devine, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Annual Report on Form 10-K of iRhythm Technologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Douglas J. Devine</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas J. Devine</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Chief Operating Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>irtc-20211231xex321.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i36c03cc56be94c748a2c91703c104ee6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of iRhythm Technologies, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:57.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Quentin S. Blackford</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quentin S. Blackford<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Douglas J. Devine</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas J. Devine<br>Chief Financial Officer and Chief Operating Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>irtc-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:irtc="http://www.irhythmtech.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.irhythmtech.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="irtc-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="irtc-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="irtc-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="irtc-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.irhythmtech.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.irhythmtech.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.irhythmtech.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails" roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestments" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestments">
        <link:definition>2110103 - Disclosure - Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestmentsTables" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables">
        <link:definition>2311302 - Disclosure - Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails">
        <link:definition>2412406 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails">
        <link:definition>2413407 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails">
        <link:definition>2414408 - Disclosure - Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandInvestmentsAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails">
        <link:definition>2415409 - Disclosure - Cash Equivalents and Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.irhythmtech.com/role/FairValueMeasurements">
        <link:definition>2116104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsTables">
        <link:definition>2317303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2418410 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails" roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails">
        <link:definition>2419411 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponents">
        <link:definition>2120105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsTables">
        <link:definition>2321304 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails">
        <link:definition>2422412 - Disclosure - Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies ("PCBAs") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>2423413 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails">
        <link:definition>2424414 - Disclosure - Balance Sheet Components - Components of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails" roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails">
        <link:definition>2425415 - Disclosure - Balance Sheet Components - Components of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.irhythmtech.com/role/CommitmentsandContingencies">
        <link:definition>2126106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesTables">
        <link:definition>2327305 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2428416 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails">
        <link:definition>2429417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1" roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1">
        <link:definition>2429417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.irhythmtech.com/role/Debt">
        <link:definition>2130107 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.irhythmtech.com/role/DebtTables">
        <link:definition>2331306 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/DebtAdditionalInformationDetails">
        <link:definition>2432418 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofFutureMinimumPaymentsDetails" roleURI="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails">
        <link:definition>2433419 - Disclosure - Debt - Schedule of Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.irhythmtech.com/role/IncomeTaxes">
        <link:definition>2134108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.irhythmtech.com/role/IncomeTaxesTables">
        <link:definition>2335307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails">
        <link:definition>2436420 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails">
        <link:definition>2437421 - Disclosure - Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2438422 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2439423 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails">
        <link:definition>2440424 - Disclosure - Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails" roleURI="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails">
        <link:definition>2441425 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.irhythmtech.com/role/StockholdersEquity">
        <link:definition>2142109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.irhythmtech.com/role/StockholdersEquityTables">
        <link:definition>2343308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>2444426 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" roleURI="http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
        <link:definition>2445427 - Disclosure - Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.irhythmtech.com/role/StockIncentivePlans">
        <link:definition>2146110 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.irhythmtech.com/role/StockIncentivePlansTables">
        <link:definition>2347309 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails">
        <link:definition>2448428 - Disclosure - Stock Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails" roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails">
        <link:definition>2449429 - Disclosure - Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails" roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails">
        <link:definition>2450430 - Disclosure - Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails" roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails">
        <link:definition>2451431 - Disclosure - Stock Incentive Plans - Summary of Non-vested Restricted Stock Units ("RSUs") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.irhythmtech.com/role/StockBasedCompensation">
        <link:definition>2152111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.irhythmtech.com/role/StockBasedCompensationTables">
        <link:definition>2353310 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" roleURI="http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails">
        <link:definition>2454432 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2455433 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails" roleURI="http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails">
        <link:definition>2456434 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShare">
        <link:definition>2157112 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareTables">
        <link:definition>2358311 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails" roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails">
        <link:definition>2459435 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails" roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails">
        <link:definition>2460436 - Disclosure - Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.irhythmtech.com/role/SubsequentEvents">
        <link:definition>2161113 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.irhythmtech.com/role/SubsequentEventsDetails">
        <link:definition>2462437 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" abstract="false" name="UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_DeferredTaxAssetsValuationAllowanceRollForward" abstract="true" name="DeferredTaxAssetsValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_PharmakonLoanAgreementMember" abstract="true" name="PharmakonLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardVested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_SanFranciscoMember" abstract="true" name="SanFranciscoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_SharesUnderlyingRSUsAbstract" abstract="true" name="SharesUnderlyingRSUsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_CollaborationAgreementMilestonePayments" abstract="false" name="CollaborationAgreementMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" abstract="true" name="ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ProvisionForBadDebtAndContractualAllowance" abstract="false" name="ProvisionForBadDebtAndContractualAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_LongTermDebtCarryingValue" abstract="false" name="LongTermDebtCarryingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_WeightedAverageRemainingContractualLifeYearsAbstract" abstract="true" name="WeightedAverageRemainingContractualLifeYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_CommercialPayorsMember" abstract="true" name="CommercialPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_WeightedAverageExercisePricePerShareAbstract" abstract="true" name="WeightedAverageExercisePricePerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_ValuationAllowanceDeferredTaxAssetAdditions" abstract="false" name="ValuationAllowanceDeferredTaxAssetAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_OperatingLeaseRentableArea" abstract="false" name="OperatingLeaseRentableArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="irtc_EmployeeStockPurchasePlanPurchasePeriod" abstract="false" name="EmployeeStockPurchasePlanPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="irtc_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" abstract="false" name="ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_CollaborationAgreementRemainingTermOfAgreement" abstract="false" name="CollaborationAgreementRemainingTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="irtc_DeferredTaxAssetsValuationAllowancesAndOther" abstract="false" name="DeferredTaxAssetsValuationAllowancesAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" abstract="false" name="ShareBasedPaymentArrangementReversalOfPriorExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_StockOptionsIssuedAndOutstandingMember" abstract="true" name="StockOptionsIssuedAndOutstandingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_AwardedFebruary2021Member" abstract="true" name="AwardedFebruary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_CommonStockSharesIssuedFromExerciseOfWarrants" abstract="false" name="CommonStockSharesIssuedFromExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_ProductAndServicesZioXTServiceCode93247Member" abstract="true" name="ProductAndServicesZioXTServiceCode93247Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_AccruedEmployeeStockPurchasePlanContribution" abstract="false" name="AccruedEmployeeStockPurchasePlanContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_DeerfieldLeaseMember" abstract="true" name="DeerfieldLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_TwoThousandSixteenEquityIncentivePlanMember" abstract="true" name="TwoThousandSixteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" abstract="false" name="EmployeeStockPurchasePlanNumberOfPurchasePeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="irtc_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_PercentageOfEligibleAccountsReceivableForBorrowings" abstract="false" name="PercentageOfEligibleAccountsReceivableForBorrowings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_GrantUnderFutureStockPlansMember" abstract="true" name="GrantUnderFutureStockPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_OtherStockOptionMember" abstract="true" name="OtherStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_InventoryAndPrintedCircuitBoardAssemblies" abstract="false" name="InventoryAndPrintedCircuitBoardAssemblies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_PrintedCircuitBoardAssembliesMember" abstract="true" name="PrintedCircuitBoardAssembliesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_LaboratoryAndManufacturingEquipmentMember" abstract="true" name="LaboratoryAndManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" abstract="false" name="ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" abstract="false" name="AvailableForSaleDebtSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" abstract="false" name="AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" abstract="false" name="CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_WeightedAverageGrantDateFairValueAbstract" abstract="true" name="WeightedAverageGrantDateFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" abstract="false" name="DebtInstrumentBasisSpreadDeductionOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" abstract="false" name="ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_InflationaryRiskPolicyTextBlock" abstract="false" name="InflationaryRiskPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_IncreaseInCommonStockReservedForFutureIssuance" abstract="false" name="IncreaseInCommonStockReservedForFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" abstract="false" name="IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_A2021AwardsMember" abstract="true" name="A2021AwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_CypressLeaseMember" abstract="true" name="CypressLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" abstract="false" name="ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_ClaimsPayableCurrent" abstract="false" name="ClaimsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" abstract="false" name="CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" abstract="false" name="RiskAndUncertaintiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_OptionsOutstandingAbstract" abstract="true" name="OptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" abstract="false" name="StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" abstract="false" name="PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" abstract="false" name="CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_DeferredTaxAssetsLeaseObligations" abstract="false" name="DeferredTaxAssetsLeaseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" abstract="true" name="CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_ContractLiabilityPolicyPolicyTextBlock" abstract="false" name="ContractLiabilityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_AccountsReceivableContractualAdjustments" abstract="false" name="AccountsReceivableContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_A2019AwardsMember" abstract="true" name="A2019AwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="irtc_ProductAndServicesZioXTServiceCode93243Member" abstract="true" name="ProductAndServicesZioXTServiceCode93243Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_AccountsReceivableForContractualAllowance" abstract="false" name="AccountsReceivableForContractualAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" abstract="false" name="LesseeOperatingSubleaseNumberOfOptionToExtend" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="irtc_MarketConditionAwardsMember" abstract="true" name="MarketConditionAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_AwardedJanuary2021Member" abstract="true" name="AwardedJanuary2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_OperatingLeaseRightOfUseAssetsAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetsAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_TwoThousandSixEquityIncentivePlanMember" abstract="true" name="TwoThousandSixEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ValuationAllowanceDeferredTaxAssetDeductions" abstract="false" name="ValuationAllowanceDeferredTaxAssetDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_OfficeLeaseMember" abstract="true" name="OfficeLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_CollaborationAgreementUpfrontFeePayable" abstract="false" name="CollaborationAgreementUpfrontFeePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_RawMaterialsMember" abstract="true" name="RawMaterialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" abstract="false" name="PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_OtherAssetsUsefulLives" abstract="false" name="OtherAssetsUsefulLives" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="irtc_IncentiveStockOptionsMember" abstract="true" name="IncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_A2020AwardsMember" abstract="true" name="A2020AwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_SiliconValleyBankTermLoanMember" abstract="true" name="SiliconValleyBankTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_CashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_CentersForMedicareAndMedicaidMember" abstract="true" name="CentersForMedicareAndMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_NonContractedThirdPartyPayorsMember" abstract="true" name="NonContractedThirdPartyPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" abstract="false" name="ScheduleOfChangeInContractualAllowanceTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_WeightedRemainingVestingPeriodInYearsAbstract" abstract="true" name="WeightedRemainingVestingPeriodInYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_LincolnshireLeaseMember" abstract="true" name="LincolnshireLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" abstract="true" name="ConsultingAndProfessionalServicesAgreementCPSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_OperatingLossCarryforwardsTaxBenefitRecognized" abstract="false" name="OperatingLossCarryforwardsTaxBenefitRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" abstract="false" name="PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_FederalGovernmentAgenciesMember" abstract="true" name="FederalGovernmentAgenciesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="irtc_DebtInstrumentInterestPortion" abstract="false" name="DebtInstrumentInterestPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_PercentageOfVotingPowerOfAllClassesOfStock" abstract="false" name="PercentageOfVotingPowerOfAllClassesOfStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="irtc_FinishedGoodsMember" abstract="true" name="FinishedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_OtherAssetsPolicyPolicyPolicyTextBlock" abstract="false" name="OtherAssetsPolicyPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_AccountsReceivableAllowanceForContractualAdjustments" abstract="false" name="AccountsReceivableAllowanceForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_CostReimbursementRate" abstract="false" name="CostReimbursementRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" abstract="false" name="CashEquivalentsAndCurrentAndNoncurrentInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="irtc_VerilyLifeSciencesLLCMember" abstract="true" name="VerilyLifeSciencesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="irtc_ContractCostPolicyPolicyTextBlock" abstract="false" name="ContractCostPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="irtc_HealthcareInstitutionsMember" abstract="true" name="HealthcareInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>irtc-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_78201bf4-1444-4613-9416-d2727634f884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:to="loc_us-gaap_PreferredStockValue_78201bf4-1444-4613-9416-d2727634f884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1d6c7f17-1a64-4208-bbeb-94d55f7f8052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:to="loc_us-gaap_CommonStockValue_1d6c7f17-1a64-4208-bbeb-94d55f7f8052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23a1b67b-24f4-45c5-abec-d10610a7ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23a1b67b-24f4-45c5-abec-d10610a7ed37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fbf50a1f-9a53-4de4-9af7-484a8534711e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fbf50a1f-9a53-4de4-9af7-484a8534711e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83d42e32-331d-4459-845e-80758ceba1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1e679b98-6a9c-436b-99d8-8aee28725400" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_83d42e32-331d-4459-845e-80758ceba1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a5e32699-b2c3-4f71-b28b-c6f39848bf8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:to="loc_us-gaap_AssetsCurrent_a5e32699-b2c3-4f71-b28b-c6f39848bf8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40a0b1e7-8bc7-4cca-a8ce-9c9d385473dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40a0b1e7-8bc7-4cca-a8ce-9c9d385473dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_db6b42cd-dd91-45d4-a729-c0d19be7d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_db6b42cd-dd91-45d4-a729-c0d19be7d4e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5aba3d5e-2faf-4181-87a8-d199fb5ba44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:to="loc_us-gaap_Goodwill_5aba3d5e-2faf-4181-87a8-d199fb5ba44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cebe9bfc-ffc4-4ba2-9ffb-1a6e09063915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_67f02eb1-8de3-4379-a15a-f661045f075c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cebe9bfc-ffc4-4ba2-9ffb-1a6e09063915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_174cce87-a443-4be1-afdc-7555aecc933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_69f0beac-53ad-467a-8c07-71765a648f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_174cce87-a443-4be1-afdc-7555aecc933d" xlink:to="loc_us-gaap_Liabilities_69f0beac-53ad-467a-8c07-71765a648f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bf28c63f-8133-4283-a416-6328e1c14ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_174cce87-a443-4be1-afdc-7555aecc933d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bf28c63f-8133-4283-a416-6328e1c14ccd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_958a6f2a-c5f3-476e-9ff3-f3a42a9d4587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_174cce87-a443-4be1-afdc-7555aecc933d" xlink:to="loc_us-gaap_StockholdersEquity_958a6f2a-c5f3-476e-9ff3-f3a42a9d4587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_75029b92-d94f-4352-8b0f-6c222f6b9622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b688c747-fbb3-46c4-aa09-87238efc2211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_75029b92-d94f-4352-8b0f-6c222f6b9622" xlink:to="loc_us-gaap_LiabilitiesCurrent_b688c747-fbb3-46c4-aa09-87238efc2211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8647ed36-8a3d-4ee3-bb60-b47504ce081b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_75029b92-d94f-4352-8b0f-6c222f6b9622" xlink:to="loc_us-gaap_LongTermDebt_8647ed36-8a3d-4ee3-bb60-b47504ce081b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44e2ef78-9f3f-4706-8234-a61794d63ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_75029b92-d94f-4352-8b0f-6c222f6b9622" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44e2ef78-9f3f-4706-8234-a61794d63ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5c32266-c805-4e9d-b88d-307270ae7398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_75029b92-d94f-4352-8b0f-6c222f6b9622" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d5c32266-c805-4e9d-b88d-307270ae7398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6039e4c0-1b0a-4017-9c33-99759d3e6af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6039e4c0-1b0a-4017-9c33-99759d3e6af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d1d35057-1bb5-4b5a-bb38-8bdd906f67f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d1d35057-1bb5-4b5a-bb38-8bdd906f67f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ee06e624-b4d2-4146-a0c3-bba05b022b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ee06e624-b4d2-4146-a0c3-bba05b022b8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e29f0110-cb66-4167-b8bc-de42e6ef42f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:to="loc_us-gaap_InventoryNet_e29f0110-cb66-4167-b8bc-de42e6ef42f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9d0ee15-efc2-483f-a763-4773a09827eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2fe7bec3-b184-4217-8c4e-35c0a9c369a6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9d0ee15-efc2-483f-a763-4773a09827eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d27ef048-b9b3-4426-8f8d-a4f1ba67c406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:to="loc_us-gaap_AccountsPayableCurrent_d27ef048-b9b3-4426-8f8d-a4f1ba67c406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_27fd4eca-d8b7-446d-bd75-f14ba240533a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_27fd4eca-d8b7-446d-bd75-f14ba240533a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d797c8ac-5458-4601-a891-ae7b1fa7945f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d797c8ac-5458-4601-a891-ae7b1fa7945f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_35aa1edb-9007-4a83-a990-ac6da81ad2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:to="loc_us-gaap_DebtCurrent_35aa1edb-9007-4a83-a990-ac6da81ad2c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa7cbb23-9fdc-413c-8dc5-343eb9ac523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_614fa5df-b4e8-47c8-972b-bad7fb9bf990" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aa7cbb23-9fdc-413c-8dc5-343eb9ac523c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f07ca781-db3c-410f-aad7-844e8b0b42c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6c5229f8-c262-4959-a118-67c9c6e68269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f07ca781-db3c-410f-aad7-844e8b0b42c4" xlink:to="loc_us-gaap_GrossProfit_6c5229f8-c262-4959-a118-67c9c6e68269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d4ee839f-9c0d-4bd2-bdf1-6cf5f1b5c40a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f07ca781-db3c-410f-aad7-844e8b0b42c4" xlink:to="loc_us-gaap_OperatingExpenses_d4ee839f-9c0d-4bd2-bdf1-6cf5f1b5c40a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ffd147d-3e78-4190-87f2-6adcc609142f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_760ee8b2-02d2-4a78-b83a-71ffeedb8777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ffd147d-3e78-4190-87f2-6adcc609142f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_760ee8b2-02d2-4a78-b83a-71ffeedb8777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f1cbf5bc-dbe9-42fb-875c-e05191f267eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ffd147d-3e78-4190-87f2-6adcc609142f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f1cbf5bc-dbe9-42fb-875c-e05191f267eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_947d45f6-167a-4cc1-81c5-5ee735297655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_251b5071-fb45-4114-911a-7a0669454bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_947d45f6-167a-4cc1-81c5-5ee735297655" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_251b5071-fb45-4114-911a-7a0669454bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08eae510-a7d7-4365-adbc-847d4010b066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_947d45f6-167a-4cc1-81c5-5ee735297655" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_08eae510-a7d7-4365-adbc-847d4010b066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1d005e84-b402-40df-aeb8-e0b3543e3442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_15d9e21b-f024-41f6-bcbc-52d1a460d154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1d005e84-b402-40df-aeb8-e0b3543e3442" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_15d9e21b-f024-41f6-bcbc-52d1a460d154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_395f2efd-5c54-4a62-8830-10243e166608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1d005e84-b402-40df-aeb8-e0b3543e3442" xlink:to="loc_us-gaap_CostOfRevenue_395f2efd-5c54-4a62-8830-10243e166608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a7695ba-6b08-4c24-aa6c-d61c55deb6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_be2b3de0-4c32-441f-9d46-c58aec127f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a7695ba-6b08-4c24-aa6c-d61c55deb6e2" xlink:to="loc_us-gaap_OperatingIncomeLoss_be2b3de0-4c32-441f-9d46-c58aec127f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7a099f74-e198-43a8-a0fd-39e55a5654ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a7695ba-6b08-4c24-aa6c-d61c55deb6e2" xlink:to="loc_us-gaap_InterestExpense_7a099f74-e198-43a8-a0fd-39e55a5654ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1abe3266-6179-427c-a8bb-0ee6551d956d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a7695ba-6b08-4c24-aa6c-d61c55deb6e2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1abe3266-6179-427c-a8bb-0ee6551d956d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_72d49a1b-508a-4c34-af1f-c547daf7ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2da1612b-9239-4c6d-a82e-d4fa9d8b8ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_72d49a1b-508a-4c34-af1f-c547daf7ef31" xlink:to="loc_us-gaap_NetIncomeLoss_2da1612b-9239-4c6d-a82e-d4fa9d8b8ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_35161d4b-82cc-4f17-a510-dc8edc474734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_72d49a1b-508a-4c34-af1f-c547daf7ef31" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_35161d4b-82cc-4f17-a510-dc8edc474734" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_675c8673-c8d6-4814-931d-89fe8825b709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_194856fd-f15b-49a2-801b-0250aeb875e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_675c8673-c8d6-4814-931d-89fe8825b709" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_194856fd-f15b-49a2-801b-0250aeb875e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76d1edf0-842f-4cad-998f-d33d0af0de8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_675c8673-c8d6-4814-931d-89fe8825b709" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76d1edf0-842f-4cad-998f-d33d0af0de8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_399f9497-08e1-4cf3-9361-a4ad324423de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_675c8673-c8d6-4814-931d-89fe8825b709" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_399f9497-08e1-4cf3-9361-a4ad324423de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b8c6fae5-08de-4b98-8748-9b309bc9597a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_ProfitLoss_b8c6fae5-08de-4b98-8748-9b309bc9597a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3ab93e94-8ed4-45d8-8518-22ca0e37d27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_DepreciationAndAmortization_3ab93e94-8ed4-45d8-8518-22ca0e37d27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e1a2f0f7-e252-40b5-a8de-6595ee38b60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_ShareBasedCompensation_e1a2f0f7-e252-40b5-a8de-6595ee38b60b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_03b2386b-e811-47cf-99a7-810bfbfee4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_03b2386b-e811-47cf-99a7-810bfbfee4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6dc7f8d8-92c1-4579-9a71-19f7c48c4a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6dc7f8d8-92c1-4579-9a71-19f7c48c4a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProvisionForBadDebtAndContractualAllowance_87a79753-5a12-424a-ae87-a5565190e945" xlink:href="irtc-20211231.xsd#irtc_ProvisionForBadDebtAndContractualAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_irtc_ProvisionForBadDebtAndContractualAllowance_87a79753-5a12-424a-ae87-a5565190e945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization_d8a631e0-319f-4a24-9071-7c2e7e2815b7" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRightOfUseAssetsAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization_d8a631e0-319f-4a24-9071-7c2e7e2815b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_723d984d-51e9-40de-97fb-41bb15f54476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_723d984d-51e9-40de-97fb-41bb15f54476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fd88b6b6-52c2-4834-b842-7bdf01a03e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fd88b6b6-52c2-4834-b842-7bdf01a03e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5c4d6378-b8bd-47f4-a1b2-9568baf01396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5c4d6378-b8bd-47f4-a1b2-9568baf01396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d0abb22b-65b6-41da-9f22-d53b000e5a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d0abb22b-65b6-41da-9f22-d53b000e5a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8e603ba-f81d-415c-a348-beb413f3d5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_e8e603ba-f81d-415c-a348-beb413f3d5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3917f667-a590-4c56-8094-1d4586202c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3917f667-a590-4c56-8094-1d4586202c57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf7ed134-fc16-4ddf-abf8-e80b4aa5eaba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf7ed134-fc16-4ddf-abf8-e80b4aa5eaba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_5b7d2788-9927-421c-a20e-bb24f214dc46" xlink:href="irtc-20211231.xsd#irtc_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_299a0da9-5e5e-48cb-9077-04f28147cfb0" xlink:to="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_5b7d2788-9927-421c-a20e-bb24f214dc46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3442eaaf-c21f-436a-b00e-00a5e5190c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cfbd82f6-c473-49d8-8528-97d65d152945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3442eaaf-c21f-436a-b00e-00a5e5190c01" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cfbd82f6-c473-49d8-8528-97d65d152945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_9d7a9a21-25cd-48f6-89cc-c9e32b343ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3442eaaf-c21f-436a-b00e-00a5e5190c01" xlink:to="loc_us-gaap_ProceedsFromStockPlans_9d7a9a21-25cd-48f6-89cc-c9e32b343ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c34ce538-e574-43b6-a97e-1f3007e74576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3442eaaf-c21f-436a-b00e-00a5e5190c01" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c34ce538-e574-43b6-a97e-1f3007e74576" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_00633a8e-3fde-4496-b76c-82740f87bd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3442eaaf-c21f-436a-b00e-00a5e5190c01" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_00633a8e-3fde-4496-b76c-82740f87bd36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed9cbc4b-5179-4341-9640-8251b687563d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_07228c2c-5ec9-420b-b885-c4eeeae86d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed9cbc4b-5179-4341-9640-8251b687563d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_07228c2c-5ec9-420b-b885-c4eeeae86d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_40868b3f-93aa-4189-a1c7-5ba5d4bc0145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed9cbc4b-5179-4341-9640-8251b687563d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_40868b3f-93aa-4189-a1c7-5ba5d4bc0145" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4cb0db9b-95bf-4748-911d-a681d7684787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed9cbc4b-5179-4341-9640-8251b687563d" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4cb0db9b-95bf-4748-911d-a681d7684787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3e5c8a1b-7b3d-4060-a0ca-b2f39d6d4cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed9cbc4b-5179-4341-9640-8251b687563d" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3e5c8a1b-7b3d-4060-a0ca-b2f39d6d4cb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b31c40f9-50ba-4ed2-835d-ba0d07d1729c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6670989d-4ef9-405c-8e19-fd255ebaeb59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b31c40f9-50ba-4ed2-835d-ba0d07d1729c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6670989d-4ef9-405c-8e19-fd255ebaeb59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec9014f8-0946-475f-a592-7bba72681057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b31c40f9-50ba-4ed2-835d-ba0d07d1729c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec9014f8-0946-475f-a592-7bba72681057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af189bea-7740-49d2-9b08-4b0d078c7c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b31c40f9-50ba-4ed2-835d-ba0d07d1729c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af189bea-7740-49d2-9b08-4b0d078c7c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_23289d95-90c9-42ff-8fe0-5217bc313229" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_9e98c4fd-aedb-4326-806a-d7c0839a045d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_23289d95-90c9-42ff-8fe0-5217bc313229" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_9e98c4fd-aedb-4326-806a-d7c0839a045d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9addcba1-1fb2-4608-8209-1ca1b4511b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_23289d95-90c9-42ff-8fe0-5217bc313229" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9addcba1-1fb2-4608-8209-1ca1b4511b7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fce0ea86-5214-49df-a098-23634ee3f8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2952c426-7cb4-4f5f-8d04-187d6d9b8e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fce0ea86-5214-49df-a098-23634ee3f8b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2952c426-7cb4-4f5f-8d04-187d6d9b8e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_32d6b68d-01a4-41d0-b5e3-7c40a2e97ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fce0ea86-5214-49df-a098-23634ee3f8b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_32d6b68d-01a4-41d0-b5e3-7c40a2e97ae4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4e7c1ffc-759e-4727-942b-28db34356c34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9a870b8f-8147-4da7-be32-547fd963febf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4e7c1ffc-759e-4727-942b-28db34356c34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9a870b8f-8147-4da7-be32-547fd963febf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e0ea1ab9-4f01-4a94-8d7c-82a9c6344471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4e7c1ffc-759e-4727-942b-28db34356c34" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e0ea1ab9-4f01-4a94-8d7c-82a9c6344471" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_121980b5-065a-452f-a641-ae41a9c5ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_us-gaap_AccruedVacationCurrent_121980b5-065a-452f-a641-ae41a9c5ac8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_87dae700-0dcf-4f4c-9bf5-2e9a6fc7c886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_us-gaap_AccruedSalariesCurrent_87dae700-0dcf-4f4c-9bf5-2e9a6fc7c886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccruedEmployeeStockPurchasePlanContribution_de4fb8ea-0e87-4a65-b1d1-eb6f185ed6c0" xlink:href="irtc-20211231.xsd#irtc_AccruedEmployeeStockPurchasePlanContribution"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_irtc_AccruedEmployeeStockPurchasePlanContribution_de4fb8ea-0e87-4a65-b1d1-eb6f185ed6c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6c9512ed-bbcf-48a4-8ae7-af88915e133a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6c9512ed-bbcf-48a4-8ae7-af88915e133a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_b178928a-bf83-4f00-b0a1-aaf02dcfe36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_us-gaap_InterestPayableCurrent_b178928a-bf83-4f00-b0a1-aaf02dcfe36a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ClaimsPayableCurrent_89680f35-0477-461a-a0b3-8bcbe96ba408" xlink:href="irtc-20211231.xsd#irtc_ClaimsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_irtc_ClaimsPayableCurrent_89680f35-0477-461a-a0b3-8bcbe96ba408" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef1f3565-e119-459d-9ead-9ebe34953ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8eee76b9-ab2e-4068-a3f7-c5600bc762c1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ef1f3565-e119-459d-9ead-9ebe34953ed7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe8b50af-9961-4d75-9c97-0df474a7e0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a02aa546-673a-4ac0-88bd-84a75af47e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe8b50af-9961-4d75-9c97-0df474a7e0bb" xlink:to="loc_us-gaap_OperatingLeaseLiability_a02aa546-673a-4ac0-88bd-84a75af47e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_65d911cf-520f-4d1a-91e8-1a4d857061fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fe8b50af-9961-4d75-9c97-0df474a7e0bb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_65d911cf-520f-4d1a-91e8-1a4d857061fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_317acf55-67f5-4493-81ac-3686f14d7313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_317acf55-67f5-4493-81ac-3686f14d7313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_62596047-ae17-40d1-93ae-bad6b514d22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_62596047-ae17-40d1-93ae-bad6b514d22e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c527c367-ce2b-438d-a3cb-abf9869daca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c527c367-ce2b-438d-a3cb-abf9869daca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6d19f28-a4d6-455b-a8ab-b765ac42c926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f6d19f28-a4d6-455b-a8ab-b765ac42c926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cccc9364-438d-416e-86d7-42d569bb82a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cccc9364-438d-416e-86d7-42d569bb82a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8bf1b01-87f0-426a-8e5f-5934457c55d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d6dd385c-b44b-40cd-95cc-dad04a0dad27" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e8bf1b01-87f0-426a-8e5f-5934457c55d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtScheduleofFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LongTermDebtCarryingValue_60452f53-af8f-44f2-bb2c-e354e622ca3d" xlink:href="irtc-20211231.xsd#irtc_LongTermDebtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5c8f975f-db02-438f-9234-67f267dfa23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_irtc_LongTermDebtCarryingValue_60452f53-af8f-44f2-bb2c-e354e622ca3d" xlink:to="loc_us-gaap_LongTermDebt_5c8f975f-db02-438f-9234-67f267dfa23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentInterestPortion_237f9ff5-b2bc-4afb-9abb-46b283014fb0" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentInterestPortion"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_irtc_LongTermDebtCarryingValue_60452f53-af8f-44f2-bb2c-e354e622ca3d" xlink:to="loc_irtc_DebtInstrumentInterestPortion_237f9ff5-b2bc-4afb-9abb-46b283014fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_2c32e438-5e0f-4111-91d4-cd8ab9749775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_irtc_LongTermDebtCarryingValue_60452f53-af8f-44f2-bb2c-e354e622ca3d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_2c32e438-5e0f-4111-91d4-cd8ab9749775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2b95cacd-39dc-4ec4-beb4-00c3585d24bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_be319702-fa92-448e-ae7a-c1ebdf1f6a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2b95cacd-39dc-4ec4-beb4-00c3585d24bb" xlink:to="loc_us-gaap_DebtCurrent_be319702-fa92-448e-ae7a-c1ebdf1f6a5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_fe65894a-5d38-47aa-971c-cfa37165facf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_2b95cacd-39dc-4ec4-beb4-00c3585d24bb" xlink:to="loc_us-gaap_LongTermDebt_fe65894a-5d38-47aa-971c-cfa37165facf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7d47e110-db71-4818-b6e6-ab5bdbd51dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_06c19932-80a3-473d-b636-dcea18179515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7d47e110-db71-4818-b6e6-ab5bdbd51dfc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_06c19932-80a3-473d-b636-dcea18179515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d049baa1-de70-42ef-9694-7d8a8db662d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7d47e110-db71-4818-b6e6-ab5bdbd51dfc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d049baa1-de70-42ef-9694-7d8a8db662d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_335f70c7-3e3c-4fd8-bb27-c6ddc7fcda3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3edc573c-b6e1-453c-9151-ee74a36dca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_335f70c7-3e3c-4fd8-bb27-c6ddc7fcda3e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3edc573c-b6e1-453c-9151-ee74a36dca8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_eca8c2c3-5a37-4e52-83f1-c262da5a0779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_335f70c7-3e3c-4fd8-bb27-c6ddc7fcda3e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_eca8c2c3-5a37-4e52-83f1-c262da5a0779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_93252cd1-5737-4895-aae5-f3106330bf06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_335f70c7-3e3c-4fd8-bb27-c6ddc7fcda3e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_93252cd1-5737-4895-aae5-f3106330bf06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_89967ebb-0d63-4f0a-9d23-f5a46101fcfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_03da814f-fb35-43a3-9c1e-9c98178d01a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_89967ebb-0d63-4f0a-9d23-f5a46101fcfc" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_03da814f-fb35-43a3-9c1e-9c98178d01a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aef2cd08-8268-4442-a9cf-11abdba02c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_89967ebb-0d63-4f0a-9d23-f5a46101fcfc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_aef2cd08-8268-4442-a9cf-11abdba02c1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a18720b-15dc-40b6-b5d7-9a3dcd834e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ccf85e7-37eb-4718-8d23-a3b7dabf7454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a18720b-15dc-40b6-b5d7-9a3dcd834e58" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_8ccf85e7-37eb-4718-8d23-a3b7dabf7454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_677f9830-33a6-4093-8dbf-5cd816a805a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a18720b-15dc-40b6-b5d7-9a3dcd834e58" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_677f9830-33a6-4093-8dbf-5cd816a805a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b2e8efde-0155-4479-9b50-1d8badd80424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1a18720b-15dc-40b6-b5d7-9a3dcd834e58" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b2e8efde-0155-4479-9b50-1d8badd80424" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3b11e332-c6a3-4edd-a1a3-6d25deed6786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3b11e332-c6a3-4edd-a1a3-6d25deed6786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_3bbf5da8-71f2-4600-8971-58cfbd4bfc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_3bbf5da8-71f2-4600-8971-58cfbd4bfc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2137aad2-8b0c-4a49-8e17-14a696d66872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2137aad2-8b0c-4a49-8e17-14a696d66872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_3e2f0075-e0be-449f-8a25-f949137992a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_3e2f0075-e0be-449f-8a25-f949137992a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_03531dac-11ec-4605-8137-689ed525a265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_03531dac-11ec-4605-8137-689ed525a265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_7f722f2a-e245-4fff-a059-2c754565a78f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_7f722f2a-e245-4fff-a059-2c754565a78f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_c1505051-b887-430e-a058-89e27183a8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_c1505051-b887-430e-a058-89e27183a8f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_4c9b1ca6-f424-43be-a5b6-a8d3f2e8003d" xlink:href="irtc-20211231.xsd#irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_4c9b1ca6-f424-43be-a5b6-a8d3f2e8003d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_29312112-ebca-457d-9ae4-122b9007a10d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ab4f9c72-6136-4572-aa3a-7c8b99f843ab" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_29312112-ebca-457d-9ae4-122b9007a10d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dc359e36-6677-41ed-afca-d6ed4dc2cede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bcb626e0-f052-49b8-b1da-246bb4ca9365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dc359e36-6677-41ed-afca-d6ed4dc2cede" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bcb626e0-f052-49b8-b1da-246bb4ca9365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb820914-43a4-4a5e-aa77-4e8de8c94658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_dc359e36-6677-41ed-afca-d6ed4dc2cede" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cb820914-43a4-4a5e-aa77-4e8de8c94658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_daf0bfe9-1e47-4700-9a64-ebd3b08bef0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_daf0bfe9-1e47-4700-9a64-ebd3b08bef0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1e135d9c-45d1-40c7-b433-84c8e3153fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1e135d9c-45d1-40c7-b433-84c8e3153fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_70075f75-2572-4dfa-a3c8-742227aa4f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_70075f75-2572-4dfa-a3c8-742227aa4f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther_210a51f6-be3b-4585-8bae-ca3d42d51743" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsValuationAllowancesAndOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:to="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther_210a51f6-be3b-4585-8bae-ca3d42d51743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsLeaseObligations_b3bab925-41cb-4b39-a6fb-f9383407c9b3" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsLeaseObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3cb7f9aa-358d-4524-b032-775f286ed1a9" xlink:to="loc_irtc_DeferredTaxAssetsLeaseObligations_b3bab925-41cb-4b39-a6fb-f9383407c9b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_fc75d2d9-b36f-4d80-aa2e-bdfa53c4d6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3d1cd282-2c51-49d4-adc8-1983ef4707ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_fc75d2d9-b36f-4d80-aa2e-bdfa53c4d6c6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3d1cd282-2c51-49d4-adc8-1983ef4707ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_00532120-4279-47b5-81de-4bb9111455c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_fc75d2d9-b36f-4d80-aa2e-bdfa53c4d6c6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_00532120-4279-47b5-81de-4bb9111455c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_881e33a7-3f8f-4175-bb96-8997d13a5907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_85a1b288-d239-42be-85e1-b067ef8f7db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_881e33a7-3f8f-4175-bb96-8997d13a5907" xlink:to="loc_us-gaap_DeferredTaxLiabilities_85a1b288-d239-42be-85e1-b067ef8f7db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_67712814-bfaf-4469-811d-13f519184da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_881e33a7-3f8f-4175-bb96-8997d13a5907" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_67712814-bfaf-4469-811d-13f519184da8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>irtc-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i704f29fad8af499db87e8efe22bd8f9b_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_15bb012f-96a8-41e7-a9ec-f07de6b2d934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_SharesOutstanding_15bb012f-96a8-41e7-a9ec-f07de6b2d934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d371106d-002d-4bc4-96d5-973bdc34df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockholdersEquity_d371106d-002d-4bc4-96d5-973bdc34df6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc1af341-f0ab-4ae5-8a3c-e26d009415c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc1af341-f0ab-4ae5-8a3c-e26d009415c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c55ab94a-e64b-4d8b-b3eb-95fe960cdba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c55ab94a-e64b-4d8b-b3eb-95fe960cdba1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_c21c42a4-a5db-4e2b-a5c4-c34e722e9296" xlink:href="irtc-20211231.xsd#irtc_CommonStockSharesIssuedFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_c21c42a4-a5db-4e2b-a5c4-c34e722e9296" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07b7bb9b-100a-4e38-aa7e-9257d9d48de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07b7bb9b-100a-4e38-aa7e-9257d9d48de9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d593b9-2548-4529-b79b-714c1fae497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d593b9-2548-4529-b79b-714c1fae497e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a6317834-f1f2-45f0-afce-46bcf9cc024a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a6317834-f1f2-45f0-afce-46bcf9cc024a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c4029f5d-dc62-4a27-829b-163dca5208f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c4029f5d-dc62-4a27-829b-163dca5208f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec2a5bcd-f663-484e-909f-bcb71bd09c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_NetIncomeLoss_ec2a5bcd-f663-484e-909f-bcb71bd09c27" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_874f5d01-3bda-4f35-a916-acadeb476cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_874f5d01-3bda-4f35-a916-acadeb476cb9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d93fa28d-3829-48f0-9587-54a6155091b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_017e8d8d-fe2b-44ac-b867-c0fdf5023c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_34b03ba6-8b5f-4b51-b505-23d6f5c15d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_34b03ba6-8b5f-4b51-b505-23d6f5c15d6b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:to="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c1bbd511-c9a1-4966-9b64-beb99838d39d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:to="loc_us-gaap_EquityComponentDomain_c1bbd511-c9a1-4966-9b64-beb99838d39d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:to="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_836eeafa-0040-44ea-8efe-56146f7cf73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_CommonStockMember_836eeafa-0040-44ea-8efe-56146f7cf73f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8b8246a-99fc-4c79-88c0-175090d3e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8b8246a-99fc-4c79-88c0-175090d3e5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c29b5389-6a29-471b-a7b4-f1422df7e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_RetainedEarningsMember_c29b5389-6a29-471b-a7b4-f1422df7e0ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_112582e4-bc77-473e-af5e-e488929b30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_112582e4-bc77-473e-af5e-e488929b30d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3121d975-b856-4870-9fbd-adfe458f5d61_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3121d975-b856-4870-9fbd-adfe458f5d61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f5e1516-35c0-4f9d-85a0-2912788d1b0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f5e1516-35c0-4f9d-85a0-2912788d1b0e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i32c301d7a80448a4a7152639a81090e9_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CostReimbursementRate_7a3855d2-f420-41ef-813c-a0813fada87c" xlink:href="irtc-20211231.xsd#irtc_CostReimbursementRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_irtc_CostReimbursementRate_7a3855d2-f420-41ef-813c-a0813fada87c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bdbf122d-f694-4e23-a1f8-da8ccfc4670a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bdbf122d-f694-4e23-a1f8-da8ccfc4670a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb1e175a-fbde-43c5-aba2-1180643708e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb1e175a-fbde-43c5-aba2-1180643708e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f787f8ad-47ff-4ef2-a618-e2e7ecd617f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f787f8ad-47ff-4ef2-a618-e2e7ecd617f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_72a610b2-0ea6-4a11-bd8d-fd83191f9311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_AssetImpairmentCharges_72a610b2-0ea6-4a11-bd8d-fd83191f9311" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f3a73e73-fce9-4c7d-aae0-78382fbb06c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_OtherAssets_f3a73e73-fce9-4c7d-aae0-78382fbb06c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4a86f32c-4d91-4379-89dd-7241b73dd141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4a86f32c-4d91-4379-89dd-7241b73dd141" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_bc89ebf1-a82f-4716-b76e-1b2251d68fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_bc89ebf1-a82f-4716-b76e-1b2251d68fa3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aead3878-d35b-47a1-8ff9-b4bde9173ff8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:to="loc_srt_ProductsAndServicesDomain_aead3878-d35b-47a1-8ff9-b4bde9173ff8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:to="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_61385cd2-1cc1-449c-91fc-76e5e2e86fee" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93243Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_61385cd2-1cc1-449c-91fc-76e5e2e86fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_5a4cda10-f1b7-42ae-ae2c-98bae038dada" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_5a4cda10-f1b7-42ae-ae2c-98bae038dada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ccc8e4ac-021f-4534-a504-6883fb635746_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ccc8e4ac-021f-4534-a504-6883fb635746_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c01352fd-edd4-4259-bb57-fe5539195c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:to="loc_us-gaap_SubsequentEventMember_c01352fd-edd4-4259-bb57-fe5539195c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60ce7360-7f28-426b-8a1c-c9659727c44a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:to="loc_srt_NameOfMajorCustomerDomain_60ce7360-7f28-426b-8a1c-c9659727c44a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FederalGovernmentAgenciesMember_4b46e670-e29b-4125-8c4b-11663c18c61d" xlink:href="irtc-20211231.xsd#irtc_FederalGovernmentAgenciesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:to="loc_irtc_FederalGovernmentAgenciesMember_4b46e670-e29b-4125-8c4b-11663c18c61d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9e3186ae-b081-4652-b1a0-60054c2fd69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:to="loc_us-gaap_SalesRevenueNetMember_9e3186ae-b081-4652-b1a0-60054c2fd69a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e021ea43-ba85-4017-a20a-9d8aa0d449f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:to="loc_us-gaap_AccountsReceivableMember_e021ea43-ba85-4017-a20a-9d8aa0d449f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4f678ee6-2020-418e-856f-7c63b6518ffe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4f678ee6-2020-418e-856f-7c63b6518ffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a88ccbd4-4832-4da3-973e-0f1a81fd5756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a88ccbd4-4832-4da3-973e-0f1a81fd5756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_349c982b-5001-45da-82b5-b9c96cc2f797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_349c982b-5001-45da-82b5-b9c96cc2f797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:to="loc_srt_RangeMember_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:to="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f09523e4-b205-4e4e-950f-7de5283b20be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:to="loc_srt_MinimumMember_f09523e4-b205-4e4e-950f-7de5283b20be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26872101-05f1-4cf5-8e6a-71e3bf09319e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:to="loc_srt_MaximumMember_26872101-05f1-4cf5-8e6a-71e3bf09319e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a5e771c-16df-4925-be7a-38dc0c68d6e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a5e771c-16df-4925-be7a-38dc0c68d6e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_05c6830c-c9e8-4001-aa42-c361e2d9410d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_05c6830c-c9e8-4001-aa42-c361e2d9410d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_238bd87a-8a5c-4b09-90ed-3d9109db1f48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_238bd87a-8a5c-4b09-90ed-3d9109db1f48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PrintedCircuitBoardAssembliesMember_421ee4fe-8b05-4ab0-b062-88bbee5c6826" xlink:href="irtc-20211231.xsd#irtc_PrintedCircuitBoardAssembliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:to="loc_irtc_PrintedCircuitBoardAssembliesMember_421ee4fe-8b05-4ab0-b062-88bbee5c6826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3e648a0c-f35d-4b69-baf8-dfd94cae17ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3e648a0c-f35d-4b69-baf8-dfd94cae17ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b690aed6-9fc4-43b3-90a8-84981b397dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b690aed6-9fc4-43b3-90a8-84981b397dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_be3d8d15-90b9-414e-b1f0-4d64b7288579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_be3d8d15-90b9-414e-b1f0-4d64b7288579" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" xlink:type="extended" id="ifd1d50939a45470082e1cef0be46177f_SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_df8db82b-9e01-4a04-b24c-ac228dc5a36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_df8db82b-9e01-4a04-b24c-ac228dc5a36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e6221ead-3ab9-46ea-b167-29ecf775dc65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e6221ead-3ab9-46ea-b167-29ecf775dc65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_901e58bb-5647-48a2-a45e-301c0ae39bb1" xlink:href="irtc-20211231.xsd#irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_901e58bb-5647-48a2-a45e-301c0ae39bb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_35dad915-18bf-4864-8837-e55de7852da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_109e375f-4dae-49ab-825e-96692102d37e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_109e375f-4dae-49ab-825e-96692102d37e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ad707dea-72c3-4954-aa4e-fcc740fd42f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ad707dea-72c3-4954-aa4e-fcc740fd42f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b53e549e-def8-470a-8dbd-c2545c0ef1cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b53e549e-def8-470a-8dbd-c2545c0ef1cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:to="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_1baa6550-260c-43e7-962b-623da3ca16a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_1baa6550-260c-43e7-962b-623da3ca16a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails" xlink:type="extended" id="i5772468da6144f5bafbfc2a6d1e3ec80_SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94f1d90f-adda-4ce5-8a69-205a17ec2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94f1d90f-adda-4ce5-8a69-205a17ec2a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:to="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d593a23-1935-41ea-934e-4c63f19e0b64_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:to="loc_srt_ProductsAndServicesDomain_9d593a23-1935-41ea-934e-4c63f19e0b64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:to="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommercialPayorsMember_c8f98e5f-adef-41a7-95c7-1a1fba329b67" xlink:href="irtc-20211231.xsd#irtc_CommercialPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_CommercialPayorsMember_c8f98e5f-adef-41a7-95c7-1a1fba329b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_NonContractedThirdPartyPayorsMember_f9f3458b-572b-4d34-ad1b-5e7b563e9466" xlink:href="irtc-20211231.xsd#irtc_NonContractedThirdPartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_NonContractedThirdPartyPayorsMember_f9f3458b-572b-4d34-ad1b-5e7b563e9466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CentersForMedicareAndMedicaidMember_b53c24e3-c3ab-4761-b30c-bfcfbad0bcdc" xlink:href="irtc-20211231.xsd#irtc_CentersForMedicareAndMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_CentersForMedicareAndMedicaidMember_b53c24e3-c3ab-4761-b30c-bfcfbad0bcdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_HealthcareInstitutionsMember_cc1df400-b936-41dc-a633-2905025b565d" xlink:href="irtc-20211231.xsd#irtc_HealthcareInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_HealthcareInstitutionsMember_cc1df400-b936-41dc-a633-2905025b565d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="extended" id="ia8faddbdc3534ae69e418664bd13080f_CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbc7b78a-5608-43ae-b133-5367f0e1f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbc7b78a-5608-43ae-b133-5367f0e1f0ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25c54aef-4d4d-40c2-8829-2008320c381f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25c54aef-4d4d-40c2-8829-2008320c381f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e44ecaa-f68c-4d77-98f8-644680da68aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e44ecaa-f68c-4d77-98f8-644680da68aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afec3026-9e4e-4b6a-8e0c-b1267b4369f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afec3026-9e4e-4b6a-8e0c-b1267b4369f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b0cc599a-dc5d-480c-a5cd-8f51664d2b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b0cc599a-dc5d-480c-a5cd-8f51664d2b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9b580ba7-f173-4868-83e7-e8901d6ac6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9b580ba7-f173-4868-83e7-e8901d6ac6d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_bb989cab-93f4-4d64-8bcc-b0a0d711ec3d" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_bb989cab-93f4-4d64-8bcc-b0a0d711ec3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a4f5dfa-460c-4774-a944-4faf21086232_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9a4f5dfa-460c-4774-a944-4faf21086232_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2adb0b9e-18a8-4368-8879-780e0684a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2adb0b9e-18a8-4368-8879-780e0684a74c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:to="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_32e06b22-386f-4e5c-840d-c042d7c49b8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_32e06b22-386f-4e5c-840d-c042d7c49b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa272c42-79be-4b4a-91db-e02d54cfa577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa272c42-79be-4b4a-91db-e02d54cfa577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_091e247a-93b3-49d9-ab77-809c9b3c8f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_091e247a-93b3-49d9-ab77-809c9b3c8f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79b60515-c9a6-4fb1-83ad-18461d88f9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_CommercialPaperMember_79b60515-c9a6-4fb1-83ad-18461d88f9ea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails" xlink:type="extended" id="i6ea1aa20efc248309e265eee42af492a_CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d137c317-9c0e-4c23-9cd7-3d5906dba57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d137c317-9c0e-4c23-9cd7-3d5906dba57a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5c15d3c9-18b3-42ac-bae5-f377eeb78ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5c15d3c9-18b3-42ac-bae5-f377eeb78ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a2d5ad36-c789-4092-ae71-8e77bc87e7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a2d5ad36-c789-4092-ae71-8e77bc87e7ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19e822be-b7b0-4527-9cbf-71657678fa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19e822be-b7b0-4527-9cbf-71657678fa94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7a7cf0e7-47e4-430e-a895-ca47996c49a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7a7cf0e7-47e4-430e-a895-ca47996c49a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_67abb34a-3908-497f-99e8-9eccde821655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_67abb34a-3908-497f-99e8-9eccde821655" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:to="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_db8747cd-c38b-4724-b8a2-867242a20016_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_db8747cd-c38b-4724-b8a2-867242a20016_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_93f27331-5d44-4b87-a52e-77b6409b0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_93f27331-5d44-4b87-a52e-77b6409b0f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_b99f3f87-8e70-41e1-b5eb-5a9fbab1fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_b99f3f87-8e70-41e1-b5eb-5a9fbab1fe2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i4957125e942a449690236a95d155284e_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2984318b-69ca-4f64-826d-3b5c98c238fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2984318b-69ca-4f64-826d-3b5c98c238fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0510ddba-3a12-43b2-9442-df42622c7d88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0510ddba-3a12-43b2-9442-df42622c7d88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8e10243-0d11-41a4-b7d8-bfc1247b85ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8e10243-0d11-41a4-b7d8-bfc1247b85ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54b0348d-ae9f-4dc2-9df1-18b42068a804_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_54b0348d-ae9f-4dc2-9df1-18b42068a804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e367aa9c-f334-40b0-ae61-7d6b13ef6075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e367aa9c-f334-40b0-ae61-7d6b13ef6075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d3c82d80-db6e-48d1-a32c-0c7c1b9374c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d3c82d80-db6e-48d1-a32c-0c7c1b9374c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_57cb1b52-4d0b-428b-9bce-f309e59f5328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_57cb1b52-4d0b-428b-9bce-f309e59f5328" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails" xlink:type="extended" id="if2f4f4460ddc4f229407ebabefd865ba_FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef027ae1-50b0-4468-9d57-6779d945c99e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef027ae1-50b0-4468-9d57-6779d945c99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ab8547d-7975-4d09-a4b3-7cbadfeac820_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ab8547d-7975-4d09-a4b3-7cbadfeac820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f0f4925d-b2e2-4860-bed2-af84355bbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f0f4925d-b2e2-4860-bed2-af84355bbc1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22736583-8bb7-42f2-961b-097294b721c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22736583-8bb7-42f2-961b-097294b721c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6b51f9f9-1377-458e-ba98-0bf5080ef0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6b51f9f9-1377-458e-ba98-0bf5080ef0cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_24427f24-a796-40dc-90f3-41d3acaa097c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_24427f24-a796-40dc-90f3-41d3acaa097c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fc996540-759d-42d9-847a-ca841db082c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fc996540-759d-42d9-847a-ca841db082c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9faef35-57fb-42c0-b6bc-1832f4b261a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9faef35-57fb-42c0-b6bc-1832f4b261a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_58532807-4d93-4707-8080-a5941502d310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_58532807-4d93-4707-8080-a5941502d310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_150cf243-c2f5-4e8e-82f7-9e68b679b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_CommercialPaperMember_150cf243-c2f5-4e8e-82f7-9e68b679b59e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails" xlink:type="extended" id="i93431b44f30a49f8ad2ab179b1f4a617_BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies_23fbd679-48a5-4340-88ba-ca66d3920147" xlink:href="irtc-20211231.xsd#irtc_InventoryAndPrintedCircuitBoardAssemblies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:to="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies_23fbd679-48a5-4340-88ba-ca66d3920147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:to="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_68af263c-2728-4619-8157-582cc3921e2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_68af263c-2728-4619-8157-582cc3921e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_RawMaterialsMember_4e14bfdb-058a-4cb5-b5c5-2d821e71f036" xlink:href="irtc-20211231.xsd#irtc_RawMaterialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:to="loc_irtc_RawMaterialsMember_4e14bfdb-058a-4cb5-b5c5-2d821e71f036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FinishedGoodsMember_c65acb3a-cb15-4a3f-8dcd-9432106eb8fe" xlink:href="irtc-20211231.xsd#irtc_FinishedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:to="loc_irtc_FinishedGoodsMember_c65acb3a-cb15-4a3f-8dcd-9432106eb8fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended" id="i93983108dbc7495489a2b535de687002_BalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherAssetsUsefulLives_d44cb267-4fd7-4432-ac35-cdf13518facf" xlink:href="irtc-20211231.xsd#irtc_OtherAssetsUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_irtc_OtherAssetsUsefulLives_d44cb267-4fd7-4432-ac35-cdf13518facf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f98706fb-ee9a-4ffa-a982-2f839cbeb0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_OtherAssets_f98706fb-ee9a-4ffa-a982-2f839cbeb0e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_f28c03d7-660c-4195-8c09-b6ce98e8bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_AdjustmentForAmortization_f28c03d7-660c-4195-8c09-b6ce98e8bd13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6c465892-f283-4602-8669-d03467841435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_DepreciationAndAmortization_6c465892-f283-4602-8669-d03467841435" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1275bbb3-acf5-462e-aa58-6f088f64c030_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1275bbb3-acf5-462e-aa58-6f088f64c030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PrintedCircuitBoardAssembliesMember_8a3c0e8a-e6f7-411e-8a76-33d02d015c2e" xlink:href="irtc-20211231.xsd#irtc_PrintedCircuitBoardAssembliesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:to="loc_irtc_PrintedCircuitBoardAssembliesMember_8a3c0e8a-e6f7-411e-8a76-33d02d015c2e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="extended" id="i5f690e4f8a7f49e7b41fb9fe9d90b925_BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_220f5992-a167-4f03-ae2d-1e58251ac5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_220f5992-a167-4f03-ae2d-1e58251ac5cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5a2a9bf-6580-4c9d-8f70-89ce17a9e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5a2a9bf-6580-4c9d-8f70-89ce17a9e44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba46dbdf-2462-4e57-9123-36e5db8ad529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba46dbdf-2462-4e57-9123-36e5db8ad529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee012ff-eb77-425c-8733-a2429b0793bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ee012ff-eb77-425c-8733-a2429b0793bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LaboratoryAndManufacturingEquipmentMember_b0eee8b0-c16c-42ec-a235-743d35f61590" xlink:href="irtc-20211231.xsd#irtc_LaboratoryAndManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_irtc_LaboratoryAndManufacturingEquipmentMember_b0eee8b0-c16c-42ec-a235-743d35f61590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ComputerEquipmentAndSoftwareMember_040e29ba-7e89-4c5d-98fd-f8fd61d7109b" xlink:href="irtc-20211231.xsd#irtc_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_irtc_ComputerEquipmentAndSoftwareMember_040e29ba-7e89-4c5d-98fd-f8fd61d7109b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b059eb23-a8f2-442a-ab2a-ec99c7740551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b059eb23-a8f2-442a-ab2a-ec99c7740551" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a953fa9a-b5bb-49d8-9ade-d9fb618285bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a953fa9a-b5bb-49d8-9ade-d9fb618285bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a89d0c3f-872e-45b1-aea5-f7fd4f06dff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a89d0c3f-872e-45b1-aea5-f7fd4f06dff1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i78d6b86e2c56430a9e568be4b9063f8d_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8963c744-81aa-46da-8172-428383ffef86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseCost_8963c744-81aa-46da-8172-428383ffef86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5452a13a-55a2-49eb-98eb-a84bf6d7fda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeasePayments_5452a13a-55a2-49eb-98eb-a84bf6d7fda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRentableArea_b6999e0d-a861-42d3-a7c0-fa57a43ddc30" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_OperatingLeaseRentableArea_b6999e0d-a861-42d3-a7c0-fa57a43ddc30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_0cd335da-cb19-4882-9dd0-b1ea5cb35e1b" xlink:href="irtc-20211231.xsd#irtc_LesseeOperatingSubleaseNumberOfOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_0cd335da-cb19-4882-9dd0-b1ea5cb35e1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_546f9b1d-41ca-4c61-9ce1-17cc1b1a703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_546f9b1d-41ca-4c61-9ce1-17cc1b1a703e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1853a47-0601-4762-9941-f0e2380dc07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1853a47-0601-4762-9941-f0e2380dc07d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6ee49e7a-5494-49d2-92a2-713ee87ede5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6ee49e7a-5494-49d2-92a2-713ee87ede5a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementRemainingTermOfAgreement_18f73788-2b60-4d90-acbc-0693e2f038fe" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementRemainingTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementRemainingTermOfAgreement_18f73788-2b60-4d90-acbc-0693e2f038fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementUpfrontFeePayable_e63acd91-bcbb-499b-8b95-d7ffbfb27c87" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementUpfrontFeePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementUpfrontFeePayable_e63acd91-bcbb-499b-8b95-d7ffbfb27c87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_e3c68adb-2e70-4736-99c4-c5564e7c33a6" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_e3c68adb-2e70-4736-99c4-c5564e7c33a6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementMilestonePayments_5602a235-446a-4131-a2a6-c79433ad6ffe" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementMilestonePayments_5602a235-446a-4131-a2a6-c79433ad6ffe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_54a0d06f-fbe7-4468-be0b-63da1ec545e5" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_54a0d06f-fbe7-4468-be0b-63da1ec545e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6bc65062-9d21-4afe-b35f-46b559d129a3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:to="loc_srt_SegmentGeographicalDomain_6bc65062-9d21-4afe-b35f-46b559d129a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:to="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SanFranciscoMember_9d2e8d85-8f64-4597-9b21-79fb10d30ccc" xlink:href="irtc-20211231.xsd#irtc_SanFranciscoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:to="loc_irtc_SanFranciscoMember_9d2e8d85-8f64-4597-9b21-79fb10d30ccc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_b2928cd4-7c37-450b-b594-801bb9c13bc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_b2928cd4-7c37-450b-b594-801bb9c13bc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeerfieldLeaseMember_7f21788a-ede3-4403-bd00-254be3c6da91" xlink:href="irtc-20211231.xsd#irtc_DeerfieldLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_DeerfieldLeaseMember_7f21788a-ede3-4403-bd00-254be3c6da91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OfficeLeaseMember_3309d5d6-0531-4003-b3c8-456a8640b16f" xlink:href="irtc-20211231.xsd#irtc_OfficeLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_OfficeLeaseMember_3309d5d6-0531-4003-b3c8-456a8640b16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LincolnshireLeaseMember_f0c752e9-8f25-4c26-a4a8-bbd4cff34b30" xlink:href="irtc-20211231.xsd#irtc_LincolnshireLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_LincolnshireLeaseMember_f0c752e9-8f25-4c26-a4a8-bbd4cff34b30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CypressLeaseMember_58f98984-247b-409b-a6f3-448b3238eff6" xlink:href="irtc-20211231.xsd#irtc_CypressLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_CypressLeaseMember_58f98984-247b-409b-a6f3-448b3238eff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f34166fd-3b01-4d19-a821-83522e6ed92a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f34166fd-3b01-4d19-a821-83522e6ed92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_VerilyLifeSciencesLLCMember_a682c450-71e2-4763-a48d-709d6dc61ccd" xlink:href="irtc-20211231.xsd#irtc_VerilyLifeSciencesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:to="loc_irtc_VerilyLifeSciencesLLCMember_a682c450-71e2-4763-a48d-709d6dc61ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_83230fb4-0128-4f21-bea3-f996b5e7f82c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_83230fb4-0128-4f21-bea3-f996b5e7f82c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_311a9bc9-ff85-4eb8-8ca7-dc158b9369e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:to="loc_us-gaap_SubsequentEventMember_311a9bc9-ff85-4eb8-8ca7-dc158b9369e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/DebtAdditionalInformationDetails" xlink:type="extended" id="ia9f411cd1f2844b3a20e2b81461cedb0_DebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e2eea5b-e916-4704-9eba-ccc8b7d2b388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e2eea5b-e916-4704-9eba-ccc8b7d2b388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_fd91fdfc-8cb4-4250-87a6-6e32154ef704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_fd91fdfc-8cb4-4250-87a6-6e32154ef704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_eaffad24-fa98-48b2-80ab-ec6bef18a59d" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_eaffad24-fa98-48b2-80ab-ec6bef18a59d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0c17abb4-1db5-4550-b7a2-aac9bd4aa07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0c17abb4-1db5-4550-b7a2-aac9bd4aa07e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_fed1ce33-d978-4a2e-9e3e-26e665fde2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_fed1ce33-d978-4a2e-9e3e-26e665fde2ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_15534aca-96dd-4d14-aab5-3c29fde09619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_15534aca-96dd-4d14-aab5-3c29fde09619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_8628c4ab-0a61-45e4-8979-26729974ea3b" xlink:href="irtc-20211231.xsd#irtc_PercentageOfEligibleAccountsReceivableForBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_8628c4ab-0a61-45e4-8979-26729974ea3b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_ecf5d43f-f344-456f-9777-901cf7d65478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_LineOfCredit_ecf5d43f-f344-456f-9777-901cf7d65478" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8609581e-d19e-4ea9-9338-42b4762dc7a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8609581e-d19e-4ea9-9338-42b4762dc7a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_3cc356a3-ead8-4b19-9432-6ff153aa6470" xlink:href="irtc-20211231.xsd#irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:to="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_3cc356a3-ead8-4b19-9432-6ff153aa6470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PharmakonLoanAgreementMember_11a7990b-1144-4be0-9c14-a7ae13908f17" xlink:href="irtc-20211231.xsd#irtc_PharmakonLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:to="loc_irtc_PharmakonLoanAgreementMember_11a7990b-1144-4be0-9c14-a7ae13908f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_21a4342f-66eb-4034-b697-799bd9e2ec5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:to="loc_us-gaap_VariableRateDomain_21a4342f-66eb-4034-b697-799bd9e2ec5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:to="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_a110b3ff-3efe-4b88-8665-3271df97e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:to="loc_us-gaap_PrimeRateMember_a110b3ff-3efe-4b88-8665-3271df97e42e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_230ea2cc-1045-41c2-a133-38743cd33eae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:to="loc_srt_RangeMember_230ea2cc-1045-41c2-a133-38743cd33eae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:to="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c2b6a56-025a-4b8c-8a4e-49f483d2eee2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:to="loc_srt_MaximumMember_2c2b6a56-025a-4b8c-8a4e-49f483d2eee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_804f6fc3-21af-48d2-a771-98d2706befab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:to="loc_srt_MinimumMember_804f6fc3-21af-48d2-a771-98d2706befab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cb89911d-9457-45d9-9f4f-9102519d4ddb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:to="loc_us-gaap_CreditFacilityDomain_cb89911d-9457-45d9-9f4f-9102519d4ddb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:to="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SiliconValleyBankTermLoanMember_850b35b9-76eb-43cd-a74e-dc2b1043dd40" xlink:href="irtc-20211231.xsd#irtc_SiliconValleyBankTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_irtc_SiliconValleyBankTermLoanMember_850b35b9-76eb-43cd-a74e-dc2b1043dd40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_232ee1e6-2d76-46a7-9386-9a669c27705d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_232ee1e6-2d76-46a7-9386-9a669c27705d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_68a1e206-df15-497b-9b6e-57031037594f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_68a1e206-df15-497b-9b6e-57031037594f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtScheduleofFutureMinimumPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="extended" id="ifa0093fe680e49ac9d517fc19bc615ea_DebtScheduleofFutureMinimumPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c08dd8a5-4664-4d43-a734-656e2fef091d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c08dd8a5-4664-4d43-a734-656e2fef091d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bd656a0-6f25-4fbb-953e-751b465d2c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bd656a0-6f25-4fbb-953e-751b465d2c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32ee0f61-4962-423a-8932-1c7e48d55c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebt_32ee0f61-4962-423a-8932-1c7e48d55c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentInterestPortion_6c031b23-362a-453f-9450-fda251049c7a" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentInterestPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_irtc_DebtInstrumentInterestPortion_6c031b23-362a-453f-9450-fda251049c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_034ab362-a4e9-4b31-b5e4-36e5cc50b03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_034ab362-a4e9-4b31-b5e4-36e5cc50b03a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LongTermDebtCarryingValue_e123b0a7-2912-475c-88fe-eb18e0fff6c2" xlink:href="irtc-20211231.xsd#irtc_LongTermDebtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_irtc_LongTermDebtCarryingValue_e123b0a7-2912-475c-88fe-eb18e0fff6c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_74ab3767-aac1-4d2f-a765-5b6df513152c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DebtCurrent_74ab3767-aac1-4d2f-a765-5b6df513152c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b36ac3d-d2ac-4624-b36e-56deefba89f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_67ffa19e-5ba6-42bd-aa79-b333d78a339a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_67ffa19e-5ba6-42bd-aa79-b333d78a339a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7531f770-694a-47d8-8cbf-d4b29179eac0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7531f770-694a-47d8-8cbf-d4b29179eac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_2b609182-c48c-4254-8cb2-6f46610f7314" xlink:href="irtc-20211231.xsd#irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:to="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_2b609182-c48c-4254-8cb2-6f46610f7314" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i5137d03fd3804271a07baf182054d72b_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_894b9ca0-a776-45f6-adb3-ba3ce048a754" xlink:href="irtc-20211231.xsd#irtc_OperatingLossCarryforwardsTaxBenefitRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_894b9ca0-a776-45f6-adb3-ba3ce048a754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c23f6be-da23-49e7-b0db-4474594a8212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c23f6be-da23-49e7-b0db-4474594a8212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cdb9f478-6e9c-4156-b38a-21c5440da1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cdb9f478-6e9c-4156-b38a-21c5440da1cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3860e64d-5c81-4158-b24b-8590417085e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3860e64d-5c81-4158-b24b-8590417085e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_c3d85e29-dfba-499b-a659-a890b0b0c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_c3d85e29-dfba-499b-a659-a890b0b0c78a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_91a55cf6-1c4d-499c-845e-da8fc2850872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_91a55cf6-1c4d-499c-845e-da8fc2850872" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8db83715-3f42-4e2f-91e6-de7f67bc8747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8db83715-3f42-4e2f-91e6-de7f67bc8747" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_87a5d12f-27eb-46ab-a176-5c2044b749e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_87a5d12f-27eb-46ab-a176-5c2044b749e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5f61239e-55c1-489d-b3f8-14c9333b15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:to="loc_us-gaap_DomesticCountryMember_5f61239e-55c1-489d-b3f8-14c9333b15dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_876635c9-ad2d-4eea-8d84-1242315645ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_876635c9-ad2d-4eea-8d84-1242315645ec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="extended" id="id89a8aecce9b445e8a07dbefdd8f5d07_StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22fa82a2-8540-47ad-b755-3358a34b4055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22fa82a2-8540-47ad-b755-3358a34b4055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:to="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f1a62f-f310-43db-bf91-b3b431a99bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c9f1a62f-f310-43db-bf91-b3b431a99bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockOptionsIssuedAndOutstandingMember_7d6d9dfe-c390-469b-906f-0799abe436a9" xlink:href="irtc-20211231.xsd#irtc_StockOptionsIssuedAndOutstandingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_irtc_StockOptionsIssuedAndOutstandingMember_7d6d9dfe-c390-469b-906f-0799abe436a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6c5f61a-658c-415a-b937-4829bd832059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6c5f61a-658c-415a-b937-4829bd832059" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_GrantUnderFutureStockPlansMember_c5973ea5-5c98-4901-ad91-44d14c11e7f5" xlink:href="irtc-20211231.xsd#irtc_GrantUnderFutureStockPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_irtc_GrantUnderFutureStockPlansMember_c5973ea5-5c98-4901-ad91-44d14c11e7f5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="extended" id="i0b425bc4d9d34806b95f0bc7484b4b51_StockIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d5f60b8-31ae-4520-83fe-13c8add56bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d5f60b8-31ae-4520-83fe-13c8add56bf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_adeae936-fe79-4cdd-b705-226eb83851ea" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_adeae936-fe79-4cdd-b705-226eb83851ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2caed961-7f2c-46c5-825a-5380a53ab365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2caed961-7f2c-46c5-825a-5380a53ab365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock_99a9412b-0402-4025-91aa-60a4d7567327" xlink:href="irtc-20211231.xsd#irtc_PercentageOfVotingPowerOfAllClassesOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock_99a9412b-0402-4025-91aa-60a4d7567327" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_83e6edf1-fdc6-486c-9941-889222749821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_83e6edf1-fdc6-486c-9941-889222749821" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_592d0c2b-09f7-4e2f-982c-226db88fe819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_592d0c2b-09f7-4e2f-982c-226db88fe819" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fa4b0a77-9307-46fa-82a4-c78b922dcd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fa4b0a77-9307-46fa-82a4-c78b922dcd9a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_01795742-bb34-4877-a5db-0ae7d492299b" xlink:href="irtc-20211231.xsd#irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_01795742-bb34-4877-a5db-0ae7d492299b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance_b4ef86b5-5bb1-40c9-b545-660959c2dcae" xlink:href="irtc-20211231.xsd#irtc_IncreaseInCommonStockReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance_b4ef86b5-5bb1-40c9-b545-660959c2dcae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_c9cb371f-bacf-4f3c-a4ec-2dde33986716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_c9cb371f-bacf-4f3c-a4ec-2dde33986716" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod_027d97d1-ef6a-4b80-9186-7f01d394ec44" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod_027d97d1-ef6a-4b80-9186-7f01d394ec44" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_d05ea773-b460-49ca-bc90-0419a9927711" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_d05ea773-b460-49ca-bc90-0419a9927711" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod_acc5a4af-4c66-4bfe-b18e-07a18f1b89e6" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod_acc5a4af-4c66-4bfe-b18e-07a18f1b89e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c9dff79a-55a6-4ff5-9771-754d4acd6fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c9dff79a-55a6-4ff5-9771-754d4acd6fff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_99d508df-92e3-415c-991f-a97fb02fe3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_99d508df-92e3-415c-991f-a97fb02fe3b4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e054544-9601-4fa9-8ff1-450dcf10883e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e054544-9601-4fa9-8ff1-450dcf10883e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8566b2e0-b740-4519-bfa9-398e483f8a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8566b2e0-b740-4519-bfa9-398e483f8a8c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b2b3aa7d-5297-4a22-982e-64f30a126c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b2b3aa7d-5297-4a22-982e-64f30a126c20" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c164799c-1553-4d13-8e68-21d5432aa19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c164799c-1553-4d13-8e68-21d5432aa19e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a60049bc-e085-4b44-a0cf-585363b9b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a60049bc-e085-4b44-a0cf-585363b9b26c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cde61304-7365-4860-b014-2f1bea2bfb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cde61304-7365-4860-b014-2f1bea2bfb8f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_0205cebc-920d-40bf-aad7-680b2e2c1ea1" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_0205cebc-920d-40bf-aad7-680b2e2c1ea1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_206f13f3-5a33-4435-9c8b-d4bd84996c5f" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_206f13f3-5a33-4435-9c8b-d4bd84996c5f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c0513c41-3a1f-4ce7-8d40-397d2e5be3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c0513c41-3a1f-4ce7-8d40-397d2e5be3be" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68407a98-a1d1-4aa8-b886-3056124be28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68407a98-a1d1-4aa8-b886-3056124be28d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_93c46240-414d-48c7-b619-77cf2365b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_93c46240-414d-48c7-b619-77cf2365b4de" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0b1a3445-2487-4c74-9343-e29d1236cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0b1a3445-2487-4c74-9343-e29d1236cb03" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fe2eec7e-f102-4265-be5c-9787bf53ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fe2eec7e-f102-4265-be5c-9787bf53ad5b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6643af7f-4855-4869-b770-5e5cdb38d131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:to="loc_us-gaap_PlanNameDomain_6643af7f-4855-4869-b770-5e5cdb38d131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:to="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixEquityIncentivePlanMember_ade93485-592f-4719-9bf7-0c5f94f5f49f" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_TwoThousandSixEquityIncentivePlanMember_ade93485-592f-4719-9bf7-0c5f94f5f49f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_75f67aa4-d288-4d6a-86e4-87dc37368c1a" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_75f67aa4-d288-4d6a-86e4-87dc37368c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanMember_a5362377-13ad-4fb2-a7ea-d016fb96a9bf" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_EmployeeStockPurchasePlanMember_a5362377-13ad-4fb2-a7ea-d016fb96a9bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3794e05c-85e2-4d06-9d3b-c144100bc0f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:to="loc_srt_RangeMember_3794e05c-85e2-4d06-9d3b-c144100bc0f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:to="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49f443c6-7108-4c92-b4a7-d8b2e9a79553" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:to="loc_srt_MaximumMember_49f443c6-7108-4c92-b4a7-d8b2e9a79553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4521a0c-c2a3-4ebf-8581-69436582b09d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:to="loc_srt_MinimumMember_a4521a0c-c2a3-4ebf-8581-69436582b09d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_38c1fbaf-8ae2-4080-a56a-27626aa37baf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:to="loc_us-gaap_VestingDomain_38c1fbaf-8ae2-4080-a56a-27626aa37baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:to="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0163864-7906-450e-b122-f5d21993890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0163864-7906-450e-b122-f5d21993890a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39d48e96-b459-4ee3-ad93-85149259be06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39d48e96-b459-4ee3-ad93-85149259be06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncentiveStockOptionsMember_01e6552f-ac24-4549-9143-62bc249efcdc" xlink:href="irtc-20211231.xsd#irtc_IncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:to="loc_irtc_IncentiveStockOptionsMember_01e6552f-ac24-4549-9143-62bc249efcdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherStockOptionMember_178effff-8bdf-4d2b-b598-7718364fcb3f" xlink:href="irtc-20211231.xsd#irtc_OtherStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:to="loc_irtc_OtherStockOptionMember_178effff-8bdf-4d2b-b598-7718364fcb3f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails" xlink:type="extended" id="i7178cc3be567468292d8119ede9f0bb0_StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19ad581b-65a2-4faa-901d-320f691e2e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19ad581b-65a2-4faa-901d-320f691e2e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a8293f7a-3d8a-44a5-adb8-30c6a8ba3445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a8293f7a-3d8a-44a5-adb8-30c6a8ba3445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_27f44a91-c061-4abd-b419-b08cea609868" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_27f44a91-c061-4abd-b419-b08cea609868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_8ec44b5e-e736-4edc-996c-800847f90a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_8ec44b5e-e736-4edc-996c-800847f90a6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3732eb59-1b86-4b83-b837-e5c002d3a263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3732eb59-1b86-4b83-b837-e5c002d3a263" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b107bbcd-f425-426e-88ca-b25c05b91bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:to="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_476d4040-cb11-4d1e-8f76-a2b5958aecec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:to="loc_us-gaap_PlanNameDomain_476d4040-cb11-4d1e-8f76-a2b5958aecec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:to="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_5f808e23-6665-4e1d-87d6-5fef760b1888" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:to="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_5f808e23-6665-4e1d-87d6-5fef760b1888" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails" xlink:type="extended" id="i484f1b8210d24fc4944564fc9d80c216_StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:href="irtc-20211231.xsd#irtc_SharesUnderlyingRSUsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ee9abbd-4515-4f9e-b8a3-34f1186081c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ee9abbd-4515-4f9e-b8a3-34f1186081c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83df177f-f01f-42e3-b28d-5d7c1eb1a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83df177f-f01f-42e3-b28d-5d7c1eb1a26e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6870a0d-5b80-4a83-a6a6-6e1a844ddd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6870a0d-5b80-4a83-a6a6-6e1a844ddd2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_22605a75-3ca0-42de-b7a0-6fa832305a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_22605a75-3ca0-42de-b7a0-6fa832305a19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf21266b-dbe4-4863-89a3-af5b60cc9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_807996fd-a5b9-40d3-aaa1-5d8f6b8a96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_807996fd-a5b9-40d3-aaa1-5d8f6b8a96c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8b67633-08ba-457e-a5fc-1ef6176708d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8b67633-08ba-457e-a5fc-1ef6176708d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3ed0cc8-8394-4970-ae66-a700462fcade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3ed0cc8-8394-4970-ae66-a700462fcade" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f19960c1-6c31-47ca-8df1-bd7ea1431eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f19960c1-6c31-47ca-8df1-bd7ea1431eaa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f0afecc-f525-46b2-9ee7-74d146601962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:href="irtc-20211231.xsd#irtc_WeightedRemainingVestingPeriodInYearsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c1eb13a5-deca-447f-ac7e-872c0de26c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c1eb13a5-deca-447f-ac7e-872c0de26c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:href="irtc-20211231.xsd#irtc_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9fd4888f-c0e1-4378-ab43-75a28a565b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9fd4888f-c0e1-4378-ab43-75a28a565b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:to="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d289dbb0-140f-4a0c-b96f-755e4123bb5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d289dbb0-140f-4a0c-b96f-755e4123bb5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_652e4a25-2ced-4a92-b895-dfab99ddc2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_652e4a25-2ced-4a92-b895-dfab99ddc2dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" xlink:type="extended" id="ifb7d8146835b47ff92d0291006c19484_StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2e0e344-7798-4713-b8ef-73d417f0d80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2e0e344-7798-4713-b8ef-73d417f0d80f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18eb0de4-cdf3-43e4-a830-f42ca54a92c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18eb0de4-cdf3-43e4-a830-f42ca54a92c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf8551c3-f11c-4276-844d-b614fb979b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf8551c3-f11c-4276-844d-b614fb979b69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_341c9afa-6828-4aca-928e-ecfe96e81af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_341c9afa-6828-4aca-928e-ecfe96e81af6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:to="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cf5bd6c8-dc1a-483c-b60a-d5dc1420fe21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cf5bd6c8-dc1a-483c-b60a-d5dc1420fe21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_MarketConditionAwardsMember_233164c8-c83a-4316-9915-c3df3f464f50" xlink:href="irtc-20211231.xsd#irtc_MarketConditionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:to="loc_irtc_MarketConditionAwardsMember_233164c8-c83a-4316-9915-c3df3f464f50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ic0c3e36daf0e45ecbf0ba4ab8f676669_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b2f71623-a60a-4241-8268-8619682c2567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b2f71623-a60a-4241-8268-8619682c2567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5efda895-a48c-45e9-bc9e-2c6298bbd372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5efda895-a48c-45e9-bc9e-2c6298bbd372" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_042c6f08-9bbe-4108-88b6-74ae41263709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_042c6f08-9bbe-4108-88b6-74ae41263709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6a58eaf7-c47a-401c-b111-3cc97c26f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6a58eaf7-c47a-401c-b111-3cc97c26f7b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_59d2646a-1e74-4120-ba07-b45f1828caaf" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementReversalOfPriorExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_59d2646a-1e74-4120-ba07-b45f1828caaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_0ad72182-e571-4f69-bdda-a073c6d66487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_0ad72182-e571-4f69-bdda-a073c6d66487" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f4c10b32-5ee8-4e95-b6c3-27050f43fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f4c10b32-5ee8-4e95-b6c3-27050f43fbde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7bf3a2c-d3fe-42b8-b2ba-9c15e040386e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7bf3a2c-d3fe-42b8-b2ba-9c15e040386e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_97093606-9509-4c55-bd54-28c0d82a31c8" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_97093606-9509-4c55-bd54-28c0d82a31c8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_76676af1-bda6-465c-9e25-5b2bb5c51c55" xlink:href="irtc-20211231.xsd#irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_76676af1-bda6-465c-9e25-5b2bb5c51c55" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40d8fc6c-acb4-4351-80ab-9048190a73da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40d8fc6c-acb4-4351-80ab-9048190a73da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_e7b5825f-7ccd-4dd6-ac9d-e26cd4888f72" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_e7b5825f-7ccd-4dd6-ac9d-e26cd4888f72" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0dd7bc5-234b-4e05-8769-3361c5917e17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0dd7bc5-234b-4e05-8769-3361c5917e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_94ec9107-eba9-488c-a288-c586270048fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_94ec9107-eba9-488c-a288-c586270048fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_30031ff3-fb5e-4207-b562-283b62048cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_EmployeeStockMember_30031ff3-fb5e-4207-b562-283b62048cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ec632de6-dfaa-411d-bce1-abff30b25ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_PerformanceSharesMember_ec632de6-dfaa-411d-bce1-abff30b25ff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_MarketConditionAwardsMember_19f43468-1d07-4ac3-9aca-cf1baca65a94" xlink:href="irtc-20211231.xsd#irtc_MarketConditionAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_irtc_MarketConditionAwardsMember_19f43468-1d07-4ac3-9aca-cf1baca65a94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_594a82f5-6796-4537-8297-c13ced949b87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:to="loc_us-gaap_AwardDateDomain_594a82f5-6796-4537-8297-c13ced949b87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:to="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedJanuary2021Member_a1bb90cc-4a03-4571-89f2-5451a94523cf" xlink:href="irtc-20211231.xsd#irtc_AwardedJanuary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:to="loc_irtc_AwardedJanuary2021Member_a1bb90cc-4a03-4571-89f2-5451a94523cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedFebruary2021Member_bd698c41-279f-4842-a554-42bff8eff899" xlink:href="irtc-20211231.xsd#irtc_AwardedFebruary2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:to="loc_irtc_AwardedFebruary2021Member_bd698c41-279f-4842-a554-42bff8eff899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6ca55452-2a9c-47ad-b380-a0f412c8dd35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:to="loc_us-gaap_PlanNameDomain_6ca55452-2a9c-47ad-b380-a0f412c8dd35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:to="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2019AwardsMember_66e7aaa9-33c3-4ed5-92e2-d4807a311b22" xlink:href="irtc-20211231.xsd#irtc_A2019AwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2019AwardsMember_66e7aaa9-33c3-4ed5-92e2-d4807a311b22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2020AwardsMember_808ea34c-65b8-44fd-88fb-24416ef45d69" xlink:href="irtc-20211231.xsd#irtc_A2020AwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2020AwardsMember_808ea34c-65b8-44fd-88fb-24416ef45d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2021AwardsMember_eadeac36-a7fb-4e8a-8539-1f11fd198ed7" xlink:href="irtc-20211231.xsd#irtc_A2021AwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2021AwardsMember_eadeac36-a7fb-4e8a-8539-1f11fd198ed7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_52faa076-adf1-4c5b-8eea-d2b92db27acb" xlink:href="irtc-20211231.xsd#irtc_ConsultingAndProfessionalServicesAgreementCPSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_52faa076-adf1-4c5b-8eea-d2b92db27acb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:to="loc_srt_RangeMember_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:to="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d9647a4-ae41-4660-ab11-cee05b4c04d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:to="loc_srt_MinimumMember_3d9647a4-ae41-4660-ab11-cee05b4c04d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_51b0bc6e-e098-4f26-a4e4-0114261ad408" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:to="loc_srt_MaximumMember_51b0bc6e-e098-4f26-a4e4-0114261ad408" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails" xlink:type="extended" id="iae30ef2b2b1b4a5894c8ce67745db89b_StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b465cce2-ae93-4692-b083-a3e62b3087e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b465cce2-ae93-4692-b083-a3e62b3087e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_504c63bc-a96b-4b03-8064-fc530898d28d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_504c63bc-a96b-4b03-8064-fc530898d28d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_eb6938fa-89a6-4a9e-813f-2140ce1d8059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_CostOfSalesMember_eb6938fa-89a6-4a9e-813f-2140ce1d8059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_418fe858-f361-405e-bad3-a31e5260d5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_418fe858-f361-405e-bad3-a31e5260d5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8ed27cb-4e8b-47c2-b69f-23ed49df28e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8ed27cb-4e8b-47c2-b69f-23ed49df28e2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails" xlink:type="extended" id="i1f30f6f3853245a2a65906ad8da115bc_NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aab3acf1-18e6-4488-81a4-f3823461708a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aab3acf1-18e6-4488-81a4-f3823461708a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7820d577-c98d-42ce-bd77-d259b1618d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7820d577-c98d-42ce-bd77-d259b1618d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dff495b7-536b-4fb0-afa9-4439fbbe1718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dff495b7-536b-4fb0-afa9-4439fbbe1718" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.irhythmtech.com/role/SubsequentEventsDetails" xlink:type="extended" id="i8527a0d16b1d475fba429ba21e4c1c57_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CostReimbursementRate_040ae30d-6e9a-4ae4-b1a0-2e6b64a92279" xlink:href="irtc-20211231.xsd#irtc_CostReimbursementRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:to="loc_irtc_CostReimbursementRate_040ae30d-6e9a-4ae4-b1a0-2e6b64a92279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRentableArea_8e361824-426a-495c-86d5-e1e8653e8cef" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:to="loc_irtc_OperatingLeaseRentableArea_8e361824-426a-495c-86d5-e1e8653e8cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:to="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e064652d-48ff-4de5-b44a-3f68d351a2b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e064652d-48ff-4de5-b44a-3f68d351a2b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3f80fb56-6018-42e2-b93a-53e2b6585fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:to="loc_us-gaap_SubsequentEventMember_3f80fb56-6018-42e2-b93a-53e2b6585fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:to="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b374abd-01c6-4904-91ce-756815c076b0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:to="loc_srt_ProductsAndServicesDomain_9b374abd-01c6-4904-91ce-756815c076b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:to="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_db3dda02-b81f-4bd1-abbe-1efe9ea982c5" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93243Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_db3dda02-b81f-4bd1-abbe-1efe9ea982c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_a5928839-275b-45c4-a3c4-48ec18caa417" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93247Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_a5928839-275b-45c4-a3c4-48ec18caa417" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>irtc-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock_ed6fcc32-3258-4b20-acc1-1659427d4305_terseLabel_en-US" xlink:label="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Risk</link:label>
    <link:label id="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock_label_en-US" xlink:label="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Supply Risk Policy [Policy Text Block]</link:label>
    <link:label id="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for supply risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:to="lab_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_57f62106-57cb-48cd-9c83-4972117bf77a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_85caeb60-044d-47bf-a24a-2284f587b968_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a14b1dc2-b82d-424c-b32e-16c6362d32f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AwardedJanuary2021Member_a0c20887-e740-4cb2-bc29-cdab5b59d8c9_terseLabel_en-US" xlink:label="lab_irtc_AwardedJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded January 2021</link:label>
    <link:label id="lab_irtc_AwardedJanuary2021Member_label_en-US" xlink:label="lab_irtc_AwardedJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded January 2021 [Member]</link:label>
    <link:label id="lab_irtc_AwardedJanuary2021Member_documentation_en-US" xlink:label="lab_irtc_AwardedJanuary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded January 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedJanuary2021Member" xlink:href="irtc-20211231.xsd#irtc_AwardedJanuary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AwardedJanuary2021Member" xlink:to="lab_irtc_AwardedJanuary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dcf1d753-0ee5-4ff0-adc9-90f66ee4c49c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_efc31c8f-bbe8-4395-b409-d11afef779c6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b56e8176-3703-4272-ace4-d617f1bcfe16_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies_f400d6d7-f140-43de-9c4c-2a01ebda1185_terseLabel_en-US" xlink:label="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory and printed circuit board assemblies</link:label>
    <link:label id="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies_label_en-US" xlink:label="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory And Printed Circuit Board Assemblies</link:label>
    <link:label id="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies_documentation_en-US" xlink:label="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and printed circuit board assemblies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:href="irtc-20211231.xsd#irtc_InventoryAndPrintedCircuitBoardAssemblies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:to="lab_irtc_InventoryAndPrintedCircuitBoardAssemblies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d4ccc0f3-a04b-4519-b841-c83bfa540eae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d08c0a85-b674-4988-826c-27a267dee951_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_305e13c2-7b77-4ab6-bed3-3bcea30b00b9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4975e29e-a70c-4f86-baa0-bdb72a45b17b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod_dfcb40eb-1486-4891-981a-3d3e1f0a1b86_terseLabel_en-US" xlink:label="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, weighted average days to maturity</link:label>
    <link:label id="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod_label_en-US" xlink:label="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Debt Securities Maturity Period</link:label>
    <link:label id="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod_documentation_en-US" xlink:label="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:href="irtc-20211231.xsd#irtc_AvailableForSaleDebtSecuritiesMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:to="lab_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_13fab66f-6ae5-4d1f-9f14-a1d3f3bf75b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_549a4e35-1c4a-432d-a4a6-e58b1758d82e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_627b3d0c-8bef-4d88-8fc5-6f5d4c62b1fa_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d058b38f-ec54-4e21-99fd-224f31d0629d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_80a11f86-9594-4f2b-9c8c-4c8c751404dd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b48561aa-ca63-4da1-a9c7-4a526c54af19_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d63f5b8d-bbbe-4e3a-949e-4b3ac6090905_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_9e82a2e2-4513-4969-b504-720de525ce36_negatedLabel_en-US" xlink:label="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: write-offs, net of recoveries and other adjustments</link:label>
    <link:label id="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_label_en-US" xlink:label="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts Receivable Write Offs Net Of Recoveries And Other Adjustments</link:label>
    <link:label id="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_documentation_en-US" xlink:label="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable write-offs net of recoveries and other adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:href="irtc-20211231.xsd#irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:to="lab_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_36660d4f-bcef-4d58-a4b3-de3f135ed4ba_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_a21fcc2a-15ad-48fa-aa3d-8620b9da4dff_terseLabel_en-US" xlink:label="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_label_en-US" xlink:label="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued From Exercise of Warrants</link:label>
    <link:label id="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_documentation_en-US" xlink:label="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued From Exercise of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:href="irtc-20211231.xsd#irtc_CommonStockSharesIssuedFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:to="lab_irtc_CommonStockSharesIssuedFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_5838d0b5-23bd-47c8-85fc-7e3d473c4857_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ContractCostPolicyPolicyTextBlock_9c6c8d48-f2bc-40af-acf9-039f49175bc0_terseLabel_en-US" xlink:label="lab_irtc_ContractCostPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Costs</link:label>
    <link:label id="lab_irtc_ContractCostPolicyPolicyTextBlock_label_en-US" xlink:label="lab_irtc_ContractCostPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Cost Policy [Policy Text Block]</link:label>
    <link:label id="lab_irtc_ContractCostPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_ContractCostPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ContractCostPolicyPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_ContractCostPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ContractCostPolicyPolicyTextBlock" xlink:to="lab_irtc_ContractCostPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2713d08f-bbe0-4f72-9762-65f660675675_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5656ae51-0e30-4f84-b21a-bfd21bc7faff_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_22631ca5-c830-40fb-86fb-0271fcaf39f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_4adf8e62-04e6-4cd2-8786-a7940c5f5838_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_684e9158-ccac-4d4e-a902-8c9241b7006a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance_7f5cc540-ffac-421b-a22b-4b246f6ffe5b_terseLabel_en-US" xlink:label="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares available for future issuance (in shares)</link:label>
    <link:label id="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance_label_en-US" xlink:label="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Common Stock Reserved For Future Issuance</link:label>
    <link:label id="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance_documentation_en-US" xlink:label="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in common stock reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:href="irtc-20211231.xsd#irtc_IncreaseInCommonStockReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:to="lab_irtc_IncreaseInCommonStockReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9218d48c-d210-49fc-bbc8-5755044bf114_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining term of operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CollaborationAgreementUpfrontFeePayable_58417256-dc1e-4cb2-9fcd-b7c518771ebe_terseLabel_en-US" xlink:label="lab_irtc_CollaborationAgreementUpfrontFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront fee related to development agreement</link:label>
    <link:label id="lab_irtc_CollaborationAgreementUpfrontFeePayable_label_en-US" xlink:label="lab_irtc_CollaborationAgreementUpfrontFeePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Fee Payable</link:label>
    <link:label id="lab_irtc_CollaborationAgreementUpfrontFeePayable_documentation_en-US" xlink:label="lab_irtc_CollaborationAgreementUpfrontFeePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Fee Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementUpfrontFeePayable" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementUpfrontFeePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CollaborationAgreementUpfrontFeePayable" xlink:to="lab_irtc_CollaborationAgreementUpfrontFeePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesTable_23024563-47cc-48ee-b6c5-9c3d76d4148d_terseLabel_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_irtc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_9a3586bd-17fe-4365-aed2-5879251c3c50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fac07fd-d781-49a6-bf46-6248038b3235_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_12fe03d2-64e2-4c3a-b75d-090227ca81a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meals and Entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b025117a-7601-40f0-bd3c-3548219f9b4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_583a7c2b-612f-49d7-9e17-53e5981e4845_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20392fc0-9823-42e6-9910-2953532f0c92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6bb2b88a-91a1-4e99-a579-ec1c30b73a6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_720fe9e9-83ce-4514-8fbf-1171b96c9c41_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AwardedFebruary2021Member_9d7e4fc3-ff19-4a4e-b430-382a208a61a3_terseLabel_en-US" xlink:label="lab_irtc_AwardedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded February 2021</link:label>
    <link:label id="lab_irtc_AwardedFebruary2021Member_label_en-US" xlink:label="lab_irtc_AwardedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded February 2021 [Member]</link:label>
    <link:label id="lab_irtc_AwardedFebruary2021Member_documentation_en-US" xlink:label="lab_irtc_AwardedFebruary2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded February 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedFebruary2021Member" xlink:href="irtc-20211231.xsd#irtc_AwardedFebruary2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AwardedFebruary2021Member" xlink:to="lab_irtc_AwardedFebruary2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_GrantUnderFutureStockPlansMember_6fcb4ab3-49c8-4d05-93a4-35c9729121e7_terseLabel_en-US" xlink:label="lab_irtc_GrantUnderFutureStockPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under future stock plans</link:label>
    <link:label id="lab_irtc_GrantUnderFutureStockPlansMember_label_en-US" xlink:label="lab_irtc_GrantUnderFutureStockPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Under Future Stock Plans [Member]</link:label>
    <link:label id="lab_irtc_GrantUnderFutureStockPlansMember_documentation_en-US" xlink:label="lab_irtc_GrantUnderFutureStockPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant under future stock plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_GrantUnderFutureStockPlansMember" xlink:href="irtc-20211231.xsd#irtc_GrantUnderFutureStockPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_GrantUnderFutureStockPlansMember" xlink:to="lab_irtc_GrantUnderFutureStockPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_LongTermDebtCarryingValue_f71f2c02-2c65-4293-bdfd-f82c7bc6d2ff_totalLabel_en-US" xlink:label="lab_irtc_LongTermDebtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Carrying Value</link:label>
    <link:label id="lab_irtc_LongTermDebtCarryingValue_label_en-US" xlink:label="lab_irtc_LongTermDebtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Carrying Value</link:label>
    <link:label id="lab_irtc_LongTermDebtCarryingValue_documentation_en-US" xlink:label="lab_irtc_LongTermDebtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt carrying value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LongTermDebtCarryingValue" xlink:href="irtc-20211231.xsd#irtc_LongTermDebtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_LongTermDebtCarryingValue" xlink:to="lab_irtc_LongTermDebtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8f825dd1-0d8c-48eb-bb8f-338dea475dce_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_698c9e29-0edf-4e81-82c1-4199581465f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_30b7deee-a5a6-46c5-9684-b131859789ef_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c0fd91b5-7802-469a-867d-5546e3cd1c39_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9d89a43c-8ed6-4018-b38a-f39ffe675467_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ec3788da-b847-4908-adf9-a89fec426009_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Cash Equivalents and Available-for-sale Investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_e4d0f24a-56d7-4d81-8ce1-25f3e51c52f1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_01c031ca-2acc-4781-818f-cc264031ea9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9c748898-4386-4eb5-9157-189d3e65c78f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases in balance related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bc0c26f-2d15-44e3-adfa-5cfcbafa2fdb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_20ccddbe-bdd0-48e4-9437-4859d327d0cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from diluted net loss (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_75e30409-4add-4d8c-9194-e33f54eeecad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f8be040a-d42a-475c-9fa6-00b4eee3fc91_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability balance, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_df75ccee-1ce3-4dc6-b91d-64b7eba3593b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions_a4624ae7-8d4f-49bd-ade9-7987add0cdfe_terseLabel_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions_label_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Additions</link:label>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions_documentation_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance deferred tax asset additions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:href="irtc-20211231.xsd#irtc_ValuationAllowanceDeferredTaxAssetAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:to="lab_irtc_ValuationAllowanceDeferredTaxAssetAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_75256285-1b21-415c-8e14-77797d47afee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ContractLiabilityPolicyPolicyTextBlock_8076d846-56a0-45d5-8201-79b116f58f59_terseLabel_en-US" xlink:label="lab_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liabilities</link:label>
    <link:label id="lab_irtc_ContractLiabilityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Liability Policy [Policy Text Block]</link:label>
    <link:label id="lab_irtc_ContractLiabilityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_ContractLiabilityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:to="lab_irtc_ContractLiabilityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_550b008d-f947-46c8-a6c6-6b027fea96ff_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7c4789ce-e924-4e7f-95e8-0bc1b718d5d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_SiliconValleyBankTermLoanMember_2e4914e5-44d4-4ae1-bbe0-4d76151cafcf_terseLabel_en-US" xlink:label="lab_irtc_SiliconValleyBankTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SVB Term Loan</link:label>
    <link:label id="lab_irtc_SiliconValleyBankTermLoanMember_label_en-US" xlink:label="lab_irtc_SiliconValleyBankTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon Valley Bank Term Loan [Member]</link:label>
    <link:label id="lab_irtc_SiliconValleyBankTermLoanMember_documentation_en-US" xlink:label="lab_irtc_SiliconValleyBankTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Silicon valley bank term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SiliconValleyBankTermLoanMember" xlink:href="irtc-20211231.xsd#irtc_SiliconValleyBankTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_SiliconValleyBankTermLoanMember" xlink:to="lab_irtc_SiliconValleyBankTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1a3d919a-9dcb-4948-8bdb-8f9c7698bab8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b2e4bc75-2dc5-44e0-914f-63547717813e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0aab2585-e6f8-4b94-adae-9afc0b603c8e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_4394cadb-d1bd-48e8-bda0-6e5d3e123d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ClaimsPayableCurrent_d42d78f2-b1db-4fda-b3fa-9e4d6d5dc8c7_terseLabel_en-US" xlink:label="lab_irtc_ClaimsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims payable</link:label>
    <link:label id="lab_irtc_ClaimsPayableCurrent_label_en-US" xlink:label="lab_irtc_ClaimsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Payable Current</link:label>
    <link:label id="lab_irtc_ClaimsPayableCurrent_documentation_en-US" xlink:label="lab_irtc_ClaimsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ClaimsPayableCurrent" xlink:href="irtc-20211231.xsd#irtc_ClaimsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ClaimsPayableCurrent" xlink:to="lab_irtc_ClaimsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_acdc558b-5a10-46fa-8a2d-0f7a522f54e0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of RSUs</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ff0919b-f9ad-4d93-9dae-c0e01dcc7fae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b82f19a7-39b5-47a0-a0bf-36975527f2a9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_60f002a0-510c-428f-927a-9c1215302d34_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f802fe68-ad6b-4f2a-896c-23b61257e0b6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_5d4f691f-9786-4088-9993-aeed51403ff8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_89c74d49-e7cc-442f-b50c-e432fcfd8986_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PharmakonLoanAgreementMember_131446ff-cdea-4447-910f-16c5369aea03_terseLabel_en-US" xlink:label="lab_irtc_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Loan Agreement</link:label>
    <link:label id="lab_irtc_PharmakonLoanAgreementMember_label_en-US" xlink:label="lab_irtc_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon Loan Agreement [Member]</link:label>
    <link:label id="lab_irtc_PharmakonLoanAgreementMember_documentation_en-US" xlink:label="lab_irtc_PharmakonLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmakon loan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PharmakonLoanAgreementMember" xlink:href="irtc-20211231.xsd#irtc_PharmakonLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PharmakonLoanAgreementMember" xlink:to="lab_irtc_PharmakonLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b42eb38a-b0f2-4837-8d63-78aa9840da7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_8b547044-20c4-481d-bb47-5d8f734c61b1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Cash Equivalents, Short-term, and Long-term Marketable Securities Classified by Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CashEquivalentsAndInvestmentsAbstract_6b7add34-49fc-4723-b31d-4290aa7e0f3f_terseLabel_en-US" xlink:label="lab_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Investments [Abstract]</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Investments [Abstract]</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:to="lab_irtc_CashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_b3aaca13-9a99-4cc5-ba1a-66e31a58eb0c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, federal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_73bd7742-3672-443c-8507-a84ac6d8dc93_terseLabel_en-US" xlink:label="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance target to be earned at performance threshold (as a percentage)</link:label>
    <link:label id="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_label_en-US" xlink:label="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Performance Target To Be Earned At Performance Threshold</link:label>
    <link:label id="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_documentation_en-US" xlink:label="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Performance Target To Be Earned At Performance Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:href="irtc-20211231.xsd#irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:to="lab_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_29737223-859e-4b02-b996-b2bbab72bc74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e7cb7d2f-596f-4444-aed8-801cfea4f4ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_47bcde8a-4991-4013-8155-685b811f7d55_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7e434055-de52-4e80-abb2-0d1e2b5e6a81_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_70c7a07b-9305-4fc7-b396-e77e448bce1d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value &#8211; 5,000,000 shares authorized at December&#160;31, 2021 and 2020; and none issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5cb2016f-d6fb-42a4-bd5f-e301ba44d0ad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_f1db8c3f-b404-44d1-a4b0-dbacfdf8005f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_85635b6a-1345-4724-bd89-ab8768f304c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0620f90f-85b3-41a8-8aa4-16eb230fc9ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod_adbeb4f0-6d86-4efe-844c-38ed6cb1c964_terseLabel_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase period (in months)</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod_label_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Purchase Period</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod_documentation_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:to="lab_irtc_EmployeeStockPurchasePlanPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_46145751-8e10-4c7d-88b2-5bd24d6bb000_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions_ed7cd208-b07a-407c-8696-062ac0fefb06_terseLabel_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions_label_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance Deferred Tax Asset Deductions</link:label>
    <link:label id="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions_documentation_en-US" xlink:label="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance deferred tax asset deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:href="irtc-20211231.xsd#irtc_ValuationAllowanceDeferredTaxAssetDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:to="lab_irtc_ValuationAllowanceDeferredTaxAssetDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cda9a7e7-f3d3-4b0d-9ca5-248d786497d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ab809329-70ad-41a2-a87a-2cd2620dd92d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_6977c5d6-d4c2-4287-a753-c0ad18d8086f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding interest-bearing obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_75ff51c4-b585-4ba0-8bed-8a1b29263ac7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_34e2b128-d9f2-4bcd-9af7-4b1ac51f6058_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e5060635-d5ac-4dbb-b87f-e70f656883d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_MarketConditionAwardsMember_049db6eb-16cf-4446-ac0a-eec2d9829177_terseLabel_en-US" xlink:label="lab_irtc_MarketConditionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition Awards</link:label>
    <link:label id="lab_irtc_MarketConditionAwardsMember_label_en-US" xlink:label="lab_irtc_MarketConditionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition Awards [Member]</link:label>
    <link:label id="lab_irtc_MarketConditionAwardsMember_documentation_en-US" xlink:label="lab_irtc_MarketConditionAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Condition Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_MarketConditionAwardsMember" xlink:href="irtc-20211231.xsd#irtc_MarketConditionAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_MarketConditionAwardsMember" xlink:to="lab_irtc_MarketConditionAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_03c67a7b-db18-40ec-bb64-82b6a78db06f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_7ccd6a23-7221-4f8c-9b33-958beb50708f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f694e586-57eb-4dcd-92b2-a20b6727ce99_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_TwoThousandSixEquityIncentivePlanMember_d90ac4b7-4b7b-4b69-bd71-9f590d0d2320_terseLabel_en-US" xlink:label="lab_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan</link:label>
    <link:label id="lab_irtc_TwoThousandSixEquityIncentivePlanMember_label_en-US" xlink:label="lab_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Six Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_irtc_TwoThousandSixEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand six equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:to="lab_irtc_TwoThousandSixEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_071de159-2708-4d05-95ce-912893247b83_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_fab7d6ac-3f0b-4881-86f1-1bac0fb69702_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_74603e5d-f44c-4188-aed2-b76ca1614f84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of payroll deductions of eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_9d82e723-34ff-4736-9961-590e8ae590a5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_3045a411-3040-4969-8d19-26c5c9c36596_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a187beb8-1663-46b1-986c-b2248b126cfc_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards withheld for tax purposes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e41ec146-7e4c-407a-8ba3-9430b2ef9623_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a42265e4-ed59-492a-930a-5eb283ba388a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_ca90bb89-107b-47e1-a0d5-59c9cf34ae8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_A2020AwardsMember_4dffda99-6ae5-4528-9b90-691c10a5c338_terseLabel_en-US" xlink:label="lab_irtc_A2020AwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Awards</link:label>
    <link:label id="lab_irtc_A2020AwardsMember_label_en-US" xlink:label="lab_irtc_A2020AwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Awards [Member]</link:label>
    <link:label id="lab_irtc_A2020AwardsMember_documentation_en-US" xlink:label="lab_irtc_A2020AwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2020AwardsMember" xlink:href="irtc-20211231.xsd#irtc_A2020AwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_A2020AwardsMember" xlink:to="lab_irtc_A2020AwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_933390b3-63fe-48c3-8be6-bac0a6746508_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a58af63e-f83f-4091-bd69-09b4c89352c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_a392dddf-3d7c-4d00-8d84-57b9e5a36bd6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_14efb56f-113d-420c-9c5e-70078db9964b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_275793b0-de64-4091-8bf5-330c39337b7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_788e0af9-37b6-4b88-895b-edf26f529e1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_WeightedAverageGrantDateFairValueAbstract_5b27f8b3-1cb2-4ab6-b229-2cf4f37d0e68_terseLabel_en-US" xlink:label="lab_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_irtc_WeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_irtc_WeightedAverageGrantDateFairValueAbstract_documentation_en-US" xlink:label="lab_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:to="lab_irtc_WeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AggregateIntrinsicValueAbstract_16517003-a1f0-47a8-b1c7-5e64b9ab4b76_terseLabel_en-US" xlink:label="lab_irtc_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in&#160;thousands)</link:label>
    <link:label id="lab_irtc_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_irtc_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_irtc_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_irtc_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AggregateIntrinsicValueAbstract" xlink:href="irtc-20211231.xsd#irtc_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract" xlink:to="lab_irtc_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d26e772d-e1de-4035-bf88-487b85951e5e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b49844d7-46fe-4a04-8a5f-bb82cf905735_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Payor Type and Major Service Line</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_799c9b91-2b98-47df-ad91-f90d8bdb1173_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c1d523f8-5b4e-46f9-a146-9427fb9e08d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_52a90af8-3ec6-4168-b1ef-831171518560_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_1440c4b9-9db4-4096-a7ad-61df13189cd8_terseLabel_en-US" xlink:label="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Classified as:</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_label_en-US" xlink:label="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available-for-sale Classified As Investments [Abstract]</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_documentation_en-US" xlink:label="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available-for-sale Classified As Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:to="lab_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_SanFranciscoMember_b9460511-b37a-43fe-8b44-a0db5cfbaa74_terseLabel_en-US" xlink:label="lab_irtc_SanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco</link:label>
    <link:label id="lab_irtc_SanFranciscoMember_label_en-US" xlink:label="lab_irtc_SanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco [Member]</link:label>
    <link:label id="lab_irtc_SanFranciscoMember_documentation_en-US" xlink:label="lab_irtc_SanFranciscoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SanFranciscoMember" xlink:href="irtc-20211231.xsd#irtc_SanFranciscoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_SanFranciscoMember" xlink:to="lab_irtc_SanFranciscoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_43e132ae-14db-4658-8f8f-d4322e1a8f85_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_48f08cf3-c9c4-4cf6-88b8-d3d02f147ecc_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_790ca4b5-11a9-4a28-b05f-6e7e7a91f12a_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding upon vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_0da079d7-bc8b-4a72-889c-91a0044d6e30_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_5bffebf6-faae-42e6-8e60-ba093e2caf5a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2dee4783-85ad-4636-9a9f-db4c28587ab1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a88b3e53-d6fe-4353-a339-e02b3ad099f5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_4e2ceeca-261f-48d0-b442-a20b06c70376_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_38c447b2-edce-4621-8c09-9df47400ad7f_terseLabel_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of purchase period</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_label_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Number Of Purchase Periods</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_documentation_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan number of purchase periods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:to="lab_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4214cfe3-5e80-4f1e-9b01-cc7529b91c90_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_06096ecc-a155-474b-b2a7-3b232d5f4501_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated grant date fair value of option vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_a8823573-3c7c-4ef3-b193-c4715ce95e1e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_55156e99-4e80-4178-805f-c6f992081d3b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CollaborationAgreementRemainingTermOfAgreement_ee457a55-47ad-464a-8a30-7a473ddcce04_terseLabel_en-US" xlink:label="lab_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of development agreement (in months)</link:label>
    <link:label id="lab_irtc_CollaborationAgreementRemainingTermOfAgreement_label_en-US" xlink:label="lab_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Remaining Term Of Agreement</link:label>
    <link:label id="lab_irtc_CollaborationAgreementRemainingTermOfAgreement_documentation_en-US" xlink:label="lab_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Remaining Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementRemainingTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:to="lab_irtc_CollaborationAgreementRemainingTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a685b20c-9d12-444c-8f9a-fc49da2e8cff_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, noncurrent portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_532746ae-34c8-45b2-8e82-dfdfe1d3a093_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8702920f-36eb-40aa-9ece-0e8b5660f007_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_2cc4f2b0-e1ed-4934-bf37-104522408536_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9318b8f6-ccd1-47cc-9a42-046eb02417d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca47263e-e343-4e1d-ae71-1fb2ca37277e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ae7c575f-fab3-41d3-897d-c5e655fda5f6_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e2eade43-560b-499b-9d47-33ef45b2fa51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_22156394-ebe9-4167-a878-95331a68dc29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_b6e4e58a-dcca-40f7-a7a6-2114bf6aa667_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_384a2149-daa6-46cb-b6e2-0c808caf5e47_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_A2019AwardsMember_06fbb99d-fa9a-4fe6-8f6c-3f83fad676dc_terseLabel_en-US" xlink:label="lab_irtc_A2019AwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Awards</link:label>
    <link:label id="lab_irtc_A2019AwardsMember_label_en-US" xlink:label="lab_irtc_A2019AwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Awards [Member]</link:label>
    <link:label id="lab_irtc_A2019AwardsMember_documentation_en-US" xlink:label="lab_irtc_A2019AwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2019AwardsMember" xlink:href="irtc-20211231.xsd#irtc_A2019AwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_A2019AwardsMember" xlink:to="lab_irtc_A2019AwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_38da5a18-8130-4181-a5ed-4634f167bcce_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:to="lab_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_81ae988b-fd4f-43f7-841a-daef527db985_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions taken in current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3dcd4b55-d1b2-427b-8762-077e28231299_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_497d1cf0-3016-48b1-b1dc-e12f77a1c1e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PrintedCircuitBoardAssembliesMember_03697e8c-f13b-468d-bcb1-abdca8b6155f_terseLabel_en-US" xlink:label="lab_irtc_PrintedCircuitBoardAssembliesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Printed Circuit Board Assemblies</link:label>
    <link:label id="lab_irtc_PrintedCircuitBoardAssembliesMember_label_en-US" xlink:label="lab_irtc_PrintedCircuitBoardAssembliesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Printed Circuit Board Assemblies [Member]</link:label>
    <link:label id="lab_irtc_PrintedCircuitBoardAssembliesMember_documentation_en-US" xlink:label="lab_irtc_PrintedCircuitBoardAssembliesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Printed circuit board assemblies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PrintedCircuitBoardAssembliesMember" xlink:href="irtc-20211231.xsd#irtc_PrintedCircuitBoardAssembliesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PrintedCircuitBoardAssembliesMember" xlink:to="lab_irtc_PrintedCircuitBoardAssembliesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_34f97ecf-9e5f-492e-b24f-0b0168598c3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees impacted by modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_36d8c3e4-ac84-45ef-a306-7ce7544a5f18_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Anniversary of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6891198b-8f40-4e1b-9a0c-77c94d360397_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_50942e9a-facc-48d8-bf4e-b6c9f5d11043_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AuditInformationAbstract_label_en-US" xlink:label="lab_irtc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_irtc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_irtc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AuditInformationAbstract" xlink:href="irtc-20211231.xsd#irtc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AuditInformationAbstract" xlink:to="lab_irtc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_a33fa151-a7b0-4db1-9257-05063531375c_terseLabel_en-US" xlink:label="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread deduction on variable rate (as a percent)</link:label>
    <link:label id="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_label_en-US" xlink:label="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Basis Spread Deduction On Variable Rate</link:label>
    <link:label id="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_documentation_en-US" xlink:label="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread deduction on variable rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:to="lab_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eada22ee-167d-4482-b7e8-60e8fae3e4bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8a3b39fb-45dc-42d8-8f71-4c07be8d6d28_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_d0e39a7a-04a8-4146-b8d9-bb0510795af2_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_081a1a45-70fe-4d54-9868-594a2c3db00e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_678511c6-a684-48e4-b613-e174b5a9aa78_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_LincolnshireLeaseMember_dc9f7e75-8049-4bc4-8e4d-d6c02df06e3f_terseLabel_en-US" xlink:label="lab_irtc_LincolnshireLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincolnshire Lease</link:label>
    <link:label id="lab_irtc_LincolnshireLeaseMember_label_en-US" xlink:label="lab_irtc_LincolnshireLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincolnshire Lease [Member]</link:label>
    <link:label id="lab_irtc_LincolnshireLeaseMember_documentation_en-US" xlink:label="lab_irtc_LincolnshireLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincolnshire Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LincolnshireLeaseMember" xlink:href="irtc-20211231.xsd#irtc_LincolnshireLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_LincolnshireLeaseMember" xlink:to="lab_irtc_LincolnshireLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_FinishedGoodsMember_11bf85d9-fb6a-4b6f-bfee-f05395dcd624_terseLabel_en-US" xlink:label="lab_irtc_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_irtc_FinishedGoodsMember_label_en-US" xlink:label="lab_irtc_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_irtc_FinishedGoodsMember_documentation_en-US" xlink:label="lab_irtc_FinishedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FinishedGoodsMember" xlink:href="irtc-20211231.xsd#irtc_FinishedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_FinishedGoodsMember" xlink:to="lab_irtc_FinishedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e6aa7518-386a-4db2-9a7d-1e8bcdfd65c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_ce910693-d27d-4001-8af6-d76fa3dff412_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2abbd1ce-5bfc-4654-8352-b149219d79c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_cd61a85f-aa3f-472a-a2a6-8e1d166ee8db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8bff5a3e-2345-4a1c-8bfc-c60331a7cb8a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0fdca47e-5c1c-4740-8741-ae024771f46d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_58229f3b-24b3-43ae-a310-4334801f31c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with employee equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_543eca66-33c0-4d87-9d6d-af2c474ff138_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_36e87049-8d4c-43e9-af7e-fbba4892986d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock_74c107ab-e5cb-4d82-ae64-a037879af396_terseLabel_en-US" xlink:label="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting power</link:label>
    <link:label id="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock_label_en-US" xlink:label="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Voting Power Of All Classes Of Stock</link:label>
    <link:label id="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock_documentation_en-US" xlink:label="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting power of all classes of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:href="irtc-20211231.xsd#irtc_PercentageOfVotingPowerOfAllClassesOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:to="lab_irtc_PercentageOfVotingPowerOfAllClassesOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_8d7d0aa1-2f10-454a-a587-dfc3d917bf1f_terseLabel_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_label_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested</link:label>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_documentation_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:to="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_6e2550f2-8fb9-472b-a6aa-80c10588d800_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_b4a1b89a-fc67-4816-be5d-4eccaea01f69_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under revolving credit line</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_19d4e617-cd3e-4e9d-9535-9bb1a9af2d2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_f8207d0b-d6de-4b8e-9cf3-9b3fe8cd4990_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e17a6625-a312-4506-9182-236d6de05e85_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_af091e41-f522-4199-8d11-0ec8e99612a6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2247b8e0-b98c-4590-92bf-68ede3a9011d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3c55cbda-6159-47b0-be74-91b352fec1d0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b42dfe31-d95b-4baf-990d-2c7b6f726094_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7caf6466-4fe9-4997-9309-6264a3d5d871_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_03a1a453-601c-454c-83c8-30427a768571_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_040396d9-d169-4a5a-84a9-ab25cc79cfa6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2c0aefb9-73e7-4380-a824-88403c934cd7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98455d79-c3d0-4ca3-ae5f-665740d6f23c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_84f5526e-9cfd-4b19-91fd-cf0e5f7f4184_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_75354893-05ef-4884-b03a-b534c8f5b136_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_d0a4c080-b534-4d18-9b85-3128eda52dfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CostReimbursementRate_8f9c59b4-db28-425e-9395-ae4171958a55_terseLabel_en-US" xlink:label="lab_irtc_CostReimbursementRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement rate</link:label>
    <link:label id="lab_irtc_CostReimbursementRate_label_en-US" xlink:label="lab_irtc_CostReimbursementRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reimbursement Rate</link:label>
    <link:label id="lab_irtc_CostReimbursementRate_documentation_en-US" xlink:label="lab_irtc_CostReimbursementRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reimbursement Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CostReimbursementRate" xlink:href="irtc-20211231.xsd#irtc_CostReimbursementRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CostReimbursementRate" xlink:to="lab_irtc_CostReimbursementRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e81209e8-b7d2-4f7a-aa1c-009485451618_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_473a3af9-c925-425f-90bc-0a7df0988a4d_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_defe2ef3-3207-4d3d-a81a-5d2f81483e96_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcd54da8-1594-4a72-9f7f-69eb28788dc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with follow-on public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a03f2c8f-2971-4f65-a947-647628646d48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_121898de-dceb-4aba-8481-a257389c4dfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_02f82d52-27d9-43fa-a7c1-91e4cb63dafb_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1097277f-da49-4e13-ae78-05912eaff7c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2b519e93-83f3-4886-bf98-649c447f6b67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0862dd47-bd15-4b09-8ff8-c814e47b684b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f2c0ec29-7278-4817-b78a-20acad01ce08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e90d310a-9399-45cb-9ac3-bb2e43cc7868_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_40087ae2-1f37-499b-bb9a-a85d67b48260_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2be91e0d-b727-456b-8952-df4eff1a46cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life for options outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c0083599-74e8-49e9-8729-0eca5ef22d8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with follow-on public offering, net of discounts and issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_7753dff3-1d28-40cb-8f83-cab209529271_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_SharesUnderlyingRSUsAbstract_e98d77df-21ec-4222-9c20-06b195b80527_terseLabel_en-US" xlink:label="lab_irtc_SharesUnderlyingRSUsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying RSUs</link:label>
    <link:label id="lab_irtc_SharesUnderlyingRSUsAbstract_label_en-US" xlink:label="lab_irtc_SharesUnderlyingRSUsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying RSUs [Abstract]</link:label>
    <link:label id="lab_irtc_SharesUnderlyingRSUsAbstract_documentation_en-US" xlink:label="lab_irtc_SharesUnderlyingRSUsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Underlying RSUs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SharesUnderlyingRSUsAbstract" xlink:href="irtc-20211231.xsd#irtc_SharesUnderlyingRSUsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract" xlink:to="lab_irtc_SharesUnderlyingRSUsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_a3f99d77-e0ac-404f-881b-cf4b257003c6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2819fe74-2af7-42e3-bb3c-2223d718e950_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_caed9b8b-4353-4e25-93ec-0467e870399e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_5a3fcda4-207c-4050-b6c4-dc70006e6015_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNoteSecuritiesMember" xlink:to="lab_us-gaap_CorporateNoteSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2b3300e5-0371-4466-bb06-40cfda677f2a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_faff7e00-2330-499f-b0bf-62865027b568_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value &#8211; 100,000,000 shares authorized at December&#160;31, 2021 and 2020; 29,493,726 and 29,019,350 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c43e0c94-986e-4b78-b480-601336ac8e41_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3dbf29e4-4db3-45af-a49c-301439e864dc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized compensation costs related to unvested stock options, expected period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72c75b81-7c52-421c-ad43-f8faaa03ac03_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2d8d1a09-3267-4697-abca-5a7467dbc407_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4b48c04f-e85a-4efa-b1be-5b9436c8649e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5242a959-0db6-4e47-bd4e-ba65d5b6cb08_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6814a3d0-1e33-46e1-b349-708c76b5af61_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1f097cfb-f9cd-46b1-8401-169ede31b1bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_6787a15f-15ad-4407-9116-b32624c71e45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_57b7472a-8fbc-4ea2-9344-c38c8891c6dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9a9d40bd-7b0a-45ed-8630-28aba1e03181_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b8787a31-031e-4f89-bc8e-73a3c3029eba_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_aa653c70-4a1d-45ac-a6a1-3b7dad6335a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_NonContractedThirdPartyPayorsMember_a61babb2-4d94-4439-ae61-a42994912403_terseLabel_en-US" xlink:label="lab_irtc_NonContractedThirdPartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-contracted third-party payors</link:label>
    <link:label id="lab_irtc_NonContractedThirdPartyPayorsMember_label_en-US" xlink:label="lab_irtc_NonContractedThirdPartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-contracted Third-party Payors [Member]</link:label>
    <link:label id="lab_irtc_NonContractedThirdPartyPayorsMember_documentation_en-US" xlink:label="lab_irtc_NonContractedThirdPartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-contracted Third-party Payors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_NonContractedThirdPartyPayorsMember" xlink:href="irtc-20211231.xsd#irtc_NonContractedThirdPartyPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_NonContractedThirdPartyPayorsMember" xlink:to="lab_irtc_NonContractedThirdPartyPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_433430cf-738c-420c-88d1-2b938c979a69_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_ea5691ea-d5e9-4723-a4f7-2b6ed37a051c_terseLabel_en-US" xlink:label="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_label_en-US" xlink:label="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years) [Abstract]</link:label>
    <link:label id="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_documentation_en-US" xlink:label="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageRemainingContractualLifeYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:to="lab_irtc_WeightedAverageRemainingContractualLifeYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a3f973b3-bcb8-4058-b52a-98d2943861ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_740566f4-f276-4a31-9098-e3bcf5b7c574_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 326</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_f8c649b2-f074-4548-b6ea-a504e8bb989d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_78e4a24d-aff8-457b-a94a-1e22d3401775_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_11311446-3ca1-4d36-9e2f-325c0c191223_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-term and Short-term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_01b7d13e-9a7d-4b93-9fee-363bdb1bb83c_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_b1c23e88-8fe3-4eaa-94fd-0af0e40c54f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5e6afadf-9383-406e-aa92-63b95208a1b2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e9955e9c-64f8-4e99-a331-f9fedb1c8276_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7d4ba212-14d1-45ae-b2e6-6836e22dbb9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fe145cf1-ff46-433b-9a65-a2fedf4e8354_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_775ef441-853a-466a-8a5b-d40bdfa22482_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1b4779a6-ac26-408d-8ab6-d7f1c615bd33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_44756cae-09d1-48dc-a3b0-18085c5b1031_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6d26c0b3-7755-4778-8c83-cfbda22ae616_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedVacationCurrent_8b52ebd0-075b-4506-b1d6-f63092a4226e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued vacation</link:label>
    <link:label id="lab_us-gaap_AccruedVacationCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedVacationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedVacationCurrent" xlink:to="lab_us-gaap_AccruedVacationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_36de11eb-fc78-45a9-96ed-e4c5bc516581_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OperatingLeaseRentableArea_350235ff-00de-4293-82a1-b85d7a941733_terseLabel_en-US" xlink:label="lab_irtc_OperatingLeaseRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease rentable area</link:label>
    <link:label id="lab_irtc_OperatingLeaseRentableArea_label_en-US" xlink:label="lab_irtc_OperatingLeaseRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Rentable Area</link:label>
    <link:label id="lab_irtc_OperatingLeaseRentableArea_documentation_en-US" xlink:label="lab_irtc_OperatingLeaseRentableArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease rentable area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRentableArea" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OperatingLeaseRentableArea" xlink:to="lab_irtc_OperatingLeaseRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fe32ad20-ee3e-42b1-bf22-c8b7897be393_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7e40f451-737b-4e96-82ea-99b0c6bc7d13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_InflationaryRiskPolicyTextBlock_8cc1456b-8129-4caf-bf48-7e17e7b54417_terseLabel_en-US" xlink:label="lab_irtc_InflationaryRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflationary Risk</link:label>
    <link:label id="lab_irtc_InflationaryRiskPolicyTextBlock_label_en-US" xlink:label="lab_irtc_InflationaryRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflationary Risk [Policy Text Block]</link:label>
    <link:label id="lab_irtc_InflationaryRiskPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_InflationaryRiskPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflationary Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_InflationaryRiskPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_InflationaryRiskPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_InflationaryRiskPolicyTextBlock" xlink:to="lab_irtc_InflationaryRiskPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_eeeb1af2-8e1f-415c-8cc5-765ca64f4ae0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther_92cc23c5-dd87-487c-a642-5fa94bd99225_terseLabel_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances and other</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther_label_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Valuation Allowances And Other</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther_documentation_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets valuation allowances and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsValuationAllowancesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:to="lab_irtc_DeferredTaxAssetsValuationAllowancesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_62caf585-48d9-4a2d-8e5a-62841cb2ccab_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b2496381-6b13-4dcc-900f-33a5825b557b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_057b1a63-29a2-4bb8-b99b-20c45a2e029d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock_e98e4594-802d-41a2-a904-bcef6770489f_terseLabel_en-US" xlink:label="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk and Uncertainties</link:label>
    <link:label id="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk And Uncertainties, Policy [Policy Text Block]</link:label>
    <link:label id="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk And Uncertainties, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_RiskAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:to="lab_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_A2021AwardsMember_372881a9-9c7d-4f25-bef6-135a50769b17_terseLabel_en-US" xlink:label="lab_irtc_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards</link:label>
    <link:label id="lab_irtc_A2021AwardsMember_label_en-US" xlink:label="lab_irtc_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards [Member]</link:label>
    <link:label id="lab_irtc_A2021AwardsMember_documentation_en-US" xlink:label="lab_irtc_A2021AwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2021AwardsMember" xlink:href="irtc-20211231.xsd#irtc_A2021AwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_A2021AwardsMember" xlink:to="lab_irtc_A2021AwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_be0365e1-6fa9-43af-b7db-da3e35ce2f4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_387a344d-2040-4749-9c3a-28db2eeecf01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0b5e8eda-2c39-4144-9f05-07823881ebea_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f51064c0-7dd3-45ab-84b0-a5543b8f674b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_54934b46-600f-435e-8337-735cc7fe7e47_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_78643a05-6c26-438a-b6cf-164ee8b8773f_terseLabel_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance threshold (as a percentage)</link:label>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_label_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Performance Threshold Percentage</link:label>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_documentation_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement By Share-Based Payment Award, Performance Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:to="lab_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_669b83fe-82d3-41fd-9a36-e893fe82e066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d248fcbd-4cc6-4114-bc87-b05b369184b4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8c9d33dc-b3ad-4097-a489-8afb56297aef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_44dafecd-98e9-498e-a5a5-8bf4f42eca3c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_86d861aa-7e1c-49d5-81b4-520438fa4025_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' and Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b642dd01-8c41-4d80-9e14-85141dff9bdd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c65cbc23-cdd9-4e47-bcef-c0331f94c2d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock_c2504ed7-8fe7-4cc4-bdc7-d6ff2b13a004_terseLabel_en-US" xlink:label="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Awards Available for Grant Under 2016 Plan</link:label>
    <link:label id="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock_label_en-US" xlink:label="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Awards Available For Grant Table [Policy Text Block]</link:label>
    <link:label id="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share based awards available for grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:to="lab_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b41a394f-78ed-48da-8100-6ef2dff8c993_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_badc9387-e662-4d6b-b5f7-789391b9d649_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_45f13902-f85a-4619-a6ab-275690234546_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ec7b7b75-0ff8-446d-93c1-bf96a661ee45_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9081a1df-ae39-4b94-84f8-9071962a0445_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CypressLeaseMember_450ae386-b818-4ab2-87d8-8cca0f705c02_terseLabel_en-US" xlink:label="lab_irtc_CypressLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cypress Lease</link:label>
    <link:label id="lab_irtc_CypressLeaseMember_label_en-US" xlink:label="lab_irtc_CypressLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cypress Lease [Member]</link:label>
    <link:label id="lab_irtc_CypressLeaseMember_documentation_en-US" xlink:label="lab_irtc_CypressLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cypress Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CypressLeaseMember" xlink:href="irtc-20211231.xsd#irtc_CypressLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CypressLeaseMember" xlink:to="lab_irtc_CypressLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_02dc4a56-d756-4d36-b5ed-457061e94b54_terseLabel_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value at grant date</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_label_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Aggregate Grant Date Fair Value</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_documentation_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Aggregate Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:to="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_8eca8024-a691-4990-b2c8-6e7cfa43288d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_84e5fcf2-4ea5-4cce-a342-631185103d38_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_e800a808-323f-47b7-bc4f-bfabe00a3fe1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8058a0a6-ce76-451b-895e-e9b85c74777d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_325c7bff-2273-41df-926f-3b21f50db970_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d59d83b5-5524-4637-ad4a-cc6c8824b4a7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_f4cd525d-cfdf-4a13-893f-fd2c5149475b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards available to reduce future taxable income</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock_88b54ab2-06ab-4e6e-9284-4a7cb25fa22c_terseLabel_en-US" xlink:label="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Investments</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock_label_en-US" xlink:label="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term And Long Term Investments [Text Block]</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock_documentation_en-US" xlink:label="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term and long term Investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:to="lab_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a8a7912d-888f-401b-b864-242678078893_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed21b7fc-b260-4c38-b2be-54929e45b7d7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_f658595a-f680-4b39-9e0e-93fb4be2080c_terseLabel_en-US" xlink:label="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="irtc-20211231.xsd#irtc_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_irtc_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e9948b3a-5681-4ac6-ab49-c7c4cf52e40c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2f697bce-0580-4f0e-9aac-04b52e28a736_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e859327e-14f5-48a9-9d17-3aeac4fa37de_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7390a2d7-05db-49c4-807a-78c4d1ef180c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4b8072f5-83d9-4682-8112-f27e00646dea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ccef69a8-2c9d-4b4c-8049-1a3299ca2cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_02ed85ee-3096-43af-8aae-43103bc3002e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_85a19208-f2d3-458a-aa38-4f9089ba8e0e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_04bc6f7d-1d66-4f4a-ac9c-05c8df6f4c76_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_12ebae8c-4959-4d44-9c4a-c38900bbf7e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_91db24cd-e6f2-4e78-b0b1-eb7ab1777738_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_e1d1c547-9f67-459f-b28d-1647a0b9879e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c6c3fe7b-8c32-491c-b3ca-a7689f0b19ba_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod_c2194d99-31a0-403f-b177-db3cad7600e2_terseLabel_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period (in months)</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_irtc_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cb1b19aa-e821-4153-a491-f14f59720902_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OtherAssetsUsefulLives_16210dc7-ab71-4866-8b18-7ccc0d91ae76_terseLabel_en-US" xlink:label="lab_irtc_OtherAssetsUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives of PCBAs</link:label>
    <link:label id="lab_irtc_OtherAssetsUsefulLives_label_en-US" xlink:label="lab_irtc_OtherAssetsUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Useful Lives</link:label>
    <link:label id="lab_irtc_OtherAssetsUsefulLives_documentation_en-US" xlink:label="lab_irtc_OtherAssetsUsefulLives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherAssetsUsefulLives" xlink:href="irtc-20211231.xsd#irtc_OtherAssetsUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OtherAssetsUsefulLives" xlink:to="lab_irtc_OtherAssetsUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_StockOptionsIssuedAndOutstandingMember_137f9758-5bd9-4840-9c97-0177b02d3f73_terseLabel_en-US" xlink:label="lab_irtc_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options issued and outstanding</link:label>
    <link:label id="lab_irtc_StockOptionsIssuedAndOutstandingMember_label_en-US" xlink:label="lab_irtc_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Issued And Outstanding [Member]</link:label>
    <link:label id="lab_irtc_StockOptionsIssuedAndOutstandingMember_documentation_en-US" xlink:label="lab_irtc_StockOptionsIssuedAndOutstandingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options issued and outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockOptionsIssuedAndOutstandingMember" xlink:href="irtc-20211231.xsd#irtc_StockOptionsIssuedAndOutstandingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_StockOptionsIssuedAndOutstandingMember" xlink:to="lab_irtc_StockOptionsIssuedAndOutstandingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e6cc8ab7-ada4-4fe9-b1f6-4c4f72877d54_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_d39bbefd-3848-46b3-89c8-7bca1565924b_terseLabel_en-US" xlink:label="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Rate Differential</link:label>
    <link:label id="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_label_en-US" xlink:label="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act Of2017</link:label>
    <link:label id="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_documentation_en-US" xlink:label="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation effect of tax cuts and jobs act of 2017.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:href="irtc-20211231.xsd#irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:to="lab_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1af0fafc-71a0-42a8-b466-ab2208c3d80c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_eed4f4f9-423e-46eb-8010-385f79e5ef3b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_1abed230-f9df-428b-a790-c0404ab24ed1_terseLabel_en-US" xlink:label="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock fair value on date of grant</link:label>
    <link:label id="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_label_en-US" xlink:label="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Stock Option Exercise Price Of Fair Market Value Of Common Stock</link:label>
    <link:label id="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_documentation_en-US" xlink:label="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock option exercise price of fair market value of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:href="irtc-20211231.xsd#irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:to="lab_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5e4f6fc3-1ace-4d4b-b1e0-b5e75b112c87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_LaboratoryAndManufacturingEquipmentMember_be17d146-7ae3-402a-b9f4-0c48a5f7fa3c_terseLabel_en-US" xlink:label="lab_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment</link:label>
    <link:label id="lab_irtc_LaboratoryAndManufacturingEquipmentMember_label_en-US" xlink:label="lab_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_irtc_LaboratoryAndManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and manufacturing equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:href="irtc-20211231.xsd#irtc_LaboratoryAndManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:to="lab_irtc_LaboratoryAndManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_dcb4259f-010e-4925-b055-a73a20a5895b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1c6b8a75-97cb-424d-9639-cc7e67a5cf4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock_4b2ef53a-7880-4da9-ab5a-1f3db55f6db8_terseLabel_en-US" xlink:label="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contractual Allowance</link:label>
    <link:label id="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock_label_en-US" xlink:label="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Change In Contractual Allowance Table [Table Text Block]</link:label>
    <link:label id="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock_documentation_en-US" xlink:label="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of changes in contractual allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:to="lab_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CentersForMedicareAndMedicaidMember_6ac2efb8-50e3-4c7c-b58b-3e9beec92c14_terseLabel_en-US" xlink:label="lab_irtc_CentersForMedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare &amp; Medicaid</link:label>
    <link:label id="lab_irtc_CentersForMedicareAndMedicaidMember_label_en-US" xlink:label="lab_irtc_CentersForMedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers For Medicare And Medicaid [Member]</link:label>
    <link:label id="lab_irtc_CentersForMedicareAndMedicaidMember_documentation_en-US" xlink:label="lab_irtc_CentersForMedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CentersForMedicareAndMedicaidMember" xlink:href="irtc-20211231.xsd#irtc_CentersForMedicareAndMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CentersForMedicareAndMedicaidMember" xlink:to="lab_irtc_CentersForMedicareAndMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5798ec84-3475-416a-97b0-ec487a26988e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_b666cc1a-efc2-41f8-af33-8b71b6f21d4a_terseLabel_en-US" xlink:label="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and Professional Services Agreement (&#8220;CPSA&#8221;)</link:label>
    <link:label id="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_label_en-US" xlink:label="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and Professional Services Agreement (&#8220;CPSA&#8221;) [Member]</link:label>
    <link:label id="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_documentation_en-US" xlink:label="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and Professional Services Agreement (&#8220;CPSA&#8221;)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:href="irtc-20211231.xsd#irtc_ConsultingAndProfessionalServicesAgreementCPSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:to="lab_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ac8a1986-1cf9-435c-816e-d893c37523f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_89f62c02-a2d4-4eb5-ab40-c10c11a6560f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_832acf92-eaaf-4d83-b2ca-8530491076fc_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a334406f-d10b-4b10-a11c-f77aa24d45f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d992d2de-ea2f-4a36-bb3c-75173b10e556_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0c22cfa6-ad3d-4174-b154-23be88f67463_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected maximum volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_34e94242-5471-44d7-9ee9-1ff686a6bfce_terseLabel_en-US" xlink:label="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible accounts receivable for borrowings</link:label>
    <link:label id="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_label_en-US" xlink:label="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible Accounts Receivable For Borrowings</link:label>
    <link:label id="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_documentation_en-US" xlink:label="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible accounts receivable for borrowings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:href="irtc-20211231.xsd#irtc_PercentageOfEligibleAccountsReceivableForBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:to="lab_irtc_PercentageOfEligibleAccountsReceivableForBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DebtInstrumentInterestPortion_e7778722-fc7d-408e-adb4-5b24ba422bb6_negatedLabel_en-US" xlink:label="lab_irtc_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amount representing interest</link:label>
    <link:label id="lab_irtc_DebtInstrumentInterestPortion_label_en-US" xlink:label="lab_irtc_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Portion</link:label>
    <link:label id="lab_irtc_DebtInstrumentInterestPortion_documentation_en-US" xlink:label="lab_irtc_DebtInstrumentInterestPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentInterestPortion" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentInterestPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DebtInstrumentInterestPortion" xlink:to="lab_irtc_DebtInstrumentInterestPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1500b8e-85fd-4637-9a16-5ce322663bcc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a02bad66-f964-4cd0-8901-32fc6d4a9d1b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option, maximum period for grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7c74530f-8279-452a-9276-400e0addb674_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6a04c248-e26b-4b20-963b-25559d5ea5c9_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs issued and unvested</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b60ae09b-34b6-4d71-a60d-25883a5550c5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b6720669-5a8f-49c9-a140-c6495a47e3b6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c905a23f-8471-4826-a6ef-55f3fde57718_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AccruedEmployeeStockPurchasePlanContribution_883e4b16-9cd7-4740-963b-e5493657e8da_terseLabel_en-US" xlink:label="lab_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued ESPP Contributions</link:label>
    <link:label id="lab_irtc_AccruedEmployeeStockPurchasePlanContribution_label_en-US" xlink:label="lab_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Stock Purchase Plan Contribution</link:label>
    <link:label id="lab_irtc_AccruedEmployeeStockPurchasePlanContribution_documentation_en-US" xlink:label="lab_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Stock Purchase Plan Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:href="irtc-20211231.xsd#irtc_AccruedEmployeeStockPurchasePlanContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:to="lab_irtc_AccruedEmployeeStockPurchasePlanContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems_c7e7b601-91b2-4197-b2f0-a6aa7687f0a2_terseLabel_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_irtc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_591914ea-d4a5-4fb3-b762-13e89a8c5fec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d542096c-3879-4f6d-9cbc-7e7d6eee5307_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cbcabd8c-d748-4235-8286-87c0d6b1e3e1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a5d9293a-dffa-4cf2-aa4a-12acfa4d713d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_42f4e27c-68ca-4e68-a7dd-dcb6dc1df9f8_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d5724655-3561-4113-a80f-e93d90b11a72_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with follow-on public offering, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_HealthcareInstitutionsMember_4e7f1090-a824-4132-84e2-5187313e3066_terseLabel_en-US" xlink:label="lab_irtc_HealthcareInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare institutions</link:label>
    <link:label id="lab_irtc_HealthcareInstitutionsMember_label_en-US" xlink:label="lab_irtc_HealthcareInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Institutions [Member]</link:label>
    <link:label id="lab_irtc_HealthcareInstitutionsMember_documentation_en-US" xlink:label="lab_irtc_HealthcareInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare institutions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_HealthcareInstitutionsMember" xlink:href="irtc-20211231.xsd#irtc_HealthcareInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_HealthcareInstitutionsMember" xlink:to="lab_irtc_HealthcareInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ba8e4c4d-b15c-4615-a7e3-4d543035e74f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_88b37929-13f6-4871-ab26-da56a5cf5e4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 162(m) limitation - officers compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_408638f5-547b-4d2f-89f4-69f14ec3c6b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a3cd4a67-e1c6-4f26-aa3b-7e996bfa09a2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Tax Expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6c380945-d083-46e8-b9a5-91ce0e088e24_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0458e689-07df-4da6-a8ad-b41706ca22c3_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4ae47fac-95b3-41dc-a0f5-dc4185d70f60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_22313f96-d19d-490f-94e4-d1eaeda8dbc7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cf3b7a39-6ae1-43fe-9d5a-791ca368681f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fa6e611d-e7a7-43b3-837f-5a43ee9ee6df_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_7cc5c6ea-b986-4e73-9d1c-e8859e6d4f12_terseLabel_en-US" xlink:label="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amended and Restated SVB Loan Agreement</link:label>
    <link:label id="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_label_en-US" xlink:label="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Amended And Restated Silicon Valley Bank Loan Agreement [Member]</link:label>
    <link:label id="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_documentation_en-US" xlink:label="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third amended and restated silicon valley bank loan agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:href="irtc-20211231.xsd#irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:to="lab_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d12846c8-1361-4e23-9dbc-32c9ba1771fe_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_793359cb-295d-4c4a-ac7e-11cebf5863c1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b4d21442-a8a0-4f0b-943a-86cf6da07088_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_656d509d-53e9-464d-9069-cf6f7cede42c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_30ac71a4-fe40-426a-a677-c7d887974f68_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_369299d6-4c3d-4c9f-85dc-402009081b99_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4eeb0754-99e3-45ef-a31f-a384a4546ff8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_614a94b9-1b79-4782-a4a2-f31d697b2315_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_590ff93a-1536-4e80-bada-8c36c696671e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_a1d700c3-d0c2-4235-b8fd-cd5adc8d6f90_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:to="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c13d1666-b991-4649-a3f7-e968d50e8b92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_6a761d1d-45ac-49b5-86af-95d1361f124f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_aa024b66-2bd9-4165-85ca-cbbbcb33f3bc_terseLabel_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_label_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Grants In Period</link:label>
    <link:label id="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_documentation_en-US" xlink:label="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Grants In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:to="lab_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d3ba4c95-c54f-4eb1-b29f-df37f6ecab84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_40bdb505-0267-4c9a-bfe8-82516df5b2a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5babce14-3195-4e1f-ac5e-93347228f694_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_408b98a9-65af-490c-8b05-ac0652ee62b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments_ae81fd8b-062d-4733-a53f-c2727c79e5f3_terseLabel_en-US" xlink:label="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: allowance for contractual adjustments</link:label>
    <link:label id="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments_label_en-US" xlink:label="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Allowance For Contractual Adjustments</link:label>
    <link:label id="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments_documentation_en-US" xlink:label="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable allowance for contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableAllowanceForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:to="lab_irtc_AccountsReceivableAllowanceForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_65bd22e7-4f31-4e3b-9336-54313d1796f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AccountsReceivableContractualAdjustments_68edfeeb-9caf-4132-b13a-ad75c8cfcc5d_negatedLabel_en-US" xlink:label="lab_irtc_AccountsReceivableContractualAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: contractual adjustments</link:label>
    <link:label id="lab_irtc_AccountsReceivableContractualAdjustments_label_en-US" xlink:label="lab_irtc_AccountsReceivableContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Contractual Adjustments</link:label>
    <link:label id="lab_irtc_AccountsReceivableContractualAdjustments_documentation_en-US" xlink:label="lab_irtc_AccountsReceivableContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableContractualAdjustments" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AccountsReceivableContractualAdjustments" xlink:to="lab_irtc_AccountsReceivableContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a355386b-4ebe-4b9f-aa87-0e21f0e35849_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bf287ed2-af65-4d6d-ba78-a2c9c8aa8c76_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unamortized compensation costs, net of estimated forfeitures related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_20949d1f-8bd4-4890-908b-677c305bc21a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1eafc02b-f129-4e16-8495-e54efcecb2a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_48a7bce3-00ca-472a-a18b-242a385c8ccf_terseLabel_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional aggregate milestone payments related to development agreement</link:label>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_label_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Milestone Payments, Due In Next 24 Months</link:label>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_documentation_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Milestone Payments, Due In Next 24 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:to="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_06ff7533-ae51-428c-9ee5-af9949e5afd2_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_41c38692-ab1d-4e47-8ef9-c6b2f9de2d8a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0fdd36af-8631-4ae7-bf96-7b0fef729a71_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a7e466c6-4b40-4782-aec8-229900499954_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1d99c672-0b1b-4016-a7bb-8a42b8c35de7_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2a5d815e-7cdd-484d-a4bc-a40830956531_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unamortized compensation costs, net of estimated forfeitures related to restricted stock unit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_e35ae118-d226-419b-b9c6-190fa5280c47_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_412e217c-5222-4e7a-9fe7-36038c247c54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0e5ba980-29b0-426a-a281-95d138186620_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_a7d82743-1d9c-4a9f-94fb-86b7c67e19be_terseLabel_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of share-based compensation expense</link:label>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_label_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Reversal Of Prior Expense</link:label>
    <link:label id="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_documentation_en-US" xlink:label="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Reversal Of Prior Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementReversalOfPriorExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:to="lab_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cbf8c05f-ddc4-4fb5-826e-8e62b8c21fc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ff34c63e-33a6-4cfe-ad2f-2f3f9f5eae3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued to employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_af30431a-f055-4e04-8992-a04fb3c6a8bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental compensation cost resulting from modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ComputerEquipmentAndSoftwareMember_dc132b8b-19dd-4f27-bfe8-4bd112dcb688_terseLabel_en-US" xlink:label="lab_irtc_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_irtc_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_irtc_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_irtc_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_irtc_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ComputerEquipmentAndSoftwareMember" xlink:href="irtc-20211231.xsd#irtc_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ComputerEquipmentAndSoftwareMember" xlink:to="lab_irtc_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_a3d848ed-7c16-4172-b0af-a62686c9203d_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4703495c-7817-4683-82ba-6437466fd170_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93243Member_cf2e0a7b-9ced-4219-8360-10b1efca6c98_terseLabel_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93243</link:label>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93243Member_label_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93243 [Member]</link:label>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93243Member_documentation_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93243</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93243Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:to="lab_irtc_ProductAndServicesZioXTServiceCode93243Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_dd26c1e8-df45-4539-90d0-cd0ff01241ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c0cecb7-55f4-4023-9c19-c249be7a5f67_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b5f84cfa-4f52-4101-8733-4801d1692152_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through three years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_89939c6b-bed8-4598-9732-424c1096ac30_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_77192eff-301d-47e7-9774-4e40d7a2c206_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-Use Software</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4f8cedbf-de70-4101-aaa2-6df850c7d9d6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ad349e4d-977e-496d-a0af-d9c789fbf02c_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_84da88d4-a46c-44b7-b4f1-0d8f1c561567_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2f53b691-b4c8-4cd3-a51f-dd52c65b893c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_960aa01d-c78c-47ba-8a78-74946dc2cb50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_5cadb506-8414-4f15-a4c1-1229b525e784_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of common stock fair market value available for employee purchase</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_ce2c459c-1d4a-4fcf-9972-50c4e92d99d1_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_76be86c0-a793-4a0e-ac72-771721f7d010_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d7faa29b-03f8-4592-9e6f-ef30aaf2e488_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_38237fc2-e838-4a45-b480-5ba9d9ac3bc7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_e7d6e118-f06d-42a4-b182-ec7930aaa7bc_terseLabel_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, additional milestone payments, between 2022 and early 2023</link:label>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_label_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Milestone Payments, Between 2022 and Early 2023</link:label>
    <link:label id="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_documentation_en-US" xlink:label="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Milestone Payments, Between 2022 and Early 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:to="lab_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_900e1048-42e5-4807-9588-56e69300af87_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c6b0f582-2534-482d-8414-c56540e6ebff_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_180b73d0-8332-4203-8ad5-016addc678ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c82938d7-9e62-428f-9fea-db12ff1fa450_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_dd20f450-8b7d-4949-9152-37f667f5ad82_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_f75fed6f-4ada-4100-8bbc-1ab895f103c8_terseLabel_en-US" xlink:label="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of option to extend</link:label>
    <link:label id="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_label_en-US" xlink:label="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Number Of Option To Extend</link:label>
    <link:label id="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_documentation_en-US" xlink:label="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Number Of Option To Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:href="irtc-20211231.xsd#irtc_LesseeOperatingSubleaseNumberOfOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:to="lab_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_04a2170d-64db-421f-85a4-c106e7edae0b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_71f9a1f0-cff2-4370-ace0-3ee9cb5fe899_terseLabel_en-US" xlink:label="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment Included In Accounts Payable And Accrued Liabilities</link:label>
    <link:label id="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_documentation_en-US" xlink:label="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in accounts payable and accrued liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:href="irtc-20211231.xsd#irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:to="lab_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0d7c0a52-5fbd-48ab-b925-1a3ba7daf715_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2dfb7f3a-77a1-4260-970d-afbfb35eb5b7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software, estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_269623c5-c15e-4e82-a4e3-109a86ccb6f9_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f40c56e1-508c-4db6-9b1d-41f1909cf035_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a5e78d4-a6bb-4e3e-bc97-f49f851f85df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_989c4a9e-9600-4b5d-8775-88047d623e03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7e71c63b-d176-482b-ad5d-28480be3ffda_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_94790751-644e-4148-a8b8-44ed3a2de513_terseLabel_en-US" xlink:label="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit recognized for net operating loss carryforwards</link:label>
    <link:label id="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_label_en-US" xlink:label="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Tax Benefit Recognized</link:label>
    <link:label id="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_documentation_en-US" xlink:label="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards tax benefit recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:href="irtc-20211231.xsd#irtc_OperatingLossCarryforwardsTaxBenefitRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:to="lab_irtc_OperatingLossCarryforwardsTaxBenefitRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_fe0cb035-455b-4b6b-91ad-23baf0ebaf15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_13a12b43-dbe0-403a-97cc-bc6f69f58a87_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_115e6f6b-d689-4119-925b-510b61038bb3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c2729528-af6b-425b-8cdb-9502a2d0f35e_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_FederalGovernmentAgenciesMember_c6af4b39-8541-4e94-a691-1123ade5f040_terseLabel_en-US" xlink:label="lab_irtc_FederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government Agencies</link:label>
    <link:label id="lab_irtc_FederalGovernmentAgenciesMember_label_en-US" xlink:label="lab_irtc_FederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government Agencies [Member]</link:label>
    <link:label id="lab_irtc_FederalGovernmentAgenciesMember_documentation_en-US" xlink:label="lab_irtc_FederalGovernmentAgenciesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal government agencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FederalGovernmentAgenciesMember" xlink:href="irtc-20211231.xsd#irtc_FederalGovernmentAgenciesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_FederalGovernmentAgenciesMember" xlink:to="lab_irtc_FederalGovernmentAgenciesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_97d4714e-b8fe-4aa6-8aed-c1f684e62c60_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c9ec8a91-bdad-45e1-8888-eeb9fb1bfbb7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock in public offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_516ea019-3064-456d-9863-6b9913e8ca1e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ea98600b-bb11-4760-934a-a07c95c12c68_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2c37f9c2-e804-4c4c-a9ee-9426c6d3c6cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization_857757cc-3751-42bd-9062-8f51215e7fcd_terseLabel_en-US" xlink:label="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of operating lease right-of-use assets</link:label>
    <link:label id="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization_label_en-US" xlink:label="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Assets Amortization</link:label>
    <link:label id="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization_documentation_en-US" xlink:label="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Assets Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRightOfUseAssetsAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:to="lab_irtc_OperatingLeaseRightOfUseAssetsAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b04ffabb-34fd-4e94-8427-60b34f7e330b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_b96b73a7-4370-4094-8e6c-a55db4353544_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ff7a1b01-ea5d-454a-818d-8d00a48a6fb4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_74551cf4-6a6b-4588-8f4b-87799d6a27b0_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_df5d5fa6-91e7-48cc-a703-9be6f06a413a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-vested Restricted Stock Units ("RSUs")</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_83db4734-3659-4c18-83a7-d4adeb595d97_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2f8e471a-8f80-494e-8c19-ba2b9a7d6a66_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bdefd37a-ff4c-40bb-a2cf-31f886fe4678_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_43c60c54-08a2-448f-906f-e975c12c0bd4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_4e992f94-daca-4628-a64c-66f2214eb7f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d86f4822-b5f0-43d7-b9b8-9bc532bac723_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term of lease (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c0e145e6-4060-40f9-a77a-4bc51d6073a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3c9e8d60-5b2f-4a7f-8428-46ddb032a060_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_eebb407a-0d50-42cd-be54-47f1d60d9148_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_c6c3548f-240a-46ac-91a9-b9dac8755267_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DeerfieldLeaseMember_09006b04-749c-4fce-9511-86b7cb13f406_terseLabel_en-US" xlink:label="lab_irtc_DeerfieldLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Lease</link:label>
    <link:label id="lab_irtc_DeerfieldLeaseMember_label_en-US" xlink:label="lab_irtc_DeerfieldLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Lease [Member]</link:label>
    <link:label id="lab_irtc_DeerfieldLeaseMember_documentation_en-US" xlink:label="lab_irtc_DeerfieldLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deerfield Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeerfieldLeaseMember" xlink:href="irtc-20211231.xsd#irtc_DeerfieldLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DeerfieldLeaseMember" xlink:to="lab_irtc_DeerfieldLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0477c02e-263b-429a-9de7-0a12ab94681c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_cdbe188c-17de-4890-9dd5-743123c0daa5_negatedLabel_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted (in shares)</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_label_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_documentation_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares available for grant granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:to="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7775c907-836e-4eb1-847d-e1e37118182c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_29f69d52-32ba-41f1-80bc-8e7cd07cad12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_f7b45c91-c872-46e4-91b6-3d0d513d2198_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_b076656c-df49-4710-a32a-f25eca60c637_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_e98c525e-32fa-42e0-8864-60ad419af04a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_b5a599a1-3035-4372-9919-2674299b354e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0dcd88a1-efb4-42b5-9511-f888e3e7793b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6ac4af4-ce2f-4e95-8ba9-09dc29457b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_407dfafe-d498-4e04-9bdd-a277381e0b74_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9404382d-a051-41b1-b136-5e7d3a03d8a0_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4838ef7e-c733-4bcc-8163-d204fc222d19_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3558e5ef-7272-42ca-8c33-cc45e1d9beca_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_235e8f91-ebdd-47e2-bea7-80b329263668_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock_6cc85578-8131-45fd-ab37-09c279c7f84d_terseLabel_en-US" xlink:label="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' option to purchase additional shares of common stock (in shares)</link:label>
    <link:label id="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock_label_en-US" xlink:label="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Option To Purchase Additional Shares Of Common Stock</link:label>
    <link:label id="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock_documentation_en-US" xlink:label="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Option To Purchase Additional Shares Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:href="irtc-20211231.xsd#irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:to="lab_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_8128a4cd-5fb4-4086-bc7a-36f448a33423_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a9d956c5-4aa1-4561-9103-d80777e53d9f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e04bbe5f-1ca3-4fba-a73a-de75c38f4b5f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_b0ef086d-8a58-4cf1-be76-093507c15a41_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_994e68d8-87bb-4b05-a732-dbd36a9310ee_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4faa020c-59ce-449a-9b0a-e190924ad212_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ProvisionForBadDebtAndContractualAllowance_c2f61c8f-ed35-4e7b-b412-070e51f28043_terseLabel_en-US" xlink:label="lab_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debt and contractual allowance</link:label>
    <link:label id="lab_irtc_ProvisionForBadDebtAndContractualAllowance_label_en-US" xlink:label="lab_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Bad Debt And Contractual Allowance</link:label>
    <link:label id="lab_irtc_ProvisionForBadDebtAndContractualAllowance_documentation_en-US" xlink:label="lab_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debt and contractual allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:href="irtc-20211231.xsd#irtc_ProvisionForBadDebtAndContractualAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:to="lab_irtc_ProvisionForBadDebtAndContractualAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b97ed5ff-788c-473c-8571-c7ce6dfab0bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a97f5c7b-f592-4bdc-ab7d-319b747022ae_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1e2f1116-3841-4445-8f12-f416ab3ae928_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted remaining vesting period of RSUs (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_68747167-ec6a-4682-998a-d957426e371a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option vesting term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3401e4d7-4e78-451e-a4d1-41b844a1ab8c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit income tax interest and penalty charges</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2061b6f6-08a6-4dc2-a369-3fa9599c1967_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1a690e94-cc09-4466-8092-a7b1b9fdf12a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Tax Expense Computed at Statutory Federal Rate and Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_76ddc3b1-0fa9-401d-97c0-20c4a14db90f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_83d3ae98-5c81-4fa3-b6ef-5e4cbb7fd364_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_10646b66-66e9-4f81-887d-90174d6f0a1a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember_a446cda5-c07a-41c5-95c7-2af79762c2f8_terseLabel_en-US" xlink:label="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand sixteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="lab_irtc_TwoThousandSixteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_ee5d4303-7f54-4d8e-b65c-c53e2d199212_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_312b4678-4337-4ba3-b17c-9e5ccee1242b_totalLabel_en-US" xlink:label="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale investments</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_label_en-US" xlink:label="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Current And Noncurrent Investments</link:label>
    <link:label id="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_documentation_en-US" xlink:label="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and current and noncurrent investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:to="lab_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_WeightedAverageExercisePricePerShareAbstract_437c3454-997d-435d-8b42-0c0a6141695a_terseLabel_en-US" xlink:label="lab_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_irtc_WeightedAverageExercisePricePerShareAbstract_label_en-US" xlink:label="lab_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share [Abstract]</link:label>
    <link:label id="lab_irtc_WeightedAverageExercisePricePerShareAbstract_documentation_en-US" xlink:label="lab_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageExercisePricePerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:to="lab_irtc_WeightedAverageExercisePricePerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_7cebda08-9bf0-4e54-b04f-a48bbbfa6177_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dd431f58-2369-4d89-9560-e8d946109c51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Financial Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_bef7608b-0da8-4a44-b398-b80d2700dc8f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_c1d9c365-39bc-4309-815c-de8a4adf4a88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eec3b0e9-fda4-4120-929c-a30a8ac86df0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_16fca563-b076-4ab4-9737-a08c90782180_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_9051ddf1-c079-4063-9ce2-0e78a1dc6276_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b79a55fa-6668-4274-b259-352e3c65a60d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DeferredTaxAssetsLeaseObligations_8baccc1c-8a98-4ce3-b442-c3bcb57a5b17_terseLabel_en-US" xlink:label="lab_irtc_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsLeaseObligations_label_en-US" xlink:label="lab_irtc_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsLeaseObligations_documentation_en-US" xlink:label="lab_irtc_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsLeaseObligations" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DeferredTaxAssetsLeaseObligations" xlink:to="lab_irtc_DeferredTaxAssetsLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_646d478b-49c8-4927-932c-c56922960015_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dbca1c11-e261-4fa0-9040-27dad2d7f69c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract_b9c0e7cb-f8fe-4d63-9be8-86f4d050462b_terseLabel_en-US" xlink:label="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Remaining Vesting Period (in years)</link:label>
    <link:label id="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract_label_en-US" xlink:label="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Remaining Vesting Period (in years) [Abstract]</link:label>
    <link:label id="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract_documentation_en-US" xlink:label="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Remaining Vesting Period (in years)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:href="irtc-20211231.xsd#irtc_WeightedRemainingVestingPeriodInYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:to="lab_irtc_WeightedRemainingVestingPeriodInYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_3b3098db-64ea-4225-a8df-b12f1ecd8a20_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6dfb33be-9f3a-4198-828b-1be31ef1e740_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1860ce19-fd2d-479d-bbdc-b374c3cd8bd2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d2d913a9-3e29-4385-8de8-11d29120f062_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_AccountsReceivableForContractualAllowance_f8022b26-f1af-4115-a9ba-412a9c689c2f_periodStartLabel_en-US" xlink:label="lab_irtc_AccountsReceivableForContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_irtc_AccountsReceivableForContractualAllowance_eddd4096-d03e-46ba-862d-b43b6b0e5a6d_periodEndLabel_en-US" xlink:label="lab_irtc_AccountsReceivableForContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_irtc_AccountsReceivableForContractualAllowance_label_en-US" xlink:label="lab_irtc_AccountsReceivableForContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable For Contractual Allowance</link:label>
    <link:label id="lab_irtc_AccountsReceivableForContractualAllowance_documentation_en-US" xlink:label="lab_irtc_AccountsReceivableForContractualAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable for contractual allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableForContractualAllowance" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableForContractualAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_AccountsReceivableForContractualAllowance" xlink:to="lab_irtc_AccountsReceivableForContractualAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_6d29a45d-ca07-42bc-a34c-dde5dc318cec_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanMember_0bc4127f-38e0-4ef0-a2ea-74eb80fa3658_terseLabel_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan("ESPP")</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_irtc_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_irtc_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanMember" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_EmployeeStockPurchasePlanMember" xlink:to="lab_irtc_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CommercialPayorsMember_efa09b3d-7ec4-484f-81f4-fc900a57b076_terseLabel_en-US" xlink:label="lab_irtc_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracted third-party payors</link:label>
    <link:label id="lab_irtc_CommercialPayorsMember_label_en-US" xlink:label="lab_irtc_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors [Member]</link:label>
    <link:label id="lab_irtc_CommercialPayorsMember_documentation_en-US" xlink:label="lab_irtc_CommercialPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Payors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommercialPayorsMember" xlink:href="irtc-20211231.xsd#irtc_CommercialPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CommercialPayorsMember" xlink:to="lab_irtc_CommercialPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5a91c5b-ffb9-41fe-84f2-c517bbc49d87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c591d62f-66d4-4940-9a80-c125de2c4c25_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_c229bbac-2145-430d-9916-7654d81e5888_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8322bc82-37b7-460b-9a42-0e10708280f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net Components</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock_6e5ab6a4-063c-4c6c-861e-7ad775199c96_terseLabel_en-US" xlink:label="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock_label_en-US" xlink:label="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Policy Policy [Policy Text Block]</link:label>
    <link:label id="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of other assets policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:href="irtc-20211231.xsd#irtc_OtherAssetsPolicyPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:to="lab_irtc_OtherAssetsPolicyPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cdd24e4a-d710-4d02-81d9-88d7e6a30dbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_a6318f8a-52bb-4f61-950b-2b8e20843d51_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases in balance related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c405a9c9-d647-43b9-8d1b-7f0d9647ba31_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_8a94c246-f518-43d5-bd53-6e02859d6567_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional options authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dc78723f-9ca5-4c24-84b7-2bf9bed98039_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3791c4c9-a791-46a0-976c-a5628eb86309_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bde31c15-7e08-4bc4-a4b6-f212ec89cdec_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_ede105a9-2d9f-4d65-9ba9-dab939591de4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d7d73be9-3dd8-4951-8c59-b3302efdbb58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_28049b7a-a487-4d9b-89c4-8a5d44d506af_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb7481d9-7479-484d-9696-bbfa0be876c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_589eca53-00c7-40e2-954e-998325c8930f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_65dc84fc-8bd4-4cf8-a742-1184b56e8f8a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5c82133d-df6a-4b78-b727-aa65f7271886_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e954b485-24c9-443c-9521-f33377bad7e0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b0890151-6ecb-4a62-b649-a192bfabe8fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9852dbcd-4093-4660-a877-70c5958d18e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_022e37df-2001-4b99-8c86-4ed4909a255d_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_df8ea444-16f9-49e0-ab49-d816f5aae0a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a8e25841-0fa1-4f77-a57f-52e277dba895_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_fe8fd7ef-d0f8-4d45-b17d-da2bad964ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8bbe0a9-affc-487c-b727-87ee71ccabdb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f7675cce-3560-4502-bb19-6eb0de39d5ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OtherStockOptionMember_7aacc1a1-8ec0-4d6b-ba12-95edd33b1053_terseLabel_en-US" xlink:label="lab_irtc_OtherStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Options</link:label>
    <link:label id="lab_irtc_OtherStockOptionMember_label_en-US" xlink:label="lab_irtc_OtherStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Option [Member]</link:label>
    <link:label id="lab_irtc_OtherStockOptionMember_documentation_en-US" xlink:label="lab_irtc_OtherStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other stock option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherStockOptionMember" xlink:href="irtc-20211231.xsd#irtc_OtherStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OtherStockOptionMember" xlink:to="lab_irtc_OtherStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_00cfabe2-ae75-48df-b4c2-f528e723e48f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid_865aa275-6734-497b-a038-7b6d499e8800_terseLabel_en-US" xlink:label="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs incurred but not yet paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="irtc-20211231.xsd#irtc_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_irtc_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_da2a7cfb-0b80-48c8-a48d-588df6ea07ea_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_618602d1-abb3-4212-b041-ed496ca7c58a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7bf25455-c977-40fc-8936-193e76c02614_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life for options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward_1e0b7edd-d5bf-44f8-947d-720b4a92fc65_terseLabel_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward_label_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:to="lab_irtc_DeferredTaxAssetsValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_964dd06f-57dc-4669-8628-88fb60fee8df_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3e1eda90-c7ce-402b-8f3e-4e4f40de4feb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected minimum volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_86945220-7f00-4e63-a27b-42e491c7e9ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OptionsOutstandingAbstract_98b3de4b-77ce-4d38-89c8-4a809d9a61d5_terseLabel_en-US" xlink:label="lab_irtc_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_irtc_OptionsOutstandingAbstract_label_en-US" xlink:label="lab_irtc_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding [Abstract]</link:label>
    <link:label id="lab_irtc_OptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_irtc_OptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OptionsOutstandingAbstract" xlink:href="irtc-20211231.xsd#irtc_OptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OptionsOutstandingAbstract" xlink:to="lab_irtc_OptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_74b209c3-b820-40cc-99cd-72c21e0bb925_terseLabel_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercisable rate (as a percent)</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_label_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Rate Percentage</link:label>
    <link:label id="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_documentation_en-US" xlink:label="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable rate percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:to="lab_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_2eabd2bf-31cb-4114-9c2e-e5474fc62830_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_VerilyLifeSciencesLLCMember_cb5c36b1-de91-40ed-a903-14b2343593cb_terseLabel_en-US" xlink:label="lab_irtc_VerilyLifeSciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences LLC</link:label>
    <link:label id="lab_irtc_VerilyLifeSciencesLLCMember_label_en-US" xlink:label="lab_irtc_VerilyLifeSciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences LLC [Member]</link:label>
    <link:label id="lab_irtc_VerilyLifeSciencesLLCMember_documentation_en-US" xlink:label="lab_irtc_VerilyLifeSciencesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verily Life Sciences LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_VerilyLifeSciencesLLCMember" xlink:href="irtc-20211231.xsd#irtc_VerilyLifeSciencesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_VerilyLifeSciencesLLCMember" xlink:to="lab_irtc_VerilyLifeSciencesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_a4dfbc06-d8e8-4399-bfd0-8c89c8b88113_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ee8955f9-bb51-4f46-856c-a7cdf50dda98_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discounts on investments, net of premium amortization</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f4c2817f-a650-42bf-8735-d675537fd580_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock_173ade7f-1f2e-4acf-a769-609709ac5dfb_terseLabel_en-US" xlink:label="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory Components</link:label>
    <link:label id="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock_label_en-US" xlink:label="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Inventory And Printed Circuit Board Assemblies Table [Table Text Block]</link:label>
    <link:label id="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock_documentation_en-US" xlink:label="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory and printed circuit board assemblies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:to="lab_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21f609e1-6cb9-4d72-a1a1-f6fb1a1446f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e92696a4-cd0a-4a20-b2f5-7564032af321_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of&#160;&#160;year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9d1e2c5d-ec91-46ae-8f72-6802bd38200a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_923bd046-8c88-436a-a46f-629f3f0201da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_51122445-67f4-45eb-9c94-8d4b577c42d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9398ad31-e6b9-4c36-9e30-2e75c06b531d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_94f713ba-71da-4e12-ba13-aa06c3fc66c3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d984fba1-2093-45d8-a519-2be7e3857d7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11dfb1f1-c4ff-4a0b-9ed6-8bf834734302_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_70f2ef46-d89f-4990-afa1-39db2f110e38_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5f256e22-2260-43f3-a0ac-29c201b71f7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7869c83b-f451-42da-9186-7a2f23ca44e7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1d2aacfb-6f01-4769-b9a5-23eb0eb0d313_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5f5d79b3-62df-4c3b-96a1-00585ff39c18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b696266b-9383-4a05-87e8-88aa35889dd9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with employee equity incentive plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2ab2b6ac-3001-4d40-9f10-88d2437ff666_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4820b7c-0ccf-4825-a004-70da7f8804cd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b282d411-6991-41c7-bd6a-02ce8f165b20_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per common share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_2dcbea0a-d612-4b8a-952f-26f5e84c861f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_cef2273f-ed8e-488a-ac05-202a06f5b80c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_705bfe1c-f430-45bc-a0dc-a16704d77746_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93247Member_81211c40-9b0c-4eeb-9323-84d679454a5f_terseLabel_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93247</link:label>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93247Member_label_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93247 [Member]</link:label>
    <link:label id="lab_irtc_ProductAndServicesZioXTServiceCode93247Member_documentation_en-US" xlink:label="lab_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product And Services Zio X T Service Code93247</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93247Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:to="lab_irtc_ProductAndServicesZioXTServiceCode93247Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_123dad13-bddd-48a8-ab85-ea2cf637e2b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity Under 2006 and 2016 Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_74fef87b-8116-405f-b56a-326faac8256f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_8cbd86f4-f714-4c0f-b3ba-4e3338f31291_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3972fc7f-1c95-4aad-ad65-770e3892f6a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_OfficeLeaseMember_709b5ca8-6687-4b71-90d3-88350c15fe50_terseLabel_en-US" xlink:label="lab_irtc_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Lease</link:label>
    <link:label id="lab_irtc_OfficeLeaseMember_label_en-US" xlink:label="lab_irtc_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Lease [Member]</link:label>
    <link:label id="lab_irtc_OfficeLeaseMember_documentation_en-US" xlink:label="lab_irtc_OfficeLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OfficeLeaseMember" xlink:href="irtc-20211231.xsd#irtc_OfficeLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_OfficeLeaseMember" xlink:to="lab_irtc_OfficeLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_660c7a51-450b-4283-83af-f2f136cdc053_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_23bbe2d4-5e4a-4777-bfd7-41f9ee49e002_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_39b9e947-3676-4452-837c-c027f06806a8_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5f62b165-7ebb-4c35-849c-2f7747ca58d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a605d4dd-55c1-468a-a2fa-3bd6dde62b21_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d64cddfb-98f2-454f-a5b1-850969547b8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_53195699-3e4a-40e8-8654-fcba60bb8715_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_03f2b077-f6f7-4d42-a6f8-612e8cfd4733_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_25be0eee-2691-4b9d-9e6c-5826801b5b98_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f9bbab8d-1223-4d07-a20a-212b5311b772_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2e6b66b7-a751-4bfb-815d-46bb4c7d435f_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_IncentiveStockOptionsMember_3966ef75-725f-40bf-92d7-fb9f2a289909_terseLabel_en-US" xlink:label="lab_irtc_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ISO</link:label>
    <link:label id="lab_irtc_IncentiveStockOptionsMember_label_en-US" xlink:label="lab_irtc_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options [Member]</link:label>
    <link:label id="lab_irtc_IncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_irtc_IncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncentiveStockOptionsMember" xlink:href="irtc-20211231.xsd#irtc_IncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_IncentiveStockOptionsMember" xlink:to="lab_irtc_IncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40644ebd-5daa-4295-ab8a-e34f498fd56d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9eec29e6-0f54-47a4-9cfe-8d61a3a3f5f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8c324cc4-5d8d-4341-9b92-c2326ed7d6e1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a1bd865f-fa51-4913-8850-b3a0df0af71a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a092b1ff-0d2c-4c4c-b62d-126991e5de10_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9a2e50fa-febb-4fc4-9104-1d414fe4d329_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_957c0bc2-fdf4-4484-ab27-bc8abc547758_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65dc6a71-1d87-434f-8cf4-c943e49b0cdf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding upon vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_9a46680d-749f-451f-96d6-4229ba04deae_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Allowance for Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c0adffad-a74b-4f0f-a5f5-f77d34aa886e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_3100f652-e275-446e-aac8-e0c7dfbdc02a_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_acad7a49-90ba-4714-93c7-143e1ac1a86f_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0444e51d-28a1-49f3-8a23-e44c2c66ac72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_09a2d98a-60c8-434d-8537-d640b6b9ed9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c07eeaee-1e32-428b-aef5-c59e44b313b7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_CollaborationAgreementMilestonePayments_99b251fd-07e0-4b32-aa0e-e90f7ffdb16a_terseLabel_en-US" xlink:label="lab_irtc_CollaborationAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement milestone payments</link:label>
    <link:label id="lab_irtc_CollaborationAgreementMilestonePayments_label_en-US" xlink:label="lab_irtc_CollaborationAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Milestone Payments</link:label>
    <link:label id="lab_irtc_CollaborationAgreementMilestonePayments_documentation_en-US" xlink:label="lab_irtc_CollaborationAgreementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementMilestonePayments" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_CollaborationAgreementMilestonePayments" xlink:to="lab_irtc_CollaborationAgreementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_78630042-f114-436c-9a94-f71aae0280b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_3e849eab-b328-4e30-b53b-411f64906ba1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_869ad29f-a5ff-45a5-b2e8-bbb9dc977fcb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in connection with employee equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4586c7a0-7108-4e42-8052-a6c4764c7ddf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_bf18681f-b66c-4950-9953-fde19a4d0174_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities in unrealized loss for more than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3f60175b-7024-454f-a22b-111fb8ffeb23_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a122473a-45c3-4028-b6e7-a1d8bf49469c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a81d0b78-7e92-4266-8451-a57b92fdd592_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at statutory federal rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_9222a264-93a1-4d3a-9ae5-7bface55082c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8d61aaea-fe7e-4fa5-ad86-73e268eb39c5_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_irtc_RawMaterialsMember_bcafd5d2-b0c7-400a-820b-ad98b75247ca_terseLabel_en-US" xlink:label="lab_irtc_RawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_irtc_RawMaterialsMember_label_en-US" xlink:label="lab_irtc_RawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw Materials [Member]</link:label>
    <link:label id="lab_irtc_RawMaterialsMember_documentation_en-US" xlink:label="lab_irtc_RawMaterialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_RawMaterialsMember" xlink:href="irtc-20211231.xsd#irtc_RawMaterialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_irtc_RawMaterialsMember" xlink:to="lab_irtc_RawMaterialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_a5902238-263b-4570-91c2-1f468d183753_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5aaa6170-cdba-4037-bce4-4cd1388458ae_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_7bdc1d2a-5cd8-488a-9be1-b6095a7287d0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a4f1d981-00c1-4961-afdd-5d9c3b17ed17_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, state</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_2f3e16ac-69ff-4cee-a394-77eed5c01cea_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7e7db1e4-0486-4b95-b202-7ee55a1aed83_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a68009be-873e-4f40-9249-a681f526cdb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1129f1db-976f-45e6-958f-f406f239a3f6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_14336cde-147a-462f-8eb2-ed5ddc4a5eb4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dd06496e-4a31-4ebf-903a-b49b9a8b0e41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_db33da9e-ce65-47ab-ad76-5e003f7f6788_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6c9eab28-6121-4230-8304-db503e1577fd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_24f6ffc7-36d2-4b3c-8e4f-8720302725a8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_166e37c7-6dcf-4a14-93f9-e3e16f92e1a8_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss, greater than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_b382e26d-2814-4dda-ac92-e9e46f069ef6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c59c8dbb-c375-4e1c-aa78-e109c96bc240_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life for options vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>irtc-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2c7c1268-a8a7-4de8-b00c-21476d34e9b7,g:334c40aa-9162-4ff0-a5a4-36ab5fab486f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CoverPage" xlink:type="simple" xlink:href="irtc-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_20b4dfd9-17c0-4513-8e53-59da4dd7711c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentType_20b4dfd9-17c0-4513-8e53-59da4dd7711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3783028b-6018-43ad-95e0-38596318a865" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentAnnualReport_3783028b-6018-43ad-95e0-38596318a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_23d92cc0-b8d7-4003-af3c-4267619e1bd1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentPeriodEndDate_23d92cc0-b8d7-4003-af3c-4267619e1bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d03542c5-f0d0-4c19-8aee-0bf3a0776960" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_CurrentFiscalYearEndDate_d03542c5-f0d0-4c19-8aee-0bf3a0776960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_168d19a8-b758-42a8-9fc9-95ef29489055" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentTransitionReport_168d19a8-b758-42a8-9fc9-95ef29489055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d80b4964-2d98-4099-bcd0-d5244787cd8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityFileNumber_d80b4964-2d98-4099-bcd0-d5244787cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8a5fc166-4adb-4845-b459-f76d62a6eb84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityRegistrantName_8a5fc166-4adb-4845-b459-f76d62a6eb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6c0f81c0-9d32-4b07-85b5-61d3de215988" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6c0f81c0-9d32-4b07-85b5-61d3de215988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_94e84194-5b96-4589-b3d1-f7b208a86d0c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityTaxIdentificationNumber_94e84194-5b96-4589-b3d1-f7b208a86d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d3b68ae2-365e-4ee8-91b7-f8fd849e2f47" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityAddressAddressLine1_d3b68ae2-365e-4ee8-91b7-f8fd849e2f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_cba4a34b-c511-4d8a-9a29-832543a52be3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityAddressAddressLine2_cba4a34b-c511-4d8a-9a29-832543a52be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2e71917c-114f-4929-adef-3d2efcb47e5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityAddressCityOrTown_2e71917c-114f-4929-adef-3d2efcb47e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_73fba81e-7700-466e-b526-c22fdcbf6f3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityAddressStateOrProvince_73fba81e-7700-466e-b526-c22fdcbf6f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_01e80008-b4b2-4a2c-a27f-354c100f8276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityAddressPostalZipCode_01e80008-b4b2-4a2c-a27f-354c100f8276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d9f14ce5-0bb5-4e67-b714-569125ce378b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_CityAreaCode_d9f14ce5-0bb5-4e67-b714-569125ce378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_837eb7c1-9a5a-4044-8256-9a69ec18d4f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_LocalPhoneNumber_837eb7c1-9a5a-4044-8256-9a69ec18d4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_71d6f512-6a2f-4b8e-838b-a44fe6599f10" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_71d6f512-6a2f-4b8e-838b-a44fe6599f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_aec9b15c-a29c-498e-8acf-deeb0cbba86e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityVoluntaryFilers_aec9b15c-a29c-498e-8acf-deeb0cbba86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d84f2100-f27b-4732-a3e2-00d6e4ff22f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityCurrentReportingStatus_d84f2100-f27b-4732-a3e2-00d6e4ff22f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ab4b3186-ebb5-459f-add9-24087965cc99" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityInteractiveDataCurrent_ab4b3186-ebb5-459f-add9-24087965cc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_16e1fd33-bb1e-4896-896c-ec998bace339" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityFilerCategory_16e1fd33-bb1e-4896-896c-ec998bace339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_987d1bf2-baa6-4ff8-a6a1-6b2ad53f7e82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntitySmallBusiness_987d1bf2-baa6-4ff8-a6a1-6b2ad53f7e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_29ea046a-ef56-46a2-9ffc-36fd3f0d5417" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityEmergingGrowthCompany_29ea046a-ef56-46a2-9ffc-36fd3f0d5417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_0ad8a803-e263-47a2-b74c-d6a58c5bb1f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_IcfrAuditorAttestationFlag_0ad8a803-e263-47a2-b74c-d6a58c5bb1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_623129b9-89de-4cfe-b069-a161c8f2ec66" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityShellCompany_623129b9-89de-4cfe-b069-a161c8f2ec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_11801813-612b-4d6d-bf48-e1274e3a5692" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityPublicFloat_11801813-612b-4d6d-bf48-e1274e3a5692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ad266289-efc8-47a1-a062-d4ba0840104f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ad266289-efc8-47a1-a062-d4ba0840104f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8bc4b2ac-81b1-4e85-a1e4-4fa94146be71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8bc4b2ac-81b1-4e85-a1e4-4fa94146be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3fdde064-0e85-4a67-af66-0828db58298c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_Security12bTitle_3fdde064-0e85-4a67-af66-0828db58298c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4d3074c1-e13a-43eb-a5ba-75527dcecf25" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_TradingSymbol_4d3074c1-e13a-43eb-a5ba-75527dcecf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dacc8e65-2b54-4693-be16-a146d39c2e7b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_SecurityExchangeName_dacc8e65-2b54-4693-be16-a146d39c2e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_31c7b00c-6a50-4d61-84e3-a8b5d4cc94f8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_AmendmentFlag_31c7b00c-6a50-4d61-84e3-a8b5d4cc94f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ea76f072-97dc-4def-83c9-bac0ed0125ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentFiscalYearFocus_ea76f072-97dc-4def-83c9-bac0ed0125ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cb177216-2289-4e24-8649-16b2d2e6c5ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cb177216-2289-4e24-8649-16b2d2e6c5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_34f1310a-5556-46a5-a4fe-ecca183494dc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258082e5-eb99-4daa-81ec-1646c9f56386" xlink:to="loc_dei_EntityCentralIndexKey_34f1310a-5556-46a5-a4fe-ecca183494dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/AuditInformation" xlink:type="simple" xlink:href="irtc-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AuditInformationAbstract_6c8934d9-77c3-48e9-b215-38111731359f" xlink:href="irtc-20211231.xsd#irtc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_2592d8d0-b1cf-4d5e-a6d4-cd79f5b24061" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AuditInformationAbstract_6c8934d9-77c3-48e9-b215-38111731359f" xlink:to="loc_dei_AuditorName_2592d8d0-b1cf-4d5e-a6d4-cd79f5b24061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_ef2ce19c-8b7a-490e-b614-4d27fb1df83e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AuditInformationAbstract_6c8934d9-77c3-48e9-b215-38111731359f" xlink:to="loc_dei_AuditorLocation_ef2ce19c-8b7a-490e-b614-4d27fb1df83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d15f927f-a069-42f5-9dd0-26d78c6f40d4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AuditInformationAbstract_6c8934d9-77c3-48e9-b215-38111731359f" xlink:to="loc_dei_AuditorFirmId_d15f927f-a069-42f5-9dd0-26d78c6f40d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3e4ca793-ef13-4b15-9433-f7ec1c572892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3e4ca793-ef13-4b15-9433-f7ec1c572892" xlink:to="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a44c24a-8dea-47a9-aca3-5533156c690a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a44c24a-8dea-47a9-aca3-5533156c690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a7318ece-1b51-470f-a0c8-faf793de17fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a7318ece-1b51-470f-a0c8-faf793de17fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_27015027-c032-4d93-aa5b-f1daaee42648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_27015027-c032-4d93-aa5b-f1daaee42648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_304e9752-8f54-461d-895a-1fec1eeac1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_InventoryNet_304e9752-8f54-461d-895a-1fec1eeac1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5479d29-87d8-4f2f-a7c0-b5b7e65610f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e5479d29-87d8-4f2f-a7c0-b5b7e65610f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44af241c-7d1e-413f-bff4-92a4a3afea08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_db40b373-bfa3-4a40-91b6-4372dbdea736" xlink:to="loc_us-gaap_AssetsCurrent_44af241c-7d1e-413f-bff4-92a4a3afea08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a203fab8-9984-4720-a9de-901aefc1e881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a203fab8-9984-4720-a9de-901aefc1e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb2a6c77-bd70-465c-b117-32fca65d3e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bb2a6c77-bd70-465c-b117-32fca65d3e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_99a2e65a-14f1-4bd5-bb37-be43ca019c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_Goodwill_99a2e65a-14f1-4bd5-bb37-be43ca019c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_da201ace-31fa-4df0-b98c-e04c6792ab3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_da201ace-31fa-4df0-b98c-e04c6792ab3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9837cd6c-eb12-43ae-bebd-12494d580b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42167cec-9034-4df3-9adf-9185e88a2897" xlink:to="loc_us-gaap_Assets_9837cd6c-eb12-43ae-bebd-12494d580b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3e4ca793-ef13-4b15-9433-f7ec1c572892" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_54a29aba-34ce-4d0f-88d6-341de19b21ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_AccountsPayableCurrent_54a29aba-34ce-4d0f-88d6-341de19b21ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7c5508c1-1c39-4ee1-897e-59096f136964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7c5508c1-1c39-4ee1-897e-59096f136964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a6e61c08-2020-47dc-9b50-c87233f797f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a6e61c08-2020-47dc-9b50-c87233f797f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_11a7320e-d6e8-4000-8a51-ae7b2615ffd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_DebtCurrent_11a7320e-d6e8-4000-8a51-ae7b2615ffd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad8e5349-f2b2-4e45-9684-93c5a88716d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad8e5349-f2b2-4e45-9684-93c5a88716d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_85248e67-6c1d-40c5-9cc0-28c999266d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_253d50df-c17c-45b0-bdb0-5d937e42267f" xlink:to="loc_us-gaap_LiabilitiesCurrent_85248e67-6c1d-40c5-9cc0-28c999266d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_68a64d7b-9d90-4507-abf8-9167d21b17ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_LongTermDebt_68a64d7b-9d90-4507-abf8-9167d21b17ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ef8b2340-ca7b-4d30-839e-2eb25f763df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ef8b2340-ca7b-4d30-839e-2eb25f763df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a491bc67-cd05-4536-b9ad-b1f84a365ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a491bc67-cd05-4536-b9ad-b1f84a365ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2a8866a-330e-4f28-a20c-231864b2bab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_Liabilities_d2a8866a-330e-4f28-a20c-231864b2bab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_13f443a5-d290-473c-a714-27dec0e25a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_13f443a5-d290-473c-a714-27dec0e25a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c2851c98-4eca-47a3-af90-5cf457549a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_PreferredStockValue_c2851c98-4eca-47a3-af90-5cf457549a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_570fdf26-d7d2-4dfc-a02b-aae31c979e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_CommonStockValue_570fdf26-d7d2-4dfc-a02b-aae31c979e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_09d041ea-9b9d-4f2b-9ade-c012aaebeb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_09d041ea-9b9d-4f2b-9ade-c012aaebeb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c546966-bf76-48e3-8fdb-f963f5448ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4c546966-bf76-48e3-8fdb-f963f5448ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2378babf-04c1-4c8f-9d03-f2c334396222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2378babf-04c1-4c8f-9d03-f2c334396222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1909dc2a-c45b-40d0-a389-ad61595ac664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c5baf46d-4310-4ad8-8219-9169b468135e" xlink:to="loc_us-gaap_StockholdersEquity_1909dc2a-c45b-40d0-a389-ad61595ac664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_53203277-5fd3-4b3c-ad3b-d64d5f8742c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6daaaa96-7f8f-4edc-8bb6-35060659b21e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_53203277-5fd3-4b3c-ad3b-d64d5f8742c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be2ebc7f-dfa2-4915-91e7-a7ac89a79823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_be2ebc7f-dfa2-4915-91e7-a7ac89a79823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f626d6f8-c814-465a-b184-58edfe6b4f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f626d6f8-c814-465a-b184-58edfe6b4f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c7721751-5b2f-4194-a232-762023041f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c7721751-5b2f-4194-a232-762023041f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6a0c6bb5-909e-46af-8c28-0c1cd43ec28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6a0c6bb5-909e-46af-8c28-0c1cd43ec28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_07ee8be0-5834-4025-8d3c-331edeea6943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_07ee8be0-5834-4025-8d3c-331edeea6943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fde15f9e-0a21-4b42-9f31-87de10bbdc55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fde15f9e-0a21-4b42-9f31-87de10bbdc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_18ae1b6d-536c-4c00-a328-7dd6a9d3cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_CommonStockSharesIssued_18ae1b6d-536c-4c00-a328-7dd6a9d3cf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_663261ba-110a-4551-a67a-2e9499d87bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9ddf5f1e-bd7d-4e0c-831b-9c34b34972c9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_663261ba-110a-4551-a67a-2e9499d87bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fee17636-f69b-41c3-ab2a-be8f219ead8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fee17636-f69b-41c3-ab2a-be8f219ead8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ba7c4847-6d2b-4e5d-affc-486845dd82ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_CostOfRevenue_ba7c4847-6d2b-4e5d-affc-486845dd82ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7b15b3f9-9971-4d0c-8a7a-638fb3de29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_GrossProfit_7b15b3f9-9971-4d0c-8a7a-638fb3de29b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a19869ff-6f94-455f-90a1-6f909d202f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a19869ff-6f94-455f-90a1-6f909d202f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d73fee63-b869-493d-9088-af8c4092f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a19869ff-6f94-455f-90a1-6f909d202f2b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d73fee63-b869-493d-9088-af8c4092f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c89e5915-ccd6-4df5-964b-126a40f6ef5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a19869ff-6f94-455f-90a1-6f909d202f2b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c89e5915-ccd6-4df5-964b-126a40f6ef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_839653d4-b66a-4771-bc6f-51424639387b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a19869ff-6f94-455f-90a1-6f909d202f2b" xlink:to="loc_us-gaap_OperatingExpenses_839653d4-b66a-4771-bc6f-51424639387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_61e62583-ec87-4569-a40e-28c5c487bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_OperatingIncomeLoss_61e62583-ec87-4569-a40e-28c5c487bc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_900a5e3c-1e2b-44ea-b47f-111639489dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_InterestExpense_900a5e3c-1e2b-44ea-b47f-111639489dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_08768866-a6ce-4b9a-b23d-18be4a9320bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_08768866-a6ce-4b9a-b23d-18be4a9320bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f71b9b96-da2e-481b-b68a-2e844ae32115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f71b9b96-da2e-481b-b68a-2e844ae32115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a0b361bf-c4a7-4fa1-8dbf-a0e8c443baac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a0b361bf-c4a7-4fa1-8dbf-a0e8c443baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74926b4c-9828-4557-ba3c-b194e51104b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_NetIncomeLoss_74926b4c-9828-4557-ba3c-b194e51104b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1e27620f-abaf-4d40-aa5e-df8d851e9a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_EarningsPerShareBasic_1e27620f-abaf-4d40-aa5e-df8d851e9a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_788df2d0-9021-4783-8303-e9295e036040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_EarningsPerShareDiluted_788df2d0-9021-4783-8303-e9295e036040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_871905d8-7e65-40a4-beeb-5de6e56bb7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_871905d8-7e65-40a4-beeb-5de6e56bb7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6837f95-718d-4812-9d0a-6b077c142f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb6b6bae-cf89-458e-bbb4-022360401857" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6837f95-718d-4812-9d0a-6b077c142f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9fec67-a6b8-4f04-9763-d96d0000f6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ab54ff1a-975d-4455-bd2c-fd07eb13ab7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9fec67-a6b8-4f04-9763-d96d0000f6fd" xlink:to="loc_us-gaap_NetIncomeLoss_ab54ff1a-975d-4455-bd2c-fd07eb13ab7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f411eb89-40e4-48a9-b9fe-8bc2e5136d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9fec67-a6b8-4f04-9763-d96d0000f6fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f411eb89-40e4-48a9-b9fe-8bc2e5136d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_998369e1-924b-4be1-b0d9-3b68797f2117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f411eb89-40e4-48a9-b9fe-8bc2e5136d8b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_998369e1-924b-4be1-b0d9-3b68797f2117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e57b7453-0ef2-4934-9a7d-51f14a2029ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1b9fec67-a6b8-4f04-9763-d96d0000f6fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e57b7453-0ef2-4934-9a7d-51f14a2029ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_1b0b3d41-9146-45ed-91ed-4a62c6e66d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_1b0b3d41-9146-45ed-91ed-4a62c6e66d18" xlink:to="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c1bbd511-c9a1-4966-9b64-beb99838d39d" xlink:to="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_836eeafa-0040-44ea-8efe-56146f7cf73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_CommonStockMember_836eeafa-0040-44ea-8efe-56146f7cf73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8b8246a-99fc-4c79-88c0-175090d3e5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8b8246a-99fc-4c79-88c0-175090d3e5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c29b5389-6a29-471b-a7b4-f1422df7e0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_RetainedEarningsMember_c29b5389-6a29-471b-a7b4-f1422df7e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_112582e4-bc77-473e-af5e-e488929b30d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e57469b5-6a76-405a-937b-e387c65ab036" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_112582e4-bc77-473e-af5e-e488929b30d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3121d975-b856-4870-9fbd-adfe458f5d61" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f5e1516-35c0-4f9d-85a0-2912788d1b0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_03e359c9-04b5-498c-9c41-91ee234444e4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f5e1516-35c0-4f9d-85a0-2912788d1b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c15cb1ce-a6f9-460b-8eaa-7fb109c00369" xlink:to="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_17f2d459-e117-457b-9cc3-3803bfa6ec9e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_15bb012f-96a8-41e7-a9ec-f07de6b2d934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_SharesOutstanding_15bb012f-96a8-41e7-a9ec-f07de6b2d934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d371106d-002d-4bc4-96d5-973bdc34df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockholdersEquity_d371106d-002d-4bc4-96d5-973bdc34df6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc1af341-f0ab-4ae5-8a3c-e26d009415c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cc1af341-f0ab-4ae5-8a3c-e26d009415c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c55ab94a-e64b-4d8b-b3eb-95fe960cdba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c55ab94a-e64b-4d8b-b3eb-95fe960cdba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_c21c42a4-a5db-4e2b-a5c4-c34e722e9296" xlink:href="irtc-20211231.xsd#irtc_CommonStockSharesIssuedFromExerciseOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_irtc_CommonStockSharesIssuedFromExerciseOfWarrants_c21c42a4-a5db-4e2b-a5c4-c34e722e9296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07b7bb9b-100a-4e38-aa7e-9257d9d48de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07b7bb9b-100a-4e38-aa7e-9257d9d48de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d593b9-2548-4529-b79b-714c1fae497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f4d593b9-2548-4529-b79b-714c1fae497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a6317834-f1f2-45f0-afce-46bcf9cc024a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_a6317834-f1f2-45f0-afce-46bcf9cc024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c4029f5d-dc62-4a27-829b-163dca5208f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c4029f5d-dc62-4a27-829b-163dca5208f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec2a5bcd-f663-484e-909f-bcb71bd09c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_NetIncomeLoss_ec2a5bcd-f663-484e-909f-bcb71bd09c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_874f5d01-3bda-4f35-a916-acadeb476cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_874f5d01-3bda-4f35-a916-acadeb476cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d93fa28d-3829-48f0-9587-54a6155091b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_SharesOutstanding_d93fa28d-3829-48f0-9587-54a6155091b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_017e8d8d-fe2b-44ac-b867-c0fdf5023c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_StockholdersEquity_017e8d8d-fe2b-44ac-b867-c0fdf5023c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_34b03ba6-8b5f-4b51-b505-23d6f5c15d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e7472db4-a3e5-4423-891c-13122c64c22a" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_34b03ba6-8b5f-4b51-b505-23d6f5c15d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="irtc-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_07e2ee8b-7614-4e7b-83dd-9d0c8720b088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:to="loc_us-gaap_ProfitLoss_07e2ee8b-7614-4e7b-83dd-9d0c8720b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ce8a2e34-c9a7-436e-a9e1-53ccb0913b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_us-gaap_DepreciationAndAmortization_ce8a2e34-c9a7-436e-a9e1-53ccb0913b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7786016f-e996-4ad4-a0c3-7506080a1b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_us-gaap_ShareBasedCompensation_7786016f-e996-4ad4-a0c3-7506080a1b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_837fc3f4-7c8f-4a99-a294-af5d1a1f94b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_837fc3f4-7c8f-4a99-a294-af5d1a1f94b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d048cf0-7246-426a-bebb-a7b2dc650939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3d048cf0-7246-426a-bebb-a7b2dc650939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProvisionForBadDebtAndContractualAllowance_d9200d6c-13f2-43ff-bd44-f51ec8e03a28" xlink:href="irtc-20211231.xsd#irtc_ProvisionForBadDebtAndContractualAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_irtc_ProvisionForBadDebtAndContractualAllowance_d9200d6c-13f2-43ff-bd44-f51ec8e03a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization_7b077edc-eed6-444e-980b-a6bd3195c92b" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRightOfUseAssetsAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf05655b-f69c-44f1-99dc-6bbafe38bcf3" xlink:to="loc_irtc_OperatingLeaseRightOfUseAssetsAmortization_7b077edc-eed6-444e-980b-a6bd3195c92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccefe950-1220-412d-9ee6-dfc426ac265c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ccefe950-1220-412d-9ee6-dfc426ac265c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9688b02a-bf58-4d37-afa3-61964f455078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9688b02a-bf58-4d37-afa3-61964f455078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c525a44-a587-4f92-92b7-402709810e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2c525a44-a587-4f92-92b7-402709810e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_25f72ef2-096a-44ce-8211-5d19b2f69a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_25f72ef2-096a-44ce-8211-5d19b2f69a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_984b65c7-3aab-4072-839a-76bb045652a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_984b65c7-3aab-4072-839a-76bb045652a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d45c37f8-a243-4e5d-b379-62db42f379ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d45c37f8-a243-4e5d-b379-62db42f379ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf0cf295-3274-4dab-9b5a-67754e458302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cf0cf295-3274-4dab-9b5a-67754e458302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_7d8c4f5c-0d96-4dfd-95a9-05c186f3cc62" xlink:href="irtc-20211231.xsd#irtc_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7ac35c1f-41b2-46cd-ae58-2b5c425dd48e" xlink:to="loc_irtc_IncreaseDecreaseInOperatingLeaseLiabilities_7d8c4f5c-0d96-4dfd-95a9-05c186f3cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c38af9d-3ab1-4530-ba7d-90ac4e284590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e294840e-608c-47e9-be1e-c382c7d66207" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c38af9d-3ab1-4530-ba7d-90ac4e284590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ee43ed7-d3f3-411d-b46d-f4d95d5f6255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ee43ed7-d3f3-411d-b46d-f4d95d5f6255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_49d520f7-5137-46d8-94cf-008803e205c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_49d520f7-5137-46d8-94cf-008803e205c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_784acc09-8b61-48ec-be5f-63eed5c40476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_784acc09-8b61-48ec-be5f-63eed5c40476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c44a2fa-f4e5-4b7a-a335-0d596aa6bd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0c44a2fa-f4e5-4b7a-a335-0d596aa6bd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_478d8286-a3dd-4138-9b26-44e601ad8f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6de30419-37fa-4773-887c-52b2d0eb5320" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_478d8286-a3dd-4138-9b26-44e601ad8f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_733ac711-840a-415f-be2f-9b52456948b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_733ac711-840a-415f-be2f-9b52456948b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_afa66eac-37a5-4081-85f4-8fc6d0d0f8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_afa66eac-37a5-4081-85f4-8fc6d0d0f8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88eb13e1-75c4-4833-8893-628a2b248d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88eb13e1-75c4-4833-8893-628a2b248d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_74657c31-382d-4871-9051-caa3d32d2958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_74657c31-382d-4871-9051-caa3d32d2958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cc88e93-c61a-4b53-8bf2-db5697458a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a401602a-5aae-40bd-ad50-d06a6935a5a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cc88e93-c61a-4b53-8bf2-db5697458a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_554b33b7-565e-4e69-babc-1e12e2630b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_554b33b7-565e-4e69-babc-1e12e2630b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bca90b17-b5e3-4d12-8121-2781466d688f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bca90b17-b5e3-4d12-8121-2781466d688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d179b3a2-b215-4354-8878-19609dd4992c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d179b3a2-b215-4354-8878-19609dd4992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f4dba6a1-1312-4dc8-90b2-498f4ae19a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f4dba6a1-1312-4dc8-90b2-498f4ae19a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_3bcbe069-7555-4cf2-ac52-b353677d90fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f4dba6a1-1312-4dc8-90b2-498f4ae19a91" xlink:to="loc_us-gaap_InterestPaidNet_3bcbe069-7555-4cf2-ac52-b353677d90fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cfd5365a-a997-43cc-8d41-d50034d6f65e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_291b5bc4-dc8f-4247-9d29-291673a03c16" xlink:href="irtc-20211231.xsd#irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:to="loc_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities_291b5bc4-dc8f-4247-9d29-291673a03c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuanceCostsIncurredButNotYetPaid_52c79353-3ab5-4aef-a961-57f8696c0fd8" xlink:href="irtc-20211231.xsd#irtc_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:to="loc_irtc_StockIssuanceCostsIncurredButNotYetPaid_52c79353-3ab5-4aef-a961-57f8696c0fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e3c580d4-bfaa-41a5-9f12-2622a04e821c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e3c580d4-bfaa-41a5-9f12-2622a04e821c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e34fab88-bd10-4f62-99ad-a4e7d5cc79d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_59b1a3c5-4bfe-4640-a381-ae14bc13d4c1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e34fab88-bd10-4f62-99ad-a4e7d5cc79d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="irtc-20211231.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2586ad83-9c46-4b2a-96d6-2d2150a1ae86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_cf46730a-e973-485b-bff2-d9f16e78b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2586ad83-9c46-4b2a-96d6-2d2150a1ae86" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_cf46730a-e973-485b-bff2-d9f16e78b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_824189b6-d631-49d5-87f4-2632bea42129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a90c06e2-71da-4724-af8e-c9cc9d5eb9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_824189b6-d631-49d5-87f4-2632bea42129" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a90c06e2-71da-4724-af8e-c9cc9d5eb9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1af203cd-93f2-4fdb-8237-00ae65cb1f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_824189b6-d631-49d5-87f4-2632bea42129" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1af203cd-93f2-4fdb-8237-00ae65cb1f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock_1626f518-5338-4d42-8f19-8e5ba5d32aeb" xlink:href="irtc-20211231.xsd#irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_824189b6-d631-49d5-87f4-2632bea42129" xlink:to="loc_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock_1626f518-5338-4d42-8f19-8e5ba5d32aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87451697-44c6-4305-8f80-9c32cd224cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_824189b6-d631-49d5-87f4-2632bea42129" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_87451697-44c6-4305-8f80-9c32cd224cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ebef8c6-0e37-4acd-a53f-62859d0560cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b08fda8e-5105-42df-99d0-740b0273af29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ebef8c6-0e37-4acd-a53f-62859d0560cb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_b08fda8e-5105-42df-99d0-740b0273af29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_abe243f3-e7d8-446e-8d7b-3c9efdca2e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_abe243f3-e7d8-446e-8d7b-3c9efdca2e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock_3f91c4ef-318f-4e59-85a9-85ad1bbdaf17" xlink:href="irtc-20211231.xsd#irtc_RiskAndUncertaintiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock_3f91c4ef-318f-4e59-85a9-85ad1bbdaf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_73b7b2be-6ccd-48a6-9fa6-af6904cbb26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_UseOfEstimates_73b7b2be-6ccd-48a6-9fa6-af6904cbb26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7b279a92-b65b-4676-a1ee-98dda73d2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7b279a92-b65b-4676-a1ee-98dda73d2ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c730974-0dcb-47a9-aa92-4bb7dfaee574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c730974-0dcb-47a9-aa92-4bb7dfaee574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_65290eb8-0703-4d9b-b21d-f7867cfad000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_65290eb8-0703-4d9b-b21d-f7867cfad000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_0a368f64-174b-4c99-8a2f-5b52557dd72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_0a368f64-174b-4c99-8a2f-5b52557dd72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_246c5733-8e84-4e2f-97fb-c008ff811b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_246c5733-8e84-4e2f-97fb-c008ff811b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_InflationaryRiskPolicyTextBlock_a81ed136-39b7-4994-8f44-e551628bab91" xlink:href="irtc-20211231.xsd#irtc_InflationaryRiskPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_InflationaryRiskPolicyTextBlock_a81ed136-39b7-4994-8f44-e551628bab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock_adf86e99-820b-47cc-a471-b2450e937ebf" xlink:href="irtc-20211231.xsd#irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock_adf86e99-820b-47cc-a471-b2450e937ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_c0271c40-ae60-4400-ae4e-ac77eed49b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_c0271c40-ae60-4400-ae4e-ac77eed49b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1a5bb173-41e4-4908-86e3-5b844a149b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1a5bb173-41e4-4908-86e3-5b844a149b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_9366a8c3-ab4f-4106-9b51-11abc7258fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_9366a8c3-ab4f-4106-9b51-11abc7258fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0cd8f8d6-1178-49b0-b050-fc7c4354e616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0cd8f8d6-1178-49b0-b050-fc7c4354e616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e691a9ba-24e8-4f9c-805e-99ca7514426f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_e691a9ba-24e8-4f9c-805e-99ca7514426f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherAssetsPolicyPolicyPolicyTextBlock_428b6298-0f4c-4874-9743-38a3289fa489" xlink:href="irtc-20211231.xsd#irtc_OtherAssetsPolicyPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_OtherAssetsPolicyPolicyPolicyTextBlock_428b6298-0f4c-4874-9743-38a3289fa489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_571b12a7-d920-41b5-8ea2-51e01e1e08bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_571b12a7-d920-41b5-8ea2-51e01e1e08bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_50ff999d-5ec9-4d3a-a38e-7a6ff17b3867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_50ff999d-5ec9-4d3a-a38e-7a6ff17b3867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ContractLiabilityPolicyPolicyTextBlock_afbd4a10-e40d-491c-9a16-1daf9a0f98fe" xlink:href="irtc-20211231.xsd#irtc_ContractLiabilityPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_ContractLiabilityPolicyPolicyTextBlock_afbd4a10-e40d-491c-9a16-1daf9a0f98fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ContractCostPolicyPolicyTextBlock_9d58300d-f58f-4059-8b6a-297bed1719bb" xlink:href="irtc-20211231.xsd#irtc_ContractCostPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_irtc_ContractCostPolicyPolicyTextBlock_9d58300d-f58f-4059-8b6a-297bed1719bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_e1900ca7-e30c-4ace-b4e5-41bd4875418c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_e1900ca7-e30c-4ace-b4e5-41bd4875418c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_dedf89fb-3d02-403b-a622-72c6cef029a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_dedf89fb-3d02-403b-a622-72c6cef029a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1b780b66-98ab-43a7-991f-9f00571894b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1b780b66-98ab-43a7-991f-9f00571894b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1c55a7d4-29b7-46ca-92e6-1862eb979f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1c55a7d4-29b7-46ca-92e6-1862eb979f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_32c1cd1d-3659-42d0-8f9e-76e0d81f3229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_32c1cd1d-3659-42d0-8f9e-76e0d81f3229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5a28af70-22cc-4455-abcb-e13e82e21eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f0e726f3-76b6-45b3-b718-aac5b4b104e5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5a28af70-22cc-4455-abcb-e13e82e21eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8be06367-eba3-4bfc-8ef2-21bf6665a647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_99bd96cc-7743-43ea-ab60-42de5de22f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be06367-eba3-4bfc-8ef2-21bf6665a647" xlink:to="loc_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_99bd96cc-7743-43ea-ab60-42de5de22f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock_583ed42a-21c4-47e7-af5c-4beb73d4ff4c" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be06367-eba3-4bfc-8ef2-21bf6665a647" xlink:to="loc_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock_583ed42a-21c4-47e7-af5c-4beb73d4ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ddc87ed8-359a-4ad3-bbe6-17e3846b7890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8be06367-eba3-4bfc-8ef2-21bf6665a647" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ddc87ed8-359a-4ad3-bbe6-17e3846b7890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bbee8466-9802-4646-bb21-d507af32cb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bbee8466-9802-4646-bb21-d507af32cb36" xlink:to="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aead3878-d35b-47a1-8ff9-b4bde9173ff8" xlink:to="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_61385cd2-1cc1-449c-91fc-76e5e2e86fee" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93243Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_61385cd2-1cc1-449c-91fc-76e5e2e86fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_5a4cda10-f1b7-42ae-ae2c-98bae038dada" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93247Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_42429829-9d8c-4d65-8ca2-fc28cb659ab2" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_5a4cda10-f1b7-42ae-ae2c-98bae038dada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ccc8e4ac-021f-4534-a504-6883fb635746" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c01352fd-edd4-4259-bb57-fe5539195c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ab7695e3-31c0-49a5-a25b-7f99231332ac" xlink:to="loc_us-gaap_SubsequentEventMember_c01352fd-edd4-4259-bb57-fe5539195c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_60ce7360-7f28-426b-8a1c-c9659727c44a" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FederalGovernmentAgenciesMember_4b46e670-e29b-4125-8c4b-11663c18c61d" xlink:href="irtc-20211231.xsd#irtc_FederalGovernmentAgenciesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a4e6adc1-6129-4aa0-9170-b2abc0b1b03b" xlink:to="loc_irtc_FederalGovernmentAgenciesMember_4b46e670-e29b-4125-8c4b-11663c18c61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b1ca7c02-126d-4449-8fb2-3f2db3de6c7e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_9e3186ae-b081-4652-b1a0-60054c2fd69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:to="loc_us-gaap_SalesRevenueNetMember_9e3186ae-b081-4652-b1a0-60054c2fd69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_e021ea43-ba85-4017-a20a-9d8aa0d449f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c670c574-5c71-4fc9-afad-04177721f192" xlink:to="loc_us-gaap_AccountsReceivableMember_e021ea43-ba85-4017-a20a-9d8aa0d449f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4f678ee6-2020-418e-856f-7c63b6518ffe" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a88ccbd4-4832-4da3-973e-0f1a81fd5756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a88ccbd4-4832-4da3-973e-0f1a81fd5756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_349c982b-5001-45da-82b5-b9c96cc2f797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a82a9c1d-bab2-4bce-b394-6ae08175fdf4" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_349c982b-5001-45da-82b5-b9c96cc2f797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4e3c6d39-ed56-4d9d-95f1-b31704ae9f27" xlink:to="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f09523e4-b205-4e4e-950f-7de5283b20be" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:to="loc_srt_MinimumMember_f09523e4-b205-4e4e-950f-7de5283b20be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26872101-05f1-4cf5-8e6a-71e3bf09319e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79b2cdb8-51cd-41fb-8730-18b2e062d6f9" xlink:to="loc_srt_MaximumMember_26872101-05f1-4cf5-8e6a-71e3bf09319e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9a5e771c-16df-4925-be7a-38dc0c68d6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_05c6830c-c9e8-4001-aa42-c361e2d9410d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3a392447-3180-46df-92c1-5de148dddec2" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_05c6830c-c9e8-4001-aa42-c361e2d9410d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_238bd87a-8a5c-4b09-90ed-3d9109db1f48" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PrintedCircuitBoardAssembliesMember_421ee4fe-8b05-4ab0-b062-88bbee5c6826" xlink:href="irtc-20211231.xsd#irtc_PrintedCircuitBoardAssembliesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_5e16eebd-2970-4d51-af87-3a211d8bb8c3" xlink:to="loc_irtc_PrintedCircuitBoardAssembliesMember_421ee4fe-8b05-4ab0-b062-88bbee5c6826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_ce7eae6d-4ec4-440b-a684-8434c0b6b4fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3e648a0c-f35d-4b69-baf8-dfd94cae17ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b4c11fc7-2e0d-4d01-918c-e40305e89761" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_3e648a0c-f35d-4b69-baf8-dfd94cae17ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b690aed6-9fc4-43b3-90a8-84981b397dc5" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_be3d8d15-90b9-414e-b1f0-4d64b7288579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a871e863-18b5-41f6-9665-eba554fdd176" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_be3d8d15-90b9-414e-b1f0-4d64b7288579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:href="irtc-20211231.xsd#irtc_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesTable_8fc06b92-dbed-488c-8fb6-b9476eece928" xlink:to="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CostReimbursementRate_7a3855d2-f420-41ef-813c-a0813fada87c" xlink:href="irtc-20211231.xsd#irtc_CostReimbursementRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_irtc_CostReimbursementRate_7a3855d2-f420-41ef-813c-a0813fada87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_bdbf122d-f694-4e23-a1f8-da8ccfc4670a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_bdbf122d-f694-4e23-a1f8-da8ccfc4670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb1e175a-fbde-43c5-aba2-1180643708e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb1e175a-fbde-43c5-aba2-1180643708e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f787f8ad-47ff-4ef2-a618-e2e7ecd617f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f787f8ad-47ff-4ef2-a618-e2e7ecd617f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_72a610b2-0ea6-4a11-bd8d-fd83191f9311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_AssetImpairmentCharges_72a610b2-0ea6-4a11-bd8d-fd83191f9311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f3a73e73-fce9-4c7d-aae0-78382fbb06c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_OtherAssets_f3a73e73-fce9-4c7d-aae0-78382fbb06c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4a86f32c-4d91-4379-89dd-7241b73dd141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4a86f32c-4d91-4379-89dd-7241b73dd141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_bc89ebf1-a82f-4716-b76e-1b2251d68fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SummaryOfSignificantAccountingPoliciesLineItems_abab087f-d65d-4f00-9214-844e68dc557c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_bc89ebf1-a82f-4716-b76e-1b2251d68fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2831847f-f520-46ba-ad35-3702764aed6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7ad72870-5366-42e5-986c-0f50d20ab710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2831847f-f520-46ba-ad35-3702764aed6e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7ad72870-5366-42e5-986c-0f50d20ab710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7ad72870-5366-42e5-986c-0f50d20ab710" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_109e375f-4dae-49ab-825e-96692102d37e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ad707dea-72c3-4954-aa4e-fcc740fd42f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3d4432e9-b2cc-4c20-ae83-d1899c5f3e35" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_ad707dea-72c3-4954-aa4e-fcc740fd42f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b53e549e-def8-470a-8dbd-c2545c0ef1cf" xlink:to="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_1baa6550-260c-43e7-962b-623da3ca16a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_810861cf-c653-4c4b-abea-3dc06388dc04" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_1baa6550-260c-43e7-962b-623da3ca16a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a2690d9b-4fb6-4a64-bf0b-75dcfc17bc39" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_df8db82b-9e01-4a04-b24c-ac228dc5a36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_df8db82b-9e01-4a04-b24c-ac228dc5a36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e6221ead-3ab9-46ea-b167-29ecf775dc65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e6221ead-3ab9-46ea-b167-29ecf775dc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_901e58bb-5647-48a2-a45e-301c0ae39bb1" xlink:href="irtc-20211231.xsd#irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments_901e58bb-5647-48a2-a45e-301c0ae39bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_35dad915-18bf-4864-8837-e55de7852da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1969c677-7912-4404-92c0-ad03bb721088" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_35dad915-18bf-4864-8837-e55de7852da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_acd7dd99-42b8-4381-a07e-93def0c82e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_acd7dd99-42b8-4381-a07e-93def0c82e8e" xlink:to="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableForContractualAllowance_b60f04fa-082c-469c-a039-254fc06bbc0c" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableForContractualAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:to="loc_irtc_AccountsReceivableForContractualAllowance_b60f04fa-082c-469c-a039-254fc06bbc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableAllowanceForContractualAdjustments_bc6cee1f-18ca-403d-91b3-4ca75388b377" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableAllowanceForContractualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:to="loc_irtc_AccountsReceivableAllowanceForContractualAdjustments_bc6cee1f-18ca-403d-91b3-4ca75388b377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableContractualAdjustments_6fabb82d-5e63-44d3-8174-c204b8721884" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableContractualAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:to="loc_irtc_AccountsReceivableContractualAdjustments_6fabb82d-5e63-44d3-8174-c204b8721884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccountsReceivableForContractualAllowance_f135b5c3-526e-4f79-8d28-b68347a57d7e" xlink:href="irtc-20211231.xsd#irtc_AccountsReceivableForContractualAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_d30f8f5a-ca08-4d0d-88e2-bd113d43b520" xlink:to="loc_irtc_AccountsReceivableForContractualAllowance_f135b5c3-526e-4f79-8d28-b68347a57d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b71e0d38-89c4-4570-930a-1db2e69810da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b71e0d38-89c4-4570-930a-1db2e69810da" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:to="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d593a23-1935-41ea-934e-4c63f19e0b64" xlink:to="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CommercialPayorsMember_c8f98e5f-adef-41a7-95c7-1a1fba329b67" xlink:href="irtc-20211231.xsd#irtc_CommercialPayorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_CommercialPayorsMember_c8f98e5f-adef-41a7-95c7-1a1fba329b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_NonContractedThirdPartyPayorsMember_f9f3458b-572b-4d34-ad1b-5e7b563e9466" xlink:href="irtc-20211231.xsd#irtc_NonContractedThirdPartyPayorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_NonContractedThirdPartyPayorsMember_f9f3458b-572b-4d34-ad1b-5e7b563e9466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CentersForMedicareAndMedicaidMember_b53c24e3-c3ab-4761-b30c-bfcfbad0bcdc" xlink:href="irtc-20211231.xsd#irtc_CentersForMedicareAndMedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_CentersForMedicareAndMedicaidMember_b53c24e3-c3ab-4761-b30c-bfcfbad0bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_HealthcareInstitutionsMember_cc1df400-b936-41dc-a633-2905025b565d" xlink:href="irtc-20211231.xsd#irtc_HealthcareInstitutionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_17f55476-c301-4f2d-9e8f-0f15bc3a762e" xlink:to="loc_irtc_HealthcareInstitutionsMember_cc1df400-b936-41dc-a633-2905025b565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ad8aa26-98ca-4400-b3f7-3542de507ddc" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94f1d90f-adda-4ce5-8a69-205a17ec2a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0c76eca7-1396-4a19-ab79-32fc473cb4a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94f1d90f-adda-4ce5-8a69-205a17ec2a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestments" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_4dbce292-e476-49ed-a9eb-fe2ebd448a64" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock_dcf04710-b78e-41e5-a975-055c2a701b79" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_4dbce292-e476-49ed-a9eb-fe2ebd448a64" xlink:to="loc_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock_dcf04710-b78e-41e5-a975-055c2a701b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f2ee6c24-ce11-4a50-8998-ff69668c0249" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_13d2f0cf-8782-48c8-9aeb-e74fa3555310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f2ee6c24-ce11-4a50-8998-ff69668c0249" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_13d2f0cf-8782-48c8-9aeb-e74fa3555310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6cc04ab5-7210-466a-8e25-b11cfa646a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f2ee6c24-ce11-4a50-8998-ff69668c0249" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_6cc04ab5-7210-466a-8e25-b11cfa646a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_09ef35e4-8f79-419b-a392-3550bec44578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f2ee6c24-ce11-4a50-8998-ff69668c0249" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_09ef35e4-8f79-419b-a392-3550bec44578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f65004c8-e063-4fb8-a5d6-4c55ffc97257" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_f65004c8-e063-4fb8-a5d6-4c55ffc97257" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_9a4f5dfa-460c-4774-a944-4faf21086232" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2adb0b9e-18a8-4368-8879-780e0684a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8757ed3b-b86b-45b5-9437-ca375c6c63a8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2adb0b9e-18a8-4368-8879-780e0684a74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:to="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_32e06b22-386f-4e5c-840d-c042d7c49b8e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa272c42-79be-4b4a-91db-e02d54cfa577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa272c42-79be-4b4a-91db-e02d54cfa577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_091e247a-93b3-49d9-ab77-809c9b3c8f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_091e247a-93b3-49d9-ab77-809c9b3c8f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_79b60515-c9a6-4fb1-83ad-18461d88f9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6fc795b6-ef52-4111-bf1b-2267053a024b" xlink:to="loc_us-gaap_CommercialPaperMember_79b60515-c9a6-4fb1-83ad-18461d88f9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_ad79925b-5951-4982-b627-1899f70e47df" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbc7b78a-5608-43ae-b133-5367f0e1f0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_dbc7b78a-5608-43ae-b133-5367f0e1f0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25c54aef-4d4d-40c2-8829-2008320c381f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_25c54aef-4d4d-40c2-8829-2008320c381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e44ecaa-f68c-4d77-98f8-644680da68aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e44ecaa-f68c-4d77-98f8-644680da68aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afec3026-9e4e-4b6a-8e0c-b1267b4369f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_afec3026-9e4e-4b6a-8e0c-b1267b4369f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_13e3b9e9-85e4-40cd-bc34-0d8aded14a51" xlink:to="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b0cc599a-dc5d-480c-a5cd-8f51664d2b77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b0cc599a-dc5d-480c-a5cd-8f51664d2b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9b580ba7-f173-4868-83e7-e8901d6ac6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9b580ba7-f173-4868-83e7-e8901d6ac6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_bb989cab-93f4-4d64-8bcc-b0a0d711ec3d" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract_2b99ad5f-8363-4c53-a54e-766b9f8cf96b" xlink:to="loc_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments_bb989cab-93f4-4d64-8bcc-b0a0d711ec3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_22753d15-c656-4538-847a-638b53f51a1f" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9de76f4c-7802-4534-815e-ac530a137d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_22753d15-c656-4538-847a-638b53f51a1f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9de76f4c-7802-4534-815e-ac530a137d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c06bc4d1-ea85-4914-9508-623282746a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_22753d15-c656-4538-847a-638b53f51a1f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c06bc4d1-ea85-4914-9508-623282746a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39a907e1-22be-4ad7-96ab-3457a69b6b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_22753d15-c656-4538-847a-638b53f51a1f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39a907e1-22be-4ad7-96ab-3457a69b6b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_0355b8ad-ad32-4a29-a7b1-3a416b552aa9" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_0355b8ad-ad32-4a29-a7b1-3a416b552aa9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:to="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_db8747cd-c38b-4724-b8a2-867242a20016" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_93f27331-5d44-4b87-a52e-77b6409b0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_93f27331-5d44-4b87-a52e-77b6409b0f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_b99f3f87-8e70-41e1-b5eb-5a9fbab1fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_35c489da-88a5-465d-a4e9-21a1e5dfd247" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_b99f3f87-8e70-41e1-b5eb-5a9fbab1fe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3e6353ed-2f60-4a13-a757-0c5b63001550" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d137c317-9c0e-4c23-9cd7-3d5906dba57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_d137c317-9c0e-4c23-9cd7-3d5906dba57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5c15d3c9-18b3-42ac-bae5-f377eeb78ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_5c15d3c9-18b3-42ac-bae5-f377eeb78ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a2d5ad36-c789-4092-ae71-8e77bc87e7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_a2d5ad36-c789-4092-ae71-8e77bc87e7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19e822be-b7b0-4527-9cbf-71657678fa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19e822be-b7b0-4527-9cbf-71657678fa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7a7cf0e7-47e4-430e-a895-ca47996c49a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7a7cf0e7-47e4-430e-a895-ca47996c49a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_67abb34a-3908-497f-99e8-9eccde821655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_87d664a8-15cf-43c9-942e-a538f26eca51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_67abb34a-3908-497f-99e8-9eccde821655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CashEquivalentsandInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CashEquivalentsAndInvestmentsAbstract_b31000b0-d30f-4460-a9dd-8fcb65937231" xlink:href="irtc-20211231.xsd#irtc_CashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod_695e2bf9-dbd5-4277-89f0-eaec2fe63c77" xlink:href="irtc-20211231.xsd#irtc_AvailableForSaleDebtSecuritiesMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_b31000b0-d30f-4460-a9dd-8fcb65937231" xlink:to="loc_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod_695e2bf9-dbd5-4277-89f0-eaec2fe63c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6e69c7cc-62a3-4f4b-9190-ac48cbfd491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_b31000b0-d30f-4460-a9dd-8fcb65937231" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6e69c7cc-62a3-4f4b-9190-ac48cbfd491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_8dd55a1d-bffb-4141-b107-f8e007b84990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_CashEquivalentsAndInvestmentsAbstract_b31000b0-d30f-4460-a9dd-8fcb65937231" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_8dd55a1d-bffb-4141-b107-f8e007b84990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1bf1a8fc-cd39-41a0-b115-8bf6214d705f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_d7ca3f67-45bf-4a80-87b7-319e093244f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1bf1a8fc-cd39-41a0-b115-8bf6214d705f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_d7ca3f67-45bf-4a80-87b7-319e093244f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_27c023d8-683e-49bb-bea6-5560ad4a2fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fca8b3aa-1677-4562-acaf-12b186f38ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_27c023d8-683e-49bb-bea6-5560ad4a2fd6" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_fca8b3aa-1677-4562-acaf-12b186f38ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a316fa5b-5058-46b4-b195-077f04183607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a316fa5b-5058-46b4-b195-077f04183607" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0510ddba-3a12-43b2-9442-df42622c7d88" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8e10243-0d11-41a4-b7d8-bfc1247b85ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b12cf5a3-4fad-4d75-97d6-53287b88966c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8e10243-0d11-41a4-b7d8-bfc1247b85ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_54b0348d-ae9f-4dc2-9df1-18b42068a804" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e367aa9c-f334-40b0-ae61-7d6b13ef6075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e367aa9c-f334-40b0-ae61-7d6b13ef6075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d3c82d80-db6e-48d1-a32c-0c7c1b9374c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d3c82d80-db6e-48d1-a32c-0c7c1b9374c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_57cb1b52-4d0b-428b-9bce-f309e59f5328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_16a99f8c-db08-4810-bb56-f3be97fa670c" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_57cb1b52-4d0b-428b-9bce-f309e59f5328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_889b4cec-f388-462f-902f-165f25168f9a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_2984318b-69ca-4f64-826d-3b5c98c238fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_12a7d36a-e3e4-4392-a130-5081344e3f7a" xlink:to="loc_us-gaap_DebtInstrumentFairValue_2984318b-69ca-4f64-826d-3b5c98c238fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_efc5a02f-fec7-464c-ac3e-727d9e4fbe25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_efc5a02f-fec7-464c-ac3e-727d9e4fbe25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ab8547d-7975-4d09-a4b3-7cbadfeac820" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f0f4925d-b2e2-4860-bed2-af84355bbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f0f4925d-b2e2-4860-bed2-af84355bbc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_22736583-8bb7-42f2-961b-097294b721c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_22736583-8bb7-42f2-961b-097294b721c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6b51f9f9-1377-458e-ba98-0bf5080ef0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_76a9c0f6-4d2c-40df-8d23-1f54de1388d1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6b51f9f9-1377-458e-ba98-0bf5080ef0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_24427f24-a796-40dc-90f3-41d3acaa097c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_fc996540-759d-42d9-847a-ca841db082c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_fc996540-759d-42d9-847a-ca841db082c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9faef35-57fb-42c0-b6bc-1832f4b261a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_f9faef35-57fb-42c0-b6bc-1832f4b261a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_58532807-4d93-4707-8080-a5941502d310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_58532807-4d93-4707-8080-a5941502d310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_150cf243-c2f5-4e8e-82f7-9e68b679b59e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6a089c15-fdaf-4e37-ad36-214e5eb7319e" xlink:to="loc_us-gaap_CommercialPaperMember_150cf243-c2f5-4e8e-82f7-9e68b679b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_073f8d5e-df83-41ca-bbf3-f6724caf5684" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_05882998-44b9-444d-96f1-ece96c5f05c2" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef027ae1-50b0-4468-9d57-6779d945c99e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_59946ca8-a7e7-4d10-ab17-3834dffc1098" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_ef027ae1-50b0-4468-9d57-6779d945c99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0578c465-12b1-4e55-9f23-c011c99aec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6d34ee16-a14f-46aa-8c12-f7d6ecbdfcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_0578c465-12b1-4e55-9f23-c011c99aec9c" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6d34ee16-a14f-46aa-8c12-f7d6ecbdfcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdcc63aa-4a3c-4b1e-a46a-8bda065ad385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock_a1f279d3-dfce-46a1-b8ce-f42e86a9e60d" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdcc63aa-4a3c-4b1e-a46a-8bda065ad385" xlink:to="loc_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock_a1f279d3-dfce-46a1-b8ce-f42e86a9e60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ee899180-9097-4d09-991c-42a2725e70d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdcc63aa-4a3c-4b1e-a46a-8bda065ad385" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ee899180-9097-4d09-991c-42a2725e70d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_acf60a4a-4423-43dc-83f8-cf1646130cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cdcc63aa-4a3c-4b1e-a46a-8bda065ad385" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_acf60a4a-4423-43dc-83f8-cf1646130cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3ea07c2-d135-46d0-b2f8-3368c172fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d3ea07c2-d135-46d0-b2f8-3368c172fcb5" xlink:to="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_68af263c-2728-4619-8157-582cc3921e2b" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_RawMaterialsMember_4e14bfdb-058a-4cb5-b5c5-2d821e71f036" xlink:href="irtc-20211231.xsd#irtc_RawMaterialsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:to="loc_irtc_RawMaterialsMember_4e14bfdb-058a-4cb5-b5c5-2d821e71f036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_FinishedGoodsMember_c65acb3a-cb15-4a3f-8dcd-9432106eb8fe" xlink:href="irtc-20211231.xsd#irtc_FinishedGoodsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_afe98955-b232-46c8-b27b-8e896e3a0f9b" xlink:to="loc_irtc_FinishedGoodsMember_c65acb3a-cb15-4a3f-8dcd-9432106eb8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_97375979-edf6-49ae-9684-23c502611d65" xlink:to="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies_23fbd679-48a5-4340-88ba-ca66d3920147" xlink:href="irtc-20211231.xsd#irtc_InventoryAndPrintedCircuitBoardAssemblies"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_db8fcb96-a3fd-4d89-8ca6-7206f7901d6e" xlink:to="loc_irtc_InventoryAndPrintedCircuitBoardAssemblies_23fbd679-48a5-4340-88ba-ca66d3920147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c5523164-6759-4810-a8e2-349b0bc19011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c5523164-6759-4810-a8e2-349b0bc19011" xlink:to="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_1275bbb3-acf5-462e-aa58-6f088f64c030" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PrintedCircuitBoardAssembliesMember_8a3c0e8a-e6f7-411e-8a76-33d02d015c2e" xlink:href="irtc-20211231.xsd#irtc_PrintedCircuitBoardAssembliesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_1860fb0a-32bd-4da8-8f56-5930a70bc333" xlink:to="loc_irtc_PrintedCircuitBoardAssembliesMember_8a3c0e8a-e6f7-411e-8a76-33d02d015c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6cc999dd-7596-4768-8b00-92e62b6793d6" xlink:to="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherAssetsUsefulLives_d44cb267-4fd7-4432-ac35-cdf13518facf" xlink:href="irtc-20211231.xsd#irtc_OtherAssetsUsefulLives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_irtc_OtherAssetsUsefulLives_d44cb267-4fd7-4432-ac35-cdf13518facf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f98706fb-ee9a-4ffa-a982-2f839cbeb0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_OtherAssets_f98706fb-ee9a-4ffa-a982-2f839cbeb0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_f28c03d7-660c-4195-8c09-b6ce98e8bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_AdjustmentForAmortization_f28c03d7-660c-4195-8c09-b6ce98e8bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6c465892-f283-4602-8669-d03467841435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_983157b9-673a-4c01-b132-19a99c5b8cc1" xlink:to="loc_us-gaap_DepreciationAndAmortization_6c465892-f283-4602-8669-d03467841435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7d26466c-023c-4232-87ea-44f4da0ea65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_7d26466c-023c-4232-87ea-44f4da0ea65e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ee012ff-eb77-425c-8733-a2429b0793bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LaboratoryAndManufacturingEquipmentMember_b0eee8b0-c16c-42ec-a235-743d35f61590" xlink:href="irtc-20211231.xsd#irtc_LaboratoryAndManufacturingEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_irtc_LaboratoryAndManufacturingEquipmentMember_b0eee8b0-c16c-42ec-a235-743d35f61590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ComputerEquipmentAndSoftwareMember_040e29ba-7e89-4c5d-98fd-f8fd61d7109b" xlink:href="irtc-20211231.xsd#irtc_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_irtc_ComputerEquipmentAndSoftwareMember_040e29ba-7e89-4c5d-98fd-f8fd61d7109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_b059eb23-a8f2-442a-ab2a-ec99c7740551" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_b059eb23-a8f2-442a-ab2a-ec99c7740551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a953fa9a-b5bb-49d8-9ade-d9fb618285bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a953fa9a-b5bb-49d8-9ade-d9fb618285bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a89d0c3f-872e-45b1-aea5-f7fd4f06dff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40a446e3-6951-45a5-8955-6c4dd87691ba" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a89d0c3f-872e-45b1-aea5-f7fd4f06dff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8a1dbd52-b6dd-45a0-b6e3-982d24c8a054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_220f5992-a167-4f03-ae2d-1e58251ac5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_220f5992-a167-4f03-ae2d-1e58251ac5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5a2a9bf-6580-4c9d-8f70-89ce17a9e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a5a2a9bf-6580-4c9d-8f70-89ce17a9e44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba46dbdf-2462-4e57-9123-36e5db8ad529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfccf2f8-ab58-46a3-ae84-e85e20840146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba46dbdf-2462-4e57-9123-36e5db8ad529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedVacationCurrent_4f798c18-f77c-4046-acf9-401ed4b411e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_AccruedVacationCurrent_4f798c18-f77c-4046-acf9-401ed4b411e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e5584d8f-98b9-47dd-af47-5a52b3de74a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e5584d8f-98b9-47dd-af47-5a52b3de74a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AccruedEmployeeStockPurchasePlanContribution_6beffc36-e760-4921-9934-cf3ae4c6c0af" xlink:href="irtc-20211231.xsd#irtc_AccruedEmployeeStockPurchasePlanContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_irtc_AccruedEmployeeStockPurchasePlanContribution_6beffc36-e760-4921-9934-cf3ae4c6c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_838f51cb-4184-4c6f-88f2-42e42dc53d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_838f51cb-4184-4c6f-88f2-42e42dc53d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_57ad0cb0-bf78-448e-81dd-249e7d156881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_InterestPayableCurrent_57ad0cb0-bf78-448e-81dd-249e7d156881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ClaimsPayableCurrent_922ca6c3-de50-4e50-8772-b515262cf1f8" xlink:href="irtc-20211231.xsd#irtc_ClaimsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_irtc_ClaimsPayableCurrent_922ca6c3-de50-4e50-8772-b515262cf1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8c634b7-678b-4e78-8029-9ab4e8117e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8c634b7-678b-4e78-8029-9ab4e8117e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab687545-fe2c-4e1c-baa5-a49326d2e494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e832a727-8b50-49e3-86f0-ed6508b4960d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ab687545-fe2c-4e1c-baa5-a49326d2e494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_477a95d0-cf39-49f8-abe4-9cbd40d6c7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6dd93a90-d7b9-419e-b8c1-7ee18abfcdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_477a95d0-cf39-49f8-abe4-9cbd40d6c7bd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6dd93a90-d7b9-419e-b8c1-7ee18abfcdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f783d7c6-06b7-4599-aae1-d1fe708dafe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_afc6ed0a-d74e-4a81-a4d9-dd0104981df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f783d7c6-06b7-4599-aae1-d1fe708dafe7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_afc6ed0a-d74e-4a81-a4d9-dd0104981df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341e4761-0013-4759-a81c-40d32b73f51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341e4761-0013-4759-a81c-40d32b73f51c" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6bc65062-9d21-4afe-b35f-46b559d129a3" xlink:to="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SanFranciscoMember_9d2e8d85-8f64-4597-9b21-79fb10d30ccc" xlink:href="irtc-20211231.xsd#irtc_SanFranciscoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8b8699f7-57ff-41f3-8ace-02e5e9515fd7" xlink:to="loc_irtc_SanFranciscoMember_9d2e8d85-8f64-4597-9b21-79fb10d30ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_b2928cd4-7c37-450b-b594-801bb9c13bc6" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeerfieldLeaseMember_7f21788a-ede3-4403-bd00-254be3c6da91" xlink:href="irtc-20211231.xsd#irtc_DeerfieldLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_DeerfieldLeaseMember_7f21788a-ede3-4403-bd00-254be3c6da91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OfficeLeaseMember_3309d5d6-0531-4003-b3c8-456a8640b16f" xlink:href="irtc-20211231.xsd#irtc_OfficeLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_OfficeLeaseMember_3309d5d6-0531-4003-b3c8-456a8640b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LincolnshireLeaseMember_f0c752e9-8f25-4c26-a4a8-bbd4cff34b30" xlink:href="irtc-20211231.xsd#irtc_LincolnshireLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_LincolnshireLeaseMember_f0c752e9-8f25-4c26-a4a8-bbd4cff34b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CypressLeaseMember_58f98984-247b-409b-a6f3-448b3238eff6" xlink:href="irtc-20211231.xsd#irtc_CypressLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f8c3c0b5-7de4-40e2-9e13-25d12b6980f1" xlink:to="loc_irtc_CypressLeaseMember_58f98984-247b-409b-a6f3-448b3238eff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f34166fd-3b01-4d19-a821-83522e6ed92a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_VerilyLifeSciencesLLCMember_a682c450-71e2-4763-a48d-709d6dc61ccd" xlink:href="irtc-20211231.xsd#irtc_VerilyLifeSciencesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e180462-f142-409b-bb05-1f9949554c0e" xlink:to="loc_irtc_VerilyLifeSciencesLLCMember_a682c450-71e2-4763-a48d-709d6dc61ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_83230fb4-0128-4f21-bea3-f996b5e7f82c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_311a9bc9-ff85-4eb8-8ca7-dc158b9369e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2655dfbb-182a-4e53-9a33-5e467e2916ca" xlink:to="loc_us-gaap_SubsequentEventMember_311a9bc9-ff85-4eb8-8ca7-dc158b9369e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_e6454509-71f9-44e5-bc69-f6cf9b2a1d7a" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8963c744-81aa-46da-8172-428383ffef86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseCost_8963c744-81aa-46da-8172-428383ffef86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5452a13a-55a2-49eb-98eb-a84bf6d7fda9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeasePayments_5452a13a-55a2-49eb-98eb-a84bf6d7fda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRentableArea_b6999e0d-a861-42d3-a7c0-fa57a43ddc30" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRentableArea"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_OperatingLeaseRentableArea_b6999e0d-a861-42d3-a7c0-fa57a43ddc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_0cd335da-cb19-4882-9dd0-b1ea5cb35e1b" xlink:href="irtc-20211231.xsd#irtc_LesseeOperatingSubleaseNumberOfOptionToExtend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend_0cd335da-cb19-4882-9dd0-b1ea5cb35e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_546f9b1d-41ca-4c61-9ce1-17cc1b1a703e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_546f9b1d-41ca-4c61-9ce1-17cc1b1a703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1853a47-0601-4762-9941-f0e2380dc07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1853a47-0601-4762-9941-f0e2380dc07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6ee49e7a-5494-49d2-92a2-713ee87ede5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6ee49e7a-5494-49d2-92a2-713ee87ede5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementRemainingTermOfAgreement_18f73788-2b60-4d90-acbc-0693e2f038fe" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementRemainingTermOfAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementRemainingTermOfAgreement_18f73788-2b60-4d90-acbc-0693e2f038fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementUpfrontFeePayable_e63acd91-bcbb-499b-8b95-d7ffbfb27c87" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementUpfrontFeePayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementUpfrontFeePayable_e63acd91-bcbb-499b-8b95-d7ffbfb27c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_e3c68adb-2e70-4736-99c4-c5564e7c33a6" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months_e3c68adb-2e70-4736-99c4-c5564e7c33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementMilestonePayments_5602a235-446a-4131-a2a6-c79433ad6ffe" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementMilestonePayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementMilestonePayments_5602a235-446a-4131-a2a6-c79433ad6ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_54a0d06f-fbe7-4468-be0b-63da1ec545e5" xlink:href="irtc-20211231.xsd#irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_16819e75-7ad1-49c7-b3f5-b7e6933a5376" xlink:to="loc_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023_54a0d06f-fbe7-4468-be0b-63da1ec545e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6017f78d-55c5-4677-aba1-b65a19fe1afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6017f78d-55c5-4677-aba1-b65a19fe1afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_186d8096-3796-4d3e-b185-62c7f04f91eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_186d8096-3796-4d3e-b185-62c7f04f91eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7810d989-c50e-4def-a54b-9e4519422905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7810d989-c50e-4def-a54b-9e4519422905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c85a7f86-280c-41f0-bfa8-ceaab5692231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c85a7f86-280c-41f0-bfa8-ceaab5692231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_28bbc0d1-266c-4975-8bc6-3ab0166d69a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_28bbc0d1-266c-4975-8bc6-3ab0166d69a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb5fb071-584d-4a33-a22b-d03442d12ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb5fb071-584d-4a33-a22b-d03442d12ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5d1074d-7f01-4ec7-a355-ea38d2326200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5d1074d-7f01-4ec7-a355-ea38d2326200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_949673a4-ee20-436a-bed2-7792e2cf0cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_949673a4-ee20-436a-bed2-7792e2cf0cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4fb362ae-313e-4678-8586-76c8ad2f22c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_37fa5825-988b-4bb5-8faf-989bc1b7acf6" xlink:to="loc_us-gaap_OperatingLeaseLiability_4fb362ae-313e-4678-8586-76c8ad2f22c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1" xlink:type="simple" xlink:href="irtc-20211231.xsd#CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/Debt" xlink:type="simple" xlink:href="irtc-20211231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e40f5f8b-8669-4695-b505-536e838b0450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_dccf5b27-a587-4e28-b8ee-1bfd9980536d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e40f5f8b-8669-4695-b505-536e838b0450" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_dccf5b27-a587-4e28-b8ee-1bfd9980536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5a63cb18-77d7-4bcb-90fb-70aaae4166c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a9471214-65ff-429a-8313-dbd54a8df227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a63cb18-77d7-4bcb-90fb-70aaae4166c4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a9471214-65ff-429a-8313-dbd54a8df227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/DebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d0c88114-96f9-41f5-9983-e861656f9c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0c88114-96f9-41f5-9983-e861656f9c87" xlink:to="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8609581e-d19e-4ea9-9338-42b4762dc7a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_3cc356a3-ead8-4b19-9432-6ff153aa6470" xlink:href="irtc-20211231.xsd#irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:to="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_3cc356a3-ead8-4b19-9432-6ff153aa6470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PharmakonLoanAgreementMember_11a7990b-1144-4be0-9c14-a7ae13908f17" xlink:href="irtc-20211231.xsd#irtc_PharmakonLoanAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_653c5c4c-ee91-470b-9b87-b6d17997c2ad" xlink:to="loc_irtc_PharmakonLoanAgreementMember_11a7990b-1144-4be0-9c14-a7ae13908f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_21a4342f-66eb-4034-b697-799bd9e2ec5c" xlink:to="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_a110b3ff-3efe-4b88-8665-3271df97e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5d846c6c-af59-400c-85ee-4fee20c9abd1" xlink:to="loc_us-gaap_PrimeRateMember_a110b3ff-3efe-4b88-8665-3271df97e42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_230ea2cc-1045-41c2-a133-38743cd33eae" xlink:to="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2c2b6a56-025a-4b8c-8a4e-49f483d2eee2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:to="loc_srt_MaximumMember_2c2b6a56-025a-4b8c-8a4e-49f483d2eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_804f6fc3-21af-48d2-a771-98d2706befab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e71d311f-9b2b-4355-a7ad-a2116778e7e8" xlink:to="loc_srt_MinimumMember_804f6fc3-21af-48d2-a771-98d2706befab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_cb89911d-9457-45d9-9f4f-9102519d4ddb" xlink:to="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SiliconValleyBankTermLoanMember_850b35b9-76eb-43cd-a74e-dc2b1043dd40" xlink:href="irtc-20211231.xsd#irtc_SiliconValleyBankTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_irtc_SiliconValleyBankTermLoanMember_850b35b9-76eb-43cd-a74e-dc2b1043dd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_232ee1e6-2d76-46a7-9386-9a669c27705d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_232ee1e6-2d76-46a7-9386-9a669c27705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_68a1e206-df15-497b-9b6e-57031037594f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cf917519-d8c0-4ed5-96b3-0672a391cd79" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_68a1e206-df15-497b-9b6e-57031037594f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_038eb0e5-9f36-4776-8d2b-9b037da70a20" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e2eea5b-e916-4704-9eba-ccc8b7d2b388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e2eea5b-e916-4704-9eba-ccc8b7d2b388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_fd91fdfc-8cb4-4250-87a6-6e32154ef704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_fd91fdfc-8cb4-4250-87a6-6e32154ef704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_eaffad24-fa98-48b2-80ab-ec6bef18a59d" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate_eaffad24-fa98-48b2-80ab-ec6bef18a59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0c17abb4-1db5-4550-b7a2-aac9bd4aa07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0c17abb4-1db5-4550-b7a2-aac9bd4aa07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_fed1ce33-d978-4a2e-9e3e-26e665fde2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_fed1ce33-d978-4a2e-9e3e-26e665fde2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_15534aca-96dd-4d14-aab5-3c29fde09619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_15534aca-96dd-4d14-aab5-3c29fde09619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_8628c4ab-0a61-45e4-8979-26729974ea3b" xlink:href="irtc-20211231.xsd#irtc_PercentageOfEligibleAccountsReceivableForBorrowings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_irtc_PercentageOfEligibleAccountsReceivableForBorrowings_8628c4ab-0a61-45e4-8979-26729974ea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_ecf5d43f-f344-456f-9777-901cf7d65478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f2571e5e-4faa-49e4-9a44-8f1bc02950b4" xlink:to="loc_us-gaap_LineOfCredit_ecf5d43f-f344-456f-9777-901cf7d65478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#DebtScheduleofFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0484bf94-125b-45b7-9174-8f09ddf65a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0484bf94-125b-45b7-9174-8f09ddf65a78" xlink:to="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7531f770-694a-47d8-8cbf-d4b29179eac0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_2b609182-c48c-4254-8cb2-6f46610f7314" xlink:href="irtc-20211231.xsd#irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f65e98dd-58e5-4aea-a6e5-df12d9b298cf" xlink:to="loc_irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember_2b609182-c48c-4254-8cb2-6f46610f7314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_90596c39-aca1-4356-a85f-6de913dde8bc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c08dd8a5-4664-4d43-a734-656e2fef091d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c08dd8a5-4664-4d43-a734-656e2fef091d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bd656a0-6f25-4fbb-953e-751b465d2c67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9bd656a0-6f25-4fbb-953e-751b465d2c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32ee0f61-4962-423a-8932-1c7e48d55c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebt_32ee0f61-4962-423a-8932-1c7e48d55c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DebtInstrumentInterestPortion_6c031b23-362a-453f-9450-fda251049c7a" xlink:href="irtc-20211231.xsd#irtc_DebtInstrumentInterestPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_irtc_DebtInstrumentInterestPortion_6c031b23-362a-453f-9450-fda251049c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_034ab362-a4e9-4b31-b5e4-36e5cc50b03a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_034ab362-a4e9-4b31-b5e4-36e5cc50b03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_LongTermDebtCarryingValue_e123b0a7-2912-475c-88fe-eb18e0fff6c2" xlink:href="irtc-20211231.xsd#irtc_LongTermDebtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_irtc_LongTermDebtCarryingValue_e123b0a7-2912-475c-88fe-eb18e0fff6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_74ab3767-aac1-4d2f-a765-5b6df513152c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DebtCurrent_74ab3767-aac1-4d2f-a765-5b6df513152c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0b36ac3d-d2ac-4624-b36e-56deefba89f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_LongTermDebt_0b36ac3d-d2ac-4624-b36e-56deefba89f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_67ffa19e-5ba6-42bd-aa79-b333d78a339a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2d6c4a08-89f9-4065-87e6-c9d968b79950" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_67ffa19e-5ba6-42bd-aa79-b333d78a339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9db444bd-e509-415f-adbc-5b9a009e6221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f0ba6638-c9e2-4a8b-bc6d-5e759b83ce79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9db444bd-e509-415f-adbc-5b9a009e6221" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f0ba6638-c9e2-4a8b-bc6d-5e759b83ce79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_48023859-e0d7-4200-ac0f-2ad3c26edd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_48023859-e0d7-4200-ac0f-2ad3c26edd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7b802d04-4374-41e5-bcea-118642680742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_7b802d04-4374-41e5-bcea-118642680742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_caad633b-b4c7-4eaa-90d3-58aa8a31f13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_caad633b-b4c7-4eaa-90d3-58aa8a31f13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_39da8ca3-559e-4ea4-8e9a-afb3eba658cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_39da8ca3-559e-4ea4-8e9a-afb3eba658cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7d479f38-5d7c-44d1-a75e-22cb8b3ebb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4dfeefd9-e3e7-4d4e-a5d5-63c93f2c364f" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_7d479f38-5d7c-44d1-a75e-22cb8b3ebb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4bf27e6a-e51f-4b13-b521-eb9909a2965e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6c7effa8-0ffb-4965-ae09-de5162753f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4bf27e6a-e51f-4b13-b521-eb9909a2965e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6c7effa8-0ffb-4965-ae09-de5162753f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6c7effa8-0ffb-4965-ae09-de5162753f28" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9a6e6921-219a-4543-861a-22c49cf6a465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9a6e6921-219a-4543-861a-22c49cf6a465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ced1f5e-6fe2-4e51-a011-3a1c5f11826a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3ced1f5e-6fe2-4e51-a011-3a1c5f11826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_62b9221e-a6e7-41a9-b432-357f25d01c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_62b9221e-a6e7-41a9-b432-357f25d01c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5050bc6-80c9-4d06-aa6d-f33911726fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d46fac35-26e6-4ed7-b193-840aeb0db1fb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e5050bc6-80c9-4d06-aa6d-f33911726fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6c7effa8-0ffb-4965-ae09-de5162753f28" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_79103443-9dbe-43dd-ace9-47e915be5dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_79103443-9dbe-43dd-ace9-47e915be5dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0c90891b-8672-43c1-9552-ef2188c92ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0c90891b-8672-43c1-9552-ef2188c92ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_051f5206-4820-4555-8d54-06f1d1a6fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_051f5206-4820-4555-8d54-06f1d1a6fd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c12511-280e-441f-9c37-aa95b6c1e2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3c6d7fc8-a3ad-4d62-ba63-290eaf389b0d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_74c12511-280e-441f-9c37-aa95b6c1e2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a14b75ad-919e-4d52-90d8-4f1cd20cbc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6c7effa8-0ffb-4965-ae09-de5162753f28" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a14b75ad-919e-4d52-90d8-4f1cd20cbc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6b7313ef-b93c-4c63-9ca2-83206d35fb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6b7313ef-b93c-4c63-9ca2-83206d35fb9b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1c136013-208a-4c76-90ab-2bc1ef0bf758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1c136013-208a-4c76-90ab-2bc1ef0bf758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c8b02338-9a1c-4c90-9f38-56d897bba10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c8b02338-9a1c-4c90-9f38-56d897bba10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6585cd94-e8c4-4cc8-989b-c87e8d4a1390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6585cd94-e8c4-4cc8-989b-c87e8d4a1390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_7e13a2da-13d0-40bd-8beb-6da199dfa2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_7e13a2da-13d0-40bd-8beb-6da199dfa2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_169563c8-e553-4497-b4cb-9ccbc43cdf14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_169563c8-e553-4497-b4cb-9ccbc43cdf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d9260229-57f3-4a39-9c0d-74a40827ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d9260229-57f3-4a39-9c0d-74a40827ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7f6cb026-2f7e-49b5-9cf5-fcbca19653f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_7f6cb026-2f7e-49b5-9cf5-fcbca19653f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_d042e5b5-6640-4f0e-a9cb-88d2e4a76842" xlink:href="irtc-20211231.xsd#irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017_d042e5b5-6640-4f0e-a9cb-88d2e4a76842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_78a086a2-4b5f-47e3-98ee-665d8737ebc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_78a086a2-4b5f-47e3-98ee-665d8737ebc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_907e1aa3-f7c3-4bbe-9987-956eb876cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0b2f7bee-2ef1-44d0-990f-5e96012af21a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_907e1aa3-f7c3-4bbe-9987-956eb876cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3d71b0b9-e950-4071-9da3-2faf9226343a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3d71b0b9-e950-4071-9da3-2faf9226343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8333464c-3461-44f8-919d-ec274f5ec458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_8333464c-3461-44f8-919d-ec274f5ec458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_73fc89bb-716b-458b-bf97-d052f81b1d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_73fc89bb-716b-458b-bf97-d052f81b1d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther_a28e0cfb-8a83-4f7d-898c-7adaad09a2af" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsValuationAllowancesAndOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_irtc_DeferredTaxAssetsValuationAllowancesAndOther_a28e0cfb-8a83-4f7d-898c-7adaad09a2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsLeaseObligations_cc38e1fd-3e06-4125-8778-ab514abf2302" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_irtc_DeferredTaxAssetsLeaseObligations_cc38e1fd-3e06-4125-8778-ab514abf2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_77a5bf26-c43d-4a1f-aa5d-0e2292587630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_dd508942-fde6-423d-8909-daf04aacc4b0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_77a5bf26-c43d-4a1f-aa5d-0e2292587630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_51c0be8d-2b01-4cbc-820c-3cdd48a65d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_51c0be8d-2b01-4cbc-820c-3cdd48a65d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d6a8f090-31ce-449f-a5d0-25451eb01300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d6a8f090-31ce-449f-a5d0-25451eb01300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1b2c84e0-4216-4954-bafa-99404c57a16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1b2c84e0-4216-4954-bafa-99404c57a16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_434a393f-1bcf-40be-a02b-c4d6354e5e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1b2c84e0-4216-4954-bafa-99404c57a16e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_434a393f-1bcf-40be-a02b-c4d6354e5e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bcc104b1-7d23-4519-918d-e2e9874509b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1b2c84e0-4216-4954-bafa-99404c57a16e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bcc104b1-7d23-4519-918d-e2e9874509b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0a01417a-2224-49b2-9e17-21ee41a6fc41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1b2c84e0-4216-4954-bafa-99404c57a16e" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0a01417a-2224-49b2-9e17-21ee41a6fc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a2e9d18d-14ff-405d-9b54-18b654aea768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e4f09d6-b2d8-4eee-8863-b90938700f9c" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a2e9d18d-14ff-405d-9b54-18b654aea768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6d04804-bb29-45e6-b0b1-3f70f4722c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6d04804-bb29-45e6-b0b1-3f70f4722c5f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_87a5d12f-27eb-46ab-a176-5c2044b749e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5f61239e-55c1-489d-b3f8-14c9333b15dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:to="loc_us-gaap_DomesticCountryMember_5f61239e-55c1-489d-b3f8-14c9333b15dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_876635c9-ad2d-4eea-8d84-1242315645ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9fc71d5d-6534-4a03-b2e7-f4d342efeee5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_876635c9-ad2d-4eea-8d84-1242315645ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_2b59e636-b481-4c51-a4c7-1c85a11f345f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_894b9ca0-a776-45f6-adb3-ba3ce048a754" xlink:href="irtc-20211231.xsd#irtc_OperatingLossCarryforwardsTaxBenefitRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_irtc_OperatingLossCarryforwardsTaxBenefitRecognized_894b9ca0-a776-45f6-adb3-ba3ce048a754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c23f6be-da23-49e7-b0db-4474594a8212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c23f6be-da23-49e7-b0db-4474594a8212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cdb9f478-6e9c-4156-b38a-21c5440da1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_cdb9f478-6e9c-4156-b38a-21c5440da1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3860e64d-5c81-4158-b24b-8590417085e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3860e64d-5c81-4158-b24b-8590417085e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_c3d85e29-dfba-499b-a659-a890b0b0c78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_c3d85e29-dfba-499b-a659-a890b0b0c78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_91a55cf6-1c4d-499c-845e-da8fc2850872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_91a55cf6-1c4d-499c-845e-da8fc2850872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8db83715-3f42-4e2f-91e6-de7f67bc8747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_604907e6-3ae4-4cd0-83db-cae71597108a" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_8db83715-3f42-4e2f-91e6-de7f67bc8747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e8eb7393-4fdb-4fac-9611-58c1b6e7dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:href="irtc-20211231.xsd#irtc_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e8eb7393-4fdb-4fac-9611-58c1b6e7dce7" xlink:to="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ca5cbf6b-9a62-4266-b9bd-e7e540810336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ca5cbf6b-9a62-4266-b9bd-e7e540810336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ValuationAllowanceDeferredTaxAssetAdditions_3b7fc7fc-60b7-4bb1-9a7d-9fe25f7bcf57" xlink:href="irtc-20211231.xsd#irtc_ValuationAllowanceDeferredTaxAssetAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:to="loc_irtc_ValuationAllowanceDeferredTaxAssetAdditions_3b7fc7fc-60b7-4bb1-9a7d-9fe25f7bcf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ValuationAllowanceDeferredTaxAssetDeductions_0235a85d-7dda-4384-873a-40dbe73b8bdf" xlink:href="irtc-20211231.xsd#irtc_ValuationAllowanceDeferredTaxAssetDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:to="loc_irtc_ValuationAllowanceDeferredTaxAssetDeductions_0235a85d-7dda-4384-873a-40dbe73b8bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b049d302-f26a-429c-b1f9-9b56a2e8fdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_DeferredTaxAssetsValuationAllowanceRollForward_507698c4-f41a-472d-9505-8f156a6f1211" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b049d302-f26a-429c-b1f9-9b56a2e8fdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747d3f41-bd4c-4a3d-889b-1796abc46fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747d3f41-bd4c-4a3d-889b-1796abc46fb6" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_20cccec4-2a24-477f-8fb2-baf6aa5911dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_20cccec4-2a24-477f-8fb2-baf6aa5911dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5b80f054-91dd-4c30-8bb2-09c8ca73abd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_5b80f054-91dd-4c30-8bb2-09c8ca73abd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c527fda-219e-4c63-8cf5-f3ba1ce6ca82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_5c527fda-219e-4c63-8cf5-f3ba1ce6ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9d3e96ac-9de8-472f-afcb-4d4849be97e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_9d3e96ac-9de8-472f-afcb-4d4849be97e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_794045fe-69c1-418c-bbef-8de99969e553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_655e694f-9319-41e6-8d8a-2f9e3dddccbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_794045fe-69c1-418c-bbef-8de99969e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockholdersEquity" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_faf73b61-6c2f-44a5-9680-444fa3937f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0434640f-12af-443e-aa34-a54e9a2d04c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_faf73b61-6c2f-44a5-9680-444fa3937f74" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0434640f-12af-443e-aa34-a54e9a2d04c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bf312f1c-bd70-496e-bc0c-07bc910a62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_4892eb82-6e71-428d-9a9b-13bb23166bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf312f1c-bd70-496e-bc0c-07bc910a62dc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_4892eb82-6e71-428d-9a9b-13bb23166bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d067e721-7a09-437c-a19b-42bae3f788a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d067e721-7a09-437c-a19b-42bae3f788a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0436b3b2-36cb-44af-ba26-bcc0922ee9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0436b3b2-36cb-44af-ba26-bcc0922ee9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9d333089-8ecc-465e-93eb-6efbadb4a032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9d333089-8ecc-465e-93eb-6efbadb4a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55ab125b-2551-4117-b9ec-a61828398cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_55ab125b-2551-4117-b9ec-a61828398cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_fbf5b0fd-dabe-4e74-8c84-2aace019fd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e0318c-9b00-4e9b-b8fc-9a72c3497371" xlink:to="loc_us-gaap_DividendsCommonStock_fbf5b0fd-dabe-4e74-8c84-2aace019fd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_de1cdc1a-92eb-4b22-b3d4-71a5474a17a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_de1cdc1a-92eb-4b22-b3d4-71a5474a17a9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:to="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c9f1a62f-f310-43db-bf91-b3b431a99bba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockOptionsIssuedAndOutstandingMember_7d6d9dfe-c390-469b-906f-0799abe436a9" xlink:href="irtc-20211231.xsd#irtc_StockOptionsIssuedAndOutstandingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_irtc_StockOptionsIssuedAndOutstandingMember_7d6d9dfe-c390-469b-906f-0799abe436a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6c5f61a-658c-415a-b937-4829bd832059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6c5f61a-658c-415a-b937-4829bd832059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_GrantUnderFutureStockPlansMember_c5973ea5-5c98-4901-ad91-44d14c11e7f5" xlink:href="irtc-20211231.xsd#irtc_GrantUnderFutureStockPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_765976fa-3b87-4962-8821-61163d4a80c9" xlink:to="loc_irtc_GrantUnderFutureStockPlansMember_c5973ea5-5c98-4901-ad91-44d14c11e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f209ecb4-3690-4ed9-b664-5497e7334544" xlink:to="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22fa82a2-8540-47ad-b755-3358a34b4055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1efe3c5d-3ef3-4781-b0a1-8a266b8f5ab2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22fa82a2-8540-47ad-b755-3358a34b4055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bb84f56-0505-4edc-8b87-9c9870304278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_968a5740-ae56-41e9-927c-abc5751cb2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bb84f56-0505-4edc-8b87-9c9870304278" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_968a5740-ae56-41e9-927c-abc5751cb2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37326c59-4564-4339-a21f-f57502652344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock_2009b4e1-398e-4326-a355-7b0eb289d53b" xlink:href="irtc-20211231.xsd#irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37326c59-4564-4339-a21f-f57502652344" xlink:to="loc_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock_2009b4e1-398e-4326-a355-7b0eb289d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3a6acf19-b459-464f-bfd0-b3f93f05a164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37326c59-4564-4339-a21f-f57502652344" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3a6acf19-b459-464f-bfd0-b3f93f05a164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4431e7f7-309d-4cf6-be75-17a564df7e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37326c59-4564-4339-a21f-f57502652344" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4431e7f7-309d-4cf6-be75-17a564df7e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61cf2fce-894a-43b5-98cd-aa1ce69469ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61cf2fce-894a-43b5-98cd-aa1ce69469ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6643af7f-4855-4869-b770-5e5cdb38d131" xlink:to="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixEquityIncentivePlanMember_ade93485-592f-4719-9bf7-0c5f94f5f49f" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_TwoThousandSixEquityIncentivePlanMember_ade93485-592f-4719-9bf7-0c5f94f5f49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_75f67aa4-d288-4d6a-86e4-87dc37368c1a" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_75f67aa4-d288-4d6a-86e4-87dc37368c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanMember_a5362377-13ad-4fb2-a7ea-d016fb96a9bf" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4976eef9-8b58-4765-997b-48b3bb331621" xlink:to="loc_irtc_EmployeeStockPurchasePlanMember_a5362377-13ad-4fb2-a7ea-d016fb96a9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3794e05c-85e2-4d06-9d3b-c144100bc0f4" xlink:to="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49f443c6-7108-4c92-b4a7-d8b2e9a79553" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:to="loc_srt_MaximumMember_49f443c6-7108-4c92-b4a7-d8b2e9a79553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4521a0c-c2a3-4ebf-8581-69436582b09d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0cc08312-c38c-42ce-8fdc-ca18e3f01e0d" xlink:to="loc_srt_MinimumMember_a4521a0c-c2a3-4ebf-8581-69436582b09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_38c1fbaf-8ae2-4080-a56a-27626aa37baf" xlink:to="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0163864-7906-450e-b122-f5d21993890a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1aa7e4da-7a4c-4092-b77d-be0d2f117956" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e0163864-7906-450e-b122-f5d21993890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_39d48e96-b459-4ee3-ad93-85149259be06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncentiveStockOptionsMember_01e6552f-ac24-4549-9143-62bc249efcdc" xlink:href="irtc-20211231.xsd#irtc_IncentiveStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:to="loc_irtc_IncentiveStockOptionsMember_01e6552f-ac24-4549-9143-62bc249efcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OtherStockOptionMember_178effff-8bdf-4d2b-b598-7718364fcb3f" xlink:href="irtc-20211231.xsd#irtc_OtherStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2404889a-7968-4790-bcaf-ed62ab3fa6b0" xlink:to="loc_irtc_OtherStockOptionMember_178effff-8bdf-4d2b-b598-7718364fcb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9b92d2f-fd85-4afc-8290-5b2f1aa90088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d5f60b8-31ae-4520-83fe-13c8add56bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6d5f60b8-31ae-4520-83fe-13c8add56bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_adeae936-fe79-4cdd-b705-226eb83851ea" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage_adeae936-fe79-4cdd-b705-226eb83851ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2caed961-7f2c-46c5-825a-5380a53ab365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2caed961-7f2c-46c5-825a-5380a53ab365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock_99a9412b-0402-4025-91aa-60a4d7567327" xlink:href="irtc-20211231.xsd#irtc_PercentageOfVotingPowerOfAllClassesOfStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_PercentageOfVotingPowerOfAllClassesOfStock_99a9412b-0402-4025-91aa-60a4d7567327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_83e6edf1-fdc6-486c-9941-889222749821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_83e6edf1-fdc6-486c-9941-889222749821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_592d0c2b-09f7-4e2f-982c-226db88fe819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_592d0c2b-09f7-4e2f-982c-226db88fe819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fa4b0a77-9307-46fa-82a4-c78b922dcd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fa4b0a77-9307-46fa-82a4-c78b922dcd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_01795742-bb34-4877-a5db-0ae7d492299b" xlink:href="irtc-20211231.xsd#irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock_01795742-bb34-4877-a5db-0ae7d492299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance_b4ef86b5-5bb1-40c9-b545-660959c2dcae" xlink:href="irtc-20211231.xsd#irtc_IncreaseInCommonStockReservedForFutureIssuance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_IncreaseInCommonStockReservedForFutureIssuance_b4ef86b5-5bb1-40c9-b545-660959c2dcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_c9cb371f-bacf-4f3c-a4ec-2dde33986716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_c9cb371f-bacf-4f3c-a4ec-2dde33986716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod_027d97d1-ef6a-4b80-9186-7f01d394ec44" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanOfferingPeriod_027d97d1-ef6a-4b80-9186-7f01d394ec44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_d05ea773-b460-49ca-bc90-0419a9927711" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods_d05ea773-b460-49ca-bc90-0419a9927711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod_acc5a4af-4c66-4bfe-b18e-07a18f1b89e6" xlink:href="irtc-20211231.xsd#irtc_EmployeeStockPurchasePlanPurchasePeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_EmployeeStockPurchasePlanPurchasePeriod_acc5a4af-4c66-4bfe-b18e-07a18f1b89e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c9dff79a-55a6-4ff5-9771-754d4acd6fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c9dff79a-55a6-4ff5-9771-754d4acd6fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_99d508df-92e3-415c-991f-a97fb02fe3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_99d508df-92e3-415c-991f-a97fb02fe3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e054544-9601-4fa9-8ff1-450dcf10883e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6e054544-9601-4fa9-8ff1-450dcf10883e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8566b2e0-b740-4519-bfa9-398e483f8a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8566b2e0-b740-4519-bfa9-398e483f8a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b2b3aa7d-5297-4a22-982e-64f30a126c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b2b3aa7d-5297-4a22-982e-64f30a126c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c164799c-1553-4d13-8e68-21d5432aa19e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c164799c-1553-4d13-8e68-21d5432aa19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a60049bc-e085-4b44-a0cf-585363b9b26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_a60049bc-e085-4b44-a0cf-585363b9b26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cde61304-7365-4860-b014-2f1bea2bfb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cde61304-7365-4860-b014-2f1bea2bfb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_0205cebc-920d-40bf-aad7-680b2e2c1ea1" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod_0205cebc-920d-40bf-aad7-680b2e2c1ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_206f13f3-5a33-4435-9c8b-d4bd84996c5f" xlink:href="irtc-20211231.xsd#irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested_206f13f3-5a33-4435-9c8b-d4bd84996c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c0513c41-3a1f-4ce7-8d40-397d2e5be3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_c0513c41-3a1f-4ce7-8d40-397d2e5be3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68407a98-a1d1-4aa8-b886-3056124be28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_68407a98-a1d1-4aa8-b886-3056124be28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_93c46240-414d-48c7-b619-77cf2365b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_93c46240-414d-48c7-b619-77cf2365b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0b1a3445-2487-4c74-9343-e29d1236cb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0b1a3445-2487-4c74-9343-e29d1236cb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fe2eec7e-f102-4265-be5c-9787bf53ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61772053-b9f8-40a4-980c-da076e22cbcd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_fe2eec7e-f102-4265-be5c-9787bf53ad5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10b5c6b1-de88-4054-a244-9c4a09e87459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10b5c6b1-de88-4054-a244-9c4a09e87459" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:to="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_476d4040-cb11-4d1e-8f76-a2b5958aecec" xlink:to="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_5f808e23-6665-4e1d-87d6-5fef760b1888" xlink:href="irtc-20211231.xsd#irtc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_963b4d7f-0312-41e7-92bc-4e29b9ab94a2" xlink:to="loc_irtc_TwoThousandSixteenEquityIncentivePlanMember_5f808e23-6665-4e1d-87d6-5fef760b1888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5d6802fc-4693-4e0a-88b3-fb5dd8dd6b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_139f89db-a340-49ae-a780-539198995a98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19ad581b-65a2-4faa-901d-320f691e2e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_19ad581b-65a2-4faa-901d-320f691e2e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a8293f7a-3d8a-44a5-adb8-30c6a8ba3445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a8293f7a-3d8a-44a5-adb8-30c6a8ba3445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_27f44a91-c061-4abd-b419-b08cea609868" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_27f44a91-c061-4abd-b419-b08cea609868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_8ec44b5e-e736-4edc-996c-800847f90a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_8ec44b5e-e736-4edc-996c-800847f90a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3732eb59-1b86-4b83-b837-e5c002d3a263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3732eb59-1b86-4b83-b837-e5c002d3a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b107bbcd-f425-426e-88ca-b25c05b91bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e22d70b0-18a1-4198-b9e1-fd1b3fa4017e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b107bbcd-f425-426e-88ca-b25c05b91bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0ac0f7b-78ba-48ba-8212-04e7cc64e6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0ac0f7b-78ba-48ba-8212-04e7cc64e6d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:href="irtc-20211231.xsd#irtc_OptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a2d6504-bb89-4a7c-b238-41930733a447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a2d6504-bb89-4a7c-b238-41930733a447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7888d4d4-e2a0-4957-9cd8-fced8f87c5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7888d4d4-e2a0-4957-9cd8-fced8f87c5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61929a43-0b8c-46a8-a6de-40d84f7ecdee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_61929a43-0b8c-46a8-a6de-40d84f7ecdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6a1ea93-25c6-48cb-ba52-c9b8faa4d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a6a1ea93-25c6-48cb-ba52-c9b8faa4d5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00b3705b-bd72-4fd4-b04e-1eeae4157ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_OptionsOutstandingAbstract_c5ac0c35-c79f-4eb0-adc4-c48a49e15013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00b3705b-bd72-4fd4-b04e-1eeae4157ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4fcb6ea-8646-4ac3-bf89-2aae7237a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a4fcb6ea-8646-4ac3-bf89-2aae7237a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e98e8475-a87a-498a-a321-3b0ec863c847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e98e8475-a87a-498a-a321-3b0ec863c847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageExercisePricePerShareAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50ae277a-2cbe-4aea-9353-956ad3010f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50ae277a-2cbe-4aea-9353-956ad3010f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3674a909-cb63-4b1a-9122-f16de0a130e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3674a909-cb63-4b1a-9122-f16de0a130e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b71530e7-eca6-4da7-86b2-026f040e99da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b71530e7-eca6-4da7-86b2-026f040e99da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b26908af-5331-4737-a561-5abd3cdc7131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b26908af-5331-4737-a561-5abd3cdc7131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_609f7585-b5fd-4184-ab41-313b8aff4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageExercisePricePerShareAbstract_ed8ea970-2e54-4158-a01a-6746873af742" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_609f7585-b5fd-4184-ab41-313b8aff4c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_660717d3-1a59-4b12-a654-73750804fa63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_660717d3-1a59-4b12-a654-73750804fa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6d7f5ec9-84bd-48b2-8401-e15af0d64b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6d7f5ec9-84bd-48b2-8401-e15af0d64b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_648e457b-273f-4b15-b6e8-eabe186b3485" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageRemainingContractualLifeYearsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6758e6a8-629e-4ff2-a80c-e40a62ba4485" xlink:to="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_648e457b-273f-4b15-b6e8-eabe186b3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e2277342-9f17-4d6a-987b-d68c8e072f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_648e457b-273f-4b15-b6e8-eabe186b3485" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e2277342-9f17-4d6a-987b-d68c8e072f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ae231096-5da8-4c3c-87c4-862d13c82046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_648e457b-273f-4b15-b6e8-eabe186b3485" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ae231096-5da8-4c3c-87c4-862d13c82046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3c94eae9-bfba-4aa5-bcce-3c8bb2e23abc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageRemainingContractualLifeYearsAbstract_648e457b-273f-4b15-b6e8-eabe186b3485" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3c94eae9-bfba-4aa5-bcce-3c8bb2e23abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AggregateIntrinsicValueAbstract_ab99f103-9308-4e31-a228-5f31143d52e8" xlink:href="irtc-20211231.xsd#irtc_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0ac0f7b-78ba-48ba-8212-04e7cc64e6d1" xlink:to="loc_irtc_AggregateIntrinsicValueAbstract_ab99f103-9308-4e31-a228-5f31143d52e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca8e7bd8-5b4a-4f27-aa86-cbe91f592958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract_ab99f103-9308-4e31-a228-5f31143d52e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca8e7bd8-5b4a-4f27-aa86-cbe91f592958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_73bdcb5d-39b0-4f92-a250-47716825e7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract_ab99f103-9308-4e31-a228-5f31143d52e8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_73bdcb5d-39b0-4f92-a250-47716825e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f4d3f22c-9151-4e4a-beac-73de57987f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract_ab99f103-9308-4e31-a228-5f31143d52e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f4d3f22c-9151-4e4a-beac-73de57987f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a01ad45-2bdc-4f46-b233-990bff7a4289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a01ad45-2bdc-4f46-b233-990bff7a4289" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:to="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d289dbb0-140f-4a0c-b96f-755e4123bb5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_652e4a25-2ced-4a92-b895-dfab99ddc2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_19d424da-2c94-446e-b571-3cc1a4e4844e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_652e4a25-2ced-4a92-b895-dfab99ddc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c501a40a-2f54-4788-a29c-183be16adcab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:href="irtc-20211231.xsd#irtc_SharesUnderlyingRSUsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ee9abbd-4515-4f9e-b8a3-34f1186081c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ee9abbd-4515-4f9e-b8a3-34f1186081c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83df177f-f01f-42e3-b28d-5d7c1eb1a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_83df177f-f01f-42e3-b28d-5d7c1eb1a26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6870a0d-5b80-4a83-a6a6-6e1a844ddd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f6870a0d-5b80-4a83-a6a6-6e1a844ddd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_22605a75-3ca0-42de-b7a0-6fa832305a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_22605a75-3ca0-42de-b7a0-6fa832305a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf21266b-dbe4-4863-89a3-af5b60cc9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_SharesUnderlyingRSUsAbstract_8d2d790d-5c08-4105-9889-7af3a17c6449" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bf21266b-dbe4-4863-89a3-af5b60cc9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:href="irtc-20211231.xsd#irtc_WeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_807996fd-a5b9-40d3-aaa1-5d8f6b8a96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_807996fd-a5b9-40d3-aaa1-5d8f6b8a96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8b67633-08ba-457e-a5fc-1ef6176708d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a8b67633-08ba-457e-a5fc-1ef6176708d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3ed0cc8-8394-4970-ae66-a700462fcade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3ed0cc8-8394-4970-ae66-a700462fcade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f19960c1-6c31-47ca-8df1-bd7ea1431eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f19960c1-6c31-47ca-8df1-bd7ea1431eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f0afecc-f525-46b2-9ee7-74d146601962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedAverageGrantDateFairValueAbstract_29dc196e-75f5-4233-8b2b-25963caafb49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f0afecc-f525-46b2-9ee7-74d146601962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:href="irtc-20211231.xsd#irtc_WeightedRemainingVestingPeriodInYearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c1eb13a5-deca-447f-ac7e-872c0de26c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_WeightedRemainingVestingPeriodInYearsAbstract_6b04ae9e-66ec-4fa2-b2c6-1c1be234c94e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c1eb13a5-deca-447f-ac7e-872c0de26c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:href="irtc-20211231.xsd#irtc_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b4553028-ed35-490c-8db8-b40d370638c5" xlink:to="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9fd4888f-c0e1-4378-ab43-75a28a565b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_irtc_AggregateIntrinsicValueAbstract_a44e81d5-508a-407d-9ca5-45073b7dfa54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9fd4888f-c0e1-4378-ab43-75a28a565b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c389e56-700b-4dde-8b93-6d9ecb96cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6245bb1b-2426-4399-a91b-d870c3c105d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c389e56-700b-4dde-8b93-6d9ecb96cc6f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6245bb1b-2426-4399-a91b-d870c3c105d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f380d861-0e01-4425-b810-2faa06147f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_823bee9c-6348-4faa-8d1e-34890837b927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f380d861-0e01-4425-b810-2faa06147f71" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_823bee9c-6348-4faa-8d1e-34890837b927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b43b184d-a36e-4f59-aea4-f1ed6ab2e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f380d861-0e01-4425-b810-2faa06147f71" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b43b184d-a36e-4f59-aea4-f1ed6ab2e77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96459c0b-7d23-4316-9b8a-19f576c332a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_96459c0b-7d23-4316-9b8a-19f576c332a3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:to="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_57d5db97-cc6c-43e0-9c83-d6ee4d8d5201" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cf5bd6c8-dc1a-483c-b60a-d5dc1420fe21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cf5bd6c8-dc1a-483c-b60a-d5dc1420fe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_MarketConditionAwardsMember_233164c8-c83a-4316-9915-c3df3f464f50" xlink:href="irtc-20211231.xsd#irtc_MarketConditionAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_313b2801-76cb-4db3-a44d-3eaa34f02e9e" xlink:to="loc_irtc_MarketConditionAwardsMember_233164c8-c83a-4316-9915-c3df3f464f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fa4d3b17-596c-41b1-9084-250e1666dc1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2e0e344-7798-4713-b8ef-73d417f0d80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b2e0e344-7798-4713-b8ef-73d417f0d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18eb0de4-cdf3-43e4-a830-f42ca54a92c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18eb0de4-cdf3-43e4-a830-f42ca54a92c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf8551c3-f11c-4276-844d-b614fb979b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bf8551c3-f11c-4276-844d-b614fb979b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_341c9afa-6828-4aca-928e-ecfe96e81af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4bf4ae53-e08a-4205-98a2-0f646c7f7664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_341c9afa-6828-4aca-928e-ecfe96e81af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d717a09-a389-46ee-80fb-ce80946972f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d717a09-a389-46ee-80fb-ce80946972f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c0dd7bc5-234b-4e05-8769-3361c5917e17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_94ec9107-eba9-488c-a288-c586270048fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_94ec9107-eba9-488c-a288-c586270048fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_30031ff3-fb5e-4207-b562-283b62048cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_EmployeeStockMember_30031ff3-fb5e-4207-b562-283b62048cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ec632de6-dfaa-411d-bce1-abff30b25ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_us-gaap_PerformanceSharesMember_ec632de6-dfaa-411d-bce1-abff30b25ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_MarketConditionAwardsMember_19f43468-1d07-4ac3-9aca-cf1baca65a94" xlink:href="irtc-20211231.xsd#irtc_MarketConditionAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4921f92a-99ed-4e2e-b079-8f0e1596cf64" xlink:to="loc_irtc_MarketConditionAwardsMember_19f43468-1d07-4ac3-9aca-cf1baca65a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_594a82f5-6796-4537-8297-c13ced949b87" xlink:to="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedJanuary2021Member_a1bb90cc-4a03-4571-89f2-5451a94523cf" xlink:href="irtc-20211231.xsd#irtc_AwardedJanuary2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:to="loc_irtc_AwardedJanuary2021Member_a1bb90cc-4a03-4571-89f2-5451a94523cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_AwardedFebruary2021Member_bd698c41-279f-4842-a554-42bff8eff899" xlink:href="irtc-20211231.xsd#irtc_AwardedFebruary2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateDomain_5e6ab566-b022-4bc0-b44c-3855eade24e1" xlink:to="loc_irtc_AwardedFebruary2021Member_bd698c41-279f-4842-a554-42bff8eff899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6ca55452-2a9c-47ad-b380-a0f412c8dd35" xlink:to="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2019AwardsMember_66e7aaa9-33c3-4ed5-92e2-d4807a311b22" xlink:href="irtc-20211231.xsd#irtc_A2019AwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2019AwardsMember_66e7aaa9-33c3-4ed5-92e2-d4807a311b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2020AwardsMember_808ea34c-65b8-44fd-88fb-24416ef45d69" xlink:href="irtc-20211231.xsd#irtc_A2020AwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2020AwardsMember_808ea34c-65b8-44fd-88fb-24416ef45d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_A2021AwardsMember_eadeac36-a7fb-4e8a-8539-1f11fd198ed7" xlink:href="irtc-20211231.xsd#irtc_A2021AwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_A2021AwardsMember_eadeac36-a7fb-4e8a-8539-1f11fd198ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_52faa076-adf1-4c5b-8eea-d2b92db27acb" xlink:href="irtc-20211231.xsd#irtc_ConsultingAndProfessionalServicesAgreementCPSAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6ca0b3a0-65e7-4f32-9db7-09b220fa9003" xlink:to="loc_irtc_ConsultingAndProfessionalServicesAgreementCPSAMember_52faa076-adf1-4c5b-8eea-d2b92db27acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96a6bf5a-c88f-40a8-ab96-488bc16e7f4f" xlink:to="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3d9647a4-ae41-4660-ab11-cee05b4c04d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:to="loc_srt_MinimumMember_3d9647a4-ae41-4660-ab11-cee05b4c04d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_51b0bc6e-e098-4f26-a4e4-0114261ad408" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1f950768-e0c3-4cc4-9aaf-4ffb60a4a16c" xlink:to="loc_srt_MaximumMember_51b0bc6e-e098-4f26-a4e4-0114261ad408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a2e9b1b1-ad8a-4bf9-9592-5a81be0d47e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b2f71623-a60a-4241-8268-8619682c2567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b2f71623-a60a-4241-8268-8619682c2567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5efda895-a48c-45e9-bc9e-2c6298bbd372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5efda895-a48c-45e9-bc9e-2c6298bbd372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_042c6f08-9bbe-4108-88b6-74ae41263709" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_042c6f08-9bbe-4108-88b6-74ae41263709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6a58eaf7-c47a-401c-b111-3cc97c26f7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6a58eaf7-c47a-401c-b111-3cc97c26f7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_59d2646a-1e74-4120-ba07-b45f1828caaf" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementReversalOfPriorExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense_59d2646a-1e74-4120-ba07-b45f1828caaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_0ad72182-e571-4f69-bdda-a073c6d66487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_0ad72182-e571-4f69-bdda-a073c6d66487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f4c10b32-5ee8-4e95-b6c3-27050f43fbde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_f4c10b32-5ee8-4e95-b6c3-27050f43fbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7bf3a2c-d3fe-42b8-b2ba-9c15e040386e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a7bf3a2c-d3fe-42b8-b2ba-9c15e040386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_97093606-9509-4c55-bd54-28c0d82a31c8" xlink:href="irtc-20211231.xsd#irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage_97093606-9509-4c55-bd54-28c0d82a31c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_76676af1-bda6-465c-9e25-5b2bb5c51c55" xlink:href="irtc-20211231.xsd#irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold_76676af1-bda6-465c-9e25-5b2bb5c51c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40d8fc6c-acb4-4351-80ab-9048190a73da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40d8fc6c-acb4-4351-80ab-9048190a73da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_e7b5825f-7ccd-4dd6-ac9d-e26cd4888f72" xlink:href="irtc-20211231.xsd#irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_754fb038-1839-438a-96c2-79cbc014cd7c" xlink:to="loc_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue_e7b5825f-7ccd-4dd6-ac9d-e26cd4888f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18980c27-e29e-4f9c-86dd-c13d20fdbb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_18980c27-e29e-4f9c-86dd-c13d20fdbb5e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_504c63bc-a96b-4b03-8064-fc530898d28d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_eb6938fa-89a6-4a9e-813f-2140ce1d8059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_CostOfSalesMember_eb6938fa-89a6-4a9e-813f-2140ce1d8059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_418fe858-f361-405e-bad3-a31e5260d5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_418fe858-f361-405e-bad3-a31e5260d5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8ed27cb-4e8b-47c2-b69f-23ed49df28e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a04eb3b7-0ad6-48e2-b79c-95971f020c98" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b8ed27cb-4e8b-47c2-b69f-23ed49df28e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_733a4a52-cd76-4037-996f-3e857327c723" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b465cce2-ae93-4692-b083-a3e62b3087e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_db0a82f4-7ba9-49e3-887a-441d53d6d4c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b465cce2-ae93-4692-b083-a3e62b3087e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="irtc-20211231.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37c468c3-6951-420b-b3f9-f54b318be1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_bee72e0e-1bdf-4693-9750-2d0a208e1e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37c468c3-6951-420b-b3f9-f54b318be1da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_bee72e0e-1bdf-4693-9750-2d0a208e1e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="irtc-20211231.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6e1746f2-a53b-411c-9d41-f01d3351f294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cc1c2ac8-e58a-45bc-a4f1-9f0aabe7306b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e1746f2-a53b-411c-9d41-f01d3351f294" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cc1c2ac8-e58a-45bc-a4f1-9f0aabe7306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c0133f78-5a84-46bb-9c92-ba6af53aa7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6e1746f2-a53b-411c-9d41-f01d3351f294" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c0133f78-5a84-46bb-9c92-ba6af53aa7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4ea92b6-ab02-40b3-a2b3-ec1a58ec615d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_32db2299-5a07-45d7-887c-ac93e053e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ea92b6-ab02-40b3-a2b3-ec1a58ec615d" xlink:to="loc_us-gaap_NetIncomeLossAbstract_32db2299-5a07-45d7-887c-ac93e053e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1d5923ba-fa8c-47f8-b554-29f6337d2caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_32db2299-5a07-45d7-887c-ac93e053e5d3" xlink:to="loc_us-gaap_NetIncomeLoss_1d5923ba-fa8c-47f8-b554-29f6337d2caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3953ffc-a646-453f-aef4-bcae6d722f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ea92b6-ab02-40b3-a2b3-ec1a58ec615d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3953ffc-a646-453f-aef4-bcae6d722f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37ebeb24-8af2-4f6a-bf92-8d401770423c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3953ffc-a646-453f-aef4-bcae6d722f75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_37ebeb24-8af2-4f6a-bf92-8d401770423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0af8bbe5-ddc5-44ad-a85a-1c4d2fbb27ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d3953ffc-a646-453f-aef4-bcae6d722f75" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0af8bbe5-ddc5-44ad-a85a-1c4d2fbb27ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3c23c57d-c4d8-40eb-861f-8803cac057c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ea92b6-ab02-40b3-a2b3-ec1a58ec615d" xlink:to="loc_us-gaap_EarningsPerShareBasic_3c23c57d-c4d8-40eb-861f-8803cac057c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ac78655-4918-42a1-98ce-a65479c60dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ea92b6-ab02-40b3-a2b3-ec1a58ec615d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ac78655-4918-42a1-98ce-a65479c60dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0d36270c-f5d1-4fd5-8a55-490a2f6deb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0d36270c-f5d1-4fd5-8a55-490a2f6deb9d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1199a9b9-6164-4cc7-b1cf-ecb6d30f1d48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7820d577-c98d-42ce-bd77-d259b1618d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7820d577-c98d-42ce-bd77-d259b1618d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dff495b7-536b-4fb0-afa9-4439fbbe1718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23f14854-902c-470c-8b7c-74ce4505d972" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dff495b7-536b-4fb0-afa9-4439fbbe1718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_20a7b651-3f2c-4142-a910-799e58287a11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aab3acf1-18e6-4488-81a4-f3823461708a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1fd6380c-1bdc-48aa-b0b5-1275c8cf51c7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aab3acf1-18e6-4488-81a4-f3823461708a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="irtc-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d9972ec9-bc17-4c42-98f6-1a5c358f4014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_942bef28-b6c5-4737-9a60-5d3d5c2e6b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d9972ec9-bc17-4c42-98f6-1a5c358f4014" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_942bef28-b6c5-4737-9a60-5d3d5c2e6b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.irhythmtech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="irtc-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.irhythmtech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_6980bed5-51dc-4bce-8651-da7734212387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_6980bed5-51dc-4bce-8651-da7734212387" xlink:to="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e064652d-48ff-4de5-b44a-3f68d351a2b0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3f80fb56-6018-42e2-b93a-53e2b6585fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bbd774c2-3497-4e32-bcf7-2f601a3bf705" xlink:to="loc_us-gaap_SubsequentEventMember_3f80fb56-6018-42e2-b93a-53e2b6585fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:to="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b374abd-01c6-4904-91ce-756815c076b0" xlink:to="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_db3dda02-b81f-4bd1-abbe-1efe9ea982c5" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93243Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93243Member_db3dda02-b81f-4bd1-abbe-1efe9ea982c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_a5928839-275b-45c4-a3c4-48ec18caa417" xlink:href="irtc-20211231.xsd#irtc_ProductAndServicesZioXTServiceCode93247Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ec695cf6-d2aa-4f9b-a675-5d0d1268e542" xlink:to="loc_irtc_ProductAndServicesZioXTServiceCode93247Member_a5928839-275b-45c4-a3c4-48ec18caa417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_257a0960-8a34-429d-9cfd-7f6715cf91a6" xlink:to="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_CostReimbursementRate_040ae30d-6e9a-4ae4-b1a0-2e6b64a92279" xlink:href="irtc-20211231.xsd#irtc_CostReimbursementRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:to="loc_irtc_CostReimbursementRate_040ae30d-6e9a-4ae4-b1a0-2e6b64a92279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_irtc_OperatingLeaseRentableArea_8e361824-426a-495c-86d5-e1e8653e8cef" xlink:href="irtc-20211231.xsd#irtc_OperatingLeaseRentableArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_95ead9fb-6f9d-461e-a1dd-d122d399b814" xlink:to="loc_irtc_OperatingLeaseRentableArea_8e361824-426a-495c-86d5-e1e8653e8cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>irtc-20211231_g1.jpg
<TEXT>
begin 644 irtc-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHKGO%WQ#MO!_B;P[I<T,\LWB2Z>UA=,
M;8BD32$M[87''K0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5YC\;_\ DKGPM_[#%Q_Z2R5Z=7F/QO\ ^2N?"W_L,7'_
M *2R54=R9'IU%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO$'B/]IE'M-#^U>&? \PVSZM(A2]U5,_,MNIYCC(XWGDCH.U-(3D1ZII]O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX"^/_ASQ[J']GK//I.MQ\2:7J49MKI#Z!6X;_@)-=O4E!1110 4444 %%%%
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M?L ?#?\ ;P_9^TWXW?&W1F^)?CCXES7&K2R:M>3M:Z3#YSQQ6EM"KA$CC1%
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MX3BIQ;5G9W6JN[---.S:TNFT53GS+7=!1117DF@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOHY+@X.&'KPJU*LHJ<O9VM",HJ2T<6YM1:;U@E>U^ISNI)^\K);:]?Z^9]*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\M_9I8:W<^.-?.YFU?Q%<(C'O%"%B3'L "*]28X%>8_LB(!\$[5_XIK^^D
M;ZFZE']*KH3U/3J***DHS?%_B)?"'A74M5DAEN$TVVDN6BCQOD"*6P,\9.*=
MX4\10>+_  QI^K6NX6VI6T=U$&^]M=0PS^!IWB73!K?AS4+,C/VRVDAQZ[E(
M_K7%_LK:H=3^ /AL,V9+.W-E(/1H7:+^2BGT)ZGH5%%%(H**** "BBB@ HHH
MH *^,_VL?ASK'["/QEOOVC?AU87E]X9U$(GQ2\*6*;AJ5J#C^V+>,?\ +U #
ME\<R1AL\@D_9E1SP)<PO'(BR1R*596&5<'@@CTKT\JS.6"K<S7-"2Y9Q>THO
M=/L^J>\9)-:HBI#F7F?/%[^Q;\#?VNOBGX5^.T-FFOWTB6>J6=[9:E*NGZJT
M'SVD\\"MY<LD.?D+C*D8/3%<5_P4#UVS^+W[5O[//PMT'R]0\6:7XTM_&^IB
M$[GT/2[&.0O-+C_5B5F6-,_>;I6IJ_\ P21\$Z3XEU+4/AYXU^*7P?@UN<W.
MH:7X-U\V>FW$A^\PMY$D2)CW,87VQ@5ZE^RY^Q7X#_9#T_5/^$5LK^YUG7I?
M.U?7M8O9-0U?5G'0SW,A+L!V7(4=A7T?]J8/#RCB88BI6=.+C2A*-N2Z:]Y\
MS5HWNE&_-9)\J,/9R?NM)7W?<]:KG[7XA6MY\3;SPND,WVJRT^/4))N/+VN[
M(%ZYW?+GIC!KH*\O^%177OV@OB-JB_,EHUGI2-[QQ%G'X,WZU\4=#/4****1
M0UT61&5AN5A@@]Q7F/[*F=,\$:QH;'_D7-=O;!%_NIYAD7\/GQ^%>H5Y;^S\
MRP_$3XGVZ?=CU\2_B\*L?UJELR7NCU*BBBI*"BBB@ HHHH *\Q^-_P#R5SX6
M_P#88N/_ $EDKTZO,?C?_P E<^%O_88N/_262JCN3(].HHHJ2@HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5Y?\ LA3!_@[Y8_Y8:I?Q
M_P#DS(?ZUZA7EO[)\?V;PEXEAZ);^)M01%'11O!Q^9/YU70GJ>I4445)05XG
M^QKXKCOO^$VT3Y5DTK7KB9%':.5VQ_X\C5[97RW\ 9O^%?\ Q/MM</R6/BK6
MM3T*\8_=6=9O,MR>W.&4?CZU4=F1+1H^I****DL**** "BBB@ HHHH ****
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M5$1=JH!T  X %&BV#5[GFW[,9SI_C3_L;+__ -IUZ;7F/[,!SI?C+_L:[_\
M]IUZ=1+<([!1114E'E?[))W>#?$?_8S:A_Z&*]4KRO\ 9+&/!WB3_L9M0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O*_P!D-EF^'6K3JNW[3X@OY#GJ3YN/
MZ"O5*\K_ &/DV?"2<_WM9OS_ .3#U70GJ>J4445)05Y?^S8[+J/Q"A8;3'XL
MO6Q[,0P_0BO4*\P^!""T^)GQ0M^C#78YOP>VC/\ C5+8E[H]/HHHJ2@HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS'XW_
M /)7/A;_ -ABX_\ 262O3J\Q^-__ "5SX6_]ABX_])9*J.Y,CTZBBBI*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA5#<8/ XSCGK6LTR1J"S*H;H2>M #J*"VT4U)%E7<K*R^H.: '4444 %%%%
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M34?AG_V*NF?^DL==/X:^&^B^#O <7AG3;(6VA0P/:QVGFNZQQ-G* LQ8+AB
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M_B+PHAW?Q9SWK9^('[.'@KXHZ]_:FMZ''<W[Q""6:*XFMS<QCHDOE.HE49.
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M,OP!\#V^C? FUC\)Z"MO>>)K>VFC%HNV6*73[J61",8*O(B,1W* ]J]WTKX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_"OX?:M\7_#7Q&U34_'7CBWGTWQ9K=KI"V6KRV\>FI#<.$X4_O ".$DW(%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRL.X()'XUY%J?[$?AW7-)LM-U+Q)XYU+2](NK:[TNSNM6\R'36@E62,(-F7
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M )*Y\+?^PQ<?^DLE>G5YC\;_ /DKGPM_[#%Q_P"DLE5'<F1Z=1114E!1110
M4444 %%%% 'G'B_]FG2_$OB74M4L=>\6>%Y-;P=4AT6_%M#J+!0F]U*-MD*
M*7C*,0!DG&:TA\ _#MM?>!Y+.WFTZ'X?O*^DVULP6%?,MGMV#@@EALD8]0=W
M))YSVCL$0L>BC)K*\#^.-*^)'A+3]>T.\34-)U2$3VMRBLJS(>A 8 _F*KF=
MB>57(/B5\/-+^+/@+5/#>M0R3:7K$#6]PJ.4< \AE8=&! (/J!7/:5\ +.TU
M;PGJ&H:]XFUW4/!]U=75E<ZC<Q222&X@:!EDV1J&4(YVX .>237;ZEJ5OHVG
M7%Y>7$-K9VL;33SS.(XX4499F8\!0 22> !3[:YCO;:.:&2.:&90Z.C;E=3R
M"".H([BE=ARIG-> _A)I?PZT76["QDO'AU[4[W5;DS2!F6:ZD,D@4@#"AF.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?MFW7B/7]<.@^)/ACH6GZ+?3Z=#;>(;F7[9J<D+%'?\ =R*((RX95)5R0-Q
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MUW#A@#D9[XSQ7J1^)/AT'']OZ+QV^W1?_%42C9V",KI,VJ:[B-2S$*JC))/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SO\
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M"^*7PJU/X@>,_#OQ NOAQ9:]/#ITVD:EX8U66SDNHHC*)(YX9"S0>8K!LJ7
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MXMNQ8:?-_;$5U<1W#1M)''/ J QEE1AE6<*V 2,YK,TW]JGQ1XLL?%%YX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M',CNJ*\]U?\ :7\-Z-#K[R+J<O\ 8.JIH86"V\V34[YHUD^SVR*2TC@. 1@
M$-SA20_P9^T+I_BG6[K2;W1?$GAG6+>S;4$L=8M4AEN[=2 \D3([HX4E0P#9
M7<N0 0:.5AS([^BO'/!W[;/AGQIH_AW5X]&\767AWQ.\,-IK-WIHCL4FF(6.
M)V#EE)<A-X4Q[CC?R#53X>_M%:]XA_:G\;>$KKPWXD.CZ6+".SD^RVRQV!=;
MGS)YG$NXQS>6ACP&.%.57/)R,/:(]NHKRN?]K704U"9HM&\67F@6]\VG3>(;
M;3?-TR.99/*;Y@WF,JR90NL90,#\V 37JE)Q:W&I)[!1112&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&<UUL]UJ'P6_:!\2:\F@ZQXFTWQ9I6FQS+HZI<7FESVXF1%D@+!A%(KDK(.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **X7]I']H;PS^RK\
M%M>\>>+KLVNBZ#!YCA%WS7,A(6.")>KR2.515'4L/K7SKX4^'O[57[46EKXJ
MU?XEZ7\!=.U0+<:9X5TSP[!K-]90-RGVVXG8#SRI!98P%4G'4&O7P.42KT7B
M:U2-*G>W-+FLY;M148RDVDTW965U=JZOG*I9V2NSZZUN=K71KR2,[7CA=E/H
M0I(KYF_X(OVZ0_\ !-+X9NJ[6N(;V:0_WF-_<Y)JA/\ L2_M#7,#QO\ M:ZT
MR2*58?\ "!Z=R#P?XZYOX/?\$ROC)\ OAMI?A'PG^U-K6E>'M%1TL[7_ (0B
MPE\D/(TC?,\A8Y9V/)[U[M+"9='+JF#>.I\TIPE\-:UHQJ)W_=;^^K?,Q<I\
MZERO9]O+S\C[6HKY"\3_  K_ &K?V>].7Q)X?^*VB_&Z'2U,E[X5UGPS;Z/<
M:G""2RVUS;L=MQ@G;Y@V$@ YXKWG]EG]ICPU^UU\$M'\<^%9ICIVI!HYK:X7
M9<Z=<QL5FMID_@EC<%6!],]"*\/&Y/*C1^LT:D:M.]G*'-HW=I24HQDKI-IM
M6=G9NSMM&I=\K5F>B4445XYH%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\ ?\ !2;X[Z)I?[>OPE\/^/M%\977PR\ VC^,[@:7X=O-4@UC6"SP
MV4+"!&!6#;),=PQN*#G)QZ1_P^G^#O\ T"?BW_X;[5O_ (S7UO7A/[3W[2&O
M_"_]I+X$^ O#L6G22?$C7+Y=6-Q$9)(M-L[-I96CPPVMYCP+N(; 8\<Y'VF#
MQF"Q].C@JF'DW2A+:JHJT5*I*5G3EJ];ZO9+9(YY1E!N2>[[?+N>??\ #Z?X
M._\ 0)^+?_AOM6_^,T?\/I_@[_T"?BW_ .&^U;_XS7T3\?O&MY\-?@5XT\1:
M?Y/V_0="O=1MO.7='YL-N\B;AD9&Y1D9'%8_[(7Q1U+XW?LJ_#CQCK/V?^U_
M%'AJPU6]^SIY<)FFMTD?8N3A=S' R<"N?_A)^K?6_JL^7F4?XRO=J_\ SZ[(
M/WG-R\R^[_@GAW_#Z?X._P#0)^+?_AOM6_\ C->8?L%?M':%KW_!2KXB:?\
M#W1?&\'P\^*6D)XFNQJGAJ\TNWTO7H&\J<KYR* )X3&Y(P&=<=0<_1_P"_:5
MUSQU^V7\</AEKR:<D7@*32+[0S! T<TUA>68=FD)8A\3I*H8 <@CG%>[UT8K
M&8++Z=7"PPTDZM..]525I*-2+M[.-VM'NM;KN*,93:E?9]OEW"BBBOBSI"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#!3!_\17'[;A__ )\UO_!D/_E1=JW=?<_\SPO_ (?0?LN?]%G\)_\ D?\
M^-T?\/H/V7/^BS^$_P#R/_\ &Z]T_P"%&>"?^A.\*_\ @I@_^(H_X49X)_Z$
M[PK_ ."F#_XBCVW#_P#SYK?^#(?_ "H+5NZ^Y_YGA?\ P^@_9<_Z+/X3_P#(
M_P#\;H_X?/?LN_\ 19O"GY3_ /QNO=/^%&>"?^A.\*_^"F#_ .(H_P"%&>"?
M^A.\*_\ @I@_^(H]MP__ ,^:W_@R'_RH+5NZ^Y_YA\&OC5X4_:&^'=CXL\%:
MY8^(O#NI;_LU]:DF.4HQ1NH!!# C! Z5U5?'O_!"I=G_  3I\.JH 5=8U< #
ML/M\U?85>?GV A@<RKX.DVXTYRBF][)M*]NI5*3E!2?5!1117DF@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>\U6UTZ>WCN+BW@DN
MG\J!9) K3/@G:H/WC@$X'/%6*XGX\?#B;XB>"/\ B7LL6O:/,FI:3-_SSN(S
ME1]&Y4_7VK0^$GQ(M_BKX%L]7A0P32 Q7=LWWK2=3B2-O<-GZC![T^EQ7UL=
M-1112&%%%% !4,FHV\-]':M/"MS,K/'$7 DD5<;B%ZD#(R1TR/6G75U'86LD
MTTBQ0PJ7=W.%11R23Z 5Y;\$H)/BCXXU7XB74<B6EPATS0(Y%P4LT;YIL'H9
M7Y^@'K3$>K4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>:6_QJ\"^*?VJ[CX>K;I>?$+PKH*ZZTS:?O\ [/L[B3R@%N"/D:0KR@(+
M*N>0*]+KS?X:^"?AU??'7QUXW\,S:??^-+S[-X?\2W-OJ#7#6YM%+16SQ[RD
M+*LQ8@*I.X$YXKNP?LE&K*JI74?=Y=E)M+WG_+:_J[+9LF5]+'6?$OQ)I/@W
MX=Z_J^NQB;1-+TZXN]00P>=OMXXV>0;.=^4#?+WZ51^"'C?P_P#$OX-^%?$7
MA.%;?PQKFE6U]I,0MOLHCM9(U>(>5@>7A"ORX&.E7OB7I6BZ[\.?$%CXD:)/
M#UYIUQ!JAEF,*+:M&PE+.""@V%LL"".N15#X(>'O#/A/X-^%=+\$R6\G@_3]
M*MK?1'@N6NHFLUC582LK%C(-@7#%B2.<FI_=?5&[2Y^9:_9M;_TJ_P"%PUYO
M(P-;^,G@?P5^U#H?@FXM1:^/O'&CW%]:72:=_P ?MK9LN^-[D#JGF;EC8YP6
M('6O2J\W^+O@CX=I\4_ /C?Q?-8V'B3P]>SZ9X8O;G4&M<W%["T;VZKO"RM)
M&K (P;[I( /->D4\5[)TZ4J:E?E][FV<DW\/]WEY?1WZ6"-[M,****XB@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHK-\4^+M*\#Z1)J&M:II^CZ?&RJ]S>W*6\*EC@ NY
M!)X'/)JHQ<GRQ5V!I45PY_:=^&H/_)0O _\ X/K7_P"+I/\ AI[X:_\ 10_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7B'Q1\1VW[,GQ;M/$4<T:Z#XRE,6KV(R7CF1<_;(P.P& X[Y!Z
MGCU_Q/XFL?!V@W6I:G=16=C9H9)99#A5 _F3T ZDUYK\)/"\WQ6\37GC_P 1
M6;1PWT#6>AZ=<I_QZ61R&=U/\<W4YZ*<=ZJ/F3+LCU33M1@U>PANK6:.XMKA
M!)%+&VY9%/((/<&IJ\:31-8_9=U&:;2[6\U[X?W#F62PAS)=Z$2<LT0ZO#WV
M]5_GZ9X)^(.B_$;2%OM$U*UU&V;J8GRR'T9>JGV(!H:Z@I&S14.H:C;Z5927
M%U/#:V\(W22RN$1!ZDG@5Y/KOQ3U?XX7;Z'\/9'M]-W>7J'B9H_W,"_Q);9_
MUDAZ;APOY$)*XV[%'XM>/[7XQ_$VU^&.GZ@MO9RLSZY<*V#.D8#-9QG^^PP6
M]%!]Q7LNG:=!I&GPVMK#'!;6T:Q11H,+&BC  'H !7G'BO\ 9QL(?A=:Z3X;
M/]FZQH4PU#3+YFS(;L<EY6ZMYG(;/4'V K=^#?Q7B^)V@.+B+^S]>TUOL^JZ
M>_$EG..O']P]5/0C\:;VT%'?4[&BBBI*"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=^)>J^
M(M%\/"Z\-Z;9ZM>0RAI;6>7RC+%SN"-TW],9XKHJ* .'^&_Q\T7XB7;Z>WVC
M1]>M_EGTN^7RKB,^P/WA[BNXKEOB3\'/#_Q5M475K/\ TJ'FWO(&\JZMCZI(
M.1]#D>U</_:WCKX!KMU&.?QUX7C_ .7N!,:E9I_MI_RT ]1SQVJK)[$W:W/8
M:*P? 'Q,T/XGZ0MYHNH0WD?\:@XDB/HR]5/UK>J2@HHHH **** "O%_V*?V8
M;[]F'POXWM]6U+3]7U;QIXVUCQ5<75I"T2LMW<%XD8-SN6,(#R0"" 2 #7M%
M%=5/&5:=">'B_=G9OSY;V_/\NQ+BF[G*_'#P'<?%+X+>+O#-I-#;W7B+1;S3
M(99@3'$\T#QJS8YV@L"<<X%97[*_PEO/@+^S1\/_  3J%S:WE_X2\/6.D7-Q
M; B&:2"!(V9-V#M+*2,@'&*[^BCZY56'^JW]SFYOG:V_HPY5?F/%?V[_ -ER
M^_:T^#&FZ!I>H6.E:QHOB;1_$5E=WD;210O9WD<S\+SEHA(H]V&<#->U4445
M,95G0AAI/W8.37DY6O\ ^DK\>X<J3N%%%%<I04444 %%%5M5U:UT/3YKR]N(
M;6UMUW233.$1!ZDG@4 6:P?'WQ*T3X8Z1]MUK4(;*$\1JQW23-_=1!\S'V K
M@;[XYZY\4KV33_ASIHGMP=DNOWZ%+*'U\M?O2'\A]16QX"_9VT[P]J_]M:Y=
M7'BCQ(W+7]]\PB]HD^ZBCV'Y55K;D\U]B7X:?$;Q-\2/$37A\/\ ]B^$_*/D
MR7S$7UV_&U@@X1,9X.3_ "KOZ**DH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KXO^*?@W2_\ @IU^V%J'@?6;2/6?@G\%
M'*Z];.S"W\1^(Y8R$MB5(W1V<3EFP>)9 .U>L?\ !0W]J>;]ESX"23:&UG)X
MZ\77*:!X5M[F58XFOILCSY"QPL,";YI&/ 6/DC.:^>OV7_C/K&B?!O2?A3^R
M[X?C\>7&FE_^$B^)^OA[?PVVHRL7N[M7XEU"9I69ML0VCY1OP./MN'LMQ5+"
M3S.C[LG>,)-\JA_/4<GLTO=AU<FW'WH'-6G%RY'\_/R_K]3SC]H/]@WP+_P2
MST2Z\:6OA/X1_$CX4>=NN/#'C33K-/$%F6;[FF7[QEKIN>()@S'@!NXQ_AYX
M(^'O_!3'QUJW@[X4_"?X0_!/0M'5!K.H:YX6T^3QI*C*"?L>GLFV",@X^T2;
MQGH.,'[0^!W_  3NT/PIXY@\??$O6K_XP?%!1E-<UV-?LNE$G)2PLA^YM4&>
M"H+\#YJZW]IO]B#P#^U2+6^URQNM*\5Z3\VD^*-%G-AK6DOQAHKA/F(X'R/N
M0]UKWO\ 72A&2C6JSJ54K>V5^5/2S]DVE4MK[TE&3O=Q;2OE]6>Z5EV_X/0X
MOX)?\$C?V>/@;X#AT*S^%_A37-OS7%_KFGQ:A>7CGJ[R2*<9_NJ%4=@*\(_:
MD_8L^#_QN_:E\&_ OP/\+?A_HJ6)B\6>/]7TS0;6WN-.TN-_]'L4E1 R27<H
MP<881(YZ'([/XC?M2?&3_@FEX/O;SXL:>GQ@^'%C'Y5EXRT98[/6K:0C;!#J
M-F2$?>^Q/.@/\62F>O9_\$H= TW6_@#>?$J;Q#HOBOQS\5[]O$'BG4--N5N(
M[6X88BT\$<JEK%MB"'&"K''-<<<5FV"IU,ZKXF55-\M.2G*493DOB:WCR+7E
MDD^;DTM<?+3DU34;=].G_!_S.\;_ ()R? %VW-\%?A<S'J3X9LR3_P"0Z^>?
M^"A7_!.OX;_#CP/H/Q4\"_"/P+<7'PMO6U36?#EOH%M]F\2:.R[;V%H@FUID
MC_>Q,02K1D?Q5]W5%>M"EG,UP8Q;A"93)C8%QSG/&,>M?+Y?Q-F.&Q$*SJSD
MD]8N4K-/1K?JFU?=;K4WG1A)6L>!?#?]BG]FOXL_#K2?$GAWX2_"N^T'Q)8Q
MWMG<0>&[0+/#*@93PG!P>G4'/<5\N_M%?\$K_ /[#EMK7Q,\!Z+\([SPA"3=
M:OX.^(]E;2::PY)^PZA*C36LIZ+&QD1C@8['-^ 7[9&H?L\_'GQE^SS\";'0
M_BAIVJ:K/?\ @.\EU3[/HGAO>&FO]/EGP?-2V?=(D=ON;;)MXQ@?3'PP_P""
M=*^)O&UGXZ^.WB67XP>.;1Q-96US#Y'AOP^_'%E89*;A_P ]9=[GKD'-?92K
M8[)<1*IB\7/V,TG&$FY3J0>JO%M<C6SDW%Q:?)S6.>T:BM&.JZ]%_G_5SXO\
M#>,?AE^WOXVTSX?_  J^!7P=^"^J:EIT5_>ZQXW\+6+ZDT4G7^R;+8JW;#!Q
M*S!0"#L'%>X>+_\ @D9X;_8H^"UIX[^!>ESW'QA^'MZ/$0U&Y(^U>*HE4_;-
M.D6,+&D<\+2!8XU55<)CIFOKC]H?]E#X?_M3>#X]%\;>';/5(;4B2QNDS!>Z
M7(/NRVUPA$D+J<$%&'3G(XKPGR_CU^P2J^7_ &I^T3\*[8G*L8X_&NA0CT/R
MQZBBCUVS<=QT4>**F+4:>6U/9)/WJ-23:J=TZLG[R:TY)\J7V;R8>P4=9J_F
MNGR_4^C/@+\;-#_:-^#GAWQQX;N/M&C>)+)+RW)^_'GAHW'9T8,C ]&4CM78
M5\ ?L,?M4> _A[^UMJWA/P;KUO>?"_XS7EQK.@6KJ;>X\)^(E&[4-)N+=\/;
MF;!GC1E W"11GJ?O^OBN(,IEE^+=/E:A)<T>96=GT?\ >BTXR\T[:6.FC4YX
MW"BBBO#-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Y%_X)9?\CY^T]_V6+6?_:=?75?G+^QM^WW\'?V4_C-^TEH?
MQ"\>Z-X5U:]^+&L7D%M=^9ODA+*H<;5(QE6'X5[Y_P /GOV7O^BR>%_RG_\
MC=?=<2</YK7S"=6CAJDHM0LU"33]R.S2LSEH5H*"3:^_S/IZBOF'_A\]^R]_
MT63PO^4__P ;H_X?/?LO?]%D\+_E/_\ &Z\/_5?.?^@2K_X+G_D:^WI_S+[S
MZ>HKYA_X?.?LO_\ 18_"_P#WS/\ _&Z/^'SG[+__ $6/PO\ ]\S_ /QNC_5;
M.O\ H#J_^"Y_Y![>G_,OO/IZBOF#_A\_^R__ -%C\+_E/_\ &Z4?\%GOV7V/
M_)9/"_Y3_P#QNC_5?.O^@2K_ ."Y_P"0>WI_S+[T<[_P0L_Y1U^'?^PQJ_\
MZ7S5]@5\>?\ !"647/\ P3B\+S1_-%<:IJLL;=G5KZ8@CV(K[#K;C'_D>XS_
M *^S_P#2F+#_ ,*/H@HHHKYLV"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQY?Q"\'N='\365Q&;>Z,\6%6Y:%L.BS+M?!'RL77JM?3M?GU_P %9_V4=/\
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MQB7Q-XDD_M#5)3]X.W*PCT6-2% [8-=[112&E;0**** "BBB@ HHHH ****
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MA5M,USR_CMX7U>'6_A_I6F6[7VJZA=*0LEN8(P7%M/$S1R,V$ (.25 /CG[
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MHR>C8/%CJ,L7B84J<O9X)Q]JE'11@M)7_FJ1=Z=Y-N4K6=I(J+Y8WWEM\_\
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M"BBBL1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9:I;_#_4M"T?Q=(J_8;O6+5[JSB.X;MZ(RL<KN P>"1UKXT_:J\=?MD?LK_
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M;X>FZM?"U(Q6[<))+U=M"HUJ;=E)?>>TT445XAH%%%% !1110 4444 %%%%
M!1110 4444 >=?M;W'C2U_9C\>2?#I(Y/'":)='15?K]H\L[=O\ M]2N>"VW
M/&:_.3_@C-8?L]ZKI'@]/&ESK]Y\6(DDET.V\>*JV*2-(QF;2%_X]WD,N[S&
MYN-X.[&!7ZP5\(_$#]GCP5\(_P!K:_\ AIX]\/Z=KGP8_:$OI=7T!+J+Y/#?
MBE5#7$,,@PT!ND42QLA4^:CJ.O/WO"N94_[/Q.62YHN5IJ4&E-J*:E'7XDHM
MRY;QNE)<UVCDQ$'SQG\M3U'_ ()4!A\%?'^[.[_A9_BG.?\ L)RU].U^9_[
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MCTRBBBD45]5_Y!=S_P!<F_D:^;/V>5'PPN_ .M[?+TOQE93:->-_"ETEQ+)
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M)-5M$N8A$HR<*P.68@!0.2Q ')%?G'^RG^SO\3OV0=#7]J3PQX+74O#6L1W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY1OI7F?[((V_ RQ'I?7X_P#)N:JZ$_:/3J***DH**** "BBB@ HHHH ****
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M6_X)T_ 3Q+J&H:_\>OBII_V7XJ?%*-"FGR _\4GHR\VNF(#RIQB20G#%V 8
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M_P 51_PM[PG_ -#1X=_\&4/_ ,57@_5JW\K^YFO,CHJ*YW_A;WA/_H:/#O\
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M+8; 8]^M?2'['7[8WBKPA\56^ ?Q[%OIWQ2T^$OH.NI^[T_Q_8KP+FW)P!<
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MB,R_"JZA?Y7MM9OXV7/W3Y[''ZU70GJ>I4445)04444 %%%% !1110 4444
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M;/KR2DU&4>R;4UM:5N9Y1E*&D_O_ ,SZ]HKY1/\ P5)N?*\E?V=?VDCJ6/\
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M]^'_ /BZ/^'-?[+O_1%/!?\ WX?_ .+KZ:HH_P!:,Y_Z"ZO_ (,G_F'L:?\
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MQ+XY\<ZG:1ZL75AE](L6E2:*08XGE:/'7:<8.1\.[_PO_P $S?B1JGCCP?\
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M;^"?[1^@6\;>#M'\'Z[IK>;IFM^'M/M[.YLI!R"4">5,F<925&!]CS7A&K^
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MM%7NBZ=%8W&E>,?%EE'K&GQQ_>;1KEYGB@)&0(G7)  \P]*]T^(/_!6OPO\
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M_E%_\:O^Q<E_]#2OIBOF?_@L?_RB_P#C5_V+DO\ Z&E>YPQ_R.,)_P!?:?\
MZ6C.M_#EZ,]T^#7_ "2#PI_V![3_ -$)725POA'1[[Q%^S?I>GZ7JLFA:G?>
M&X8+34HX5F>PE:V54F"-\KE&(;:>#C%?/:?L&?M"!1G]L#Q63CD_\(7I_/\
MX_4T<#AZ]2HZ^(C2LWI)5'?TY(27WV%S225E?[O\SZ^HKY"_X8-_:$_Z._\
M%?\ X1FG_P#Q=>K_ ++'[/WQ'^"FH:S)XZ^,^L?%6'4$B6T@O-#M=.73F4MN
M93$2S;@0,$@#;TYIXK*\)2I.I2QD*C7V5&JF_1RII>>K01J2;LXM?=_F>6Z
MY;_@N)KV=WR_!V$#/;_B;+7UQ7R/X?\ ^4XFO?\ 9'H?_3JE?7%;\1?%A_\
MKS3_ "%1^UZL****^=-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *^K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^8\9SBK7@+XBZ'\4?#J:OX>U*UU;3))'B2YMVW1LR$JP!]B"*G4JZ-JBBB@
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M873V+5%?/GQL\2?%3X/^%8;A?''AG5M<U6X33]&TJ+PLRR:G=OG;&#]J.U0
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MN;>RU"2"V8&1IE9(S+$K*K\'*%<_-@_8,6GV\"3*D$*"X8O*%0 2L1@EO4D
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MBK1_A=^U]XJU/QE?6.D0:QH>GQ>'M0U&58;<1Q-/]J@21R%5_,:-RF06!!Y
MX]>LO!>CZ:LBV^DZ;;K,5+B.U10Y4[ES@<X/(ST-6M4T6SURV\F]M;>\AR&\
MN>)9%R.AP011S*U@Y7>YY/\ LF!-1O?B#K&DQF'P?KGB1[O0QL*I.OD0I<3Q
M_P#3.6X65E(X/)'7)P?@=H]C/=_M#3-:VLDUUXJNX+AVC#-*BZ9:81O51N;@
M\?,?6O?HHE@C5$5510%55& H]!4<5A!!YWEPQ)]H8O+M0#S&( );U. !D]A2
MYA\A\EV^F66C_P#!./X,R6L%M;_Z=X4NE=% _>RWUJ9) ?[SEWR>IWGUKT#P
M=XZ\/?"+X]_$[_A.-2TW0]2UJ\M[O3KW4YEMXKW3%M8T2.)W(#>7*L^Y0<@N
M"1R"?<O[(M?L4=M]FM_L\.WRXO*&R/;@K@8P,$#&.F*9JF@V.N+&+VSM;P0M
MNC$\2R;#ZC(.#5<_<7L[;'R+H?A])M'^$HNK+R_#^I_%F_U#0;.YBVB*P:WU
M&2VQ&WW5XWJI P"IXXKT;Q@8[;]K/XA+'Y<?G?#.WEE"@#S&%S?*&;U( QD]
MABO>I[*&Y>)I(8I&@;?&64$QM@C(]#@D9'J:1]/MWN'F,$+321^4SE!N9.3M
M)ZXY/'3DT.I<%3L?)_@+Q-IW@S3OV4]8U:^M-+TB+P?<P27MU,L-NDDFG69C
M0R,0H9MC8!/.TXSBN^TGQQH/PR_:J\=:EXOU33=)C\0:=IK^']0U"=(H)[..
M)A-#%*QVY$Q9V0$$AU;!&#7MEWX>T^_TZ.SGL;.:SAVA()(5:-,<#"D8&.WI
M1J6A6.M6R0WEG:W4,9#+'-"LBJ1T(!&*.=/^O,%!K^O*Q\@^)='L_$/PI$RV
M<;>"O$WQATRXT6UFBVPW%I)=0+(ZJ?\ EE+,)G48 *OTP>?LB.-8D"JJJHZ
M# %1S6$%Q''')##(D+*\:L@(0K]T@=B.Q[5-4RE<J,;!1114E!1110 4444
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M$J&MV>.?M8:C;^&/&WPE\0:C-'9:+HOBIGO[V8[8;)9;"[A1I&Z*IDD1=QP
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M)QG'-=54RDGL$(M;A1114F@4444 %%%% !1110 4444 %%%% !1110 4444
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MOE3W;'&:^RULX5NVN%AC^T.@C:3:-[*,D GK@$GCW-)%8P0&8QPQ(;AM\I5
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M0<961@%#-]XX&37T#4R5GH7%MK4****DH**** "BBB@ HHHH **** "BBB@
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M)E($.2ZYVX";F;CFB,4U_7<)3:?]=CZHT[Q/INKR7"VFH6-TUKQ.L4ZN8?\
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M0W/)(P54'J2>!5:#Q-IMSH[:A%J%C)IZ@L;E)U,*@=27SM_6O+?VGKC3=?\
M$O@KPK<:+;>(M6U>[N+S3['4;PV^E$V\7SR7("MYNSS 5BVL2WS<;2P^=OBE
M82>&/"W[2GA__BF;:VA\'V%W-I_A^ P6%K<N;E6.PD_O3&D6Y@%!&SY0>21I
MW*E4LS[=MO$6GWFJ36,-]9RWEN,RVZ3*TL0_VE!R/QHO]?L=,O(+:XO+6"ZN
MLB"&295DF/HJDY;\*\!^-?PD\-_!YOA1JGAO1['2M7B\8Z9ISZA!$$N[F"XW
MQSK-*/FE\Q22V\G)YZT?#?P;X3^(VO\ Q<U3QY9Z9=ZSIOB"ZLY9]0"^=I6G
M1QH;4Q,W,"&,^8&3&68MDGHN56N'.[V/5OV>/BI)\;_@KX=\636,>FR:Y:BY
M:V24RK"=Q& Q ST]!722^*]+AGBB?4M/66:9K>-&N$#22*<,@&>6!X('(->6
M_P#!/XJ?V,_AYM8LO]E+AB<EAO;FO)_#_P '?"^O_ 7X^ZY?:'I]]K$?B/Q1
M-#>3Q"2:U>%Y6C,3'F,JRALH0=W/6GRJ[#G=D?5T.O6-QJLEC'>6LE]"N^2W
M653,B^I7.0/PI+[Q)IVEW\%K<W]E;W5UQ##+.J22]OE4G)_"OF'4_A]H_@/X
M:_ 7Q)I=C#;>)-2\0:*E[JX&;Z^%W"WVD33??D$FXY#$CIZ"LKXZ:/IWC_P'
M\8O$VFZ!X1AM=+?4K6]USQ%,]UJ?VJTA*!;10%^S(CJ!'B3EOFV?-R>SU%[1
MGUOJNL6FA637%[=6]G;I]Z6:01HN?4L0*Y'P3\7CXQ^,OB_PNEI"MMX9L]-N
MX;V.??\ ;!=K,WW<8 7RA@@G.[MCGR3PW:6/Q5^,WP_T_P ;16^KZ?\ \(#;
MZGI-MJ $UO?:@S*+J4HWRR2I'Y6,Y($KD8ZUYGX_MK3P'KWQ^M/ MQ;:=I<,
MOAFWU)K:5_(TNW>287BKY9#1HL;$LJ%=H9\;>SC3Z?UN*51[_P!;'VAI?B;3
M=<N)H;'4+&\EMSB5()UD:(_[0!./QJS>7L.G6LD]Q-'!#$-SR2,%5!ZDG@5\
MV6'P>E\#?$KX=ZA'=?"WPJ_]I"&T_P"$=TN>&YUJ P2&2U)#E7C*#>6<$*8U
M.03SW'[3]QINO>(O!7A:XT6W\1:MK%Y/=Z?8ZC>-;:6QMXLO)<@*WFA!("L6
MUBS<\;2PGE5[(KG=KL]2MO$VFWNFK>0ZA8RV<CB-9TG5HV8D  ,#C)) QW)%
M6+F_@LVB6::&%IW\N,.X7S'/.T9ZG@\#TKY/\$_"<^-?B?\ &;X>R2>&;".\
M\/Z7="U\/0-;V.FZ@7NC'*$).)E\N!BP"Y"I\H(R>H^%OQ&/[1WQ"\,ZSJ$;
M1P_#30WO=8A"9,&MS*\#Q%?[T,<=P<=?WZ].*?LP50^@$\2:=)K#:<M_9MJ"
MC<;83KYP'7.S.?TKA?BI\9=7^&'A+XDZY+I&EW%CX+TG^TM/":CF;4&6!Y)$
MF0(3  R@*?FW DX&,'YK\7:7;VOPC\#^-M%T7PCX<L=6\2Z->:9?R7#W?B:^
M^TW\6]I;G"X9XY'WQYD 0LO&..J^-B*(_P!KA@!EO"]CD^O_ !*YZJ--7_KN
MB?:-K^NS/IR+QA96WARQU+4;JSTV.\BCDS/.L:!F4-M#-C/6N=^,7Q=;X8IX
M1:WLX=0C\4>(K/1-WG;!"DX<^:" =V-G3@'/6O+?$VE6/Q.^)]CI%GX<\.:Y
MK7AWPQ937-QXGF:33M/@N&?'DVH4B25O);<^4PJJN[G%>2I-INL?LC_#FUUK
M4+1M!M_BP]@\T,[16L=HFH7L:)&VXE(=H"J-W"8&>])4T$JC/MC1_$6G^(8Y
M&T^^L[Y86V2&WF64(WH=I.#[&N4^!/Q>;XP?#B3Q!=6<.EB+4=0LFC$_F*JV
MMW-;[RQ ^\(MQXXSCG&:\^\6^#?#_P +_P!I'X9KX)TW2]'U/6)+RVU6STV%
M+>.YTQ;9W,LJ( #Y<X@",1UD(!Y(KQ_38]1U3X'_  _TE9M*A\/:Q\0-?M]4
M75%D-A<N+Z^:VAN/+928VF ^4G:SA 00<%*":_KS!U&G_7D?9FCZ_8^(K4S:
M?>6E]"K;3);S+*H/IE21FKE> _"?X:W7P]_:0M0U]X"T6XNM$G:\T/PWIT]L
M-0B62,17$JEC&IC8LJM@,PD89(7CWZIDK;&D9-K4****DH**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KFM.^#WA?2/B!=>*K70]/M_$5\A2XOXX]LLP( .['!.
M% R>>*Z6B@#C/#_[/'@?PIXR;Q!IOA71;/669W^U16RJZ,_WF7LI;G)4 G)J
MA^TW\+M0^,'PO31=,^Q_:/[8TR]873E8VBM[Z">4'"G)*1L ,8)(!QG(]"HJ
MN9WN3RJUCD?!OP&\&?#SQ)<:QH?AG1]+U2Z#*]S;VRK(%8Y95/\ "I/)"X!J
MOJ'[-_@+5O%ESKEUX1T&XU6\+///):*QF9EVEF!^4L1P6(S[UVU%+F8^5'$:
MA^SAX$U;PUHNCW'A?29M-\.L6TR!HN+')R1&>J@^F<' ]!70V/@31M-OM:N8
M-,LXYO$3J^IMY0/VXK$L(\P=&Q&JKSV %:U%*[#E1QW@']G[P3\+=8EU#P]X
M8T?2+Z9#&9K>W"NJ$Y*J?X5)QPN!P*T]/^&/A_2? 4_A>VTBQA\/7$,\$NGK
M'B"2.8N95*^CEW)]=QK>HHNPY4<GXN^!WA'Q[I.DV.L>']-U"UT+:-/26+_C
MS 4* AZJ-H P.N!5[QY\+_#OQ0T=-/\ $6BZ?K%I"V^..YA#^4W3<AZJ?<$&
MMZBG=ARHQ_!'@'1?AMH*:7H.EV>DZ>C-((+:(1J6;JQQU8]R<DUE_$3X'>$/
MBW<6\WB7P[I>LS6BE(9+F ,Z*3DKNZ[2>=IX/I7644KO<+*UC%LOAWH6F:Y8
M:E;:386]]I=BVF6<L4(0VUJS(S0H!@*A,:' X^05-9>"])TSQ!JFK6^GVL>I
M:VD4=_<*G[R[6)66,.>X4,P'U-:E%%V.R.+\'?L[^!OA[XF;6=$\*Z+I>J-O
M N+>V56C#_>V=DSWVXS3;_\ 9P\!ZIXT'B*X\):'+K0G%R;HVJ[VE'20CHSC
MKN()R.M=M13YF3RKL<SX@^#_ (7\4^-=/\2:AH>GW6O:2 +2^>/]]" <@!NX
M!)(!R 2?6NFHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 50\3^&-.\:>'[S2=6LK;4M-OHS#<6UQ&)(YE/8@_P"0:OUC^,?%
M-QX6CTUH-'U+6/M^H064@LE0FS21L&XDW,/W2=6(R<= :.H>IDR? ;P;/\/H
M_"LGAS2YO#L+^9'8R1;XXWR6W+G)#9)Y!SS6IX#^'>A_#'0AIOA_2;'1[$.9
M##;1",,QZLW=F/J<GBMJBGS,7*C,\4>#]+\;65O;ZM8V^H06MU#>PI,NY8YX
M7$D4@_VE=0P/8BKM]8PZG936]Q&LUO<(T4B,,JZL,$'Z@FLWX@^,;?X=> M<
M\074,T]KH6GSZA-%#CS)$AC:1E7) R0I R0,U/X1\1Q>,?"FEZO!')%!JEI%
M>1I)C>BR(' ."1D ]B12Z!I<?X<\.V/A#P]8Z3I=K#8Z;ID"6MK;1+MC@B10
MJ(H[ * !["N;\:_L]^"/B1XCCUC7O"^C:KJ4:JGVBXMP[.JG*J_9P#T#9 KL
MJY;XF?%2S^%UQX;CO+:ZN#XFUN#0[?R O[J65)&5WW$?(!&<XR>1P:I7OH)V
MMJ6_'GPO\._$[0DTSQ!H^GZM8Q.'CAN(0PB8=&3NI'3(P<54M?@IX2L? \?A
MJ'P]I4.@PW$=TMBD 6'SHY5E20CNPD16R><J#6AX:\43Z_JVM6LVCZEIL>D7
M@M8;BY5!'J*F))/-AVL24!<I\P4[D;C&"=FE=[!9/4S-:\'Z7XCU72[Z^L;>
MZO-#N&N;"61<M:2M&T;.A[$H[K]&-<X/V</ :^-U\2#PCH2ZXL_VH70M5#>=
M_P ]<=-_^UC/O7;44KM;#Y4<?X__ &?_  5\4]7BO_$7AC1]6O84$8GN+<-(
MR#D(Q_B7V.1S6GXN^&?A_P >>%%T+6-&T[4-'39LLY8%,46S[FT?PE>Q&,=J
ME\ ^*)_&G@^QU2ZT?4M GO(][Z?J"HMU:G)&UPC,N>,\$\$5L4[L5EN<[X5^
M$WAGP1X4GT'2="TNQT>ZW_:+2.W7RKC>,/Y@(^<L."6SD<5C>&/V9/A_X*O;
M6YTKPCH=C<6%T+RVECMP)()0CH&5NHPLC@ <#<>*WM3^(6EZ1\0-)\,S22KJ
MVM6ES>VL8B)5HK<Q+*2W08,T?!ZY]JI^"?BK9^.?&OB[0[>WNH;CP?>PV5S)
M*%\N9I;:.X!3!)P%E .0#D'MS3]X/=$D^!_A&3QI?>(CX?TW^V]2@:VN[P18
MDN8V78P?'#94 9/.!5K4/A9X<U3X<+X0N=%T^X\,+:)8C3)(@UL($ "1[>FU
M0JX'; KH**5V/E1G:SX3TSQ'X<FT?4-/L[S2;B+R)+.:%7A>/C"E2,8&!],"
MLCX=?!;PI\)/M)\-Z!INCM>;?/>WB"O*!T#-U(&3@9P,UU%<OXC^*EGX8^*'
MA?PI-;W4EYXJ@O9[>9 OE1"U6)G#Y.<GS1C /0YQQDUV0G;=E[QY\.]#^)^@
MMI?B'2;'6+ N)!#<Q!U5QT9>ZL/48/)]:SO#OP.\'^$K+4+;3?#.C6=OJ]K%
M97L4=LNR[AC#A$D&,,!YC]<YW'.<UU=%%V/E6YP.B?LN?#SPW]G-CX/T.U>S
MNDO8)$MQYD4R9",K_>&,G SCD\5G?#CX7ZU=?&S7/'WBJUT>SU*6PCT/2K:Q
MF:X^SV:2/*SR2,B$O([ [0,*$ R<FO3Z*?,Q<J.+\=_L[^!OB=KBZEX@\*Z+
MJNH*JH;B>W#22*O17/\ &H]&R*["W@CM8(XXXTCCC4(B(NU4 X  [ 5)14W9
M5@HHHH **Y;XB?%2S^&^L^%;*ZMKJXD\6ZNNC6[0A=L,A@FFW/DCY=L+#C)R
M1QC)KH=5O6T[3+FX2WFNGMXFD6&(#S)B 3M7) W'&!D@9- %BBN&@^-]NOB?
MP+H]YHVKZ;J?CJPN+Z*WN%C#Z:8(HI)(I\,<./-"X3<,JW/0UW-%K"3N%%%%
M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC_%/P!\$^
M-_%L>O:OX7T74-7C"#[5/;*SN$^[O[/M[;LXKL**+VV"U]SD_#'P-\(>"[^S
MNM)\.Z7I\VFRW,]JT$.W[,]SM\\IV7?L7..#@5M0>#]+M?%MSKT=C;IK%Y:Q
MV4]X%_>RPQL[I&3_ '5:1R!ZL:TJ*+L5D>?2?LI_#>6[U"9O!/ATR:H=UR?L
MBXD.\2$@=%RZ@G;C)'.:[VXMX[J"2*6-)(I%*.CKN5U/!!!Z@U)7+?##XK6?
MQ3/B+[';75O_ ,(WK=SH<_GA?WLL&W<Z;2?D.\8S@\'@4]6+1&5H7[+GP[\,
M74<VG^#= M)H;N&^B>.U4-#-$V^-D/\ #M;D!<#/:KFN?L^>!_$WC+_A(-0\
M*Z'>:T2I:ZFM59I"HPI88PQ Z%@2,#T%=E11S,.5=CA]1_9N\!ZMX3TS0;CP
MKI,NDZ+*TUA;&'Y;-VR6,?=<Y.0#@U-KW[/7@?Q1XLCUW4?"NB7FK($'VF6V
M5F?9@)N[-M  !8'  ]*[*BCF8<J,;P-\/]%^&>A?V7X?TVUTG3Q*\XMK9-D:
MNYW,0.@R><#BLF_^ ?@O5/ ]MX;N/#.CSZ'9R/+;V;VX:.W=G9V=.ZL69CD$
M'DU/\.?BI9_$O4/%%O:6]U;MX5UF31;@S!<32I%%*73!/RXF4<X.0>.E'@;X
MJ6?CSQ?XNT:VMKJ&X\'W\6GW3RA=D[R6T5P&3!)VA95'(!R#VP2]0T-#P/\
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MBG7M6U&Q-]-XET>+0M1AFD+03VD;2NJ;.@.9Y,D<G(]!5N:_KU,XTY+U_P"
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M] 22 >5).",TW470%3:.&_8BTIM"D^*]DVH76K-:>/+N+[7<N))I@+6T WL
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M"\?A?Q+IMTVM:M)XLT]])U+4-1U&6ZOI+5E9?*65B2BC>Q 7 R<\GFM#QO\
M /0?'-GHZRMJFFWV@Q>18:CIM[):7T$>T*T?FH02C!1E6R"0#C(S2YT'(SRG
MXM>')/A5H_@W2=,\5:IJ5FOQ*TB..WEO6EGTV"0Y-F\FXR21GE@)23M<#D 5
M@_'6W_X3=OB-KFBP>,/$-YX=%U''JXUXZ3I_AR:UM]QBMHT?=,Z."SLT9#,2
MI; P/:++]F3PG8:!INGQVUZRZ;KD/B,W$EY))=7E_$<K-/*Q+2GH"&., #@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M';37T1B91$MP',1#$;6R(WZ$XQSC(K<KP;]F_0]0\-?M4?%^RU+5IM<E@L=
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M5)]&DMHFCCNY]OF2+-CS,$KG9G )].*RQ^RO8#]EW2_A?_;%]]ATN*SB6_\
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M_P )!X9T*7P[?Q7%K.UE<V[O _F1;6#K(/LZ?>)!R>G%%XK8+2>YQOA*;6?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\J\2_$GQ9XT^+.L^$_
M!#:!I_\ PBMO;RZMJ.KV\MTK37"EXH(HHY(S]P;F=FXW* #R::5Q.5CU&"UC
MM0WE1QQB1B[!5 W,>I/N?6I*\?\ %?Q1\?>'_ ^E2:I;^#/!]\]Q<6^J:KJE
M]YNGP+&<1/!$'220S_>5&92@!W9.,\C;_MBZL_P'^+.K0MX?U?7OAK"9(+ZR
MAE73=3#VZS1,(V?>N,E6&\C*Y#$'BO9M[$>T2/HZJ<FNV,6MQZ:UY:KJ,T+7
M$=J9E$\D2E59PF=Q4%E!(& 6'J*\DUOXK_$#P9X7TB/5+?PK-XJ\<:I#I^A6
M5NLRVVFAH6FE-S(7)F\N..1LQA-Q 48SFL+P\GBJV_;J\-V_BJ31+RXB\$:F
MT%[ID,EO'.IO;'<K1.[LC*0.=Y#!AT((I<H<Y[MH'B*P\5Z1!J&EWUGJ5A=
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MO4/+GVV>IZ'.9+34H=H/F!"6,; DJ5WL,KD'!I.+2U*C--Z'94445)04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5Y]'M+F]CN9
M+6WDN(?]7*\89X_H<9'X58HH **** "BBB@".&UCMY)&CCCC:9MTA50"YP!D
M^IP /PJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%W,>@QSZ910Y-@H)!1114E!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>irtc-20211231_g10.jpg
<TEXT>
begin 644 irtc-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO96QE:2!(
M:6=G:6YS    !9 #  (    4   0J) $  (    4   0O)*1  (    #,S(
M )*2  (    #,S(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,C8@,#<Z-3DZ,3( ,C R,3HP
M,CHR-B P-SHU.3HQ,@   $H ;P!E &P 90!I "  2 !I &< 9P!I &X <P
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "A 6T# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
M  %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$!
M 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Z!UK7=.\/6(O-
M7N#! T@C4B-G+,>@"J"2>#VK#/Q.\*#_ )?;K_P6W/\ \;JSXM_X_/#6/^@S
M'_Z)EKH5)Z&@#E/^%G^%/^?V[_\ !9<__&Z/^%G^%/\ G]N__!9<_P#QNNMH
MH Y+_A9_A3_G]N__  67/_QNC_A9_A3_ )_;O_P67/\ \;KK:0L%4EB  ,DD
M]!0!R?\ PL_PI_S^W?\ X++G_P"-T?\ "S_"G_/[=_\ @LN?_C=;L.N:7<7%
MO!!J5I++=(9($CF5C*@_B4 \C@\CTJ6RU.QU(2-I]Y!=")]DGDRA]C>AQT/M
M0!SO_"S_  I_S^W?_@LN?_C='_"S_"G_ #^W?_@LN?\ XW7427,,4\4,DB++
M,2(T+<M@9.!WXIY8*"S'"@9))Z4 <I_PL_PI_P _MW_X++G_ .-T?\+/\*?\
M_MW_ ."RY_\ C==%#JEC<6L5S#>0/!,VR*19 5=O0'N>.@J:"YAN8$GMIHY8
MI &1T<%6!Z$$=: .7_X6?X4_Y_;O_P %ES_\;H_X6?X4_P"?V[_\%ES_ /&Z
MZAKB%)3$TL:R!-Y0N,A?7'I[U!::OIU_8F]L;^VN+1<YGBF5D&.N6!QQ0!SW
M_"S_  I_S^W?_@LN?_C='_"S_"G_ #^W?_@LN?\ XW75"6,QB0.I0KN#!N,>
MN?2FVUU!>6R7%I-'/#(-R2Q.&5AZ@C@T <O_ ,+/\*?\_MW_ ."RY_\ C='_
M  L_PI_S^W?_ (++G_XW769^GYT9_P YH Y/_A9_A3_G]N__  67/_QNC_A9
M_A3_ )_;O_P67/\ \;KK>O3^=% ')?\ "S_"G_/[=_\ @LN?_C='_"S_  I_
MS^W?_@LN?_C==;10!R7_  L_PI_S^W?_ (++G_XW1_PL_P *?\_MW_X++G_X
MW76T4 <E_P +/\*?\_MW_P""RY_^-T?\+/\ "G_/[=_^"RY_^-UUM% ')?\
M"S_"G_/[=_\ @LN?_C='_"S_  I_S^W?_@LN?_C==;10!R7_  L_PI_S^W?_
M (++G_XW1_PL_P *?\_MW_X++G_XW76T4 <E_P +/\*?\_MW_P""RY_^-T?\
M+/\ "G_/[=_^"RY_^-UUM% ')?\ "S_"G_/[=_\ @LN?_C='_"S_  I_S^W?
M_@LN?_C==;10!R7_  L_PI_S^W?_ (++G_XW1_PL_P *?\_MW_X++G_XW76T
M4 <E_P +/\*?\_MU_P""RY_^-T?\+/\ "G_/[=?^"RY_^-UK>*_$$7A7PIJ.
MN7$+S16,)E:.,C<P'89KQC_AJ_01_P R_J/_ 'VG_P 50!ZC_P +/\*?\_MU
M_P""RY_^-T?\+/\ "G_/[=?^"RY_^-UY=_PU?H/_ $+^H_\ ?4?_ ,51_P -
M7Z#_ -"_J/\ WU'_ /%4 >H_\+/\*?\ /[=?^"RY_P#C='_"S_"G_/[=?^"R
MY_\ C=>7?\-7Z#_T+^H_]]1__%4?\-7Z#_T+^H_]]1__ !5 'J/_  L_PI_S
M^W7_ (++G_XW1_PL_P *?\_MU_X++G_XW7EW_#5^@_\ 0OZC_P!]1_\ Q5!_
M:OT+''A_4?\ ON/_ .*H ]7M?B-X8O;V"T@OYA-<2+%$)+&>,,[' &YD &3Q
MR:Z>N0U[45U;PCH>HQ(T<=WJ.FS*C'D!KB,@&NOH YOQ=_Q^>&?^PU'_ .B9
M:Z3O7-^+O^/SPS_V&H__ $3+72=Z "BBB@ JCJ]M<7FC7EM9S"">:%HXY2,[
M"1C-7J* .!\'?#<^&-6M[NXU WBV-J;2TVIY>$,CO\P'!QOP,5CV7PJUC3XY
M?LFLP(9KSS7VAN8\?^A=/8<^M>F:C>KI^FSW;KN6%2Q&<9JG9ZY;W6GQWC13
M1+(S(%=/F&"1S^6?QH \]NOA)>MM6TU=(]M@L'F$OO,F#OY_N,>3WR36WI'@
M"]TJ>]F&JLTMU8-:;R6;:?+1$;G^Z48_\"KL5U%)$#I#.RGH1'2_;O\ IWN?
M^_9_QH X;3_AWJ)\&0:#J^KM*L%]'/&\+,IC@0 +$I/((]?>L5?A!K,%A-:6
MWB%0'@@A5FW?((UQP!T((!!Z\FO4_MW_ $[W/_?L_P"-'VX=X+@?]LZ ..TC
MX?'2]>DU,SPS7%Q:W$%Q,X8NS22%E8>P!P?H*YR/X.:A#8V6FQZU&;* 2>9E
M&WR>9'L<$]QZ ]A7J4>I)+&LB6]P58 C]V>E.^W?].]S_P!^S0!PNC?#[5=(
MCUL)JX#:A9):P!"Q2W(7:#M/8<X^M9P^$.HP:/\ V;;>(W6"*T>&$!"@+;_D
M9L=@C.I ]<UZ2-10NRK!<%EQD>7ZU7EUV&"=HC:7KNH!(2 G% '!3_"W5"MN
M;;6_*E2Z$TLN6+E%C1552?0ANO\ >JAHWPRUZ:..>_O39A&N4^RK,1E7 57W
M+GDX.1[UZ5_PD47_ #X:A_X#FG1:_#+,L7V2]1G.!O@(H 7PSIESHWAFPTZ^
MG2XGMH1&\J+@,16I6#KWB_2O#.EMJ6N-+9VBLJ&22/C+=*YG_A>OP^_Z#T?_
M 'P: /1**\[/QV^'H!/]O1_]\&NTBU6*XM8[B&.=HI$#JXCX((R#0!H45YJ_
MQ\^'L<C*VL,K*2"/)/!I/^&@/AY_T&6_[\F@#TNBN;\,^.M$\7Z?)>^'I9;N
MWBE\IW6(\-@''Y$5H2Z[!#,8VM;QF4<[8"<4 :E%9'_"10]K#4/_  '-.CU^
M&298A:7JLYP-T! H U:*SKC5X[1%:2VNCN.%"Q$DFH?^$BB_Y\-0_P# <T :
M]%8Y\0P]['4!];<U934TE@65+>Y,;*&!\KL1F@"_16.OB.!E#)9:@RD9!%N:
M7_A(HO\ GPU#_P !S0!KT5G6NK1WA(CM[I-K8(>(KCC-:- %;4;.VU#3YK6_
MMTN;>5=LD,BY5QZ$5RX^'O@UF/\ Q2VE-Z'[,.E==+_JFYQQUKQWQ+XJO;7X
MS62P2WJ:98>38W2Q*WD&2=6)9V' 9?W6/J:I;$2W.U_X5YX.'7PMI0_[=A1_
MPKWP;_T+&E?^ XK ^#MMJB>#Q?:PSR/?;9$EDO))FD&6&2')V=AA<"O0*9-V
M<]_PKWP;_P!"QI7_ (#BC_A7O@W_ *%C2O\ P'%=#1185V<]_P *]\&_]"OI
M7_@.*0_#WP;_ -"OI1]OLRUT5%%@NS&\6016N@Z7!;(L<,>JZ>J(@P% N8\
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M\JR=!W_&M[ R3@;CU;')I<GU/YTT!@_\),QX72+[?_M)@5N].O7%+N/J<4E
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MXYH X?XE^"]3^(/@R703=6MCYDT<OG;6?&TYQCBO&S^R=J0Z^*;;K_SYM_\
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MX2%;(!7IS4UO;PVL(BMHUBC!)"J. 3U--")****8&5XS_P"0/IW_ &%]/_\
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MO^^Z #^RK/\ YXG_ +[;_&C^RK/_ )XG_OMO\:/[,A_O3?\ ?=']F0_WIO\
MON@ _LJS_P">)_[[;_&C^RK/_GB?^^V_QH_LR'^]-_WW1_9D/]Z;_ON@ _LJ
MS_YXG_OMO\:/[*L_^>)_[[;_ !H_LR'^]-_WW1_9D/\ >F_[[H /[*L_^>)_
M[[;_ !H_LJS_ .>)_P"^V_QH_LR'^]-_WW1_9D/]Z;_ON@ _LJS_ .>)_P"^
MV_QH_LJS_P">)_[[;_&C^S(?[TW_ 'W1_9D/]Z;_ +[H /[*L_\ GB?^^V_Q
MH_LJS_YXG_OMO\:/[,A_O3?]]T?V9#_>F_[[H /[*L_^>)_[[;_&C^RK/_GB
M?^^V_P :/[,A_O3?]]T?V9#_ 'IO^^Z #^RK/_GB?^^V_P :/[*L_P#GB?\
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M&.3Z#GK5?Q=_Q^>&?^PU'_Z)EH\8ZM/I%I!+;::NH%F.Z,KD[05R!Z'&3^%
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M ,_UQ^='V"7_ )_KC\Z@MYKB>4)YUQ&67<I>-.1^56OL]S_S^O\ ]\+_ (4
M,^P2_P#/]<?G1]@E_P"?ZX_.G_9[G_G]?_OA?\*ISW%Q!(ZF:X=8^7D2-,+Q
MGGB@"S]@E_Y_KC\Z/L$O_/\ 7'YT_P BY/\ R^/_ -^U_P */L]S_P _K_\
M?"_X4 ,^P2_\_P!<?G1]@E_Y_KC\ZBO'N+.$/]IFE9B0B1Q*Q)QZ8I]KY]U
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MV%]/_P#2F.NDK,V.;\7?\?GAG_L-1_\ HF6NCP">>W2N<\7?\?GAG_L-1_\
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M]PVX_P#C] &IX<T^[TW25MK^0R2+(Q4ELG:3QD]S6N>E<I]F^(/_ $%/#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>irtc-20211231_g11.jpg
<TEXT>
begin 644 irtc-20211231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %T =T# 2(  A$! Q$!_\0
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M 8))XH27]?/_ "#F?]?UYF=_:WQO_P"@)X?_ ._@_P#CM']K?&__ * GA_\
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M+=-<);!7(=4+2JF_/=<'/.*?*',SG/[6^-__ $!/#_\ W\'_ ,=H_M;XW_\
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M?>)M(LFRMC<V]N3(;=0\\DJN<XW9504/*[@.YYI))C<FBM_:WQO_ .@)X?\
M^_@_^.T?VM\;_P#H">'_ /OX/_CM:.H_$*?1?$.LV5S:1W,%M(RP".4+(NV
M2X*XR5.#\W;(J*?XHO%:&5-%262-I3*([Q2@2-$D)5MOS'#@8[$4))A=E/\
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M'96ZPH"JIY2X /7MW[^M6J* *PT^S6\2[6VB6X16575<$!L%OSP,GVJS110
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M>M*R*NR_X;\.:=X4T2'2=+C9+>,EB6.6=CU8GUK6JE%JD$VH_85602^2LV6
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M'V^#^TQI^X_:##Y^W'&S.W.?K3X[N"6ZFM4E5IX K2(.JAL[?SP?RH D9%<
M.H;!!&1G!'0T/''(5+HK;&W+N&=I]1[U4AU%)M8NM."$/;Q1REL]0Y88Q_P&
MG6^HP74EZD9;-G+Y4N1_%L5^/P84 66C1V5G16*'*DC.T^HIH@B%PUP(U$S*
M$9\<E020,^F2?SJJ^L6*6=I=^=N@NY(XX753\Q?[OYU.+N%KY[,/^_2-967'
M122 ?S4T .DMH)8?)D@C>+(;8R KD'(./KS3O*C$QF\M?-*A2^.2!SC/IR:B
MEO8(;ZWLW<B>X5VC7!Y"XW?^A"D%_:D71$RD6C%9_P#8.T-S_P !(/XT /FM
M;>X@,$T,;PD@E&4%20<CCZC-2/&DA4NBL4;<N1G!]1[U2FUBTAM["X#&2*^E
MCC@9!][>,J?IBGP:E%/JMWIZJPEM4C=SV(?=C_T$T 6O+02F4(OF%0I?') S
M@9].3^=)Y4?G>=Y:^:5V[\<XZXSZ5';7MO>>=]GE63R)3#)C^%QU'ZBH=3U*
M+2].>]D5I(U95PG4EF"C]30!:6*- X6-%#DL^% W$]2?6HKJRMKV...XB61(
MY$E0'H&4Y4_@14.IZDFF):L\9?[1<QVP .,%SC/X5-<7L-K<6L$I(>ZD,<6!
MU8*S\_@IH E:*-I$D:-3(F0K$<KGK@]J%BC21Y%C57?&]@O+8Z9/>H+F_BM;
MNSMI Q>[D:./ X!",YS^"FF#4D.N-I>P^8ML+C=GL6*XQ^% $LUC:W%B]E+!
M&UJZ[&BQA2/3 J:2..9"DJ*Z'JK#(-,AN8+B29(I%=H7V2 ?PM@'!_ C\ZJ#
M6K%M.M+]92UM=O''"X4_,7("\=N30!>,:,ZNR*63.UB.1GKBEP,$8Z]:A6[@
M>]ELU?,\4:R.F.BL2 ?QVG\J6VNX+M9&@D#B.1HG([,IP1^!H ;;V%I:V"6,
M%O&EJB[%B"_*!Z8I9K2">XMYY8PTMNQ:)C_"2"I/Y$C\:JG6K4:1>:G\_P!G
MM/-\SCG]V2&Q_P!\FII-2MHGLE=R&O&V0C&<G:6_D#0!.L$23R3+&HED #N!
MRP&<9/MD_G44=A9Q6BVD=K"MNARL6P;0<[LX^O/UJ1+F&2XEMTE5IH@ID0'E
M0>F?K@UF/XA@;1K74[>-Y(;F>*%0_P I&^01Y/T)S0!H_8[;[=]M\E/M7E^5
MYN/FV9SMSZ9YI\=O#%+-)'&JO,P:1@.6( 4$_@ /PJ*ZOH+-[99V*FYF$,6!
MG+D$X_)30+^W.IMIP8_:5A$Y7'&PDJ#GZ@T 3JB("$55R23@8R3U-((HPK*(
MU"N26&/O9ZYJ*SO8;Z.1X"Q6.5X6W+CYD8J?U%03ZS8P:-)JWF[[.-"Y=!G(
M!P<#ZT 6C;0%(D,,>R(@QKM&$(Z8],4[RHQ,9@B^85"E\<D#D#/IR?SJO<ZC
M%;:A96;JYDNRX0@<#:NXYIUO?075S=V\1)DM9!'*".A*AA^C"@"6&WAMXS'#
M$B(6+%5& 23DG\233MB>7Y>Q=F-NW'&/3%,@N(;J+S8)%DCR5W*<C()!'X$$
M4V[O(+&W^T7$@2+<J;O=F"C]2* '3V\-S&(YXED0,K!6&1D'(/X$ TYXHY"A
M=%8QMN0D9VG!&1[X)_.F7=U#8V4]W<-MA@C:21L9PH&2:D1UDC5T.58 @^HH
M 9]F@^U&Z\E/M!01F7;\VT'.,^F3FE,$30O"T2&-\AT*C#9ZY'?.34E% %>[
M@B>V^:-3Y0+QY'W& ."/0UD>'?\ D5](_P"O&'_T!:VKC_CVE_W#_*L7P[_R
M*^D?]>,/_H"U42)E7QI<R6=E9W,5K+=/%J-NP@B^^_S<A?4XR<=\5R^F>)+Y
M?!MWI<7A_5[F<_:H#-'"H5)F9SL;)&-JL,MC (QDGBNQ\2?>TS_L)V_\S6ZD
M4<:E4155B6( QDDY)_$TF4CS.Y\37-YX#DM8] U![)K)%M[Y$W1R(@ =V'!0
M#!(SDL.15F^\4W,^L:-J$_AS588HI9#:+L!:Y\R,J@Q_ QPQ*M]T#)->B[%V
M;-HVXQMQQB@JI*DJ#M.1D=*0SSJ3Q7J/_"36U\?"^HI+):2VUO;.RJ\SAE:3
MOPJA3R>&XQU%)+XGU#_A-9+FU\,:L\LFG)'!#/&(O, D+.Q;D* I'!Y+8&.:
M]%,<;2+(44NH(5B.0#UP?P%.H \H_P"$BN[GP_KMG9>']2D2ZDNGNG>$QM;B
M5?D^4CYC\V6 .5 R:O:IXLEO/#\2?V!JJ6'G6[Q7GV<LDL*,K,Y4?,OW> 1D
M\>M>D;1SP.>O'6E  & , 4 >=:]XONKO1Y(YO#&LVHCN([AI'@&Q8$D5PY/]
MX[?]6,L#U]:@OO%6HR^*=(NG\-:G#+;K<VP@901)-(J-$N\< %02S=%Y')%>
MED C!&12T >?2>)]23Q%!=2>%=7%T^GM"ELL:E6DW*Q_> [548^\V.W%5I/%
M>J'QA)/9^'=3\Z:PC@AMKJ$Q*TB2,TOS\@ *1@]&/2O2J* /'(O$ES#X3%B=
M'OQ:0ZBQO;V2(XMW^TF;:5 )("]6' .!R36RGB^Z_P"$TCN[CP_JL?G6+PV5
MJ(@9+D>8K[QG 7"X)#$;>!U->D+&B@A44 DL0!U)ZFD,49E64HID52JOCD X
MR,^^!^0H \JGURYN/!U_IB:'J+YGE>]N)$5([7,ID(8D\D(,G;G!(%7;GQE+
M=>*M&OET#5S:(EP+9HK<O]J5POELO0+D*Q(;H,$]:](:*-XWC>-61\[E(X;/
M7-.  & .E ' V/BF]@UK52/#NL332R1326P5=UO%L"9^]M)+*<*IR<$U#I_B
M75+;7-7G'A/5?,GFBN+F)MFZ&$1A,J5)#N2I(0'.,^U>B!5#%@!N/4XY-+0!
MY]HGB2_MK_5POAK5I6FOS=3(456@A:.-4/)PSG;G8#D#.>1@U]%\3ZC8WNKG
M_A'-3EB;4I+BZ B/F0Q,B"/"#[['&2H.0.O/%>DT8 [=: /)K36=5N/!=SI@
M\-ZA'$TURL]W*RQK 3.[G(SG:$SENQXYK0G\937?B'3+L:#?FWS+_9SK&<WB
MN@"D9P$.0Q^;H@#=Z]%EMX9X)()8D>*0%71ER&!Z@COFE\F+]W^[7]W]SC[O
M&./3B@#S^;Q3>+XGCN8_#6I_;);#R;>TF4(97$@:3YN0JJ,?,< Y&,YJ&'Q-
MJ</BG5KBS\.:C+)=):R);S1^6XMT#!W/4!LDA4)!)'I7I&T;MV!N P#CFC S
MG')H \[B\37UMXNU&=/#6IM-=6T++;-L$GD1E]TO!(S\P 0D$GBH[7Q+J$-U
MJIM?#NI2-<W!N+F,PD20PF)5C..[DA3LSD+G/(KTC:N_?M&XC!..<48&<XZ]
M: /(8/%$Y\(>&FN]%U.ULK!K6XN+R2+*$1_*XP/F^\5 XR>3T&:U[7QA>?\
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MX171/^?'_P C2?\ Q5'_  BNB?\ /C_Y&D_^*HY6',CI>E%<U_PBNB?\^/\
MY&D_^*H_X171/^?'_P C2?\ Q5'*PYD=+17-?\(KHG_/C_Y&D_\ BJ/^$5T3
M_GQ_\C2?_%4<K#F1TM%<U_PBNB?\^/\ Y&D_^*H_X171/^?'_P C2?\ Q5'*
MPYD=+17-?\(KHG_/C_Y&D_\ BJ/^$5T3_GQ_\C2?_%4<K#F1TM%<U_PBNB?\
M^/\ Y&D_^*H_X171/^?'_P C2?\ Q5'*PYD=+17-?\(KHG_/C_Y&D_\ BJ/^
M$5T3_GQ_\C2?_%4<K#F1TM%<U_PBNB?\^/\ Y&D_^*H_X171/^?'_P C2?\
MQ5'*PYD=+17-?\(KHG_/C_Y&D_\ BJ/^$5T3_GQ_\C2?_%4<K#F1TM%<U_PB
MNB?\^/\ Y&D_^*H_X171/^?'_P C2?\ Q5'*PYD=+17-?\(KHG_/C_Y&D_\
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M/VG_ .Q]J5KN^49-E#UQQ<^^/[OO0!?HJC]IO_\ GS@_\"?_ +&FK=WS;O\
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M^QIJW=\PS]BA'..;G_['VH T**SVO+Y64&RAY[_:?_L:=]IO_P#GS@_\"?\
M[&@"Q:VMO96R6UK"D,*<+&BX [\"GO%'(RL\:,5SM++G&1@X_"J2W=\R!_L<
M(!&>;G\?[M+]KOMX7[%#R,_\?/\ ]C0!>1%C1410JJ,!5& !2U0-W?!2WV.
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M-TWS+]\]QZ"G2.F4^9?OCN/4TR&*/=-^[3[Y_A'H/:G211Y3]VGWQ_"/?VH
M>&7'WEZ>H]![TV%T^8[E_P!8W<>M.$4>/N)T]!Z#VID,4?S?NT_UC?PCU^E
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M'W5/ZM0 Z8/]GDZ#Y#U!]/K4@#\<C\C_ (U!--$+=\R+]P_R^E2":+@^8O\
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M_#Z_\\L?TK8FW;.?[P]?[PK T;S#K.M-YB\R+_".V\>OM6U,LNS_ %BCYA_
M/[P]Z +'S8[_ *^]1Q;OWF,_?/KZ"DQ)C[Z_]\#W]ZCB$O[S,BGYS_ /0>]
M$TF<+G_GHOKZFG_-M[]/?T%5Y%E(7$BCYQ_ /7ZT_$FW[Z]/[@]/K0 6V<28
M_P">K?\ H1H?=YL><]\=?[IJ*W67#CS5SYK?P#^\?>E82>;'B11@G^ >A]Z
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MZ^E5IUEV+^\7_6+_  #^^/>I,28^^O\ WP/3ZT +%G+XS]\_S%)+NW1=?O\
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MR6Y'W3T/L?:DAQY$?3[@[^P]J &+(?M+?NI/NCM[M[TDTA\A_P!T_P!WT_\
MKU(N/M+=/NC^;438\A^1]WU]A[4 'F'C]T_Y>_UK,U:0_P!DZM^[<8M&YQ_L
M-[UK\9'(_/W^E9.LD#1M5Z<VI4<^J$?UH DLI"-$LOW4G^IBZ#_=]ZO!R!_J
MG_+_ .O56R&-%LAZ11?^RU=&-O4?F/3Z4 5X9#NF_=/]\]O8>].EE(*?NI/O
MCM]?>EAQF;I]\]_9:?)U3I]\?S- "!SC_5/^7T]ZCAD/SGRI/]8W;W^M3#&.
MJ]/4>@]J;#U;I_K#_.@".20^9$/*?J>W^R?>LB]<GQGI#>4_RV]QGCUV>_\
MLUM/C?'TZGO_ +)]JRKG!\867(^6%L<^N?\ "@#2@D/D+^ZDZ>GU]Z'D/VB,
M>5)T;M]/>I(<>2O3IZ_6D?'VB/IT;^E $=U(?LD_[I_]6W;V/O5FV_X](?\
M<7^50W6/LL_(_P!6W?V/M4UM_P >D/\ N+_*@#/UE0TVE@Y_X_%Z''\#5<\H
M=C)_WVWM[UF^(XY)ETZ*-F3?>*K,IPP&QLX/K4$4UMHEZ]NR1VUI,@DBW.JH
M&& PSZD;30!K10J%.#)]]OXV_O'WI)(5\Z+F3//\;>GUK.B\06; B-99FWG
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M"MVG6ZMV>U=))5DD9"PRN9U(!]QG%6+N^^V,=/L\M(S;9Y(G4B%<<Y8<!B.
M.O.>U &C# H\SF3_ %A_C;_&DFA7=#S)]_\ OMZ'WK-TEA97-WIR6_EQQOYL
M";A]QNN,^C _F*L7NIVUH8C</%'^\QAI4R3@\ =2>>E %_R1_P!-/^^V]O>H
MX85$?!D^\?XV]3[U0_ML2?ZC3+^8'HRPA0>G0MC_ #^%,&HZD4_=:'(?F/\
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MTJ6'/V>/K]P>OH/>DY^U]_N?^S4 1R&7R7PB?=/\?M_NTY#+A3L3.!_']/\
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M^R;#_GTB_P"^:** $_LG3_\ GTB_[YI?[)T__GTB_P"^:** #^R=/_Y](O\
MOFC^R=/_ .?2+_OFBB@!/[)T_P#Y](O^^:7^R=/_ .?2+_OFBB@ _LG3_P#G
MTB_[YI/[)T__ )](O^^:** %_LG3_P#GTB_[YH_LG3_^?2+_ +YHHH 3^R=/
M_P"?2+_OFE_LG3_^?2+_ +YHHH /[)L/^?2+_OFD_LG3_P#GTB_[YHHH /[)
MT_\ Y](O^^:7^R;#_GTB_P"^:** $_LG3_\ GSB_[YH_LG3_ /GTB_[YHHH
M7^R;#_GTB_[YI/[)T_\ Y](O^^:** #^R=/_ .?2+_OFE_LG3_\ GTB_[YHH
MH /[)T__ )](O^^:3^R=/SG[)%_WS110 O\ 9.G_ //I%_WS1_9.G_\ /I%_
MWS110 ?V3I__ #Z1?]\TG]DZ?_SZ1?\ ?-%% "_V38?\^D7_ 'S2?V3I_P#S
MZ1?]\T44 ']DZ>>MG%_WS2_V38?\^D7_ 'S110 ?V3I__/I%_P!\TG]DZ?\
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4R,&SB(_W:N !5"@8 & !110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>irtc-20211231_g12.jpg
<TEXT>
begin 644 irtc-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKC_CK\:=*_
M9]^&U[XIUJ#4+C3[%D61+&W,\QWL%&%'N:-] ;LKL["BOE,?\%?_ (:D_P#(
M%\>?^"5_\:Z7X8?\%+OA_P#%K0O%FH:7;>(5A\&Z8VK7PGLO+)B4X(7YL%L]
MCBM/9S[&?MH/2Y]#T5Q?[/WQQTC]H[X3:5XRT&.ZBTO6/-\E+E LJ^7*\;9
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M &F+_P"%<=OJ2^(-.T\:E)*T0^S&,A3@-G.?G':H2;V+<DMSTNBBBD,****
M"BBB@ HKS7X?_M1^'_B1\>?%GP\L;?4DUKP?$LMY)+$%@<,5'R-G)^\.PKTJ
MFTUN)23V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***YJ7XP^&+?XHP^"7UJQ7Q7<6AOX],W_Z0T )!DQ_
M=X/Y4!<Z6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS7X'?M1>'_C
MYXR\9:'H]OJ4-UX(O5L;YKF((DCDN 4()R/W;=<=J+/<7,EH>E4444#"BBB@
M HHHH **\0^#G[?7@?XW_';5OA_H_P#:2ZOI9N1YT\*K;W1@<)((VW$D\DC@
M9"D]J[G]H+XZ:3^SC\++_P 6ZY#>7&G:>\:2):QAY6+N$& 2!U8=ZKE:=B5.
M+5TSMJ*^18_^"R?PYE4,OAWQTRL,AETP$'Z'=7M'[+G[6&@_M8>']6U'0=/U
MK3X='NEM)EU&V\AG9D#@J,G(P?SIRIR2NT3&K"3LF>I45SGQ<^)MA\&OAIK/
MBC5([B33]#MFN9T@4-(RCLH)&3SZU%\&OBKIWQP^&&C>+-)CN8=.UN#SX$N$
M"RJNXK\P!/.0>]39VN7S*]CJ****0PHHHH ***XWX^_&S2OV=_A9J7B[6H;R
M?3=+V>:EJ@>5MS!1@$@=3ZT)7=D#=E=G945C_#_QG:_$;P)HOB"Q65;'7+&#
M4+=95VR+'+&LBAAV.&&?>MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *;+"LZ%9%5U/4,,@TZN7^,_P 7='^!'PSU;Q5KUP(--TF$RL,_/,W18T'=
MF;  ]31OH#=M6>'_ /!1?]IY?@%\/;7PWX8MH[KX@>-#]CTJW@B#36Z,=AGQ
MCKD[4]6/^R<1?!;]GUOV%?V*/$MY''9WGC*32YM5U6XGC\Z.6X$998C_ 'HT
MY&,\DL?XJX;]@;X3:Q^TE\7-4_:$\?0?O[Z5HO#%C(,QVL*Y3S%!Z*@RB'N=
M[=2"?I#]KI@?V7_'W_8#NO\ T6:VVM#[SGC>5ZC^1PO[.G[4RM^P?8_%#Q@M
MC:BWLKFZNX["W\F)MD\B*J)DX+84?4UY/X%^,?[47[2?@F;Q]X1A\'^'?#LQ
M>72M&NX1)<:C$I('[Q@>I!^;*!B.,"N4BT"^\1?\$.[>.P$C26L#W4JQC<6B
MCU%V?CTV@_E7U#^PGXTTGQ'^QOX"O+&YMQ:Z?HD-I<X<!;66% DJ,?X=K*>O
M;!Z$54K1NTNI,6Y-1;Z7,_\ 86_:];]J[P!J+:II\>C^+/#5R++6+%,[5<YV
MR*&Y56*N-I)(*,,G@GTCXX>,+SX>_!SQ1KFG^3]NTC3)[NW\U=R;T0LN1D9&
M1TS7RC_P3)F7QM^T[\=_%VE[O^$;U+5MEK(%Q'.S32N-I]0N#])!ZBOIK]JC
M_DVSQW_V KO_ -%-42BE.R-*<FZ=V?*WPD_:(_:7_:R^$,7B;P;'X5T&STJ$
MQ237%N&E\072<R"%6#*B X4=,D'YL\!WPC_;6^-O[8OARWT/P!HNA^'?$&A1
M-_PDVMW\>ZTCEWLL<<,;;L,X0E@0V#G& ,GV'_@EE&L?["_@?:H7,=PQQW)N
M)":\_P#^"/<*KX+^*,@4;V\9W*D^H"K@?J?SK25M=-C.*D^75ZHZC]A7]JCQ
MO\2?B'XR^'/Q+LK*'QAX-VRM<VJ!$NHRVTY"_+P60AEP&#] 1DXOQ0_:U^)'
MQF_:.U7X8_!6WT6V;PRI_MK7]20RPV[C *HN"/E8[>C%B#@ *2:O[.W_ "EA
M^,/_ & HO_0[6L'_ ()GWT7@K]JWX[>%]7E$/B*ZU1;N))?EDN8DEN-Q7U"B
M6,\=GSV-+E6LK=$'-)VC?J]3IOA#^UQ\2/A/^TKI_P +?C3;:/-/XB4?V+KN
MG)Y4-RYR%5E P0[ KT4JQ&00<C#^*'[;?Q:_X:_\5?"KP1H^B:I>,(HM)DN(
M2JZ<-BR2SS-NPP"YP.!DCKPIA_X*'WT/CK]M;X$^%]'D\WQ!8:C]KN?)^=[6
M%Y8F5FQTPL4C<]%YZ&M+]GJWC?\ X*X?%J1E!DCT%0I_NY>TS_(4_=MS6Z"O
M*_)?K^A+X&_:4^,GP _:;\+> _B\^@Z_I?CAO(T[5--@$)AF)P%X"@@,55@R
MYPP8$]#V_P"U)^T'K7PR_:N^$/A?3[;1YM.\67GDWLES:>;<(/,5?W;Y^0\G
ML>:Y/_@H1_R=?^S0?^IH;_T;:51_;I_Y/V_9Y_["/_M=*22;3MT8VVDU?9K]
M#RGXUV7QL_X>)>!([J^\%GQJUA=GP_+'$XLH[3_23B8'DOLW].^*^A_VC?VN
MO%'[*7P(\*V^M66E^(OBQXF;[%!9V*NMF\^<&0+]XH-R +P69NH&2.4_:#GC
MM?\ @K9\&6E=8U;0KE 6. 6*W8 ^I) ^IK%_X*03KX'_ &QO@/XKU9O*\-V.
MHI'/,X_=0.ES&[.3[*0?HOM5:2<4^Q.L5)I]?\AWQ%^,W[4'[,/A.W\=>,(_
M!_B;PW&\;:KI=E (YM-1B%QO4 ]2!N!< D9XKT[]J+]L2Z\)?L7V'Q0\"R6D
MG]JO:/;F[A\U421L.I4$?,I!7KU!KHOV_O&FD^%_V-/'=QJ%Q;B'4M)DLK7+
M#]_-,-D07^\<D-QV4GH#7RC\3_#M]X<_X(L>&X=06:.6>XM[A(Y%VM'')<.R
M#'NI!'L14Q2E9M=2I-Q;2?2Y[9^R9\9/CA^TK\1=.\9WUGI/AWX37*RK#8O&
MGVR_41E4E!(+\R8.057 (&<9/U57)_ 6SCT_X&^#8846..'0[)54=AY"5K^-
MO%MIX#\&ZMKE_((['1[.6]N&/\*1H7;] :QD[O0W@K1U9\3?M%?#O_ANO]O3
M7_!ZR%M'^&_A6>/<&(1-1G0^5N^CNA_[9$5WO_!(+XJ3>*_V<+KPK?%DU3P+
MJ,E@\3\-'$Y+H".O#&1?J*\>_8S^#?QZ\<>'-<^)O@KQ9X3\,K\1M1FO[A-3
ML_M-Q+ME< AC$^$!+  'H.E3?LEV7B?]D?\ X*0ZEX3\:WVG7EW\2;%[J6[L
M(S%:7-RS/.C(I50IW"92 !RP]:Z)+W7#M_3.2$K24VM_UV'_  M^._@OX!?\
M%*?C=J'C;5;32;&_9+>VDN(C(KR#RV(& 2#BOJ[X/_M??"CXZ>,QH/A'Q%I6
MK:PL#W8MX8&5_+0J&8$J.A9?SKYO_9M^'^A?$/\ X*=?'6WU[1]-UJWMU22*
M.]MDG6-B8P2 P(!QQFOL7PG\%_"/@/5OM^B>%]!TF^*-%]HL[&.&38<$KN4
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M*TFD:TI-P384445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@?>'8DD#J #S7:?M2_L?>$_VM-"L;;Q!]OL;_2)#+8:E82B.YM2<;@"005.
M<$=0""#S7JU%'M)7O<7LXVY;'RB?^"1'P_UKPYJ%OX@\0>,M>UC4'B)UBXO4
M-U;(A)\N+<C*JMGYL@D@  CG/L7[2'[*_A[]J#P#I_AWQ!=ZQ:V.FW<=Y$]A
M-''*SH" "71Q@@\X /TKTRBG[25[W$J<4K)$<5LL=JL.-T:J$PW.1C'-?+OB
MW_@D]X(U7Q9J-_H/B+QAX0T_6G+7^EZ5>+':R@G)505)5>O!W 9P !Q7U-12
MC)QV*E",MSQO]GK]AKP3^S#X^U;Q!X3_ +6MY-6L8K"2TFN$DMXDCV_,GR!]
MS%=S%F.2QX%<S\9/^";'@[XG?$BY\7Z/K'B3P/XBOB7NKC1+D11W3,<L[(1]
MYNY4@$\D$\U]%44>TE>]R?9QM:QY#^S+^Q3X-_9;FOK[1QJ&J^(-4&V\UC5)
MA/=S+G.T' "KG!( R<#).!C3^'G[+7A_X:_'7Q7\0K"ZUB76O&$8CO(9Y8VM
MHP"I_=J$##E1U8UZ711S2ZE*$5LCSCXK?LR:!\8/BWX'\9:E=:M#JG@&>2XT
M^.VEC6"9GVY\T,C,P^08VLO?K7H]%%3=CLEJ<'^T9^SQH/[3_P ,;CPIXB:^
MBL)YHKA9K.14N()(VW*R,RL!GD'*G()%6_@[\#M!^"/PATWP3I,4MQHNG6[6
M^+O;))<AR2YDPH5BQ9B<* <]*[&BGS.UA<JOS=3Y4UG_ ().>$;?6[ZX\*>+
MO&W@NQU-B;C3M-OA]FP>JJ"-P'L2V/I@#U/]G;]C7P9^S+X1U33/#\-]-=:X
MNW4=2O)A->7?! RV  !N)   R23DDFO6**;J2>C9,:<4[I'D/[*7[%WA7]CZ
MWUR/PS>:Y>+X@DBEN/[1FBDV&/?MV^7&F/OGKGM7JFM?\@:[_P"N+_\ H)JU
M0PW"DY-N[+C%)61^;G_!/K]C7P[^TQ\(?$6N-K&O>&_$>E^);RSAU31KL12-
M"4C/ER#!#*"6/8\]>U?8_P"RW^QAX/\ V3K+4&T'[?J&KZN<WVJZA();JX .
M=F0 %7/. .3R23@UZII^E6ND1-':VUO:HS%V6&,(&/K@=ZL5<ZCEZ&5.C&*7
M<^>_CG_P3D\&_&'XB2^,-/U+Q!X+\47'-Q>Z)<"$7+=-\BD'+8&"5*Y[Y-;W
M[-/[#7@W]F36+[6M/DU37?$VI*4N-9U:<3W14G)5< !0<#.!DX&2<"O9J*GV
MDK6N7[.-[V/,_@K^RUX?^!/Q"\:>)-'NM7N+[QU=K>7Z7<L;Q0NI<@1!44@?
M.WWBQZ<U)\4_V8]!^+OQ9\&^,M2NM6AU3P/,;BQBMI8U@E8D']X&0L1D?PLM
M>D44<SO<?*K6/._VE_V:-!_:G\!VGA_Q!=:M:65GJ,6I(^GRQQRF2-74 ET<
M;<.<C&>!S6]\5OA;I_Q@^%^L>$]2EO(--UJT-G-);.JS(AQRI96 /'<&NFHI
M<S#E6YYBW[)/@^\_9NM?A9J$%YJGAFSMEMHFN91]J7:Q99 ZJH#ACD$ #M@@
MD'R3P]_P2B\*V9L['5_&?CSQ%X7TZ026^A7=^%L^#D*X51E?9=M?5-%-5)+9
MDNG%[H\E^!?[&_A;]GOP'XH\.:%=:S)IOBR:6:Y6YFC9K;S(S&5BVQJ%4+T!
M#=.];G[-_P"SOHO[+WPQA\*>'[G5+K3X;B6Y$E_(DDQ:0Y.2B(,<>E=]10Y-
M[E**6QYO\._V8M ^&GQT\9?$"PNM6EUKQPL*WT,\L;6T0B "^6H0,,XYW,WX
M5YO\6/\ @F9X-\??$6\\6:#K7B;P)KFI,7O'T2Z$,-RS'+N4(R&;.3M(!/."
M<D_2%%"G).]Q.G%JS1Y+^S)^QGX-_96@OIM!COM0UK5O^/[5]2E\Z\N1G.W=
M@!5SSA0,GDY(S5_X6?LM>'_A#\8/&7C;3;K6)M5\<2++?17,L;6\)!)_=!45
MAR?XF:O2Z*.9L:A%;'F_Q$_9AT#XF?'3P;\0+^ZU:+6? RS+80P2QK;2^:"&
M\Q2A8XSQM9?QKF?VH?V%?#/[3OBG2?$-QJ>M>&_$VC1^3;ZGI4HCE,>2P5@0
M<[26((((W'G!Q7MU%"FUJ@<(O1G+?!GX;2?"/X<:=X?DUO5O$4FGAP=0U*3S
M+F?=(S_,?;=@>P%?*7_!5O1['Q'\7?@3I>HQ17%CJGB(VMQ!(<+/&[PJR^O(
M)Z5]K57O-)M=1EADN+:WN'MVW1-)&&,9]5)'!^E.$^67,3.G>/*CY;B_X)'^
M I]>L_[0\1>-M6\-Z=+YUKH-UJ :SB.<E,[=VSM@8./XC7K'[1G['O@O]IKP
M%I^@ZW:SV,>BD'2[G3V$,^G84+B/@KMV@#:01P.A (]4HI>TE>]P]G%*UCY=
MTW_@E9X1U(R-XN\5>-O&S);/:V0U.^#1Z=N&/,C7:1YBC&"V5&/NFO7/ O[+
M_A7P7^SS#\,9H;K7?"T=M):O'J;K)+.CR-(=S(JC(9N"H!&!W&:]&HHE4D]P
MC3BMD?)=O_P2#\#QW$5G-XL\>77A6&;SUT*34%^S%LYP2$!V_3#?[6>:^@_&
M_P  _"/Q#^$K>!]4T6UF\,"W2VBLD&Q;=8\>68R.59< @CD$5V-%#J2>['&G
M%;(^2[/_ ()$>#5\G3[SQG\0-0\+V\@E319=140$YS@E4''^Z%/OWKW+XD?L
MS^%_B-\ KCX:^1/HOAF:U2T2+3"D3V\:,& 0LK#J.20<Y/<YKT*BFZDGNPC3
MBMD<SX?^%NG^&_A):^#();MM+M=+&DI([J9S$(_+R6"[=VWOMQGMVK(_9N_9
M[T7]E[X46?@_P_<ZG=:98RRS)+?R)).QD<NV2B(O4\?**[VBIYF/E5[GEGPM
M_9"\*?"G4_'UQ;-J6IQ_$>X^T:M;:A)')#SYF4C"HI"GS6'S%CTYKR.+_@DO
MX5TN2\L=)\<?$+1_"^H2F2XT6UU%5@<'JN[;G;CCD$X[]Z^KZ*KVDEK<GV<7
MI8\;^ O[#G@C]FOXF:IXF\)KJEC)JE@NG/8-.CV<4:E&W*-F_>2@)+.WWF]:
MVO@=^RWX?^ 'C+QEKFC76KW%WXXO5OKY+R6-XXG!<@1!44A?WC?>+'IS7I5%
M)RD]RE"*V1Y;K7[)?AO5?VE=/^*D%YK6F>)K.V^R3)9S1K:ZA'M*_OD9"S?*
M0.&'W5[C-<;\<_\ @G)X-^,/Q%D\8:?J7B#P7XHN.;B]T2Y$(NFZ%W0@Y8C@
ME2N>^3S7T)10IR6J8G3B]T>,_LT?L-^#?V9-8OM9T^35-=\3:DI2YUG5YQ/=
M%2<E5P %!XS@9.!DG K<\)?LM^'_  ;^T9X@^)UK=:O)KWB2R6QN8)98S:(@
M,9RBA P;]VO5R.O%>E44<SW'[.*T2"O-YOV7] N_VF(OBI<7>KW'B"UTTZ9;
M6TDT9LK5",%T39O#D%@3OQ\QXKTBBDFUL-Q3W([FVCO+:2&15>.52CJ1PP(P
M0:^>]"_X)J>!?#GP3\5> +75/%B^'_%E]%J$ZM=0&2S>-E*K"?)PJG:H.X,2
M!USS7T113C)K84HI[F-\/?!%I\-? NC^'["2XDLM%LXK*!YV#2,D:A06( !.
M!S@ >PK9HHJ2CG/BW\,M/^,WPVUGPMJDMU#I^N6QMIY+9U69%/=2P8 \=P:^
M?/$W_!)[P/>7[-X=\1>,/!MC=V\=MJ%CI=Z%@OE10NYE*\.P&6/()).WDY^I
MJ*J,Y+8F5.,MT<1\ _V??"_[-GP^@\-^%K$VMC&QEEDD;?-=R'K)(V!N8\=@
M    !Q7AWB[_ ()-^"=<\8ZIJ&D^(_&'A?3-=E,NH:3IMXJ6LV3DJN5RJY)X
M.X#.!@8%?5%%"G).Z8G3BU9H\?\ V??V(O!/[,?Q USQ!X3&J6KZ]9P64ME+
M,CVMND0&#&-@?<Q!9BSMDL3QFM7X6?LM>'_A%\8O&7C?3;K6)M6\<2+)?17,
ML;6\)!)_=A4##D_Q,U>ET4<S8U"*V1YU^TG^R]X3_:J\$IHGBJUF9;:3SK.\
MMG$=U928P6C8@CD<$$$$=N 1XM9_\$C? ^HZ?>1^)/$_C;Q-<26_V6RN+N^0
MOI:;@<Q HR[\#;E@1@G !YKZNHHC4DE9,4J<9.[1Y_XA_9H\)^,?@/8_#G6K
M%]6\.Z?86]A#]H<>>HA14CE#J!MD&T'<H'.>,'%>&V/_  2+\&AK>QU#QEX_
MU3PO:R"6+1)]146_T)51Q_NA3[BOK*BG&I);,4J<7NCSWXK?LS^&/BQ\"I?A
MU-%<:+X;:**WCCTLI"]ND;!E";E91T'4'/ZUU7@'P7:_#KP+H_A^Q>>6RT2R
MAL('F8-(T<:!%+$ #=@#. !["MBBIYG:Q?*KW/._V:_V:="_99\$WV@^'[K5
MKNSU#4I=4E?4)8Y)!+(J*P!1$&W"# ()Y/)KT2BBDW=W8))*R"BBB@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<;\>?%_BCP+\,[[4O!WAY/%.O0L@@TYYO*$P+ ,=WL,
MG\*[*B@'JCY+F_:O_:.MX6DD^!-C''&"S.VJ[54#J2<]!4?[+O\ P4"\=?M*
M^%O'M]9_#^U\SPIIYELUM;B29;Z\R=MOR!DD GY3Z>HJM_P4@_: UCQ7K^E_
M GX?LT_BWQDRQZI+&?\ CPM6Y*,1]W<N68]HQ_M"O2=1^#5G^R3^PIX@T'PS
M--:W&CZ'<SO?Q'RYI[HQDO/D=&)''H H' %=&EE=:LY5S<SLW9'H'[.GCKQ-
M\2?@]I&M>,/#K^%?$5YYOVK2V# VVV5U7[W/S(%;G^]7<5\G? +]IC4/A;_P
M2YT_XA:W=76O:O96-RR27<QDDNIC=21Q!F/) )4?05PWP<_8_P#B+^U7\);3
MXC>*/BYXLTGQ/XDB.HZ3;V,OEV=C&_,>Y 1PPP=J;=H(ZG-1[/5MZ&BJ:))7
M=KGW57"_M(>.?$WPR^#.M>(/">DV>N:QH\/VH6-RSJL\2',FW;R6"9('<C%>
M-_\ !-W]HWQ1\3]*\6>"?'4S77B[X>WHLI[ML;[N(ED!8C[SJT; MW#+G)R3
M].LH=2K#(/!![U#CRRLRXRYXW1Y%^R)^UGI/[4'P&B\7,;73+JRWQ:S;>9\E
MA*@W,<GG85PP)['U!KS/X??MM_$+X[^"_B!XF\ ^!-/UC1-!OH[#P]YLSI/K
M;><JRN>0H5(B6X/4J,G!Q\F_MC^%[C]E/]I+Q9X%\)^)K?1?"GQ0AMGU.%&R
MNF12S$LC@<KM^<C')CDQT)K],O@G\+=%^"WPKT/PSX?1%TK2K58X77'[_/+2
MD]V=B6)]36LXQBN;N8TY2D^5]-SY!^(?_!1GXY?"C6M#T_Q#\)-'TV]\23-;
MZ9%)<R%KN12@*KACR#(G7^\*]J_9M^./QH^(/Q&;3_'GPSL_">ABUDE^W17#
M.WF@KM3!8]<G\J\K_P""I'_)P'[/?_8<N/\ T;9U]I4I-<J=MQP4N9IO8*\0
M^./[5&I?"G]J'X<^ K?2K&ZL?&Q87%U*["6WPQ7Y .#T[U[?7Q[^V-_RD:^
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M/X8Z7I\7V"ST743:SZK=N6\QIV7YU5  % ZYZCG.!^QIK^L>&?V@?BG\./\
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M-O,GW98W4,K#Z@BN7_:"^.FB_LX_"G5/%FO/)]CT]0$ACQYMU*W"1)G^)C^
M&2> :\I_X)7>+;CQ=^Q1X7:X>21M-DN+!6?J4CE8+SZ ' ^E>I?'S]G?PO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\R_:Z_:+M/V6_@;JWBNXA-U<P[;:PM\<3W,G$8
M;T4'DGT!KTVN?^)'PL\.?&#PY_8_BC1=.U[2_-6?[+>PB6+>OW6P>X]:<;7U
M)E>VA\-?\$\OBC\+_AU_;7Q(^(GQ$\-R?$CQA-)),MS<@RZ="S9*'CY7<@$@
M?=4(O'(KZ#^,_P"T_P##_P"-_P"SW\1M-\(^+=&\0:A:^'+JYF@LY][QQ;=N
M\CTRP'XUTW_#!/P7_P"B8^#?_!;'_A6OX0_9)^&7@ :DNB^!O#6EC6+-M/OA
M;V2)]JMV(+1/CJI(''M6LIQ;YM3&%.<5RZ'RMX&^%FH?&'_@BQ:Z1I<+W6H1
MVD]]!"GWIC!?22[1ZDA3@=S7H7[%W[=GPWM?V2/#BZYXHTO1=2\*:9'8:C9W
M4HCG#0KMW(G5@X4$!0>3MZ@BOI3P-X!T7X8^%;70_#VF6>CZ18AA;V=K&(X8
M0S%CM4<#+$G\:X'Q7^PY\(O&_BF76M4^'_AJ\U*>0RS3-:@><YZLX& Q]R*/
M:1=T^]Q^SE&SCVL>#_\ !+/2+WXA_$?XL?%B:RFLM+\::LRZ9Y@VF9/,>21@
M.X&Z,9Z9W#L:^EOVB?CGI/[./P>UKQ=K#K]GTR$F&+=AKF8\1Q+[LV![#)[5
MUVC:-:>'M+M[&PM;>SL[5!%#!!&(XXE'0*HX K%^)GP>\+_&72;>P\5Z#IGB
M"RL[@74,%] )HXY0" X!XR Q'XFHE).5WL7&+C"RW/C#X._L#W?[4?[._C+Q
MOX^7_BX'Q,_XF.E33#G28U^:!0.RO@ C_GGM''.?0O\ @EK^T=?>,/ NH?#/
MQ6TEOXR^'KFT:.<_O9[5&V+G/):-OD/ML/>OJV"!+:%(XU6..-0JJHPJ@<
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M2XN$L[M)F@C"'+MM/ ]Z^Y?&_@?1_B1X6O-$U[3;35](U!0ES9W48DAG4$,
MRG@\@'\*\Y'[ _P6'_-,?!O_ (+8_P#"JIRC%\S%5C*2Y4=!X$_:8^'OQ&UZ
MWT?0?&?AS6-4F0M':VE\DLKJHRQ"@YX'-=Y7G?@#]DOX9_"KQ1#K?AOP-X:T
M35K=62*[L[)(YD5AA@& SR*]$J96Z%QYK>\%%%%24%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%&<&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH @U.\;3M-N+A89;AH(VD$40R\A SM4>IZ"OE"]\,_M%
M_M;R&ZFU:'X(^$9CF"RB3[1K4J<X,I&-A(ZC<F/[IZGZVKY;_P""L\#V/[.5
MCK-OXID\+WVCZQ#):L)Y84OW*.?()C_B(4D;OE^4@XR#6E/>QE6^&[,5/^"1
MFFWR^=J7Q8^*EW?-\S3)J:HN[N0"K$?G4UI^QE\:/V?\7?PU^+UYX@M[?)&B
M>*D,T,XZD>;EL,>F=J_44GPI_P""Q_PK\2>$+.;Q1<W_ (;UH1@75O\ 8I+F
M$R8Y,;QALJ3R-P!'OU/J7P3_ &_?A;^T+X]C\,^%-?GU#6)H9+E86T^XA!C3
M&X[G0+QD<9K23JK=?@9Q5%_"_P 3J_V>?B/XE^)G@)KKQ=X3N_!VOV=R]G=6
M4KB2*5D _>PO_%$V>#ST/)QFN\HHKG9T+16"BBB@84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%&<T4 %%%% !1110 4444 %%%>(_MG_M%^*_@
MGI.@Z3X%\*3^*?%OBZ>2UL%"EH;0HH9I7 Z@ ]RJC&2<#!J,6W9$RDDKL]D7
M6+1M3:R%U;F\5=Y@$B^:%]=N<X]ZM5^>?[$G@7Q-X!_X*<>(K/QKJD>M^*Y-
M -UJ%VIW+YDRPR>6I_NIN"C  XX %?4_[>G[0TW[,W[-.N>(;%E36)MMAIK%
M=P2>4X#D>BC<WX"JE3M)11$:EXN3TL>KWOB;3=-NQ;W&H6-O.W2.6=5<_@3F
MKRMN%?#_ ,&O^"3GAKXI?"*S\1?$;5/$FI^//$=LNH2WQO65M.>50ZJ%.0S+
MD9W9&<XP,5M?\$X_BUXA\!_$3QU\%?&NJ3:G>>!W:;3;R=BS/:JV&&YN2N"C
MKGD*Q]J'35GRO84:CNN96N?7VHZK:Z1;^==W%O:Q9QOFD"+^9I;#4K?5K<36
MMQ#<PDX#Q.'4_B.*^!OA-\*F_P""IOQN\9>+/&VH:P?AUX<O3INBZ/!.T$<N
M,D$D="%"LQ'S$R#D 8J/QGX#G_X)8_M.>"]0\,ZIJLGPO\:W/]GW^FW,QF2T
M?*@XSQD;@ZMUPK@Y&*KV2VOJ+VSMS6T/T$HI$=9$5E.Y6&01WI:Q-PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *X_XZZ]X-\)?#.^U?QY'I<GAW2\7$WV^V6XC5ONKM0@[G);  &237
M85\K_P#!6BQ9_@/X;U"ZM9M0\-Z1XHLKK6[:)22]L-ZDDCHO.WGC+K50C>21
M%25HMG+_  *_:S^$G[0?QWTOP;HWP?T^UM=62>2#4[[3;6(.L2%]RQA&R#C'
MWN,_A7J'[)WQQ^%7Q?\ ''B#3_"_A?3_  OXN\,S36US;/ID-M<M")"GFQLH
M!*-@9'!&1D="?+_$?Q7\%^+/V_\ X(ZQX9UC1)/#,'AC4ECDMY4C@M1@X1AP
M(R,8VD C&,<4S1O&?A_XP_\ !6C2=2\!R6][;Z%X=N(?$>I68W6]TYRJJ77A
MBI*+GN5QSMXVE%>>QA&33Z;GVG1117.=04444 %%%% !1110 4444 5=8EO(
M=/D:QCAFNAC:DK;5/U-8?]H^+/\ H&Z1_P"!+?X5TU% ',_VCXL_Z!ND?^!+
M?X4?VCXL_P"@;I'_ ($M_A7344"L<S_:/BS_ *!ND?\ @2W^%']H^+/^@;I'
M_@2W^%=-10%CF?[1\6?] W2/_ EO\*/[1\6?] W2/_ EO\*Z:B@+',_VCXL_
MZ!ND?^!+?X4?VCXL_P"@;I'_ ($M_A7344!8YG^T?%G_ $#=(_\  EO\*/[1
M\6?] W2/_ EO\*Z:B@+',_VCXL_Z!ND?^!+?X4?VCXL_Z!ND?^!+?X5TU% 6
M.9_M'Q9_T#=(_P# EO\ "C^T?%G_ $#=(_\  EO\*Z:B@+',_P!H^+/^@;I'
M_@2W^%']H^+/^@;I'_@2W^%=-10%CF?[1\6?] W2/_ EO\*/[1\6?] W2/\
MP);_  KIJ* L<S_:/BS_ *!ND?\ @2W^%']H^+/^@;I'_@2W^%=-10%CF?[1
M\6?] W2/_ EO\*/[1\6?] W2/_ EO\*Z:B@+',_VCXL_Z!ND?^!+?X4?VCXL
M_P"@;I'_ ($M_A7344!8YG^T?%G_ $#=(_\  EO\*/[1\6?] W2/_ EO\*Z:
MB@+',_VCXL_Z!ND?^!+?X4?VCXL_Z!ND?^!+?X5TU% 6.9_M'Q9_T#=(_P#
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M,_VCXL_Z!ND?^!+?X4?VCXL_Z!ND?^!+?X5TU% 6.9_M'Q9_T#=(_P# EO\
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MX4?VCXL_Z!ND?^!+?X5TU% 6.9_M'Q9_T#=(_P# EO\ "C^T?%G_ $#=(_\
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M$=<548MNQ,I)*]SJE^..H77B2'2;&UTW4[R:01M]DE>5(/4NP& !WYXKXO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY+N 2[$;N2V2,]JWG=1U;9S4[.6B2/7J***YCK"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%&>:KZM)<0Z9.UKY!N50F/SF*Q[NVXCG%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTOQ/4J***Q.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#N?@A=^+/V5OV[)?AGJOB2\\4>$OB!:76N:2UXY:;3Y@[.Z#D[5X<8& ?E.
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MCWP/:J]U:F?OMVV_K[OS/-1^S+XZ^-@:X^*GC2==/DRP\->&6:RL\?W)9_\
M62^AZ YKJ_AY\#Y_"FC?V7HMCI/@'0P>;71XPUW<#GF28CKR>>3SUKU:BESL
MM4T4]#T>+0-*ALX6FDCMUVJTTAD<]^6/)-7***@L**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7%H;*RM+0YM],B;[P!P 3@  *  "V2Q.:VV3;:,=VE%-6/J"BBBN<Z0HHHH
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M*YG_ (6WHO\ SVNO_ 63_P")H_X6WHO_ #VNO_ 63_XFBS#F1TU%<CJ'QO\
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MPJBT=K#IRU5V_F?1E%%%8'2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW7+>^BM;^7RXM3(5]UNO!!D902 < A6'>KI_$C.KI!LY6T_X*??VW;+=:9\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@_%
M'Q \276N7>E^'_#Y1K5MLFI:BWEVJ# .Y0#EQ@^U"5Q-V.\K%\=Z]J7A[1!-
MI.E/J]Y)*L2PB0($!_C8_P!T=\<UXK-^USI/P\U2\T:UU+5OBQXVNF4G2_#M
ML)8[0CC:7!$42\\LS#..F:</AS\8OVAOF\6^(H?AAX=D/.C>&I?.U29?[LMZ
MPPA]HU]0<]:OEMN1[2^B*_Q.^.VG_#77;-O''C)EUA91):^%_#D;7-[.XY"F
M./+'WW<8/45'>_$GXL?&B_M[6WCTKX.:+J#^7!)JSI=Z]=@[A\D .R(G ^\2
M1G\*Z_0OV1=%^%VGPVO@%+/PM)<%AJ>I&$W6IWH[$W$A,F<Y_B&,\8Z'K?!G
MP*T#P=>+>^3+J6J [S?7S^=,6]1GA>_09JN:*V)Y9/?^OZ^1ROP[_8Q\(>!]
M4.L7RWOBSQ0PRVLZ]+]MN%;GE%;Y$P3T5170Z1\"K.:X6Y\07UUXDNUZ?:CB
M%?I&./3CI[5W=%1S,TY$B.VMH[.!8H8TBCC&%1!M51["I***DH**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOX^>'? VO_#2[F^(MIH]
MUX7TEA?W!U- UO R @/S_$-Q QR=V!UKM*^5O^"MQ"_ ;PRVH+<-X77Q39'7
M!!NWFW^?/3MU_P"!;>^*J"O)(BI*T6S@_@U\0/V6_C[\;+/P3X9^%MC>7%\)
MBE])I,<-N/*0N?O-OY ./E].E>M_L?WGP%\<>,M9O?AKX=T/1_$WAN6;3[Q5
ML1;7<2;RA9?[T;E/O#Z'!XK@M7/A.#_@H1\#&\&G18_#8\+:D;4Z<4%OY>TX
M^[QT]>>OO52TU#P[J?\ P5XTIO ;6K,OAVY'BJ2Q(^SR2?P[BOREP?*W=\XS
MR*WDKKKL81T>MM[;'VE1117,=04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16'XG\?V/A>
MZ2U9;F\U"5-\=G:Q&69QR <#A1D$98@<5ROBKX\6?PHL)M9\>:AH'A'1=F+>
M&YN]]Y*V>.!P<_W5#'/>GRMDN21W'B+Q!;>%M(FOKPR""$ MY<;2,<\ !5!)
M-<!XM^(FO7NCSW@:R\$Z'&I+ZGJ\BI)CGE4/"],C/6N('[1_Q&^/C>3\+/!;
M:3H\O \3^+8WM8"O]Z"T'[V3V+;1GJ"*D'[%,.J7$>M>.=2OOBQXF613''K$
MWV72;,D\M':H"@5>N"&/IBK4;?$0Y-_" _;.N?'[#2OA7X9U+XA7L($4VLNO
MV'1D;'+&=A\_3.$!Z]:D7]E?Q5\9)!<?%?QE=:A9.0W_  CN@LUCIJ_[,C@^
M9-^) KTK2?A;)*EK_:FH,8;1E:'3M.3['8P$'(&U3N?!_O''M794<UOA'RW^
M(\]\*_!-/"-@VE:'%IOA'0(V*I;Z/;B.XG7^\\A'#$=< GWKL/"_A.Q\'V#6
M]C&R+(YDD9Y&D>5SU9F8DDFM*BHNV4HI!1112*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWXLZ;X;U?X<:S;>,%T]O#
M,ULRZC]N8);B+N6)(Q@XP000<8YQ715\K_\ !7'P]JFO?LW:<T*7\N@V>NVT
M^NI9H6D6T&X%SC^%203G@$J>U5!7DD34E:+9\V^*?V>?V5QXC:;2?C?J&DV@
M=B+>*3[0L*GJD<FP$#W.XGN3UKZ5_8,N?V??AUJTWAGX7^([;7/$VJPM/=7,
MSM+>WB1\G+;5557=G:H YR<GFN[^&?[*OP+\1^"]/N_#O@OP-JVDS0H\%REG
M%<M*I P6=@6+$==QSGKS7;>!_P!G7P'\-->75/#W@_P[HNI+&T0NK*PCAE"-
MC<NY0#@X''M6LJB:MJ8TZ33NDCM****P.@**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK/\1>*=-\):>UUJ=]
M;6-NHR7F<+GZ>OX4 :%-EE6WB9W94C0%F9C@*!W-<3X.^-D'CSQ T6FZ7J#:
M+%&SR:M,GDVX(Y&-W)!YYXZ5Q/Q"_;A\)V.N7'AOPG9:E\2_$PS')IF@0_:(
MH2>HGG_U48QUR2<=C5<K;L3SQ2N>@W?Q2749&@\/:?<:[< X\R/]W:QG_:E;
MC_OG)KG/B7^UEX1^#<-O9Z]J4-QXEN% 71=)5KZ\D<_PK&@W8SW;%>?^(_ G
MQ6^(_AJXU#QMK?\ P@?ANWCW'PYX.'GZC,F<;)+HC'L1$,$>G6M/X._ 23PI
M:L/"?AG3_ MK<?Z[4KP?;-9O.H+-(Q)R1@\G\:KEBMS/FD]OZ_KS&#7?C/\
M'Z3=I.GV/PF\/7  -[J,:WFMS)P?EA_U<1Y/WR2,]JS="_9AM?!?CR2?3_#M
MUXN\5Q;3+XK\63F\925'S0JWRKTQ\H!'?-?2$*&.)5+%BH )/4^].H]IV*]F
MNIS?P\\+:KX;MKE]8UJ?6+N\97.5"108&,1KV!_#IT%=)1169IL%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P *ETC_ *?O_ M_\:/^%2Z1_P!/W_@6_P#C1H&ITVZC=7,_\*ETC_I^_P#
MM_\ &C_A4ND?]/W_ (%O_C1H&ITVZC=7,_\ "I=(_P"G[_P+?_&C_A4ND?\
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M_P *ETC_ *?O_ M_\:/^%2Z1_P!/W_@6_P#C1H&ITVZC=7,_\*ETC_I^_P#
MM_\ &C_A4ND?]/W_ (%O_C1H&ITVZC=7,_\ "I=(_P"G[_P+?_&C_A4ND?\
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M)B ./FR<<]J\,\<?M%:7\==?MH_AWX"N_B5J&FLR0ZI<@VFB6C'&2TSC$F,
MX53R.HZT_P +?#]_$&E?89I-0^)E_@B2_OH5M=*A)QD(O\>.HY/UKUKPE\'K
M6P\,V=O?*([J-,2I93/';AO]E>,<8[4:1)]Z1X+XP^$7B#X@:Q'IOQ.U[6?%
M%PT:S+X0\*H^F:-$ISM$TP_>2J".Y&,\Y%>W? GX=77PZT]K6/1_#OA?14B"
M6ND:5;JHA.<[G<#YFP2...:W!\)])7I]N&>"?M3Y/ZT?\*ETC_I^_P# M_\
M&ARNK%1A9W.FW4;JYG_A4ND?]/W_ (%O_C1_PJ72/^G[_P "W_QJ-"]3IMU&
MZN9_X5+I'_3]_P"!;_XT?\*ETC_I^_\  M_\:- U.FW4;JYG_A4ND?\ 3]_X
M%O\ XT?\*ETC_I^_\"W_ ,:- U.FW4;JYG_A4ND?]/W_ (%O_C1_PJ72/^G[
M_P "W_QHT#4Z;=1NKF?^%2Z1_P!/W_@6_P#C1_PJ72/^G[_P+?\ QHT#4Z;=
M1NKF?^%2Z1_T_?\ @6_^-'_"I=(_Z?O_  +?_&C0-3IMU&ZN9_X5+I'_ $_?
M^!;_ .-'_"I=(_Z?O_ M_P#&C0-3IMU&ZN9_X5+I'_3]_P"!;_XT?\*ETC_I
M^_\  M_\:- U.FW4;JYG_A4ND?\ 3]_X%O\ XT?\*ETC_I^_\"W_ ,:- U.F
MW4;JYG_A4ND?]/W_ (%O_C1_PJ72/^G[_P "W_QHT#4Z;=1NKF?^%2Z1_P!/
MW_@6_P#C1_PJ72/^G[_P+?\ QHT#4Z;=1NKF?^%2Z1_T_?\ @6_^-'_"I=(_
MZ?O_  +?_&C0-3IMU&ZN9_X5+I'_ $_?^!;_ .-'_"I=(_Z?O_ M_P#&C0-3
MIMU&ZN9_X5+I'_3]_P"!;_XT?\*ETC_I^_\  M_\:- U.FW4;JYG_A4ND?\
M3]_X%O\ XT?\*ETC_I^_\"W_ ,:- U.FW4;JYG_A4ND?]/W_ (%O_C1_PJ72
M/^G[_P "W_QHT#4Z;=1NKF?^%2Z1_P!/W_@6_P#C1_PJ72/^G[_P+?\ QHT#
M4Z;=1NKF?^%2Z1_T_?\ @6_^-'_"I=(_Z?O_  +?_&C0-3IMU&ZN9_X5+I'_
M $_?^!;_ .-'_"I=(_Z?O_ M_P#&C0-3IMU&ZN9_X5+I'_3]_P"!;_XT?\*E
MTC_I^_\  M_\:- U.FW4;JYG_A4ND?\ 3]_X%O\ XT?\*ETC_I^_\"W_ ,:-
M U.FW4;JYG_A4ND?]/W_ (%O_C1_PJ72/^G[_P "W_QHT#4Z;=1NKF?^%2Z1
M_P!/W_@6_P#C1_PJ72/^G[_P+?\ QHT#4Z;=1NKF?^%2Z1_T_?\ @6_^-'_"
MI=(_Z?O_  +?_&C0-3IMU&ZN9_X5+I'_ $_?^!;_ .-'_"I=(_Z?O_ M_P#&
MC0-3IMU&ZN9_X5+I'_3]_P"!;_XT?\*ETC_I^_\  M_\:- U.FW4;JYG_A4N
MD?\ 3]_X%O\ XT?\*ETC_I^_\"W_ ,:- U.FW4;JYG_A4ND?]/W_ (%O_C1_
MPJ72/^G[_P "W_QHT#4Z;=1NKF?^%2Z1_P!/W_@6_P#C1_PJ72/^G[_P+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1Y8Y1MJYR RY (Y!.LZ<5W,:=23MJCZJHHHK Z0HHHH **** "BBB@ HHHH
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M8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUO<^D****Y3M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*?_!7;PGJ'B7]G
M#2[F&.YN-%T?7+>[UF&W/[PVP#*7]]N?PW9[9'U/>WD6G6DUQ/(L4,"&21V.
M B@9)/T%>:?%KX2^!?VX?A!96-UJ3ZMX;FN8]1M[K2+\*)'574?.N<C#L"#_
M $JZ;M),SJ1YHN*)/@IXB^%MW\,=/?P;/X4A\.O JPQVYB0*H ^60'G>/XM_
M.<YYKYM\$Q^#M9_X*F1ZU\.I=-M-#T;0IH_$]Y:,D>GSW+_*D:$84N3L+;>"
M4/<&NL?_ ((Q?!B1MS1>*&/J=5/_ ,31-_P1G^"Y3,B>*-J#.6U4X4?]\UI&
M4%?5F<HU';1:'U58:G;:K!YMK<07,8.W?$X=<^F15BO)_P!C_P"$_P /?@O\
M.M0T'X<:F-4T>WU28W3_ &X7GE76%#H7'&0 O':O6*QEHS:+;6H4444B@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJCXA\3:?X3
MTUKS4KRWLK53@R3.%!/H/4^PYKFM,^)=]XKNHI-)TF2/158--J6HDV\;Q]_*
M0C<WLS8'6G9BNCLZY:_^)/VNXDMM#TZZUJYC8H77]U:QMT.Z5N./]D&O//&'
M[<'AV/7YM!\"Z?JGQ,\31?*UGH*B2VMSG'[Z[/[J,=03EB".0*Q7^"_Q6^.M
MN\WC_P 3KX.T-E+?\(UX1DVW$RXSLFO6^;)QTCP,YY(JE'^8ASOI$ZCQG^US
MX=^$BKIOB#4;?6/%DSGRM$\/1/>W;9^ZNP9(/NVT5S\MW\:OC^"MK#9_"/P[
M-_RVG"WNN2KST3_5PGIUR1[TGPE^!=]X<TW[+X1\-:;\-]+FXFNY$^T:O=CN
M6=LL"3D_,1@GC(->X^&]';P_H5K9O=7-\UL@0W%PVZ27'=CZTVTMB8J4M_Z_
M4\3\.?LC:?\ #3Q3'=:/I4?B'Q)<1B2Z\5^)[@W]RC$GB-3PK#&<*%49KU;P
MC\/V\/W\FH7VJ:AJVIS)L>6:3;$@ZX2,?*HS]3[UTE%2Y-[FBBEL%%%%24%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ,G@2ZA>.1%DCD4JRL,JP/4$>E?,'CO_@G!_P (
M[XCN=>^#WCC6_A;JETYDFLK9C/I4S'J3 3A2?;(&>E?45%5&36Q,H*6Y\A_\
M*_\ VR-)Q:V_C7X9ZA ORBYN+9EE(]2/)Z_G38/V$OBY\;9U7XN?&*_FT=SN
MFT;PZAM89?56DPI*D=BIKZ^+ 4!LU7M'TL1[%=6_O.8^$?P<\-_ KP1:^'?"
MNEV^DZ5:Y*Q1\EW/WG=CRS'N373T45GON:K31!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 444V218D+,P55Y))P!0 ZBN&UCX^:+;ZY'I>EK=>(
M-0DD"/'IZ>:L0R 2S=..O!/3M5GXL?'KP?\  _2Q=^*->L-)#C]U [[KBX/I
M'$N7<_[H-/E9/,B]XO\ BGHG@CY;V\0W)'RVT7[R9C_NCI^.*_.7]IW_ (.2
MO#WPO\=WWA_P3X%F\3-I=PUO/J%W?B"W9E.&"*JDMW&<XR.]?2VJZ[X_^/L>
MLR?#7P';^";?6H9A_P )3XJ5H[EF="HDM[49<$\$,V!SGGI7\[/C7POJ7@CQ
MEJVC:Q;W%KJVEWDMM>0S)LD257(;([9//XU^P^$W!^69S6KSS%<_LU&T+M7Y
MKW;LT]+6WZZ]#S<;BIP2Y.O4_<[]ES_@L59_\% Y;?PWX/\ ACYOQ$L$:^:S
MUB_B&FV<:_)]H$N-TF-PRH4,,\$]:]:\<_L^>)/%TUG-\5-<USQY-?L3#X8T
M$-I^A1;<';,5/F2C!_C.#CH,9K\G_P#@WZ^'FO>+?^"C6AZOI,5PNF^&M-O+
MC5;E%S'%%)$8UC8_[;L ._'M7] E>#XE</X+),X^JY?\#BI6O=Q;;TN]>B:O
MK9FV$E*M3YIGF?P8^&&L>"WM1Y.B^&-"M4*Q:'I5LJQ<J!EV'5AC.>3[UZ91
M17YXW<[8QLK(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXUT]% 6.8^S^+_\ GYT/_OU)_C1]G\7_ //SH?\ WZD_QKIZ* L<Q]G\7_\
M/SH?_?J3_&C[/XO_ .?G0_\ OU)_C73U3UKQ!9>'+)KB_NH+2%?XI7"Y]AZG
MV'- &)]G\7_\_.A_]^I/\:K:IJ'B30[1KB\U+PY:PH,L\JNJC\2:ZI]1ABL?
MM4DL<=N$\PR.=JJN,Y)/08]:^;_B)\?/!/B;XBW4/A32]<^+'B,83[#I;F32
M[)@,9DG.(D!QG@MGGK515R)2L>H>$/'^N>.[NZCTNZTNXBM,;KC[+*L+DY&%
M8GDC'IZ5Y_\ M"?M :/H%E)X;US6-+US5+QE":'H<$UUJ,[ Y5=D9^7)'\1
M/-8^L^#?'GQ)=+7QWXM7PGIK#Y/"/@E2UY*F?N2W&-R@C'W0HZ\UZM^SU\&-
M!^%&D7"Z3X/L?#'F,-LAD$][<@CEII.6W$\XW&KT6I-W+0\[TBY\6:I\-/WE
MK#\&=,N!LC)\IM2FXRN% <JV.Q)<>@JK\#_V<5\%^(6UC1_#<.J:M,X>7Q/X
MIDEN-0FYSF,R$NH],!< XZ5])3V<5U)&TD4<C0MN0LH)0^H]#4E3[0KV:ZG,
M?9_%_P#S\Z'_ -^I/\:\&_:3_P""8/P[_:V\3#7/''@OPI?:[@*^IVGGV=U.
MHZ"1HV ?' RP)P ,X&*^H**Z<%F&*P=7VV$J2IR[Q;3^]6'*G&2M+4\;_9]_
M95TS]E3P@V@_#WP[X/\ "^FRN))EM;>4R73_ -Z61B7<\GJ<#)QBN]^S^+_^
M?G0_^_4G^-=/16.(Q%6O4=:O)RD]6VVV_5O5CC%)61S'V?Q?_P _.A_]^I/\
M:/L_B_\ Y^=#_P"_4G^-=/16([',?9_%_P#S\Z'_ -^I/\:/L_B__GYT/_OU
M)_C73T4!8YC[/XO_ .?G0_\ OU)_C1]G\7_\_.A_]^I/\:Z>B@+',?9_%_\
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M/XO_ .?G0_\ OU)_C1]G\7_\_.A_]^I/\:Z>B@+',?9_%_\ S\Z'_P!^I/\
M&C[/XO\ ^?G0_P#OU)_C73T4!8YC[/XO_P"?G0_^_4G^-'V?Q?\ \_.A_P#?
MJ3_&NGHH"QS'V?Q?_P _.A_]^I/\:/L_B_\ Y^=#_P"_4G^-=/10%CF/L_B_
M_GYT/_OU)_C1]G\7_P#/SH?_ 'ZD_P :Z>B@+',?9_%__/SH?_?J3_&C[/XO
M_P"?G0_^_4G^-=/10%CF/L_B_P#Y^=#_ ._4G^-'V?Q?_P _.A_]^I/\:Z>B
M@+',?9_%_P#S\Z'_ -^I/\:/L_B__GYT/_OU)_C73T4!8YC[/XO_ .?G0_\
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MG0_^_4G^-'V?Q?\ \_.A_P#?J3_&NGHH"QS'V?Q?_P _.A_]^I/\:/L_B_\
MY^=#_P"_4G^-=/10%CF/L_B__GYT/_OU)_C1]G\7_P#/SH?_ 'ZD_P :Z>B@
M+',?9_%__/SH?_?J3_&C[/XO_P"?G0_^_4G^-=/10%CF/L_B_P#Y^=#_ ._4
MG^-'V?Q?_P _.A_]^I/\:Z>B@+',?9_%_P#S\Z'_ -^I/\:/L_B__GYT/_OU
M)_C73T4!8YC[/XO_ .?G0_\ OU)_C1]G\7_\_.A_]^I/\:Z>B@+',?9_%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=>'YO%*VLL<:VFL/=2^2=OF?(788X'..*TE&-M+F<92OK8^CZ***Q-PHHHH
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MJN5O8ES2W/2]4^(%U-JLVGZ+H]YJ%U;L4DFE7[/:Q'W=OO?\!!KY,_X*3?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW<$DM@HHHK, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  MM&3P!4=O
M<QW4>^*2.1>FY&#"LOXAG'@#7/\ L'W'_HMJ^</^".DLDW[%MDTCO(W]KWO+
M,6/WQZU7+[MR'*TE$^IZ*^;_ /@GS\9?$WQ=U7XN1^(]6FU1/#_C&ZT[3Q(B
M+]FMU)VQC:!D#'4Y/O7TA1*-G8<9<RN@HHHJ2@HHHH **** "BBB@ HHHH *
M*JZSJJZ+ITERT4\RQX^2%-[GZ"L+_A:-O_T"];_\ S0!RG[67[8_@#]BCX:?
M\)3\0-9&FV,DGD6L$49FNK^7&?+AC'+-CD] !U(XK\\?VD?^#E;P]KWP;\1V
M'PS\->(M)\9W"BWTJ_U6&-K:%68!Y]JL?G5<E588+ 9]*\A_X.4]<U37_P!I
M+P#--;ZE;Z#_ ,(\ZV0N(FCC,_GOYVW/&[;Y>>^-M?FZQV#)^M?TIX>^&.3X
MK*Z&:8U.I.?O6O[JL](M==O>OZ'BXO&U%-PCHCIOB3\9O%WQDU>:_P#%OBC7
MO$EY<2>=)+J5])<%G]?F)'Y 8'3%<S7M7A+_ ()P_'KQVVEG2OA1XPN+?6H(
M[JSNC:A+:2&0 K(7)PJD$'GD>E??W[,G_!O=X7T(Z'JWQ4U_Q%K5Q&D<]_H.
MEZ<8K7S.K0M<$[GCZ E0I//(K]*SCC;(,FI)5:T>MHPM)Z=+1T7;6ROU.*GA
MZM1Z+[S\S?#_ .S7\1/%:::VE^!/%VH)K$:36+V^DS2+=H_*.C!<,I'0@XK]
MVO\ @B/^PKXA_8G_ &8;W_A,8_L?BKQE>KJ5YIX<-_9L:ILBB8CC?C);'0G&
M>*^G/#WB[2/"6A6.EZ;H.IV.GZ; EM:V\%@5CMXD4*J*!T    ]JN_\ "T;?
M_H%ZW_X!FOYUXR\4L7GV#^H1HJG3;N];MV=TNENC?FM['KX;!1I2Y[W9T]%<
MQ_PM&W_Z!>M_^ 9H_P"%HV__ $"];_\  ,U^5G?='3T5S'_"T;?_ *!>M_\
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M<Q_PM&W_ .@7K?\ X!FC_A:-O_T"];_\ S0%T=/17,?\+1M_^@7K?_@&:/\
MA:-O_P! O6__  #- 71T]%<Q_P +1M_^@7K?_@&:/^%HV_\ T"];_P# ,T!=
M'3T5S'_"T;?_ *!>M_\ @&:/^%HV_P#T"];_ / ,T!='3T5S'_"T;?\ Z!>M
M_P#@&:/^%HV__0+UO_P#- 71T]%<Q_PM&W_Z!>M_^ 9H_P"%HV__ $"];_\
M ,T!='3T5S'_  M&W_Z!>M_^ 9H_X6C;_P#0+UO_ , S0%T=/17,?\+1M_\
MH%ZW_P" 9H_X6C;_ /0+UO\ \ S0%T=/17,?\+1M_P#H%ZW_ . 9H_X6C;_]
M O6__ ,T!='3T5S'_"T;?_H%ZW_X!FC_ (6C;_\ 0+UO_P  S0%T=/17,?\
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M_P#H%ZW_ . 9H_X6C;_] O6__ ,T!='3T5S'_"T;?_H%ZW_X!FC_ (6C;_\
M0+UO_P  S0%T=/17,?\ "T;?_H%ZW_X!FC_A:-O_ - O6_\ P#- 71T]%<Q_
MPM&W_P"@7K?_ (!FC_A:-O\ ] O6_P#P#- 71T]%<Q_PM&W_ .@7K?\ X!FC
M_A:-O_T"];_\ S0%T=/17,?\+1M_^@7K?_@&:/\ A:-O_P! O6__  #- 71T
M]%<Q_P +1M_^@7K?_@&:/^%HV_\ T"];_P# ,T!='3T5S'_"T;?_ *!>M_\
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M<Q_PM&W_ .@7K?\ X!FC_A:-O_T"];_\ S0%T=/17,?\+1M_^@7K?_@&:/\
MA:-O_P! O6__  #- 71T]%<Q_P +1M_^@7K?_@&:/^%HV_\ T"];_P# ,T!=
M'3T5S'_"T;?_ *!>M_\ @&:/^%HV_P#T"];_ / ,T!='3T5S'_"T;?\ Z!>M
M_P#@&:/^%HV__0+UO_P#- 71T]%<Q_PM&W_Z!>M_^ 9H_P"%HV__ $"];_\
M ,T!='3T5S'_  M&W_Z!>M_^ 9H_X6C;_P#0+UO_ , S0%T=/17,?\+1M_\
MH%ZW_P" 9H_X6C;_ /0+UO\ \ S0%T=/17,?\+1M_P#H%ZW_ . 9H_X6C;_]
M O6__ ,T!='3T5S'_"T;?_H%ZW_X!FC_ (6C;_\ 0+UO_P  S0%T=/17,?\
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M=%%%<IV!1110 4444 %%%% !1110 4444 >7_M7_ +'W@+]M7X9-X4\?:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD4; J%"CJ1R?XATJ;X._$OXH?"S]HK2_AQ\2=8T'QA#XFTVYU'2M6L+86MQ
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M_#X;\*V36MFKF6:61M\]W*0 9)'[L< =@    .*[BE4E=Z%4XN*UW"BBBH-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC=?2N<^)G[<WPW^$/BOQ%HGB#6)K'4/#%G%>7<;6SD.LGW$C.,.YS]T=LDX
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M 4B# C(YV >\IYVC&;^UC_P3,\%_#3X+^//&VFZ[XQ74-+L;K5+>W?4<VZN
M7";=N=@Z8SG%7[-:*3U)=1ZN*T/MX:S9D_\ 'U;?]_5_QJ=)TDD95=69,;@#
MRN?6O@#]C+_@FYX1^.W[/OA;QGJ_B#QE#JFI*9Y8[?4=D*E)6  !4G'RCO7I
MW[16J3?LA_MB^"_'UO<W"^%?B!L\-^(X7D+1),@ @GP> P7GCDB-_P"]0Z:O
MRIZA&H^7F:T/K2BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,'&<>7G\C27-[/S/COXB?'CX=ZS_ ,$]])^%MCH?C2/Q#H@AO8KJ31Q';_;
MY,S,^_(4K)*,X]#BOL[]DGXP_P#"[?V!;/5))!)?6>B7&F7OM+!&T9_-0I_&
MO?M2L(=6T^>UN$62WN8VBD0CAE8$$'Z@U\D_L/?LQ>/_ -G73/BWX-U+20OA
M;4I)IO#EW]MAD^TEEDC"[0Y9,H(L[PO(:K<E*/SN1&G*$EUTL>'_ /!.G]E7
MQG\9_P!GTZQH'Q;\2>![$:C- =.L(MT1=0N9"=PY;([=J^WOV8_@=XB^!GAS
M5+/Q%X\UCQ]<7UV+B&YU%-K6B!%7RUY/!(+?4UP?_!,;X$>*OV>/V;#H'C#2
M_P"R=6.J7%S]G^TQ3_NVV[3NB9EYP>,YKZ*I5JEY-="J--**;W.9^-?_ "1O
MQ9_V!KS_ -$/7S#_ ,$;OA9H>G_LR3>)/L-K-K6N:C<0W5R\89_*C(1(@3T7
MJ2!U)Y[5]3_$_1KCQ#\-?$&GV<8FN[[3;FW@0L%WN\3*HR< 9)').*^*?V<_
MAY^T3^PIX#ATG3/!NF^.-'UM?MSV,=ZB3:'>-P\9(?#J<*25RONO.2&L&@J:
M34FC3_9YT"W^"_\ P5O\>>%]!06FA:[H9U&6S@&V&&3]RXPHX #/)CT\S'2M
M?]@;_D^K]HK_ +",7_HR6NJ_8@_9;\8>%_BAXL^*_P 3C:Q^./%W[F.QMY!(
MFF6^1E=RDKDA4  ) "#)))QQWC?X1?%S]EC]KOQ=\0/ASX6M/''A[Q]&C7ME
M]H6*6UF&.Q(/#;B&&X$.0<8!JW).Z\D9QBTE*W5DW[2<RR?\%:O@>BLI:/3K
MK<,\KF*YQFN1UWX,Z/\ &W_@L;JMEK]K'?Z7I.D1:HUK*-T=Q)'%&L8<?Q*&
M?=@\$J*O?#_]F3XV^,/VXO OQ:\=:3I\<+-.U];6EY%L\/P+;S1PP8+[G+&3
M=\F[!8Y/4#U3P?\ L^^+M*_X*7^)/B%<:6J>$=0\/K8P7WVF([Y@(LKY8;S!
M]T\E0..M/F2Z]!<KENOM?H>:_P#!42P@\0_%KX'_  [:-;+PQKFMHUW! HBB
MD!FBBVX7C.V1\>A;->U_MX?"3P[KG[&?BJQDTNQAM] TQKG3 D*K]A>+!7R\
M?=Z8XZ@XJA_P4'_9*U3]I?P'H]_X7NH[/QIX/O/[0TIY'\M9CP3'NZ*V55E8
M\!EYP#D>/_%C_AIW]JGX5WG@;4/ NE^$8&MC_:NH&]CSJC1KN6&(;R%\QU4$
M@[1GE@.#,=5&SV*EHY75[F)K7CC4/!'_  1+T633Y)H9M4B.G2R1'#)%+?3!
M^?0J"I]F/K6K^R]\0/B+\,_V<]!T'0?V=SJVAW^FQS2W9U6!5UD3(&,SJRY(
M<-D!LX4@=J];^$W[(]YXH_X)W:;\*_&5N='U9[":*4+(DYLIS<R2Q/N1BK8R
MA(#<@D9%>;?##7OVG?V:/ 47@&/X=Z5XSBTE#::-K2:@BQB(<)O!<':HP &"
M$  '.*KF332MN3RM--WV.2^"GPE\<_!O]E3]H"Q\2>%[[PKH&J6LNH:1937*
M31VVY7#1J58]%\L$D#.P5[)_P2L^"_A_PW^QYH>K+IEG-J7BL7%QJ,\D*NTP
M$SQ+&21]P(@^7IDMZU%X'_9>^)6E_LD?$;3_ !9KUUXJ\>>.H)Y5LFO UK8N
MP.V&)G(1<EB3C"#@#@9/IW[#_P --:^#W[*O@_PWXBL_[/UK2[>6.YM_-2;R
MF:>5P-R$J?E8'@GK4U)W3]?T+IT[26G3]3Q3_@EMI4/A7XF?'S0[%?)TW2/%
M0AM(%^["H>X4 #Z(H_ 5]>:I=-9:;<3*NYH8F<+_ 'B 3BOGK]B3X#^*O@_\
M7/C7JGB+2Q86/B[Q)]OTF07,4WVJ#S+@[\(Q*\2+PX!YZ<&OHQEWK@\@]:SJ
M.\KFM%-1LSY,_P"".]LLO[.?B347/F7FH^*[QYY#]]L1PX!/MDG_ (%2?\%*
M/VE-5L(=-^#W@,O=>.O'96WF\AOGL;5^#DC[K. W/\*!F],UO^"<GG?!?XF?
M&#X2W0*WVA:NVLZ='(?^/FWF 429]"H@/_ J\D^$_P $?VEOA-\=_$7Q#?X9
MZ)XH\4:X\@%YJFL6O^BHS<^4J7 VY4*OLHP,<UKRKG<F8<S]FHKYGV;^R;^S
M=I?[+'P8TWPOI^R:Y0>?J-V%PU[<L!O<^PP%4=E4"O W_P"4SZ_]BM_[1K9T
M;XS_ +65QK5E'>?"#P;#927$:W,JZO"6BB+@.P'VH\A<GH>G>MIOV?O%I_X*
M:K\1/[+'_"(#0/L7V[[3%_KO+V[?+W>9U[[<>]2M&VWNF6]4E%/1KH>8_P#!
M-'1;7XO?M*?&;Q]K]NM[XAL]62UM6N5#O91N\V=H/W?EBC4$=%4CH:3]M'P_
M:?!C_@H;\%O%7AVW6QU+Q-=-::G':J$^V*)$C)8#J728J3W"#TK5\4_ 'XK?
MLC?M*^)/''PHT.S\8>%O&C&?4]%DN5@DMI<[LC<RYP[.5*YP'92.YT/A+^SC
M\2OV@_VH]+^*WQ>TVP\-V?A6,)H.@6]P)F5QDK(Y5B!AF+')W$@# 4#-\ROS
MWTL9J+Y>2VM_UW/KZOF7_@JC\2='\/\ [-TWA.XL8]8\0^.ITT[1K$#,BS;U
M/V@#K^[)7'JS*.A-?35?+?PI_9Q\9?%3]LW6/BE\3M)72['P[_H?A#2WNX;D
M1H"V)SY;,%(!+8.#NDSQM%8T[)\SZ'14NURKJ>;_ /!)OQ?_ ,*5\:^,?@WX
MHTN'1?%T-U_:,;G'F7H$:AXBPX;8N'7&059SVY^DOV\O^3,OB9_V+UW_ .BS
M7EG[?O[)'BKQOX\\*?$[X6VL<GC[PY<QI-")X[?[;"IRC%I&525Y4@GYD?'.
MT"O5_P!H7PKXD^,W['GBC2(=&:U\5>(/#TL TQKF+]W<O'@Q>9N\OAN-V['O
M52:<E,SC%QBX?<<S_P $Q?\ DQ_P+_U[R_\ HYZY?_@L'91R_L:W5ZP'VC2=
M8LKJV/\ $LF\IQ[[7:O2/V%OACKGP:_9:\*>&_$=G_9^LZ;#(MS;B9)O+)D=
M@-T;,IX(Z$UY7_P5%N)?B19_#GX5:;^\U;QMXAAFEC'/EVL&=[-Z+EP<^D;>
ME$7^]OYA+^#9]CZ6^'%_)JOP\T&ZF+&:ZTZWED+?>+-$I.?Q-;55],T^+2--
MM[2!=L-K$L48]%4 #]!5BL3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>irtc-20211231_g13.jpg
<TEXT>
begin 644 irtc-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .Q%$2
M  0    !   .Q        8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( 04"M@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW7_&FC^%
M&C75-6TW36F!,8NKI(=X'7&XC/X5I5\2?MV^!YO'O_!0+X=VD/PE\&_&-X_
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M%%% !1110 4444 %%%% !1110 4444 %0:CJEKI%OYUW<06L.Y4WS2!%W$X
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MAU"PN[-K-V:*&XC$WDLS-&LJHLH1F)428R<9KYU^&.HW?AS]FB;]F&WO+O\
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MS)9(E,<CLXV./,"JGRD1' U&F[K3_@K]&4\5!-+77_@?YGZ"4445QG0%%%%
M!1110 5Y#^T!^QIH/[0?C[1O%%QXD\>>%=>T.QFTV"]\,:Y)I<KV\SI(\;E
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MA)I]O^!_D%%%%<IL%4_$6A6_BCP_?:9=;S:ZC;R6LVQMK;'4JV#V.">:N44
M>9Z/^R1X'T3QYX!\30Z;*VN?#70I/#FB74DQ9XK-XXXRK_WV"QC#'D;W_O&N
M-G_X)P?#^#PQX5T_2=0\;>&KGP>M[#8:IHOB">QU%K>\NC=7%M+-&09(7F(;
M:1QL7!&*]^HK98BJMI/^K_YO[S-T8/I_6G^2/#?^'>GP]L?@QI_@?2CXFT'3
M=%UN;Q#I-[IFM3P:EI-Y,TC2/#<Y,@W":52&+9$C9SUHU[_@GG\/?$OQ&;Q%
M>-XFD2\N;;4-5T8:U.NCZ_>VX00WEY: ^7-,/*B)8C#&)2P8BO<J*KZU6WYG
M_P .+V-/:R/*]<_8Y\%^(?A?\1/"%Q'JG]C_ !0U2XU?7 MXRRM/.L2R>4W6
M-<0I@#ISZUE_%_\ 8/\  _QG\>WGB&]NO%VCW6LVT5EKMOH>OW.FVOB2",%4
MCO8XF E 0LF>&V';G  'M%%3'$54[J3_ *M_DON&Z,'HT>&_%[_@GI\.OC)X
MADU"[7Q)HBWVE1:'JMEH6LSZ;9ZY91*RPP7<43!9EC5V"YP=IVG*\5ZEIWPN
MT2Q^%=OX+DLH[[PY!I2Z*UI=@3+<6JQ"'RY,_>!08.>N37045,JU222;>@XT
MXIW2W/$?A!_P3^\ ?!OQ;:ZO;R>*=??2;2;3M$M?$.N7&JVGAVUE79)!9Q3,
M5B5HP(R3EM@VYP2"[X,_L!^ ?@=X\L->TN3Q1J#:#%+;^'M/U;7+B_T_PO%*
M-LD=C!(Q6$%,)GDA!M! )!]LHJY8FJ[WD]?Z_KU8E1IK9(\M\._L@>#?"_PH
M\#^#+6/4_P"Q?A[JEOK&D![QFE6>%Y)$\Q^KKND;(/7BL;Q3^P3X)\6:WXQN
M)KSQ9;Z?XZN(;[5='@UJ5=+>\BGMYQ=QP'*QS,]M$&9<;ANX^8FO:Z*2Q%1.
MZD_ZU_,/90:M8\G^/?['/A;]H+Q58Z]?:AXL\.:]8VCZ:VI>&];GTFZO+)VW
MM:3/$1YD)?Y@#RIR5(R<ZO@W]EKP7\//&7A76M"TUM)D\%^'I_#&DVMO*1:V
M]E-)!(ZE#G<^ZWC.\DG[V22Q->AT4O;5.7EN[#]G&_-;4****R+"BBB@ ILR
MEXF4=6! IU% 'RU^QG_P34T7X#>&/ =_XHNM6UCQ1X.@DD@T_P#MNYNM TV^
MD,@DN[6VDPB2LCL-VT ;VV@$YKVC]H[]FWPM^U3\.?\ A%O%]O=7&EK>P7Z_
M9IS!*DL39&''(!!9&'=78=Z[VBMZF)JSJ>T;U_+T,XT81CR):'COQ=_8?\&?
M&+XAKXFNKOQ9H>H3Z?'I.IIH&NW&EP:Y91ES';7:0L/,C7S)0,8($C#.#5SX
M;_L9^!_A7=>$9-+M;[9X)\-W7A/3(9[DRQ+I]Q)#))&ZD?.<P1@$] ".]>K4
M4OK%3EY>9V#V4+WMJ> _#'_@FY\._A/\0O#7B/3[KQG>7'@F:63PW::CXAN;
MRQ\/Q2PR0O;VT,C%8XBDA&WD@(@!P,5H>#_^"?OP_P# _P 1[;7K&3Q3]ATW
M47UC3?#DNNW#^']*OG9F-S!9%O+1]SR,!RJER54'!'MU%5+%5GO)]A*C36R0
M4445SFH4444 %%%% !116;J'A.QU2[:::&1I&P"1,Z]/8'% &E16/_P@FE_\
M^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"
M":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_
M !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?
M_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_
MP@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G
M_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":
M7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4
M?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1
M)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@
MFE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q
M5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X
M$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\
M()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_
M\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?
M^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8_
M_"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2
M?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\
MG_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16
M/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!
M$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/
MO)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\ S[R?^!$G_P 50!L4
M5C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\
M@1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_ ($2?_%4?\()I?\
MS[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_ ,^\G_@1)_\ %4 ;
M%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5 &Q16/_P@FE_\^\G_
M ($2?_%4?\()I?\ S[R?^!$G_P 50!L45C_\()I?_/O)_P"!$G_Q5'_"":7_
M ,^\G_@1)_\ %4 ;%%8__"":7_S[R?\ @1)_\51_P@FE_P#/O)_X$2?_ !5
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MU'Q-XKFG6U_M"=H;.UA@C$DTLC(K.<910JC)+CL#4N#3L-5$U<] HKY9TO\
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M9Y<RP):QKO#[MOE>?*&,Q3<9%B:+( !KV*IE%K<J,KZH****104444 %%%%
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M[.7@6\O+BXO+RZT*SEFGGD,DDSF%269CRS$\DGDT2C8(RN['=4445)04444
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MKF:61I99-J\+N=V(4< $#M6]12YGL'*EJ%%%%(H**** "BBB@ HHHH ****
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MM5_Z#3?^ B4?V-JO_0:;_P !$K8HH Q_[&U7_H--_P" B4?V-JO_ $&F_P#
M1*V** ,?^QM5_P"@TW_@(E']C:K_ -!IO_ 1*V** ,?^QM5_Z#3?^ B4?V-J
MO_0:;_P$2MBB@#'_ +&U7_H--_X")1_8VJ_]!IO_  $2MBB@#'_L;5?^@TW_
M (")1_8VJ_\ 0:;_ ,!$K8HH Q_[&U7_ *#3?^ B4?V-JO\ T&F_\!$K8HH
MQ_[&U7_H--_X")1_8VJ_]!IO_ 1*V** ,?\ L;5?^@TW_@(E']C:K_T&F_\
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MWB;XJ?%;2/&5[X*USP_IW@'3;][6QO9;<WVKWL\:H4C6.1E$:HI 9F&YI!P
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M'_XY0!K45D_\)/<?] 75ORA_^.4?\)/<?] 75ORA_P#CE &M163_ ,)/<?\
M0%U;\H?_ (Y1_P )/<?] 75ORA_^.4 :U%9/_"3W'_0%U;\H?_CE'_"3W'_0
M%U;\H?\ XY0!K45D_P#"3W'_ $!=6_*'_P".4?\ "3W'_0%U;\H?_CE &M16
M3_PD]Q_T!=6_*'_XY1_PD]Q_T!=6_*'_ ..4 :U%9/\ PD]Q_P! 75ORA_\
MCE'_  D]Q_T!=6_*'_XY0!K45D_\)/<?] 75ORA_^.4?\)/<?] 75ORA_P#C
ME &M163_ ,)/<?\ 0%U;\H?_ (Y1_P )/<?] 75ORA_^.4 :U%9/_"3W'_0%
MU;\H?_CE'_"3W'_0%U;\H?\ XY0!K45D_P#"3W'_ $!=6_*'_P".4?\ "3W'
M_0%U;\H?_CE &M163_PD]Q_T!=6_*'_XY1_PD]Q_T!=6_*'_ ..4 :U%9/\
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M?QJ^('C#QM/HVAKXX6/0=$TZY\[PYIVG7#75Y<P&7?<_:W7]SP $B )(?+#
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M9PK8D9<'(Z''')H&I?\ &WC6X\.Z]I=C!_9T?]H1S2-/>3&../R]G''4G?\
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MPJ*KJ50%64(N,'&1G%"L&ICZIXPU;1/%/_"/M=K-->3VHM[UH5WQ1R"4OE0
MI8>2=O'\8SG'.IH/C5K'^VK/5+F"6ZTBX:.)B5C>[C\M)5^7IN ?:<#' ..:
ML2?#:UNHIGN+J\GOI98IA>L5$T;19\O;A0HQEN-N#N;.<U/'X(M[71[Z%?\
M2+J^\R22YN &=Y&4+N.  , *, # 44:!J85W\;(=*TV&>\T^2V>]M(;NS0S
M^<LKJ@#'&$*LZYZ@ YYZ5)I?Q=_M:\MK6#3S-<S7,MN3'/F'$<:R%U<J"RE6
M[#.X8]ZFTWX1VBZ%:6]Y<74UW:V<%K'.LF&M3$58&(XX^=0<MDG !XXK2MO
MEO'>VMU<7FH7MU:M*XDFF^\9$",,  *  ,!0 #D]231H&ICV/QDBU'26NHK$
MR,[110PK<*9!+(X18I5X:)QD$Y! &>3C%31_$ZXDUB/2_P"RC_:AN);>2/[2
M/*0I$LH;?MR596'\.0>"*DE^$6G74AEN+G4;BZ6)(8;B253- $<2*0VW+,&5
M>7W'CW.;FE_#RSTW58;]IKJXOHYI)WFD89F=T6,E@ !@*J@ 8 Q1H&HV+X@P
M2:9H=[Y$BVNM2"+>S ?9F925#?5EVY'<BL%_CQ:_:=JV;&.,0M(K2XF993\I
MC0*2^$*N1D8#8Y(K4\3?#=-5\ 1^&[9@MDVR-Y9)")8D5PVY2!RW''(_I5V?
MP!;'57NK>ZOK%9Q$)X;:4)'/Y?"9XW#@!3M(RH .:- U,J\^,=K8:K<6LEL"
MT<=RZ!+E'D)A4N0RC[FY5)')/J!2Q?%G_3K.WFT_[//>0Q7"1RW2H\JR$@"/
M< LCJ!EE#9'&,YJ4_!W2V\M3/J'V>W%R((/- CA^T!Q)CY<G.]L%B2.U6=8^
M&-CKEHMK/<7QL_*BB>V\P-'*(\;3A@2K<<LA4G\J/=#4Z.BBBI*"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>irtc-20211231_g14.jpg
<TEXT>
begin 644 irtc-20211231_g14.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M_P#Q5=-10!S/_"GO#G_0._\ )B7_ .*H_P"%/>'/^@=_Y,2__%5TU% ',_\
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M/_"GO#G_ $#O_)B7_P"*H_X4]X<_Z!W_ ),2_P#Q5=-10!S/_"GO#G_0._\
M)B7_ .*H_P"%/>'/^@=_Y,2__%5TU% ',_\ "GO#G_0._P#)B7_XJC_A3WAS
M_H'?^3$O_P 57344 <S_ ,*>\.?] [_R8E_^*H_X4]X<_P"@=_Y,2_\ Q5=-
M10!S/_"GO#G_ $#O_)B7_P"*H_X4]X<_Z!W_ ),2_P#Q5=-10!S/_"GO#G_0
M._\ )B7_ .*H_P"%/>'/^@=_Y,2__%5TU% ',_\ "GO#G_0._P#)B7_XJC_A
M3WAS_H'?^3$O_P 57344 <S_ ,*>\.?] [_R8E_^*H_X4]X<_P"@=_Y,2_\
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MCK/6-;U?5K30_'+6FFP7EY)/'I\.PGRH58D1I_LK@>U?45 !17,_&CXK:?\
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M?#OA_P +76B7%N\L@O7FED9E9%"%"@##)+@^QH ^4?B%^QEI_P"S_P#\% /
MOPQ^%_BCQ=\.? /Q9T>ZF\0Z=I6JS2/.;/=(WERS,[Q-(H5#(K%@"X& Q!Z_
M3?@'H/[!_P#P4\^$>A_#)M4T/PS\4M-U:+7M'EU*XO+6XDM;<RQSCSG9O,W8
M^8L< $# 9L^__%G]F37O'?[<_P *_B=9WFD1Z#X'TS4K._MYI9%O)7N8RJ&)
M0A0@$\[G4CL#3?C=^S!K_P 2OVV?@U\2;&\T>'0_AW!JT6I03RR+=SFZM_*C
M\E5C*-AN6W.N!TSTH \]^!7_ "F$^./_ &*>C?\ H*5#I/\ RG&U7_LDJ?\
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M&_#-OIGBKQ3X/L&U34%N)I'NS+#%-)E7<JNZ0!OE QT&!Q6E\ OV)]2\(?\
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MP9^WA-XTO->T:Z^$NFZY?>+="T!))/M5IJUW%&KR,GE!-JLI*XE;&Q"%!9J
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MV17@/[?G[*_B']JGP]\/;3P]>:-9R>$_&5AXBNSJ,LD:R6\&_>L>R-\R'<,
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M.  ,DDU:HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O#?C#_ ,E&U'_ME_Z*2O<J\-^,/_)1M1_[9?\ HI* /3/@]_R3G3O^VO\
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MG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XF@#IJ*YG_A</AS_H(_\
MDO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/^@C_ .2\O_Q-'_"X?#G_
M $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'_P EY?\ XF@#
MIJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XF@#IJ*YG_A</AS_H
M(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/^@C_ .2\O_Q-'_"X
M?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'_P EY?\
MXF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XF@#IJ*YG_A</
MAS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/^@C_ .2\O_Q-
M'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'_P E
MY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XF@#IJ*YG
M_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/^@C_ .2\
MO_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'
M_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XF@#I
MJ*YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/^@C_
M .2\O_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\+A\.
M?]!'_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_X
MF@#IJ*YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%P^'/
M^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\ $T?\
M+A\.?]!'_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)
M>7_XF@#IJ*YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9_P"%
MP^'/^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO+_\
M$T?\+A\.?]!'_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01
M_P#)>7_XF@#IJ*YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z:BN9
M_P"%P^'/^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"/_DO
M+_\ $T?\+A\.?]!'_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\ "X?#
MG_01_P#)>7_XF@#IJ*YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)H Z
M:BN9_P"%P^'/^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")H Z:BN9_X7#X<_Z"
M/_DO+_\ $T?\+A\.?]!'_P EY?\ XF@#IJ*YG_A</AS_ *"/_DO+_P#$T?\
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M2*-5CCC4*JJ,!0. !3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPWXP_\ )1M1
M_P"V7_HI*]RKPWXP_P#)1M1_[9?^BDH ],^#W_).=._[:_\ HUZZ:N9^#W_)
M.=._[:_^C7KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8/$W_@=_]C1_PK7_ *F#Q-_X'?\ V-=-10!S/_"M?^I@\3?^!W_V-'_"M?\
MJ8/$W_@=_P#8UTU% ',_\*U_ZF#Q-_X'?_8T?\*U_P"I@\3?^!W_ -C7344
M<S_PK7_J8/$W_@=_]C1_PK7_ *F#Q-_X'?\ V-=-10!S/_"M?^I@\3?^!W_V
M-'_"M?\ J8/$W_@=_P#8UTU% ',_\*U_ZF#Q-_X'?_8T?\*U_P"I@\3?^!W_
M -C7344 <S_PK7_J8/$W_@=_]C1_PK7_ *F#Q-_X'?\ V-=-10!S/_"M?^I@
M\3?^!W_V-'_"M?\ J8/$W_@=_P#8UTU% ',_\*U_ZF#Q-_X'?_8T?\*U_P"I
M@\3?^!W_ -C7344 <S_PK7_J8/$W_@=_]C1_PK7_ *F#Q-_X'?\ V-=-10!S
M/_"M?^I@\3?^!W_V-'_"M?\ J8/$W_@=_P#8UTU% ',_\*U_ZF#Q-_X'?_8T
M?\*U_P"I@\3?^!W_ -C7344 <S_PK7_J8/$W_@=_]C1_PK7_ *F#Q-_X'?\
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MP>)O_ [_ .QKIJ* .9_X5K_U,'B;_P #O_L:/^%:_P#4P>)O_ [_ .QKIJ*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<N?V)77I+^E]YMT445\6?8!1110 4444 %%%% !1110 4444 %%%% !1110
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M444 1WLLD%G-)#%Y\R(62/<%\Q@.%R>!D\9KG?\ A*/$?_0K?^5*+_"NFHH
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MX2CQ'_T*W_E2B_PH_P"$H\1_]"M_Y4HO\*Z:B@#F?^$H\1_]"M_Y4HO\*/\
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MWJYS/_"4>(_^A6_\J47^%'_"4>(_^A6_\J47^%=-17.;G,_\)1XC_P"A6_\
M*E%_A1_PE'B/_H5O_*E%_A7344 <S_PE'B/_ *%;_P J47^%'_"4>(_^A6_\
MJ47^%=-10!S/_"4>(_\ H5O_ "I1?X4?\)1XC_Z%;_RI1?X5TU% ',_\)1XC
M_P"A6_\ *E%_A1_PE'B/_H5O_*E%_A7344 <S_PE'B/_ *%;_P J47^%'_"4
M>(_^A6_\J47^%=-10!S/_"4>(_\ H5O_ "I1?X4?\)1XC_Z%;_RI1?X5TU%
M',_\)1XC_P"A6_\ *E%_A1_PE'B/_H5O_*E%_A7344 <S_PE'B/_ *%;_P J
M47^%'_"4>(_^A6_\J47^%=-10!S/_"4>(_\ H5O_ "I1?X4?\)1XC_Z%;_RI
M1?X5TU% &9X=U34M2\[^T-+_ +-V;?+_ -)6;S,YS]WIC Z]<UIT44 %>&_&
M'_DHVH_]LO\ T4E>Y5X;\8?^2C:C_P!LO_124 >F?![_ ))SIW_;7_T:]=-7
M,_![_DG.G?\ ;7_T:]=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KXF_X+%^.O+T?P7X9C;_ %TT^ISKGIL41QG\=\OY5]LU^</[<TS?'?\
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M G3/_ 5/\*/^$*T?_H$Z9_X"I_A0 ?\ ":Z/_P!!;3/_  *3_&C_ (371_\
MH+:9_P"!2?XT?\(5H_\ T"=,_P# 5/\ "C_A"M'_ .@3IG_@*G^% !_PFNC_
M /06TS_P*3_&C_A-='_Z"VF?^!2?XT?\(5H__0)TS_P%3_"C_A"M'_Z!.F?^
M J?X4 '_  FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-'_"%:/_ - G
M3/\ P%3_  H_X0K1_P#H$Z9_X"I_A0 ?\)KH_P#T%M,_\"D_QH_X371_^@MI
MG_@4G^-'_"%:/_T"=,_\!4_PH_X0K1_^@3IG_@*G^% !_P )KH__ $%M,_\
M I/\:/\ A-='_P"@MIG_ (%)_C1_PA6C_P#0)TS_ ,!4_P */^$*T?\ Z!.F
M?^ J?X4 '_":Z/\ ]!;3/_ I/\:/^$UT?_H+:9_X%)_C1_PA6C_] G3/_ 5/
M\*/^$*T?_H$Z9_X"I_A0 ?\ ":Z/_P!!;3/_  *3_&C_ (371_\ H+:9_P"!
M2?XT?\(5H_\ T"=,_P# 5/\ "C_A"M'_ .@3IG_@*G^% !_PFNC_ /06TS_P
M*3_&C_A-='_Z"VF?^!2?XT?\(5H__0)TS_P%3_"C_A"M'_Z!.F?^ J?X4 '_
M  FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-'_"%:/_ - G3/\ P%3_
M  H_X0K1_P#H$Z9_X"I_A0 ?\)KH_P#T%M,_\"D_QH_X371_^@MIG_@4G^-'
M_"%:/_T"=,_\!4_PH_X0K1_^@3IG_@*G^% !_P )KH__ $%M,_\  I/\:/\
MA-='_P"@MIG_ (%)_C1_PA6C_P#0)TS_ ,!4_P */^$*T?\ Z!.F?^ J?X4
M'_":Z/\ ]!;3/_ I/\:/^$UT?_H+:9_X%)_C1_PA6C_] G3/_ 5/\*/^$*T?
M_H$Z9_X"I_A0 ?\ ":Z/_P!!;3/_  *3_&C_ (371_\ H+:9_P"!2?XT?\(5
MH_\ T"=,_P# 5/\ "C_A"M'_ .@3IG_@*G^% !_PFNC_ /06TS_P*3_&C_A-
M='_Z"VF?^!2?XT?\(5H__0)TS_P%3_"C_A"M'_Z!.F?^ J?X4 '_  FNC_\
M06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-'_"%:/_ - G3/\ P%3_  H_X0K1
M_P#H$Z9_X"I_A0 ?\)KH_P#T%M,_\"D_QH_X371_^@MIG_@4G^-'_"%:/_T"
M=,_\!4_PH_X0K1_^@3IG_@*G^% !_P )KH__ $%M,_\  I/\:/\ A-='_P"@
MMIG_ (%)_C1_PA6C_P#0)TS_ ,!4_P */^$*T?\ Z!.F?^ J?X4 '_":Z/\
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M/\:/^$UT?_H+:9_X%)_C1_PA6C_] G3/_ 5/\*/^$*T?_H$Z9_X"I_A0 ?\
M":Z/_P!!;3/_  *3_&C_ (371_\ H+:9_P"!2?XT?\(5H_\ T"=,_P# 5/\
M"C_A"M'_ .@3IG_@*G^% !_PFNC_ /06TS_P*3_&C_A-='_Z"VF?^!2?XT?\
M(5H__0)TS_P%3_"C_A"M'_Z!.F?^ J?X4 '_  FNC_\ 06TS_P "D_QH_P"$
MUT?_ *"VF?\ @4G^-'_"%:/_ - G3/\ P%3_  H_X0K1_P#H$Z9_X"I_A0 ?
M\)KH_P#T%M,_\"D_QH_X371_^@MIG_@4G^-'_"%:/_T"=,_\!4_PH_X0K1_^
M@3IG_@*G^% !_P )KH__ $%M,_\  I/\:/\ A-='_P"@MIG_ (%)_C1_PA6C
M_P#0)TS_ ,!4_P */^$*T?\ Z!.F?^ J?X4 '_":Z/\ ]!;3/_ I/\:/^$UT
M?_H+:9_X%)_C1_PA6C_] G3/_ 5/\*/^$*T?_H$Z9_X"I_A0 ?\ ":Z/_P!!
M;3/_  *3_&C_ (371_\ H+:9_P"!2?XT?\(5H_\ T"=,_P# 5/\ "C_A"M'_
M .@3IG_@*G^% !_PFNC_ /06TS_P*3_&C_A-='_Z"VF?^!2?XT?\(5H__0)T
MS_P%3_"C_A"M'_Z!.F?^ J?X4 '_  FNC_\ 06TS_P "D_QH_P"$UT?_ *"V
MF?\ @4G^-'_"%:/_ - G3/\ P%3_  H_X0K1_P#H$Z9_X"I_A0 ?\)KH_P#T
M%M,_\"D_QH_X371_^@MIG_@4G^-'_"%:/_T"=,_\!4_PH_X0K1_^@3IG_@*G
M^% "/XXT6)&9M8TM549)-TG _.OSM_8QU"#XQ_M_7OBR_FAAM8;B_P!;S.X1
M1O+)$N3_ '3*A _V:^SOVM9](^&G[-?C36(]-TV&>'3)(()!;("DLV(8R..H
M>137SI_P2$^%]KJ>D^,O$=]9V]TK30:;;&:(.%*@R2XS_OQ?E7V>1_[/E&,Q
MG624%\]_P:?R/D,Z_P!HS;"83I%N;^6WY/[S[0_X371_^@MIG_@4G^-'_":Z
M/_T%M,_\"D_QH_X0K1_^@3IG_@*G^%'_  A6C_\ 0)TS_P !4_PKXP^O#_A-
M='_Z"VF?^!2?XT?\)KH__06TS_P*3_&C_A"M'_Z!.F?^ J?X4?\ "%:/_P!
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M?$#_ (51^T;KOA75;B&UBU>UDMWWRA8_M-LQ8<GC[OG#\17Z"_\ "%:/_P!
MG3/_  %3_"OSG_:WT6+]F?\ ;[M]>BM8UTJXN[77%A\L>7)$QVW"8QC#,DPQ
MZ-7VG"?^TT<3EK_Y>1NO\4=OT?R/C^*/]GK8;,5]B5G_ (9;_K]Y^C'_  FN
MC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-,M_"6AW=O'+%I>E21R*'1EM
MHR&!Y!'%/_X0K1_^@3IG_@*G^%?%GV ?\)KH_P#T%M,_\"D_QH_X371_^@MI
MG_@4G^-'_"%:/_T"=,_\!4_PH_X0K1_^@3IG_@*G^% !_P )KH__ $%M,_\
M I/\:/\ A-='_P"@MIG_ (%)_C1_PA6C_P#0)TS_ ,!4_P */^$*T?\ Z!.F
M?^ J?X4 '_":Z/\ ]!;3/_ I/\:/^$UT?_H+:9_X%)_C1_PA6C_] G3/_ 5/
M\*/^$*T?_H$Z9_X"I_A0 ?\ ":Z/_P!!;3/_  *3_&C_ (371_\ H+:9_P"!
M2?XT?\(5H_\ T"=,_P# 5/\ "C_A"M'_ .@3IG_@*G^% !_PFNC_ /06TS_P
M*3_&C_A-='_Z"VF?^!2?XT?\(5H__0)TS_P%3_"C_A"M'_Z!.F?^ J?X4 '_
M  FNC_\ 06TS_P "D_QH_P"$UT?_ *"VF?\ @4G^-'_"%:/_ - G3/\ P%3_
M  H_X0K1_P#H$Z9_X"I_A0 ?\)KH_P#T%M,_\"D_QH_X371_^@MIG_@4G^-'
M_"%:/_T"=,_\!4_PH_X0K1_^@3IG_@*G^% !_P )KH__ $%M,_\  I/\:/\
MA-='_P"@MIG_ (%)_C1_PA6C_P#0)TS_ ,!4_P */^$*T?\ Z!.F?^ J?X4
M'_":Z/\ ]!;3/_ I/\:/^$UT?_H+:9_X%)_C1_PA6C_] G3/_ 5/\*/^$*T?
M_H$Z9_X"I_A0!9T[6[/6-_V2[M;KR\;_ "95DVYZ9P>,X/Y5:JKIVBV>C[_L
MEI:VOF8W^3$L>['3.!SC)_.K5 !7AOQA_P"2C:C_ -LO_125[E7AOQA_Y*-J
M/_;+_P!%)0!Z9\'O^2<Z=_VU_P#1KUTU<S\'O^2<Z=_VU_\ 1KUTU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'RI_P5O\=?V#\ M)T2-]LVOZJI=?[T,*,[?^/F*NU_X)O>!?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_&@#IJ*YG_A%_$?_ $-7_E-B_P :/^$7\1_]#5_Y38O\: .FHKF?^$7\1_\
M0U?^4V+_ !H_X1?Q'_T-7_E-B_QH Z:BN9_X1?Q'_P!#5_Y38O\ &C_A%_$?
M_0U?^4V+_&@#IJ*YG_A%_$?_ $-7_E-B_P :/^$7\1_]#5_Y38O\: .FHKF?
M^$7\1_\ 0U?^4V+_ !H_X1?Q'_T-7_E-B_QH Z:BN9_X1?Q'_P!#5_Y38O\
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M%^S9\)-=\ ? 3PEI4/B#[$L&F0R/!_9\;>5)(/,D7).3AW;D]:[?_A%_$?\
MT-7_ )38O\:X\ZQ7UG'UJW1R=O1:+\#KR?"_5\#2H]5%7]=W^)TU%<S_ ,(O
MXC_Z&K_RFQ?XT?\ "+^(_P#H:O\ RFQ?XUY9Z1TU%<S_ ,(OXC_Z&K_RFQ?X
MT?\ "+^(_P#H:O\ RFQ?XT =-17,_P#"+^(_^AJ_\IL7^-'_  B_B/\ Z&K_
M ,IL7^- '345S/\ PB_B/_H:O_*;%_C1_P (OXC_ .AJ_P#*;%_C0!TU%<S_
M ,(OXC_Z&K_RFQ?XT?\ "+^(_P#H:O\ RFQ?XT =-17,_P#"+^(_^AJ_\IL7
M^-'_  B_B/\ Z&K_ ,IL7^- 'CW_  4[^&W_  GG[+=]?1Q[[KPS=1:DF!\V
MS)CD'T"R%C_N5C?\$H?B7_PEO[.UQH4LFZX\+7[PJN<D03?O4/\ WV91]%KV
MGQ?\+]8\;>%-3T:^\3"6RU:UELYT.F1?,DBE6[^AKX3_ ."<FM:M\./VG]8\
M$MJ1TBYU2.>QF'D+*&N;5F8 AO15F]^:^TRW_:\AQ&%^U2:FO3K^"?WGQ^8?
M[)GE#$]*J<'Z]/QM]Q^D=%<S_P (OXC_ .AJ_P#*;%_C1_PB_B/_ *&K_P I
ML7^-?%GV!TU%<S_PB_B/_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%<S_PB_B/
M_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%<S_PB_B/_H:O_*;%_C1_PB_B/_H:
MO_*;%_C0!TU%<S_PB_B/_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%<S_PB_B/
M_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%<S_PB_B/_H:O_*;%_C1_PB_B/_H:
MO_*;%_C0!TU%<S_PB_B/_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%<S_PB_B/
M_H:O_*;%_C1_PB_B/_H:O_*;%_C0!TU%9GAW2]2TWSO[0U3^TM^WR_\ 1EA\
MO&<_=ZYR.O3%:= !7AOQA_Y*-J/_ &R_]%)7N5>&_&'_ )*-J/\ VR_]%)0!
MZ9\'O^2<Z=_VU_\ 1KUTU<S\'O\ DG.G?]M?_1KUTU '!_M"_LU^$/VG_!0T
M/Q=I%EJ%O%*DUO/):03SV;!U9C$TT;A-X78Q R5)&1UK>M/A7X7L/A\WA*#P
MWH,/A5H'M3HT>GQ+IYA?):/R OE[&R<KMP<GUK>HH Y?X:_!#P7\&8[Q/!_A
M#POX374"INET;2H+$7)7.TOY2KNQN;&<XR?6H?"?[/\ X#\!>,KSQ%H7@GPC
MHOB#4/,^U:G8:/;VUY<^8P>3?,B!VW, S9)R1DY-==10!R/BO]G_ ,!^._&=
MIXDUSP3X1UGQ%I_E_9=4OM'M[B]MO+8O'LF="Z[6)9<$8)R,&MRU\&Z/8^*;
MO7(=*TV'6K^".VN=02V1;JYBC)*1O*!N95+,0I) W''6M*B@#D?"?[/_ (#\
M!>,KSQ%H7@GPCHOB#4/,^U:G8:/;VUY<^8P>3?,B!VW, S9)R1DY- _9_P#
M8^(__"9?\(3X1_X2[?YG]N?V/;_VENV>7N^T;/,SL^7.[[O'2NNHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS?_ &NV_P"&@?\
M@HM9^&T_?6L-[8:'Z[8P5>;_ +Y:27\J_1R\O(]/LY;B9UCA@0R2.W1% R2?
MH*_.?_@GW:2?&W]NG4O%ERC/]E^WZXY;HKS,8U'U'GD@?[/M7V?"/[B.*Q__
M #[@[>KV_+\3Y#BK]]+#8'_GY-7]%O\ G^!^C@&T8%%%%?&'UX4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \O\ VTO'7_"N_P!EOQKJ*OY<
MSZ<UE$<\AYR( 1[CS,_A7S__ ,$=O OV;PEXQ\2R)S>7<.FPL1]T1(9'Q]?-
M3_OFMK_@KUXZ_L;X+^'M!1]LFN:H9W']Z*!#D?\ ?<L9_"O3/^">G@7_ (03
M]DKPJC1[+C58Y-3E./O><Y9#_P!^_+_*OLX?[-PW)]:T[?*/_!3^\^/E_M'$
M272C"_SE_P !K[CVJBBBOC#[ **** "BBB@ HHHH **** "BBB@ HHHH *^:
M?VKO^";^B_M!^++GQ-I6K2>'M>NH\W*_9Q/;WKJN%8C<I1C@ L"0>#MSG/TM
M17=E^8XC!5?;8:7++;Y=FGHSCQV7X?&4O8XF/-']?)K4_//_ ()0^,XO ?Q]
M\1>$]3M8[?4=:M#%$TB_OHYK9F9X1Z94NQ'K$*_0ROS?_;?\.WG[+?[;=CXT
MTF/R[?4[B+7K<#A7E#8N(B?]I@2?::OT2\,^(K3Q?X<T_5K"3SK'4[:.[MY!
M_'&ZAE/X@BOI.,*:K3HYG3^&M%7\I+1K\E\F?.\)U'1C5RVI\5*3MYQ>J?YO
MYHO4445\:?7!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>&_&'
M_DHVH_\ ;+_T4E>Y5X;\8?\ DHVH_P#;+_T4E 'IGP>_Y)SIW_;7_P!&O735
MS/P>_P"2<Z=_VU_]&O734 17U['IME-<3-LAMT:21L$[5 R3@<]!5#P3XRTW
MXB>#M*\0:/<-=:3K=I%?64S1/"9H94#HVQPKKE2#A@".X!KQ7]N7X8Z]X[NO
M >I6WA63XB>#_#VJ2W/B;P>D\*G68&A*Q2^5.RPW)@D D$$C .VW'S $5O@;
M\?\ X/\ PY_9Z\7^)O!^B7G@W2_#]Q]HUSPM+IDFF7VE:@\,06T%BV%BFE_=
M*J0CRY)')4LS,Q /H>BO@&_3Q-^S7\7/B=X_U0F3XCZI\'[[Q3J05C-'8W?V
ML^1;1@DCRK:-(HACAO*9NKDUV7QB^"OAW]FCX&?#/XC>%=.M['QU8:[H2ZEK
MZH!J7B-+^YA@O%OI_P#67 F\YG/F%L.JD8*B@#[,HKY#^'7P3\,_M:_#?XK>
M,O&FD0:IXHF\1:WIFE:G=1!K[PU;V$TD%JEC*?GMBC1^;F(J3([,<DUU7A;]
MH[Q$?^"54/Q.ED-QXJA\ /JQF"[C)=I:$B4COEQO(^M 'TE17Q5\>?A)X=_9
M4_9V^'OQ/\*Z7#;>.]'UC17U+6XT U/Q,E[/%#>)?3_ZRY\[SF<^86PX4C!4
M5@7OPTTG7O\ @F9=?'*>S@_X6\VC2>-T\6F(?VO!>*3,D*W'^L6W6-1 (0WE
M^4-NW% 'WI16=X/UA_$7A+2]0D54DOK2*X95Z*70,0/SK1H **CO;G[%9S3>
M7+-Y*%]D:[G? SA1W)["N=_X65_U+_B;_P  ?_LJ .FHKF?^%E?]2_XF_P#
M'_[*C_A97_4O^)O_  !_^RH Z:BN9_X65_U+_B;_ , ?_LJ/^%E?]2_XF_\
M '_[*@#IJ*YG_A97_4O^)O\ P!_^RH_X65_U+_B;_P  ?_LJ .FHKF?^%E?]
M2_XF_P# '_[*C_A97_4O^)O_  !_^RH Z:BN9_X65_U+_B;_ , ?_LJ/^%E?
M]2_XF_\  '_[*@#IJ*YG_A97_4O^)O\ P!_^RH_X65_U+_B;_P  ?_LJ .FH
MKF?^%E?]2_XF_P# '_[*C_A97_4O^)O_  !_^RH Z:BN9_X65_U+_B;_ , ?
M_LJ/^%E?]2_XF_\  '_[*@#IJ*YG_A97_4O^)O\ P!_^RH_X65_U+_B;_P
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M65_U+_B;_P  ?_LJ .FHKF?^%E?]2_XF_P# '_[*C_A97_4O^)O_  !_^RH
MZ:BN9_X65_U+_B;_ , ?_LJ/^%E?]2_XF_\  '_[*@#IJ*YG_A97_4O^)O\
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MXF_\ ?\ [*C_ (65_P!2_P")O_ '_P"RH Z:BN9_X65_U+_B;_P!_P#LJ/\
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M+_B;_P  ?_LJ^)/LCIJ*YG_A97_4O^)O_ '_ .RH_P"%E?\ 4O\ B;_P!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1_X* 6_[,VO6_A[1]+AUGQ%)"+B?[0Y2WLXVSMW;>68XS@$8&#GD"H/V,?\
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MUS3W\RQU>TCNX#WVNH8 ^XS@CL16I7QLHN,G&6Z/KHR4HJ4=F%%%%24%%%%
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M_"GO#G_0._\ )B7_ .*KIJ* .9_X4]X<_P"@=_Y,2_\ Q5'_  I[PY_T#O\
MR8E_^*KIJ* .9_X4]X<_Z!W_ ),2_P#Q5'_"GO#G_0._\F)?_BJZ:B@#F?\
MA3WAS_H'?^3$O_Q5'_"GO#G_ $#O_)B7_P"*KIJ* .9_X4]X<_Z!W_DQ+_\
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MW_DQ+_\ %4?\*>\.?] [_P F)?\ XJNFHH YG_A3WAS_ *!W_DQ+_P#%4?\
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MS&GB*523C3DFUNDT[>O8Y_\ X4]X<_Z!W_DQ+_\ %4?\*>\.?] [_P F)?\
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MC_A3WAS_ *!W_DQ+_P#%5TU% ',_\*>\.?\ 0._\F)?_ (JC_A3WAS_H'?\
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M;'O7V9!X/^%7[.7@33-&U?5-'TU-+M4A_P!)U Q37# ?,_EA\EF.6(4=2:^
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M=3QM^S_X?\126JVVH:M;E;PJ6Q,\,LD6_!) W;2V!@?-Z8KU2LWP;X0T_P
M>%=/T72K=;73M,@6WMXA_"JC')[D]23R22:TJ_:<OI5J6%ITL1+FG&,5)]VD
MDW\WJ?A>8UJ-7%U:N'CRPE*3BNT6VTODM KPWXP_\E&U'_ME_P"BDKW*O#?C
M#_R4;4?^V7_HI*[#C/3/@]_R3G3O^VO_ *->NFKF?@]_R3G3O^VO_HUZZ:@
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M$>U;^37O#[=";RP,B#Z&$R''X"O7?&7[-?P_^(&]M8\&^'+R63[TQL8TF/\
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M2C#-*<X2_FY='Y_\,C]%J*^5?AS_ ,%:_ /B7RX_$&FZUX9F;[S[!>VZ_P#
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MXQ_''PU\!O#*ZMXEU!;.WD?RX8U4R37#_P!U$')QU)Z#N17,_ _]LOP+\?\
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MZ[6!% 'YL_!'X+>)/C5XCFL_#BK'+:PF6:XDE:**)<X + 'D]AWP>P->I_\
M##WQ<TKY;;4K4J_+>3JSJ/QR!7VGX>\+:9X1L/LNDZ;8Z7:[MWDVEND,>?7:
MH S5Z@#X>/[&WQF3YEU$[EY&-:;/\Z/^&8_CS_S_ .K?^%%_]LK[AHH ^'O^
M&?\ ]H32?EM;[Q&5?EO(\3*@_',PKQ_XN>#O%7@OQG-;^,(KY=:F59I)+JX%
MP\X(P&\P,P?@8R&.,8[8K]0:R_$W@K1O&L$<6LZ1I>K1PDE$O;5+A4)ZX#@X
MZ"@#\\/@3^S1XF_: -Y_8QM;6QLRJSW-Y(\<)8\A1M5BS <XQQD9(R*]K\.?
M\$P96VMJWBZ-?[T=G8EOR=F'_H-?5^D:-9^']/CL["TMK&UA&(X;>)8XT'LJ
M@ ?A5F@#P7PY_P $Z/A_H^UKQM;U9NI$]V(T/X1JI_6N]\.?LN_#WPKM^R>$
M=%9DQM:YA^U,,=\R[CGWZUWM% %?3M+M='M_)M+:WM81T2&,(H_ <5QOQ!_9
MH\"_%+6O[2USP]:WE]@!ITED@>3'3<8V7=Z?-GC KNJ* ,_PKX3TWP1H<&FZ
M18V^GV%N,1PPIM5?4^Y/4D\D]:T*** "BBB@ /->(>+/^"?OP_\ %?B>;4]N
ML:;Y\GF26ME<(EN2>3@,C%0?12 ,\8KV^B@##T+X;:#X;\)VFAVFE6:Z38IL
MAMWC$BJ,Y).[.23R2>2>:P=?_9E^'_B4L;KPAH>YNK06PMV/XQ[37=44 >'Z
M]_P3V^&^L;OL]KJVE9_Y];YFQ_W]#UQ.O_\ !,+39@QTOQ9?6_\ =6ZLUFS[
M$JR?GC\*^IJ* /AKQS_P3L\9>$=(O+_3]2TK6([6)Y##$9([F50.0J;2"2,\
M;N>G.:^?BC+(5*L&!P1CG-?K-6&WPP\-/K_]K-X=T-M4W^9]L-A%]HW==V_;
MNS[YH YC]E'P_J7A;]GGPO8ZLLD=]';,[)(,-&CR.\:D=B$91CMC%>AT44 %
M>&_&'_DHVH_]LO\ T4E>Y5X;\8?^2C:C_P!LO_124 >F?![_ ))SIW_;7_T:
M]=-7,_![_DG.G?\ ;7_T:]=-0 44V>=+6!Y)'6..-2SNQPJ@<DD]@*K:#KUC
MXIT2SU+2[RTU+3=0A2XM;NUF6:"YB<!E='4E65@0002"#F@"W1110 4444 %
M%%% !1110 4444 %%%% !17'?$7]H/P1\)5;_A(O%&BZ7*G6"2Y5K@_2)<N?
MP6O _B/_ ,%;O OAOS(_#NDZUXFG7[LC 65L_P#P)\R?G'7J8/)<=B_]WI2D
MN]K+[W9?B>;C,XP6%_CU4GVO=_<KO\#ZKFF6WB:21ECCC!9F8X"@=237R?XZ
M_P""M_@_PSXSFT_3-!U77--MY#&^H13)$LN.K1HPRR^A)7->'>/O^"B_Q6^/
M-EJ&B^'-'M]/L[JWDBGBTRQ>\NO)92'W.V[;\N?F55(ZY'6O!+7X97,MMNEG
MCAD(SLQNQ]3_ (9KZK!\/8#+TYY]-)R^&*;;\V^57[>7<^7Q6?8['M1R.#:7
MQ2:27DES.WKU['ZG:+^VC\+]8\%6.N-XRT.QM[Z/>MO=721W<1Y!5X<EP001
MT(Z$$@@GC/%G_!3SX1^&@WV?5]2UIUZK8:=)R?0&41J?SQ7R'\$_V.O"/C'P
M=!K'B[XGZ1X<EF=P=,BB66Y15<J"Q+C:3C(&P\$'/:O5]!_9L_9C\(?-J?C#
M5]>:/!=9)I?+;..@MX5;'T8]^:YZF#X:H3?-6G4\HK3[VE?U3.BGB^(JT%RT
M80\Y/]$W;T:-CQ7_ ,%C='MRRZ'X)U*\YPKWU\EMCW*HLGY9_&O.]6_X*I_%
M+QM=&U\/:#H=F[#Y5MK*6\N/U8K_ ..5[#H/BS]E_P"'Y_XEOAW2[QH<;'FT
MB:[8X[@W )R/4X/%=;;_ /!0'X8^%;0V^FZ;K"0(?ECL].BB0_0%U%9_VQD=
M#_=\&Y><Y?I[R+_LG.JW\?%J/E&/ZZ,^8[O5/VJ/CO;30/!XTCM+Q3&R?94T
MB%T88(R1$"I!QDD^YKYZ\:?#+Q!\._%LNA:UI%]I^K0OY9MI(CN<]MN,AP>Q
M7(((()K]$]0_X*:^%HE;[+X?\03'^'S3#%GZX=L?K7S]XM_;+^(7B?Q1+J4/
MB"\TN,N6AM+1@D$*]EVX^;'JV<UVX/CR6';4,-",>T?=U\W9I_<<F+X(5=)S
MQ$W+O+WON5TU]YZ3^QE_P3=\/W'P\LO$'Q&T:]N-;O9&EBTRXF:&*UAX">9&
MN&WG!8AB0 5!4$&OKCPEX)T?P%I2V.AZ3IVCV:\B&SMT@CSZX4 9]Z^/K#_@
MIAXHM=$MX9=#T>ZOHXPLMR[.HF8'[VQ< 9'8'&<G@<#+U7_@I-X\N0WEVOAF
MQ7G!2VD9@.WWI",CZ5\EFN=8G&U)5<1-VO>U_=7DD?4Y7D^'P<%2P\%>UKVU
M?JS[IHK\\]5_X*"_$:[)V^)+&R![165O_P"S*QKF]3_;0\=ZA_K?&VIKT_U+
MB+_T "OG*V<8"E_%KPCZRBOS9]'1R7,*W\*A.7I&3_)'Z3:[KEIX:T:ZU"_N
M([6RLHFFGE<X6-%&237SK)_P4P\,IXE-NN@ZNVF"3;]L#IYA&<;O*].^-V?:
MOD'6/C9XF\9:=,M]XA\3ZM9,-LPFN;B:$ ?,0P8D8'7VK'%Q&8O,\Q?+QG=G
MC'UHPN<8'%<WU:M&?+J^62=EWT>P8S)<PPG+]:H3AS.RYHM7?976Y^KOASQ%
M9^+=!L]3TZXCNK&^B6>"5.CHPR#[?0\@\5=K\WOAI\,/BIXJT"SOO#&G^*/[
M,G4M:S0W?V:%EW$$J6=>"<_SKK[C]F7X[W\3">WUR16QE9/$,+9QT_Y;XK>C
MC*=:'/0?,GL];/YV,:V"JT)\F(7*UNM+KY71]X3SI;1-)(ZQQJ,LS' 'U-86
MJ?%;POH9;[=XDT"SVYSY^H11XQUZL*^!]:_8C^)UU<!KSPK<74A!(8WMO-C/
M7D2&L:Y_8N\=6X?=X)U0^7G.Q V<>FT\_AUKAQ%3-?\ EQ3I_.<OT@=V&IY3
M_P Q%2I_V["/ZU#[8^)?[:_PY^'?A>]U"/Q-H^N7-LF8K+3;R.XEN7/11M)
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M,+\FG>]MWOH].ZT.^CQ=PS@H?4L)@'4HR^.53E]IK_+:^RV]Y:]GJ?4>I_\
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M\_)$CKH\+*?5?W09>_0Y]ZW='_:\\?:FAL?!/AO1-#C^ZL&@Z&'8>G&&&?\
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M/0L0>^:^EZ* .97XP>&U&!J& . !;R\?^.T?\+A\.?\ 01_\EY?_ (FNFHH
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MZUJGPW\1ZLM_J&GZ'?WRXQ<W.D^;,,=/F:,GCZUN+\8/#:C U# '  MY>/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X;\8?\ DHVH_P#;+_T4E>Y5X;\8?^2C:C_VR_\ 124 >F?![_DG.G?]M?\
MT:]=-7,_![_DG.G?]M?_ $:]=-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5X;\8?\ DHVH_P#;+_T4E>Y5X;\8?^2C:C_VR_\
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MH_X5K_U,'B;_ ,#O_L: .FHKF?\ A6O_ %,'B;_P._\ L:/^%:_]3!XF_P#
M[_[&@#IJ*YG_ (5K_P!3!XF_\#O_ +&C_A6O_4P>)O\ P._^QH Z:BN9_P"%
M:_\ 4P>)O_ [_P"QH_X5K_U,'B;_ ,#O_L: .FHKF?\ A6O_ %,'B;_P._\
ML:/^%:_]3!XF_P# [_[&@#IJ*YG_ (5K_P!3!XF_\#O_ +&C_A6O_4P>)O\
MP._^QH Z:BN9_P"%:_\ 4P>)O_ [_P"QH_X5K_U,'B;_ ,#O_L: .FHKF?\
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M_4P>)O\ P._^QH Z:BN9_P"%:_\ 4P>)O_ [_P"QH_X5K_U,'B;_ ,#O_L:
M.FHKF?\ A6O_ %,'B;_P._\ L:/^%:_]3!XF_P# [_[&@#IJ*YG_ (5K_P!3
M!XF_\#O_ +&C_A6O_4P>)O\ P._^QH Z:BN9_P"%:_\ 4P>)O_ [_P"QH_X5
MK_U,'B;_ ,#O_L: .FHKF?\ A6O_ %,'B;_P._\ L:/^%:_]3!XF_P# [_[&
M@#IJ*YG_ (5K_P!3!XF_\#O_ +&C_A6O_4P>)O\ P._^QH Z:BN9_P"%:_\
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MH_X5K_U,'B;_ ,#O_L: .FHKF?\ A6O_ %,'B;_P._\ L:/^%:_]3!XF_P#
M[_[&@#IJ*YG_ (5K_P!3!XF_\#O_ +&C_A6O_4P>)O\ P._^QH Z:BN9_P"%
M:_\ 4P>)O_ [_P"QH_X5K_U,'B;_ ,#O_L: .FHKF?\ A6O_ %,'B;_P._\
ML:/^%:_]3!XF_P# [_[&@#IJ*YG_ (5K_P!3!XF_\#O_ +&C_A6O_4P>)O\
MP._^QH Z:BN9_P"%:_\ 4P>)O_ [_P"QH_X5K_U,'B;_ ,#O_L: .FHKF?\
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M''(6&?W3E3D\+BO2* *NM:W9^&]'NM0U"ZM[&PL8FGN+FXD$<4$:C+.['A5
M!))X %0^%_%FE^-]!M=4T74K'5M,O8Q+;W=G.L\,Z'HRNI(8'U!KC?VM=%O/
M$G[+OQ$T_3[2XO[Z^\.WT$%M!&9);AV@<*BJ.68DX '7->2:+_P3XT_0/"VE
MZ[\,=>USX->,+C3[=KO^R5#Z7=S"!4_TK3I/W+E?F^Z$;<Q))- 'T[17%_ L
M?$&+PC<1?$C_ (1277(;N1(+CP^9UM[JVX\MWCE&Z.0\[E#,OH>P[2@"KK6M
MV?AO1[K4-0NK>QL+&)I[BYN)!'%!&HRSNQX50 22> !4/A?Q9I?C?0;75-%U
M*QU;3+V,2V]W9SK/#.AZ,KJ2&!]0:XW]K71;SQ)^R[\1-/T^TN+^^OO#M]!!
M;01F26X=H'"HJCEF). !US7DFB_\$^-/T#PMI>N_#'7M<^#7C"XT^W:[_LE0
M^EW<P@5/]*TZ3]RY7YONA&W,2230!].T5Q?P+'Q!B\(W$7Q(_P"$4EUR&[D2
M"X\/F=;>ZMN/+=XY1NCD/.Y0S+Z'L.TH R_&?C?1?AQX:N=:\1:QI>@Z/9A3
M<7VHW26MM!N8*N^20A5RS #)Y) [UH6MU'?6T<T,D<T,RAXY$8,KJ1D$$<$$
M<Y%>0?MZ>"+CXC_LT:AHMMH\VO&\U?1A-8Q6INO/@75;1IMT8!W((U<MD8"A
MB> :YJ]_8,D^%&JS:M\#_&6J?"VYFN#=7&@,G]I^%=0=I!)(&L)&'V=I-JIO
MM7B*(,*M 'T117.?"23Q=)\.]+/CR'PY#XL$9&HKH,TTNG,X8@-"9E60*5P=
MK E22-S8W'HZ ,?QC\0M!^'=K9S^(-<T?0H=0NDL;634+R.U6YN'SLA0N0&D
M;!PHR3@X%;%>(_MH?"J'XOWWPGTN^\-Q^*-#C\;PW&JVD^G_ &VU2W%A?+OG
M0JRB,.T8W.,!F7N17-G]BKQ9^SW;^=\!/'USX=L;=#Y?@OQ6TVM>&I,(P5(F
M9OM=D#([2,89&#-C*$#% 'TE15'PO)J<OAO3VUJ&QM]8:WC-]%93/-;1S[1Y
M@C=U5F0-G!95)&,@'BKU &;XO\9Z1\/O#EUK&O:II^BZ39*'N+R^N$M[> $@
M L[$*O) Y/>L/6?C_P"!?#NB:+J>H>,_"MCIOB0JNDW4^JP1PZF6QM$+EL29
MR/ND]:\V_P""@/A:?7OA?H%_)X5O_'6@^'?$%MJ>N>';*S2\GU>S19%*+ Q"
MRE7>-]AZ[*^3+'X<6OA;4/%'BSQ%^S1XJUSP=X\3[-X&T"#1XKZY\'X#B3SK
M)SML/.E/F[HR0O3CB@#]*@VX9'(/0T5QO[.WA35O GP%\&Z+KTGG:UI.C6EI
M?.6W9F2)5?GOR#S794 8?Q ^)WAOX3Z&NJ>*-?T;PYIK2K"+K4[R.UA+MG"[
MY"!N.#@9SQ5?6?C+X1\.^*-)T34/%'AZRUG7E#Z98SZC%'<:@IZ&&,MND!]5
M!KPS]OW08;;Q3X#\4:]\.=8^*W@S0VOH-0T#3-)CU:<7$Z1B"Y^S.0'";9%)
MZKYF:^8+3X#ZMX7\#:UX<USX"^(M0\<?$*Z-SX*UZWLX]3A\%VCE!:VL]RY#
MV)M0,E5ROH3@X /TVHJ'3H9+?3X(Y6WR1QJKM_>(')J:@##^('Q.\-_"?0UU
M3Q1K^C>'--:581=:G>1VL)=LX7?(0-QP<#.>*KZS\9?"/AWQ1I.B:AXH\/66
MLZ\H?3+&?48H[C4%/0PQEMT@/JH->&?M^Z##;>*? ?BC7OASK'Q6\&:&U]!J
M&@:9I,>K3BXG2,07/V9R X3;(I/5?,S7S!:? ?5O"_@;6O#FN? 7Q%J'CCXA
M71N?!6O6]G'J</@NT<H+6UGN7(>Q-J!DJN5]"<' !^FU%0Z=#);Z?!'*V^2.
M-5=O[Q Y-34 <_XT^*_A?X;WNF6WB'Q%H>AW&M3_ &;3XM0OHK9[Z7(&R(.P
M+MDCA<GD4T?%WPJ?B%_PB/\ PDN@_P#"5>3]H_L?[?%]O\O&=_D[M^W'.<8Q
M7S'^W-X8M]-^/-OK?B3X0Z[\8-#UCPW_ &+H]OIVDQZ@-&U#SG9I)"Q!MUD5
MXQYR\KY?M7D_PB^!6M^$-4\#>!=8^$.NK\7M/\0VFMZG\2$LX[RPFM4N/.E!
MU-B)=Q@!A\DCKQR""0#]%J*** ,'5_BIX7\/^-].\,W_ (DT&Q\2:PAEL-*N
M-0BCOKU!NRT4+,'<#:V2H/W3Z&F^'OBQX5\6^+M4\/Z3XF\/ZGKVA_\ (1TV
MTU&&:\T_G'[Z)6+Q\\?,!7QO^UY\,KZ^^.OQ!T[_ (4[KWC?Q=\0(K#_ (07
MQE;:5%)9>$)(K=(@TU_N\VQ\FX5[CY!\^['.<4[]EKX5G2OCI\--%T[X)Z_\
M/_$WPY2Y/C/Q=<:1!'8^)@UC+ 1#J*GS+[SKF2.;YE!&PDA2I  /N:BBB@#!
MU?XJ>%_#_C?3O#-_XDT&Q\2:PAEL-*N-0BCOKU!NRT4+,'<#:V2H/W3Z&F^'
MOBQX5\6^+M4\/Z3XF\/ZGKVA_P#(1TVTU&&:\T_G'[Z)6+Q\\?,!7QO^UY\,
MKZ^^.OQ!T[_A3NO>-_%WQ BL/^$%\96VE1267A"2*W2(--?[O-L?)N%>X^0?
M/NQSG%._9:^%9TKXZ?#31=.^">O_  _\3?#E+D^,_%UQI$$=CXF#6,L!$.HJ
M?,OO.N9(YOF4$;"2%*D  ^YJ*** .-^(W[17P_\ @_JL-CXL\;>$_#-[<Q^;
M%;ZIJT%I+(F<;@LC D9XR*W_  ?XUT?XA>'K?5]!U73M:TJ\7=!>6-PEQ!,,
MD95T)4\@C@]J^!/C_P##JWTW5/B5X1\1?L_^)OB)\0/'6IWLN@>,8=!@U&PA
MBN<)9[[QVW6JP#"E< *(]W1LU]$?!SX$I\!/VH-/M?"OAV'0?#>K>#R^OIIU
MH;?2GU&*:)871% C64JT^[')4*3G&: /H:BBB@#C?B-^T5\/_@_JL-CXL\;>
M$_#-[<Q^;%;ZIJT%I+(F<;@LC D9XR*W_!_C71_B%X>M]7T'5=.UK2KQ=T%Y
M8W"7$$PR1E70E3R".#VKX$^/_P .K?3=4^)7A'Q%^S_XF^(GQ \=:G>RZ!XQ
MAT&#4;"&*YPEGOO';=:K ,*5P HCW=&S7T1\'/@2GP$_:@T^U\*^'8=!\-ZM
MX/+Z^FG6AM]*?48IHEA=$4"-92K3[L<E0I.<9H ^AJ**CND:6VD6-MKLI"MZ
M''!H X;QQ^U/\,_AEXCFT?Q'\0O!6@ZM;J&EL]0UJVMKB,$9!*.X89'/(KM=
M(UBT\0:7;WUA=6][9W<:RP3P2"2.9&&0RL.""#D$5^<Z_!FQUVPT7X6ZI^SK
MK5_\3AKUM+J_CK4?#MO<Z3?(MZ+FXN7U!F+2++ &'EMU+^7C/%?67[./PM_X
M4U\?/B1HF@Z+-H?@&2+3K[3[9(&BL8[V1)1<BV'W%3:L)94X#$\#- 'MU%%<
MQ\:O#NK>+_@_XHTK0;HV.MZEI5S;6%P'V&&=XF5&W=L,1SVH PM8_:[^%/A[
MQ+-HU_\ $KP'9:O;3?9YK*?7K6.XBESC8R%]P;/&",UZ%'(LJ*RLK*PR"#D&
MOSY^&?P;\(?&/XE_#CPA;_LPZAX2NO"%WY_BK6/$7A:U33[Z**TDAD1;G+?;
M&>=T92<YV[^U?4G['/@J^^&FG>.?#JV%]IOA?1_%%Q%X;@NE<>79-%$Y6+?U
MA$S3!,<!0 .E 'LE%%<S\:?#VK^+O@]XKTGP_>'3]>U/1[NUTZZ#E#;7+PNL
M3[AR-KE3D=,4 8>M_M<?"GPUXFN-%U+XG?#W3]9M9_LLUA<^([.*ZAESCRVC
M:0,'SQM(SFO0J_/OX9?!KP;\8?B1\,_!UK^RKJ7@N?P;>?:/%FK^)O!EE'I=
M]!#8SV\D27>7%^SW$D3*QSNV>;SM)'U#^QQX(O/ACI7COPVFG7VE^%=%\67,
M'ABVN4D416#0V\A6'?U@%P]P(]ORA  .!0!['03BBO+?VT_A_K7Q2_9E\4:'
MX?M9-0U"]CA+6$=R+=M4MTGC>XM!(2H7SX5DBR2!^\Y(&30!H:'^UQ\*?$WB
M>WT33?B=\/=0UJZG^S06%MXCLYKJ:7./+6-9"S/GC:!G->A5\,_!OX)?#K]J
M;]H:PN;7]E^X^'?@WP_H-_:ZNOB[P+9Z.-3N;F2V^S?9XUW>8\:PSDRCF,/C
M(WC/TE^Q7IVN:)^SCHNGZ]#JD%SIMQ?65HFIK(+P6,5[/'9^;YGSE_LRP\MR
M>O>@#U2D9@BEF(55&23VI:\O_;-^&NM?%W]FOQ/X?\/QFXU*^AC(M!=&U_M&
M))4>6U\W(V>=&KQ[B0!OYXH E'[9WPA;6?[._P"%I?#W^T/.^S_9O^$AM/-\
MS.W9M\S.[=QCKFO2E<.H92&5AD$=Z^!Y/B-\&[34FTV3]B7XA?:HY/L[,GPS
MLGBW@[<B8/@KG^/.".<U]3?L7?#W7OA9^SAX?T/Q% UC?6?GF*Q:Y^U-I=LT
M[O;VADR0YAA9(\@D?)P2* /4Z@U/4[?1=.GO+RXAM;6U0RS33.$CB0#)9F/
M '.34]>)_MU_#'4OB9\,=$%GH,WB_3=#U^TU76?#D4RQOKUG$6WP@,0CE6*2
M>6Y"OY6WO0!TWAG]L#X3^-=?M=*T?XF> =4U2]?R[>TM->M9IIV_NJBN2Q]@
M*]&K\^=4\5_"?XC:7>>']%_8K^(-EK&L6\MG97%Q\/;/28H9G0JC-=[QY !(
M/F @KUK[<^!OAS6O!_P9\*Z3XDO/[0\0:;I-M;:C<[R_GSI$JNVX\ME@>>]
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M'=M^SC\;/!W[2WPCU7QI\5KSXJ:'8ZU=-+;P^$K?38]*)T^Y5;B26$GY26"
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MV[\;2W5S_;VLZ<FH)IS6:)-&+>WD(22Y+E67<<*L;L 2!CR_XI^"OC5^SO\
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MO/B+\4/#?QF\-ZWXDT[2GT>^\*VNG7-K++-B*ZM7B8AI8I-CD,IPB,05(!H
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MEPZI%;KD(A52S/'-E@% IWP[U7XL?LX?&OP7X5^(7Q,TGXL:=\1+B]M()O\
MA&X=#U'1YK>U:X5U6"1HYK<K&Z/N4,KR0X8@E: /I2BBB@#Y1US]N3XRZA\6
M_&7AGP?^ST_B:#P?J)L9;J7QG9Z?),I4/%-Y,B;@DB'<I!(/(SD$"7X(?M#_
M !:^(W[9>BZ'X_\ A[<?#'3?^$5U&[@T\>(;?5H]4D6YM%\T^2 %,88@;O\
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M@GKOV0?CC\2/BQ^TC\1+/XA>$[CP#)I6C:2]GH!UF+5(XA))>;K@21 *"^T
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MP$8$L7X'5SWKS7X?? /X\>._"%CXCT']HKPKX/T[Q-$NL+I.@^!K&XT^U>X
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MP>8=#M[<S,((YBQ9X@9FV*PRB@+D@#'M5  S!%)/ '))[5^>?Q%M/V4?C_\
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MKZ'0]-\+320Q1:Q=29D5'DF!2)46)Y#(0=GEY&" 1\G? W]CGX!Z3XKMM/\
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M0?B!X'USXCKXBN&BL- T336OM2E=$)DFA"LK1^6A.9%92 V >:]ZKYM_:?\
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M #-M7)X Y)]*\'^+7QU_9K^+=@VD^-/&?P>UR*VD;$&I:Q82M;R8*$KN?*.
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M#"8D53M.3$6R O+].,GTF@"OJNJVNA:9<7M[<0V=G:1M-//,XCCA11EF9CP
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M@3:_LW?"F+PG8W%O<6-MJ.H7MN(+,6D5O'=7DURL"1JS!5C$HC&" 0F<+G
M.]K-\7>,=)\ >';K5]=U33]&TFR4-<7E[<+;V\ ) !9V(5>2!R>]:5>/?MM7
M&@ZI\&KCPSXJ\)^+/$WAOQ:W]FWLNA::=0?2<_,ES)$A\W:C*&W(CD%1D4 <
M)\7O&/[)_P <M0AOO$?C+X2SZQ;/$\&K6WB2UL]2MVB;?'LNH95F7:W( ;%:
MW[!"ZEXD\(/XBT[XB>)/%W@.X>\T[3;/7C!?7:26][-%]I6^C57ECD11A9-Y
M Q\YK!_9B^#7[,_QJ^'NFIH>@?!SQKJ=C9PK?SP>&;.UNG?!7S);5D\R$NRL
M=K <YKV;]FGX$6O[-WPKC\*V-Q#<6=OJ%[>6XAM1;1P1W%U+.L*H"0%02!!C
MJ%S@=* .^K"^(7Q-\-_"C0/[3\5:]HOAW2VD$/VK4[R.U@+MG"[Y"!DX/&>Q
MK=KYP_X**S^$?$G@"U\->./#WB5]$D)UB'Q+:^'SK6FZ!<6OSJUU#'N?85R"
M"FQE9@6'. #FOC/K?[)_Q)O+GQ'-XZ^'.E>*K=9;B+7/#GBJVTS6!*83'N$\
M$JM(VW@!]R].#7J'[$L'B#4/@WI>OZIXRUGQ7H_B;3K+4-'AUBW@_M#2XGMU
M+12W$*H+@EN=Y0-UR6ZUS/P]_9Q_9M^/G@.:X\(^$?@[KBS0&!KS3-#L9#;2
MM&#R@7=&P#!MC$,.*]?^!?PR_P"%+?!GPMX1^V?VA_PC.EV^F_:O*\K[1Y48
M3?LR=N<9QDX]: .KKE_B;\:/!GP?M+:3QCXH\-^&8+YF2!M7U"&T6X*X)"^8
MP#8R,XZ9%=17RG^WO?\ PX\1>./#=M\2O#VK:;8^#[F'5;3Q-J/A@ZQX=G26
M189K.8IN";P0,RJ@5@C@G R <A^T=X@_9;T_PQX@\:>&/&WA70?&EG93S0W'
M@+Q9;Z7JFH.SK*T>R%]DS2.HSYD<F<GBOJOX'^&?$7A3P5]G\2>*Y_&-U-<2
M7%M?7%A#9SI;O@QQ2"(!'=!P755W?W17CWB3]B?X"_M(?!36(/ OAOX5V_\
M;5K+;66OZ+HME<&RD^[YB-$!\R,.S @CJ*^B]-M/[/TZWM]V_P F-8]V,;L
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MY^E7.K7%GH^M0^(/#MJL=[ TD;V<K2>2\WG. 87BV@< \BOM1>!SUKQ_P/\
ML:>"_AE\>]-\<>#=&\-^%8;;1;K2;FQTC28;5;XS2P2+*[Q[<[/)( *G[YY&
M,'V"@ KQ_P"+WQ^^ ^N"^\+>._&7PKN_L\PCO-*UO5+)_*D1L@/%*W#*PSR,
M@UZSJ=V]AIUQ/';S7<D,;.L$6WS)B!D*NX@9/09(&3U%?%7PQTO]G#Q;\>/$
MUWXN\.^']!\0^.)(=2_X1KX@^%(K+4+:[:1H7>"XN 4F69E4^7$SC=N8'YB
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M "3G3O\ MK_Z->NFKF?@]_R3G3O^VO\ Z->NFH **** "BBB@ HHHH ****
M"BBB@ KYE^.'[;OPSU3Q9KO@?Q9\./''C'P=HER8->\0'P8=7\*Z9-"HE<7$
MGS<PG;N(B8(<'. 2/IJN%^"OP8;X,W7B^.'5&OM+\2>(+G7[6V>WVOISW.UY
MXM^X^8K3>9(#M7:)-O. : /G[2?@KI?@'XX^%/#?P1\;>)/ ^C^)O#=WXEM$
MLM477/"TL,5_9O(L>GW(D5!.MXV)+2> *,$!LFOKNOGOX>?LM^%?@C^VA;ZQ
MH?BB?3XM4\.ZFUAX),)>UL?-N[*2\NK5\X@B:00DP!=N^5V7;EA7T)0 5\W^
M*_VI?V:_VEOB;-\,/$&K>$?$VO6=T]NEGJ=@S0K<C]V5AN)(Q&9?F*CRWW$Y
M Y%?1MQ#]HMY(\E?,4KD=1FO'/@U^RC9:5^R_%\,_'>FZ%XAT^W:XM<HA9;N
M SN\,KY52L^"K$KR'&0W>@#C_A9\%H/AE^T'=>$?AYX\\>:'IWA2#3+_ %+P
M[JTBZQHTMA(L\26]J\[-<6[?N225?:,+\I' ^EJ\'_9<_9D\7_ _XS^-M6\0
M>*8_%>C:EI^GZ7H5S<;O[32VMFN&"71VA9'7S@HD!)<+E@#G/O% #99%AC9V
MX5023Z"OC7XQ?\%,_P!D?XLZ+-IOBS6-)\41VC.T<%]X8O9_+EVE<H[6YV-@
MD;E((SUK[,KPGXC_ +(-YX=NM6UWX0ZM9>"=<U))GO=(N+43^'M:E=,;IK=<
M&&0D#,T!5CU82=* /'_^"?7B/PO\<++3]6^#?Q*\9Z'IFB_86\0>"=5\[6-,
MT^'RG06EO/=QK+&3MSNBE*C:/DP17VM7!?LO?"^_^#'[/?@_POJS6,NK:'I4
M%G>269)@DE1<,4+ ,5STR :[V@#/\5>*+#P3X9U#6-4N4L]-TJWDN[J=\[88
MD4LS''/ !/%?.O[;_C/X0ZMX*\.MXM^&FM?%*]\56LCZ58Z#H+7>M1VA5'DG
M0Y26!!NB!(96#,O'7'T)X[\&6/Q&\$ZOX?U)&DT_6K.6QN54X)CD0HV/?!-?
M).M_LZ_M1^#/BGX?U3PKX@^#>OV?@_2)M"TZ^UVUOK6]OK67R6(N4AW)O1H$
MPT;*#@DCG  .]_8UT-O$:VGB;P?\1O'T_@_S[N'5O!WC"$7=_I%UA +?SI/]
M)@:$C[CO*K!A@\Y/T?7F/[+_ ,%];^$GA[7;WQ5JMAK'BWQCJC:WK$NGV[06
M4,[11Q"*!6);RT2)5#,=S8R<$XKTZ@"GXB\06?A30+W5-0F6VL=.@>YN)6^[
M'&BEF8_0 U\=_%7]J[X$_M)^ ;R3QW\*_&%UK 7R-$T;4_"[1>(-<AFY$NF%
M6\QD;9DLDBE=N3C(S]8_%3P#!\5?AGX@\,W4KP6_B#3I]/DD0?-&LL;(2/IG
M-?+%M^R-\?M>US0_%VM>+/AO;^,/AC:R6/@RTLK&X?2K^*1!',^H;_WJN\:H
M!Y)PA&>>E ':?L7Z1-XF,'B/PGX]^)$?A2*YNK?5_!?C>V%QJ&E7)5"D(FD_
MTB'R^#M:2565Q@CK7TE7E7[)_P (?$_PQ\,:]J'C>\T2\\9>,=6?6=7&C)(N
MGP2&*.%(X?,^<J(X4Y;DDFO5: .5^-?Q?TOX#?##5O%FLQZA<6.DHA^SV,'G
MW5W([K'%#$F1NDDD=$4$@%F&2!S7R-\7[?XB?'WQ7:ZAXJ_8EM[VZL[F![;7
MX/B/I=EKUI'#+OB>*X@\N>-E)+"-9P-QQGO7U[\9/A/I?QR^&>K>%=9:\BL=
M6B"F>SF\FZM)%97BGA?!VRQR*CHV" R X(XKP>?]E+]HS^UG:']JVZ33O.)C
MAD^&^DO.L6>%,N0"^WC?L )YVCI0!U7[%&CW]YX.L?$.F_$CQQXL\$ZE8-!;
M:-XRM+>36M&OH[F19TFNT597:-@T+1S>:5:+(E(P*]TK@/V8_#'A;P7\'K+2
M/!^J76M:1IMY>VTM_=2^;<7EXMW,+R25]JAI&N1,6*J%)SM 7%=_0!P_[07Q
M\T?]G'X>-X@U>SUK5?,N8K&RTS1K,WFHZI<RG$<%O$"-\C<G!(&%)S7@&FP_
M!']LO6M4UB;P3XH^&WQ<TFRFU<B\LY_"'C**(QO;K=K-"RO/$5&P-OEC7*JZ
M@D*??OCG\&6^,-KX9DM]4;1]3\)^(+37[&Y\C[0A>+>DD3Q[TW+)#+-'G<-I
M<-SMP:/[3'[/.C_M >"5CNK^Z\.ZYHOF76C>(K)@EYH<Q0JSJ> T;(2LD3?)
M(A*MV( ,#]AI?$NK_ O0_$>M>,M9\4Z;XKTC3M4TFVUB"V;4-&CDM(V>"6[@
MCA6[)8Y$K0H_7<6)S7LU<#^RMH.F^%?V9?A[IFC:PGB+2-/\.6%O9:HD!MUU
M&%+=%2<1DDH'4!MI)(SC-=]0!RWQF^,_A?X ?#R^\4>,-6M]&T'3PHGN)59^
M6.%544%G8DX"J"3Z5X-IGA_]G7]N+0M2\>^$9K636M)$UQ-KGAN2;1=?LY/)
M>/>Y7RIB2@(7S04;'<5ZQ^TI\'=3^+-IX/N-'FL%OO"?B6SUP07Q(M[N./<D
MB,0K$-LD9E./OJO3K6/^TO\ LL?\+5A_X2+PA?0>$?B1I]I):V.L)"#'=PL#
MNL[M0/WMN^>AR4;#+@CD F_8YM-7NOA;9ZY/XW\0>,O#?B.RL[_0EUZRMX=4
MTZW:!<QSRP +,Q/S;BN0<@ENM>N5Q/[-OPYOOA!^S_X+\*ZI):S:EX=T:UT^
MZDMF9H7DCB5&*%@#MR#C(!Q7;4 >6_M+?MD_#;]DN'2?^%A:_P#V(FO&5;(?
M8+BZ\_R]F_B&-\8WKUQG/%?%OQ'_ &O?V1?&/Q?L9/#6K:MX)U35K2Y-QXN\
M(6VHZ+>6TYFA=8G@CMPMR9FW$M(C@;.?O"OO;XP? WPQ\=O#\6G^)=,CO!:2
MBXLKE&,5WITP^[-;S+AXI!@?,A![<CBO)_AQ^S'\0O"G[36@ZYK_ (LT?Q?X
M/\-:'>Z=875W:>1KK/<2PL%N#&HAF"+" ) $8DG*DY8@'K/P8\*>(?!WA.2U
M\1^+9_&EP]U+-:ZA/816<ZVS',<4BQ (SJ."X5=W]T5UM%% &'KOQ!T71/&.
MC^'+VZ5=6\0I.]C:^4SF=(55I6) (55#+RQ RP'4U\5_%OQ9\#+_ .-^HQZ;
MX+^*7P_NK>]DTF[^)O@[3I-*T>"=IE,HFN8F\N0?:%$;M+$Z[L\X^:OI[]HS
MX+>(/'E_H/BCP3K.GZ)XX\(_:3ISZC:FXL+Z.:,+);7"J5=4<K&=Z'<I4'!Z
M5\[^!?V3?VDM;\ :M\._%VM?!W2O /B:\O+K5)]%M[ZXU**.ZG:XFA@$NR,!
MF=E#-EE#9^8@4 ?5WP<\(^(O!/A::S\2>+IO&ER;N66UU":QAM)A;,<QQ2"$
M!'91QO55W?W1765'9VJV-I%"F=D*!%SZ 8%24 >.?M*?M?\ AGX!>(],\/ZM
MX;\7>*IM4@:ZO8]#T<ZE'I-F&V-<W0!^2'EN0&)"MP:^=+?5O@;KOQWM+7X:
MVGQ*^&[:E>6UG%XW\&6;6?A34+I"PCLY 0UK*Q9ROS0$%N-U>X?M)?!#XI7W
MQ:C\7?"?5O!EA?:SHZ^'M:'B*&XD$%LLKR1SVWE'F53(_P K_*>*X'P%^PU\
M2OA^GA+X<1^)O">I?!?POJ=MK27-Q:2Q^)))H9_M0@.S$!C,XSOP&VG&"1D@
M'T[\+] USPMX!TW3_$FO+XHURUBV76JBR6S^VMDX<Q(2JG& 0O&1G Z5OT44
M ?//[1O[2?B#4_%&O_#_ ,"?!6X^-$FEPQ0>*(+W5K+2=)MEN8BZ6Y>Z#"XD
M:/#/&J%561,G+8KQ7X2_#74M+^)5OI,?@GQW^R-XI\627T^ACP[XFL?$'A76
M;Q;5=ZW%AA[6.58TWJBPQ%UAD(E#*,>^?&[]E#QAXB\>ZCXI^%WQ8U3X5ZUX
MA%NNN)_85IK=CJ9@1HXY1!<8,4VPJA='PR1("I*@UB?#CX!>(/A[\6?"&K?&
M/XUWWQ*UV.^N+?P?9?\ "/VFAVL-V]G,9G,=N&,THMDF"L[A45G&"S T ?0N
M@VUY9:'9PZA=1W]]# B7-RD/DK<2A0'<)D[ S9.W)QG&3UJU110!X%^T7^V9
MX1\%^.;SX=ZE\._B)\28I+6)=?30/"AUS3=+AN,[4O1GHT89R@1R4'0G /F&
MH?##P#IVI_#G6/@#XHUSP%;?%C5+^&VO/"FI*V@+<#3)Y?/GTBXCEM7*&S$;
M1(EO(K9RZLN!])^"?@RW@7XV>-O%EMJC267C=+*6YTUX.8+NWB,!F27?]UX5
MA4ILX,6=WS$#S/QY^RUX5\-?M=^ ?'5GXHF\+W&HZW=7,WAM(3)8^)-3;3+J
M/[2BY @N!;F4R2 $2B) PW!6H ][T&VO++0[.'4+J._OH8$2YN4A\E;B4* [
MA,G8&;)VY.,XR>M6J** /G_XW?MC?L]W?Q)E^%?C_7O"][JSRQI<:;JU@UQ9
M12??02RO&8$88!^9P02.A(KF9/V=M'^$/QIT?PG\*O&GC;X>ZAJ^EW&LP:;%
M(NK>&6@BO(6G!MKAF,3R&? ,#( "3VP?3O@Q^SLW@NP^(6B^(K;1-=T'Q7X@
MO-5MUDB\U[B"["M)#<(R[3M;<HY8% O3&*XWX.?L<^(/@O\ M06>M6?B*'4?
MAMHN@7FF:)IEVSO?Z,UQ/!(;=),$26RB'Y-S;D#!>5 P ?12\#GK1110!\K_
M !U_X*1_LQR:MK7@GQ]KVFZI)I-XUIJ&G7_AN[OH8YX7((/^CLA*NO!&1D9!
MKRO]C3QO\.?C]XEOK#X"_$3QA\-]9TV2XF;PUMN-5T&6S2^#&X\B[B"0F=6'
MR0R1LGF8P=IKZ?\ B;^RA:ZOXPF\8>!]5D\ ^.)V5[J^M+9)K/6MN?DOK4X6
M<8)&\%95_A<=*G_8W^$/B3X,_!UM.\82:!-XDO=6U#4[Q]&$GV/-S<R3 1^8
M X #@8.<>IZT >K+P.>M-DD6*-F8[549)/84ZFRQ+/$R,,JX*D>H- '@7[2_
MQ?\ A+XL^ &E^)O$/A.3XG:/K5U]GT/3;+0_M^H:E.0Z$VL3A6#"-9&W@K\B
MD@],\-^QOX;L/%=Y'=_#/Q=\4O -AX=O;:#6OA[XTMS=&RM5B81Q1QW!:>V6
M1=KJ\<S)\N-O&!F?$#]D;X^>!-8\'Z?\,M?^%^I>%? FI3:KH7_"36UW#?V7
MF)/$;-V@W)+"L<Q <!'Z>F3[/^S%\%_&WA;Q/XB\;?$K5?#M]XV\56]I9W%M
MH%O+%INGV]MYOEI&929)&)E=F9L<M@# % 'LE4_$7B"S\*:!>ZIJ$RVUCIT#
MW-Q*WW8XT4LS'Z &KE8'Q4\ P?%7X9^(/#-U*\%OX@TZ?3Y)$'S1K+&R$CZ9
MS0!\G?%7]J[X$_M)^ ;R3QW\*_&%UK 7R-$T;4_"[1>(-<AFY$NF%6\QD;9D
MLDBE=N3C(SWW[%^D3>)C!XC\)^/?B1'X4BN;JWU?P7XWMA<:AI5R50I")I/]
M(A\O@[6DE5E<8(ZUQ=M^R-\?M>US0_%VM>+/AO;^,/AC:R6/@RTLK&X?2K^*
M1!',^H;_ -ZKO&J >2<(1GGI7N/[)_PA\3_#'PQKVH>-[S1+SQEXQU9]9U<:
M,DBZ?!(8HX4CA\SYRHCA3EN22: /5:S?&?B[3_A_X0U77M6G^RZ7HMI+?7DQ
M4MY4,2%W; Y.%4G K2K/\5^%]/\ ''A?4M%U:VCO-+U>UELKRW?.V>&1"CH<
M<X*DCCUH ^,?CCXP\=?M;:+')J/[%-OXX\,WEKNT?4-?\9Z5IFK1VTRJ^Y4P
MT]G(P"DJDH<$#)!&!Z=^QIH&J:IJ,VJ:3XX^)%CI&CZE?:;XD\!^-)(-9N=(
MOML12*#4"6N!$BE9$+33I+',A&PDUFS_ +&WQX\.F/3_  G^U)J^D^&]/BCM
MM.L]4\":7JUY;PH@55ENF*-,PQ]]E#'ODY)]2_9<\":+\-](\4:79^*+[QEX
MF36VF\6ZM>*B3W6J26UN[92-5CC40-;A(XQM1 JY+!C0!ZA7._%OXIZ/\$OA
MMK'BK7I9H=)T2W-Q/Y,1EE?D!41!RSLQ554=68"NBKBOVB/@VGQ]^#VL>%6U
M&31YK_R9K6_CB\UK*Y@F2>"79E=X66-&*[AN (R,YH \$TKQI\$_VY_B!I]A
MXX^%OBSP+X_9EGT.3Q?H4OAK7[Y;0B7?87T+B5O*9MQCCF##YF*;<FNN_80T
MOQ'=>%[K5IO'GBOQ!X5CN=1T6TTCQ(]OJ5_:7%GJ=S;M<?VBD4,LJ2)&/W<R
MR,G'[T@<^I?%WX*Z/\=OATWA[Q,LDW,=Q#>V;-:W6GW<?,=W:R EH9D?YD8$
MD=#D$@\K^Q+X"L_AE^S]:Z+9>+O^$Z%GJ^K?:=:-I]E:[NFU*Y:X!C!(#),9
M$)4[6*$@ $"@#UJLOQMXUTKX<>$=1U[7+ZWTS1])@:YN[J9ML<$:C)8_X#D]
M*U*\[_:L^#]]\=_@3K7AK3+FUM=2NC!<6K70/V=Y89DF5)< GRV,85L \,>#
M0!Y/X4\1?LT_\%(-6FN-&DT+Q%XBT=HI1>00SZ3K=L(F#QO'+B*YV*S#E3M!
M.#SQ73?L7Z+J#:9=:II_Q"\9>*?!<;W>DVVF^*H()M1M+NVO)8I91>1X>2,[
M"%63<V IW#I75?&K]G#3_C;X;TRX=U\-^--! N=&U_35'VG1[G:-VQB!YD+?
M=>-AMD7@CIB#]C;X0>(_@=\"K30?%EYI6H>(/[0O[^\N--#BVD:XNY9\J& (
MXD&1C@Y&3UH ]3K@OVA_VE_!/[+'@F'Q!X\UC^Q='NKI;%)_LLUSNE968+MB
M1FY5&.2,<5WM8/Q+^%WA[XQ^$+K0?%&CV.MZ3=_ZRWNHPZAAT=3U5UZAEPRG
MD$&@#X'^/W[<?['WQ!\::+JEK<2V_B"_OY$N_%&@V6I:'JNCJUM(GVKS8H%>
MX/"1[&W#YLD$ BOL;]ECP_JFF^"%U"3XA:Q\0?#.M6UK=^'[C5]/CM[^VMC"
MO$LB)&92_#9>-7&2#D\UYW<?LB>/-%^,?P^-IXPLO$GP[\*:S+JS6^O1L^MV
M -M+"D$5RHQ<1YE)_? 2 */G?M]**NU< 8 Z =J "L/7?B#HNB>,='\.7MTJ
MZMXA2=[&U\IG,Z0JK2L2 0JJ&7EB!E@.IK<KRW]HSX+>(/'E_H/BCP3K.GZ)
MXX\(_:3ISZC:FXL+Z.:,+);7"J5=4<K&=Z'<I4'!Z4 ?,/Q;\6? R_\ C?J,
M>F^"_BE\/[JWO9-)N_B;X.TZ32M'@G:93*)KF)O+D'VA1&[2Q.N[/./FK[$^
M#GA'Q%X)\+36?B3Q=-XTN3=RRVNH36,-I,+9CF.*00@([*.-ZJN[^Z*^4? O
M[)O[26M^ -6^'?B[6O@[I7@'Q->7EUJD^BV]]<:E%'=3M<30P"79& S.RAFR
MRAL_,0*^UK.U6QM(H4SLA0(N?0# H DKS']IG]I_2?V;-'TMKSP_XJ\6ZCKD
M[0V>C^'--_M"_G5%W22>7D?NT&-Q)XW"O3J\9_:I^$7C[Q-XB\+>,?A?>>%(
M?&7A<75K'!XD2=M/N;:Y5!*"8?G5P8T*D9'4&@#YP^*/Q$_9X\4>.K74_"N@
M_$7PYJ%[$!JOCGP!IT^G6_AQIY$E9-2>/">86"EUEBD*Y.X"OLGX-^$O$7@O
MPK-9^)/%TWC2X:[EEM=0FL8;286S',<4@B 1V4<%U5=W]T5\N1_L)?&'PQX.
MU7P7I?C'P3JGA/XF7<NI>.+G4K":/4;6ZN2OVO\ L_RL(T; 803<KCJ<\?9=
ME:K8V<,*9VPH$7/H!B@"2O&?VCOVFM;^'_BN'P7X%^&^I?%+QG=:=_:MSID>
MHV^EV5G8F4P^9/=7'R!G8.$C569Q'(3M"Y/LU>0?M#?LS:Y\2O%%OXJ\!_$'
M5/ACXX@L/[)DU.#3;?5+6^L_-$HBGM9QM<HV\QNK*R>;)RP8B@#YB\)> YO#
M/Q,TR^U[X(>,/V56\0ZI8Z9;^(O /C.PN].NKO,@MK>_L(4-KY3N^P226T@+
MR(K%0V3]O?"_0-=\+> -+T_Q-X@7Q5KMG#Y=YJZV"6'V]\G$A@0E$.,9"G&0
M2  <#YYMOV;/&7A;5]%U3XX?M!7WCSPSINMZ?-IVDQ>%;+0H)]4-RB6?G/!O
MDE43O&5C!5=X1F)52*^I* "O&_VF/VQ]$_9ZU[3_  _)X-^(7Q UK5[22\?2
M?".A'5KBVM PC,TZ[E"QLYV DG)R,5[)7#3?!EH_VCH?B#:ZHUN9O#YT#4=/
M:#S%O$2<SV\JOO'EM&SS@C:V\2_P[1D ^9O$?@OX.1^"--^(WP=_MWP#J5_X
MLT?PUJ2>#KX^'7M;AKU+4P7^F2PR6QDA-R7:*>UWL,?,%<,?K3X7Z!KOA;P!
MI>G^)O$"^*M=LX?+O-76P2P^WODXD,"$HAQC(4XR"0 #@>,?M9_LM>%?%7CK
MPQXZF\43>!=0A\1:(NJ/#"9;;Q3Y-_"UG:W$0(!E$^Q(Y_O1J[@Y0D#Z%H *
M\1_:7_;+^"?PC\1P^!/B9X@T:.ZUZ !]-O;"2\A>&0[!Y^V-T1&_Z:$# )Z#
M->W5YCX!^"5]X1_:!^(?B*Y.F7VA>-H[&:-9 6NK>>&$P/$05VF$J%8?-G<S
M\<YH \A\:?L]^!?AQXF\)7'PK\4^*OAQJ'Q'O;E-+E\+7,=WX?N;@V32B>>Q
MF+6[1^7!P854DXY'4?4'AZUO+'0;*'4+I+^_A@1+FY2'R5N) H#.$R=H8Y.W
M)QG&:^=Q^P[JG@3]H[P1K'@W6+'3_AKH>JW6LW7AB=2%TVZEM9H2U@5!"1R-
M-N>$D(I!9<;B*^E* "OE?XZ_\%(_V8Y-6UKP3X^U[3=4DTF\:TU#3K_PW=WT
M,<\+D$'_ $=D)5UX(R,C(-?5%>1?$W]E"UU?QA-XP\#ZK)X!\<3LKW5]:6R3
M6>M;<_)?6IPLXP2-X*RK_"XZ4 ?,'[&GC?X<_'[Q+?6'P%^(GC#X;ZSILEQ,
MWAK;<:KH,MFE\&-QY%W$$A,ZL/DADC9/,Q@[37WXO YZUY3^QO\ "'Q)\&?@
MZVG>,)- F\27NK:AJ=X^C"3['FYN9)@(_, < !P,'./4]:]6H *\A^-?Q>^&
M.O\ P3\4:MXDTVU\8^'?#M^VFW=@^E?;6N[^*146VABD7$LIF*HNWC>>HP<>
MO5\C_M&_LA?& +J6G_"G7O +^'=;\1Q^*I++Q/;7"3:1?1SQ7&;>6'<'CDF0
MLRR)E=Q 8YX .=_9ET#0?'OB.^L?A1JOQ@^ >N::BW9\'^*; OI]W:O<^9+<
M165RT@5&8O&6@DC*$CCD9^VEX'/6O!_V??@O\4+[XLK\0/B]JO@N37]/TN;1
M--T[PK;W"V4,$LL<LDLDDYWO(QC0;<!5"YY)->\4 (S!%+-PJC))[5\F?$3]
MM/X'_&JTUK3?'O@?6KK1=+:4Z/>Z[X:\RT\2RJ3"1I<GS&64EMJA=K$-D< D
M?6-Q"MS;R1M]V12IQZ'BOC1/V#_B]KEIH?AC4/&'@S3?!WPNOAJW@>6QL9IK
MZ[NXF8VW]HK+E/+168,(B"V<Y!% &G^QIH%GXKU19_AQXF^+?PZL/#MW:IJ_
M@#QQ9FY6&R$;K&L"W!>:W20#*O',5RA!3L/KNO%?V6?A#\0?#_B[Q1XT^*5Y
MX2F\8>)(K73_ +/X:2==/M[6V\PQ\S'>9&::0GL,#%>U4 #-M&3T%?&_Q:^/
M7BK]J[08V\/_ +)]O\8/AS-)(^E:KXC\1Z7IOVQE+PM<P6UPKR1JPW>7*=KL
MC!@%!%?9!&17S%J?[$OQ6\$S?V9\+/VA=4\!^"K<NUCH-[X/T_7/[-WR/(8H
MKB4I)Y*[MJ(^XHJA=Q   !A_L=> M5M_$S:7H>L?$CX2ZAX.FTX>(/AOXBU*
M#Q5I,>GM;NL*Z?=R%YHX9-K 213A5>!T:'Y0!]<UXS^S+\+H/A;XY\40>(/'
MU]\1/BG?V.GW'B'4KFSBL=EH#<I9I%;0J(H8LI<':"S%B[,<,H'LU %/Q!KU
MGX5T&]U34+B.UT_38'NKF=_NPQ(I9V/L%!/X5\GZC^T)\#?VY-0T_0?B5\*?
M%>C6FM$:?X;UKQSX4;3;;56G!98]/OPQ:*2545E >)W^4+EN!]1?$GP)9_%'
MX>:]X9U+S/[/\0Z?<:;<F-MKB*:-HVP>QPQQ6#IOP2L];_9_L_ /C9K/QE9_
MV3%I6I236GD1ZD$0+YACWL8V.T-D.2K#(((& #RK]ECPAKFG?&;QM:Z3X^\:
M3>#_  7XBN=(NM \1WB:[]J:2RL[F*2WO)46[MTB,Y7RI9;@,!G*DFOHVO$_
MV+O@Y8?!"/XB:/:^.M0\>7;>*3->W&H1G[9I[_8+-8K6:7)^T2+;K 3+@%M_
MS#<&)]LH *\-^,/_ "4;4?\ ME_Z*2O<J\-^,/\ R4;4?^V7_HI* /3/@]_R
M3G3O^VO_ *->NFKF?@]_R3G3O^VO_HUZZ:@ HHHH **** "BBB@ HHHH ***
M* "OD?4_^"?_ (N^(GQ\\?7VO?&7X^Z+H&H7J:EH,GAWQJ+*QABF!\RR^S%'
M:-H74X881HY8Q]Y7S]<44 ?,/P,_8BUC]GS]KS2_$D7C7XG?$#0)/"FHZ?<W
MWC'Q$FJ/IUR]U8O%%"NU'42)%*S$*5_=KD@X!^GJ** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH X/]I[X::]\8/@'XH\.>%_$FI>$?$6I6973
MM5L;AK>:UG5@Z?O%^958KL8KSM9L<UX#X)_X)GZCKW@_2[W5_CK^U5H>JW5K
M'+>:<_Q%CG:QF*@O%YD<)1]K9&Y3@XS7UU10!X_^PK\'-8^ ?[.EGX6UTZA)
M?Z?J^KR">_NTN[J[AEU*YEAGEE0D-))$Z.QX.7.0#D#V"BB@#QW]N?X/>+OC
M3\")=/\ !/B/Q1X=UW3[Z#45&@:M_95YJL,9/FV:W)XB,B,VUF^02+&6!7->
M7ZK_ ,$NIKGP_<^7^T!^U))<26[;+>?QZI5V*G"-^YQ@G@\X]Z^LJ* //OV3
M?!&J?#/]E[X=^'=<M?L.LZ#X;T^POK?S$D\B>*WC1TW(2K892,J2#C@FO0:*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7/C9^Q/XN^,O[5
MFH:M-\5/C1X;\$:OI,3VT7A/Q<-+M](O(=L;Q/;LK%UF0B17095XY0_#)BAH
MG_!/G6/A+^T7\+?%.F_$;XQ_$2PT35[N35(/%_BI-1M=.ADTV[B6>.)D0^89
M9(TRFX@2-QC)'UE10 4444 ?+GQL_8G\7?&7]JS4-6F^*GQH\-^"-7TF)[:+
MPGXN&EV^D7D.V-XGMV5BZS(1(KH,J\<H?ADQ0T3_ ()\ZQ\)?VB_A;XITWXC
M?&/XB6&B:O=R:I!XO\5)J-KIT,FFW<2SQQ,B'S#+)&F4W$"1N,9(^LJ* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO'?AV;QAX(UC2;;4KW
M1;C5+*:TBU"S;;<6+R(5$T9[.A.X'U K5HH ^,_@_P#\$T/%&L_#ZQD\:?'7
M]IK1_$T9D@OHK/XAB2UF='9!/#^Z9EBE4"14<[T#A6^8$UZQ^P[^SGK'[-5M
M\1])U34O$FO6NI^*SJ&F:OX@U--0U+5+8V%E'YLTJX.1)'(@#*K!8QQC!/NE
M% !7!_M/?#37OC!\ _%'ASPOXDU+PCXBU*S*Z=JMC<-;S6LZL'3]XOS*K%=C
M%>=K-CFN\HH ^1?!/_!,_4=>\'Z7>ZO\=?VJM#U6ZM8Y;S3G^(L<[6,Q4%XO
M,CA*/M;(W*<'&:]:_85^#FL? /\ 9TL_"VNG4)+_ $_5]7D$]_=I=W5W#+J5
MS+#/+*A(:22)T=CP<N<@'('L%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?./[6O[*'B[X[_'?P=J6F_$+XJ>%_"+64^FZO:^$/$PT=K.4;
MI8;UE8$3*3NA=0"XW1,/E5P?HZB@#XW^('_!-#6/#=SX4U;0_BQ\>/'MUHWB
MO1M0FTCQ-XR2\TU[:&_@DGE>)XT#&.-6=0&W;E& 3@'[(HHH *^<?VM?V4/%
MWQW^._@[4M-^(7Q4\+^$6LI]-U>U\(>)AH[6<HW2PWK*P(F4G="Z@%QNB8?*
MK@_1U% 'QO\ $#_@FAK'ANY\*:MH?Q8^/'CVZT;Q7HVH3:1XF\9)>::]M#?P
M23RO$\:!C'&K.H#;MRC )P#]D444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 ,,CT]Q7QG\-_^":_B[6I=?7QC\=OVDK&[M=7G2QNM,\>B.SU
M.S8B2&5(O+=X657\MT8_?B9E^1E ^S** /G;]D;]DK6/V9_C]\0KJX\2>.O&
M6AZ]I&CQV6M>+-;35+^6:&2^,T 8!76-!+$0&4#,C8)YQ]$T44 97COP[-XP
M\$:QI-MJ5[HMQJEE-:1:A9MMN+%Y$*B:,]G0G<#Z@5\D?!__ ()H>*-9^'UC
M)XT^.O[36C^)HS)!?16?Q#$EK,Z.R">']TS+%*H$BHYWH'"M\P)K[,HH \+_
M &'?V<]8_9JMOB/I.J:EXDUZUU/Q6=0TS5_$&IIJ&I:I;&PLH_-FE7!R)(Y$
M 958+&.,8)]THHH *\-^,/\ R4;4?^V7_HI*]RKPWXP_\E&U'_ME_P"BDH ]
M,^#W_).=._[:_P#HUZZ:N9^#W_).=._[:_\ HUZZ:@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/\ %/BS2_ ^
M@W&J:UJ6GZ/I=J 9[R^N$M[>')"C<[D*N6( R>I K0!W#(H **H:IXITO0]4
MTZQO=2L+.]UB5H;"WGN$CEO9%1I&2)2<NRHK,0H)"J3T!J_0 4450\0>*=+\
M)6UO-JNI6&F0W5S%9PO=W"0K-/*P2.)2Q +NQ"JHY8D  F@"_1110 4444 %
M%%% !15#Q!XITOPE;6\VJZE8:9#=7,5G"]W<)"LT\K!(XE+$ N[$*JCEB0 "
M:OT %%%% !16?I_BW2M6U_4-)M=3T^ZU321&;ZSBN$>XLA("T?FH#N3>H)7<
M!D D9K0H ***S] \6Z5XK:^72]3T_4CIET]C>"UN$F^R7"8+PR;2=DBY&5;!
M&1D<T :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7YFV@X')P* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\-^,/_)1M1_[9?\ HI*]RKPWXP_\E&U'_ME_Z*2@#TSX/?\
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MA9+>ZDUC[0MNY& YC\A=V#SC<,XKY2E^-GC";Q:=>;Q/KO\ ;#2>;]K%[()
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MF+.,,!72_"_]B*;X;Z9\*[ ^+#?V/PGUC4K[34;32CS6=S!<P0VC-YQP8$N
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M  G)T\_9/L^S[%]E@:'[^X[]^[/W5QC'/6J_QI^ _P#PM_QO\.=9_M7^S_\
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MW\Z([I'MPZ2HPW&7RR3D28YW=6_:I\2_L^_$#7M"^)LGAO6(+/P==^,K&_\
M#VG7%B6CLV"W-K)!+-/EAOC9)!(H8$@HN,GF/VD?V6=:\/\ P?NM+T'4-9U"
M^\5_%O3O%+76EZ<&N-$CEO[=GD"GS580*A<R.NS RR@ Y]&L/V3;OQMXDU[6
M?B7XBL/%VH:SX<F\)Q1Z;HYTFSL]/F.Z?$;SW#--*P0LY?:!&@5%Y+ '-S?M
M!?$[X:>&?!'C3QI'X*F\+^,=2L=/NM'TO3KN/4/#_P!O<);,;MYW2ZV.\22
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M-*^!@99E).!Q0!\V_P##T;_J1?\ RL__ &BO%OCY^U%X@^.GB0W#S7.DZ7&
MMOIT%RS1Q<#+,0%WL3SDCCH*^\/^%!>!?^A*\)?^">W_ /B*\O\ C3_P3^\-
M_$O6DU#1;J/PG,5"2PVMBCVKXZ$1JR;6]<'!ZXSDD \&^ '[<NO?!G2;G3]2
MM9_%%BY#6R7%\8Y+0\Y <HY*GCY3T(XZG/H7_#T;_J1?_*S_ /:*]6^#7[%G
M@[X6:)-#?6-CXIOKE@TMSJ5E%(JXS@1HP8(.>>22>IX '8_\*"\"_P#0E>$O
M_!/;_P#Q% 'E_P  /V[+7XW?$6U\.3>&Y])N+U)&@E6\%RA*(7(;Y$V_*K<\
M\X'>OF[]A?Q!<?LZ>([K5+ZZF;P?\;/$?B#3)GE8LEAX@M]0NQ;G)^Z+JV4Q
M^[VR?WJ^\?#GPN\,^#K\W6D>'="TJZ92AFL["*"0J>HW*H./:O)+#]AC3S^R
M=X@^%NH:Y)>+K&HW^JVVJQV?DRZ;<SWLEY!*B;VRT$K(0=PW;/X<X !XO\-O
M&-UI/_!)3X7^&=+G:WUSXE16O@ZPD3.^#[9.\<\RXYS%;^?)GL4%=Y^S%H]]
MX,\(_&;X#>&M0_L+5O <UQ_PBMW(6?[%9:G"]S9N,@EE@F>5,C/$0'7BM+P-
M_P $Y](L/#7PM\/^,-4TSQUX8^&.CW5G'I&H:%']EU.^F8 7LJ/)(O[N/>BQ
ME6 ,A;=D 5T$/[#FB^!/C%'XK^&MQI?PN2XT&ZT34[/0- M(DOB[+);W(&WR
MEEA<$Y>*0.K%3@4 >9_L::AX%^$7COPSX+\5_#2;X7_&;^SFM/[3DM5\CQO(
ML8:YEBU*$E;YCA)G2X/F(\@^4LI85/V+/V3/AS\9OA!XPU+7/"&AR>(9_'?B
M$1Z_!9I;ZU9O'JDQBDAO4 GBDC*J597!&!VXKV>V_9S\4^-_BCX3\2?$/QAH
M?B"/P//+?:1I^A^'9-(A-Y)$T/GW!EN[II"D;N$5#& 7).[@#GOAO^R;\0OA
M9X<UWPWH_P 3M#L?#>O:WJ.K22P>$I!K5FM[<O/(D-T]\T"R+O*K(UJX& 2A
MZ4 >0:+\2M4_:J_9N^$_PN\27LFK7WCKQ'J&E:_>YVOJ.D:+=3&:4LN.9S!;
M1,P !,[],UH:=^T7KOPO_P"":GC33[.^DM_&GPIOF^'S7K+OEA=+J*SMKO#8
MR3;S0R@G@MSR*]2\-_\ !.;P%8^-K.ZUW3-'\7^&O#_A^#0/#VAZWI<=]'I0
M$KRW-RSS%Q-/<2,A9RBE=A&3N-36'_!/_P ):/K_ ,0[/38]/T7X?_$C1H-/
MO_"^E::EC#:W<6]1>P21D+&Y1E!41_?C5]Q/% &+\=/V*OA_\.OV=?$NM>']
M$MM'\<>&=(NM6LO&," >(FOHH7E^TS7W^OF:1\^8)'99%=E8%3BO2=!\:7OQ
M'_8]M/$.I1I#J&N^#UU"Y1%*JLLMEO< 'H-S' KS_P"+7[+7Q:^)_P %-2\#
MW7Q8\/7FD7-JUKYDOA.6#4=4B .V"\NH[W84D&U)G@@B=@6V>7G%>K>#]/U;
MQG\%I-)UO08?!NI2V4VE26=O<1WEK;@*8ED@9"-T)&&0.L;[<!D0Y  /A']F
MG1=+\$>"/V6_$-E\-9OAC')<65OK7CE+?3XH_$(GLG2.UD-G,]PZ75P8OFNT
MC56"$_,0*]W\/_M5:EX?TSQE8^'_  OX1L_%.M?%:[\%Z.(+1[:TGF\I)&U"
M_P!A+3.L:2.Y4H9/+504SN&UX)_8;\30?##P'X!\6>/M%UOP+X!EL)X;+2_#
M$FFWFJ/8E6MEN+B2]N%,8D1'98XD+%0-RC(.I<?L+*V@^(A;^*)+77K[QY+\
M0-$U)=-5ET>\9558GB9SY\6T,K@-&760@%#AJ (]9^+GQ&\->/-8^'.N:MX/
MD\0:MX8N/$'A[Q!I^@W=O:J+>1([F":T:\=]Z^;&R2)<J#OY4;/G\U^%_P"U
M1XO^!_[!?PN\0>+/%OA'4]8\>0Z7IND:IKD4UE;Z69H&DEN=3N9;MS<E(T9R
M5,!D90HVE]R^Z>"?V<M4F^*%]XU\=^)-/\3^(I=(?0+!=+T<Z38Z992,KRA(
MGGN)&ED=5+2-*1A$"JN&+<GX<_8GUK1O@?X:\'S>.+-[CX<WEO>>"=6M]!,-
MQIA@22*-;Q&N'2[4Q2&-]@M]REB-K$,H!F_"3]O.SOK'XK+K7B+P5XWA^&.E
M1>(#KG@QLV.HV<D4S>48_/N/*N$>WD4KYS J\;<9('3>'M8^*'BGX.W^N^+I
MO ZZ3KWAJYO?[+TVPNK>\T9Y(-\437$D\B76%8J["*W^8;@,':.N@^$6N>.?
MA_XFT#XC>(M/\36OBBRDTR:WTG2#I-G;V[QNC[%>:XF\U@YRS3%?E3:B$,7P
M?AU\!/'7AGP='X9UOXBZ?K7AW3]'ET>RCM_#8M+V93'Y44EY,UQ(LS1H/^6,
M=ON;D\?+0!XW^R]\8?B%\(OV>?V<YM6C\'W'@WQA:Z1X:%A;6]Q_:6G>;9?Z
M-<FZ,OER[VB4O$+=/+\W:)'V%VZ;Q'^TM\6-5L_C1JGAVV\ VNE_"'5+FWBA
MO[2ZN+C7XX;*"[>'<D\:VKA9"!+B8.9 /*3RR9.XB_9'\KX+?"'P?_PD&?\
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M0QJ,+&B@*JCV  % %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O#?C#_ ,E&U'_ME_Z*2O<J\-^,/_)1M1_[9?\ HI* /3/@]_R3G3O^
MVO\ Z->NFKF?@]_R3G3O^VO_ *->NFH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\-^,/\ R4;4?^V7_HI*]RKPWXP_\E&U'_ME
M_P"BDH U/"7QD_X0[0(--.F_:#:EP9/M&W=EV;IM/K6E_P -$_\ 4'_\F_\
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M#_\ DW_]A1_PT3_U!_\ R;_^PHHH /\ AHG_ *@__DW_ /84?\-$_P#4'_\
M)O\ ^PHHH /^&B?^H/\ ^3?_ -A1_P -$_\ 4'_\F_\ ["BB@ _X:)_Z@_\
MY-__ &%'_#1/_4'_ /)O_P"PHHH /^&B?^H/_P"3?_V%'_#1/_4'_P#)O_["
MBB@ _P"&B?\ J#_^3?\ ]A1_PT3_ -0?_P F_P#["BB@ _X:)_Z@_P#Y-_\
MV%'_  T3_P!0?_R;_P#L*** #_AHG_J#_P#DW_\ 84?\-$_]0?\ \F__ +"B
MB@ _X:)_Z@__ )-__84?\-$_]0?_ ,F__L*** #_ (:)_P"H/_Y-_P#V%'_#
M1/\ U!__ ";_ /L*** #_AHG_J#_ /DW_P#84?\ #1/_ %!__)O_ .PHHH /
M^&B?^H/_ .3?_P!A1_PT3_U!_P#R;_\ L*** #_AHG_J#_\ DW_]A1_PT3_U
M!_\ R;_^PHHH /\ AHG_ *@__DW_ /84?\-$_P#4'_\ )O\ ^PHHH /^&B?^
MH/\ ^3?_ -A1_P -$_\ 4'_\F_\ ["BB@ _X:)_Z@_\ Y-__ &%'_#1/_4'_
M /)O_P"PHHH /^&B?^H/_P"3?_V%'_#1/_4'_P#)O_["BB@ _P"&B?\ J#_^
M3?\ ]A1_PT3_ -0?_P F_P#["BB@ _X:)_Z@_P#Y-_\ V%'_  T3_P!0?_R;
M_P#L*** #_AHG_J#_P#DW_\ 84?\-$_]0?\ \F__ +"BB@ _X:)_Z@__ )-_
M_84?\-$_]0?_ ,F__L*** #_ (:)_P"H/_Y-_P#V%'_#1/\ U!__ ";_ /L*
M** #_AHG_J#_ /DW_P#84?\ #1/_ %!__)O_ .PHHH /^&B?^H/_ .3?_P!A
M1_PT3_U!_P#R;_\ L*** #_AHG_J#_\ DW_]A1_PT3_U!_\ R;_^PHHH /\
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M_P#84?\ #1/_ %!__)O_ .PHHH /^&B?^H/_ .3?_P!A1_PT3_U!_P#R;_\
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M_)O_ .PHHH /^&B?^H/_ .3?_P!A1_PT3_U!_P#R;_\ L*** #_AHG_J#_\
MDW_]A1_PT3_U!_\ R;_^PHHH /\ AHG_ *@__DW_ /84?\-$_P#4'_\ )O\
M^PHHH /^&B?^H/\ ^3?_ -A1_P -$_\ 4'_\F_\ ["BB@ _X:)_Z@_\ Y-__
M &%'_#1/_4'_ /)O_P"PHHH /^&B?^H/_P"3?_V%'_#1/_4'_P#)O_["BB@
M_P"&B?\ J#_^3?\ ]A1_PT3_ -0?_P F_P#["BB@ _X:)_Z@_P#Y-_\ V%'_
M  T3_P!0?_R;_P#L*** #_AHG_J#_P#DW_\ 84?\-$_]0?\ \F__ +"BB@ _
MX:)_Z@__ )-__84?\-$_]0?_ ,F__L*** #_ (:)_P"H/_Y-_P#V%<7XJUAO
:&?B&YU%85M_/*CRR^[;M15ZX'IZ444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>irtc-20211231_g2.jpg
<TEXT>
begin 644 irtc-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH@JI$R'8S;E4AO@C]@:UF^&NK_LQ_%7Q4SP_#7PW\0-=T75+Z\^2W\/7MPD
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MD>.]4\</J7CSQ*+EKAIIKY8K.*.19U4LRM.VP;ALQ(Y/I7PX^ '@?1?VAO\
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M"[[G9=BH-O/_ &9%P4XSO=72MKU\_+I=];&OUUJ7+*.SLW?3IY>?6W8_1O\
M;#_;%\*_L2_#&P\4>*K;6=0BU?6+;0=.L=*ACDN[^\N-Q2-/-DCC7Y8Y&+/(
MH 0\DX![WX>^*K[QGX5M]0U+PUK7A&\F9P^F:M+:274 #$ LUI//#A@ PVR,
M<$9P<@?GO_P<4_#SP_JO@KX*:Q=:'H]SK%Q\0+#2);Z6RC>YELFCN':V:0C<
M82WS&,G:3SC-<G^RI^S;\-_VE?VWOVP-(^)'ASPR=)^'MM!X6\,:7-IT"6?A
M31V^VEIK& *$MR"B2B2$*RO-(^=TI)<,#3EA56;:W;TOU2LM5W"6*FJ[IV[6
M^YOMY'ZG45^ O[($-_\ M@_$G]COPC\1+C4-8\/S'6]%>&>=\:IIEE(+F&UE
M.09(%DA6/:<@+$J_PC'Z??\ !7[Q1JO[*W_!+CQHWPNLX_"@TV&TTVW_ +$@
M%FNC6DMU''*T"P[1%\KE05QMWY&",TL1E?LJT*'->4G;;1:M=_+L.CC>>G*K
M;1?Y7/ISXL_$BQ^#GPK\3>+]4ANI]-\*Z5=:Q=Q6JJT\D-O"\SK&&95+E4(
M+ 9QDCK67^SI\==(_:;^!_AGQ]H-OJ5IH_BJR6_M(;^-([F-&R )%1W4-QV8
MCWKX&^)G[%/P(^!'[(FC^+/#/BB'X=^-KKX-ZO:6FG:;J]I9_P#"PX9=)>:;
M[5;RJTEZ0S^9N0AD/EG.(X]GSA<?"#P_^SW_ ,$FOV8_B_X9T]+#XGWWQ"L)
MKGQ/&Q&J31,;V+[,9B2?LZPV\$0A_P!7M0_+EW+:4\MI3A[LG=RLG;R?GY;Z
M^A$L9.,M4K6OOZ>7GL?MY17X\_%[2/!O[4?@7]K[QQH?P_;XA:?X=2_MV^(?
MQ&\9BWOM)N[6.:>.WT*U@L7:&&&4HT<32P^<)(XW;#,BY_[/NE1_ME_MQ_LE
MP_$Z2Z\86VN?!H3ZS!J$[R1Z\;2^OY(!>C/^DJ);>"5EEW+(\2EPW.9_LGW'
M.4K6WT7:_?\ .P_K_O**6^VOG;M^5S]EJY>]^.'@O3?BA:>![CQ?X7M_&FH1
M&>U\/R:K NJ7,81W+I;%O-90D<C9"D81CT!K\5_COJ&I>#?@9^T3\-/#FK3:
M;X3TWX_66CZ3X1@NYK6WU:UNFOS)H\#1@I;Q.T:2D.8XP+=N2Y56[C]L+]GS
MXE_LB^%?VE/B_P"!?A[)\"? /B3P[I/AFST6WO;)KYFDO+-)KY4L)IHK5=BS
MQ%5EY-SOY8DC2.3QNHRGK+1=/Y;=;_:Z)[;DO,)6NH[;_C_EU^X_9BBOR1U[
M]C2^^&GA+]GGQMX9U7]GC]FEM)TR**?Q4/'LT-]XML;BUA,[2(^GVRS7 CW2
MC=,^"^-P4!AQ_@7P+HO["_PZ^&/B/XN>#Y(K'P_XE&I:1^T#\(?$EEJDWB.Z
MNY)':WO_ #XQ/-9F-YXY7<,'$/EHC"1M^:RN+7NSN^UE?KYV>RT3;UVT*>.:
M?O1T[W]/+\[+SU/V>HHHKQST HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L/XB?$[PW\(?"\VN>+/$.A^%]%MW6.74
M-7OXK&UC9CM4-+*RJ"20 ">37S1_P5I_;$\7_LP_#WP#X>^'MQ:Z;XW^*WBF
MV\,:?JMU:I=1:.DA >X$;_(\@9X@JN"N&8GH ?F+_@M+\-_CA\-?V,/B7#XP
M^(.D?$;X7WDNB/I-SJ%G!8^(M/OEN81*C):6L-M);N?-8$GS%_=KSAF;T<+E
M[JN'-))2=EW>J3MI;KWZ')7Q7(I<JNXKY;7/TLT+XR>$/%/CF\\+Z9XJ\-ZE
MXFTZUCOKO2;74X9KZUMY C),\*L76-EDC(8@ AU(/(KI*_+;XN?M_?%SX9?$
M3]I#P_H?BS[#H_PQ^%^AZSX:M_[+LI/[-NYH--,DFYX2TF?.E^64NHW< 8&.
MJLOVL_CA\'-+_9'\;>)/B.OBZV_:$US3['6O#[:%86NFZ;;ZFD#VXMGBA6Y$
MD*S?,TD[J[ ?*!P;EE=2R::UVU>ON\W;M_PY$<=&[33T_P [=S[]^'WQ=\)_
M%J/46\*^*/#OB9='NFL;\Z3J4-Z+*X7[T,OELVR0=U;!'I7 _M;_ +$WA/\
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M5X"/A>\L+J#3KJ8S6I^QVGGV\WE9!V2!0R@.2K,WOO\ P00_Y1-?"C_N+_\
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MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  3XRNM/C66ZAT/7+74)+9&. SK"[%03P"< FJ_PR_:N^%OQK\1-H_@WXE>
M?%NK1PM<M9:+XAM+^X6)2 TACBD9MH+*"V, L/44>UQ*35Y>>_:VORT] Y*+
ML[+RV_K<\>N/^"-?[.=]X9TG1KKP)J5]I/A\,-)M+OQ;K5Q#I :43/\ 95>[
M(M]\@#-Y6W>?O9KM_'__  3X^$WQ+^)'B3Q=J7A[4[?7O&5B-,U^?2_$>IZ5
M'K=L(S%Y5U#:W$<4XV':?,5B1C/05F?\$\OVW_\ AO3X2^(_%'_",?\ "*?\
M(_XGO/#?V;^T?MWG_9TA?SM_E1[=WFXV8.-OWCGCM?%'[8/PD\$:M)8:U\4O
MASH]]%>R:<]M>^)+.WF2ZCV&2 J\@(E3S8]R8W+YB9 W#.E2IBU4<)2ES+S;
MWU9$8X=P4DE9^2.1U#_@FM\%]0\)> ]%7PC=6-M\,1*/"]SI^O:E8ZAHXE8L
MXCO(;A+@@L2<-(1FH)/^"8?P,F^%B^"Y/ JR:!_PD0\62(^KW[75UJH#@74U
MT9_M$SXD<8DD9>>G KT73?VE?ASK/Q0D\#V?C_P3=>-(I)(G\/PZY:R:HCQH
M7=3;!_-!5 6(VY !)X%5_$?[5WPM\'?$;_A#]7^)7@'2_%WG0VW]B7GB&T@U
M+S9@C0Q_9VD$FZ0.A5=N6#KC.14>VQ6R<N^[^_\ X)7LZ.]EVZ?<9_Q._8V^
M&?QH^*]KXV\5^$['7O$5GHT_A^.:\FFD@:PFW^; ]OO\B0-YC\NA89X(P,<G
M\.O^"97P5^%NM^$;[2_"NI7#> 9'G\-6VJ^)=5U:QT*1^3);6MW<RP1/N 8,
MJ AE5@0P!'?^/OVH_AE\*M2OK/Q1\1? GAN\TUH5O(-5U^TLY+0S*SPB19)%
M*&14=EW8W!&(R :T+WX[^!]-^%B^.KCQEX4M_!+1I*/$,FK6ZZ44>01(WVDO
MY6&D94!W8+$ <G%)5,0HI)RMMUMZ?C^)7+2;NTK_ ",C]H;]E7P#^U9I.AV/
MC[0?[>M?#>J1ZUIR?;;BU^SW<894DS#(A; 9OE8E3GD5R_Q8_P"">OPE^-7Q
M*UOQAKGA[5(_$?B;2AHFLWFD^)-4T=M8L@NWR+E;.XB2="H"D2!LJJJ<A5 [
M[X>?'KP+\7?#%]KGA/QIX3\4:+I;M'>7^DZO;WMK:,J!V622-V5"$(8AB, @
M]*\_M/\ @HW\$=<^(VA^$=!^(FB^,O$7B(L+.S\*)-XB90I4,\S6*3+;H-X)
M>8HH 9LX5B"F\2M(<VG:^G5^FUPE[%ZRMKZ:E[2?V#?A+H/C#X=Z]8>#;6QU
M/X3V4FG^%7MKNYACTJ&1661?+601RE@[$M*KL68L3N.:]*\;>"=(^)/A'4M
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M7EQ+#$& P=B XJGH7_!*KX#^'8M,MK?P7=R:/HVKG7K'0[GQ'JEUH=K?'?\
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M_P#'OC?YJ_?SMXP>]^+W_!+W2_C7^T#\+?&&M^)O/T7X?^#]0\'7^B?V8?\
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M=)^%7A?0?'VJ^*['PWH%EXHUV..'4M8@T^*/4-02-56-)IU422*JH@ 9B %
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%;#0GDM?$6CP1:4;J""]FB:Q^T%;>91;RL3(R;#&Z.P/Z(5QOBG]HGX?^!_
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M@9Y9@!R15VI_UKJ>S2=)-)**;Z*,>5).W->UN;WN5MWY%)IH^KJ^_P#7]?\
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M "!/>32RA?E&$#;0<D $G,/P@^#/AKX#>#O^$?\ ">F_V5I!O+F_\C[1+/\
MO[F9YYGW2,S?-)([8S@9P   *TK8R,Z4H6=VT_+K_P !;O;[YIX>49J5^EOR
M/DWX ^(/B9I?BS]J"+P?X1\"Z[HS?$K46N+K6?%MUI-U%+_8^F!E6&+3;E74
M($(8RJ268;0%#-S/[!GCKQA\0OA'^SW\)_#_ (LO_A_I4/PIA\7ZCJVEV5G<
MZGJ!$ZVD=I";R&>".)2YDE;R6<GR55D#-N^V/!OP9\-?#]O%1TC3?LG_  FV
MJ2ZUK7^D2R?;;N2"*!Y/F8[,Q01+M3:HVY !))XN\_87^&-SX+\&:#!H>I:3
M:_#VU:R\.W.DZ_J.F:EI=NR;'A2]MYTN3&R@;D:4JQ52P)52*^N4FFG'MTOM
M%K9NQ/U>:LT^_ENT^B/#OV>?VR/'OQ-^(WP-T?5M2M<:MJGC3P_XCDM;*-(-
M?DT9O(@NT!#-#O9#(5C8+N9ARH ')']K'XL^/AH6E:+XYATNY\1_'KQ+X#&H
MC2;.X-MHUO'?^0L:F/8TD2PQO'(P8LZ)YGF(71OJSQ!^QS\.?$'@7PKX='AY
M](TWP/(TOA]M#U*[T:\TAFB>*0PW5I+%.GF))(),2?O-Y+[CS4/A']B?X7^
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M7GPXT:[U'4]5NVN[_5;HWES&UQ-(<#<5C0!45(T5%2-$1519OB3\'M-\ ?\
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M?H#7R^8\'YW@$Y8K"SBEUY6U]ZNOQ.B&(I2^&2/H3_A+_P#IW_\ (G_UJ/\
MA+_^G?\ \B?_ %JQ$=9$#*0RL,@@\$4M?-FQM?\ "7_]._\ Y$_^M1_PE_\
MT[_^1/\ ZU8M% &U_P )?_T[_P#D3_ZU'_"7_P#3O_Y$_P#K5BT4 ;7_  E_
M_3O_ .1/_K4?\)?_ -.__D3_ .M6+10!M?\ "7_]._\ Y$_^M1_PE_\ T[_^
M1/\ ZU8M% &U_P )?_T[_P#D3_ZU'_"7_P#3O_Y$_P#K5BT4 ;7_  E__3O_
M .1/_K4?\)?_ -.__D3_ .M6+10!M?\ "7_]._\ Y$_^M1_PE_\ T[_^1/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6+XO\ ^7?_ (%_2MJL7Q?_ ,N__ OZ4 8M%%% !1110 44
M44 %%%.1&E<*JEF;H .M #:DM[62[?;&C.?85JZ;X7W8:X./]@?U-;,,"6T>
MV-55?0"@#%L_"C-\TTFW_97K^=:=MH]O:?=B7/JW)JS10 4444 %>=?M?_\
M)I?Q1_[%'5O_ $CEKT6O.OVO_P#DTOXH_P#8HZM_Z1RUVY;_ +W2_P 4?S1,
M_A9_+%#_ *I?H*=38?\ 5+]!3J_T#/D0H!Q110![%\ /V_/B_P#LR3P_\(?X
MZURQLH2/^)?/-]JL6 [>1+N09]0 ?>OT _9<_P"#C6UO9+?3?BYX3^QLV$;6
MM !:,?[4ELY+ =R4<GT2OR=HKY//>!\ES=-XR@N9_:C[LOO6_P [KR.BEBJM
M/X6?T\?!']HCP1^TAX476O _B;2O$FG\;VM)LR0$\A98SAXV_P!EU!]J[2OY
M>?A-\9O%7P*\86^O^#]?U3P[K%L?DN;*<QL1_=8=&4]U8%3W!K]3?V$/^#@+
M3O%DMGX9^-=O!H]\^(HO$ME$1:3'H/M,0YC)[NF4YY5 ,U^ <6>#N88!/$96
MW7IKI;WTO1:2^6O]T];#YC"?NST?X'Z<T55T/7;'Q/H]KJ&FWEKJ&GWL:S6]
MS;2K+#.C#(964D,I'0@XJU7XW*+3L]ST@HHHI %%%% !1110 4444 %%%% !
M1110 4444 %%%% !15?5-5M=#TVXO+VXM[.SM8VEFGGD$<<**,EF8X"@#DD\
M"OSD_;J_X+^^'_AO+>>'/@[;6OBK6(\Q2:_=*?[-MFZ'R4X:<C^\=J="-XKW
MN'^&<QSJO[#+Z;D^KVC'S;V7YOHF95JT*:O-GZ _%#XN^%_@IX4FUSQ=K^D^
M'=)@^]<W]PL*$_W5R<LQ[*N2>PK\_OVGO^#BGP=X,EN-.^%OANZ\77:95=4U
M/=9V /\ >2/_ %L@]F\NORJ^.7[17C;]I/QA)KOCCQ)JGB+4GSM:ZES' IYV
MQ1C"1K_LH /:N+K^AN'/!7+L,E5S:3K3_E5XP7_MTO6Z7D>/6S*<M*>GYGT=
M\?O^"L?QV_:(DFCU/QQJ&BZ;-Q_9VA'^SK<#^Z3'B1Q[.[5\ZW=[-?W$DT\L
MDTLK;G=V+,Y]23U-1T5^O8#+,'@:?LL'2C3CVBDORW/.E4E)WD[A1117<2%%
M%% !1110!-8:E<:5=QW%K/-;SPMNCDB<JR'U!'(-?27P _X*Z_'G]GJ2"*R\
M;7GB'2X<#^S_ ! /[1A91_"'<^:H]D=:^9Z*X,PRO!XZG[+&THU(]I)/[K[?
M(N%24'>+L?LI^S!_P<1>!?'LEOIWQ.T"\\%7TF$.I6.Z^TYCZLH'FQCV DQW
M-??7PY^*'ASXO^%K?7/"VN:7X@TBZ&8[NPN5GB)],J3AAW!P1W%?RXUWGP"_
M:<\>?LO^+DUOP+XFU+P_>Y'FK!)F"Z _AEB;*2+[,"*_(.(_!3+\2G5RB;HS
M_E=Y0?YRC]\O0]&CF<UI4U_,_IPHK\Z_V%/^"^?A?XNS6?AOXM6]IX-\028B
MCUF$G^R;MNG[P'+6['U)9.I+)P*_1"RO8=2LXKBWFCN+>=!)%+&P9)%(R&!'
M!!'.17\\Y]PWF.35_J^84W%]'O&7FFM'^:ZI'KTJT*BO!DE%%%>&:A1110 4
M444 %:GA/_D(O_US/\Q676IX3_Y"+_\ 7,_S% '04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXUVJ/UJ2@ HHHH **** "BBB@ KSK]K_ /Y-+^*/_8HZM_Z1RUZ+7G7[7_\
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M@Z^$KRPV)BXSB[-/=,]^,E)<T=@HHHKE*"BBB@ HHHH **** "BBB@ HHHH
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MHHK\U.T**** "M3PG_R$7_ZYG^8K+K4\)_\ (1?_ *YG^8H Z"BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH *Q?%__ "[_ / OZ5M5B^+_ /EW_P"!?TH
MQ:*** "BBG11--(JJ-S,< 4 3:=I[ZC<B->!U9O[HKJ+6U2S@6.-<*OZU%I>
MG+IMJ$'+'ECZFK- !1110 4444 %%%% !1110 5YU^U__P FE_%'_L4=6_\
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M]",@@G^8NOL#_@D%_P %#)OV+_C@FCZ]=M_PKSQ=,D&J*[';ILQ^6.\4=MO
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MS_,4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB=]6%%%%6 4444 %%%% !FOV>_X((_MUM\8_A1/\)_$=]YOB/P7!YNDR2O\
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M1N;NUUPW>R_^RO=(8T-O&7A,:H"[%&#28", 6HY)![2.QZO]CUS_ *".D_\
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M7Y_4J2G)SF[M[M[G0%?>W_!.KXJGQM\')-#N)?,O/#4WE+D_,8),LGY$.OL
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M8I)%(I5XV'4%3R#[&F5]R<H4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '[-_P#!O'^T^WQ$_9^USX;:C<-)J'@6Y%S8!VRS
M6-PS-M'KLF#Y]!*@K]$:_GS_ ."/'Q_;]G_]O7P;/-/Y.F>*)3X>OLMA66Y(
M6//TF$+?\!-?T&5_'_BYD:R_/I5J:M"LN=>KTE^*YO\ MX^BR^KSTK/IH%:G
MA/\ Y"+_ /7,_P Q676IX3_Y"+_]<S_,5^7G<=!1110 4444 %%%% !1110
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MX-TOQ5;ZQ!I4T=U;3I=1P_;[DV8N$B$*W!MC)Y!G$:JOFE#)P#NR,UPNA_\
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M#URXUBYUE-0LWMGE@>XMX;>:%4FADB,3+!$<.C,&4$,.E=M]CUS_ *".D_\
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M-3/7:V,_I3O^%W^$O^@]I_\ WW_]:LI7;N:QLE:YU5%<K_PN_P )?]![3_\
MOO\ ^M6SX;\6Z;XPM))]+O(;Z&)_+=XCD*V <'\"#^-39E\R-&BBB@84444
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MN5-O,6J_MC_#G1(+=[K7KB-KB"YN/*_LJ\:>!+9]EP98Q$7A,1!WB0*4 +,
MH)!RR[!SQ[GIU%1V=Y#J-I%<6\L<]O.@DCDC8,DBD9# C@@CD$5)4E!1110
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M]Y_@>Q1T@@HHHKSC0YVV^&.FKXSEU^Z^T:EJ>?\ 1GNW\Q=/7 &V!,!8\]V
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M $.S+E>NOF?H%6IX3_Y"+_\ 7,_S%9=:GA/_ )"+_P#7,_S%?QZ?1'04444
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M-X?T>:6VOO$,5HDFGVLL=OY\BNJN;@*J<&3R?+#?+OSQ5<LD0IQ9VGV/7/\
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M]'V/7/\ H(Z3_P""Z3_X_6M14E&3]CUS_H(Z3_X+I/\ X_1]CUS_ *".D_\
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M[*YI3J.3L>R4445D;!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8OB_P#Y=_\ @7]*VJQ?%_\ R[_\
M"_I0!BT444 =9I5U]LL(Y.^,'ZBK%8?A2]VN\#?Q?,OU[UN4 %%%% !1110!
MR?B_XTZ/X(UIK"]L_%DTZJKEM/\ "VIZA#@],2V]N\9/J V1WQ6?H'[3/@GQ
M'X"U_P 30ZO-;Z)X7N);35+B^T^YL3:318\R(I-&CEP2%VJI.XA<;N*R?VQ/
MB=J/PS^"-V-#9E\3>)+J#P_HI0'<MW=/Y:N,$89%+N#ZH*\__: ^%VG?!_X.
M?!CP7I\2R:#;>.]$L;Q'7*WBF221FE'(/F7&UV!R"S5I&*:,Y2:;/7O!W[07
MA?QQXP'A^UN-5L]::V-Y'9:KHM[I4T\*G:SQK=11F0 GG9G'?%6/ GQP\,?$
MO7+S3M%U*2ZNK-&E^>TG@CNHUD,;2V\DB*EQ$'&TR0ET!*Y/S+GS;]L +8_%
M#X'W]H\D>M1^-4M(C&3N-I-;3"Z'^Z56//M7 ?$#PYXF^$.D^&]'O-2TZS/@
MGPK?:98WVC2RS7RZ/$D)NM2G1HU6"58+2&&.-'<-<76=ZK&::@FB74:9]/\
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MC/;XQJ.T=%\M_P 3U,/#EAZA6IX3_P"0B_\ US/\Q676IX3_ .0B_P#US/\
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MQEX@\ Z7X/U;Q[9^%?!NKV?A/44/BNW:Y-LTJP?;93"+F4A()F<K'L9Y$92
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M.<^M5_\ A,/ /_00\*?]_(*W]IY',Z2ON?&/V63_ )YR?]\FC[+)_P \Y/\
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MT[EV+,<LQR2>] "4444 %%%% !1110 4444 %%%% !71Z!JWVV#RW/[V,?\
M?0]:YRG03M;3+(AVLIR#0!V5%5=*U1=3@W#Y9%^\OI5J@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJIJ^JKID']Z1ONK_ %H J>*-
M01;1[7:LGGJ5=6&Y=IZ@CWK!ITLK3R,['<S'))IM !1110 5J>$_^0B__7,_
MS%9=:GA/_D(O_P!<S_,4 =!1110 4444 %%%% !1110 4444 %%%% !1110
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MW,XU34+O2=)O&\)P^#H_$UOJK6<-PV7E9,F+[7$S)\ICVC:V]2<^7ACU=O\
ML<Z;97#7UOXO\;6^O2:I=:M)K"SV;7CRW-M#;3* UN8E1D@C("1J4(^0JN%%
M2Y_85\,R>%K?1H=<\56FGQZ"_AN=(YK9FO+0RO,OF,\#-O220L&0KG #;AD&
MER"?M#;U?]J[0]%UZZMYM)\0G2;74I=%_MI8H/L,E]'$TC6ZCS?.W91DWF(1
MEQMW]";7P5_:7TGXW7L=O:Z1XBT6:ZTFWURT35;5(OMME,S(LJ;)' PR$%7V
ML058 JP8UM6_93T/6==O)YM6\0?V5=ZE+K7]C++!]ABOY(V1KE3Y7G;LNS[#
M*8P[;MG QL> /@)H_P .=<T?4+&YU*6;1/#5OX6@6>1&5[6%@RNV$!,I(Y((
M7_9%3[MBESWU.WHHHK,T"BBB@ HHHH **** "BBB@#XC^-+$?%GQ%R?^0C/_
M .C&KF-[>IKI_C3_ ,E9\1?]A&?_ -&-7+UV+8X);B[V]31O;U-)10(7>WJ:
M-[>II*X_XX^&]0\4_#Z^M[/6[S0X%AEDO'LU N;B(1/^Z24_ZG+;<NH+;00I
M1B'7;#4HU:L:<I<J;WU=ON!['8[V]31O;U-?/?P:T?P>_P"P?X.UKQGH.AZY
MIOAOPX+[;J5E%<B(+'N;9YBD!FV@<=3@54\%?LX?V!\"=-N4\)Z??77B+6(/
M$7B3PY8PP6]O=PLK;+*.*4QP[(-T+;)" Q@8DEFY^@ED="$JD*M9Q<:CIZQ2
M3:;NTW-6LE=WT3<4W9\RS]H^B/H_>WJ:57.[J:^6O@W\0?[&UC16U_2]8N]-
M\$VS6MJUMY=Q:Z*99W@:ZED9UWHBEK-#")2!:W38","?J1/O5Y^<93/ 553D
M^;?7IOZOHXMWM:_56;J$N97/OS2_^0;;_P#7)?Y"IZ@TS_D&V_\ UR7^0J>O
MG3T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K%\7_P#+O_P+^E;58OB__EW_ .!?TH Q:*** "BBB@ J:QOI-/G$
MD9^H[,*AHH ZS3]1CU&'<GWOXE[K5BN/MKF2TE$D;%6%=!I>OQWP"OB.7T[-
M]* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH+;1D\"@ JAK&MKI
MR;5PTQZ#^[]:K:MXE"@QVYW'H7]/I6(S%V+,<D]2>] "RRM-(S,Q9F.23WIM
M%% !1110 4444 %%%% !1110 4444 %%%% $EK=26<RR1MM9?UKIM+U:/4HN
M/ED'WE]*Y6G13-!(&1BK+T(H [*BLO2O$:76(YL1R=C_  M6I0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%&:R]5\1K;YC@P\G=OX5_QH L:KJ\>F
M1_WI&^ZO^-<W<W+W<S22-N9J;+*TTA9F+,W))[TV@ HHHH **** "M3PG_R$
M7_ZYG^8K+K4\)_\ (1?_ *YG^8H Z"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y_Q_P#%#1?AE!9MJT]T)-2F-O:6UG8S
MWUU=.$9V$<$"/*^U%9B0I"@9.!705Q?Q5^%U]XTU[PYKFBZM:Z/KOAF:=[:2
M\L&OK66.>(Q2))$LL3'C:P*R+@KSD$BG&U]12O;0YOP[^U;IWCOXX:-X3\.V
M,NJ:?J6D?VQ-J[17<444;;PBH/LYC8EEVL9)8@C!D^:13'6I<_M"6]O^T3;^
M _[-FDAFMBIU59?W<=]Y37 LRFW[WV93+N#< J,<DBE\&_V:(OA!XOM=6CUF
M74##H7]DRI);!&FF:]FO)9\AL*&DG8"/!V@#YC6?JO[(]OJMTNM-X@U9?%\?
MB!?$*W_VN\:P,J2_(AL#<>3M%J%M=PP^Q<[@:OW+F?OV(_$G[='@.S^&WB+7
M]%OKK7I-#T>75XK5-.O(1?HI,8*.T)!C$P$4DBAEA8GS-N"*W5_:B\-6MSJG
MVV:XMX[&>SMH;==-U!]2GEN83*D9LS;"42%59@B"0[5+-LP0.0A_8CB_X5U:
M^'9_$;30V_@W5/"1E%CLW&\FAE%SCS>/+,6-F3NW?>'0WI_V7->G\<77C#_A
M+=+C\72:A::A!<)H3_88FBLY;.1&MS=%V22*9NDJLK $,1D%V@*]0Z9OVK/
M0:SVZY)-%>103&>'3[J6WLEGD,<7VJ58REJ6=67%PT9!5@0"#C1?]H#PC#XA
MO=-EU;[/-81W$DD\UK-%9R?9P3<+%<L@@F>'#"1(W9HS'(& *,!PVO\ [*6L
M^)!K$-WXU6YM?&%K9V_B=I=&7[1>FW+9-JZ2JEL'1MF'CF(55.2VYFY/Q/\
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M?:"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** /B/XT_\ )6?$7_81G_\
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M3U!IG_(-M_\ KDO\A4]>6>B%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8OB__EW_ .!?TK:K%\7_ /+O_P "_I0!
MBT444 %%%% !1110 4444 :6G>(Y;3"R?O8__'A6W9ZE#?K^[<$]U/4?A7)4
MJL4;*DJ1T(H [.BN<L_$MQ;\/B9?]KK^=:=MXEMY_O;HF_VAQ^= &A13(KB.
M<9C=6^AS3Z "BBB@ HHHH ***BGOH;4?O)$7V)YH EHK+NO%4,?^K5I#Z]!6
M7>:[<7G!;8O]U>* -R_UN"P&"V^3^ZO]:P]1UJ;43ACMC_N#^M4Z* "BBB@
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M 'U;U\J?&B1E^+'B+#,/^)C/T/\ TT:N8\YO[S?G6_L_,YG6UV/M+^T/ /\
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M#'G-_>;\Z/.;^\WYT>R0>W?8^Y_^%E>'?^@]HW_@;'_C1_PLKP[_ -![1O\
MP-C_ ,:^&/.;^\WYT><W]YOSH]D@]N^Q]S_\+*\._P#0>T;_ ,#8_P#&C_A9
M7AW_ *#VC?\ @;'_ (U\,><W]YOSH\YO[S?G1[)![=]C[G_X65X=_P"@]HW_
M (&Q_P"-'_"RO#O_ $'M&_\  V/_ !KX8\YO[S?G1YS?WF_.CV2#V[['W/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ H#;3Q110!8BU6XA^[-)^)S4Z>)+M/XU;ZJ*H44 :0\57(_AA_[Y/\
MC0?%-R?X8A_P$_XUFT4 7G\27;_\M%7Z**AEU2XF^]-(?;.*KT4 !.31110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV#[GPQY;?W6_*CRV_NM^5?<__"M/#G_0OZ)_X Q?_$T?\*T\.?\ 0OZ)_P"
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M,5:)#14W]FW'_/O-_P!\&C^S;C_GWF_[X-<91#14W]FW'_/O-_WP:/[-N/\
MGWF_[X- $-%3?V;<?\^\W_?!H_LVX_Y]YO\ O@T 0T5-_9MQ_P ^\W_?!H_L
MVX_Y]YO^^#0!#14W]FW'_/O-_P!\&C^S;C_GWF_[X- $-%3?V;<?\^\W_?!H
M_LVX_P"?>;_O@T 0T5-_9MQ_S[S?]\&C^S;C_GWF_P"^#0!\<_M2?\$4OA7^
MUQ\=M=^(7B37_B!8ZUX@^S_:(=-OK2.U3R;>*W78LEJ[#*1*3ECR3T& //\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>irtc-20211231_g3.jpg
<TEXT>
begin 644 irtc-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#SS]IG]E/P#^V)\.H_"?Q'T'_ (2+P_#>QZ@EK]MN+/$Z*ZJ^^"2-^!(X
MQNP<].!7YT?&'_@DG^S[\9OVL]+^#_PE^'_]D1^$Y8-7^(_B:+7=2NAH]JV6
MATN$37#Q_:[D DDJ?+C!;!/ ^RO^"J'[;S?L%_LIW'BJT6%==UW48O#NBSW,
M;26MC=SQRN+F=5#,T<4<,LA558L45<?-7SO^QK_P5#_8Y_9$^#4'A^W^,,NL
MZ]J$[ZIXCUVX\,:RUUKVI3'=/<R,;3/+<*#]U0H]2?:P/UN%%U*/,ULDKVOU
M;2TTZ=WZ'G8KZO*IR5+>;=K^BO\ U;U/>/ ?Q*\#V7_!3[XM:?\ \(?'H_BC
M1?!6G7^K^+Y-;F=+ZSSE86M&'E0B+&3(IRV.:\YE_P""P7C#Q#X7U+X@>$?V
M;_'/BKX(Z5+*9/&,>KV]M<W5M"S++=6^G.GFRPKL8[@X "G<5((&/:>%_P#A
M>'_!3W]I71=*NEC_ .$P^#MA96=PRE57[3$R(Y!P0/G!]:X+]GS_ (*>>#_V
M;_V%;+X'^*?#/C>S^.'A/1)?"L?@N/0+BXN=6N@KPQ/#(BF)HG)0EBP/)VA^
M"VD<+&5FH<[M#2[T36KWO^B[$.LT[.7*KRULM7?1?UJS]&OA/\4M#^-WPTT/
MQ=X;O%U#0?$=E'?V-P 5\R*10PR#RK#H0>000>E?FE^UY+\*O&'_  4U\=:'
M^U[K7B+3O <-AIS?#C3I+N_M?#=]$T'^E2O);%2+A9N"Q95RK*68!!7VU_P3
M/^!&M_LS_L(?#/P3XD58]>T?2=U]"#N^S2S2O.T)/0M'YNPD9&4."1@UX_\
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M5F6^^$7PADGT/X?@@^1K>JL +W5@K?>6//DQ-C&1N4AE-5OV./VS?AG\#O\
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M''[0,/PI^+7PGUGX,^/M6L9-2T*UGU>#6K#788ANF$-W JH947YF3!P <D'
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M?3OB;X$T7Q)H\S7&D^(+"#4K*4KM,D$T:R1MCME6!Q7QG^R(NW_@@):X&/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%'U9=PYCKO[2M_\ GXA_[[%']I6__/Q#_P!]BN1HH^K+N',==_:5O_S\0_\
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MK'CG1/#OB/1]'U#6-+L=6\0O+'I5C<7<<5SJ;11F658(V(:4I&"[! =J@DX
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MO%%E\9M<M_'GC_QE^S3H6H:;HP^']W?^&+9_#^LWMWI[75Q'J=]=V4PBE@N
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M_P#N,K]$\*/^2JPO_;__ *;F<>8?P)?+\T?D?1117]F'S9^N'_!K)_S77_N
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M.9+=M0:[E1)45=DS0E3"_F[Q+M"(Y)!4@'*PYT>B4445)05\R?L8_P#-8_\
MLJVO_P#MM7TW7S)^QC_S6/\ [*MK_P#[;5T8?<SG\2/9Z***[ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'D+YL;X'.!QD]:]:K\1QF%J8:O/#5E:4&XOU3L_Q1Z49*2YD%%%%<Y04444
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M_P!IKE?V!- _X1/PK\4-+^W:AJ7]F_$O6K3[9?S>==7?EI:KYDKX&^1L;F;
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M604445)04444 %%%% !1110 4444 %?D?_P=-_\ -"O^X_\ ^XROUPK\C_\
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M5V5>-6HU*4N2K%Q?9JS_ !-$T]4%%%%9C"BBB@ HHHH **** "BBB@ HHHH
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M!X,I'(POCO\ '/6OB5^S=\;-!UE8[B3PWIVF75O=IX=OM :YCN96&TVMX[2
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MS-,_:DV7%QX?3XD:3=:;_;N8_&=]/I\,::7'#;O+AE1+9Y6N)&MHV6/#8E8
MF!S3]F]P]HKV9].44V&9;B%9(V62.0!E93E6!Z$&O(?BG^WQ\)?@KX\OO#/B
M;Q9_9NN:;Y?VFV_LR\F\OS(UE3YXXF0Y1U/!.,XZY%1&+>Q4I):L]@KYD_8Q
M_P":Q_\ 95M?_P#;:MK_ (>E_ C_ *'K_P HNH?_ !BN5_8$\4V'CGPK\4-;
MTN?[5I>L?$O6KZSFV,GG0RI:NC;6 895@<$ C/(!KIHQDGJC.4XN2LSW>BBB
MNHH**** "BBB@ HHHH **** "BBB@ HHHH **** "OD#X-6W_#?/[:%W\4KI
M5N/A?\';F?1/!"-AHM9U7 6\U/;R&2,_NXFY!*JZ[65A7T3^T?\ #'6/C5\#
M/$_A+0?$TG@[4O$5DU@FL)9_:WLHY"%E*Q[T^9HRZA@ZE2P8'*BN&^!OP"^)
M7P*\$>&/">E^,OA?'X5\-00626EMX"O8)Y8(\!L2G5V E<;B9&1LNQ8JQ)!^
MARNM0P^$JU544:TO<5U+W8M>\TU%J\E[BUT3E?=,QJ)N25M#Q#X<?M<_$?XG
M_#GX5^&8?$#6OBKXF^/->TF?7X[*U\_3=+TRXN99!!$T1@\XP0I$K21N "S%
M6;!'L7P8^(_BOP/^V#XF^$GB;Q%>>-+%O#5KXPT35[^WM;>_MXFG:TGM)A:P
MPPN!+&)$81JP$C!B_&W$T?\ X)X-X7^$_A/3-+\8);^+_ OBZ\\6:'KLNDF2
M"-KNZEEGM9[43J987AF>)MLT;$A7!7!4^@_!S]G/4/"'Q>\1?$3Q=X@L_%'C
M;7K*WT>.>PTQ],L-,TZ EUMX8'GN'!:9Y)7=I6R6  4 [O5S+&95.%7ZORV:
MG9*%I<SJ7C)/E]V*A96NMI+EUUB$:BM?RZ^7^9XI_P %9=<NO@+X?\)_&+P;
M>6]K\4/"\T^E:99?9VG;Q)8W$;-<VKQH-SK"L?VH%CM3R7_B<9[KP_X+\-^"
M/^";GB"/POKA\5:=JWA'5-7EU]_]=K]S=6\T\][*>N^61V8AN5R%_AQ7H<?P
M(?4_VEW^(FM:M'JBZ7I/]D>&M,%GY<>AB5@UY<%V=O,GG*1)O58]D483#;G9
MN3^%7['$OPE^#/Q$^'ECXF$G@[Q5)?\ _"/63:<0WA.&\C<26J-YN)H$D<O&
MNV,KN92S9!7".98;ZC1PSJ>]3E&3=G:2;;Y-K_N[MJ^C<IVO:-WR2YW+O_7X
M_P"7F;7["7_)D'P;_P"Q&T3_ -((*]6KE?@1\,O^%*? _P &^#?MW]I_\(CH
M=EHOVSR?)^U_9K=(?,V;FV;MF[;N;&<9/6NJKYS,*L:N*J5(:J4I->C;L;03
M44F%%%%<904444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2W$OD:!
MK,F_R]FG3MOW[-N%Z[MZ8QZ[TQ_>7J$I;B7R- UF3?Y>S3IVW[]FW"]=V],8
M]=Z8_O+U!U7JOS [.BBBO+- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BOS#_ ."G?[<7B?Q-\8M7\!^'=4O-%\-^'9?LEV+67RI-1N5_UA=U
M^;8K?*$S@E23DX"_-_P=_:0\:_ ?Q1#JWAGQ!J%E-$^^2!I6DMKD$Y*R1D[6
M!]QGN"#@UTQPS<;W.66*BI6L?N917(? +XMV_P =O@UX=\76L/V>/7+-;AH=
MV[R9.5D3/?:ZL,]\=JZ^N;;0ZD[JZ"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y?XX>-KKX:?!;QAXDL8[>:^\/Z)>ZE;
MI.I:)Y(8'D4.%()4E1D @X[CK745Q_[0WA:_\<_ 'QSHFEV_VK5-8\/W]C9P
M[U3SII;:1$7<Q"C+,!EB ,\D"G'<4MCSNV^-?CCP;JWPSF\07W@_6[#XB7,=
MG]BTW2;BPOK-I+9IA,I>ZG$L4>W$GRI@,ISVKNM'_:2\&Z]XCMM-M=4N&>^N
MY+"TNWTZZCTZ]N4WAH8;QHQ;RR QR#:DC$F-P 2IQYKHG[+W_"K?&7PS\0>$
MO">DZ3=1Z;+H'BQ-,BMK2;R9X(S]JW<*[Q3PKEE)=A(V-PXKD_@Q^R]X@\(V
M/@7PWJ7A/5IIO"&KQW=UK=]XON[C1)8H)&>.:TLDO 5N&RF%DMUC0ER=PP&U
M<8LR4IK3^NA[[IG[0O@W5_B#)X7M];ADUB.>6T"F&5;>6XB"F6VCN"HADG0,
M"T*.9%PV5&UL5O#7[3/@GQ=XIM='T_67FN=0EG@L9VL;B.QU&2$D2I;W31B"
M=E*ME8I&/RM_=./.?A9\(_&'@[PGHGPYNO#>DW&C^'=4N;L^*;J>*59;=Y9)
M8I;2('SHM0!GP6=1'&8W97DW*#C_  _^"7C:;P'\+/ 6H^&TT>W^&NL0:E>Z
M[]LMWLM1CM&D6(6T:.TYDG#JS>='$$Q)RQVAERQ#FEV_K^NIZ=9_M@?#O4-!
MU+5(=>FDTW2)A:W-RNEWGE+<%P@MU;RL23EF7$*;I"&5MNT@G%^'W[6VF^*?
M'/Q+_M"XMM+\)^!;;3YA<WME<6%W$TR3F59XIPKJ0T:A%\M6(88#;E-<3H?[
M._B[P[^S-X+M8=#AD\2>$?&TOBBXTG[3"K:G$+^[94$N[R_,,,T;J78 %%!*
MD<9_C_X ^.OC;+\7-2D\.7GAN3Q%)X?N]&L;S6(8Y-1.G22/)#,]K(_DE\#:
M5?Y6:-MP*L%?+#^O47-/3^NA[=%^T]X+.BZY?7&I7VG1^&[=;S4H-1TB\L;N
MV@;(67[/-$DS1D@@,J$$@C.0:Z+X??$72?BEX<75]#GGN]-E<I%</:36Z7 &
M/GC\Q5\R,Y^61,HW9C7SAX__ &<_$'COP1\2)M)\%ZYI=YJOA@Z'ID?B+Q3+
MJNK7TC2B5AO>^GMH8!A<#=O+;B2HX;Z<\*Z<='\,:;:-&L+6MK%"8UQMCVH!
M@8XXQCCBHDDEH7&4F]2_1114&@4444 %%%% !1110 5^1_\ P=-_\T*_[C__
M +C*_7"OR/\ ^#IO_FA7_<?_ /<97Z)X4?\ )587_M__ --S./,/X$OE^:/B
M7_@GSHL7QJUY?AO%X>^(4FMWE_\ VII7B?P=?RK=^&I?+\HS3VS.MN]L 1ND
MW0R*"P$I!"'L/VB_V>?B)X"\)>+H]1_:N^''C'3=(2XCGT>#XC75S>ZHD9(,
M0M&!5I&Q_JRQ&>,GK7SM\/\ XY?$+2/AW??#7PMK6LV^A^,+Y&N](TM-LNLS
M,HA2%S&OFS*P(40DE"3G;DYI/&7[+WQ"^'VB>(-2UGPAKEA8^$]0CTK69Y+<
ME-+NI%5DCF(SL+!EP3P2P&<D"OZAK9?4^ONK.M"$6U:+2DWJM4Y:QNVERQTO
MK=MGAJ:Y+),_33_@UD_YKK_W /\ W)U^N%?D?_P:R?\ -=?^X!_[DZ_7"OY>
M\5_^2JQ7_;G_ *;@>YE_\"/S_-A1117YV=AYS\<_@]?>.?$_@WQ5H9TR3Q'X
M%OI;FSMM2++9WL4\1AGB=T5GB;:0R2!7VL@RC G'!ZO^REXF^(=YXQ\3:UJ&
MB:-XRUB\TJ]T2/3WEN[+2)-,=I+9I'=8C.79W5R8U 5B%'>OH*BJ4VB7!,\N
M\)_#;Q7XJ^,FG^,?&T?AVR;P[ILUAH^G:3=S7B1RW!C-Q<O-)%"<LL2(L>PA
M06.XDUA7WP#\4#68/&?E^'-6\<-JT]U/:WM[+'IRV;6T]M!:I*(&?]RDH;=Y
M0WM)/D+YFY?;J*.9AR(P_AAX0?X??#3P[H,DRW4FAZ9;:>TRKM64Q1+&6 [9
MVYQ[UN445)6P5\R?L8_\UC_[*MK_ /[;5]-U\R?L8_\ -8_^RK:__P"VU=&'
MW,Y_$CV>BBBNP HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD%N7C^XT[LTDNWU'F.V#W'I7?T45S-W=V=:5E9!1112&%%%% !1110 4444
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M?\^\W_?!HYD!#14W]FW'_/O-_P!\&C^S;C_GWF_[X-',@(:*F_LVX_Y]YO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<<:JB(JJJ(H '3))/3444!L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "LWQI/]F\':M)YGD^79S-O\
MSR]F$)SN\R/;CU\Q,?WU^\-*LWQI/]F\':M)YGD^79S-O\SR]F$)SN\R/;CU
M\Q,?WU^\-*7QKU TJ***S **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_(_\ X.F_^:%?]Q__ -QE?KA7Y'_\'3?_ #0K_N/_ /N,K]$\*/\ DJL+
M_P!O_P#IN9QYA_ E\OS1\&_L\?M;^!_AQ\ [[X?>/OA.OQ)TJX\0?\)#;/\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LWQI/\
M9O!VK2>9Y/EV<S;_ #/+V80G.[S(]N/7S$Q_?7[PTJS?&D_V;P=JTGF>3Y=G
M,V_S/+V80G.[S(]N/7S$Q_?7[PTI?&O4#2HHHK, HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y'_\
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MZ!HHHJ#0*Q_B'XVM?AIX USQ)?1W$UCX?T^XU*X2!0TKQPQM(P0,0"Q"G )
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M]4AMI="O_P#1D(8127:B(&UC9U^].8P5^;.WYJ\U^(O[/7C+XFMXF\1/X?\
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MUU_[@'_N3K]<*_C/Q7_Y*K%?]N?^FX'TF7_P(_/\V%%%%?G9V!1110 4444
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MV433W%Q.X2.%%&69F/   SDT_4]3M]%TZXO+RXAM;2UC::::9PD<**,LS,>
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M?T11)):!%MZA1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?G7_P %]/V$_BK^VM_PJ?\ X5EX5_X2;_A&?[7_ +2_XF5G9_9O/^P^5_Q\
M2Q[MWDR?=SC;SC(S^BE%>UP_GE?)\PIYEADG.%[*2;6L7%WLT]F^NYG6I*I!
MPELS^=?_ (<3_M5?]$L_\N72/_DJC_AQ/^U5_P!$L_\ +ETC_P"2J_HHHK],
M_P"(Y9]_SZH_^ S_ /EAP_V72[O\/\C\Z_\ @@7^PG\5?V*?^%L?\+-\*_\
M",_\)-_9']F_\3*SO/M/D?;O-_X]Y9-NWSH_O8SNXS@X_12BBOS/B#/*^<9A
M4S+$I*<[744TM(J*M=M[)==SNHTE3@H1V04445XIH%>7_M:>-=5\*_#G2]/T
M6^ETG4O%VOZ=X=CU&(*TFG+=3JDDR*P(+B,.%Z89@<\5ZA7*_&;X4VOQE\!7
M&BW%U<:?-YL-Y8W]L!]HTZZAD66&>,G^)'53[C(Z$U4;7U)E>VAXG\8HO$WP
M-^(+>'?!^J>)-2M_'?A;56L;2^U:YU*YL-0LTC<2V\MP\D@:2*5E5-VSS%0D
M#G.);_&A-&\37'A)M6\>:=X7DUM=126^M]6N->_L]+:-Q:HK(UZ!/<Q73!FP
MRP6UP255HB?;? _P:UFV^):^+O%WB2S\2:O8Z<VF:;'9Z4=/M+".1E>:01M-
M,QFE,<89PX&U H4#-9;_ +.&I6<4.K6'B.RB\<#5[C5I]8N=*:XMYS-"]OY'
MV?SU811Q-&L8\TE?)4DL&<-IS+J9<DMT>H:/K%KX@TBUU"QGCNK*^A2XMYHS
MN2:-P&5E/<$$$'WKR?XI_&?XM>$_'E]I_AGX+?\ "6Z';^7]FU;_ (2^SL/M
M>8U9_P!S(I=-KEDY/.S/0BO2O 7A*'P!X&T70;>62>WT2P@L(I),;Y%BC6,,
MV.,D+DXK6K.Z3-6FUV/G[_AHGX[_ /1N?_E_:?\ _$5X]^R#\9_BUX>_X6A_
M87P6_P"$B^W?$'5KO4/^*OL[/^S+Q_*\VS^=3YOEX7]ZN%;=P.*^XJ^?OV O
M^:V?]E6UW_VA6D9+E>GY_P"9G*+YEJ_P_P @_P"&B?CO_P!&Y_\ E_:?_P#$
M4?\ #1/QW_Z-S_\ +^T__P"(KZ!HJ.9=E^/^97*_YG^'^1\_?\-$_'?_ *-S
M_P#+^T__ .(H_P"&B?CO_P!&Y_\ E_:?_P#$5] T4<R[+\?\PY7_ #/\/\CY
M^_X:)^.__1N?_E_:?_\ $4?\-$_'?_HW/_R_M/\ _B*^@:*.9=E^/^8<K_F?
MX?Y'S]_PT3\=_P#HW/\ \O[3_P#XBN?\ ?MM_%KXH_VW_87P!^W?\([JT^AZ
MA_Q7%G%]GO(-OFQ?/$-VW<OS+E3G@FOJ&OG[]@+_ )K9_P!E6UW_ -H52:LW
M;\_\R6I72N_P_P @_P"&B?CO_P!&Y_\ E_:?_P#$4?\ #1/QW_Z-S_\ +^T_
M_P"(KZ!HJ>9=E^/^97*_YG^'^1\_?\-$_'?_ *-S_P#+^T__ .(H_P"&B?CO
M_P!&Y_\ E_:?_P#$5] T4<R[+\?\PY7_ #/\/\CY^_X:)^.__1N?_E_:?_\
M$4?\-$_'?_HW/_R_M/\ _B*^@:*.9=E^/^8<K_F?X?Y'S]_PT3\=_P#HW/\
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M@_X:)^.__1N?_E_:?_\ $4?\-$_'?_HW/_R_M/\ _B*^@:*GF79?C_F5RO\
MF?X?Y'S]_P -$_'?_HW/_P O[3__ (BC_AHGX[_]&Y_^7]I__P 17T#11S+L
MOQ_S#E?\S_#_ "/G[_AHGX[_ /1N?_E_:?\ _$4?\-$_'?\ Z-S_ /+^T_\
M^(KZ!HHYEV7X_P"8<K_F?X?Y'S]_PT3\=_\ HW/_ ,O[3_\ XBC_ (:)^.__
M $;G_P"7]I__ ,17T#11S+LOQ_S#E?\ ,_P_R/E[_AMOXM?\+4_X0G_A0/\
MQ4_]E?VY]B_X3BS_ .//SO)\WS/*\O\ UGR[=V[OC'-=!_PT3\=_^C<__+^T
M_P#^(H_YRH_]TI_]R]?0-5)I=/S_ ,R8J3OJ_P /\CY^_P"&B?CO_P!&Y_\
ME_:?_P#$4?\ #1/QW_Z-S_\ +^T__P"(KZ!HJ>9=E^/^97*_YG^'^1\_?\-$
M_'?_ *-S_P#+^T__ .(H_P"&B?CO_P!&Y_\ E_:?_P#$5] T4<R[+\?\PY7_
M #/\/\CY^_X:)^.__1N?_E_:?_\ $4?\-$_'?_HW/_R_M/\ _B*^@:*.9=E^
M/^8<K_F?X?Y'S]_PT3\=_P#HW/\ \O[3_P#XBN:^,/[9_P 5OA-\-M4U[Q5\
M Y-+T"S18[NZC\=VCO$)76)<"&,R9+.HRHR,YXQD?4U?/W_!4O\ Y,1\=?\
M</\ _3A;5=.2YEI^?^9,XR46[O\ #_(/^&B?CO\ ]&Y_^7]I_P#\11_PT3\=
M_P#HW/\ \O[3_P#XBOH&BHYEV7X_YE<K_F?X?Y'S]_PT3\=_^C<__+^T_P#^
M(H_X:)^._P#T;G_Y?VG_ /Q%?0-%',NR_'_,.5_S/\/\CY^_X:)^._\ T;G_
M .7]I_\ \11_PT3\=_\ HW/_ ,O[3_\ XBOH&BCF79?C_F'*_P"9_A_D?/W_
M  T3\=_^C<__ "_M/_\ B*/^&B?CO_T;G_Y?VG__ !%?0-%',NR_'_,.5_S/
M\/\ (^?O^&B?CO\ ]&Y_^7]I_P#\17/^ /VV_BU\4?[;_L+X _;O^$=U:?0]
M0_XKBSB^SWD&WS8OGB&[;N7YERISP37U#7S]^P%_S6S_ +*MKO\ [0JDU9NW
MY_YDM2NE=_A_D'_#1/QW_P"C<_\ R_M/_P#B*/\ AHGX[_\ 1N?_ )?VG_\
MQ%?0-%3S+LOQ_P RN5_S/\/\CY^_X:)^._\ T;G_ .7]I_\ \11_PT3\=_\
MHW/_ ,O[3_\ XBOH&BCF79?C_F'*_P"9_A_D?/W_  T3\=_^C<__ "_M/_\
MB*/^&B?CO_T;G_Y?VG__ !%?0-%',NR_'_,.5_S/\/\ (^?O^&B?CO\ ]&Y_
M^7]I_P#\17/_ !3_ &V_BU\%? =]XF\3? '^S=#TWR_M-S_PG%G-Y?F2+$GR
M1Q,YR[J. <9STR:^H:^?O^"I?_)B/CK_ +A__IPMJJ+3DE;\_P#,F:DHMIO\
M/\@_X:)^._\ T;G_ .7]I_\ \11_PT3\=_\ HW/_ ,O[3_\ XBOH&BIYEV7X
M_P"97*_YG^'^1\_?\-$_'?\ Z-S_ /+^T_\ ^(H_X:)^._\ T;G_ .7]I_\
M\17T#11S+LOQ_P PY7_,_P /\CY^_P"&B?CO_P!&Y_\ E_:?_P#$4?\ #1/Q
MW_Z-S_\ +^T__P"(KZ!HHYEV7X_YARO^9_A_D?/W_#1/QW_Z-S_\O[3_ /XB
MC_AHGX[_ /1N?_E_:?\ _$5] T4<R[+\?\PY7_,_P_R/G[_AHGX[_P#1N?\
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ML%O;P($CA11A551P  ,8%1^&_#>G^#] L]+TNSM]/TW3XE@MK:! D<**,!5
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M_P#E_:?_ /$5] T4<R[+\?\ ,.5_S/\ #_(^?O\ AHGX[_\ 1N?_ )?VG_\
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M ?[2T/4O,^S7/_"<6</F>7(T3_))$KC#HPY SC/3!KZAKY^_X):?\F(^!?\
MN(?^G"YJKKEO;\_\R;2YK7?X>7D'_#1/QW_Z-S_\O[3_ /XBO;?!.K:GKOA#
M3;S6=)_L'5KJW22[T[[4MU]BD(RT?FIA7VGC<.#6I142DGT-(Q:W84445)04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/[.OP.N/@A_PG7VC
M4(=0_P"$O\7ZAXFC\N,I]F2Y\O$1R3EEV<D<'/2O1J*=^@K:W"BBBD,****
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MTZ"VN?[8LQ*%198GB^V222!9-[0R*D6"02J,3T4OB7Q9\:OC#XP\-Z5XDO/
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M-XB_9>UGQEH^I:E<>-?LOA<>)=#N]0MX+>X27[2EF]M-]GCBC>,2RP2!E1'
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M ).H_P"(FCX#_P#0I?%S_P %>G__ "=7X9T4?\0;X;_EG_X&P_M*MY'[F?\
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MX<\3-X,T7Q)=: PU#0KFRU2-(/,#W=Q %DB@B1XVAE/GL(YU:,DE2:\Z\6?
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ME\7/_!7I_P#\G5^&=%;_ /$&^&_Y9_\ @;%_:5;R/W,_XB:/@/\ ]"E\7/\
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M,_\ @YH_Y/P\)?\ 8A6?_IQU*OW,K\W_ /@L#_P1^^)?_!0+]I;0_&7@W7/
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MQ-HLFHW_ ,<] \00FZU"+S9X!+J)N+U-S9,8$B;Y1\H#KD\BO1O^(9?X\?\
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M%V28.M5G6Q=*TGHU*;E\<Y6?-HDN9V44M6R:N'JR22B_P[+_ "/SBHK]%/\
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MK?RL_.NBOT4_XAE_CQ_T-OPC_P#!IJ'_ ,@T?\0R_P >/^AM^$?_ (--0_\
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MME8<L,%R,*<9:OW&J'3=-M]&TZWL[.WAM;2UC6&""%!''"B@!551PJ@   <
M"IJ_C3B_B[%\08WZUB-(K2$5M%?JWU?7R227TF'P\:,>6/S"BBBOE#H"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#\-/^"-W_!&ZX_:BU&Q^)GQ,L9K7X;VL@ETW3908Y/$SJ>I[K:@CENLA
M&T<9-?N+INFV^C:=;V=G;PVMI:QK#!!"@CCA10 JJHX50   . !1INFV^C:=
M;V=G;PVMI:QK#!!"@CCA10 JJHX50   . !4U?6<7\7XSB#&?6,1I!:0@MHK
M]6^KZ^222Y\/AXT8\J"BBBODSH"BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>irtc-20211231_g4.jpg
<TEXT>
begin 644 irtc-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,]!EX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/^&^H?\ H2)/_!H/_C-%F!];45\E_P##?,)_YDB3_P &@_\ C-+_ ,-\0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7$\/RJ3&#\DBYZ@>A'7TKPG0?$$5M,EO>>;&T$?V:Z,B;A*GW4D/J0R@9[\
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M?NADR3C/YU-[:HNUS@;W1T223RF)[KZ5F/#)"^UD(;TKM[BW3C826)X;M_\
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M'&?:DYJDP'Y]*44WFG+UI@/%))Q&W/8TJFDD_P!6_P!#0!^B'AG_ )%O2?\
MKTB_] %:=9GAG_D6])_Z](O_ $ 5IUB 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%-:18QEF"CWH =15";5XH\A?G:L^;6+B3
M[@$8H WBP'4XJ)[R"/[TJC\:YQY)I?ONQ_&F+&.O7- '0'5+8<;\GV%(-6MS
MW/Y5B #\:4#(]OI0!M#5K;.-_/TIZ:A;OTE4?6L#:%Z4F/7 ]J .G65&Z,#^
M-/KE=S+RIP3Z5-'?7$/W9,CT- '245CPZYCB5?Q6M&"[BN%!1P: )Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKR+&,L
MP4>]4;C6(8ONY<^U %^BL&;6IW)"*J#\ZK///-]^5C^- '2M,B\EU'XU']L@
M'_+1:YQ5]>?7)IZJ.WX4 ;_VR#_GJM.6[A;@2*:YYAN'6F;1P-M '4*ZMT8'
MZ&G5R^YEZ$@X[&I([^XBZ,?H: .DHK%AUIUQYJ9'JM7X-2@N!P^T^] %NBD_
ME2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_6HI(6C)!Y^E?5X;'4<3I%V?9GQ^*RZOA=9*Z[H:/7%.%-IRUZ)YA)_#3\X
M]:9^-.YH D[T[CIGI3%/?M3N] "=?>G+_D4GIBI ,^U(!5Q^-.]*93MW-,!]
M.IB_E3NM #N,<"E';--%.^M "_K3U/\ ^NFC]*5: )=QI?6F+3J '4X4RG ]
M*0$BT]?:F*>*?SBF ZE%(M&<B@!].!Z4RGI0!(M+^E-%+TQ0 X5+'4/>I%^M
M+H!,*=35[4O%2 [Z=:6DQF@52 =2KVIM I@2_C22?ZIOH:%I)/\ 5O\ 2@#]
M$O#/_(MZ3_UZ1?\ H K3K,\,_P#(MZ5_UZ1?^@"M.L0"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***2@!::[!%+,0JCJ34-U>):K\W+GHHZ__
M *JQ+J[DNFRYX[*.@H T+G6 O$0W?[1_I67<7,LS9=R:9COVHZYH 9_.G?AQ
M0>/I2[=QX&30 @ZXIW'_ -:E\L\;N![U(%M]O,WY"@"(8I=QR>/RIV^T_P">
MKD_[M&VW;.)MH'=E_K0 W/R\TAZ?XU+Y$>0$NH6^IQ2FQG"Y 5QZJP- $&W/
M.>::RX J22&2,?O(V3_>&*9P>O7U% $;#YNM"R-&P*G!IS=P>U1_K0!IVNMO
M'A9AN7^]6S!.EPNY&#"N34>]/@N)+60/&VWV]: .NHJA8:FEV-K?))_=/?Z5
M?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BD-4KS45ARJ?-)T]A0!
M:FF2!=SL%%9EQK'41#'N>M4)IGFDW.Q8U'_.@!9;B29LR,33!BEQWHQ0(..:
M4?I1MI\<.[JRJ/5J &]\4M2>3'QFXCH\N+!(N%S]#0,CW9Q01Z<U*EF9!N26
M,\9^]BE^PS]E#?[K T 5S2;>1Z5(T,D?WHW'U!J.@!C#C/:F\KST/8BI&XYI
MC=3U% %JVU2:WP,[E]#6O:ZI%<<$[37.?_KI>5((.".F* .O!R.*6L"QU8QL
M$E.1TW5MQR+*N5.10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#PK]L==WPEAR6 _M*+[N,_<D['K7PC;?Z%--9W1W6IW/#-#T!ZYQVYZ
MBOO?]K;26UOX5Q6L<ABF.H1&-O\ :"28S[5\&76C7<6H&WO-UO=C#0S+QNP<
M$#U!Q_\ 7KXC./\ >?DC]"R)_P"R_-F_!<W"J$*L\D1.95YS'CH6'IU!KJ['
M50L 658V9OE*C[DJYZ>Q!Y'IGWKDM/\ M]NQN(X=LL>$E,?(.1CYE/YUI:?J
M;6,=T[1;)-V)+61>#G'SKD<?_7ZUX5NQ] ]3J[.WGT^Y#VY:ZT^12T<;CS %
M]#CD>E=-IOE3()(I50+R54;@I[#/O^5<;HEZRHEQ:/EN?W9.&]QGU]O:MFSO
MHYWFE@E\J;<#(#@ D_PX[\U%B=6>FV=X8U:-=K!<;61?7']:O)<>6I)E5BIP
M%8C!_P#K_P"%<#H^JR)*B-\Z@<LPP0I[>XKI8;XW\VR(!(8U'.WY"?4^N:N+
M.>4;&O',D<)C$0>5CA22,-S[UAWDT#,999//"$$1QC*O]1W_ /U430M<S$,6
M:)3LVAMJ@]>F>:JW%I;6I/GN))W;*JI!$0 Y)'7UQ5ZLBRO<S[RRMFD>6="9
M%!VQR<[6/J!TX&/PZUR7B36I)+N:&!AYKC=)YBG"QC S['/&:U;C5KOR)[2V
MW1P2Q$--*#ND7IG..2W./I7&W&GW5I;7/VN9DD<@"W1AA5(P 3DY/6E=6T-H
MQUNR[I5ZS7#+)=+M4?*HP6D)^]D=AQ^-=3:PS:PHN7NDTVR#*5VX+N-P)4=A
MGUQQFN&LVMI%,$,*O;KAIII/E!(XQGT [?G70:?KEK9V\I5&D:0CRV#8 '<*
M/ZTO4J7D>CR-8P0Q/<L%M<':F\[V(&!C';^=<GXC\0_:'ALK*$),S9$*OEB!
MGYCV'>L2Z\037UUGRMEK&Q R<J[9' _7I0MX?(&8E!9AG:NZ1F/8'T]J<I=$
M*-/EU9F7T3RM]G\@RF0_<A)RV!U+'ICUKEK^R2:0&:X\H#*E54L>.Q[?E6]J
M!,2&5W7SF!C$(XV\]ZY_4I+6&(L\SR1\%608W''H>PK-'5$RKP2OY3;ED+'
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M)A)R&_BC;U']1WH N\Y/ITHP<\=,=34:LT;&-\&0#(9?NN.S"G\\?G0 O1<
MXYS5JQOS:S9)^0\,O]:K#KZ4F2I./Y4 =8KAU!4Y':GUB:->%6\AVX/*5MT
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M7('!P<=JQ=26QCD:5 TC9+&1FPJ<8 QZUB^(/B!;17"++<&9(U*BTA<9&!@
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M&*8*<.M(!Z_K4B\+45/6@!ZFG<BD ]*521UH <M._2HZ<IH ?3\TT>U+T I
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MT>X,<QA8Y1N5_P![O_GVK:KDU=HVRIY!R*Z>UG%Q D@_B'Y4 34444 %%%%
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M;HDG[AH_[IR/I6E0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.O
M[=,P@^#-HQ5F_P")Q ,+U_U<M?"=IJDFT?.TB@8\L8!.>Q.*^Y?V]I/*^"=F
M^=N-9MR/^_<U?!%C>,)/WA^3O(/\/6OB<W_WGY(_3.'_ /<OFS:61XXV:5-K
M= H89'OTJ]%:JUJD<<8BW-N\QR>?J>]8_G[9D B9H6ZMP<?45L6_E+L:Y,G
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M@-@L3N+,"6/L>?I46OL/X3-L=+FD6&0)@XPKL<<D=5%;L>CBVV;3]_DOU)]
M!VK8M]+ENI/*@5I6&"6/0#WK8CTD&:- ?-9>Q'\/4D^@_6JY3&50Y<Z)]HF\
MR5E(4#:HXY]^>M:=GHK-:N0N HX11Q[DG_/6NC_LA;H[YQY5KN.9$0<D=OY5
M9;RXXDC1> ,"'J?;-:<G<Y^=O8QK;1Q'%D-L7 S(>23Z 'GK2P:,]VP=B4B1
M\ $CG\*Z./3?,6-"^&89);*A?\_K5]K01PI'"8XSMVY P6P/3/2H=,R=4YRW
MTT+O^19#CJ"2!6E;Z7Y,+,BJ7QNW)\W].#_C6Q]@:UC VJ\BC($8_/&:B9FC
M67+8R.6'6CD)Y^;8R)+58H\.<^O.3]*S[B]&YG8_*>%VCD>@X[UH7V_=@E=H
M& .Q![GGK7+ZE>,\FR(-D' X'Y\]*AFL=2U-<*RNQ5@%.=N0PSZUSFIWSW"@
M*2BJ"<X%6YKC;#\SD+T))V[C6/<7 D)5!B/<?F '-258S]29I%W G) /WOYU
MAWEN%PK%=O5FSS6M-*L$9EWXC93T/^>*Y>\FDF>0(V8QP,&F@,G4IC>3!8P
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MVF&YSN$,P.T$ G(QMS[YH>P(Y:Y(%U\YV*!\NW<P8'&0 .G]*RFD^TPD?9I
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M7Z%?M_,5^!EL0Q7_ (G%N.!_TSEK\\899!ECQL7DXZCVKXO-O]Y^2/TSA_\
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M+_\ (M:3_P!>D/\ Z *TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQR+\KKCE5 ZYYP?_ -5("+4BJK<R[MS95EVYR-O)Y ^\!69<9;S+M%61EY5
M0N<<;OF]B>>O!!J4R,ZM!'-EMK%F>,AN<8).1V!K-O+"?7M4MO#UC^_FO6Q>
M2#<IAM<?/)R2,GA1QUSUI;E>9Z'\#M+FM_"IOY@1+J-Q)<?,,%4W84?3 _6O
M4(N^.*SM/M8]+L+>TB3;!#&L<:J. H& *TK?!3..:Z5HK&#'J67MFG*?4?2E
MVGB@KCIUH)N/^[C%.7G&:CQP*<O ]J8$P;'T]JVM.F.%<@[)(_+;W(XS^6W\
MJP@>ASP.:U--EVJY&#Y3K)M]0>#_ #%4-%_/((.1BE_ASG]:21?+E=<8&?\
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MAJ0/T:\+_P#(M:3_ ->D/_H K3K+\+_\BSI'_7G#_P"@"M2H **** "BBB@
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MN?M A2-RS+P(U7'5B3Q]1SP*0RKXKUQO#NDH;..6ZU74'6"UB4*//D;J<@\
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MNXN_S BNJH **** "BBB@ HHHH *2EHH **** "BBB@ HHHH **** "BBB@
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M=7%;U "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\SY+*W;%1^?Y'T=#&8%$;#"D$\G('%:5G9A;<9PY8#Y5/'^>E1M#N3;&A9N
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MVK<B:.X5@YX)P,'@>E3RM&7/;0J+;C=(401[6PJGKBF26Y#,S.OR_P!TC/\
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M2^<,'Y6'_ 35WCI2T 9WG+G^+/\ NG_"HWF0]0W_ 'P?\*U::P[4 9'VB/\
MO'_OD_X5 UPF\#D\_P!T_P"%;3<>WUJ,Y+ +R32"Y\H?M*7&_P"-6D1QQ%V;
M1H\[@,;1+)D $>P]_:N(N(I)F"R1ROYBY4,BA=H&21D8[=/>O1_CII=MXX^*
ML5]97,:QZ=8C3K@/&3N=9&<[<#D#=CJ.0:YK_A7-^D8*ZE8GS/E+,C#@DXXQ
MP>:X9-<SL=*5DB+X87D=IXXUD;"!]DM_NIPI,DA(R!VKZ0T?5K-H=OG*,<')
MQCBOG3X;M>>%_BAK^CZG"896L;2:VN8V#1749>4%E(YR&!!##(/U%?2?A^\6
M6%?7&*Z::]U&,]S3AO+<KQ*A_P"!596[@ _UBG\14T*K_=4'Z5*(U[(O_?(K
M6QF5_M,2X.]<_6C[1%V<59,:?W%_[Y%(8XV_@3_OD4:CN0>9&W\2YI-R_P![
M-3^3%G_5)_WR*/)A_P">2?D*07*S,IZG\<TTMM[\59\F+O&I_"F_9X,Y\I/R
MHL!4;YCC=Q2[ECXS5G[+;;@3;QD_[M'V&U//V>+_ +YH"Y);7,*VMVI=%WQ@
MC=W(85T_A5?,ORPR0D9R<<9)'?\ .N8AL[7<,6\>1T.WH:]%T-=NCV@Z_NU_
ME3&7J***8!1110 4444 %%%% !7/^+K<R6UO*J[C')@X'8@_UQ7050UJ/?IT
MO^S@_D: .$;S%8MY,@^@H:1FY,4GY5I2?-S43<K0(H%RO'EOT_NF@.?^><@^
MJ&KN/SI1WH$468_W''T4TQI./N2'_@!_PK2VTE S*:51GY7'_ &_PJ-I5V_=
M?_OAO\*U66HF^M(+F5),&L[T!)#F"09V$?PGVKX4\"W$D_A^/RXV&5(3RV4L
M!MZ=-W4Y]_>ONKQ-X@M?"^@WFI7NXP(NP*@RSLW"J/J37Q[X:^%YMM/AMQJ$
M65'#M;$AE!^Z37-5M=(VALS)U#"Z?=S%7"F%QER&8D#TP>><5[C\(]06/PKH
M_FQR1A;& _,A'\ KRSQ!\.]5C\/:L^FW=OJ-]#:R>18J!"9B%)"AF!&3CC=Q
MFO3/@MXBAU3P3X=GAR$:PM\HW5?W2Y%%+=BJ;(]=M]2MB!E\?4&KR7MOQ^]7
M'UIEC-YD8/45H*<KG%=-C$@6ZA/21?S%'VF'! =2/8U:XHR/0?E0%RL)XS_$
M!1YD9_B'YU8X/\*GZBDVJ/X%_(4!<@,B8X8&F;EYY%666/\ YYH/^ BF>7$>
ML2'_ ("*+ 5W<<\U&&3KO'U)%6_)AQCRHR/=11]EMV'_ ![PX_ZYC_"E8"LM
MQ&RXW#I6P+B.XO&DCD$N40G8,G.T U1^RV__ #[Q?]^Q_A6SX:AC75+<1HB+
MSE54 $TQG5Z%#Y.EP@YRW)SQ6B*!2TQA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'S7^WX?\ BQ]IC_H,V_\ Z+FK\["3T#_*QP=O;W)K]$?^"@#%
M?@;:$8XUJW/S=/\ 5S5^=MPRC:QY+8)[(*^-S7_>?DC](R'_ '/YL47 M83"
MBY!&'D[MZ#FH4MPT#R!2V[@LW\/^14BX64JJDCH<]1466\YE.3'G!5C@9] *
M\<^B0Z.)/E"$ 'G:< GZU9:1R"RMN*]CQ_\ KJ!"AE^<A=QZ\C^5/7<TS.=K
M#H W%9LW1+)LD16\TE\9*XX/MFERRLI4[U' 4'BH-KK(6?&"<J@_PJ[%!,ZE
MF0AO]GD\^OI63T+2$+#E3(T;Y)Y[#TK/U#;M+%LL1RRYR?\ Z]7F62-"6&X^
MX_"J%W;O+"S;PI7G\:2W*2.O601VUM'&^Y4A7V/W1_C4GG$;R5[_ '5[53A0
M26\$@; DC5@?7C!J9FVQL"V"O!;-".22+O@71O\ A,OB=H>B76'TZ%7U&YC[
M2K']U/<%BN?6OKNS^9ESM^7_ #Q7R1\,=<@\.?'#P[/,5CL]2@ETW>3PKN!L
M^F64#\:^M[>,PD1[?\YKZ?#Q7L58^$S1R^L6>UC8MX3)ST)'X5>AC21621 Z
M,N&5AD,#V(]*KVA(7:3T'TJTNV/'\+'WS6RMLSR=3R/X@>!8?"M]%J5JA_L2
MZ?RGBZ_9I"/E_P" D]#VZ>E<<TD<,IVX/.,9[U]%ZMI-KKFC7.G7J>9;7"&-
MU'7G^(>X."/<5\Y:_I=QX=OGT^_7=/;G9N53MEC(^20'OD?D0:^<S#"\CYX;
M'V64XWVL?9U'[R_%"-="%28DRRC=QW-59-4"*0QV%LD$$C/MGTS_ "K._M V
MZL%*H<9QG)'M^M4+N\#2%2VY@,>W![5XR6I]'?J='9:TRNDAVHB#Y2PR"QX%
M)=^(T6=HAO5AURW!/Y<5QDNH2GY?,4 '=R>O;I67J&I&W69C*H*<'!RIQW!^
MG\ZZXPTLCCE+6YZ%+X^M-%MQ)<W*QQE<LS'MUQ[_ /UJ]0\#^(_[:TBUN/+D
MM(I/F E?_6@\YVGH,=,\U\J_"O2S\3/&,NJZBAET+2 SQ6['$<DH^Z6]5!P<
M=Z^Q/AMI/_";:M+<R0[M*TJ$"%CC$PQ\I(''S,"V/3 KU:.%;7FSQ\3BHTWK
MTZEHC5/$%Y]BTFTCN9Y01 ;B0B)<8RS8Y( Y)/3CZ5V.E_!C]WLU/5YM1U(
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M59^T$[ KMO4_=]\GI^=4B=S1DN<9*A0_)*J.,55N)5V@Y&XC !!P<TD*R22
M.<ECR< <?_J_G4=Y)P,@D _*,\TQ&-? $AMN[&>5X /U]JY#5+<+&XW$*?E'
M'7W'^>]=?>MO+=%ZLW89Z$US.I0\$G. <+Z9Z4TW%IHU2NK,\\9?+9EST)6H
MI3^[?Z5?UBW,.H2#'#_,!5"3_4M]*_2Z-15:<9KJC\QKTW1JRIOHS](_"_\
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M.U0&^O>OK#XFV@C5W'(QC).17S#X@A!GGSC&3^=>E2?NCCNCYNUJV^SWWB:
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M_.LFYG;)&?W?.%%/F:,G%,=HMU>Z)?O=:->W&E/@L3 _R,1_?3[I_*NAT_\
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MCY^92V57UQP.?\:Q-2L86MVVS/"_\23*1GWW=*48J^XG)VV,"ZOPS,=RAE.
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MBX()7+$GG_/%/FROE$$-R"Q/?C]*M&9*6CMO+0'*J.AY/7_]?Y5<LU\QH0'
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M^17T?_KSA_\ 0!6K65X5_P"17T?_ *\X?_0!6K7Z*?F 4444 %%%% !1110
M4444 %%%% !1110 4444 %,FD6&)Y'.U$!9CZ <T^N7^)VJ?V+X!URZW;"ML
MR ^[?+_6E)V5QK5V/GGX?VTWQ&^+6I:]/DVT<S70S_>)VPK_ ,!4$_@*]I\>
M^(+?PGX;N+R==T,,?F&->LF.$0>[,0*XK]GK3XX?"\MVC&47$S$,V.@PN![9
MS1XXU2+Q1\4O#?A8I(]O%YNLW>,;?*MR%C4_[TL@_P"^#6%-<M-=W^I<WS2+
M_P ._#MUH.B7&HZKAO$6LO\ :KU\?ZL'E(AZ!1C_ "*WG7TYJ6:Z$\C-DCJ?
MFJ"9BL;-U/11ZUHM""K=73+-%;6\;3W4A VJ<8'<D]@.O_UR*P_%6N7WA'0[
MQ] T^#7?$ .P?:)?(MH1U:21^2L2#DA<NQX R212^+WCVZ^$OA.T31;&/5O'
M_BB[72/#VF2'"2W3J3YDGI#"@:61O1<=Q7FS:1KT=U%X<UG6&\:VVFQ1_:M0
MO($B%[>Y+W$A1>/*7<JJN. -ISS1YB/'H_%6K?$7Q()KJ\E\9:N)<V_FQ#R(
M6/ -K9*2L0_VF+R8P6D%>C7\?A+X2Z+%J?Q>\5VFE)<_/%I@F,C7'^R(T!9S
MGLH(_P!JJGC3Q5+X+\5>'_!_PZ\,VMQXD\0$DRVL(658QDEV?HJ+G))X4 =Z
M]'^'/[)OA3PKXD_X3#Q>?^$\\=/S]NU/,MM9G^[!$V1Q_?;)] M'-K9(GEZM
MF'X#^,%MXT3?\.O@WXGU'2^D>J7&G6^F6\GNK7#AB/PKT&.Y\?-]_P"';+GD
M*VMV  _(&O3Y+QY.&?@< =A]*B-R/6BR*/-HY/'4:@?\*Z#D'.?[>L5_]EI[
M77CPQ[5^'*J.N#XDM /TCKT"2]"_Q8JO_:@[FBP'G;#Q\\P8_#Z(;>@/B2SP
M?_(7^<U4,?Q"+EC\/H"#P5;Q5:@#.,](3Z"O3_[3#?Q4JW8;HU.R \Z@A\:3
MHD4WP\L+>,G+$^+(BQ/_  &W^M22>&M=9ED_X5_I<LJCAY/%/S?G]GKT59QM
MR#3#< 'KQ19 ><S:7XK528_AGI,_HO\ PEJ '\[>J\NH>.8XQ]L^$]U+%$V<
M:3X@L;QB <@A)#$21^=>G_:![$U(EP/6E9 >&S?&&]MY/[*U2WU30I)G"BQU
MK3I[>21CP=A;,3X'9)#GWKE_&W@?P[\6+&VM+NRMO$%O"3_Q[[5N[23^_"1P
M",Y^7:?<]*^I8[D31^6[;T/\+<BN&\8?">VU6275M!1+'75&[8#LCN3Z,1]U
MC_>Q]<TN5K5 >&_L]VOCKP3XTUSPWJ5ZNO>!8;9'TW5Y'(NHI-WS6]PIY)QR
M&P,8YKZ3\LZ>IN4!$,AW/&.=N?XA_6O+=/UJ>."*YO8I 8YC%<6\A*R!EX>*
M0 _> /?CH1VJC\'[Z[^&?C2X^'M]=W&I>%-3BDU'PC?7#&1X(Q\T^G.Y^]L!
M\R//.S>O\%"MT#U/;F@%TN1@G&:BCM8)(;BTO($N;&YC:&X@D&5DC8$,I'H0
M33;?-K.83DIC<C'T]/PJ])'YD>X>G-4!\U_"F2Z^&WC#7O 5W,TTGA2ZC^PR
MNV6N=)G!>U<D]2H#PD^L8KI/VGO"Z3:'IOBJU4+>:5,I,J]3#(0#SZ!MA_ U
MG_'NT_X1[XP_#+Q/& JZQ'=>$[YNS;D-S:$_22)P/]ZO3=0L5\;?"5[>9<O=
M:>T3+Z/M(Q^!_E2Y>:+BQ\W*U)'H/PM\0'Q1\/\ 0M1?'F2VRK)@Y^=?E/Z@
MUUE>+_LHZFUW\+X[63(EM9BI#')&0#C\\U[113;E%-CDK-I!1116A(4444 %
M%%% 'G'Q]\0-H/PWU!(F*3WY6S1E/(#?>/\ WR&_.N7^ OA4Z3X62^F3%W?'
MS6/<+T1?P&3]7-4_VG=02:?P[I!=LS2,^Q"0=S$(A_//ZUZ':[='\/*$'$40
M51^  _I7/%<U64NVAH]()' ?$B2Y\9>(K3PC9R-%#=#S]1G4_P"JLT;&W/8N
MP('TKL9(8;>**WMXUAMH4$<4:C"JH&  *X7X5WQUR/Q+XHEA*MJ&I2V5J2>3
M:VS&)#TZ,RNWXUVOF!\ 'D^M:+>Y QV6/+,<*HR:SV4ZA#-<W*-%IL8XX^>4
M]U ]#TSWYZ#DZ*V+ZA=+ &Q&!ND/M7B/BWQ5>_%'XD:K;Z5J%YIOP]^'4WD7
M1TV;RGU_7=H(M-PZP6X9=Z]&E;!X0TQ&-^TI\1];L(4L8-770-!;$8M=-N#'
MJ5Z^,OO=?FMH%&/]7^\DS]Z->O#_  U\$:EXHT6 V<EIX=\,1?OFG5/*M^?F
M)'(9FX;+D\\Y<]*].\-V,]A8PS^(VAU"Y9%DFN)4#F:1!DOR/NYSCMR:XKP'
MX+\0_M23:M=^*Y;C2/AK!<M;V<-H?)EU((=K*@'2,$8,G<Y"CKB>;LM1<M]W
MH.T3]H#P'I>MR^'?AKX0U[XL>);=]MQ-HMJK00MTW-<284+GNH8>]>OZ/=?&
M/7H?-N?"'A[PRK 8M[_Q))+,/KY-LR@_C7?^"_"?A[X<>'H-"\*Z/9Z#I,(^
M6VLHP@8]V<]78]V8DGUK8:X'=JICV//?['^*,BC,'@]<<X_MB]/_ +:TO]E_
M%$-_QZ>"6!Z[M6OC_P"VU=ZUT!W_ %JO+J 7H:5D!PLVB_%"7/\ HO@<#&/^
M0G??S^SU4D\.?$X1&-8/!.#DG=J=^?\ VWKT#^U!ZT#4 W&:=D!YY#X?^)<+
M)FR\!N%X!:^U!L#K_P \1ZFK\/AOQK<-YE[9>!WFSGA[Y@/S _E7;K=#UXI_
MV@#OQZT[(#ASX9\81 ^3IO@)>,8(O5'Z+5630_B7"0;32_ASQU_TG4(RWMGR
MF_E7H/VD>M.6Y7UI60'DVM2?$K385,W@2WOMIR;CPUJ\5UCCJ8;A;=CC_98G
MVK&N/&4MS%(VN1ZM8P^9Y'FW^GR6YWD?Q1R)S@_4'JI(KW=+I?[V*DNHK/5K
M:2VO(8[J"1=CQ2J&5E]"#VI<O8#XR^)'P8N=;T^7Q/X5G70O&L*G[%KNG(7A
MN".B3Q<\' 'S;AZ'M7TMX#DO;KP_I.G^(FMX]>DM(WN889,@R(H$C19Y*!CU
M[9%8'B;P/+X$OHKS3Y3_ ,(]<.$9I"2;20G"ASGF-B0 QZ'@G!!KC_'/A*7Q
MIIT4>D7 T3QQH-TVI:!JBC:8K@#YX7 ^_%(!M=3]Y2>X%3UU0;'O=K,\<CV\
MN6*\AC_&/7Z^M/FLQPR\CK7.>!_%A^(/@W3=;^PR:5J#H1<Z?,?GM;E"4FA8
M]]KJR@]Q@]Q7564PFC![,*L#QG]IS2WT_P )Z=\0[*,OJ?@V7SKQ4SFXTJ0J
MEW&<==HVRCT,5=QX OHM6T6>TWK<1 "2)NJR1L,@_0\'_@5=3J&E6VJ6MUI]
MXGFV5["]K<(>C1R*48?D37SW^R7JUY:Z#I^A7[2/=:,]]X>N&F.7:2SG,:$G
MOF)4H6X=";X*M)\-_C5J7AT?)8-<?ND8$9C?E#^ ;'_ :^OUKY2^)EC_ &'\
M:M U>) OVBV,;,3U:-P1^CG\J^JH9!)$CCD, 0?PK.FN64H_UJ:2=TF24445
MN9A1110 4444 %-_BIU)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X-^V='YGPC@'7_B:0]\
M?P25\6VS-YR;>47J6X'_ ->OM;]L:$S?"FU&&.-5A)"MM)_=R]Z^+Y-/CNL)
M(6";@512/E/KG_/2OB,W_P!Y^2/T/(W_ +)\V;"JK0"0J5*G'U'MBG2*C;6V
M%BI^Z.JYZ?G26J^6X7<9"/D&Y>N*U;6UC9F^7=,3N)!R".H]_K7C(]N]C'U#
M25M<3,?ED.%CZ# '0GL/\*YV^MD-U%M91\N&7GG'7'J<8KK]2R(E3&&QO3."
M?KCUSZUS%Y&S6[8)3G=G&3Z;<U1K!F:8%CN@J1[U90^ ,$'_ !Z?G3[AO/>&
M%1L   5223G^M3S(?.!5=C, ,.02<XY%(8S;W$:%COD09*C!YR,_6I#FU"&-
M;:YDDQAMFWS&.><?XX_*L..1]VU\Y'7ZGL *W;M=EC.BJ5)&"V[W_3H*Y^:%
MH_G;:9"<JJ=!QSG\Z1<97,V];=).=P*JV0<9[X&/P_G566;<T2=&4]AC:2/\
M*L2RCS&C*AAUXSCV%4_]3*6VY7T'/)JK"<AT.J07%S<PQS*9[5</&W4?_KYJ
M6WOI.?FW G&<X&?4UC--&T[2;%\QSM+'@D?_ %OZ59@F,BKEP47@/C(_*DT3
MS:&W;7C%1D[EQG@$5?CDVQHQZGG!QQGH:Y]+EU7"9 /;-:$%Q\I+DGC)SVK(
M9LPKEM[=Q@<]O6GW5MOC'R_)CGI^516LC-  V7=O08 7L#5U=J@)DG/0@'"U
M GW.4U#12OFO WED_P   PWMMKG&TR.:]6&5%M68X\P'$9]<@]/PKT\VP*@!
M69SD!NG^36?J6AQ2PJK1JRXQNP>:UIU7!F$Z?.CE_AUXFMO GCZ\LK@A;/4U
MP[9RIR,?I_(FO3? >J7/P.\9;M^/#^H3B:UN#]R"8X^5CV5N.>QP>]>)>+/!
M=[9QF>R96VY*,R[MI]ZW/AY\8K+4+,^%/&,;VZ8\L2S<H.PY[K[]N]?4X7%0
MJJRW/DL;@YTG[1*ZZGW5XG^)6I^*;*WU&Q*R^6,7$/=O7*_Y]:C\&^.G=[9-
M+G3RP^7TNY<KC/4P/U0Y[?=^E?,KZ+XLTGPGJ^EZ!K*M;74'E6MT69IHHS]Y
M0P/(V\!N2OO5WX.^+]0A$<&MJ8+HS_V;9W14;S+MS)(1T947DL.F1Q75S3E+
M<\5J%K'VKIOQNM=/U V6L6]]I2Y BO+^V_T:7/I/&63_ +Z(KTRVU%+ZW$WV
M820LNX21L""/4>M? ,/Q:NI/&-X-(FGM;4*(K:&-MPNX5&W<H'#$XR0>>:]S
M\'_$Z]\/R"*XNPZQNL#R C89-N6CV]]O0FG&LU\2T,G24E>)]%#2=/U)F>)I
M%'?RV*UIV5E!9IY<0/ON8D_K7$>&/B%87:;8XU&\[CM./TKSK]I/]K"V_9Y6
MQF/A:\\1/=VOV@-;WD4"+^]6(*=V68[G7[H.!S7;3JTOB.:4);,^AC7FOCN:
M76O$UMI:_):P())';H6)Z?@!72> ?%%QXP\$Z+K=S9_8+B_M4N)+96+"$D9*
MY(&<?2O.?''Q$L_"5MX@U;4;9I[+3$$DDMLP,D\A;"0H. 2<]SVHQ%:,H)IZ
M;FE&G+G:M=B>*_ ]MJ'AM(K8,+VQB9X-K?ZQC@N".Y./PQ7BRM)?7$4$.YY,
MX5!P>/\ "NUTW]J3X?7]W:VYU6YLIKDC#WMH\2*Q[.W('UZ>]=?J7A>QU:Y3
M5K0QV]]@.MS#RDP/]X#A@?[PYKYBOAHXA\T&?1X?$3PON5HO7:YYQ;0^1=.&
M.(U 49]>I/YTM_(8QL!X/<&KNM6\]C.YN(A;+G&4YC/T/IGUP:YNYU);B0D'
M$2CUSCWS7S=>G*,VFCZ&E4C.*E%DTSI'MZDGM[U%)(NS(/([&J<ETHWL)/E"
M_,O7'O51KP%RI+'N"< GTKFY3;F)[B[;<<'G.3S7-ZQ=)'NDC?E?O(> ?I[U
M8NM1B7)!VL!G&<UPWBKQ %C8L<<8.VM8IW#FL<3\0_$TD+2F.5E;;RO0XKYX
M\6>(%\FXN9=H,0)^;^+%=[XW\1B\W(TF=N<-W%?.7Q0UYE8V*<,WS%EZ-Z8K
MZ+!T74DHKJ<6(JQIQ<I;(XC4;UM:U*>68LP;*C S@'K3M.F>W<K(V)8<13-[
M?PM^6!1I<"Q1K+(2J@;R?8>E5&O([>XBO)!C[4S!U[+%T4GW!'Z5]Y""A%17
M0_/JU5UJCJ2W9^D_[+GQ&C^(WPQL[2:;&JZ"%L[A6_BBQ^Y?Z%05^JUZ\T(\
MO;E@-N?3Z_ABOSG_ &<_BV?A;X_L[^\9AI<RBRU)$Y_<L1\X'<J<,/49ZU^C
M44PN@MQ'+'/:RH&BD1LAU(R&!]"#7P6:85X?$-KX9:K]3[?+<3]8HI/>.A39
MV5FPP9<8SQQZ&F[MI5L91N/FZ#TJ>ZMSY@*A=I;OTZ<FH/+#@/(<YSD ]/>O
M'/;BQS,GEEW!]0/7VJ*51<0D$8.,[O2I=P=1E_DP0!U/2J\>YE8L^P+TP?O#
MTI%F=:*TK,@^7;CYB>IS6C"592&3E<@[?XJJR(;:Z(QO5N2H],5<7&Q6(*;2
M,$_RH*%\D)EAP.QS_#C/\ZBA?RY "H.7R>< BKJD&3:J949 ..#G%5658V9]
MA4*6 8FKMH*Y;>02(Q /+8;!QQ_6J,V&N-P.4^Z?<^WM5N-G5"5ZXP?0GUJO
M*ZI"5'S'IZ?+[>_6@DF+)<2,. D9V_=R#_G%6HY(VPRC. 2/;&<9_P ]ZJ3$
M1E1&!M3GYNG^>13(YE8*74I$N>,\GV/K5$FH)A&P)X .67N">?Q-/C577,R_
M,OSC<._TK/EEW8<?,X4L>YQG@#WJ] TDVXM\P7HN>_K]:.H%^V8LN%+9'(/\
MZM0R>2JI@2$'GZU0LU:/80"&P><_I]*G5_+5@OW3T/X]13N+J6+A1&H(8@=6
M8#'^1526,G<K'8&.?H/I4C7 5@BMYF%VGG S3&V[B^[<.V%^]_GF@-45;I1'
M&4SN&01@<<CUKG]8AW6[[=N[:0<#CUKHIFW?ZP#(.,-V&.N/\]*PM2.Z%]F3
ME20.A/%7$9][^%_^1;TG_KTA_P#0!6K67X7S_P (WI.?^?2'_P! %:E?IT?A
M1^4S^)A1115$!1110 4444 %%%% !1110 4444 %%%% !7E7[25\UK\.'B0X
M>XNHXA^I_H*]4KQ?]J"1E\+Z5&K[";O<#WR  #^M8UOX;+A\2-GX7Z2NB^$;
M&UC7'EI@_7K_ #-<GX9\NX^(WB:Y*YN;73+.W,@[>;)-*1^B_I4?]L:W;^'S
M<V:^9=?:@J^6I;,98#*@=QC&?4&M#0;%K/Q%XIN5"XOI;9]V<D[$9<>P'''U
MK1Z61%SH'^6$L!FI[":.YN$.W<D*AROJQZ"D.%M6)]*Y;7O%T?@WPYXCU=B-
MNDZ=<ZF_?B&%G7CZK2Z <#I=\GB[XU>,/'M[()+7PZ7\&^&@YRB2J%DU.Z7M
MDR%8=WI P[U>M;JTU#3]0E&ZSTJ!1<3W7\<B*3A!_O-^)Q7GWABV/@WX'^"/
M#DUQYFJMHD%_>W$F0\MY?LT\S'W+2'KZUZ/'I(M[7PUH$R!3=7/VJZCSG,<(
MRB^XX7\ZRG+M_78J*-WX>^$;7PR+C7I[8#7]5C42RR<O!!G*0*>PZ%@.K?05
M>\6?$'3?"-K#<:E-)'%,_EH4C+DMC/059O[IN3GDFO,_BYX=U+Q5I-A!IT*S
MRQ7!D=6<+A=I&>?>M(Q2LA-WU-W_ (: \*E<?;+G_P !7II^/OA1O^7NY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6:U/"K8.=#WZ+=CN[CPC8?-^]NE4CE?/.,?E6:O@_2(8FQ'<%N[><Q-;S3#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU&HZ3,V(YP. 1_=<=F_ Y%>!F.6K$KVE/2?YGO9?F+P[]G4^'\C]/F+,NY4
M6,\G=]WFI9D7S$E0A9 2,#HP]N.:YOP/XXTKX@>&;'7="NOM6G78W!?^6D;8
MR8W7^%E[@_49%=/;L)(R"WF M@<=,<U\0XN+<9+5'VL9*24EL&[:5;9A\9.3
MDX^E9>L1F:UF0 JK ]#[5J,LN$QVX.!SQU'Y?RJGJKQR+G: O]UL^F.:1I$\
M;O-5W+$%PLT\K84]2HQU^@JSYHN6==QVY^4#DG!Q@5QMU?;_ !C?QN6,&E_Z
M.FW[HD/)_(8'XUIV-\DTBF/</)09QTR>,_S_  KIZ&S.ECD#73RL2IW81%/
M'?CUJ];R><H<X0*=X'KCK^/_ -:L*UF9GP2JY^\3U'_U^];&FS X9L!ERJ=\
M_6H9)M6[23QI)LV,Q!"28&WCH?\ /:M2!6B"(I!8\N%R3GV_"LJWQ#N8@,S
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MMKBQD013]#Y<BI*<H< '@_0UC:9HWB'3]-L=+U^QOM*\,D*U[%9A9KR_.?\
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M4 %%%% !3>G%.I.] "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX%I;^/M+=V.T+:0SW#?DD9I<JZ,>O8]5O!J%Y,;F_N2+F0?-)*V3Q_",=!Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >&_MA9_X53:D8XU2'K_N25\4[(FV
MGJ1_"Y]>*^U?VPMO_"J;<-GG4X0,#/\ !)7Q7)"L:QARO&2&!Y-?!9U_O7R1
M^@Y'_NOS9%'^\AW/^[;H >?\BK-N"JJR%EW'[N>!]*B1'E4*&PPY![&G0GYM
MBD!E;()Z?_JKY_R/IDS4L[KRU"%5.WD,.]:7]I*JAF!VL/EXSR>U84;-YCX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!2J-J^O&,],4P%'4]< YQ3L>V<')!]*-H4C[V/YTG// R.B@8H >I. 5Y '
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MZ1S!GB"LA*G>>%R.#Z]#TKI=6B=O,#^2F,LHP4"X[CGKZ?CQ6;+&IDVL@FW
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MG/2E7.[IQ2'H.>_XTX+E?>@#;TE?*MT[ML>4^V2%'\C5CTIL/[N/RQCY0J'
M]!S^M._6K NZ3\M]"WO_ $KJ*Y73>+V(=?F!KJJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4GI3 .>,G=SFD9ANW!23TXYS28*YP.?RQ[4Y?FW C@G)]*0",H7)^;*C/%*
M67C!YZ#I2+@'+,.F![T*P5L$[AV_*F BA@VTG<?K_*G.&X)"XS_#21D-DXR.
MM 8].%^M(!-P'!Q]:-H.?;\A0,,I4[>.?FZTN!D #@\G/6@!IR<?-D8Y'K0O
M3VSR:7'1P><YQ2LN\9^[0 BJ<N&7/9?\_2G;MJC: 6)_/BF[%4]W)-*N%ZC'
MOB@ 4%NO '7(I?E#8.0?I0K%>"OMDT*VX@D[<CT_6@!ZH.,\'I0V1R<-QD<X
MIK$!<A>5'6G8W+G@#&: !?EY&.F10P*XV\<]!V-)MW=. ./K0PP3QM'8T //
MJ3[8-(,+SG)(I%)Y&<D>HQ4F P.>![T (#P0!NXQ]:5,[=IQ^7%(NX= 1[?X
MTY<,>01_GI0 %>G93W-+O/&.G84A)QS\OI2Y ^G0G_"@!X_U8 & #V'%/W8
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MCE>*OPQA<\Y!KF_">K1:]H]K?1DL)XUDVDY R!FNDM\B/ALCKEO2NDQ)5 7
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P_P#\%?\
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ME30"TQO<TC&FM\Q&*H#4\/Q[KXD\[%S_ )_.NEK"\-Q_+,^.<A16]0 4444
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MT#8[GP!X?_X1OP[IFFJ,+;P(K#/\6,D_G77*I;'H.:JV5KY* 'D^HK05-JC
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M N)EAC+.?*V#_62$9QU';^==GJ5CYRAE^\O0$\-[?0UQ^H6YLP\JA]A.T*J
M[6')!//3G]*AEHSOWC!T8R(@Z_,=W&2,<=/PI+CR/.5&)9S\QVR -DU8"AL
M1QR-U4_>.1CG'Z<=*CDD!5A$&?@\[NO3/0=*DHHRVL:S>:$);I)A]S >G;!Z
MU7F4W%L8G+1R1'=M5Q^9X&[CK5IY-L<J(^""0=J\>V>.3U_.HI,QJHD?:,9
MSN(P"<T@*C1L^^2*-T#KDR;L$M]><$#%5;J-Y]RRY7<!M9@1@'L/3/MS6I#
MF[<Z[5W9+-]XL,$<8K#U7S]5U2/1M)4MJ,A)FN(Y/^/2!N#(WHQZ*.YR>@YD
M!OPYTW^V/%=]JQBS9V2-96DX4;9&S^\*GDX!&W)[J:]HM8]L:KR1BLO0O#MK
MH=C:V=M#Y<4* *!WXQD^I/K[UOPQD'I]:VBK(S>H"/MUXJ15.?3U%.5>OTIR
MKD<]*H0FTT;=W &>U/"CO4BKT^M $]C&1*KXSMY J\V00N<X&*CLU,:DE?IG
MO_G^E..3STJ@!OPJ+.,D#..W>I>WO20VYNIXH0.7;GZ4P.FT.W-OI\8/WG^8
MUHTV-!&BJ!@ 8%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT!7S@$9Y.>]!X91PQ'&10 +\RD#&<_E2M\_S'=Z<4UL*W' )[T,!P .<<!:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3FEZ<UHZ/8&ZE\QU_=K^I]* +NAV'DQ^>X^=NGL*UZ;M_"G4 %%%% !1110
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ML2A4&U1V%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\-_\ !85MO[*6G'_J9[/_ -$7-?BRI(^[Q[U^T_\ P6$S_P ,IZ=@9/\
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M$/PWZ?V;;?\ HI:WZ^TCLC\TE\3"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
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M=Z#Z4OO2<\CI0 8X)SQ2;=QP 2?05>M=)GNMI*^7'ZG@UM6>G0V8^49;^\U
M&;8:(6Q)<?79FMQ5"J HP!T'I2TM !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%7U\=D?G,OB844451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'PO_ ,%C/^33]._[&BS_ /1%S7XH9]LU^U__  6,
M_P"33]._[&>S_P#1%S7XH<# [4T ,QX'0=:0'CUH/&,'CO0I..*8"\_A1P%
MX)I/:C/3/(H 7=UI=W^%-W8Z4;NGKUH =D' Z?2DR-O//O3?,]#Q2_J: %W8
MP#UI&;IVYI,]./:@X'?FD X=.*7<!]?K3/H?PI0W/!%,!=W7VH!_R*3=\N,4
MF,9XS0 _/.:16.> :3G [>]#&F $^G7.>:4M\P[&FD=NU*O?FD JD<G Z=,T
MF-W?.*-N??C'O28SU/- "+QWS3@P(X'-(WXT+G/ZT@#]:&]N31CKC'OBD'Y=
MZ8"KC_(H8\>@H/?M29X_&@ '4<4@P/>E/S9[48&<]?2@!"=W%&,\9Y-!PO.?
MZTF?FZC .*0!]U@:4," *0L,&DW=LT 2>@S^%)SP,8[]*9NVCZ4NX]SGM0!(
MK\AEX.:/O,2<<GBF#!Z"ESD9["@!V[&%Z$<?6E#8XZU&K;2.<X-.91P1GIS]
M: '!NZFG!AP<&HP?E]":5B>W)H EW\#!(]*59>N/IG%1*1]!3F;)RHQZ\YH
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M=OC_ +#EA_\ 'J_>6B@#\'%_X);_ +2//_%"6X/;_B>6'_QZI5_X)>_M(_\
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M #/R(G_8#^.4BC;X/@![_P#$VL__ ([5&^_X)\_':X$@'A"':RD?\A6S]/\
MKK7["T4_J-/NQ?VI7[+\?\S$\%Z;/H_@[0K"Z3R[JUL(()4R#M=8U5AD<'D'
MI6W117?L>0W=W"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 2EHHH *2EI* "BEHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>irtc-20211231_g5.jpg
<TEXT>
begin 644 irtc-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ
M/W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S7
M0_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_
M .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S71/\ H1-2_*+_ .+H_P"(S70_
M^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ
M/W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S7
M0_\ H0]2_*+_ .+H_P"(S71/^A#U+\HO_BZ /W<HK\(_^(S70\_\B'J7Y1?_
M !='_$9KH?\ T(>I?E%_\70!^[E%?A'_ ,1FNA_]"'J7Y1?_ !='_$9KH?\
MT(>I?E%_\70!^[E%?A'_ ,1FNA_]"'J7Y1?_ !='_$9KH?\ T(>I?E%_\70!
M^[E%?A'_ ,1FNB?]"'J7Y1?_ !='_$9KH?\ T(>I?E%_\70!^[E%?A'_ ,1F
MNB?]")J7Y1?_ !='_$9KH?\ T(>I?E%_\70!^[E%?A'_ ,1FNA_]"'J7Y1?_
M !='_$9KH?\ T(>I?E%_\70!^[E%?A'_ ,1FNA_]"'J7Y1?_ !='_$9KH?\
MT(>I?E%_\70!^[E%?A'_ ,1FNA_]"'J7Y1?_ != _P"#S71/^A#U+\HO_BZ
M/W<HK\(_^(S31?\ H1-1_*+_ .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S7
M0_\ H0]2_*+_ .+H_P"(S71/^A$U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_
M .+H_P"(S71/^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_
M^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ
M/W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S71/^A#U+\HO_BZ /W<HK\(_^(S7
M0_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_
M .+H_P"(S70_^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_
M^A#U+\HO_BZ /W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S70_^A#U+\HO_BZ
M/W<HK\(_^(S70_\ H0]2_*+_ .+H_P"(S71/^A$U+\HO_BZ /W<HK\(Q_P '
MFNB?]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?
M_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\
M0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70
M!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1
MFNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?
M_%T?\1FNB?\ 0B:E^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNB?\
M0B:E^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70
M!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1
MFNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?
M_%T?\1FFA_\ 0AZE^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FFB_\
M0B:C^47_ ,70!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FNA_\ 0AZE^47_ ,70
M!^[E%?A'_P 1FNA_]"'J7Y1?_%T?\1FFB_\ 0B:C^47_ ,70!^[E%?A'_P 1
MFNA_]"'J7Y1?_%T'_@\TT3_H0]2_*+_XN@#]W**_"/\ XC-=#_Z$/4ORB_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\5_\%>?^"M'A
M'_@G'\%K^^U"Z6?6+@?9['3X'_TG4)R.(H_[H'5G_A'3FOK+XJ^-8_A]X!U+
M5I9%A6UA9O,?[L> 26/L!D_A7\;'_!7W]O34OVZ/VPO$GB+[7-+X=TFYETKP
M_$S[E2W1R&FXXW2-DY]"*I=P.7_;H_X*4?$S]NCXC7FL>+M=NC8R2%[71;>9
MEL-/7HJA,X=@.K'J<YS7SQ-=23GYF8^W85'14@%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444T 44450!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444P"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J6&ZD@^ZS"HJ* /I?\ 8)_X*?\ Q._8,^(-OJ7A/6KF32W(6]T2YD,EE>)D
M$@*?]6_'#+C&3ZU_5#_P27_X*L>$?^"COP4L=6TN\$>J1J(+VRF8?:+&X YB
MD'?_ &6_B'O7\8]?8W_!%_\ ;]U+]AO]LCP[JDM]+#X7\17<.E:_&&(58W8+
M'<X'\4;$'/<4@/[-J*P_AQXM3QOX+L-21D?[1$"Q4Y!/<_CU_&MRH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^2_P#@M[X\OOAI_P $T?BGK6F3-!?V.AW+0N#T+)L/Z,:_C!U1
MANA1?^6<2@_4C)_G7]D7_!P"V/\ @E1\7O\ L S?S6OXV]5_X_6_W4_]!%/H
M!7HHHI %%?J#^RY_P:F?'G]K']GOPC\2/#_B;P';:+XQTZ/4K.*ZN95F2-QD
M!P%(!_&N]_X@QOVD?^AN^&__ (%S?_$4 ?D#17Z_?\08W[2/_0W?#?\ \"YO
M_B*/^(,;]I'_ *&[X;_^!<W_ ,10!^0-%?K]_P 08W[2/_0W?#?_ ,"YO_B*
M/^(,;]I'_H;OAO\ ^!<W_P 10!^0-%?K]_Q!C?M(_P#0W?#?_P "YO\ XBC_
M (@QOVD?^AN^&_\ X%S?_$4 ?D#17Z_?\08W[2/_ $-WPW_\"YO_ (BC_B#&
M_:1_Z&[X;_\ @7-_\10!^0-%?K]_Q!C?M(_]#=\-_P#P+F_^(H_X@QOVD?\
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MD#17Z_?\08W[2/\ T-WPW_\  N;_ .(H_P"(,;]I'_H;OAO_ .!<W_Q% 'Y
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M0!^0-%?K]_Q!C?M(_P#0W?#?_P "YO\ XBC_ (@QOVD?^AN^&_\ X%S?_$4
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M / J7_XBC_B#'_:2_P"AM^&__@5+_P#$4 ?D!17Z_P#_ !!C_M)?]#;\-_\
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M^,?^"!W_ "C)^&W_ &";;_T4M?9U3+<%L%%%%( HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ^+_\ @X _Y14?%[_L S_^RU_&WJO_ !^M_NI_Z"*_
MLC_X. 3_ ,:J?BYQ_P P&?\ ]EK^-S5?^/UO]U/_ $$4^@%>BBBD!_:I_P $
M1?\ E$]\!_\ L4[3_P!!KZ,^)?A*;Q[\/=;T.UU2\T6XU:REM([^U.)K,NI7
MS$/]Y<Y'N*^<_P#@B+_RB>^ _P#V*=I_Z#7U10P1^;GPC_X-\YOA3^S)XZ^#
MR_'CQMJ'P_\ 'MC=P7^GRZ;9J\ES<2+(]V\H3S)9<J!EV/&!T K&\(_\$+?A
MC\;-8-QX<^*WC!/!_P!JTF+Q?X<2"%&U2_T? MFD++YD)W*&('##I7Z>5Y?\
M4/V5M#\?^(Y=?TV^UCPCXHD7!U71;DV\DQ'W?.3[LH'HP_&M:%.A*\:K:[/=
M+U7^7W,Y<;B,;"T\,E+>\6[-]FGM==GH^ZL>7_%G_@F^_P"T-K4=M\0/B!K/
MB3PMI_VEM.L#86T%S;&>WDMV!N40.55)&P.,X&<UY/J/[-/P[^%?Q/\ "_@/
MQM\7-:\0>*M2NM$M]'LDM(ED@@TQ]UM'((U^7>,!F;DXSQ7M6H_L=?$_4[%K
M5_VB/&D<+ J3%I-JDA!_VJZ3]GK]@[P'^SQKLNNVEO>:]XMNN;G7M8F-U>RL
M1R59ON ^B]*[XX7 4XN52ISNSLHIK7HVY):>B;]#Q9YCG5><*>'PZI1NN:52
M47[M]5&,).[?=N*6^NQY#KG_  1W\+:_X@\*ZE>Z\VJW7A_2(O#UPVIZ3:WB
MWFGP74MS!&%=2$=3*5+C[P[9YK[#L[2.PM(H(56.*%!&BJ,!5 P !4M%>4E8
M^FE)O<*S_%/AZ'Q9X<OM+N&D2&_@>!V0_,H8$9'O5]F"+D\ <DFL=OB'X?1B
MK:YHZLIP0;V/C]:N-[W1G-QM:74\H\3_ +$&D^,_#E]8:CXF\432:E8Q:7-<
M1W"Q,]I&CJD)"J 5'F.>><FM;3_V0M!L-<N;Q=0U9H;A;4&S\Q1;!K<@K)L
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M,_X)V>&?!\R7!\1>*M4U!9I96O+ZZ6>>59(4A=&9EYRJ+SUR*^@Z* /";/\
M8"\*6VIVTC:EK,UII^I0:K8VCNGEVLT<T4QP=NY@S1+D,3@$XQ6AX0_8I\/^
M!_BA9>*--U;7+2>TN9[I[:&81PWC2NS$3;0#(H+' ;.,#TKV:B@ HHHH \K^
M//['_@[]HK7;;5/$5GYVJ:;;B/3+ORT:72Y5E65)X2P.V164>Q'!!K@_$_\
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MQ^$/P[TGPSIC3/I^C0"W@,I!<J"3S@ =ZZ&BB@ HHHH **** "BBB@ HHHH
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M5XC??\$XO .H'2Y&?5DN])@U"WCN(YPCRK=W#W.7P,,8I78QD_=R?4Y]^HH
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M7S-A'<!LBO2P-HP*X<CX6J87$?6\5-2DMDMO5[=-D=6;<01Q%#ZOAXVCUO\
MD>?_ ! _9;\ _%/XH>'_ !GK_AC3=2\2>&&+:?>2I\T9YV[AT?822NX':22,
M$UZ!117VA\N?#G_!R#_RAD^-?_8,A_\ 2B.OXYJ_L9_X.0?^4,GQK_[!D/\
MZ41U_'-51 *TO"O_ "$9/^N$G_H)K-K2\*_\A&3_ *X2?^@FG+8#^QS_ (('
M_P#*,KX;_P#8)MO_ $4M?9U?&/\ P0-_Y1D_#?\ [!-M_P"BEK[.J6);!111
M2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\7_ /!P!_RBH^+W_8!G_P#9:_C;U7_C];_=3_T$5_9)_P '
M '_**GXN_P#8!G_]EK^-O5?^/UO]U/\ T$4= *]%%% ']E7_  1D\&7NH_\
M!*WX%S1^(M7M%?PK:XBB*;$^7ME<U]-?\*^U#_H:]>_./_XFO!?^"*'_ "B?
M^ __ &*EK_Z#7U%4RW*CL<O_ ,*^U ?\S5KWYQ__ !-'_"O]0_Z&K7OSC_\
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M_!%3X%>%]:M=2T_1=6L[ZQE6>":/5;@-$ZG((^?L:^M**7]I8MZ>UE_X$_\
M,%D>7)W5"'_@,?\ (Y6/X=ZA%&JKXJU[:H"C)C/ _P" T[_A7^H8_P"1KU[\
MX_\ XFNHHKCNST['+_\ "O\ 4/\ H:M>_./_ .)I/^%?:E_T->N_G'_\374T
M4786.7_X5_J/_0U:Y^<?_P 31_PK[4/^AJU[\X__ (FNHHHNQV.7_P"%?ZA_
MT-6O?G'_ /$T?\*_U#'_ "-6O?G'_P#$UU%%%V*QR_\ PK_4?^AJUS\X_P#X
MFC_A7^H_]#5KGYQ__$UU%%%V%CE_^%?ZA_T-6O?G'_\ $T?\*_U'_H:M<_./
M_P")KJ**+L=CE_\ A7^H_P#0U:Y^<?\ \31_PK_4?^AJUS\X_P#XFNHHHNQ6
M.7_X5_J'_0U:]^<?_P 31_PK_4?^AJUS\X__ (FNHHHNPL<O_P *_P!0_P"A
MJU[\X_\ XFC_ (5_J/\ T-6N?G'_ /$UU%%%V%CE_P#A7^H_]#5KGYQ__$T?
M\*_U#_H:M=_./_XFNHHHNPL<M_PK[4O^AKUW\X__ (FE_P"%?ZC_ -#5KGYQ
M_P#Q-=111=CL<O\ \*_U#/\ R-6N_G'_ /$T?\*^U#_H:]>_./\ ^)KJ**+L
M+'+_ /"O]1_Z&K7/SC_^)H_X5_J/_0U:Y^<?_P 3744478K'+_\ "O\ 4?\
MH:M<_./_ .)H_P"%?ZA_T-6N_G'_ /$UU%%%V%CE_P#A7^H_]#5KGYQ__$TG
M_"OM2_Z&O7?SC_\ B:ZFBB["QR__  K[4/\ H:]>_./_ .)H'P_U#_H:M>_.
M/_XFNHHHNQV.7_X5]J'_ $->O?G'_P#$T?\ "O\ 4/\ H:M=_./_ .)KJ**+
ML5CE_P#A7^H_]#5KGYQ__$T?\*_U'_H:M<_./_XFNHHHNPL<O_PK_4/^AKU[
M\X__ (FC_A7^H_\ 0U:Y^<?_ ,37444786.6_P"%?:E_T->N_G'_ /$TO_"O
M]1_Z&K7/SC_^)KJ**+L+'+_\*_U#_H:M>_./_P")H_X5_J'_ $->O?G'_P#$
MUU%%%V.QR_\ PK_4/^AJU[\X_P#XFC_A7^H_]#5KGYQ__$UU%%%V*QR__"O]
M1_Z&K7/SC_\ B:#\/M0_Z&O7OSC_ /B:ZBBB["QR_P#PK_4?^AJUS\X__B:/
M^%?ZC_T-6N?G'_\ $UU%%%V%CE_^%?ZC_P!#5KGYQ_\ Q-'_  K_ %#_ *&K
M7OSC_P#B:ZBBB['8Y?\ X5_J/_0U:Y^<?_Q-'_"O]0_Z&K7?SC_^)KJ**+L5
MCE_^%?ZA_P!#5KOYQ_\ Q-'_  K_ %'_ *&K7/SC_P#B:ZBBB["QRY^'^H?]
M#5KOYQ__ !-'_"O]1_Z&K7/SC_\ B:ZBBB["QR__  K[4._BK7?SC_\ B:/^
M%?ZC_P!#5KGYQ_\ Q-=111=A8Y?_ (5]J&/^1KU[\X__ (FC_A7^H_\ 0U:Y
M^<?_ ,37444786.7_P"%?ZC_ -#5KGYQ_P#Q-'_"O]1_Z&K7/SC_ /B:ZBBB
M["QRX^'^H?\ 0U:[^<?_ ,31_P *_P!1_P"AJUS\X_\ XFNHHHNPL<M_PK[4
MO^AKUW\X_P#XFC_A7VI?]#7KOYQ__$UU-%%V.QRX^'^H=_%6N_G'_P#$T?\
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M_P#XFNHHHNPL<O\ \*_U#_H:M=_./_XFC_A7^H?]#5KWYQ__ !-=111=CL?
MG_!P]X/O-*_X(Z_&>>7Q!JU\BZ="##-LV-_I$?7"@U_(=7]AW_!QQ_RAE^-7
M_8.A_P#2B.OX\:UCL9A6EX5_Y",G_7"3_P!!-9M:7A7_ )",G_7"3_T$TY;
M?V.?\$#EQ_P3+^&__8)MO_12U]G5\9?\$$!C_@F7\-_^P3;?^BEK[-J6*.P4
M444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !$G*>T__ 5_F?NY17X1_P#$07^T9_T$/"/_ ()D_P :/^(@O]HS_H(>$?\
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M9M:7A7_D(R?]<)/_ $$U3V _L<_X('G/_!,OX;_]@FV_]%+7V=7QE_P00/\
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M[^T-_P!'"?L\_P#A&S__ "91_P /??VAO^CA/V>?_"-G_P#DROQJ'[>W@O\
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M-[>"\_\ (IQ_^ J?XT ?MQX$_P""WGQRTKPM!]M\:?LN^-M0:4 20ZI-I37
M)X3RC(^UNW4\UZYX0_X+L^/O#,4TGCOX$2WUO#N8W'@S7X-2 4#(_=R%&)]A
M7\]LW[97P[\22QQ3Z*UH&R"R0>2H^I0\T#XS^&;HAM U^]TE_O 073+\W][.
M=P/XT ?U/_LK?\%A/@1^UEJ(TG2_%G_",>*U<1OX>\3P-I&I;R,X2.; E'^U
M&6%?3\;K*BLK!E89!!X(K^0GP-\>_B9XH\,LTW]E?%OPW8'9/8:C$)M2LD[.
MDPQ,H'8ACSBOK']@;_@N#\1OV<H%L]%\5^)?%'@33TE-]X+UQ8;W5]%##:&L
M;J4;Y$C(!$#L1C@>E S^D>BOACX5_P#!:C1?B/-H#:'X4U3Q1X5E?0K#5?%,
M%[!$MI=ZI\D2FV^_N64%7 ^Z0:V?BY_P5*N-%^)?C;P#IOA^WL]6L="UO4-"
MUN'4X=0MYI=-BWR":)0#&3D84D]"#0(^SJ*^-OVM?VP/'GPQ_P""?GPN\=:/
MJ?\ 9_B;Q?>Z#:ZC=VVBKJ,H2\"^<8;4\._)*J.^!7G7PA_X*U^(O!'PIU35
M/%MC>>-CK'C1_"G@F>>P3P]>:RT46^Z^U0D%;8PL"O(RW'% 'Z'45\:^.O\
M@K=)H?@72-?T/X4^)=>M9O"5SXTUB)K^"SET6QMIS#/E9!F1P5)4+C<,'O6U
MJO\ P50T_3?'J*/!&L2> ?[5M-!D\4&\B54U"ZM_/AC%M_K&0CY2_0,: /K"
MBOB3Q'_P4O\ B9XF^'7P[\6>$_A"MOHGCKQ;::%8OJ.OVWFW\,D\D+X11F%B
M8R06SQ]:]+^#_P#P4*A^*O[5^K?#*;PG<>'?[/FNK:"[U+48H;F^DM\;VCM2
M-[1MGY74G(&<<B@#Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY/\ KA)_Z":J6P']C7_! _\ Y1E_#?\ [!-M_P"BEK[.KXR_X((?\HR_AO\
M]@FV_P#12U]FU,MQ1V"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?Q+^(FD
M_"3X>ZUXHUVZ6ST?P_92W]Y,W2.*-2S'ZX''O7\P/_!0?]LSQY^WQ\<9_'MW
M'>2W_BFY;2/ 'AZ(;ETVP#X63RR>9&^\\@')('05^MW_  <@_'74F^$GP_\
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MB5Y/"/C.Y7PZFGZ%9M9:AH9F!WZI<7Q=LQQ 9V1HAYX.>:-0/!-2_P"#2O\
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MX:?%OQ[H%QKJZQ=^$_#OAJ3PY;Z&NK7D?GQO,)6,\ZS"293R"DA8'-=]?_\
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M_5_QH M455_MNS_Y^[7_ +^K_C1_;=G_ ,_=K_W]7_&@"'7_ +UE_P!? _\
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M_AA[XR_]$P\;?^"UJ/\ AA[XR_\ 1,/&W_@M:CZU1_G7WH/J&*_Y]2_\!?\
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M?^"UJ/\ AA[XR_\ 1,/&W_@M:CZU1_G7WH/J&*_Y]2_\!?\ D>7?-[5^XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^'W_!9[XEMJO\ P4&^*VOZ
MA.JZ7\(_APEC8M(A$<-Q=9=AGN69T&1[>E?'OQ,F/[-'_!&'11:M)9:KXJL9
MM6NI-WSK/=-C ([+T7TS7M?_  5V\8:E>^*/VV]0OEAG_P")MI6AV@5=ODPK
M%;MSZG.:\)_X*^&'X??\$^/ &BP[FADTFPACR<G) <_S- SW;_@RY_9:TK4=
M7^*WQDOK6.XU;2Q#X;TF9NMF)!YMP1[NIC&>P7W-?KY\1?\ @I=\&?AG^U7X
M9^"5[XNM[KXF^*+H6D&BVB&66U8J6!G.,1@@'&>M?'?_  :0:#9:;_P2:AO+
M>U@ANK_Q-?&YE1 'G*[0NX]\#CZ5^@WC']FKX?\ Q ^)FB^--8\'Z#?>+_#L
M@DT[6GM5^W6I' Q*!NP!V)(J7N-')W?[<O@[1/C1KW@N^>ZT_4/#4#W-Y+*0
MN$54.]4^\RG> &'&>*DO_P!OWX2Z7X1C\13>,K1-':TFO_MFTE(TAYE5L<K(
MO]WK5KQ]^Q;\._BEXROM>\1:-<:O?ZA:S6;BYO9GACCE"B01Q[MJ;MB\J!TK
MDV_X)<? MELU_P"$'MT73]-;2842ZF55MV&&& V-S=VZGUI: =!XA_;U^'_A
M_P ':AK$>H:M>6FF&$7"164BL#+)&@4 CEQYJ$IUPP]:](^'?Q$T;XK^"=/\
M1>'=0CU+1-6C,MK<QY"S*&*GCU#*01V(KD;G]E'P/=^)M0U1]-NO/U1XIKF$
M7TPM9)8VC99?*#; ^8D^;&3MKK?AY\/=(^%7@VR\/Z#:"QTG3PXMX Q;R][M
M(W)R>69C^-(9LUP?[2G[,G@?]K[X/ZKX#^(GA^S\2>&=83;-;3K\T;#I)&W5
M)%ZAAR*[RB@#\#_VO?\ @S"O+GQ#J&J?!/XG:>FFS/)-#HGB2W=9802-L23Q
MY# #/S. >!7SW_Q!V_M/?]!;X>_^#0__ !-?TZ457,Q6/YB_^(.W]I[_ *"W
MP]_\&A_^)H_X@[?VGO\ H+?#W_P:'_XFOZ=**.8+'\Q?_$';^T]_T%OA[_X-
M#_\ $T?\0=O[3W_06^'O_@T/_P 37].E%',%C^8O_B#M_:>_Z"WP]_\ !H?_
M (FC_B#M_:>_Z"WP]_\ !H?_ (FOZ=**.8+'\Q?_ !!V_M/?]!;X>_\ @T/_
M ,31_P 0=O[3W_06^'O_ (-#_P#$U_3I11S!8_F+_P"(.W]I[_H+?#W_ ,&A
M_P#B:/\ B#M_:>_Z"WP]_P#!H?\ XFOZ=**.8+'\Q?\ Q!V_M/?]!;X>_P#@
MT/\ \31_Q!V_M/?]!;X>_P#@T/\ \37].E%',%C^8L?\&=G[3Q/_ "%OAYUZ
M_P!J'C_QVOK3]B3_ (,U?#O@;Q/8:Y\<_B$GBR&TD$QT#P_ ]O;7&,$)-/)A
M\ ]0@P1WYK]P**.9A8\K^,/[.5YJO[+\OPY^%?B+_A4,EK;PVNCZCI%FC_V1
M'&ZG;'$>/F4%3G^]7ROKW_!$"Z\7_M'^(OB%K'Q:UC4I=>U/4=22SGM-ZV7V
MS2CI[I'N8A0"3+A0 3Q7WY12N%CXR^"7_!("U^$'P@^'?@Y?'UQ-8^"= &@7
MEQ%H\:7FJQK+/*A$^\&)09W!3# _B:VO%_\ P2UD^(WPR\3:#X@^)VI:C=Z[
MJ6E7UM>?V#;"'3DTZ57AB^S,QCDW;0&)QG'2OK.BB["Q\W_$#_@FSX5^(W[1
M/PN^*&J7$U[XJ^$=N8="D#&UM\M'L<R0H-I!Y( P%S7O$D/B"567SM(&X8R%
M?C]*V**0S+\&>$K?P5I"VUL/F9O-F<#'F2'JV.V:_F1_X.M_V<=/_9B_X*F:
M=XV\.0KI2_$/38=?F$!V_P"G1N$FE'H6(4_7/K7]05?A3_P>PZ'9CPA\#=2^
MRP?V@US?6YN=@\PQ[0=F[KMSSBJB)GC/[6FK6_C3]B3X1_%-=K7_ ((\06<A
MEW?+]FN-OF%NY"A<CZFOT(_X(77%KH'[9/QX\(&WM;C1?$-IIGBZPWVX97:1
M-CNI/3.X9'?BOS3BEA^(7_!#W6;MMP&FV5I<PC/\:'9S^9K] /\ @CMXKU%_
M^"D/AAHO*ATWQ1\';>:YAVY;S('A52#^=4(_7+_A#])_Z!FG_P#@.O\ A1_P
MA^D_] S3_P#P'7_"M*B@1F_\(?I/_0,T_P#\!U_PH_X1'2,X_LW3_P#OPG^%
M:5?.?B3X1_$3_A9OB'4-)TV..2^N[EK?5)-9&V2UDC5%A,&,J0=Q!['IUH ]
MZ/A+1P<?V;I^?^N"?X4@\)Z.5S_9NG8]?(3_  KY\;]G+QQ=>#;[[9';W'B:
MU\.7FE6MXFI,!>W!(\B4Y^Z=A*DG)&,]ZZ37?@GXD\7?"7PIHL-E:^'IK34D
MFU.,WGG*(@C!G4IC<VX@@>HH ]@_X1'2!_S#=/XZ_N$X_2D'A/1S_P PW3O^
M_"?X5\ZZE^SQX^,VIVH;4+A?-?=J::PBRZQ$/+\J-HV!"*-K;@>""<=:T[[]
MG[Q5K/AIKV32;#3]>70WM8K>VU%O*2Y$QV8)XYBP">@SB@#W<>$M';IING_]
M^$_PI?\ A#])_P"@9I__ (#K_A7@NF?!OQM%K_A6:#08])^PFR\^XCUE66R$
M<P:X7RP/WGFQ@KQTS7T90!F_\(?I/_0,T_\ \!U_PH_X0_2?^@9I_P#X#K_A
M6E10!F_\(?I/_0,T_P#\!U_PH_X0_2?^@9I__@.O^%:5% &;_P (?I/_ $#-
M/_\  =?\*/\ A$-(!_Y!NG_]^$_PK2KQGXQ_ OQ-\1/B5JFIV.I+I]FNB1P6
M$D<I%PMT#,6"]D5MT8+')(^E 'J9\)Z/C_D&Z=_WX3_"E_X1+1QG_B6Z?QU_
M<)Q^E?->D?LX_$'PUXCM7N+&SUW35DC=K5-2$-O"?+ +JK@GS-V2QSAC@C%:
MS?![QY%>ZI"^BIJ&CMJL=XT<NLK'>:O'^_W1NZ@*BH6B*]R%P>E 'OP\(Z03
MC^S=/S_U[I_A2'PGHX&?[-T__OPG^%?/?A[]GOXBZ=XD\4Z@\\,*ZOJ5[+9(
MFH%I8;=G0P(['C"J&  ^[[YK!TS]G[XH6J_Z9I%O?V:ZU!=2V!UI0MW"HN0[
MDXP"3)#P>3M]A0!]1CPCI!/_ "#=/_[\)_A1_P (?I/_ $#-/_\  =?\*\C^
M WP:\7>"?B]X@UK6I8UTO5+R]EMH(KKS&CB>13 K@\':@( 7[OO7MU &;_PA
M^D_] S3_ /P'7_"C_A#])_Z!FG_^ Z_X5I44 9O_  A^D_\ 0,T__P !U_PH
M_P"$/TG_ *!FG_\ @.O^%:5% &;_ ,(?I/\ T#-/_P# =?\ "C_A#])_Z!FG
M_P#@.O\ A6E7'?&SPSK7BKPI!;Z%*8;M;N*1SYWE9C!^;GZ4 ;Y\(Z.O73=/
M'_;!/\*3_A$]'_Z!NG?]^$_PKP[3_P!G#Q7=7L=CKEU_;.E:;=V0L)Y;UA,;
M52S3))_>9<JNX\N ":HWGP!\::GHOB#3X=+TZQN+C4?.M+V?4/-CN8 3M1U7
M##''!/:@#Z _X1'2,_\ (-T__OPG^%(?">CK_P PW3N?^F"<_I7SI>_LN^/M
M0T#Q#-_:[1ZE<:?9V5BLMZ6DN,1P+-YT@XP"DA&T9.X^M:W@CX#>+M#\=:6F
ML:?;ZOHL4,T#R_V@ MF&=B/+C/S;2I'&<B@#W7_A$]'_ .@;IW_?A/\ "E'A
M#23_ ,PW3_\ OPG^%?/^E_L\>*O"GB'0&AT6'4K&%+G[4K:J%,$C3,8I!N^\
M0A7ITQBNR_96^$GBGX5W/B+_ (22Z%PNI-!);+%<>9"A'F;R%/(D.Y=QZ-@8
MQB@#T[_A#])_Z!FG_P#@.O\ A1_PA^D_] S3_P#P'7_"M*B@#-_X0_2?^@9I
M_P#X#K_A1_PA^D_] S3_ /P'7_"M*B@#-_X0_2?^@9I__@.O^%'_  A^D_\
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MX(^)-=L]/M;[QL+B_G2WB\SP;JB)N8X&6,& ,GJ>!18#Z<HI2,&DI#"BBB@
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M1_PD#?\ /E>?]\?_ %ZT:* ,[_A(&_Y\KS_OC_Z]'_"0-_SY7G_?'_UZT:*
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M'_!,WX;_ /8)MO\ T4M?9E1+<4=@HHHJ1A1110 4444 %%%% !1110 4444
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MX-UKXS^+6^SQ-(UW-NN+DJ?)AS]XGZ>@K[#U7PQINNS+)?:?8WDB#:'F@5V
M],D=*GT[3+;1[7R+.WM[6');RX8PBY/4X'<^M?*?ZIRG47MZSE!=+:_F>_\
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M';MPT8<YW9'%?5%9^H^$]+U?4[>]N]-T^ZO+7_43RVZ/+#_NL1D?A0!\N_\
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M4E@A?[5);"6!@,31%H\A@1E2*^NJSK/PEI6G6T,-OIFGPPVX"Q)';HJQ@<@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ.%?H#_P1U_Y/]^%_P#V1P_^C8:L70_7W[+J'_/U#_WY_P#KT?9=0_Y^H?\
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M?^$WT4Z[;:7_ &QI?]I7D/VBWM/M2>?/'_?1,[F7W Q6I0!1^RZA_P _4/\
MWY_^O1]EU#_GZA_[\_\ UZO44 4?LNH?\_4/_?G_ .O1]EU#_GZA_P"_/_UZ
MO44 4?LNH?\ /U#_ -^?_KT?9=0_Y^H?^_/_ ->KU9]_XITO2M3M[*ZU*PMK
MRZ_U$$MPB2S?[JDY;\!0 [[+J'_/U#_WY_\ KT?9=0_Y^H?^_/\ ]>H]>\7Z
M3X5$?]J:IIVF^=G9]JN4AWXZXW$9J];W$=W;QRPR++%(H9'1MRN#T(/<&@"K
M]EU#_GZA_P"_/_UZ/LNH?\_4/_?G_P"O4PU:U:&&075N8[A]D3"0;9&]%.>3
M["K% %'[+J'_ #]0_P#?G_Z]'V74/^?J'_OS_P#7J]10!1^RZA_S]0_]^?\
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M_P#>LO\ KX'_ *"U%*143)\<[O\ A'OEP6^TV^,_]=4K<,EYG_5V_P#WV?\
M"L/QM_R ?^WFW_\ 1J5TU$0D5?,O/^>=O_WV?\*/,O/^>=O_ -]G_"L3QA\7
M/#_@+Q+I6DZMJ$=G?:TD\EFC@XF$*;Y,'ID+SSZ5RT_[7W@:VTJ;4'U&X&G6
M\0E>[^S-Y(RNX+G^]MYQBJ)/1/,O/^>=O_WV?\*/,O/^>=O_ -]G_"N-U?\
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M_F?DW_Q#M6O_ $6;6/\ OS_]E1_Q#M6O_19M8_[\_P#V5?K)_9-K_P ^]O\
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MQ:UG6M"\#7LWA_0V\1:DR^7'9+<I;E]W&=[\#&<_A71?:(_^>B?]]4?:(_\
MGHG_ 'U0!XU\"/"OC#X"?LH:-X7FT/\ M[7O"FAVMFJ0WJ*NIS!!Y@1W(VA2
M2,MC.*^?;+]G#]H[P9IIL?#NLOIZR:=YNGA-1C^R:;.[7+W$<R$%I)&+P;'4
M[5*'\?N?[1'_ ,]$_P"^J/M$?_/1/^^J /BKXU_LI_&;7?B)\-1I^M:MX@T;
MP[J.FZW=/?:M&D:74*SFX\U0H9]S.@3;P #3?#/P3_:>USP-J5OK'BRZL-0_
MX2"\U&R:"ZAC=+<VDGD0$C<#$+G8<'!*YSBOM?[1'_ST3_OJC[1'_P ]$_[Z
MH @T=+B/2+5;I@UTL*"8CN^T;OUS5JF?:(_^>B?]]4?:(_\ GHG_ 'U0 ^BF
M?:(_^>B?]]4?:(_^>B?]]4 /J'4/^/";_</\J?\ :(_^>B?]]4DDL4L;*SIM
M88/S4 >"_&OP1K7Q)^%NKZ'X=\47G@O6M015MM:M;=;B:Q(<,2J,0&R 5Y/>
ML$?!WQ;_ ,+2M]<_X61JS:-%X>.DOHGV*/R9+S&/[0WYSOSSLQC->_'P3I>?
MO-_W\H_X0G2_[S?]_* /&_@#\/M>^%OPRTO0_$OBZ^\=:S9LYGUJ[MDMYKO<
MY89120-H(7KVKZ @_P!0G^Z*Q$\%:6CAMS'![R5LK/&HQYB<?[5 %/7_ +UE
M_P!? _\ 06HINN2J[V05E/\ I Z'_9:G5,BHF3XW_P"0!_V\V_\ Z-2NFKE_
M'B&7PVRJYC9KB !P,E?WJ<\_UK2.@7Y/_(:N_P#OS%_\31$)&'\4O@1X=^,E
MQ;MX@M9+Q;:%X$02&,!7>-SR,$',:C((R"1R":YV_P#V0O"^H036K3:HNG7#
M)*UFLX\GS4 "R 8^]A1[5WO_  C]_P#]!J[_ ._,7_Q-'_"/W_\ T&KO_OS%
M_P#$U1)R5K^S'X8L)-3^SQWD,>J0W4$D2S?)&MP4:4(,?+ED!]B34'C#]EGP
M[XYEOEOYM2>QU!DEELEF @\U0J^8!C.XA1GG!YKM/^$?O_\ H-7?_?F+_P")
MH_X1^_\ ^@U=_P#?F+_XF@"#X??#C2_A?I-QI^CP"UL9KE[I8% "1,^"P4#M
MG)YSUK>K(_X1^_\ ^@U=_P#?F+_XFC_A'[__ *#5W_WYB_\ B: ->BLC_A'[
M_P#Z#5W_ -^8O_B:/^$?O_\ H-7?_?F+_P")H UZ*R/^$?O_ /H-7?\ WYB_
M^)H_X1^__P"@U=_]^8O_ (F@#7(R*\EU;]CSPSK&OR:I)<7WVZ299PP6+RU9
M2Q!\O9L9LL?F(+'CGBO0_P#A'[__ *#5W_WYB_\ B:/^$?O_ /H-7?\ WYB_
M^)H XE?V3_"<5[J5U%'=0WFKG-Y<1NJR3G>C@DX[&,8[=:@T;]D;PWX3OH[K
M0[O6-(N%E2=WAN=WFRJFS>P8'YBF%/LHKO?^$?O_ /H-7?\ WYB_^)H_X1^_
M_P"@U=_]^8O_ (F@#EOB%^S9X:^)^J6U]J\=U+>6LT,RS1R[&8Q]%..JGJ0>
M,\\50_X9+\*WT*)JBWVM>5/'-&;R4-Y8C7:B# 'RA<CW#'/6NX_X1^__ .@U
M=_\ ?F+_ .)H_P"$?O\ _H-7?_?F+_XF@#S#_AA?P2HA2..\CAMHVCA160&(
M,&& VW=M 8C;G;C'%;MG^RWX9M[S2;J2.2XO=#$:V,Y2-&MPCNPVA5 &2[9P
M.?UKLO\ A'[_ /Z#5W_WYB_^)H_X1^__ .@U=_\ ?F+_ .)H UZ*R/\ A'[_
M /Z#5W_WYB_^)H_X1^__ .@U=_\ ?F+_ .)H UZ*R/\ A'[_ /Z#5W_WYB_^
M)H_X1^__ .@U=_\ ?F+_ .)H UZYOXH?#.Q^*_AE]*U"21+:0Y;8B,3QCC<I
M //4<BKO_"/W_P#T&KO_ +\Q?_$T?\(_?_\ 0:N_^_,7_P 30!Y_=?L:>";J
M6QF:SF6ZT]IF2Z#C[1)YD8C8/)C<PP!@$\&MA?V9/!IL+.W;1[62.TO&O3O0
M,UQ(=_\ K#CYA\YX/%=1_P (_?\ _0:N_P#OS%_\31_PC]__ -!J[_[\Q?\
MQ- ''2_LR:&E]K4]G<7FG?VW*DT@M5BC,+H05V$)D $< D@>E6K7]G_3-*TG
M0[73=0U73FT&2XDAGBE4R2-.[/+OR"#N9F/0=:Z?_A'[_P#Z#5W_ -^8O_B:
M/^$?O_\ H-7?_?F+_P")H X:3]E/07N//%]K2W4$D4EE,+@;K#RY&E41_+C&
M]V/.>M.G_90\,WFIZQ?7$VL7&H:]%)#>W$EX2TR/&L97'0 !01@<$GUKM_\
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M69B223R2:X7_ (+B?\F8_#/_ *\;#_T4*]*_;?\ ^32OCM_U]Z5_Z E>:_\
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M*6T\N2[1Y"A,:\D[=I)'7&/6NE^$?QDM?C'IK7=GI.O:; L:29U*T-LS;L\
M'G(QS]17S[^S9_P4VU#XV^._$/AO5OAEXF\-ZCH>G:CJB27"[$NXK:0J@1&
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M1;WUE+YD,I5MK8;V((_"O;H/]0G^Z*8&3JNE6]G/9/%$J-]H R/]UJL4:_\
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M*M__ $4M?9E9RW%'8****D84444 %%%% !1110 4444 %%%% !1110 4444
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M 'I]M4J6^7$IP1C&#W(]:VK']GGQ?!?W?F?%;Q9-:W +1IY$8>%F8Y ..@7
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M1/)++C#Y0+SO&WCK0!BVGQ4L[_5]-LU\'_%)6U"]2T,LHD$-L&4MYKMYG"#
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MY.]LG?(Q9OPR:M?V\W_0/U#_ +]C_&C^WF_Z!^H?]^Q_C0!H45G_ -O-_P!
M_4/^_8_QH_MYO^@?J'_?L?XT :%17RE[*95Y+(0!^%5/[>;_ *!^H?\ ?L?X
MT?V\W_0/U#_OV/\ &@#RWQ3X.T_QKH5SI.M:7:ZMIMT L]I>6XFAE ((W(P(
M." >>XJF/A=X>&OKJP\.Z3_:D=G_ &<MW]A3SEML8\D/C/EXXV],5ZY_;A_Z
M!]]_W['^-']N'_H'WW_?L?XTK >7^#/!&E^ ]'MM)T'2;/1]-MV)AM+*V6&&
M/)R<(H &22:]@AXA7_=%9_\ ;A_Z!]]_W['^-._MYO\ H'ZA_P!^Q_C3 -?&
M6LO^O@?^@M15/4M4-Y<62FUNH?WX.Z1 %^ZWO5RID5$R?&__ " /^WFW_P#1
MJ5TU<SXZC\SPZ5Y^:X@&0?\ IJE;!T&$_P#+2Y_[^FB(2+U%4?[ A_YZ7/\
MW]-']@0_\]+G_OZ:HDO451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_G
MI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L
M"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O4
M51_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_I
MH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN
M?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_
M #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]_31_
M8$/_ #TN?^_IH O451_L"'_GI<_]_31_8$/_ #TN?^_IH O451_L"'_GI<_]
M_31_8$/_ #TN?^_IH O5BK_R-%__ -<HO_9JN?V!#_STN?\ OZ:SK*T6S\2:
M@JM(W[N(Y9MQ_BI2V&MR_1114%GQ#_P<<?\ *&7XU?\ 8.A_]*(Z_CQK^P[_
M (../^4,OQJ_[!T/_I1'7\>-=$-C,*U?!_\ R%_^V4G_ *":RJU/!_\ R&#_
M -<9/_035,#^QW_@@L<_\$T?AS_V"K?_ -%+7V77QI_P05_Y1H_#G_L%6W_H
MI:^RZSEN*.P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J^JAFTNY"*SL8F"J.K'!
MXJQ10!_-7^VA>RW/[)O[0$-U8WVEZA8ZEIEM>65Y%Y=Q:3*B;D=?49'3@YKS
MW_@N)_R9C\,_^O&P_P#10KWK_@KMNQ^V?NSN_P"$PT[.>O\ Q[P5X+_P7$_Y
M,Q^&?_7C8?\ HH4#9^F'_!J)_P HB]+_ .QHO?\ T-:_2_X^^&D\6_"^[T^7
MPW;>+K>X>(3:7/@QW";ANR"0&QUP3@XK\T/^#43_ )1%Z7_V-%[_ .AK7OG_
M  5R_P"">/A/]HJVM_'S>"_$'CCQII=O'80:;8^);S2TN82W  A<+D$Y+$=!
M6O*Y62,I34=6>IZ9^S1H<NH^']/?X2+8:3JMK(=:6/4G,5A+ (S;(H$@#*Q+
M#..-HK$\+_"+5/!FO2&X^"EO(UN98[&XTS7I ILURJ1R!VYD*LW'3..1C-?G
MWJ'_  2Z\-R>'H9[/]F;XCP74<TD=S'<_$K47++'*$W($D_C4EAGI5ZZ_P""
M7?@'2++7OM'[./Q9N+BQ,ILUM_'^HNE[P/*"$2?=!.&+<T_82,_K,?ZL??5G
M\%;7Q'\0=/L[[X"W5M8W=RINM7?Q"<VVU' D*AMS?>(]?F/I7T=\//AAHGPJ
MTF>QT&Q^PVUU.UU*OF-)OD8 %B6).3@?E7Y _!;_ ()&>#?B9I4=KK?P*\?>
M$=073YYYKZY^(&IO#YT=O&Z(D?F9)>5V0 ] AJC/_P $G_".EPZEI/\ PH/X
MC:CJ5GI[2VFKKX^U*.SO;E8MQB,?F;EW/A5/3&31[%A]9B?I]^V!\-[CQ[>^
M$9(/ -CXV6SO76XEEF\F;2X'3#R0MN4AR0HX/3->2^(/V6_#?C>_CU#4_@KX
MDO+^XN1:*LU_Y<,$#H0)&471&U<?, /ER-H.3CX9/_!,SP"=$DD7]FOXJ?VA
M:RR0S0_\+$U-HYF2.-OW;"3@,SL 6_YYG/:LWQG_ ,$QO#.EWFE3:?\ LT_%
M"2SFM)KJZA7X@ZC+-N&/+BSYF%).<]_2CV+#ZS'^K'WZW[.]YH-[;:/IOP=+
MV&ERF873:],L;L5?)C_?%B3T^;&T$#GM2^&?@CQQX9U1O$(^!-I8W6DR(MA"
M-6)N)+>.0+&,&4H) K,V23D#'>OD/6_^"0'P[_M'PBMA\%?B*L>M0:=/K"R>
M/=3D_L?S9)%NEW"3YC&H0CV))[5Q\W_!,WPGIAUFS_X9?^*NJ7.GFX-K>1?$
M?4(;>]VRE8HPK2[MQ7#,P^7GBCV,@^LQ/VZC)9%)7:2,D>E&&K\6_A?_ ,$M
M/ VN^"/&6H^)/V;_ (I:?J6@VOVK2;"V^(NH-+K):5E$(S+A76,(Q/0DG%:?
MB+_@DW\/],^"VG^*+/\ 9U^)5UK%XC32>'V^)6H_:[9%Z*Q$FW>QZ#TH]BP^
MLQ/V1PU&&K\5[G_@ESX*N]%M[ZS_ &9_BA:Q273VMQ'=_$K4%N+89?9,%$F'
M0! 2.IW@"OHGP1_P0-_9QUSP?IEYJ'AOQ]9WUU;))<0'QOJ8\IR.1CS*/82>
MPGBH(_1_#48:OSU_XA]_V9?^@'X^_P#"XU+_ ..T?\0^_P"S+_T _'W_ (7&
MI?\ QVG]7D+ZY'LS]"L-1AJ_+SXY_P#!"KX ^#O"[7&@:#XPEU#*"..[\>ZC
M%%(2V,%C)QGI7FNJ?\$5?"<%Y<+:_"S5IH(Y@8G;XHZBCS1\$\&3Y6ZCGVK6
M."J-7,)9G2B^5W_#_,_8W#48:ORW\'?\$+?@+J?AJUGUKPOXVTO5)%/GVL/C
M[49XXCD]'$G/&*]*_9N_X(Y_ GX(?'3PSXM\.Z7XRAUK0;U;JT>Y\6W]U"L@
MZ;HW<JP]B,4Y8&HE?0F.:TI244G_ %\S[*\9>$_%6I^(9+C2=0T"WM6AVI]J
ML#+-')_>W9&1VQ[T[0O"GB6TM;5=0N?#]W/#M\V2*Q,6_DYVC)VYXK\W?V\O
M@+\'/BC^V_X\N/'GP?\ B/K<VEBP-QK^C^)-3M;2:.2VDD(\N-Q$LBF,  <$
M$DUYCI_['_[)OB7Q9I.A:)\&?C?JFJZYIMI?VB?\)CJ,,.ZX#%8I)6FVH1M)
MR>"#7$>F?KMJGACQ%+-*UE>:+;@RAD#V6X[<'()SU)QS4GA#PYKULNW7;C1;
MR Q[3%;6?E@-GKR3Q[>M?C+\6_V-/@3\/!\$KZT^!_CFZTCXCV5]J'B5W\?Z
MU*_AB.U\M64-&Y0L6<C]Y@<8K/@^"_[)$EG-J<GP1^-L.@JTEO'=/XTU(32S
MQW"0M^[\W B_>*0^>>E '[I*NU<#BF2VD<Y'F1I)MZ;AG%?"6C?\&\G[+^M:
M1:WB>'_'L:7<*3*LGC/5%90P!P1YW7FK7_$.A^S!_P! /QQ_X6NJ?_'J /M]
M=)M455%K;A8SN4",?*?44?V3:^:9/LUOYA&"WEC)_&OA[_B'2_9A_P"@#XY_
M\+75/_CU'_$.E^S#_P! 'QS_ .%KJG_QZ@#[A;2;5_O6MOQTS&.*=;:?#9$^
M3!#%NZ[$"Y_*OAS_ (ATOV8?^@#XY_\ "UU3_P"/4?\ $.E^S#_T ?'/_A:Z
MI_\ 'J /N#7/^01<?]<S_*OP-_X/2_\ DEWP)_Z_+W_T"OVA_9F_9 \$_L3_
M  8NO!_@&UU2UT/S9;O9?ZE/?R^8_P!X^9,S-CVS@5^+W_!Z7_R2[X$_]?E[
M_P"@54?A8NI\W_"7_E!%XG_[!T7_ *.%?9W["_\ R<7\#/\ L$>'/_2V&OC'
MX2_\H(O$_P#V#HO_ $<*^SOV%_\ DXOX&?\ 8(\.?^EL-2,_;ZBBB@ HHKS+
M4M8\4#5OB-!'J;QI96L<VCL+12+4F'<0./WAW#OGK0!Z;17EVA^+/$GB:/1[
M.*ZEM;@>&_MU]<M;#'VET C^4C@[LMM'IBN!MOC9XB.G_":*Z\1WEGKWB#3X
MKK4;=]-46TJ*,SRS-L)1CT1$*DG/84 ?1]%?/WBGXJ^)H+CP>1KUSI6I>*M=
M:6WT^2P5H4L%D ,<K["1F-25((8M(!G K'\,?%[QUKFE^.FBUB[DFTTK-"SZ
M:H^P2"\>-K91M&\&$*V3N/S9S0!],T5X%X5^+WC'5/VPKS09Y)!X7CM_+2!K
M<*V\1*YD^[G:6. ^_!Y&T8S7OM !1110 4444 %%%<3%X[O;?X[:EHMS^[T>
M'1[6Y@8Q'YKB2:=6&[O\J+QV_&@#MJ*^=]"_:*\<I\3;JSU+1UC\-6OBG5]/
M.H!3N:UMX \(\L+GELC?GYL5-X:_;!\0^*-.AF@\'30B.VO[NZ-QOC^2W,04
M(.>7\W(R>BG\ #Z"HKYE_P"&V/$VA:DT%QX1GUPW&HR11MIN3$D*A>C-M^;G
MWQ@]:Z*S_:M\20:C<2ZAX3CMM'L_)EFG261Y1#+/-"I"[?O+Y)9ASPP_$ ]X
MHKY_TK]KOQ)K_P#;$=CX.F,FD3D^9<[X$NX/*\T/&/FY(X'/7L.E>[:+J0UG
M2+6\6-XUNH4E".,,FX X/N,T 6J*** "BBB@ HHKD_B[XHU#PGH=C/IJ[I)M
M1MX)/W>_$;N _';C//:@#K**\E^,GQ<\4>'M=T\>$])CUZSO-(N[QLR>2$9%
MRC;BIS_N\$UQ\7[8^NV,UMI__",W.I7DFF0RFX$+QQ+=-Y8>-SUX\S/ ' ZG
ML ?15%?./Q%_:^\4> ?%.I+)X;^W6_AZSE:ZLK)7DN+R8+#@ID8$>9#CG)"G
MI5S0_P!K3QAXK7%EX%^RM']C247T[1DO<&0 J%!&U?+R>3C(H ^@J*\&M_VQ
M=0N=2T.V3PI?-+JV@MJ<R!&VV-P(A((&?'.<XX6O2_@S\0-0^(?AF>XU73%T
MO4+.X-M-$C%HV.Q'RI(!(P^/J#0!UU%%% !39)%AC9FX51DTZH=0_P"/";_<
M/\J ,@_$&QS_ ,M3[[:/^%@V/_37_OFO%_CY\5KCX'_!_6O%5KX;UGQ=<:.B
M.FD:4@:\O-TBIA >.-V3[ USQ_:3O3\7[?PK_P *_P#& M[CPT?$']K>2OV1
M) N[["3G_7]L=,T@/HI/']B[J/W@R<9V]*W%.Y<^M?.O[-WQCN/C[\)M)\57
M7A?7/!L^I-(&TC6$"7EML<K\P'][&1[&OHB#_4)_NBF!1U_[UE_U\#_T%J*-
M?/S67_7P/_06HJ9%1,GQM_R /^WFW_\ 1R5TU<SXW_Y '_;S;_\ HU*Z:B(2
M.&_: _:&\._LS^!3XD\4_P!K)I,<GERRV&FSWQ@^4L6=8E8J@"G+$8''K4_@
M3X^>%OB-H-OJ6G:D%M[J;[/;BZC:VDN),!MJ)( S'!'05SO[6'[/VJ?M&^"]
M)T6Q\1?V':6>JP:C?0-;^=#JT<666VF&0?+,FQB ?FV '()!\H\<?\$SU\<>
M)[?5YO%MQ'=-K%QJERJVH\M/-97VP#/[IE90 PYV\51)V/B;_@I/\)_"WA_4
M-2DU;6+RWT9VCU1;'1;NZETI@[H1<(D9:+F-OO <8/0BO7_ASX^L?BCX(TWQ
M!IB7T>GZM MQ MY:R6L^QN1NCD 93[$ UX-X._X)YQ^%K'XK+)XNU"^NOC$D
MDVORO @'VLY5)HE'W0L.R/;T.S/4FOHO2+#^R=)M;4,7%M"D08_Q;0!G]* +
M-%%% !1110 4444 %>*_$C_@H)\+?A;!XNDU'7+RX_X06^AT[75L--N+Q]/E
ME"E-PC0G:2P7<,J&^4G/%>T3*SPLJMM9@0#CH?6ODVS_ ."56FZ;_P )3+%X
MY\137/C:T>WU@W"I)'*QOEO0Z+CY2)-XZGAS0![;IG[57@_5-/CG6YU**630
MW\1-:S:=/'=0V:L%+O$5WJQ)&$(W-V!KBM)_X*8?"'5]"T#4AKVH6MKXDU63
M1K/[5I-S;N+B-U1_,5D!C0.RKO8!=S 9YJ37_P!B5]0_:ET_XHV/CKQ%875J
MC)/I6R&2SN1]E>W0$E=X5=^[;N(R,\5R/Q._X)C:3\1-*^'MJVN/&W@F5YY9
MI;59)+N:2YCN9+A3_!,SQXW<\,: /8?''[4_@OX?^'O%&IWU_=36O@VXCM-4
M%I92W,D,SXQ&JHI+MSR%SCOBL*U_;T^%]]X^TGPY#XC\Z]UBVBN8IDM93:0^
M;&98XI9]OEQ2O&"ZQN0Q7G%<+HO_  3SO_!,?Q&_L?XCZY>1?$0YN;36;.WN
MX(2TC-*>%5F+*VS).0 .>!6;X=_X)AP^%;HV=CXVU2+P_?R6=]J,'V=/M4M[
M:V/V**:*;_EFOE!3MP?F4'UH ]0\!_MT?#/XD^ [[Q)I.O23:7I^J)H\C/9R
MQR27,DGEQJB,H9P[9VD @@$UZ\#N%?%.B?\ !&O3=(\ )I%O\0/$.C7%GJ)U
M&TFTNWACA\WRVC$LL3JRO*0Q8OP0_P PP:^RM TQ]&T*SLY+B2\DM8$A:>0#
M?,54#<<<9.,\>M %RBBB@ HHHH *RO$?C;2O"-WID&I7T%G-K-T+*R60X-S,
M59@B^^U6/X5JUY7^U)\(?$GQ0MO!]]X5NM'M]8\(Z['K$::FCM;W 6*6,H=A
M##_69S[4 >D7VOV.F.ZW%Y:P-'&TS*\JJP11DMC.< =ZR/ 7Q;\,_%#PQ8ZU
MH&MZ?JFEZD':TN(9@4N%1BK,GJ 0>1Z5\N?&?]AGXI?M ?'/0_%>M>(_!NFV
M5@T)N+2QTT^9)&L;I)#Y[?O61RP.TMMP,$&J6K_\$UO%T7BGX/VNCZ]X7TGP
M;\-[*RAN[*VTM8[F[>-G-T%EQN$<P8?*"!G.<YH ^RYM6M;>+S)+FWCCX^9I
M !STYSWKGS\;?!Z^)IM%/B?0UU:UO$T^6S-['Y\=RZ>8D)3.0[)\P'4BOA*#
M_@F9\2/BW\%H]WBO4_#^H6_BFYGM;#6HUF:7144PVD$JY=!)&/WBGG!P>#7:
M^'/^"5&J>%/C2_BH:AX;UAG\0Z/KQFU"V=[QC:67V656?/+'B16_O#F@#[:M
MKZ&\:189HY6A;8X1PVP^AQT-35\P?\$__P!A_P 5?LF^)_%VH>)?&'_"3-KC
M!(2B>6L@$CN)I5P-TQ#!2QR2%'-?3] !1110 5BK_P C1?\ _7*+_P!FK:K%
M7_D:+_\ ZY1?^S4I;#6Y:HHHJ"SXA_X../\ E#+\:O\ L'0_^E$=?QXU_8=_
MP<<?\H9?C5_V#H?_ $HCK^/&NB&QF%:O@[_D+M_UQD_]!-95:O@[_D+M_P!<
M9/\ T$U0']CO_!!<8_X)H_#G_L%6_P#Z*6OLJOC7_@@OQ_P31^'/_8*M_P#T
M4M?959RW!;!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 57U5F32[EE8JPB8AAU4X/
M-6*KZM_R"KK_ *Y/_(T ?S7_ +9.DG2_V2OV@7EO-0U*\OM3TV[NKN]G:>XN
M9752SN[<D_H  !C%<#_P7$_Y,Q^&?_7C8?\ HH5Z7^W ,_LE_'C_ *^]*_\
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M_P#(-SG[(G3<*/K+[!]3CW*+>);-6;,[?*,GY&X'Y42>)+&)&9IBJJ-S$HP
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MNC[-KW_/WI?_ (#/_P#%T ;%%8_V;7O^?O2__ 9__BZ/LVO?\_>E_P#@,_\
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MQ_\ PIKPO_T!;/\ [YH_X4UX7_Z MG_WS1S!RL[#^T;?_GO#_P!]BC^T;?\
MY[P_]]BN/_X4UX7_ .@+9_\ ?-'_  IKPO\ ] 6S_P"^:.8.5G8?VC;_ //>
M'_OL4?VC;_\ />'_ +[%<?\ \*:\+_\ 0%L_^^:/^%->%_\ H"V?_?-','*S
ML/[1M_\ GO#_ -]BL>RO(K_Q'J3PR+*B+'&64Y 89R,^HR/SK'_X4UX7_P"@
M+9_]\UO:5I%KHEC':V<$5O;QC"QQKM44<PTBQ1114E'Q#_P<<?\ *&7XU?\
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M_DS'X9_]>-A_Z*%>F?MM_P#)IOQV_P"OO2O_ $!*\S_X+B?\F8_#/_KQL/\
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MEN+GKAG8C+-SUK/V<NP_:1)O#G@?4=*LY##J_CC[*KR^7;--:-'"N3A%RN[
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MMV[/ITI^SEV#VL3+\->$M2;P*K>(%UC5;[[(JHP>(16HP%!C&?O8 .6SR3C
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M1D4,,#(P>#[5[AX)/_%56/\ UU%8/]N6?_/U#^=:W@76+6?Q?IZ)<1,S2@
M]:UJ.*@TGT,:49.K%M=5T\S#^,VO?%JT^*U]#X=^'=AX@T/SK9(+R76VL]\;
M*?-8@/P48#^'D'O6]\"8_%?CB\U!?&G@6X\'Q011M;,FNO=?:')8.OROQC /
M/K7LU)\WM7SI]@87_"NM*_NWG_@=-_\ %UPOQ>T/Q-X9N+5_"/AN/7K7R9'N
MTGUB:&;>!\BIE\')X.2,5ZO\WM7DW[16CZ+=^(-#NM4\=ZAX/FA29((H;CRX
M;PL.KCH2O4>] &]\.O!S:UX:6;6]%N="OO,=3:QZG+(H7/RMD/CD<UXI:^(?
MCLGA_6)I_ACIKZE9W$ZV,$?B"0+=1+<JD1W&7@M 6;G&",5]!_"H1CP'I_DZ
MW-XBA*DI?S'+SJ22,GO@8&>^*^1-8TGX=^(X?%&L6?Q_O-)LSJ-S]IBM)F2'
M3;@7L657<-R;)%$?''SGUH ])^%GBCXL>)/%FGV^O?"*/P[X?N-6GLKJ=/%#
MR36ULJDI=; WS!VXV_>YS7H_CJQU#P[XACM]*\(ZOK=BUO)*]S%JYCVN%)6,
M*T@R6.!Z#->&? 6]T4?$_0UA_:<UCQEJ#^(+C;ILLZ-#J0\H_P"@[0,#9]_C
MGCTKZLOM%O+G5I)H]0EA@> Q+"!PC?W_ *T >1>%/$'BO5-8CMM4^%>N:=;M
M@O=#Q"LBJ,C.%$N2><_@?;.GXDDU[3]0>#3_  'K%ZN]ECG.L[(R!W.9<@'M
MQGZ5O1_"[Q4FLV5S_P )UJ'D6H42V_V6,K=$8Y8XR/XNG7/M6A;^ _$$6JW$
MS>*[N2":[DN$C:!/W",N%B7U53SSR: -:RT]=.\',HAFMVDAWO%)*96C8C)&
MXD].G7%?@_\ \'I?_)+O@3_U^7O_ *!7[U74$EKX::.:9KF:.#:\I4*9#CEL
M#@9]J_!7_@]+_P"27? G_K\O?_0*J.S%U/G#X1C/_!"3Q/\ ]@V+_P!&BOK?
M]CKQG8^&/VGOV>;6ZDV3:MI_ARWMQ_>?[;#Q7R3\(?\ E!+XF_[!L7_HT5]A
M?\$[?V=-!_:)_P""@_[/;>()=1\GP)X!MO%=A#:W!A6:]MIHC 9<<LBMAMO0
MXP>*DH_<BBBB@053?7K&,W6Z\ME^Q#-QF0?N,C(W>G'K5RO/[[X._;-6\>2M
M!8M#XMM8X@C#[[K"4S)QZX]>E ':R:[90PQR/=6ZQRH948R !D R6!],<YJ'
M_A+M+#VB_P!HV6Z^4-;#SE_?@]"O/(^E<3X=^#MU')ID.J"RN+'2?#XTJ*'[
MRR2NH64D$?=V@ >H)Z5Q5K^S]XFTS0_AQHG]F^';W2_"VGPIJ,_V@Q7,L\.?
M*C1MA_<AOF(R"?;'(![5/XNTNUNEADU&SCF>;[.J-,H8R<?)C/WN1Q[BA?&.
MDNEPRZE8E;-_+G/GKB%LXPW/!S7D>O\ P UJ\C\*6;66CZE;Q:J=8UZZDG,5
MU+/Y@D3RVV'(#!,C*Y$8'K65H'[*.KPZ=XP@O5T;&K1K#:A"66<B[>X$\GR_
M*^'V]_N]: /=T\0V,FK&P6\MFOE7>8!(/,"^N.M7*\/\,?LVZUH_[5-UXWFN
MK5K":/:H24Y"^4$">7M^\""2^[D8&!BO<* "BBB@ HHHH *ADOX(96C::%7C
M3S&4N 53^\1Z<'GI4U>!_M&_LL>(OB_\1-6UK1]<CT7[=X;&@GYV_P!(B=YF
MFC91PN=T6UQDC#<<\@'NEQJEM:6+74MQ#':JN\RLX" >N>F*=97T.I6J36\T
M<\,@RKQL&5A[$5Y+XT^#_B'7_@9H?A^&VTV2Z\-W6GS+;2W3>1JT5L5+0R-L
M^4/M(Y##US7+^)/A%\3M2\>Z'>Z+:Z#X6T>SLWBGM;'6;A0C.L@*B,((6^9D
M(<ID8H ^B**^9],^"?Q@MM-\&0_;-)@DT75Y+J^G&OWLSR6Y?(!W<2DK_"XV
MKVQ5CQ!^SS\3;/PS=6NE^(KFZ:\N([N5)M=GC?SO](W%)=I9(U+6S>6/E;RV
M'&3D ^D**^=?&?P0^+%SHVO6EKX@M=62X:&2P^TZI<V<BM(0UR&>'!5488B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJP+:5<A59F,38
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M^$/_ "@E\3?]@V+_ -&BOT _X([_ /*0#X8_]D=/_HV&OS_^$/\ R@E\3?\
M8-B_]&BOOK_@D)8I?_M]_#!)/,VCX.D_(Y0_ZV'N#4CZ'[(45G?\(O:_WKK_
M ,"'_P :/^$7M?[UU_X$/_C0(T:*SO\ A%[7^]=?^!#_ .-'_"+VO]ZZ_P#
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M_P#C1_PB]K_>NO\ P(?_ !H T:*SO^$7M?[UU_X$/_C1_P (O:_WKK_P(?\
MQH T:*SO^$7M?[UU_P"!#_XT?\(O:_WKK_P(?_&@#1HK._X1>U_O77_@0_\
MC1_PB]K_ 'KK_P "'_QH T:*SO\ A%[7^]=?^!#_ .-'_"+VO]ZZ_P# A_\
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M^-^O?!RW\8V>GZAI_P 0O!NI^*-4NQ=1J]JR7<<4)B18Q\@SLV9S\^XDXQ7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX]O?&%QJWAFPOIO'L-M!KKR DWZVV/(W<\%,#:1@@BNM_P"%AZ%_T%K#_O\
M"C_A8>A?]!:P_P"_PH X8?L:?#V'XE#QA#H:V_B+8H>X2XD"3NL?EK)+&&V2
M.%XRP)/?->(_L^_\$AO#'PJ^)_BKQ%XFUJ'Q?!XBTUM'CTQ-)33K6VMFN//8
M,J.V]MX'/ &WI7U/_P +#T+_ *"UA_W^%'_"P]"_Z"UA_P!_A0!P5[^Q1\--
M4^)T/B^\\-0WNMVS-) ]S-)-%;NT1A:1(V8JK&,E<@#@UJ?#;]ECP'\(]3TF
M\\/Z!;V%UH-E-IMA(&9FM;:60RO$N2?E+DG':NI_X6'H7_06L/\ O\*7_A86
MA_\ 06L?^_PH \Q\-_\ !/[X1^$Y]8>S\(6:KKUC<Z;=QO([QFVN)/,FB52<
M*KO\Q"XYJQ>?L(_"O4-$U"QF\*6DD>J6EE97$AD?SFCL\_9L29W*8\G!!!YK
MT;_A86A_]!:Q_P"_PI/^%AZ%_P!!:P_[_"@#A/"W[%7PR\%II0T[PK8P/HMI
M>6-K(2S2+%=_\?(9B26,G\1))-5+S]A#X6:CX@T/4KCPM;S2>'5MQ8P//(UK
M";<8A;RBVPLG8XR*]&_X6'H7_06L/^_PH_X6'H7_ $%K#_O\* -FBL;_ (6'
MH7_06L/^_P */^%AZ%_T%K#_ +_"@#9HK&_X6'H7_06L/^_PH_X6'H7_ $%K
M#_O\* -FBL;_ (6'H7_06L/^_P *7_A86A_]!:Q_[_"@#8HK&_X6'H7_ $%K
M#_O\*/\ A8>A?]!:P_[_  H V:*Q_P#A86A_]!:Q_P"_PI/^%AZ%_P!!:P_[
M_"@#9HK&_P"%AZ%_T%K#_O\ "C_A8>A?]!:P_P"_PH V:*QO^%AZ%_T%K#_O
M\*7_ (6%H?\ T%K'_O\ "@#8HK&_X6'H7_06L/\ O\*/^%AZ%_T%K#_O\* -
MFL5?^1HO_P#KE%_[-2_\+#T+_H+6'_?X54T358=>U6^O+5C):MLB23&!(5SD
MCU'/6E+8:W-2BBBH+/B'_@XX_P"4,OQJ_P"P=#_Z41U_'C7]AW_!QQ_RAE^-
M7_8.A_\ 2B.OX\:Z(;&85K>"O^0T?^N,G_H)K)K6\%?\AO\ [8R?^@FJ8']C
MG_!!C_E&I\._^P7;_P#HI:^RJ^-?^"#'_*-3X=_]@NWS_P!^EK[*K.6Y,=@H
MHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#^>/_@K=_P WF_\ 8XZ?_P"D\%>"
M_P#!<3_DS'X9_P#7C8?^BA7O7_!6[_F\W_L<=/\ _2>"O!?^"XG_ "9C\,_^
MO&P_]%"@;/TP_P"#43_E$7I?_8T7O_H:U^E'Q0^)5MX%UJSCETW6KZ26$NOV
M/29[R,#..6C4@'V-?FO_ ,&HG_*(O2_^QHO?_0UK] OVR?A;XH^,OPQ;P_X1
M\9W7@+5KB2*4:Q;(7FA5&#%5 (^]C!SP0:WBKM+R.:M*T;GA]Y\ OAGJ-[K,
MUUX=^(D_]O2O+=H=*O@@9IC+^[PGR'<>QY'%>J>!/B%HOPZ\,Z/H^F>'?%_]
MGZ+";>!9?#M[(^TYZL4Y/->:0_LJ_&K3H=/>U^/%XUU837OSW.F>:CP7#HP1
MEW89X]I".V2H8XQ4_P 0OV*O&7C3Q1?:S:_&/QEI-Y-X930K6&WO9UM+:X!R
MUZ8@X5I3ZD9 [UK[%=CE^L2[GK-K\>+*"R:/_A'_ !0W+G/_  C5YQN)/]SW
MJ(?'"Q6\L[C^P?%'^BHR8_X1J\PV[_@%>0:A^R!\7/$?BS3-9U3X[:U)<::8
MOW%G:M9VLZQLY >*-@K9W ,2"3M^E/\ #G[*WQKTCQ,VM77QYNK[498Y%E0Z
M7BSW,K %8-VQ0I*GIGY?>CV*[!]8EW_K[CUVY^/%A<W"R?V#XF7;$\6/^$;O
M/XL<_<]J?#\?K&&Q6'^P/$WR1F/=_P (W>=QC^Y4_P $_"_BWP7X(BL?&7BQ
M?&6M1MEM12R6SWC R-B\=<G\:Z_S&_O-^=/V$2?K$C@-&^-MCI-K9Q_V'XG?
M[):K;9_X1J\^; QG[M.'QOL/[=:\_L/Q/\UJ;;9_PC5Y_>SG[E=[YC?WF_.C
MS&_O-^=/V$0^L2.#'QSL!I*VO]@^)OEA$.[_ (1N\[=_N4-\<K%M1^T?V%XG
M_P"/;[/M_P"$:O/4'/W/:N\\QO[S?G1YC?WF_.CV$0^LS.#G^.=A.;C_ (D/
MB8>=$L?_ "+5Y\N._P!VC4_CC8ZC87,']@^)T^T0>3G_ (1J\^7W^[7>>8W]
MYOSH\QO[S?G1["(?69G$R_'NPD\W_B0>)OWH _Y%J\XQ_P  K!U?XBVFI>*I
MM5AM_'%E)-#% T$7AV[\ET1LD%2G\73/4"O5/,;^\WYT>8W]YOSH]A$/K,SR
MWQC\<=-OKZ.1M'\5P_)C:OAZZ4?JM9'_  N/2Q_S#?%O'_4 N?\ XFK?[96O
MW7ASX0ZI?6NBZGXCN+>)6CTZPO#:W%R=X&$D .",YZ=J\K^$/CF\^.E[I\?B
M#P9XL\'R2Z:"@DU-IH6"M@QR$*N'XSDCD9KT*-XP44>/B+2J.;7XGI'_  N3
M2S_S#?%A^F@7/_Q-;OPT^*6GZQX[TRUCT_Q-')-,%5I]%N(8U_WG9<+^-9W@
MGX:Z?X!N)Y;&74))+@8<W%T\H_ $X7\*[;P4['Q58_,?]:.]:5.;D=WT,J+C
M[6-EU1ZA=>(K&SN6ADN(UE7EDZL/J*C?Q9I\?WKA5^H(KX^_:)T=F_:-\73-
MIGQOT^:ZFTZ*TU'PM?AK><JH+?N\ 1Q#(5B2V3NP!WZ#]GOXOQ_!CQK?Z$WA
M;X^:S:Z]<0RQWFNQ-J,&G;BRL3*\I9 6.2J@JH"X Z5\Z?8GU#_PF&F_\_<=
M-'BS36_Y>HS] :YWX5_$K4?B#K_BJUOO#4^AVN@:@+.RN99O,&JQF-7,RKM7
M8 25QEN1UKG_ -H3Q6N@:[H-D]KXPDAU:5;=Y=#Z0?.#F0XRH/3((.* /0_^
M$LTW_GZC_(TO_"6:?C_CZ3\C7R+J/Q<UC1=:EO-(TWXO:T-)OH+:[L+NX%M'
M.TK2*75MARL:PACC@F4#W.MXG\?V\.LZ??26_P 9IK1[6:-Y8)2OE,&#A!$!
M\YW':)#@@4 ?48\6Z:?^7J/CV-!\6:<P_P"/I?R->*^'?',/QKT?P>UR?B1X
M;O-:N8=12(1"'[%(D.1;W+* -A!.Y2""W7H*]#N_@JUV]_(?$WB9)KZ%HMZ7
MA40$C!=%^Z&_#C% '4?\)9I__/TI_ \4T^+--3K=1_E7,77P06YN+<CQ+XHB
MM[8[EA2^(#\*/F;[S?=[G^(UN>#_  ./"1F8ZEJ>H&4 ?Z9,9-N"2,#MUQ[X
M% %V]OH=2T&XEAD62/8P!%?@K_P>E_\ )+O@3_U^7O\ Z!7[X:V,:3<?]<VK
M\#_^#TO_ ))=\"?^OR]_] JH[,74^<?A#_R@E\3?]@V+_P!&BOO7_@D=K5OH
M7[>OPOFNG\N-O@\5! )Y\V&O@KX0_P#*"7Q-_P!@V+_T:*^^O^"0'_)_?PO_
M .R.G_T;#4EH_7+_ (65H_\ S\-_W[;_  H_X65H_P#S\-_W[;_"KV/I^5&/
MI^53S!RE'_A96C_\_#?]^V_PH_X65H__ #\-_P!^V_PJ]CZ?E1CZ?E1S!RE'
M_A96C_\ /PW_ '[;_"C_ (65H_\ S\-_W[;_  J]CZ?E1CZ?E1S!RE'_ (65
MH_\ S\-_W[;_  H_X65H_P#S\-_W[;_"KV/I^5&/I^5','*4?^%E:/\ \_#?
M]^V_PH_X65H__/PW_?MO\*O8^GY48^GY4<P<I1_X65H__/PW_?MO\*/^%E:/
M_P _#?\ ?MO\*O8^GY48^GY4<P<I1_X65H__ #\-_P!^V_PH_P"%E:/_ ,_#
M?]^V_P *O8^GY48^GY4<P<I1_P"%E:/_ ,_#?]^V_P */^%E:/\ \_#?]^V_
MPJ]CZ?E1CZ?E1S!RE'_A96C_ //PW_?MO\*/^%E:/_S\-_W[;_"KV/I^5&/I
M^5','*4?^%E:/_S\-_W[;_"C_A96C_\ /PW_ '[;_"KV/I^5&/I^5','*4?^
M%E:/_P _#?\ ?MO\*/\ A96C_P#/PW_?MO\ "KV/I^5&/I^5','*4?\ A96C
M_P#/PW_?MO\ "C_A96C_ //PW_?MO\*O8^GY48^GY4<P<I1_X65H_P#S\-_W
M[;_"C_A96C_\_#?]^V_PJ]CZ?E1CZ?E1S!RE'_A96C_\_#?]^V_PH_X65H__
M #\-_P!^V_PJ]CZ?E1CZ?E1S!RE'_A96C_\ /PW_ '[;_"C_ (65H_\ S\-_
MW[;_  J]CZ?E1CZ?E1S!RE'_ (65H_\ S\-_W[;_  H_X65H_P#S\-_W[;_"
MKV/I^5&/I^5','*4?^%E:/\ \_#?]^V_PH_X65H__/PW_?MO\*O8^GY48^GY
M4<P<I1_X65H__/PW_?MO\*/^%E:/_P _#?\ ?MO\*O8^GY48^GY4<P<I1_X6
M5H__ #\-_P!^V_PH_P"%E:/_ ,_#?]^V_P *O8^GY48^GY4<P<I1_P"%E:/_
M ,_#?]^V_P */^%E:/\ \_#?]^V_PJ]CZ?E1CZ?E1S!RE'_A96C_ //PW_?M
MO\*/^%E:/_S\-_W[;_"KV/I^5&/I^5','*99\50^)M4MH;..>2.!_-DF,96-
M>" H)ZDY_2M2BBI&E8",BJS:)9.V6L[4D]3Y2_X59/'M3?,!]?RH&5_["L?^
M?.U_[\K_ (4?V%8_\^=K_P!^5_PJQYG^]^1H\S_>_(T$Z%?^PK'_ )\[7_OR
MO^%']AV/_/G:?]^5_P *L>9_O?D:/,_WOR- ]"O_ &'8_P#/G:?]^5_PH_L*
MQ_Y\[7_ORO\ A5CS/][\C1YG^]^1H#0K_P!AV/\ SYVG_?E?\*/["L?^?.U_
M[\K_ (58\S_>_(T>9_O?D: T*_\ 85C_ ,^=K_WY7_"C^PK'_GSM?^_*_P"%
M6/,_WOR-'F?[WY&@6A7_ +#L?^?.T_[\K_A1_85C_P ^=K_WY7_"K'F?[WY&
MCS/][\C0/0K_ -AV/_/G:?\ ?E?\*/[#L?\ GSM/^_*_X58\S_>_(T>9_O?D
M: T*_P#85C_SYVO_ 'Y7_"C^P['_ )\[3_ORO^%6/,_WOR-'F?[WY&@-"O\
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M/;S#ZK3/0)9M5A:4-HDV84#M_I<70_C4>H:AJ&F12--I$BF.(S;?MD6YE'7
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MTJ*?*',S-+./^6,W_?-&Y_\ GC-_WS6E12Y0YF9NY_\ GC-_WS02X_Y8S?\
M?-:5%'*',9H9S_RQF_[YHWO_ ,\9O^^:TJ*.4.9F:6<?\L9O^^: SG_EC-_W
MS6E11RAS,S=[?\\9O^^*-S_\\9O^^:TJ*.4.9F;O?/\ J9O^^:"S@_ZF;_OF
MM*BCE#F9F[G_ .>,W_?-&Y\?ZF;_ +XK2HHY0YF9NY_^>,W_ 'S1O?\ YXS?
M]\UI44^4.9F;E\?ZF;_OFC<W_/&;_OBM*BCE#F9FAF)_U,W_ 'S1N?\ YXS?
M]\UI44<H<S,T/\P#*R,W0,,9IU&NG:]G[S@'Z;6HJ6$2CXDN9+32M\9VMYT2
MY]C(H/Z&MX#:*YWQ;_R!?^WB#_T:M=%3B$@HKQW]M']KS3/V0?AG#JLUHVK:
MWJ]RMAH^F(X5KRX;ID]D'<^X'>O@G]H#]N#]I[X70V_C"XUWPNFA7%XUI)9Z
M3%'<P:?.G)MYMPWA@,9(.#ZU]!E?#V)QT5*#C%/1<SM=KHM&?#<2\?9=DLY4
MZT9U)12<E"-^1/9R;:2OVWMKL?JQ17RK_P $V?\ @HY%^VII-_I.M6-MI7C'
M18EFGCMR?(O(B<>;&"21@X!!)QD5]37-S'9VTDTTB1Q0J7=W.U44<DD]@!7F
MX[ UL'7>'Q"M)'T.2YU@\VP<,?@9<U.6SV]4UT:>Y)163X)\=Z+\2?#EOK'A
MW5M-US2;K/DWMA<I<6\N"0=KH2IP01P>HIVM>-]'\.27":AJFGV3V=J;V=9[
MA8VA@!P96!/" \;CQFN,]8U**AL;Z'4[*&YMY8Y[>X19(I(VW+(C#(8'N""#
MFIJ "BN*@_:0^'USXU_X1N/QOX4D\0&Y-G_9JZK";KSP,F+R]V[?CG;C-=7J
MNKVNA6$EU?7,%G:Q8WS32"-$R0!DG@9) ^IH M453L_$-AJ&JW5C;WEK->6&
MW[3 D@:2#<,KN7JN0.,]:N4 %%4[/7;'4-2NK.WO+::[L=OVB!)0TD&[E=RY
MRN1G&>M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
M<2-_PD%['_"J1L![G.:V*QO^9EOO^N47_LU*6PUN6:***@L^(?\ @XX_Y0R_
M&K_L'0_^E$=?QXU_8=_P<<?\H9?C5_V#H?\ THCK^/&NB&QF%:W@K_D-_P#;
M&3_T$UDUK>"O^0W_ -L9/_035,#^QS_@@U_RC6^'?_8+M_\ T4M?95?&O_!!
MD_\ &M3X=_\ 8+M__12U]E5G+<F.P4445)04444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8_#VNF_"1PZ<3&!-']G))/SK@ YSF@#]1**^;?V"[WXF:;X\^+GAOQ[K&O\
MB+2?#NLVJ>&]4U>UCAGN[>6V#R@-&BJZK)D XXZ5])4 %%%% !1110 4444
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M'?\ V"[?_P!%+7V56<MQ1V"BBBI&%%%% !1110 4444 %%%% !1110 4444
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MR?45\N_&7PWX^E_:9U"ZMO@7X \:^'[C3VCL->N+F*WOXG\LEHIV96+([8
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M/\-M,O=*^%JQZAHFE^'[QXB\UG8 ")7(^8\<9)SW-?AQ_P 'I?\ R2[X$_\
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M]1_Z!?\ Y,K_ (4?VGJ/_0+_ /)E?\*TJ* ,W^T]1_Z!?_DRO^%']IZC_P!
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M-C,*V/!'_(<_[8R?^@FL>MCP1_R'/^V,G_H)JF!_8Y_P0<_Y1K?#O_L%V_\
MZ+6OLBOC;_@@V,?\$UOAW_V"[?\ ]%+7V36<MQ+8****D84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&,>]>CW]E,KWW^GZE\MK'CE?4_[-0>,]&^W>%]4CFNKV:*2R^:.0(RL/<;:
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M?]!!/^_'_P!>C^SM0_Z""?\ ?C_Z] &E16;_ &=J'_003_OQ_P#7H_L[4/\
MH()_WX_^O0!I45F_V=J'_003_OQ_]>C^SM0_Z""?]^/_ *] &E16;_9VH?\
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MQ0DC]]*Q=FD9OO')D8E?NY(]!7<?V=J'_003_OQ_]>C^SM0_Z""?]^/_ *]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\+1_9EQ_S_3?]\+7#Q>([XRK_I4AY'<5Z)$VZ)3Z@4P,C5+.:">R9[F25?/
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M=F]G:C[0W]HEKIO.'W0$D:6)P@0A-NT8 Y /NJ;5+:VOH;62X@CNKD,88FD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0R#9&D;ZK JK)/N4]/\ GED<\\D8S1SR[A[*'8U?^&3_ !U_T7+QG_X*M/\
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MXU\!ZSH\EO:W4>J64MJT-P6$,H="I5BOS '.#CFM+^UK7_GX@_[[%']K6O\
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M/LD7_/-/RH /M,?_ #T7\Z/M,?\ ST7\Z/LD7_/-/RH^R1?\\T_*@ ^TQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!0,$YKI/%?[;O@WPY\)E\;1/>77AT:K#I<ET8'C5?,;;YHR,L@_V0<UBV?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&VL>&[*.ZLX)M9M5FNKE4?>TW *YR$." <CZU.?BCIOBB%%L=0\'B'31+/\
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MF]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH R)O\ CWU?_/\
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M)/LMUHR^'I"UPYD^PJS,L ;.0H+MT]:Z_P#MN[_Z!-W_ -_(_P#XJC^V[O\
MZ!-W_P!_(_\ XJ@#S2W_ &&?AI#9>&;=M!>:'P?(DFEK+=2/Y&QUD13EOF17
M16"G(!&:V?'_ .RIX%^)VE:M9ZQHJ7$6MZA'JMV5E:-WN40QK(&!R"$)7CL3
M79?VW=_] F[_ ._D?_Q5']MW?_0)N_\ OY'_ /%4 /\ "GA:P\#^&K'1]+MH
M[/3=-@6WMH4^[$BC  K0K,_MN[_Z!-W_ -_(_P#XJC^V[O\ Z!-W_P!_(_\
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M2&3:5)5E.1E21]#7J/\ ;=W_ - F[_[^1_\ Q5']MW?_ $";O_OY'_\ %46
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M  BK?:!-_9J^<J>6)/(&X)_=SC.WVZ5W_P#;=W_T";O_ +^1_P#Q5']MW?\
MT";O_OY'_P#%4K <+IWAF:Q$<-O8_9XE/RI%$$5?P'%>EPC;$H] *SO[;N_^
M@3=_]_(__BJ/[;N_^@3=_P#?R/\ ^*I@/U_[UE_U\#_T%J*I:AJ4]W=62R6-
MQ;KYX.]V0C[K<<$FKM3(J)E^,"5T(X&X^?!QZ_O5K;-W.#_QZM_WV*QO%O\
MR!?^WB#_ -&K7141"15^V3_\^K?]]BC[9/\ \^K?]]BK5%425?MD_P#SZM_W
MV*/MD_\ SZM_WV*M44 5?MD__/JW_?8H^V3_ //JW_?8JU10!5^V3_\ /JW_
M 'V*/MD__/JW_?8JU10!5^V3_P#/JW_?8H^V3_\ /JW_ 'V*M44 5?MD_P#S
MZM_WV*/MD_\ SZM_WV*M44 5?MD__/JW_?8H^V3_ //JW_?8JU10!5^V3_\
M/JW_ 'V*/MD__/JW_?8JU10!5^V3_P#/JW_?8H^V3_\ /JW_ 'V*M44 5?MD
M_P#SZM_WV*/MD_\ SZM_WV*M44 5?MD__/JW_?8H^V3_ //JW_?8JU10!5^V
M3_\ /JW_ 'V*/MD__/JW_?8JU10!5^V3_P#/JW_?8H^V3_\ /JW_ 'V*M44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#^>/\ X*V?>_;,_P"QQT__ -)X*\%_X+B_\F9?#7_KRL/_ $4*]Z_X*V?>
M_;,_[''3_P#TG@KP7_@N+_R9E\-?^O*P_P#10H&S],/^#43_ )1%Z7_V-%[_
M .AK7Z(?&72M5O/B!IDVFZG?::L=CB7RM&2\BD'F@D%SRIQV';FOSO\ ^#43
M_E$7I?\ V-%[_P"AK7Z ?M#^#]<U#Q;9ZMH]OXTOI+?3FA2#1]52QMW?S P$
MF>6)]>@&:N6R)ZF#/#J4VL6]NUUXD9K\M,IC\-P>6D<;9P['N1C:>O'2M:/P
MUK>AZ-<ZG_:VM7"K)$8HDT6'[0Q((; XSNXR3TQ6/X>\(>(%\77EU-X5\20W
MMU-<W!EGU?S+ X.8P54[L-A< =.:;I'PD\1ZS9VL]Y'XJM9]6FN-0ODN]7>:
M2PE*X2& KPL1('!^Z#ZU R9=5O+?3+?4HX?%R27%NC6<<?AZ$/9]#(2./WAV
M@'I][C/;(>]UOQ?JMK<S2>,M-6S7$D4WANW?=Y9\QP6R?O# &._K67X-\!^+
MK;[?#>^&_B+I6K:A+#<ZA=6/B%9()$3S-JQ._P PWDY90,CY<UZ5HM]KEE_Q
M,)_!OBN>\TU1;013:I'+YP4@"0$GJ023GTH Y#Q9JVI>'AINJ3KXTO(;R3[)
M!8V_AJWDDM26)WMS\JD+C.>P]16EH$\UWI5Q(MAXG:1H9%LRWAZWAD@P=[(N
M3CGIS@'/XU)I?PHU#2-<\17=II?BC38]9@FG8P:P_G1SG:VU,Y4%VR 5X  ]
M363+\$O$D31ZII]QX^MKS47,=U;WGB!Y#%'LQN38-H)YZ]"* -C2KJ[TK1I-
M/N(/$4M_J"K=C51X=@5;0N3A=H/WAM;/4_-7+^(-'U+4+74-2_M;Q.D5A9,\
MT,OA""8S#.0$7JS* 1M'K70:1X'\7:9:K#-;>,))-;62-WM=<98M)!C'S8?Y
MLEB<;>FVLV3P-X\T?PPUS%;^+;[45MS:_9(-=D3*]%E#N,>?@9+'CGB@#0T'
MQ%;WUAJNI+I?BG[#86L>EQVDGAF*-I;@Y9[I%ZMV&.%!'?-<>OC'7;?4IKC3
M;7QS96VK-)-$S>%K=/LD; ;(T4')92IY8C[W/:NA\0^#_$'B^?4C'X>^(J@@
MP0B\\0B.TE:*2)5E,:?/\P3=D<D;O[U=S\-_@)J<&D0W&O>*O%$VIG=YT,>I
MR-:I\K* F\;B,-G)YR!Z4 <O9:)XHU6_FNSKVO)8VMHIN[6?PY"1=N0NT@YR
M2#N)7'4]L<WM4AU+PY)-97FJ:Q))/=JRWT.@Q;9$D4;+=<==N/O$<'K70C]E
MC3_[/@LSXH\;-9PJ4,+:NY6084#=QDXV\>Y/K3[G]EK3;B\CD_X23QDD<,BR
MQ0KJK^5&RH5X'XY^H% '!_"7Q+XFGGOIKK4O%"+K$UT((W\-QV_V-5=1'E@<
MMM&0"?O#TQST5MK'B2U\!W$<VL>+'U")G$=\^D1AWVG<?W8.#P-HZ9S77^'?
M@<GA[4([C_A)_%UWY<!@\NXU)GC8D8+D8Y;WJ7PU\&(_#'C&XUA?$7BF\\Y%
MC%I=:@9;:(*<_*N._>@#=DM)K'PO:PW%Q)>3Q+$LD[J%:9AC+$#@9K8[&J/B
M!L:?[>8G_H0KB?B/\*?$7BSQ:VHZ1XWO]!@,*1_98HEDCR#DMSZT >AX_P!G
M]:78*\FB^"/C""WN%'Q(U9GFQL=HU;R>23@=\].?2JWB+X&>.]8T1K6U^*.H
MZ=+YH*W$5LC.D>X';SU. 1N//S>PH ]AQ_L_K2[!7C=G\ _&UGXC74&^*&KW
M2J[;;5XE6'86!VG')(Q@-UP:EU/X!^+KO28;>W^)6KV<T-P]Q]H5%D=MV<)@
M\;1Q@>U 'K^P4;!7C?\ PH'QL-*EMO\ A:FL%II,O.T"&0(<91?[O0X8<C)I
MTWP!\8S:1<V?_"SM959)0\$BHOF6R@@A-W\8Z@[NN: /8M@I,?[/ZUX[9_L^
M^+K743<-\3-:F7SUF6%@!& "24([AL_A@4UOV>O&#W_G'XH:WM^T><8@BA"N
M<^7].V>HH ]DQ_L_K3J\>\3_  $\2W[W%Q:>/]<L5DN4N6ACD\U3&H.8%#=
MQ/7KP*H> ?&/B;X7Z3?:.='\6^*!9^;>I?7R%I)02"($;^(CH* /;_F]J/F]
MJY+X?^,M:\<^&(=0GTG^PI92RM9Z@K)/'@XY'O6WYNJ_WM,_-Z (IO\ CWU?
M_/\ "*_!O_@]+_Y)=\"?^OR]_P#0*_>*0L;35MVW=@9V],[!TK\'?^#TO_DE
MWP)_Z_+W_P! JE\+#J?.7P>_Y03>)_\ L&Q?^CA7W_\ \$=_^4@'PQ_[(Z?_
M $;#7P!\'O\ E!-XG_[!L7_HX5]__P#!'?\ Y2 ?#'_LCI_]&PU('[%4444
M%%>1?M8S>+K)? ESX3O-7MS'XHLX]3AL81(MS9NVV02\'$8')(Q7*>+_ !+\
M0/"_B#XQ)9R>(-02XN],M_#(^S[H[,S0H)C"0.41BS,3G!% 'T117R[\3_$G
MC3X8>.OB=+J>I?$+5/"ECX.LKJQ70['S[O[:&9)$L\(=TSX!.<XW9XQ6/\-/
M&WQ(U/X?>%9M>OO&<-CH?AF^UW7WMK!SJ-[+,Q6TL8]R!GN(55BWR@,67M0!
M]=45^>FC_%'XW#0?AI=)JGQ$NGU354D%O)HT@DB5]0@4VM^S1CA+4RL9"%7)
M."=O/4_M2^*_CAX&^$GQ2_X1?4/%>H:M'XVMTT:<63GR=.> NZ1^6C/Y*OA=
MRJQS@' )( /N*BN2^ ^IZQK7P6\*W7B".ZCURXTNW>_6YC\N83&,;]R]CNSQ
M76T %%%% !117(_'V_U?2O@?XNNO#XNCKEOH]U)I_P!F3S)O/$3&/8O=MV,#
MN: .NHKY/_X)U>,/BQ;:AXATOXM#7(KJ1; Z3%=+)>*X:V,DLWVGRT5=S<&(
MC]VPP3R*\1M?VD/VCOAY\?/&UW%X?\6^)M!L8=6^S6;V4\L2LMS"MLX5XT08
MC:0JL4C[PISMP,@'Z/45\:Z9^U]\>)5^'^H2_#P-9:QIUN=;M1I\XG@GF9UW
M@]$$8569&]>HX-<[>?MO?M&>&?"WAB.^^%[:AJ6JZG;K>7=EIL_DVL,MM!,(
MGC8Y7#221M)DA3$>.: /NRBO@^[_ &G?VAO >H^-KR32+_Q--HEQX@&FZ/'X
M<EB2]\EHC9JDP/S*49RI'W]I%?47[(?Q,\5_%SX&Z;K?C+19-#URXDD1[>2
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MX_O"4_Q[@ H'&<@4:@>^:1X^DU#48H6MU59#MR&Z5TD\OD0LY_A!->=^&O\
MD/6O^_7H&H?\>$W^X?Y52 Y=OB7*6.VU3;GC+4G_  LJ;_GUC_[ZKROX[W?C
M:Q^$NL3?#FUT6]\:(B_V9!J[E+-VWC=YA'/W-V/?%<X-4^,1^+<$/]E^#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV/@K2;VRBF:UEB:10Q1IWW(?0\]JE_X0'1_^>+_^!#__ !59G_"$7QZ_9O\
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M_1P/@O\ [XNO_C5'_$0E^QA_T<#X+_[XNO\ XU7\9M%'*!_9E_Q$)?L8?]'
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M^QA_T<#X+_[XNO\ XU7\9M%'*!_8YXF_X+V?L7^(1%_QD-X+B://_+.Z.?\
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M_P"-U_'S11R@?V#Q_P#!<C]C%9%)_:,\%8!!.(;K_P"-UU*?\'"'[%Z(J_\
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M_P"-4?\ #_7]B[_HXKPM_P!]77_QJOXW**.0#^R/_A_K^Q=_T<5X6_[ZNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6EF%SF:*Z;_A$M/_ .>VH?\ ?E?\:/\ A$M/_P">VH?]^5_QHLPN<S173?\
M"):?_P ]M0_[\K_C1_PB6G_\]M0_[\K_ (T687.9HKIO^$2T_P#Y[:A_WY7_
M !H_X1+3_P#GMJ'_ 'Y7_&BS"YS-%=-_PB6G_P#/;4/^_*_XT?\ "):?_P ]
MM0_[\#_&BS"YS-%=-_PB6G_\]M0_[\K_ (T?\(EI_P#SVU#_ +\K_C1RL+G,
MT5TW_"):?_SVU#_OPO\ C1_PB6G_ //;4/\ ORO^-%F*YS-%=-_PB6G_ //;
M4/\ ORO^-'_"):?_ ,]M0_[\K_C19A<YFBNF_P"$2T__ )[:A_WY7_&C_A$M
M/_Y[:A_WY7_&BS"YS-%=-_PB6G_\]M0_[\K_ (T?\(EI_P#SVU#_ +\+_C19
MA<YFBNF_X1+3_P#GMJ'_ 'Y7_&C_ (1+3_\ GMJ'_?E?\:+,+G,T5TW_  B6
MG_\ /;4/^_*_XT?\(EI__/;4/^_*_P"-%F%SF:*Z;_A$M/\ ^>VH?]^5_P :
M/^$2T_\ Y[:A_P!^5_QHLPN<S173?\(EI_\ SVU#_ORO^-'_  B6G_\ /;4/
M^_*_XT68[G,T5TW_  B6G_\ /;4/^_*_XT?\(EI__/;4/^_*_P"-%F*YS-%=
M-_PB6G_\]M0_[\+_ (T?\(EI_P#SVU#_ +\K_C19A<YFBNF_X1+3_P#GMJ'_
M 'Y7_&C_ (1+3_\ GMJ'_?E?\:+,+G,T5TW_  B6G_\ /;4/^_*_XT?\(EI_
M_/;4/^_*_P"-%F%SF:*Z;_A$M/\ ^>VH?]^5_P :/^$2T_\ Y[:A_P!^5_QH
MLPN<S173?\(EI_\ SVU#_ORO^-'_  B6G_\ /;4/^_*_XT687.9HKIO^$2T_
M_GMJ'_?E?\:/^$2T_P#Y[:A_WX7_ !HLPN<S173?\(EI_P#SVU#_ +\K_C1_
MPB6G_P#/;4/^_*_XT687.9HKIO\ A$M/_P">VH?]^5_QH_X1+3_^>VH?]^5_
MQHLPN<S173?\(EI__/;4/^_*_P"-'_"):?\ \]M0_P"_*_XT687.9HKIO^$2
MT_\ Y[:A_P!^5_QH_P"$2T__ )[:A_WY7_&GJ.YS-%=-_P (EI__ #VU#_OR
MO^-'_"):?_SVU#_ORO\ C3U"YS-%=-_PB6G_ //;4/\ ORO^-'_"):?_ ,]M
M0_[\K_C1J%SF:*Z;_A$M/_Y[:A_WY7_&C_A$M/\ ^>VH?]^5_P :-0N<S173
M?\(EI_\ SVU#_ORO^-'_  B6G_\ /;4/^_*_XT:A<YFBNF_X1+3_ /GMJ'_?
ME?\ &C_A$M/_ .>VH?\ ?E?\:-0N<S173?\ "):?_P ]M0_[\K_C1_PB6G_\
M]M0_[\K_ (T:A<YFBNF_X1+3_P#GMJ'_ 'Y7_&C_ (1+3_\ GMJ'_?E?\:-0
MN<S173?\(EI__/;4/^_*_P"-'_"):?\ \]M0_P"_*_XT:A<YFBNF_P"$2T__
M )[:A_WY7_&C_A$M/_Y[:A_WY7_&C4+G,T5TW_"):?\ \]M0_P"_*_XT?\(E
MI_\ SVU#_ORO^-&H7.9HKIO^$2T__GMJ'_?E?\:/^$2T_P#Y[:A_WY7_ !HU
M"YS-%=-_PB6G_P#/;4/^_*_XT?\ "):?_P ]M0_[\K_C1J%SF:*Z;_A$M/\
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M_P#9A0!Z%+JEO"'W2JOELJ-[$]!^HK$\9^+[VQTM3H%O9ZI?_;4MGMYI_)&
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M\?/_  K37_\ H4?$/_@JF_\ B:;_ ,*T\0?]"AXB_P#!7-_\37]A(\/::?\
MF&:9_P" <?\ \32_\(_II'_(+TS_ , X_P#XFCF%RL_CW_X5KK__ $*'B+_P
M53?_ !-'_"M=?_Z%#Q%_X*IO_B:_L(_X1[32?^0;IG_@''_\32_\([II/_(-
MTW_P#C_^)HYA\K/X]O\ A6FO_P#0H^(?_!5-_P#$T?\ "M-?_P"A1\0_^"J;
M_P")K^PH>'-._P"@;IO_ ("1_P#Q-'_".:;C_D&Z9_X"1<_^.T<P<OF?QZ?\
M*T\0?]"CXB_\%4W_ ,32_P#"M-?_ .A1\0_^"J;_ .)K^PL>'--!Q_9FF_\
M@''_ /$TH\.Z:I_Y!FF_^ <?_P 31S!R>9_'E_PK7Q!C_D4?$6?^P5-_\32_
M\*TU_P#Z%'Q#_P""J;_XFO[##X=TW_H%Z9_X!Q?_ !-'_".Z:Q_Y!FE_^ <?
M_P 31S!R>9_'G_PK37_^A1\0_P#@JF_^)H_X5IK_ /T*/B'_ ,%4W_Q-?V&?
M\(YIO'_$MTL<]?L<7_Q-)_PCNFLW_(-TOZ_8X_\ XFCF#E/X]/\ A6FO_P#0
MH^(?_!5-_P#$T?\ "M-?_P"A1\0_^"J;_P")K^PS_A'=-/\ S#--]/\ CSC_
M /B:#X=TT_\ ,+TW'_7G'_\ $T<PN4_CR_X5IX@_Z%'Q%_X*IO\ XFE_X5IK
M_P#T*/B'_P %4W_Q-?V&'PYII_YANF?^ D?_ ,33?^$<TTM_R#-,_P# ./\
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M8/\ S+.M?^"Z7_XFOZ@5\/:?C']G:?\ ^ L?^%31>'=/"_\ (.T[_P !8_\
M"CF#E/Y>/^$"UC_H5]:_\%TO_P 31_P@.L?]"QKG_@NE_P#B:_J-'A[3_P#H
M':=_X"Q_X5+%X>T['_(-T_\ \!8_\*.8.3S/Y;O^$"UC_H5];_\ !=+_ /$T
MUO FK1GYO#.LCZZ=*/\ V6OZET\/Z=N_Y!NG_P#@+'_A7#_%>PT^VT^3_0=/
M7C_GVC']*.8.0_F?M_!&JW<OEP^&]8FDQG8FGRLV/7 6K'_"M/$'_0H>(?\
MP5S?_$U_3A^P?\#%AU[5O&%_I5I';W$7V.Q$MJG[P$@NP!7IP!FOIH^'M-/_
M ##=+_\  ./_ .)HYB>5G\>O_"M-?_Z%'Q#_ ."J;_XFC_A6NO\ _0H>(O\
MP53?_$U_84?#NFX'_$MTS_P#C_\ B:!X=TT'_D&Z;_X!Q_\ Q-',5RG\>O\
MPK37_P#H4?$/_@JF_P#B:/\ A6NO_P#0H>(O_!5-_P#$U_81_P ([IH_YANF
M?^ D?_Q-./AS3@?^0;IG_@''S_X[1S"Y3^/7_A6FO_\ 0H^(?_!5-_\ $TW_
M (5MX@_Z%'Q#_P""N;_XFO["CX=TW'_(-TS_ , X_P#XFG'P[II'_(,TS_P$
MC_\ B:.8?*S^/7_A6FO_ /0H^(?_  53?_$T?\*UU_\ Z%#Q%_X*IO\ XFO[
M"O\ A'M- /\ Q+-,_&TC_P#B:#X<TW 7^S-+_P# 2/\ ^)HY@Y3^/7_A6FO_
M /0H^(?_  53?_$T?\*UU_\ Z%#Q%_X*IO\ XFO["CX>TW;C^S=+Z_\ /G'_
M /$TC>'=-'_,-TS_ , X_P#XFCF#E\S^/;_A6FO_ /0H^(?_  53?_$T?\*T
MU_\ Z%'Q#_X*IO\ XFO["3X<T['_ ""]-/O]CCX_\=I1X<TT'_D&:9_X"1__
M !-',+E/X]?^%:Z__P!"AXB_\%4W_P 32?\ "M/$'_0H^(?_  53?_$U_83_
M ,([IO\ T#-,_P# 2/\ ^)I1X=TX?\PW3?\ P#B_^)HYA\OF?Q[?\*UU_P#Z
M%#Q%_P""J;_XFC_A6FO_ /0H^(?_  53?_$U_82WA_33_P PS2__  #C_P#B
M:0>'=-(_Y!FF^W^B1\?^.T<P<I_'O_PK77_^A0\1?^"J;_XFC_A6FO\ _0H^
M(?\ P53?_$U_82/#NFC_ )AFF=.]I'_\32?\([IN/^0;I?\ X!Q__$T<P<I_
M'O\ \*TU_P#Z%'Q#_P""J;_XFC_A6FO_ /0H^(?_  53?_$U_80?#VFY_P"0
M;IG_ (!Q_P#Q-!\.Z:?^89IO_@)'_P#$T<P<K/X]_P#A6NO_ /0H>(O_  53
M?_$T?\*T\0?]"CXA_P#!5-_\37]A!\.:;_T#=,_\ X__ (F@^'=-'_,-TWI_
MSZ1__$T<P<OF?Q[_ /"M-?\ ^A1\0_\ @JF_^)H_X5KK_P#T*'B+_P %4W_Q
M-?V#'P]IJG_D&Z8?^W./_P")IDGA_3MW_(,TW\+2/_XFCF#E9_'U_P *T\0?
M]"AXB_\ !7-_\33O^%:Z_P#]"AXB_P#!5-_\37]@#>']-QSINF?^ D?_ ,33
M?^$=T[_H&Z;_ . D?_Q-','*S^0#_A6VO?\ 0H^(?_!7-_\ $T?\*VU__H4?
M$/\ X*YO_B:_K]?P_IQ'_(-TW/\ UZ1__$TUO#^GY_Y!VF_^ <?_ ,31S"Y6
MC^0/_A6NO_\ 0H^(O_!7-_\ $T[_ (5KKW_0H^(/_!7-_P#$U_7LWA_3S_S#
M=-_\!(__ (FFMX>T_P#Z!NF_^ D?_P 31S#Y3^0K_A6VO?\ 0H^(?_!7-_\
M$U0E^&7B;[6VWPOXC5<\ :7/Q_X[7]@)\/Z?G_D&Z;_X"1__ !-(= T_/_(-
MTW_P$C_^)HYA.)_('_PK+Q-_T*_B/_P5S_\ Q-'_  K+Q-_T*_B/_P %<_\
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M *=8_P#XFD_L"PS_ ,@[3O\ P$C_ /B:7,/D/Y%O^%9^)O\ H6/$7_@LF_\
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MW[9G_8XZ?_Z3P5X+_P %Q?\ DS+X:_\ 7E8?^BA7O7_!6S[W[9G_ &..G_\
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M80)7?.UF 4'+8X P#BO2?F]J *VN?\@BX_ZYG^5?@;_P>E_\DN^!/_7Y>_\
MH%?OEKG_ ""+C_KF?Y5^!O\ P>E_\DN^!/\ U^7O_H%5'9BZGSE\'O\ E!-X
MG_[!L7_HX5]L_P#!,D9_;B^%G_9(CV_Z:15\3?![_E!-XG_[!L7_ *.%>KZ9
M\8=4^"GQO^#^JZ3J5UI=S-\-5@,L#;6*ED./TI1W'T/W,V$<'BEP?3_Z]?DI
M_P /#/&V/^1RUK_O^/\ "G+_ ,%"?&W_ $.FM?\ ?X?X5N9GZU;#C[M 7/K7
MY+C_ (*$^-O^ARUK_O\ C_"@_P#!0KQMC_D<M:S_ -=A_A0!^M&W!]A3MOS=
M_I7Y*_\ #PGQL2O_ !66M?\ ?\?X4'_@H5XVS_R.6M?]_P ?X5-BN8_6H#GT
MH4'/_P!:OR5;_@H5XVQ_R.6M?]_A_A0/^"A7C<-_R.6N?]_A_A1RDGZU@<?=
MI2IS]*_)0?\ !0KQLW3QEK8^LX_PI?\ AX3XW(_Y'36O^_X_PHY2N8_6H(Q[
M=:4H5K\E/^'A'CC _P"*TUK_ +_C_"G#_@H7XV(_Y'/6O^_X_P *.4+GZU8)
M_P ]: IS]W]*_)7_ (>&>-C_ ,SEK7_?\?X4O_#PKQK_ -#EK7_?\?X4<H<Q
M^M(7!_\ K=*4 CM7Y*?\/#/&G_0Y:U_W_'^%!_X*%^-<_P#(Y:U_W_'^%'*'
M,?K448"@@D__ %J_);_AX7XU!S_PF6M_]_Q_A2M_P4)\:C_F<M;_ ._X_P *
M.4.8_6?'M2["3T]Z_)8_\%#/&V%_XK+6O^_X_P *4?\ !0GQJQ_Y'+6O^_X_
MPHY0YC]: ,=J-C =Z_)<?\%"O&H_YG'6O^_X_P */^'A7C4_\SEK7_?\?X4<
MI)^M Z]#^5&WCH?:OR7'_!0KQI_T..M_]_Q_A0/^"A7C4'_D<M;_ ._X_P *
M.4#]9+NSCU"UD@N(HYH91M=)%W*P]"*X[_AGWPW!=M-:VLUCO;<4A<[,_3M^
M%?F8/^"A'C1GX\9:U_W_ !_A3A_P4%\;?]#EK7_?\?X4<H'Z=GX.:2Q^]=_]
M]TA^#&DL/O7?_?8K\Q?^'@OC8_\ ,Y:W_P!_Q_A1_P /!?&F?^1RUK'IYX_P
MHY1W/TX'P3TD_P 5Y_WV/\*:?@CHY/+7G_?8K\R3_P %!/&Q_P"9RUK_ +_C
M_"@?\%!_&O\ T.6M?]_Q_A1RA<_30_ O1NNZ]_[[%-/P(T4_Q7O_ 'W_ /6K
M\S?^'@GC4_\ ,Y:U_P!_Q_A3A_P4%\: ?\CEK7_?\?X4<H79^ES? 30ROWKW
M_OL?X4#X!:(#CS+[/^__ /6K\T!_P4&\:_\ 0Y:U_P!_A_A2#_@H+XV//_"9
M:S_W_'^%'**[/TP'P$T5#]Z]_%__ *U.'P)T4?Q7O_?=?F;_ ,/!?&V/^1SU
MKZ&<?X4?\/!O&N?^1RUK_O\ C_"CE _33_A1>C_WKW_OL?X4Y?@CHXZ/>?\
M??\ ]:OS)_X>"^-<_P#(Y:U_W_'^%+_P\$\:A?\ D<M:_P"_X_PHY0N?IL?@
MKI(_BO/^^A3O^%-:2H^]=_\ ?5?F.O\ P4$\:D?\CEK7_?\ '^%)_P /!?&H
M/_(Y:U_W^'^%'*.Y^G0^#>E?WKO_ +ZJM'^S_P"&3?K/<V<E\RG*K.Y9 ?\
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M%!_X*%>-L?\ (Y:U[?OQ_A1RCN?K/@^_^%+M(/3\:_)7_AX3XV/_ #.FM?\
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M@_C3'_(WZS_W^'^%(?\ @H/XS+?\CAK./^NP_P *.4+GZJLIYXJ/[QK\K?\
MAX)XRS_R.&L_]_A_A33_ ,% O&7_ $.&L\?]-A_A1RDGZH..?K32,]J_+'_A
MX#XRQ_R.&L_]_A_A0?V__&)_YF_6/^_P_P *8'ZF$'--V''>ORU'[?\ XR'_
M #-VL<=?WP_PH;]O_P 8?]#=K'_?X?X4N4=S]1V&![TP\9%?ER/V_P#Q@?\
MF;=8/_;8?X4?\-_>+C_S-FL?]_A_A1RB/U$P:1BR]OTK\N_^&_\ Q<?^9MU?
M_O\ #_"D_P"&_?%Y'_(VZQSV\X?X4<H'Z@RC*MQ6+J X;_.:_-@_M^>+L?\
M(V:O_P!_A_A4<G[>7BIOO>*-5/MYH_PIVZ ?HA>#K]:P]0X#5\#G]N?Q,S<^
M)-2_[^C_  J-_P!N#Q"W_,Q:@?K(/\*=@/M[4.]<SXA(%NWXU\B-^VIKCGG7
MK\_\#'^%12_MB:M,GS:U>-]7'^% SZ$U+ D_&K6G'+K7S2_[5MY+][4IV_$?
MX4U?VL[V+_F*3KCI\P_PHMU$??'PJC_=QU[1H,)-DW&/DK\R? /[2/CWQK?1
MVGAF7Q'JMQ)]R.PB,I/Y+7UA^S[^RY^TA\5[F*;6M<U3P7H[ %I;Z<&X9>X6
M(#.<?WL"E+8#ZQ_85&WP!X@'_4<N/Y+7M]<C\$_A#9_!/P-#HMK=7>H/O::X
MN[D@S74K=7;'';IVKKJP9H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '\\?_  5L^]^V9_V..G_^D\%>"_\ !<7_ ),R
M^&O_ %Y6'_HH5[U_P5L^]^V9_P!CCI__ *3P5X+_ ,%Q?^3,OAK_ ->5A_Z*
M% V?IA_P:B?\HB]+_P"QHO?_ $-:_2;XI?LV>%?C-XCTS5M>M[Z:\TE56W,%
M]+;J '#\A"-V2.<]17YL_P#!J)_RB+TO_L:+W_T-:_61*N6R)ZF+X$^'VD_#
M;PK#HNCV[0:;;[MD4DKS$9.3EG)8]>Y-9UGXKT+Q+97<>BW%G,UI,B7*P+M,
M;G. W'7@UUGS>U84=]HFC7-Q!;M86LMO(@NDC4*59@2N['J,XJ8NSN*4;JQF
MB-MR_*?XNU'EMM^ZWW?2K_\ PE&F^;'_ *9!TD[TA\4:;Y)_TN#_ %'K[UM]
M8\CE^JZ[E.6-@6^5NH[4T1L77Y3]X]JT;SQ/IN)/],@^^G?Z5%:^*--\_P#X
M^X/^/B3O[4_;OL/ZJNY56-A']T],]*^=_P!K/]I/6/V=_CE\.8OLLR^$?$U^
M]CK-ZEN9O(86[M"FT?,-S@?,!@5],?\ "4:;]C_X_(/]6>_O6/=>(=+DU6\#
MW%JX_P!&QNP?6JC7=I>GZHPJX5*4->OZ,^/_ !=_P5[\#P>#/!NI:#>6-^WB
MBUU6:X5]Z7.FW%BBY1H,;MK,2,G& ,U:TO\ X*X_#^Z\":7?:M?KX6OY-*M-
M:N5NT9D^R3,5=X^[ 'H?>OHA/@[\+XO%<>J1^$_!\>I27LEL]RFFPK(\<JL9
M$)V\ACU!ZYJ^W@'X?^)M*TNVU+P_X7O[>&RDLXX[BPBD6. ,2(@"O"<#Y>G%
M9^V9T_5HGQUX)_;;UC]HI=;\(ZA9>9?0:AHL]@D=N\<DEM(T<AD(QST+>P/M
M7W5?#-Y-Q_RT3]>E58-5T:UTS]R]C%Y>G0HFQ0NP D #CH!4UQXFT_\ M&;_
M $N'_76?>CVS$\,NY(J$OT_Y:8Z=^:;"APORGH>U6K7Q/I_G_P#'Y!_Q_'H?
M]DT6/BC3?+M_]+A_U;]_<U7MWV%]57<\Q^,G[2_A7]GOQEHMGXHNKBR;Q+ T
M=E)Y+-#F++,'?&%)!&,]>W2O-[/_ (*B?"[4Y-#6'7M)+:Q'<RN&NP/LOD9R
MK>YQ].:^FFO=!U5(_M1T^X;R0N9$#8'/J*Y^\^&OP\DGL2VB^'O]#\R*'%L@
M\M9 0X''\63GUS4^V8_JJ[G@2?\ !43X3S:59S1^(+'[9=:%<ZU%!]IC(Q&"
M'C)!X8$#Z@\9Q4?PD_;N^'4'P)D\1:AK4-O'!9B_NX(T+R11RL"K!>K+VSC%
M;.K?L%?LYB73U7X3_#7%OIU_;QXT6'Y8^#M^[TSFJGC[]BGX%^,3=SW_ ('\
M,332>%(K:5UB\LRQ1LOEQMMQN5>P/2CVS#ZJNYD?'G_@J%X ^%NFW3:?>'4]
M0T_7-/TR^M?+(:*.Z7*2CU&,5PWPM_X*XZ?XU\3V\=YX?U"/1;CQU?>&Y=6M
MK*:6UM(TAW0[V ^60MD,#T!%>[:'^Q_\$_A_KFL:IIO@[PTFH7%S9"2XFB\^
M1O+V^7\SY/R]O3 ]*[/PA;^&_#.K36]A;:386]QXHO)YHK>!(TEE:(;G8 8+
M'C)ZFCVS&L+$P?V/;@77P3T>X"R)'>7FI7,/F(59HVNG96P><%2#^-=%\$;&
M;3_A)H\,\,D,B0S;T==K+F>0C(^A'YUI:%X@TZ!=-5;BW15CU !1P%&X5T#^
M)].-@?\ 3(/^/0=_I1[;R$\*NY-HR,NJ+\IZ^GM5GQ3X#T7QMY/]K:;9ZA]G
M),7G1[O+SUQZ9J73M?L;N]DCAN(GD8C"@\GBM/YO:LYRYG<VIT^16.>TSX4^
M&M%OK.ZM-#TVWN+ L;>2.$*T.X8.#[C ^E6-4^'VAZYM^W:38WH2\34$%Q$)
M1'<H05E4-G:X(&",$8K9V"DQ_L_K4FAAZ]\,O#_BC4H;S4-'L;JZ@=9$E:/Y
M@R_=.1UQCC/2MWYO:DQ_L_K3J *NN?\ ((N/^N9_E7X&_P#!Z7_R2[X$_P#7
MY>_^@5^^6N?\@BX_ZYG^5?@;_P 'I?\ R2[X$_\ 7Y>_^@54=F+J?.7P>_Y0
M3>)_^P;%_P"CA4O[4.@>(O$7BGX*P^&=-NM4OU\ QL\4&-P3Y<GDCVJ+X/?\
MH)O$_P#V#8O_ $<*^P_^"??P+L/V@?VS?A3HVHLR0P?";[2"#W$D0_K4CZ'P
MN?A=\7A_S)NM?]]+_P#%4+\,_BZHY\'ZU^:__%5_0,__  2_\,'_ );2_P#?
M51R?\$M_"\AYED_[ZK3VC)Y3^?\ _P"%=?%M?^91U@?\"7_XJD_X5Y\6A_S*
M.L?]]+_\57[^M_P2P\+D_P"MD_[ZIC_\$JO"S_\ +63_ +Z-+VC#E/P$_P"$
M ^+&?^13UC_OI?\ XJ@^ _BL?^94U;_OI?\ XJOWX;_@E)X58_ZU_P#OJHG_
M ."4'A5_^6DGX,:?M&/E/P*_X0?XK?\ 0JZO[_,O_P 533X*^*F?F\+ZL/\
M@2?_ !5?OH?^"37A4_\ +23_ +Z-12?\$DO"LO\ RVDQ_O&E[1BY3\#_ /A#
MOBE_T*^J_P#?:_\ Q5'_  BWQ0/_ #*^J?\ ?2_XU^];?\$B/"A/^NE_[ZIC
M?\$A/"C?\MIO^^J.=ARGX+GPO\3Q_P ROJG_ 'TO^-(?#GQ.3_F6=4S_ +R_
MXU^\K_\ !'[PJY_U\O\ WU3&_P""/7A4_P#+:3_OJCG8<I^"U]X7^)US!MCT
M'5K9O[R%"1^9J'3_  G\3K)R9M(UBZ!'1_+X_(U^];_\$=?"KC_72?@U,/\
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M:1%9-#U>Z;U<QC^1J<>&OB:W3PSJG_?2_P"-?N^O_!'3PJO_ "VD]OFJ1?\
M@CUX5'_+:3_OJCG8N4_!W_A%OB@?^97U3_OI?\:7_A%OBA_T*^J?]]+_ /%5
M^\L?_!'_ ,*H?]?-C_>J0?\ !(7PHH_UTW_?5'M&/E/P5'@[XI?]"OJO_?:_
M_%4\>"_BH1QX6U;_ +[7_P"*K]Z4_P""1'A0'_72_P#?53)_P23\*H,>=)C_
M 'C1[1BY3\$?^$'^*S?\RKJWM\R__%4X> _BL?\ F4]6_P"^E_\ BJ_?!?\
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M_P *F^,1_P"9+USKZI_\50GPC^,9_P"9+UP_BG_Q5?T&)_P3-\,K_P MI?\
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MZ0O\4G_?1I^T8<I_-[_PR9^T0X'_ !;/Q1^2?_%4]?V1/VBCS_PK'Q3^2?\
MQ5?TBI^S5I*?Q2?]]&IX_P!G;24_BD_.CVC#E/YME_8]_:-<_+\+_%7Y)_\
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MF,QO!/P[T'X:Z.NG^'M%TO1+%>1!8VR01C\% %;-%%2 4444 %%%% !1110
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M9KAOK%'1K1KJG_6S-"UOKZ_T&^:^M_L[JI"@?Q#'6OPA_P"#TO\ Y)=\"?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2]1/_!2'P?;"W::U\._!R)+NY4C9&\LD)1?7D9_*I _8RBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /PI_X+3^ ;A?V[/CIX8O%N5L_B'X!M=7L/X?/EM_E(4]P&B
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M>!?#=Y;77CCQKK7B8QL&EL[2);2WDQU&[E\&M[_AZA^U]_T8CXJ]?^1OMO\
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MP_X*E?",:W>27W[;GPQNK6Y,TR11WK1) XEW6X7"YQM9UDR<, F!Q79>,/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4USS3J:XH Y/XM_"7PK\;
M?"%SH?C#P[I/B71[J-HY+74+59T*L,-C<."1W&#7P#\4_P#@@QX;\/ZS->?"
M/XC>)O >G;!M\-:G$NMZ+&1DD(LV98U8D?*K8&.,5^DDL6\54FTA9NJB@#\-
MOB7_ ,$:/B4FN?:M8^$/P#^(4V7:>^TV]?P_=SG'WB"&#$],$U\_:K_P3UTS
MP[97C:I^Q/\ &:"2-F#S:?XKDEC!S]Z,>;\R]QQTK^CZ7PK;S'YH8S^%5I/
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M[6Y\4.#I^GD 8$%DF(5P1G<5+9/M7W-I-E;Z58PVMK;PVMM"H6.&%!''&/0
M< 4R#2UAZ+BK<<>T4 2(>*=2(,"EH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** #%&*** #%-\M?2G44 -\M?2CRU]*=10 WRU]*3R1[?E3Z* &>2/;\J/)'
MM^5/HH 9Y(]ORI# IJ2B@"/R%H\A:DHH C\A:/(6I** (_(6CR%J2B@"/R%H
M\A:DHH C\A1_^JE\D>WY4^B@!GDCV_*CR1[?E3Z* &>2/;\J7RU]*=10 WRU
M]*/+7TIU% #1&H[4[%%% !BC&*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>irtc-20211231_g6.jpg
<TEXT>
begin 644 irtc-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO96QE:2!(
M:6=G:6YS    !9 #  (    4   0J) $  (    4   0O)*1  (    #,#0
M )*2  (    #,#0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,C4@,3@Z-3<Z,38 ,C R,3HP
M,CHR-2 Q.#HU-SHQ-@   $H ;P!E &P 90!I "  2 !I &< 9P!I &X <P
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "V 7D# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MPR,3(WSA8_ESS[5RGP*3^T/A5I<UZID:V:XMXMYR AD/&/T^E>B1:=;PK:A
MV+0$0Y8G (Q^/%<DJ+E-MI6T_#_,[(8A0@E%M-7_ !O;[OU$O1AK0#_GNO\
M(U;JI???M/\ KX7^1JW76<1R.OZ1>7VO37%OI*.5LWCM[I6C!\UE(RV>< 8
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MFDZO<:TVJM)<:A;1RA9%2.[9K]2ICD$I;<4;;]U  0#TKWWR+S_G\7_OR/\
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MHJKY%Y_S^+_WY'^-'D7G_/XO_?D?XT 6J*J^1>?\_B_]^1_C1Y%Y_P _B_\
M?D?XT 6J*J^1>?\ /XO_ 'Y'^- @O,\WB_\ ?D?XT ,UB]GT_2IKJTM6NY8P
M-L*YR^2!Q@'UKFV\8ZRBLQ\-7'RQI)@;B?F .W[O4;A^(;TKKI5=HR(G\MO[
MQ7/Z5!Y%Y_S^+_WY'^- &!?^)-2@NPMM8;XUC4R923Y&(.0<*<@8ZBJ\_B[6
M+>9$ET3:) "@+-DDEL+C;]["X] 3Z5T_D7G_ #^+_P!^1_C2&WNSC-VIP<C]
MR./UH YAO%6O&/STTB..% 0P<2;G."<#Y1C&,<]2.W!J[?>)+^WF86FFM.@9
M552L@9LKD_P\<D_]\-[5M^1>?\_B_P#?D?XT>1>?\_B_]^1_C0!6T2_OKZ*?
M^TK-;:6*3:-A8JXQU&0/>M.JOD7G_/XO_?D?XT>1>?\ /XO_ 'Y'^- $$F@:
M7-XAAUV6SC;4X(3!%<G.Y(R<E1V[TZZT/3;V>6:ZM(Y))E19&.?F"-N7/T/-
M2^1>?\_B_P#?D?XT>1>?\_B_]^1_C33:V)E&,E:2N1:E8Q.'O4L$O+R.%HHT
M9@NY6ZKD\ '%<OI7A5AXALKF/0X-&L[,M*56<2O-(05'3HHR376^1>?\_B_]
M^1_C1Y%Y_P _B_\ ?D?XUI&K**:1A4PT*DE)]/3_ "O^)6E\.:1-+>226,9:
M^ %SR?WH!!Y&?859N=,L[N6*6YMUD>%72-C_  AAA@/J.*/(O/\ G\7_ +\C
M_&CR+S_G\7_OR/\ &HYI=S7V<.R_K48-(L!;V<(M4\NQ8-;+VB(& 1^!J:*Q
MMH;V>[BA5;BX"B60=7"C"Y^F:9Y%Y_S^+_WY'^-'D7G_ #^+_P!^1_C2YGW*
M4(K9$.N?\@T?]=X?_1JUH5DZK'.FGDS3B4>=#@"/;C]ZOO6M1T'U,[_F9O\
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MI]Q_:PCU."S\N5Q._EO*)$8/L VGY0XR5_BIJZGXGLQO:VFEC",Y-PBKO8R
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M\R9RP9UVY49([ELGOC%1?\*X$C^9!KSVIF5#LL8?)C;:@7(4-R,<D<CFF!V
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M/28A>KLE.3Y>,>6,\+U/ 'O0 [R=5_Y_;3_P$;_XY2B'5,C-[:8[_P"B-_\
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MNC?]\Q?_ !ND_L_]H;_H.Z-_WS%_\;HLPYD>\T5X-_9_[0W_ $'=&_[YB_\
MC=']G_M#?]!W1O\ OF+_ .-T68<R/>:*\&_L_P#:&_Z#NC?]\Q?_ !N@6/[0
MK9VZ_HIP<' BZ_\ ?NBS#F1[S17@W]G_ +0W_0=T;_OF+_XW1_9_[0W_ $'=
M&_[YB_\ C=%F',CWFBO!O[/_ &AO^@[HW_?,7_QNC^S_ -H;_H.Z-_WS%_\
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M_:)_Z#NC?]\Q?_&J /=:*\*_LG]HG_H.Z-_WS%_\:H_LG]HG_H.Z-_WS%_\
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M>671FCM9,;Y,OE03U"E>1@_H?:MY](TH31 6%I@DY_=+Z?2E32-*\Z0?8+3
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MV\I-)(IW;21RHY&=K?3BBZ%RM'?:OI5OK6ERV%V9%CD*L'C;:R,K!E93V(8
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M9&CC+)$\I_NH1D_F0*K_ &R;_H'77_?4?_Q=<AZ!;HJI]LF_Z!UU_P!]1_\
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ML[E"6^;>.%/O[4D)AM;"SMXV<K"$0$J<D 8]* *%[%9IJZ26L<*R20R&1HU
M+?,G4CK7-W?@]+R\N9IM3N2EQ?17IB$<?R-&%"A6VY'"CGKU]:ZG4I5DU*#8
M3Q!)U!'\25#6\/A.6J[2.7N/ \-YX>;2KO4[J;==O=-<M''YC,P8$'Y<'ACS
MC(X]!6;;?"W3_F>_N9)I#.TBJJ+M5?-+J.1DGG!)YY/;%=U15V1GS,K:;8QZ
M9I5K80LS1VL*0HS=2%&!G\JM+]X?6DI5^\/K3))_%DU];^%;^729C!=I&#'(
ML32$<C.%56.<9&=K8ZX.*XQ/%_C*%4:'09YD:,.R74#F4'R8R%R@"_?+9X[$
M<=O2Z*Y#T#C_  OXHUG6==>WU#2WM+-K=Y87-K(AXE*C<7Q@E<$+C/4\=*["
MBB@ JAKC7B:-.=,)%W\HC(4-SN'8^U7ZK:A?PZ982WEUN\J( ML7<>2!T_&@
M#E%\0^(K8F&339+B?9)(5,#8!\W"J&7@@(?_ !WOFNS4Y0'KD>F*S+7Q)IEW
M(D<=R%>1V2-7X+E6*G ],C@]\CUK4H \^\::KXPL?$,T?AY6EM/[/WD+ 6\H
M[L%\[#ENF "> ?E-0:SXM\3Z/#I=Y#ITTD3Z2TUU#<P,VR15+$LZ@!2,<@@9
M'  -=3JOC/2M&U:73KOSC<16RW)6-,[E9]BJO.2Q;C ]1G%-;QKX>;[)'=7B
M11ZA9F[B-P-JO'CD'/?&<CV- '+6OC7QG<7MI_Q(8C:.Z"23[).I=3*5+J"?
ME&S!P>G>O2)6V0NX(&U2<GI6)'XV\,R7%O;QZY9&6XP(4$HR^6VC _WABMN2
M18HVDD8*B LS$\ #O0!S4?BIY-*N;D"+S(K2.X \N0#+(201C)Y&,#GGFF3>
M,;F+4#:IHEW*9)I$A;8R*554(8DC&"6//L*WGUC3DMI+A[V$0Q!6=]XPH8 K
MGZY&/K4D6H6<X<PW4+B-F1\./E(ZC\* ,B7Q%<'0X[R*Q:.X,PC>WD#,5!)Q
M]T9YP #C +#/%5(O%5VS6X:V5C)-)&52-\RA=Y&ST.%7KUS@>W1SWMK;0":X
MN(HHF8('9P 23@#/UJ#^V],"QM]OM\2%@A\P?,5SD?A@_E0!0DO)M0\)V=W<
MP-;S3&W>2)E(*,9%R,'FMVLO59XKG18Y[>19(I)8&1U.0P,BX(K4IO874SC_
M ,C(?^O/_P!GIMO<I;7-SYJ2_.RE2L3,"-H'4#VI6R?$AQP?L77_ ('4/V>\
M_P"?W_R M5N2W9F GAK381YEH;R "0RB!+<A02V2!\O Z_C@]JT(]/LXM5M;
MQY;VY,,KR*)XG<(S*1N&1P><<>M7_L]Y_P _O_D!:/L]Y_S^_P#D!:.47,6!
MJ,/VMVV3[2B@'R'ZY/M[U&+^/['.GES[F,F!Y#\Y)QVJ/[/>?\_O_D!:/L]Y
M_P _O_D!:.4.8G;4(C%& D^0RY_</_A3CJ,/VA6V3X"D?ZA_4>U5OL]Y_P _
MO_D!:/L]Y_S^_P#D!:.4.8M)J,(>0E)\%LC]P_H/:HSJ$7V,)LGW8''D/_A4
M/V>\_P"?W_R M'V>\_Y_?_("T<H<Q9?483-&0D^ 3G]P_I]*:E[;+=2RB*8,
MX4%OL[Y.,^WO4'V>\_Y_?_("T?9[S_G]_P#("T<H<P^>[MY]-GMY89G65'4H
M8'^8'/'3WJ274(28-L<^%?)Q _ P?:H/L]Y_S^_^0%H^SWG_ #^_^0%HY0YB
M4W=J=16Y,,Q=(C&K^0^0"02.G? _*GQ:C"KRDI.-SY'[A_0>U5_L]Y_S^_\
MD!:/L]Y_S^_^0%HY0YA8KBVAM0(H)E>1XY)<0/RPV@GIZ*/RJ=M1A-S&P2?
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MBMLUC+:37EU-%)#'"1*(VP$& 1\G4]_TQ5=O VEO?&=S(R%F=HSM(+''?'3
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M\51_PC6F_P!VX_\  J3_ .*HHHYI=PY5V#_A&M-_NW'_ (%2?_%4?\(UIO\
M=N/_  *D_P#BJ**.:7<.5=@_X1K3?[MQ_P"!4G_Q5'_"-:;_ ';C_P "I/\
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C.9]PLA5\/:>LB/MF8HP8![F1AD'(X+8ZUIT44FV]PLD?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>irtc-20211231_g7.jpg
<TEXT>
begin 644 irtc-20211231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO96QE:2!(
M:6=G:6YS    !9 #  (    4   0J) $  (    4   0O)*1  (    #,#0
M )*2  (    #,#0  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C$Z,#(Z,C4@,C,Z-# Z-34 ,C R,3HP
M,CHR-2 R,SHT,#HU-0   $H ;P!E &P 90!I "  2 !I &< 9P!I &X <P
M /_A"R%H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B
M96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED)S\^#0H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U=6ED.F9A
M9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D
M,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(Q+3 R+3(U5#(S.C0P
M.C4U+C T,#PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I;VX^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN
M;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z4V5Q('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^/')D9CIL:3Y*;V5L96D@2&EG9VEN<SPO<F1F.FQI/CPO<F1F
M.E-E<3X-"@D)"3PO9&,Z8W)E871O<CX\+W)D9CI$97-C<FEP=&EO;CX\+W)D
M9CI21$8^/"]X.GAM<&UE=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_VP!#  <%!08%! <&!08(!P<("A$+"@D)"A4/
M$ P1&!4:&1@5&!<;'B<A&QTE'1<8(BXB)2@I*RPK&B O,R\J,B<J*RK_VP!#
M 0<(" H)"A0+"Q0J'!@<*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "V 6H# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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MCKT\/_E/6MY^H?\ /M#_ -]4GVC4?^?6+_OJ@#*W>.?3P_\ E/1N\=>GA_\
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M+9FF\Z.)(O*;"YSG^0YI\7B#5+S[1&D CN%1'CB*D'EP,GVQF@#L ^>E+O\
M45PNG:KKMO97DUVCM(TJ^6'0GCH<?CQ3M0?5X-+M;A)YQ.;<&4!3C<S>GK0!
MW'F+CK2[LUQ$_B#5[;4I;5(Q(2Y\O?$WH.,_CFNAT*^NKNWD748_+N(WQ@*0
M"I P?YT :]-;@'Z4N<#FD;[M '.>)+^ZTSP'J-[IQVW4-L[0G;GYNW%<6/B+
MJFC2+;ZG;^>%0&:>3Y3&=F1A5'(SUYKTVWB26P6.50R,.01D&DETZTE),MK$
MY/!)0<T >8V_Q%U6\T5]8AB"J;F-?LV.@V_, ?0GO1%\4M9CN USIEJ5F=%2
M!)6W)\I+,21R#CC\:].32[&.,1I;0K&""%"#&::VE6,C O9PD\?P#/'2@#SM
MOBAJZWBVC:/;-.ZHR(EP25#8.3\O'!_.J7_"VM36%KZ>PMHX#&HBMR[%Y&,H
M7@X[#U[UZ=#HEA#>SWB6L8GFV[GP/X1@?2D_L73]JJUG;D ]T'&3G^= 'FEO
M\3]5M-DE]:PSM*<E(W("J">!Q_K#QQTX-=]X/UZY\0Z)]KOK9+699&1DC8L/
M;D@5H'2+ D;K2#*OY@^0<-Z_K5F&".W3;"BQKG.%&* )L>]&/>C(I00>E "8
M]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10 F/>D8?*WTIU-;[C?2@#E
MO% Y\.?]A+_VA-75URGBCKX=_P"PE_[0FKJZ .:T?/\ PG?B;_=L_P#T6U59
M/%5Q;:C>I<V32012[(G48SC'^-6M'_Y'OQ-_NVG_ *+:I[C5](%Q+;3!6=&^
M==F>>/Z_K0!DIXW W@V;,V_:@5N2, \_A4K>-8(TD::W?8N.<^_3\N:G.K>'
M+:?_ %2;@N<K'G&<]?RIS:OHUQ8W<R6BSP6NUSB,?.3TQ0 V#Q6'CN9KBU,,
M414#YN3D=ZKR>-E21 UFP&#N4'G/4?ABK4.M:%>0RL\:Y*&25'CZ!?6GG4="
MN;G8R1^;Y6\DQ\JOH3_2@"DWC+RT EM7$C$,B9ZH>AJ1/%PN+*>2TM"\L;A5
M0MUSUSZ<BHSXCT%M2C:&,S"1%42*H**,^GUI\&JZ'8:G>K)&\4DDN79UX9A@
M?+0!!=^,69XTBL=X4!Y@QY4Y'3\"35@>,X1IMS?SV<BQVZJXP<D@G'%..KZ)
M;W=V)X=LOF9PRY\P@#E?0=J7_A(]#> *D(??M#0B/GD]_I0 EGXMAU"XDALX
M3O\ *9D9CPQVY _QJ*R\9*RHMW%N)P'E7 56]*GEUC0[&[>-[=$E#,KLL?'
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MQOI0!RWBCKX=_P"PE_[0FKJZY3Q1U\._]A+_ -H35U= '-:-D>//$W^[:?\
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M&-&O-*^T_;Y/->5E_>%RS/@=3Z?A71CI0 4UON-]*=36^XWTH Y;Q1U\._\
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MQ/<--L&$8 J1UJ6Z\2:C:M:DZ>99&MR\P53D'/;BK6N>(UTG4;6U2%)FF4L
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MV1S],T 7[WPN=1+C[81!*_F;0F<''.#_ )Q6>G@)Y9)&O+WS/F#)A,;O7/\
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MND6L VAHXV\V/S#\S;]RX/\ WU7:6ZLEC&KC#*@!&<]J "S_ ./..K%5[/\
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M'K0!QQDU98X6N(Y6B5H3'Y77K\V[_/2JWEZQ'J4UZHN&C2X^:%CPR^H]J[K
M]*3 H XK73?2ZLKV$-RL86/S1_#(N3T],'&?K73:0TDFGQ&X5A(!@[NIK0Q1
MB@ HHHH **** "BBB@ Q1110 8HHHH **** "FM]VG4U^E $-E_QY1_2K%5[
M+_CRC^E6,T %%)G'>C/O0 M%&:,T %%%&: "BC-% !11FB@ HHHH **** "B
MBC- !36^XWTI<BD?[I^AH Y;Q1U\._\ 82_]H35U=<IXH_YEW_L)?^T)JZN@
M#FM&_P"1\\3?[MI_Z+:NEKFM&_Y'SQ-_NVG_ *+:NEH **** "BBB@ HHHH
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MB:3L2IXXQ_*K=I9M:*X4KL8EC@>V/Z4 8?BC_F7/^PE_[0FKJZY3Q1U\.?\
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M (BC_A"W_P"AI\0_^!:?_$444 '_  A;_P#0T^(?_ M/_B*/^$+?_H:?$/\
MX%I_\1110 ?\(6__ $-/B'_P+3_XBC_A"W_Z&GQ#_P"!:?\ Q%%% !_PA;_]
M#3XA_P# M/\ XBC_ (0M_P#H:?$/_@6G_P 1110 ?\(6_P#T-/B'_P "T_\
MB*/^$+?_ *&GQ#_X%I_\1110 ?\ "%O_ -#3XA_\"T_^(H_X0M_^AI\0_P#@
M6G_Q%%% !_PA;_\ 0T^(?_ M/_B*/^$+?_H:?$/_ (%I_P#$444 '_"%O_T-
M/B'_ ,"T_P#B*/\ A"W_ .AI\0_^!:?_ !%%% !_PA;_ /0T^(?_  +3_P"(
MH_X0M_\ H:?$/_@6G_Q%%% !_P (6_\ T-/B'_P+3_XBC_A"W_Z&CQ#_ .!:
H?_$444 -/@R*&:&\N-:U>]:S9IHHKFX5DW;&7) 4=F/>NIHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>irtc-20211231_g8.jpg
<TEXT>
begin 644 irtc-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O 9(# 2(  A$! Q$!_\0
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MG@7P_=77AO1Y[B;3K>2666QB9W8QJ2S$KDDGDDUN?\()X/\ ^A4T/_P70_\
MQ-)X"_Y)WX:_[!=M_P"BEKH: .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T
M*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'
M_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH**
M .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$
M\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?
M_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B
M:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!
M_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_
M^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")
MKH** .?_ .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_
M .$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]
M"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA
M_P#B:/\ A!/!_P#T*FA_^"Z'_P")KH** .?_ .$$\'_]"IH?_@NA_P#B:/\
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MGCN)O-8W!7(.T#C ''%%AIIGR;XR9K/QSX@M;5C!;PZE<QQ11':B*)6 50.
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M(UF7 R3W]35S_EN?]T?S- $/_+I/]7_K4C=8?K_0U'_RZ3_5_P"M2-UA^O\
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M/BK2VAN(KR1]/G,S-Y-ZGEM@^8!['Z9JY!I%MIE[?20*Z2R2,)%\YV3.;K.
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M-TO(Y_PIJD>1$,\C;7G$_P 3KJT62:[\):U:6K.GES3VQPJDQ@[]N<'YVQ]
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MQ]8LLXCM)(D6.Z=@L4S!9\J#GG!_#BBP7.^:6.*:66214C6-278X Y/>E/\
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M$*O,Q/\ XZM4MF1+XH_UT+S->[)OW-O_ -_6]!_LTNZ]V1_N;?J/^6K?_$U
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MJU[]J?\ <V_W%_Y:MZG_ &:3==_9_FB@"YY(E/K_ +M1+>R?:7.U?N+_ #-
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M<+U]?:@">-+?[3-Q'_#Z>E+LMOLXXCZ#TJHEG+]HF&%_A[^U'V.7R!PO0=Z
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M\NW](_TIZ! /W87'M5#['-_=7\ZMVL311D, "3GB@#XG\=_\E#\3?]A6Z_\
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M[KGE75K800S1_9)VVNJ ,,A"#@@]*V/^%V_#S_H8?_)*X_\ C= 'H%%>?_\
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MTSH#.NV7_6=_^6;>GTI?/7;'_K.H_P"6;?X5SO\ PNOX=X(_X2#KU_T*X_\
MC=+_ ,+L^'>!_P 5!T_Z<KC_ .-TAFZ)U^W/_K/]4O\ RS;U;VI?/7[/)_K/
MXO\ EFWJ?:L#_A=7PZ\PO_PD'S$8)^Q7'3_OW[T?\+K^'6TK_P )!P<Y_P!"
MN/\ XW0!ORSKYUO_ *S[Y_Y9M_=/M4BSKO;_ %G;_EFW^%<X?C5\.F*D^(,E
M3D?Z%<<=O^>=+_PNSX=YS_PD/_DE<?\ QN@#;DG7["W^LZ?\\V]?I4[3KYH_
MUG?_ )9M_A7-GXT_#ED*'7\J>WV*X_\ C=._X79\.\Y_X2'_ ,DKC_XW0!T
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M_P \V_PKG?\ A=?PZ( _X2#IT_T*X_\ C=+_ ,+L^'><_P#"0_\ DE<?_&Z
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0@KN1I&93@X(R".M% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>irtc-20211231_g9.jpg
<TEXT>
begin 644 irtc-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "5 9(# 2(  A$! Q$!_\0
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MG@;P_=77AO1Y[B;3;>2666QB9W8QJ2S$KDDGDDUN?\()X/\ ^A4T/_P70_\
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M/_P70_\ Q-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\
MQ-=!10!S_P#P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-=!10!S
M_P#P@G@__H5-#_\ !=#_ /$UQ5[K_P &-.O[BRNK#0([BWD:*5/[(!VLIP1Q
M'ZUZK7F&J?!/P?JFK7E_<IJ!GN9GFDVW.!N8Y.!CIDT6$W8I?\)9\$?^?/0/
M_!./_C='_"6?!'_GST#_ ,$X_P#C=._X4+X(_N:E_P"!0_\ B:/^%"^"/[FI
M?^!0_P#B:=F+F0W_ (2SX(_\^>@?^"<?_&Z/^$L^"/\ SYZ!_P""<?\ QNG?
M\*%\$?W-2_\  H?_ !-'_"A?!']S4O\ P*'_ ,319AS(;_PEGP1_Y\] _P#!
M./\ XW1_PEGP1_Y\] _\$X_^-T[_ (4+X(_N:E_X%#_XFC_A0O@C^YJ7_@4/
M_B:+,.9#?^$L^"/_ #YZ!_X)Q_\ &ZZ3P[IOPV\66<MWHF@Z#=012>4[C2XU
MPV <?,@[$5SO_"A?!']S4O\ P*'_ ,37;>#/!VD^"],GLM($XAFF\U_.DWG=
M@#T'8"BPTTSY%\9,UGXY\06MJQ@MX=2N8XHHCM1%$K *H'  '  HI/'?_)0_
M$W_85NO_ $:U%(9]?> _^2=^&O\ L%6W_HI:Z&N>\!D#X=^&B>@TJV_]%+6S
M:W]G?*S6EU!<*IP6BD#@?E0!8HJ)[B&.5(GFC61_NJ6 +?04&X@#E#-'N#!2
M-PR">0/K0!+1110 =!FJ5IJ]A?>;]GN%;R0#+D%=F<CG/3H:ND9&#WK+%II]
MG8W L(X8CY0#&+&<#.,]^YH N?;[/_G[@_[^"D_M"R_Y_+?_ +^C_&LW1B6N
M9,RL_P G0_6MK ]!0!7_ +0LO^?RW_[^C_&C^T++_G\M_P#OZ/\ &K&!Z"C
M]!0!7_M"R R;RW_[^K_C1_:%E_S^6_\ W]7_ !IUV!]BGX'^K;^52H!L7@=*
M (/[0LO^?RW_ ._H_P :/[1LLX^V6_\ W]7_ !JQ@>@JM*!_:-MP/N2?^RT
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M5L8W'57N$!_G3/\ A(]#_P"@SIW_ (%)_C7RW\=@!\5M0P/^6,'_ *+6O-Z
M/NS_ (2+0R<#6=/_ / I/\:M?VA9?\_=O_W]'^-?"%E_Q_V__75?YBOO? ]!
M0!1.N:2"0=4L@1P1]H3_ !H_MW2/^@K8_P#@0G^-+I]O";"$F&,DC^Z*L_9H
M/^>,?_? H K)K6E2.$34[-F/0+.I)_6I&U*Q52S7ML% R295P/UIMQ#$CVY6
M) ?-'(4>AIVHJ#82@@$''!'N* (O[=TC_H*V/_@0G^-']NZ1_P!!6Q_\"$_Q
MJU]F@_YXQ_\ ? H^S0?\\8_^^!0!7CU?3)B1%J-HY')"SJ?ZTZ35-.B7=)?V
MJ+G&6F4#^='E1IJ$>R-%S$V<*!W6EN41[BU#(K#>>",_PF@"+^W=(_Z"MC_X
M$)_C1_;ND?\ 05L?_ A/\:M?9H/^>,?_ 'P*/LT'_/&/_O@4 11:GI\^/)OK
M:3)P-DJGGTZU:JI:QHEQ=A451Y@X Q_ M6Z "N2\>:])X=\,75[;S0PW;R1V
M]M)-C8LCL%#-GC &2?85UM<SXIFT.V6RGUR!9D2\7[,&7=ME((#8[X&>N::)
MD< ?'6O:I;^%1IMQ)YE];W'VTV-DERS2PNJ$JK, %)).0>A%>L#H,^E<3;:I
MX)T^\COK6W6"Z8R21;8F4EI<>8 IX!.P9[9%:LWC31[:[D@NGF@\N5XC(\?R
MDH2"1C)QD$9Q5$LZ&BN9?QYH4+R+---&4&1F(DN>> .N>#UQ5JT\7:)>W,-K
M%>?Z1,_EI&4;);TSC':@5C<HHHI@%6(/N'ZU7JQ!]P_6I>PX[GQ+X[_Y*'XF
M_P"PK=?^C6HH\=_\E#\3?]A6Z_\ 1K45)H?7W@/_ ))WX:_[!5M_Z*6N62S\
M':[>"TBN[HE5FE)7"H@21MQZ>I./;%=!X3N19?"C1;LIO$&B02%<XW;80<9_
M"N6^'GC/1O$OAS7M1A\.P:5':H(I4@<$RJ5.!D 8/;\: +5II7@VY LH==FN
M#)*K!"Y:3S&8[3G&0<D_H34XB\(-;SZ6VK/'$CI%G.W<8T.?FQAOODD_X5M>
M&+719PTVGZ1%;I (UCFQDN=N>N.2-Q&<D]:NW'A'0;E9M^F6ZM,'5W1<,0_#
M<^XXH O:1;6UII%K!9NSVRQCRF8YRIY'Z&KM(JJBA5 "J, #L*6@ K%CT2ST
MF"^FMMX,T8#!FP %SC'''6MJL2'3[NR@O6FNVN%:(+&"Q)XSDG)(SS^E ":(
M5-S)@@_)V?=W^E;E8NBE_M,FY2/D] ._M5R$7D\?FBZ10Q.%\K..3[T 7J*J
M>3>?\_B_]^?_ *]-D%W!L=KE'7>JE?*QD$@=<^] $]W_ ,>4_P#US;^52I]Q
M?I45W_QY3_\ 7-OY5*GW%^E "U6E_P"0C;?[DG_LM6:K2_\ (1MO]R3_ -EH
M 2]ZVO\ UW7^1JU56]ZVO_7=?Y&K5 !5:#_C\NOJO\JLU6@_X_+KZK_*@#P?
M]I?[WASZ7'_M.O :]^_:7^]X<^EQ_P"TZ\!H *^S_A5_R2[P]_UZC^9KXPK[
M/^%7_)+O#W_7J/YF@#YY^.W_ "5;4/\ KC!_Z+%>;5Z3\=O^2K:A_P!<8/\
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MS6+0/+D.IP>A'RD+V'IGN:5+'Q!YRM#J,4=NLSL8RWF;U,C$ L5STP, \8-
M%G2]1U>XO?)O]+6WBV$B59"?F&.",?7O6UVHIK@E&"MM8C@^E &%8W>MB::*
M]MPT/E,\<ZQX8')P"HR#QCIWJK!J_B0JH?1MS>5&=S_("WS;CQDC^'@@?TI=
M*MM0@DF,^L0SPRPD+"+@MM)X#!B,\G//^%6M-LM=BN+>2ZU"-[98U5X1ALX3
M!.[;DY;G.: -FUDDFM(I)HO*E9 7CSG:>XJKK4U];Z5-+IT8DNEP50J3NYY
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M6Z[T-H-J,T88,3N^_DCY.G)YXHN%CTJBN>\,3>(I&O$UY5(7:8)! (L\N",
MG/"HW_ JZ&@058@^X?K5>K$'W#]:3V''<^)?'?\ R4/Q-_V%;K_T:U%'CO\
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M^%'V:?\ Y_9?^^4_PIG^E>:(OM4.\KN \D]/^^O>G^7>_P#/S#_WY/\ \50
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M_LT 28U#^]:_]\M_C1C4/[UK_P!\M_C3M][_ ,\8/^_I_P#B:-][_P \8/\
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MSC)K0_X::_ZE'_RI?_:J** #_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JHHH
M/^&FO^I1_P#*E_\ :J/^&FO^I1_\J7_VJBB@ _X::_ZE'_RI?_:J/^&FO^I1
M_P#*E_\ :J** #_AIK_J4?\ RI?_ &JC_AIK_J4?_*E_]JHHH /^&FO^I1_\
MJ7_VJC_AIK_J4?\ RI?_ &JBB@ _X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J
M** #_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JHHH /^&FO^I1_P#*E_\ :J/^
M&FO^I1_\J7_VJBB@ _X::_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J** #_AIK_J
M4?\ RI?_ &JC_AIK_J4?_*E_]JHHH /^&FO^I1_\J7_VJC_AIK_J4?\ RI?_
M &JBB@ _X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J** #_AIK_J4?_*E_]JH_
MX::_ZE'_ ,J7_P!JHHH /^&FO^I1_P#*E_\ :J/^&FO^I1_\J7_VJBB@ _X:
M:_ZE'_RI?_:J/^&FO^I1_P#*E_\ :J** #_AIK_J4?\ RI?_ &JC_AIK_J4?
M_*E_]JHHH /^&FO^I1_\J7_VJC_AIK_J4?\ RI?_ &JBB@ _X::_ZE'_ ,J7
M_P!JH_X::_ZE'_RI?_:J** #_AIK_J4?_*E_]JH_X::_ZE'_ ,J7_P!JHHH
M/^&FO^I1_P#*E_\ :J/^&FO^I1_\J7_VJBB@ _X::_ZE'_RI?_:J/^&FO^I1
M_P#*E_\ :J** #_AIK_J4?\ RI?_ &JC_AIK_J4?_*E_]JHHH /^&FO^I1_\
MJ7_VJC_AIK_J4?\ RI?_ &JBB@ _X::_ZE'_ ,J7_P!JH_X::_ZE'_RI?_:J
F** /%M<N_P"W-?U+5]GD?;KJ6Y\K.[9O8MMSQG&<9P**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466227400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iRhythm Technologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8149544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">699 8th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">632-5700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,513,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the information called for by Part III of this Form 10-K is hereby incorporated by reference from the definitive Proxy Statements for our annual meeting of stockholders, which will be filed with the Securities and Exchange Commission not later than 120 days after December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $.001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IRTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001388658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462695816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461240216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 127,562<span></span>
</td>
<td class="nump">$ 88,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">111,569<span></span>
</td>
<td class="nump">246,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">46,430<span></span>
</td>
<td class="nump">29,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,268<span></span>
</td>
<td class="nump">5,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,693<span></span>
</td>
<td class="nump">7,363<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">305,522<span></span>
</td>
<td class="nump">377,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">55,944<span></span>
</td>
<td class="nump">34,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">84,587<span></span>
</td>
<td class="nump">84,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">16,052<span></span>
</td>
<td class="nump">14,091<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">462,967<span></span>
</td>
<td class="nump">511,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,509<span></span>
</td>
<td class="nump">4,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">51,486<span></span>
</td>
<td class="nump">40,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current portion</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="nump">11,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">11,142<span></span>
</td>
<td class="nump">8,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">87,853<span></span>
</td>
<td class="nump">65,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt, noncurrent portion</a></td>
<td class="nump">9,690<span></span>
</td>
<td class="nump">21,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent portion</a></td>
<td class="nump">85,212<span></span>
</td>
<td class="nump">81,293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">183,452<span></span>
</td>
<td class="nump">170,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value &#8211; 5,000,000 shares authorized at December&#160;31, 2021 and 2020; and none issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value &#8211; 100,000,000 shares authorized at December&#160;31, 2021 and 2020; 29,493,726 and 29,019,350 shares issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">685,594<span></span>
</td>
<td class="nump">646,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(406,045)<span></span>
</td>
<td class="num">(304,684)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">279,515<span></span>
</td>
<td class="nump">341,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 462,967<span></span>
</td>
<td class="nump">$ 511,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461063960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">29,493,726<span></span>
</td>
<td class="nump">29,019,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">29,493,726<span></span>
</td>
<td class="nump">29,019,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466244712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 322,825<span></span>
</td>
<td class="nump">$ 265,166<span></span>
</td>
<td class="nump">$ 214,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">109,258<span></span>
</td>
<td class="nump">70,277<span></span>
</td>
<td class="nump">52,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">213,567<span></span>
</td>
<td class="nump">194,889<span></span>
</td>
<td class="nump">162,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">38,671<span></span>
</td>
<td class="nump">41,329<span></span>
</td>
<td class="nump">37,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">274,839<span></span>
</td>
<td class="nump">197,233<span></span>
</td>
<td class="nump">179,523<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">313,510<span></span>
</td>
<td class="nump">238,562<span></span>
</td>
<td class="nump">216,822<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(99,943)<span></span>
</td>
<td class="num">(43,673)<span></span>
</td>
<td class="num">(54,755)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,169)<span></span>
</td>
<td class="num">(1,519)<span></span>
</td>
<td class="num">(1,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">1,591<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(100,994)<span></span>
</td>
<td class="num">(43,601)<span></span>
</td>
<td class="num">(54,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,361)<span></span>
</td>
<td class="num">$ (43,830)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in USD per share)</a></td>
<td class="num">$ (3.46)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in USD per share)</a></td>
<td class="num">$ (3.46)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares, basic (in shares)</a></td>
<td class="nump">29,331,010<span></span>
</td>
<td class="nump">27,754,404<span></span>
</td>
<td class="nump">25,265,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares, diluted (in shares)</a></td>
<td class="nump">29,331,010<span></span>
</td>
<td class="nump">27,754,404<span></span>
</td>
<td class="nump">25,265,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128467244664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,361)<span></span>
</td>
<td class="num">$ (43,830)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net change in unrealized gains (losses) on available-for-sale securities</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (101,433)<span></span>
</td>
<td class="num">$ (43,901)<span></span>
</td>
<td class="num">$ (54,470)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458777656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,368,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 52,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 257,955<span></span>
</td>
<td class="num">$ (205,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' and Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans, net (in shares)</a></td>
<td class="nump">540,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">734,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans</a></td>
<td class="nump">$ 9,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CommonStockSharesIssuedFromExerciseOfWarrants', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with follow-on public offering, net of discounts and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with follow-on public offering, net of issuance costs</a></td>
<td class="nump">107,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">107,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding upon vesting of restricted stock awards</a></td>
<td class="num">(5,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">26,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net change in unrealized loss on investments</a></td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,682,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 135,409<span></span>
</td>
<td class="num">$ (461)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">395,695<span></span>
</td>
<td class="num">(260,393)<span></span>
</td>
<td class="num">$ (461)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' and Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">ASC 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans, net (in shares)</a></td>
<td class="nump">868,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,079,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans</a></td>
<td class="nump">$ 20,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with follow-on public offering, net of discounts and issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with follow-on public offering, net of issuance costs</a></td>
<td class="nump">206,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">206,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding upon vesting of restricted stock awards</a></td>
<td class="num">(10,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">34,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net change in unrealized loss on investments</a></td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,019,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 341,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">646,258<span></span>
</td>
<td class="num">(304,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' and Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans, net (in shares)</a></td>
<td class="nump">90,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with employee equity incentive plans</a></td>
<td class="nump">$ 8,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding upon vesting of restricted stock awards</a></td>
<td class="num">(25,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">56,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(101,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net change in unrealized loss on investments</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,493,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 279,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 685,594<span></span>
</td>
<td class="num">$ (406,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CommonStockSharesIssuedFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares, Issued From Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CommonStockSharesIssuedFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128467143656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,361)<span></span>
</td>
<td class="num">$ (43,830)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">54,527<span></span>
</td>
<td class="nump">41,515<span></span>
</td>
<td class="nump">26,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discounts on investments, net of premium amortization</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="num">(884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ProvisionForBadDebtAndContractualAllowance', window );">Provision for bad debt and contractual allowance</a></td>
<td class="nump">37,074<span></span>
</td>
<td class="nump">31,431<span></span>
</td>
<td class="nump">24,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRightOfUseAssetsAmortization', window );">Cost of operating lease right-of-use assets</a></td>
<td class="nump">6,752<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
<td class="nump">8,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(53,572)<span></span>
</td>
<td class="num">(37,957)<span></span>
</td>
<td class="num">(28,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,960)<span></span>
</td>
<td class="num">(1,389)<span></span>
</td>
<td class="num">(1,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,329)<span></span>
</td>
<td class="num">(3,027)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(1,831)<span></span>
</td>
<td class="num">(6,149)<span></span>
</td>
<td class="num">(4,732)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">6,135<span></span>
</td>
<td class="num">(3,881)<span></span>
</td>
<td class="nump">5,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">7,946<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">264<span></span>
</td>
<td class="num">(4,819)<span></span>
</td>
<td class="num">(5,241)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,753)<span></span>
</td>
<td class="num">(13,759)<span></span>
</td>
<td class="num">(21,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(28,067)<span></span>
</td>
<td class="num">(13,551)<span></span>
</td>
<td class="num">(20,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of available-for-sale investments</a></td>
<td class="num">(122,184)<span></span>
</td>
<td class="num">(277,510)<span></span>
</td>
<td class="num">(165,915)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of available-for-sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,525<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of available-for-sale investments</a></td>
<td class="nump">255,515<span></span>
</td>
<td class="nump">144,145<span></span>
</td>
<td class="nump">95,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">105,264<span></span>
</td>
<td class="num">(132,391)<span></span>
</td>
<td class="num">(89,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock in connection with follow-on public offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">206,025<span></span>
</td>
<td class="nump">107,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock in connection with employee equity incentive plans</a></td>
<td class="nump">8,943<span></span>
</td>
<td class="nump">20,244<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding upon vesting of restricted stock awards</a></td>
<td class="num">(25,853)<span></span>
</td>
<td class="num">(10,009)<span></span>
</td>
<td class="num">(5,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(11,667)<span></span>
</td>
<td class="num">(1,944)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(28,577)<span></span>
</td>
<td class="nump">214,316<span></span>
</td>
<td class="nump">111,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">38,934<span></span>
</td>
<td class="nump">68,166<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">88,628<span></span>
</td>
<td class="nump">20,462<span></span>
</td>
<td class="nump">20,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of&#160;&#160;year</a></td>
<td class="nump">127,562<span></span>
</td>
<td class="nump">88,628<span></span>
</td>
<td class="nump">20,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="nump">1,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities', window );">Property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_StockIssuanceCostsIncurredButNotYetPaid', window );">Deferred offering costs included in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">6,625<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">88,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based compensation</a></td>
<td class="nump">$ 3,593<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OperatingLeaseRightOfUseAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right Of Use Assets Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OperatingLeaseRightOfUseAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ProvisionForBadDebtAndContractualAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for bad debt and contractual allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ProvisionForBadDebtAndContractualAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance costs incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460817768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iRhythm Technologies, Inc. (the &#8220;Company&#8221;) was incorporated in the state of Delaware in September 2006. The Company is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. The Company began commercial operations in the United States in 2009 following clearance by the U.S. Food and Drug Administration.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is headquartered in San Francisco, California, which also serves as a clinical center. The Company has additional clinical centers in Lincolnshire, Illinois and Houston, Texas and a manufacturing facility in Cypress, California. In March 2016, the Company formed a wholly-owned subsidiary in the United Kingdom. Additionally, in June 2021, the Company formed a wholly-owned subsidiary in Singapore. The Company manages its operations as a single operating segment. Substantially all of the Company&#8217;s assets are maintained in the United States. The Company derives substantially all of its revenue from the provision of services to customers in the United States.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 10, 2019, the Company issued and sold an aggregate of 1,575,342 shares (the "2019 Shares") of common stock, in a public offering at a price of $73.00 per share. The 2019 Shares included the full exercise of the underwriters&#8217; option to purchase an additional 205,479 shares of common stock. Total proceeds received from the offering were $107.3&#160;million, after deducting discounts and issuance costs.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2020, the Company issued and sold an aggregate of 1,257,142 shares (the "Shares") of common stock, in a public offering at a price of $175.00 per share. The Shares included the full exercise of the underwriters&#8217; option to purchase an additional 163,975 shares of common stock. Total proceeds received from the offering were $206.8 million, after deducting discounts and issuance costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460862120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of iRhythm Technologies, Inc. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The financial statements of the Company&#8217;s subsidiary use the U.S. dollar as the functional currency. For all non-functional currency balances, the remeasurement of such balances to functional currency results in a foreign exchange transaction gain or loss, which is recorded in the consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, the Company has experienced significant business disruptions, restrictions on its ability to travel, reduction in access to customers due to diverted resources at hospitals, slower response times from payors who are also facing business interruptions, and shortened business hours as governments institute prolonged shelter-in-place and/or self-quarantine mandates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, Company personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where the Company's headquarters is located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. The Company is also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the Company has instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While the Company has continued to deliver its Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">measures at the Company's facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminishe</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, the Company has adapted its service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended June 30, 2021, the Company experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, the Company experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions within the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could meaningfully impact the volume of our patient registrations in future periods.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is continuously reviewing its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. The Company believes it will have adequate liquidity over the next 12 months to operate its business and to meet its cash requirements. As of December 31, 2021, the Company is in compliance with its debt covenants. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on liquidity, capital resources, supply chain, operations and business and those of the third parties on which the Company relies, and could worsen over time. The extent to which the COVID-19 pandemic impacts the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the COVID-19 pandemic or treat its impact, among others. The full extent of potential delays or impacts on the business, financial condition, cash flows and results of operations remains unknown. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing the Company&#8217;s ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact short-term and long-term liquidity and the ability to operate on a timely basis, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for the Zio service, which would significantly harm the Company. Government and other third-party payors require the Company to report the service for which it is seeking reimbursement by using a Current Procedural Terminology (&#8220;CPT&#8221;), code-set maintained by the American Medical Association (&#8220;AMA&#8221;). For Zio XT, the Company had historically utilized temporary CPT codes (or Category III CPT codes) used for newly introduced technologies and specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and Centers for Medicare and Medicaid (&#8220;CMS&#8221;). On October 25, 2019, the AMA&#8217;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. In November 2021, CMS published the Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;2022 Final Rule&#8221;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Company&#8217;s Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#8220;MAC&#8221; or &#8220;MACs&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#8220;NCD&#8221;) by CMS, or at the local level through a local coverage determination (&#8220;LCD&#8221;), by one or more of the regional Medicare Administrative Contractors (&#8220;MACs&#8221;) who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#8220;IDTF&#8221;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the published Medicare reimbursement rates are not adequate to support our cost structure, or we are unable to reduce our overall cost structure, the Company may be unable to provide the Zio service or would experience a significant loss of revenue, either of which would have a material adverse effect on our cash flows, results of operations, and financial condition.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, the Company will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if the Company is unsuccessful in improving the Medicare rates, the Company believes that commercial rates may begin to be more negatively impacted next year. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (&#8220;PCBAs&#8221;), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are carried at fair value based upon quoted market prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically assesses its portfolio of debt investments for impairment. For debt securities in an unrealized loss position, this assessment first takes into account the intent to sell, or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value through interest and other, net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses on available-for-sale debt securities are recognized in other income, net in the condensed consolidated statements of operations, and any remaining unrealized losses, net of taxes, are reported as a component of accumulated other comprehensive loss. The Company did not recognize any credit losses on its available-for-sale securities during the year ended December 31, 2021 and there were no impairment charges for unrealized losses in the periods presented. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of available-for-sale securities sold is based on the specific-identification method and realized gains and losses are included in earnings. Amortization of premiums and accretion of discounts are reported as a component of other income, net.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable includes amounts due to the Company from healthcare institutions, third-party payors, and government payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts and contractual allowances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on its assessment of the collectability of customer accounts and recognizes the provision as a component of selling, general and administrative expenses. The Company records a provision for contractual allowances based on the estimated differences between contracted amounts and expected collection rates. Such provisions are based on the Company's historical experience and are reported as a reduction of revenue.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews the allowances by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to administrative delays with payors and a combination of negotiations with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, inherent uncertainty caused by the longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for doubtful accounts (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: adoption of ASC 326</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: provision for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: write-offs, net of recoveries and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the contractual allowance (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,433&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,205&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: allowance for contractual adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,916&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: contractual adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,466)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,068)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,290)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,274&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,433&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company&#8217;s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), accounted for approximately 14%, 27% and 27% of the Company&#8217;s revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. CMS accounted for 8% and 20% of accounts receivable as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inflationary Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously monitors the effects of inflationary factors, such as increases in cost of goods sold and selling and operating expenses, which may adversely affect its results of operations. Specifically, the Company may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages paid to its employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict the Company's ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. The Company's inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio monitor and the adhesive that binds the Zio monitor to a patient&#8217;s body. These components and materials are critical, and there could be a considerable delay in finding alternative sources of supply. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A global semiconductor supply shortage is having wide-ranging effects across multiple industries. The supply shortage has impacted multiple suppliers that provide the printed circuit board assemblies to the Company. The semiconductor supply shortage may have an impact on the Company until global supply is sufficient for global demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Supply Chain Constraints</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economies worldwide have also seen other indirect COVID-19 pandemic related disruptions including supply chain impacts, material inflation, and labor constraints in certain markets and geographies. Such economic disruption has had an adverse effect on the Company's business environment as increased lead times and component shortages have resulted in higher inventory costs. While the Company has increased inventory safety stock levels to help mitigate the delays and disruptions in supply, the Company cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not further impact its supply chain.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory owned by the Company is valued at cost, on the first in, first out (&#8220;FIFO&#8221;) basis, or the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand. The Company also records market value based write-downs on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d">three</span> to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal-Use Software</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs related to internal-use software during the application development stage. Costs related to planning and post implementation activities are expensed as incurred. Capitalized internal-use software is amortized, and recognized as cost of revenue, on a straight-line basis over the estimated useful life, which is up to five years. The Company evaluates the useful lives of these assets on an annual basis, and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Capitalized internal-use software costs are classified as a component of property and equipment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible net assets acquired in business combinations. Goodwill is tested for impairment on an annual basis and at any other time if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Such events or circumstances may include significant adverse changes in the general business climate, among other things. The impairment test is performed by determining the enterprise fair value of the Company, which is primarily based on the Company&#8217;s market capitalization. If the Company&#8217;s carrying value, as a one reporting unit entity, is less than its fair value, then the fair value is allocated to all of its assets and liabilities (including any unrecognized intangible assets) as if the fair value was the purchase price to acquire the Company. The excess of the fair value over the amounts assigned to the Company&#8217;s assets and liabilities is the implied fair value of the goodwill. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. The Company did not record any charges related to goodwill impairment in any of the periods presented in these consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company annually reviews long-lived assets for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. To date, there have been no such impairments of long-lived assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects this decision will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022. Refer to Note 13. Subsequent Events for further details.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses Printed Circuit Board Assemblies (&#8220;PCBAs&#8221;), in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the ZIO AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT or Zio AT monitor, or a wireless gateway is used with a Zio AT monitor a portion of the cost of the PCBA and/or gateway is recorded as a cost of revenue. The PCBAs are recorded as other assets and were $13.9 million and $12.6 million as of December&#160;31, 2021 and 2020, respectively. The Company has based its estimates of how many times a PCBA can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. The Company periodically evaluates the use estimate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents all changes in stockholders&#8217; equity during the period from non-owner sources. The Company&#8217;s unrealized gains and losses on available-for-sale securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s revenue is generated primarily from the provision of its cardiac rhythm monitoring service, the Zio XT service. The Zio XT is a cardiac rhythm monitoring service that has a patient wear period of up to 14 days and is billable when the monitoring reports are delivered to the healthcare provider, which is also when the service is complete and the Company recognizes revenue. The time from when the patient has the Zio XT device applied to the time the report is posted is generally around 25 days. The Company has concluded that the Zio XT service is one performance obligation on the basis that the customer cannot benefit from each component of the service on its own or together with other resources that are readily available to the customer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what the Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating patients that require more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria. The Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report with two performance obligations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes as revenue the amount of consideration to which it expects to be entitled in exchange for performing the service. The consideration the Company is entitled to varies by portfolio, as further defined below, and includes estimates that require significant judgment by management. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, will pay the Company for some or all of the service on the patient&#8217;s behalf. Separate contractual arrangements exist between the Company and third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A small portion of the Company&#8217;s transactions are covered by third-party payors with whom there is neither a contractual agreement nor an established amount that the third-party payor will pay. In determining the collectability and transaction price for its service, the Company considers factors such as insurance claims which are adjudicated as allowable under the applicable policy and payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments. Certain of these factors are forms of variable consideration which are only included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Contracted third-party payors &#8211; The Company has contracts with negotiated prices for services provided to patients with commercial healthcare insurance coverage.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CMS &#8211; The Company has received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant CPT code rates for the services rendered to the patient covered by CMS.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-contracted third-party payors &#8211; Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for determining revenue recognition is based on factors including an average of the Company&#8217;s historical collection experience for its non-contracted services. This rate is reviewed at least quarterly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Healthcare institutions &#8211; Healthcare institutions are typically hospitals or physician practices in which the Company has negotiated amounts for its monitoring services, including certain governmental agencies such as the Veterans Administration and Department of Defense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition whereby services provided under each of the above payor types form a separate portfolio. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, the Company has concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For contracted and CMS portfolios, the Company recognizes revenue, net of contractual allowances, and recognizes an allowance for doubtful accounts for uncollectible patient accounts receivable. The transaction price is determined based on negotiated rates, and the Company has historical experience of collecting substantially all of these contracted rates. These contracts also impose a number of obligations regarding billing and other matters, and the Company&#8217;s noncompliance with a material term of such contracts may result in a denial of the claim. The Company accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price recognized as revenue. The Company estimates the denied claims which require management judgment. The estimated denied claims are based on historical information and judgement includes the historical period utilized. The Company monitors the estimated denied claims against the latest available information, and subsequent changes to the estimated denied claims are recorded as an adjustment to revenue in the periods during which such changes occur. Delays in claims submissions could lead to an increase in denials if we miss the payors&#8217; filing deadlines and could result in a reduction in the Company&#8217;s receipt of payments. Historical cash collection indicates that it is probable that substantially all of the transaction price, less the estimate of denied claims, will be received. Contracted payors may require that we bill patient co-payments and deductibles and from time to time we may not be able to collect such amounts due to credit risk. The Company provides for estimates of uncollectible patient accounts receivable, based upon historical experience where judgment includes the historical period utilized, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to a combination of negotiations with payors and administrative delays with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021. For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For non-contracted portfolios, the Company is providing an implicit price concession due to the lack of a contracted rate with the underlying payor, the result of which requires the Company to estimate the transaction price based on historical cash collections utilizing the expected value method. All subsequent adjustments to the transaction price are recorded as an adjustment to revenue.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For healthcare institutions, the transaction price is determined based on negotiated rates, and the Company has historical experience collecting substantially all of these contracted rates. Historical cash collection indicates that it is probable that substantially all of the transaction price will be received. As such, the Company is not providing an implicit price concession but, rather, has chosen to accept the risk of default, and any subsequent uncollected amounts are recorded as bad debt expense.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with customers by payor type. The Company believes these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. Disaggregated revenue by payor type and major service line for the years ended December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracted third-party payors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contracted third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare institutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires an entity to present a revenue contract as a contract liability when the Company has an obligation to transfer goods or services to a customer for which the Company has received consideration from the customer, or an amount of consideration from the customer is due and unconditional (whichever is earlier).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s customers pay the Company directly for the Zio XT service upon shipment of devices. Such advance payments are contract liabilities and are recorded as deferred revenue on the Consolidated Balance Sheets and revenue is recognized when reports are delivered to the healthcare provider. During the year ended December&#160;31, 2021, $0.9 million relating to the contract liability balance at the beginning of 2021 was recognized as revenue. Total revenue recognized during the year ended December 30, 2020 that was included in the contract liability balance at the beginning of 2020 was $1.2&#160;million.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 340, the incremental costs of obtaining a contract with a customer are recognized as an asset. Incremental costs of obtaining a contract are those costs that an entity incurs to obtain a contract with a customer that it would not have incurred if the contract had not been obtained.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current commission programs are considered incremental. However, as a practical expedient, ASC 340 permits the Company to immediately expense contract acquisition costs, as the asset that would have resulted from capitalizing these costs will be amortized in one year or less.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes direct labor, material costs, overhead, data analysis, customer care, equipment and infrastructure expenses, amortization of internal-use software, and shipping and handling. Direct labor includes payroll and personnel-related costs involved in manufacturing. Material costs include both the disposable costs of the device and amortization of the PCBAs. Each time the PCBA is used in a wearable Zio XT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are expensed as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, laboratory supplies, consulting costs and overhead charges.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognize taxes on Global Intangible Low-Taxed Income as a current period expense when incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. The fair value of market condition awards is determined using the Monte-Carlo option pricing model and the fair value of stock options is determined using the Black-Scholes option pricing model. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For restricted stock, the compensation cost for these awards is based on the closing price of the Company&#8217;s common stock on the date of grant, and recognized as compensation expense on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant, net of estimated forfeitures. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Common Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effect of potentially dilutive securities are anti-dilutive.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Identifying a lease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both of the following terms:</span></div><div style="text-align:justify;text-indent:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to obtain substantially all of the economic benefits from use of the identified asset; and</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to direct the use of the identified asset.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Discount rate for leases</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in the lease is not readily determinable for our operating leases, the Company generally uses an incremental borrowing rate based on information available at the commencement date such as a synthetic credit rating and current cost of borrowing to determine the present value of future lease payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease term</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term is generally the minimum noncancellable period of each lease. The Company does not include option periods in determining the right-of-use asset and operating lease liability at inception unless it is reasonably certain that the Company will exercise the option at inception or when a triggering event occurs. As of December&#160;31, 2021, no renewal options were included in the determination of lease terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease Modification</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The San Francisco Lease is in the same building with the same landlord as the lease for the Company&#8217;s prior headquarters in San Francisco (&#8220;existing lease&#8221;). Upon the commencement of the San Francisco Lease, the existing lease which had an original expiration date of February 2020, was modified to expire in September 2019 and accordingly the right-of-use asset and lease liability was remeasured as of the modification date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461007064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash Equivalents And Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock', window );">Cash Equivalents and Investments</a></td>
<td class="text">Cash Equivalents and Investments<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of cash equivalents and available-for-sale investments at December&#160;31, 2021 and 2020, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total  cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company's cash equivalents, short-term and long-term marketable securities classified by maturity (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through three years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company's available-for-sale securities that were in an unrealized loss position as of&#160; December&#160;31, 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses as of December&#160;31, 2021 were not material. Available-for-sale securities held as of December&#160;31, 2021 had a weighted average maturity of 95 days. At December&#160;31, 2021, 13 investments were in an unrealized loss position and no investments have been in an unrealized loss position for more than one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents and Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term and long term Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460889800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The corporate notes, commercial paper and government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s outstanding interest-bearing obligations is estimated using the net present value of the future payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company&#8217;s outstanding interest-bearing obligations at December&#160;31, 2021 wer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e $21.4 million and $21.7 million, r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">espectively. The carrying amount and the estimated fair value of the Company&#8217;s outstanding interest-bearing obligations at December&#160;31, 2020 were $33.0 million and $33.9 million, respectively.&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no transfers between levels of the fair value hierarchy of its assets measured at fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,569&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460818328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Other Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,268&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company uses PCBAs in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the Zio AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT monitor or Zio AT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue. Each time a wireless gateway is used with a Zio AT monitor, a portion of the gateway is recorded as a cost of revenue. PCBAs which are recorded as other assets </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">were $13.9 million a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">nd $12.6 million as of December&#160;31, 2021, and December&#160;31, 2020, respectively. The amortization wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s $4.4 million and $3.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the years ending December&#160;31, 2021 and 2020 respectively. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,667&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,661&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,416&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,648&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,097&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,704)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,850)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,944&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,247&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $9.8 million and $6.9 million, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued ESPP Contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460850776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Arrangements</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company leases office, manufacturing, and clinical centers under non-cancelable operating leases which expire on various dates through</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2031.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> These leases generally contain scheduled rent increases or escalation clauses and renewal options. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease right-of-use assets also include any lease payments made to the lessor at or before the commencement date as well as variable lease payments which are based on a consumer price index. The Company is also subject to variable lease payments related to janitorial services and electricity which are not included in the operating lease right-of-use asset as they are based on actual usage. The Company recognizes operating lease expense on a straight-line basis over the lease period. The total operating lease cost recognized during the year ended December&#160;31, 2021 was $13.5&#160;million which primarily consisted of lease payments and common area maintenance costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for operating leases during the year ended December&#160;31, 2021 was $12.2&#160;million.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 4, 2018, the Company entered into an office lease (&#8220;San Francisco Lease&#8221;) to rent approximately 117,560 rentable square feet in San Francisco, California, which became the Company&#8217;s new headquarters in October 2019. The term of the San Francisco Lease began on May 13, 2019, and expires on August 31, 2031. The Company is entitled to one option to extend the San Francisco Lease for a five-year term, subject to certain requirements. </span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2009, the Company entered into a lease for a clinic (&#8220;Lincolnshire Lease&#8221;) to rent approximately 41,500 rentable square feet in Lincolnshire, Illinois, which became the Company&#8217;s clinic facilities. The term of the Lincolnshire Lease began </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on November 1, 2009,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and expires on July 31, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 18, 2021, the Company entered into an office/industrial lease (&#8220;Cypress Lease&#8221;) to rent approximately 68,933 rentable square feet in Cypress, California, which became the Company&#8217;s new office and warehouse facilities. The term of the Cypress Lease began on October 25, 2021, and expires on April 30, 2032. The Company is entitled to one option to extend the Cypress Lease for a five-year term, subject to certain requirements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects these decisions will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The weighted average remaining lease term of the Company's operating leases as of December&#160;31, 2021 was 9.62 years. The weighted average discount rate of the Company's operating leases was 7.27% as of December&#160;31, 2021.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a lease for 44,616 rentable square feet in Deerfield Illinois ("Deerfield Lease"). The Deerfield Lease commenced in January 2022, and will be recorded as a right of use asset to the Company's financial statements in the first quarter of 2022. The Company is currently assessing the impact to its consolidated financial statements. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in claims and legal proceedings or investigations, that arise in the ordinary course of business. Such matters could have an adverse impact on its reputation, business and the financial condition and divert the attention of its management from the operation of its business.  These matters are subject to many uncertainties and outcomes that are not predictable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2021, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that the Company and its former Chief Executive Officer, Kevin M. King, violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On August 2, 2021, the lead plaintiff filed an amended complaint, and filed a further amended complaint on September 24, 2021. The amended complaint names as defendants, in addition to the Company and Mr. King, the Company's former Chief Executive Officer, Michael J. Coyle, and current Chief Financial Officer, Douglas J. Devine. The purported class in the amended complaint includes all persons who purchased or acquired the Company's common stock between August 4, 2020 and July 13, 2021, and seeks unspecified damages purportedly sustained by the class. On October 27, 2021, the Company filed a motion to dismiss the amended complaint. The motion to dismiss was fully briefed and the Court held a hearing on the motion on February 4, 2022, after which the Court took the matter under submission.  The Court has not yet issued a ruling. The Company believes the class action to be without merit and plans to vigorously defend itself.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2021, the Company received a grand jury subpoena from the U.S. Attorney&#8217;s Office for the Northern District of California requesting information related to communications with the Food and Drug Administration and the Company&#8217;s products. On October 14, 2021, the Company received a second subpoena requesting additional information. The Company is cooperating fully and is providing the requested information.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Development Agreement</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On September 3, 2019, the Company entered into a Development Collaboration Agreement (the &#8220;Development Agreement&#8221;) with Verily Life Sciences LLC (&#8220;Verily&#8221;). The Development Agreement, which is over a 24 month term, involves joint development and production of intellectual property between the Company and Verily. Each participant has primary responsibility for certain aspects of development and approval, with all processes to be performed at each respective party&#8217;s own cost. Costs incurred by the Company in connection with the Development Agreement will be expensed as research and development expense in accordance with ASC 730, Research and Development.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company and Verily will develop certain next-generation atrial fibrillation (&#8220;AF&#8221;) screening, detection, or monitoring products pursuant to the Development Agreement, which products will involve combining Verily and the Company's technology platforms and capabilities. Under the terms of the Development Agreement, the Company paid Verily an upfront fee of $5.0&#160;million in 2019. In addition, the Company has agreed to make additional payments to Verily up to an aggregate of $12.75&#160;million in milestone payments upon achievement of various development and regulatory milestones over the 24 months of the Development Agreement, which payments will be made in cash to Verily. </span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have achieved milestones tied to payments totaling $11.0&#160;million to date, $3.0&#160;million of which is associated with a milestone achieved during the quarter ended December 31, 2021 and is included in Accounts Payable on December 31, 2021. We have agreed to make additional payments over the term of the Development Agreement up to an aggregate of $1.75&#160;million, subject to the achievement of certain development and regulatory milestones including provision Zio Watch and completion of market evaluation scheduled to begin between late 2022 and early 2023. </span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Development Agreement provides each party with licenses to use certain intellectual property of the other party for development activities in the field of AF screening, detection, or monitoring. Ownership of developed intellectual property will be allocated to the Company or Verily depending on the subject matter of the underlying developed intellectual property, and, for certain subject matter, shall be jointly owned.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company enters into agreements pursuant to which it agrees to indemnify customers, vendors, lessors, business partners, and other parties with respect to certain matters, including losses arising out of the breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims made by third parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by applicable law. The Company currently has directors&#8217; and officers&#8217; insurance. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions, and believes that the estimated fair value of these indemnification obligations is not material and it has not accrued any amounts for these obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460861400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bank Debt</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2018, the Company entered into the Third Amended and Restated Loan and Security Agreement with SVB (&#8220;Third Amended and Restated SVB Loan Agreement&#8221;). This Agreement amends and restates the Second Amended and Restated Loan and Security Agreement between the Company and SVB dated December 4, 2015, as amended by the First Loan Modification Agreement between the Company and SVB dated August 22, 2016.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Third Amended and Restated SVB Loan Agreement, the Company obtained a term loan (&#8220;SVB Term Loan&#8221;) for $35.0 million. Total proceeds from the SVB Term Loan were used to pay off the loan agreement with Biopharma Secured Investments III Holdings Cayman LP (&#8220;Pharmakon&#8221;), totaling $35.8 million. The Company made interest-only payments through October 31, 2020. Beginning in November 2020, the Company began monthly payments of principal plus interest, which will continue through October 31, 2023. Interest charged on the SVB Term Loan will be the greater of (a) a floating rate based on the &#8220;Prime Rate&#8221; published by The Wall Street Journal minus 0.75%, or (b) 4.25%. The weighted average interest rate was 4.25% and 4.25% for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Third Amended and Restated SVB Loan Agreement, the Company may borrow, repay, and reborrow under a revolving credit line, but not in excess of the maximum loan amount of $25.0 million, which includes an $11.0 million standby letter of credit sublimit availability. In October 2018, a $6.9 million standby letter of credit was obtained in connection with a lease for the Company&#8217;s San Francisco headquarters. Any principal amount outstanding under the Third Amended and Restated SVB Loan Agreement revolving credit line shall bear interest at an amount that is the greater of (a) a floating rate per annum equal to the rate published by The Wall Street Journal as the &#8220;Prime Rate&#8221; or (b) 5.00%. The Company may borrow up to 75% of eligible accounts receivable, up to the maximum of $25.0 million. As of December 31, 2021, the Company was eligible to borrow up to $13.8&#160;million and no amount was outstanding under the revolving credit line. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Third Amended and Restated Loan Agreement requires the Company to maintain a minimum consolidated liquidity ratio or minimum adjusted Earnings Before Interest, Tax, Depreciation, and Amortization during the term of the loan facility. In addition, the SVB Loan Agreement contains customary affirmative and negative covenants and events of default. The Company was in compliance with loan covenants as of December&#160;31, 2021. The obligations under the Third Amended and Restated Loan Agreement are collateralized by substantially all assets of the Company.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future minimum payments</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank at December&#160;31, 2021 are as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt Issuance Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Carrying Value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460836536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents components of the Company&#8217;s provision for income taxes as for the period presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company&#8217;s tax expense for the period presented (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,446)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and Entertainment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation - officers compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,734)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,908)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company has provided a full valuation allowance against its U.S. deferred tax assets, and, therefore, no benefit has been recognized for the net operating loss carryforwards and other deferred tax assets. The U.S. valuation allowance increased by $30.9 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. The current year change in the U.S. valuation allowance is primarily related to the increase in net operating loss carryforwards generated during the year. The Company recorded an immaterial deferred tax asset related to the Company&#8217;s foreign operations in the United Kingdom.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance for deferred tax assets consisted of the following activity for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had approximately $464.3 million of federal and $279.1 million of state net operating loss carryforwards available to offset future taxable income which expires in varying amounts beginning in 2027 and   2020 respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had research tax credit carryforwards of approximately $7.4 million, and $6.1 million available to reduce future taxable income, if any, for both federal and state purposes, respectively. The federal tax credit carryforwards expire beginning in 2028 and the state tax credits can be carried forward indefinitely.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 382 of the Internal Revenue Code, and similar state provisions, limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its net operating loss carryforwards and tax credits could be limited.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2019, the Company adopted ASC 740-10 (formerly known as FIN 48), Accounting for Income Taxes, guidance that addresses the recognition, measurement, and disclosure of uncertain tax positions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefit amount is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total amount of gross unrecognized tax benefits was $3.3 million, $2.3 million, and $1.8 million as of December&#160;31, 2021, 2020, and 2019 respectively. None of the Company&#8217;s unrecognized tax benefits that, if recognized, would affect its effective tax rate. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. Management determined that no accrual for interest or penalties was required as of December&#160;31, 2021, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company files income tax returns in the U.S. and UK jurisdictions. All of the Company's tax years are open to examination by the US federal and state tax authorities. The UK is open to examination for tax years starting 2017 and forward. The Company currently has no federal, state or foreign tax examinations in progress, nor has it had any federal or state examinations since inception.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460890920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common stock</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s amended and restated certificate of incorporation dated October 25, 2016, as amended, authorizes the Company to issue 100,000,000 shares of common stock with a par value of $0.001 per share and 5,000,000 shares of preferred stock with a par value of $0.001 per share. The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the board of directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. No dividends were declared through December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under future stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,016,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,164,880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,740,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461314776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">Stock Incentive Plans<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2006 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2006, the Company adopted the 2006 Equity Incentive Plan, as amended, (the &#8220;2006 Plan&#8221;). The Plan provided for the granting of stock options to employees and non-employees of the Company. Options granted under the Plan were either incentive stock options or nonqualified stock options. Incentive stock options (&#8220;ISO&#8221;) were granted only to employees (including officers and directors who are also employees). Nonqualified stock options (&#8220;NSO&#8221;) may be granted to employees and non-employees. The board of directors had the authority to determine to whom options will be granted, the number of options, the term and the exercise price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options under the Plan were granted for periods of up to ten years and at the fair value of the shares on the date of grant as determined by the board of directors. In general, options become exercisable at a rate of 25% after the first anniversary of the grant and then monthly vesting for an additional three years from date of grant. The term for options is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The Company issues new shares upon the exercise of options.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Plan</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company adopted the 2016 Equity Incentive Plan, (the &#8220;2016 Plan&#8221;). The 2016 Plan was subsequently approved by the Company&#8217;s stockholders and became effective on October 19, 2016, immediately before the effective date of the IPO. Following the effectiveness of the 2016 Plan, no additional options will be granted under the 2006 Plan.&#160;In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2006 Plan are subsequently forfeited or terminated for any reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2016 Plan. The remaining shares available for grant under the 2006 Plan became available for issuance under the 2016 Plan upon the closing of the IPO. On the first day of each year, the 2016 Plan authorizes an annual increase of the least of 3,865,000 shares, 5% of outstanding shares on the last day of the immediately preceding fiscal year or an amount as determined by the Company's Board of Directors. As of December&#160;31, 2021, the Company has reserved 7,159,947 shares of common stock for issuance under the 2016 Plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the 2016 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2016 Plan at an exercise price of not less than 100% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed ten years from the date of grant.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company&#8217;s Board of Directors and stockholders approved the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). Under the ESPP, the Company initially reserved 483,031 shares of common stock for issuance as of its effective date of October 19, 2019. On the first day of each calendar year, the number of shares reserved increases by the least of 966,062 shares, 1.5% of the shares of the Company&#8217;s common stock outstanding on the last day of the immediately preceding fiscal year, or an amount as determined by the Company&#8217;s Board of Directors. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for 12 month offering periods that each contain two 6 month purchase periods. At the end of each purchase period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the purchase period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 515,231 shares of common stock have been issued to employees participating in the ESPP and 1,851,538 shares were available for issuance under the ESPP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2021: expected term of 0.5 &#8211; 1 year, volatility of 93.99% - 106.96%, risk-free interest rate of 0.04% - 0.18% and expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2020: expected term of 0.5 &#8211; 1 year, volatility of 68.72% - 75.78%, risk-free interest rate of 0.11% - 0.18% and expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2019: expected term of 0.5 &#8211; 1 year, volatility of 43.61% - 48.05%, risk-free interest rate of 1.60% - 2.35% and expected dividend yield of zero.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plan Activity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of share-based awards available for grant under the 2016 Equity Incentive Plan is as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,717,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,528,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,505,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,159,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December&#160;31, 2021, 1,009,457 restricted stock units ("RSUs") were granted, 285,331 RSUs vested, and 200,019 RSUs were forfeited.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock option activity under the 2006 and 2016 Equity Incentive Plans:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,094,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,976&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540,307)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,503,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,401&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868,614)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.31&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">609,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,939)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.15&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">504,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,675&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercisable &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,548&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options vested and expected to vest &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,884&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,667&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company granted options with a weighted-average grant date fair value of $38.29 per share. The Company did not grant any options during the year ended December 31, 2020 or during the year ended December 31, 2021 . </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised was $10.9 million, $109.2 million and $36.9 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The total estimated grant date fair value of options vested during the period was $2.8 million, $4.9 million and $7.8 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-vested restricted stock units (&#8220;RSUs&#8221;) is based on the Company&#8217;s closing stock price on the date of grant.&#160;A summary for the year ended&#160;December&#160;31, 2021, is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vesting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460806824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Options Valuation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee and director stock options was estimated at the date of grant using the Black-Scholes option pricing model with the weighted average assumptions below.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant stock options during the years ended December 31, 2021 and  December 31, 2020. </span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market-based RSU Valuation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of market based RSUs was estimated at the date of grant using the Monte-Carlo option pricing model with the assumptions below. Additional details on the Company's market based RSUs are included below. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:2pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s Board of Directors determined the fair value of each share of underlying common stock based on the closing price of the Company&#8217;s common stock as reported on the date of grant.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the share-based awards are expected to be outstanding. As the Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants the Company has elected to use the &#8220;simplified method&#8221; as prescribed by authoritative guidance to compute expected term.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded companies in a similar industry on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to expected term of the option award.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company&#8217;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company&#8217;s stock-based compensation calculations on a prospective basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,066&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,761&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,121&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,527&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,515&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was total unamortized compensation costs of $0.8 million, net of estimated forfeitures, related to unvested stock options, which the Company expects to recognize over a period of approximately 0.4 years and $113.5 million, net of estimated forfeitures, related to unrecognized RSU expense, which the Company expects to recognize over a period of 2.4 years, and $3.1 million unrecognized ESPP expense, which the Company will recognize over 0.9 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance based RSUs (&#8220;PRSU&#8221;) and Market-based RSUs</span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company grants PRSUs to key executives of the Company. PRSUs can be earned in accordance with the performance equity program for each respective grant</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">2019 Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2019, the company granted PRSU's (&#8220;2019 awards&#8221;) to be earned based on the compound annual growth rate (&#8220;CAGR&#8221;) of fiscal year 2020's revenue compared to fiscal year 2018's revenue.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the impact of the COVID-19 pandemic, management determined that the Company&#8217;s achievement of its performance targets described above, was not probable in the first quarter of fiscal year 2020. PRSU expense of $4.8&#160;million recognized in fiscal year 2019 related to the 2019 awards was reversed in the first quarter of fiscal year 2020. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2020, the Company modified the terms of the 2019 awards to vest based on the Company&#8217;s average stock price for the 60 days preceding January 1, 2021. The modification impacted all active recipients of the 2019 awards, a total of ten recipients. The total incremental compensation cost resulting from the modification of $13.6&#160;million was recognized ratably through March 31, 2021. The Company recognized $2.2&#160;million of compensation cost for the year ended December&#160;31, 2021 in connection with the 2019 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">February 2020 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the company granted PRSU's (&#8220;February 2020 awards&#8221;) for fiscal year 2022's annual unit volume CAGR compared to fiscal year 2019's annual unit volume CAGR, measuring a minimum performance threshold of 19.7% to earn 50% of target, and a maximum threshold of 29% achieved to earn 200% of target. A total of 133,834 PRSU shares were granted with grant date fair value of $11.0&#160;million. The 2020 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that vested was recognized ratably through March 31, 2021. During the year ended December 31, 2021, the Company determined that it was probable that the February 2020 Awards would vest and recognized $0.8&#160;million of compensation cost in connection with the February 2020 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">January 2021 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company granted PRSUs (&#8220;January 2021 awards&#8221;) for fiscal year 2021's annual consolidated revenue compared to fiscal year 2020's annual consolidated revenue, measuring a performance threshold of 10.0% to earn 100% of target. A total of 53,862 PRSU shares were granted with a grant date fair value of $13.9&#160;million. The January 2021 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2022. During the year ended December 31, 2021, the Company determined that it was probable that the January 2021 Awards would vest and recognized $9.9&#160;million of compensation cost in connection with the January 2021 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">February 2021 Awards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company granted PRSU's (&#8220;February 2021 awards&#8221;) for fiscal year 2023's annual unit volume Compound Annual Growth Rate (&#8220;CAGR&#8221;) compared to fiscal year 2020's annual unit volume CAGR, measuring a minimum performance threshold of 19.7% to earn 50% of target, and a maximum threshold of 29% achieved to earn 200% of target. A total of 112,872 PRSU shares were granted with grant date fair value of $17.3&#160;million. The February 2021 awards also include a service-based component.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2024. During the year ended December 31, 2021, the Company determined that it was probable that the February 2021 Awards would vest and recognized $2.4&#160;million of compensation cost in connection with the February 2021 awards.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Non employee Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, the Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) resigned and entered into a Consulting and Professional Services Agreement (&#8220;CPSA&#8221;) with the Company to provide consulting services through July 2, 2021. Pursuant to the original terms of the awards, the CFO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in 2020 as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended  December 31, 2020, was $1.8&#160;million.</span></div>On January 12, 2021, the Company's Chief Executive Officer (&#8220;CEO&#8221;) resigned and entered into a CPSA with the Company. Pursuant to the original terms of the awards, the CEO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant or a member of the Company's Board of Directors. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in the three months ended March 31, 2021, as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended December 31, 2021 was $5.4 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461019096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company had net losses for the years ended December&#160;31, 2021, 2020 and 2019, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of the basic and diluted net loss per share during the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except share and per share data):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,361)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,331,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,754,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,265,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.46)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.16)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per common share for the years ended December&#160;31, 2021, 2020 and 2019 because their inclusion would be anti-dilutive:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460877688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Novitas Announcement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, CMS published its Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;Final Rule&#8221;). In the Final Rule, CMS did not finalize national pricing for the extended external ECG patch, medical magnetic tape recorder (SD339) supply, and ruled to contractor pricing for CPT codes 93241, 93243, 93245 and 93247. The Company has been working with Medicare Administrative Contractors (MACs&#8221;) to establish pricing for these codes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 10, 2022, Novitas Solutions, the MAC which covers the region where the Company's Independent Diagnostic Testing Facility in Houston, Texas where almost all Medicare services for Zio XT are processed, published reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2021, the Company entered into a lease for 44,616 rentable square feet in Deerfield Illinois (</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deerfield Lease&#8221;). The Deerfield lease commenced in January 2022, the Company will recognize a related right of use asset and obligation in its Consolidated Financial Statements for the quarter ending March 31, 2022. The amount of such asset and obligation has not yet been determined. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company plans to consolidate operations and will begin marketing the excess space for sublease by the end of the first quarter of 2022. Depending on the outcome of marketing the sublease, the Company believes these decisions could result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128467563016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and include the accounts of iRhythm Technologies, Inc. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The financial statements of the Company&#8217;s subsidiary use the U.S. dollar as the functional currency. For all non-functional currency balances, the remeasurement of such balances to functional currency results in a foreign exchange transaction gain or loss, which is recorded in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock', window );">Risk and Uncertainties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic, the Company has experienced significant business disruptions, restrictions on its ability to travel, reduction in access to customers due to diverted resources at hospitals, slower response times from payors who are also facing business interruptions, and shortened business hours as governments institute prolonged shelter-in-place and/or self-quarantine mandates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, Company personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where the Company's headquarters is located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. The Company is also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the Company has instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While the Company has continued to deliver its Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">measures at the Company's facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminishe</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, the Company has adapted its service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months ended June 30, 2021, the Company experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, the Company experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions within the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could meaningfully impact the volume of our patient registrations in future periods.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is continuously reviewing its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. The Company believes it will have adequate liquidity over the next 12 months to operate its business and to meet its cash requirements. As of December 31, 2021, the Company is in compliance with its debt covenants. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on liquidity, capital resources, supply chain, operations and business and those of the third parties on which the Company relies, and could worsen over time. The extent to which the COVID-19 pandemic impacts the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the COVID-19 pandemic or treat its impact, among others. The full extent of potential delays or impacts on the business, financial condition, cash flows and results of operations remains unknown. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing the Company&#8217;s ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact short-term and long-term liquidity and the ability to operate on a timely basis, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Reimbursement</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for the Zio service, which would significantly harm the Company. Government and other third-party payors require the Company to report the service for which it is seeking reimbursement by using a Current Procedural Terminology (&#8220;CPT&#8221;), code-set maintained by the American Medical Association (&#8220;AMA&#8221;). For Zio XT, the Company had historically utilized temporary CPT codes (or Category III CPT codes) used for newly introduced technologies and specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and Centers for Medicare and Medicaid (&#8220;CMS&#8221;). On October 25, 2019, the AMA&#8217;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. In November 2021, CMS published the Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#8220;2022 Final Rule&#8221;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Company&#8217;s Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#8220;MAC&#8221; or &#8220;MACs&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#8220;NCD&#8221;) by CMS, or at the local level through a local coverage determination (&#8220;LCD&#8221;), by one or more of the regional Medicare Administrative Contractors (&#8220;MACs&#8221;) who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#8220;IDTF&#8221;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If the published Medicare reimbursement rates are not adequate to support our cost structure, or we are unable to reduce our overall cost structure, the Company may be unable to provide the Zio service or would experience a significant loss of revenue, either of which would have a material adverse effect on our cash flows, results of operations, and financial condition.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, the Company will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if the Company is unsuccessful in improving the Medicare rates, the Company believes that commercial rates may begin to be more negatively impacted next year. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Supply Chain Constraints</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economies worldwide have also seen other indirect COVID-19 pandemic related disruptions including supply chain impacts, material inflation, and labor constraints in certain markets and geographies. Such economic disruption has had an adverse effect on the Company's business environment as increased lead times and component shortages have resulted in higher inventory costs. While the Company has increased inventory safety stock levels to help mitigate the delays and disruptions in supply, the Company cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not further impact its supply chain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (&#8220;PCBAs&#8221;), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, which include cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments consist of debt securities classified as available-for-sale and have maturities less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are carried at fair value based upon quoted market prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically assesses its portfolio of debt investments for impairment. For debt securities in an unrealized loss position, this assessment first takes into account the intent to sell, or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#8217;s amortized cost basis is written down to fair value through interest and other, net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses on available-for-sale debt securities are recognized in other income, net in the condensed consolidated statements of operations, and any remaining unrealized losses, net of taxes, are reported as a component of accumulated other comprehensive loss. The Company did not recognize any credit losses on its available-for-sale securities during the year ended December 31, 2021 and there were no impairment charges for unrealized losses in the periods presented. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of available-for-sale securities sold is based on the specific-identification method and realized gains and losses are included in earnings. Amortization of premiums and accretion of discounts are reported as a component of other income, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable includes amounts due to the Company from healthcare institutions, third-party payors, and government payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts and contractual allowances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on its assessment of the collectability of customer accounts and recognizes the provision as a component of selling, general and administrative expenses. The Company records a provision for contractual allowances based on the estimated differences between contracted amounts and expected collection rates. Such provisions are based on the Company's historical experience and are reported as a reduction of revenue.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews the allowances by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to administrative delays with payors and a combination of negotiations with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, inherent uncertainty caused by the longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company&#8217;s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#8217;s ability to pay. Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), accounted for approximately 14%, 27% and 27% of the Company&#8217;s revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. CMS accounted for 8% and 20% of accounts receivable as of December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_InflationaryRiskPolicyTextBlock', window );">Inflationary Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Inflationary Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously monitors the effects of inflationary factors, such as increases in cost of goods sold and selling and operating expenses, which may adversely affect its results of operations. Specifically, the Company may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages paid to its employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict the Company's ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. The Company's inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock', window );">Supply Risk</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Supply Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio monitor and the adhesive that binds the Zio monitor to a patient&#8217;s body. These components and materials are critical, and there could be a considerable delay in finding alternative sources of supply. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A global semiconductor supply shortage is having wide-ranging effects across multiple industries. The supply shortage has impacted multiple suppliers that provide the printed circuit board assemblies to the Company. The semiconductor supply shortage may have an impact on the Company until global supply is sufficient for global demand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory owned by the Company is valued at cost, on the first in, first out (&#8220;FIFO&#8221;) basis, or the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand. The Company also records market value based write-downs on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d">three</span> to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Internal-Use Software</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal-Use Software</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes costs related to internal-use software during the application development stage. Costs related to planning and post implementation activities are expensed as incurred. Capitalized internal-use software is amortized, and recognized as cost of revenue, on a straight-line basis over the estimated useful life, which is up to five years. The Company evaluates the useful lives of these assets on an annual basis, and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Capitalized internal-use software costs are classified as a component of property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible net assets acquired in business combinations. Goodwill is tested for impairment on an annual basis and at any other time if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Such events or circumstances may include significant adverse changes in the general business climate, among other things. The impairment test is performed by determining the enterprise fair value of the Company, which is primarily based on the Company&#8217;s market capitalization. If the Company&#8217;s carrying value, as a one reporting unit entity, is less than its fair value, then the fair value is allocated to all of its assets and liabilities (including any unrecognized intangible assets) as if the fair value was the purchase price to acquire the Company. The excess of the fair value over the amounts assigned to the Company&#8217;s assets and liabilities is the implied fair value of the goodwill. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. The Company did not record any charges related to goodwill impairment in any of the periods presented in these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company annually reviews long-lived assets for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. To date, there have been no such impairments of long-lived assets.</span></div>In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects this decision will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OtherAssetsPolicyPolicyPolicyTextBlock', window );">Other Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses Printed Circuit Board Assemblies (&#8220;PCBAs&#8221;), in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the ZIO AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT or Zio AT monitor, or a wireless gateway is used with a Zio AT monitor a portion of the cost of the PCBA and/or gateway is recorded as a cost of revenue. The PCBAs are recorded as other assets and were $13.9 million and $12.6 million as of December&#160;31, 2021 and 2020, respectively. The Company has based its estimates of how many times a PCBA can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. The Company periodically evaluates the use estimate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss represents all changes in stockholders&#8217; equity during the period from non-owner sources. The Company&#8217;s unrealized gains and losses on available-for-sale securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s revenue is generated primarily from the provision of its cardiac rhythm monitoring service, the Zio XT service. The Zio XT is a cardiac rhythm monitoring service that has a patient wear period of up to 14 days and is billable when the monitoring reports are delivered to the healthcare provider, which is also when the service is complete and the Company recognizes revenue. The time from when the patient has the Zio XT device applied to the time the report is posted is generally around 25 days. The Company has concluded that the Zio XT service is one performance obligation on the basis that the customer cannot benefit from each component of the service on its own or together with other resources that are readily available to the customer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what the Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating patients that require more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria. The Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report with two performance obligations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognizes as revenue the amount of consideration to which it expects to be entitled in exchange for performing the service. The consideration the Company is entitled to varies by portfolio, as further defined below, and includes estimates that require significant judgment by management. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, will pay the Company for some or all of the service on the patient&#8217;s behalf. Separate contractual arrangements exist between the Company and third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A small portion of the Company&#8217;s transactions are covered by third-party payors with whom there is neither a contractual agreement nor an established amount that the third-party payor will pay. In determining the collectability and transaction price for its service, the Company considers factors such as insurance claims which are adjudicated as allowable under the applicable policy and payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments. Certain of these factors are forms of variable consideration which are only included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Contracted third-party payors &#8211; The Company has contracts with negotiated prices for services provided to patients with commercial healthcare insurance coverage.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CMS &#8211; The Company has received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant CPT code rates for the services rendered to the patient covered by CMS.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Non-contracted third-party payors &#8211; Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used </span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for determining revenue recognition is based on factors including an average of the Company&#8217;s historical collection experience for its non-contracted services. This rate is reviewed at least quarterly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Healthcare institutions &#8211; Healthcare institutions are typically hospitals or physician practices in which the Company has negotiated amounts for its monitoring services, including certain governmental agencies such as the Veterans Administration and Department of Defense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition whereby services provided under each of the above payor types form a separate portfolio. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, the Company has concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For contracted and CMS portfolios, the Company recognizes revenue, net of contractual allowances, and recognizes an allowance for doubtful accounts for uncollectible patient accounts receivable. The transaction price is determined based on negotiated rates, and the Company has historical experience of collecting substantially all of these contracted rates. These contracts also impose a number of obligations regarding billing and other matters, and the Company&#8217;s noncompliance with a material term of such contracts may result in a denial of the claim. The Company accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price recognized as revenue. The Company estimates the denied claims which require management judgment. The estimated denied claims are based on historical information and judgement includes the historical period utilized. The Company monitors the estimated denied claims against the latest available information, and subsequent changes to the estimated denied claims are recorded as an adjustment to revenue in the periods during which such changes occur. Delays in claims submissions could lead to an increase in denials if we miss the payors&#8217; filing deadlines and could result in a reduction in the Company&#8217;s receipt of payments. Historical cash collection indicates that it is probable that substantially all of the transaction price, less the estimate of denied claims, will be received. Contracted payors may require that we bill patient co-payments and deductibles and from time to time we may not be able to collect such amounts due to credit risk. The Company provides for estimates of uncollectible patient accounts receivable, based upon historical experience where judgment includes the historical period utilized, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to a combination of negotiations with payors and administrative delays with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021. For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For non-contracted portfolios, the Company is providing an implicit price concession due to the lack of a contracted rate with the underlying payor, the result of which requires the Company to estimate the transaction price based on historical cash collections utilizing the expected value method. All subsequent adjustments to the transaction price are recorded as an adjustment to revenue.</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For healthcare institutions, the transaction price is determined based on negotiated rates, and the Company has historical experience collecting substantially all of these contracted rates. Historical cash collection indicates that it is probable that substantially all of the transaction price will be received. As such, the Company is not providing an implicit price concession but, rather, has chosen to accept the risk of default, and any subsequent uncollected amounts are recorded as bad debt expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ContractLiabilityPolicyPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requires an entity to present a revenue contract as a contract liability when the Company has an obligation to transfer goods or services to a customer for which the Company has received consideration from the customer, or an amount of consideration from the customer is due and unconditional (whichever is earlier).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s customers pay the Company directly for the Zio XT service upon shipment of devices. Such advance payments are contract liabilities and are recorded as deferred revenue on the Consolidated Balance Sheets and revenue is recognized when reports are delivered to the healthcare provider. During the year ended December&#160;31, 2021, $0.9 million relating to the contract liability balance at the beginning of 2021 was recognized as revenue. Total revenue recognized during the year ended December 30, 2020 that was included in the contract liability balance at the beginning of 2020 was $1.2&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ContractCostPolicyPolicyTextBlock', window );">Contract Costs</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Costs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 340, the incremental costs of obtaining a contract with a customer are recognized as an asset. Incremental costs of obtaining a contract are those costs that an entity incurs to obtain a contract with a customer that it would not have incurred if the contract had not been obtained.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current commission programs are considered incremental. However, as a practical expedient, ASC 340 permits the Company to immediately expense contract acquisition costs, as the asset that would have resulted from capitalizing these costs will be amortized in one year or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text">Cost of RevenueCost of revenue includes direct labor, material costs, overhead, data analysis, customer care, equipment and infrastructure expenses, amortization of internal-use software, and shipping and handling. Direct labor includes payroll and personnel-related costs involved in manufacturing. Material costs include both the disposable costs of the device and amortization of the PCBAs. Each time the PCBA is used in a wearable Zio XT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s research and development costs are expensed as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, laboratory supplies, consulting costs and overhead charges.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recognize taxes on Global Intangible Low-Taxed Income as a current period expense when incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. The fair value of market condition awards is determined using the Monte-Carlo option pricing model and the fair value of stock options is determined using the Black-Scholes option pricing model. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#8217;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For restricted stock, the compensation cost for these awards is based on the closing price of the Company&#8217;s common stock on the date of grant, and recognized as compensation expense on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant, net of estimated forfeitures. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Common Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effect of potentially dilutive securities are anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Identifying a lease</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both of the following terms:</span></div><div style="text-align:justify;text-indent:39.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to obtain substantially all of the economic benefits from use of the identified asset; and</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The right to direct the use of the identified asset.</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Discount rate for leases</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the rate implicit in the lease is not readily determinable for our operating leases, the Company generally uses an incremental borrowing rate based on information available at the commencement date such as a synthetic credit rating and current cost of borrowing to determine the present value of future lease payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease term</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term is generally the minimum noncancellable period of each lease. The Company does not include option periods in determining the right-of-use asset and operating lease liability at inception unless it is reasonably certain that the Company will exercise the option at inception or when a triggering event occurs. As of December&#160;31, 2021, no renewal options were included in the determination of lease terms.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Lease Modification</span></div><div style="text-align:justify;text-indent:39.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:39.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The San Francisco Lease is in the same building with the same landlord as the lease for the Company&#8217;s prior headquarters in San Francisco (&#8220;existing lease&#8221;). Upon the commencement of the San Francisco Lease, the existing lease which had an original expiration date of February 2020, was modified to expire in September 2019 and accordingly the right-of-use asset and lease liability was remeasured as of the modification date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for supply risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ContractCostPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract cost policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ContractCostPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ContractLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract liability policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ContractLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_InflationaryRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inflationary Risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_InflationaryRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OtherAssetsPolicyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other assets policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OtherAssetsPolicyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_RiskAndUncertaintiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk And Uncertainties, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_RiskAndUncertaintiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460851736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock', window );">Schedule of Changes in Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the allowance for doubtful accounts (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: adoption of ASC 326</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: provision for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: write-offs, net of recoveries and other adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock', window );">Schedule of Changes in Contractual Allowance</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the contractual allowance (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.708%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,433&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,205&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: allowance for contractual adjustments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,916&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,518&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: contractual adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,466)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,068)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,290)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,274&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,281&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,433&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Payor Type and Major Service Line</a></td>
<td class="text">Disaggregated revenue by payor type and major service line for the years ended December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracted third-party payors</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,845&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-contracted third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare institutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,166&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in contractual allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128542573720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash Equivalents And Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value Cash Equivalents and Available-for-sale Investments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of cash equivalents and available-for-sale investments at December&#160;31, 2021 and 2020, were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total  cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,663&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value Cash Equivalents, Short-term, and Long-term Marketable Securities Classified by Maturity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of the Company's cash equivalents, short-term and long-term marketable securities classified by maturity (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through three years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and available-for-sale investments</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company's available-for-sale securities that were in an unrealized loss position as of&#160; December&#160;31, 2021 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Greater</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents and Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460875000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Financial Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value of the Company&#8217;s financial assets determined using the inputs defined above (in thousands).</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,444&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,137&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,569&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,706&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,423&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,489&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,823&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,589&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,412&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128464793096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock', window );">Schedule of Inventory Components</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,101&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,469&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,268&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,313&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net Components</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory and manufacturing equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,029&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,667&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,174&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,661&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,416&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,648&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,097&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,704)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,850)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,944&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,247&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities Components</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued vacation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued ESPP Contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional services fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Inventory and printed circuit board assemblies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460813336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460904632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Minimum Payments</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum payments under the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank at December&#160;31, 2021 are as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Debt Issuance Costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Carrying Value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466161704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for Income Taxes</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents components of the Company&#8217;s provision for income taxes as for the period presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.096%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Tax Expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Tax Expense Computed at Statutory Federal Rate and Tax Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company&#8217;s tax expense for the period presented (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at statutory federal rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,446)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,049)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,762)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,560)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and Entertainment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 162(m) limitation - officers compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,734)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,908)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,742)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance for Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance for deferred tax assets consisted of the following activity for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at end of year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefit</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the Company&#8217;s unrecognized tax benefit amount is as follows (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions taken in current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases in balance related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460812056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had reserved shares of common stock for issuance as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under future stock plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,016,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,164,880&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,740,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128464787272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock', window );">Schedule of Share-based Awards Available for Grant Under 2016 Plan</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of share-based awards available for grant under the 2016 Equity Incentive Plan is as follows:&#160;</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;Available<br/>for Grant</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,717,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional options authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(649,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,528,132</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,505,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional awards authorized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,289,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards withheld for tax purposes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,159,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity Under 2006 and 2016 Plans</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes stock option activity under the 2006 and 2016 Equity Incentive Plans:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life (years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,094,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,976&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540,307)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.59&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,593)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,503,247</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.40</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.43</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,401&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868,614)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.31&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,752)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">609,881</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.24</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,163&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,939)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.15&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">504,106</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.97</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,675&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options exercisable &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,548&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39.61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Options vested and expected to vest &#8211; December 31, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503,884&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,667&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-vested Restricted Stock Units ("RSUs")</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of non-vested restricted stock units (&#8220;RSUs&#8221;) is based on the Company&#8217;s closing stock price on the date of grant.&#160;A summary for the year ended&#160;December&#160;31, 2021, is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vesting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131,871)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(412,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based awards available for grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462362840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee and director stock options was estimated at the date of grant using the Black-Scholes option pricing model with the weighted average assumptions below.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of market based RSUs was estimated at the date of grant using the Monte-Carlo option pricing model with the assumptions below. Additional details on the Company's market based RSUs are included below. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,066&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,761&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,121&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,527&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,515&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,241&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460793544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text">The following table sets forth the computation of the basic and diluted net loss per share during the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except share and per share data):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,361)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,830)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per common share, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,331,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,754,404&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,265,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.46)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.16)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per common share for the years ended December&#160;31, 2021, 2020 and 2019 because their inclusion would be anti-dilutive:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and unvested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,649,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,153,667&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466118200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Aug. 21, 2020</div></th>
<th class="th"><div>Sep. 10, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">1,257,142<span></span>
</td>
<td class="nump">1,575,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued, price per share (in USD per share)</a></td>
<td class="nump">$ 175.00<span></span>
</td>
<td class="nump">$ 73.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock', window );">Underwriters' option to purchase additional shares of common stock (in shares)</a></td>
<td class="nump">163,975<span></span>
</td>
<td class="nump">205,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock in public offering</a></td>
<td class="nump">$ 206.8<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriters' Option To Purchase Additional Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459816328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract liability balance, revenue recognized</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefit income tax interest and penalty charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember', window );">Printed Circuit Board Assemblies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Internal-use software, estimated useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=irtc_FederalGovernmentAgenciesMember', window );">Federal Government Agencies | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=irtc_FederalGovernmentAgenciesMember', window );">Federal Government Agencies | Accounts Receivable | Accounts Receivable Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration of credit risk (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93243Member', window );">Product And Services Zio X T Service Code93243 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CostReimbursementRate', window );">Reimbursement rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93247Member', window );">Product And Services Zio X T Service Code93247 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CostReimbursementRate', window );">Reimbursement rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CostReimbursementRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Reimbursement Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CostReimbursementRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=irtc_FederalGovernmentAgenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=irtc_FederalGovernmentAgenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93243Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93243Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461111896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, beginning of year</a></td>
<td class="nump">$ 12,711<span></span>
</td>
<td class="nump">$ 9,049<span></span>
</td>
<td class="nump">$ 7,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Add: provision for doubtful accounts</a></td>
<td class="nump">9,615<span></span>
</td>
<td class="nump">10,515<span></span>
</td>
<td class="nump">9,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments', window );">Less: write-offs, net of recoveries and other adjustments</a></td>
<td class="num">(8,314)<span></span>
</td>
<td class="num">(7,314)<span></span>
</td>
<td class="num">(7,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, end of year</a></td>
<td class="nump">14,012<span></span>
</td>
<td class="nump">12,711<span></span>
</td>
<td class="nump">9,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | ASC 326</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for doubtful accounts receivable write-offs net of recoveries and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128467234072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AccountsReceivableForContractualAllowance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 21,281<span></span>
</td>
<td class="nump">$ 15,433<span></span>
</td>
<td class="nump">$ 9,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AccountsReceivableAllowanceForContractualAdjustments', window );">Add: allowance for contractual adjustments</a></td>
<td class="nump">27,459<span></span>
</td>
<td class="nump">20,916<span></span>
</td>
<td class="nump">15,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AccountsReceivableContractualAdjustments', window );">Less: contractual adjustments</a></td>
<td class="num">(17,466)<span></span>
</td>
<td class="num">(15,068)<span></span>
</td>
<td class="num">(9,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AccountsReceivableForContractualAllowance', window );">Balance, end of year</a></td>
<td class="nump">$ 31,274<span></span>
</td>
<td class="nump">$ 21,281<span></span>
</td>
<td class="nump">$ 15,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AccountsReceivableAllowanceForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable allowance for contractual adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AccountsReceivableAllowanceForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AccountsReceivableContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable contractual adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AccountsReceivableContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AccountsReceivableForContractualAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable for contractual allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AccountsReceivableForContractualAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458300008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 322,825<span></span>
</td>
<td class="nump">$ 265,166<span></span>
</td>
<td class="nump">$ 214,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_CommercialPayorsMember', window );">Contracted third-party payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">193,871<span></span>
</td>
<td class="nump">135,939<span></span>
</td>
<td class="nump">101,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_NonContractedThirdPartyPayorsMember', window );">Non-contracted third-party payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">26,929<span></span>
</td>
<td class="nump">15,295<span></span>
</td>
<td class="nump">10,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_CentersForMedicareAndMedicaidMember', window );">Centers for Medicare &amp; Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">44,529<span></span>
</td>
<td class="nump">72,536<span></span>
</td>
<td class="nump">58,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=irtc_HealthcareInstitutionsMember', window );">Healthcare institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 57,496<span></span>
</td>
<td class="nump">$ 41,396<span></span>
</td>
<td class="nump">$ 43,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_CommercialPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_CommercialPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_NonContractedThirdPartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_NonContractedThirdPartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_CentersForMedicareAndMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_CentersForMedicareAndMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_HealthcareInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_HealthcareInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459016264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 221,767<span></span>
</td>
<td class="nump">$ 306,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">221,706<span></span>
</td>
<td class="nump">306,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract', window );"><strong>Classified as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">110,137<span></span>
</td>
<td class="nump">59,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">111,569<span></span>
</td>
<td class="nump">246,589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments', window );">Total cash equivalents and available-for-sale investments</a></td>
<td class="nump">221,706<span></span>
</td>
<td class="nump">306,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,490<span></span>
</td>
<td class="nump">190,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">50,444<span></span>
</td>
<td class="nump">190,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,158<span></span>
</td>
<td class="nump">26,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">31,143<span></span>
</td>
<td class="nump">26,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,982<span></span>
</td>
<td class="nump">29,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">29,982<span></span>
</td>
<td class="nump">29,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">110,137<span></span>
</td>
<td class="nump">59,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 110,137<span></span>
</td>
<td class="nump">$ 59,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents And Available-for-sale Classified As Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and current and noncurrent investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462625000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash Equivalents And Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 221,706<span></span>
</td>
<td class="nump">$ 306,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Due after one year through three years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total cash equivalents and available-for-sale investments</a></td>
<td class="nump">$ 221,706<span></span>
</td>
<td class="nump">$ 306,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents and Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459796200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">$ 81,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">81,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss</a></td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">50,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">50,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss</a></td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Fair value, less than 12 months</a></td>
<td class="nump">31,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized loss, less than 12 months</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss, greater than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">31,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized Loss</a></td>
<td class="num">$ (15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128464878088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Investments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>investment_security</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash Equivalents And Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod', window );">Available-for-sale securities, weighted average days to maturity</a></td>
<td class="text">95 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Available-for-sale securities in unrealized loss position</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Available-for-sale securities in unrealized loss for more than 12 months</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AvailableForSaleDebtSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale debt securities maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AvailableForSaleDebtSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents and Investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462309128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Outstanding interest-bearing obligations</a></td>
<td class="nump">$ 21.4<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Outstanding interest-bearing obligations</a></td>
<td class="nump">$ 21.7<span></span>
</td>
<td class="nump">$ 33.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458401304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 221,706<span></span>
</td>
<td class="nump">$ 306,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">110,137<span></span>
</td>
<td class="nump">59,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">50,444<span></span>
</td>
<td class="nump">190,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">31,143<span></span>
</td>
<td class="nump">26,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">29,982<span></span>
</td>
<td class="nump">29,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">110,137<span></span>
</td>
<td class="nump">59,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">110,137<span></span>
</td>
<td class="nump">59,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">111,569<span></span>
</td>
<td class="nump">246,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">50,444<span></span>
</td>
<td class="nump">190,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">31,143<span></span>
</td>
<td class="nump">26,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">29,982<span></span>
</td>
<td class="nump">29,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466251368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies ("PCBAs") (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_InventoryAndPrintedCircuitBoardAssemblies', window );">Total inventory and printed circuit board assemblies</a></td>
<td class="nump">$ 10,268<span></span>
</td>
<td class="nump">$ 5,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_RawMaterialsMember', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_InventoryAndPrintedCircuitBoardAssemblies', window );">Total inventory and printed circuit board assemblies</a></td>
<td class="nump">5,101<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_FinishedGoodsMember', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_InventoryAndPrintedCircuitBoardAssemblies', window );">Total inventory and printed circuit board assemblies</a></td>
<td class="nump">$ 5,167<span></span>
</td>
<td class="nump">$ 2,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_InventoryAndPrintedCircuitBoardAssemblies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and printed circuit board assemblies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_InventoryAndPrintedCircuitBoardAssemblies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_RawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=irtc_RawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=irtc_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458293352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 9,842<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="nump">$ 3,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember', window );">Printed Circuit Board Assemblies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OtherAssetsUsefulLives', window );">Useful lives of PCBAs</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OtherAssetsUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Useful Lives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OtherAssetsUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=irtc_PrintedCircuitBoardAssembliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458333384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Components of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 78,648<span></span>
</td>
<td class="nump">$ 48,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(22,704)<span></span>
</td>
<td class="num">(13,850)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">55,944<span></span>
</td>
<td class="nump">34,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_LaboratoryAndManufacturingEquipmentMember', window );">Laboratory and manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">5,029<span></span>
</td>
<td class="nump">4,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">20,431<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 46,661<span></span>
</td>
<td class="nump">$ 28,416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_LaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_LaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=irtc_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459800152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Components of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation</a></td>
<td class="nump">$ 7,431<span></span>
</td>
<td class="nump">$ 6,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">34,484<span></span>
</td>
<td class="nump">19,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AccruedEmployeeStockPurchasePlanContribution', window );">Accrued ESPP Contributions</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services fees</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ClaimsPayableCurrent', window );">Claims payable</a></td>
<td class="nump">2,988<span></span>
</td>
<td class="nump">4,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,779<span></span>
</td>
<td class="nump">7,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 51,486<span></span>
</td>
<td class="nump">$ 40,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AccruedEmployeeStockPurchasePlanContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Employee Stock Purchase Plan Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AccruedEmployeeStockPurchasePlanContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ClaimsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Claims payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ClaimsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458090440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>ft&#178; </div>
<div>optionToExtend</div>
</th>
<th class="th">
<div>Sep. 03, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 04, 2018 </div>
<div>ft&#178; </div>
<div>optionToExtend</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 25, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 29, 2009 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term of operating leases (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of operating leases (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">727.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementMilestonePayments', window );">Collaboration agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023', window );">Collaboration agreement, additional milestone payments, between 2022 and early 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementMilestonePayments', window );">Collaboration agreement milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=irtc_VerilyLifeSciencesLLCMember', window );">Verily Life Sciences LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementRemainingTermOfAgreement', window );">Term of development agreement (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementUpfrontFeePayable', window );">Upfront fee related to development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months', window );">Additional aggregate milestone payments related to development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=irtc_LincolnshireLeaseMember', window );">Lincolnshire Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=irtc_CypressLeaseMember', window );">Cypress Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="nump">68,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=irtc_SanFranciscoMember', window );">San Francisco | Deerfield Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=irtc_SanFranciscoMember', window );">San Francisco | Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend', window );">Number of option to extend | optionToExtend</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term of lease (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Milestone Payments, Between 2022 and Early 2023</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Milestone Payments, Due In Next 24 Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CollaborationAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CollaborationAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CollaborationAgreementRemainingTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Remaining Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CollaborationAgreementRemainingTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CollaborationAgreementUpfrontFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Fee Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CollaborationAgreementUpfrontFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_LesseeOperatingSubleaseNumberOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Number Of Option To Extend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_LesseeOperatingSubleaseNumberOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OperatingLeaseRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease rentable area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OperatingLeaseRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=irtc_VerilyLifeSciencesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=irtc_VerilyLifeSciencesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=irtc_LincolnshireLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=irtc_LincolnshireLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=irtc_CypressLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=irtc_CypressLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=irtc_SanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=irtc_SanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=irtc_DeerfieldLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=irtc_DeerfieldLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=irtc_OfficeLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=irtc_OfficeLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458773064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 12,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">12,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">13,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">13,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">14,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">69,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Payments due</a></td>
<td class="nump">136,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(40,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 96,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459760600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under revolving credit line</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Maximum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfEligibleAccountsReceivableForBorrowings', window );">Percentage of eligible accounts receivable for borrowings</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Minimum | SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Minimum | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement | Prime Rate | SVB Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate', window );">Basis spread deduction on variable rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of debt</a></td>
<td class="nump">$ 35,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, basis spread deduction on variable rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_PercentageOfEligibleAccountsReceivableForBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible accounts receivable for borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_PercentageOfEligibleAccountsReceivableForBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=irtc_SiliconValleyBankTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=irtc_SiliconValleyBankTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=irtc_PharmakonLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=irtc_PharmakonLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461114760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 9,690<span></span>
</td>
<td class="nump">$ 21,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt, current portion</a></td>
<td class="nump">11,667<span></span>
</td>
<td class="nump">11,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">9,690<span></span>
</td>
<td class="nump">$ 21,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember', window );">Third Amended and Restated SVB Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">12,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">22,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_DebtInstrumentInterestPortion', window );">Less: Amount representing interest</a></td>
<td class="num">(883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: Debt Issuance Costs</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_LongTermDebtCarryingValue', window );">Total Carrying Value</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 22,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_DebtInstrumentInterestPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_DebtInstrumentInterestPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_LongTermDebtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt carrying value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_LongTermDebtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459952008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense (benefit)</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax Expense (benefit)</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459957304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate</a></td>
<td class="num">$ (21,198)<span></span>
</td>
<td class="num">$ (9,172)<span></span>
</td>
<td class="num">$ (11,446)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(7,049)<span></span>
</td>
<td class="num">(20,762)<span></span>
</td>
<td class="num">(5,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and Entertainment</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Section 162(m) limitation - officers compensation</a></td>
<td class="nump">4,856<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="num">(347)<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(381)<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017', window );">Foreign Rate Differential</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">24,111<span></span>
</td>
<td class="nump">30,607<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total Tax Expense (benefit)</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation effect of tax cuts and jobs act of 2017.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459977496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 114,856<span></span>
</td>
<td class="nump">$ 91,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">9,174<span></span>
</td>
<td class="nump">7,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">9,812<span></span>
</td>
<td class="nump">8,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_DeferredTaxAssetsValuationAllowancesAndOther', window );">Allowances and other</a></td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">14,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_DeferredTaxAssetsLeaseObligations', window );">Lease obligation</a></td>
<td class="nump">23,868<span></span>
</td>
<td class="nump">22,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">178,698<span></span>
</td>
<td class="nump">144,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(154,734)<span></span>
</td>
<td class="num">(123,803)<span></span>
</td>
<td class="num">$ (88,433)<span></span>
</td>
<td class="num">$ (66,435)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">23,964<span></span>
</td>
<td class="nump">20,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and Amortization</a></td>
<td class="num">(3,212)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(20,696)<span></span>
</td>
<td class="num">(20,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(23,908)<span></span>
</td>
<td class="num">(20,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_DeferredTaxAssetsValuationAllowancesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets valuation allowances and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_DeferredTaxAssetsValuationAllowancesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128459959032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLossCarryforwardsTaxBenefitRecognized', window );">Benefit recognized for net operating loss carryforwards</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">30,900,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net operating loss carryforwards, federal</a></td>
<td class="nump">464,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards, state</a></td>
<td class="nump">279,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards available to reduce future taxable income</a></td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax credit carryforwards available to reduce future taxable income</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OperatingLossCarryforwardsTaxBenefitRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards tax benefit recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OperatingLossCarryforwardsTaxBenefitRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466244776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_DeferredTaxAssetsValuationAllowanceRollForward', window );"><strong>Deferred Tax Assets, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at beginning of year</a></td>
<td class="nump">$ 123,803<span></span>
</td>
<td class="nump">$ 88,433<span></span>
</td>
<td class="nump">$ 66,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ValuationAllowanceDeferredTaxAssetAdditions', window );">Additions</a></td>
<td class="nump">30,931<span></span>
</td>
<td class="nump">35,370<span></span>
</td>
<td class="nump">21,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ValuationAllowanceDeferredTaxAssetDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at end of year</a></td>
<td class="nump">$ 154,734<span></span>
</td>
<td class="nump">$ 123,803<span></span>
</td>
<td class="nump">$ 88,433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_DeferredTaxAssetsValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_DeferredTaxAssetsValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ValuationAllowanceDeferredTaxAssetAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax asset additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ValuationAllowanceDeferredTaxAssetAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ValuationAllowanceDeferredTaxAssetDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax asset deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ValuationAllowanceDeferredTaxAssetDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458303752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">$ 1,842<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions taken in current year</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases in balance related to prior year tax positions</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases in balance related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 3,310<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">$ 1,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128461098872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128466210232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">11,164,880<span></span>
</td>
<td class="nump">9,740,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=irtc_StockOptionsIssuedAndOutstandingMember', window );">Options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">504,106<span></span>
</td>
<td class="nump">609,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">1,649,561<span></span>
</td>
<td class="nump">1,114,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=irtc_GrantUnderFutureStockPlansMember', window );">Shares available for grant under future stock plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">9,011,213<span></span>
</td>
<td class="nump">8,016,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_GrantUnderFutureStockPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_GrantUnderFutureStockPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128455055112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>numberOfPurchasePeriod </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,164,880<span></span>
</td>
<td class="nump">9,740,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested', window );">Restricted stock units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted stock units forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 109.2<span></span>
</td>
<td class="nump">$ 36.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Estimated grant date fair value of option vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan | First Anniversary of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage', window );">Stock option exercisable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option, maximum period for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan | Maximum | ISO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan | Maximum | Other Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember', window );">2006 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfVotingPowerOfAllClassesOfStock', window );">Percentage of voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">3,865,000<span></span>
</td>
<td class="nump">3,865,000<span></span>
</td>
<td class="nump">7,159,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option, maximum period for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock', window );">Percentage of common stock fair value on date of grant</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan("ESPP")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">483,031<span></span>
</td>
<td class="nump">483,031<span></span>
</td>
<td class="nump">1,851,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_IncreaseInCommonStockReservedForFutureIssuance', window );">Increase in shares available for future issuance (in shares)</a></td>
<td class="nump">966,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of payroll deductions of eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_EmployeeStockPurchasePlanOfferingPeriod', window );">Offering period (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods', window );">Number of purchase period | numberOfPurchasePeriod</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_EmployeeStockPurchasePlanPurchasePeriod', window );">Purchase period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of common stock fair market value available for employee purchase</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued to employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected minimum volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.99%<span></span>
</td>
<td class="nump">68.72%<span></span>
</td>
<td class="nump">43.61%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected maximum volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.96%<span></span>
</td>
<td class="nump">75.78%<span></span>
</td>
<td class="nump">48.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.18%<span></span>
</td>
<td class="nump">0.18%<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan number of purchase periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_EmployeeStockPurchasePlanPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_EmployeeStockPurchasePlanPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_IncreaseInCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_IncreaseInCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock option exercise price of fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_PercentageOfVotingPowerOfAllClassesOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting power of all classes of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_PercentageOfVotingPowerOfAllClassesOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Grants In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Restricted Stock Award, Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_TwoThousandSixEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_OtherStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_OtherStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458968840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details) - 2016 Plan - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Awards Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Beginning balance (in shares)</a></td>
<td class="nump">6,505,390<span></span>
</td>
<td class="nump">5,528,132<span></span>
</td>
<td class="nump">4,717,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional options authorized (in shares)</a></td>
<td class="nump">1,450,967<span></span>
</td>
<td class="nump">1,333,928<span></span>
</td>
<td class="nump">1,218,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod', window );">Awards granted (in shares)</a></td>
<td class="num">(1,289,567)<span></span>
</td>
<td class="num">(595,915)<span></span>
</td>
<td class="num">(649,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Awards forfeited (in shares)</a></td>
<td class="nump">356,999<span></span>
</td>
<td class="nump">156,623<span></span>
</td>
<td class="nump">181,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Awards withheld for tax purposes (in shares)</a></td>
<td class="nump">135,886<span></span>
</td>
<td class="nump">82,622<span></span>
</td>
<td class="nump">60,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ending balance (in shares)</a></td>
<td class="nump">7,159,675<span></span>
</td>
<td class="nump">6,505,390<span></span>
</td>
<td class="nump">5,528,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458564904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OptionsOutstandingAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">609,881<span></span>
</td>
<td class="nump">1,503,247<span></span>
</td>
<td class="nump">2,094,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(90,939)<span></span>
</td>
<td class="num">(868,614)<span></span>
</td>
<td class="num">(540,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(14,836)<span></span>
</td>
<td class="num">(24,752)<span></span>
</td>
<td class="num">(70,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">504,106<span></span>
</td>
<td class="nump">609,881<span></span>
</td>
<td class="nump">1,503,247<span></span>
</td>
<td class="nump">2,094,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">483,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest (in shares)</a></td>
<td class="nump">503,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_WeightedAverageExercisePricePerShareAbstract', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 40.18<span></span>
</td>
<td class="nump">$ 27.40<span></span>
</td>
<td class="nump">$ 23.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share)</a></td>
<td class="nump">31.15<span></span>
</td>
<td class="nump">17.31<span></span>
</td>
<td class="nump">9.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in USD per share)</a></td>
<td class="nump">68.81<span></span>
</td>
<td class="nump">66.89<span></span>
</td>
<td class="nump">54.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share)</a></td>
<td class="nump">40.97<span></span>
</td>
<td class="nump">$ 40.18<span></span>
</td>
<td class="nump">$ 27.40<span></span>
</td>
<td class="nump">$ 23.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in USD per share)</a></td>
<td class="nump">39.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest (in USD per share)</a></td>
<td class="nump">$ 40.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_WeightedAverageRemainingContractualLifeYearsAbstract', window );"><strong>Weighted- Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life for options outstanding (in years)</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 26 days<span></span>
</td>
<td class="text">6 years 5 months 4 days<span></span>
</td>
<td class="text">7 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life for options exercisable (in years)</a></td>
<td class="text">5 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life for options vested and expected to vest (in years)</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in&#160;thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 38,675<span></span>
</td>
<td class="nump">$ 120,163<span></span>
</td>
<td class="nump">$ 62,401<span></span>
</td>
<td class="nump">$ 97,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">37,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options vested and expected to vest</a></td>
<td class="nump">$ 38,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_WeightedAverageExercisePricePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_WeightedAverageExercisePricePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_WeightedAverageRemainingContractualLifeYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life (Years)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_WeightedAverageRemainingContractualLifeYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128458020168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Non-vested Restricted Stock Units ("RSUs") (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SharesUnderlyingRSUsAbstract', window );"><strong>Shares Underlying RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs issued and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_SharesUnderlyingRSUsAbstract', window );"><strong>Shares Underlying RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,114,159<span></span>
</td>
<td class="nump">886,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,289,567<span></span>
</td>
<td class="nump">595,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(412,002)<span></span>
</td>
<td class="num">(235,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(342,163)<span></span>
</td>
<td class="num">(131,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,649,561<span></span>
</td>
<td class="nump">1,114,159<span></span>
</td>
<td class="nump">886,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_WeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 94.25<span></span>
</td>
<td class="nump">$ 77.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">98.80<span></span>
</td>
<td class="nump">104.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="nump">104.94<span></span>
</td>
<td class="nump">69.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">113.95<span></span>
</td>
<td class="nump">59.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share)</a></td>
<td class="nump">$ 91.01<span></span>
</td>
<td class="nump">$ 94.25<span></span>
</td>
<td class="nump">$ 77.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_WeightedRemainingVestingPeriodInYearsAbstract', window );"><strong>Weighted Remaining Vesting Period (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted remaining vesting period of RSUs (in years)</a></td>
<td class="text">1 year 7 months 20 days<span></span>
</td>
<td class="text">1 year 4 months 17 days<span></span>
</td>
<td class="text">1 year 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in&#160;thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of RSUs</a></td>
<td class="nump">$ 194,137<span></span>
</td>
<td class="nump">$ 264,290<span></span>
</td>
<td class="nump">$ 60,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_SharesUnderlyingRSUsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Underlying RSUs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_SharesUnderlyingRSUsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_WeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_WeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_WeightedRemainingVestingPeriodInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Remaining Vesting Period (in years)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_WeightedRemainingVestingPeriodInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128460011544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember', window );">Market Condition Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128454277304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 19, 2020 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unamortized compensation costs, net of estimated forfeitures related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unamortized compensation costs related to unvested stock options, expected period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,527<span></span>
</td>
<td class="nump">$ 41,515<span></span>
</td>
<td class="nump">$ 26,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=irtc_ConsultingAndProfessionalServicesAgreementCPSAMember', window );">Consulting and Professional Services Agreement (&#8220;CPSA&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs issued and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unamortized compensation costs related to unvested stock options, expected period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unamortized compensation costs, net of estimated forfeitures related to restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289,567<span></span>
</td>
<td class="nump">595,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unamortized compensation costs, net of estimated forfeitures related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unamortized compensation costs related to unvested stock options, expected period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | 2019 Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense', window );">Reversal of share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of employees impacted by modification | employee</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation cost resulting from modification</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | 2020 Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | 2020 Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage', window );">Performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold', window );">Performance target to be earned at performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | 2020 Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage', window );">Performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold', window );">Performance target to be earned at performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Awarded January 2021 | 2021 Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Awarded January 2021 | 2021 Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage', window );">Performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold', window );">Performance target to be earned at performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Awarded February 2021 | 2021 Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Awarded February 2021 | 2021 Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage', window );">Performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold', window );">Performance target to be earned at performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance shares | Awarded February 2021 | 2021 Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage', window );">Performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold', window );">Performance target to be earned at performance threshold (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember', window );">Market Condition Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Performance Target To Be Earned At Performance Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Aggregate Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement By Share-Based Payment Award, Performance Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_ShareBasedPaymentArrangementReversalOfPriorExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Reversal Of Prior Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_ShareBasedPaymentArrangementReversalOfPriorExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_ConsultingAndProfessionalServicesAgreementCPSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_ConsultingAndProfessionalServicesAgreementCPSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_A2019AwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_A2019AwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_A2020AwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_A2020AwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=irtc_AwardedJanuary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=irtc_AwardedJanuary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=irtc_A2021AwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=irtc_A2021AwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=irtc_AwardedFebruary2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=irtc_AwardedFebruary2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=irtc_MarketConditionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128465966488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 54,527<span></span>
</td>
<td class="nump">$ 41,515<span></span>
</td>
<td class="nump">$ 26,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,565<span></span>
</td>
<td class="nump">7,727<span></span>
</td>
<td class="nump">4,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 47,066<span></span>
</td>
<td class="nump">$ 33,761<span></span>
</td>
<td class="nump">$ 21,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128467578136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,361)<span></span>
</td>
<td class="num">$ (43,830)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per common share, basic (in shares)</a></td>
<td class="nump">29,331,010<span></span>
</td>
<td class="nump">27,754,404<span></span>
</td>
<td class="nump">25,265,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per common share, diluted (in shares)</a></td>
<td class="nump">29,331,010<span></span>
</td>
<td class="nump">27,754,404<span></span>
</td>
<td class="nump">25,265,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in USD per share)</a></td>
<td class="num">$ (3.46)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in USD per share)</a></td>
<td class="num">$ (3.46)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (2.16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462022664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted net loss (in shares)</a></td>
<td class="nump">2,153,667<span></span>
</td>
<td class="nump">1,724,040<span></span>
</td>
<td class="nump">2,389,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted net loss (in shares)</a></td>
<td class="nump">504,106<span></span>
</td>
<td class="nump">609,881<span></span>
</td>
<td class="nump">1,503,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs issued and unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from diluted net loss (in shares)</a></td>
<td class="nump">1,649,561<span></span>
</td>
<td class="nump">1,114,159<span></span>
</td>
<td class="nump">886,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140128462163288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 10, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_OperatingLeaseRentableArea', window );">Lease rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Product And Services Zio X T Service Code93243</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CostReimbursementRate', window );">Reimbursement rate</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Product And Services Zio X T Service Code93247</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_irtc_CostReimbursementRate', window );">Reimbursement rate</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_CostReimbursementRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Reimbursement Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_CostReimbursementRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_irtc_OperatingLeaseRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease rentable area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">irtc_OperatingLeaseRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>irtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93243Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93243Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93247Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=irtc_ProductAndServicesZioXTServiceCode93247Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>irtc-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:irtc="http://www.irhythmtech.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="irtc-20211231.xsd" xlink:type="simple"/>
    <context id="i27fbdeea3c094ae8871771606084496b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93d690f4bdf3453780103c6489d41661_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic3c55699c69d45888a86b4cc7ec1c790_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="i0124649f48144c50ba45fea5ba1d4440_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i632162ae05734a44b80f1fdf5560120e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3d3f70e09ee54d849d92393b3efb75fc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifacca0dbed9549a594071a1cd185cd79_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia05eac998f1044e4967c9890b0d2a65e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i40721ab01cb74086a6725dda65e33834_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i432949efa6c64c78b50dceeab40e000b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6b02c96d685b4c76b557a50fb39ac9f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i704ac771209d404fabd6c01f42ca5256_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd0dc96bbc744424acc7449cb5f9e134_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibe09ccc9143a4642b389d469b06bd919_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic2201df0cbe746b8a0639b3748578218_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia897aa3797f647999451688e21df6eeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib239f55d6fa744e4b1ae93b2be580360_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a97f947148a4da3ae69e61dd1e1f636_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1767edc2ad274e82aaee985c123834f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0664e61690104fa2bf238691cd944c77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide789f0109144f18a87971e164951119_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdd2b799a58640109328cde5026037c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61d9a9c176034c01bafbe635f0ba6f6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad3589afc968435cb10d5cb10bf4738a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fea2d8c84be4bf68ebf457a8a6c2b3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie425bc192eea43c4998ce9d1e84e53a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3fa6df92e00f41ecb73a3d3d2c300e65_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08b094e744ff4732b19b6fd8fa91c517_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97a474771fc24576ab925990fae0b21d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81c8908741ec4840961679280bd8d5d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie322229942454b178e796984276627cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2019-09-10</startDate>
            <endDate>2019-09-10</endDate>
        </period>
    </context>
    <context id="i1486d77445c34613a8e3383fbbdb5025_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2020-08-21</startDate>
            <endDate>2020-08-21</endDate>
        </period>
    </context>
    <context id="i4e80ace037a44aa1bc75148d38174bb5_I20200821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2020-08-21</instant>
        </period>
    </context>
    <context id="i64b979f3794644df876abe57a7d76980_I20220110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:ProductAndServicesZioXTServiceCode93243Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="i3706f468116148dbabf8b4fb4c6f96e7_I20220110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:ProductAndServicesZioXTServiceCode93247Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="ie9ed4074ebd54c72b7c475f8882ba2ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f3ebc6891a9455e9c6fb6ea48899e99_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61d7a2d6f1774f9cb8ba5206eeae226e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idfb7f500e8934bd2b96bfe5eda7af356_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9db8564ddc2f47cfb7aaa008517d05ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0624798b12fa464ca5bea6b9c12f361b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i50fcb4b97216498585c183117c671309_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39c78456bd4045eab249ad061311ce9e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">irtc:FederalGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia00144f28bbd4b3b8d6872c91909a2d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i325e1cd03bd94e598819e2c8159b85ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id60332e77ea34183a58d2508319463aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id814a6da95c1480a914c87a5028a3a5b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e0e1acdecce4bc3890820a3d9e96ee2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5af04eb3c79a43ebbb272cec9b11188a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CommercialPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7c6ac2500f824b45a5cffbbccaa42236_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id50f5215d1174ad28382c2494c5399c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic7a7ea2b4b2b4143afc1c82e0fa1f8dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:NonContractedThirdPartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1a1fb6ef69b842c6bc4f8e224841fd0e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id16459be997449c3b7b484cc95d1339e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie651d17a114348fdb3edf9a8b0b5827c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:CentersForMedicareAndMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34f360678d4246b89d728c59cd20976d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82a7c57c18f549c5852ef8cd95cdc265_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifddd05d06ccf4b7d89a49501aaf7f236_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">irtc:HealthcareInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id929e42695a1425db8d875f569956607_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d7fcae5bab84669835f080a9618b3be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5efc11c28170439fb0e0ade90d22cd61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3848c1d4a184a1eb78ecfae9590242e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d649d197bda45e596f9af06665706a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad8d5012263e4befa279cf0bd28d07fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i544774a11590471697b6d8b7df26516c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d3915c703cd486c8d2ddb5c86644b14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1386205dcb64400c8549d89adf0e66c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad512d72fba24e88bc963667bb17d917_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadc05c01347a43d4839f5af04b73fb66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia90655704d594a51bf0f84615c1aac60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3286b0953db143438a81b1243412ad19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i661ccccd2342454cadb45ffd6ac1cdf8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8141234416514b26856b026454673afd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91b9d94fd49d43a1a73305efd5b103fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51e6fab54d734357843ce9f2f235a342_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d2ad0e7093a4f1d983b41003553428a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f7a85404cf446fba9e007019f906e7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2cd6a7df09a4e08a91ace7c629e1a29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3e65c8c9f154d91b116d7c006a7f126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia000fc56e55e41559e67dd102c2dbf14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i117f9b88ed88410697d8af034364839b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1ead7a95130417d9939c1641c99b464_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf07b6a8c12148a5b3ef09aaeed1bb3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea7ed4e30c8343c989fb2a52999238d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d8bc8f58f314b7dbda7fa3d301c42fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6da38639ddac4da59033ac85cd253110_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia3ea2f79999340578304ad9bf5ee9000_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93d61d9f2150452f8914338857d1ec28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5831875e85f74ca397d08ba1b12b77b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69e1c45b9cf14077ba98cd181deae320_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8e3f6dd8127416aa1c4b2182d28bf1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id359b2cae0f94347aea71e824f7d93b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic63032f4fbea4c8cb31c3a1f550699f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i105f7310b335489e8b39cfa28972fa27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i436d569dcf544ec4b7f8f38f9ca866f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1f57aaa377ac4100b7afae26cd7bc6ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6218693389e54b8a90202c61bf65dc84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd2ccd64143145f6bc932f06c1f08a5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8350a688f64d4a83b788ae9b0d39c23b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d6cbcfa7d0c4b59951bd7970942f9cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9c0eeaf2a7e4830a84e5a3e15aaccca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc0754b2aa6645d49d7942e54354b1f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2335277db35e4da9bc6053ad827c6b6c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabe8b8dfb0134468b31a854434788716_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00b53675a3ce4bbf8c3f060474b55387_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie60805415d1e4c0bb61070f850509317_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i28ab4afd0d0c40b89860d2c5c5281a69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:RawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57913d02322c4309a6e6b2296ed4ae43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:RawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4fdff6e9039430eba2e53b4f1ac3997_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i599e4ae97436440ebb5518c8ed6cd48a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:FinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b1a81becd2e4d4d9eab5264496e678a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">irtc:PrintedCircuitBoardAssembliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e9b27deda984a24813a7638b456e4b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cdcfe3d98f64ac28d89432c71dc7330_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e29bf199ddb4f14a081a37d488b00d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d87a54ba7c9421f9e5c705844818d32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">irtc:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01d4a41e7e284759a1cdb699a6d54241_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c8e622beead4bf5bdede9b59f014923_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec9c5185f80148638094fa6bbf5f7ceb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e8d067edb8c4d64bdd24a8de4d79690_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51fe3bdc1dc34b259a371515f18bdb86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa0786295f5443bd811598620bb82a9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-04</instant>
        </period>
    </context>
    <context id="i6c6807592d254ff88a10a57aea41b8c5_D20181004-20181004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-04</startDate>
            <endDate>2018-10-04</endDate>
        </period>
    </context>
    <context id="i295d5c0437d34174bf44c52749a0ac5a_I20091029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:LincolnshireLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-29</instant>
        </period>
    </context>
    <context id="i0fde8b0fa6ab4dfe86bf892cb5232e3d_I20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:CypressLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="i473a9e8ce4c04091aa983711246e3313_D20210318-20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:OfficeLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="i247ed5aae14d46398ee4c08aefa80fc9_I20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="ibc473ee2e3f047b9becb2198e94c3342_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">irtc:SanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">irtc:DeerfieldLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="i3d8d51dc95ba423b813f74a49801e062_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i583c6b3e405b4a20a3da03740a2eb9f3_I20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">irtc:VerilyLifeSciencesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-03</instant>
        </period>
    </context>
    <context id="i7f3ae94beacb488f8fa3638f2d2170e4_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="i658ecfa8506846dc82b0e01ee90a18e1_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i8bd3de617d2f41cbbeb04e8d26d24912_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i634d244c801140b8ab07eeabd8d14ef6_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i0e385fae9c694ac58ec7814ba00a5b71_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">irtc:SiliconValleyBankTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i91e808628b6a4613b5438a4e78004a62_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i79eb7c2fe0da4198aa7a5eea32e35ebd_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i1a67f248e25942c7be0ace4b0a88b4e1_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="id79b2be320cb4762a45bd10e6a3c51f4_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i9ec1526aa3b646a98a400738b384e12d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18aaaa80c4654a52a50440835da85723_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">irtc:ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba739cc6baef49ae98b4d255720f346f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fbbed17d9fc4fb0935e56255354c327_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib83d09b0b4814982af13362f56c4531a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5a2d071786e4b82beeb20f9e6115f40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86359793df1b40e2af06185a48d324e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9466bdc61cfa44fda7e517775eb15b05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ae8319ea0074645a500405f0e3d6579_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:GrantUnderFutureStockPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6546f2892d4749599e08c50b5624c54d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:GrantUnderFutureStockPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i330f02be0068413f808f4f28a9e5df09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b76829668ea4e88ae1e21924f45a625_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67d4bd0b270848488c2997023ea615dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id412c2fe707d4befae3144ed0cfbb2d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieee82ee8a6ae43a08349bfe55fba2da0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i731d5a16540847ed99546bb8519fea22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:OtherStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i25aed7f0402b404688f5892cc0328e06_I20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb6e1927b5a42bdb8c43f08b9014d6a_I20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="i0b57f096a6b04e42bb623131e05c164d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea8afaf349a043cc9d3265230b6be88c_I20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-30</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedcc9216016246979e44e071acb39f72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65041d451358415cbfcfe6fed3a436d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f6a3e4be968456eb56ea5292deeb1ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f36de2be3c245f5ae385981bc73b6e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i95dab85175994185bd642051f38f6586_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i759c278fc6f747e3ba280896f23d9bbc_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0400993af6a41d99753781144b0a14e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibad41d5498b1410b8ada5b20ae638221_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0a4c3b7811b486b8f1f6dab487979c1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i8555106470244294838f2dcfdde58a82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibc42661c3194491383dc17aab6af6e5c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie012b38e16cc401f802ea87af3684400_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">irtc:MarketConditionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42ec867e77104c7c880eca8b43778fb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3077a0d7299d4f5aabbf2184ffe9be97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibac55be5040a4d65a2fa2138c70bc7f7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51c63a57313342ee870d007775314912_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i036e8e19c0244562aa901632c01f81c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic5a9f2820af84e70bfdad6b84dbcdbbb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6f92497acfec4d779bc015e79d7a07a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57a2b1da44734fbd961217ea3df13e21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9032a6810bae4fa187e1e649dd2ad127_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65aa22d39afd4fdeb7a543c352ccd14b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad223dfee47d4235be238a5c63906545_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f9db1a2a402414e83610b8705c23f4a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-19</startDate>
            <endDate>2020-06-19</endDate>
        </period>
    </context>
    <context id="ia53dfea28b67446ea357092412155f6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2019AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i0e8a36476e6e476ba97c7dbc8c1d08f6_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i285f97c5349f42d09fbf05bf4afa82fd_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i48d4090f1770461094499a8926219715_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2020AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i7bf36d99211d4d7bb644f4a40a5aa345_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i4171790573c447c9bd09afc513f59f75_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i1db5399825c5480b91e101758d1f1cbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedJanuary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i7fd28149e2f14307ab0e6573f2a75749_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ibd15311b9e074984b42d19b85d262583_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i7a2ac6ed88094e85ad351dfffe1b0bcc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">irtc:AwardedFebruary2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:A2021AwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iccce65a61f0b4298b073d981b57911fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:ConsultingAndProfessionalServicesAgreementCPSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f49daad3c3e4a63954ae45aeab81118_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">irtc:ConsultingAndProfessionalServicesAgreementCPSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibef8252f0e0e4c2080743e4f89a810c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i869c663a60864d6dafba82faf152398d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9215b3bc96c4411aa73e32bdd167b66d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec01902a609c42cca84e32a7417ad2c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb08d6c4a54f49048409724c6ec35971_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icab020b110c64525bd57c35617d3162e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001388658</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment_security">
        <measure>irtc:investment_security</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="optiontoextend">
        <measure>irtc:optionToExtend</measure>
    </unit>
    <unit id="numberofpurchaseperiod">
        <measure>irtc:numberOfPurchasePeriod</measure>
    </unit>
    <unit id="employee">
        <measure>irtc:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml8zLTEtMS0xLTI0NTQz_42cbe345-c3b6-49f3-8691-90ed5782ea4b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml81LTEtMS0xLTI0NTQz_d6163968-dd2c-42a1-99d3-b6b65d468fb6">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml82LTEtMS0xLTI0NTQz_2f2fdf87-1417-4610-8831-8e8f26ac26a9">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV80L2ZyYWc6Yzk0YzM5MDc0ZGNiNGE5NzkxMjU0OTJlYmE2NjU2YjIvdGFibGU6MzU3MjkzYTA1ZDIwNGZjYzljZTk1ZWQ1OWQ5ZWYzNTIvdGFibGVyYW5nZTozNTcyOTNhMDVkMjA0ZmNjOWNlOTVlZDU5ZDllZjM1Ml85LTEtMS0xLTI0NTQz_d0822755-bf0f-4783-bb7a-eb545405023d">0001388658</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMC0xLTEtMjU3Njc_6a589db0-786c-44fa-92b8-d954be45f1b9">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xODk_d3616d36-845c-4a0b-b062-7f6a63ad6f0a">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6MjJkNDkwYmZlMjYxNGEzNmIyNDUzZWU3MWQ0NGRhM2UvdGFibGVyYW5nZToyMmQ0OTBiZmUyNjE0YTM2YjI0NTNlZTcxZDQ0ZGEzZV8wLTAtMS0xLTI0NTQz_d35c13d5-2dd7-4b20-bd81-041bb12fcbf1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY_8efe950d-0060-4736-ac28-398d265b24d9">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY_60479ff1-4100-40a3-9c6f-490776331cc8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6N2YyMGFlNTJhZmVmNDAyYjk2MTkwYzc0MGZiYTY4YWYvdGFibGVyYW5nZTo3ZjIwYWU1MmFmZWY0MDJiOTYxOTBjNzQwZmJhNjhhZl8wLTAtMS0xLTI0NTQz_b0e7fd8b-21b8-4c17-a047-bbafa42e2c08">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjg_7e5ce145-f31f-4f82-b3a7-96acf6c533f6">001-37918</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80NzY_c2d61352-0ea3-4eef-ae4c-3fe9f3743447">iRhythm Technologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8wLTAtMS0xLTI0NTQz_0fbf414d-5402-4887-9fc9-4ec189f17abe">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8wLTEtMS0xLTI0NTQz_bad507a5-6ad4-42d9-bfc1-3f37a41e6075">20-8149544</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfNQ_b9486175-0a65-476f-915f-54cda4698b88">699 8th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfOQ_b01bd4cb-d5c6-4d99-ae84-5e0e26733c82">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfMTI_d13f9bde-d088-4867-9c4e-96211482fee2">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTAtMS0xLTI0NTQzL3RleHRyZWdpb246ODgwNDIzMzgxY2FiNDljOWI5OThjZWUzOTMyZGNkNTRfMTY_9f012bd6-d968-43ff-8cba-752608c7b339">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6OTQwNWRjNWFlMDkxNGJlZWI1YmI0MThmMTc3MzYzMTAvdGFibGVyYW5nZTo5NDA1ZGM1YWUwOTE0YmVlYjViYjQxOGYxNzczNjMxMF8yLTEtMS0xLTI0NTQzL3RleHRyZWdpb246OGMwOGYxMTkyNmIwNGUzOTkyMGM1ZDQyMDhmZmJmZWFfNQ_327d1cf9-f131-459c-8f65-3a1dba291db8">94103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV82OTQ_6a56015b-b6eb-4fb5-bcdb-d73d45bfca02">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV82OTg_51c0a41f-c0dc-4b59-8d53-f53725290b75">632-5700</dei:LocalPhoneNumber>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xMTM5_3303e0ff-9949-4c8d-b5ba-e18376b2add8">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xMjcy_3facbd44-22e2-45ce-b4cd-bdb39f44fab9">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xNjIz_3036f4e7-c67e-44c3-9556-a229b0add894">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8xOTUx_0fb71b2a-818c-49ca-8f7d-73580fcd740f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8wLTAtMS0xLTI0NTQz_71da41fc-ed5a-4182-be08-5cbd5a3c0cd9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8xLTMtMS0xLTI0NTQz_f3b03c91-aa30-4bf3-9063-f7e900848ecc">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6M2U3MmVlODFlOGE4NGQwN2FmNzZhYmVjM2MyZGZiNGEvdGFibGVyYW5nZTozZTcyZWU4MWU4YTg0ZDA3YWY3NmFiZWMzYzJkZmI0YV8yLTEtMS0xLTI0NTQz_a12a8c91-8433-42ac-994d-17f5d86b10d1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8yNzQ4Nzc5MDczNDkz_c2240c73-2fcf-45b7-a679-04a461d7adf0">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zMzY5_d0f783ce-8c1b-41f3-bef3-700bfe793cd0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i93d690f4bdf3453780103c6489d41661_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjA5_9b0e647e-4ca6-4e3a-9ae3-c5292dee7c7b"
      unitRef="usd">1900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic3c55699c69d45888a86b4cc7ec1c790_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV8zNjg4_e6d8eddf-2944-40d6-a0f7-49d9e92de658"
      unitRef="shares">29513264</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDEw_923b27f0-f68b-4748-b3d9-89cc06755952">Portions of the information called for by Part III of this Form 10-K is hereby incorporated by reference from the definitive Proxy Statements for our annual meeting of stockholders, which will be filed with the Securities and Exchange Commission not later than 120 days after December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:DocumentPeriodEndDate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDA1_8efe950d-0060-4736-ac28-398d265b24d9">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGV4dHJlZ2lvbjpmODUzMzFkOTcxMjE0YmMzYjJmNTk0NzY5YTZlMmI3ZV80MDA1_60479ff1-4100-40a3-9c6f-490776331cc8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:Security12bTitle
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTAtMS0xLTI0NTQz_037d4a6b-0838-496c-83a0-9ae6f1febd11">Common Stock, Par Value $.001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTEtMS0xLTI0NTQz_d9f731c6-f534-45d0-b896-180ee98a00e5">IRTC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xL2ZyYWc6Zjg1MzMxZDk3MTIxNGJjM2IyZjU5NDc2OWE2ZTJiN2UvdGFibGU6NGY5ZjcxM2QxMTM3NDRlZDgxMzU1YTY0NmZjYmM4MzkvdGFibGVyYW5nZTo0ZjlmNzEzZDExMzc0NGVkODEzNTVhNjQ2ZmNiYzgzOV8xLTItMS0xLTI0NTQz_4f1cbde7-a2d9-4aed-abbb-02cd3f48971a">NASDAQ</dei:SecurityExchangeName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNC0xLTEtMS0yNDU0Mw_d3011d38-6eae-4361-9b0a-72cbcf89956b"
      unitRef="usd">127562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNC0zLTEtMS0yNDU0Mw_892a1fcf-f96c-435c-a7ce-7be06534a181"
      unitRef="usd">88628000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNS0xLTEtMS0yNDU0Mw_5474335c-38aa-40ab-8b51-f9035cf26e5a"
      unitRef="usd">111569000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNS0zLTEtMS0yNDU0Mw_ba93a8e9-7b8e-4306-a76d-4461bce7f68a"
      unitRef="usd">246589000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNi0xLTEtMS0yNDU0Mw_4f2aec39-9c0e-45f2-b37f-d829311d84d7"
      unitRef="usd">46430000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNi0zLTEtMS0yNDU0Mw_5ac07c17-f5f7-462b-b321-a6ee273ca834"
      unitRef="usd">29932000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNy0xLTEtMS0yNDU0Mw_b5dc0f9b-59de-416e-893d-6d33ccf2f4bd"
      unitRef="usd">10268000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfNy0zLTEtMS0yNDU0Mw_e461b279-47ae-4912-ae64-8cbbca0a3eb0"
      unitRef="usd">5313000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOC0xLTEtMS0yNDU0Mw_6ed566e4-2ab2-4a79-af60-d0725290eb22"
      unitRef="usd">9693000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOC0zLTEtMS0yNDU0Mw_89482823-ef8e-4b8b-9806-9dcadad118d8"
      unitRef="usd">7363000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOS0xLTEtMS0yNDU0Mw_fe18c287-beff-4ce2-af19-3403eaa37aca"
      unitRef="usd">305522000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfOS0zLTEtMS0yNDU0Mw_5411c893-2864-4443-9923-5f667155fae2"
      unitRef="usd">377825000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTEtMS0xLTEtMjQ1NDM_06ce8b5c-2994-48f5-af81-32bad0841c70"
      unitRef="usd">55944000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTEtMy0xLTEtMjQ1NDM_8473fe6e-4bbe-48a2-976d-5d4ae2bdff94"
      unitRef="usd">34247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTItMS0xLTEtMjQ1NDM_da0731e1-bf25-45ae-914a-94cf9a904861"
      unitRef="usd">84587000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTItMy0xLTEtMjQ1NDM_c5ee2b4c-f16a-4f1f-91ae-02c09d9c65eb"
      unitRef="usd">84714000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTMtMS0xLTEtMjQ1NDM_4437f575-ea21-42f8-9950-165aea4e3684"
      unitRef="usd">862000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTMtMy0xLTEtMjQ1NDM_b7079b6c-5820-4e6b-a1f0-a8650837fdf5"
      unitRef="usd">862000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTQtMS0xLTEtMjQ1NDM_86a1a15b-934b-44e8-a18e-e85a4ba7315e"
      unitRef="usd">16052000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTQtMy0xLTEtMjQ1NDM_14e0706d-6813-4dc1-9fab-5490df05ac78"
      unitRef="usd">14091000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTUtMS0xLTEtMjQ1NDM_030c7a9d-6ae2-4d7c-b775-5be9ab3aab2c"
      unitRef="usd">462967000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTUtMy0xLTEtMjQ1NDM_5a6e2271-f72d-48e8-a63c-c9e8a6781a62"
      unitRef="usd">511739000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTgtMS0xLTEtMjQ1NDM_37d41b2a-d5cc-408c-bbad-4cddc48af224"
      unitRef="usd">10509000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTgtMy0xLTEtMjQ1NDM_5531b771-bb10-406f-b9af-a3f873a38234"
      unitRef="usd">4365000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTktMS0xLTEtMjQ1NDM_b50713c6-fb81-4a3e-b31c-94bdf9d4b697"
      unitRef="usd">51486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMTktMy0xLTEtMjQ1NDM_3fb7407f-c928-4f3a-8816-f479769f9cb0"
      unitRef="usd">40532000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjAtMS0xLTEtMjQ1NDM_dac837f9-65cf-4757-abb0-02ec8c90902d"
      unitRef="usd">3049000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjAtMy0xLTEtMjQ1NDM_e958088b-2088-497a-ba9d-4ad8d30f584c"
      unitRef="usd">930000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DebtCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjEtMS0xLTEtMjQ1NDM_22e01986-b301-4c7c-804e-3fdb46854892"
      unitRef="usd">11667000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjEtMy0xLTEtMjQ1NDM_46b54724-5795-4569-9564-7527bc36ef6a"
      unitRef="usd">11667000</us-gaap:DebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjMtMS0xLTEtMjQ1NDM_81a8a04d-3159-4e38-a4e2-89b0553c71b4"
      unitRef="usd">11142000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjMtMy0xLTEtMjQ1NDM_f1b5784b-6571-4ad9-b1f6-da030ea82a86"
      unitRef="usd">8171000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjQtMS0xLTEtMjQ1NDM_4d978133-0df6-4c41-b2a3-99785e7458e0"
      unitRef="usd">87853000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjQtMy0xLTEtMjQ1NDM_2060e7d9-815a-4cec-862b-6ba62c36417b"
      unitRef="usd">65665000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjUtMS0xLTEtMjQ1NDM_d5fe705a-63af-47fa-806b-e23745a81f2a"
      unitRef="usd">9690000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjUtMy0xLTEtMjQ1NDM_7fb1c57e-6a56-4a4b-91c0-d578b9b9a63b"
      unitRef="usd">21339000</us-gaap:LongTermDebt>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjYtMS0xLTEtMjQ1NDM_d22ec7d3-3eb4-4cf5-87ca-4ab1201ffc02"
      unitRef="usd">697000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjYtMy0xLTEtMjQ1NDM_4353b100-7d33-40f9-8904-51dbba39bd71"
      unitRef="usd">1830000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjctMS0xLTEtMjQ1NDM_a94d4266-b676-49e0-aff8-cdd0ef76ca50"
      unitRef="usd">85212000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjctMy0xLTEtMjQ1NDM_4c4d0386-294e-4bab-a263-f409f1c83913"
      unitRef="usd">81293000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjgtMS0xLTEtMjQ1NDM_56396521-32c7-48ca-b339-791f8e4c42f2"
      unitRef="usd">183452000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjgtMy0xLTEtMjQ1NDM_58c389ae-ef58-4baa-862e-0370e90639d1"
      unitRef="usd">170127000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjktMS0xLTEtMjQ1NDM_ceda72a7-fa96-40d7-b324-bfcd0a516203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMjktMy0xLTEtMjQ1NDM_cfcc330d-bde4-4798-ac16-0ac032a62d96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8yMw_4901a43d-0816-4b00-989b-71820f855a60"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8yMw_fdd5208e-9308-4510-950d-a0516a51a37e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8zOA_14d06339-e22b-4adb-94e1-4b768f443091"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV8zOA_5dacd7db-6ec2-4e1f-92f4-ea8469315c35"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_5624fbef-c24f-4dac-9cd5-7c490f8dfe48"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_5e2bdbc2-ec39-4fca-b5c0-8d77a287057e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_637af92b-0b50-4fd2-855d-cb94f2a78820"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjo4OTQ3MDgwMmI0OWU0NTcxODczYTU4ZGY1YWEwZTIyNV83Nw_c0245536-10b8-4394-b547-026977284fcf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMS0xLTEtMjQ1NDM_59e71f8d-6e96-4dab-8a2a-9649f1fef5eb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzEtMy0xLTEtMjQ1NDM_d0c8af5b-32df-432b-8c17-109fc832ee1f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8yMA_6a3a29b9-95b5-478b-bdb5-c823360ea4df"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8yMA_78bef688-729f-4619-af6b-ac92617d745b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8zNQ_2178a188-2ef2-48da-8271-538b94af3729"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV8zNQ_22061c44-a0f4-49ae-8ec3-7016f62b16fc"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83MA_2f7dc360-3c97-4c01-9888-2febd0a80f90"
      unitRef="shares">29493726</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83MA_80f84952-cec9-459d-bcf3-209780963d27"
      unitRef="shares">29493726</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83Nw_4a0f7988-ce6b-4e84-b025-1bd17ac78db9"
      unitRef="shares">29019350</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMC0xLTEtMjQ1NDMvdGV4dHJlZ2lvbjpjY2RkZTdjY2Q3YWU0ZGUzYmI3ZjExZGY0NmI1MTc1NV83Nw_bb977a0d-1482-4d34-a64b-f4aef4650810"
      unitRef="shares">29019350</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMS0xLTEtMjQ1NDM_03d9ad8d-e8ce-41a2-94aa-3fa67a347592"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzItMy0xLTEtMjQ1NDM_aaf7871b-29af-4c5c-91f0-8ddf84a9d80c"
      unitRef="usd">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzMtMS0xLTEtMjQ1NDM_b1f21914-b81a-4fbe-88b8-bc5abdef316c"
      unitRef="usd">685594000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzMtMy0xLTEtMjQ1NDM_16fa8572-042a-409e-a7f0-0634c9f5a550"
      unitRef="usd">646258000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzQtMS0xLTEtMjQ1NDM_25ece597-4c05-4a82-9c19-2b79033737a7"
      unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzQtMy0xLTEtMjQ1NDM_dbb4b8ef-98da-450b-b256-d622b51f906b"
      unitRef="usd">11000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzUtMS0xLTEtMjQ1NDM_f48fbde7-bec8-47d7-9b34-e23764714f3f"
      unitRef="usd">-406045000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzUtMy0xLTEtMjQ1NDM_c65b84b7-41e3-4a36-aecf-8d4001c5c62f"
      unitRef="usd">-304684000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzYtMS0xLTEtMjQ1NDM_764c0b62-b61e-4c9e-b912-b0cdb46d51dd"
      unitRef="usd">279515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzYtMy0xLTEtMjQ1NDM_05dde8f1-7dbb-4490-8b5b-b6c1fd659d7c"
      unitRef="usd">341612000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzctMS0xLTEtMjQ1NDM_9f01d01b-60bf-4cb4-a782-4cab60029cb9"
      unitRef="usd">462967000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV82Ny9mcmFnOmU3MzdjZDg3OWM0ZDQ4Yjg4ODJhNTljMzA2M2EzNTIxL3RhYmxlOjQxNzdmOTA3NDUyZTRkOTNhYzEzNzExNmFiMWZjMzQzL3RhYmxlcmFuZ2U6NDE3N2Y5MDc0NTJlNGQ5M2FjMTM3MTE2YWIxZmMzNDNfMzctMy0xLTEtMjQ1NDM_caabc679-99a2-448d-a8c8-97dcdf57eef8"
      unitRef="usd">511739000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi0xLTEtMS0yNDU0Mw_f4281882-414b-46d2-80c2-5e771383b31d"
      unitRef="usd">322825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi0zLTEtMS0yNDU0Mw_07d10df1-717c-4a7b-9acd-34697991fb07"
      unitRef="usd">265166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMi01LTEtMS0yNDU0Mw_0c195268-223e-4569-87cc-e10dad229626"
      unitRef="usd">214552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy0xLTEtMS0yNDU0Mw_880d8e9f-1f9c-4057-91a7-1322802152bc"
      unitRef="usd">109258000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy0zLTEtMS0yNDU0Mw_35991370-b642-47d5-a931-9d0d95262e7f"
      unitRef="usd">70277000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMy01LTEtMS0yNDU0Mw_be63dc3e-b18e-4c60-8303-e64983ff7fc7"
      unitRef="usd">52485000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC0xLTEtMS0yNDU0Mw_792a1c4a-95f9-467a-b63c-17bb991f342b"
      unitRef="usd">213567000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC0zLTEtMS0yNDU0Mw_4e7eb357-0d3a-479c-94e9-59eccb5110ef"
      unitRef="usd">194889000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNC01LTEtMS0yNDU0Mw_c8780522-716c-4ac1-8b60-ef4f60a111e0"
      unitRef="usd">162067000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi0xLTEtMS0yNDU0Mw_2b72bf56-4693-451b-8b46-7f08e5918ace"
      unitRef="usd">38671000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi0zLTEtMS0yNDU0Mw_390283de-e17f-40b1-90cd-66b6218523d2"
      unitRef="usd">41329000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNi01LTEtMS0yNDU0Mw_90311890-1a83-43c1-8585-c8bdc6d3470e"
      unitRef="usd">37299000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy0xLTEtMS0yNDU0Mw_70c680b7-5fa4-4b37-ab86-31335da00ba3"
      unitRef="usd">274839000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy0zLTEtMS0yNDU0Mw_a9540a7b-3756-46d5-a782-0009cf806043"
      unitRef="usd">197233000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfNy01LTEtMS0yNDU0Mw_ea28b06d-3fb6-48a5-bb03-7200e4ac4f92"
      unitRef="usd">179523000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC0xLTEtMS0yNDU0Mw_88ff82a8-0040-48fc-855b-c2fbd60e78fc"
      unitRef="usd">313510000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC0zLTEtMS0yNDU0Mw_2f938365-4f29-475e-a2fb-bb0097e16cdd"
      unitRef="usd">238562000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOC01LTEtMS0yNDU0Mw_e3dc2558-8d0a-46e3-b9d7-7ef557827455"
      unitRef="usd">216822000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS0xLTEtMS0yNDU0Mw_5d34a89c-c790-45a2-992e-830bd5856d16"
      unitRef="usd">-99943000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS0zLTEtMS0yNDU0Mw_a5ccc253-9889-41f8-82b7-32b293d57e43"
      unitRef="usd">-43673000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfOS01LTEtMS0yNDU0Mw_d7d854ff-e41a-401e-bb5b-e3a11a40651b"
      unitRef="usd">-54755000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtMS0xLTEtMjQ1NDM_da8b1bbd-5bee-4815-a0df-c32cf024d065"
      unitRef="usd">1169000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtMy0xLTEtMjQ1NDM_c58ec4de-7e61-4202-a6f6-f0c3388023f0"
      unitRef="usd">1519000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTAtNS0xLTEtMjQ1NDM_e4e6b45d-da34-407c-a0c5-aa4dd5a40abf"
      unitRef="usd">1643000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtMS0xLTEtMjQ1NDM_d17cce2f-b1eb-46ed-8bb7-052ebcba4fe4"
      unitRef="usd">118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtMy0xLTEtMjQ1NDM_78015c44-9a9d-4331-be1a-52f87c9274d0"
      unitRef="usd">1591000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTEtNS0xLTEtMjQ1NDM_16d32d08-7755-4a90-aa51-680c513132d0"
      unitRef="usd">1895000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtMS0xLTEtMjQ1NDM_86bb5835-f2c0-4c19-86cc-360298d19789"
      unitRef="usd">-100994000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtMy0xLTEtMjQ1NDM_04049352-f2c0-4137-a4a0-20e825e7e617"
      unitRef="usd">-43601000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTMtNS0xLTEtMjQ1NDM_04bce399-e751-4c29-b92f-22d9e7f5afab"
      unitRef="usd">-54503000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtMS0xLTEtMjQ1NDM_f852a198-0c6b-4022-864b-d61b4f368aaf"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtMy0xLTEtMjQ1NDM_2019d7b5-e66b-4fb4-b358-608c58d50837"
      unitRef="usd">229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTQtNS0xLTEtMjQ1NDM_e7fb0f07-c146-4715-b1cd-481d02281cbe"
      unitRef="usd">65000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtMS0xLTEtMjQ1NDM_f183b407-914d-40b1-91c5-2f7951467f21"
      unitRef="usd">-101361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtMy0xLTEtMjQ1NDM_e3890031-4d46-44d0-a837-024c35674312"
      unitRef="usd">-43830000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTUtNS0xLTEtMjQ1NDM_03aab695-e087-49ff-bf26-53d8e8e75d60"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMS0xLTEtMjQ1NDM_15b9f241-2a26-4318-b165-34d7e7577a3a"
      unitRef="usdPerShare">-3.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMS0xLTEtMjQ1NDM_f9f421cb-4a42-4222-966b-5e0503c9db34"
      unitRef="usdPerShare">-3.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMy0xLTEtMjQ1NDM_83575b64-809c-4d48-a94c-dfc6da0655b3"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtMy0xLTEtMjQ1NDM_a8d02354-882c-4b79-a32a-863c5063e5a2"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtNS0xLTEtMjQ1NDM_804e2cf9-9984-44a7-913e-45bf891d108c"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTYtNS0xLTEtMjQ1NDM_e4589b7c-8d77-4009-935c-c6d4d5f29714"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMS0xLTEtMjQ1NDM_62dd7a7d-7a27-427c-9f47-a9b717c05296"
      unitRef="shares">29331010</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMS0xLTEtMjQ1NDM_899ad9de-2b86-4429-9569-f7be5d287aef"
      unitRef="shares">29331010</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMy0xLTEtMjQ1NDM_89751266-dd28-4568-8224-4824de1cd470"
      unitRef="shares">27754404</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctMy0xLTEtMjQ1NDM_fc898e8d-fbfb-468e-8361-3431f84945e8"
      unitRef="shares">27754404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctNS0xLTEtMjQ1NDM_0d820e02-1d86-4c81-90cd-13a67ba1dbab"
      unitRef="shares">25265918</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83MC9mcmFnOjhiMzI1MTQzNGY4YTRiYWU5OGI3Y2RmMjhmZDUwNDVhL3RhYmxlOjVmNTg2NWE5YzY5MTRhNTU5ZjYzZjA2YTUxMmJhZjU5L3RhYmxlcmFuZ2U6NWY1ODY1YTljNjkxNGE1NTlmNjNmMDZhNTEyYmFmNTlfMTctNS0xLTEtMjQ1NDM_68e7de61-ec54-43cf-a2ba-354071c70f86"
      unitRef="shares">25265918</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi0xLTEtMS0yNDU0Mw_4f5ceb20-ea8a-4c7e-8726-e31570279e90"
      unitRef="usd">-101361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi0zLTEtMS0yNDU0Mw_77abc9a0-00f8-4033-bed7-53a3ee370fa9"
      unitRef="usd">-43830000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfMi01LTEtMS0yNDU0Mw_24b9c155-89e1-4169-bd88-c3055ee63996"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC0xLTEtMS0yNDU0Mw_1691d640-11ef-4464-8eac-a6e4a2fd3512"
      unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC0zLTEtMS0yNDU0Mw_8b76e03e-d496-42bb-a630-e2e9b286c27d"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNC01LTEtMS0yNDU0Mw_e208cc02-7d18-4d57-8d03-ae88d1912c17"
      unitRef="usd">98000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS0xLTEtMS0yNDU0Mw_e5140111-a973-4205-8b10-d1ff4ef3ca82"
      unitRef="usd">-101433000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS0zLTEtMS0yNDU0Mw_ba73cb29-c995-4c2c-9c38-66ca39fe22ac"
      unitRef="usd">-43901000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83My9mcmFnOjBjMGY0NGQ2OWE2ODQxZTY5ZGFiYTlhYWVjOWY1YjM5L3RhYmxlOjVjNDJiMTRlNDdhMzQ2NTRiNmUxYTNmYWFkZGU5NjdhL3RhYmxlcmFuZ2U6NWM0MmIxNGU0N2EzNDY1NGI2ZTFhM2ZhYWRkZTk2N2FfNS01LTEtMS0yNDU0Mw_0d0525d0-05ff-4c49-b18d-e888df16d97b"
      unitRef="usd">-54470000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i632162ae05734a44b80f1fdf5560120e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0yLTEtMS0yNDU0Mw_87cb711b-3685-4073-91b0-f21f5953c540"
      unitRef="shares">24368073</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i632162ae05734a44b80f1fdf5560120e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS00LTEtMS0yNDU0Mw_2a129f15-4daf-4751-800d-6d2da5f44882"
      unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d3f70e09ee54d849d92393b3efb75fc_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS02LTEtMS0yNDU0Mw_f4158115-5a57-4cbf-bdc1-0688f022588f"
      unitRef="usd">257955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifacca0dbed9549a594071a1cd185cd79_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS04LTEtMS0yNDU0Mw_390412b1-ebcf-4fba-b32a-b7bb63ad2b41"
      unitRef="usd">-205825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia05eac998f1044e4967c9890b0d2a65e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0xMC0xLTEtMjQ1NDM_fe47e757-68cc-42ab-b009-0328e3abade4"
      unitRef="usd">-16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfOS0xMi0xLTEtMjQ1NDM_996e9ace-5c62-42db-a7f2-efd8dfcfafc3"
      unitRef="usd">52137000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMi0xLTEtMjQ1NDM_a8379018-8d96-4679-b9e7-647c026503fb"
      unitRef="shares">734453</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtNi0xLTEtMjQ1NDM_917b43b4-0ea5-46ec-954b-0c247c329564"
      unitRef="usd">9495000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMTItMS0xLTI0NTQz_cc7daa69-d072-4f88-8856-40c17ecf2e90"
      unitRef="usd">9495000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <irtc:CommonStockSharesIssuedFromExerciseOfWarrants
      contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTEtMi0xLTEtMjUwNTY_1cb53be2-7f39-4569-878f-d9b6945190f0"
      unitRef="shares">4852</irtc:CommonStockSharesIssuedFromExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMi0xLTEtMjUwNTY_63d03fe5-804b-4c0d-891a-919cbed9d94c"
      unitRef="shares">1575342</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief7bf2ba80c047e6b865590d1b4a5a99_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNC0xLTEtMjUwNTY_891ed095-61a3-49a7-a9a5-64fee7e8e44f"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNi0xLTEtMjUwNTY_f3a1e250-1753-48e8-805a-6e0e16a2520c"
      unitRef="usd">107292000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMTItMS0xLTI1MDU2_35da8cf3-cc56-4ba6-bf0b-0ea0f0dbd58a"
      unitRef="usd">107294000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItNi0xLTEtMjQ1NDM_6ed9025c-de6e-460c-95bf-51e270bf22ac"
      unitRef="usd">5288000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTItMTItMS0xLTI0NTQz_1b8d9723-0c28-4704-8028-7419d4068bff"
      unitRef="usd">5288000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i80a08450e75b4533afb0ff8d59848de7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTMtNi0xLTEtMjQ1NDM_5cc9a0ab-c96f-42a7-8548-756b60d7219d"
      unitRef="usd">26241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTMtMTItMS0xLTI0NTQz_d6f0072c-d0ab-4b74-ad5b-1a1ab14e02e5"
      unitRef="usd">26241000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i432949efa6c64c78b50dceeab40e000b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTQtOC0xLTEtMjQ1NDM_dbdad204-c16e-471c-8c0d-a55d80863fcc"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTQtMTItMS0xLTI0NTQz_dc9025a9-b7da-4471-8d94-6fa9c15fb842"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6b02c96d685b4c76b557a50fb39ac9f2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTUtMTAtMS0xLTI0NTQz_d73ced8e-45b0-4fbd-9c6d-30aaa7821ad7"
      unitRef="usd">98000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTUtMTItMS0xLTI0NTQz_4c95e01b-1f77-4c3b-9494-6f1318b5eb8a"
      unitRef="usd">98000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i704ac771209d404fabd6c01f42ca5256_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMi0xLTEtMjQ1NDM_5bb66e3f-b35b-4032-b69c-e32a343b82e5"
      unitRef="shares">26682720</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i704ac771209d404fabd6c01f42ca5256_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtNC0xLTEtMjQ1NDM_626f9a01-6bb1-4bef-85b9-dd36b5e31231"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd0dc96bbc744424acc7449cb5f9e134_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtNi0xLTEtMjQ1NDM_4af68a3d-beaf-4ff3-bdcf-7553277df214"
      unitRef="usd">395695000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe09ccc9143a4642b389d469b06bd919_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtOC0xLTEtMjQ1NDM_a55acd94-9278-44fa-b0ee-85ec42f014c0"
      unitRef="usd">-260393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2201df0cbe746b8a0639b3748578218_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMTAtMS0xLTI0NTQz_d26eab77-dfd9-4171-b628-fd9187e0bfdd"
      unitRef="usd">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTYtMTItMS0xLTI0NTQz_4a242c92-da0a-4245-b4cf-6b2232e0b59d"
      unitRef="usd">135409000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMi0xLTEtMjQ1NDM_1ec06124-70d4-40fa-976c-25ef4006a258"
      unitRef="shares">1079488</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctNi0xLTEtMjQ1NDM_3de57fd8-ea3b-4f6c-8e80-23faf6ed946b"
      unitRef="usd">20244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMTItMS0xLTI0NTQz_2aa2983b-de14-44a2-adb6-bb5f0f6c9e56"
      unitRef="usd">20244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTctMTItMS0xLTI0NTQz_5abb257c-36b7-4273-975f-0b9b83d11d33"
      unitRef="usd">20244000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktMi0xLTEtMjQ1NDM_28875863-92e2-4381-8226-931cd168ac9b"
      unitRef="shares">1257142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6d01dd6d475b48d89b3d84448fd563ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktNC0xLTEtMjQ1NDM_4e2259e1-131b-4cb2-81c4-c05c9ed763f1"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktNi0xLTEtMjQ1NDM_923125c0-d581-4845-8b4f-16395072f387"
      unitRef="usd">206023000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMTktMTItMS0xLTI0NTQz_9368e97e-daec-47d6-bb46-fd1c7c2a3ed2"
      unitRef="usd">206025000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjAtNi0xLTEtMjQ1NDM_4a0c6ab2-31c8-44c9-b63f-0db7115f0310"
      unitRef="usd">10009000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjAtMTItMS0xLTI0NTQz_c2c376eb-4f45-494d-a13b-eeb6df55603f"
      unitRef="usd">10009000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1b0c4e8f277b42b19bba8144f8c66e59_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjEtNi0xLTEtMjQ1NDM_2c18b353-972e-4234-9325-04ef27d58a01"
      unitRef="usd">34305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjEtMTItMS0xLTI0NTQz_e9a8a210-8837-472b-a9d3-cafb4b158be9"
      unitRef="usd">34305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="ib239f55d6fa744e4b1ae93b2be580360_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItOC0xLTEtMjUwNTY_118b1523-ad77-4ccb-a5f3-67971de703ee"
      unitRef="usd">-461000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a97f947148a4da3ae69e61dd1e1f636_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMTItMS0xLTI1MDU2_976971b1-8188-4827-a4a8-d3ea0992f0cc"
      unitRef="usd">-461000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i1767edc2ad274e82aaee985c123834f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItOC0xLTEtMjQ1NDM_9d6c84cf-d02c-4b40-bcb1-e3858c760181"
      unitRef="usd">-43830000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjItMTItMS0xLTI0NTQz_656cb971-61a3-4027-86f5-3d95d2324376"
      unitRef="usd">-43830000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0664e61690104fa2bf238691cd944c77_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjMtMTAtMS0xLTI0NTQz_53ffbe73-7fe9-4aeb-bebf-6c6dc2e7ed0b"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjMtMTItMS0xLTI0NTQz_9fc07a93-0079-4c00-9f04-81ae42aba591"
      unitRef="usd">-71000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ide789f0109144f18a87971e164951119_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMi0xLTEtMjQ1NDM_5ee228f6-3698-44ba-9a50-42b6582f1745"
      unitRef="shares">29019350</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ide789f0109144f18a87971e164951119_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtNC0xLTEtMjQ1NDM_7512dc3e-fd43-4259-840d-60ec0ba9a2e6"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibdd2b799a58640109328cde5026037c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtNi0xLTEtMjQ1NDM_27a9f264-f32b-49b2-b846-c411ab4dfd35"
      unitRef="usd">646258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61d9a9c176034c01bafbe635f0ba6f6a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtOC0xLTEtMjQ1NDM_4147a97e-0cef-4c82-9c23-eaac2378c646"
      unitRef="usd">-304684000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad3589afc968435cb10d5cb10bf4738a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMTAtMS0xLTI0NTQz_cd50538e-0edc-4df4-bc1a-3a8f594f6965"
      unitRef="usd">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjQtMTItMS0xLTI0NTQz_aa14aeaa-c923-4a2b-9a01-b87f8c4b54f2"
      unitRef="usd">341612000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3fea2d8c84be4bf68ebf457a8a6c2b3f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtMi0xLTEtMjQ1NDM_d459284c-dd1e-4fcc-bb7c-60c31700f712"
      unitRef="shares">474376</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtNi0xLTEtMjQ1NDM_9bcd2809-62b0-4935-817a-496b008d840f"
      unitRef="usd">8943000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjUtMTItMS0xLTI0NTQz_fac78723-4c6c-4f71-b46e-4ee906b22baf"
      unitRef="usd">8943000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjctNi0xLTEtMjQ1NDM_2f5230c2-e762-49e4-81fe-82438d1476af"
      unitRef="usd">25853000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjctMTItMS0xLTI0NTQz_d897fdf2-16f7-421c-958b-a6195001dc3b"
      unitRef="usd">25853000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic886e29bea9a4187b9294970cfa62044_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjgtNi0xLTEtMjQ1NDM_2e640453-e0f0-4ac6-8a1a-6ad479d5c6b6"
      unitRef="usd">56246000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMjgtMTItMS0xLTI0NTQz_13fd9c15-331f-4afe-96ad-1f5d71668740"
      unitRef="usd">56246000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie425bc192eea43c4998ce9d1e84e53a4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzAtOC0xLTEtMjQ1NDM_294a6968-d3bc-4e08-b454-30aa59bcd6d5"
      unitRef="usd">-101361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzAtMTItMS0xLTI0NTQz_c43b54f4-33a1-445a-9c46-393a366f40a1"
      unitRef="usd">-101361000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3fa6df92e00f41ecb73a3d3d2c300e65_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzEtMTAtMS0xLTI0NTQz_e9e79756-b8da-4906-98f1-f92833e1238d"
      unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzEtMTItMS0xLTI0NTQz_d1a0d140-cc1a-42ef-93d3-37cb236628e9"
      unitRef="usd">-72000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i08b094e744ff4732b19b6fd8fa91c517_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMi0xLTEtMjQ1NDM_cf44f272-03b6-4ce9-b8d3-baf3bce8332b"
      unitRef="shares">29493726</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i08b094e744ff4732b19b6fd8fa91c517_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItNC0xLTEtMjQ1NDM_29e7d03f-5aea-4b33-8b34-2a81ee8988f3"
      unitRef="usd">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97a474771fc24576ab925990fae0b21d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItNi0xLTEtMjQ1NDM_278ac426-a1b7-40d5-9486-f9e2d39609e5"
      unitRef="usd">685594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81c8908741ec4840961679280bd8d5d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItOC0xLTEtMjQ1NDM_70f623f0-605b-4376-a0e6-15413ab1d774"
      unitRef="usd">-406045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie322229942454b178e796984276627cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMTAtMS0xLTI0NTQz_8f3c9aea-a22f-4baf-9cd5-830fcaa04380"
      unitRef="usd">-61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83Ni9mcmFnOmM1NGY1ZjFmYmY2NzQzMzBiZTU0MTQ4NmI4YmU3NDk0L3RhYmxlOjgyNGYzYmQ3MjUzZTRlOTlhNzM1YzEyMjM3YzZkZDQyL3RhYmxlcmFuZ2U6ODI0ZjNiZDcyNTNlNGU5OWE3MzVjMTIyMzdjNmRkNDJfMzItMTItMS0xLTI0NTQz_31536131-31e3-451e-99c3-a44cdb2b0002"
      unitRef="usd">279515000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy0xLTEtMS0yNDU0Mw_8e14c783-3843-4997-860f-37d75bc6fe39"
      unitRef="usd">-101361000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy0zLTEtMS0yNDU0Mw_2aadc314-d90d-4873-b722-f470b1b10227"
      unitRef="usd">-43830000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMy01LTEtMS0yNDU0Mw_e1eaae2f-ef0a-4c3c-9a50-8b3cc05bd067"
      unitRef="usd">-54568000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS0xLTEtMS0yNDU0Mw_34b32dc5-a2ec-4ca8-9248-6ba3c557c03e"
      unitRef="usd">9842000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS0zLTEtMS0yNDU0Mw_8fd7a538-c958-4a75-bf40-385ecce241f7"
      unitRef="usd">6900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNS01LTEtMS0yNDU0Mw_81ee14ec-e36d-4580-9f85-9fc9adcc3271"
      unitRef="usd">3445000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi0xLTEtMS0yNDU0Mw_42d8609e-d21e-4162-af3c-927aae59e3cd"
      unitRef="usd">54527000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi0zLTEtMS0yNDU0Mw_fbb1d295-0f6d-4add-b4bd-5114f69ab40a"
      unitRef="usd">41515000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNi01LTEtMS0yNDU0Mw_f76da336-ead9-44ce-8bb6-a1b2bd6c202a"
      unitRef="usd">26241000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy0xLTEtMS0yNDU0Mw_9af54dda-487a-40d6-8aeb-6910d77d762e"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy0zLTEtMS0yNDU0Mw_5808702d-dbe9-41dc-ae6f-5e0795199b3c"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNy01LTEtMS0yNDU0Mw_1f6059dd-da93-4319-8c1b-93c2c92af4a3"
      unitRef="usd">37000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC0xLTEtMS0yNDU0Mw_f88c8e2e-786f-474c-82d5-1f7bbd0bee90"
      unitRef="usd">-1641000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC0zLTEtMS0yNDU0Mw_ab2b9d0d-1ca9-4b30-acf3-5bf4bac04980"
      unitRef="usd">-430000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfOC01LTEtMS0yNDU0Mw_f7e4b7a5-d71e-4219-9a6d-456b7671b04e"
      unitRef="usd">884000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <irtc:ProvisionForBadDebtAndContractualAllowance
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtMS0xLTEtMjQ1NDM_ee2f933c-c19c-4c9c-ba22-e06f910545b2"
      unitRef="usd">37074000</irtc:ProvisionForBadDebtAndContractualAllowance>
    <irtc:ProvisionForBadDebtAndContractualAllowance
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtMy0xLTEtMjQ1NDM_2ea8201f-d73e-4e5b-8b3d-8ca2cd70eeb3"
      unitRef="usd">31431000</irtc:ProvisionForBadDebtAndContractualAllowance>
    <irtc:ProvisionForBadDebtAndContractualAllowance
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTAtNS0xLTEtMjQ1NDM_96d812be-f510-4eb6-a4d4-a94362d8eac4"
      unitRef="usd">24647000</irtc:ProvisionForBadDebtAndContractualAllowance>
    <irtc:OperatingLeaseRightOfUseAssetsAmortization
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtMS0xLTEtMjQ1NDM_3792a153-1c9f-4270-b264-d33f56f59c4f"
      unitRef="usd">6752000</irtc:OperatingLeaseRightOfUseAssetsAmortization>
    <irtc:OperatingLeaseRightOfUseAssetsAmortization
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtMy0xLTEtMjQ1NDM_5124839e-7ebe-4042-a215-3e15ac02b76c"
      unitRef="usd">6030000</irtc:OperatingLeaseRightOfUseAssetsAmortization>
    <irtc:OperatingLeaseRightOfUseAssetsAmortization
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTQtNS0xLTEtMjQ1NDM_3205e3ff-0551-40c1-8c42-d47365315bcc"
      unitRef="usd">8953000</irtc:OperatingLeaseRightOfUseAssetsAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtMS0xLTEtMjQ1NDM_304864e9-bb67-4311-b8b1-0facd4d8a861"
      unitRef="usd">53572000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtMy0xLTEtMjQ1NDM_1541221e-705c-402f-b1e4-1214bf04a82d"
      unitRef="usd">37957000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTYtNS0xLTEtMjQ1NDM_1b87e5de-5e4b-4f6c-b586-f551b9b29135"
      unitRef="usd">28725000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctMS0xLTEtMjQ1NDM_f1165e69-18d0-448f-aab4-94a143773826"
      unitRef="usd">4960000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctMy0xLTEtMjQ1NDM_28817909-1ff4-4f33-aeb5-68374fceef38"
      unitRef="usd">1389000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTctNS0xLTEtMjQ1NDM_f7787f2b-3598-4bfc-b0ed-8b06c746f375"
      unitRef="usd">1974000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtMS0xLTEtMjQ1NDM_2364a498-baf2-40a6-a9a0-41a4149b9f14"
      unitRef="usd">2329000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtMy0xLTEtMjQ1NDM_def2e3e7-8ad6-46e0-a229-372140da1240"
      unitRef="usd">3027000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTgtNS0xLTEtMjQ1NDM_8125257e-faf4-4276-a785-7d1f3483072e"
      unitRef="usd">696000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktMS0xLTEtMjQ1NDM_b9f618f6-3273-44cf-b251-543584e35d07"
      unitRef="usd">1831000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktMy0xLTEtMjQ1NDM_3e8bf22a-ce76-4f3c-aac7-55eee9a70a2d"
      unitRef="usd">6149000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMTktNS0xLTEtMjQ1NDM_b1f2ce0c-3a22-4a14-ac9c-534ce959d083"
      unitRef="usd">4732000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtMS0xLTEtMjQ1NDM_dcf091b6-cb31-4763-a7c8-8d37e70c0599"
      unitRef="usd">6135000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtMy0xLTEtMjQ1NDM_a158dcf9-2990-4d94-8eac-c31bd76c0b0c"
      unitRef="usd">-3881000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjAtNS0xLTEtMjQ1NDM_777b9b1c-dcbe-4578-8069-084edfd43b04"
      unitRef="usd">5604000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtMS0xLTEtMjQ1NDM_87038775-681a-4b61-868c-70a5966753a0"
      unitRef="usd">7946000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtMy0xLTEtMjQ1NDM_5c1b934e-bcd2-479d-ae6f-cc4481933b77"
      unitRef="usd">1308000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjEtNS0xLTEtMjQ1NDM_7725ac91-ab07-427f-a05e-c8b272875680"
      unitRef="usd">6002000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtMS0xLTEtMjQ1NDM_2bb50f09-a69f-4777-84dd-dee2b76a2496"
      unitRef="usd">2119000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtMy0xLTEtMjQ1NDM_410ca1e2-16bc-4536-9b9e-6c4ac54b7f9f"
      unitRef="usd">-321000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjMtNS0xLTEtMjQ1NDM_48cc666c-13fa-4775-8d02-5ba5635fc2ce"
      unitRef="usd">28000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <irtc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtMS0xLTEtMjQ1NDM_dd7659c0-8a96-4918-b6ca-dc5f1c06ac9b"
      unitRef="usd">264000</irtc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <irtc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtMy0xLTEtMjQ1NDM_fe4b1646-b462-4119-8e8b-f909729934bb"
      unitRef="usd">-4819000</irtc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <irtc:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjQtNS0xLTEtMjQ1NDM_910000db-4e70-4542-aefc-afbaade7ae06"
      unitRef="usd">-5241000</irtc:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtMS0xLTEtMjQ1NDM_6bedb807-c9f8-44a2-b920-84c1911ac978"
      unitRef="usd">-37753000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtMy0xLTEtMjQ1NDM_e5bcae75-b9d6-4e79-a32e-2005bdabf461"
      unitRef="usd">-13759000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjUtNS0xLTEtMjQ1NDM_c3457e1c-d678-47bf-99f9-7a55fbc36c7d"
      unitRef="usd">-21863000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctMS0xLTEtMjQ1NDM_51234ae4-0d87-42f5-a2e6-7c7dfad3c534"
      unitRef="usd">28067000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctMy0xLTEtMjQ1NDM_9101771f-8e5d-4e1d-8c07-b3a6ef3e78a8"
      unitRef="usd">13551000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjctNS0xLTEtMjQ1NDM_3d9e6ee2-29d0-460e-9bfa-b39ff4ea07c4"
      unitRef="usd">20457000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtMS0xLTEtMjQ1NDM_4da9dd5f-7571-450c-9285-76c7af2899d9"
      unitRef="usd">122184000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtMy0xLTEtMjQ1NDM_e925b568-9dbf-42da-b271-9562409232ff"
      unitRef="usd">277510000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjgtNS0xLTEtMjQ1NDM_0c865b6b-115b-4609-b161-ba876196e022"
      unitRef="usd">165915000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktMS0xLTEtMjQ1NDM_559e1e98-902e-4173-9c0c-d839d31f30e9"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktMy0xLTEtMjQ1NDM_67e5f314-4a37-4aed-b254-22f8e2d7369f"
      unitRef="usd">14525000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMjktNS0xLTEtMjQ1NDM_f537ce2f-365b-4e50-b2ca-8b19581a1827"
      unitRef="usd">1498000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtMS0xLTEtMjQ1NDM_3dead6a5-f7b5-4893-ae71-723c250579ce"
      unitRef="usd">255515000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtMy0xLTEtMjQ1NDM_b547d68b-4758-4d8f-9d4a-b92d62dced1b"
      unitRef="usd">144145000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzAtNS0xLTEtMjQ1NDM_ef4b0b28-28b2-447e-9034-61830d2151a0"
      unitRef="usd">95600000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtMS0xLTEtMjQ1NDM_e17e42c5-8c1d-46af-9260-6c52bfc386f9"
      unitRef="usd">105264000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtMy0xLTEtMjQ1NDM_6862917a-ee62-4954-845b-4a4e2cbfac43"
      unitRef="usd">-132391000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzEtNS0xLTEtMjQ1NDM_b4a23542-ca1a-456f-af4d-0a58ac597de7"
      unitRef="usd">-89274000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtMS0xLTEtMjQ1NDM_62c1c2e5-323c-49b3-a14f-10da35517fe1"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtMy0xLTEtMjQ1NDM_4b782d95-0bf4-4880-83c1-b1d1a0b23ba3"
      unitRef="usd">206025000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzMtNS0xLTEtMjQ1NDM_7ba316f9-f7ac-4c5e-b069-a6877420aa39"
      unitRef="usd">107369000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtMS0xLTEtMjQ1NDM_a0d93c4c-9027-484a-b641-39273f39e056"
      unitRef="usd">8943000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtMy0xLTEtMjQ1NDM_364c1783-e2d1-4c0c-8e54-8efc6c983847"
      unitRef="usd">20244000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzQtNS0xLTEtMjQ1NDM_18b873a3-4645-4adb-b30b-0b39ef3f6fd5"
      unitRef="usd">9495000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtMS0xLTEtMjQ1NDM_34edca93-c116-4890-8866-a67a893abda0"
      unitRef="usd">25853000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtMy0xLTEtMjQ1NDM_dd0b8a87-0a9b-4644-8e91-dbcdb70ed013"
      unitRef="usd">10009000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzUtNS0xLTEtMjQ1NDM_2e5ffad6-2844-4fc3-a3d6-8fdb9e5cd8c2"
      unitRef="usd">5288000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctMS0xLTEtMjQ1NDM_768c5586-b4bd-41a6-a592-ab88ff8f0913"
      unitRef="usd">11667000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctMy0xLTEtMjQ1NDM_10432393-90a9-48ff-ba83-50aa03ae83d6"
      unitRef="usd">1944000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfMzctNS0xLTEtMjQ1NDM_7c46117e-85aa-48e3-a3ac-fa58da9eb2ff"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtMS0xLTEtMjQ1NDM_7d94cbea-cea9-4f6b-afac-bb46a6e429cd"
      unitRef="usd">-28577000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtMy0xLTEtMjQ1NDM_f57146db-7e7f-420c-9191-b0a18201aa03"
      unitRef="usd">214316000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDAtNS0xLTEtMjQ1NDM_803f4956-1619-444a-b356-bba67fa47012"
      unitRef="usd">111576000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtMS0xLTEtMjQ1NDM_720696df-c4dc-4f2f-aed2-a53815dd290e"
      unitRef="usd">38934000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtMy0xLTEtMjQ1NDM_7707e6c6-bb36-48d2-a871-c170c350f696"
      unitRef="usd">68166000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDEtNS0xLTEtMjQ1NDM_2ba06211-4a69-4453-9c6e-b66a3f4adf1f"
      unitRef="usd">439000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItMS0xLTEtMjQ1NDM_a69fa9c2-bfce-4240-b54a-57a508253388"
      unitRef="usd">88628000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItMy0xLTEtMjQ1NDM_2b37f637-fb14-4699-96de-950e621335d5"
      unitRef="usd">20462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDItNS0xLTEtMjQ1NDM_f1fd96a8-39d3-4f7e-acbc-1c86de428ba4"
      unitRef="usd">20023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtMS0xLTEtMjQ1NDM_a9dac06e-d8d4-4c55-b895-e266f43c45b0"
      unitRef="usd">127562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtMy0xLTEtMjQ1NDM_7209eadc-5fc5-4fc8-b1b4-9f450ec9fb03"
      unitRef="usd">88628000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDMtNS0xLTEtMjQ1NDM_d8d53480-e46c-42a3-9e54-cfd77934a220"
      unitRef="usd">20462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtMS0xLTEtMjQ1NDM_728a7050-d18e-4602-9010-34aaa0b76015"
      unitRef="usd">1194000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtMy0xLTEtMjQ1NDM_0269ae0c-7edb-44b1-9503-b37f457a6437"
      unitRef="usd">1502000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDUtNS0xLTEtMjQ1NDM_7cde4549-5f38-4fdd-8245-2a4aa235bcee"
      unitRef="usd">1644000</us-gaap:InterestPaidNet>
    <irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctMS0xLTEtMjQ1NDM_dd088202-79c8-4c73-88f5-73f12ea83f8e"
      unitRef="usd">9000</irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctMy0xLTEtMjQ1NDM_207df3d6-8a44-4e8c-a5be-93d0e24a4dc8"
      unitRef="usd">3000</irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDctNS0xLTEtMjQ1NDM_73353609-2c09-4ab2-8e5f-bb1cb314a98b"
      unitRef="usd">293000</irtc:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities>
    <irtc:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtMS0xLTEtMjQ1NDM_911616f3-4083-4e13-98fe-ac7cab6d3f30"
      unitRef="usd">0</irtc:StockIssuanceCostsIncurredButNotYetPaid>
    <irtc:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtMy0xLTEtMjQ1NDM_5ddd15b3-4dea-4ceb-9036-93761903b1c9"
      unitRef="usd">0</irtc:StockIssuanceCostsIncurredButNotYetPaid>
    <irtc:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDgtNS0xLTEtMjQ1NDM_47d9b97e-11fc-4c71-8456-3c07666a4da3"
      unitRef="usd">77000</irtc:StockIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktMS0xLTEtMjQ1NDM_ecf3aa5a-1685-4bf9-ab43-1d08b1cd0c7c"
      unitRef="usd">6625000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktMy0xLTEtMjQ1NDM_c822057c-fbb5-43dc-b3d9-60e41f35c83d"
      unitRef="usd">621000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNDktNS0xLTEtMjQ1NDM_28612ebd-701d-43df-9c23-2155bd85445f"
      unitRef="usd">88860000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtMS0xLTEtMjQ1NDM_37501099-23a7-4d68-9ff9-cb621f941b5c"
      unitRef="usd">3593000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtMy0xLTEtMjQ1NDM_1e8a0276-1fba-4a87-a5ea-e82f09f13a93"
      unitRef="usd">1129000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV83OS9mcmFnOjRmNDQ2MDlkMjJjMDQ0OTY4N2Y4MDI5ZmI2ZDU4OTc1L3RhYmxlOjIyYmEwNDIwYjlkMzRkMjE5NTA0MjNlN2I1NjMyZGIwL3RhYmxlcmFuZ2U6MjJiYTA0MjBiOWQzNGQyMTk1MDQyM2U3YjU2MzJkYjBfNTAtNS0xLTEtMjQ1NDM_516abb96-81cb-4ac1-8812-0473cfa639e8"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMzUxOA_3ae59437-ffcc-47ec-8233-aa97566e7d11">Organization and Description of Business&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;iRhythm Technologies, Inc. (the &#x201c;Company&#x201d;) was incorporated in the state of Delaware in September 2006. The Company is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and deep-learning capabilities. The Company began commercial operations in the United States in 2009 following clearance by the U.S. Food and Drug Administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is headquartered in San Francisco, California, which also serves as a clinical center. The Company has additional clinical centers in Lincolnshire, Illinois and Houston, Texas and a manufacturing facility in Cypress, California. In March 2016, the Company formed a wholly-owned subsidiary in the United Kingdom. Additionally, in June 2021, the Company formed a wholly-owned subsidiary in Singapore. The Company manages its operations as a single operating segment. Substantially all of the Company&#x2019;s assets are maintained in the United States. The Company derives substantially all of its revenue from the provision of services to customers in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 10, 2019, the Company issued and sold an aggregate of 1,575,342 shares (the "2019 Shares") of common stock, in a public offering at a price of $73.00 per share. The 2019 Shares included the full exercise of the underwriters&#x2019; option to purchase an additional 205,479 shares of common stock. Total proceeds received from the offering were $107.3&#160;million, after deducting discounts and issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 21, 2020, the Company issued and sold an aggregate of 1,257,142 shares (the "Shares") of common stock, in a public offering at a price of $175.00 per share. The Shares included the full exercise of the underwriters&#x2019; option to purchase an additional 163,975 shares of common stock. Total proceeds received from the offering were $206.8 million, after deducting discounts and issuance costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTEzOA_4374321e-8403-43e8-9b96-8680960bd762"
      unitRef="shares">1575342</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1486d77445c34613a8e3383fbbdb5025_I20190910"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTIyMA_b51cf04a-5190-41a7-9d7b-f493adabe364"
      unitRef="usdPerShare">73.00</us-gaap:SaleOfStockPricePerShare>
    <irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock
      contextRef="i1486d77445c34613a8e3383fbbdb5025_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTMzMQ_c982f4f3-0156-45f5-9c75-fa30f8b64b57"
      unitRef="shares">205479</irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i798de6acec2e4b729b30d989e6844c51_D20190910-20190910"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTQwNQ_bfc4f3e5-e78b-42cb-a530-e9666e3b746b"
      unitRef="usd">107300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTUyMA_5c877827-9cf7-4235-9187-8d66492b9268"
      unitRef="shares">1257142</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4e80ace037a44aa1bc75148d38174bb5_I20200821"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTU5Nw_37dc0c94-1822-46b4-9f4c-b6e534cdc857"
      unitRef="usdPerShare">175.00</us-gaap:SaleOfStockPricePerShare>
    <irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock
      contextRef="i4e80ace037a44aa1bc75148d38174bb5_I20200821"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTcwMw_a7693c38-c9cd-4806-ba3b-4a0bbdd4db51"
      unitRef="shares">163975</irtc:UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84NS9mcmFnOjkyNDNiYzVjMzk1OTQ1NWNhOTBhNWY3MzE2ZDYwYWE5L3RleHRyZWdpb246OTI0M2JjNWMzOTU5NDU1Y2E5MGE1ZjczMTZkNjBhYTlfMTc3Nw_d6d3685a-dea9-4dca-96d2-be9c01dd1b1b"
      unitRef="usd">206800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTc_72f98496-a636-479b-b4b2-e1263227eabb">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of iRhythm Technologies, Inc. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The financial statements of the Company&#x2019;s subsidiary use the U.S. dollar as the functional currency. For all non-functional currency balances, the remeasurement of such balances to functional currency results in a foreign exchange transaction gain or loss, which is recorded in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the COVID-19 pandemic, the Company has experienced significant business disruptions, restrictions on its ability to travel, reduction in access to customers due to diverted resources at hospitals, slower response times from payors who are also facing business interruptions, and shortened business hours as governments institute prolonged shelter-in-place and/or self-quarantine mandates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, Company personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where the Company's headquarters is located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. The Company is also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the Company has instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While the Company has continued to deliver its Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;measures at the Company's facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminishe&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, the Company has adapted its service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the six months ended June 30, 2021, the Company experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, the Company experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions within the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could meaningfully impact the volume of our patient registrations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is continuously reviewing its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. The Company believes it will have adequate liquidity over the next 12 months to operate its business and to meet its cash requirements. As of December 31, 2021, the Company is in compliance with its debt covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on liquidity, capital resources, supply chain, operations and business and those of the third parties on which the Company relies, and could worsen over time. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the COVID-19 pandemic or treat its impact, among others. The full extent of potential delays or impacts on the business, financial condition, cash flows and results of operations remains unknown. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing the Company&#x2019;s ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact short-term and long-term liquidity and the ability to operate on a timely basis, or at all.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Reimbursement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for the Zio service, which would significantly harm the Company. Government and other third-party payors require the Company to report the service for which it is seeking reimbursement by using a Current Procedural Terminology (&#x201c;CPT&#x201d;), code-set maintained by the American Medical Association (&#x201c;AMA&#x201d;). For Zio XT, the Company had historically utilized temporary CPT codes (or Category III CPT codes) used for newly introduced technologies and specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and Centers for Medicare and Medicaid (&#x201c;CMS&#x201d;). On October 25, 2019, the AMA&#x2019;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. In November 2021, CMS published the Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#x201c;2022 Final Rule&#x201d;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Company&#x2019;s Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#x201c;MAC&#x201d; or &#x201c;MACs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#x201c;NCD&#x201d;) by CMS, or at the local level through a local coverage determination (&#x201c;LCD&#x201d;), by one or more of the regional Medicare Administrative Contractors (&#x201c;MACs&#x201d;) who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#x201c;IDTF&#x201d;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;If the published Medicare reimbursement rates are not adequate to support our cost structure, or we are unable to reduce our overall cost structure, the Company may be unable to provide the Zio service or would experience a significant loss of revenue, either of which would have a material adverse effect on our cash flows, results of operations, and financial condition.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, the Company will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if the Company is unsuccessful in improving the Medicare rates, the Company believes that commercial rates may begin to be more negatively impacted next year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (&#x201c;PCBAs&#x201d;), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have maturities less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are carried at fair value based upon quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company periodically assesses its portfolio of debt investments for impairment. For debt securities in an unrealized loss position, this assessment first takes into account the intent to sell, or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value through interest and other, net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses on available-for-sale debt securities are recognized in other income, net in the condensed consolidated statements of operations, and any remaining unrealized losses, net of taxes, are reported as a component of accumulated other comprehensive loss. The Company did not recognize any credit losses on its available-for-sale securities during the year ended December 31, 2021 and there were no impairment charges for unrealized losses in the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of available-for-sale securities sold is based on the specific-identification method and realized gains and losses are included in earnings. Amortization of premiums and accretion of discounts are reported as a component of other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable includes amounts due to the Company from healthcare institutions, third-party payors, and government payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts and contractual allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on its assessment of the collectability of customer accounts and recognizes the provision as a component of selling, general and administrative expenses. The Company records a provision for contractual allowances based on the estimated differences between contracted amounts and expected collection rates. Such provisions are based on the Company's historical experience and are reported as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly reviews the allowances by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to administrative delays with payors and a combination of negotiations with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, inherent uncertainty caused by the longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the allowance for doubtful accounts (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: adoption of ASC 326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: provision for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: write-offs, net of recoveries and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the contractual allowance (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: allowance for contractual adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: contractual adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company&#x2019;s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;), accounted for approximately 14%, 27% and 27% of the Company&#x2019;s revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. CMS accounted for 8% and 20% of accounts receivable as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Inflationary Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously monitors the effects of inflationary factors, such as increases in cost of goods sold and selling and operating expenses, which may adversely affect its results of operations. Specifically, the Company may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages paid to its employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict the Company's ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. The Company's inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supply Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio monitor and the adhesive that binds the Zio monitor to a patient&#x2019;s body. These components and materials are critical, and there could be a considerable delay in finding alternative sources of supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A global semiconductor supply shortage is having wide-ranging effects across multiple industries. The supply shortage has impacted multiple suppliers that provide the printed circuit board assemblies to the Company. The semiconductor supply shortage may have an impact on the Company until global supply is sufficient for global demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Supply Chain Constraints&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Economies worldwide have also seen other indirect COVID-19 pandemic related disruptions including supply chain impacts, material inflation, and labor constraints in certain markets and geographies. Such economic disruption has had an adverse effect on the Company's business environment as increased lead times and component shortages have resulted in higher inventory costs. While the Company has increased inventory safety stock levels to help mitigate the delays and disruptions in supply, the Company cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not further impact its supply chain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory owned by the Company is valued at cost, on the first in, first out (&#x201c;FIFO&#x201d;) basis, or the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand. The Company also records market value based write-downs on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Internal-Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs related to internal-use software during the application development stage. Costs related to planning and post implementation activities are expensed as incurred. Capitalized internal-use software is amortized, and recognized as cost of revenue, on a straight-line basis over the estimated useful life, which is up to five years. The Company evaluates the useful lives of these assets on an annual basis, and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Capitalized internal-use software costs are classified as a component of property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible net assets acquired in business combinations. Goodwill is tested for impairment on an annual basis and at any other time if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Such events or circumstances may include significant adverse changes in the general business climate, among other things. The impairment test is performed by determining the enterprise fair value of the Company, which is primarily based on the Company&#x2019;s market capitalization. If the Company&#x2019;s carrying value, as a one reporting unit entity, is less than its fair value, then the fair value is allocated to all of its assets and liabilities (including any unrecognized intangible assets) as if the fair value was the purchase price to acquire the Company. The excess of the fair value over the amounts assigned to the Company&#x2019;s assets and liabilities is the implied fair value of the goodwill. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. The Company did not record any charges related to goodwill impairment in any of the periods presented in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company annually reviews long-lived assets for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. To date, there have been no such impairments of long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects this decision will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022. Refer to Note 13. Subsequent Events for further details.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses Printed Circuit Board Assemblies (&#x201c;PCBAs&#x201d;), in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the ZIO AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT or Zio AT monitor, or a wireless gateway is used with a Zio AT monitor a portion of the cost of the PCBA and/or gateway is recorded as a cost of revenue. The PCBAs are recorded as other assets and were $13.9 million and $12.6 million as of December&#160;31, 2021 and 2020, respectively. The Company has based its estimates of how many times a PCBA can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. The Company periodically evaluates the use estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents all changes in stockholders&#x2019; equity during the period from non-owner sources. The Company&#x2019;s unrealized gains and losses on available-for-sale securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s revenue is generated primarily from the provision of its cardiac rhythm monitoring service, the Zio XT service. The Zio XT is a cardiac rhythm monitoring service that has a patient wear period of up to 14 days and is billable when the monitoring reports are delivered to the healthcare provider, which is also when the service is complete and the Company recognizes revenue. The time from when the patient has the Zio XT device applied to the time the report is posted is generally around 25 days. The Company has concluded that the Zio XT service is one performance obligation on the basis that the customer cannot benefit from each component of the service on its own or together with other resources that are readily available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what the Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating patients that require more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria. The Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report with two performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes as revenue the amount of consideration to which it expects to be entitled in exchange for performing the service. The consideration the Company is entitled to varies by portfolio, as further defined below, and includes estimates that require significant judgment by management. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, will pay the Company for some or all of the service on the patient&#x2019;s behalf. Separate contractual arrangements exist between the Company and third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A small portion of the Company&#x2019;s transactions are covered by third-party payors with whom there is neither a contractual agreement nor an established amount that the third-party payor will pay. In determining the collectability and transaction price for its service, the Company considers factors such as insurance claims which are adjudicated as allowable under the applicable policy and payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments. Certain of these factors are forms of variable consideration which are only included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Contracted third-party payors &#x2013; The Company has contracts with negotiated prices for services provided to patients with commercial healthcare insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;CMS &#x2013; The Company has received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant CPT code rates for the services rendered to the patient covered by CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Non-contracted third-party payors &#x2013; Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for determining revenue recognition is based on factors including an average of the Company&#x2019;s historical collection experience for its non-contracted services. This rate is reviewed at least quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Healthcare institutions &#x2013; Healthcare institutions are typically hospitals or physician practices in which the Company has negotiated amounts for its monitoring services, including certain governmental agencies such as the Veterans Administration and Department of Defense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition whereby services provided under each of the above payor types form a separate portfolio. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, the Company has concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For contracted and CMS portfolios, the Company recognizes revenue, net of contractual allowances, and recognizes an allowance for doubtful accounts for uncollectible patient accounts receivable. The transaction price is determined based on negotiated rates, and the Company has historical experience of collecting substantially all of these contracted rates. These contracts also impose a number of obligations regarding billing and other matters, and the Company&#x2019;s noncompliance with a material term of such contracts may result in a denial of the claim. The Company accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price recognized as revenue. The Company estimates the denied claims which require management judgment. The estimated denied claims are based on historical information and judgement includes the historical period utilized. The Company monitors the estimated denied claims against the latest available information, and subsequent changes to the estimated denied claims are recorded as an adjustment to revenue in the periods during which such changes occur. Delays in claims submissions could lead to an increase in denials if we miss the payors&#x2019; filing deadlines and could result in a reduction in the Company&#x2019;s receipt of payments. Historical cash collection indicates that it is probable that substantially all of the transaction price, less the estimate of denied claims, will be received. Contracted payors may require that we bill patient co-payments and deductibles and from time to time we may not be able to collect such amounts due to credit risk. The Company provides for estimates of uncollectible patient accounts receivable, based upon historical experience where judgment includes the historical period utilized, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to a combination of negotiations with payors and administrative delays with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021. For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For non-contracted portfolios, the Company is providing an implicit price concession due to the lack of a contracted rate with the underlying payor, the result of which requires the Company to estimate the transaction price based on historical cash collections utilizing the expected value method. All subsequent adjustments to the transaction price are recorded as an adjustment to revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For healthcare institutions, the transaction price is determined based on negotiated rates, and the Company has historical experience collecting substantially all of these contracted rates. Historical cash collection indicates that it is probable that substantially all of the transaction price will be received. As such, the Company is not providing an implicit price concession but, rather, has chosen to accept the risk of default, and any subsequent uncollected amounts are recorded as bad debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts with customers by payor type. The Company believes these categories aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. Disaggregated revenue by payor type and major service line for the years ended December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracted third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contracted third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centers for Medicare &amp;amp; Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare institutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requires an entity to present a revenue contract as a contract liability when the Company has an obligation to transfer goods or services to a customer for which the Company has received consideration from the customer, or an amount of consideration from the customer is due and unconditional (whichever is earlier).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s customers pay the Company directly for the Zio XT service upon shipment of devices. Such advance payments are contract liabilities and are recorded as deferred revenue on the Consolidated Balance Sheets and revenue is recognized when reports are delivered to the healthcare provider. During the year ended December&#160;31, 2021, $0.9 million relating to the contract liability balance at the beginning of 2021 was recognized as revenue. Total revenue recognized during the year ended December 30, 2020 that was included in the contract liability balance at the beginning of 2020 was $1.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 340, the incremental costs of obtaining a contract with a customer are recognized as an asset. Incremental costs of obtaining a contract are those costs that an entity incurs to obtain a contract with a customer that it would not have incurred if the contract had not been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current commission programs are considered incremental. However, as a practical expedient, ASC 340 permits the Company to immediately expense contract acquisition costs, as the asset that would have resulted from capitalizing these costs will be amortized in one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of revenue includes direct labor, material costs, overhead, data analysis, customer care, equipment and infrastructure expenses, amortization of internal-use software, and shipping and handling. Direct labor includes payroll and personnel-related costs involved in manufacturing. Material costs include both the disposable costs of the device and amortization of the PCBAs. Each time the PCBA is used in a wearable Zio XT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s research and development costs are expensed as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, laboratory supplies, consulting costs and overhead charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognize taxes on Global Intangible Low-Taxed Income as a current period expense when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. The fair value of market condition awards is determined using the Monte-Carlo option pricing model and the fair value of stock options is determined using the Black-Scholes option pricing model. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#x2019;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For restricted stock, the compensation cost for these awards is based on the closing price of the Company&#x2019;s common stock on the date of grant, and recognized as compensation expense on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on the estimated fair value of the options on the date of grant, net of estimated forfeitures. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effect of potentially dilutive securities are anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Identifying a lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both of the following terms:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The right to obtain substantially all of the economic benefits from use of the identified asset; and&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The right to direct the use of the identified asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Discount rate for leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the rate implicit in the lease is not readily determinable for our operating leases, the Company generally uses an incremental borrowing rate based on information available at the commencement date such as a synthetic credit rating and current cost of borrowing to determine the present value of future lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Lease term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term is generally the minimum noncancellable period of each lease. The Company does not include option periods in determining the right-of-use asset and operating lease liability at inception unless it is reasonably certain that the Company will exercise the option at inception or when a triggering event occurs. As of December&#160;31, 2021, no renewal options were included in the determination of lease terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Lease Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The San Francisco Lease is in the same building with the same landlord as the lease for the Company&#x2019;s prior headquarters in San Francisco (&#x201c;existing lease&#x201d;). Upon the commencement of the San Francisco Lease, the existing lease which had an original expiration date of February 2020, was modified to expire in September 2019 and accordingly the right-of-use asset and lease liability was remeasured as of the modification date.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTg_303fb8c0-5b43-4880-93e5-e1ea36942bf3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include the accounts of iRhythm Technologies, Inc. and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. The financial statements of the Company&#x2019;s subsidiary use the U.S. dollar as the functional currency. For all non-functional currency balances, the remeasurement of such balances to functional currency results in a foreign exchange transaction gain or loss, which is recorded in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <irtc:RiskAndUncertaintiesPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTE_75bcf2ab-6957-4071-a25a-71d4b95716aa">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the COVID-19 pandemic, the Company has experienced significant business disruptions, restrictions on its ability to travel, reduction in access to customers due to diverted resources at hospitals, slower response times from payors who are also facing business interruptions, and shortened business hours as governments institute prolonged shelter-in-place and/or self-quarantine mandates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, Company personnel and personnel at third-party manufacturing facilities in the United States and other countries, and the availability or cost of materials, which could disrupt our supply chain and reduce margins. For instance, on or about March 16, 2020, the Health Officers for the counties of San Francisco (where the Company's headquarters is located), Santa Clara, San Mateo, Marin, Contra Costa and Alameda, where many employees are located, issued mandatory shelter-in-place orders and all employees transitioned to a remote work environment. The Company is also subject to orders in Southern California that temporarily shut down its manufacturing and distribution facilities in Cypress, California. For a limited number of employees who continue to support essential operations, including those at our manufacturing facilities, the Company has instituted protective equipment policies and, to the degree practical, social distancing measures to protect the safety of its employees. While the Company has continued to deliver its Zio service by operating with remote employees and essential employees on site, an extended implementation of these government mandates could further impact the Company's ability to effectively provide its Zio service, and could impede progress of all ongoing initiatives. Appropriate social distancing techniques and other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;measures at the Company's facilities have been implemented for the limited number of employees who have returned to work to support essential operations, and will not return until the risk to employee health has meaningfully diminishe&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;While hospital systems and healthcare facilities shift their focus and resources to treating COVID-19 patients and combating the spread of the coronavirus, the Company has adapted its service to meet the immediate needs of physicians, customers, and patients and significantly increased the utilization of its home enrollment service which allows patients to receive and wear the single-use Zio device without going to a healthcare facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Government mandates related to the COVID-19 pandemic have impacted, and are expected to continue to impact, payor processing times of our claims and appeals. This increase in response times may be due, in part, to staffing shortages at the payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the six months ended June 30, 2021, the Company experienced an increase in the level of Zio service patient registration. This increase may be due in part to re-opening of certain regions within the United States and increases in the vaccination status of patients and providers. During the six months ended December 31, 2021, the Company experienced a decrease in the level of Zio service patient registrations. This decrease may be due, in part, to staffing shortages at providers in certain regions within the United States. The status of provider capacity and resource prioritization, vaccination levels and other pandemic-related effects could meaningfully impact the volume of our patient registrations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is continuously reviewing its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. The Company believes it will have adequate liquidity over the next 12 months to operate its business and to meet its cash requirements. As of December 31, 2021, the Company is in compliance with its debt covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. This impact is having a material, adverse impact on liquidity, capital resources, supply chain, operations and business and those of the third parties on which the Company relies, and could worsen over time. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 pandemic and the actions to contain the COVID-19 pandemic or treat its impact, among others. The full extent of potential delays or impacts on the business, financial condition, cash flows and results of operations remains unknown. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing the Company&#x2019;s ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact short-term and long-term liquidity and the ability to operate on a timely basis, or at all.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Reimbursement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government payors may change their coverage and reimbursement policies, as well as payment amounts, in a way that would prevent or limit reimbursement for the Zio service, which would significantly harm the Company. Government and other third-party payors require the Company to report the service for which it is seeking reimbursement by using a Current Procedural Terminology (&#x201c;CPT&#x201d;), code-set maintained by the American Medical Association (&#x201c;AMA&#x201d;). For Zio XT, the Company had historically utilized temporary CPT codes (or Category III CPT codes) used for newly introduced technologies and specific to our category of diagnostic monitoring. The process to convert Category III CPT codes to Category I CPT codes is governed by the AMA and Centers for Medicare and Medicaid (&#x201c;CMS&#x201d;). On October 25, 2019, the AMA&#x2019;s CPT Editorial Panel established two new Category I CPT codes which are applicable to the Zio service and took effect on January 1, 2021. In November 2021, CMS published the Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#x201c;2022 Final Rule&#x201d;). In the Final Rule, CMS did not issue national pricing and continued carrier pricing for calendar year 2022 on Category I CPT codes 93241, 93243, 93245 and 93247 for extended external ECG monitoring, the relevant codes for the Company&#x2019;s Zio XT service. These codes were designated by CMS for contractor pricing in calendar 2022, which means that prices will be determined regionally by each Medicare Administrative Contractor (&#x201c;MAC&#x201d; or &#x201c;MACs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determinations of which products or services will be reimbursed under Medicare can be developed at the national level through a national coverage determination (&#x201c;NCD&#x201d;) by CMS, or at the local level through a local coverage determination (&#x201c;LCD&#x201d;), by one or more of the regional Medicare Administrative Contractors (&#x201c;MACs&#x201d;) who are private contractors that process and pay claims on behalf of CMS for different regions. In the absence of a specific NCD, as is the case with Zio XT historically and for Calendar Year 2022 following the Final Rule, the MAC with jurisdiction over a specific geographic region will have the discretion to make an LCD. The Company is seeking to establish LCD pricing with one or more MACs to establish pricing for 2022 and will be subject to LCD pricing until such time CMS establishes a NCD.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, Novitas Solutions, the MAC which covers the region where our Independent Diagnostic Testing Facility (&#x201c;IDTF&#x201d;) in Houston, Texas is located and where almost all of our Medicare services for Zio XT are processed, updated reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022. These rates were higher than the rates posted by Novitas in 2021, but continue to be significantly below our historical Medicare rates for our Zio XT service. We are continuing to negotiate with Novitas and other MACs to establish higher pricing for the Category I CPT Codes but can offer no assurances as to the timing or outcome of those discussions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;If the published Medicare reimbursement rates are not adequate to support our cost structure, or we are unable to reduce our overall cost structure, the Company may be unable to provide the Zio service or would experience a significant loss of revenue, either of which would have a material adverse effect on our cash flows, results of operations, and financial condition.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, a reduction in coverage by Medicare could cause some commercial third-party payors to implement similar reductions in their coverage or level of reimbursement of the Zio service. Given the evolving nature of the healthcare industry and on-going healthcare cost reforms, the Company will continue to be subject to changes in the level of Medicare coverage for its products, and unfavorable coverage determinations at the national or local level could adversely affect its results of operations. Although a large majority of commercial customers have re-contracted the Zio XT service since the establishment of the Category I codes on January 1, 2021 matching to pre-existing rates, if the Company is unsuccessful in improving the Medicare rates, the Company believes that commercial rates may begin to be more negatively impacted next year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company is unable to achieve a level of revenues adequate to support its cost structure, or is unable to reduce its overall cost structure, this would raise substantial doubts about the Company's ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Supply Chain Constraints&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Economies worldwide have also seen other indirect COVID-19 pandemic related disruptions including supply chain impacts, material inflation, and labor constraints in certain markets and geographies. Such economic disruption has had an adverse effect on the Company's business environment as increased lead times and component shortages have resulted in higher inventory costs. While the Company has increased inventory safety stock levels to help mitigate the delays and disruptions in supply, the Company cannot be certain that any prolonged, intensified or worsened effect from the COVID-19 pandemic would not further impact its supply chain.&lt;/span&gt;&lt;/div&gt;</irtc:RiskAndUncertaintiesPolicyPolicyTextBlock>
    <irtc:CostReimbursementRate
      contextRef="i64b979f3794644df876abe57a7d76980_I20220110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNzE0NjgyNTY2NDgxNg_25ad3b28-01a4-423f-b250-2a7f083b90ea"
      unitRef="usd">223</irtc:CostReimbursementRate>
    <irtc:CostReimbursementRate
      contextRef="i3706f468116148dbabf8b4fb4c6f96e7_I20220110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNzE0NjgyNTY2NDgyMg_755788d0-ed8e-47e2-b8f3-3eac43a24a6c"
      unitRef="usd">233</irtc:CostReimbursementRate>
    <us-gaap:UseOfEstimates
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTM_2289c83d-4b12-47eb-8221-5457677613f4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, contractual allowances, allowance for doubtful accounts, the useful lives of property and equipment, the recoverability of long-lived assets including the estimated usage of the printed circuit board assemblies (&#x201c;PCBAs&#x201d;), the incremental borrowing rate for operating leases, accounting for income taxes, and various inputs used in estimating stock-based compensation. Certain of these estimates are impacted by uncertainties surrounding COVID-19 such as revenue recognition, contractual allowances for revenue, allowance for doubtful accounts, and stock based compensation. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjY_f3cd9ee8-d1a5-4019-bdb1-6cff7563904a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, which include cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTQ_38998a43-203c-4857-8c92-e5ecd7735689">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDM_229d9da7-f42d-427e-9a8f-a894956f590a">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments consist of debt securities classified as available-for-sale and have maturities less than one year as of the balance sheet date. Long-term investments have maturities greater than one year as of the balance sheet date. All investments are carried at fair value based upon quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company periodically assesses its portfolio of debt investments for impairment. For debt securities in an unrealized loss position, this assessment first takes into account the intent to sell, or whether it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of these criteria are met, the debt security&#x2019;s amortized cost basis is written down to fair value through interest and other, net. For debt securities in an unrealized loss position that do not meet the aforementioned criteria, the Company assesses whether the decline in fair value has resulted from credit losses or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates expected credit losses by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. Expected credit losses on available-for-sale debt securities are recognized in other income, net in the condensed consolidated statements of operations, and any remaining unrealized losses, net of taxes, are reported as a component of accumulated other comprehensive loss. The Company did not recognize any credit losses on its available-for-sale securities during the year ended December 31, 2021 and there were no impairment charges for unrealized losses in the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of available-for-sale securities sold is based on the specific-identification method and realized gains and losses are included in earnings. Amortization of premiums and accretion of discounts are reported as a component of other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjE_d133852a-fdf5-4079-9576-24e84f642a68">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable includes amounts due to the Company from healthcare institutions, third-party payors, and government payors and their related patients, as a result of the Company's normal business activities. Accounts receivable is reported on the consolidated balance sheets net of an estimated allowance for doubtful accounts and contractual allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company establishes an allowance for doubtful accounts for estimated uncollectible receivables based on its assessment of the collectability of customer accounts and recognizes the provision as a component of selling, general and administrative expenses. The Company records a provision for contractual allowances based on the estimated differences between contracted amounts and expected collection rates. Such provisions are based on the Company's historical experience and are reported as a reduction of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly reviews the allowances by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to administrative delays with payors and a combination of negotiations with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, inherent uncertainty caused by the longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDg_c5210890-5e39-4fc9-adb5-7dcbe62f6595">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the allowance for doubtful accounts (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: adoption of ASC 326&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: provision for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: write-offs, net of recoveries and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi0xLTEtMS0yNDU0Mw_bac8b67d-7664-46c4-a096-d9425243ba63"
      unitRef="usd">12711000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi0zLTEtMS0yNDU0Mw_245274c7-b4f4-4799-8763-562f7ccf12ee"
      unitRef="usd">9049000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMi01LTEtMS0yNDU0Mw_a6053a19-b9e1-4c94-a527-2eba6af545f2"
      unitRef="usd">7296000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ie9ed4074ebd54c72b7c475f8882ba2ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy0xLTEtMS0yNDU0Mw_3b21e8ba-770c-493b-9b5c-6cdb79b1b000"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9f3ebc6891a9455e9c6fb6ea48899e99_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy0zLTEtMS0yNDU0Mw_81d1d692-518d-46a4-8f43-02b8c3c45b38"
      unitRef="usd">461000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i61d7a2d6f1774f9cb8ba5206eeae226e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfMy01LTEtMS0yNDU0Mw_a4cac223-29d1-4c1b-9bd2-3fadd0b84013"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC0xLTEtMS0yNDU0Mw_f71e7bae-fe57-4e46-aab9-cc489a24e25b"
      unitRef="usd">9615000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC0zLTEtMS0yNDU0Mw_119c62c6-f4c8-4fc1-a87e-ad988e3f378a"
      unitRef="usd">10515000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNC01LTEtMS0yNDU0Mw_6f6643bc-7381-42fe-be08-0e99ccb83b69"
      unitRef="usd">9129000</us-gaap:ProvisionForDoubtfulAccounts>
    <irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS0xLTEtMS0yNDU0Mw_ca89e0f1-bead-4366-b7d2-5a6defff3929"
      unitRef="usd">8314000</irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments>
    <irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS0zLTEtMS0yNDU0Mw_4a2b0345-23c9-4ced-a17b-8ad9ff57e171"
      unitRef="usd">7314000</irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments>
    <irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNS01LTEtMS0yNDU0Mw_763556ce-0ce2-4440-a407-606231d82643"
      unitRef="usd">7376000</irtc:AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi0xLTEtMS0yNDU0Mw_e3094ca8-301d-490f-815f-5326e80a054d"
      unitRef="usd">14012000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi0zLTEtMS0yNDU0Mw_c01482eb-7b8c-4dba-af10-ea123356783a"
      unitRef="usd">12711000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOmY0ZjRlMGM1MzAyNjQwZmRiMzk0MjNmZTQxNzM3YmZjL3RhYmxlcmFuZ2U6ZjRmNGUwYzUzMDI2NDBmZGIzOTQyM2ZlNDE3MzdiZmNfNi01LTEtMS0yNDU0Mw_0ead9ebf-2a7d-43f9-8418-5d0b00578cfe"
      unitRef="usd">9049000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <irtc:ScheduleOfChangeInContractualAllowanceTableTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjc_787f8565-052d-4d91-aaf5-e4d859d6d6d3">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the contractual allowance (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.708%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: allowance for contractual adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: contractual adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,466)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</irtc:ScheduleOfChangeInContractualAllowanceTableTableTextBlock>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi0xLTEtMS0yNDU0Mw_d2254b9d-014e-4d7c-80d0-642a3105113d"
      unitRef="usd">21281000</irtc:AccountsReceivableForContractualAllowance>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi0zLTEtMS0yNDU0Mw_383101c4-f354-41ac-8051-bb59ae16baa2"
      unitRef="usd">15433000</irtc:AccountsReceivableForContractualAllowance>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMi01LTEtMS0yNDU0Mw_69127478-1174-43c6-8e70-6073e8329014"
      unitRef="usd">9205000</irtc:AccountsReceivableForContractualAllowance>
    <irtc:AccountsReceivableAllowanceForContractualAdjustments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy0xLTEtMS0yNDU0Mw_ed5cae31-8fc4-486c-8a46-339bfe151b82"
      unitRef="usd">27459000</irtc:AccountsReceivableAllowanceForContractualAdjustments>
    <irtc:AccountsReceivableAllowanceForContractualAdjustments
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy0zLTEtMS0yNDU0Mw_892fa86d-fdf5-43f7-b445-618bfab71666"
      unitRef="usd">20916000</irtc:AccountsReceivableAllowanceForContractualAdjustments>
    <irtc:AccountsReceivableAllowanceForContractualAdjustments
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfMy01LTEtMS0yNDU0Mw_16030ca2-d298-40cc-a4c0-99b53aaa3c6b"
      unitRef="usd">15518000</irtc:AccountsReceivableAllowanceForContractualAdjustments>
    <irtc:AccountsReceivableContractualAdjustments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC0xLTEtMS0yNDU0Mw_4ac0e89e-f980-4328-b649-f830f657c775"
      unitRef="usd">17466000</irtc:AccountsReceivableContractualAdjustments>
    <irtc:AccountsReceivableContractualAdjustments
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC0zLTEtMS0yNDU0Mw_f4bfe4a1-8d9f-4891-b74e-87f6c950e7d4"
      unitRef="usd">15068000</irtc:AccountsReceivableContractualAdjustments>
    <irtc:AccountsReceivableContractualAdjustments
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNC01LTEtMS0yNDU0Mw_d3680579-64e7-4044-8f00-f6aea58b1943"
      unitRef="usd">9290000</irtc:AccountsReceivableContractualAdjustments>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS0xLTEtMS0yNDU0Mw_37a089fe-6c35-44ba-bd01-ebc789c9cea2"
      unitRef="usd">31274000</irtc:AccountsReceivableForContractualAllowance>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS0zLTEtMS0yNDU0Mw_6bbbd1ba-47b4-4f1a-9118-31fadd1e76f5"
      unitRef="usd">21281000</irtc:AccountsReceivableForContractualAllowance>
    <irtc:AccountsReceivableForContractualAllowance
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjkxYjU4ZmQxMzczYzRjYzBhN2YzYWEzOGViZDc5ZmQyL3RhYmxlcmFuZ2U6OTFiNThmZDEzNzNjNGNjMGE3ZjNhYTM4ZWJkNzlmZDJfNS01LTEtMS0yNDU0Mw_3c92830d-df98-4ca9-aa7a-ad997242fc33"
      unitRef="usd">15433000</irtc:AccountsReceivableForContractualAllowance>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjI_d4c9bbda-18fc-4095-a19f-c7d0182406ce">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, investments and accounts receivable. Cash balances are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, U.S. government securities, corporate notes, commercial paper and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concentrations of credit risk with respect to accounts receivable are limited due to the large number of customers comprising the Company&#x2019;s customer base and their dispersion across many geographies. The Company does not require collateral. The Company records an allowance for doubtful accounts based on the assessment of the collectability of customer accounts, considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer&#x2019;s ability to pay. Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;), accounted for approximately 14%, 27% and 27% of the Company&#x2019;s revenue for the years ended December&#160;31, 2021, 2020 and 2019, respectively. CMS accounted for 8% and 20% of accounts receivable as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idfb7f500e8934bd2b96bfe5eda7af356_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNjA_d8979cd3-eb5d-49d6-8bb3-548438b609d7"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9db8564ddc2f47cfb7aaa008517d05ab_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNjQ_277cfd3a-04f6-4128-ae61-80e37b9e882e"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0624798b12fa464ca5bea6b9c12f361b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkyNzE_8b20de65-7207-4a08-8303-60c54b872d2b"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50fcb4b97216498585c183117c671309_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkzNjY_011f4db4-ca9c-4155-a03f-8bb85e17de84"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i39c78456bd4045eab249ad061311ce9e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMTkzNzM_d097caf0-9f29-47ab-b00f-33745612c8cc"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <irtc:InflationaryRiskPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzg0ODI5MDc5OTU1OA_67223237-8bb3-4bd5-9196-fb4f08c7e8ea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Inflationary Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continuously monitors the effects of inflationary factors, such as increases in cost of goods sold and selling and operating expenses, which may adversely affect its results of operations. Specifically, the Company may experience inflationary pressure affecting the cost of the components for our Zio service and in the wages paid to its employees due to challenging labor market conditions. Competitive and regulatory conditions may restrict the Company's ability to fully recover these costs through price increases. As a result, it may be difficult to fully offset the impact of persistent inflation. The Company's inability or failure to do so could have a material adverse effect on our business, financial condition and results of operations or cause us to need to obtain additional capital in future earlier than anticipated.&lt;/span&gt;&lt;/div&gt;</irtc:InflationaryRiskPolicyTextBlock>
    <irtc:ConcentrationRiskSupplyRiskPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjM_1f01e6ef-88f4-4f30-9542-d615094f4738">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Supply Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on single-source vendors to supply some of its disposable housings, instruments and other materials used to manufacture the Zio monitor and the adhesive that binds the Zio monitor to a patient&#x2019;s body. These components and materials are critical, and there could be a considerable delay in finding alternative sources of supply. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A global semiconductor supply shortage is having wide-ranging effects across multiple industries. The supply shortage has impacted multiple suppliers that provide the printed circuit board assemblies to the Company. The semiconductor supply shortage may have an impact on the Company until global supply is sufficient for global demand.&lt;/span&gt;&lt;/div&gt;</irtc:ConcentrationRiskSupplyRiskPolicyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTU_5a0ea879-7c33-404c-894e-32ebcd63dad4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory owned by the Company is valued at cost, on the first in, first out (&#x201c;FIFO&#x201d;) basis, or the lower of cost or net realizable value. The Company records write-downs of inventory that is obsolete or in excess of anticipated demand. The Company also records market value based write-downs on consideration of product lifecycle stage, technology trends, product development plans and assumptions about future demand and market conditions. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Inventory write-downs are charged to cost of revenue and establish a new cost basis for the inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzU_1ba4b108-cc7c-4415-aae8-e836bb94d21c">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNTc_d6060af2-01e6-4672-99b4-527d588ba79d"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjEwNjM_7e4e8988-da37-461b-88b0-140b0f6ce149">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTI_111a9199-579a-4a60-8dc4-8cd5a6e41d7a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Internal-Use Software&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes costs related to internal-use software during the application development stage. Costs related to planning and post implementation activities are expensed as incurred. Capitalized internal-use software is amortized, and recognized as cost of revenue, on a straight-line basis over the estimated useful life, which is up to five years. The Company evaluates the useful lives of these assets on an annual basis, and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. Capitalized internal-use software costs are classified as a component of property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia00144f28bbd4b3b8d6872c91909a2d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjE2NjM_02a08bef-6151-42f0-84d5-f3bc639b4446">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTY_f01a33d5-4f28-4bbb-a9b5-be80f8beeed4">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible net assets acquired in business combinations. Goodwill is tested for impairment on an annual basis and at any other time if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Such events or circumstances may include significant adverse changes in the general business climate, among other things. The impairment test is performed by determining the enterprise fair value of the Company, which is primarily based on the Company&#x2019;s market capitalization. If the Company&#x2019;s carrying value, as a one reporting unit entity, is less than its fair value, then the fair value is allocated to all of its assets and liabilities (including any unrecognized intangible assets) as if the fair value was the purchase price to acquire the Company. The excess of the fair value over the amounts assigned to the Company&#x2019;s assets and liabilities is the implied fair value of the goodwill. If the carrying amount of goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The Company performs its annual evaluation of goodwill during the fourth quarter of each fiscal year. The Company did not record any charges related to goodwill impairment in any of the periods presented in these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDk_4749c17c-ddae-4715-a371-d749d524e691">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company annually reviews long-lived assets for impairment or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. To date, there have been no such impairments of long-lived assets.&lt;/span&gt;&lt;/div&gt;In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects this decision will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDA_7094b5e9-af53-4d7a-8dfb-3956ef4e4022"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <irtc:OtherAssetsPolicyPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzY_6f8b81c3-c6e9-4b86-a6f5-0fd8e611df9a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses Printed Circuit Board Assemblies (&#x201c;PCBAs&#x201d;), in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the ZIO AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT or Zio AT monitor, or a wireless gateway is used with a Zio AT monitor a portion of the cost of the PCBA and/or gateway is recorded as a cost of revenue. The PCBAs are recorded as other assets and were $13.9 million and $12.6 million as of December&#160;31, 2021 and 2020, respectively. The Company has based its estimates of how many times a PCBA can be used on testing in research and development, loss rates, product obsolescence, and the amount of time it takes the device to go through the manufacturing, shipping, customer shelf and patient wear time and upload process. The Company periodically evaluates the use estimate.&lt;/span&gt;&lt;/div&gt;</irtc:OtherAssetsPolicyPolicyPolicyTextBlock>
    <us-gaap:OtherAssets
      contextRef="i325e1cd03bd94e598819e2c8159b85ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjQ1Njg_4d6124eb-f239-4aed-9526-773da4ebaff4"
      unitRef="usd">13900000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="id60332e77ea34183a58d2508319463aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMjQ1NzU_b83bf943-dee0-4611-a3f6-d963e2847e98"
      unitRef="usd">12600000</us-gaap:OtherAssets>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDQ_603c3ec5-d6e6-47c0-852c-c496389348ce">Comprehensive LossComprehensive loss represents all changes in stockholders&#x2019; equity during the period from non-owner sources. The Company&#x2019;s unrealized gains and losses on available-for-sale securities represent the only component of other comprehensive loss that are excluded from the reported net loss and that are presented in the consolidated statements of comprehensive loss.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDE_ed29c64f-40f7-4ca9-8b3f-1dd1d935adda">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s revenue is generated primarily from the provision of its cardiac rhythm monitoring service, the Zio XT service. The Zio XT is a cardiac rhythm monitoring service that has a patient wear period of up to 14 days and is billable when the monitoring reports are delivered to the healthcare provider, which is also when the service is complete and the Company recognizes revenue. The time from when the patient has the Zio XT device applied to the time the report is posted is generally around 25 days. The Company has concluded that the Zio XT service is one performance obligation on the basis that the customer cannot benefit from each component of the service on its own or together with other resources that are readily available to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Zio AT mobile cardiac telemetry monitor, a wearable patch-based biosensor, offers what the Zio XT offers plus the additional capability of transmissions during the wear period to assist physicians in diagnosing and treating patients that require more timely action. During the wear period, physicians will receive notifications if there are significant events that meet predetermined arrhythmia detection criteria. The Zio AT service revenue is recognized over the prescription period and delivery of an electronic Zio Report with two performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognizes as revenue the amount of consideration to which it expects to be entitled in exchange for performing the service. The consideration the Company is entitled to varies by portfolio, as further defined below, and includes estimates that require significant judgment by management. A unique aspect of healthcare is the involvement of multiple parties to the service transaction. In addition to the patient, often a third-party, for example a commercial or governmental payor or healthcare institution, will pay the Company for some or all of the service on the patient&#x2019;s behalf. Separate contractual arrangements exist between the Company and third-party payors that establish amounts the third-party payor will pay on behalf of a patient for covered services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A small portion of the Company&#x2019;s transactions are covered by third-party payors with whom there is neither a contractual agreement nor an established amount that the third-party payor will pay. In determining the collectability and transaction price for its service, the Company considers factors such as insurance claims which are adjudicated as allowable under the applicable policy and payment history from both payors and patient out-of-pocket costs, payor coverage, whether there is a contract between the payor or healthcare institution and the Company, historical amount received for the service, and any current developments or changes that could impact reimbursement and healthcare institution payments. Certain of these factors are forms of variable consideration which are only included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the payment arrangements with third-party payors and healthcare institutions is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Contracted third-party payors &#x2013; The Company has contracts with negotiated prices for services provided to patients with commercial healthcare insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;CMS &#x2013; The Company has received independent diagnostic testing facility approval from regional Medicare Administrative Contractors and will receive reimbursement per the relevant CPT code rates for the services rendered to the patient covered by CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Non-contracted third-party payors &#x2013; Non-contracted commercial and government payors often reimburse out-of-network rates provided under the relevant CPT codes on a case-by-case basis. The transaction price used &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for determining revenue recognition is based on factors including an average of the Company&#x2019;s historical collection experience for its non-contracted services. This rate is reviewed at least quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Healthcare institutions &#x2013; Healthcare institutions are typically hospitals or physician practices in which the Company has negotiated amounts for its monitoring services, including certain governmental agencies such as the Veterans Administration and Department of Defense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is utilizing the portfolio approach practical expedient under ASC 606 for revenue recognition whereby services provided under each of the above payor types form a separate portfolio. The Company accounts for the contracts within each portfolio as a collective group, rather than individual contracts. Based on history with these portfolios and the similar nature and characteristics of the patients within each portfolio, the Company has concluded that the financial statement effects are not materially different than if accounting for revenue on a contract-by-contract basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For contracted and CMS portfolios, the Company recognizes revenue, net of contractual allowances, and recognizes an allowance for doubtful accounts for uncollectible patient accounts receivable. The transaction price is determined based on negotiated rates, and the Company has historical experience of collecting substantially all of these contracted rates. These contracts also impose a number of obligations regarding billing and other matters, and the Company&#x2019;s noncompliance with a material term of such contracts may result in a denial of the claim. The Company accounts for denied claims as a form of variable consideration that is included as a reduction to the transaction price recognized as revenue. The Company estimates the denied claims which require management judgment. The estimated denied claims are based on historical information and judgement includes the historical period utilized. The Company monitors the estimated denied claims against the latest available information, and subsequent changes to the estimated denied claims are recorded as an adjustment to revenue in the periods during which such changes occur. Delays in claims submissions could lead to an increase in denials if we miss the payors&#x2019; filing deadlines and could result in a reduction in the Company&#x2019;s receipt of payments. Historical cash collection indicates that it is probable that substantially all of the transaction price, less the estimate of denied claims, will be received. Contracted payors may require that we bill patient co-payments and deductibles and from time to time we may not be able to collect such amounts due to credit risk. The Company provides for estimates of uncollectible patient accounts receivable, based upon historical experience where judgment includes the historical period utilized, at the time revenue is recognized, with such provisions presented as bad debt expense within the selling, general and administrative line item of the consolidated statement of operations. Adjustments to these estimates for actual experience are also recorded as an adjustment to bad debt expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We submitted the majority of Zio XT claims from the first and second quarter of 2021 on a delayed basis due to the CPT code transition. Claims were being held due to a combination of negotiations with payors and administrative delays with payors. Most of the held claims were released and submitted by the end of the second quarter of 2021. For the contracted portfolio, once submitted, the number of claims from the first half of 2021 which contained differences between the submitted price and reimbursement and overall denials increased significantly compared to our historical experience as a result of CPT code transition issues with the payors. We continue to work with the payors to collect on these claims and the collection cycle for these claims is significantly longer than usual. While we believe we have properly estimated the impact to our contractual allowances and allowance for doubtful accounts, the inherent uncertainty caused by longer-collection cycle and claims adjudication process could result in additional provisions for contractual allowances and doubtful accounts which would negatively impact our results of operations in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For non-contracted portfolios, the Company is providing an implicit price concession due to the lack of a contracted rate with the underlying payor, the result of which requires the Company to estimate the transaction price based on historical cash collections utilizing the expected value method. All subsequent adjustments to the transaction price are recorded as an adjustment to revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For healthcare institutions, the transaction price is determined based on negotiated rates, and the Company has historical experience collecting substantially all of these contracted rates. Historical cash collection indicates that it is probable that substantially all of the transaction price will be received. As such, the Company is not providing an implicit price concession but, rather, has chosen to accept the risk of default, and any subsequent uncollected amounts are recorded as bad debt expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzM_f99b203d-1e98-4a52-a0cf-39923e420da5">Disaggregated revenue by payor type and major service line for the years ended December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracted third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-contracted third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Centers for Medicare &amp;amp; Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare institutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id814a6da95c1480a914c87a5028a3a5b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi0xLTEtMS0yNDU0Mw_657df917-76a7-4339-b953-8f9563bd3e51"
      unitRef="usd">193871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e0e1acdecce4bc3890820a3d9e96ee2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi0zLTEtMS0yNDU0Mw_1e08295d-7c38-4193-bc65-42cc88a1cd66"
      unitRef="usd">135939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af04eb3c79a43ebbb272cec9b11188a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMi01LTEtMS0yNDU0Mw_52235a13-d815-4792-9fb1-8869fb284096"
      unitRef="usd">101845000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c6ac2500f824b45a5cffbbccaa42236_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy0xLTEtMS0yNDU0Mw_21e34388-d2d9-41a1-aeb8-0774e9eca7e5"
      unitRef="usd">26929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id50f5215d1174ad28382c2494c5399c6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy0zLTEtMS0yNDU0Mw_8eb7ab5c-9a3e-4af3-8b05-f9e8205e8c88"
      unitRef="usd">15295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7a7ea2b4b2b4143afc1c82e0fa1f8dd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfMy01LTEtMS0yNDU0Mw_2e220715-eed1-431c-8d77-b028b9c54d13"
      unitRef="usd">10770000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a1fb6ef69b842c6bc4f8e224841fd0e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC0xLTEtMS0yNDU0Mw_bd36f020-0fd9-402a-8fa1-52e445c39c5e"
      unitRef="usd">44529000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id16459be997449c3b7b484cc95d1339e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC0zLTEtMS0yNDU0Mw_666b16a8-6d61-40f0-8862-33256d22bcd0"
      unitRef="usd">72536000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie651d17a114348fdb3edf9a8b0b5827c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNC01LTEtMS0yNDU0Mw_8e3dc698-7696-4576-a6bd-053ff73e07bb"
      unitRef="usd">58918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34f360678d4246b89d728c59cd20976d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS0xLTEtMS0yNDU0Mw_0499721f-e91d-461a-95a2-a096d961c889"
      unitRef="usd">57496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82a7c57c18f549c5852ef8cd95cdc265_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS0zLTEtMS0yNDU0Mw_00c8a476-b753-4516-b434-1e1d844bd339"
      unitRef="usd">41396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifddd05d06ccf4b7d89a49501aaf7f236_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNS01LTEtMS0yNDU0Mw_1acf76f8-c6d9-4fc5-a355-c706178d1f50"
      unitRef="usd">43019000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi0xLTEtMS0yNDU0Mw_c70b5b8b-9a4f-456e-8e3a-9dc1b67d21f0"
      unitRef="usd">322825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi0zLTEtMS0yNDU0Mw_b8316ae8-7f01-4d2e-a143-4444021190f3"
      unitRef="usd">265166000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RhYmxlOjY1ZDFhNzdmNmVmMDQ4ZTE5YzNlNGFkNjMyNWNmMmI5L3RhYmxlcmFuZ2U6NjVkMWE3N2Y2ZWYwNDhlMTljM2U0YWQ2MzI1Y2YyYjlfNi01LTEtMS0yNDU0Mw_f732e586-d418-4a1c-a476-caa2ffc5c55d"
      unitRef="usd">214552000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <irtc:ContractLiabilityPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzc_4fe65234-349e-41e9-93e5-018969bb3cc5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requires an entity to present a revenue contract as a contract liability when the Company has an obligation to transfer goods or services to a customer for which the Company has received consideration from the customer, or an amount of consideration from the customer is due and unconditional (whichever is earlier).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s customers pay the Company directly for the Zio XT service upon shipment of devices. Such advance payments are contract liabilities and are recorded as deferred revenue on the Consolidated Balance Sheets and revenue is recognized when reports are delivered to the healthcare provider. During the year ended December&#160;31, 2021, $0.9 million relating to the contract liability balance at the beginning of 2021 was recognized as revenue. Total revenue recognized during the year ended December 30, 2020 that was included in the contract liability balance at the beginning of 2020 was $1.2&#160;million.&lt;/span&gt;&lt;/div&gt;</irtc:ContractLiabilityPolicyPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzQxOTg_2e769647-bd4f-449a-9b4c-e4191231eaaf"
      unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfMzg0ODI5MDc4MTQ3Mg_ab6a81f4-959e-460e-8360-b659419993dd"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <irtc:ContractCostPolicyPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDU_ec809914-ffd0-499e-8576-4cf25db8bcf6">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 340, the incremental costs of obtaining a contract with a customer are recognized as an asset. Incremental costs of obtaining a contract are those costs that an entity incurs to obtain a contract with a customer that it would not have incurred if the contract had not been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current commission programs are considered incremental. However, as a practical expedient, ASC 340 permits the Company to immediately expense contract acquisition costs, as the asset that would have resulted from capitalizing these costs will be amortized in one year or less.&lt;/span&gt;&lt;/div&gt;</irtc:ContractCostPolicyPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDY_544fa264-2802-4682-9239-95840e260b5c">Cost of RevenueCost of revenue includes direct labor, material costs, overhead, data analysis, customer care, equipment and infrastructure expenses, amortization of internal-use software, and shipping and handling. Direct labor includes payroll and personnel-related costs involved in manufacturing. Material costs include both the disposable costs of the device and amortization of the PCBAs. Each time the PCBA is used in a wearable Zio XT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjU_91f00c8a-03d7-4a33-8c90-b8d4195324a9">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s research and development costs are expensed as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, laboratory supplies, consulting costs and overhead charges.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNTk_e8d05bc9-9765-404c-90b2-a392f2389670">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recognize taxes on Global Intangible Low-Taxed Income as a current period expense when incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNjA_31a23e33-72d8-41d1-9c1f-1b006441a18d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwNDc_baf12aab-be7e-4de8-a325-141de1e295da">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures its stock-based awards made to employees based on the estimated fair values of the awards as of the grant date. The fair value of market condition awards is determined using the Monte-Carlo option pricing model and the fair value of stock options is determined using the Black-Scholes option pricing model. Stock-based compensation expense is recognized over the requisite service period using the straight-line method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest. As such, the Company&#x2019;s stock-based compensation is reduced for the estimated forfeitures at the date of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For restricted stock, the compensation cost for these awards is based on the closing price of the Company&#x2019;s common stock on the date of grant, and recognized as compensation expense on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on the estimated fair value of the options on the date of grant, net of estimated forfeitures. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzg_9864195d-2261-4bfb-9f82-4ed0c5caa62b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effect of potentially dilutive securities are anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV84OC9mcmFnOjkyZTdhZmJkZmYwYTQwNjU4MmVlOGU1NmM3NmM1YmQ0L3RleHRyZWdpb246OTJlN2FmYmRmZjBhNDA2NTgyZWU4ZTU2Yzc2YzViZDRfNDgwMzk_7eed2632-782f-43ff-accd-032235d6b593">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Identifying a lease&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract contains a lease at the inception of a contract. If the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration, the Company considers the contract to contain a lease. The Company determines whether a contract conveys the right to control the use of an identified asset for a period of time if the contract contains both of the following terms:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The right to obtain substantially all of the economic benefits from use of the identified asset; and&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The right to direct the use of the identified asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Discount rate for leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the rate implicit in the lease is not readily determinable for our operating leases, the Company generally uses an incremental borrowing rate based on information available at the commencement date such as a synthetic credit rating and current cost of borrowing to determine the present value of future lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Lease term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term is generally the minimum noncancellable period of each lease. The Company does not include option periods in determining the right-of-use asset and operating lease liability at inception unless it is reasonably certain that the Company will exercise the option at inception or when a triggering event occurs. As of December&#160;31, 2021, no renewal options were included in the determination of lease terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Lease Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The San Francisco Lease is in the same building with the same landlord as the lease for the Company&#x2019;s prior headquarters in San Francisco (&#x201c;existing lease&#x201d;). Upon the commencement of the San Francisco Lease, the existing lease which had an original expiration date of February 2020, was modified to expire in September 2019 and accordingly the right-of-use asset and lease liability was remeasured as of the modification date.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <irtc:CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzUx_53cf92d5-03a3-49a5-9458-558bac8b8b18">Cash Equivalents and Investments&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of cash equivalents and available-for-sale investments at December&#160;31, 2021 and 2020, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total  cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the Company's cash equivalents, short-term and long-term marketable securities classified by maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company's available-for-sale securities that were in an unrealized loss position as of&#160; December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses as of December&#160;31, 2021 were not material. Available-for-sale securities held as of December&#160;31, 2021 had a weighted average maturity of 95 days. At December&#160;31, 2021, 13 investments were in an unrealized loss position and no investments have been in an unrealized loss position for more than one year.&lt;/span&gt;&lt;/div&gt;</irtc:CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ1_845424fa-7fa9-4667-ba32-56d07ce0c455">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of cash equivalents and available-for-sale investments at December&#160;31, 2021 and 2020, were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total  cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id929e42695a1425db8d875f569956607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy0xLTEtMS0yNDU0Mw_3c85d9fe-2ff6-4a87-ae4d-51fa10040102"
      unitRef="usd">110137000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id929e42695a1425db8d875f569956607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy0zLTEtMS0yNDU0Mw_daaf3dfd-c08f-42ae-be4e-32113eb3b5c2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id929e42695a1425db8d875f569956607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy01LTEtMS0yNDU0Mw_68ae8f30-50ff-414d-9e9f-bfd467fc8a93"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id929e42695a1425db8d875f569956607_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMy03LTEtMS0yNDU0Mw_bafb603e-30fc-43f2-95f6-6f08408f5f63"
      unitRef="usd">110137000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC0xLTEtMS0yNDU0Mw_bb618a77-1e6e-4353-a49f-61997f6c505a"
      unitRef="usd">50490000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC0zLTEtMS0yNDU0Mw_ebbb2e33-8467-4640-b817-dfdba9b3d5fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC01LTEtMS0yNDU0Mw_dbc79a26-259a-4f1f-92e4-90d742004e24"
      unitRef="usd">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNC03LTEtMS0yNDU0Mw_9f35dd7a-dec0-49f7-a961-0f28bf3f8b96"
      unitRef="usd">50444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS0xLTEtMS0yNDU0Mw_0b466a97-f2d4-4cf2-a2e5-46466833a639"
      unitRef="usd">31158000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS0zLTEtMS0yNDU0Mw_2e5c1538-20ea-4041-a74b-05b16b0bef6a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS01LTEtMS0yNDU0Mw_76fbb5cb-0d4a-41ca-9088-17331537df79"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNS03LTEtMS0yNDU0Mw_4d7e056c-79d9-4c25-96e8-09e4d6e0678c"
      unitRef="usd">31143000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi0xLTEtMS0yNDU0Mw_81932603-653a-4298-9a12-627eb820cb12"
      unitRef="usd">29982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi0zLTEtMS0yNDU0Mw_9ef89860-187c-4883-ab60-80c12f88ff08"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi01LTEtMS0yNDU0Mw_daedc7e7-b1fb-4308-ac51-42d13379b2e1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie3848c1d4a184a1eb78ecfae9590242e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNi03LTEtMS0yNDU0Mw_380f2515-685b-4477-b48e-c03e46809968"
      unitRef="usd">29982000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy0xLTEtMS0yNDU0Mw_28c5cc51-35f3-40d8-b1b4-3402d178fbcf"
      unitRef="usd">221767000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy0zLTEtMS0yNDU0Mw_e3fee90c-9706-42b2-b5d2-c8f10371222f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy01LTEtMS0yNDU0Mw_965e8ce7-01e2-41e5-81a2-c367bc339c5a"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfNy03LTEtMS0yNDU0Mw_c54adc34-ed75-4fc4-bfa3-eb38effc4c67"
      unitRef="usd">221706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfOS03LTEtMS0yNDU0Mw_3e31b97e-03c9-4024-8a1b-0211b1146985"
      unitRef="usd">110137000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMTAtNy0xLTEtMjQ1NDM_d1d5f0d8-d1db-46b4-911d-9cbb1b95b24d"
      unitRef="usd">111569000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOmUzMGJlOTllMjM4NDQzMDU4ZGVkZjE0MjZiMGQ2NDk3L3RhYmxlcmFuZ2U6ZTMwYmU5OWUyMzg0NDMwNThkZWRmMTQyNmIwZDY0OTdfMTItNy0xLTEtMjQ1NDM_46d4482b-0046-4778-bf78-6c4b33e99fac"
      unitRef="usd">221706000</irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy0xLTEtMS0yNDU0Mw_e82a1734-7ea0-49e7-8ea9-5ff4b66673ae"
      unitRef="usd">59823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy0zLTEtMS0yNDU0Mw_e209bf3c-10be-4911-82be-284917313a47"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy01LTEtMS0yNDU0Mw_3a3392a0-f8ed-4145-bb75-f8091ac0ffc1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa5012fcbfc144eaa3ae8abe42dd9382_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMy03LTEtMS0yNDU0Mw_c30cc7b8-b87a-4e42-aa2d-5a7c68f97f3e"
      unitRef="usd">59823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC0xLTEtMS0yNDU0Mw_06ae8286-95c0-4e8d-b488-c934688a056c"
      unitRef="usd">190663000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC0zLTEtMS0yNDU0Mw_ad9a2026-bb36-4bce-84be-f9bf3eb817a9"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC01LTEtMS0yNDU0Mw_60fd78de-e2e3-4a6e-9bc0-45e79a70abff"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4be80603ceb43d3b961e3e1e66c84ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNC03LTEtMS0yNDU0Mw_12b02f20-4090-4f25-9a35-f55103c84c0f"
      unitRef="usd">190677000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3d649d197bda45e596f9af06665706a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS0xLTEtMS0yNDU0Mw_1cd56063-6ebe-4247-8f7f-bc9478dfffec"
      unitRef="usd">26426000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3d649d197bda45e596f9af06665706a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS0zLTEtMS0yNDU0Mw_89cffb4f-f17b-4cda-9c7d-8844e76aabfd"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3d649d197bda45e596f9af06665706a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS01LTEtMS0yNDU0Mw_2535db2b-29e5-4c5a-8c59-508837fb2855"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d649d197bda45e596f9af06665706a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNS03LTEtMS0yNDU0Mw_ec691f06-3cc8-44f9-9ac1-a98c328420d0"
      unitRef="usd">26423000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi0xLTEtMS0yNDU0Mw_0a1835eb-9e6e-4eb1-b18a-ba8a76a59fd3"
      unitRef="usd">29489000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi0zLTEtMS0yNDU0Mw_9856c60d-aae2-43da-80fb-b4fdf5e52bec"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi01LTEtMS0yNDU0Mw_3f547893-738d-446f-a960-9b3f4d11b110"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad8d5012263e4befa279cf0bd28d07fb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNi03LTEtMS0yNDU0Mw_51d0980a-a3cb-4030-ad78-db0a3240f10f"
      unitRef="usd">29489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy0xLTEtMS0yNDU0Mw_0ddb1769-5a09-4afa-a849-00d19e0bea1b"
      unitRef="usd">306401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy0zLTEtMS0yNDU0Mw_d2944f22-935e-4864-b095-ea4713baca24"
      unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy01LTEtMS0yNDU0Mw_ad71b492-a9fd-4df9-be8d-5a9f24ebcf58"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfNy03LTEtMS0yNDU0Mw_db5a9453-b3df-4654-b4f1-50474957e6b7"
      unitRef="usd">306412000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfOS03LTEtMS0yNDU0Mw_f5a74b5f-454d-495a-9cf1-95a77153c6dc"
      unitRef="usd">59823000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMTAtNy0xLTEtMjQ1NDM_bb74413b-1327-47df-8706-2884e82a2433"
      unitRef="usd">246589000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjRmOWRmYmUxYThlYTQxYThiYTRlYWJlNDNjMzc5MzFmL3RhYmxlcmFuZ2U6NGY5ZGZiZTFhOGVhNDFhOGJhNGVhYmU0M2MzNzkzMWZfMTItNy0xLTEtMjQ1NDM_dba48f22-9d00-46db-9bad-54f02c18815a"
      unitRef="usd">306412000</irtc:CashEquivalentsAndCurrentAndNoncurrentInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ3_07f22e93-ff4f-4617-b5a5-c09e2ee643b1">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value of the Company's cash equivalents, short-term and long-term marketable securities classified by maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through three years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and available-for-sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMi0xLTEtMS0yNDU0Mw_593ae3aa-a7c1-4eda-8b09-a29fef9a6693"
      unitRef="usd">221706000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMi0zLTEtMS0yNDU0Mw_21441f9c-1992-4752-980a-487bc20e6d05"
      unitRef="usd">306412000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMy0xLTEtMS0yNDU0Mw_5a7ab45a-c054-4aba-80aa-c4f24535af1f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfMy0zLTEtMS0yNDU0Mw_849fc700-a90b-4e7c-9ff4-0485083a70b5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfNC0xLTEtMS0yNDU0Mw_2805d19b-eeec-4e65-ba7a-c20ff7c582e6"
      unitRef="usd">221706000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjdmM2U3NGUyZDFiZjQyMThiODQ0ZjE3MzYxMGFjN2MxL3RhYmxlcmFuZ2U6N2YzZTc0ZTJkMWJmNDIxOGI4NDRmMTczNjEwYWM3YzFfNC0zLTEtMS0yNDU0Mw_cf308c40-5eef-48b8-ba06-4e5c34351c30"
      unitRef="usd">306412000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNzQ5_c3717ed2-5017-469d-bb68-bedb10cfabb5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company's available-for-sale securities that were in an unrealized loss position as of&#160; December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0xLTEtMS0yNDU0Mw_c49f6b9a-0d83-470c-8cdc-818aee351156"
      unitRef="usd">50445000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0zLTEtMS0yNDU0Mw_ef5efaa3-d3b5-4f0c-9244-7d256301c03a"
      unitRef="usd">46000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy01LTEtMS0yNDU0Mw_fed013ec-dbba-421b-8597-30625789488b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy03LTEtMS0yNDU0Mw_283e675c-17b2-484d-bfef-735d581440fd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy05LTEtMS0yNDU0Mw_ff512c34-ec97-4b67-9196-aae677835c64"
      unitRef="usd">50445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i4d7fcae5bab84669835f080a9618b3be_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfMy0xMS0xLTEtMjQ1NDM_ca00098e-4f83-4d12-958d-e820b8b37ce5"
      unitRef="usd">46000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0xLTEtMS0yNDU0Mw_1a7fe0e8-7494-4c69-9cfe-b20dfcd66b09"
      unitRef="usd">31143000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0zLTEtMS0yNDU0Mw_8d357171-aee6-426e-a415-3b98461fb228"
      unitRef="usd">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC01LTEtMS0yNDU0Mw_c3c8813b-5a1c-4810-8f1c-8eff37168996"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC03LTEtMS0yNDU0Mw_999e8839-52f9-40be-8db4-b9cbbb32e44c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC05LTEtMS0yNDU0Mw_d1ab28c5-35ce-4c27-972c-9a2942b88388"
      unitRef="usd">31143000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5efc11c28170439fb0e0ade90d22cd61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNC0xMS0xLTEtMjQ1NDM_9372cb69-9dd0-4080-ad43-361056b25755"
      unitRef="usd">15000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0xLTEtMS0yNDU0Mw_c40b6a96-6c63-4a2d-bdb6-cff0651c7370"
      unitRef="usd">81588000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0zLTEtMS0yNDU0Mw_b92e7d4d-1ce8-4f40-80c4-172fe3c548bd"
      unitRef="usd">61000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS01LTEtMS0yNDU0Mw_8a012527-2572-4565-b64e-0f934fd45ee2"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS03LTEtMS0yNDU0Mw_aeed5e1b-3784-4633-bbed-5e5c21bc8099"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS05LTEtMS0yNDU0Mw_fad887d1-a552-49d9-981c-b7e055cc3a59"
      unitRef="usd">81588000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RhYmxlOjE4ZmRiNGYwYTU2YTQ2Zjg4YzFkYmQyMjM3NDA4YWI5L3RhYmxlcmFuZ2U6MThmZGI0ZjBhNTZhNDZmODhjMWRiZDIyMzc0MDhhYjlfNS0xMS0xLTEtMjQ1NDM_d8ac0252-fbbd-4c36-9c4f-f553d8115f10"
      unitRef="usd">61000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <irtc:AvailableForSaleDebtSecuritiesMaturityPeriod
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjAx_e0c8cd9e-eaff-4bb5-b79f-85a2d9e846b5">P95D</irtc:AvailableForSaleDebtSecuritiesMaturityPeriod>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjEy_29ba57ef-2e4c-4ee9-8969-8c1e5bcfd910"
      unitRef="investment_security">13</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85MS9mcmFnOjdkNTVjZGU3OGVlOTRkN2JhYzc3YzJkZGNkYTNkYWE0L3RleHRyZWdpb246N2Q1NWNkZTc4ZWU5NGQ3YmFjNzdjMmRkY2RhM2RhYTRfNjY3_0ec0f862-ea93-49ad-9da6-d43f55c895fb"
      unitRef="investment_security">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMzA1Ng_79e75bed-7dc7-4e71-9e08-6e8bd3f335a8">Fair Value Measurements&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The corporate notes, commercial paper and government securities are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s outstanding interest-bearing obligations is estimated using the net present value of the future payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company&#x2019;s outstanding interest-bearing obligations at December&#160;31, 2021 wer&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e $21.4 million and $21.7 million, r&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;espectively. The carrying amount and the estimated fair value of the Company&#x2019;s outstanding interest-bearing obligations at December&#160;31, 2020 were $33.0 million and $33.9 million, respectively.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no transfers between levels of the fair value hierarchy of its assets measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i544774a11590471697b6d8b7df26516c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjYzNg_946becb9-01f8-4f2f-93a8-aa93ce5fe554"
      unitRef="usd">21400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i2d3915c703cd486c8d2ddb5c86644b14_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjY0Mw_0b5e65b5-d601-4b60-8858-8da2a18a8728"
      unitRef="usd">21700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1386205dcb64400c8549d89adf0e66c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjc3OQ_c029ce7b-f002-4b82-8aed-e8acb7a7cd05"
      unitRef="usd">33000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iad512d72fba24e88bc963667bb17d917_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMjc4Ng_7bbb2dca-da19-445f-9a6b-89c75fd97936"
      unitRef="usd">33900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RleHRyZWdpb246Zjg1ZDI1YWNlYWJlNDY4ZjllMDliMzBiZWU3YWNmZTJfMzA1Nw_b7741dfb-27bf-4274-a0b2-177c016b1611">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair value of the Company&#x2019;s financial assets determined using the inputs defined above (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iadc05c01347a43d4839f5af04b73fb66_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy0xLTEtMS0yNDU0Mw_f56a4f2a-0e7b-4700-9c50-a11f6ba1bd27"
      unitRef="usd">110137000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia90655704d594a51bf0f84615c1aac60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy0zLTEtMS0yNDU0Mw_1058ee38-5af7-4b36-927a-b5abb451f64a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3286b0953db143438a81b1243412ad19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy01LTEtMS0yNDU0Mw_07c84fbf-2d05-44fd-b706-c88561acf11a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i661ccccd2342454cadb45ffd6ac1cdf8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfMy03LTEtMS0yNDU0Mw_78a8ee39-02f2-4e82-b1a6-474f88a78526"
      unitRef="usd">110137000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8141234416514b26856b026454673afd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC0xLTEtMS0yNDU0Mw_35c0bf18-182b-4814-93b6-bbdc31f03f56"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i91b9d94fd49d43a1a73305efd5b103fb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC0zLTEtMS0yNDU0Mw_1ec8e6f1-7f73-46b9-8b46-ff5c48672da9"
      unitRef="usd">50444000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i51e6fab54d734357843ce9f2f235a342_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC01LTEtMS0yNDU0Mw_96aa4d63-ff61-4ffd-8bcc-cecbff4cf370"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d2ad0e7093a4f1d983b41003553428a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNC03LTEtMS0yNDU0Mw_a0e1b6e9-b3a0-4b40-99eb-1ed13434aad4"
      unitRef="usd">50444000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f7a85404cf446fba9e007019f906e7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS0xLTEtMS0yNDU0Mw_86339a6a-dec4-433b-9890-4611427891a5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib2cd6a7df09a4e08a91ace7c629e1a29_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS0zLTEtMS0yNDU0Mw_c9592d1c-802d-454f-b526-b4a46c77fbfd"
      unitRef="usd">31143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie3e65c8c9f154d91b116d7c006a7f126_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS01LTEtMS0yNDU0Mw_e6886e68-b735-47c1-bfad-18abb776ea10"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia000fc56e55e41559e67dd102c2dbf14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNS03LTEtMS0yNDU0Mw_ee1c3a42-a77f-4e42-aac9-4393b5eccbd5"
      unitRef="usd">31143000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i117f9b88ed88410697d8af034364839b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi0xLTEtMS0yNDU0Mw_41d2eb2c-41ef-4928-895c-ac70a47a2fc2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1ead7a95130417d9939c1641c99b464_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi0zLTEtMS0yNDU0Mw_229243e3-5ff6-40c2-9e07-e738945e51f2"
      unitRef="usd">29982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaf07b6a8c12148a5b3ef09aaeed1bb3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi01LTEtMS0yNDU0Mw_f098f6ed-50ca-4427-9cd4-f60002941674"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iea7ed4e30c8343c989fb2a52999238d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNi03LTEtMS0yNDU0Mw_6fa08b1c-0670-4001-95f6-5c74eca41d3e"
      unitRef="usd">29982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9d8bc8f58f314b7dbda7fa3d301c42fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy0xLTEtMS0yNDU0Mw_dbc53b43-a771-48dd-8b06-7e187c140bb7"
      unitRef="usd">110137000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6da38639ddac4da59033ac85cd253110_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy0zLTEtMS0yNDU0Mw_e2163283-1b1a-45f9-b72d-4fea9a777119"
      unitRef="usd">111569000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia3ea2f79999340578304ad9bf5ee9000_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy01LTEtMS0yNDU0Mw_5834017a-bbef-4b9c-b988-09f9eecb3cc8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjk5OWE4OWEwZmNhYTRkNGJhMmFjYTJjMmZlYWRjYzkwL3RhYmxlcmFuZ2U6OTk5YTg5YTBmY2FhNGQ0YmEyYWNhMmMyZmVhZGNjOTBfNy03LTEtMS0yNDU0Mw_2255a78b-7a01-4b06-99eb-ce981e5a7724"
      unitRef="usd">221706000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93d61d9f2150452f8914338857d1ec28_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy0xLTEtMS0yNDU0Mw_84bfe91d-d95d-41bf-a3f3-1d619d879ed0"
      unitRef="usd">59823000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5831875e85f74ca397d08ba1b12b77b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy0zLTEtMS0yNDU0Mw_6f461cb1-9c03-4312-83f9-94ab51ef28d7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69e1c45b9cf14077ba98cd181deae320_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy01LTEtMS0yNDU0Mw_9120341d-887b-4425-9f7e-0fd2352de5bd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8e3f6dd8127416aa1c4b2182d28bf1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfMy03LTEtMS0yNDU0Mw_7d8c236b-8081-40b3-8a0a-f75fa4c11c27"
      unitRef="usd">59823000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id359b2cae0f94347aea71e824f7d93b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC0xLTEtMS0yNDU0Mw_75ada976-ce54-45dc-ae16-1f9b40daf33c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic63032f4fbea4c8cb31c3a1f550699f5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC0zLTEtMS0yNDU0Mw_e3cd1610-0821-4a55-955b-0be1c7c82b0d"
      unitRef="usd">190677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i105f7310b335489e8b39cfa28972fa27_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC01LTEtMS0yNDU0Mw_d463724d-854e-47ae-82d5-63632d7f9f28"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i436d569dcf544ec4b7f8f38f9ca866f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNC03LTEtMS0yNDU0Mw_a0fcb80f-b62b-4c22-8819-35820bbbe499"
      unitRef="usd">190677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f57aaa377ac4100b7afae26cd7bc6ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS0xLTEtMS0yNDU0Mw_a5b084d8-258d-483e-95b9-bb0e8a12eb0d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6218693389e54b8a90202c61bf65dc84_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS0zLTEtMS0yNDU0Mw_420426de-fee6-4cac-bb0b-300d7e04cd57"
      unitRef="usd">26423000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd2ccd64143145f6bc932f06c1f08a5a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS01LTEtMS0yNDU0Mw_a40ba746-47e5-48bd-ac1e-eecf9a7f870c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8350a688f64d4a83b788ae9b0d39c23b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNS03LTEtMS0yNDU0Mw_e9d8e705-29ef-4040-8644-ef054d2fdfb8"
      unitRef="usd">26423000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d6cbcfa7d0c4b59951bd7970942f9cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi0xLTEtMS0yNDU0Mw_911e753d-f287-4d4c-9324-ae1a134fadab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9c0eeaf2a7e4830a84e5a3e15aaccca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi0zLTEtMS0yNDU0Mw_8c926599-2627-4208-b4bd-49dc2538db27"
      unitRef="usd">29489000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc0754b2aa6645d49d7942e54354b1f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi01LTEtMS0yNDU0Mw_4abb6c83-7e1d-4190-ab59-d2ab70e92a36"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2335277db35e4da9bc6053ad827c6b6c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNi03LTEtMS0yNDU0Mw_862fb0e4-27e9-45bd-8c23-60a15e25fc7a"
      unitRef="usd">29489000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iabe8b8dfb0134468b31a854434788716_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy0xLTEtMS0yNDU0Mw_7301e3e8-3126-4476-a1c7-fdf7da59fe93"
      unitRef="usd">59823000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00b53675a3ce4bbf8c3f060474b55387_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy0zLTEtMS0yNDU0Mw_1ad7910d-ea51-4fcf-a3c6-96b227250d84"
      unitRef="usd">246589000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie60805415d1e4c0bb61070f850509317_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy01LTEtMS0yNDU0Mw_09417782-3a4e-440e-af45-6b0b02cafd7a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85NC9mcmFnOmY4NWQyNWFjZWFiZTQ2OGY5ZTA5YjMwYmVlN2FjZmUyL3RhYmxlOjI0YzZlODNiOTJmMzQ3N2RiOTI2Njg3ZGViNDRiODhkL3RhYmxlcmFuZ2U6MjRjNmU4M2I5MmYzNDc3ZGI5MjY2ODdkZWI0NGI4OGRfNy03LTEtMS0yNDU0Mw_130e948f-54a3-443d-9dff-fff4310dfd8f"
      unitRef="usd">306412000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA4MA_fbf47c8e-4cb5-4dd0-8457-b61c863c2c15">Balance Sheet Components&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company uses PCBAs in each wearable Zio XT and Zio AT monitor as well as the wireless gateway used in conjunction with the Zio AT monitor. The PCBAs are used numerous times and have useful lives beyond one year. Each time a PCBA is used in a wearable Zio XT monitor or Zio AT monitor, a portion of the cost of the PCBA is recorded as a cost of revenue. Each time a wireless gateway is used with a Zio AT monitor, a portion of the gateway is recorded as a cost of revenue. PCBAs which are recorded as other assets &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;were $13.9 million a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;nd $12.6 million as of December&#160;31, 2021, and December&#160;31, 2020, respectively. The amortization wa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;s $4.4 million and $3.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for the years ending December&#160;31, 2021 and 2020 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2021 and 2020 was $9.8 million and $6.9 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued vacation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued ESPP Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA4Mg_8b638389-83b1-419b-8b6f-8221a0be5b49">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="i28ab4afd0d0c40b89860d2c5c5281a69_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMi0xLTEtMS0yNDU0Mw_9d4d3674-2326-4e56-b848-0e38c2eda749"
      unitRef="usd">5101000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="i57913d02322c4309a6e6b2296ed4ae43_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMi0zLTEtMS0yNDU0Mw_9b95d77a-0477-4802-b179-003ab4f51c2a"
      unitRef="usd">2469000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="ie4fdff6e9039430eba2e53b4f1ac3997_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMy0xLTEtMS0yNDU0Mw_4b0e23d4-0b2b-4d52-84c2-bae9c9e36b89"
      unitRef="usd">5167000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="i599e4ae97436440ebb5518c8ed6cd48a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfMy0zLTEtMS0yNDU0Mw_fe4003ab-2444-448d-bbe8-2913e25c89be"
      unitRef="usd">2844000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfNC0xLTEtMS0yNDU0Mw_9463db1f-885a-4124-a851-3c3315f3b8b3"
      unitRef="usd">10268000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:InventoryAndPrintedCircuitBoardAssemblies
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjMzMzkyZWVlZTYyMzQwMjQ5ZTg2YTNhNzA5Y2JmNDc2L3RhYmxlcmFuZ2U6MzMzOTJlZWVlNjIzNDAyNDllODZhM2E3MDljYmY0NzZfNC0zLTEtMS0yNDU0Mw_db7bed3d-c526-496a-ad1b-22b5dced42bf"
      unitRef="usd">5313000</irtc:InventoryAndPrintedCircuitBoardAssemblies>
    <irtc:OtherAssetsUsefulLives
      contextRef="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzE0NjgyNTU4MTY0NQ_f370e60d-6639-4e36-aae4-194bbfe721b0">P1Y</irtc:OtherAssetsUsefulLives>
    <us-gaap:OtherAssets
      contextRef="i325e1cd03bd94e598819e2c8159b85ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNjc3_4d6124eb-f239-4aed-9526-773da4ebaff4"
      unitRef="usd">13900000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="id60332e77ea34183a58d2508319463aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNjg0_7bc9f128-03d9-4b64-a217-f8c723e3540c"
      unitRef="usd">12600000</us-gaap:OtherAssets>
    <us-gaap:AdjustmentForAmortization
      contextRef="i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzQw_12d941bb-dc2f-4318-8353-d24cff35934a"
      unitRef="usd">4400000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i2b1a81becd2e4d4d9eab5264496e678a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfNzQ3_bc3e7d29-37a7-4c6a-b21f-75881904c627"
      unitRef="usd">3000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA3OA_f1845966-d3c2-43c0-a73a-4d887be6c7d2">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory and manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9e9b27deda984a24813a7638b456e4b6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMi0xLTEtMS0yNDU0Mw_1dc2d58c-929a-4d91-a397-14fff9539c43"
      unitRef="usd">5029000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1cdcfe3d98f64ac28d89432c71dc7330_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMi0zLTEtMS0yNDU0Mw_721ffcd1-280c-4245-b5eb-958e7bbb1c20"
      unitRef="usd">4667000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0e29bf199ddb4f14a081a37d488b00d4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMy0xLTEtMS0yNDU0Mw_3adecb7b-009d-4dde-9f94-b11f9cbe6ebe"
      unitRef="usd">2353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3d87a54ba7c9421f9e5c705844818d32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfMy0zLTEtMS0yNDU0Mw_23ccb8dd-7acc-4307-9873-d0ddd5b4ac47"
      unitRef="usd">2005000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i01d4a41e7e284759a1cdb699a6d54241_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNC0xLTEtMS0yNDU0Mw_f07a164b-fc54-4447-9e21-34b36fde48c7"
      unitRef="usd">4174000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c8e622beead4bf5bdede9b59f014923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNC0zLTEtMS0yNDU0Mw_faaaee51-e8ae-4073-9d7e-059fa2ce480a"
      unitRef="usd">3794000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iec9c5185f80148638094fa6bbf5f7ceb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNS0xLTEtMS0yNDU0Mw_6de2bd37-3a3c-4d7d-9db2-84c51c5ba07b"
      unitRef="usd">20431000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7e8d067edb8c4d64bdd24a8de4d79690_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNS0zLTEtMS0yNDU0Mw_320e9953-0e57-4cdc-903b-9997227bd165"
      unitRef="usd">9215000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i51fe3bdc1dc34b259a371515f18bdb86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNi0xLTEtMS0yNDU0Mw_ec7c96b0-c48f-41bb-bec5-4425e0f183b6"
      unitRef="usd">46661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iaa0786295f5443bd811598620bb82a9a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNi0zLTEtMS0yNDU0Mw_7a60acf4-d812-4bdb-9fd3-3e068de533f6"
      unitRef="usd">28416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNy0xLTEtMS0yNDU0Mw_c6195463-9818-413b-9393-306431a25560"
      unitRef="usd">78648000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfNy0zLTEtMS0yNDU0Mw_10299b75-2e73-4623-ae0a-c42755b85f46"
      unitRef="usd">48097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOC0xLTEtMS0yNDU0Mw_835e23a3-1377-4345-a876-6da7218072e0"
      unitRef="usd">22704000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOC0zLTEtMS0yNDU0Mw_ccabdf8b-ead8-40f9-bd11-7ae26a8911be"
      unitRef="usd">13850000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOS0xLTEtMS0yNDU0Mw_c225617b-3e20-476f-be9e-d607bc95e623"
      unitRef="usd">55944000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjAyNTY0MTEyMWY2NDRkOGNhZGE5ZjMwNDc0NzE1YmNlL3RhYmxlcmFuZ2U6MDI1NjQxMTIxZjY0NGQ4Y2FkYTlmMzA0NzQ3MTViY2VfOS0zLTEtMS0yNDU0Mw_78f8ba6f-1841-4e88-90d5-321682d983f4"
      unitRef="usd">34247000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfOTY5_d16f653a-5fff-428f-a1a1-8a22a890775a"
      unitRef="usd">9800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfOTc2_64852c32-7869-44b2-817b-0c1f5b644380"
      unitRef="usd">6900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RleHRyZWdpb246YWEwMDk2NWRmOWYwNDlkZWJiZWI2NmRhYWYzMWM2M2VfMTA3OQ_c301ad60-3a9a-46fe-b85a-eb5538de4a88">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued vacation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued ESPP Contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional services fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedVacationCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMi0xLTEtMS0yNDU0Mw_953cf99e-7350-4b38-9254-992e39db82f2"
      unitRef="usd">7431000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMi0zLTEtMS0yNDU0Mw_cc558ff1-a71d-4347-83a2-ad62821499f5"
      unitRef="usd">6007000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMy0xLTEtMS0yNDU0Mw_785b3ddd-2c5c-49e1-a4f5-25c5f813af72"
      unitRef="usd">34484000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfMy0zLTEtMS0yNDU0Mw_5e768952-819a-43e3-bb2a-2c85287768ed"
      unitRef="usd">19709000</us-gaap:AccruedSalariesCurrent>
    <irtc:AccruedEmployeeStockPurchasePlanContribution
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNC0xLTEtMS0yNDU0Mw_00522415-fb92-47db-a1b3-02be8959ca2b"
      unitRef="usd">1002000</irtc:AccruedEmployeeStockPurchasePlanContribution>
    <irtc:AccruedEmployeeStockPurchasePlanContribution
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNC0zLTEtMS0yNDU0Mw_2db8b9d6-f2d7-4f85-814b-ff06bf5cfbae"
      unitRef="usd">851000</irtc:AccruedEmployeeStockPurchasePlanContribution>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNS0xLTEtMS0yNDU0Mw_e255aced-f3fe-4bb6-aa41-75793f072f6e"
      unitRef="usd">1724000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNS0zLTEtMS0yNDU0Mw_f5c17c8f-2e8a-422f-a9c7-cd012b3f31fd"
      unitRef="usd">1709000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNi0xLTEtMS0yNDU0Mw_a1801399-3175-4a24-8d8d-8d163ee5f861"
      unitRef="usd">78000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNi0zLTEtMS0yNDU0Mw_87bddee0-a037-498a-8c83-d16ef892e972"
      unitRef="usd">121000</us-gaap:InterestPayableCurrent>
    <irtc:ClaimsPayableCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNy0xLTEtMS0yNDU0Mw_64b758c4-2b2b-497f-b315-cd5dfedb6f6e"
      unitRef="usd">2988000</irtc:ClaimsPayableCurrent>
    <irtc:ClaimsPayableCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfNy0zLTEtMS0yNDU0Mw_5973d694-6aa8-4757-b242-07942870f485"
      unitRef="usd">4757000</irtc:ClaimsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOC0xLTEtMS0yNDU0Mw_f53e312b-1321-4a0f-8374-dcc4f62e98bd"
      unitRef="usd">3779000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOC0zLTEtMS0yNDU0Mw_9258262c-23cb-4f44-a162-c36d4f89ad79"
      unitRef="usd">7378000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOS0xLTEtMS0yNDU0Mw_73a75038-dd81-4262-b15a-4a527b515c85"
      unitRef="usd">51486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV85Ny9mcmFnOmFhMDA5NjVkZjlmMDQ5ZGViYmViNjZkYWFmMzFjNjNlL3RhYmxlOjBjNzdiYjcxMzNjOTQzZjhhMDNhOTU2MmMyMjZkZTQ1L3RhYmxlcmFuZ2U6MGM3N2JiNzEzM2M5NDNmOGEwM2E5NTYyYzIyNmRlNDVfOS0zLTEtMS0yNDU0Mw_16af4a2c-d494-4d89-b2e1-36c45472678b"
      unitRef="usd">40532000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcwODQ_bd59dfad-c4bc-4f97-9658-ddd36adcb8a8">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company leases office, manufacturing, and clinical centers under non-cancelable operating leases which expire on various dates through&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2031.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; These leases generally contain scheduled rent increases or escalation clauses and renewal options. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease right-of-use assets also include any lease payments made to the lessor at or before the commencement date as well as variable lease payments which are based on a consumer price index. The Company is also subject to variable lease payments related to janitorial services and electricity which are not included in the operating lease right-of-use asset as they are based on actual usage. The Company recognizes operating lease expense on a straight-line basis over the lease period. The total operating lease cost recognized during the year ended December&#160;31, 2021 was $13.5&#160;million which primarily consisted of lease payments and common area maintenance costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for operating leases during the year ended December&#160;31, 2021 was $12.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 4, 2018, the Company entered into an office lease (&#x201c;San Francisco Lease&#x201d;) to rent approximately 117,560 rentable square feet in San Francisco, California, which became the Company&#x2019;s new headquarters in October 2019. The term of the San Francisco Lease began on May 13, 2019, and expires on August 31, 2031. The Company is entitled to one option to extend the San Francisco Lease for a five-year term, subject to certain requirements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 29, 2009, the Company entered into a lease for a clinic (&#x201c;Lincolnshire Lease&#x201d;) to rent approximately 41,500 rentable square feet in Lincolnshire, Illinois, which became the Company&#x2019;s clinic facilities. The term of the Lincolnshire Lease began &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;on November 1, 2009,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and expires on July 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 18, 2021, the Company entered into an office/industrial lease (&#x201c;Cypress Lease&#x201d;) to rent approximately 68,933 rentable square feet in Cypress, California, which became the Company&#x2019;s new office and warehouse facilities. The term of the Cypress Lease began on October 25, 2021, and expires on April 30, 2032. The Company is entitled to one option to extend the Cypress Lease for a five-year term, subject to certain requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company expects these decisions will result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The weighted average remaining lease term of the Company's operating leases as of December&#160;31, 2021 was 9.62 years. The weighted average discount rate of the Company's operating leases was 7.27% as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company entered into a lease for 44,616 rentable square feet in Deerfield Illinois ("Deerfield Lease"). The Deerfield Lease commenced in January 2022, and will be recorded as a right of use asset to the Company's financial statements in the first quarter of 2022. The Company is currently assessing the impact to its consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in claims and legal proceedings or investigations, that arise in the ordinary course of business. Such matters could have an adverse impact on its reputation, business and the financial condition and divert the attention of its management from the operation of its business.  These matters are subject to many uncertainties and outcomes that are not predictable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2021, a putative class action lawsuit was filed in the United States District Court for the Northern District of California alleging that the Company and its former Chief Executive Officer, Kevin M. King, violated Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 promulgated thereunder. On August 2, 2021, the lead plaintiff filed an amended complaint, and filed a further amended complaint on September 24, 2021. The amended complaint names as defendants, in addition to the Company and Mr. King, the Company's former Chief Executive Officer, Michael J. Coyle, and current Chief Financial Officer, Douglas J. Devine. The purported class in the amended complaint includes all persons who purchased or acquired the Company's common stock between August 4, 2020 and July 13, 2021, and seeks unspecified damages purportedly sustained by the class. On October 27, 2021, the Company filed a motion to dismiss the amended complaint. The motion to dismiss was fully briefed and the Court held a hearing on the motion on February 4, 2022, after which the Court took the matter under submission.  The Court has not yet issued a ruling. The Company believes the class action to be without merit and plans to vigorously defend itself.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2021, the Company received a grand jury subpoena from the U.S. Attorney&#x2019;s Office for the Northern District of California requesting information related to communications with the Food and Drug Administration and the Company&#x2019;s products. On October 14, 2021, the Company received a second subpoena requesting additional information. The Company is cooperating fully and is providing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On September 3, 2019, the Company entered into a Development Collaboration Agreement (the &#x201c;Development Agreement&#x201d;) with Verily Life Sciences LLC (&#x201c;Verily&#x201d;). The Development Agreement, which is over a 24 month term, involves joint development and production of intellectual property between the Company and Verily. Each participant has primary responsibility for certain aspects of development and approval, with all processes to be performed at each respective party&#x2019;s own cost. Costs incurred by the Company in connection with the Development Agreement will be expensed as research and development expense in accordance with ASC 730, Research and Development.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company and Verily will develop certain next-generation atrial fibrillation (&#x201c;AF&#x201d;) screening, detection, or monitoring products pursuant to the Development Agreement, which products will involve combining Verily and the Company's technology platforms and capabilities. Under the terms of the Development Agreement, the Company paid Verily an upfront fee of $5.0&#160;million in 2019. In addition, the Company has agreed to make additional payments to Verily up to an aggregate of $12.75&#160;million in milestone payments upon achievement of various development and regulatory milestones over the 24 months of the Development Agreement, which payments will be made in cash to Verily. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have achieved milestones tied to payments totaling $11.0&#160;million to date, $3.0&#160;million of which is associated with a milestone achieved during the quarter ended December 31, 2021 and is included in Accounts Payable on December 31, 2021. We have agreed to make additional payments over the term of the Development Agreement up to an aggregate of $1.75&#160;million, subject to the achievement of certain development and regulatory milestones including provision Zio Watch and completion of market evaluation scheduled to begin between late 2022 and early 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Development Agreement provides each party with licenses to use certain intellectual property of the other party for development activities in the field of AF screening, detection, or monitoring. Ownership of developed intellectual property will be allocated to the Company or Verily depending on the subject matter of the underlying developed intellectual property, and, for certain subject matter, shall be jointly owned.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company enters into agreements pursuant to which it agrees to indemnify customers, vendors, lessors, business partners, and other parties with respect to certain matters, including losses arising out of the breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims made by third parties. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by applicable law. The Company currently has directors&#x2019; and officers&#x2019; insurance. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions, and believes that the estimated fair value of these indemnification obligations is not material and it has not accrued any amounts for these obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwNTM_ef2a4d5d-3b4b-4409-bbaf-ee9c4b77161c"
      unitRef="usd">13500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzExOTU_b34f19db-ced0-48b7-a5a7-75659ec16581"
      unitRef="usd">12200000</us-gaap:OperatingLeasePayments>
    <irtc:OperatingLeaseRentableArea
      contextRef="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTgzNzU_29d4caaf-4042-4d28-a39c-490351e0476f"
      unitRef="sqft">117560</irtc:OperatingLeaseRentableArea>
    <irtc:LesseeOperatingSubleaseNumberOfOptionToExtend
      contextRef="i6c6807592d254ff88a10a57aea41b8c5_D20181004-20181004"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTgzODg_3de17b25-98dc-41fa-84be-5b85e9b24930"
      unitRef="optiontoextend">1</irtc:LesseeOperatingSubleaseNumberOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i86d015db8fe54d278b4d3a0b46b4ccee_I20181004"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MDg_f5bfb2ca-5d0b-4f6c-b8a0-29d7fd1cd799">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <irtc:OperatingLeaseRentableArea
      contextRef="i295d5c0437d34174bf44c52749a0ac5a_I20091029"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MTA_8a2350e4-9fec-4c18-a2c1-8263ff0f7dca"
      unitRef="sqft">41500</irtc:OperatingLeaseRentableArea>
    <irtc:OperatingLeaseRentableArea
      contextRef="i0fde8b0fa6ab4dfe86bf892cb5232e3d_I20210318"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MjA_15891356-338d-45f2-af85-bb7181857e32"
      unitRef="sqft">68933</irtc:OperatingLeaseRentableArea>
    <irtc:LesseeOperatingSubleaseNumberOfOptionToExtend
      contextRef="i473a9e8ce4c04091aa983711246e3313_D20210318-20210318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0MzI_f6a8f2ec-e1da-4c08-81bf-7cb699b8f0d0"
      unitRef="optiontoextend">1</irtc:LesseeOperatingSubleaseNumberOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i247ed5aae14d46398ee4c08aefa80fc9_I20210318"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTg0NDg_59095d3a-255d-4623-85cc-94e101346bdb">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcwODY_82f61f9b-4c8b-4d39-aed6-027d3ffefcac">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzEtMS0xLTEtMjQ1NDM_03991fa6-275d-43cc-8341-5e0bbd02b069"
      unitRef="usd">12617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzItMS0xLTEtMjQ1NDM_27cc6fe2-23b1-407f-9e51-a12413ade7c1"
      unitRef="usd">12912000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzMtMS0xLTEtMjQ1NDM_efff57bb-0b1f-494d-ac95-785e5b3660aa"
      unitRef="usd">13304000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzQtMS0xLTEtMjQ1NDM_d7bc35e1-7f74-4d34-a5bf-39224e7ac9d3"
      unitRef="usd">13696000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzUtMS0xLTEtMjQ1NDM_8fc15c90-56fe-43a0-93c9-8f58ac127c45"
      unitRef="usd">14100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzYtMS0xLTEtMjQ1NDM_266d83e6-0dfc-48fa-b4c3-88c775f11385"
      unitRef="usd">69898000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzctMS0xLTEtMjQ1NDM_f626c95a-0d59-464b-aa89-377e603489fa"
      unitRef="usd">136527000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzgtMS0xLTEtMjQ1NDM_75793723-cc75-4619-b47c-b12e9ccb09bf"
      unitRef="usd">40173000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90YWJsZTo0NTg3NTMwMjFhN2Q0YTYwYmY3OGFmOWQxNTMxNGI4ZS90YWJsZXJhbmdlOjQ1ODc1MzAyMWE3ZDRhNjBiZjc4YWY5ZDE1MzE0YjhlXzktMS0xLTEtMjQ1NDM_a5a8c8a7-5a23-4b6a-8c87-1ff7966b7a95"
      unitRef="usd">96354000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzIzMjM_990537e6-2eb2-425a-8384-572dd9fb2216">P9Y7M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzI0MDY_519c6912-be02-451f-ab8d-7e896df7d320"
      unitRef="number">7.27</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <irtc:OperatingLeaseRentableArea
      contextRef="ibc473ee2e3f047b9becb2198e94c3342_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzcxNDY4MjU1OTE5NTM_bba44f7f-b770-45bc-be1d-dc9da4d29d96"
      unitRef="sqft">44616</irtc:OperatingLeaseRentableArea>
    <irtc:CollaborationAgreementRemainingTermOfAgreement
      contextRef="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzM2NTY_307fec08-d067-4e75-9063-2ca5e9ee78af">P24M</irtc:CollaborationAgreementRemainingTermOfAgreement>
    <irtc:CollaborationAgreementUpfrontFeePayable
      contextRef="i3d8d51dc95ba423b813f74a49801e062_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ0Nzk_e1e449e7-df44-4960-ae78-f11a7cc922c0"
      unitRef="usd">5000000</irtc:CollaborationAgreementUpfrontFeePayable>
    <irtc:CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months
      contextRef="i583c6b3e405b4a20a3da03740a2eb9f3_I20190903"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ1ODc_c4877aa0-8441-4e29-bec9-1cf4c605ce12"
      unitRef="usd">12750000</irtc:CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months>
    <irtc:CollaborationAgreementRemainingTermOfAgreement
      contextRef="i6c6678788696456d91031a3ff8951f0a_D20190903-20190903"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzQ2ODc_af8b91a8-8dcc-41a3-a0fc-136c370347c9">P24M</irtc:CollaborationAgreementRemainingTermOfAgreement>
    <irtc:CollaborationAgreementMilestonePayments
      contextRef="i7f3ae94beacb488f8fa3638f2d2170e4_I20220225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ1ODA_7da11135-e1e5-4b9f-b7ef-f0b4db50703a"
      unitRef="usd">11000000</irtc:CollaborationAgreementMilestonePayments>
    <irtc:CollaborationAgreementMilestonePayments
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ1OTU_13efa50c-81c1-4424-9b3f-7957230e5221"
      unitRef="usd">3000000</irtc:CollaborationAgreementMilestonePayments>
    <irtc:CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDAvZnJhZzozNjg3NzRjZDkwNTE0MmJlOWNmYTI0NTQxZjcyYTk0MS90ZXh0cmVnaW9uOjM2ODc3NGNkOTA1MTQyYmU5Y2ZhMjQ1NDFmNzJhOTQxXzEwOTk1MTE2NDQ2MjM_4eaec0e0-9fb4-41a5-a81a-e6fbd50c8c20"
      unitRef="usd">1750000</irtc:CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzM0MjI_9c7997a8-bfce-4cb0-8ddc-41563775561e">Debt&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bank Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2018, the Company entered into the Third Amended and Restated Loan and Security Agreement with SVB (&#x201c;Third Amended and Restated SVB Loan Agreement&#x201d;). This Agreement amends and restates the Second Amended and Restated Loan and Security Agreement between the Company and SVB dated December 4, 2015, as amended by the First Loan Modification Agreement between the Company and SVB dated August 22, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Third Amended and Restated SVB Loan Agreement, the Company obtained a term loan (&#x201c;SVB Term Loan&#x201d;) for $35.0 million. Total proceeds from the SVB Term Loan were used to pay off the loan agreement with Biopharma Secured Investments III Holdings Cayman LP (&#x201c;Pharmakon&#x201d;), totaling $35.8 million. The Company made interest-only payments through October 31, 2020. Beginning in November 2020, the Company began monthly payments of principal plus interest, which will continue through October 31, 2023. Interest charged on the SVB Term Loan will be the greater of (a) a floating rate based on the &#x201c;Prime Rate&#x201d; published by The Wall Street Journal minus 0.75%, or (b) 4.25%. The weighted average interest rate was 4.25% and 4.25% for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Third Amended and Restated SVB Loan Agreement, the Company may borrow, repay, and reborrow under a revolving credit line, but not in excess of the maximum loan amount of $25.0 million, which includes an $11.0 million standby letter of credit sublimit availability. In October 2018, a $6.9 million standby letter of credit was obtained in connection with a lease for the Company&#x2019;s San Francisco headquarters. Any principal amount outstanding under the Third Amended and Restated SVB Loan Agreement revolving credit line shall bear interest at an amount that is the greater of (a) a floating rate per annum equal to the rate published by The Wall Street Journal as the &#x201c;Prime Rate&#x201d; or (b) 5.00%. The Company may borrow up to 75% of eligible accounts receivable, up to the maximum of $25.0 million. As of December 31, 2021, the Company was eligible to borrow up to $13.8&#160;million and no amount was outstanding under the revolving credit line. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Third Amended and Restated Loan Agreement requires the Company to maintain a minimum consolidated liquidity ratio or minimum adjusted Earnings Before Interest, Tax, Depreciation, and Amortization during the term of the loan facility. In addition, the SVB Loan Agreement contains customary affirmative and negative covenants and events of default. The Company was in compliance with loan covenants as of December&#160;31, 2021. The obligations under the Third Amended and Restated Loan Agreement are collateralized by substantially all assets of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:39.6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Future minimum payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum payments under the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank at December&#160;31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i658ecfa8506846dc82b0e01ee90a18e1_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzEyNTU_a1c0c479-60ad-44ed-9b17-bc0ce19b73bc"
      unitRef="usd">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i8bd3de617d2f41cbbeb04e8d26d24912_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE0MTk_2f575713-0b01-447e-959b-66c9f91a1587"
      unitRef="usd">35800000</us-gaap:RepaymentsOfLinesOfCredit>
    <irtc:DebtInstrumentBasisSpreadDeductionOnVariableRate
      contextRef="i634d244c801140b8ab07eeabd8d14ef6_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3MjA_75d3c365-0fab-42bc-948e-86f879267739"
      unitRef="number">0.0075</irtc:DebtInstrumentBasisSpreadDeductionOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0e385fae9c694ac58ec7814ba00a5b71_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3MzE_80b3a3e2-411a-42f3-8067-5a4d77b70c1a"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3NzQ_f25e8bbd-650c-49fa-9a23-6e1353d6d2d7"
      unitRef="number">0.0425</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE3ODE_be501e36-72f8-46f2-827a-de0366575a1c"
      unitRef="number">0.0425</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIwMTE_cdb12f8c-2756-4b45-bb8d-b10cfc418134"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i91e808628b6a4613b5438a4e78004a62_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIwMzM_14745437-e051-4d86-bbce-dce95a8e38a2"
      unitRef="usd">11000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i79eb7c2fe0da4198aa7a5eea32e35ebd_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzIxMDM_82c99ecd-4f16-445a-a645-30804c948758"
      unitRef="usd">6900000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1a67f248e25942c7be0ace4b0a88b4e1_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI0OTY_eb57583b-cfdc-422e-8276-80e3b2562d6d"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <irtc:PercentageOfEligibleAccountsReceivableForBorrowings
      contextRef="id79b2be320cb4762a45bd10e6a3c51f4_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI1Mjk_72acaeed-9521-4919-b21d-c032929d2232"
      unitRef="number">0.75</irtc:PercentageOfEligibleAccountsReceivableForBorrowings>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI1ODY_0818498d-10de-460a-b550-53513bba6a40"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9ec1526aa3b646a98a400738b384e12d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzE2NDkyNjc0NDY1Mjc_a5ba14e9-18b0-4439-9b00-c194adeadd4f"
      unitRef="usd">13800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i52e9a180e54c425a8f4d05638f8ec7fe_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzI0NzM5MDExNjI5ODM2_438e9ad9-954b-48ce-a7e6-b696d7438c44"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90ZXh0cmVnaW9uOjBiYWEzN2MxOWU4ODRmNzJhYjFmODg0Njk5MGU3ZGIyXzM0MjE_eb7622c4-353f-4fd6-b424-f73a4d5c248c">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum payments under the Third Amended and Restated Loan and Security Agreement with Silicon Valley Bank at December&#160;31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amount representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Debt Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEtMS0xLTEtMjQ1NDM_f2bb5745-551f-4577-b7c0-1f83b0b7d023"
      unitRef="usd">12357000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzItMS0xLTEtMjQ1NDM_dd0f259c-0797-40a5-b10a-5b4fb27fbcc3"
      unitRef="usd">9914000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzQtMS0xLTEtMjQ1NDM_5decfd44-945c-41f2-9be8-6aa26bd8fb64"
      unitRef="usd">22271000</us-gaap:LongTermDebt>
    <irtc:DebtInstrumentInterestPortion
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzUtMS0xLTEtMjQ1NDM_61887c8f-9cf6-42a4-af82-58a6e37fd9de"
      unitRef="usd">883000</irtc:DebtInstrumentInterestPortion>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzYtMS0xLTEtMjQ1NDM_b0cc74f9-7f82-444d-91d4-a40c3f84a635"
      unitRef="usd">31000</us-gaap:DeferredFinanceCostsNet>
    <irtc:LongTermDebtCarryingValue
      contextRef="i18aaaa80c4654a52a50440835da85723_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzctMS0xLTEtMjQ1NDM_6db26f7e-5b98-4024-8694-461e7b53624c"
      unitRef="usd">21357000</irtc:LongTermDebtCarryingValue>
    <us-gaap:DebtCurrent
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEwLTEtMS0xLTI0NTQz_22e01986-b301-4c7c-804e-3fdb46854892"
      unitRef="usd">11667000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzExLTEtMS0xLTI0NTQz_d5fe705a-63af-47fa-806b-e23745a81f2a"
      unitRef="usd">9690000</us-gaap:LongTermDebt>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDMvZnJhZzowYmFhMzdjMTllODg0ZjcyYWIxZjg4NDY5OTBlN2RiMi90YWJsZTo2YzYyZTA5ZTI0NjQ0NzhiOWQ4MTA3NzdmOTA5NzQ3Ny90YWJsZXJhbmdlOjZjNjJlMDllMjQ2NDQ3OGI5ZDgxMDc3N2Y5MDk3NDc3XzEyLTEtMS0xLTI0NTQz_b93e53e8-5349-426e-af43-1e4cfe2319a9"
      unitRef="usd">21357000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzk_cad6f7ce-3646-43d7-9de9-645ef6434f3f">Income Taxes&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents components of the Company&#x2019;s provision for income taxes as for the period presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company&#x2019;s tax expense for the period presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and Entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation - officers compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the uncertainties surrounding the realization of deferred tax assets through future taxable income, the Company has provided a full valuation allowance against its U.S. deferred tax assets, and, therefore, no benefit has been recognized for the net operating loss carryforwards and other deferred tax assets. The U.S. valuation allowance increased by $30.9 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$35.4 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the years ended December&#160;31, 2021 and December&#160;31, 2020, respectively. The current year change in the U.S. valuation allowance is primarily related to the increase in net operating loss carryforwards generated during the year. The Company recorded an immaterial deferred tax asset related to the Company&#x2019;s foreign operations in the United Kingdom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance for deferred tax assets consisted of the following activity for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, the Company had approximately $464.3 million of federal and $279.1 million of state net operating loss carryforwards available to offset future taxable income which expires in varying amounts beginning in 2027 and   2020 respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had research tax credit carryforwards of approximately $7.4 million, and $6.1 million available to reduce future taxable income, if any, for both federal and state purposes, respectively. The federal tax credit carryforwards expire beginning in 2028 and the state tax credits can be carried forward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Section 382 of the Internal Revenue Code, and similar state provisions, limits the use of net operating loss and tax credit carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event the Company should experience an ownership change, as defined, utilization of its net operating loss carryforwards and tax credits could be limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2019, the Company adopted ASC 740-10 (formerly known as FIN 48), Accounting for Income Taxes, guidance that addresses the recognition, measurement, and disclosure of uncertain tax positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions taken in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in balance related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases in balance related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total amount of gross unrecognized tax benefits was $3.3 million, $2.3 million, and $1.8 million as of December&#160;31, 2021, 2020, and 2019 respectively. None of the Company&#x2019;s unrecognized tax benefits that, if recognized, would affect its effective tax rate. The Company does not anticipate the total amounts of unrecognized tax benefits will significantly increase or decrease in the next 12 months. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits within the provision for taxes. Management determined that no accrual for interest or penalties was required as of December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company files income tax returns in the U.S. and UK jurisdictions. All of the Company's tax years are open to examination by the US federal and state tax authorities. The UK is open to examination for tax years starting 2017 and forward. The Company currently has no federal, state or foreign tax examinations in progress, nor has it had any federal or state examinations since inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODA_9d7b5dd8-6fe5-41f3-9239-4811ed21b22e">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents components of the Company&#x2019;s provision for income taxes as for the period presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.096%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Tax Expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtMS0xLTEtMjQ1NDM_e3e297de-3e22-40a6-b334-383f2ed449f8"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtMy0xLTEtMjQ1NDM_ae27c3e7-9171-4507-a45a-efe690b5e23e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzMtNS0xLTEtMjQ1NDM_f3db1410-0056-4988-a7da-a85c97df073c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtMS0xLTEtMjQ1NDM_10331f30-f112-4c15-9260-6e32b640bdc7"
      unitRef="usd">223000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtMy0xLTEtMjQ1NDM_0805e962-f173-44f2-9184-8d38fc6f4531"
      unitRef="usd">181000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzQtNS0xLTEtMjQ1NDM_d0e1b2f8-95ff-4baf-8073-be87a8e874cc"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtMS0xLTEtMjQ1NDM_c911c167-43ad-4812-9f9a-0b407ee352fc"
      unitRef="usd">150000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtMy0xLTEtMjQ1NDM_a7fe6f0f-3a58-474a-b9a5-e469248b2a18"
      unitRef="usd">59000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzUtNS0xLTEtMjQ1NDM_933a557b-81fc-46ef-90c4-d62a3388a071"
      unitRef="usd">68000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtMS0xLTEtMjQ1NDM_9470fd51-c866-4c67-8f37-2ab445275ee1"
      unitRef="usd">373000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtMy0xLTEtMjQ1NDM_b33525d5-f95a-444b-ad93-f91aee7d98b1"
      unitRef="usd">240000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzYtNS0xLTEtMjQ1NDM_f485c9fb-a097-401e-bf0c-7947dc260ea3"
      unitRef="usd">68000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktMS0xLTEtMjQ1NDM_b0bdce7d-eae5-42f0-b38a-5ac9b7c5ba61"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktMy0xLTEtMjQ1NDM_75ee4560-4c11-4cf4-a718-acd9a42df640"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzktNS0xLTEtMjQ1NDM_c321ee66-9188-4c1f-a2ec-f4a6e2ecd839"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTEtMS0xLTI0NTQz_d8b2fc1c-619b-479a-8ff1-bd05bd919fca"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTMtMS0xLTI0NTQz_eb6b80b5-9148-4377-90d6-ae7177e01b4e"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEwLTUtMS0xLTI0NTQz_41e61f2b-8153-4c3d-b24d-cb95cd4f1df1"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTEtMS0xLTI0NTQz_9312be7f-970f-4a4a-94da-36ad58c0e8cd"
      unitRef="usd">-6000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTMtMS0xLTI0NTQz_53bde6e6-a6cc-41b2-8f77-c506b1f71395"
      unitRef="usd">-11000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzExLTUtMS0xLTI0NTQz_05086ed2-30ad-40f7-a30c-bb0dc66ea3d4"
      unitRef="usd">-3000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTEtMS0xLTI0NTQz_c832866c-c581-48ea-a76c-1fb59acfe87f"
      unitRef="usd">-6000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTMtMS0xLTI0NTQz_fdab7194-8034-453e-a373-c377349d19b2"
      unitRef="usd">-11000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzEyLTUtMS0xLTI0NTQz_4055d2af-d53d-4688-8c0a-77b15ca927f5"
      unitRef="usd">-3000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTEtMS0xLTI0NTQz_2be5b63f-aed4-4ecd-a864-54b3d51a1303"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTMtMS0xLTI0NTQz_904aec3f-62fa-4d5d-a13b-a3c4de8c43a9"
      unitRef="usd">229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo2OTUyZGZlNDkyODY0ZGNjYTFlOTM3YWEzMGRlMDU2NC90YWJsZXJhbmdlOjY5NTJkZmU0OTI4NjRkY2NhMWU5MzdhYTMwZGUwNTY0XzE0LTUtMS0xLTI0NTQz_4e128fc6-7abd-4777-9214-a69a12eb184f"
      unitRef="usd">65000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODM_4c694d17-7337-4972-b0e8-f9f3c56eb464">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense computed at the statutory federal rate and the Company&#x2019;s tax expense for the period presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,762)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and Entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 162(m) limitation - officers compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItMS0xLTEtMjQ1NDM_6c71239f-c2c3-400a-a8e3-2da3415b4dd8"
      unitRef="usd">-21198000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItMy0xLTEtMjQ1NDM_d8cf3630-3d6a-4dd9-93ef-a4bca32bfa5e"
      unitRef="usd">-9172000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzItNS0xLTEtMjQ1NDM_7c391034-8a0d-40ab-9af9-37e238c05edd"
      unitRef="usd">-11446000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMS0xLTEtMzEzNDk_3cb94ca7-a8e9-4058-926f-9152430c114b"
      unitRef="usd">223000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMy0xLTEtMzEzNTU_bbceb6a0-0552-45ee-82c4-582506830bb5"
      unitRef="usd">181000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtNS0xLTEtMzEzNjI_deb41881-7666-4f60-ac66-ed6dd7e14861"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMS0xLTEtMjQ1NDM_eb77d503-002f-4f39-83c0-a9fb10d5e853"
      unitRef="usd">-7049000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtMy0xLTEtMjQ1NDM_8cb7e360-1d98-4bc1-80d1-2886ce330818"
      unitRef="usd">-20762000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzMtNS0xLTEtMjQ1NDM_e58731e4-cdd2-4a71-be41-d9c59bca00ae"
      unitRef="usd">-5560000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtMS0xLTEtMjQ1NDM_94cbb2d9-e8a3-4341-b7cd-19ebac3539b8"
      unitRef="usd">182000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtMy0xLTEtMjQ1NDM_6ca626e9-37e2-4eac-bb4a-223818fe94bb"
      unitRef="usd">177000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzQtNS0xLTEtMjQ1NDM_4ee26ecd-7a8d-4117-bd3a-f26f1722aa47"
      unitRef="usd">409000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtMS0xLTEtMjQ1NDM_daf65bca-2a05-431a-8969-86f2145492db"
      unitRef="usd">4856000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtMy0xLTEtMjQ1NDM_08829c82-221a-44ad-a928-e340e5523beb"
      unitRef="usd">544000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzUtNS0xLTEtMjQ1NDM_6bcfa8e3-95a8-434a-a206-4b98feab2630"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctMS0xLTEtMzMzMDQ_ae0a9c19-4a1e-4a53-822e-c6bbaa7f3103"
      unitRef="usd">-347000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctMy0xLTEtMzMyOTg_49f78e15-f52b-4440-b660-8d76b7df3e12"
      unitRef="usd">89000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzctNS0xLTEtMzMyOTE_497e1cd0-0541-4b69-93aa-f21d60d0e025"
      unitRef="usd">614000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtMS0xLTEtMjQ1NDM_5d31dbe6-26ef-4d94-8679-2f3e0f09b3d2"
      unitRef="usd">381000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtMy0xLTEtMjQ1NDM_e94aeea6-8b0b-42ac-9485-81fd2582856e"
      unitRef="usd">1426000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzYtNS0xLTEtMjQ1NDM_24c8a422-f6db-41ff-ad0c-e7fd692735d2"
      unitRef="usd">1128000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMS0xLTEtMzEzOTI_68d383ca-c850-4cf4-bff9-10d009d11f7e"
      unitRef="usd">-30000</irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017>
    <irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMy0xLTEtMzE0MDA_e2bb04a0-89fb-4430-88aa-4b15aeb186c2"
      unitRef="usd">-9000</irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017>
    <irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtNS0xLTEtMzE0MDY_ae7ea84d-34b2-4e6e-93cf-c8308b20a634"
      unitRef="usd">0</irtc:IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMS0xLTEtMjQ1NDM_21f71290-426a-4afd-b57e-0abca9b1ac01"
      unitRef="usd">24111000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtMy0xLTEtMjQ1NDM_1733b7df-8bd0-4837-9364-6edecc237bf6"
      unitRef="usd">30607000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzgtNS0xLTEtMjQ1NDM_aba224be-6c28-44ca-b437-30b15b914fb1"
      unitRef="usd">17176000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktMS0xLTEtMjQ1NDM_579c8af9-bd26-4124-832c-7caabb882158"
      unitRef="usd">367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktMy0xLTEtMjQ1NDM_198abdbf-a784-4e60-9ce2-684a1b300c88"
      unitRef="usd">229000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo3N2I2YjJkZjBkNDI0MDllYmVjNTc1YWIyNzU5ODQ1Ny90YWJsZXJhbmdlOjc3YjZiMmRmMGQ0MjQwOWViZWM1NzVhYjI3NTk4NDU3XzktNS0xLTEtMjQ1NDM_d4739a59-9412-4c8e-86f0-8a8ab4d19918"
      unitRef="usd">65000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5ODQ_71cbda83-eed7-42e8-862c-3241ba208b30">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzMtMS0xLTEtMjQ1NDM_ace85dad-2aa0-48a7-ac97-efcd148a8b95"
      unitRef="usd">114856000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzMtMy0xLTEtMjQ1NDM_d0bc3fa0-8552-4ef3-a65b-3be156afe349"
      unitRef="usd">91034000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzQtMS0xLTEtMjQ1NDM_9079ecbb-9d4a-4c21-a416-bf5abc65fe18"
      unitRef="usd">9174000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzQtMy0xLTEtMjQ1NDM_396a7b97-3e3d-4287-8517-beb2b8db8a40"
      unitRef="usd">7110000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzUtMS0xLTEtMjQ1NDM_77f1ce29-104e-4b10-bb42-2496f0934d0d"
      unitRef="usd">9812000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzUtMy0xLTEtMjQ1NDM_28b79f5f-1dd9-4ba9-868a-8736cc82dcc2"
      unitRef="usd">8831000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <irtc:DeferredTaxAssetsValuationAllowancesAndOther
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzYtMS0xLTEtMjQ1NDM_d0644ef6-0c41-43d5-9a2f-9d8a0780d746"
      unitRef="usd">20988000</irtc:DeferredTaxAssetsValuationAllowancesAndOther>
    <irtc:DeferredTaxAssetsValuationAllowancesAndOther
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzYtMy0xLTEtMjQ1NDM_0ca70ce7-d95f-4c75-808e-94b638cbc050"
      unitRef="usd">14996000</irtc:DeferredTaxAssetsValuationAllowancesAndOther>
    <irtc:DeferredTaxAssetsLeaseObligations
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzctMS0xLTEtMjQ1NDM_fa96f047-7701-4a5a-b906-901d198c37f0"
      unitRef="usd">23868000</irtc:DeferredTaxAssetsLeaseObligations>
    <irtc:DeferredTaxAssetsLeaseObligations
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzctMy0xLTEtMjQ1NDM_a6f1194d-d0f2-43dc-8dbc-44dcc488e9dc"
      unitRef="usd">22624000</irtc:DeferredTaxAssetsLeaseObligations>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzgtMS0xLTEtMjQ1NDM_b63f23f3-dad7-4f0f-ba73-1880265ffd94"
      unitRef="usd">178698000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzgtMy0xLTEtMjQ1NDM_55cde727-196e-4a47-8b72-0afe585a50a0"
      unitRef="usd">144595000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzktMS0xLTEtMjQ1NDM_8e4d980e-2969-4365-84e0-335f92e856c8"
      unitRef="usd">154734000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzktMy0xLTEtMjQ1NDM_f24c3cc2-dc80-4d14-9c2d-3fe38023c1bd"
      unitRef="usd">123803000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEwLTEtMS0xLTI0NTQz_58fa98b9-f954-43ed-a929-9c6e81015b27"
      unitRef="usd">23964000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEwLTMtMS0xLTI0NTQz_deaab83e-98c1-44ef-8eca-653b6cc54fe8"
      unitRef="usd">20792000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEzLTEtMS0xLTI0NTQz_fde82471-35da-4b30-b3bd-40257a18ce75"
      unitRef="usd">3212000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzEzLTMtMS0xLTI0NTQz_2a232a85-9847-4c71-b0f2-c939cb93fc69"
      unitRef="usd">108000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE0LTEtMS0xLTI0NTQz_900ab478-5d74-4978-9b6b-9b691ab4c613"
      unitRef="usd">20696000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE0LTMtMS0xLTI0NTQz_a56f7f02-334a-4663-a67d-80a02347aacf"
      unitRef="usd">20634000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE1LTEtMS0xLTI0NTQz_c98d2df2-0123-428d-ad1b-6e1b84920795"
      unitRef="usd">23908000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE1LTMtMS0xLTI0NTQz_5e01766f-f244-4d48-b1e9-20f632a48af5"
      unitRef="usd">20742000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE2LTEtMS0xLTI0NTQz_00239295-1d79-4e38-9cb6-617fab981be8"
      unitRef="usd">56000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTpiNWM1YWQ4YmI2NDk0NWM1OGUzNzY0Y2EyYzI0YjE1Mi90YWJsZXJhbmdlOmI1YzVhZDhiYjY0OTQ1YzU4ZTM3NjRjYTJjMjRiMTUyXzE2LTMtMS0xLTI0NTQz_f8a2b0db-5c6b-4086-ab03-aebcda5ca533"
      unitRef="usd">50000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <irtc:OperatingLossCarryforwardsTaxBenefitRecognized
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzg1Nw_c1a74d4a-6ada-48b4-bb17-a671b0d0ec68"
      unitRef="usd">0</irtc:OperatingLossCarryforwardsTaxBenefitRecognized>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzEwMDI_92ebad8d-d8f5-4ceb-8045-a9adcd157be5"
      unitRef="usd">30900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzEwMDk_7b44c55c-f6c3-497d-b8be-2f953ef7f9f0"
      unitRef="usd">35400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzc_63b28a67-9d21-4f5a-a071-5bd8086d9e74">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance for deferred tax assets consisted of the following activity for the years ended December&#160;31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMS0xLTEtMzMxNjI_1ecc31d3-8282-4e4b-bf79-6f21c817aed5"
      unitRef="usd">123803000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <irtc:ValuationAllowanceDeferredTaxAssetAdditions
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMy0xLTEtMzMxNjI_1c985d6b-7653-4159-ab91-a219dddab3cc"
      unitRef="usd">30931000</irtc:ValuationAllowanceDeferredTaxAssetAdditions>
    <irtc:ValuationAllowanceDeferredTaxAssetDeductions
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNS0xLTEtMzMxNjI_873fa6cf-281a-4945-8863-e6434b72ca2a"
      unitRef="usd">0</irtc:ValuationAllowanceDeferredTaxAssetDeductions>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNy0xLTEtMzMxNjI_3db7b875-e877-4458-b27a-31017cef7511"
      unitRef="usd">154734000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItMS0xLTEtMzMxNjc_f8107a82-19dd-4b7a-b137-685629b948f7"
      unitRef="usd">88433000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <irtc:ValuationAllowanceDeferredTaxAssetAdditions
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItMy0xLTEtMzMxNjc_891b8d9c-f560-4ea7-8460-7414c8865b98"
      unitRef="usd">35370000</irtc:ValuationAllowanceDeferredTaxAssetAdditions>
    <irtc:ValuationAllowanceDeferredTaxAssetDeductions
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItNS0xLTEtMzMxNjc_846d11dd-0e21-4a6f-8036-f8b833f2bd45"
      unitRef="usd">0</irtc:ValuationAllowanceDeferredTaxAssetDeductions>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzItNy0xLTEtMzMxNjc_43720d80-d413-4bbc-84ff-7ca5bd16ba2a"
      unitRef="usd">123803000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMS0xLTEtMjQ1NDM_fedd085f-72cb-424f-8b4c-a0c92bb3a4d8"
      unitRef="usd">66435000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <irtc:ValuationAllowanceDeferredTaxAssetAdditions
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtMy0xLTEtMjQ1NDM_77f4316c-1564-4563-8582-a140a29a0df6"
      unitRef="usd">21998000</irtc:ValuationAllowanceDeferredTaxAssetAdditions>
    <irtc:ValuationAllowanceDeferredTaxAssetDeductions
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNS0xLTEtMjQ1NDM_6814ade5-1e82-4b45-a3aa-12470be11d9e"
      unitRef="usd">0</irtc:ValuationAllowanceDeferredTaxAssetDeductions>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZTo0NTM4NWFiZmY2MDY0MzI1YWY5NDI1YTc2NTExNjUwMS90YWJsZXJhbmdlOjQ1Mzg1YWJmZjYwNjQzMjVhZjk0MjVhNzY1MTE2NTAxXzEtNy0xLTEtMjQ1NDM_12d7346a-3c21-499f-ae05-36ae6b9c98c0"
      unitRef="usd">88433000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE1MTA_d9b73c1d-fc75-4a29-9016-b2ba8098b8c4"
      unitRef="usd">464300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE1Mjg_9c7b9e2d-6f26-4855-8c3c-66299a97b371"
      unitRef="usd">279100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="iba739cc6baef49ae98b4d255720f346f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE3Njk_972a5298-5bd7-4664-933c-f129270553bb"
      unitRef="usd">7400000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i3fbbed17d9fc4fb0935e56255354c327_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzE3ODU_6b578998-d69d-4cad-9d4a-4c84778c049c"
      unitRef="usd">6100000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM5Nzg_754268c1-bcb8-4b79-93dc-8ad4de3e86d0">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the Company&#x2019;s unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions taken in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases in balance related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases in balance related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItMS0xLTEtMjQ1NDM_fcf804a2-0d77-4cfe-b24a-7bfa12fbbe30"
      unitRef="usd">2302000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItMy0xLTEtMjQ1NDM_28a79264-50e0-4757-a766-02b2a98f359d"
      unitRef="usd">1842000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzItNS0xLTEtMjQ1NDM_24a847cd-a278-4e1e-b416-a5b6cba48c5e"
      unitRef="usd">1459000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtMS0xLTEtMjQ1NDM_b5aad57a-a7bc-4ef3-bc62-1d760dd77718"
      unitRef="usd">772000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtMy0xLTEtMjQ1NDM_2bcc4b19-6ad8-4716-824c-e92789e58510"
      unitRef="usd">488000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzMtNS0xLTEtMjQ1NDM_f9ab9821-3c8a-4c2a-8755-08d772c9650c"
      unitRef="usd">383000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtMS0xLTEtMjQ1NDM_b27b1da5-0b14-4d77-ab89-c8f6e09f9ae3"
      unitRef="usd">236000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtMy0xLTEtMjQ1NDM_1929a843-dadb-4f76-b2d8-44bc96252221"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzQtNS0xLTEtMjQ1NDM_d72f07a2-24a4-478b-8bb2-74aeba52d6a4"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtMS0xLTEtMjQ1NDM_68e35cb3-2e59-4b9c-b8a1-cb05662753e2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtMy0xLTEtMjQ1NDM_48811e9e-63ae-4dd8-9c25-e4d6a361fda9"
      unitRef="usd">28000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzUtNS0xLTEtMjQ1NDM_ebc550c4-2974-43c3-a177-952d7c78f99d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtMS0xLTEtMjQ1NDM_703d6e27-3314-410c-94c7-18fa275fdd27"
      unitRef="usd">3310000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtMy0xLTEtMjQ1NDM_a731804b-7c58-4222-99b4-9b66e6ae204b"
      unitRef="usd">2302000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90YWJsZToxZjVmMzRiMGFkODM0NzQxOTE4ODhlYmNmYmIzZGE2OS90YWJsZXJhbmdlOjFmNWYzNGIwYWQ4MzQ3NDE5MTg4OGViY2ZiYjNkYTY5XzYtNS0xLTEtMjQ1NDM_d624c42a-9faf-4965-8ac5-6911b2d7f4e4"
      unitRef="usd">1842000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNjA_413c3204-9bee-46ca-8724-e26a558b64f4"
      unitRef="usd">3300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNjQ_9523eef3-b270-45f8-8e9e-7644e90bf122"
      unitRef="usd">2300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzMwNzI_674a521a-9b5d-4d5b-ac83-86f264196e9c"
      unitRef="usd">1800000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_397d6955-57ee-4f94-8d6a-f23e0bf934b5"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_3d308603-505c-43e9-9ad0-17aa4835b860"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDYvZnJhZzoxNWY5Y2IyYjc3ZWQ0MzhmOWRiNGRlZTE1ZDk1YTJhMy90ZXh0cmVnaW9uOjE1ZjljYjJiNzdlZDQzOGY5ZGI0ZGVlMTVkOTVhMmEzXzM1MTI_ad1c9245-4b00-4dda-b754-544b2df398b5"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2NQ_27f56340-7d33-46d7-8caa-6b11fe478860">Stockholders&#x2019; Equity&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s amended and restated certificate of incorporation dated October 25, 2016, as amended, authorizes the Company to issue 100,000,000 shares of common stock with a par value of $0.001 per share and 5,000,000 shares of preferred stock with a par value of $0.001 per share. The holders of common stock are entitled to receive dividends whenever funds and assets are legally available and when declared by the board of directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. No dividends were declared through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under future stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,011,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,016,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,164,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,740,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzE3NA_7145dd55-ae0c-48de-bf1c-a779ff79e09e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzIyMA_4485a893-6268-4221-8f32-cbbccedb49cf"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzIzNw_dfe8b184-052b-49eb-a78b-568c71ba36f4"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzI4Ng_7c5fb6c6-1681-4446-a5e1-28d10d6807b4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DividendsCommonStock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2Ng_6c5ebc33-c335-4b6e-ae2d-282241480144"
      unitRef="usd">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90ZXh0cmVnaW9uOjc4M2I3Yjk5NzIyNTQ3YWJhM2Q5ZTI4ODRiMWNmZWU2XzY2Nw_e1795968-cc9d-4356-88b8-e05ed82ad079">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had reserved shares of common stock for issuance as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under future stock plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,011,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,016,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,164,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,740,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib83d09b0b4814982af13362f56c4531a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzItMS0xLTEtMjQ1NDM_f91a693a-0c2e-49b1-9076-529d1d13f35e"
      unitRef="shares">504106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia5a2d071786e4b82beeb20f9e6115f40_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzItMy0xLTEtMjQ1NDM_01f05ffb-d637-45dc-9431-a2ee807a79a0"
      unitRef="shares">609881</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i86359793df1b40e2af06185a48d324e7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzMtMS0xLTEtMjQ1NDM_295fd920-d88e-4f61-93a5-8f8ef4d78aa1"
      unitRef="shares">1649561</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzMtMy0xLTEtMjQ1NDM_010d7a13-71f8-4655-87d3-f999877ff9b0"
      unitRef="shares">1114159</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8ae8319ea0074645a500405f0e3d6579_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzQtMS0xLTEtMjQ1NDM_72a6e666-d714-46f2-aac0-23eb202d1e19"
      unitRef="shares">9011213</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6546f2892d4749599e08c50b5624c54d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzQtMy0xLTEtMjQ1NDM_78416896-71b4-497f-9b0a-11b172af606d"
      unitRef="shares">8016517</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzUtMS0xLTEtMjQ1NDM_2061cae8-3348-4a7a-84c1-56ad14bd1ae6"
      unitRef="shares">11164880</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMDkvZnJhZzo3ODNiN2I5OTcyMjU0N2FiYTNkOWUyODg0YjFjZmVlNi90YWJsZTozMTRmNjJhZTFkOWE0ZGE2ODMzNTRlOTZmMTQ5ZDQzMy90YWJsZXJhbmdlOjMxNGY2MmFlMWQ5YTRkYTY4MzM1NGU5NmYxNDlkNDMzXzUtMy0xLTEtMjQ1NDM_7f7fd846-bf0d-4a06-bf3e-74f12a4976b9"
      unitRef="shares">9740557</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NjY_c4f31426-f898-4aae-9f89-ff41b62d3351">Stock Incentive Plans&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2006 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2006, the Company adopted the 2006 Equity Incentive Plan, as amended, (the &#x201c;2006 Plan&#x201d;). The Plan provided for the granting of stock options to employees and non-employees of the Company. Options granted under the Plan were either incentive stock options or nonqualified stock options. Incentive stock options (&#x201c;ISO&#x201d;) were granted only to employees (including officers and directors who are also employees). Nonqualified stock options (&#x201c;NSO&#x201d;) may be granted to employees and non-employees. The board of directors had the authority to determine to whom options will be granted, the number of options, the term and the exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options under the Plan were granted for periods of up to ten years and at the fair value of the shares on the date of grant as determined by the board of directors. In general, options become exercisable at a rate of 25% after the first anniversary of the grant and then monthly vesting for an additional three years from date of grant. The term for options is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The Company issues new shares upon the exercise of options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2016, the Company adopted the 2016 Equity Incentive Plan, (the &#x201c;2016 Plan&#x201d;). The 2016 Plan was subsequently approved by the Company&#x2019;s stockholders and became effective on October 19, 2016, immediately before the effective date of the IPO. Following the effectiveness of the 2016 Plan, no additional options will be granted under the 2006 Plan.&#160;In addition, to the extent that any awards outstanding or subject to vesting restrictions under the 2006 Plan are subsequently forfeited or terminated for any reason before being exercised or settled, the shares of common stock reserved for issuance pursuant to such awards as of the closing of the IPO will become available for issuance under the 2016 Plan. The remaining shares available for grant under the 2006 Plan became available for issuance under the 2016 Plan upon the closing of the IPO. On the first day of each year, the 2016 Plan authorizes an annual increase of the least of 3,865,000 shares, 5% of outstanding shares on the last day of the immediately preceding fiscal year or an amount as determined by the Company's Board of Directors. As of December&#160;31, 2021, the Company has reserved 7,159,947 shares of common stock for issuance under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the 2016 Plan, stock options, restricted shares, stock units, including restricted stock units and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either ISOs or NSOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are governed by stock option agreements between the Company and recipients of stock options. ISOs and NSOs may be granted under the 2016 Plan at an exercise price of not less than 100% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of ISOs may not exceed ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2016, the Company&#x2019;s Board of Directors and stockholders approved the Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). Under the ESPP, the Company initially reserved 483,031 shares of common stock for issuance as of its effective date of October 19, 2019. On the first day of each calendar year, the number of shares reserved increases by the least of 966,062 shares, 1.5% of the shares of the Company&#x2019;s common stock outstanding on the last day of the immediately preceding fiscal year, or an amount as determined by the Company&#x2019;s Board of Directors. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP provides for 12 month offering periods that each contain two 6 month purchase periods. At the end of each purchase period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the purchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, 515,231 shares of common stock have been issued to employees participating in the ESPP and 1,851,538 shares were available for issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2021: expected term of 0.5 &#x2013; 1 year, volatility of 93.99% - 106.96%, risk-free interest rate of 0.04% - 0.18% and expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2020: expected term of 0.5 &#x2013; 1 year, volatility of 68.72% - 75.78%, risk-free interest rate of 0.11% - 0.18% and expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used the following assumptions to estimate the fair value of the ESPP offered for the year ended December&#160;31, 2019: expected term of 0.5 &#x2013; 1 year, volatility of 43.61% - 48.05%, risk-free interest rate of 1.60% - 2.35% and expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Incentive Plan Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of share-based awards available for grant under the 2016 Equity Incentive Plan is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,717,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,528,132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional awards authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,505,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional awards authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,159,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended December&#160;31, 2021, 1,009,457 restricted stock units ("RSUs") were granted, 285,331 RSUs vested, and 200,019 RSUs were forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock option activity under the 2006 and 2016 Equity Incentive Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,094,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,503,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;609,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;504,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options exercisable &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options vested and expected to vest &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company granted options with a weighted-average grant date fair value of $38.29 per share. The Company did not grant any options during the year ended December 31, 2020 or during the year ended December 31, 2021 . &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised was $10.9 million, $109.2 million and $36.9 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The total estimated grant date fair value of options vested during the period was $2.8 million, $4.9 million and $7.8 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of non-vested restricted stock units (&#x201c;RSUs&#x201d;) is based on the Company&#x2019;s closing stock price on the date of grant.&#160;A summary for the year ended&#160;December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Underlying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Vesting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i330f02be0068413f808f4f28a9e5df09_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzc0Mg_606ed9a8-ce0b-4808-b760-f96e9ffcbaa8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage
      contextRef="i9b76829668ea4e88ae1e21924f45a625_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzg5NQ_c6a0b4e9-a9bd-49c6-91f8-3ae147d3691d"
      unitRef="number">0.25</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i67d4bd0b270848488c2997023ea615dd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzk4Mg_fe6eebc9-4c3b-4938-8b38-b8a860b5af23">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id412c2fe707d4befae3144ed0cfbb2d5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzEwNDQ_01a38d01-67da-4c12-8e49-641fbd6465fb">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <irtc:PercentageOfVotingPowerOfAllClassesOfStock
      contextRef="ieee82ee8a6ae43a08349bfe55fba2da0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzEwOTY_b8a20135-6c8a-43bf-8b43-0250d3dd7f1a"
      unitRef="number">0.10</irtc:PercentageOfVotingPowerOfAllClassesOfStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i731d5a16540847ed99546bb8519fea22_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzExNjI_20a69fbb-166e-4e90-8381-eada9a895f6f">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzE_8ef19d86-a3f4-43e8-a837-6da7a9fdf7d2"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i25aed7f0402b404688f5892cc0328e06_I20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIyMDM_e1e33912-d20f-4077-9e3d-96805ca76d2d"
      unitRef="shares">3865000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i3357aa34eaf749f189b1cce7587e3d3b_D20161001-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIyMTQ_17dbb7b7-8b52-490d-9c90-76eb9e35e5ff"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzIzOTU_02c144c1-d2cb-403e-9699-be0233d515f9"
      unitRef="shares">7159947</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <irtc:PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock
      contextRef="iffb6e1927b5a42bdb8c43f08b9014d6a_I20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzI5MTA_47f75de2-f0da-4d4d-a498-39c2edb133e1"
      unitRef="number">1</irtc:PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i0b57f096a6b04e42bb623131e05c164d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzI_30864230-1d26-483a-8a4e-1bd86839060d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iea8afaf349a043cc9d3265230b6be88c_I20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM0MjI_36e9f5af-d8af-4363-97aa-2f696c08d119"
      unitRef="shares">483031</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <irtc:IncreaseInCommonStockReservedForFutureIssuance
      contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM2MDI_1de56ef2-721d-4fd8-a57c-9616c103e22a"
      unitRef="shares">966062</irtc:IncreaseInCommonStockReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM2MTM_5801ba21-f312-4863-992a-0c1207737939"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="iea8afaf349a043cc9d3265230b6be88c_I20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzM5Mjg_dde3813a-2888-47cc-878f-d9b02ef1b038"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <irtc:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQwMTg_b4e02f8c-a16c-4f75-b12d-6b3126184ee3">P12M</irtc:EmployeeStockPurchasePlanOfferingPeriod>
    <irtc:EmployeeStockPurchasePlanNumberOfPurchasePeriods
      contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0ODA_37841148-4ebd-411c-b069-ad34a4e67f66"
      unitRef="numberofpurchaseperiod">2</irtc:EmployeeStockPurchasePlanNumberOfPurchasePeriods>
    <irtc:EmployeeStockPurchasePlanPurchasePeriod
      contextRef="i8c8fe5cc88884933a5ed1ad4583ab64c_D20161001-20161031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQwNjY_fb8497aa-761b-4e00-a225-a778f1835aca">P6M</irtc:EmployeeStockPurchasePlanPurchasePeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i60e99e2fd0094899b46eda57ee418bbc_D20161030-20161031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQxNzA_272e0479-c580-4929-b30f-f3d5de5bfc9d"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQzNDI_cb7ce005-fa40-49cd-8555-779aa64dbd46"
      unitRef="shares">515231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iedcc9216016246979e44e071acb39f72_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ0Mjg_3455ddd2-5b11-4e99-805a-5d07c7879f82"
      unitRef="shares">1851538</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0f64470d379d4d338b7c8f500acdec03_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2MTI_abf7d1ef-4147-4397-be28-ff734f6ffebb">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i15108c41228647aa9f35bec3a4b93e71_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2MTc_0400b67b-2435-4d3e-af82-43ba47b0cdbc">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NDA_bfa26c7a-1632-499c-a658-65109ed58e7a"
      unitRef="number">0.9399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NDU_968158c0-fba8-4035-8d06-3fcb0dc26888"
      unitRef="number">1.0696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2NzY_dc9d27b3-264e-47d1-8a2b-5753cf6bce66"
      unitRef="number">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ2ODE_b6b9ca4f-50b0-4a97-af52-772514f4d49f"
      unitRef="number">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3d89acb2beae4fbc9b5baf33696ecaae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ3MTU_0a2892c5-046d-44e7-a6a4-5b730145db4d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i65041d451358415cbfcfe6fed3a436d8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4NDk_1c75a32e-1419-44c0-b6a5-366679ab12f2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1f6a3e4be968456eb56ea5292deeb1ac_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4NTQ_cfb6cca6-5197-4600-8a72-42c58d722ce4">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4Nzc_66e9bcbb-7aea-44f1-9264-56ff5591d344"
      unitRef="number">0.6872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ4ODI_9246130a-ed50-499b-a4da-3007f27ae61b"
      unitRef="number">0.7578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5MTM_4cf4eaf3-2537-4d27-ae15-3565e533c442"
      unitRef="number">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5MTg_8087889d-a367-45dc-a00d-1f6aede8dc81"
      unitRef="number">0.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i45f5fbadb2c44e0d950606c7abd00dec_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzQ5NTI_d9872d65-8db3-41d4-b20e-990579c7edf7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3f36de2be3c245f5ae385981bc73b6e3_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUwODY_9098d0f6-6265-42db-af92-a5d5b6a2691d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i95dab85175994185bd642051f38f6586_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUwOTE_f903d1fe-86e0-4b60-a3fe-9c490ff693d4">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxMTQ_df1502c2-d5f3-464e-acf7-094ee80ef475"
      unitRef="number">0.4361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxMTk_90ec61fb-210a-456e-b586-6bb7e6b6a314"
      unitRef="number">0.4805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxNTA_d3ab3c04-5103-44bb-a02c-b8bb0de24d49"
      unitRef="number">0.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxNTU_e3baf279-b133-4000-a1f1-c48f4b555097"
      unitRef="number">0.0235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i68258fe3b39e4078af0741b6a59aac0e_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUxODk_f7c274cd-16a4-4408-b6d5-457bd53cadc9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0Njk_6d0ba85e-a4d5-4f02-bdde-521bf2c81bd1">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of share-based awards available for grant under the 2016 Equity Incentive Plan is as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,717,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional options authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(649,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,528,132&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional awards authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(595,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,505,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional awards authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,450,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,289,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awards withheld for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,159,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i759c278fc6f747e3ba280896f23d9bbc_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEtMS0xLTEtMjQ1NDM_67af97bc-f32b-4df7-b76f-3087149f481d"
      unitRef="shares">4717292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzItMS0xLTEtMjQ1NDM_7fcbebbc-b2fb-4013-acb3-1441b254cde7"
      unitRef="shares">1218402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzMtMS0xLTEtMjQ1NDM_cef554ce-1c7f-4f83-9807-c04d70787170"
      unitRef="shares">649911</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzQtMS0xLTEtMjQ1NDM_738afdc4-4a32-442f-aaa4-d0e903cbe931"
      unitRef="shares">181513</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i766e06bee8524445b129ffbe7da4b666_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzUtMS0xLTEtMjQ1NDM_79076c5f-6860-4eef-bc72-f125bb0a2fda"
      unitRef="shares">60836</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if0400993af6a41d99753781144b0a14e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzYtMS0xLTEtMjQ1NDM_2081df03-4ddd-4538-988a-037ad1f1a715"
      unitRef="shares">5528132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzctMS0xLTEtMjQ1NDM_0e27376d-1402-4650-b000-eddebac7632c"
      unitRef="shares">1333928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzgtMS0xLTEtMjQ1NDM_e90bc550-ef80-4edc-8ab2-58b48540a4f1"
      unitRef="shares">595915</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzktMS0xLTEtMjQ1NDM_21c51c3f-04f0-464f-8407-a3ec2383ff80"
      unitRef="shares">156623</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i02d116f997f54af399f93d2c326ba08e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEwLTEtMS0xLTI0NTQz_95f6cb71-d367-4401-bd47-f1c20cfd1efe"
      unitRef="shares">82622</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ibad41d5498b1410b8ada5b20ae638221_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzExLTEtMS0xLTI0NTQz_fc023353-675e-41a9-8455-096c5aac7558"
      unitRef="shares">6505390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEyLTEtMS0xLTI0NTQz_16ecd045-ab9b-4e04-b5cf-428b802e5ca0"
      unitRef="shares">1450967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzEzLTEtMS0xLTI0NTQz_62f99aa7-376c-4077-b008-a8c3f1cc07d2"
      unitRef="shares">1289567</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE0LTEtMS0xLTI0NTQz_4423866f-1bc5-4cd6-ac09-ff5bdd4e811f"
      unitRef="shares">356999</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i49bd1291f83c4232ab931d00863a5aaf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE1LTEtMS0xLTI0NTQz_55cd91ef-c5b1-4d55-a31d-eaabf094a2e9"
      unitRef="shares">135886</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ia38b3aeaaa574bcba8219f7aaa245bbd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpkYzEwOGQ0MDAyMGU0MGUxOTY2ZGFlYThlZmNjZjE2Mi90YWJsZXJhbmdlOmRjMTA4ZDQwMDIwZTQwZTE5NjZkYWVhOGVmY2NmMTYyXzE2LTEtMS0xLTI0NTQz_2173a9c7-ef48-4737-a3ab-dfcb7709cf19"
      unitRef="shares">7159675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzUzNTg_a2021286-8e9a-4773-9a74-e76810f5ad64"
      unitRef="shares">1009457</irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod>
    <irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardVested
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU0MDc_d06cb5b4-ab6d-4a44-b7d9-144bead0f351"
      unitRef="shares">285331</irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardVested>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU0Mjc_259cd632-9918-4195-83b6-4558f8635072"
      unitRef="shares">200019</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NjU_09ffc194-e31f-4ff0-8a9c-96472d4fe457">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes stock option activity under the 2006 and 2016 Equity Incentive Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,094,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,503,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27.40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,752)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;609,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;504,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.97&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options exercisable &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39.61&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Options vested and expected to vest &#x2013; December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;503,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItMS0xLTEtMjQ1NDM_0d443ed7-ba80-45d7-a461-04ca00428587"
      unitRef="shares">2094137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItMy0xLTEtMjQ1NDM_24088597-0e61-4e6c-a392-3499312b2e55"
      unitRef="usdPerShare">23.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id0a4c3b7811b486b8f1f6dab487979c1_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItNS0xLTEtMjQ1NDM_68d25725-6f15-4eb4-b402-821f3291bddb">P7Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i40721ab01cb74086a6725dda65e33834_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzItNy0xLTEtMjQ1NDM_9c0edfd2-3c9a-4600-8a75-fe0cb8fa4697"
      unitRef="usd">97976000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzMtMS0xLTEtMjQ1NDM_eea1c9a8-7eb0-4659-8228-c5781d39aea0"
      unitRef="shares">20010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzMtMy0xLTEtMjQ1NDM_de223932-db2c-4527-8611-f089ca72ee47"
      unitRef="usdPerShare">82.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzQtMS0xLTEtMjQ1NDM_70ddfce3-eb14-4d76-bc03-e4b828eb32e7"
      unitRef="shares">540307</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzQtMy0xLTEtMjQ1NDM_6f64338f-969c-46fd-b947-2783ab093538"
      unitRef="usdPerShare">9.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzUtMS0xLTEtMjQ1NDM_5f2b5d99-ce51-40d8-9f01-df89bbbd02d3"
      unitRef="shares">70593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzUtMy0xLTEtMjQ1NDM_68eace4b-7f1c-4629-ba65-5bfc862b56dc"
      unitRef="usdPerShare">54.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtMS0xLTEtMjQ1NDM_222e24f1-f7af-4514-a522-1c344c2efaeb"
      unitRef="shares">1503247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtMy0xLTEtMjQ1NDM_b31589e0-440d-4ad8-a352-6b99d0885b7b"
      unitRef="usdPerShare">27.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtNS0xLTEtMjQ1NDM_a430f5ea-7cb4-4360-b4a4-cdd7a9db6fa7">P6Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia897aa3797f647999451688e21df6eeb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzYtNy0xLTEtMjQ1NDM_42f31dfc-f739-4962-ad44-8b48b851aa5a"
      unitRef="usd">62401000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzctMS0xLTEtMjQ1NDM_ef34db71-45dc-48cc-b87b-73c484bd9c42"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzctMy0xLTEtMjQ1NDM_acab836b-f9aa-4c01-9de0-720f7d3f8e07"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzgtMS0xLTEtMjQ1NDM_b7fa20e3-5589-4340-bafe-54ef53a126cb"
      unitRef="shares">868614</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzgtMy0xLTEtMjQ1NDM_1763c34d-59ff-4ebd-8582-ba19bf0c72ae"
      unitRef="usdPerShare">17.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzktMS0xLTEtMjQ1NDM_d3df4184-064c-4d51-b96b-1bc485579962"
      unitRef="shares">24752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzktMy0xLTEtMjQ1NDM_50d8ba8a-0478-4951-8830-d2cb00ba6f67"
      unitRef="usdPerShare">66.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTEtMS0xLTI0NTQz_aa241b3f-46e3-43de-9fa0-b674a3467d43"
      unitRef="shares">609881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTMtMS0xLTI0NTQz_061c7736-55c4-4a8d-bad1-7b81017ffce5"
      unitRef="usdPerShare">40.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTUtMS0xLTI0NTQz_08205f40-4d72-4240-a25f-9313354f29a3">P6Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5bcf3584e3054380b50e7dcd8ca83f70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEwLTctMS0xLTI0NTQz_e21ca695-c9f3-452c-a224-cd78a74c317f"
      unitRef="usd">120163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzExLTEtMS0xLTI0NTQz_2010562d-b40b-40a1-98dc-483978fdaa82"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzExLTMtMS0xLTI0NTQz_5e04e105-c518-4d0e-83fa-8ff0b6275df2"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEyLTEtMS0xLTI0NTQz_d9895834-56d0-4a9e-8164-c8c7282f499a"
      unitRef="shares">90939</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEyLTMtMS0xLTI0NTQz_d7d38a9f-7da3-40cc-9150-6bfa5d5cbe31"
      unitRef="usdPerShare">31.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEzLTEtMS0xLTI0NTQz_1acbc58e-7a52-40b7-9ca7-733ba1d4bfa2"
      unitRef="shares">14836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzEzLTMtMS0xLTI0NTQz_fca17d09-3b10-4353-90ad-a8e31adf44ab"
      unitRef="usdPerShare">68.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTEtMS0xLTI0NTQz_32080317-eccc-4a5e-98a6-7f489b7c0c68"
      unitRef="shares">504106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTMtMS0xLTI0NTQz_cb6b181a-5cd1-49d1-9e98-19a07f657a0c"
      unitRef="usdPerShare">40.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTUtMS0xLTI0NTQz_3d8de7ad-d8a2-4ac6-8d74-67d6480ad0f3">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE0LTctMS0xLTI0NTQz_225bcae8-673c-4fa5-9cd7-599adfea2402"
      unitRef="usd">38675000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTEtMS0xLTI0NTQz_c9f33c1a-3259-42ef-979e-38d71dc4bef0"
      unitRef="shares">483548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTMtMS0xLTI0NTQz_9ac55f26-15e8-4a6f-84fd-4d695f48e1b3"
      unitRef="usdPerShare">39.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTUtMS0xLTI0NTQz_8dc2a2bd-ffde-4084-87e7-234d8c10144c">P5Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE1LTctMS0xLTI0NTQz_6e5d5b5a-a121-4749-b210-d0c53b6e5a0b"
      unitRef="usd">37756000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTEtMS0xLTI0NTQz_46be7b9d-c90e-4b36-80bc-1b9e2903d075"
      unitRef="shares">503884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTMtMS0xLTI0NTQz_986f6f0a-9cdd-4ac1-b006-3035cfbf9156"
      unitRef="usdPerShare">40.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTUtMS0xLTI0NTQz_4a704c50-6e8a-49de-b939-21dd78234663">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTpiOTE1NTQ0MGFiOGY0Y2NjODYxMzc3MTMyY2NlMjEyYS90YWJsZXJhbmdlOmI5MTU1NDQwYWI4ZjRjY2M4NjEzNzcxMzJjY2UyMTJhXzE2LTctMS0xLTI0NTQz_0c7249e3-2963-404a-bebd-0d0763030da7"
      unitRef="usd">38667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzU5MTU_adfbeea0-6dee-4ae5-b2a9-37a73596bb5b"
      unitRef="usdPerShare">38.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzY_6888fd81-3080-4995-a68a-9246620a49de"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzY_6f7ccee0-9d97-4a72-8c96-b848f2ebe7d3"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwNzg_6b68402e-fb40-4809-ac5b-26e3ef458172"
      unitRef="usd">10900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwODI_d22cc013-3c6d-4520-8599-fd679b0b4bbc"
      unitRef="usd">109200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYwODk_db21b086-a3e8-40f3-9b08-595c653319db"
      unitRef="usd">36900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMjM_9e6dbba3-8492-4bd1-af19-5c32b0269100"
      unitRef="usd">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMjc_ae78f177-2aae-4bb9-8108-f34bfe61d5ff"
      unitRef="usd">4900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzYyMzQ_ff9cd903-316b-4422-b51b-95d1ae9066eb"
      unitRef="usd">7800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90ZXh0cmVnaW9uOjM4MWIxNTIzZmMyZDQ3NmE4M2ZjOTNmOGQzZjkyMzdmXzY0NzA_42d01f2d-0877-42b3-aef5-5a46c5899a89">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of non-vested restricted stock units (&#x201c;RSUs&#x201d;) is based on the Company&#x2019;s closing stock price on the date of grant.&#160;A summary for the year ended&#160;December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Underlying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Vesting&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(131,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(412,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8555106470244294838f2dcfdde58a82_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtMS0xLTEtMjQ1NDM_191fa0a4-cea9-4d2f-acbe-a949412cc7b1"
      unitRef="shares">886030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8555106470244294838f2dcfdde58a82_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtMy0xLTEtMjQ1NDM_2e56c78f-0999-4add-bbee-350f81885077"
      unitRef="usdPerShare">77.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ibc42661c3194491383dc17aab6af6e5c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtNS0xLTEtMjQ1NDM_9c204189-3581-4d41-ad9a-bad600657861">P1Y4M20D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i8555106470244294838f2dcfdde58a82_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzEtNy0xLTEtMjQ1NDM_005e8cd2-00c8-4d9b-93c4-a2c2595eaefd"
      unitRef="usd">60330000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzItMS0xLTEtMjQ1NDM_212cafc1-b701-45f9-8253-57ef597b1746"
      unitRef="shares">595915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzItMy0xLTEtMjQ1NDM_dff51337-40ec-4a87-b08b-4a8aa48567ea"
      unitRef="usdPerShare">104.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzMtMS0xLTEtMjQ1NDM_ea60a475-6225-44d9-9cc6-4e54dd9a4893"
      unitRef="shares">235915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzMtMy0xLTEtMjQ1NDM_62090536-8f19-4b4b-ab9c-2fdb8f4ce255"
      unitRef="usdPerShare">69.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzQtMS0xLTEtMjQ1NDM_e9feb84f-d523-4647-930b-8918480af947"
      unitRef="shares">131871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzQtMy0xLTEtMjQ1NDM_238d2ed7-688d-408b-abc0-ef8edebd64cf"
      unitRef="usdPerShare">59.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtMS0xLTEtMjQ1NDM_9a342b39-20d0-4f20-84e7-809666faa1cf"
      unitRef="shares">1114159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtMy0xLTEtMjQ1NDM_fd99110e-3c62-4a32-9aa1-95a1c73486f3"
      unitRef="usdPerShare">94.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="idd17ad0471a444c5af0f2d47d2398304_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtNS0xLTEtMjQ1NDM_817aa320-b5d8-4ca1-a6ef-e9b128f07a63">P1Y4M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i9466bdc61cfa44fda7e517775eb15b05_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzUtNy0xLTEtMjQ1NDM_93e2e957-74b1-45e2-a639-4670eb72d27a"
      unitRef="usd">264290000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzYtMS0xLTEtMjQ1NDM_0d111969-8ef9-4a95-aea8-df552cf31250"
      unitRef="shares">1289567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzYtMy0xLTEtMjQ1NDM_207d68f2-4e04-4f29-a110-2804e6d42763"
      unitRef="usdPerShare">98.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzctMS0xLTEtMjQ1NDM_be22b5f1-c0c8-4a90-86a3-3219ab92072a"
      unitRef="shares">412002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzctMy0xLTEtMjQ1NDM_433f9d1c-01f7-48de-9ec6-18662ccd73e4"
      unitRef="usdPerShare">104.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzgtMS0xLTEtMjQ1NDM_1fb36e90-a515-4665-856d-796a8e5bf7fd"
      unitRef="shares">342163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzgtMy0xLTEtMjQ1NDM_ea2b5cad-f4f8-4582-82e3-36020a48c3c5"
      unitRef="usdPerShare">113.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i86359793df1b40e2af06185a48d324e7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktMS0xLTEtMjQ1NDM_804d1673-8b38-4d3b-81c5-cfeaeae341b3"
      unitRef="shares">1649561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i86359793df1b40e2af06185a48d324e7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktMy0xLTEtMjQ1NDM_842f1285-b027-4543-bd6f-836bd92f7384"
      unitRef="usdPerShare">91.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktNS0xLTEtMjQ1NDM_bb529367-60c7-4d01-90ed-91e2bbbc9e1a">P1Y7M20D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i86359793df1b40e2af06185a48d324e7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTIvZnJhZzozODFiMTUyM2ZjMmQ0NzZhODNmYzkzZjhkM2Y5MjM3Zi90YWJsZTo2NzI4NzkzYzc5YTg0MDkwOGVhNzM4ODE0ZGZmMzU1ZS90YWJsZXJhbmdlOjY3Mjg3OTNjNzlhODQwOTA4ZWE3Mzg4MTRkZmYzNTVlXzktNy0xLTEtMjQ1NDM_6aa3d419-7fd0-48db-88f6-bcda6b42cd8c"
      unitRef="usd">194137000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTE_8ed1f08b-5dc9-4b30-9d5e-f18dbfe6b512">Stock-Based Compensation&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Options Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee and director stock options was estimated at the date of grant using the Black-Scholes option pricing model with the weighted average assumptions below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant stock options during the years ended December 31, 2021 and  December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Market-based RSU Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of market based RSUs was estimated at the date of grant using the Monte-Carlo option pricing model with the assumptions below. Additional details on the Company's market based RSUs are included below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s Board of Directors determined the fair value of each share of underlying common stock based on the closing price of the Company&#x2019;s common stock as reported on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term represents the period that the share-based awards are expected to be outstanding. As the Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock-option grants the Company has elected to use the &#x201c;simplified method&#x201d; as prescribed by authoritative guidance to compute expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Since the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded companies in a similar industry on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to expected term of the option award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assumptions used in the Black-Scholes option-pricing model, the Company also estimates a forfeiture rate to calculate the stock-based compensation for the Company&#x2019;s equity awards. The Company will continue to use judgment in evaluating the expected volatility, expected terms and forfeiture rates utilized for the Company&#x2019;s stock-based compensation calculations on a prospective basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was total unamortized compensation costs of $0.8 million, net of estimated forfeitures, related to unvested stock options, which the Company expects to recognize over a period of approximately 0.4 years and $113.5 million, net of estimated forfeitures, related to unrecognized RSU expense, which the Company expects to recognize over a period of 2.4 years, and $3.1 million unrecognized ESPP expense, which the Company will recognize over 0.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance based RSUs (&#x201c;PRSU&#x201d;) and Market-based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company grants PRSUs to key executives of the Company. PRSUs can be earned in accordance with the performance equity program for each respective grant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;2019 Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2019, the company granted PRSU's (&#x201c;2019 awards&#x201d;) to be earned based on the compound annual growth rate (&#x201c;CAGR&#x201d;) of fiscal year 2020's revenue compared to fiscal year 2018's revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the impact of the COVID-19 pandemic, management determined that the Company&#x2019;s achievement of its performance targets described above, was not probable in the first quarter of fiscal year 2020. PRSU expense of $4.8&#160;million recognized in fiscal year 2019 related to the 2019 awards was reversed in the first quarter of fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2020, the Company modified the terms of the 2019 awards to vest based on the Company&#x2019;s average stock price for the 60 days preceding January 1, 2021. The modification impacted all active recipients of the 2019 awards, a total of ten recipients. The total incremental compensation cost resulting from the modification of $13.6&#160;million was recognized ratably through March 31, 2021. The Company recognized $2.2&#160;million of compensation cost for the year ended December&#160;31, 2021 in connection with the 2019 awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;February 2020 Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the company granted PRSU's (&#x201c;February 2020 awards&#x201d;) for fiscal year 2022's annual unit volume CAGR compared to fiscal year 2019's annual unit volume CAGR, measuring a minimum performance threshold of 19.7% to earn 50% of target, and a maximum threshold of 29% achieved to earn 200% of target. A total of 133,834 PRSU shares were granted with grant date fair value of $11.0&#160;million. The 2020 awards also include a service-based component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation cost in connection with the probable number of shares that vested was recognized ratably through March 31, 2021. During the year ended December 31, 2021, the Company determined that it was probable that the February 2020 Awards would vest and recognized $0.8&#160;million of compensation cost in connection with the February 2020 awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;January 2021 Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company granted PRSUs (&#x201c;January 2021 awards&#x201d;) for fiscal year 2021's annual consolidated revenue compared to fiscal year 2020's annual consolidated revenue, measuring a performance threshold of 10.0% to earn 100% of target. A total of 53,862 PRSU shares were granted with a grant date fair value of $13.9&#160;million. The January 2021 awards also include a service-based component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2022. During the year ended December 31, 2021, the Company determined that it was probable that the January 2021 Awards would vest and recognized $9.9&#160;million of compensation cost in connection with the January 2021 awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;February 2021 Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company granted PRSU's (&#x201c;February 2021 awards&#x201d;) for fiscal year 2023's annual unit volume Compound Annual Growth Rate (&#x201c;CAGR&#x201d;) compared to fiscal year 2020's annual unit volume CAGR, measuring a minimum performance threshold of 19.7% to earn 50% of target, and a maximum threshold of 29% achieved to earn 200% of target. A total of 112,872 PRSU shares were granted with grant date fair value of $17.3&#160;million. The February 2021 awards also include a service-based component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation cost in connection with the probable number of shares that will vest will be recognized ratably through March 31, 2024. During the year ended December 31, 2021, the Company determined that it was probable that the February 2021 Awards would vest and recognized $2.4&#160;million of compensation cost in connection with the February 2021 awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Non employee Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2020, the Company&#x2019;s Chief Financial Officer (&#x201c;CFO&#x201d;) resigned and entered into a Consulting and Professional Services Agreement (&#x201c;CPSA&#x201d;) with the Company to provide consulting services through July 2, 2021. Pursuant to the original terms of the awards, the CFO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in 2020 as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended  December 31, 2020, was $1.8&#160;million.&lt;/span&gt;&lt;/div&gt;On January 12, 2021, the Company's Chief Executive Officer (&#x201c;CEO&#x201d;) resigned and entered into a CPSA with the Company. Pursuant to the original terms of the awards, the CEO will continue to vest in outstanding awards as long as services are provided to the Company under the CPSA as a non-employee consultant or a member of the Company's Board of Directors. In accordance with ASC 718, the Company recognized expense related to all awards expected to vest over the duration of the CPSA in the three months ended March 31, 2021, as an equity-based severance cost as the consulting services are not substantive. Total expense related to non-employee stock-based compensation recognized for the year ended December 31, 2021 was $5.4 million.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTI_d6f9ac06-d732-44bb-a4e4-3f1b8f52e668">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee and director stock options was estimated at the date of grant using the Black-Scholes option pricing model with the weighted average assumptions below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of market based RSUs was estimated at the date of grant using the Monte-Carlo option pricing model with the assumptions below. Additional details on the Company's market based RSUs are included below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzItMy0xLTEtMjQ1NDM_8c47f7a5-6dc0-4010-ba0b-b021742bab3f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzMtMy0xLTEtMjQ1NDM_a21dbd18-2b04-4c15-b5c0-c83400d0c947"
      unitRef="number">0.450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzQtMy0xLTEtMjQ1NDM_4485aede-0e30-4fef-a761-5f624c3f0ad1"
      unitRef="number">0.0239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NGVlY2Q1YzZkMTc0MDQ4YmJjZGQwY2NhNWRkMWI1YS90YWJsZXJhbmdlOjY0ZWVjZDVjNmQxNzQwNDhiYmNkZDBjY2E1ZGQxYjVhXzUtMy0xLTEtMjQ1NDM_c0d2cf91-e674-408f-975d-3907d7e431dd"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzItMS0xLTEtMjQ1NDM_6445b11d-f87c-48b0-9cf9-ea537738c0ca">P0Y8M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzMtMS0xLTEtMjQ1NDM_a86f5c29-0ebd-435a-b815-6a693997b011"
      unitRef="number">0.630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzQtMS0xLTEtMjQ1NDM_77bec192-5d2b-4085-9aaa-649c246656d8"
      unitRef="number">0.0017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i52e5fc7ee0414b6d9dac863c2b48c66d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTo2NWEyMTNmZGFjNmI0YzkxYTk3MjIxYWUzMWFkNWRhMy90YWJsZXJhbmdlOjY1YTIxM2ZkYWM2YjRjOTFhOTcyMjFhZTMxYWQ1ZGEzXzUtMS0xLTEtMjQ1NDM_ab2f8141-451e-4f07-8a0d-55fd80b204f7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzI0ODY_8937f7a5-81f4-4197-bbb0-867293adbcc7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzY0MTQ_9941c3a6-344c-4ef5-b74e-bed426288756">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense included in the statements of operations and comprehensive loss for all periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i42ec867e77104c7c880eca8b43778fb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItMS0xLTEtMjQ1NDM_edff33da-1953-4143-a9e1-8b731aa5436e"
      unitRef="usd">1896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3077a0d7299d4f5aabbf2184ffe9be97_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItMy0xLTEtMjQ1NDM_4fd7521f-751a-4e7c-a824-bac61e192b7c"
      unitRef="usd">27000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibac55be5040a4d65a2fa2138c70bc7f7_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzItNS0xLTEtMjQ1NDM_33163f38-7111-4c90-8966-a6fd0bf101a4"
      unitRef="usd">658000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51c63a57313342ee870d007775314912_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtMS0xLTEtMjQ1NDM_ee09969b-1bc3-4a04-b7bb-008e342cc976"
      unitRef="usd">5565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i036e8e19c0244562aa901632c01f81c0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtMy0xLTEtMjQ1NDM_f9d028c6-1624-4399-b3b8-4439f4fa5eb6"
      unitRef="usd">7727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5a9f2820af84e70bfdad6b84dbcdbbb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzMtNS0xLTEtMjQ1NDM_39f7d7bd-d453-429f-95b7-fd0a34921dab"
      unitRef="usd">4462000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f92497acfec4d779bc015e79d7a07a4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtMS0xLTEtMjQ1NDM_56adff12-d936-4ef8-b3f4-1f3b12cb5520"
      unitRef="usd">47066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57a2b1da44734fbd961217ea3df13e21_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtMy0xLTEtMjQ1NDM_ce581589-f759-42b7-befa-b0c0e44624cf"
      unitRef="usd">33761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9032a6810bae4fa187e1e649dd2ad127_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzQtNS0xLTEtMjQ1NDM_d0aadbeb-aafe-408e-ba19-4d7cd3bfdb44"
      unitRef="usd">21121000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtMS0xLTEtMjQ1NDM_1925f56d-a10e-43ca-8f96-c0efdd886a6f"
      unitRef="usd">54527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtMy0xLTEtMjQ1NDM_2809770d-4923-43e7-8659-9a7482428624"
      unitRef="usd">41515000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90YWJsZTplOTNhYzdlM2FkNzc0MDA5YjA5NjQ2MDVmNmQ1MWI3Ny90YWJsZXJhbmdlOmU5M2FjN2UzYWQ3NzQwMDliMDk2NDYwNWY2ZDUxYjc3XzUtNS0xLTEtMjQ1NDM_8841f8e2-be25-44fa-bd4e-1472083d9f64"
      unitRef="usd">26241000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMxMzk_182abb4f-8841-4b50-a805-5675802011d7"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMyNzg_0d4e917b-b9b1-498c-aee1-00bc6f506ab6">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i86359793df1b40e2af06185a48d324e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzMyODI_6bf22711-d8da-4df4-bd66-0a0bd8044645"
      unitRef="usd">113500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie012b38e16cc401f802ea87af3684400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0MDk_cc313f86-50b3-49b2-8411-83e9a8bf2e56">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i65aa22d39afd4fdeb7a543c352ccd14b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0MTc_1bf3e0cf-f19d-4653-b34e-334cde0f1052"
      unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iad223dfee47d4235be238a5c63906545_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzM0ODU_7d096fbc-49f5-4782-baca-d2889a88c0a0">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <irtc:ShareBasedPaymentArrangementReversalOfPriorExpense
      contextRef="i9f9db1a2a402414e83610b8705c23f4a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQxMjE_50fe15ff-c052-40b7-93a7-179dbc34b004"
      unitRef="usd">4800000</irtc:ShareBasedPaymentArrangementReversalOfPriorExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ0Mzc_c0ca3dd4-392d-4b4e-9735-b3b42a6787f8"
      unitRef="employee">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="ib48e53890f0c48318d08a0d7748ab6fb_D20200619-20200619"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ1Mjc_038716fe-ca62-4d70-a56b-d38b3d4463ca"
      unitRef="usd">13600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia53dfea28b67446ea357092412155f6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ2MDM_bc503cf3-cbcb-41d1-9c39-a1c0bf3a51b9"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage
      contextRef="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5MjQ_dcaefb6f-a5d9-45a0-ab3f-ff797d5269e1"
      unitRef="number">0.197</irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage>
    <irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold
      contextRef="i8ee70fc83daf49b1b8e682a9c59fac0a_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5MzU_05c7d56f-dc65-4ca5-9243-945e4b3119c0"
      unitRef="number">0.50</irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold>
    <irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage
      contextRef="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5NzY_34541cd9-8433-4b03-9e33-0438824925d0"
      unitRef="number">0.29</irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage>
    <irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold
      contextRef="ifd079746288644ea8fc309e60f3083e5_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzQ5OTY_772d701c-821f-4d0c-845b-3955f65deca1"
      unitRef="number">2</irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0e8a36476e6e476ba97c7dbc8c1d08f6_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzUwMjE_89876ea7-f89e-40ce-b710-76a20f924488"
      unitRef="shares">133834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="i285f97c5349f42d09fbf05bf4afa82fd_I20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzUwNzk_c940deaf-6743-475d-870c-8447b409821a"
      unitRef="usd">11000000</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48d4090f1770461094499a8926219715_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzU0MTI_758c4c0b-707e-4dbf-ae1d-ba12392b6650"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage
      contextRef="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MjU3_c1baca8b-bb81-4ff8-8d87-d2cb32f4aa8d"
      unitRef="number">0.100</irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage>
    <irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold
      contextRef="i382dd23ff8de4663af982c567258f3b8_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MjY5_22307bc7-1ce3-420a-8c42-d8a7f9eedcad"
      unitRef="number">1</irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7bf36d99211d4d7bb644f4a40a5aa345_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2Mjk1_54d77880-20f6-45bc-ab4c-35d36fcdd621"
      unitRef="shares">53862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="i4171790573c447c9bd09afc513f59f75_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI2MzU2_2aecb5fe-8684-4e1a-9586-d04dd60d1942"
      unitRef="usd">13900000</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1db5399825c5480b91e101758d1f1cbb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI4MjQ0_cf867ee6-5d61-4136-b695-427c962783a6"
      unitRef="usd">9900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage
      contextRef="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MDY2_db58885f-17eb-4e5a-bb7f-1a491d44eafc"
      unitRef="number">0.197</irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage>
    <irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold
      contextRef="i02312c8748c24fefba55c6485ae1ecb6_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MDc4_2b6a2e8f-b563-44f1-9a91-9d70f4977e46"
      unitRef="number">0.50</irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold>
    <irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage
      contextRef="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTIw_824fff12-bc74-434e-9486-1d5f2b6fffb8"
      unitRef="number">0.29</irtc:ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage>
    <irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold
      contextRef="i8afb5531276b43108d243ab52b02e01b_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTQx_6f8125f6-65bc-47c8-9d1e-9b8ef8b59c0a"
      unitRef="number">2</irtc:PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7fd28149e2f14307ab0e6573f2a75749_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MTY3_c13f3aa2-15e0-461e-92a2-137bd4409fb2"
      unitRef="shares">112872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue
      contextRef="ibd15311b9e074984b42d19b85d262583_I20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI3MjI2_7dc23f04-de7f-41d9-91f3-fc75c04c600d"
      unitRef="usd">17300000</irtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7a2ac6ed88094e85ad351dfffe1b0bcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEyNjQ0MzgzNzI4Nzk1_d0dfc07f-bb55-409d-b13f-a1b0de55ebbe"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iccce65a61f0b4298b073d981b57911fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzEwOTk1MTE2Mzg3NjY_74f69af4-2adc-478f-a94e-df07c77c9103"
      unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f49daad3c3e4a63954ae45aeab81118_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTUvZnJhZzpmYWM4YjI0ZWYwMWI0Zjg3OTkzZGExYzBkN2ZiMmRmMC90ZXh0cmVnaW9uOmZhYzhiMjRlZjAxYjRmODc5OTNkYTFjMGQ3ZmIyZGYwXzE2NDkyNjc0NTM1NDM_50390e22-72be-4f24-a75f-9820feaa3736"
      unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1NA_448778f3-8215-452a-9d05-34895a74a67f">Net Loss Per Common Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company had net losses for the years ended December&#160;31, 2021, 2020 and 2019, all potential common shares were determined to be anti-dilutive. The following table sets forth the computation of the basic and diluted net loss per share during the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,331,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,754,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,265,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per common share for the years ended December&#160;31, 2021, 2020 and 2019 because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs issued and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1NQ_f4944831-474d-4d42-9bad-c48aea138278">The following table sets forth the computation of the basic and diluted net loss per share during the years ended December&#160;31, 2021, 2020 and 2019 (in thousands, except share and per share data):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,331,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,754,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,265,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtMS0xLTEtMjQ1NDM_3e561a4b-1acc-4f77-ac44-9d49e782f9ed"
      unitRef="usd">-101361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtMy0xLTEtMjQ1NDM_d994fb03-c923-4aee-8ea4-f4914793456b"
      unitRef="usd">-43830000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzMtNS0xLTEtMjQ1NDM_c4eec405-6bcb-44ff-ad71-d2e8e904cf3c"
      unitRef="usd">-54568000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMS0xLTEtMjQ1NDM_82cf8126-f371-4478-a8f1-aeedf6f9f3bc"
      unitRef="shares">29331010</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMS0xLTEtMjQ1NDM_8f73d7e3-623b-4920-95ec-ec08e7025f90"
      unitRef="shares">29331010</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMy0xLTEtMjQ1NDM_91b9029d-4146-4fa2-81e4-8921fd155068"
      unitRef="shares">27754404</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtMy0xLTEtMjQ1NDM_e35c3d88-9320-42f8-8360-6fba76fc40bb"
      unitRef="shares">27754404</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtNS0xLTEtMjQ1NDM_3b0bf428-5a9f-4a27-9ece-fed9e318c5a8"
      unitRef="shares">25265918</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzUtNS0xLTEtMjQ1NDM_789c6930-50ef-4ca5-931e-95beb18b0f5e"
      unitRef="shares">25265918</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMS0xLTEtMjQ1NDM_1956a634-8f6a-4bdf-99da-103851856319"
      unitRef="usdPerShare">-3.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMS0xLTEtMjQ1NDM_eb7449c3-a72b-4777-b91b-525c1660332d"
      unitRef="usdPerShare">-3.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMy0xLTEtMjQ1NDM_469d06ef-4dbd-4d81-8398-c8d8ada93bf0"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtMy0xLTEtMjQ1NDM_6d7a4ad8-71f0-457a-b6f4-c99cab895424"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtNS0xLTEtMjQ1NDM_09a1e904-2199-4b6c-99a6-4b05a3128c14"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZTo1YTYzYmY4MjM4M2E0ODhjOTZiOWE3MDJkODJjMjRlMi90YWJsZXJhbmdlOjVhNjNiZjgyMzgzYTQ4OGM5NmI5YTcwMmQ4MmMyNGUyXzYtNS0xLTEtMjQ1NDM_88d4acba-4c13-422d-bd92-35111e0d44b1"
      unitRef="usdPerShare">-2.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90ZXh0cmVnaW9uOjRmNWIwNzUzNjM0MjQxYTA5NDMwMDk3MzMyNzM4YTAyXzU1Ng_31cd3a74-f2e0-4492-b231-faadef6443f0">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding shares of potentially dilutive securities have been excluded from diluted net loss per common share for the years ended December&#160;31, 2021, 2020 and 2019 because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs issued and unvested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,649,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,153,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,724,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,389,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibef8252f0e0e4c2080743e4f89a810c7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItMS0xLTEtMjQ1NDM_1282ecef-6e6d-4587-a2e4-037dd5c4b6d8"
      unitRef="shares">504106</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i869c663a60864d6dafba82faf152398d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItMy0xLTEtMjQ1NDM_3316f03f-05cf-4618-bf88-bc1cdb3bf47e"
      unitRef="shares">609881</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9215b3bc96c4411aa73e32bdd167b66d_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzItNS0xLTEtMjQ1NDM_f99d1820-c5fe-47e6-8ac6-c1974b40c74a"
      unitRef="shares">1503247</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec01902a609c42cca84e32a7417ad2c3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtMS0xLTEtMjQ1NDM_b465d0ff-5f76-4f5f-8bed-74af353f1742"
      unitRef="shares">1649561</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb08d6c4a54f49048409724c6ec35971_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtMy0xLTEtMjQ1NDM_ebbf8d14-4c74-4c7b-87e6-3e7db2024894"
      unitRef="shares">1114159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icab020b110c64525bd57c35617d3162e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzMtNS0xLTEtMjQ1NDM_d5005095-ac77-4091-9849-646a62073198"
      unitRef="shares">886030</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtMS0xLTEtMjQ1NDM_e1f556f1-4676-41ef-9398-ae1f6f810d09"
      unitRef="shares">2153667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i69939f1392e44c2da8748b53fb905e01_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtMy0xLTEtMjQ1NDM_367d4d55-52b7-43a2-84a5-f0f3fb403c47"
      unitRef="shares">1724040</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i17570f0f5a2c4024bb6affad51936c2c_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMTgvZnJhZzo0ZjViMDc1MzYzNDI0MWEwOTQzMDA5NzMzMjczOGEwMi90YWJsZToyMDdlMmY1MzI1ZmI0ZmI1OTYzMzI2MGI4NjQ0ZDA5ZS90YWJsZXJhbmdlOjIwN2UyZjUzMjVmYjRmYjU5NjMzMjYwYjg2NDRkMDllXzUtNS0xLTEtMjQ1NDM_a3634736-e5ab-4a9d-b099-24ab5476d31a"
      unitRef="shares">2389277</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzI1Mjg4NzY3NDQ2NDQ2_1783bf3b-d826-4a46-97fa-2b126f6a19ce">Subsequent Events&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Novitas Announcement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2021, CMS published its Calendar Year 2022 Medicare Physician Fee Schedule Final Rule (the &#x201c;Final Rule&#x201d;). In the Final Rule, CMS did not finalize national pricing for the extended external ECG patch, medical magnetic tape recorder (SD339) supply, and ruled to contractor pricing for CPT codes 93241, 93243, 93245 and 93247. The Company has been working with Medicare Administrative Contractors (MACs&#x201d;) to establish pricing for these codes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On January 10, 2022, Novitas Solutions, the MAC which covers the region where the Company's Independent Diagnostic Testing Facility in Houston, Texas where almost all Medicare services for Zio XT are processed, published reimbursement rates for CPT codes 93243 and 93247 for the Houston jurisdiction to $223 and $233, respectively. These updated rates are retroactive to January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2021, the Company entered into a lease for 44,616 rentable square feet in Deerfield Illinois (&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deerfield Lease&#x201d;). The Deerfield lease commenced in January 2022, the Company will recognize a related right of use asset and obligation in its Consolidated Financial Statements for the quarter ending March 31, 2022. The amount of such asset and obligation has not yet been determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In February 2022, the Company's Board of Directors approved a decision to pursue reducing its leased space for its headquarters in San Francisco, California. The Company plans to consolidate operations and will begin marketing the excess space for sublease by the end of the first quarter of 2022. Depending on the outcome of marketing the sublease, the Company believes these decisions could result in an impairment of the right of use asset for the San Francisco office lease and is assessing the impact to its Consolidated Financial Statements for the quarter ending March 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <irtc:CostReimbursementRate
      contextRef="i64b979f3794644df876abe57a7d76980_I20220110"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE4MTQ_531c979e-04e6-4d22-baa4-49dd7ad45fdd"
      unitRef="usd">223</irtc:CostReimbursementRate>
    <irtc:CostReimbursementRate
      contextRef="i3706f468116148dbabf8b4fb4c6f96e7_I20220110"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE4MjA_437741e2-dc44-4a9c-b224-7686d7bc9965"
      unitRef="usd">233</irtc:CostReimbursementRate>
    <irtc:OperatingLeaseRentableArea
      contextRef="i0124649f48144c50ba45fea5ba1d4440_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xMjcvZnJhZzozOWY0YWM0ZDRlMDg0MTczYmI1N2JmMmMyYjg1OGQ5Mi90ZXh0cmVnaW9uOjM5ZjRhYzRkNGUwODQxNzNiYjU3YmYyYzJiODU4ZDkyXzM4NDgyOTA3MDE3Nzg_51a52348-0cf6-4df5-97f7-0ebb6dc17e63"
      unitRef="sqft">44616</irtc:OperatingLeaseRentableArea>
    <dei:AuditorName
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODU_66e6dbbd-208b-4ff6-b6b9-02a6aa00793d">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODY_c781b396-ac4c-4b26-a54e-88a1ab932701">San Jose, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i27fbdeea3c094ae8871771606084496b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMzAzYWI3MzQzNTRhNGY4ZmFkZDI4YTcwY2U2NjNlL3NlYzo0YTMwM2FiNzM0MzU0YTRmOGZhZGQyOGE3MGNlNjYzZV8xNTQvZnJhZzo2ZjRiNzk0OTU0YTU0YzdjOTI2YmYzODZmNGU5ODY5ZS90ZXh0cmVnaW9uOjZmNGI3OTQ5NTRhNTRjN2M5MjZiZjM4NmY0ZTk4NjllXzI3NDg3NzkwNjk4ODg_e7f05b92-a719-415a-b268-69199922ae0d">238</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &A 7%0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !H0%Q45XK"<.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)1
M2\,P$,>_BN2]O39%T=#E9<,G!<&!XEM(;EM8DX;DI-VW-ZU;A^@'\#%W__SN
M=W"M#D+W$5]B'S"2Q70SNLXGH<.*'8B" $CZ@$ZE,B=\;N[ZZ!3E9]Q#4/JH
M]@B\JN[ (2FC2,$$+,)"9+(U6NB(BOIXQAN]X,-G[&:8T8 =.O24H"YK8'*:
M&$YCU\(5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.31S+N]0P_OST^N\;F%]
M(N4UYE_)"CH%7+'+Y+=FO=D^,LDKSHN*%_Q^6S>BXN+VX6-R_>%W%7:]L3O[
MCXTO@K*%7W<AOP!02P,$%     @ :$!<5)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJKW<< ;D#0"^7PO0X]V-.7??_\ZR_!M02P,$%     @ :$!<5+W1Y'C/ @
MLPD  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX;6R=5LMNVS 0_!5"Z"$!
M4HN2_ QL XF#H#T4,&*D/10]T-+:(D*1*DG':;^^2TI1[<3/^&#SL3,[LUJ9
M'*Z5?C(Y@"4OA9!F%.36EM=A:-(<"F9:J@2).PNE"V9QJI>A*36PS(,*$<:4
M=L."<1F,AWYMJL=#M;*"2YAJ8E9%P?2?6Q!J/0JBX'7A@2]SZQ;"\;!D2YB!
M?2RG&F=APY+Q J3A2A(-BU%P$UU/(NH /N([A[79&!-G9:[4DYM\S48!=8I
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MD+'.GPYA6(7<9]:$7-,_[N;_/Z&,$M 21F@ZM0]M9CO*=%[TVS7!U0H =TL
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M_/4>!ZR_\M*N:54Y-(8G*/.J_Q1/0R#.&I!PI@$=&E"[ 9]IP(8&[+4-^-"
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M! _!L2@)(CM\"([&$9TITV12<;(LXY\@SZM6U<\H"^[>E2>A7;DP&&%Q8G/
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M\?EI(TM:4'S?W'BLQCN40M=D@W96>%J=#2ZR9Y='+)\$?M?4A;UOP9$LG?O
MBU?%V6#"#I$A%1E!XL\M79$Q# 0W/FXP!SN3K+C_O45_D6)'+$L9Z,J9/W01
MJ[/!\4 4M)*MB6]=]Y(V\<P83SD3TF_1];)'L*C:$%V]4<:ZUK;_*^\V/.PI
M'$\^HY!O%/+D=V\H>7DMHSP_]:X3GJ6!QA\IU*0-Y[3EI"RBQZF&7CQ_XTMI
M]=^RI\@6XIJ"\KI):[<2EVV 1@BGXPAKK#-6&^3+'CG_#'*6B]?.QBJ(GVU!
MQ2' &&[N?,VWOE[F7T2\)C42TVPH\DF>?0%ONHM]FO"FG\&[4,JU-FI;BAMG
MM-(4Q)\7RQ ]:N6O+Q@XVADX2@:.O@.YWP99Z+?5.E:U>$>JLLZX$D$.Q2L+
M)G^*%8D??SC.\\GS*U<WTJ[3*GO^6'02JE8YWS@O(Q58"!8/$2LV<$U&=M(3
M'RRHB50OR0L>!2/Q#H(;0*&#D*+0I8[2B(JDB95B-;4Y]X06TI9SP/B=7 N<
M%UHJ(;U/OFOXDE1 @E;2F#4 96E=@%_+-4,M>X2.I)=+0V*I<8C!P:C;P-?H
MK%@!Q;7%$V[D0A3H&+ GS3IJ%1*/!5'SQ  G 2K9R*4V.H*UP[B6A 2PZ9J\
MTH@-8]*G=(0M5^^M9N863%G:!#LG8N4,!F$"9S/2*N(@DL)H,1(OG"OZC/JV
M%!<%>EYS13+TOZ@%H<7'5OI(OL_1 DZ]8% =E!N**VDT!K?5<BBZ2JM*2!.<
M".1OX1+SNF-5*+* .311L4A1:#;.(H>R*:C?N$QP;U3:$PK+0,3IGLN7CN>7
M':+X[F2_)3&[;+M"?[6>.< 7T[MFI*LUKI40]KT>H5+%:^GA>#[)G@X335OG
M^$8BANPJ<+I^XCJ+96B70:,^_/J3//P*>X6K1^!T&Y!9#UGHE]92FBE?C[\
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M&39/F&8Y>N(N[XNJ]OVX9R 66'X@.I3KIB."<LIEW=3# ?BBT]^X!H]5H^!
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M+P]E<4F"J.1?"(K!=0L 4[>X \(-?4X(*/DX%TVY<U4)!&";'2[([?9-=W#
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M\"#V#M]JTA%3P8"MOJPW1FL7N60%:5$)H69$ (V!#4"^:ECUJ2$-)P6F!M&
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M)K(&Q3D03)W%MTQ>"'M)F"?' 8)3.$O> 'F(]2)YG$+OV-]+09Q@CC1T.L,
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MOGCV0++8]LO0[;$DW->AV_&/2*N['@_0Y^NN&^P7; "CC\'[X?\ 4$L#!!0
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MWW%DNJ1Q'Y 3JS24JT1"7(+$Q['@M4(VH&I3B)5(2#/&1%$(G4@D?<4KNB\
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MSHC4ND.*X*VZ@8OK)7>!CDBAO4%EZU13^5LL)LW"H:QC9YK7$ A2#<5U#4Q
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M.)[%'>NU"(,VN<1KR]BHTA3[[*2[+RZ!;314:HC4:SY:6%&.2U.3YHQL)Y)
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MYQ#EN:1'+EVATTNP5;RVSFQ &L5'[DS2\09\GUL;VA<^H/L_QL5?4$L#!!0
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M-$Y,.G^ REQ2[VV0T<9"2KZ;M TR7[%T5E<M>L@3YUN+ -J/BG>_$!HG-?1
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M0FL$C^ "Y>"^07TX*CT>JO.,?%/:4:8"XT )!):_FY1'R 4K(-O&[-S8#DQ
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M\B A3%U8_&+T1A[L,S@X(<P2%N%F!RG%\\'R%#A];CR6A$UE%*:(+(,,"9(
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ME:D0+V8J"F8[O5J=V^[TVN.:71"/&O+BG-MD4/MQUZYV FWRIR/FZ^D3;_(
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MLC0Y_SE7$MB@!7@_-::L/] !S2_5WOX;4$L#!!0    ( &A 7%0F?,>5Q0,
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M(1%F9T7E<&S'0WAWI^%PTA_ ?%^;!HXQ]G&):<%VK*BH/K9NENLB*H']D'S
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MWM C/L4C3@KK):\%73JG+4&C2S.*LAJDM:ZOE(>3I1J2JO:YK3%/ST6=6#X
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M6<AO5S1\HG8"]'VAE-T=G(/].#OY U!+ P04    " !H0%Q4I,,];;4$  !
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M@ )+WE;VD]K_BGT_8X>7J\KX)^R[V"P.(&^-576?3 QJ(;LW_]KK<)0P.Y?
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M*36^' T"T-U#T3E6-7XX-\K2J'NSHK<5M0N@_:U2]N@X@OZU7OP%4$L#!!0
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MS>K20F_<>RFKI6Y<91IB]>QL-&''%QG:!X,OE=ZXO3;!E=P:\Q4['\JS48R
M=*VG'CTH^+O3KW5=HR. \:WS.>I#XL3]]M;[N[!V6,NM<OJUJ?^L2K\X&Q4C
M4NJ96M?^RFQ^T]UZ4O0W-;4+OV33VF;YB$S7SIME-QD0+*NF_5?W71[V)A3Q
M$Q-X-X$'W&V@@/*-\NK\U)H-L6@-WK 1EAIF [BJP4VY]A9&*YCGSZ^]F7XE
M'YJI;C ]Y+)6C2-'G]5MK=W+T[&'&&@YGG;^+EI__ E_C)./IO$+1]XVI2Z_
M=S &<#U"OD5XP0<]OM'3B A&"8\Y&_ G^A6+X$\\M>*%LOH5[F1)+M4#%)@G
M$VM5,]>A_=?DUGD+U?+W0+"D#Y:$8,E3P8!$Y;K6Q,S(?N#)1MG2D<F=JFI,
M-0%ZD?< PI,;R)N%Q;(L;,:A+1B,B30^=BLUU6<CX*G3]DZ/SB=;VB$2MX=$
MM4C4=TCF <DZ(/$+W:)Y^VU=^8<?:H54,-?!I!KH[8[;1>XO[$*!U503Y0GL
MI%[>@LMV-UE!$IJSG'+)R:0L*Z2IJHE980/<KOW"V.H? ,DH9P5-8KY-7  (
M T=9(JED[.5V -#/=(5#K& T96([L*G\8J'K,JS/JWNR6MN5<8 UBVDALB&@
MDJ0TY05EXCN@V]3MXQ1"4,F+1SA3F0+.]!#.-*,9_PF<!0<[/H"3QR2C:9Q2
M(>/G<"9I3&66/\()F2XD3;/\ %(!2*64SR-E(J5%,912SDA.62IIEJ=D@&=I
MS[/TYWD6).U3J"(R0=7'LMW2*LZ(:LH=O]PA@@T&.TRPSPO=L:!JYI .K/V6
M<I!Q1UP U99V>Q0AJ'V&[0,[2#5@UZ>.&I_6WGFPQE"'OOT9#B-=O@(B:@N'
M*WE[K^VT<N#)5K CEQ V4/6 Z97&PQS=O 8E1R5<0Q']7LTT.7K0RCHHC?G<
MZKGR&B!Z6\$1/25?5+T&BZJ!]9BU R1@.,A^3F.9 *ER\H)P$4'YYA%0_ 61
M.95YUJ]L6YP\IC&+8;S@49[WP[I;&K(LB:F(H7;!1Y3*WF17PT=Y3%,IT")-
MHC09ICTH2"PH3P+"/$J 8%$BH)-Q4"/V".&OOQ2<\1,PV+8.@"RR@F8L00@L
MCP0[A)*#,J8<3;(L*N0SI(\ET(V!<1)'D-<LX@EAD"V6B?\'48(X"(GA!8M8
M>@@A2U U \(B@N"#7$]CV&<H\(!0YB3%S19%8/\/X0-Q C1V<L!34@B:)@4B
MDU$&GA&>R"%;NWJYTPXA(IOT_0JN?]#Q)GP>\(P[711)AS'=8025'%"HK%>H
M[*<5Z@_3O.I 7L$?,!*;K6[=-)6'"]CHZOK&C0Y>P ;C#(B3JBRY"R0%",T.
M@MU!:%5JW4+ 5/'X!(&$)CMYB:=]>VTP39"MUV:Y4LU#R&I^XLBT-@Z5HW6T
M"EK3F98H%Q Y%&)$=A>2<'R  6H+T7AK?+P[](E[1E#U^@%#(LY>S7HQ:^]4
M;S#V.TQ JU*]V4[KOD 6\!^4L3)ET+'_*G9[VPI08:F/!05.11H+U+ \C^#:
MPR(AD4(@6_#U?<?1[K*  A$G42P#N" +HKM%P!09@0"]VR,D!"ER%I1-1D7Z
M+!PH;T89\!C.813,).(I D)R\2R!:]D.47\M0$/@>]Q#2AC(>!RD"L'*9!^3
M2#B*4!AD EGU+"@&L?!2EV8H:)+A*EF4(2]9=UH<8N-X[PFTU'8>'GI0CV;=
M^/8UU'_MWY*3]@FU,V\?HA^5G<,NDUK/8&H<Y7 ;L.WCKNUXLPH/JEOCX7D6
MF@MX#VN+!C ^,\9O.QB@?V&?_PM02P,$%     @ :$!<5/\AXRH\!   UPD
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M;CR204YK;I[D[C.T>F*;+Y5<NR?9M;&!1]):&UFV8&10,M&\Z6O;AQX@')T
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M=;B$A.ESN0*!;^92)<S@HUHT]4H!BS)0$C>IYW6:">.B,>AG:Q,UZ,O4Q%S
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M*F1P\II-O^/\A/E&50ID9*W\PGZJ*,J/KPV/ \EVU9NW!9.2Y=7CEN 5X=I
M?;]FZM16#_3+O.;E[?0_4$L#!!0    ( &A 7%2LMJDNE0(  %L&   9
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M:W-H965T<R]S:&5E=#0R+GAM;*U536_;, S]*X1/&]#6B=VD6^$82-H.ZZ%
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M-+6&VY-P5\+#C.\G >2 ]LF@??+OVH$K:!3-#\%_D'ZAK85:V]!A^T1W5--
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M,U]3(&V >9\)H5\F]K[>?9\M_P502P,$%     @ :$!<5/#T2[ + P  % D
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MBX$Y#[*]0=J)%K7KV@NAS1W@AI6Y=4':!>;[4@C]/K$707>/3_X 4$L#!!0
M   ( &A 7%2 $:MV5@0  *\2   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q
M+GAM;+58:T_C.!3]*U:U*S'2+HF=/F!4*K5T1HL$VJK,X\-J/KC);6N1Q%W;
M;4':'[_73IJ4(;@P:A&"Q/$YOB\?/_I;J1[T$L"0QRS-]55K:<SJ8Q#H> D9
MU^=R!3E^F4N5<8.O:A'HE0*>.%"6!BP,NT'&1=X:]%W;1 WZ<FU2D<-$$;W.
M,JZ>1I#*[56+MG8-4[%8&ML0#/HKOH![,%]7$X5O0<62B QR+61.%,RO6D/Z
M<1R%%N!Z?!.PU7O/Q+HRD_+!OMPD5ZW06@0IQ,92</RW@6M(4\N$=OQ;DK:J
M,2UP_WG'_MDYC\[,N(9KF7X7B5E>M2Y:)($Y7Z=F*K=_0>E0Q_+%,M7N+]F6
M?<,6B=?:R*P$HP69R(O__+$,Q!X >9H!K 2PGP'M5P!1"8C>"FB7@+:+3.&*
MB\.8&S[H*[DERO9&-OO@@NG0Z+[(;=[OC<*O G%F,(:9(7^289((FP>>DIN\
MJ":;E;,Q&"Y2_0&[?+T?D[/?/O0#@\-:<!"70XR*(=@K0U!R)W.SU.13GD#R
M'!^@N97-;&?SB'D)_X[-.8GH'X2%]*+!GFL_? SQ#LYH WS\=GCH\2:J,A Y
MOLB7@9M<&[7&^63(/[?8@=P8R/0/#WV[HF\[^O8K]-]=Y4-"^ 84SF0B<@,*
MM"&*&VB*GI^O?<XZOS=%[=VP9^YT*G<Z7IXO2Z$2,L1()=:G/"%3](5;!^^_
MC<BMY#D9+A2 B^5_KO$+J,Q]\8S?K<;OGB);O8J^YW7OCC^*;)V1F52(%/F"
MQ'S%8V&>FN9=P=5S7%;@-X.H$[J??K!IL.*BLN+BJ$&>PD:F&VOMM0(4$O(9
M34Y?&/W,ELO*ELM3!)R&M0"&1PQY2=;=BSG[.>;%-"I[[F>'1A>>[- ]S:9>
MDX>97&,H<!G'K.2)M7F-J5*X$.\2$1>)L,A&-^@+-UZSBM56L>-.36O[[(G<
M@D%%TD3.R_+QI;5657H26:6UKE*_HKVS;MHO DZI;Z[26A&I7Q(G2L8 B29S
M)3.7<1O*N"&4I2F=%X79O?194FLC[1ZU G8A_#4%H;6HTMY):J'62^H7S FH
M&(GM\HJAAU0LQ"P%W-3&=J)JG)<QB VW;;BYJDM&-^;'/U:O<QZ&OJ64UM)*
M+X^;+Y&7^7KKLLIJ&6;A*7+$:M%D?M&\.;#O&1W ']K!L%HHV7&%L@[[KTP3
M5DLF.XEDLEHRF5\R#Z? CS]4^:S63';<;>1$X6&73+'#>XJ_%DYVDETEJQ60
M^?>5(ZZ%)L75 !Z+DW5QZL;?#5?""9/-"3GCFG"R*N2L\:QW8*#PO.>?);6F
ML@.:NN1X#'U $Y]GPT=>*Q\[R:XRJN4L\N\JI[#B3XX:%X0$1VN*9?1RBQAU
M&K>(P=X)/P.U<#<EFKCEI3CL5ZW5;<S0W4$$=??B*N>.JX7(-4EACE";KQ91
MQ>U(\6+DRMT7S*0Q,G./2RP;4+8#?I]+:78O=H#JCFKP/U!+ P04    " !H
M0%Q4.)@[_BP#  !!"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6RU
M5DU/XS 0_2M6Q $D(''23]16@E9HD4"J*+"'U1[<9MI8)';7=BC\^QTG(6VW
M26!9[:6-DWEOWHQGQAYLI'K6$8 AKTDL]-")C%E?N*Y>1) P?2[7(/#+4JJ$
M&5RJE:O7"EB8@9+8]3VOXR:,"V<TR-Y-U6@@4Q-S 5-%=)HD3+U=02PW0X<Z
M[R_N^2HR]H4[&JS9"F9@'M=3A2NW9 EY D)S*8B"Y="YI!=CVK: S.*)PT;O
M/!,;RES*9[NX"8>.9Q5!# MC*1C^O< 8XM@RH8Y?!:E3^K3 W>=W]NLL> QF
MSC2,9?R=AR8:.CV'A+!D:6SNY>8;% %E A<RUMDOV>2V731>I-K(I "C@H2+
M_)^]%HG8 =!6#< O /YG 4$!"+) <V596!-FV&B@Y(8H:XUL]B'+38;&:+BP
MVS@S"K]RQ)G1!.:&G)$9ED>8QD#DDERG)E5 [KC@29J0*7O#;3.:'$_ ,![K
M$[1_G$W(\=$).2)<D(=(IIJ)4 ]<@Y(LL;LHW%_E[OU:]XMS$M!3XGL^K8"/
M/P_W]N$N)J+,AE]FP\_X@J9LW AM5&IC)C]NT8#<&$CTSP;ZH*0/,OI6#?V#
M-"RN2E(.ZV8PVW@OHWZGCP&][*;BT,BG0= OK?8DM4I)K49)-N)3+#2E;+QK
MJ6QS54G,:3H[WBGM=+I_:/S(:D]CN]38;M1X*\7JS(!*L#_GIDI<^\!M1?[:
M?Y._3JFM\[4M[1Q(0F_MFDQT2V_=9F\15R&YQ-H,(238<N0>M&$&%[.G*W(K
MF2"7*P5@J[>A8'NEO][_Z(=^2=]O# >[UJ_*7?^PBOS:W%%O.^J\C]P%E2/*
M.RR?/FW5N-N9K/1KI5'@]FK#][NTQN%V>%&_N4] ZPNL#IGB5BG 8UWCIG&Q
MPB&-[8.54JG&/U!SUNL%-6*VHXXVS[I<3%Y 6J=,+(",I3;5AT1PJ"&HR\=V
MM-'FV99M !DSI=YL$IY8G$*E]\.IU="K=#NVZ+_.+5HQDRHJP=TYW^WEZHZI
M%1>:Q+!$G'?>11J5WU?RA9'K[,B?2X,7B.PQPCL>*&N WY=2FO>%O464M\;1
M;U!+ P04    " !H0%Q4XX0>-#D#  #_"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6R=5MMNXC 4_!4KZD,K;9L;!*@ J9!6VX=*J+2[SR8Y@:B)
MS=JFL'^_MA-"R*UL7R!V9L8SON6,]Y1]\ V 0(<T(7QB;(38WILF#S:08GY'
MMT#DFXBR% O99&N3;QG@4)/2Q'0LRS-3'!-C.M9]"S8=TYU(8@(+AO@N33'[
M.X.$[B>&;1P[7N/U1J@.<SK>XC4L0;QO%TRVS$(EC%,@/*8$,8@FQH-][]NN
M(FC$KQCVO/2,5)05I1^J\1Q.#$LY@@0"H22P_/N$.22)4I(^_N2B1C&F(I:?
MC^I/.KP,L\(<YC3Y'8=B,S&&!@HAPKM$O-+]3\@#]95>0!.N?]$^QUH&"G9<
MT#0G2P=I3+)_?,@GHD2PO1:"DQ.<*J'70G!S@GLIH9<3>GIFLBAZ'GPL\'3,
MZ!XQA99JZD%/IF;+^#%1Z[X43+Z-)4],GTE 4T!O^  <W:(Y3;>4 !$<T0@M
M&/V,]0K+#8;.H-<^"!PG_$:2WI<^NKZZ05<H)NAM0W<<DY"/32']J5',(/<R
MR[PX+5YL![U0(C8</9(0PG,!4P8KTCG'=#.G4]&'X ZY]@_D6([=8&A^.=UJ
MH/L7T^U11QJW6"M7Z[DM>O,=8W)I$!SDJ>> KE= ((K%S7V'>*\0[VGQ7HOX
M$X3 <-*T:AEQH(GJ'OF<RLGX+$_CEPB_"W'FMU_X[7?Z70HLH,EM1O-*(SF.
M6_%;Q]A#N^*XCFEQ[!6.O>X9IDS>0J3)LU?WTZ_.<1W3'U4LUR'>L-GSH/ \
MZ/3\1@5.Y#V4;3R!#_7-UY1G4#/B#JIK4,<XO>JNJ6/: @V+0,/.,^1#!#),
M^'^':%2HC[Y[B$8=VRF;D"\1?A?BS*]MG:Y_ZWO'*.=U&?X:XG="SBV7OECV
M=\]1SBP/=^M573=@[.KA;P*Y+<:=DW'G@L,4'G?@Q:<IE^U.U8"IIVH M:4Z
M?91L]X)4LBI CQ>%<6M? M<;5-/408Y3O>T:0%Z_DL8L548IL+6N,#D*Z(Z(
MK(PH>HLJ]D'7;I7^F:IN=<5UDLE*XQ?,UC'A*(%(2EIW _GA8%FUF34$W>KZ
M:T6%K.;TXT96Z, 40+Z/*!7'AAJ@J/FG_P!02P,$%     @ :$!<5/']!HH2
M!   4@T  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULC5=;;^(X%/XK
M%AII6ZEM8B<D,*)(+72T\U!MU<[E8;4/)CD!JXG-VJ:T_WYL)PV0&-H7B)/O
M')_/Y^K)5LAGM0+0Z+4JN;H>K+1>?PT"E:V@HNI*K(&;+X60%=5F*9>!6DN@
MN1.JRH"$81)4E/'!=.+>/<CI1&QTR3@\2*0V547EVRV48GL]P(/W%X]LN=+V
M13"=K.D2GD#_7#](LPI:+3FK@"LF.))07 ]N\-<YCJR 0_QBL%5[S\A260CQ
M;!??\^M!:"V"$C)M55#S]P(S*$NKR=CQ?Z-TT.YI!?>?W[5_<^0-F055,!/E
M;Y;KU?5@-$ Y%'13ZD>Q_1L:0D.K+Q.E<K]HVV## <HV2HNJ$3865(S7__2U
M.8@] 9P<$2"- .D*Q$<$HD8@^JQ W C$[F1J*NX<YE33Z42*+9(6;;39!W>8
M3MK09]SZ_4E+\Y49.3W]SC-1 ?I!7T&A2_0(F> 9*QEU7A&%_8+N7DV8*4 S
M4:TW&G)$-7K25&^TD&_H&^0@:8D>J09$>>Y@E+_]I0Z$S^:@*2O5N=GFY],<
MG7TY1U\0X^C'2FR4D5.30!M&UJX@:ZR_K:TG1ZS'!-T+KE<*W?$<\D,%@3F*
M]CS(^WG<DI,:YY!=H0A?(!(2[#%H]GGQT",^_[0X'I]@$[7>C9R^Z(B^NZ(
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MSGPH')..6^9>&":C(QSV6CX^R<$,3&8<XG4CF#/3(Z3)#D9++R/L811V"7E
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M"+6?!#1XVOC,UQOK-L+I>,O6< _V87NG<1766G)>@#1<2:)A-0ENZ/6"]AS
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M=#5 ;KH:'JN%55L_3BV5Q>',OVYPX ;M!/!\I91]6C@#]0@__1]02P,$%
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MFVG1VCYAYMCG2NBW1./4^)YEO 3TC#] HJ]H7I\^XDOTBFF%[=E,J"X.S#)
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MW>I&Y,OR$]/77(@\+2\7C$:,JP'R]UF>B^V-^FJU^7#Z[K]02P,$%     @
M:$!<5.#0:>%/ P  0 H  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
ME99=<]LH%(;_"J.K=F83"21DT;$]8\>[;2\ZDZEGM]=$PA83";2 X[2_OH 4
MQ9%DQ[VQ ;WG<!X.'V=^E.I1EXP9\%Q70B^"TICF4QCJO&0UU;>R8<)^V4E5
M4V.[:A_J1C%:>*.Z"E$4I6%-N0B6<S]VKY9S>3 5%^Q> 7VH:ZI^KEDECXL
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MLX=?M?5*VS&R\2_X@S2V'O#-TI9X3#F!_;Z3TKQTW 1]T;C\#5!+ P04
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M%96R8E!DU%SQCRH01PHHZ%! E0(:JN!7"OY0A:!2",K(&%?*.,RPQ-,)9WO
MM;1"TS=E,$MMY7Y&==[GDJNOF=*3T[EDZ1MXH"FA.@'@,<=4@"LP-^L L"7X
MF]&K'1&2+,"3NO LU;=&\9EF4H +YVG^+)Q+<#$C$F>YN%0(S_,9N/AT"3X!
M%X@UYD2 C!J%S^JENO]GS;8"TX68N%*YH@FY:47[SM!&';0A M\8E6L!_J0+
MLC@%<%4,ZD"@0R#N4"_BC*0CX,// 'D(6@C=#U?W+.JSP>HPZ?'&K]/JEWA^
M5UI-P)]5<'C^GM$5T!GJ 0YJX* $#CJ OW),=?HO5/Y,5B]MV3,@80FB2\]N
MJH*R.PYGG\0)LW'-;-S+3#L(,B&VBIU:5&!+S:+M<3JLH<-?&\VH!HYZ.=^1
M54:I!GS%:N.EY&=QC<ZB!B$,X#AI1?=<+HY#S^\(<5S3C7]%\N-SDBA.QF'4
M(GDN-T[&"1S;228UR:27Y(LI53_AF)S9O@J@:I:HQ=$BA_QNDM!KZJ[72U-U
MK27)!C"M<$XH^ &"H=^B:A.$/HPCV,'UJ$? 7JZJQGY@C59@)_D/ Y5_V"9L
M$;2MYIE%L&\Y0]0XAGHW]O?R6*!R<+LC7!US0+G"@>JD!'S!&0<O.-^2GHT.
MFX(,_?^QU763W!!NPFF/IH%-CGQ/@A$:MV-Y+A9%HP1U1*@I]W!XO1] UH#I
ME=BPC4=QFZQ%#'K!R$LZZ#8] /8W@:/-/X#MV$XC"=I\+8)A,O*@U_QU;;*F
MQ\#P P5A /O0PA[ZH^1L:5@$Q\DH[BIA3?."_=W+4A8&T([.US/L"F7E@$7E
M? O,+&)]6Z!I>C >5B2>B!ZDM,MZF>GK(^$9,PE[)YBWZ^&IP::!P?X.5AOD
MM<%=97!C#*I3>7G<Z3)<A;K?#"Q5000*<Y)&'EC@=]MA_'X84G! @E$7TNR#
M2%9.I^?[IN,BKS>/MZL5)RM=VA^HFF+4Z)J:^J[#^/MO,/3^D(>)I"^1J.F;
MJ+]O-A:SVN*NM%@ET):U"C,ZWM9) /WVZ<DBA\( ):V#]LPBIUKG6>]TCV;(
M@O!5.8L+D+(ME6:*JM_6\_YM.>6VWM_!ZYF9VAL8\R/"-\Q5#Q0@)TL%Z8TB
M55:YF<O-@V2;<E)]95+-O>7MFF!UZ-8"ZON2,7EXT ;J7T>F_P%02P,$%
M  @ :$!<5+OF2U1: P  10P  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N
M>&ULS5=1;]HP$/XK5J1)F[22.*'03H $H=,FK5K5:MO#M =##K!PXLPVI?S[
MG9TTL X<I.UA+\1V_'W^[GQW.09;J=9Z!6#(4RX*/0Q6QI3OPE#/5Y SW9$E
M%/AF(57.#$[5,M2E I8Y4"[".(IZ8<YX$8P&;NU.C09R8P0OX$X1O<ESIG83
M$'([#&CPO'#/ERMC%\+1H&1+> #SI;Q3. L;EHSG4&@N"Z)@,0S&]-V4]BS
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MKKC%I5Z'IM; <P^JRC"B- TK+F0PF_B]:SV;J,:60L*U)J:I*JY_7T&I-M.
M!8\;-V)=6+<1SB8U7\,2[-?Z6N,J[%ER48$T0DFB834-+MF;!:,.X"V^"=B8
MG6?B4KE5ZLXM/N33@+J(H(3,.@J.?_<PA[)T3!C'KXXTZ'TZX.[S(_L[GSPF
M<\L-S%7Y7>2VF :C@.2PXDUI;]3F/70)#1Q?IDKC?\FFLZ4!R1IC5=6!,8)*
MR/:?/W2%V &P] 0@Z@#1(2 Y 8@[0/Q<0-(!$E^9-A5?AP6W?#;1:D.TLT8V
M]^"+Z=&8OI!.]Z75^%8@SLX^8VM]5,:0:]!DKJH*M5@67 -Y39;89'E3 E$K
M<BFM>)V+LG$RD25DC196@"%O'[*RR2$G*ZTJLG 6N.AIZT/:%PNP7)3F)3HP
M;L=,0HN)N'#"K OZJ@TZ.A$TB\@G)6V!WB6ZWB<(L0)]&:+',EQ%9QD7D%V0
MF+TB$8W8D8#FSX?3(_#%L^%L?":;N!<U]GSQ"3XGUM^U0EGJQG+_^:'";[F6
M0J[;3FBU^O$1B<D'"Y7Y>2:LI \K\6$E9\+:]I#9Q@5[<>5=#TGLH=+UT LA
MNU9Y>:Q76J>I=^J.N?M9Q 9QF@XGX?VNA$_MV#!*:$+W[19'^.+1.!IN^?:R
M'_39#\YF_Z5VE3;$*E(W.BOPL")9^V7@5Y[=G2EPVKM(_R?=AWU8PW^A^_")
M3@.:,)H>R/[4+*7CT8@=J/[4C UH'"4G5!_UN8_.YGZS_&J(,*;!Q+C,22/O
MP=BS9]:XIQ[_3VHSNKU2Z+_0N_.Z)U&:C ?I@93S8X:,)6PP/M#\B.%HE-*8
M'F@>[MRO%>BUGU,,?KV-M.T=T^_VL]"EGP .]J_<C.3O[2U-.V!]XGHM\'0H
M8864]&*(AXEN9Y9V857M;_%;97$F\(\%SGF@G0&^7REE'Q?.03\YSOX 4$L#
M!!0    ( &A 7%3E*@/:< (  /@&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;+6576_:,!2&_\I1-DV=-!'BT 2Z$*F%3>W42:BLV[1I%R8Y@%4G
MIK8#G=0?/]L)$6L![6*]2?QQWL?G/7'L9"/DG5HB:G@H>*F&WE+KU9GOJVR)
M!54=L<+2S,R%+*@V7;GPU4HBS9VHX#[I=B._H*STTL2-362:B$IS5N)$@JJ*
M@LK?%\C%9N@%WG;@ABV6V@[X:;*B"YRBOEU-I.GY+25G!9:*B1(DSH?>>7 V
M&MAX%_"5X4;MM,$ZF0EQ9SM7^=#KVH208Z8M@9K7&D?(N069-.X;IM<N:86[
M[2W]H_-NO,RHPI'@WUBNET.O[T&.<UIQ?2,VE]CX.;6\3'#EGK"I8Z/(@ZQ2
M6A2-V&10L+)^TX>F#CL"$AP0D$9 G@B"^( @; 2A,UIGYFR-J:9I(L4&I(TV
M--MPM7%JXX:5]BM.M32SS.AT.JUF"N\K+#5\6)NG@I,Q:LJX>IOXVBQ@P_RL
M@5W4,'( ]HF6'0BZ[X!T";F=CN'D]3[*Z#AEC%D'PL!1@KE^\RJ(^^__QOC&
M96N5M%:)XX;_:!5^7IL(N-)8J%]'^&'+#QV_=X!_C68[F9U=:CKC"-3\5/ (
M^PW4=:AYD>/9WVV=]GI1$"7^>D\:O3:-WM$TGME\A(D4>95I."]SF*)<LPP5
M_& "OL.7[0",1(Z#D/3"(Z4X;7,X?9%21RT_.NKQ!EDQJZ3"PL(EU;AOL]:,
M>*>\A(3[BQNW"\<O6MSXB/E^FT/_18H[:/F#_U#<P?/BAD^+Z^^<2_9.^$SE
M@I4*.,Z-JMN)S2Z2]3E;=[18N:-J)K0Y^%QS::XFE#; S,^%T-N./?W:RR[]
M U!+ P04    " !H0%Q4(_GL!QP#   N$@  #0   'AL+W-T>6QE<RYX;6S=
M6%%KVS 0_BM&':.%4<=QZ\9K'-@"A<$V"NW#WHH2RXE ECQ9Z9+^^NDLQTE3
M7<CZL*5S2"W=I_ONT]VY,AG69B78W9PQ$RQ+(>N,S(VI/H9A/9VSDM;GJF+2
M(H72)35VJF=A76E&\QJ<2A'V>[TD+"F79#24B_*F-'4P50MI,G+1F0)W^Y)G
M)$HN2.#HQBIG&7DX??]SH<SUN\#=3SZ<G/3.>P]GU[O(:0N=D=!+?'D ,4J+
MD28'J>WMT]M#R:\.(]_'W5"';>9'PT+)30%BX@PV-BU9\$A%1L94\(GFX%70
MDHN5,_?!,%5"Z<#8RELQ$5CJ)P=';@9-T?*47"K=Q'81W-])NWP'6,] (!>B
M$]@GSC :5M08IN6-G32+&^,+*&C']ZO**IQINHKZEV3CT-QLD(G2.=-=F(BL
M3:.A8 7(T7PVA[M150B@,:JT@YS3F9*TT;#V: >6=LJ$N(,GYD?QC'M9;%6U
M!S65W= *:H>.QDV ?YO-<6_3OHXWJ/BC,I\7=CNRF4.SL%O-"KYLYLNB$X"Q
M1S@[K2JQ^B3X3);,;?[@@*,A7?L%<Z7YDXT&K3*U!J9)\,BTX=-MRR]-JWNV
M-.MV6A:XYOX;U/QW\SQCDFDJMD7;WC_F++]:<7O$_ O-S;^57<5>D?'5\6ML
MC]1C%YF\!9%OH-QQ>I0:P_9HW#I_GYV^G36 MYR,?(<W*K$)&DP67!@NV]F<
MYSF3+PYA2V_HQ+X,/^.WZW-6T(4P]QV8D<WX&\OYHDR[5;>0B';59OP5MA<E
MW2N6C<5ESI8L'[=3/9LTP\ .;-3V H==Y*:Y_ CFXS _ A@6!U. ^3@O+,[_
MM)\!NA^'8=H&7F2 ^@Q0'^?E0\;-!XOC]TGMY=]IFL9QDF 9'8^]"L98WI($
MOGXV3!MX8'$@TI_E&J\VWB'[^P"KZ;X.P7:*=R*V4SS7@/CS!AYIZJ\V%@<\
ML"I@O0/Q_7&@I_P^<0Q5Q;1A3S".I"F&0"_Z>S1)D.PD\/'7!WM*XCA-_0A@
M?@5QC"'P-.((I@ T8$@<-^?@SGD4KL^I</,+T>@W4$L#!!0    ( &A 7%27
MBKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E
M\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!
M2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/
M06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3
MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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MZTJIBW#N1G\VO'C9-OVRY?OL/U!+ P04    " !H0%Q4VW:P<3$"  ")*0
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MIZSWSJW_.'Y\EIUM^K=\-OY9<?$"4$L! A0#%     @ :$!<5 =!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    " !H0%Q45XK"<.\    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    " !H0%Q4F5R<(Q &  "<)P  $P
M        @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &A
M7%35,IVWH 8  ) :   8              " @0X(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    " !H0%Q4VJ]U6!L"  !M!0  &
M        @('D#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ :$!<5/4$"Y Z!@  <QD  !@              ("!-1$  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( &A 7%2]T>1XSP(  +,)   8
M              " @:47  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    " !H0%Q4R-\C[.,$  !W$@  &               @(&J&@  >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ :$!<5&HHOV#; @
MW@<  !@              ("!PQ\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( &A 7%2X)6-9%0<  !DB   8              " @=0B
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !H0%Q4_"22
MUKL(  !M)0  &               @($?*@  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ :$!<5.5>>@X3!0  2 P  !@
M ("!$#,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &A
M7%3H<>B[]BL  .>%   9              " @5DX  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ :$!<5.C'-H:@!   I T  !D
M         ("!AF0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    " !H0%Q4^\F'NM@&   ^$P  &0              @(%=:0  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( &A 7%3QH@"E+@4  !<,
M   9              " @6QP  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ :$!<5*^&@0..#P  FRH  !D              ("!T74
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !H0%Q4K,2<
MF<T&  #3$   &0              @(&6A0  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( &A 7%0XQJ%@+0H  *\;   9
M  " @9J,  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M:$!<5!C"RZ^D P  #P@  !D              ("!_I8  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    " !H0%Q4E?!@G=<,  !!)P  &0
M            @('9F@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( &A 7%39%2PH@0P  +4F   9              " @>>G  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ :$!<5"9\QY7% P
MGP@  !D              ("!G[0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    " !H0%Q4<"(EU#8%  "H"P  &0              @(&;
MN   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &A 7%2?
M?D =!C8  (RX   9              " @0B^  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ :$!<5(@L,()5!   V@H  !D
M     ("!1?0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &A 7%0,B4#QY@(  /8%   9              "
M@5H( 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ :$!<
M5'4"-#9O!@  21(  !D              ("!=PL! 'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    " !H0%Q4.HR.T[\"  #&!0  &0
M        @($=$@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( &A 7%1H_LOL^04  &T/   9              " @1,5 0!X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ :$!<5/\AXRH\!   UPD
M !D              ("!0QL! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    " !H0%Q4(Q*,1<\#  #8"   &0              @(&V'P$
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &A 7%0)0],H
MU (   ('   9              " @;PC 0!X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ :$!<5 >\5"S1!   C!0  !D
M ("!QR8! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !H
M0%Q4[NBI9YL#   J"P  &0              @('/*P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( &A 7%16O_C2%0,  )((   9
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M970T,2YX;6Q02P$"% ,4    " !H0%Q4.>.7KGD"   6!@  &0
M    @($10@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (
M &A 7%0;$*A)C@(  -@&   9              " @<%$ 0!X;"]W;W)K<VAE
M971S+W-H965T-#,N>&UL4$L! A0#%     @ :$!<5-R\74'B!   RAP  !D
M             ("!AD<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"
M% ,4    " !H0%Q4#ZEB.YL"  "A!P  &0              @(&?3 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &A 7%3*P:QXZ0(
M $8(   9              " @7%/ 0!X;"]W;W)K<VAE971S+W-H965T-#8N
M>&UL4$L! A0#%     @ :$!<5$W"DM>+ P  JPT  !D              ("!
MD5(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !H0%Q4
M\/1+L L#   4"0  &0              @(%35@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;%!+ 0(4 Q0    ( &A 7%1TZNV<+ 4   86   9
M      " @959 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%
M  @ :$!<5)BB@^W1 @  TP<  !D              ("!^%X! 'AL+W=O<FMS
M:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !H0%Q4@!&K=E8$  "O$@
M&0              @($ 8@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+
M 0(4 Q0    ( &A 7%0XF#O^+ ,  $$*   9              " @8UF 0!X
M;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ :$!<5..$'C0Y
M P  _PL  !D              ("!\&D! 'AL+W=O<FMS:&5E=',O<VAE970U
M,RYX;6Q02P$"% ,4    " !H0%Q4\?T&BA($  !2#0  &0
M@(%@;0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &A
M7%2R[+^>S0,  &,-   9              " @:EQ 0!X;"]W;W)K<VAE971S
M+W-H965T-34N>&UL4$L! A0#%     @ :$!<5 6)U[M\ P  S@L  !D
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M=#8P+GAM;%!+ 0(4 Q0    ( &A 7%3&E[QT!0@  $0M   9
M  " @=^% 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @
M:$!<5.#0:>%/ P  0 H  !D              ("!&XX! 'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6Q02P$"% ,4    " !H0%Q46'T3Z)$%  #G%P  &0
M            @(&AD0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4
M Q0    ( &A 7%3*QG#AC@0  "D1   9              " @6F7 0!X;"]W
M;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ :$!<5+OF2U1: P
M10P  !D              ("!+IP! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX
M;6Q02P$"% ,4    " !H0%Q4 I*]]44'   K+   &0              @(&_
MGP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( &A 7%14
MQ0LL=@,  !,,   9              " @3NG 0!X;"]W;W)K<VAE971S+W-H
M965T-C<N>&UL4$L! A0#%     @ :$!<5 Q-(BLH P  '@H  !D
M     ("!Z*H! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
M" !H0%Q4S):S=B8#  !%"@  &0              @(%'K@$ >&PO=V]R:W-H
M965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( &A 7%3E*@/:< (  /@&   9
M              " @:2Q 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L!
M A0#%     @ :$!<5"/Y[ << P  +A(   T              ( !2[0! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !H0%Q4EXJ[',     3 @  "P
M        @ &2MP$ 7W)E;',O+G)E;'-02P$"% ,4    " !H0%Q4C\C*V3,%
M  !V+@  #P              @ %[N $ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ :$!<5-MVL'$Q @  B2D  !H              ( !V[T! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :$!<5*3(PW?Z 0
MM"@  !,              ( !1, ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $X 3@!9%0  ;\(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>237</ContextCount>
  <ElementCount>481</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestments</Role>
      <ShortName>Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2134108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2146110 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2157112 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2161113 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/CashEquivalentsandInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/BalanceSheetComponents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2343308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2347309 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/StockIncentivePlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/StockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2358311 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/NetLossPerCommonShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails</Role>
      <ShortName>Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Cash Equivalents and Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Cash Equivalents and Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies ("PCBAs") (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails</Role>
      <ShortName>Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies ("PCBAs") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Balance Sheet Components - Components of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Components of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Balance Sheet Components - Components of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Components of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/DebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Debt - Schedule of Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails</Role>
      <ShortName>Debt - Schedule of Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2440424 - Disclosure - Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Stock Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Stock Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Stock Incentive Plans - Summary of Non-vested Restricted Stock Units ("RSUs") (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails</Role>
      <ShortName>Stock Incentive Plans - Summary of Non-vested Restricted Stock Units ("RSUs") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="irtc-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2462437 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.irhythmtech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.irhythmtech.com/role/SubsequentEvents</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="irtc-20211231.htm">irtc-20211231.htm</File>
    <File>firstamendmenttodevelopmen.htm</File>
    <File>irtc-20211231.xsd</File>
    <File>irtc-20211231_cal.xml</File>
    <File>irtc-20211231_def.xml</File>
    <File>irtc-20211231_lab.xml</File>
    <File>irtc-20211231_pre.xml</File>
    <File>irtc-20211231xex231.htm</File>
    <File>irtc-20211231xex311.htm</File>
    <File>irtc-20211231xex312.htm</File>
    <File>irtc-20211231xex321.htm</File>
    <File>secondamendmenttodevelopme.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>irtc-20211231_g1.jpg</File>
    <File>irtc-20211231_g10.jpg</File>
    <File>irtc-20211231_g11.jpg</File>
    <File>irtc-20211231_g12.jpg</File>
    <File>irtc-20211231_g13.jpg</File>
    <File>irtc-20211231_g14.jpg</File>
    <File>irtc-20211231_g2.jpg</File>
    <File>irtc-20211231_g3.jpg</File>
    <File>irtc-20211231_g4.jpg</File>
    <File>irtc-20211231_g5.jpg</File>
    <File>irtc-20211231_g6.jpg</File>
    <File>irtc-20211231_g7.jpg</File>
    <File>irtc-20211231_g8.jpg</File>
    <File>irtc-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="877">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>104
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "irtc-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 29,
   "contextCount": 237,
   "dts": {
    "calculationLink": {
     "local": [
      "irtc-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "irtc-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "irtc-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "irtc-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "irtc-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "irtc-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 617,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 59,
   "keyStandard": 422,
   "memberCustom": 35,
   "memberStandard": 40,
   "nsprefix": "irtc",
   "nsuri": "http://www.irhythmtech.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.irhythmtech.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Cash Equivalents and Investments",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestments",
     "shortName": "Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Fair Value Measurements",
     "role": "http://www.irhythmtech.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Balance Sheet Components",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.irhythmtech.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Debt",
     "role": "http://www.irhythmtech.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134108 - Disclosure - Income Taxes",
     "role": "http://www.irhythmtech.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Stockholders' Equity",
     "role": "http://www.irhythmtech.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146110 - Disclosure - Stock Incentive Plans",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.irhythmtech.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.irhythmtech.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157112 - Disclosure - Net Loss Per Common Share",
     "role": "http://www.irhythmtech.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161113 - Disclosure - Subsequent Events",
     "role": "http://www.irhythmtech.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Cash Equivalents and Investments (Tables)",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables",
     "shortName": "Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.irhythmtech.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.irhythmtech.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Debt (Tables)",
     "role": "http://www.irhythmtech.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.irhythmtech.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347309 - Disclosure - Stock Incentive Plans (Tables)",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.irhythmtech.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358311 - Disclosure - Net Loss Per Common Share (Tables)",
     "role": "http://www.irhythmtech.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i4f5749ec23ec4a79bb0d8bc07ab9958a_D20200821-20200821",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i5bcf3584e3054380b50e7dcd8ca83f70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Allowance for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i40721ab01cb74086a6725dda65e33834_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfChangeInContractualAllowanceTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i5bcf3584e3054380b50e7dcd8ca83f70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "irtc:AccountsReceivableForContractualAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Changes in Contractual Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfChangeInContractualAllowanceTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i40721ab01cb74086a6725dda65e33834_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "irtc:AccountsReceivableForContractualAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details)",
     "role": "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails",
     "shortName": "Summary of Significant Accounting Policies - Disaggregated Revenue by Payor Type and Major Service (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "id814a6da95c1480a914c87a5028a3a5b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details)",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails",
     "shortName": "Cash Equivalents and Investments - Schedule of Fair Value of Securities, not Including Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details)",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails",
     "shortName": "Cash Equivalents and Investments - Schedule of Fair Value of Short-term and Long-term Marketable Securities Classified by Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
     "shortName": "Cash Equivalents and Investments - Schedule of Available-for-Sale Securities Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:AvailableForSaleDebtSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Cash Equivalents and Investments - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails",
     "shortName": "Cash Equivalents and Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "irtc:AvailableForSaleDebtSecuritiesMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i544774a11590471697b6d8b7df26516c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i544774a11590471697b6d8b7df26516c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details)",
     "role": "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Company's Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "irtc:InventoryAndPrintedCircuitBoardAssemblies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies (\"PCBAs\") (Details)",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails",
     "shortName": "Balance Sheet Components - Components of Inventory and Printed Circuit Board Assemblies (\"PCBAs\") (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "irtc:InventoryAndPrintedCircuitBoardAssemblies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i2f46613cf83f4b0ba3abd94c82d299fc_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "irtc:OtherAssetsUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Balance Sheet Components - Components of Property and Equipment, Net (Details)",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Components of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedVacationCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Balance Sheet Components - Components of Accrued Liabilities (Details)",
     "role": "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Components of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedVacationCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "role": "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Debt - Schedule of Future Minimum Payments (Details)",
     "role": "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails",
     "shortName": "Debt - Schedule of Future Minimum Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails",
     "shortName": "Income Taxes - Reconciliation of Tax Expense Computed at Statutory Federal Rate and Company's Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "irtc:OperatingLossCarryforwardsTaxBenefitRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "irtc:OperatingLossCarryforwardsTaxBenefitRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i5bcf3584e3054380b50e7dcd8ca83f70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440424 - Disclosure - Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Valuation Allowance for Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "irtc:ValuationAllowanceDeferredTaxAssetAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i5bcf3584e3054380b50e7dcd8ca83f70_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "role": "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i40721ab01cb74086a6725dda65e33834_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DividendsCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details)",
     "role": "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule Of Common Stock Shares Reserved For Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "ib83d09b0b4814982af13362f56c4531a_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Stock Incentive Plans - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
     "shortName": "Stock Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "irtc:StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "ibad41d5498b1410b8ada5b20ae638221_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details)",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails",
     "shortName": "Stock Incentive Plans - Summary of Share-based Awards Available for Grant under 2016 Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "irtc:ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i759c278fc6f747e3ba280896f23d9bbc_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i5bcf3584e3054380b50e7dcd8ca83f70_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details)",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails",
     "shortName": "Stock Incentive Plans - Summary of Stock Option Activity Plans, Including Grants To Nonemployees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Stock Incentive Plans - Summary of Non-vested Restricted Stock Units (\"RSUs\") (Details)",
     "role": "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
     "shortName": "Stock Incentive Plans - Summary of Non-vested Restricted Stock Units (\"RSUs\") (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "ie012b38e16cc401f802ea87af3684400_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)",
     "role": "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i07a2fb6e3f634ec19d37cf2d78d3e4de_D20190101-20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details)",
     "role": "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails",
     "shortName": "Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense for Options, RSUs and ESPP Included in Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i42ec867e77104c7c880eca8b43778fb5_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "role": "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails",
     "shortName": "Net Loss Per Common Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details)",
     "role": "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i632162ae05734a44b80f1fdf5560120e_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i632162ae05734a44b80f1fdf5560120e_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i0124649f48144c50ba45fea5ba1d4440_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "irtc:OperatingLeaseRentableArea",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462437 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.irhythmtech.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Description of Business",
     "role": "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "irtc-20211231.htm",
      "contextRef": "i27fbdeea3c094ae8871771606084496b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.irhythmtech.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "irtc_A2019AwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Awards",
        "label": "2019 Awards [Member]",
        "terseLabel": "2019 Awards"
       }
      }
     },
     "localname": "A2019AwardsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_A2020AwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Awards",
        "label": "2020 Awards [Member]",
        "terseLabel": "2020 Awards"
       }
      }
     },
     "localname": "A2020AwardsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_A2021AwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Awards",
        "label": "2021 Awards [Member]",
        "terseLabel": "2021 Awards"
       }
      }
     },
     "localname": "A2021AwardsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_AccountsReceivableAllowanceForContractualAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable allowance for contractual adjustments.",
        "label": "Accounts Receivable Allowance For Contractual Adjustments",
        "terseLabel": "Add: allowance for contractual adjustments"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForContractualAdjustments",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_AccountsReceivableContractualAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable contractual adjustments.",
        "label": "Accounts Receivable Contractual Adjustments",
        "negatedLabel": "Less: contractual adjustments"
       }
      }
     },
     "localname": "AccountsReceivableContractualAdjustments",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_AccountsReceivableForContractualAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable for contractual allowance.",
        "label": "Accounts Receivable For Contractual Allowance",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "AccountsReceivableForContractualAllowance",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_AccruedEmployeeStockPurchasePlanContribution": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Employee Stock Purchase Plan Contribution",
        "label": "Accrued Employee Stock Purchase Plan Contribution",
        "terseLabel": "Accrued ESPP Contributions"
       }
      }
     },
     "localname": "AccruedEmployeeStockPurchasePlanContribution",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in\u00a0thousands)"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for doubtful accounts receivable write-offs net of recoveries and other adjustments.",
        "label": "Allowance For Doubtful Accounts Receivable Write Offs Net Of Recoveries And Other Adjustments",
        "negatedLabel": "Less: write-offs, net of recoveries and other adjustments"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffsNetOfRecoveriesAndOtherAdjustments",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "irtc_AvailableForSaleDebtSecuritiesMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale debt securities maturity period.",
        "label": "Available For Sale Debt Securities Maturity Period",
        "terseLabel": "Available-for-sale securities, weighted average days to maturity"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesMaturityPeriod",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "irtc_AwardedFebruary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awarded February 2021",
        "label": "Awarded February 2021 [Member]",
        "terseLabel": "Awarded February 2021"
       }
      }
     },
     "localname": "AwardedFebruary2021Member",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_AwardedJanuary2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awarded January 2021",
        "label": "Awarded January 2021 [Member]",
        "terseLabel": "Awarded January 2021"
       }
      }
     },
     "localname": "AwardedJanuary2021Member",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents And Available-for-sale Classified As Investments",
        "label": "Cash Equivalents And Available-for-sale Classified As Investments [Abstract]",
        "terseLabel": "Classified as:"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleClassifiedAsInvestmentsAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and current and noncurrent investments.",
        "label": "Cash Equivalents And Current And Noncurrent Investments",
        "totalLabel": "Total cash equivalents and available-for-sale investments"
       }
      }
     },
     "localname": "CashEquivalentsAndCurrentAndNoncurrentInvestments",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents and Investments.",
        "label": "Cash Equivalents And Investments [Abstract]",
        "terseLabel": "Cash Equivalents And Investments [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "xbrltype": "stringItemType"
    },
    "irtc_CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term and long term Investments.",
        "label": "Cash Equivalents And Short Term And Long Term Investments [Text Block]",
        "terseLabel": "Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermAndLongTermInvestmentsTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_CentersForMedicareAndMedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centers for Medicare and Medicaid.",
        "label": "Centers For Medicare And Medicaid [Member]",
        "terseLabel": "Centers for Medicare &amp; Medicaid"
       }
      }
     },
     "localname": "CentersForMedicareAndMedicaidMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ClaimsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claims payable current.",
        "label": "Claims Payable Current",
        "terseLabel": "Claims payable"
       }
      }
     },
     "localname": "ClaimsPayableCurrent",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Milestone Payments, Between 2022 and Early 2023",
        "label": "Collaboration Agreement, Additional Milestone Payments, Between 2022 and Early 2023",
        "terseLabel": "Collaboration agreement, additional milestone payments, between 2022 and early 2023"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalMilestonePaymentsBetween2022AndEarly2023",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Milestone Payments, Due In Next 24 Months",
        "label": "Collaboration Agreement, Additional Milestone Payments, Due In Next 24 Months",
        "terseLabel": "Additional aggregate milestone payments related to development agreement"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalMilestonePaymentsDueInNext24Months",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CollaborationAgreementMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Milestone Payments",
        "label": "Collaboration Agreement, Milestone Payments",
        "terseLabel": "Collaboration agreement milestone payments"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePayments",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CollaborationAgreementRemainingTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Remaining Term Of Agreement",
        "label": "Collaboration Agreement, Remaining Term Of Agreement",
        "terseLabel": "Term of development agreement (in months)"
       }
      }
     },
     "localname": "CollaborationAgreementRemainingTermOfAgreement",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "irtc_CollaborationAgreementUpfrontFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Fee Payable",
        "label": "Collaboration Agreement, Upfront Fee Payable",
        "terseLabel": "Upfront fee related to development agreement"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontFeePayable",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CommercialPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Payors",
        "label": "Commercial Payors [Member]",
        "terseLabel": "Contracted third-party payors"
       }
      }
     },
     "localname": "CommercialPayorsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_CommonStockSharesIssuedFromExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares, Issued From Exercise of Warrants",
        "label": "Common Stock, Shares, Issued From Exercise of Warrants",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedFromExerciseOfWarrants",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ConcentrationRiskSupplyRiskPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for supply risk.",
        "label": "Concentration Risk Supply Risk Policy [Policy Text Block]",
        "terseLabel": "Supply Risk"
       }
      }
     },
     "localname": "ConcentrationRiskSupplyRiskPolicyPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_ConsultingAndProfessionalServicesAgreementCPSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting and Professional Services Agreement (\u201cCPSA\u201d)",
        "label": "Consulting and Professional Services Agreement (\u201cCPSA\u201d) [Member]",
        "terseLabel": "Consulting and Professional Services Agreement (\u201cCPSA\u201d)"
       }
      }
     },
     "localname": "ConsultingAndProfessionalServicesAgreementCPSAMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ContractCostPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract cost policy.",
        "label": "Contract Cost Policy [Policy Text Block]",
        "terseLabel": "Contract Costs"
       }
      }
     },
     "localname": "ContractCostPolicyPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_ContractLiabilityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liability policy.",
        "label": "Contract Liability Policy [Policy Text Block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "localname": "ContractLiabilityPolicyPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_CostReimbursementRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Reimbursement Rate",
        "label": "Cost Reimbursement Rate",
        "terseLabel": "Reimbursement rate"
       }
      }
     },
     "localname": "CostReimbursementRate",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_CypressLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cypress Lease",
        "label": "Cypress Lease [Member]",
        "terseLabel": "Cypress Lease"
       }
      }
     },
     "localname": "CypressLeaseMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_DebtInstrumentBasisSpreadDeductionOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, basis spread deduction on variable rate.",
        "label": "Debt Instrument Basis Spread Deduction On Variable Rate",
        "terseLabel": "Basis spread deduction on variable rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadDeductionOnVariableRate",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_DebtInstrumentInterestPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "irtc_LongTermDebtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest portion.",
        "label": "Debt Instrument Interest Portion",
        "negatedLabel": "Less: Amount representing interest"
       }
      }
     },
     "localname": "DebtInstrumentInterestPortion",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_DeerfieldLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deerfield Lease",
        "label": "Deerfield Lease [Member]",
        "terseLabel": "Deerfield Lease"
       }
      }
     },
     "localname": "DeerfieldLeaseMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_DeferredTaxAssetsLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Obligations",
        "label": "Deferred Tax Assets, Lease Obligations",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligations",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_DeferredTaxAssetsValuationAllowanceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance [Roll Forward]"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceRollForward",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_DeferredTaxAssetsValuationAllowancesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets valuation allowances and other.",
        "label": "Deferred Tax Assets Valuation Allowances And Other",
        "terseLabel": "Allowances and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowancesAndOther",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan(\"ESPP\")"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_EmployeeStockPurchasePlanNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan number of purchase periods.",
        "label": "Employee Stock Purchase Plan Number Of Purchase Periods",
        "terseLabel": "Number of purchase period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberOfPurchasePeriods",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "irtc_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan offering period.",
        "label": "Employee Stock Purchase Plan Offering Period",
        "terseLabel": "Offering period (in months)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "irtc_EmployeeStockPurchasePlanPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan purchase period.",
        "label": "Employee Stock Purchase Plan Purchase Period",
        "terseLabel": "Purchase period (in months)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPurchasePeriod",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "irtc_FederalGovernmentAgenciesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal government agencies.",
        "label": "Federal Government Agencies [Member]",
        "terseLabel": "Federal Government Agencies"
       }
      }
     },
     "localname": "FederalGovernmentAgenciesMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_FinishedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finished goods.",
        "label": "Finished Goods [Member]",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "FinishedGoodsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_GrantUnderFutureStockPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant under future stock plans.",
        "label": "Grant Under Future Stock Plans [Member]",
        "terseLabel": "Shares available for grant under future stock plans"
       }
      }
     },
     "localname": "GrantUnderFutureStockPlansMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_HealthcareInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Healthcare institutions.",
        "label": "Healthcare Institutions [Member]",
        "terseLabel": "Healthcare institutions"
       }
      }
     },
     "localname": "HealthcareInstitutionsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "ISO"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation effect of tax cuts and jobs act of 2017.",
        "label": "Income Tax Reconciliation Effect Of Tax Cuts And Jobs Act Of2017",
        "terseLabel": "Foreign Rate Differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationEffectOfTaxCutsAndJobsActOf2017",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_IncreaseInCommonStockReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in common stock reserved for future issuance.",
        "label": "Increase In Common Stock Reserved For Future Issuance",
        "terseLabel": "Increase in shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "IncreaseInCommonStockReservedForFutureIssuance",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_InflationaryRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflationary Risk",
        "label": "Inflationary Risk [Policy Text Block]",
        "terseLabel": "Inflationary Risk"
       }
      }
     },
     "localname": "InflationaryRiskPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_InventoryAndPrintedCircuitBoardAssemblies": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and printed circuit board assemblies.",
        "label": "Inventory And Printed Circuit Board Assemblies",
        "terseLabel": "Total inventory and printed circuit board assemblies"
       }
      }
     },
     "localname": "InventoryAndPrintedCircuitBoardAssemblies",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_LaboratoryAndManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and manufacturing equipment.",
        "label": "Laboratory And Manufacturing Equipment [Member]",
        "terseLabel": "Laboratory and manufacturing equipment"
       }
      }
     },
     "localname": "LaboratoryAndManufacturingEquipmentMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_LesseeOperatingSubleaseNumberOfOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Sublease, Number Of Option To Extend",
        "label": "Lessee, Operating Sublease, Number Of Option To Extend",
        "terseLabel": "Number of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseNumberOfOptionToExtend",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "irtc_LincolnshireLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincolnshire Lease",
        "label": "Lincolnshire Lease [Member]",
        "terseLabel": "Lincolnshire Lease"
       }
      }
     },
     "localname": "LincolnshireLeaseMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_LongTermDebtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt carrying value.",
        "label": "Long Term Debt Carrying Value",
        "totalLabel": "Total Carrying Value"
       }
      }
     },
     "localname": "LongTermDebtCarryingValue",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_MarketConditionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Condition Awards",
        "label": "Market Condition Awards [Member]",
        "terseLabel": "Market Condition Awards"
       }
      }
     },
     "localname": "MarketConditionAwardsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_NonContractedThirdPartyPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-contracted Third-party Payors",
        "label": "Non-contracted Third-party Payors [Member]",
        "terseLabel": "Non-contracted third-party payors"
       }
      }
     },
     "localname": "NonContractedThirdPartyPayorsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_OfficeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office lease.",
        "label": "Office Lease [Member]",
        "terseLabel": "Office Lease"
       }
      }
     },
     "localname": "OfficeLeaseMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_OperatingLeaseRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rentable area.",
        "label": "Operating Lease Rentable Area",
        "terseLabel": "Lease rentable area"
       }
      }
     },
     "localname": "OperatingLeaseRentableArea",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "irtc_OperatingLeaseRightOfUseAssetsAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right Of Use Assets Amortization",
        "label": "Operating Lease Right Of Use Assets Amortization",
        "terseLabel": "Cost of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsAmortization",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_OperatingLossCarryforwardsTaxBenefitRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards tax benefit recognized.",
        "label": "Operating Loss Carryforwards Tax Benefit Recognized",
        "terseLabel": "Benefit recognized for net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTaxBenefitRecognized",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_OptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Outstanding",
        "label": "Options Outstanding [Abstract]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "OptionsOutstandingAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_OtherAssetsPolicyPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other assets policy.",
        "label": "Other Assets Policy Policy [Policy Text Block]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsPolicyPolicyPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_OtherAssetsUsefulLives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Useful Lives",
        "label": "Other Assets, Useful Lives",
        "terseLabel": "Useful lives of PCBAs"
       }
      }
     },
     "localname": "OtherAssetsUsefulLives",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "irtc_OtherStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other stock option.",
        "label": "Other Stock Option [Member]",
        "terseLabel": "Other Options"
       }
      }
     },
     "localname": "OtherStockOptionMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_PercentageOfEligibleAccountsReceivableForBorrowings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible accounts receivable for borrowings.",
        "label": "Percentage Of Eligible Accounts Receivable For Borrowings",
        "terseLabel": "Percentage of eligible accounts receivable for borrowings"
       }
      }
     },
     "localname": "PercentageOfEligibleAccountsReceivableForBorrowings",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Performance Target To Be Earned At Performance Threshold",
        "label": "Percentage Of Performance Target To Be Earned At Performance Threshold",
        "terseLabel": "Performance target to be earned at performance threshold (as a percentage)"
       }
      }
     },
     "localname": "PercentageOfPerformanceTargetToBeEarnedAtPerformanceThreshold",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock option exercise price of fair market value of common stock.",
        "label": "Percentage Of Stock Option Exercise Price Of Fair Market Value Of Common Stock",
        "terseLabel": "Percentage of common stock fair value on date of grant"
       }
      }
     },
     "localname": "PercentageOfStockOptionExercisePriceOfFairMarketValueOfCommonStock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_PercentageOfVotingPowerOfAllClassesOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting power of all classes of stock.",
        "label": "Percentage Of Voting Power Of All Classes Of Stock",
        "terseLabel": "Percentage of voting power"
       }
      }
     },
     "localname": "PercentageOfVotingPowerOfAllClassesOfStock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_PharmakonLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmakon loan agreement.",
        "label": "Pharmakon Loan Agreement [Member]",
        "terseLabel": "Pharmakon Loan Agreement"
       }
      }
     },
     "localname": "PharmakonLoanAgreementMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_PrintedCircuitBoardAssembliesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Printed circuit board assemblies.",
        "label": "Printed Circuit Board Assemblies [Member]",
        "terseLabel": "Printed Circuit Board Assemblies"
       }
      }
     },
     "localname": "PrintedCircuitBoardAssembliesMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ProductAndServicesZioXTServiceCode93243Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product And Services Zio X T Service Code93243",
        "label": "Product And Services Zio X T Service Code93243 [Member]",
        "terseLabel": "Product And Services Zio X T Service Code93243"
       }
      }
     },
     "localname": "ProductAndServicesZioXTServiceCode93243Member",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ProductAndServicesZioXTServiceCode93247Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product And Services Zio X T Service Code93247",
        "label": "Product And Services Zio X T Service Code93247 [Member]",
        "terseLabel": "Product And Services Zio X T Service Code93247"
       }
      }
     },
     "localname": "ProductAndServicesZioXTServiceCode93247Member",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment included in accounts payable and accrued liabilities.",
        "label": "Property And Equipment Included In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "PropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_ProvisionForBadDebtAndContractualAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for bad debt and contractual allowance.",
        "label": "Provision For Bad Debt And Contractual Allowance",
        "terseLabel": "Provision for bad debt and contractual allowance"
       }
      }
     },
     "localname": "ProvisionForBadDebtAndContractualAllowance",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_RawMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raw materials.",
        "label": "Raw Materials [Member]",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterialsMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_RiskAndUncertaintiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk And Uncertainties, Policy",
        "label": "Risk And Uncertainties, Policy [Policy Text Block]",
        "terseLabel": "Risk and Uncertainties"
       }
      }
     },
     "localname": "RiskAndUncertaintiesPolicyPolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_SanFranciscoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Francisco.",
        "label": "San Francisco [Member]",
        "terseLabel": "San Francisco"
       }
      }
     },
     "localname": "SanFranciscoMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_ScheduleOfChangeInContractualAllowanceTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in contractual allowance.",
        "label": "Schedule Of Change In Contractual Allowance Table [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contractual Allowance"
       }
      }
     },
     "localname": "ScheduleOfChangeInContractualAllowanceTableTableTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Inventory and printed circuit board assemblies.",
        "label": "Schedule Of Inventory And Printed Circuit Board Assemblies Table [Table Text Block]",
        "terseLabel": "Schedule of Inventory Components"
       }
      }
     },
     "localname": "ScheduleOfInventoryAndPrintedCircuitBoardAssembliesTableTableTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based awards available for grant.",
        "label": "Schedule Of Share Based Awards Available For Grant Table [Policy Text Block]",
        "terseLabel": "Schedule of Share-based Awards Available for Grant Under 2016 Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedAwardsAvailableForGrantTablePolicyTextBlock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Aggregate Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Aggregate Grant Date Fair Value",
        "terseLabel": "Fair value at grant date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodAggregateGrantDateFairValue",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant granted in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period",
        "negatedLabel": "Awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options exercisable rate percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Rate Percentage",
        "terseLabel": "Stock option exercisable rate (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableRatePercentage",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement By Share-Based Payment Award, Performance Threshold Percentage",
        "label": "Share-Based Payment Arrangement By Share-Based Payment Award, Performance Threshold Percentage",
        "terseLabel": "Performance threshold (as a percentage)"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementByShareBasedPaymentAwardPerformanceThresholdPercentage",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "irtc_ShareBasedPaymentArrangementReversalOfPriorExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Payment Arrangement, Reversal Of Prior Expense",
        "label": "Share-Based Payment Arrangement, Reversal Of Prior Expense",
        "terseLabel": "Reversal of share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementReversalOfPriorExpense",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_SharesUnderlyingRSUsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Underlying RSUs",
        "label": "Shares Underlying RSUs [Abstract]",
        "terseLabel": "Shares Underlying RSUs"
       }
      }
     },
     "localname": "SharesUnderlyingRSUsAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_SiliconValleyBankTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon valley bank term loan.",
        "label": "Silicon Valley Bank Term Loan [Member]",
        "terseLabel": "SVB Term Loan"
       }
      }
     },
     "localname": "SiliconValleyBankTermLoanMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_StockIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance costs incurred but not yet paid.",
        "label": "Stock Issuance Costs Incurred But Not Yet Paid",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Grants In Period",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Grants In Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGrantsInPeriod",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_StockIssuedDuringPeriodSharesRestrictedStockAwardVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Restricted Stock Award, Vested",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Vested",
        "terseLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardVested",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_StockOptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options issued and outstanding.",
        "label": "Stock Options Issued And Outstanding [Member]",
        "terseLabel": "Options issued and outstanding"
       }
      }
     },
     "localname": "StockOptionsIssuedAndOutstandingMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third amended and restated silicon valley bank loan agreement.",
        "label": "Third Amended And Restated Silicon Valley Bank Loan Agreement [Member]",
        "terseLabel": "Third Amended and Restated SVB Loan Agreement"
       }
      }
     },
     "localname": "ThirdAmendedAndRestatedSiliconValleyBankLoanAgreementMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_TwoThousandSixEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand six equity incentive plan.",
        "label": "Two Thousand Six Equity Incentive Plan [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "TwoThousandSixEquityIncentivePlanMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_TwoThousandSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen equity incentive plan.",
        "label": "Two Thousand Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEquityIncentivePlanMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters' Option To Purchase Additional Shares Of Common Stock",
        "label": "Underwriters' Option To Purchase Additional Shares Of Common Stock",
        "terseLabel": "Underwriters' option to purchase additional shares of common stock (in shares)"
       }
      }
     },
     "localname": "UnderwritersOptionToPurchaseAdditionalSharesOfCommonStock",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "irtc_ValuationAllowanceDeferredTaxAssetAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance deferred tax asset additions.",
        "label": "Valuation Allowance Deferred Tax Asset Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetAdditions",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_ValuationAllowanceDeferredTaxAssetDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance deferred tax asset deductions.",
        "label": "Valuation Allowance Deferred Tax Asset Deductions",
        "terseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetDeductions",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "irtc_VerilyLifeSciencesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verily Life Sciences LLC",
        "label": "Verily Life Sciences LLC [Member]",
        "terseLabel": "Verily Life Sciences LLC"
       }
      }
     },
     "localname": "VerilyLifeSciencesLLCMember",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "irtc_WeightedAverageExercisePricePerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Per Share",
        "label": "Weighted Average Exercise Price Per Share [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "WeightedAverageExercisePricePerShareAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_WeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Grant Date Fair Value",
        "label": "Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_WeightedAverageRemainingContractualLifeYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life (Years)",
        "label": "Weighted Average Remaining Contractual Life (Years) [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeYearsAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "irtc_WeightedRemainingVestingPeriodInYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Remaining Vesting Period (in years)",
        "label": "Weighted Remaining Vesting Period (in years) [Abstract]",
        "terseLabel": "Weighted Remaining Vesting Period (in years)"
       }
      }
     },
     "localname": "WeightedRemainingVestingPeriodInYearsAbstract",
     "nsuri": "http://www.irhythmtech.com/20211231",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r58",
      "r60",
      "r118",
      "r119",
      "r280",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r125",
      "r133",
      "r139",
      "r222",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r488",
      "r490",
      "r491",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r125",
      "r133",
      "r139",
      "r222",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r488",
      "r490",
      "r491",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r125",
      "r133",
      "r139",
      "r222",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r485",
      "r488",
      "r490",
      "r491",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r187",
      "r351",
      "r356",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r279",
      "r317",
      "r373",
      "r374",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r608",
      "r612",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r279",
      "r317",
      "r373",
      "r374",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r608",
      "r612",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r187",
      "r351",
      "r356",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r184",
      "r351",
      "r354",
      "r565",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r184",
      "r351",
      "r354",
      "r565",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r279",
      "r317",
      "r364",
      "r373",
      "r374",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r608",
      "r612",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r279",
      "r317",
      "r364",
      "r373",
      "r374",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r608",
      "r612",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r118",
      "r119",
      "r280",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r351",
      "r355",
      "r610",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r351",
      "r355",
      "r610",
      "r643",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASC 326"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r126",
      "r127",
      "r128",
      "r129",
      "r194",
      "r195",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r264",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r459",
      "r460",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r545",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r26",
      "r188",
      "r189"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of discounts on investments, net of premium amortization"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails",
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r46"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r46"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r12",
      "r46",
      "r363"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r250"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r64",
      "r65",
      "r66",
      "r596",
      "r620",
      "r624"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r63",
      "r66",
      "r73",
      "r74",
      "r75",
      "r122",
      "r123",
      "r124",
      "r477",
      "r615",
      "r616",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r418",
      "r419",
      "r420",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r100",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r126",
      "r127",
      "r128",
      "r129",
      "r139",
      "r194",
      "r195",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r264",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r457",
      "r458",
      "r459",
      "r460",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r545",
      "r566",
      "r567",
      "r568",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Tax withholding upon vesting of restricted stock awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r375",
      "r377",
      "r424",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r377",
      "r407",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": {
     "auth_ref": [
      "r190",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on financing receivable.",
        "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Changes in Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r191",
      "r225",
      "r226",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r100",
      "r299",
      "r308",
      "r309",
      "r529"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from diluted net loss (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r100",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r173",
      "r176",
      "r182",
      "r217",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r473",
      "r478",
      "r509",
      "r546",
      "r548",
      "r572",
      "r594"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r57",
      "r113",
      "r217",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r473",
      "r478",
      "r509",
      "r546",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r199",
      "r230"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r203",
      "r205",
      "r587"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r196",
      "r200",
      "r230",
      "r576"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Total cash equivalents and available-for-sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r198",
      "r230"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": 2.0,
       "parentTag": "irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments",
       "weight": 1.0
      },
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails",
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r198",
      "r230"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Due after one year through three years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofShorttermandLongtermMarketableSecuritiesClassifiedbyMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r378",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r378",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r121",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r37",
      "r102"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r96",
      "r102",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of\u00a0\u00a0year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r96",
      "r518"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails": {
       "order": 1.0,
       "parentTag": "irtc_CashEquivalentsAndCurrentAndNoncurrentInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r258",
      "r577",
      "r600"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r259",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)",
        "verboseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value \u2013 100,000,000 shares authorized at December\u00a031, 2021 and 2020; 29,493,726 and 29,019,350 shares issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r68",
      "r70",
      "r71",
      "r79",
      "r580",
      "r602"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r187",
      "r506",
      "r507",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r187",
      "r506",
      "r507",
      "r626",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r187",
      "r506",
      "r507",
      "r626",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r159",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r163",
      "r164",
      "r187",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration of credit risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r187",
      "r506",
      "r507",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForCreditLossRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinContractualAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r340",
      "r341",
      "r352"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Contract liability balance, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r365",
      "r372",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).",
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate notes",
        "verboseLabel": "Corporate notes"
       }
      }
     },
     "localname": "CorporateNoteSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r83",
      "r113",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r509"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Accounts Receivable Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r453",
      "r463"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r453"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r453",
      "r463",
      "r465"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r453",
      "r463"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r162",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r300",
      "r301",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r112",
      "r120",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r308",
      "r309",
      "r530",
      "r573",
      "r574",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Outstanding interest-bearing obligations"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r48",
      "r305",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r112",
      "r120",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r306",
      "r307",
      "r308",
      "r309",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r112",
      "r120",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r306",
      "r307",
      "r308",
      "r309",
      "r332",
      "r335",
      "r336",
      "r337",
      "r527",
      "r528",
      "r530",
      "r531",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r212",
      "r235",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r212",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized loss, greater than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Available-for-sale securities in unrealized loss for more than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r212",
      "r235",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Fair value, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r212",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized loss, less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Cash Equivalents and Available-for-sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r208",
      "r231",
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r209",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r207",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Securities in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r210",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Available-for-sale securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r454",
      "r463"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r41",
      "r289",
      "r529"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "irtc_LongTermDebtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Less: Debt Issuance Costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r454",
      "r463"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r114",
      "r454",
      "r463",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r454",
      "r463"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r444"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Net operating loss carryforwards, federal"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Net operating loss carryforwards, state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r449",
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r431",
      "r446"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/IncomeTaxesSummaryofValuationAllowanceforDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r451",
      "r452"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r100",
      "r248"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregated Revenue by Payor Type and Major Service Line"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r338",
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r80",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r140",
      "r142",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r491",
      "r492",
      "r581",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r80",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r491",
      "r492",
      "r581",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Capitalized stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unamortized compensation costs related to unvested stock options, expected period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unamortized compensation costs, net of estimated forfeitures related to restricted stock unit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unamortized compensation costs, net of estimated forfeitures related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r73",
      "r74",
      "r75",
      "r122",
      "r123",
      "r124",
      "r127",
      "r136",
      "r138",
      "r154",
      "r222",
      "r331",
      "r338",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r490",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r615",
      "r616",
      "r617",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r493",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r494",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r493",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r291",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r291",
      "r365",
      "r366",
      "r371",
      "r372",
      "r494",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r365",
      "r366",
      "r371",
      "r372",
      "r494",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r494",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r291",
      "r306",
      "r307",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Internal-use software, estimated useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r240",
      "r241",
      "r548",
      "r570"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r82",
      "r113",
      "r173",
      "r175",
      "r178",
      "r181",
      "r183",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r509"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r173",
      "r175",
      "r178",
      "r181",
      "r183",
      "r569",
      "r578",
      "r583",
      "r605"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r252",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r434",
      "r442",
      "r448",
      "r461",
      "r466",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r137",
      "r138",
      "r172",
      "r432",
      "r462",
      "r467",
      "r606"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision",
        "totalLabel": "Total Tax Expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails",
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxesDetails",
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r429",
      "r430",
      "r442",
      "r443",
      "r447",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "terseLabel": "Meals and Entertainment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Section 162(m) limitation - officers compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofTaxExpenseComputedatStatutoryFederalRateandCompanysTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r99",
      "r562"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' and Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r171",
      "r526",
      "r529",
      "r582"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r94",
      "r97",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r46"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Internal-Use Software"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r55",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r56",
      "r107",
      "r153",
      "r237",
      "r238",
      "r239",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r216",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Cash Equivalents, Short-term, and Long-term Marketable Securities Classified by Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Payments due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term of lease (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r113",
      "r177",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r474",
      "r478",
      "r479",
      "r509",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r113",
      "r217",
      "r509",
      "r548",
      "r575",
      "r598"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r113",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r474",
      "r478",
      "r479",
      "r509",
      "r546",
      "r547",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r22",
      "r574",
      "r592"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under revolving credit line"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r22",
      "r290",
      "r304",
      "r306",
      "r307",
      "r574",
      "r595"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total",
        "verboseLabel": "Debt, noncurrent portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets",
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r120",
      "r263",
      "r295"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r120",
      "r263",
      "r295"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtScheduleofFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails",
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r96",
      "r98",
      "r101"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r67",
      "r69",
      "r75",
      "r78",
      "r101",
      "r113",
      "r126",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r143",
      "r173",
      "r175",
      "r178",
      "r181",
      "r183",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r492",
      "r509",
      "r579",
      "r601"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r139",
      "r150",
      "r194",
      "r195",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r264",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r457",
      "r458",
      "r459",
      "r460",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r545",
      "r566",
      "r567",
      "r568",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r173",
      "r175",
      "r178",
      "r181",
      "r183"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r538",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesScheduleofFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r534",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate of operating leases (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r541",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining term of operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r46"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r19",
      "r571",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net change in unrealized gains (losses) on available-for-sale securities",
        "verboseLabel": "Net change in unrealized loss on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Tax withholding upon vesting of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r88",
      "r197"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of available-for-sale investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r378",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "verboseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.irhythmtech.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value \u2013 5,000,000 shares authorized at December\u00a031, 2021 and 2020; and none issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of stock in public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r86",
      "r87",
      "r197"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of available-for-sale investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r86",
      "r87",
      "r197"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sales of available-for-sale investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r90",
      "r413"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with follow-on public offering, net"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock in connection with employee equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r67",
      "r69",
      "r75",
      "r95",
      "r113",
      "r126",
      "r137",
      "r138",
      "r173",
      "r175",
      "r178",
      "r181",
      "r183",
      "r217",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r472",
      "r475",
      "r476",
      "r480",
      "r481",
      "r492",
      "r509",
      "r583"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r249"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r251",
      "r548",
      "r588",
      "r599"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails",
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r251",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net Components"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r81",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Add: provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofInventoryandPrintedCircuitBoardAssembliesPCBAsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r33",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Allowance for Doubtful Accounts and Contractual Allowances"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r93",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r427",
      "r564",
      "r659"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "RSUs issued and unvested"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r338",
      "r421",
      "r548",
      "r597",
      "r619",
      "r624"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r122",
      "r123",
      "r124",
      "r127",
      "r136",
      "r138",
      "r222",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r490",
      "r615",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r169",
      "r170",
      "r174",
      "r179",
      "r180",
      "r184",
      "r185",
      "r187",
      "r350",
      "r351",
      "r565"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesDisaggregatedRevenuebyPayorTypeandMajorServiceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r540",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Shares issued, price per share (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r163",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities Components"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareScheduleofAntidilutiveSecuritiesExcludedfromDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-dilutive Securities Excluded from Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r204",
      "r206",
      "r211",
      "r212",
      "r213",
      "r214",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Tax Expense Computed at Statutory Federal Rate and Tax Expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r377",
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r377",
      "r406",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense Included in Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Financial Assets"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-vested Restricted Stock Units (\"RSUs\")"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r378",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r384",
      "r395",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity Under 2006 and 2016 Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Employee Stock Options Estimated Using Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r52",
      "r110",
      "r155",
      "r156",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r324",
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r312",
      "r313",
      "r314",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r441",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationSummaryofTotalStockBasedCompensationExpenseforOptionsRSUsandESPPIncludedinConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock option vesting term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of shares granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted remaining vesting period of RSUs (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected maximum volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected minimum volatility (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of payroll deductions of eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional options authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted during the period (in shares)",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r386",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-Based Awards Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation cost resulting from modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "terseLabel": "Number of employees impacted by modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock issued to employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r376",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails",
      "http://www.irhythmtech.com/role/StockholdersEquityScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "First Anniversary of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r378",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value of RSUs"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofNonvestedRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option, maximum period for grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r401",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockBasedCompensationScheduleofFairValueofEmployeeStockOptionsEstimatedUsingWeightedAverageAssumptionsDetails",
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life for options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life for options outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life for options vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Estimated grant date fair value of option vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of common stock fair market value available for employee purchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r339",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Awards withheld for tax purposes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponentsComponentsofPropertyandEquipmentNetDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r260",
      "r261",
      "r471",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r54",
      "r73",
      "r74",
      "r75",
      "r122",
      "r123",
      "r124",
      "r127",
      "r136",
      "r138",
      "r154",
      "r222",
      "r331",
      "r338",
      "r418",
      "r419",
      "r420",
      "r459",
      "r460",
      "r490",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r615",
      "r616",
      "r617",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r154",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r331",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with follow-on public offering, net of discounts and issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r24",
      "r25",
      "r331",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "terseLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Awards forfeited (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofSharebasedAwardsAvailableforGrantunder2016PlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r331",
      "r338",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock in connection with employee equity incentive plans, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.irhythmtech.com/role/StockIncentivePlansSummaryofStockOptionActivityPlansIncludingGrantsToNonemployeesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r331",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with follow-on public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r331",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with employee equity incentive plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r113",
      "r193",
      "r217",
      "r509",
      "r548"
     ],
     "calculation": {
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets",
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r525",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r525",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r525",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r525",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SubsequentEventsDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Valuation Allowance for Deferred Tax Assets"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "terseLabel": "Tax credit carryforwards available to reduce future taxable income"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r126",
      "r127",
      "r128",
      "r129",
      "r139",
      "r194",
      "r195",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r264",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r457",
      "r458",
      "r459",
      "r460",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r545",
      "r566",
      "r567",
      "r568",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesScheduleofChangesinAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r117",
      "r365",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/FairValueMeasurementsScheduleofFairValueofCompanysFinancialAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government securities",
        "verboseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofAvailableforSaleSecuritiesUnrealizedLossPositionDetails",
      "http://www.irhythmtech.com/role/CashEquivalentsandInvestmentsScheduleofFairValueofSecuritiesnotIncludingCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r428",
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decreases in balance related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefit income tax interest and penalty charges"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions taken in current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases in balance related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r157",
      "r158",
      "r160",
      "r161",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/DebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/StockIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares, diluted (in shares)",
        "verboseLabel": "Weighted-average shares used to compute net loss per common share, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares, basic (in shares)",
        "verboseLabel": "Weighted-average shares used to compute net loss per common share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.irhythmtech.com/role/ConsolidatedStatementsofOperations",
      "http://www.irhythmtech.com/role/NetLossPerCommonShareComputationofBasicandDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r664": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r665": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r666": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r667": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r668": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r669": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0001388658-22-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001388658-22-000020-xbrl.zip
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MDYE*P3>$_R,>YCQO6O_XPYSW3#!%HQ=N4-6=.0A94760F*IQ-EZ= *-M84J
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MB_FHVDZ?<.\"CM0K;5S:%6 "B]9IRRT(:BJT",Z84&]5/B/*F9&2]:!8"19
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MIYW8OC$HTI<OS]]*8PM@+[JAX5(%X>>-43&$CSV0BW 9:.5K<V]'#6 8$'!
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M#$B*5?) _<#G9_^E[M_#A!Q(!+#P'%A^:U)%<A]W[(B+.>C7A(U-MBEF= 7
M<LT2.'4);(9%71;U8!2VKL%[%"/ G=$RLBB*?_8Y M,=[ )D(TI8*YCA_]+C
M]-.I1BQDW3DBD)"%NB&)W,/J:PBAGG8-G;A+MQ.,H:;) -E/ZW95-Y*KZM=8
MR8-C]E:-9G!.%YELUKJ^(CNEEUQ74^3<&3,KES0#6@BUQ^;D8\,JY]UDDX3D
MN337A>2NZ::T2#!K8>-Z21+B%_7[G%?(:[OEU01K@*!%?44^TL6F!7U7I8$#
M$4M$;S:1_*YJ$N!_]L7L?2G9@!R4M-A?^IE>0!9DD[GDC9-7B[=DEW4Q3U9D
MRA5K'ND\%W@Y'(&./'^2AN=9@Y.16QK0YIW(*+!$=0.3,75%$ED'<XYLTFE#
MJR5NBDGFZ0LGF#[B$RP<F6SY)6*/P3136Q86U;5L&(:X@B?)80H:-JQ,PR5=
MY"7H>&1Z6".HFKIOR=Z^JMJ.!'OEOBSF:9C;I@_4[_-)<E[ A&WR64Z6+8XL
M#B^;M2Z&^**NYT+NT_3+Y#3 I@1S?O'LU$V:C/K#_?VG[(+R*=.SO74<.*IZ
MB7 8U(^*77!ZS?(GK:L>)G^ZKG PY,/DCS0LJ!*JFGN!98%.Y81C9F9H.]ET
M*HB.DU1$<*RP1"5%"U^?#68<_U@9D.*Q,?([$-PAE<;G1V?:)KT>P<S%U[D+
M^!S[#E3@=*.'QI1O>$2]%H5J<N?5M =\BEP.7H!*TE-!_T\?7#9U"^<#UQV"
MW30L3XKG0JHMR8;FW ;'-MZFPNJJ<%6&/AC4N0M6_30YGX3W5+MIR7SXL[Z>
M=7R][O6LR.=2FL>%)%OY$;:L_'UX1 UF1&J3[KJ>/T6_VI-,+Z.UA'7*OX$A
M&WS2"JA6]X2[X'^#&T:1B^+JGK'1*RKC6='219(G9T'R0-MW2&D<5,H'#KR3
M!CHX$*Z K2,WBF#B,YB-JT3)ISL]QH%.4D=T?I!5H4>WM(A2#-=MUFSA^T]#
ML$Y?R'=.5SG*X*KD!W[-:=O6M(>Q7OW!Z9@@C: Q]%9O#I+JXH/7)7F]]G')
MD6F=OM!SVL$2 ?R/EIW1O+Y0R:W.-,?JTWV]6I-+3;^=)7J_T5BLLJEH[#(K
MN#R/9*V8]S@GTE3U!5MD"ZB#CL6#E7=9O,?&T,ZV/8?0,U71WY&*\XFFY$<#
MEI[S7T?7Z<=SKXL'RR0&PY/];QGFR(]H]8UB$>J"A4-=BQBQON'?YX/K4I,W
M0$OBVNF@:.["@8-87F\$"O#+].,>+3:M4M%>F(Z$#M(-F"<GDT?QJ5,Q@1BQ
M(6)1)2A]CF))EF%+<E.?]XHO,U9Y,.=H:'\XG.R[6U+'6:]AX)*MVFT<U"G0
M\Q,0^CE+ZOJ9=S6Z6/;J1P2V')YK\@]];6>'UX.4@98\1*:/&54_U"7BM!Q%
MTU=* R)],:PD=H!@WXA2H9?#'*"7\C'2JXAL>#*FP'^!B&6#^AA-?,ZC24!:
MTJ2JJSW%^;']E/'EPB:'B7?#X43Z#AD4_6H*M" =>""-?#*0WN@O,+KTRP)V
ME"3NL#'9:EV&Y8_!6KL9P4AS2U8ONKRB5Z_JRWSD2[8H) WTL;8DHX$'V$)A
M\/P0M?^0-[.BY3^8JT7"LLB*DC/3-9PTCG?2\C CB+-I<D[ K0I+1G FLICV
M'7^-[$;,D92 L]U;6RI87Y!H?JO(*N08^46)JG*ZLY_6:YR-,K[VV>JC4\@E
MH:T/[(K%H%;%75 OUQA<SHP4\[')+^".TP<Y<,LI$;[TI)X+GY-$<+>U:>R
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MDZFUJ8""5B=JVA?E?,35 A!! &Z\9%/NK=ZU(Q[475"OKOIG9UV!6 *?K;@
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M&-2S(U%_%_S#EY53=JFN8LC2$A1324Y JI!M+^D+7*O#/\AIX7 BAUE,=N6
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M<O)&2I#M2$=-&Y6X+C2QDQ7((UGN63D::"D^.&QEL$W$37;(@'9E 9 WB%;
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MG;&T8GQ$M592F;35.\L11!BI '#<D#)FIH/P^:*6L,F,U$ MC)R;OE]7QI^
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M\'#_X"@5J^9?6AHHKLCAH_3QR8%/0XJM/9[N R%* YP>Z!&-G>8O6=63AR7
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M =FZF,LZ3G-4\3(R4^Q)A]E&S9O1<B?9M((5([S[/,1^3<N.,)2A._!+?N3
M0!IDN,TJ&LP" =G')_'TT&ZAX:;!LJ98/MA5B)2NBQ9U7A*+]#C5<2"EF>L*
M/]6PD;3::& Y&;U=I+:WUXZ?LT"-#7L3_;K)PL@7:FC6]$5I_/@! 3NW=VE
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M"Z=QM\Y1B*>A$:S6VC4C/BY]^_L&\[VLDA]A8&M%V5,NT\ZJBJ01WB'WAG%
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M?^2JI!.$(!)'Z-_FJ[IS]R\LIU,RF=N6Q<ONW;=O?5=2':Q(T<!T/\=J0_>
ME#,TX$WS^*YZ].E7F?4U_:DJB_=HT[3'E15^:331BY'/:Z31:\VH,DL#K?S6
ME+/.^IAS,E=6E\9_)^C/SHIFUM,QF=;<%I24+NGGP,#=\K0\80?C#X,&ZQ;H
M"ZG8(S <;]\>&*F2G\Y/1=C^3L-NDU<QUPM3(-B9BV78<1H/HG+3&I@N1T F
M#/;HJ6;7L "W8$9Q7SO#"+CGR&.>[DN28P[%OZ9+LTFNFH(NQ(J[C6C?N$:-
MQ$ E!KVF9_0%:4WG5U/JLZ9[ZCP6;.R#MH973J*<=$7.F0,*)TM_L!Q*F_O
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M/?;D8/_!^X>!E)&/V\(?QBC.)2 @FE4_Z7*U_FB3/4K^&AT0=W)6B/8N:V?
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MWW%N=MKHI;Q.D6G^G3>Y.L:;K7".ZQ<3=:'F[9R9>;.%<G+7:$^29+[1^<-
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M=]/HQI!6DI8<:Y]8R!W5ZV!PQ((/7:6P=6WMO\/_UG(O2&VU]$#6,-'4"HL
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MM[2Y] "@]7CE80ZJ [*."E^)97U=M0I3M#8L06[)OMZ6#1U5LH XFWA3K-_
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MT13M<K#,L*V&^5DK0A2B*<]&]1WYC8]K[$/76'=5<L:2QN4$).1D=(S@2TE
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MD5E0TH+X&$2P 58XX$;T,:'U7DLE05L=DW<O!DYBB& A.#8:?DD\%;1Y:##
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MT'80X1'6;!,BED,;5JLG$T# 6#[Q$KZL_ZI>K7>E95P$XS5$Y%G0WPK\TN"
MFLP9A0W6>>YYM=%ZD70LTW1PX>5JZI$/OZ1"[*?XZN9I4UOR4")<?0/YE-L4
M94B3\< *=IL1EP@J]FWDH77^@EYG99F2JG!J:^[/Y'<:X^<G7NN4/MZ4 R,/
M9V^1#^0NU(!TD:)*KCQ)ZCA:\P%TTN3U%$FDUP(:C;&$6=<7LKYW<OV$":IJ
M],W12RGN:K" 1^]^.COC3"9,Q2)RPZF+'RM.R"D<\/03:9QL!OGOR,HOK1H>
M((]7Z(OT3:-I/?AM.G@0 SK-C5FJ@U8TATTJ7"FW9/ZHEIA-T:ZG:AL3*?2_
M4(357HX5S)0@Q6YO:=G;K*AF%'P4F?.ZI2'H_2H>M0HY10$&;,XL%<8\4QU,
M"&>&72RB=%2G84_#7=02CA5M>[7OKS95,4UM,U,R*=I]3:MP9#<!(Q#Z:_2?
MYOA,FLG42Z;(.OEQ.N1&>0(V U%O,(& M.VXF 40-A+J=-= <W,Z&W$N%B.;
MJ&@C.;OXM$FGC!<7?!;GDUQUA5S)%TO>$.7,IB%ME*H4GTTM^TBVG9-M\R0*
MYEGK__ <KKD'^U+;"]Z;7_XXQ@-"\W> 2AX'^9]5;N0,N,-,C\/YS\K:"#I=
MBP]EV9XXT#:(%'='P8./81^@H*[8I5TW+/C ]_:>.,=IU&7/?24//8O_"L5V
M@#3,$7E3)C3&DLPDJ%.%F<'*/WDKO^1[,I=JX$9QB;$'N(4C!7>8/*SAI$[9
MAPAT"-N>'R"+;&KS>TXN]B?R!A=%5Z$UIY#XC5D(=BXCS89JO8\4B<Y)N42(
MW.>]&^0N44"P**7PQ]^2 "U\>;7B;!>*3/K=;(#RZ$M!V;?D^9!)B$6RZP)J
MTQ*ANV80_74W+EM:'=^TRW/I*V-DE9*,8DRT9#]$! PS=>JB\OVUX&ZAEU24
M@<602$EJ+9RN$T2'M6W6I39,O(6CBRJJ82\QDTBE\$SB'SJ3*?">IC:U!WS$
MN;NS=TG85>SSMRB6CW)WXV0.1\@(O"V;,4HV3! 3>O\<(%O%9:L32B%;N5*"
MPH/X(ENC*1-H-_2,-KKCZ%I\X1#*]GOC?\Y2/580!A&VE8KQ\$KHX](#Z%#L
M]7WBLTR07HP?#_A=S1/&R*RA[7WI\+1++M8SC[AFR!)<=U/TK.DP]T+Q1)M&
MJ'"">H7AM7E**L]'QMC.=!+,JO)M3#X2@*<D'FE2(UP9%0ASUGE&_W:[EADS
M8].M5.M^T&$2AJM<NAE+K5&60%R\J9N;=;G4^CRR5S=%Z@QWXP8A=I7E398N
MF[DL=<'B.D8(H]BR=U@J5U+/'UTV-;L8>&GBY"?GZZJY854/H,X6$(.4=1Q)
MC=R\8J5QAH6SR30KEVB3MV';>28@DLF?SLY\)GMMW!KNU@7X\S79#!!]R'),
M->SGS<$C)/ECMJ(?QW)6/4 \@_W)>:]U =B,?F&4&9H/:U0Z$\.3-B$8M<0
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MD PU)/S<C?QL>*9.YSWI!T@WX+PP:<4+&IE592I,.+N9&=$HI29;G1ZOT1F
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MD=";8HPRJ7L(\_?(YO"5V.9$!T9099<YID*A7'8L7)?DK3'S6&JLHC8+[);
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M*I(^CUZ^= 5$N(!/3+D6A C-IPU+KL05DL8["B#DF]K%?F\IH^-2N76I,/#
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MTK%W,QF+U-$.E"%\TYZ@CY#W[D*(5;"&I9?Z>:)T1[] =6R&CL=*.50MK@4
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M_2C_) <BJ/$MZ<[-808G#F?CXPW@91ACA9*E\3S @EU2ZBP69R*!_GM5SID
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MXF$P2>XJ-[,J>$ICEO21'"@5B+JY7V+&I86D^VJA6IE@E6%)"CZ&)J?0GBU
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MZ"3B5=(96W%60+'9.GL1?^L="P!PB6HA6*L/SS7^8!R+OVM;UB5A_.AT]%X
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MW+"MPV1;3T^G]5SJT_GOG[WW[^_J!NP--G #/B<#/FGICAVH@_Z.S:!!*W1
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M7UFMUY=W[0!:Y_YA^L;BO51Q85O>NJH5<-(9([6+A1VFXR-T%Z-L7CBR74B
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MA[(\+49Y07D9M):-:'N[<__Q/X?I#S_N(7?\Q4&+]R9 );<2PECI<X$='_2
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MFNUFHLB6^L_OPO%_!ZT02 47]O@%<CMYJSHGHB+]+YCA__T97;$A\"ST7MW
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M7RI-&$%5US0@#YYC<:=^22JU.3O7E,:C^R;3*;X88+"/2PJ'*\!N)4QQ;).
MWA\[MP:&Q;4C=5#I;C8M)[MA$J"QI0/'3\7,!KYJ=/TEDZ/DT]&U36@@8W$M
MF2.<F8*)G0+[1R,6#E0K<1R.<"SGJ1F-PB\S+5Y@9:XZW4VTEJH7H.RBE#4Q
M<B4U7TL3PM)!X_V6&H*=I!>"D%KMD]4>-\<K2PT!2Y)DA;-K=UU9WA\$XN%
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M!-"8&=#,16TT8DKDTW2LS=7"U%2J/)H+Y;J,C +E^X/RE)7A>$C&!',0L3#
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M&=(1.T4UI@G.N$WTP@G0YD4L5JQ>H]1I-,4(N>(B%7ZJCY]FFYYQ0;7@) ]
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M?(@EERBBR UQ#!%FK3 Q&L^QIL(1E_D0ZW,^Q+KP8=/Y$$_SH<.:$Z& $!J
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M#!32+@=K%!C-'/CHA#=(<&[IG53?O>V#8@35LQ.,\HA0GG:"(FDG6*G!4&)
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ME2(@&L G1@=&K$U@IP@""=H2E;P3Z1/B:PA7%L0_>%7Y/<QO*3AO!LZGW==
MD'(.$9 >*V">2U >4<AFG<^"=7E:K)YU7><M"ZX/[&ODHOY8_/:SG/ <Y=1K
M'3ZL;QV:S=7-\,>N(>SOQ%N"BC6Q\IL9?RMPS!#&&(R6-%E?B(.R&('',;(0
MJ3.*3#+&C,XQ>;<V\-1KI_TJ95*XKW#?_7NFA?ONA_NF/4]K)'66:'!:\SQT
MW(%V5($0SB11!T*,J]+'R?THU%>H[]%2W_*RQX7Z[H?ZIIUQY!$GW"- /,9$
M?4R#Q<I#,NF5CUAX+6V52V9RCLJ9!Z>^<A"W',2]_B NK^4@KB@'<<M!W'(0
M=\&#N&_& _?I<-!+TAW]G_]1!,O?6]O_[[0[/KOQ(9OR5#^<P&VWPE<7LB([
MG)"UKR9X37Y*#VX>Z(ANHI0G:$(K\Y[1I>@)I60IYU/O=NKU9S>KGS BRKV6
M>UV1>\7H"6-Z16XV+2SE\YS]GC(O*:G"#,NO2M2K>7+\^63.8Z4+:ZH.'0Z^
M3!<5K-22/$OWF@T_T_N/'?ZV^;?I>MCI5]\_-R?=<?K]3Q;J)T^_UHOFW.GQ
M:2^;6=5*;878==UQ6:E?KE15*#+975>C4-5O=LZKMW-]R$RXHZSEYOY@?([2
M:XSYZO=3!OW-B@+?EZ)8QZX&DYZ'I2'$7>C@>'#:_RE/+G#8X<*5ZP^J2,I/
MKE[>N>[O+%NEO+-LE?+.LE7*.\M6*>]L\CO+5BGO+%NEO/->M\IMAWY."@O1
M0U46ZEN%%?XP/=-WN7YG_$-+V!9!>0;"KP,U]S#?9C9ZLU:'#*^?FD4)%L0$
MQ"5EAC&K4,311\X%P@2%#SM90-.EBSN=%],EBRLZ9J33/2]4/-[%Z;KX_=&+
MXX/C ]))G[7[[8_N^_VW:'?_%>L<I\\Z?DL[6Y_0]T+%CV?I;[X='+^BNT=O
MO[W??]W;V^\=IL_%!]^VSW:/=FGZE'2?K\ZF"Q7WMG;0^Z-.]_V6.^OLI_MY
M^9;OO4OW]NV?H]W]G;/=;_ZH<_SZ4V?KOW'O#3J;/ATLG9486Z!"<6!(4M#8
M(H@$1ZXY=9RAC4W"VNGU=GJUWJ$BOP#* T^V6B+:5Z=>>\&'7U&*N^9XRIWX
M;?;X]-5\SB2'TYA:ZQ6A,#3=M\M@HB-.[.5-!"8Y!H60!^&)-SPRIO(1.U*H
MJU#7XZ0NZFF4*" = F=>,>TUH9I:&J*5/+I%J&L5SI"L"*^1*5Z+#'.%$Z]Q
MPR4P9R-8[S @H51$A/#T3QX )]N:\T)NA=S6A]SF.3P7C7,&>1N\YDP;KO-X
M1(.=QXH[+_7-[';#F;E"<TNE.39%<U0CAHG%$*Q+YENT!BPEZ8NT5E#CB64X
MCQ?A;45F:6Z.)E4-9KB5B =!DD$20?J0)7%2(>3&RGX>0C:(!^.T5A$CQ@+3
M0CJM-++($R/X3SSE.0BY<.X\G/MU]_F/PX5C8#+(9%8*Y1PP8BQ8A#0@2E2@
MQAH?V,8F%FO*M\6B?&P$-@=_)?N18&,1=E8RI(01DG#O,W51JB@K[G)#.*W[
M(Z=I+8(V+@!W@B1.\Q:,C 1"],I'%TUT=&.3DS:F<B7<Y;G3NK'Z3\/3NM?C
M<V<T.LUYW7Q^V4V.;HTR?EJY]WN"9S],</NE.SYLA>.3WN LA%:H8)5G 81^
M;JW0.NFE6VBW^N$VA>>_7, [I8*O$<):)GQ#E#82:Q1R*!D3PBK!N48>6V:X
MT?H736NNR_QF@>>-$/S5!K&3A'#UXMY)OK'1]M<P=-U1\"4U7!>A[F8BG2)4
MHZA, E2@?.X<+:0&JT.R&9ETB B.:+0;FY*R-N,+9U=^PEW+,@H?-]JKPV3D
M]R*F9HMI#L-5(8,4XR@Y=C8ADIIH48S*<ZV8\D'.W>K[!D+^Q_1.PP)\7 S<
MV_%Q9]K Q=(R:AF@8'CBX^! <V8!.9(8F1+-17+:=9OIA=-!!>:%C8N8BIA6
M5$P/.1^C*,V'=6+V=W)V,2G.'=39?_7M@W/2&R,T>"0)L*B2/Z-X\F>0PS*X
M2*J9W4W3FC65]-\ZY'.E%]SY)2"_OXK>5-?H]GWHCY^"KGCD 2)$$UG,?GUG
MAD.3.]^%"T!-]2)\H+, ZT2;2PX =8=C]W32L*EBR$G$9\*A+X:#XPNJW(L7
MPBZ!G^4$?MY^Z>P??,#.<FH# 1FI!L83>2JI(GAMA69),R:%N;')VHK/S@F\
M6R"]0;G <HURC:5>HZ1UW*?KLCIQT.L-OD#Z\>34]KHN_4T,V8"N\CGY"MV+
MJ[G!:'RKKDS%+VJ$@K]5AB<]8_524>XU*O>=&>4NJ$<T!@X*,0O,(0]*8P,:
M:Y>+:+UF;F,3M[GD;<H65O E]M$4C,_&/A8$^'RQCROP+B&-N1!\.<;[',$)
MKL$CS4%@0X%I(\%HDWYD,0095& L'PPIR%U?Y-YKJF].Q5Q@?4M83RGF2 T.
MA"/ DB=8JZ"2BN8&1$ !"T,X05DQ(]DFNH![U<"]=IFCIEQC/;=+4S-811<L
MQTG[GK7"NUMOR0?*O5$N4G NYZJL$6 CLKGT(\G:6\^5N5 &K$'*H.2M;INW
MVC=?J[A7/B&0I]*=GB28?PZC<?YA$%O#].VPZ_)XITG(S'PQ0S\JR:U[5< -
MSD\4,14QK<2!T-J=U6?^Z'0TKN;=O0[5P)']0:+3=]_9],5@6 65_S"CX//X
MD= ?54,/B]FR'!=V4J$J@M>(<)<65 1@ N4*51N!)\=6(ALG$[]YFRBU^,G2
M O;"R45,14RK)J9[G@Q?5&<C5>=,G2JVRFM):#[.H8!)Q$"A])UD6'N&A+(Q
M-DIWUE3'\@A<_2J@!C8#*E?!7"*J%;[F[\,"/OWCCI*N75"]B*F(:15R#LMT
MZ?<'WP?5YAFU._WSZ;2566*GS9+7N0G$J#L.;\+P<]>%2;+B=7"#C_WJ*E7>
MHA@O]1DONS-^/W=.&V0L."UB;B<E07&6;!<NK$!>DF3";&P2T28,-RA946BA
ML'<14Q%30Y7L,IW_HF0;KV1G(@1>1(0D<>"SJF56,DB;P0(VV%C, B*!-U#+
MEI* V\8).F'<Z@U&)<=?(N!%3$5,14Q%3#7GDQ@EFND0C7"".:DL1SX]N+$,
MA727]A8FY0U-NI/NVNF[P7'X*RFP8@C69PB^&N]-->_VUAM/$ .'<Y6%Q Y4
M/L9G./<**4&CRU46K,U%0U)%!<B%;]=&3/><OR]\>]]\.^MXNUS59C18Z0VP
MQ+BY)2X#$8UVF$>K&&D6X9;<_#P^MSLT_8\A]Z0X[0]#>K1OP5>.>"NAN]O/
M1?E5T*SDZ4MLNHBIB*F(J8BIB&E-Q#3/#'"+B-/""\4M<U)8SJ7A*%JJC=.1
MS)V0VQL?AF'.LPW#8>B/NI_#Q*9_>VF&_#DIRGUINOULZ._UWP1W.NR.NV'T
M;-@=I9>N'M%-QLQ>W#=?B\D_E\G_-IG\SZ9,?DE=\"H XQ;EJ90>M!,>*#+&
MR 1LX^7&IIXU]PO<UP;NM>??"]P; _<I#Y\YS0/"%G"4>=8VM:!9Y>%CBI7E
MP>;C]HV">TUI]8:UD937@O8/T\M]'T<M,VYM!1>.;1BV*&ZW,N[NU >RQA#F
MC4/@T&WF0ZX00U[;)%(B9IR4F*!\2H5%8[UP"$=&G.&$BVI:XJUZ0U97WSL=
MC\:FG]>LM(&LC_(.9H9[\:3-1* 1+.46&*($K- . B6&,FK513&14*0M"5KV
MQ,1IL*Q0#N/1$,"LB70W]-]N5FJQ:>8">&<J2RR(B-HDVU18BX'9$"&YK1J\
MI\EQ#;02RB99>.A% ?8Z MM[Y)U.6\=)QAA)*,_?:&=YU &?#T&^([!+KK)&
MU$^I=6:B4(9ZL,%$8#%2L-Y%D)Q3(J6/!+.-3:IY6RP^[Z9 ?V6@/T_1@@U(
M.^<T9M0PP8BE*FEWH2T2UFNL;\;^#;4*A0262P+3!6*&<^-R@8(F4@%+9AE8
M%$+2_\$Q$A%F#F7;'K6IGAW<.W?!0L%_\_$_!_P=2?#V$3D;)!-6&22HME0R
MQ7/@6Q6;_OZ<]IFT!!'!6"G!1Z^!88F3UTX4I)^PD@'9Z/W&IJIK+%-!]EHA
MVR@MC:%2RRB8U#K/\A)*!9+@+D*PQ:AO"NRGTQ.&,.(T 6^0@>2.<; L6?7"
M$D))@CW/Y^LQY6V&]*I@O\S!NGX.5C@^Z0W.0FB%"EKI+2[TQ]W/H7722W=0
MQEXM.:,A?#)_O/ L]S917B7;QRO&F(J>"QI\3OL2=)[V382YX-BK!68"E]S'
M;?C4S>0^<'!(8,) (L^ H>0?:2D<$!YBVD%YUH;*(["0U&UV3;NU4N/1;+R7
MRKN5$-,\I3@6.194)%):1BS6UAJ%&8O*"1&X_@4GERGM#6/DZ; U]8'+Z!4$
M0RVPF,A8!86 T&AB[BK-A-W8)*A-6).F712<%SHN8BIB:JC6%%I3'3'5)##F
MB#=*,F4YC5:C7.Y8M.9J:<V9N! QAFB5-*8/.#DRS! PW@JPED>4E*@.7)0=
M4W;,]QW#C;6$2P=46 F,2)I<7QX!66T5]1A[2F\TM!ID>2V]^GGZU'*3HHDW
MG66>)\H8![W>X ND'T].;:_KTM_$D ':;O7#.%^A>W$U-QB-[Q9V?-R-(AH=
M=IQSD&,)-=Z&<#_-A!J)4I(KD5B6! *,*@R*$ &:8N>Q4,9IFT.-B9/;F-65
MMUW1U.PZ8?P:VVHQ@-]Y3FLQF>9"\'0=-0N$<!TP8(HM,&<)*.P8.,23?>VE
MH#'741?DKB]R[S7Z7"8L+P?64XI9)R$1[A!XGG0R4XR#LBP"%E1S)$FD2F9'
M2+01F:V1+.!N-KA+*[TBIB*F=0\Y%U6Y'!]V.FBHJ5!!RP#>! =,^AQA9@*B
MQTXZ8I+S0BYT95V'BDJ%X7PQP7WSM0KLG4_Q;)V>)*#FSH7YAT%L#=.WPZX;
M!W\>$S1?S-"7:L*2)VW,-=9SN\S5+KAN1[.,^VV"3CUZ=LTY7>2$L00H=OF(
MGM-@!8V O)48\X@H1AN;&+71-07]MS^A5UAG9:Y1V*]VWZ&P7T/8;\:C<,11
M*4(N]60<F&8>#*860K#"1\X%HK%9]+>>[=:N!^VMYY67$$J)=!4Q%3$U.""Y
M3)>J#%%MN.6Q/>-W$8>5I3Q7/9( C% &FA(.B(6T13Q7!N&-3<K:%#4IDEEH
MH;!W$5,14T.5[#(]]Z)D&Z]D9]S[H(TR!"-0BDI@DE@PVE-P)EIF,5<VZ 9J
MV<>4+_SA,],U''2_PF'7^]!_6C;\3S=\VNR7-:+I'H[<!V&XTMXBD$JX2<,]
M3:P"KSFS@?&(;=KOSYQ+FZ=*R+[)/<YS_K7U?."[,>V)BF(I$2UW>GS:,U6_
ME[2O@QNWS"493K*ZQ@^J0U.7$%EB"K=<HYG7*-D"2Y+)P;D7T4C&0E(K)FAJ
MB0U<(2I0+5U*BR$P%R]^;T3Z]DMG_^ #3LXVYH2"\=58%9?L !XI"*DE]D$B
M&L+&)A.X&3'^)@*]D$4=9$&-EE$SB9DRS!MJ@M!!8.]QP%'0G\PI*&2Q-"/J
MN]> =[?>D@]:BD0+%H/"2@%31()A)EE1-!BD-8DHS[5O#%L\IHQ@GI*<!R*7
MS%^)=A4Q%3$5,14QU5;T*H4,WA'CB61!$6-"T(J[9(TIRB*[1?#X!B,M::W)
M@,T\2[.$?)?CZ9T?I_3"J=R2VB/B@%F&P+IDR@6JN')2(*QPLMUH6]'947)S
M3YPH0"Y\6\3T<&6VA6\?T%F>I-@$%\XF=QD$-A082LZR$I$#]9I[0@FC4C2+
M<&O*KMW:3?;=SQ?7/K\$Y/=7'N]T=Z]F]?'*WK8[-/V/(7?N.KV<#EZYX*V$
M[FX_G^RKTN.7DDR/6\*'C_D87Q%3$5,14Q%3$=/*BVD><QX)P8+ 0B>+G45#
M;"14"8WS $CFI+R[.;\W/@S#7%LW#(>A/^I^#A/K_NVE0?+GY!3=2]/M9Y-_
MK_\FN--A=]P-HV?#[BB]=+5G1S)K]N*^^5J,_[F,_]W9,8#)68LV2 HR!@W,
M! LVV C"">](D,$CN[$I&Y(H*YA?'1>^8+XQF)]NPA,=DD930$@FS#N$0$?$
M0&$3&#'6<(V;@_GU3([+:Y'[A^GE/MFCEAFWMH(+QS8,6Q2W6QE[2\V8W^(:
M-XYQ_%E<I7GL.%\O;1^D2N# 2.>3?E@E?M02!RR8YAA/)IC?KH5V=?6]T_$H
M%^RFU2K=LNLCN5<SW;)Y"(2H*( *G;NB6 /:< 2,6,$5B5@ROK%)=!MAW:9\
M-K#YT/4ICWBX\-TP5\:&+P%6TRVL)<?$.QH@>D83F+@&Q9 '@8)#UFA#@DBP
MDJLR.;@ ^SZ!;;TG5NI$Q$JPC&]*E/.!(R(0E4XL NR2(JP1]=-'W9.W$(E@
M$"FQP+0E8!43X!C&QC(?/4W*5##1)GSA&;<%^BL#_;D"#=AKHQV6">K)Y<36
M1!L$Y3&I#1&%N1G[<]3-%Q*HCP2FZ[(89HD&9 #D0@3F% 'M"(5@3/I'*I?P
MO[%)$6L+-3OP:^XZ@8+_YN-_#OB;I"*4-M'IM#LH=Q8C7WVUD4FJ?@+_8M/7
M[2I/YP"<YXA3E9 =O(.DSAE8APU0HR+7+ HMDGK'L_' HMD+LKO<NIBPS0)%
MG%&%+$=!>N>5,XI&B8I1WQ383Z4!C,',).T-3B<USDPR[;5!.)GV,BK'+&>1
MY-8:N"UP74.IEH[]Q]1X8YXAG>'XI#<X"Z$5*FBEM[C0KUI#G/32'93F_4O.
M(] 8#$F<J'(7#QN%"LGPX=(H(QRQ-%9Y5GR19\6+SN1<8"!RR3C<AD_?SF0<
M/..:*.8@'P4'%IT#:Z4#@1S%$J$H<:)3)EF;2M&@^<<%[:7<;6W$-(?=ZI02
M@6@;C#8,*VDUT4Q+Y*(1!#'V"T8N ^H;QL<S8QFM\T0A#8)8!$Q3#@I+D[X3
M%B'E%4-Q8U.U-5MX*&.!>6'C(J8BIA45TQQ*D\AH?0B&.J29"4I)+&62KD"*
M96(M2G.UE.9,4"@:)Y7,\2"7^T\FIP4L$\F?"4$C80FQIH%:<SUK1!]^/./C
M/@J_=AT+FG*-]=PN\U1#U.Y\E@%EC="H;K9V*G)"D2,0I"#)^0SYG$4,H BC
MRF,F15:HA+<5G]6H:]'.IERCL-^2O8C"?@UAOQE_PBLMHX\$L(@2&,$.-%<6
MC,":(X2]H[99]/>8,LA+&<_XN(,I)>95Q%3$M [YO#(Y:G4LCX^S?E<0##%.
M(:"(@!DG0!EL0!C/I/;<"2LV-KEH$U:J,5:-%@I[%S$5,:U#_J\HV552LC/N
M/:;1:X<Y4(ICTK(Q@$X:%G#D/NT+H21##=2RCRE?6 :NE 1@$5,14Q%3$5/=
MB9S "+<.:Y),0D8=TUJYH#T.B@5.S6UB+F4 P+T:<=^>S1SL)\F2%UKDZ7C6
M 0M(@66< 47&\%Q%+7P^_HMPFRXT,*\@N1!N$=.#9\X+X=XWX<YXS8[1?+HZ
M42PU&!CC!K1C JBFA@H1&3*X88S[F++B=QJ:4L*-)2I<Q%3$5,14Q%3$M*IB
MFL<6I]$('S4)"$6&@[,R66^>>N(H0D'PN]OB971"(RSW[=E6:4$'J2478)7/
M1\F1 *TBAK0-%*4A#QKV&YMRMEU2&9>R%IA?GO]=,-\8S$^7L&.#/&8(7&Z*
MR$B(H!// Y7.DN2N$Q5T<S"_GJGM^<>EX(:,2YFLSU.:EM0/3FTO3$:F/,IA
M*DC91)M!,A9SUU=BL;8B>A6-QHYC6;6*O%7OLS),97D4N#/3VLS%)#$B"2!J
M!3 7=+9_*%@3J74A63[$5L-4F*9M268K?9:!Q87P]U,(3J/P6COF_KCPEE#\
MUQU[<=:Q0"M*4M>,P+P30Y4VU4L@H>G1,R2Y7A[1"-R$9(992D%9RH 8A4-0
M6JE(ZQ\]4P,Z'CA[6GBR\&3M/*FE89(EUS<ZPK@4QFK"M4;1!&0)]HOP9$D]
MUTBB,Y-\E'&,"##82F#(<]!,"8@Z$$^U0#KD23Z*M[F>'>)1F+0P:6'2FD.*
M"CNED9(YA< 40UI@(351R'KEN:<W4VD9C/0@G#I=/RE1%(1&! )Q"XS*Q*XH
M","<86HL]E*RC4V&1!LQ7MM@I$*GA4X+G5Y3DDY)^H_6+-FES&*I@M1"*T:D
M$$2ZGUBF<]!I8<SYXHG3:=3DJCN=W7A#2$R^O(F@7;)%%471&8/R'*%DAM90
M^UC8LK#E(V/+><*=F##!=&0*,^8XLH;Q& RW!GO&&"IN?%,(="HG33&G E,,
M% <*C., 6CL*)HG16V+3#B,Y&*K;',_:G*OJQU>Y[=_&)GUH^M=W/V_^)WVY
MN/%C,_S8[5<?+WXDKSSJ*@SO'XZDZM=\&%K&Y>YJIG^6>S3W!^.<LAZF7^=2
M\G'X.#2]UHD9CG/[YO%A&(6,TFKY<BO#5NSV3=]UTYM&X_2+JN[\R:7TII?A
M_,,9>2)YNL&3P:CJAO!TF!LC=C^'W[]T_?CP@BNN_.&Y8-'W/S$VW<3I^.8_
M:<H:*_'C<ES]FF^W(AEF*$K^F*2,<F985#%M2:*,1"X(0<,'J3<N_NAP>/$(
M)^9C #L,YA.8F)[PJ>E],6>CC=]^W'MIXTTM_/2:W;@R,2YM928@2*P[&%8]
M,YXF5(=A?E>Z)].8>VD=#K,Z^I];B"CW/\^<DY#R/&NRZ@B&V;Q._ ^Z3V<*
M5JI]NO/ZSX/]/W=;^]O/_^SL_;7W<F?[3;NUTWE^,YP?G-6N?Y+G5PGJS24M
M57(QH\/6B][@R^C&AVK*4_Q[IY\(=W":KN%'E[Y%I6"^LV*EU-(=]<S)*#R]
M^.9WWQV=],S9TVZ_NF[U1[^?2^N<2C,-3"FTZLDG+Y\SA-9/))*9),ZKMLX_
M^)P_GE3\,:6C)Z\)\H0P>N/+Z F^\;6?71:C)X+>_/+/+OOSUS@M-ROH[6[H
MO(QO2JF3B4\XY5(.$]2FZG-_6<"&^<Q[K_'Z)N"\'^]&W:KD[R"886L[:0[_
M0\7?#[;L]6N'R75K]R/*;V6Z-GN!;EOZ>)L'ODWYXSHM'"H+=Z>%P_HZ_"U:
M@ORK\%-:NH<I.ZX,G)@-G%8<#HY;@Y.03=KDVF7_^G-5D;](Q6-M6^P>RIO7
M[29K.N?>@+T[7S>XA<_U-.T0_^WCP]<]X0-%>&_W:,TXL/3W<!"[X]7I%K+W
MYCS6>_3ZN+/UBNQN]3[M'OWW:'?K%=K;/V =<L!VMW;X^^,=\G[K+=O;=_A[
MK'?G[.!X^TMG:^?+P5'ZNV^OT]]N\\[^,[2;[J=#=G#G:/?L_<N=+].QWO09
MW8/J?7]T]]ZEYTKWMKO_":?//=LE;^G!T5NR^^V_GPZ._HB[9^>E!6_066?K
M+=K]\D$%S)Q4%*AB%)C6$I1 $:CTDELG8J"ZCEXAS3MV6"AI/2E):$UUQ%23
MP)@CWBC)E.4T6HUX0+BB)'1!2:A0TD-3TK<I2B+&>$<Q Z^1!Z8D!2L)@<@D
MLMAB1(C<V&2TK2@JC%08J?&,A"67**+(#7$,$6:M,#$:S[&FPA&7&0GK<T;"
MNC#20S,2GF*D@(,Q@40($1E@CCK0AJ-\0,@YQ*U'(C$29VTN5#,8:7UB)-?#
M[TI?_]9XT!J&!#C7[856_]P!S;_-W[L<3#G- \BZ_6LC*4\?^B#WVE^CUMY^
MY GA#=Z76^$D[<7N9,J=Z?N6.1ZD._M6_>+&G;9BC4]NMQ0/.?;CJAB>]?VS
M*T(HBK(N1=EY,Q--H,Q2XAT'0X)+BM(HT(0I$#;)EG/I$ T;F[JMV&P[D]*[
M;%W@7(,'7N#\$'">]L15]-)PJL!IKH 9R<%&AH J'I+&)PS'9/>*MD:SCGB!
M\[K N0;WM<#Y(> \[<;F1A:8)<4<J/# N$*@H^+IB]/&.T>)Q!N;M,VN.4>X
M)L.T&NX^W#0P^TZ>0P-'%C3?<ZA:?_TQ/0RPT%)MM-2=<1H8\2IWA@!/< "&
M!0$3<XB-2&,"UX$Z/XFNU=9]IT$'[PJ4E^4U%"@O'<K3#D.T%GNB.:"8+8RT
M7<$RZX%CS*+0QC)D-C89KO'86(%R\Z!<N\=0H+QT*$\["U$*;R@5$(S7D!@Y
M@$IRS)V=B/5)BH@D*),\>G>V+NCAH/R8D@U7'>=\,LH'.V[Y[LBEYQM7V8?N
M:'2:6QBGI1C]9)C08X]PU#]V_(ID]N*+R0';_L?G60K/^G[K7$936?O8_1H\
M? O#02&O><AKMJI1F\B9SR,4E#2Y#YT 98(%H3'R4GHI2+@<FM*@6$<)73;<
MIRC OE]@3SL87"$E$?'@;4A6"?8.3! 1DC"E3N:EMM058*\_L&OW,&X/[ +@
M>0 \[5;@*!#7/@'8: J,8@W*80N:)JEI8B(S=&.3+ASH*PF(N[D4S@W#I3]Q
ML>FGAI*VJ\JZ](:383CNGAXO7N3T&((BRSLJ=2FT'TGLDK,2?_T]D=1HY[L4
M2_2D+IJ[[-AZ)7JBE%.!!) J62=,,@>*> XX2FL]LB%HM+&)VZ)1P9,2!VV<
M^U$SY NJYT'UM/=A++':(P_8&9UGA" P+E+@-K*TPQ'3N:\HN^984L%THS%]
MSZ=Y"I;O'\NS^8W K#0<O,Q5!R0Y(MI495'"2B&Q12QL;"HU.Z9B[B;!):\Q
M'QK_'@X^=T<9ALE";5GC)YF-G-#(2,QR.#6]ENGU!E]R=J/D-9:=U^@.Q^[I
MI5A>#(9_&+^59)*HZ?EWB3R[$$AQ+6H[C'C9VOS[0(@02-24.G!8YT,6Z8LU
MA$! (FJ,...6Y!!*&\F%9^R4$&ACP5U;;J. ^R'!?38U02L8E805DUE"DUD2
MN,VGC#THE\Q-+U$(-L='<9O1A2,'!=R-!7=M3D8!]P."NS.EN;7P"A,;('*,
M$KAS.17S#(QF5!"O@G%L8Y.PMF E ?(P&,T)OYS:^-XJH!?,*+2J98)!A-/T
M@QF-PAW+J58V1/)@;L?>A23^RH)XG6]I+[X=A6>5$,KAL>60UZL9MX-*30SF
M%+#3$1B1""P1##RED8O(M6,Q'P:5?.&SW27\V5ALU^MU%&P_$+:GO Z."5-4
M!Y A62<,,0*&8 XT8&X<(E8*E[&-2FICC;%=K]-1L/TPV)YV.BA)Q$QC!,0Y
M3MAV&)1+ /=,4L$IYM8E;*NVYK1!V'Y,^8[GAZ;_,5WMQPYE%4RJI$>O:VRW
MMT"WLMM&7<HUZG5V"9_,ZFKJQGOFSNO[AL&%[N<\8NAQ.;7WW.K\Q[S_3M\-
MLVK<"I-_=_H7\GA]*8ZB&NM3C0>S+BUB2K"@(5DZ,A<C8[#*8D#1.,^\,DK@
MC4U.VUS.^K0/4@903-[F=0LOJ'Y@5$\YLY@S3'(K$8FX2P8OB6!Q8( )9C8B
M9A3Q57Y<\]DH>T'U.J"Z]AJ]@NK[1O6T&XNMDH'[ #PP"RP*!Y8K 3%YM59;
MHC'E&YM$M269;2VR\B5[3?<D<F%J?SP8GCVN6KR&^0\74NB&<KJG1C)R,XY#
MQ%CP(#1@Y1$PIB(88QDDP6)&I:2*B(U-UM9BO2:4%#3?H]]0T+PL-$_7W"F%
MI48)S3&R9%I0"B98#D)1R6(V"*C*A_6HT@7-:XGF>_ 7"IJ7A.9I1R%*J60D
M%BC7"I+'GQP%%#PHBX233$0J>4:SOJ8Z?I5G]:R$G_#W,)R8KF^%K[F+7YCD
MMP;CPS!LN=/A,.2^98^PN*YA?L2YE+9"#$DF?GLBK&=]OY<E-4G@%Q*KC\0^
MSC@8A IF6.(O:R(!AHP HTUR-;!AF&F;3,]<*=RF9!&3I(0PFPOS>W P"LSO
M'>93GH</D00:)"CC!3 1$!A"-%!),$/>8,)0GLB KNE\7F"^#C"_!\_C=C O
M2)X+R=->A\*$$RY#VE YAD!D4MA2<9 >1\H413)W'!5:- /'CRDW46WS1=R*
M1Q$"N0>WHA)$9] _]_2*@5$W+7V:\2.2HR"PB@(HD31W<8]@"<? &>6*!<H]
MDCD8HJXY35Q"F^N ZWOP(PJNEX_K*<>!!F4C(09<2)8&R^.2C'$2. \A:".1
MR35.HHU925FL)Z[OP7$HN%XZKJ?="(LC<0$YH+FC3ZXF ),;_'#*7-!<>Z1H
M+BR0=)&"Y)*\6.RXQ(DY>WQG)9KE2US(XN^)* HKU<9*1[,=Q[R+2&,KP%F*
M@4E!P4BG0'DJ@T0.<:TK:X.6J6XKANI[=B5N:&=<\'V_^)[R)@SF*F%< ]$:
M ?.:0>Y%!(YBZZ5PR"*7TQ!*+1(E*-!NK,*^Q_,2!=!+ /2T&R&EM-IB!][E
M?AY<)EV-A(9D?P4?/:,6L8U-WA9HX0ZA)2EQYT$KI^&'L_V/*S?1.'<BB^.O
M[](H!%4?06W/>!1*(JJDS#76V "S H,2RH%$AFLA)*<&;6S*MF:S"=/2Y71=
M@'T_AZ\+L)<)[.E.8@Y;35D ZSP!)K6?#&ATCC&5K$EJ995PI$@58*\ML._'
MGRC 7B*P9UT*PHW3&(Q%,A<X13")I,$I2R11DHL\^TBT$5JX_6=3TQ.LV6W$
M+@K\6L/P.?1/2WKB ?V)B][J[[KCP^>GH[0J87A!56>%J.HCJMW9HQ/6\J1[
M-!B1^Q1+*4&Q/' VA-S'U) DXGQT N/9THB2K&@TQIN:K/@%V@N@YP/TE$O!
M,'(&!P)86 >,4P':Z@#",>,XLS+JN+%)2<E-K Z2F^5+%/S6B=]ISX$IYX00
M#C"-)BMD#LHC MP:+BB/288A=VYJD#:N-Q/18)]A;VK,24E'_'_VWKRY;239
M%_TJ#)_S[IF)8&FP%+;N\QRAENT>S6O);B_3U_['41LDV"3! 4C)\J=_F5F%
MA8LLR9:L#??<<4LB4:@E\Y=[UL^^WF1+VN5*X_05!\> 1%= HLTK3+1.XBA3
M'DM%%C.>^2F3L1),JRCWE1<+E4E HGBX-O&><>_M&@97Y^/!_K]&)E\S%W+#
MI1_SF$D>!XR#F<]2DTJ69UZ6!'#XH$%B"G6ZQ?X?2B,> H=?@\4P</@=XO"-
M:Q1]I#4M&3>)QWB$MQ697#&12R&T283Q8LQN"O@=*6J\SBA$F-QA<^+0+$9*
MU,>C96WTVGTFL/\GWV]8N!V19:5-Q6"!O^"&U.6DT"-<U@.'M&NP.<[Q9L*1
M[<&)T16QVNC?SM[!T?6@;;<]MP'4K@_4WFW8)K$T6J9>PE26IXQS$3"9!6"J
M< 4BR@?3)$FI:WVRY9ZF*SLZ+\=']\@%^EB!X>;"' ,PW!(PK-DS)I)*F"0"
M., >42;)F @# \?I15(+F7.\I,8/ 1BNH1?<  P/!!BNWP@:@.%V@6'=#%(A
MCQ*#11YQ AI#(G.697G&$A%%N51PRHE^\C3PQVE\YS6&:PJXW '#*-E^Q2,:
M1?FD/*U'>55.P30Z,?5E[:)+[,/%IW/;ERT^N!E>DU%_!TCVG%;-RTH="^S1
M7.:C>866_.*,^C6;_RR+^=3,%H\KP_!6NZF]$F>XX_7;<E?!]E?FE3N15Q,Q
M6^S.]//F4 :A>WU"=_/FEPB."@Z4,T^GF :=1TP$)F8)"%O0KD(5A9RNH?+B
MH67KP^3M:Z]:&GC[EGC[;".N@"B=L]1$&BQM7[-4>0F3H8A-'IHD%2E9VE$T
MY!H^3-Z^]F3#@;=OA[?7C>509R8V)F!!AC>VQ9YAF<P%\':6Y]P(+U$HM[TQ
MORN7PCX<D_@2]H4X$<4$^X(P8 )6 ZD[$YF8YW&E(MXM.V.W.9D79?4&SN6-
M4<N*_!7/C!Q ZQI!:_,6&*Y%IG64,Y!*/N.1IU@68%/Y6"4B#](LTQDH)$$P
M]M,[<IG5D,QT[ZR-@<-_(H>O!_>R())1G+),RYQQ.%XF ^#U+(H#[F5!&.0Y
MJ"5),H[\X2K9A\GA-V]S#!S^\SA\W?#P5!I',I;,]R.)AD?&I!_[3 *0QWX6
M&R\(0(;'T3CS?^3B^KN7KGAG+0]D@9NR.NZME^16C8ZJA&W3]8NJG.+AO,RO
M@EAY\<5H]M54Y0!65P*KS>MBHB@SOLE '?$"P[B?A"Q38'7H-,QTZ.>A9\#@
M^#__E09^\.L=JM<<_*!WO#';CW'XH)/\()NO61UQ8J(\]#GC(DS@'X!/&42<
M!4&>FD G88P=%7P^CH*AH?O#Y?+K-SP&+K]%+E^W//(H3)0)<A;&:'F8R ,N
M5X*ETL^BU!=^&E K1IX]P-8+=];X.! +QP%#W.-N6B#="='-N=:7LCO3>V(R
MJ;\%:0.<71N<?=V\A";41NA81"Q/9,1XFH5,F,1G21"J(/*B)*,V,E$TCK8X
M4H8&#@^%]V_4-AEX_V[P_IK!(B.>Z#@%+2:)4L9UFK-,<X$5DCH.M#+:EVBP
M\+'/!]Y_N+Q_HQ;+P/MW@O?7S1B3<^G)(&5!*@/&>6)8YH6<Q7X:>CKP(Q^O
MBLCP,IO-".G#Z#Q]/WH^S%U!X$B>C?[F&D#\_6J53H^LGO,V+9YSJCCWF^,:
MJCAO MXV;\(Q?F)XH"*6*E\S#O*,94'LL5A%@<Q5F,8YYGAYT?@:^M(-1=YW
M'Q3N=/>' 1YN&A[60S5I'&1^(I@QV,TNBSA+.;IS!3>!DKE0/,2:E& <9M=0
ME#(@PP-!AI_>_F% AAM&AG6[2'(1A-C[3@F\0B^*<R9RKIDGHE2H*$NT29X\
M3;-QD/Q(;OC0_N$&VC_DQ4S,U$]H_W O^BO<[TG^I&S)EF%T<=*,[89@^'VB
M1!JCF&DS6_S",IKC+<BI_;I> GD;#'"J<CHM<0*E^HP-(4%(S8R57J?% IBB
MG !;,/AUOI230L$S.;QT=C0>S4S78 (6/21P_.1$3#RREW.<0_W\BZE4 7)^
MR+R\%FF^>6M5'"A?!29B81 JT/-ER(3/<^9[6H11Y">Y\8?,RX?/TC>;>7DQ
M2P]:^@_R]?KE53)) YU%S),Y9SQ-/9:&RF?2U[[P9!!*$6+=>3SVAES+!\S7
M-YMK.?#U3?/UQG6XP+=^G&<L3P3(:Q49)KT8+YU,DX0'GA AN>V3<1C?I7LF
M'XZE?4Y7"<<6KLWB%2P1,YU/RC-C1O\KJW\\Q1YWBS/XG@);JC@QH_D$)C4D
M9-Z:)8+]<@:/XC5BVN;U6,+36:BXPNJO!'053+"*N<] &4W"/,R,%\5/GJ;C
MC&_VDQURK!X**]^\!3*P\O6S\IK9$<9<^4D:,A-H']033V%3.P[_Y"I661JF
M/*%V5P$?+KM[N+Q\\U;'P,O7SLOKIH:?RC0)1<AXS"/&A99,AIYDG@21G(=Y
MG.OHR=-LS+.[E/K\T)M(O!5?R&XX+B<XW]%R#JS8I#J"N5'!CU6A%D8[DT.<
MBDH_LJ82=Z*5W6LS$7 ,;TLXLK^Z$\,T[F-1F=]$;?1>.9V;62UPD@.:71^:
M;=YS%7*CE<A"IGP_QC(NCZ5I'#,1)R+-0B$UIG,'T3B]CGNN!E?H'>3T&VMI
M-W#ZK7+ZV?IMVYY,X6R9)S+L?,71_,A\IJ72,O&,]GQ,7?3&GG<-%U<-G'X'
M.?W&6ML-G'Z;G+YNH00FPE.-60"J&N.Y"ID(X=<TUS(SD=*I"NA"WG2ST\30
M6_L&>/1U6[^(ILBDG!VQA:FFP%KR^R[MN;?.DENU0+IC>)G_ 8?P%LY@Z'MS
MO6BT>45/$J<JBM*822XUX[X XR+* B9DFN9YFGL9Z1W^./ZA*WH&M^?=Y>1K
MMS &3OXIG+QF0?@>#X,P"UD&)@3CP+W8-C=DD2>$%P)"@Y*!':RR+4&,@9'O
M*B/?IOUP.3X>\IJ_FX4W\J04CWT_,2R-A  6-F@:" 6$%:5:9$92@_MKRFN^
M>^&+>]2^H6O9T&_D<*5*I1^IQWSX)9G78%Y<K23S17-V0TGF]8/=X;/-%G6)
MSKB21C!E4%_)8\E$#F G)8]%;'B0*4V7@T;)-5PR=FE6ND?NT <&#[=IL@R@
M<$N@<+;>AC?Q>:PE2TR"5_S@)5Z@JC+I80=>ST=3!D#!Y^/0CV^ZP<L #?<0
M&J[="AJ@X7:@8=TX2KTPYUD4,S_V05_@F' =PJ]2BCC)!4\ YM%3Z8/"<&^@
MX:''5M!@*F:J,J(V5$>"QI.8:?L#UHV< %/\8/?NA]2VYC8C, AS^+_GW;&\
M;A/S\(/=F5[]0^^;KV"Y)>"B/>MGQOX7?I\L\0B>?U''8G9D7HN%>9[G1@W>
MX&M$R\U.>4G@Q5FL<Z:X5F!=!3D31@=,1&'J1UH'F6>>/ W3<19>5T[[W6B'
M=8W>XD>**]=N7 VX<H]Q9<U 2Q(O,;%"M2O$C%2$%! \3/F)I\+(RP%UGCR-
MT[$?_[ 2-N#*@\*5:[?,?C:N#-!Q)>C82'R3PHM!#V5<Q&C 17A?8FR8C&,!
MIIW0N9\_><K#'^X \%-PXZ&7[.R=9ZF-1](<%;.9*]TY,Z)Z7'4Z5X"\2*H\
MC%)N0B_B8>K)R#.)QA1/D89YXGW<_PD:U* 071^J[6_V 8BS7&0J8#)7AO&
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M]WH<5A\7.3%@40%?@<GN;)/&0"<SWUB%JF? P;.-:QH+^.SGI-6!KBMTXY$
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MBIG--B[:5:,L B:JCBBK X9K.Y#4\.ZJL&[E[>MJ0SDNK.GT1.$$TN8#Z&Q
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MWZ8??M__^O+MGV<'P8?)X3.8YU==?)@>Y@>%]^6/M\\7!V^\L\-G[[R#TX]
MUJF,$\V2..:,QXHSX64QTQD/HH"'4L3ADZ=^,$Y\?Z,1V?_Y+S"=?[TQAL%/
MK\@XWY)6%\'VNL0;@&\ OC7@$VE&V8=9DL<\R;*,1WZ<IB;P=1X;(Q'X_&P
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MC6\;D 8@&8&>7+$2]JS>^"Z%S !B0'XM6E-<EOJ,8+5>$5$X;C<3],TJC.N
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M=6W0=&]<<H2!*WL*>Z18\84=%QJV_9='PZX'GYZ#:J8^:L0^D0<,HQ^,QTF
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MK O5NS]#A76KYN-)^G#EHAL%<4OWJ.S@B.&R\D5+O\*5[V22:)Z;6\!3>V?
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MFQNL%K+,61B#3!OMP=$H-M^-N9=\GCM,$89]YN/2*=3AU#HM9&%=LB/QR3F
M)WM1KW*]R6F*N5LC+11VM=LYKQSEF:@FOR^4V^OG]KE?LR,7MJ];E'5XD(N9
MD >P!)4'O?77]/8O><D,&]2!X4Y1QH>CS2GD4?*(6H>P,\/*O=]M"?Q_54-H
M'_6 BL9O'^]>ZW4AR<(?]=0K9T-_],K*H5."%ZE34< L:4YQ5IRB\..S<%@E
MJ_@<DYAM<%TY+ :5[Z?,HQ@L7=LIS#(R6(#4SKI3W%%@)G9C:A=C:'JY:MLF
MA^L+0Y1P#8RZN,%+R.+Q,D;PO'KU<6H2(&E_J:<PT;I&,W_5#>_J):D=)+,!
M]-3^)P;T(_9[X]@Y?HXZVO&K+XQ8RB)C2-&0^Q4%@HPG"1&',6C=!-3HL+'=
M[2WFC8R)#HA\0G.5?1LJ1NA,\O" :B^DP2L2VVZ=IKSJN6XE\74I:M:Z$ZS=
MKYV> V4#R!D0H9W%\N^][RCKF:%5*YV5M[*.M-5H,@IY%4DU=HS\C*R&$?-^
M ,*(OV0U+,\6!E?UKS_-?Q=^S?X%4(+^Z,!B/E]_YH[_XFPBU%J'7%01\1 U
M6$Q4( +<&4G,W<7L#<RFE;&1/@S!%$:5)CY- S>REU9+S:F%.TA1D*2#J?G9
MHI^W3FPHU@2HR9W>><RVQ,@0*6H1(-%)$=')@B60-<\XCHC4C[#C7QSV[5A-
MS8.8W).O@,7Z&K.'LTXC'MV?DXPG=E"E_N>G[6;^1J]MO]-K]0H7MDZ![_/7
M)[T0.R,+9>XU99+U#1<__)>.A:7XX(]ZG3RA)8_?:DV3@Y\BAS%VS:KTV7PH
MSRX9Y*#4Q7%6;XUYD]</AGV;=PSEW1L9J26:-K<!XVD516P2(9K>RCH9>+2>
ME0DQ:&47[\DDOV"DTW^#/04K JCAS!]M+DU?'EPT\3+A;$>$<?[R%(7T^BFV
MAX7::NTUDT(>;448=2IQ&QZ[F97IL7VRF87QX,Q5QNY(1 SR-3EN!])E^MF5
M(3?*5L_Z^&@,H'R^[15[%4SE,M\RD\TZGC8UD1(ZJZ<PB%.4.+/X'FS;O&.9
M+N*%N=Z]DY.<LUV177=QWIOUQ*=3@I:24V:).<J X<"@KJ2L)VR<+5VI*;LA
M+\N;&KPJCFW]<=8')0\NRY*Z]:^\4Q2_?//ACS_*1_+RWU>#W&BW1SBR?&.[
ML5AZ2WE@UA :D^@<4$Z]<G,,:%4V3[$>KX"@S1M!6J'XF"/4IZ,EJNFGC'7I
MJ(IG813#NII">YDW"\\L(\S'5>C>V'Y.JQO\$?M%MVM\WKL_#K\8+7/0.2!*
M<\ENEQPR25/$8\!>>&LE=>NHO.T!+_Z>?9% >9GM,BB7;5]_;S<8)< >&6PZ
MHPF.I,Y1*?L+,&D[_JP"19=]G=_:880+X_M<=12I>E660\"T]A N."OG&+)6
MD1\WJ$Z&34NUL^$ K+ORQ*G#$!6+;Q:7.5PR=YH,'G+:RR&UMNUT\I Z9\6%
M/(A@ZQ5?:4[PR;'=</G4BKYD*S/27;$2&>#@=6,-HCZVEQ4.P$D?YWQ]5PRP
MN,, $]MH].7U<R-7\?SR"!A_S^?\X^\Q._(;4-S]\?6+BC%0R2A2FB;$64K(
M>A\09KE-;)!.&#8?S 40U<8YXI1WG"3NN,Y=]J*-R6)N+@71U0P4%G=/118W
M\%/=UK_U$V:\W,'U+G,D#*A*P>_D^3_"]&?AP&RMAN8]-I8'V3.77>O31POR
M!]O.H8IJF49V7H;6TQ'J3Z[?:KV;.UL '[[%\PK32]&(K,*7;WN=R@4[*/JU
MS0D695?:Q6#*@=V"[2-3.JOG[2IZ%O^I@Q'Y@AD9-&/=CK\:S ZI'D!UB*+,
M:E9SOW)%[GE"BRM6+7E)4*VMDM3+@;\BAV%L@Q=W)KLJJCS.PBJU0(#\.O9T
M$%^,/KS,J;$=>_ZBW2U$5&YZ66M1=>I6SE6:JP-27EA]/4ECVL)5*E-='+5^
M<_WU5OEJKK9)]1T,F/ +O\5;Y,+O+GLJW5)4WOM3F=BB@J[+8PG9DN)ZBU"7
MM9U+]V,5)4V5UI+CTEI7EK"^P:7L\DN7UMQ=?/PUZVF!<;!$<O]DU"Y2J_@R
MY,LYA?3J=5TR\1$T+)W[SPHYC=&T/N&6_8-#.]+6LY)?@V$$B.R=@)H\CA@7
MUV -O$4\S2'OR^QIN; _RO7HZTKBO^(Q#T/\#9_<DD_,^O-)?;AG2NE81OM;
M,W0_6Y5KC73VG?:@2N?K%W=E.;IX0[OE8@5\C77Y5[4JFE>E?7(*B]D>CO)X
M*I6]/2@)2OUH0[LS46^+ IC7L7<&?TZ+!@WZ9;6JLXKT(>!LOZ!P2;VTW9G3
MTJ ]]BO=M QB[&EO=ZL$EQ+Y^V;;G?+&VH#(3IR<FC?.<RO1J2IQ8'#>A4N&
MV0]291C60RLYA^/CN]51J,G+,T.,-/?*6U57<!J[]^M$RVI51@5UFF,/-SSV
MH)IC#ZLQEH<Y]G!;U\?RXQ+7.OZP>-^5GK9UD5K%MU9L]N<NI_;'\BBO1A9*
M$ZF2T1JPH'UR=@*BJNMS@G.G$A<39TD)8RYSU_1B)>!&!WM'@=!13D%W+!=&
M<8RB0:%>*@>3)X<(YH3@U*&"*D6[]GB==7/1A%Q@HV1'V$$OR]+SEJ]+Q)5T
MC&GQ68HPQ']BW[<'<2K(//O84NTO9I_4$,9W6 55\T'?2:+MJQ*IN:AR6C?G
M?'?C=Q#)HR#V]]@?'P8?9_>.%8"1_VZR+3?*>UQ[-W#%G+N] -JROSSOZQDQ
MZ0=X[=M^/E$""G?K]Y$*61-/B<NYLW:GQ ;'9V?*KSOY''^O'T:52RJZ&N4-
MS:?1G )[]G/%P/"_9[8_C-51CMFWCU(YQD=7RB-'21U;K8^GH\2=:76R-H26
M3*12:V>?5N>XYR(XN58G\%Z[6]5U:=>!S5$.R-OH^F?Y=$6NI[99"K:=%.*I
M$E/*'<5!_0%8NBH5EPMV5Q4$RH$C>&D-=Q= T#SP5-7K)F<$QIEW)U-46R7@
M+>JQ<P67EVJR1=Q>J4 8LG%%JM&#)@9<F@; MEH/6OW,#H[>_.]9&ZR(K#:]
MZH8/1[W^<!_0$C[_WNL>YH_ONCG+KA@4*Q)9%;L?1I'5\'5O_^_CS[]^9.]_
M_;OS?O^OKWOTMZ.#'YX=_/CMZ^=?][X>[,.?3V\6(JM[]$^R]VGOZ^=]SS]_
M^BCV?OV3'9R\/=[[$8YW3_[Z>D!A#O 'QI'V?GS\YXM@/AD:! )Z8H@;*Y#A
M0B,AM+->.^V(G@^K!F8%:'B<6A$X 3ITAB?%@C8T)AX7RD?G'6E-;4EAG*D-
MN'99F)N%YQ>UU*L'/CM1+J)3QF@-Q,:QHTYI(:6V'H> X;</?AAX)[KAAW&R
MPZN13?ZVU\^%C(J)\'RI]T_R17/!*4\6J60-XE(JY"RC2,B E8_8<W%U,?/5
M.+\QF]CH,\O$.989^V00B&@TL.5\Y9B+LG*Z7-,L-]<B,.N7()2J\.2@]:^B
M)?3.8/1A\.]QE/)Q@XW&;&G!;A-KY&)+/5"@C:E;/?;R[P1K!KM>@^77&] 5
M;42O[@],KA/=J/R(C],V1U^ERQ6/WZ3$<HTUB[&+A4!<SG*_?20.+NT#<IW.
M=56^07.4:S=H>DQG[O66^]6H*N1UC-6?.=!<W^Z*>!Z[V>9=2!#FSD2P>FSU
M:[\W&%1"/!]8KDZ(7R,<?K>5?-:L]69T0F356>MM5A3_SHKB$@9[(,2]^:5/
MB!=S;M]C\-Z36[E\UB->9^FNG_UR_YW9?VK3P=U>-YZ/CMTFF,O":ETUVZ8_
MY;-K/QD,-9%3:80EO#0N"%J))*0Q0DJLOKR[7F_U>7?2G+-II&IF52X?;QJL
M1<O)V_JAJI:3)Q]_[/[Z&US;Z>P>[_*]G3]_[.Y\Y)]__?OKY^,W>/?X<WOW
MUS_IWLY7-M]R\C.,\>#DHWC_Z>-Y;BJRM[/[?6__Z.OG3W^=[.[_>;YW\N[[
MYYT#_'X_I-WSA<;JS&L13(J(IB01MUHA&WE @B0+%,(QP71CFQ"\29BZWY:3
M3Z6);X.!#0;>,P9Z?W92G=DL%MG$%LM*X2\1\# N].)=4ABJP<1K8>)\Y_-@
M;6(A ;ECG1"G-B(7>40,=I9%QYSPM,H>)O1E@XD-)C:8^#,Q,9M[#2;>,R;.
MMR:7VD:=&$8")\!$ BJBB28AEP*7*GEM#6LPL<'$!A,?%!,G>#B+CHV-?(_8
MQ^:PS]GD)&:@ .+D<PD(BHP :UDFK#FHB/"9K9V-?&,W9RK_K96;\^/6AZW6
M8:Y U2WYGI/Z+1<ZA^G-5F I8J\U<O$ TMQ&X:S37$JCF0 RQ]9(HL'TB8V7
M;]41;._U@I?/.=@]JQ0B449 ,,&0Y:"]26*,2M(++.S&ML";W."[ MARG'A0
M_6SNE1=GNS3,_2C,W;BO'I/9Y]U7T3E'<UETV&*%N.2YG1Q1**3@K'$LB.3N
MS51KN/V1N?U?:\3N<YZ9AJUOPM;S'IC@O#*62D2%L8@GDI"AD2.#@^(48QXI
MW]CF<H&C_]TP\ZHR\PKP<N-1> 1>GO<HF,1$",KF]<0(-'&%\D8BG*AVB27M
MC*ST<<Y72$(_A]2HU[U^;@LV+)U5;^DH6#+MIP=((B9/B*>@6F+.3'(X8ALB
MB"-*?9"D<12L/#!]6' 48 >RQ1J%$@T<<9\HLC2*;$5(J1FSDIF-;48VB=#W
MY.E<H4!.P]R/S-R-H^ QF7W>40",[8E@&E$<;>YQ2Y!5W"$L')$.NYBDO>^8
M;L/MJ^@H^-GLWC@*[L#6\XX")9-SP@,?!PYL3;Q%!FN-B&(,V%V%I$"&$W$'
M1T'#S,]/=#>.@D?@Y7E' 0\J8B$]4B88T,>I0$9&C;")/,B(I=*^TL<Y6R$)
M_1R2"W(CH5RIS79:I_8T]IN4@HL0*3+-M2<A%W:$/]$I'7VRT0B#*:=-2L'J
M(U-[P5.@B6%48H:D8*!E4*.1L80B255TFF+O"-W8IF;3:+I"+LPF+K&>S-UX
M"AZ3V><]!28F;;3$B&CE$=>:(>O@1XT]H4GKE+!N4@H:;G_LC(*&V^^#VQ<R
M#6P,7D6%'$D.<88ULEX0$/*!,*:,HY$TW-YP>Y-SL,I</>]*8!HG*HA 4@O@
M:JZ O[F.R&,6N=38&*E74&%_#CD'^[W<'N4VQ3>;LBW-4;0K0!P3RB4WB6O"
MN1?862Y2M,)9 ';.<>-]67DP7RS;0K47/NMD3"2&. X:E#7'$>,8E#2ED_,)
MP)R23277YDA:<QRWP<"UQL#&2?68F+AP[H6E& WVR"@LP5AU%#D1*/(Z$<P4
MH92FID1!@XE/&1-ODO3SLT&Q2?JY _C-^^R,%%'[J! FD2).HD":6  _)I7S
MC!F?3_A*<O>DGP;R&LA;I8FO .(U_LQ'0+QY?Z87W ;/.(I!"<23Y\@ERU!T
M3 -]>^ZEJDU@O'@H<D75O6>1.-6Q@\&H[_B+"].FKC'KJ>U@L."A=Y;;!]VF
M]OFM8T3-*%=]E,\A@/!Z+G)P*Z:Z;H9U\XQ'TU&?@1K::)J7:9KS346'KVV_
M?P[K51JQ-/KE?>F7[Q=3[UEDQ!D5$6;>((XI1]H2A_*^.4*X-%K<=]6_1H6\
M'B>6SKJHZ@]_<3#\L963YAE-@M5J.R1>G_7[P"F-W+BW:K'[KX;C\/SQGP2N
M_1)($"E'Y.&#0UPZC@PA 1GO'$@4X2@/67"032'-^F1:C;KNPF#CY8#07#E[
MY7.P0*L4MGO(8%L5TZQYQJW"*77_[27.F0M]I\_!RKVOU6DTGUKS:?>'?L$Z
M[H9:P8%/>[VNKWYX-P&;1O&Y/\7GW8+BPR5LG:9@(F,N$5=*(Y?@+^FY8RP:
MDZQ_H(C,71GK3CK3?X99NFU?T+FWW0U >B^8+'!:S<[U_[.]T.\7YIN?,YYR
M-7"8;L>>#N*+T8>7(Q6CW2T<6&YZ>6+[A^WN:!W$Z<*XRUBJKU]6?>2-V=*"
M9;:M=9/ZQ5<WJ.=B2XF'Z7O/U*T>>_EW@C6#7:_!\NL-Z*Z^KHL]$^1.#K/5
MZXF\$WT\<;'?8F2S!:(5SP#M+=IWW\ESM*S=^S5"?FO>EWI\1J+@?SXH<4_!
M[XO7Y<)-,,]IX4OB8:5?3-(/?][:/UL&>#,8@J(]K!G@K6WW6R6.]5.QZ)'3
M%M9\"_-)ACL%6N[,.L]GK7."]"45J&]+N\_!';G;Z\;S%AA%7^.PE6 NS4G9
M)CWX*I^4M0(3FKQ+GG >K64V:NLBIR$8IFGQ2>'FI.PMO%+'\-Q/?YT<G'S\
MYV#_J'.P_V?^MPWOZQQ\^JVSM[-WO/O#B]T?;T_FO5(P!_'YU\_MS_MOC^!]
M1WL[^=_?8&Y_PW4?\2[=_;'WX^N/W4^?<_/&^9.R45-+%.-(19M;+42%=+0&
MB92XDU(JV.2-;6$V-;VO"HK-"8D& E=IXJL'@<U!V<>$Q(6#LA0;EYA'!+L(
MD$@(TA0^40V?%2/,<M4<E&TPL<'$E<#$9U3S[O$P<?[\++.,&0H:8M*PHIQP
M@9Q3 G[$AEB/$VQ^@XD-)C:8^*"8^(Q/TCX>]BV<I&78>^4T<EI9Q&$3D;4T
M(&&5ESH9E=C:F<A7.#G7R9?Y<>O#5NNP!T/JYB2FUF#,%==H.?"T\^<C=U%C
MB9F/CK/ G)$DLDBBE%[S&!J/W:K#T=[KQ1Z$$F0)U1(9D9NC1AURH5*-O&%<
M:FUS/Y2-;6+PII0WQ*.'4ZIN<-:E8<E']" UK'@35ISW%-E@+&R7!%N(2<2=
MCTC#_J*4_4?1::)L;B5VPV3.A@L?OKC7SV;#)UC<Z_'8<-XY(7$*2H>((HT,
M<2LC,B[+1A&5L0I;EW*UUVO7]FH8<&W%8&,@/P+_S1O(A#I,$P6&PP;^2KD+
MGV4")2$([+#F'J=:(U4W+ 70E,B_;K>]_FFO#X*FU>T-KV7Y/M/VGRQ(;@(Q
MR@4+\D$8F8Q-6$HI%%A6IC&)5QZ /BR8Q,0'(;%D2,8<L:5<(9U40LX;#HI!
M2BGFDU5RD]/[.EBU0O&'AKD?F;D;X_HAF'K>N-;&I^1X0HDHA[@/%AFO M*:
M\ZBD!:T^+-/J&WY>;7Z^B9G^LQFZ,=/OP-#S9CH53 1'':(F"F!H89'VPB"!
MM68J.:J%V-@6=R_!W?#R,Y+-C<7_"*P\;_%'+PV!S4/,>XTX3P8L?D^0-=HS
MJCG% =<*]WV%Q)O:?]?U!)R<Q+YOVT[KU)[&_JU< <^BNIP-.N0T'2I9=D<F
M2Q6HG-@%J@,&>=2X E8>F=J+T7%+-!/1(1-E1#PZ@AS1%CFK+1@-PJ3 2AM/
MKE>IN%Q3.G(]F;LYJ?&8S#[O(C!:2"]Q0-;FKCXL@$6!DT..IY! QZ0N^_V:
M3MP-MS=G$-:/VQ?.("3!E38,*:8#&!TR@;TA,3*.)1Y*U7'<<'O#[;?F]L:5
M\ A</>]*$"1@H[%%EGF'.&88V: T"@Y;1CE.)"</K)S"_AR2"NZM:'%S0JHY
M(36'X<+YQ(3FD6'!F<9.X*B"#]I;S9+"C?-EY;%\L9@(#L$1)0T2%AO$;0)4
MU]P@C ,Q$;MHB=O89EAN<KS8:G5%CTHUIT0;#%QK#&S251X"^^9]48$:SA.E
MR# 1$=>2(X>-0-%R11B0O:5\8YOH!O8:V'N"L'>3K)Z?C7M-5L\=<&_>*P?&
M.G'<4&1-"HB'9)#+9U(%_$QYA*T6>F-[,>W_QED]#>(UB+=*$U\!P&L<EH\
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M7XP^O!P9J^UN695RT\MZXVH!DQ%U3@*6%U9?UV!KS)86+.-M;>76+ZZA>*M
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MT@:>:BP",0[%&#V@O13(@4*&P"1,27FA:90/Y"B[!Z9:#T]: Z\-O*ZN1MW
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MQ4E/>$/IZFSHOWJP^/U*GZQW<P1VHTWUG;, OX;=K<GQWX4,8KO<&=H Q$/
MS;S5W<E/$ZS(1)!W> S.$R0&1N^='1Z!5.[W8Z="B^_PW-$8@!#L1012$&ST
M['#6K^ZNT:+='8!ND:\MTU4OLTBKL#M/L=-.3YK V.H06#^F#I $[&C7'L:9
M'7%9\,"?=G;IY9W[GL7),EE;"7U0'S(59L+,\O8"FKH(3T CZ@X C&I" 24C
M"^?N2%SUVX.O\'0@Z7P'O&96AHVUF+'@7'K#1 $J8^B%V+D6G1&ZT@KEJ^5:
M8;W&(:_YE'S.Z. [L#6@$53  8L!WV8YT(^P1956T>M.*R!%VA<M-"]AI5G
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MVCF+M8VY;BZ1L]D;/S]'[O(<$*IL+#$3G?B#N\4/5"A^#5%4RYJ=U<;YI^@
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M,%$@DY>ED=8;V"3X*9\EU:IJM<KV%B.';/463U0H;14BFW,T\+LRP6<HO<.
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M4@4B4!34 M_G&-FBP$AY65CI(PN$KFVJ>Q<97B5%?=GZ^*CDO=;'>^KC57)
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MKWBKP^A)WVT!7RHFE!=<1ZX(YTY@L.]$#$980WRJ-W6\>[>#[ADSZV H77^
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MKU_H?ZX/Z=ZG(YAA(1G'2 7&$)=!(=@N+9*.D!2YTGD3KO7%,89WO>),'^?
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M;CNU'[9Y48C;K4[ /V.G6+IG$)$_;6>_4[1-+GISQIM;OUIIV+G:?7?$N18
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M8N_C1_N7/<\.]]+-\KE/*CZT.Q\N>A>=N--G$.OM=>D?S[_>A6OOG<#W#S[
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M9F\S64MO,[G5VTSF>IO'/<QDEH=Y^')18+M[X;KQ?R_*.LKV/'N>;[PBDQ5
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M0,5YOJ*<T!ST?Y,CZK$X'C0(BM\: $^2<X4#4R;PP)@&/-%)8&P]J )F3QD
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M'!%)6A:YBT!"N9#1P3\KJ*$A1D>LKT1A643AX-.13TYZ;R42!'9N+C$&EJ?
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M_G\TBTJSKVQ7.,1[)Z=',F!GM8@YI I[ 0@N<B%$)"AQB7I-7&Z;%V'O/,^
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MZ99[PT9IX5Z@/&,RE@YW9\_%@K@K9<32Q:@%Y9P+1ZA)R445+'=2S@XZ/RT
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M,-+"&)2"5,9A!Z:V+W;;33I7B HORB)R]$!SOI*C99.CTZ/@*'%82V193B+
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MI$X(KQ/QX'C>0@I8N8$K-_!3LN3[86&5T;,6.#A!C5,PAA <<W5KBKAE%!D
M/V0$(*!B7,O$-K8,WZ0/IL;KX?A=^;R<>]G(55[.VB+"9%Z.SDE:#/B0$T$C
M[@$,K(P)1>,(U0DKFWN\DDVFER$OYQ6DWJQG=LW]2$B57;/&0#1!30R+-!JA
MD.(NGS2/%( (+#8N%8Y.T4"5W=BBDM>I>:STFBJ#ILJ@>2R74P3T<DQ'(KWG
MF"2-:;1:V<2DYG"#5>F26+F>'H)KAU.N)QP((48:I&/*111R1TX0#!22$-0G
M1JC V?5$M:F+A_?C7KZ(1!6&77,'TP.1K\JA61_LFXS$8A6D3A3QB'EVNQMD
M"<&(:LRC#)RJ;%P:O:D?S.B6#_?6YAJO(1);I="L%\.M4FB>"N7]%,-UD5(G
M$D&^J(MA#49:6H88)<8Z YL !<N=$UK'>+I06)5"LTR04,5.5Y3:5BDT3PQZ
M$]26,Y9,(!Z!5"C$=8C(1"\1T5)2[X-BD9?IX897H=2EO<9K\-Y6.31K1V^K
M')HG!/OOT[7$DV,R J^U@@C$I11("QF0,M+J*%Q2N?(;X[1.)*MR:)8:#2OG
M[8HRW"J'YBD1[VJR+ :8]-X&E'@"FUYHBC2-8--+3+'EVC,O@-X2MFFJ))KE
MO<9K<-W^,HF&/$(23;\M, .Y#.V+W&1X\&"OO.N.9,(HPT(BCN-(;<*2: $(
M$1CE417GNEZ6*U>)-D^V;YQ.,66->2!2,:2!5" >F$.:>(%\BA;^SSAQ^3AI
M7?)\VN&QJHL\GI)6#N7*H?RD[77NA9=5,LY:8.4$Q]:<)D*U0 Y3!1R;,^2"
M3$@SZ8*A23'--[8,J:HPK4LRSKV,[2H99VT183(9QSE!#9,*2>P!$0+(@<$Q
M($,B=<YY$TFN.;PI>96,LX1D9!EPYTZM;NY%0JIDG#4&HLD"D=:RP(E!*N5Z
M"3J &:>31,X'*QVG/F@/0&1XG; ''UE_[&2<WWL6;+]A<^E)H(2_LS8T6A>%
MN!8=LTN5W?IOU_G]!DJ'[;0+$>*686:=8IP);GG2"<9+M5781RE9/")$;,QH
MPGUF.]\;K=+TU./X>'+1[372U9,#QE1;;IH!@Y#-VFUDA:KD0HR6>6RXC5HK
MHA0LK,3 58QT=R KVXVN;[:[%YVXGT8AXG-L@FX#:G1[W2FVTCV (?S1;/O3
M%U?>+WWE/3\[_+K+#T]V\+>OAY>[7^&_A7*!XGY\__/P^H_3/?JML7OV^6SW
M7P9_^\\Q]F=_M^Q7<[%_]NWX\/JXL7ORN?GMY-W/PQ.XW[87H)BGAP<?3G8_
M?F+?SG:NOGT\O/S/]2'>/7A_I&,@*5>M$L'GZJP,(Q-$1(F 'J8HG2"T1'20
M82!I&0,5CCRG<5.011X2,]8H1[&CG@;#M-JH18#$<U@;@%S@\G_U8'Y1,>VU
MT969RRL*L9Y0G7)Y?GWK\:$2;AUC2D8<!$_4&0'Z1*1TN5DD:-3&//61SZP]
MQ17?-'IP.W\'?7I_=MYL7\58Z^]AM;QE]2=U$E'Z@YW[-+.0Z&E5]2]_',-%
M$Q1UMOE0",S@K-G@P=YUNQ=GY6L'&7-?M^;N'('U;JS'$@7%*.+<.61YY(@!
MT=))9 W1D^H@$J.:$IN")IPGX;0%O=!1.\&YSYH^KKFWRT^I((U6@'5[PV3!
MYY^9C1;*<' <:\DV.K4?F;?EJ$P<J ?PMUIH=*+OM3LP+)"66KNO,9>V"T_;
M PI71'-Z-:"%M0!_Y M\SQZHVD47.$+Q^A]-8!((Y+;=A'&7EZB=@V[D#YRU
M0VS6+AN]X^*SEWV#MF9+B[9F;R2WYF*S?;FYF)(6%&-(:4KO,LQMTYYWXYO!
M+V]#HWO>M%=O&JUBAHHOO>TC6M]9+<ZG*$UQP_+MMY>-T#O.#'\3ERR_'\SK
MW[G_]F;QU@31*M_3:I-B/O=MO$GFOG?;90G>%$;>Z;*_B$$NX""ZQ0_D0=YC
MYWD,,OTK>E6LU&&TG=I[4,108/EH4'*,&3_>]-RYW-AR3UQNL[K(#,TP*%+"
MR2\:Q'Y1Z_W]SW, 1  H6(RSVF^-5BV[T;I31\<6>?[7T7@<*TN3DY$ER7CT
MQ 2F?*)!Z< B#_&NC<?OX\<8QD)&B-!@);.#E"RO@_1^!&GHE_CX=_.0?B)P
MM=/= X]WMS_QP[-_G\"]8%Q[QWM?/Y_"M<CAM%\"[O/WR;?MOT_VSC[]W+O^
M=+FW?=PX/-N#Y_KCY)"^)W -(%M_'\]JRJ8]5TE9@63P&'%85>0L=CF"0A2G
M#BR+M+$E-\FM_M$[0NY*X<:/-IC4C6:C=W6'TR[W.Y:R#! P[=YL]4]U/!P4
M;ER=LSV=]XFZW(80?P^7[#-0W*'/$M$*'.X #M-=;2PEP06B$74YV]P3@9P
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MS])P-.4(2FIV\\3UL37H#K3NYG[%L9N1D7D *#!UX+EA4GTW/W2C5^^?HRE
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MC&=RGI%I79,K=$WR588IW;%O,A14I(&24>3%7(&I)9E/)"ADBB1>DJ;6-_F
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M5+]TNOJ\QP4>YD(O.ES_VGE.EWB7R&!T<WT<[4*#?35*U*^SQ^HT:1HO\<@
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MY'SX:,G6>FTWG6IM/L0GOPEJ\R%:MJW9MLZ'^-M ('%>WM24O9S'O$JD':>
M+TKG!#\L2B<KBS.G#\.$P<'ZWW-1]O7=I8*/\IZ3B>]P89%9XK;$;8E[K5%]
MS3J_.<1M\R9N)G'/\4W7>1/WB[YR/@[@01@./$W8P[2)Q-3&HSKIDC".[!;2
M-_+U%4;T-LQ\5I2]7#C_4J+;[VR+4CGO"^B=[F;+J4>Y<G1\ KRSH72\O?GL
M(]!_CFF>+AULL&5KZ].V?+VQ214WQ*?M_X]EZXUDZSEF=IU2\=W9>;>XU 3]
M0?5A3:(Y_(?Z#N;O7MOY V9WF(2B>]EHL_0J@IZXV?*JM8(WG55M9L0G;P4'
MEE@ML=;$&EQ!K#OB>RZ=K;;S9U'.6,1U;9\KC_-,/,"2JR7732?7C<V7N#GD
M&EIRM>1:DVMX%;FJLLS34^=P,#1:]P2\JSDG>V5LUOC-EE<MKVXZKVYLTL3-
MX=7(\JKEU9I7HRMX=4_T@3 OG.VV\YLH2_A\)A'%]5[AV8=8EK4LN^DL:U,E
M/GF6M:D2-XID_8#[L4="C[(PCE[F91][!PP;'Q/>9/PORC.=]Z(C>B?##!AE
MT:UCG6$.12\=CYT"%DZ4H[),I9APQ1F<%X9ETVY1X1XM/ /_+."*TFZ[FK7G
M?MI4=/WO?Y# >PW2Z((0;FX^WM7"[YIU?A1H:;Q?X1,E6+:ZG%Z68-> 8*^P
M8EF=.?$@RW*@3U,:]OGA(.\KQ_>\%Y-E8N-;5HFUW&KMU@VW6U>(N6O6^8VQ
M6YE-.K69M#I[L(>1L8,]2(M_B5)3Y!*'?)HS/O6Y'G%6@+$ZAVGQHW-55D6O
M,@=V>_V\G\. =>$J>&)M[AZF'24')FND.8);E'!#OR_PB]%!G\IY9V;$V3*/
M6W DR'*Y/?9CV7QCE;G-./;#;"JKC:+RH0N:^&$0C%S0C!Z'P1P+N0F5NJSI
M.KS*)/XL9!=6S(?\+-?':$79[P%O=_)SRZ76YVQ]SJO%VS7K?.U9"Y^VP]GF
MJMI$.HT\$I. C]$I.XZO/$0KROP,?_;SB3KN)E@JNO(([>A6RZJ652VKKA9V
MUZSS-:L:?W/T5%G5)I*RK(JLRH^)7V>2>I^7(/<35=S'+59-I_[U;/J7*+OX
M[WC.QNWB#*;YTK*K95?+KJN%WS7K_&:PZ^IRD%AV71]VC3W/C^DXN_K'Q.-D
MH1.XV1#AU[/J=&S42D*C[*43ESXA@%I='@<+4.L#4)%'?>Z-[5&1XR9_SE$G
M+V]>X:Q5 YFH,$2D@;,Z5BMJ#0%M3EFSEB/&D\M"=\_K'K?TR_+/G<M^Y\PY
M4FFG!P-_DJO*%-;&.W=45UQ@)MJQ^ZQU\29R_]A4Q=(:%PVX;WQ\"8V?MG6Q
MNF01EKS7@+S-KVA=>![U#'E3M#9BYOW0+&XH7!^O,'MC2CF'_2(]'<6,?NR*
MWGCN=^>]2LJ!*"\=:C+#QZV)A.T9'IH4#<]7EENMY\Z2ZVK!=\TZ/TH_8M3[
M^*G2Z^K$V]+K8Z!7>F6RGO+4V1&7M1T\.J^DUXAW96QG<Z_E5LNMEEM7B[QK
MUOF-X=88I#T,7UN&M0P[QK!U#=(=]5UUBW--L=#;KDCJ5HP,T<F3C7]"#[N7
MSH<\P[.*N>JE2F^,M9IO=M&<A<OK\Q/7>98M$5LBMD2,,+VIG=\4(N8VC<_C
MIN#J5AQ,L>DD]%^J'RH=8&Z[5"?%RWLIM*JL#=WFNR9C7MY;D#'O8]'-TTO+
MFI8U+6NN%%/7K//C!Q&I]U0ITZ;HV5C*I"QX*0C!3=$BTP^_*/,^S)XPE/EE
M[*.Q]#P3QNIBLU-?]'O[8]O9*\H3F-LZT"HWUJQQ%M??]$4/(ZC^6YR=OP96
M;IL+,-/.>:DJ>*E YJZ:#+65YNJN,VRS*BNG)\Z:G#QYKS69I@^CMG 16UO8
M!E-94E\IZJ]9YVM H.1IL[K-UK.1K$ZP[>'0&4TQP0#1SFA>[_?N#;K]W#U2
M/=RO-8<W7N[V)*R),@=&-><X:H9O=GFOX?@_@&F[7?$2#W&H$L@<%(6^9O#Q
M^FDU!1-+P=:PMAR\6HQ>L\YCEC#?H,%3Y5]F=X0?.0MGF#= -&D#^H4<;N..
MYQ40XWD%I-WI??BUM[GFK255!-Y-[?SHY(.A5OI4J95;:GWDU I-*WIR'K<:
M:CW4WUMN73.$L=RZX=RZL>E]EN#6EWV1=%4##?"C:6+]($[;H0\O.R^J7*.B
M/I*8?U>O+W+9[]0O&K\Q*0 9SUYYHUM$4A7=07_V%C,H;_XW*5].8]38STXY
M&OD3Y2:E$J>NR&"@7XGNA;BLGKV<:,!9WG.G6K^HK1-L4PW.SF"P%D_5[;B'
M>-?-%7U8<OS5!M;L^(^<"^8QD82,,Y\+GD49K!0:B=!+51 P=1P^>W.$XM94
M_<2SK'/XJ1%%6(#ZZJ%@E?!*5[/H>:5>-;^\EGEUWA67K_*>;K6^Z35,Y0D(
M0BV-* 33JQ([9+ZNY2..VZ$7HHC4&F?]XEIZVEIZ&F"8^"YL!W&X\%NO36[Y
MG<_8K>Z\JJW<;P<A?R2-]=O4>RQMC=N!=[NGKKZM03L.'LNX$M[VX^4>^T3,
M14I6F#;$VHGWL1%Z5X4]*:GS27S(JS[RYN$@J7*9BS(W<46C8ZS6U+.U.3>Y
MFM=*47/-^KX9I3DIL[SXB'EQ&-U#J([NH4UQ3; %,5C6%+:4ZAQS(L&?AMI4
MB:6V!DDW3YVM-"T&/1W7^SXOSVS&59MQ]19,"3SQW_^(*.5V,^;I@ EK%.5M
M'.4,QEGOL@"D?"SS7IJ?BZXS.DMG(@A+S,A6#839JOD\Z$+K"1,NX<_%"[VO
M0GQ9_Z4;8.KPCLX#O/MA3NP!,&GT C6>Z[QN6[(XUR4"QYX/]^DF,8\V!P(.
M19F(GJK<@Q]XCJ!^"O4\:K-)6VR[';91BVU/#]OHM=CV/N\)^!5^L]AF+WV2
MV$:MWO8$L8W>1F]#_%H6^TCD?&D?MK?;0Y0BS/>NA;+8"RR4K=NE3P3*,$OT
M[O[A&L#8 W3^WV\_?W!V>U5?9RW9*=(!1L'=SUC82Y_J\CG<_M<&+Y\C\:/H
M%6>70(U]U:N0KP[3CCH3=CW9]72K];2]]<&NI_'UM"VZZ:!KM-$/>>\TP1/&
M=G79U76;U;7S[KU=7>.K:T=E>2^WB\LNKE]?7!^VWMK%-;ZX/HA$=>VZLNOJ
MU];5Q\_O[+H:7U<?ATG=+&T]Y/*:.;1TQU+B3TE)..= S+,WQ_?\OTFW\MBI
MI7I@7%PSKUC0+*1<1TV]<O&3E:\;:I+D3.S.K+P%KR='AK1]'(FCCG+2\<V%
MRA']OD@[IE3N.[,_XF!84 M_4KV[@+M-3K\C^HY(T^(,NG()?^:5L]7K#437
M^:S.B[+O !"\Q^)\>,BTY6 -7(FG>J63#<I>7G7J\KV]HN]D>1?^NLC[G>FM
M5KQBN-VZ79R=Y97&&WTJ&!Z)=_<+)\'DSTV)77A4<NF4*E,EGA&&;^ *;"2\
M!N/CBNRJ_%=S=WQ'&[ULO#AARRF6WQP>WG/149C3TCD34D'+LP+Z <_1Y_;T
MTS#)EME@N690\Q)@]QQW9;[K&["3)ZJG,VF.Q@/'JPM-&H@3K$,,* W"(3%;
M=C5(._6HM&?6U!U+Z5)GZ9Z]^1^33FKVYX,MG6=O=GL2UP<\#YX$@U@?6>_I
M742<.EP%0(2B7Y27SCF,];J,IDFLL(9#NEWTLAQ!&;<F^Z42?3VH'5@G"2:H
M*]5_!JJJ"WPZ*/H:G9I%4>_<MAU ,- SAM]WQ'=E'E"<Y?U^#3&C3S70Z$.U
MB\:D4N<",:1[>1,\FIWO9CS7Y[ P/CN7__?L^L.H) B>O;F_(\;K>XKXP=MR
M;P>&FQ[.G-.X:W5H9@3F:XB'N[_M;QU]^?SN<.'*J8\I@ZD#]TR:1-\&%>@L
MEQ/*W7WH=DNB['B,!.(%@E=>FH+$^F":B9LP $,8,@;QG\L7PR"*FV@/4P4:
M$3'E - J%8-*9\L&>*R5!:,853!B\ 4H 7D?T;4CNADJ2/@@+7GF@I9)M#U
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M'<][QB?#2,BXU);I,D])ZY8JIZ+?GN0OPR?P!IWX2\Z7;W!MKQ)32^?D5R#
MGV$%Y0>P![! X?7UF5F)&4':H,S2-8?2N5YND0&R)2KL?QCUU1@C,V@D)'U4
M[#YFF._*.?WB'>F,P?/^_,/_ 5!+ P04    " !H0%Q4NHKDL)TB   (5@$
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MW0K>D%1L?_XT%%5K%IU[TK=!18D>ZP7M7)AZO,<%%J+A3&0?(6?/M>RK>>X
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M6TU-U-.Y2JSVEI,UI,R]DCPI+_9"O6[PGS ?&^BW1=+ AHMX3=]=+H*CUI@
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M$^HZ/ K>4Q5XB Q<1WL-F/?K>(3??H7)GSA[>3K*YZ@DY,C)N* M'NJ%675
MO O,>8[<>@U.MRD16(YG]_&MW>ETW+M"&MQ@7CH6M1QL_L:H.HD\2LF4MX5I
M-(EYS3-+7,OLD@[1=\H&7ILBM[$\;@MJ2]DWN(6YCN@%S/#C>#+\%URIF^V"
ML*E]=#_&_5A!VVKS3G+TIHH&)TT'I+8D%TRT#(N13 LA6"PB,BFMXT8!ESH^
M*K+<8Z_LGBOK:* !1WY___?:Q714,;X83SZ-)W-P\TC;1QS-NZ=?[*SGG8%
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M3'FE<RE)\-!H1-)]T!YZZL Z#+PU*J)7O;489K@*X  +EPY0,%,MZCH0C+Q
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M% WM6\%=";2E=O9$),U!Z_KRV&!$?9<,FV>^V:1S]LX&$=M,YMX;@>Z+BQX
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M:=J\ M#6UX3T06_*BPF2)%]"JF-:OOT*7X<GIR?/QY/)^ L9:R_@$_W-[-N
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M:NAG!N036><\NFZIT8>AQCNJY_K5XCIBZUE[B_S%<SHE&2T8R[@T4+=W.BI
MTT8?BO8J2Z03HS?]77OTCFOC-A7^N _)]7PP_DJBN@3BN2ZV),7(PBM,T[%
MRW&"!?K*\9I6UBW9IIL*KS[Z :IP8\DUL&&OYQ7/]Y84?0A"9!:TJ3V/<J #
M7],R!;%,A*QS;I,X=1O+0[=^>I)R@P2IZX@6-GL73$U#%LM0[2=HL:W&[B3
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MNGAHZ2%K:??^RN=UI+S+$M<NN)YVY?-:FNM:Z[J)V'=)BV(-!I\S,QX-TX#
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M@"L29)2121,LD0A*[.B5=W[DTW+1VVCB0;DL%\2^?S*8YRX$6S(#$P.KLF4
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MQ?H_[HN2RI#CG@G4*B0)OO:[285'^M_HX+M-*?KQZR^/@<6@\F_0:FA#2XT
M7E>_>Q6<*!J,]0:4EA:<J,7P7";,7OG8Z&+< S+>HP_'::3!;?E;8FY::70@
MIVG@8(>@$_K\QZEHG[)[R+>!O?&(+#2![!U#^YT0A.?$("J50#JM,604"AMV
M9&JM[BY.<AMM'R#6P:<75EHP_RW,K\+RSRK^[8$4>(R>I50'04ABT')POM#>
MI32GLT@+F;I=S=_WAO&M@5YR7PPMM*&[:VR)^AGC<H>JF(UW27$0UA?R=96
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MS_G]P7-ZQ,%'H6N8$/?X(MR)7O,B63%%.BV%TD$$HSTS(;L<.-<QS4:AL&<
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M*'.GE+2OW(8NV-]>&I]_^Q7#BO:/^;KZEF=+##.'DDXN4;O[&"++:]H.3=:
M')W1$EW";NVN]K_C1]#I0!)LD1)^R.LV:J!I7_2&@0NR$D;,^E0RV&(LUZEX
M'LP8&]&X8UR&U/I@XIU*_'"7D9NN]\B,,EJ07%PIH#+JVD L@"S&9:EY$+'-
M[9(]!)TL;M=;T2\@YQB!C[!?T)]M+>,NA+6=BK*/M-/$R@91X,N@Z"']4>$1
MJ[.KD@"IO 6%4D!,Q8(HAO$@8[&L32N^D6'Q0DAK7%0<(O3V:+BITRZ.E:@-
M$ V.=L5Z0\K+0'XOBFBTT^3UCH&$DW57'T9=SX/@"%D/7!/_>;G(5VG]:;FM
M KENU1"E52%FTDXR9.TR!9XG!*N-HQ.16=/-7.A4&O\4!:_>/AA$M .VFKI'
MS^ILGF_Z'6T1W86HP9O+["5G_%8S_37U6.T#B7G@+B;[B<-DR*LM!K*HLSN*
MCQ",U: S(Q?*.-2J4TYKBKI_IC_-2*H_1+I#=P7<4G6/J/\]7_SW;]LO/BPR
M>BF4O EP1YES8'0".4XF3LQU? OMGAP+>@S>B;1C >Z)%1WTVG%;H@RDI\4H
M0AXZ3MB-4GO3]%U[X>JX6V%U!*63@B#I@W*8N$LAJ-U9K;W@8-\4'(X1\J%)
MI>VWZX<85OB?__'_4$L#!!0    ( &A 7%3\G903L_,! &]1 @ 4    :7)T
M8RTR,#(Q,3(S,5]G,2YJ<&?LO =44]VZ-KJ0CBB@@ A"E"X(*%5J!*2+"$AO
M*B!-B/10HR"]"0@(2)-> M*E=Y FO?>FTA-*""0D-W[[G'//WF>?__[_'N>.
M?>X]WTR>,<+(6BOS7?.=[_L\\YT+_#1^&:!55U93!HB(B(#WA!> 7P'8E:!V
M+P% 4Q/@ P" @O#=%8"8\(F(\/JCX>< 1> "$='O][\T8E+BWXV,A(28E)R,
MG/PW*"@O4E)04%&0DU-=HJ*Z2$UHY)27:2Y17_[]^?=%?I_^^RS"FYJ"G(+Z
M_[CA6P$Z"A(-,G-B(G;@ AT1,1T1OA, $?I*2O1' _ZE$5T@)B$E(W2)ZB+A
M@&I:0O>)B2\0.DM*0D+XUH_P/4!"1WKEUCUYLJO:S\G9G>F%W\9F47 HE+<Q
MZ(P@.$5>N 104C%>8[K.S,7-PWN;3U1,7.*^I)3B0R5E%54U==VG>OH&AD;&
MEE;6+VUL[>Q=W=P]/*%>WH'O@H)#0L/"X^(_)"0F?4Q.^9R=DYN77U!85%%9
M55U3^[6NOKVCLZN[YUMOW^C8^,3DU/3,[,KJVOK&CY^_-K>0!X='QZ@3].G9
M;[N( &*B?VU_URXZ@ET7"&- 0O[;+J(+GK\/H",AO76/[(J\-OESYZOLPF\I
MZ!5BL\K;*#E$=! ,+UQ&J!@Y15>XD+]-^\.R_SW# OXAR_[-L/_;KEF FIB(
M,'C$=  8.,=^#N<%_L2?^!-_XD_\B3_Q)_Z_A9^-9LC+<VTX;L1>DJA(OT28
M8/KDM4>.H3F:MP1V@WK8JHB&1Y3H >T_\=\*!A^Q$#P05X>HQ75< YUI<'F[
M>\5TXX%3_HR+L)U[SG@@IT)/Q<7*VYU>6^?)/[NW_P- U.OK."P60^LKTVA!
MLVAJM*W_*BGQ)0__3YE7+'VOW W:=*1N3"P%+=$Z^O.BKVE-[@I'>('V7X"]
M%[4[NA>W6F/:ZZF02[2/P"_+PBH<0*YM<H)?B;6IY,SX3K]>Q:CP*/<H_RAT
MR!)2<9TNR.MA'PCOZ^OKN!GX7DDJ)_/W3"X3J4 *G'1FS!+!C[;[0WVEES_.
M"$4^UI?>WC2XP(T[Z [A]'@A2VJ.7D/*_6Q/K/&^'% ^CV[H?-B6_T#K+ @G
M'7+T\+K<NN5D33.#KT0U6F\YPHQM8M8C1GA^ON6LOVXNF<MROAP76*W?M[ZW
MX_9!6TE-7HG^"='?@[DEL@6G_K-]"4-M"MN\D[ Y\0/,@@?62WT%\,"7KAY<
M7*\>:V_LYOC_ZB*FL![6J\:3<FSSO2N8X@A'&\U8H5U]'GY48NC>W1JIXLA2
MJ2M*'O1/R&@Z(" CK"9"+JW4R/?+TD/6;)X?03TT+#[%%\!4BV5L$X+74';H
M+*Y#__TV.>$&D&W/PJ@[&1Y(3!_I7QH)]F]NCN9\TJ=X^SJ)9U[GQRW>S^_;
MP_F'_"6QCQJ'V2L14R$>0ZO[5ZY>BK."9:D$-F^<,Y"I'M_?'KSX9+HX&YV"
M6;7IF7N;OVBJM-)"VHTZD=-=E54X4VI3G$GDE)6^AV+83!C"WD5[6B,JVSR\
MQ:(W&><94UZ"&NL2ZKPL)I(K8.=ZP[HO8CX2?"B87EL)^!/_)WC:*+\J#:+:
MO&JQ99"($M??KE?+?QT:N 7KS;Q8O68\< \WUD(/TN2KE2-%1.:8T\[$Z#?/
MO67B*'IX68W5<&P/J[LJ-*MI/-;AZ$X8OOZ#(;AJD. QY_?K N\/PKV]0FK5
MC_;)H!*::-A*L1F'6G7T]^Y!<15F7$[Z>KJ:K*9^YYZ7>=@JJPK*;#Q)!4D]
MQ1SR]N7K^I<5'3Z;1IL0UVB/R^'G]Z98FZ+[4*S*H](17I;IE!^$U5C(#,BS
M2%XK<1U'2J5]2CRYV^4,$?X0)TDO?%\V5(;.W'ZILKKGG6!.:NLB][B,T(VH
MIJJ32',[3,-NV'==W(7V*";[&EF%KY ("Q:!9K:/1X-R"]5##/8@@>@$)U>.
M>*P+':[TWGAY#ZML!6BEK!-">RM0%WD,CRI^_5-M5)\EA&U46GRIX#K#F*\$
M6C(3>R?8,L]$>M'LQH*%Z;>7]?7@W6_S&9FMJ.R'S)6#QQ8SM29UB/E%[B0=
MD[*P7F>V7(;1C6>1/9^,;@[1)G!Y;3W6]+9IAX4E9C!@6<D*G> 0J?* @U'Y
ML%<_S=EX6.7)#TG8CL<,4M&8%65X#CK/@A'*MCK;;_J1J,#0U-FFI.AH*:9.
M\/X5FIZZ;+_VR>FC</Y0M -R2!-Y?I1B-B#RRY^K&K0II82Z CT?JPKU#C9%
M;IHU/>XR7_E_-0 I/4&"PMSP (7MH3US[D935,+7!<ZQKP\M.D]06PY]I03/
M \]:LXTI8@R"?6GNSLG!V>F;)G3!PG.%/^Y_6_-:CPZL%GVWKE)DA\(#U>#.
M7@&;**=&TA4):,ZMH:1BBX39!P0WI%R'T6'35O;I[2TJN7-20&$_OS8C3".O
MJD_=<'*484L\X70C_MP[=@,$>8J(>5>%!RZ@7<;41N&6E5\JY6]HW_PEJU4H
MJR83;R!V26I)OR)Q=HO)R?&G3IP2'[D*>3EYP.U#MU^"YDTJQF9=,,<;PVHW
MAONRXAX^ZUL^NAE-4<C?CP=6TH5DKKMRII,AE;-6/EIQ1:>)OL!HD9]_G-\
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M!]1?EGW^?SY$EX9P!#,>.#Y+PL4:)F'U")-!U$^1D.Z_IX)8?97QP(>?6$*
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MPA$CZ@+Y#G!=3>Z4F9SCZ?#W/U0Z+:J2=IP1)C@JQ>7BH<@SK<XTGX<C[@*
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M"T+W.N)/%(@#TU,=WA*.%3$9A/L/^@LADV9^5H_Z<_K*3V%ULWOX=L'/OS9
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M_]<]%LCPPY\#G8!D>=C8;-L,LG793(S>$/R!?-'*QC6T?UVS;N8@\KU:#]P
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MQ<TX3?YXF6([O_&NY/NC^0/JU- =)2HUY8X/)@E#LN>YC58$;YSJZ@>Q*C?
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MN^]UF:&C$-D=>(#1[:N C'R>8H&*@U"&$V;Q-CRG6T*%G<'MU17A'*L;NJ@
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M(4T42Y(,-/0HG#^E<$@LKR#3N'XAJ-W2ENJ7 6;2N%"5T5%';H)D'#H?8V\
M89=::Q<'HEKXJ&80ZJERY0A:E,;$S AD*GOORY?7/[F2"#KD/H,R7ZX3QG2L
MC9+HXL_6X"R0NKV!(-Z)(R$?,U.-B6H7L F3L+R@.G>S&>X&X&GG&Y\;%[PA
M/]X <-@XH7#<" #U*431*=!VLCH$\4[2K4D>! TR7=BV**9$;2CNM=Q5=&%5
MT;*'FN /UMA"/C)G1<8T'DBK1ENDHV4.16AY6XVZA;A>*OEND))O?)Q]<4&3
MNU)'W\>%E&?X+@>;):Q8:=J.;+AZAS/ 1_KX6-M[^=BN52M7;Z73^K,KV'M]
MMA(O9?=&*FFF>1D]R^>33MYY"DD9OQ3/0M21F-(UTB=R;[!'O,@>]LHA%>7+
M(67<O+X'#?A]BT4PV>[SIC"Z8MJ:[++ADF'< HQC:9SJ;\5&;EP=%[\,-VLH
M(GN=/H'>-*-7GF1:$D8G'1:1X5KN[/?<-](O@+7B;J) M^23;D'QC(P\?7V%
MN"F%.O!@K/$9.)9RIXTM^NBH1LX85HY:8.%UUD]3;BRCS+1['\.O;OY(Y5TH
M.8 SOWX"C<L[2RRNS,&78F7?XI76"*J=*GUXLI90\U1N(1LK'AXL".@CF16!
MC>V0U%]B']CZ$U$$_>9T>(IU\".MU5%0G^$RV^3/&6O=+)1/WLL'9%&VL#1R
M$K=!U;?X$Q J8S5^+*23R+$M"[\P8#(PE748 50J<^+=G=47+EOP3)8>?DC1
M./N#^&XY(=7O.+=I)/_.MS,MVI/$_N8V?-BZ IU4<CE4 WMO,$/0I-N;1=D[
M4/1ENLS@G[AXSNK^BG-[(6X"#M\X"WAO8BSJK!?*A&UJ+5=#@?I%*52+=VN/
M!)W)OUI=O*$GSD2%]_[Z%"SQ>4PI?+BX#^44R*3LG['?5>ED+HU)KUPG>[E[
MK 8U*Q\-+#'5$J2IGYRE,A7@D#'[$_HNH9I?#FN>K7?J*R*RNZ9,H_?X?]SO
MWI /:XJ^SL:D:G]/.9Y]-P5O=,ZOW?GGFTV4[Q\H,NA9]BDD_+4=3Q2 ?WC'
MW'YUC,3\>N+C#2"^4>O= *O0^.PK+-ER6+&) ZHH7<RHN%;_)%,';<SMTG5$
M(#+QE=1>WMX#+'U A!8-_I<?Y2/L"M2L-C09=SML&-4((&R]X&D\)OGR^BVA
M*W^<F$V/C6N77\S$4[,WQ;H+KW83Z:&O)J[9\'3K_1]/QXIV?'6J!T9&&>R:
MWX5$O%_T?$A (#?9./98)!P=2*'IJO"^S=53O9!>"G=QL(]HR7KSZ_R<P!55
M2B2D".>Y 81&X0W(0#@%["MUCS+D50:AE^K&LCI]UJL**[,B_]@(/F<;&X(I
M @,YTY)%J#!^%&/?]\^\%LT@N?3JW70XVMPI=>G%*J/WL<"/"3&1BE7Q"&Y^
M@L<#(N^GKU3Y)0]VSO/FE:$C&/@:KAH+ZP-1-6II(\UEFO.UL';-SD7"Z7!A
MQ$>G5^YK,N\NNA^L<2^&*.I\M9?),FA&FU+,5ZYM#XPDTD-23@881Y=C_H6W
MFZ5-'%IVM$8\Y* +^ZOQS6[(UNPBX]G&),[RX/G<OYG6+FJH[B24'TO2)\_8
MIEDR)6>,^V8S/LC(<R'WTE@Z9S-(3RS8,U"P6Z4:#8_/>XXMGOIGWZ]9*4QA
MUO;[],^E+%I&,CO@=;- ^SSIT+'&ON:6HJ$S.P'#SR2^:.!*U T \!6;Z8!0
MXI;G:D2D+&^2QA7,%:AOO?:-9GP:I\%,Q/=X@'6LZ^QK1S'NNE$^KRJ1&;^N
MB7=>(WME/G.8CE2?L'2.K8Q0\7A$7DK\4"$8>(++Q%+WFW/B]=>.(BFJ0*+Q
M8]%,?8PEA33[&9K.=J]/S"*)W!V%"4'2>K,$.5F[7:O?KIDC3:\2+ATF1@/I
M<6YY?W5C \HY'M6%?K-!J7[)%^-A$E CC M15WW_Y:HDOG!!_U/,8V_+9$V0
M[*4KYNVW-:V -:)/" 7T&+TC7=91E BZH\W5Q+FR]=OU6$O:NKC&3^W%<Z^D
M^ @ I<#?_@-.,L%^$[8P5^!1-"-VXK1/XL\_X$7U:?L&AP@<>#^96?3';MD'
M-X[$T>:PS\_&/A9TRJ:BB>(:0>&X-B[G9?;?9V02Z"5X!&=;"M9-%%WGP9SW
M_KB<7^RN7JMLR!VOEE#M,J7"Y4N*JQ(YM@+'94XL;VD1?D1SFO%XP61JH\O(
MOI'RN1:3FB:'O/-]?0XU),'=[%(+?9& 8MKCL9"C1OB=O>>$*Y1 <+0\"_8U
MZK/.\NZH%^Z(=+=.G7><F+->&<R<G68ME%R7@D@A!T.%\'Z54,OQ(&XGD]($
M*-A9*AN]Y#:FKBEL;@HY[8_P?=B;OPQ0?<BK\X28AG3C/P,K*'*2-G$M_[%H
M])F9T[3WE<'(!1W&N*'9]_J]8>0/=;DA)CXH3'YI$?JCKQ':5^S<R?/]ZDLG
MVZ5Y"Q86+2KWKM+,80*TT#AO)K+%-%(FO!&V_Q_0\@Q92!]^V,XQM+6ONNVX
M4@IL0G(2E6^6V>NPI 99?*A#+Y:"IGRK V;3X]K4SI<(5_)SKFK6GR^^G?+0
MGC3WD3DVB#[6*IK?A5$A@&C!*]:=:F\0XYO9F>:3@G)C=(LHYY:XYPY37.5&
MV:"S[-J+JQM R*7EF@S4LASZ%K,2 W:CFS@_,X4?L)#TTPO%MSW)-$:'>86.
MK[Z>,VMY-L <<D#Q%?%P_1YV):)P:E)[VKLQW;C@0JH0O/%!-$,0V5+REK;)
M[5V>_F=LUAP\ \J&5>C/6*FG#W4U_#!5,'7IN.Z\0J%=)5=B6BD+:UY)L?;[
MQ382_/K3MMMF]ZJA-MI,_ (7B,]=6Q+5P%)$ [7X!GT_IG6,UE26:\*$BW"X
M> ^6*3TUS:_GQ#)$;C9QP12Z?:9WRXO' @HZ7]358HD^*5@<$*#K(>N#?LLB
MDZ>"9!:2_ZKB[=U+1W@?N@Z+#57%-^:&>,Z[SL._*3AV1:$B>_.#KSEG&^#"
M/H)&CV0=N<W&%Q!UW"\-6*:ECUY\+TF-:#(/KG#TV_6;1OZ!,9P>T4"UIA"B
M)7-[]'4.I2-3P"<'2%Q@T07M]:\).L*1QJDT?78W!G:LN366J/=CY/X"?3A4
MJ01?/Y U/8#K*/WSK[JILKQC@['(STN(?(<)^GTH#JU\'!I,$T<)"<,]Q5M:
MKZVP0?4[;_EQ/[6Z]3I3QPNNUNE#$8YD^1&;BV5I3[C(6[G!>[A5>P*:<_T:
MYE\X^?""&$$)Q?_YNN=_K8!G==EKSW/ Y4FN\HVF$!YKCHVNJN]3#29<SJA=
MR?Z]N!H<]!'XF;UZW",F3J<G,08\K:;5T!+DM*59FM\.$KC*.GUAKSLAVI!]
MX-Q+_T\D_RH5[/%MD:<=^(6]NKVRL)#S^X]-SZ(<JM2<7%D<$%,=$;TN##R2
M4_8OQ1]+7L]$[.E(^*=6A%]HM)JA[5!%N0.>A<1$M'OO=7_VI?#E.>775R=T
MK8XJO)EJO '0.#&F)WNZG5[YFK9,ZM=^CB\JBF:L(4XIUJ"UY:9T?OX7IXHY
MK%_-IW9D+"E&"YOL#8SWW2^N-#>KRCA6)@'' %U#)95EH_05Q7_Z\P%W/]\^
M(YEY)5;^L>.R.+8YO'&O7"3];Z^T-+V4)G5X/,K9KQGVE%*=B5NFAWE]QXR'
M-OD&\' F]?:R<LFEX))XX;?/AH+9H!8Z1[?\@^P\FIGP@UX'[RH%7_M'I%Y0
M0V!]J!=;V27X#*2)6VJEV8>E70,IU/<$%J5#'G_NE4^+P4>"%P6?RABXCS^*
MT@:-?N1M+7>41NGC&F]U+9,VHW+'8*1[T[Y+R#W7>3,68D& ZD@+\VI<SMFU
M%+8D [/=:Q+146W&$Y%:U#TK[4=>-4+J)/[S92@$=[]A+<V-PYCRT)#I\[\P
M_5%.?^O:C3;POO-:(/V;J6I7'S::WK:(HJPI+S+=T8%X?*+UDK*(]'D*Z=&R
ML2FW*P#=="EQ(>WP7'W&=KK&!TQOOH=3F/=K_KBQYR&4#A.[D'E0%LUJ'$W\
M-<5370;Y=48U N%3A._3F1'V7A@ZK)%D&MN_4J(U"LR""7//>=Y_.TRY80-=
M^C@^RLM<JTJUEC]OK_[;QY77>10VL,Q>^]O.-%Y4:[J1RL/1FC.4RX>)H%WE
M(;&MO>!L&:%H=)=M+D7_1URM#UTU.I!WI-]EPIG1/+?,G^YY3EP(PX96<5JF
M(JFUS5)BMMQV(U8UH2'_WH<=,2<_JQDMSW/)$4IKNY-#!I89A<_,MM9>J2%(
M\[1:5<EF<J-]?[=D#.M)3UM7WPM9I2GX@9P$YOJ'J3J=YF277N(0)9*Y5N">
M9Y'@T1!*Z<[;_80%-"C8I5, *C<K)U&N[L&:#Y\;+5UL;+^79IU&+*:G=.<[
MA)O5V3/FPYB[KN;+IN029*&C;Y-[NIA)?U+)H5%%\'V80#\^$-/W%N_LA>9O
M.!<I E,['>\9!@5$D,@E(YD(NQ^_>=U"Q/=LJTV#G]:JIKD !4E5:9\\.D"W
MUW:&'QRRI_EQC[<(_.AK84_&SR8[P6K9(GU&>4=NVZSZ>JZFYH3(?VPE9:M-
M?T9J.? 8<SV0LNU^6"^>P?$0$#8:\()F*FLN@^:O7-^[J[0&TP,OHY;FF4OC
MXIT@SM:4DW?C53YLO+TXX_L\GE+GL5L^[@G?HKD3WD*TX]D ,[.KO/$8D-+D
MI7:5\:[>*[+.:D_];[^%K7)9,K=UOMC$B0]^I7.[PY<*4M;5TOKVW&G E4V]
M^;=WMBF36CJ)Z1.]!]:ZX?$T]_19NP$"H[J1_6V!$Z OX&J[ZQ$OVM48G:WI
MWDB!5>;*>[:RVC+L?VDIPJ"6)9=*F+S<&H>_ZH%%N[@=/T?W&'V[Z"GQ[Z1W
M& A9%8$\69]U]=W.1E@4]!KJ6Q"-H2<Z(L(6*?K&(AHBVW-%FTUP/H;NK6#A
M__%CPVU6T:LL[ZY'^ R]:2&?(SJ(N1:8Z'VD<A?=[UTA&MZ_>O%-+X/Y(3_$
M #8Y=@V1W0KD"R (JZ:L?\.?(#8$O&C!]*F1X<^F %_R!SP1PX_/B/RX\[Q0
MLH0OD05Q63\P"@F2\&C61Y-G!^18(!G?^T_:MR#Z4<_Q1]&"8DN@-3=ZTY =
MGX8YT<37KPJ_Z_LX):Y5O$<)[.@M_.Q.P9$6J4)XEZ*,=LP1!! Z ((?[C)&
M=*!=_70P@=/3TVF_"KUH4M3<V!T8;.89(W02?%<)\M2!"[LF:9WQI1_,S3^\
M<K9W9M*2.Y%)D-%5,<Y,O*-(F (!O#NHL>YH2G"P27"PT_GS9R%MZO@!5QE7
M2[$O<WG.;/#U(T<8>8.96^^@)C+2?.K(QS15,B33KBUIF%T/T!MA'>RI>.A,
M<SUJSG8#"&?[>JEP<J:]KT">*[>@OBV*,MWW4I4T77 C-^%9"F<@7&=Q_OVG
M,#-28.X$3A<T^@\6)6=<YFP"OKVM:8Y:\$^I1 <U87=)*VAM?+S=N8GO'FE5
M*3+P$= UK,RO]'UDK5YMKY9GRJ;%,/OI[B0IBQYF'XCM?QYIH?.5:SKH3N?.
MV6I3((=LJV-]RZN,=_XF+YE!@C!&NU05WZ4FOTSH1++?]56+'U0=W4LVI3G_
MXED]1H7GPV 1QA<JD'9T^&SDF39%]57N;;I,=\7.I26BSO,V"X;G$5&%>D%6
MWS=6J<S+L=3=)N !40*G9989#N=X49.F -,OTS$27*3,5+\3OOZ+057!"/#;
MZOCDM3*?>+H#<,-"-$_,LU#Q^PY%#D6/+2C(XYY[)<@,D&OM$O,+,C=E7LC-
MFYI!]+9UL$319WMC1"NC94:+N])BZH*(I@E3FJ0J)X:[:OV .TO#?,4*R!M
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MTC+HSS*SJ]7NH7/P)A=;>XI,LH&XNJW0P/>G--M%,PJV1%C5/@HVQX_-T35
MBD?0U_47K-^J@2D%/8S?U%($?5R$'$A8BH>%?FHR8QO714.RPL?BA2^UUD"/
MV$B=!P=?2)UO?#==,-,@Y"D\X1")_$CG6E/S@+S[D-#22_7?.44Z:/9G(LX1
M^S<*85OH;-#)V3C-<!IPQ#GROF,B_TV@U5*RF<W3YS6S>B92J+LIF0""F!/8
M)U92+#CV6OC2[AJ)_91'/7EP:>%[E:$=NAN0^2O?-I4CT_BUA4MO&:FZRW=T
M1_,:.%@$05!D5E-8X\3*.>TC6X) =+2>T^94E!D5$%;I5E0$Q^9]2E'GQAC
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MNV@@J<@NE@V,=&3C%J:Z*;90N6K7$(-2]O%RM\]2^Q8A)E GD,AK8">@?@Y
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M<'OE<=",.2<&V1-H]8^%2Q.!;4I$F\;?:3@C3S^)TOQEHV,*DU*S83Y>7C1
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M(I=(6,6?JKY0/'KRGZ5,U6!((BX0'U:*]T+SA5\"R_ J+PB0&<_C_X% YS<
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MI3+MRXPF<2S:6;_@.8(;(!K22(# .$7Q*-&81LN!(2;+"!9+<.)<IU_R(=P
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M_.3-U(]ZH"^UI$//8 *!0$# )X_BYQBP]&A1 N/(LR9,/CR$=)WP'*>SX=*
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M(1X;.SN*N?(5?C0X).=@51#["OQ721 ]]/3_@H#>$-UUQOL3N(F?2>(!XZ;
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M0+]J%=7&$&>Z14,6;[919+N Q[HY:.MZV/AQ+]?>I-#5VPW4S1^KZ)(:LJK
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M_)S[(Y=1@J-2)5L\U-IOZSA^MK[[4T>.>,T)B!ZBZ<%W1O]#/L%*YF?=53^
MJ5"6/MW;E:\VNI]3]%-XJN?R4N*UJLM:HUWUB3M0>=80O"SL\,A@_FSI;"P3
MM.>#9S'!U6,=)B3@H6<NJ4@@*^1A8SP(S?_+>7IQ<>!L2>B6P#<& <\EICC4
MRXP$RV \;\"XK]V>'9KZ,:8ND]9XL$AUE**4PT_F-/\\Z_-PNKG-(6.0FF$-
M\+UN;K1[0ID*-&A$#X)#-)!@4K -HPVXKZKDA]1BI KS@V-W-X!-+1%8^TC%
M$L'@R1_$8*AKQ$'XF5(G8N[N\>NF']T<P*@I-ZZLB/JQBHD=":ML%\CI:XQ!
MD99(;P_>WC)?ZGA=RZ1'0?]SXD:T9L%D8O/70@F]C;AYI0E"//ROV\]'WTZ3
ML!3U'&0-!F*K:U.[SYPS IAQM7F!/MG@TE>4:=\8=2B:=N&]4>2G1]K>08\W
MU5Y@M&9Y25>:5^!7(8_8@, 63@G9#['%6M^<+!^@B=6:5T.+S!K4WTR]&V47
M]@UCNFF?R?Y\/HUXZ:]2K+TQ+S$"^JY<^O\A[KVCFOK"O<\H*F)#J2(E*B!(
M$0N]141 0$20WJ(B-6)41%I(1*272/]1H_0>Z8) Z$B7&@@]])Y00B!MXEUS
M9^:6=ZU[[SMKYH^]$E@GR=G[[/-\/]^S][,W_J<)<BZQG36@>1H4&'RDCLI#
M% [MZ]BE6-^8-E-]\3651(E WK685"TK@JE5QJ_:5HI@VT[K6[M+OTR.LXFQ
M*>Y:EK:"H7&:S%-<ZB]0/3^_R8GW#'Q=V7_!%??Q5Z:K$5LQM.@6#W[Z@]J9
MVACV.6ON'40;>$P:?GS-JK\5[*]^.V!V*9]#-V_]BE:/(X)U_=@Q;Z&E(=#*
M9O6[>]:;+["LJ0<SA"<SN*UY$IX6+PL*,;>2NL+=ERG76U1%.CCE)3@;GW&W
MO?74SF3)XCD6P%M(2[N#["C?/.'9<D96QE:Q>)=N15:5I^YX6V5.@?38J!Q0
M0:1:K2M,''UN^+^*>QW$Q=%*^]EB*^@%*XL9\F=^7?"3JOK4)K=W;[D.783S
M1$VJCEWE. DK0'$CWES/]&P&?YHH[5.U9H)M.V1#0G*X>U?\1<:\Q,5\>+GQ
MQ[W%N,>+%]X4 [G $%25?+:G:%M_X\QX%][[@ITN3.O]UO+D/W==9:K@6 9@
M3X,!<)RABM\"D=O\:K1\4.NR9N%L^EM,'NMF(X&F$<&'P$NT<A*3V3/8*?(,
MP)P&4YK;Q2E.FP@&X"&0Y,:DY<_S#$"$^40<D\HMF>)Q/ZYA#47]H88\0,W1
M=5H1KVE,(5@)H/=BR$]M$,0P]7$*F GVK+04!.';3P9@GINTR(4H8EJD;WI@
M#T.ZA5 'I9_   CC0?_A'('__LLH[\/ Z[),]Y%(-V$ %OTW$'5,D[.CKE1!
MCJ:\<2%UGL<T S^];;F(8U+8KS83H4^GWTJ.81QD>&'N1-G:0>HK@N<GF(S
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M+V$:-U#'TSJTAKMM7;8W@E7P_121L'W7FU/A\?>Z/R!Q:G5J^3HYY-V'M83
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M,^F]>7GBO2=G5K6R98<S1@[KU\K*!V0:EI'T?A#!$'J&"B2BJ6)"-X8]P&%
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M8R47DA-3<>C K[76DS_R[D#BPSH-T0($F\L0T7,7@HF4.840&"]>W[3^#]7
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MG]"3""9N0]ZI4[K11\MO4K)CZ<=SB[U&JIDF>VZK(LB-LQ$E4*=C/VRWF@[
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MXUG[A$-0\P/0.\<L[GO':@Y9(OQ1!-0L*A SFPPB&*NQMTSS#VSNH8(1 GO
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M613P[RKG,!8&X&$_Z0OSO:>O#E4]N!&T]_AOVU,5/"M))[D[:-]CF PJ@"%
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MOX"H8P9>3OYN!<>MU[8D7?EP ?!YG^O+A(17P^*A[]42<23*?)6=D.7'993
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MIB)AGA2>U]IZUAO 79WSE]M0S"MAIF7(+4(6HA("S-Z>.;3+N#+S\-<G-\8
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MC.O_2G>A%B/_F^X>;VO^.\SXS6A&0;&6$L/]_^HC_]>0>#%M,V?X)C'X.E<
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M1_O&7<-XL=9W%'2QTI<SN9BJP_8F];E6,V,XJ7'6)>+!+23"KP8W?M-R+G>
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MP(#,07H?5A/5/ ]O"( (%BK7>S2'A]=&F[S<O;^@Q-Y-I_NLIT1CR:6!@WY
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M)VL-JM6;)_3@(*LTM*YZ9M6@BSCZN'_\?O](60Q</\Y%B3?D1')A#CN-TS:
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M>;QHM,O"X/NQ_Q:@WU:/PK26NQZX*2QO;P8%>?2U2F25WP.E2,L--G/E6'5
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MO,_.TZP'9MVSMB0@S=$MDNKMF/;;T]1^U*^_CT92OU@U(FGJ$\-5"5M)HW$
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MM@'830<1MRZT90CMJ_]S[B[AS<W_([2(+27OP\NOF_)(=G*+P.X-LQ\^2A=
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MCW9/ ]NCXCMO1"9=S8BQS@.Z:-Y8KR*SP6_G?B_:<6I71C"C3%YZ9.+YP$_
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M<,.\[4_N^K0(ZZ]2-;DO_Y-<9)*XAW]W=.7'968VEUT49,3X]PA:*?BT@]'
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MS,U36V^E7@J.'D$5SEW8;.'H0?F79SIY#?S<!0URP4(0EB9,J1\)MLP:F<.
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M&$J]:1D6%Q>BQ+H6\:'FY4T,Q[YP*V#Y,/C[M+55"]H@.B6(80^NSY6!G&R
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M/]^QX%+OL5[P#KW@"]XTS2488+XV,GEA6G94I&HX9@13_,F"+1>=4K12M![
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MH!U)W:K9OOG;##.];O2,8?9*K-3!+^]*?=:[JZ4O[@*BT7:(OU^##T1AEB+
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MR7]&#&3V.TTKLJ&70Q21<+N[_SOS5X;O=_;*U-XN479C@N@W4?IESF.P:H,
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MO)F4,%V4\H!"'<L'\%H^>>Y#.8)L\W=UYNG)&#"%8;)J9,2%M-B4[ H;0K0
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M-U4.4'M;<KX?.6L0(POEVDZK119:6(,3?6M3\'/Z$,7RC2G^EWR\"2"80!2
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ME[Y7Z7U\]A'3VQ5/.KC*ZMZ5Q3PM"Y2];(56G,"?K5-"EFA9%)*X+1MK\?$
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M/]PU8&C>+ZM3)!UG1X?7]*"Q'! W[F#(D&'B0A&.\N>DKJR@1:S[I55>*UD
MYUOD"=*BJI5T5@Q^P2_KB2R#N-;V;N3%=+-OSBK:,S+BA6@GAD/-M;T+:O$Y
MN4B^DYQ7 M$]E1BW>?TQ85@F.9&EDV]>7QK2,ZNFTRNG9R61]P=7*._1;]R@
M"&UN]Q@V[;-I*$:E-R: Z@>UP=C>F^1NM!J3^6R_S(/LFL443P%^@@@.J]>
M5'XO$@J]N#KFU+3J$WS:%4N:P+?,MP!B/V5M_$Z4,,$?W[KD@ODE9Z:Z<A=1
M,*+F8)ZVN;&OO$]I'?K-P([]*2\)>GD_-+#<3[X1_$F+TQCC<,6EZVVIG3J\
M'J\QN97Q5,R+'RST2!T.C7I 8>V!AW:ZE!!V8IX]'\S\ME>>E^'$&<:@CTB2
MP=?7$0'Q!@$.=;=]\RO@=Z<T,5/T<?!@&L9#]W'%V5H1UU2M?@V^SQE,ZO.J
MVAU#KX%>CBB3-6(/%X\5VE5$I'AH/:*OO6099+P>2A@4#)WJI*H(C_WRA)$
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MAY990$2 6YB#FX?[NQ (WOGS^!?PR0D(R+GIJ>FY_Y<)TP20G@?>0ARQ("S
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M_:PSCC'LL7LJB7()-)>[QC^;N? ,<,5YN<_L% ?0@86G(QX#!,]'(?4;B3#
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MG"^4LR!>CXW(V^6N7"O_!:S3C$(-+$L,H/=YOXA5>Y>]-[O2TXPJS*8VU,3
MF)M_/,G:FU&BF;IH6OW <3_?]UK''>X8LJE%LUWK3+[H5^H[P[L9MRT$NZ]2
M*&BI (3WHX&38;Z%E)N&K2Z-U(WC%<?Y<GS1D@*,#=(.%5.=-:B5J9EI:(HP
ML20)_9</W1P['>^RT@#FTX(Z)Q7I'7>TN\F3._6#BR=I?;&)%S45R)NZ_[XD
M>Y&@TR?>9Z'[&.",*[+VUH>IKRA3,$=2:3% R3#LY(KA4A"O3TX[FFG$@SJ
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M*\Z]6W2&Q.=(+4E]R*(^GB5<N.DLQX\9(H>]B0.GW[PWG5W;CV?;R#+(SX^
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MMGH<]L?*YPQ$K:L-[>=M[%<76B(2E!2MA2,+8]6N&U8TU)=?R/YREJC1MG5
M+?I%N$<#/C@?=GC\KD;/?"\4SX5MUEWV4F"(Z3&Z&K5RBHWX=N9Z/(3N=\<
MT&(,$"" U!*EXLR*6#?SA=;=2XL'Q#?(,$#_0>>RTF=V#)"V'M67#D^<][WA
M.T::8-)]3W0Q2-=AXPCZ[00#'+5@@%! Y%\&I!WZIQV?P4[G8"UY_:ZNV)'9
M#D\,CGW)1%MV4WW2":#W7Z%A15!)F68!% 8P#O+  "R+&*!G 0/,@*<M?)D_
M&:>!]3O7KSZL\716ES^&3EC'OXY^1G^K+=G//,UA^8LLFU&-?C*%[<N+2G.R
MQ+_Z.4S@(-1HV_=6YMPY7"7CQ,I#_^)?[6H,VCEZ4N^(MWG9%^9+F9LH/NG$
MM$G<V;WWP3&'ID/2(APXVBY1!<T88TIA^M7>R MJ/>8,JKX=+KF(.>VDWWT,
MIGY@Q>"<PZ0-!J ?!3,.\EPT94"S^#R?6[==SYAJF=_X,.@[P'._2"A2>GTH
M0%SZL'#.44"CIL%,^DNRB#*E&"#"S$'OT95.1/(7E3DH<#>RJ0%C"IZ3&ZE0
M/"G(AWGVJ0S(P$+["<>Y4Y.L E7*E9BPN<C/7X/%VU\\MC2]HU2:^=MTW%/?
M4>V48=]]$BI&D&+O+MW>\#GD"TLH*_5X7:JTPXACXX@[Y3=WM@=T#EP1/JP[
MZ7AG89H80* <[:DF./%\DO_]1K/25FO$^++,<<%W.QB<39FV!)#Z(3[^<SGA
M%3,39$?M5-'<=F%;7V%2RA<^3Y9X+:S*,F[Q6C5A@#MIW[)^G801?]^OJ<Z<
M:NZD/#6WHW,)\>;T_IQ^&MB7C*2XL[:=9&QTZ(\X*#A^RZ)Z[<,P&>$0DXL^
M>MMZEQ^GNI9:WY&C<R]G"O6#/=G:MMAI?'5X^KRCVHA3K4>4N]TXG</UX""=
M:*DLWEBH_DVP1+.T_9*ND7]P4U*G66J0PO)^@0XP#AV!#^;ICL/ G^HS^79]
MOZ <3WNIZX%NT8+CHJP\W+-D2D-BRGU*2@KN\$;NFO)$=AFF8>MPY9LARDV\
MA2%>I.M1RS?17+4A74[0.<9AAL0;!1<[9)LN)PU)G''%661DU,S-UZA5N!4]
MS*/RMMSK!A2I)&0ZCP=5YVO,$SG';@S3UQ:4?A8,SI4Z#8')R[[WT-'GEG)P
MK5YH-<SD[+^,)[7;>;QJPOYNV]T">Z]E0*JTH$+]*#HF)6?UMA7)?Z@P1OX-
MI40!J?X>1>[_ EV8-7"!IGWR!LZ,8+#L!G/;JWI,6"ZHWX<;D;Q4E[5O3$PL
M&6*E^B9_V/#1>+-[@8-!:)(BVT&XPT1S@Z)H[J&3=Y5NDNUD'#S;WSR8=[,1
MW H/P8JP\OU?+&/A)S>M1)JP"&'Y4)3NY<";L!XZYU/D#$J-T3H#[R3)//"=
M%/HEA'9\FBVZI.;QL5T)"><>=#O_-?L1Z@B. 1"@D>'O2')CT/EC:#3XX)+B
MICS:UQ"L#Z,88-X6,NF,6&Y G)V TO5C.[9N5FN[GO_60;(516]Q.L)_IL0A
M9!0HU0&RVLG/))-2P*'[P]\KE< K/TEUR$D;#)EO I_Y-CV#/F-"<R<AP+1/
MU4,<'2"0B5*]LK >'HM^U+[S3CIN%\YZ%]WQP"4Z2JQNJ1VEHX:5L.E#9F0J
MR9L>BVXI&S3.+2M$OY 1R?LG*"[O-3RTP<2_,U'V$/YQ4+#Z$7^2H+D,!MC4
MJ3M@.EYRP  P.@SP[)VP/99$^&?8I-[W<>=2,J;K8T+#Z&#EQ0D;K5X+#X>H
MYXO_$EY=,H)%;QZB$MYQYVDX!S5ZNQ(:E(D!I IAV^NP75&(NN9 QDB;A4[5
MD+-4^<MOFUB;)Y8CU>EU8>R1-'RQHA!=/3* ,=AI/DI$@Y6%SNP@!M'RLO%M
M*DM5YYF',_I*,$/5*=I_$G0$%-JNS0ZOK0[-2-FTB@BC82238YRMY#_[\UP(
MY,+ZZ9Q;%'\8'[ORS9#-0O7J52/C4H.-G<)F^N#6T?>&DZ;-I#.>3AM]'XT^
M<$M@@(?:/3-'X5,DIH+@K%SW>CO65=5_YND$VYT O'JVCS>=,4!0% :@T%1U
M\&8.Z'6B&3(S(^T#$R3H3.D/U7;B:]>NA4^BT:"4<=MS]1KWNMPLO\U^I'D*
M(3T.@Z /#"\$8@#I30RP_0EDSWM^>,!71:=9O8C>K05%B&Z>1*%VP?T& 9XN
MV@: W7O7(-G!P7(80*\UV@T:GJ]&M)J@+/699"+^F3,OJAKP.QUI.'F"V@7Q
M&2("'#)$;4I%/&#DI!DJ8^&:VI![3M=HJF@UG2?5E114ES^B0P*K\59P@DC-
M*_9!N>&RA-'S(FFWOA7Z:U?"=W%:3'RB=,LG9GTO&FTIHW4[B*5A*9XR$HTC
M'OU8]F.IC*$YPW-P/D?:-DM>=)+2E49/*"E:O$K5Q]Z:HVB3I@NM\XG/^"!7
MC,XHBN/VJW;)-]6QHL^2C<AIIJ;BUH*V4;A5A2BN7$/C=Y]\$HX_)*MRJU8\
M(V?4WZ.8@^V4-HHO,B$5V?O<TS; I,/W1O$B(F'[_%,88/;MZI1Q3G77'-U1
M%%Z[7[KC.,<2"N_.S.![CK"M)^-MT\S#5PQL1"YZ10FZZ-ZY?HZG&3%G'0!N
MX&_]EC$ #HD2BK<_,FU?P/B[J)5JM]19-%GC7H9R@&[>#3**B*>M3DT=\W=\
MO];R*--.=%/3ZK_)B-#Y@ %\=SO4 L"<(Q!9R#DC&(,B.?V@WP5OSZT7H\BE
MJ:AX:O:9_E[KBD3TJNMJ=Z!/BL1$][;9$4.,'CQPAZ2GSPF]EBN]/*\\^>L?
M0,9N$H,##4L#M#/7:"L+G]L>Z8V.)>@_]Z0SN3&H^%E/"[^ :P5=F79H^I0U
M.V\N#44Y!=L] =9%%!WB3L7;!$[PD3:@CW F5%!4>< -#)!>' ;;,7+% )TK
M6.][:8K4-V8N(E9X?ALIT[M+@ YI!(MVLV,G!F!*)RZ+!B3UN0Z=GYKN4^ST
MHPF<H,@S)FMD* :0,R4$(U8%(J"H 5SX,UYG,0;ZYAS5);6&.]X4L_Y1_3M%
M]TR)'$Z-XE\M1W>$K0;CNX?*M$<M/5PW- 4%S.C\+LX*^3!53/T/:7A*.3=&
M)QSKA46N=](6B-#'RG:XZ_&\_,4AG_^I0^>2IQG&B%#%] L]ONR\A!OB;Q<%
MJEPD/6@*U0E6)2.3I#:#9GAC.JX>AZ+O$\]+2SY$ZL+* F1!&3EA[I-H]A]"
MRU!RF_D^EK"IJ[^8HJ=.T8=,NM4XG 5W8-WCKOT@-9CB.L28R;J;/S\Y3Q6H
MW0I%\E5C@(7]P*1YDC.<[Z?OD,DH-%26G*\>.G_9E[ PD/YV%,'M:3LS0;T>
M0J]]QOHQMVL,Z_&@.TQ_<B=N W'QB=H?XB #:X(]KME3"@\FV7T^:"??GZ^>
M02I6CNAI,G\V%*DPAF,S&@12O?![,?IJO/$R;.#[2-X?(],LD<%^:ZFTT".B
M7R3ES?7*;*L-ZDV@Y=F>LU*PEWG%=:B[&RYGN:59(Q^!,_E'[#_]=:8!\;L#
ME4DIYD8%%T(*I!SI:)0GX9-OJ3^@[&J)'Q:,.ZQ[NTN<<I()Q%KSXZH3RF0F
MQH'Y%(5J_ST*2N-!S(<C?P2%P6"^3$K)S#?7@,TO((GM;GR?09'LT:$4FN+5
M#\WD?TJ*1V"*=&& :JL?F4BXOU-5-F=>_>K(LAM"1?1Z8-G^=.^C.[I[S!F;
M97KBFDXI::Z&NG;X5YF>73QT2.KW'/XQ,O.O*0ZL=<U7:\X5!MRFV\1'DFT3
MN<PT],MM)M UE-F#1;GQLO?(GZR785Y&W_A#5OH%%&OFFJ'J/9CME%0>?S^?
MR1%%R^R8:N(B&M1:E3<7@P%<?AGY?4[T_YA-Z+.*"%7-^DC5"ZYD32M=7U^R
M)9_X+<)F9 [BJ<(J9S9Y[B[6<BUUD28HO([A9 I8*-V0SC\"@X<!!O[("0+U
MIP 3\LV/-?T*S)E@R5KC,8Y_6IQX>KZ93(9+?U_;_Q(7#" )E?RO9!,Z*-+^
MA_I"(".& :+UTK;?&WAA@)S7ZYE%5Q?D=Q,*Q)(-^_+>TET38*Z-<7QP186N
M.\88Z!7"8E>R,(G__1W6_XD+AAG_'U!+ P04    " !H0%Q4WOJD&LJ3  #=
MGP  %0   &ER=&,M,C R,3$R,S%?9S$Q+FIP9^RZ=5!<7]<F>M#&"01WUT""
M!I?@$#QX@A.TL<8E6+#&(4!"<'=M)$""NP6'Q@*-!*?Q!!M^W\Q\<^>M6_7>
M>ZON5$W=N[OZC[7/.6OO9SUKK?/LJO.P\/ +>**JJ*((H*"@ .://^!A"9 #
ML# Q09@86" 0"!L;"P>/!!\/%Q>/DO@I(0DM%3T=+14-#0,++SL#TS-F&AJ.
MEYS/7O )"@K2LXM*BO!+\ H(\O_C! 4;&QL/%X\"'Y^"GY&&D?__]GCH!(BP
M4#Q05M!0F !4(A0T(I2'7H > % P4/YC /]MH*"BH6-@@K"P<7 ?;VA\ J"B
MH*&AHJ-A8*"C/UX-?+P.H!-A$#/RR6(^U;8 ,;F1\(<DY6$QOZKK(M69/&$1
ML'0/Q<8A(Z>@I&)E8^?@Y!(4$GXI(BHF)Z^@J*2LHJK[1D_?P-#(V,K:YKVM
MG;T#Q,/3R]O'UR_L8WA$9%0T-#GE4VI:^N<O&?D%A47%):5EY?4-L,:FYI9O
MK=T]O7W] X-#PU/3,[-S\PN+\/4-Q.;6]L[OW3WDZ=GYQ>75]9^__^!" =!0
M_OOX/\5%](@+%1T=#1WT#RX45.]_;B!"QV#DPR26U099N#UEX@_!(GF5E%?7
MA<TLH'-":ND^B4/&(KC.BOP'VG\@^[\&+/3_$;+_!/8_<,$!/#241_+0B !I
MX*A=KS1 .ZSW)=&UH]KDSE2P)IM:.LH0_*7M#GU?]FS<716RXSXXF_X!Z A[
M .+GR\?N8?.?;U]?%TM02HAII(-I5^O$(GI+-L,UT:0*_[XO[X6()P8Y!K@\
M +GLD0_ \:\'  '[UXG&P3%D6/\]\=SAX:U1L9$*'C+ZM58P#:/(<'T=Y:\3
MQQ7![ZK31E.'GMR4$B,FGWN3FDNE?MR5JKP %XP'-?YX^0#\?-KS %R=!"'A
MTO]B']VJ5]9$W@J5.E2%SB&?4N5L0+H3 NI(.^WO)9%D-9#<1>-GS[WYLH2(
M2&M97SL7N!K8<!49TIOZ:24[=WD[)O_[S<\YBHUM_6CTM'*!N#C24.FN^DX7
M;SWO<-A)ZNPZ7M9G\AF^W";$5@&7VU=!REG4W=YK6:3?&[<$KK&)H82J;'Q,
MOSA[ !BV@^8OMFW__6I!W71B'3,7U"V>'!GKN+G--Z1UEB%9\SRAKCD<6[60
M;*[J/,2*SK1FA[)SI7.UQ1Q^8@:I%G/DR%I+Z,($ABP+JET];EO2OU_G6^%U
M^8XNTB8\M:G T<U1,O%;2[.=O,[2D8QN5F^:5;(!#<Y8RW6J5&I@Y=+*HH)'
M4_-+;!2H>2699*888HM>>E527>J=$^][O?NYZ[4'0$:3\ %8ZWH !NS^=<+A
M=NUIH4P,';1!Q)[,,CW,?)%+X1.X0X1U0,*["E^@/^+T?EBM#C\KJZ^J*]54
M1IZ_YT7L[:V-B@A].,Y+>H$7_\KXO]H+2+.H=B4K!"X^O6QS_*\1^\O(CUWM
MS<>O,IO6Z[Q2)B1FR!X DJKW/UJ:'5D--UJA1"(YFQQ'0^W)F"\,'H :U4'J
M]]Z7S?T/P%]4GZ#[>\)[<:7_V=1?VFCG,ZGJA:NQZ!CAEKI)(3CO?W<CT+Z)
M7'1510>80-Q^1<PQP&YXIM^RUAHPSN*JEG5(SH,D-G(X( *9_S9 CNXC [C/
M$SQYF$[MP!XW=@*4&<**O/06E@.QQ#X/P/[,!U*D<U&E3X_>M//J,KR['H;"
MW!.0_&D_^4-;\$ZQ DL*B*UFT^H!^+>DV]QS_[%[\CO6>?28LOGI*;2B+6TI
MKM<#2#HVJ)9BDO"SN<\C2*?N D,N7:L\T O0(WR?H.KY("C98AC:8Q,.7>(>
M@'/TDP?@[I;^UNM?[=85YMXRW\I5^(0$*IF)_;,ED;7M?A/SB55I3JD6H? -
M>HH]/^GHFBJ6;(I#8KA2HV&!"N6*):]WUE+BIK6-5Z+8F9S^,LE7@0?@WQ#^
M\P$(__SS:XCP)R,&J&5]3,@74Q8EIVHI+;F+G2)#S>@G(V4F,FG*X/<__*4;
M[PHX6TC1*$ I;;L#Q@&M"V_'Y_G^[0K+2/HHH0K_%<LUM>0IMCJU=QWV7&B^
MX3%-AB%7!H!MM:. ^G6(;^ &F&FHONFE\.7F('A&XE2U&A*WJ(=!R-U"L).A
MPO:2#;H&7Z-^ 'YCKS\ -]?2UX?T_V+;[4D_*9D,D*M<? M7@F# 8FNQMG"9
M#H/50EN&=,/.O 9+2Z[SD<:4N@HJUG%%_%'')+G*DRRL)BZCKK^LZDA8/K_[
M]&^Q_(9-D*TX&/=_Q37A:=446BD\.2;05Y8Q[VI!@$#Q%_/36^3B$FTW)HB@
M.Q0)Z0<@"/0 T!8\VM[_![M&.S]>:\<V+<@A /R84>21'<=UCYEKKUB&A.'A
MX_9T^HO\DU][;[2'P[*RC>[*D VB]]TGQ]*'"??BLK-2PD1A>3[^.9<#__C2
MS8]_0S-ZFE<:8$\,*^BYIR'F#W_^S5WFM\#V^>:]Q_&A9EPDY<]VR0'-S,?]
M7XAQ;!%X^2HM20D$%BX_ -VBZS4P4BR;Y;9:430I%U5_!S.J%=6FL/4YW1ER
MF@=@T_A"E6-+=GR"6UT)\<8N*@,42:H%UL/+Y3BG_UZLZ8O,V":+0/3\H$YC
M$[7VTB$4W=V>KYA4>JS4X1RMZVD61?;'A(ZD$MXK^A1V[0M;+P]P,LT@CU04
MH7#[IU9G?A>D@@0D&FYT$>\A=^'K!^<WB,<WY4\AS;B"XO#U];7(QU+XK@$5
ME<O*-KG[;^%9.%]]9)O]LJ1_>><&MV?QXA_3+XO$/5)<HN9&$V%V!P2(/P"!
MC\%2NRM!-B1<)_EXQ^?\UYAZ: _3')Q.'$K'?9FX)(P,^H_(VU'E]'>Z"SXG
MV)GW^<^[1D^+.JY_QA]ETY]L-/P2QWS;)&9[!4.4W3J)CH>M3R>%G<4KW=W5
MZ-:@7Y<AY7J%Z5X$$?SVEK: HD:=<:$>#8#*?HL>JGUR4,^2>:0L_A%UY"W>
M(P5FAV9Q:^=H)U=WEX_[=I_7#E"JC3=ROH50*5$Z?4;PT^;B"9-"QOT\-\I,
M36\UILZIOSN[D'++68^RQ (#C-TH5_X[@C!NW<;[Z>O%@5OE /'_2JUV18 S
MK:#T?_;!H/6@6-X QU\7,\^MY-LCWH=:471_ YYT>OV"'NQ51FU;IP15"9VF
M]Q\*;R]M!"Z?A=:N%NK(,0=.Y;W*&0PSTW\4*W/T4;<\!3X-FF3&8QG+BB7N
M+\1-!?8J14E,9+Y_.;WJQ3I_ &I]O _$5G-*A8JST]R+*OBXA@U3!FD"NG^$
M7VN6K.SFX)W[/$=[5AG'H;A7/FJDM FYGJ6E_]4<)A@HZX)1>.7.["S?FN['
M>7CZRQ99\ZHP-:M;IU79*4F)_V.:8)(L'ND,4=*@Q%]=A4I<T18R)':"D;R5
MVT2':<]I91#YHID#'>GWQNDPH9Z/?TB;OCQYP1M\R2I+'^=VZ6=:5RP=R?M5
MOB/](#U=YU.\GA78Z>92OK.9Q48#TPV:9R+W<V>Z\JC$Z(C',DTA+A]C7IK9
M/)6Y99#6OD!E^DU?G/ H1;Q5+_8IS<X6(MYWH_W$!V(JQ3Q]; S?5M^FA+L)
M3Z+>(TNBJOV:MFC%O?H,3\93@ZA@!E1"1U_Q^\[>J;RWQJ=Q*_1YHXCG;GC(
M+C(TAD4H&SJUNKCIZ&^79V_B$2'2G2Y50JLN=Y=2?)#,5V)T\"F,Z2[+==.=
MGV]"JG%'_YZL?5:"TZIPQ<Y;/YFM]#K-/F+?_WWBH&HJ9%9&XS;CZ%:)9,KG
MPYZXLK-U)M<?%:<;,X98\TVW_3$4L),IF7",YV6>K3,O7\B+:&\$Q<W"A&I5
M4)Y]1FKC*+FP5NHWE/?6,M4(AM.>[%S] 'K'0+\]&]@,.(])Z,_)$*_RLX5G
M7K_<.FDGBK2;XZ]&IO/N)V8+^%:57Q^S(6C\ZP7.;KM"^C5<47*57C>1.4!C
M;)V)%&>UB7_A[: EF'YH1/_+EN[&Z%O)X/Z&<Q@9?-,YH/E]XENUW]&$8<;>
MAN;Y2A$:&3H*DP4?W:Q%Q#*]R "H2LF&'?KJ+A;VPTF-2G6+)!^5)*O2UY92
MTF?CHSAM>BI]UHZO_78XG 7^TFI:TDWO 6@0/&7%[)XFSAR4"/\S#DD9D#@;
M>S,941IJ,U-H+Z(3.UR0[2YR*RTVFZN@-^U$.E(57NJ>;62!LV-[Y>=QF7<^
M0BEX.3V6B3K6CX<3HEOM1^C7J  HL,*>!E6%<O+GJ7C@)Q+([#3Y%L;/P2F+
M,KCMK#)TO[ H=]K^31JZ=7#@0,VYU/BZ^3FHH?(V_]Y"D]'KZ/Z2;WXUBS>]
MY/648&M@880.7O@OW0Y:@0&1BC=:&(R%]MW'AZ_&GTNH[8 &&"\/0">FH-PR
MX^ZA(ZKU@T.X][LX;OFB+X'8_<J7%21:Z/26L)T[XK7,L)NBHQ?^W@#::W4!
MC;A\Z^E#TGR6?GT,#.PC$<3)/YY5SMMPRS8S-L:Q"Y/YJ!_+P ;$\,1'A 6Q
MKW.7O#0>[](@M]W;QASTS%GA'%1[22I$@J)XI31]@57-W-(0'M<+)JE'1UDT
M-(_KR4YE,;;Y2#;D0IO:VAU<7O*I!;@X7.NH,LX/YL:7&G,A/@3GFWS4U_-\
M^X0:HT,"+\>A08$$T/Z7OZY\U!1,=F8P5X!!(MB/6!K'$]+\@;+EJ]Y7G3 =
MOF75'J[)+6%>X1IT.M'CY9\@>2FGPQT0B [6(I7:WQ&BHD(LOAFEK&)K&.7>
MZPYI*_L=6&[?3O6:3OW[50IE^BB#HJ97OR@""+G6HJ)554YV/ETQ<1: [5!N
MYT'OQRTXH7N4Z$K$8%>OP$!N7.63DDN%OK;"GQ):)W6^\EPGF%M_6IQ%I;8+
M?YS #!K4&#,9?>GT&*40PN-^%]2:.YJES/GP0'P*YM)J[ #6"MC(%^9HXU];
M<W*M@L"'$\A]72UD*7NV;7T-G_?CZ> 5#X0[/[]MAP.%)22[-SMLZJ-P\LO?
M^=!7.!SYP?_Q/^N@NV6=;K?UORO#&%ET".;Z0OXID>!K9.D%*5S-GTN=&8TB
MGI-,@#IP>PB-^:R$YSQ2NP5V2DXDST*,+3+TNVI@6-,L-Y=H\TD ,1(?EL!"
M]R+MI=>ST>I?R?[35M>DY?5?_7-(AYVVI'_$J=$BQ!- H9 )R?TY)Z'KY[P6
M,)]L[C(K>STE#FW#ZI/5C^=_H7F^&]>'0MPQF/400?'/J-?+4&R>Z9\T?E/U
M7 <=ZQT$]JLDDXQ3'BV+/ C6:*LT+TG#'..Y<FV'1/72NW!]V>?)#3;!0-GY
M#LL]J=<7-N^HG=8(;FM8RXU$.GEBIPU6M9[A6? B9?G<7/J\@7?:Y'7\V2C,
M,_XU7#8V%8_OU(]('5FTMN#D=/21>-QRAF>X!^?(E\"5A%!'N9*6?H L+2.^
M66@EOKA!TSVYL=Q8(GFI-%HK'7!MFPE6A,Q80[3&B,4< X7_'JVP-R/E3[L1
M7+M@E$=)15,\4;(*AW&_A/(^&6. 2L"[SOC0$4=^:'\,N(NO^X<GNG>4A)O'
M=^U9-)\]$82F@]@'Q=WE@MW]";8+@BCM#XNO/=\WSU@U-R1CXQ^D)6RIZO-7
M/KE@AP"84D[(# /:I,4'P,K!O^E1,*E!VB@'%G/'I8^A\;3"?]>+# .T7;?)
M3S=1YPA3:PD(AWXKN"==[PD@>IZU\C939ST?(<LQAS FJJK01>*\V1'Y4S</
MS7F%K,I*O80UBWTHI5-7*$[2'QN1?:H8*ISD%[?0"3P]P"#'9?9S]/_LL5]Q
MMO$UO;G1B$I?S9! V-;U)DL1_[7'_M8+3*1"M^ .486)#"Z-+=KF?K#F^EN]
MCAAB3:Q]*H\,YW+VC(U3-J99:.<$<ZH*UDV)+7LL2FRVP]U$O$?Z]TG>SZ:L
MJ5_%OPZ!%RTS*8Q(^M?ZOD4#GNQ-HOGKUIYRBC,CI'2LWP;WI,9 ]-=;;Y1M
MD[NIMY#6#X#-EU2K1'@G&IEYN:C&9HBAGUG<0<K;V:,CL)"A338%X<*/'NX1
M@LZN9@S=?D3LN0CBNU98KU=/%]PKLVF^R*GXXZHIA>;B8:Q[A(VWR*95(LH.
ME)=,R9XMM51>2V7#=]K?Z=W<)0+B1YA2)?(;_IF!GG@YU(^P07;B7O1M]3?$
M(?_OW_5W7[6:XFD517FIMH=FY-O,[%A07PJ_*:4<M%C>R"F_7B6;.W=,G6KT
MB<7T]/<]6'UI3R6A1(5L_!(E28C&LA$3GC29)7S]CJ<,J3"0/6A-=)>&EXJ.
M^F&GC)3]4JJHP_:695Z\+JOC?9C(Q4WJT 2",VB= _J7ENJNFEK3W["2]>,
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M^6W#&8'<IC N E?-H370:37Q4I]79/</VJ8WWX@6WLFRY?G\K.\"E,13,Q\
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MU2]E\*#>)CN%BJ6Z9)71NB0J/(LE.YZN3EI[CP> %LXP\\7))<9,X^HY>7+
MDMUKAS+NW*&>)[E6V1#X8Z>8#[)9B_K8<?))<RL1*ZAAZ==.B3@7]PCU/A;Z
M]'7: 6,2\R L^'24) A41MI;$U-Y_('2ODD+[L"U@?L^PXB'Q3!?>06O<NH)
M.0YIV]F24$W-]=S4 R!G.2>6E:_@BS[Q[-*9^91,+^A%TPL4!7;TG4RBC,?"
M4;]+* -A/P+@&=_@!RWF3MR'Z.4UMF?5H%YG_ Z,U^2UG$L$2NQ<CCQZ<+:/
M;UT[3M+MF[7M6O/8AC>X?=B">^>)&^2UM;)%M<:2?= RWQA[QSIM-R.?>9&)
M9=V-'<[$)QDOBG+@<7RQ= 5QAXT'ECZ6C?MCV9BP#OL40]!*;5(.+F^4)0F\
MO,<(2TS[(/@-U\6>&>;]@L(_;4(1(G_$K0T8_3?&A'>ZM':UY?R;., #\/!O
M+_CE!VW,$7%EL% -T=V,!D]$#': 4>'*\I+9(KR/=#"\N#%@Q65QZW,PR,V\
M)OQFV>-1/W@,E9BI/)MDA]K:,PYDY,/QBA45'WMNQ##\Z$:]L>/Q%:""/\7<
MMVV\5"8>B7;D>5G]@9Y*)J.XD:<ZO7Q%<EIQG\:KNH:&$=6WR! M;A&P8D</
M"3&JOZZ?HL?W\5H$UR3#^X]F5LPH"!=_,ELJK"V7=>Z&^E#^D\OK'DL[K<F+
MCY+,-DYO16H,4\]$Y+%<IO^\*5"<&7?;,$D)"[N/^4?30,2"XGB>]AJ';Q=8
ME1J./"-23$MP.!;@<K&\T:*IIB%6>N4V#XV10]Y]?-DZ?H/_#@%6R%8A[I?;
M[+>*51QM67Y)!P#9_*X<CV$VNV0K>TP UOE[U*X'H%?/\+"ZL"'CP"=_4Q9-
MN5X4%@P^7:@( ED6?WL \*^WJ@XRN*NH#=+O>#=5D28",'[*S %<CAVWMS3G
ME$!21LECCA@3@ASUM>S%*M.?!M81+%EV<V[RZK ?48/8ZY$I8X]RHLI?K5!-
MWX5D&=SFFDA?+WN67!1YXH<:A)-I3Q6=5$#'UL*;2_PH81CH<KH.@K@VBI']
MV2/KTRP&?/:7*04#_IL-"N[H!)$6:-67<)#^GDB%F$N\SG.2O;-5.[]1 V(3
M$S2[)J=3Q5+KU=YXG+C.S:>9OZQ#_\$J5)2Z=9'Q;LDG?^M7P&%0O0Q*%\.%
MID/=74RYE?1)\KN@7\_H;Q5<6U_&'@:MOQ7./C%M7%O8B5 A7LP0L16_[-Y2
M&KX3Z0>Y\W/--2*4V4\$+T]V_9;HZYAQ$VI%XE+0/$):PVDNNHY0:"9=Z\7*
MVD6].?&%OW/S_1(P-ME9 MF\NG]J)1'_M^O,F7#<>'B-G\8J)R6;F]P$F56U
M[.4NG%-A9 PWE?.4G%TIBV?$8L?/N4P /"_0H/%7 T\FRGZGOQ0SK;!EA9WZ
MSIT:B0N0QZ4)Z6#.O1\4 <5#8JEXR11AIA31U:;]M-;1X%3*)"=S#)(=%W&Q
M@!)H5CNO<YI*CLE9FC[>D=/A I_IYL&A(1F=2%-8G]_WOOZ<,H9O$3,F2]3Z
M-[*XV]$FME=:\8;6?K:QFWT("OKUS%8/_?0'P-&G1)=I<6A+_MZ*-G[AC\:J
MA@]:V03)4??@H3/,]Y"7N26EE[]J9C&"7=C5V9*DZ:>7'Z=TN)W=%?\C,8$S
MFY0EC5 5+ J,+[(27IOSG)4^:Z];ODUM/W'@@R^-GT9G]ZNGY$4G&?.#QI*O
MT<JZ1 :$IGT@.;B_=^XSS1^ 24<-EB'L#<WOQ4$+&FM_,I:5F>+MV91G;=*I
MEPE,: 7.*Z6) P\%[KN]'H#1N:KJ D=?2Q?+E#L:<HP%<_S"B%M^?#8=ME X
MKN&H%Y)%V;#NS5N\E.0/A9G3V1Q;>D;,2CA=G_C#0D71_:&.*[*T9:V^2>!N
M%WZR/UY_=Z8*LO_B^H^8&&&?.<=@==+05K3<AR8.Q?)]Z>TC'\/1DA(%$I7O
M0%NOY$C<59@4H:=/WH7^JD-#DVK'TU4?9=H%OX[9J:=$]>;"0K^W_N"QUK1T
MUW$@97ZCF;KCZR.ZF&E[EHLM47I9?_"N)JN'AN9BC.Z-/Y$$#/X9+AS+*V8U
M5=93N:AN'^C!PHW_*5E)O#619. JH864=:X ;&O9G-QQ1%F@9T,Y?HG348$#
MU#+%JDY]U&;FT ]PEQG'#!25SI)SL[#WMKZ$+/5?3ESE<Y]F0Z;WQZ2V]W!%
M)/:CT=V.])8#C4)#KI-!"!76S2>K)G!Q(L'U#*$!K9:),Q(4EB0EKO DTD[S
MSA?C6**@/:PQ;B9Q9GYN$O%/25<:6(.WV/1Q>F!%H3G=UPNKCDN-G<X+>!4)
M-6,Z,4N0#W-,FN?A4:JZH*-D&>G/@BB<\0)<@]JOH5CZS(D$_"A7G;>EIXBS
M@)68;8RE#AK$M%3J%\SO]KS)\-B0C6 -<_$(C77V-#&_YK.*#G#S_4\R*=N_
M*C'CBPF_Q@7^_$2OZR%A'77+=[$\AEE!Z'9FI@:HY$.8%>1I216!<@.JOKBF
M+VZEL*6JJI%GL6%>.$US%!?HEE4P),MD]Q1'LHPJHT23&&(W28;XS7NLUSS8
M4(&GJ)3"<262/E=E7(+9G*QI+$E4RE'$'*)<RH,3)30_T;)%-I>^DS8U;2T+
MA.U)[L8XHKX;\JCCR)9_X\LWI)T,^FE][Y'XKLO]K) ?T]%7HDQ1:M]<6)H-
MA"P]:,1Z#O\MUR8\#2-VIO@3C'Y/ P4:0I)=^?TRC(=GA3[!3BZVR^SK$8.*
M7 (]_)E$?T*YSIMK9;U=')DW'.-6=1#'8$KI(D#\H&EC_N"'?) M;L/P@O#A
M^<!K7;B@*UI^+8B!*/,-O4O8S6O[FP0XGM2'9;<&<4A.E91X"VMKQBRK?C90
MQ4103BT>)$$_',QB;0"(172A6]NB>PA*N V^:>5V H^TV-I?T%WHT"JPS?'"
M?GV4;-<>-I&42Z,8N,7,<BGM\F3=4S01=O^CLQE$UO=!&I,$Q:9 R<96P3*2
M2WE\>H\S'RN\YRW6S.MAHAR:5/1$@=WD(+'ROWU0(_B[/TNY;<DBZYZZ9^0W
M'5D:O.N..PV$-^=Q-C8#"BS!04*"P"Y/;AH]FS*S3SVU%0-WHCN!5/MT>VEO
MOPM/P%2>&B(9)#)1PI:?=HGE4G6P,IB]_J[@+=TKA/?]1TZ,NS)R^=>%QGQ&
M#\""N!SD 4!AN!<$_E2!CQA>J..Y8#-\LL%0 3$GE(XI(PO#U?+K%)>_478]
M(E4%6TY1^^,&]RO7%,6+4()65_E+=J$!5)]T]YK]_"JPP3HO(0N1*PEWZ#\Q
M:GC0B[5BMDEQS&@2!4)R-#1W5+:4=GQ7C?\4>1T/B.S'_GWC-=]TE>V]N&4D
M$?V:W^I1C=*7EGI*JO(\U_!?)"V,,S+ GDDS+[@01+&WC$,+CR,1?7:M]?+I
M3(XQ=&\8?BF":(FV5MY4T:(+^;2E^4M!KFQ/I9BU0L+F?A)"6PL@,,8%KM_,
MD]?"EXV[.!F/"OGZ0F9#&\ZN.7.QC3G@\DD%NDS6W$3#.]6$#F0<4TI)5GK>
M_9>X(U;%FGZAV_?<)FWB]FCD;4D%"6C!KP0R[W'LPW3DJH73:__$./&^M*VS
M;!E8ER$>LW)TL[S4Z:(V;CVPJPMGGD8M3A;9?I6<WTI7WL,PS?@M=$,EF9,4
M3K[(0-^]  *=,)^5AQG7@<6F[FQXP%[( =QP:3YW5.12B@QYK-UX]6!1BKAA
MO*+?1CH:NE6-<;CS+_]%I]DS">W*^,^_*Y5!2'@0EXEC"^^<8JC,AB@5.W,#
M9Q=]2"[FTH*Q\0)K+!FRJ)RW+^KY,*B8\STLU#_&=RM6L.G F$VZ6YE+<U/Y
MUJ%LKDHQR;?L]@&PA9T%C(O>+3+6/0 !&1GJJG#V>@-W*F33*[[,K**.1$$4
ML2YB3981JFAK0#QD!"73^L;ZWI/$B\S-F*?0J[:JE:;2!/,GI$WD[]E%&?$V
M)2]KLXI><11G$LJ6[&Y.-?Y[Z2AS,-6\;G/<9L2V3Y[6 \!)O4FT>8<]!MC=
MQ2\=KH%/=0]-S5*W$=N+F8<3Q;XE RYX.F,L;N7MHU2*:&D,&.CW &%W?NN/
MT+'#-"\NY_=/^D(ROZ$C3G5E.IK%OMIW)<#UB43?NM4FY^[LX0,:I5%8"GI#
M++^L6"X$0SFZZZ-FN),-K8YMJQVXQ1=<"I)^/=,7-25;;OF3!,V9>?-T7_B%
MW93#JO.-R,]O'I2#(!#:O@Q9' R#20[/GXFAOTWQ2?SG\S[QX=C7[[%^6&@5
M(8?0'DMTZ';O^W@!:5.>S?N];;7Z=2P:_(J6[2R70(S9L95V^2\\UD3#6+]5
M(^@+<( T:A\P@J^'F(GLF9XB"LMF3F^*QD*V67J=EY7SLEO":UV&EHB]Y\+8
M9,JG!NZ9L:&R]"'HNL['#'7--PJ](4S+96TKGSGNE'-!FB[XHY:B&T9/^&OU
M*2E!#/?H:!H^!8EY'OI\39LLMO9=E'37[&?%[U;DK&PD5WK $5AP%6K*[I!D
M!WG/9"$/47T@;(\#)>=]V*'B_I FC(3HB]?MDNRXP&Y*ABZZ.F[W)&/<*2U.
MK+#?IO>XNHH"8- 6RM[TIT!W"Q6Y&=@/_$J0,Z*C?0"2S)0?@!J*H'.,JHJ$
MZ\OTNY[;"O*>CE/N7?H+!.%]<*,VDXT9U=LA6QM;"&EELR99@7,WUH^;V^7P
M"Y&A@0"#Y\4^R7\"J+V+^M;O3+<AEZ5XD]UY.N]MQ:E9K!QJ1ZR 6.ML[CHD
M^^JT] &[R^V8<Z%V?Y$VJ5ZT)="O(LJ.%/RB?":>\_3MJ@^!FN$YONQ!QA#9
MZI^G'NY, .V"JQ8>L4!R3Y*^2[LN1*JNP.'I-40O@J,H$<[;:;PS&EN.%X1&
MP\>UYH&78AI3Y^4$%T90N_5S<!66<1%,)R5-)4Z(I?3Y)=RRS,T/=/^%JK$6
M-LU=C@_7"$3HIW3@Y&FR1R!H%5A^L,](KPLE;\_W4#6,L&4F=>$AH]H[69X=
MF"3F<M+0J9E;99SKTH"9!K752AD-XV4D78-0-'().1Z C]"CG9Z_AUGID1><
MQ'MJ):W>'_OG-O3^2.E(69W9!(MJ\3M<EFT,N4A($P>9.Y19[)BT&^38/DON
MCJT<?Q,P<N6#;HW<-TV"03IW:FCM90!S/!09.L\:GQ][QTK)HNU\E?"H(^86
M>SJ4.G,5TIZ4.T3SG>$(VOQ<[@^D?L%SJ$=,R<E<"5[3/L2)P09=11 :1WQ,
M [PA'IOTI4DR39-A1K?6^0G*4=D(5)%0P)C))IWMF]X]Q#%YYJ!7N%P9Y$,P
MJYW0OG#8I_\8I#SDQY3%:V_=L^+:>"QP=1X?MW*R@-K9*8"C2*@HR3U5FDM(
M$].;_N+ZM6$6W:VQ7&G=]^_)S#'>-RI?[;6P&9[KTZ"%# G59S]O?0S+E'A;
M N%>W9^YY_BII5&4O$J?:]IM45Q;6/BH?6C5_5[U0['>:&$_DZ%5V;/'T_ZB
MKP.UUN.JB9<1&9SX =KD0!LNF>=UEJ -*F:++/UAFWKLS**@? CA3(Q@.7V%
ME_6MBT%O*8=2S7.CBNJ/!_Y;.--;W/?0Y0YX:O<?I^^HF]S$U+E=DHY35!RK
M+^,0^DKC6\P1$V^G@P%S@D\HG0O7Q9?XCGK,/:V]TVHLNBI.I-XF?;5L'RZG
MU#B[RX:ZA AR-M[I++V=W:%[.ALPM W=V&9;;*60M^ O4B'8+&-$&1<X-(TB
ME2,#G"4U1 5A*#MP]NCGAS47KC^H9HOL:\9F!K7U<L,+XK1.7<>]=LQ%T40W
MS><G S1+%U;W=NZ)QC0,O^HD;_S&2OB"]SJ*N9OPQP E%X',_@3IKJ YP8H=
MVE"54)8^HLM;S/QD-8]&76AXPIO[F2.*0%MF[([=ZZTV.M$J[%L;H;4HCY&Z
MW+6O 2-WF?N48QNM0*$M"H$<_==\8&5_TJ8YPH<EU#!I(Y'4PV;0W"]4?#M]
M*.8JJ,ULY6Y<ZI@",0T%SOZTZ_K\8(_?EL9W"')*ZQEJAGUY1?E6F4KS:V)Y
M 3U?IRC%N -%@'I9ST:6\<9$3T9L_3O6RF@7P0\F,1YXM!-:U"SAKV19_ P*
MP=3-YLYH "+CA4"FNQW:^ 92Z*(YII%RNL?XJ[HG&)>GP8G8ERA]Y3EZ[&TG
M.@NQ3^EA@%JIG&?Y5S."/1VAL:Z6;['=\HG=EGJQB+9DDH/Q5SL2T/.XBHX/
MDRVQ3^/=%#$A\=_MT ;-D?([W714CM_)=1OK:QU-8F*&F(:)Z(<1:-LW?3((
M]I2?[QL/ RQ\'\_@0F.CJY2S?0=-?(I-?/(4B=6'':,BK\&)WGO*>]R3G?]\
M6WRH)D/G[[U1$=VN6;2<@+_/N54XMTM3QP5+:5I+#%CHQ%$)..S<<Y1"O)L'
M5UUL-I_T%]JVMO@>6?DT.P5WU\7%%E9\8_R@I0ED7!"C,"1BTQ*(/9;;)T+2
M/O;( -[C(H?:A87OL'I3%0=YER;^KUJV$.)>E '1B>]V"S[5_B[$>RG+UQ C
MM9%2!@LK&JZCNN)?4]:T;1\LUEA.0*2_+3FZN;!FF*P<#M?=IDD.\)=J^14%
M9.@@ZP\ F:8-6V-'3\9RJ:>*]:<^)UQY"MY.75%+1>Q.D<%Q;CIU%UUZ IU)
M#_'K<%@%Z]AF:3['[;>K8;XVMTYT5!![B>K%K_+"5"U^=U>Q#.%JOI"$UUJ@
MK_L_>#*.YOK]JPAU&II@,XQMR5Y1K8&9- 4>0U[#<<'$)54JY==-^X>M-BO;
M84&633IM8J-?VX=8% VM8DO%1VPS U<COI,$^T%?H?3+B(C2S:!L_XV,\51L
MFRII/5DYA%W6PURV"5>&/)#US]RR*PLSC]$H)HJX?-)U-(D":Z]MM=+U'4EA
M-_QERJOR*?RD21'H5JX]]-\3,?Q$]2RQM50S8^,CTH(ESE210K-->55%'1&-
M7Z/9VF[DRYGE[>3DH<%'%LFJYZ"0H8U:D][3KER[D\:/:XM4GKUT@7N,C&S1
MS1*V2T>ESK+.W//)%%,J+,JSIJ]P:VG^XXRJ@^LC_XJ1&*MK^:E=/R03L3\&
M^![E;-R4MNN6J02N?]?CC8.I7L[5_;DA5<M:BD##4Q:A%!T\?#T98 8I^?H1
M3'"D/'=J)$0:'3!496K Q@+_AN<6MR#-^\MQZK$B\,['F!23TCB@1>/;#%9N
MC]IWLVR#>G)=TDP-C'E>F+S2YX7D1;@(CA\D_;+U'NZ!H(4_X[K;B7'FY16D
MWO[9J 86G@NHG);1JZ;,\S2<D_Z![0Z(=.UGG'<"OX$)05+\V&!7=WZQ1PYW
M[WF^-R%Y*X0F(BX28!,N+MR+ \0-KZ(HWX5,C+^DP6]O(L"P-7($DX?"1JBS
MN'4BX/T>_DLWGP-:+!<YV<N6!Q@"?RIJ")@VU,FEX[Q\@N+D+O-;6O?/E!A+
M3..LD>9[2A*4';_FV _SPG$2V?3SC&17W0'4PBY\.&)L4R*LS65+,Y!,\ZD'
MH%O3FSP&OJ=)L.<8Z&9>VV/>+7E M))UA<D-PS2%##$0.$YB@4K'.7^\^>"=
MM5630>Y\"XEOF2@"7#_0(=5[A<_ZR".%OJ;=O)U:)OG(&.F?IB57OU4KRPB)
MA?:_L])QB3RS=UD_5!K62V)M3WK#5#]L-$3=#-:;&%N.Q9NOU'F"D\KPQ"^4
M VW\XCF%Z*Q'UBMU7)T($GNRF1$R_,DD/JJ:=Y6]=!36!!I<M(1]5XD.&0CI
M\(MHY^)6%?;F4%:VM2OE8.(^;]3A!>;:95?N*6@9EVH8;--M*I&)NZ&<X_U-
M+X'F7+#$3<\JQW?8=%SRM?O]%CA;^2A[-@G.'>$5]-Q9T94Z#00@#6MJ]I[_
M4J/V^GG\H\<!#-_1<K*@XM3;I"8<[03#*6QYDI:$]K7E2'#T.69)ZBQ)K%@R
M4R[8LF!6%!3G?8"KWT[4A:2:S$PEX<>+*"I_^Z=C%G2]^F:IT2OSZ)MXJ<R8
M-48^_4<FRJO/<1S=7R$K3%K[@P<_W_0*X$=*HFS&4NW_C:42P\,!-B=B&@-N
M?X#F-6</(^]G\]I-*DO1K^E-1,_3%AZ 0^-]CER"5V:D^SSH!?=/ NT"(EE&
MP+L/P#M'N?\N!$'W,<;PE@<@P3YH67JX[I\/])A^)#T IB\>@-^X>L1L[-%2
MEU\>  OQH&W'W&K'O@D)5T-)&+<@0KN9DUJJ<T#RI3GBM(Q>&ZF!V+KV&W !
M_TT"K15Z?%'^;5?MLR?%-3@06>FV=L]F*QUY]%NL)EK.ZIXH*FI N[3D 7BJ
M;"NG[K40N[:"/@>Z;(X62+A6F-Z_R\^Y55?R+?4I5WNOYD)HC$T=.U)ZF^O]
M.\MM*E@(]DYF#\Z:EF]%]/6S_KN0AF;7">,.T\#U,=V^%[__^AGY^-I.5^61
MA;-\EA-H/;%Y-T!G@ Y\L)HO\L"M\$F*IC^)5?P1WDC2=?OI)V9$<Z!PCA7-
M3XQG\R_DER(5?/4,[^7GXEQ-V;\C59HB'+,(9@47>)G2W%S<IR=.6UQ2O4HE
M^1)TLV?S,+]OE&ZD'TJ1)ONNW X2XT9-$C-/OLOJF".XICC/):C-1 WDBH\N
MS3*3;YC!LY2&];(L4+M27AT;GNYE\V0,9:SU"/\<2_CF5AJ?-3!<:(OL@]Q3
MS=SJNA0MW*6_\H_CGUM>_(P>35,_7$+GT/""S@S#=W-'D@-M<E^X1SOM6&\6
M3$MDU9 F^$H@;87"*J=WSEIL/GI+NZW;5$7Z;%HG(:'ZI^.7V@[D1[&Y.CP_
M06:MY&WJBM#ZXV 99CV^@JP.<2>108IQ=<#OW7NV/&:??(2Z>$#I04&FV[C1
MBN9]*#>_I'=O_1C,1\RPX.#,X4G"**?5V_.K[&=T+*UQ'B,^0C$C0M!91/IX
M<X2@9;\*-HXL]65(O&8CX"=ILV(V1AXMN(^^M+DL*Y&0-*[5CRE]7&"4]G<'
MRMH]].LJ!K IG+'HDKP_<L35F950<=D8X?Z:A2DM6K43IAD/1XP1BQ^(?$IL
M0ST<DN2;9@N6)&X0PMT]; QDFF/X\6ZF_MDWFG6K]Q2W,I4F9D_WS^03@[I9
M UD/?-32;9495GY^7OR<IJ-$X\'4X F6ZWNQ+V9S,1=.%,[JV=@,:SECM:?B
MS[-FP<"=2:,%CF5H[]X[4J7L3NU"0Y3;OIMX/1-#K?2Y^J-@L;0OQ=?0&+]Z
MW'U8NE)FP3/V?9E/_C:35!^\PC?C57GG:#C??B>\KWLRFC9'-A_-\.(M3^_H
M-5<Y45#[6P#23^#*@=91^=U1)T6=*BB]^8[MDMMK65P8DO"!FVKZ+=):O_)Y
M.\<5.>L(9^.W:&8L7RWO']Z JT^_;)^-3X(.DCF+Z^BL)ULAO/%<5[GV;4Q,
M:&<B"0.%> S'H+/H. ;@1VKKF!&VF^$"M\(QF8B0>'%PRI4S@#Z'W]2(P/7!
M6?4Q7'TKD*[?W H5F23 *5M>?/:-2^.%6])<N4_: ] [84638J<E5Z(@Z+[\
M^:A]M], _Y3A[4L9OLRS0QG:69MKZ'V@@$QK>Q,P1O&N+4+I&>BBTI''L8]S
M9\1__5M)_/LSL ZVI6($OTB\^KC4!WYE1*97Y1KQ7C9;V\E=9TX/T_ H,$\L
M>2J1E%]KV47R9 '8M)7DRP".]ZI+W.>,];;@@#$6G0(HCZOP 5#=VD""8KS'
M/"2X>6:+^NFF6+,Y;,)]*=+] Q'!RQ[CA$QQ[F=]Z7",K>\=D> \^UR?A:'2
M,AN\0FN@A>5IYM-X?,!3++#GW6Y3,R]@GZ="0= ;[##F*J;8MN$-@[77GIRG
M^XG#^TC;U9EDA5_%#B]-8"UVTGYX>U7EZ^E"UHY_&82[5%B0L[;''2HII2>1
MO?*H1G5[FINITB,/:GB;_IPI?;N,Q=N&[4](O*R\#N7&Q3KT,*H67))WM)\8
MKA][,3%&^1YM1$<XV2]E +7)Y!WR;6]11QB<C'DK^5@KBN'OP;,@56#NY+Z
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MB="O][,TPJ5%ES$":,3FW@4'FD<LX"6"_^]NIDU=BK(YM\$+\'YT??FOO%9
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MONF_^7>FKM'Y\+*&I93)/S9(1!B,/=$_$Y^0>B=?2CW-]O]#IH3V/QT@\!,
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MA:M%HP^:U243RLM<GEGZT;9I@,R (,LLUV1'+V*8]V; WNC5X1=_8R^W1*_
M":QV:,_' R,?</^>PG[Y6=]<.G-N4EM7>R%YB%A>[6=3.0OFTOQ)* @);$J2
MV)DL!LH;+'8RJ1Z(*#Y_@XT5MI' _;):Y&X3L70U>:0%B!G3=+M5]A$,_36?
MGXGIK"$@,6;.XZZ6%RWSZ= OL.BJ%:L:9CER'CP5L'/@&]BRY92)@;P]T- L
MY4":$N:S[Z'@C"TFO:3,_SCB@M4D\8G<%=QOY3AJC-;*JB,&\^-"TULBP?5U
MCJP*[3P$+&UEU=,[XB/$ ,"!LR4.S;/(Y>;)C;TJ([']'.[;^?TL,C<!S$K
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M0 S(<+!(CA0/XENOLQS'X)[G50.GCSUP;Q/@!?C<93[EOCEQ'K<$&MECC?U
M4)U7CAMB."1ZWD4@0!#/NT)>[5W"S9?[>S"M3?#M8L!9G:I$&%1FCV+U;<%=
MP$.X-M+]ZQ%L%5/I%P$BL*G7%C58R,5Q"9_3F#G49BI^3,EB$B9\:U AZ,)%
M<9?E)!(F9<<T5]_Q7QR3-Q,#Y[*H'U>:L1PDF3PT<Z%99*%I2=2OP$^H(/IJ
M#(8H01SEV,&80T.6(:U1Q> E_^7&JG(5UC4A>0D)G@KYD:&.Y/R[9ZVPBCO8
MO@[ *0#S*%WHR&'S(REVEE%Y CQS:%C0FWPB9&:&O5R41TP'H[2\&M 9AT=A
M5A$'QSTRCQ7@5T"8X29LQK^[!2T051873I$@_3*$'ZJ'NXN!5B/ @(N)&& A
M!\5 KQ57CRPL+_/\=4\,K#_W<RQK5T;Y&R2^P0_33O.O$P,?[*34GCX&.U<N
MTM^_S%#-V(F'[ :W(A<04U>PGR,%:$U'J+9J+I,-]AVGXD@!$XB1RS1FY,\
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ML9Q2UX:HW4A7XLXQ,0<46=YL0S/>72XWE;)4W1VI'$%$ ,3WBTD@,Y4<I6M
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M_MD/$D<T%8 ?)"S72X@Z_P-02P,$%     @ :$!<5(1'=H*GX@  ,$\! !4
M  !I<G1C+3(P,C$Q,C,Q7V<Q,BYJ<&?LNW=04]_W+AP$I1>E20U* *5*1RD1
MD2Z]=Q$0 6DB/204 44Z"A]I08I(C?3>(4B7#J$W!:0D("&8PIO/=^[]W7EG
M[A_O??^[,[]]\LR<F7WV.6OMM?:SGS4GYW+A<AW HJ>EJP6@H*  I)(/P.4&
MX+9FB,=S ,#  " *  !HR'TW )3D,PKR\9]VN030 %RAH/CW]S\:Y57*?]LU
M*BK*J]37J*G_!0TM/2T-#1T--34=(QT=/0.Y4=,R,3,R,/U[_N]-_AW^[RCR
MCX&&FH;A_[A==@.NTU!Z7G.DI+@-N'*=@O(ZQ64_ $BV]2K%?QK@?S2**Y14
M5Z^13:*C)U_0P$(VGY+R"MG8JU14Y-X(<C^ ZOK5&[>DU:^QFCA3W_9GDXE*
M^TPC^*BFA]UT$@V2??8JFI:.@_,F%[>0L,B=NZ)R\@J*2O<?:#S6U-+6T=4S
M,[>PM+*VL75Q=7ON_L+#,^!U8%!P2&A8S)O8N/BW[Q+2,SY\S,SZYU-V85%Q
MR9?2KV7EM77U#8U-S2VMO7W] \C![T/#4],SLW/S"XNHC<VM[9V?OW;W]C$G
MIW_.L.>XB[__^D4!H*3XG^U_Z]=ULE]7R#&@HO[7+XHKP?]><)WJZBWI:S?4
M3:B=_5EORT31L#U*^US30RLH:XIF?_9JDHX#)+<AA/G7M?]X]O_-L>C_7Y[]
MEV/_RR\4@(&2@AP\RNL ,(!(*$RX _AO_#?^&_^-_\9_X[_QW_C_ARW2 X+'
M5)?[6MQ\Y]VY@AE).3R'9IJX]^@IWP&;LW9+401%FUC=M\).,R#:ZA(05WP)
M^,XY",<)P3#561OQ!+:VC4O 0!7]0'9<EO<F>WQ/JXOG?&^XE/@_']9C+[[9
MJ2:+&;FK(:$H9GVXQJ2]TP$1,ZA#+.ID]7"4^>'2^EY_3F5-2-)8O&)G&-/X
M$!2QK?K7RL.F0^[YNQ6'JVPF#__?L,HBV!,KVQ71[EO & AS>=_7H8J03;?H
MGHVW<CI(]9NKNE2OPBD-A+&LZ7;YGS4#PB8&CAEPP9N2'S=X#CV12_VMVT:J
M<;G'[XZ*'@Y\TBZ@64NK3D\]8C/1!/P'5AFD6:=&D5B8JP2K;CM&+BQI$#MS
MS%BO8$(+4F:3E:9*I$B[F"\(H41B@3?:F8M#8O33BJ?/*G2.)4;\EO@T -K/
MN7KXWLK;5\^+?')<,4@0^VF4< E 6S #"+=QGZM##/$Z&+?5DH+EB.R-*O%,
MZQ%OQH\7=2G_!+';=9.OLP13A)PC46JQ7N19Y=$(K')2=Z8?^W*8Q&_#(2\>
M[%?P;>A UN*@U&L![DV/^C7SP<31HX0TDP^<O01XO+\$Q/HO[>MO,BH;<7](
MK]<X0,JPK2L$P'.#ONIVO'^E'S"U6YB@07>G,/(_$!N# DDS4" N#?-K ,XL
M[GT&FFL'WA@)!=5<C>IC!PJZBQPS]7:(YACX"(&PY"&IO0EW"J[\'T$L.VN+
M.4Z"=*=O/6NNTFH@F"..I"H+^ZOQD/;:$UAPS(4QYP/;_VG0_Q8(>1P?WB0$
MMO4KL=WM\R[V[P=%1YH..YZ?+6]OZVPW7Z41$3SWGN?[6K=L/_0BS(*<)O_+
M2@QS#+QI/HJD2 B:[03N7@)0^A5[S[=#IWLK?%\_]4NG6?('G>BLN]Y5K6@A
M%G0^\ #7I?2.7 (X?J>NVGN@PI'I0I7..\^.6)[>H+;DVV^Q#1(RE'"0;2SL
MU$PAT8N@?UHP=/)AIL48XASNL4#C \.U#UKPUB_ #?'Q9][:ZM-G56I\_'O>
MP@Y:2]_=GS]<_SKTO8>P-YR;WO8860DZ^+1O;G4?$[#I'=^#B,N>2)#7.0)-
M_U%^WI(G8#PEDSQ,RZ7R=\;I6J?HWAJOVLT7J^)3+BWQAG/KI^OZ;^A%JS>[
M[E&=IH;/+*)V3L46]N_\5VRK%;>.D6-BV&"<35E(FVW<282B_N+/DG+JCTWW
M3")U^(RJ:!T6*8.LW-TT70A@3!ZBW_?*BTZ!&AO+0?N:&.,F&ZN7[WEK*A-N
M!BDYP\,6_@]#_G\!<L3%'K"G6<R<,<@P/FB!)5X".%_#HH ,9[[L7O-7&!5U
MWPSW@57&)EW45SY] YS)^18H>MN05R3:!(8*A5) 5!O0:W$21:VXJ"T-K*KH
M*DV,@4]B$!<FN479;#8%+W(=PD&$VV'9B0DJ^J&\0<'Y,AGZ.1:S/B(IX\EV
M45QN;R\!87+;+BKI@[B*.&)4)ZL7L#YK8,P,^P;S!]C5^;$0/9 8(XWJ;3&2
M5M_]*O,V/.]P)AJ:2JS^![@(&US#4K9> B:?-Z)^X,=#5JV^DK3I\0^@,\-K
MWR)2!IAO2B1];:IM:6U+[ET;>M=H=%NTT'6]D2W"(!0<!94FS3C5PZ.?8\[?
M.*-A\1!EZ=#75=Q'UX6013?2J8]O\A<#<^[<3+XG]N']PTX,)X'E:%690E#7
MBW)%KR9IH##%) BJJA!S834#_@9/DH-?)R%)5]IK6IHX6J'O&$O&>:\V9++1
MBDJ3^"I+$2_YWUCH3;;IETG[&&AV9LE> IQ]46==GL< 3XER#\PN21P]^[UV
M3MQ,V6(\Z/OG%HMGU0KI.G?Z1*(C!+?B$Z74^ F\&*V6T@NPSY3<T-$A878Y
M9Y)>4DM+2_O)_# 8_>13%G*M_G@0QND1WK7!,]/@G5E[M3^@SD LJ71&DGE*
M?5]L#X$J(AG4#<*P5]K(4V9@<J=$65#OE4_>XDE3KQ%*$)M%K.QD&=CTO3:X
MX7!M0N_- &B>8Z,$<W4J0"#66J:0,I9/1OVBKCNX%[QDM^5[^'YC)(*YFULR
M?F.-Y86)(@&$6B&$5PEFA8O[]_'X]"D]LF99N(\$#&&!.*$/7L #J?6(<D[I
M9>G!5SX@X?9+ (GFG X13;KSG<W7EVNY3*U =!U:>EHEY/UZ85S4*,NJ_$'*
M@A7V*Z:K'_X6*H,+P$@.#P-OABB^K KPC+JQ+[-D^(C0SO&(R^\F^*&6H=0
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MP.CY3?R+L%E$8J%+B2?JY6V^6@9"LW%!8E(Q.X-,*8@7B*C8!B[EI"Q-8[W
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MX/N$7LJF$5(*YP!$:\&:]!4_191$9.BVJ?:GVB-C3@WB54\=>)I'1G<<]S]
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MNTYA* K(H4);!G._!#S%R0MX*P]'%B\^HUA=2C[^;I4<,H+=Q_5L.J$4D9<
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M,FJ_;T>=QS_3I?P*.'4H/=3' T.,L/4_*KW;U;%X'N)M#8FX$N<[R3]G<GT
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M_$'>W"<7\3I0TPDHHR9MI%'OMI39X+!81V'IIY2/CK\R(1+$U/:[Z%(SS-E
MG:=M+NSZD=IDA9WG#6V0RL4GG=["U-(QYU,.U?L(P?=DQ;CA(*D_PB<R"&2I
MA]'OW_@D*6?GH&E)35U^M)37O)5JJ'R.J-@MQZ;;+L/=.4M2>'#T>*800:P7
M[E-Y2$ZO5[GU4+FU9"Z6\8%JKDF9UG+1<^)V :BN:=77%H7CPTO@8.O4B>UN
MU2_F;3L&UI*E+/]>2 DE;;WK^0]Y.JTJKHJ'!3A^U!2YJSILG+#(;U<%'8+R
MS,(\',";Q9S9<Y\VO91]:Y]D!F@UMKX)UR-=<-$K#C_<B%]QW))'$@+^_5-
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M*[=@^UA0:D'@1<I6;71K4N=SR:*ZCV<'$1)X6^C< ^:#3^@>B'JYMG!)8(1
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MBZ0*5;"+@U\B&J(]!<)K!E5<]7X)7E?F,NH1'%%D1/_M9:XRR'6)GBB&-_'
M]F+XRQS10&8(_VZ "4,^9N%E5),B6V9(7W>E:L@W!][I.85U$#O((3N"#."M
M29V /ED^XW@ZP70WL/BIST"?RL7^D#O'@]8.9?V2T>]M3G(;]@<+8LJ08"!>
MS"ZR!DPO9P<101L6I1D:LAPK/4Z3N)B%_C9;??QTYE @^QL2747D.<^U"F3
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M#8 F?844T8T,J22MK7[OS?=!3#R"BIW_:.]Y=!4)DUC#:0^2 1%_<C@YS,B
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M"8XK@\[2S39%6TN<-6&OHU;!%7C88 .A(D[07AWV(F!R7RK?=K0E'%?0F\U
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M70\[!#'!E/R/HWK27L3]CGK)?+%5X),S9'&G15?MFE-[6Q#W")'>V8-<;]@
M>C'NIA+<+\3BJ0T4Q14N1\P.ID#<-H[WN.07HB@ 4.Y<[AH>3->@[@Y0K(MR
M]B_I2P,E@@X\!" +PE'XXCEZ_--*+!0IG '!;DU$-IARC$A%$!\K-]B)Z/1?
MJ/[1*+W[2@<^,7PQ*T;$L#/B%9TZI%$%Z3B)LJ]+6V@?I'=JXJVJ#;0QSS"K
M;[#S2J!CX^+J<)X$M>??M!)A,[%/_>=8!M,TN!>I&$Y]H@A=JYJ7F<@>6AG+
MB;,PAEE#Y!\6V.R&1'%8-U4,N]T1%4Z8^KUO.IA/OA"/O0$\$I! 8#G<R)<;
MN]O3KY7A'$(W?4HTT/8C/N)&#=49V\6Q*F$FJYEB-U?2LL=_&Z19]PUE-[W$
M)1'911>1P6J/KR!],#@/'X;T1ST.=O)]%UH6D=)L7UKWKS06M8 N[D,B@M@J
M)]14"\V=>?37M]^N3.O_)N=,QBSN7O6(&\N,PLS%*Q3\F5BJ816?24HK1CA)
MO2U"1]\V&Y?3@U;FC>CGW_TB7&\\T>O2$OQ&^7NW$OOOL3T0D5V\4V4NHQ7)
M1'"[/2HIE]S@C.&U$L"L7YGL85T5K[FH*5&M)"3(/#MV:_M>AY&CUNQ>*H(@
M3 &T@X';P:!(@2LC1STQ$H;3S!GN -0=4A+X&?(LD9;0?:XVAWAO0DV_4,=!
M[EJ^M=//@2A4M=<F].-6-S3@Z+ 3BGV ""-SDJJ(K-CMW57+NB&B#KJWJ,<A
M$4L?OHT137@!SP%\JA&*6*< [)%3\;=)$>#%'(4@_A3%L26<=IB7%[K?X)?T
MH!,GR9LEFXA,>/2VY;>*[>LA"=/.GRL1ND3UEQD!0UKL/WS_09)X"TO+<F^7
MKNU:6/JG&WT<Z!9;^%@,)AC5Z9# B$4+"B :X#U3,&<Y2!2S$B)G-&,E*( N
MY-]^KT[S9<0UQ\<+C/WBC3P.H@!:JBD 'C#:< VT3SI%A6YDN><\GQ36%?]X
MH+Z0=)<"R-\ATB-P.61VR5@* +) X*  EK1?_S7*7Z/\-<J?-XJ4:%N)@)R]
M?8.Q09S^S"O:5<MI_<690;;VG,=S"TZ<PV6F'!,R=]^[^_O24N??7_D4ZC6B
M:*JX!(E4 ;[JFMGX3?X9M-4 ;4ANBE NU<$TE6'W%A.C\3OLSKTYMV:UXZ'-
MJ<JK]'Q/$CT]7K$).'=YGS0Z8Z(\+8E*V.O33,@04:+(O$P"FDJU06%JC\]&
M2>KU.HV13>!CF4\5.B,<S2S>DPUL*?@24:(0WHZ^&1]9?$602>-%FM=T@VPW
MJ,(D"3<!K4*B%UZ5DD6<>)QE;A=:ACAFFTMWZ=U?8K$!H(UV56(J* !Z.!AQ
MT1'Z-$7_-L:.?#Z.?,Q>.9PERGV^N3LF)_X 98Y-:MVP #),S2Q<C5F7Z_AB
M)]OMRDM*6.*SJ>2YDQ&@$TQH1W.^TQ!T9EYK9JW<<NCD9.3I:[J(+=1(SKF3
MKWIG!#A_+S/FEXW:+]-J.!W!QP>[ 7$VVT<P$:!:=X/-UWB,ZPK>K*I^:CE*
M/1NCM%)-VQ8H$A!8XQ <-'H$+@']W2[QE18;/77P^CRGO;Z"^-L=0[3E#8/7
M3BB ,PM$)SFI1__V?SS_*:_B,NI:ZO!W@J'SMPH\FOJO,?X:XZ\Q_OPQO/X>
M254TJ*+IP?0-)<[XJ#Z FXQ]?/YG_4OK3O^MLH)I![BZ.Y(HA!Z<Z45;3<38
MED'I?]?QD^8P<YVKVB?AY^MO^$G;<7']BC@):$(0OF 7%C.ZFJ=G;I?C1/J;
M\G&<[?@@;Y[[29(VSTT/(U>T#GEY#U_Y*PV<YW/4GYI+'M?O^KXKQ1@T#?I&
MKL=8!&H<MHP?,S8NO:D>E0<S=#,6MU  '(MTQH>"5%:'1'9JS [QVL+DMQ4I
MIA[&;[!7K;G3C44N9EN?=-VNH[AV)ZCYGDQXG7C#5; 9X0@[*2[@Q:DUW/1:
M@&6U0GR%4XFCRK4;'UP+];:L5;:[ PC5F)C7I? _.DXIP41-:O0BP]5D"\N[
M+XDDN]P9N56,F-)OU<DT,.\:=K*V9_6,\-C5Z".E@FV@-/ ;I'3O#(9YF)O.
MZ)6FK]IC*S55CZWQ#IJV(A\=N(6OTBX#;,8;I/!TNLWVS3,O,8C6&KO8_7,4
M0'AI,N]WR]:VNQGA;XT97GY@/YAHS1!X#(<0]-&#%]=VKX\'5'UB[+,52'UO
M!\EZ]%[GV?DMJ CQS"Y9B@)HM2 +P7+TSP6*MBN IG;<,];[VJZ6_/CE[CG4
M@[3#?XE*-324--#M[#AQBKA:S/3JS[JT08F3OC;;?T0X(4-,!?A.O!S-$QH[
M_(Y=?I^-=/ZX5_&5;^O2.Z5?#FI+[.L)>PM$MC#\6YQH"S#85P+-_W6#+#*Z
M-%Q2FDP=F 03_K8:O0HX$V";GFG\J%FFC)W' #[#Y]<%G6S&.'0TAX*!/H,$
M/;D#0C^6E"M>*-K#N,NII'^B@PU5MCT*?S+G94CN WWK[M0WQ8>'89*Z7)PA
M#6/[@>K[6U>Z^K+,;F,';@$B;EB$]HB$J]/8.D*_YG<7S:EP5P*G9:TK&F)O
MZS,PZUWWD%XOG'_V"VB5W0C$>Y(2@J[ 10B?F"HQ&5''J]$5'[?R0BOJ/_(+
M^;UP\;P?I6$I,+?A("YNQ54PKSM%6OWYX8]BN9?^J6_<QF/RJ>I,LWK^/F[.
MO#<>#M<\U%VD2C]0V^MVIO]O >MB2,/G5-5)7]?P@_(=9>T,-M>W6XUU:N5O
MMY&E1HC.3T7&D]VK3<I^_#PJ9!JWZ_*-/PQ3UV'?VXFA )Z#:=?3%6M&Y)JW
M!J,$+L<\6G94N44[LJF\J"?8H1>S'"F@8FSEIDT(Q8GWEN,0$9>Q DF"5'"I
MQ<Z]@VNF)W&S-K^VF5IH&QTW3Y)/'G2[G#PD.A.\T%D.N80DRZ::T3>AV3\K
M3%]&;FDN\3)(VY6EKSX7R*[YB"*+$+IOT>=-/F^F@G-+@1P;C>HGMM^O;K>!
M_5CY* !F!]JS#GD!W9LD++ -<;Z"/54+FQ; ?] %7RLULX3V3\K%LYC%J3I$
M[)166*AN3+K:5P4[1[K?,50Y]WQOXNS^[ZLK>G<D30X0$P>[:HJ+#IL3:# C
MK$W]&8AQG7QE3'AV0D <I]^=$2CNTZ<K^.,+>-:(&B6_\T@SB5G.4ZR'ET'F
MZ_>GV]=&C7[H;UL^B_O&RZ9WUBFV,+N@Q9@+$'AM]#])_P73$/(X^&MZ[,D]
M6(@^3B.CQ$F $=<5D77]H(BJ-N*+B(G6C\1IW5:&\SWK2BA8=J&,XQSKU2_B
MLDNDVV2ZYB54E"*'+X*M2=;9^@IV.2U;>^3Z5G]-7?>M ;-7@?BRU6"@_/X2
M41B[F4&/#*8 OKF8MH.>DOM/ )9W!&>JW5 /2%Z#ULZYV>'Z9=II)MU=B1G8
M^Q0 "*[X]N0. 8$[Q<,[(3MY?CSPJLU="]J3UL>69^YNGW$X0/F3/H#MI(#D
M'B@0JC5DFX+?QM_T*%A7!-"A\KK^Z O)MV7M$=\C'+]N]"A!5][^ZG"4U4\#
M+?9S?UKL"E01T6H(?XS.8"+W>3TFA&AE6->.2V57#DLL?FB74X0]BQ=_=7>2
M:I&ZWG?^3>Q^-'R# J!1P$:O1H(=G!&;&<"-:7RC3;'%G"-BBFX%8J-"*ZXJ
M.5(G'5VL=-*>]MH4@M'V<?N^Z0]N.\F84=7$6H56I$##I')BV)@U2M2;9\XL
MVO2)+29V6RTH!.Q9UYXH.X,K[ X[S]L0$G()#WK;%NP_]$B\*1CQG_5_0N/I
M'O0"-]TPT4H!8 V 428" E5AEJ1THO$7)X-,5LMI[A*;CT@,<P6P6B.U;/]T
MVSZ!7T!XB$Z$5([0$B(W#ASL?5B5Z#LF5<J/UK[_],:3FXF#($6G<=VI>B$N
MS[G'S1N_ FFTV$R51_^L4,'_AVX^*8IO.?CCUKJ/K 2'#)-YM0\%KN(^9Z!=
M^+^6W::B ![4*_VN[?59/&L8V$EOH&CG-6R(4;[R?%S+4:AKF7%/,L#61+%#
M(@C$ #-<V5TU_XK=OQ@]#+5FVUTTZ 5]#!V@ZO)4CX:?Y!.?X12J\R"B[=!S
MK6AUCHUS;NRPSA16]W/NN!;=E$<3O%_5BQZA'39+T,A(4Q VEK#4P7-JGAX,
M>!;XV-Y82]Q6[N,(80Y=%?PT/[EF[FGQF'E+*EOZ*2E+(DC0:1C15H)-+,+=
M-HI*0+!L,+EXJ\J2T-=?T5*73GZP]7X&*\019<'<:HX.^7!#'#YO2;PH7!,!
MA-D)3-SZMA.>[+Y'%67W_;M:22 SA@((K8-&5:A:R=BE#T(JW'O='$2GEGQ:
M><]#T:N9G<\)T-8Z:/ FQX1>6559J+8T"\!B/2"C*\;G9X;]_"^-\X27642Y
MGY>'B>#<M6.%C/-4@A6ASV[&J/IHK*949\,<(-C9^U4*OOCL6X_[GE,KJ_>L
M(W@:_\0XT?_LQ+Z')+)-=%A+8L$MD5(78:J=C.CZ.=%',7IO.'5=IZ.T+&Y\
M<6N:=7BR_.J%=^NQ2L,"OF"HB7\=3(N2;+HZ/6E%@-R-E<JU^-I7)+;\L!#5
M-^"7 /"1,*9UO**E!:OP %]H7LS+.!\D1+@U\K >YYN$KE\3>N3UM% /[^^2
MV]V7647]*D F[OS^+Z F 7%B0%0FE&",AHB*2Q"FC93BV(HB9X> N!_?:V9G
M;@Z<TX)#L:*6I+0_;'W,,33$V^TU!6!7.3;L_V1T)_=Y2.Y="\\N>E=:KI-9
M!RS*EO1.4H.:D(%);Z0 SBL&H['(&#7)0P[3BY9"(NTW5U[(Z"0J:T_7?F>H
M!<3<5!E(,_7B\1'>*M0HS(X0I_[';/'_2"J5Q2B&-QC8P:O,F9*<RBJL7]3E
M;;:Z;'6YPS9B)YJ'&[P@I+R*01I"U?'$W3&UF[B771-TOW0__[[+T_4S^ $/
MY,  <),F7)AZN/"&VS,1 XG!;#4M+W^'[-G>? L=_T ^VU;JGN7BDDF.+:@J
MT9K0GTOP,[0 \L&JG/NMX?X:+-@*%Y] A0!Q,5OD_5IJH1TC+($3X[ E^F7V
M,:&W*S&(9CCA=C^ZF6Z6=E2MZCN]1X"_Y?YE05H^9NO7:/ 4I!U\H0%T)6G1
M D84]?&XW#B0?_;9RXV,G9V4^_6R/K,0\X)IU?='>64K*1,=H @P\U:)R[9D
MQ4)P$W_-%,.9=:U1N)9O&E65=,*;#'<SOT'S?4@HHJPY.(C+B0*887D\"XOO
MB/.2+"_I<W/C;IZ2VLT?TNST)I\G"&42!!"56B\FIN,]#R=0J[/*![-S8 93
MZ)W\(78NG]A."J -.8PBZGD4.HU8.S_2OQ9W=?O7'/O7Q5!COB>^_;X<_U([
M[N%_KQWWDLK0P,"WUT#O27;$-89_=DF'_TPDOHP@B&O%5[<@&-<Y3>*=!/B&
MB 9V/B4S=W*3JGA'XUY*B?@O28JO1ZR0)0DA[1I<!+=B:]@/%PT00UZ]Q%&C
MU<\*EU;#&M7R-!I W%V ?2%+1?SE7#<.Y >B#LZA54."U-QT?D. 9[Q" =LG
MP#4:IRRQ?#>S@O?!Z-.6J"@;1T"4-R9G".Z(I@"BH%B30%%#+%_B8=4Q,,SU
M$HXCSU[18D[Y1W:2-=>7J[7;IM2JL*.B[CKD9GXQK,F_ L$ -U+QLI1..M&X
MHV?"30$D.@MQ&.^?_2(PAA\DLI9W@L[Z2)VUGH(+ORZ6S)H^SJL\CBU4%!:_
MIZLZ44!C5K#66AJNDP"U*O9LLQRN'#_4>'^J(SYL_<<'NQ6#V6&8A;;RVZXN
M/O0G&^_O*XR_Y^9O68R#&5./?;P F"V0YZWZ.K+RZ6D<.BLZ38>KM^=U&M#+
MVF\)$C..H$-;672KC(>B]>7$_7T9I::E).GX@$F)ZOBN8LB74D$BG/ )1[H/
M92""3E7D0+@B/0;!T?5L/I^P6 Z=!Q=(WDH_T3>,G TS>.&3+DH(Q?!&,^D_
M,JP;)@L0@N3G)%;RQ<+'8&0<%<2Z1G"IQ*,.LN58")NX'ZE#,$"70+M=GJ??
M3Q<>\[+)?<O5FVQV[L.!TLUC+W,>X*;J9UTO4N-2]*.'A#S,]YN)<P='"FM5
MPUC-B#&J&'G:6H9)M7CK<&";WWA)3J3U*,_*L,B%%)>(P+@N>3Z:R7PO@-)1
MC'KA#IO6YT&Y$+S6!%GZ>U(&1X.C/X;>]U+7ZYS$K\./IJHR9%R;.S25UJSF
M,[ \_!R3OX_O5*5S8QN>7#?AD?]:Y:^MO" *_=%X9GA8E?<Y.I1#Z>G#=X5*
M#Y4 1@E\FT./[G9ADU[)(:EGOCGZ&EA4A*S&[^B*GO3YRY=KL8O\A2'^9YAB
M-X/(/M,6$!:.<&"47.':=I6S EE6UX\_K08W*+3()!W.9+3[OK0-A+STY_CD
M*-^Q>_UARUM=_I@S5[F%233^^9VH-TTTI)J@BX_-YIP@13!7YX\'O"]++A.O
MQHY9Z0S4?F__*D@!W*MS';X_D.N?C0G7N "+1+LLM/.K$WG!H9>P&RU%#+XK
MPA<R@8F:_O/@2(3R@#\J%<X*"JG,((C9!DRT?_&>T0=J__R,[#A,C(I=VYMM
M_A&;Q67X:U.B.OCAX;FZ;@H@6!K.%5LM9WW59MWGT1\IR(I$YHS%VOO?TZ].
MARB[&*%U2'OFV@]-QY)_R/-7F(.,S9Q\IXL%7$HZ.*5#JN$/^+W68DW$>R@
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MAA)A9C$LNM)?[:8'^GSG0-*7^\N?XQ@^7XS?NW'U]Y*'2-#3^"ZQWV"L(4B
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ML>8JCC-ZW&+]4(LB 20&2+@NVCX'-JO3EVIO4L)QQ-M<B@FT;G_PR/[CNN<
MD^JOU[']@?18G:6,MXCG"*H90GQ;7? ZSXM-@V]YPL$WQY4O[A;+*&ED[C(Y
M);5(!0<HM@Z^G@:]*=YTT>AV?LIG^J1#VE]<<,_6@Z@U6:9\T'T3>IW<:1)Y
MHHIHU2*+P:5&IIYB\5D71S=+=.;>;,48T9,WO3X<3JN+^3\;6?YM*H>94'RT
M+78UNTSQWS6:&+(:W!^[L+F*W=WI2+_2:&&AZO$NVY(;)0SVO9H$E@5]]U&B
MEI\V[5H -3^U0'$Y@5C)PG M',.\L+ZJ_J@]MBOFF^*4]_?Q<]+EU*]K[XHZ
M13G$6636:"E^^:2K*^5]+(5W(E  ^4$C"+H7<&B>V<):E=^P+D^K?_G K2BC
M51N9/:1Y)#Z*E-\@=")!D)?/X(#*UUDJ1XQ/G]V3E.)C2(A67:I5HJY%29ZZ
M8_<1/7$P/W*3*P6P[V6:3"C7#\$GG/Z]?N9WP+!.8"91>:AIBC$MO.[*_]7>
M>44UM7W_/@B(J(#T3I0B B*B%%%(5 Y-#D61(BW2I$0(2(>0T)$N("@U!P$!
M*9'>"1UITJ274)1>$H002$ANSGV[]^7_>[CC_L>XUX?/R]XO:\PURW?NL?::
M'R_,K0FS[5_7I )J7WJ:?FO(V(@F)":!2O>:&6F!ZT(,7$'ROMB\OQB[RL98
MGM_N"E-L8HR<?>;']*;J"F:7O=HQ66:SS,ZZ D>(\BS&6EG,;A+<:[J..>K-
M5N(U=5/& 9X9>!3Q!JS=ZNXJTT[V2E=C30BZ6AAD96&05;@ON\AXYTKA6;[)
MWUXG+0][OU$!_&!G/8MN%.X)F'YSUVNH")H12D0</#I>BYQ.J=N." =: LVY
M%67N)6_=4RJ876_<!N/,D%&U 07#!-](LF^Y4^T;OK5)5X4)DH!=\<"]>_O?
M&&).Y9:F>E L9 1.&!VM*EO46^SL^\*PC3M9$N@O;"#=6:]HL<S6KL:VK-P^
M)-->FQ&4Z5SK(P/UX ]_W61;GS3O9;M;GW4ZU0_\R@7!Y8)I5HVE BZ^QKJ%
MH79U+R%&5@=>\DYKW9=L;=>Z:0YO81JZ5S/T@Q03<Z-4K^._<0+:92J Q]D(
MVLKSH]2U7&!RY6#23#3+.V+F8B29F0F'CD,PDY]"9CR7C5&=6 XR'=Z;T/*Y
M9&[(HV#S-N3%-BR%A+][6Q()#TM$A.UN2>?).'U[?VLOD>[L[;_7)4&6-!L*
MB4V=/N9ZJ)BCD@43.99^'C^O >=IKCJ;XS=,$@_;% .7UG<T/B.&@0+7\4RA
MWD,6FKC67(:2H&7;-0NF](I*LTI/$6QFG$CS2P_K90U6M_W!)QF5![1XRQ_Y
MW\\7G]A1+M'AQG[W8BM9)G[%R2HL"F*BGJ7 %K4U?R9%C8 0P5,UE"$L[R$F
M'G*N67G%%;3&?+7Y:]P\XSM@Y6 10P4F3^8<*Z*%%5H]H=#D"M.KKVH.%2S1
M+9KESTU5UY*^W2E#W\[ (0^1W,;@M"$7^DH@0#;B0*\(]ZBWI!PHU<&/I97-
MV*KS7B]0:4^MODQT/%%&_KU]P9"P/HQ@T1!+"*>%%XJL0PPKV*W''4>Y\NJ&
M[@IZO>G[E4]O(ZQ^(=\]"/2I=;X<N,2V<[R,G"E<)H,$<64IYC,EZ:_2-+%J
M\_D ^R1219MP,   6&F*,9;PS7V^LE+S'RG!_ZD&^Z@ %\@<9P>DLC!R,LC6
MIW42?5YA5V!DKZD5$7:)+)7ED"B2?H^I'<2.Z&]5.JM$2,R0_R8N\U>.ELX-
MCC1?Z^_E<)1^973\?(F#;9!X\K7>: -9#29SBK4CJQ.[!]#\+J<TQS\\>[9U
MPU;*QN.<!E^<S9/]B(\B5$ @NL!3DL),M\RC F8'W<RB GZXR%'N6O0\U=4J
M'KXQ-&!<6"Q)YN%<KIF*H0(<G!0M+B'EFZ6*U?UOZ%\VO&+WBGZZD@)\<DJ_
MY-N]*[-*"T.V[HR@B>:T@/@8 WF.<[+Y%U6GYPGVKFWK8[E$(YR@#M$"9SW5
M%KEJB#^?"&.H'0-5B,[K^0J5[PQ<FZ5GRTH("Y997["C,-,O<Q99:^42IWJM
MA4>\F>1 2<Y^G[%,7XIMLNP2,SV.AO165OL7N\V?6/:Y>2(KWE>0 V@;F0@W
M)R9]IFWD7N:5,==;(?U_S]DEW@B,-+NT/AH1U&+IV(8.;N4_RVH%6A!A';5@
MN_%E.[&JVI-R>W" CB#QXU(@ , 'N+BSY?)D_W%Q=S>T_K^\U-NRMP>*XGA!
MOH[GRF&OB]SNOE0X=/:!JY3;>M5Y)EE;V.-'2+?7H6$("H6J[.VD*6H9@NF8
MXMM#;(0Y:TV)7PQNT<6\/+<DS\I*_CM7ZGN6?]+ )I(M;X"5CEV0.'/E73N\
M]>_.5L91;P-V%].O5$"'EIW:^@>>-/@4%6 RU[.'GC]$CTL?[(=A*]/"<!:K
M3/%DY\]8**_ A\3K.NC<AF2ET'.E@PR/GII=KB -+C!Z!=KO>WD&\F3\<OS.
M>_H>7(4D<Q]8:9DY[7A!H@7 ,V7E/]TK_$O%M@+..808H4XV6 +KR%QB*ZW9
MN$R"#C[KN(Z]TZ/4>6S31)Z';CW#6SX^KW6D>[@R8P/LG#ACV@&I@84MC\&?
M0I5(RG=F(.;U"5M]PPQY+^.$+A<S"+'>H4,+X[3('+ . 8/8ZC.#;A%I/#+A
MZIB96EEDF9? C/9/-X!#%'U<L,<WL9@<IR;E$7B5:5Q =AV9$[:<.M6!F5[O
M4%(>R0P<V$ ]2[X[ 3^^<RN(D J.#ZQ1NC?)-V%L;*P)H ^6FL@J\/5TZDTU
MN_%?#>#[M]B&EL/!S?C]'0>T8GR3Y;Q3'<]IKC&IXT:6?S@K\7$O#IWO(KA]
MP_N!5-F>:$)@8+C3K_@?=[[EORP6;N?G?IJ:W9?E_VG%+Y',F=S9D8:L!(;-
M=:#LY(=L$XN:S7Y;'U,L3EJ.HQ;:-^03Y*W9<0-:8]YHHHQR7!F<E^#QS[R3
M43<Z*(6B1EZ/YL8G?@!Y6%(!-8U-Z"LT%2RN*D8%,+/\FHIHMEF%,6Z>QN[7
MCWO-M1,0 >'?^A.+7[,R"9E64@:QE8ZTWLX!>&FXT,]ZTB?G)&QQB_<-L]O^
M"\_X'0 ?_SUCP.4<E2'G(6Z?G#5I#I]8DXK?:#*'0==3LN($2!Q^8V+V ?"*
M4\!AW:C%@_CQ'F/;H+!ZB!1SKS/=$:T5#&W<'B5K(Z/ %[T^)_SNLKXV]:DQ
M\/E+\QN/JW6;?2X[V*I]<CG"T'H[YOTEFH_?[3$DYNW.3D6H&E\,=S72^J@A
MT1$2LG9.Y:I'_<M50#* "SM316'>7@;.K/:,$3_KJ9OC?6/RGT5_@7(R6\^S
MA_T*OB?ND:S3\_ JAW3#ZM#P5 7H.[QUN-!SOEI-WLN*Y_L08K>4^<*I= 0E
MU>4_.HQ.O+N:DX.M@9&Y6EKYB%CSEG$XYS_3$D,)J=Q]=7K6ZAS:;Q[]2L^.
M#%BY>4M%\3C;C]:**I(X_"0)16G??UO&&HY[[RKZF$,%[*D Q^80S^RFK\:1
MGO%MJY)\0\[Z3V[M?"^U3(OZ2)D X_3!X6)+Y15?G!NM4"%';&S3.MZPXIEO
M-H:CQ2\E&%;TNNA2?MO'">$0GOBL5IFS3YBEY,F M:)C@=3]D","^X*VKJY$
M#"#'QF[@]1W784O)FB!N23)'HA9>Z&O["BH:PJ'Z-&_NF[#7=O8C$UYZHF6P
MSFE\X3CW8504B(>([("P7</EH/)GYH@^EXQ>U8I8;YB+7G!XB2#L9*4DZX@?
ME:E]LH(5)U:\@>DZV5.&L;S5F'@PHQ<;U^:QH8YKD)U0RLI#Q-"-1VL]ZU5B
MYYE J0?#._$*R']/G-(\@:M5S#G3357MTUQYJJM/6:,*RMX]-*K>(6(>^%@-
MFC>)67IGS>ZJ?^(%%/#;[KPO\NG7^MCK?;JZ]JV2>D>^U;5Y1(O,AD$P!@"_
M2U(B@^MPV(C7B#X[P72'I#GXU+.<2FUL5R_]"*V8TAGY=8.L"PZ^ZWG*)DS^
M1Z*L'CG[VI'@CL=MTQ:Z2P504OJLNN&852!1 AT%AY5O'==!V$'2TE#EN_-Z
M+AE=$$>(XDR&HA'SR?D5@,HJ?4;1[&G2@[F_+/_5XI<170@A*@"=675T]ILF
MQC\81A'<:2]:VTNW6803HO""FB0AWC?WS,*[-#'RJO1KCVGJTI71>U:.S"'7
M@1"L3L :$*/Q)CVS2HM?+;9&-/A4^DY, "KH5V>Y2/O]"Y1Q"%L9'+P"#4Q'
M5K4IF>*^<1R,=D3,HT-5Z-\],IIWET<K^&=N##9(?/OPW(Z"!?)X[8=#*I'Q
M<G+E8C&KS\>OC^WDW:0?5MBP-<QK,*3E8 'B\,K4SG*)GRF%^=%2D.',':S3
MZ4<\XP^[_4[&OJO@GS:@]I;X(,8E+%$<$W:(Y78^C8HF&Z^R"<YNWA29TI]P
M"S,/51%LX[<9#WZH=G /7:2(9C4CQG8>W]<[RFZ9S/2GM]!S%:7G2KH]:XC^
MF[U'2JKHA99AJHK^GKFS'?W2>O>"Y"IOAYY@=V/01-.TBXFSIUCT^3G'N73V
M1-OX>J'#;G@VB;61[$VS8@3\)3&S$)V]O&VH$"OSSYLJX$)A?V#H5]AP7IE7
M )K,3BMUHJ<'PKP]BP]&X&#D-?_J6(L)I]L!13?O^YR$ 2VG1B'T"$8_*,&'
M& 1=1EV<CA6^/_W!=JC5(IIM,5ES:S ($?P2<*/9%B7W]%\?\GH@\!]UC'_X
MPQ_^_^5NC,PZBBAE&E,CR[GT*C%_<S9B,@48IZICEPNQMFA(,)-UN#7FZM&_
M=X%3+$O^Z$N<V\[?!?WE073.2,;3JD<*=Z6S. 4CV\E2!]_3EN&]S^=]XGOY
M:454<;AC 4A0.ZNE\&RVTI-,,O.)6Y.$WA=CC(,IZLHI?/8-UZ([]\33A'V4
MBXNK'VQBW)!S*D<7'--;^>$B]?(/1QO,:K(M0O4?G22KTF\>H(^'3*NV1Q*=
M1_>"7#6XA1=^^"@EZ\DPQ'#=V@F0#DF&WC7D?9>9*#F8.+1=Y;YP\CQ\R?3G
M9#P>W15@NJN>3T;4YZQ3V-5\>WSOVYNEIIM/G.OJA#V\?,N#,E97@,@C:V6!
M.ZT"M+%7-S]<+BU$[V4R"(QYG;RVTT>K#1GL-H%/2#54 *:$HBC1F@?S(=GF
M\ OR=]RSBR'/T))[(*(MA__L"PA 2^)/5U@"NR>G!HJ&7G$,&QZLSO!9"EW1
M]U?;WC:805.82<O@&>0*UZ+XJ'<B%V11STXB)-:PA?,Q^Z*R^*W1WZ_DPS;T
M.,+M"HXN>DN*9U<?J2U_%/V)8S+:_#MTY<''8\U-42K 7U_#$\6_D$<$K_28
M.#B,[GV[NI0XWP+7(EU$+"XRGF4B'5C8=/ 2!'3Q=LKBPO=)\Z F:\M'["E1
M*3?/%>^F)#]X*N#V9*/X^=/4]%-&#7<4'=B)"KB &!?A"++K$/CBPH/#I'I<
MDDH(-%6-2&*32?JF=F%#3[(3,@ONP/ @1(DE'8VR$X.SO6$%9M[W?M8ZC2F)
MA]2\[7Q36& @(Y,N_(N[G5A%B,>A0UL5B;[+E%QO3V TW)@KQ1E75J7@5E0^
MU-#6@8N?&FL8CD;5*7<BPT$R>)[H%19;J+!Z)X^'M57/Y'?U4I2'V+W.AN$%
MX4I]@+A0V4Y8CHQ/P)GB@NWC05K7HR,),$TA @D_<'+QH'.6Y"?)!_OJN)K2
ML8<'6^YO"QP?G^?FJK#MBO_''O4$1P7$8W#/,)%@OE9&O[E'X]XLCD]^*+*(
MK*G=M]+LWK7!!&5=R.\33'SIKJ>HKS?;U9__K&6X4C3=,4[A=7G9Z/N? MY^
M8#*G"TT+[\@N/8@M_OZCNL%?(L.@D?''R<VN0X#O!J,ML9!RL0J7V(D0K:^(
M_&TU:5/UKM>CR+G1;OY%A]8S^V_S:C^N!+Y*?+4WQN8L8BQ9,)Q?5"XZ3'B+
MBRS!6:^N,$96L.8M0Z&F3<E;,W]'&(-P4L=A"1':#"(3/W-D:5Y6"K^&JTG(
M5C"/K"D%Y;K=FA5^8'"GSY'_^^6YF'!51S>='M;;&A+,:DGZ^28[IT]B?K9>
M)+OCAG>9EIQ4-9;U=!1EE5[)R\\^TQ;G6Q#,_65F[QYX1?,1PU'- Z=^_=/<
M9/UWE27W2[3=_\ER X5FP'*-!D?9B'SH5 J_BR=B$ES7^[9F\W,Z^1KNM;"<
M3HB]#-=I7#JG?F?>*C0X$!#5,$BY2END 5'0<A)=P]QLC#\GV9R^)\Y<QOW7
M35VAR^[GH?K/JU\/S.IL<P7])6=C%W+3/B?X]EIBC=;ZB;4]PNTN+6P3"Q!V
ME&%DE7=4#W+NC2X8L+UX$[6\'[QG6X^9@"GR?EP<$DSFN'.[R6H*X'D@I@QG
M*V$-67I$!3#>X,7B4OQ2*)S8'8.3<R<0_,T#U>RF8U?2G*9'4YF*D:[N(9=+
M+=JM%O3N4W,4(>JL'B%"&6PL%8"]K9&)C7=95NT:.YQFF5A<['Y_A4MD[NWP
MZY7"LVRD*Q! ^<&Y8$ZT>Y[NK<N-!64&T=4V:>RULRT"<$]2PN)61?/23%JJ
M%0A)&-DC->N\F#VI J=)[9E54C\?!^;I,],.<$W0YV+2><KT++A[5P(MB8/$
M%2KE7*WFN*O%A0Z[?MY=F9$#3=)>_4QW3<31UL4@U9)4'OAV-P\K'BUP."!T
M,7Q;Z245T#M1=W8&P:/C6J7]:C!+N9B:G.@E",L6AP%NN"U2S0Z"J4Y-4].T
MI=,..W='99JIN3 [CQ]30VO2[[8C64"7B+][9MV:5KE_*#0)ECU;7#@2FBL)
MMKR^T#!]WTZE&U)E+J6FXRU2+J.^NUPZDT(% $VPQT?(GD*=,1U^XXET^7KZ
M_O7)5L!9'&8I,X>=N$L"$2UZ C!O51U8BXNE<LQVCX3?%>N8 >B>>1PD'&UB
MJTV*E7>B2+9$N=[)8^5+RY"W@JK**_>L'X^*?P.$PD7H&=<3M..I@!;US^C^
MG%R!Q _I96QE-S[%?)O^[YX2\_\2,DG$7S@C];-<D("+"#?^\IV^0JRKA[A<
M)=3Y:9AX11VN\2L#L/.=GO>/*=NB+JG7EY>\%21=#=6\'#N!U:@.*&J&9#KF
MJH#A]T.O\/;(";4M"N F>JH4_IYES$JWB TWFWB<76H:Z/E;?IC%M)7)$JZ.
M@T6H&BT#PS"XF&DB=%DHRJ QT[C.OUSU:?%-6VA*@_;!CS0^-X.K06I:!"B1
M>:7,D1")]^U&1YL'.)\>==9^6&Y1F.]]HY"MYH=M5')@N^[?_FU@?9_=<A[#
M1I&A#(%4B>G0)23##'&NDPI@ET.9?FT4*%72R[,:N)*@D2Y^M?'<ET[82W^&
M)2_/H&Q6:Y.67:31'-@!G<A#!52CVQ+9B/V"L I0V7DWV:JFG=]2,J+T\^>9
M1":ZJ8!V;9!<7?OP#&\WK\D!WY&PFWS>BRONB_8G)F(+=ARWC\TWJ0 [=/ X
M8@A9A8F"2_A["Z_EV0GJ!2D@W^A&\_5=Q[H.:@:N*K8AIC!TS2](CR@CR(NO
M/XU-0J(HPJWW6ZM\IN2EJ[^\J>"+97H=WB:=SZ9P<-LCR]^?'"\QM$,>3J"(
MPOV(OJ6TE:@=HB)J[P/CQ?"L;Z^UQ&SI"6G!"&T_!P=)!URER7&K(RNMW\^2
M$;=IDF/W+.3UD8XX!^3%Q@<!A_WJKYJCJ*''J)X6TK.O42;CZS7U&LF+:THQ
M?XE%FC!<0?PSU0?^>KS3O4H%S$S]3:Q;6M#5N;3L^D3G,^X7=LXF95<B3;MC
ME_7%G=";^Y>^N=1)W"#O_>7<SV'E5;%,!>#T43.F/4A^6BD<+W4"\I!UE@+9
MBX;HQDM%%]B]+Z4SSZN\3E@HV=V?25SR?=MZWL_S>16>-U$Q$6@)L8I]Z^;-
M-3OYEMUTP-J (11K9 DD<PHN:<5@'!-GOFZ(W!ZC BJ][;Y86IZA=N4-2+5S
MU7O1Z?[MJRKH3\4FQ?Z*(U\4QF)@GNG$*2I '-:-(IQOI@)&V2 T,[0+MO(X
M!2!W^I2C09U0I9IR%^4K"Y;--JC^N'#M$#7>XJO>DCD31^"N,X'5+C +_%'A
M3,_UIM9Q-]>EQ^V^35W]>9( ^Z2^>^@8I",X"E5ML".U=,\K^VY[(RQ!(<@5
M,4^07_RDE[NHS,9_#;?EGI_:3T*K7"L5N)BAIY-G0/ ?D:5<^G>0,-E_.8B1
M\7-$^8;CT[3O=+5\]F<#<3>6 ,/7U50'O<J0TX(4@Q)"#!7P-0YR>L=\"V/+
M-@/K$>$EYJX,TYYRQI<B[N%]]^PJZMYI9SBT:IJ^26ZX9@A@!ESM$\_R6%0F
M:N ]"69GY60K//WR<$29JL?R/E S/M"!$!%C\2+R 0<;2WVD8 CKHQZZDC?Z
MVWW\/;(2,M[VV.JL 4DR=\E2@(R4T^%V6:=JN6U##S1I"G%Y@PH01"Y5-):E
M8:#"E _YF^PN\= ;"\)=2=T"/4)(CLB@:56.3V@X^"P=I$3L)*S@Y+K1PL[W
MX>Y5^E.3DQ^27N/(EV *[NVAI*R*%-^^)L8$ T,UHW8JH&H_MAI-E$)&@ZY9
M.KODL/]0!=7>A@1]%FM]*=I_8M/<?FP@\7"U#&3?>,@KD[:]BXC*H)GPZ<VK
M>+9N= @5P#JK6(GK:2C+LVH_]_;3._Y/L6Z\<;M)^ T+Q5UD752' >LVJ@(5
M4VH_MF-3-Z+0TS!^[G$)@3>6$=X<M/AQM>C>%R#.$#DC\_RL@,R4AR5:;ST
M"_B!?I/4G_@#!UXD,O0V?:HU?F&&X_=O4Q$!X^TH KZ$8J*I_Y*K>ELC)/PE
MU.ZLI$AP^O<7!6B#S5O8-7BO,4-8M6,:?9C\A.:P;4%>ZL2>+=3ZW@]5=BJ
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MYX3X89B>FSL0%6Y?:9]B%O#6T3UW\2KQO(=QDMNYV6?<MU<*RD"C=]&U?_*
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MR_^*96B[EBZ)?UTJH>GUT!3--M^Q_FJ[7F U Z$2R^1/V.RE%^JS&TO*[SZ
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MEGBPA6CC%^B$0W_$".7V$LXX9&FJ!V/LXEV\-,*4]6)*BO&Y?;B"]=OZ7!8
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M+%C#OWE1:VO)"_ZTVZM<-Q'U7?@%CM,TW=NF9?_2*_&S^]+ S15Y!1R[K;\
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MFR2\+EN?\Z ^"Y%?PXI"<MO-K_U8Z39TD)2'1^IP\8Y&\R,@J%\,D\GY6A+
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M]J2C9V:,<P@9C5?I,<ZN'\K[3R;]^+_FRO\?&=G?Y?\ 4$L#!!0    ( &A
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M#_G]]M_OHG]SL#"S</R+#UH+P,MRH.:@)B.#)'" EX&1EX'6 4#H2)D8_G8
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MP,5-\LMT&A"71Q78C8$NB]. 9WPT@& Q9';Q2#_YU"87\KL&#3AQG ;@BFA
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M)=F7RO4YF$U;9M<[0]+7*TDG0!,JZXM98^8YX5:_$E"5U/Y@^I5ZS0NALL!
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M]\X3SRULA!-7[>U0:N7.4)JRF7ZR9GW(Q2>M'*=\P53 ]2V8F.^%JG1K0\9
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M,Y;DE_VWS-39%R25YD5>52'/N1R<]<M;?Y$(L;HWH"[LXGCS-X97_(O9JPA
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M-#DOY]"66)_B"%9ZIH,,!3N@+TW#?B)J;,<B_42]4-V%!L)1ZL*2E3I6KVQ
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M*S/=A6[F["ZG=DA&&7,>#>Z7/_I<NK.<\)[IT7O!V!Y9UH$1%W2E69!39'&
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MO1)L\6OF.-WVZ>J\T)U/X!:C 6"S^C7]2Q)T53W@9\FOU+=K+19HSC!JFM8
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M<T@>2ZB<\G,VMXRZ;[317-<>)+A]4-,O-P1V\ JOO\EO]')/^'OG]D<Y$@W
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MU$+Y#DDBS3!N_KX<S6E%V9G2E<U=I?VZ:JL$1;CJVY;I^# CK<0]*:N[\"Z
MAFDK_K07#\T.DHJY8E\_;F<O<&U]5>KH*\WZ0U!5W#'O8#V:./W ;.D]TM5>
MHARAV(*B-Q\]/;&>7I-9V(78MAFG,%!TDHJ_]6YAP'\>/,G/:_UI!OVP>O;V
MMWA'+$7SP;QY(TRJ?,<U2;O43]6._[U\RBLY654-G+4$-A._1XC%3G>EC4^U
M5!3[A=WS9YC:@F:^3#USA*P5%F\OZN;=8,0TS+.3+H]J, @HJQ5&*!K0VSU/
MZO5U=F?Z/M%_(B74?4!@S'P2YJSV[=+>E E31<2,5?3"B9F5>A<L@FU1[."G
MB:I1"3!4%G4E>\=U[EA3O8SE6,.J744\6/_,*V_QWL74!V!GQ.X44:IY&>%8
M?"!$@\3TWL.?J8!$$-W<C%=W=G$IR#JIQC.@D,39;OT.6.$'NENWF*BUJU=Q
M1%\N9DC.:;G,MJR[</K@9PN0YLQ_Y8 VK5C2L;<7[]RT[FT_'-,R6_R>,#6R
M*A3FYK=C!9ZP-#,E-,0]1S4] "W!,1Y40*D 4-_<[$4>%=#\&+PROG!;F<1!
M!6"BHD6=]F>YVY/V7DEMB67<S#GM>95W?\$A P1AG;K=::OFEEDN#I(E<D=T
M(%E8YZ() YM6DD!ZE%-3DM T@N,F/P @)')WE($8&G)]C0%]#U59V"VE;:X>
M?X]LVV68C4@S(=%E@#>L74&+*S6@[='>H[NPS7Y#0P*O@2A%K.^H P=,'(-S
M:9BZ%X"#[M2.<[P6X7H,GI9J3(A#&],+=JNLT@TGZ+8"617+?#OQ2@&NG36I
M2S_O^SZ>DRI]::,G.51QPH\AA\P@QKDY+QARDK"*UHZ/7XV)2S<YE!S4EFU4
MEKAP3C /WFCX:#-LW7*G%15A2CO\E(L33GPA:U/K>PI$Y;+2VVE)D;H G^\]
M%WW+G?V,TD?<"JXTZXVX:CF*!DLM42APX2]:TBO&R?F1G^YQ#$%2M:<M\)#?
MFPCWC*BMEK3QTU90#/35R+Y#';)AQ(X*^/[PJX8CH5G3)0[.@&0NV'-?C#<A
MIQ.\J #690L*O0(N:3J[$"6$,G<"8^];G9Z'XN'1!X$#X,I6P1;8#D*NR8H!
M3T> Y+K*.Z=/I<@$EJRK'K_YP3K,N?8(VQVUL*/VP+HJ?6UP90QG^J:@C*DB
M*D_XN""(7SDBB-FER;8.9X^C G+B Z'.5$#"D1R1AN"Y,H12BJS\U6 1R5LY
MT2*'\OKCE ^-K- F<-X4Z];R HC9]0_3H+=?VS7+ZP<M/#A#AI1_'7;=K]<H
ML?!SQ0BRBS"BWB*LHTXM&8><D]2"9%(!]QHP&)6=-Q)!?@TDN PEQ78788F-
MWPD735#O$UK5)M[R3])61+X]BDU69J:9[+E0^93OG0ZSZX,;#U]D*/FU]EQ[
M:3H#Q"%&$J.!C!K*.%_#F/$.<X/:0H%3U=J](DF.Y>./>1SK&;)8[T5] ]&1
MQ+ H_8:J7_OJ$NJ!_=(G3CMD!<C?-7L?>"'FT#X=;1_IIVP0J%36:Y?K-F8N
M=,I3TM)=G^^+_E1A"*1.XK!IA%2A15^38S76&)?VV.W'V7>210PP.5D+T%TJ
M0.A@S?H4810'1X=?FQ)J_@+ADHV?NW>OL?1NV)A\\V=PD>&W\>GY\ZCG\"C4
M^: >?ATKH74J8+GE_;QC-XGN-*@/TOZG1\.IL7$%9_/5MJF#\H\5V>O,4YG.
MX[\DRHWAGK4MPFSH%C!OXZ3KO??^A^'9+:N('H7@%6#'5M=#8T\U8YSLMDH)
M>=,P,];A3UEL@H1216%C*P;!-#FWK6X=K.90EQ3\$UI_8;L!,JLE!&N]3>$F
M$+H%,D:FZ$>R+XT^DWU]D.2K ^+FW$4D(A47=Z(^)';-\5#&JA.7Y%WPMW#7
M)TVV0[R%>L3+#2EL-"Q-D>1W>X&\B>8OX&%?WV/6Z3-$I%PWNP$\F(RW.="2
M[:4"7IOS%)6G6%82]TEV?93F5O]TW-I(6]]!V$KB;,F1>.YO! UYUG&WP\,-
M7-+-IS:&K<4R!<P?3+==J.(RF9"?EDI9MQ)K0TVIMZ)X2,)*-;D0$RK MMI=
M\%<CR#%Y,.$N"S]//POK[;#0E^Y'T'*25N*#\=_;6P?BWF=YP.>M2@V 4]Q%
MKO$_CL\'G ](@'BB8=]4M2YOF,9Z8@R9"6Y=G9Q+#:/2R%QIS(VGN8#J^%81
M%L"&/^!HA) ;FPJ%&,DT*TT],E<@UOGF']?GC0T4KX^@'S![::9J=(U>?I>5
M4UPX*"$:J/DN*V76"W0'Z4AT(4ECKWHC<9'I[I=AO>HGQTL-"YZ?.W&<9*V_
M*$.0X [W^KSYB>!K.29B36>IX>,.^K4\#7S"N8"'G6QA)MQ9M2"\QK"R?T=6
M\W&EXMWA-T4F38[C0CA+''%G%VCJ[";=I7#UE-YOEO;>ULL;&&-KE"<\;Q8*
M4>QRY7OJO;JC_^=B*E1CP/';A-2R*3NI>8(*V$[$.22^02T4P=DT;+SQ8):U
M *V,(7(K)S(]'13Y8)@*"#*!XG6W%7%H6" 5<.:=TM[NG81&#<G"49@7;^"^
MZF'9+!"/Q.$+(KM;M?@'%50H&ZT?UVPF MPC>:F 5XGY5D!6F)-,[&N#F9PK
MD7.&2&F$=KCM)M<RB+">2];NQJ"6G-^/9 06!<8>@(^NL1Y0 =)ML.\E4OFG
M:]^1#X^NH+!7@B8QB/#QN?,X*7QZL+>]Z&A<P57S.4,US<4=YAFZL+?N,WQX
MUDD$_LJO$#F"G(&%.6XV+5;!UX!A(M=8[AJ T4&Z-WYR$1#'TO!= -&Q$SYW
MD:"'<5;H"^B"!,8MB[0ZE9^@B(3$L=8%A859P[&^>&:<<B>4H;S"W9OEM<#0
M\SG^[\"?'V1!_@F?#%\<= 78:AIK7/]^M7I63,+W7<U!E86_Q<_E#K^2CB<<
MR5]R0P83<M(-8>I'@BM_4H_J"##5J'Y<6HW_BI#6@&*E_ZO]Z7?032LE&E,_
M545PMJ_[68_37AE.607K* ?[W$'E^Y.[21<D.L]>W45J?VSTD:XL)M7"5XW3
M*6>Z<6?U39*GGV+'2+;GYV8D9 ?([G3S90'5!/Y+4>T1B?T[>R]VK[D?GA\A
M5'@>F87H"0T7TDB+%OODBST%]<V^AH'LXGYELH_</K[[WM0PR@88WO@4+-.:
M)E6ELE?N=F5SL^4VO*LE$%3!VCDKK:@?_'@RJ?)NE&G2+<JS1\I;[3C,@$=W
MT4;RM6*Z7AP+W3DOWK?!JIV^P^BX''AK! UPO-(E)6H5<JX^T=*P I-8P"LT
M+,A-.1%T<4CKFI7Y>HOJF*3705;TLS ]HI=)(2')<<_XK2H@(LA7C!//T :<
MS$7?!S%7)^41H.U:EX>GF ==3!N#N$VY_<4D=^7L:CVN=\W8TO$ <Z9R,MUS
M7>0G9]M%FT>KWN?':$\-?E6YF-!ABB!=Q3EV)49JG:NC L(=#7'L:\JG9KJX
M=8G&DJPFI[HZKFZ^O:$).<?*N$10JRR+:N^\9_&;LC2MYR\2CR/99R\ZWTH0
MNR#&LUU)G-*K6YEVG)S']LVS4 %K-[%@"N,VBA #0F?^^;_LK[ %%(EM&H;C
MW/U ;FJ1\+MA:SRTCY]N#V[23P.Z^53ZDB&V]_Z TLV'E>2FMD:KMM4D^I&W
MJ_"7Y))12F\K%3#PGH9H)4B)8D0+VH0@F@)?@_:TWM&\IQO!EPJXQ1I*X]2Z
MKE1 APDL!D4+^U%:5[&S^(P@7G0LL/;;K]A,S6N,TA=%GJFI?;S67J0UNJ1F
M2.+8T\V$3B/%BBV.C[B=E4 [^??6%6@.7YRV/3*7'-*F.TQ*/V97FNM,)WZ4
MN+2YD]A6X/_@M+M[*L_D.A:Q>XVW2XO=*-YY%H(#[6E(&Q)$ZF)0:/'=X4XA
M(*5S3U;ZG@&^[,/FLNMTDR#R9^#X%/ALB  -!C!2@,Y:_$.C$6DI@ C>EOVH
M$G58]4]]H"=81H^&1-5&HJ+U92*V8!6DGXQ][<%Y!0&_B0W=KO4# :.X=!+'
MRI""'?8P4OJ*[9"KCCL/F'#2;8",E_CQG: K^>/:@W(FKG?5KK7[<S^(,@/%
MFXXD^XQ5!;0^4+U++2_9?-O7=7ZAIE*K],MQ>87CQTG%OH/1YNS&X'7'=SJQ
M!Y(W$&_@^&3"+*[SAY/2^!B^4@#6D6MXE8_L\*P3ME-AM [^FM@Q'YU>XH^)
M?\RO[&9V<'8%6;_ZZZK-43TB7\OR6+@+7HMJA].[F8SGCEX!']D7ZK@I!PN$
MT$B.$(*+4$9;GZ@K]';+,$GFL]53/>\+VD*?O-6BGPWPIRF><A-,V NS@H6B
M%C):.(>4>LHA?.55UP[NADZUS3]45EYJ:[9MFZ\R?844=/HU03#5??C=UC'C
MA/O5Q[(Z1\K*(', :3BP)P\)B4S3R8;_E.,2[754';!<S1H?%*(1G]!$0DK;
ME&!V0G'NQ";,-OZY\FG?2,Q+I/WT"GU%7);G6'..(4$,UMZ-XYZNW8R%KD")
M "30L<NS3EWCYY_[3H1Y(P&"GMZ6XY>(9]!MJ*Z+MDG@+5U,8N-P9:*C^P9@
MS0?XG7Y-6Z$R=KM_?MN0>5/)CKQ3I2_X'7@XGDZ!7=NN!DZ/HPMJJO5+K9Q+
M9[DVNL KKZ,VIVIIKGR2 5WWYM"?<F'XD]3<2',Y:&=:O%P"3!/;W>^L\<R8
M+Q_^_6RXJ?YEUB(OL8./++U/<+YMAO%O&;W/[IS:[(P<U>]^70 ^O$U:W)#X
M#G."$\1,PX)N8@\?CB(9H$*II3?@3A'T1TJF%STV[L?=LG,\)?OP1O]I=],_
MS[*?>;O*=%(!=W^7@O#>,'(:LAM#!6Q!%T&O<\XWCEUI&=ZI3K5+6-R2UZ^7
M$#BY]N/TS(*WIK9?0QW+\F2JZFWN>U(U;A!I^Y5\2$'@!Q"[@YG]W0$&\T=Z
M\VD[J4<J<WWRWX($L25/<(A85Z] V-=I V^Q]%4K:^US; E;EK6RIPUYQ;Z*
MG6PATV*H,RH"527VJIH*8'$Z?+AYP;EVL/WR&OZ'R8KVPS*)G@[[]W$I#8FJ
M*RU\#Y\N>!BZ$/47ZD@7!MJ5YH2&O64X](HV?,=-!@<4HZ%5[6Y;GS+DZU:?
MYRVJ1[H/U_AK7&]5$4@P*H[R>)=O[V]QIU%"% 5.VL*9"MKNK=U*$]6Y'C&;
M&VRQ\7MN5LN1?A%($#>-UP@.)L/1S%R"UPM$G^]BE,?CUZMMH>BO9 CH/CDE
M1#HHJ"6!V*F<SO6P8D9D]/>'[!.4)8EDU*WSII,A+ 38)Y+65Z)T5-[ZL:5*
M*]>O4GOR1,)38K+!"],)($<0$;M*.3.XL'/VR!.2SCTGTF#)7C[O4#= ?.,;
MXJ9;$^@8A:3[1##4<56_/Z0PS<_+;=O*W/CYKIK@-]9,5=5^SXRQSZ^N(U6Q
MJ^T4EJ;DQ;N_O%RE_2-%DOM_J AV6[)_.4."./Q[ >52J&"0YF#(%2>#@LTI
MU]I\NY_\O>^"NX =I;+&Q%#6*[5.'UF4T8@M\L)\N++'C)_OK=KAWPY6\==]
M,ZQ:7B\Y/&-]R<APLNG:_[KSZ?_TYQ]J22,\$,P$&L 6Y7]$!=2"CZ^*TPUK
M_8^UI$L^$#2I )'5![2/4<>*FP4?6>$T9-:G:SD,_E8F$B*7@B[-R.I9!!.T
M35:)!E*DT&?/7=V]:GO%?Q:<!#H!EO7I:HB2,F$U\$G,(H5C( %HAMT>2AV4
MEMFY,O89NQ><HZCOFJ(V<RJ1B0IPS+BQB2P2;WKB"W*:%PJZ0;#/,]^T/HOM
MCUV44'\YN,%W_U#9I&ZWJH==6Q3YME7E6H/G906P[SE!G[<3J),AIPDI:"M:
M^('SS.NBIQ/Y@NZ@#/2J,]6+;89>9)SU#F74&K*14WW6E%>_RY%,TMZ-_R:D
MC@W$U$6C'.$G*2,9"<V8G?-^^#UTY]ZLV<SFX\B91;W0I<_:/$_1;WZNLG5\
M,A9:%9DCQ.=!X%6.;; HT(6+.'A<#8+-"F*NC8K.'5'L+<E6MXA]E*/BQBF9
MW5=3V_U> ^R8H!DJBPR].46 $:^3;HT>#,29""D-DE@A:'C<L)[H?H9N]._?
M"(54-2^?0#:188Q9]/7(&6L-M[6)E8V0?M2%%C&"Z;<Y)MS^W%DP$T&.TD\Y
M-!JJ.?L!0;K_PLQ\U'I*WRMA1#W/0S]Z99E)AKGAQO4@L8\;\!K?4*TK?E-0
M7K_AVZ,*LYY/AC2D&W4:?&T<<W4+[V([=B 72I4-1 :1R<&?1&?*+T0\E*C"
M[FQ;!(-(%Y*!<:9I7[/-0?1**$G <[$&B^=+S[QN7UR?X.M-7.#NE(G H\YK
MR"\$)M+/^-EV\V7/E3@6;S1&_%2+BLQO%IFEK]7W9]]^TJLOY!@EBE>F<U]#
MJA/E7?A\V[*-T*(=&==(XF#&V^@^N:?FT.VJJ]'H^F0/F&=UL8Y5UF^IG.LW
MA(QP#LR.>!."Q (PIG<1Q =1.\27O\NYFD %6#0V#A_40Y<3)"+TQ3Q=72L*
M6+DG%Q.?Q<E<?.L.]39DAP"_:G9O,P/C@JQ8$T_G4*Z'\APTY0_FUNE(-[H/
MA\6:Q&YM7)9^OG?VPJ5@TGBN/E&)I$^H6I@_1>#&<+2<%6+#QF_G+U,*\UVX
MY<$$^)8DWZ@03<?Z-WXG]4A/TG2,8&[V0).36D3$MHZ4OZT@L8DDB0\BP2I^
M;URX0=.07(4<FQHB]R0)KFXCZS_O/%W'[N]_)$ZWCCBW*=P1(C!\0!_758<?
MG#DEINY;]"*$MV24);.P/6\=CZ]=$ZZKB7\>SX#]$G>"<,+HX2G?NJ3U,4_+
M^].77I]+F!!S>9W\4G4=G(WB1$'F^4BZN(A.<GESB5- R*Z49*GTW*Q-+$C\
M>3CTA8=94TH<C:U)@85(^G_JV$&XM60;,]L:RV.%XE]VW?V(2GZZ5-,CUDO_
MZ/!:G$TT0X6 W<_4N29.;ON"5=X\6.LMRD6G$,8H_42B$)XB\'%DYZ._P]6N
M7T_,GKSWW,M:C0OU,/P0=(N PUW %+YO'$]0[*I-"7-]WFM[0BA"&"!+!00J
MX@V_#4R VK5.8C%P#K,)0HIY*JD[*8R<<^*51O7C&\]8'JP\?!!PSK1X'46/
MY,^]+U*%A4>6V5G?[BRX$7\4,>"RT;["DW'VD,O:QY1X9$%Z$$ 04/0E;K9L
M_)[WE0._/M)UQA(-Z^%."9!BGMUSX16@".@ZG,&M$+A&X1VY8K+HBP]*EEDQ
MCB';A#)N/W^ZJ)V@N' M_F,(Q\:7HRY74TP'R#!@_O@Q^+6"7-:7]/8HZS^I
MW?OI1_ /2O S&NY?S+I=&JWS\=HJ;+T>25W9#+..0F$?MRUKRW)GG0+>I?FF
M[4Y;W?)!>DCSP'(Z7FJ'( :M@RX]4K[:]X,\1%(C;V>/7GOLK'/^D7X5+'Z?
MF Q210H2KT*LI7[9H#*?_MH'5Y\KJ]FP"OZD<[?WU)NB_A/ ZRH:B_ENK<0+
MEHTR'Q;A+%W=._3#OY?.[A_IP.X1=V-6BE][NO[(:[Y026*'18\;RAIC<OD>
M'KCLX%Q#&-I\J("OS5F5&&ATFFR!6C=Z?69US0[87VX1TJ8EQ 8'8=[U3RYT
MHL=N,/QJ,IWA,&'O<=+'I!J2^!^%&.G@!JZS$6S^9 @^AF7QXKR 7^&O]X#9
M.*!E"H_,\OHGY8#%914RC&]W@)/R,T?D%TE?*B<G[7@T@:0-XRAADO.13.;T
M5MD O!!8R"G<3X[Y8F:@INPEIE*'0B[#2*R9V K%JH#4THKSX<G3LP_K*&>7
M2&Y!L=A-O!+! HK.U,'YY/N70%[DS9 S+-Z4/<R)>?WH:83@@,C2PKD34\ZP
M*O WP8MAP*AMNV>>'Y::,\76MG310RV1GZO26>V3X=4EM]A3YA['I$";IQ03
MV1W>1E7FO\FZ7!MG+Y[79";?[86(0M$KN+;H1I D4KOXK+C[;!*B9'C_9 \(
M?2@/4A_4D=S:A]P_R9"2[Q\D9'AW$_6Y27R98 YN*^3Y4R%&@+-*T@J,&7W7
M;#>_TF_XB/ );65KF#.T\5L]UJ)HZNKGY"D=/;9(WKO3WR\FQ1SM&D[$+KS(
M$:?\HOS"G9SFU1C80LN3TWG[?QY9N\W-;\KO@$T'+8\2]%]UUR/MQ0?2(273
M%(:T[@<6.0Z\ <G?QE*U7(^L$%0 0]6L0$(23J8MX'2JJZV]MV!9=I;^N?/=
MKI?S[N8R?71=  !*@-CZ/XD3-X&D]'0J(+H\(V9_D2,UK?O#554M9S=/T#]^
MG$OA9HT"K0E3 <F[5 !.<?C1_91HG&D\B7L1QFKEK%:*FUL_[%GN.SO=&P4,
M73K_\J9 Z G.Q3E^<EH(,\&W(VE#J@C"%]I&>3YE5:78HBM\Z;G),\VSYP-7
M6M(_OU)-);2B:WCX(@$+)Z R0,+V?Q7N3T^MEP1/2BCH2$:&"KB@2Y(&LL!^
MZ=) R#(5@($4?'ZEL8-Y4+8 BK7FR-09O\+M8W2^_5"NI&,Q-Y?^NTT.ZJ''
M&<[5/[UE'.'AL',:IBP5T"*7QNS9DFBI3LJZ\.ON2Z%Y^LGJ;OUJ!ZV(SW][
M:/L/:U: M:&QJ^13L%UK,.7*?_3?:D</'#-2 4M(%,G@GTB]Y V.#F$;]SJ2
MDBF7VI%RX$GFW9J[.^.]?.\\C*\0#><@,+0^TA.*/YV>E]?!R]5KH(3^OO[V
MC3QAW/MO;9'^%YOPY[GM/^C!Z3^)]._/^\Y&M</WV:B 'G\8(0/T#XK\CPY-
M_\/:$@F66G\Z-"52]'MIP.AOKW>9<;!VMWR+A^=*96_6I<-)/LA%#&L;(@S%
MKMSC;P-Q]B*1"]KF+,SD-WS$34 [=-:SVH 0>Y('P01U%NGN#[$1[<1'#C1V
M[=X1_GD[@6?[$=)+@^7#FK9;$",Y6YCP15JZ)MN&I%S0QOTCM33'MTFLZ 8C
M@'5':!4@Y'Y\71L05(5.G+R 9DFLJ6&&6(PN4413@J[#/]YMARUV-?.W4>@)
MJ@N[!=VW!^NZ9!'NME*]B'IGSH3@O0P\DSA=:C6A!!UXUCMR;O=O"5GJ9IS&
M@8#ZXO];FOC7;$K.IGEA.XQMHQ=6Y'PL2-Y=Y%96,\R4[3;\D"N66.8FT\7*
M7/1M1)8!<-;?CPKHAOS;$^]_D&9,JPQ!TAQ_3?0N2 QL0L#SCV@'LB57JZ!I
M0YRNZP :!:,_*#V:.AV9B5J-"$^C HZE3.IA;U!5P#9-:+ORYL>=(46'B/C2
MS_H-E]EW=9:#YZ]J"'@)2JS_$*?;Q5%8_3XH@BNH@.<;IPV(RF\2WP4?DF=H
M]OJ=P(:=1J/:J(!3Z^[S4VO'46^$WRC.;M6RRO/JB6Q+1IWPK&:+>[UC?4A3
MUAE<8+O[QR<C)[_$ :26OP$/^V3^J^'^YX4-_J<#N_XO,L;_Y$(>;M"8G$3)
MTSZ(MS=S7TT;SW*,A9F@B%'K*<Y6AE_C9MH O\*H$"X2-[;PS>)HJ5>LRLXG
MF)R25V.JL%NG;=!'X5H&P9)!V/^Y,_0O,>R_1/E+E+^)\@$]S[/>(KF'JOJM
M-8@/;G'\/>FSJD+\%B"46OBO*-WU3PH__O_SYR]-_K]/DZ9A)'/"_.* 0)#I
MF 8#ME!_R,($>S_#(1?#?-ML5*N=KE,^6OL=DY2;?O6O[LO5$0^UF^^E09MV
M.'<'MHT\L2!C0GJI"U]BQU$+)\D$NUVMU%?DG#'MK%8S<X]KA2>D5^SW@?C3
M5'Z-XMN"@\7G& % ?3]3(^08\GJAM8O:BT:E3]ZN G5*[/=3--^5?JS67A3E
M*6%O>O?6/:G3R?0-B:>),(ICQ7MC68J+7.:XL/!8Z>K\%.NZ<8VK[H$*50(O
MH-(2T^"JAD<-B]<F'(7/U'%NOXUZ:GSWQ] S-WNK+X8>IQ]H?5  ;(A_?L5T
M37T:6CO9Q_I!4LN#8Y[?U>M[ES%>N*+<E\*)(-\7ND(%?-NA=+U2<Y'X$U$A
M5( 10S0*JTX%5.3^->*O$7^-^&O$7R/^&O'7B/^/CI!O;^&C L)]^VE<(K(P
M>-65"DAL(,V^'YA=L%5=79-X\.I_WD?V(^O]_W2W5^ZX<$CZO\C[[Z F_OC_
M%PV" E("*" U*%5 4"" =$2:B%&47J(@S4B5$B0$1.D=!!2D"8C4B)0 QB =
M1:2#!"D)381 0HDK"7#Y?.?>N7=^]_QQSIPY_YRS,[O_[<R^]M6>C]GW>U]9
M!=J'A"/0[ZFZO*C3_^F,_\Z^8RU5CIA3&MF;^623>X^R_Z/Y3-B/MTQ:50/;
MITY/6S,K<FN[R33__WQFK%IWF"V*;0RO-;WSJ6ELE\[F0EKYLV*=*(),%P@-
M=3U1]5XJTP#D46O;"6]20%8O]#W#V2^$;[TX O&@)=;TE*A+Z(O11Z NAT<(
M@;:F9^.7ZC8?8TJY5CH[H<BS6BIF[Z/4F4^"Z*K$H9XA=H;KZ+MV2EH"0Y=4
M+>*-2JA32S$1^?TVBZE9]?IWYOO/HY]$@Y_^1BS-_YSI4D?+';SUU4$LM#__
M;[J8,DL?<3HHY=J S<BE7?:FF9TG9S]\I9VS6WZ0?)/EQZFM1GX6LN;^MRC>
M-Q=RW)KN/<PB?-3AI9XQ %Z_3;'HRIO+PGAOD,^UCFTNML8%OE'9O&9BN) Z
M45*EH/?:OXI#]?H7IO$WPO_ -+\C4/33WU/PAM7H)K+&(1_L1?N9\V.2CI]A
M)A[UA9ZVH>QAC[J^%5BDVYGEOY(3B2H&U\MA- X*@XH2"\6PX[OS"5H5+QC&
M_*]C=17L1FN7&]O&>62DPJM#O@?TVWG^O75OB=*",2MF\60K?T6V%I*BU:2Q
MH*X/Z\EXE5I15K!EZX1P;1.E('K+YH-?%9R?TC/2D9)-7H\2A]XYR4=_'[D,
M"I8]A3<ZR#\"+12V0:<V_BW4AEL>AU<64;F[/ZA_<NONR.L:S]<3LYTN#A^V
M*ZR6!/AD5DZ?6I!CWKBA,'@$\BR0)57$^>SI:I!N51+U>8T]'J3=F%2K#O-1
M:F)A3Q#_,]L@&B@@=#"6?55'26%4[D1=4^TTX&?:-@[EJ X7X3B7%YZ4G\ 2
M8"B<W/!)G-^ )1,)NJ<G2/7(78PX-75O)%A!S/'FYV0+OU!/K2'.WT]5VC+/
M06XC4@YJ@QR'^- #[;QJ!WJCI,-]>A=VV-"'Q</<5ZS8_WW550^I!:8IZ%*>
M,N/,(FQ8YU+Y>CMG,/G)PE2RDAH]Y-/AU]O[SK\Z3\)V:[5@OUKA^9LO?+Z;
M2PVSCC7:"E(4489)G1J\*+/C-V'E'"C2RL>1!GX].?=G)NW2W%63WTLZF[>_
MX^,^D/]O9P^S<B]:8P0MBGRTZD 5J"__K:7[ZFY Q/M9Z=I&D5?R6YG7^ ._
M@[XNI6M/QM2.ATZ.#')F#')^$[_*^URA4HB%MX/E28:+(?TI\L(B27]CY+U7
M,T&'0,5-[#Z )MN\6Q]Z%NQHDA]T7ZQ?TO921E1)PH+P"B;R_E>]LX\:'LTS
M,]RK4)=:\Q9FG;PXBPAH_G&Q,CXSX4X3B*>W>I5?$S)1HK,6%,%K_*2(78H:
M5,2]V[#8C[H*3F)Y^$BA>%"M[8FF*_,U#^OTBTYB->Q69K]^_GJJ!>JCIG5?
M8B7.UKXYE)A2BS@M=FU-T>?AN+)DDV-^W(_^VZU,98]%Y;YJ:O+7NTC2O5#R
M<:2#OYT12O2N *#4**V7\NM1<];:$<BGR2+@ >K3ZK6:MY?)YWXM,KT.SW":
M/DC$V=-U9_[-,^E$/"'.B 3IP:,9-F,(%^$LM@XK&0^Z<[J*MEFOT#E5-SF#
M'E"$M/$="B[O#5YD;,8AMG?>#H$<W+6YJS,Y,M08%JT1;/.0ZXV M92;A+C\
M'L@#:.]]:MJUQ>V,$*955OQNL\R,:\'A6RS"D4P2)WYTRV\;+/VMT?5</ (]
M0VF_]6HK+%G4/_US#2\EWV8YOE_#VU69TSO"D=/]NI]>MH?Y;PA+%. 0$4Y$
M/XN4C?%C!!<#H=T"A,)6XHR"&J[(ML$XXX8BY[5OUG,:/Y]N8+(4T:(.@.-M
MJFF2CC%=#5GM1 E-.[,Q=VI88H2$;Z6@F1-TUF6U'^NLP?+;5*[M+B:"#N2Y
M6AX&@HV, ]H;L#%0OQ.HDQ3?)(SY*L+A5HJW-VH9Z_$PP?K?5K_.E+O!N4@>
M/5FD'U$OMJTB$7H@TI6'N/$AJ?;6MK:=1;/_IR4)7TU-H2%^N#TP0(1P Z7F
M(U#P6>33 ?NIEWJOW?1*SX8*1Q?&GAOP38=8G\*IT@Z&'S1385&,.QC4U4D]
M!:2J$>(WE(OYYJC;1(7@F3)7CJ*&JTR=/AGF?_ >B!4.6-0^-H;!58M\X@1P
MD"X9]4%XZE*&HIO6PS7W-%&"7LLG:VO^*AG]S+^M8AV(?[&PP+Q+2(R[%6L1
MH<>V[+-M*ER-_1LOFI<7=?E0 G6+,M\9P14,.XO8UXA3F\Q^(.A0L!3R(?<Q
M,;3?X)>_OVJA/+Z!FMNI)T8UR7K[2%R.LI?3@)&+4.F-,)';A)[4Y;R2,RNA
M5\6%]"33B[M\2$5,0*D+\*0&94/QB)T:?B1\ZG597_4M)5FS;D%]CT#F%S,7
MLB90WZ>^"Q0Q[?EQ "(.E)56BF"W0URJWGEGD:*3B$E:P!]_0&GD&X>C_:93
M7+UZ\<.JY0CVCB^L:TW\W 6<.?LHWF\S2ZE06[\MGJM0*.C)H1J (4;&_FUS
MQ\:CC$M^APJ/'X$\QDCCRF^;P]<"3_4__Z T+1GS=>FN:<_\Z:)X."7^"-1I
M47Q\L5XZ**5#R-2(]H'>T'_:6'+?U=XK\"N'O^;.8<?0.C/K:"G J(YQ?W@O
MC>L(Y/J;MA^2)5ZLYF/T(\1;2M$0:\^_*!ZXC8<WA>EW*C]SF'\!A3$C!>V.
M[\'TD/6[U?/F*JCG%1=Q'_(FE'36#,=_)H2>8XK[*HD1C68''0B\391C9K4%
M*HF18&#^%N6X,26HB4#X$&SN'T;KH&RE^,^&GRZ=5>SXQ56;67PP]ML;+P[4
M$^$"P*=[E,,LDA_XSU-:W!'HO)CZV)U8Q*#^&_2^M"MUI^_[290?W06E@L<#
MZU368\44HXU!SO?,\USX<%Q*!7MM"/>L[)'7S&I')<;@FSN/4?DQX6GI*'K]
MCX!;!SEX_@*%Q8HN2\%;@"R&H4_5Z'K9JJ=*#>[-8 G1D^%R4V0Q>E^YHXQ;
M?RV9OW+;I-/,J@P$;GW_-A'4,7$HCX1W'6J,X50C29:G^KKS.H4>JU6G7)/;
MPMSV'3#FN!S*C'CX7C]H7]@O#J^(M.W!*TWHZ)<!^5W[A9]+CD#]II:-XP_R
M=F"K$'R"'0Y%W6&"BQQ.%7%B,'@MAN%8._'6^IP&-;2;K4:?>)*:W9Q]-L>%
M)U,A*%YMBHZ;@<@071:7('H;3][<;7?'Q'C> -8H8\9C>/;U(Q"884E95H(E
M,YP#R@S%TA*>VPTP\?R11PUL::V8K?Q[R?LA\VPEB'GST;&&U)R/GV^T[3H"
M/=^O4==3I&)?,%3#GT#R^?&5U8;>B@EO?#DD3Y@@^VN/0*S E"D00UR/@!M.
M!)$1-W#.PRYVOZ2[SW!F9 =)PR12P8^ ,\>UKJLZ0N,>D$V$\**'#F6 !"IS
MGT/!1AMK\H/A^^./SR>NLGOBJ3/!55\NE_N?B/\;]'AJ!,*JQU+Q!49X#FNB
M8.(>#*,TJI$Z>'Q>< EVM.A.HE>.X/7;DO8W&NGU7V^7K0H5@TO^\\(B6A(]
M @<?@O]\^ DT],Z=H0R2OZ,?V^R_JSU9]E$FH$4QF5UH\0*6 5ETAI $XVKW
M(EBMQYIJY:FAAF%N_KD\-U5,K(>S=:(U=:L78&E'(.[:W=F[)-L7*&.Z/I!/
MDNT&BST*_?A;_$J<X?,['V(5WD@7TOM\)JM!G=E?3DO.CC3 KZ-$ ;XB)OU'
M7'I3G7BQ.$/*7.W"]OZ^]V3L_(T(DXMO[9QY#5+<Y<<V^Z2O9;WQB-*+?9N8
MNB;LZ"V@3M@H4W@JZN_%'$OM(\,H0\3<^)41ABF5H\.!N]:WI+QA'%J-0,1W
M"+&4MCS(&+KPR5G2KI%Z*M<OXD&P7[AGJ/  "\5,*O7A@_1O7=%L5UEL5[48
M0O53C]7@,6T5&^NU<,8MX;W&MO;4)@CWS*\UC7[LVQ72\MXIUU'%#Z?$'8.5
MEQ=U;"?A#6F=\\!=.$1/RBN/.TD];D'HPABFD?[PV=OZ5-KUETY)#_[RJ]=(
M9VMRPIC5F,CC=YSZ>C'<?^:4 7U2BH)AF[K67'FYTXR=$^O/!P4D=Y/9&4Y3
MW??,''8'=8=G@?#N!J^I(Q ?CM6]>L:2%E93,57KUI+HM.AV/J*CH9=M\.G9
M0,7W-<>'"MO54^UZ:"&&""6N5S\ADEOGO!_]\A]QOC9*S'P1J=:MVT6@R5)O
M7ZY6*O:ZXQOLC-!JD+OLU9GVI@ASNB@@3R>^*U@LXJZ-H>43(R ]@KQ(7X[R
M@.5IM3M7[;![+VZ.L?0Q&3"7@\*ES]JJ4BNZ".U)># 28TXY(([MD6&FQSQ4
M]_RE^I0R1PVL)5"]]6[&V%FFN-K#*<AI%)2$2!&T @HH?V&3/IYTQ4E!/<F&
MQ#]"3](NE7HSLPZ)F/U #%?O;!%S.S"G& ^ #,I0QV3[Q[KRA5:&2!@M3>#1
MH0S%_>53YUV>GT-^4N:AN8(;?_FN?^O3;@[#D:4BC.BBR L[Q-3LQ7:N=P41
MY8"M,=7]N_BYYE;SL\;WAV?Z;<0.[@N"_25GME^ N$^"PL582(G;\S,PXF$3
MU8+F3C6)(]+MH5S7:)H6=J:!EV;N8<T7PY,,S\L+#L4\3))Z1O]A)J3&5%+R
M/]98DL(CSEC^9\WMR;H*NIJ P)QD0]X?[V-KW.PY5%=3BCVAOZV/36B/AG.W
M/_(C"'>N3-'@+4#HPCSXMP:MK0WX]*7YJ>;XIN_#9KK&]*+SG%OOAQ\W2U]U
M+4HBAT;A]2X%=5Y%#:E)%>O#?]*=UK""DS8)E371%+N><)T0M-_KG5RZ2M=
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M*+P*W(D &/4>\E*M!_/8?2^,["6%KTE<\Q>:E'4M+E1!#@9/4"J>[VYQ,7R
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M^F?J<,%EQ[ZP&V-8TXR'E\;Y#H+B>U*JV7+LOIBPU*-9;777YZM[(]U@PG-
MM3FU-J>!-6Z%*AO+,%?/KEH7AK['8JDLE9S2OJ\#S7(''IJ>S$?T&FB"P![%
MG$7B0/1.9R'K)-12_V:^ WZLYETK]D-"IWGXA?/N"784#AZ0WMYV452DGW+:
M$>@L"O( \UN_@>^/L$D%)-]/BV'XP7)1BL>ZE+.&3:(:9,C"PX9YKZ>,7('%
MZI_&F9,T'Q=9Y1N.*2F/3G +$]^FO)'87^3?'NK:BHH4UPDE<D!X?^LWVL:@
M(!7(/.E)0?-A%)=;0 7A\Q>^EE3;+%14 Y]SJZNYKA?S:/O](U"2BQK0@I9U
M1JZ;M5#FZBN ZHVDDJ_OI??7>)-$;'@5ZZ.2V5T9W'7A4^VVR8>]A=#/5)NL
M1<=+'F#PX'\_G,CT4;">5$/<\?,CL5N=NS&KLI2AG-.?RJ$^E1SE#Q(?-!"%
MD'5)0T( > &2",7$M=W*KT-V631H.$3$;/</SYZ][QS2^^W[G%U$U3D!GU*=
MJ2A MC>R6:,;SKKVE)843)>?]]8:K EM#F4_^-SL57;[VT^=Y&A-G=38SV.T
M)J#O/8KYH$C'B%0K,V_9,MZX%ZO@1Q;TVK@?5I'*!.U2_BX1_W7%S)#554/R
M_3:RW4.9<*<)BCL"Q58T>-U\ZU>?%NL0@%5X\R\<MZ7JH?F#_/-0<<= #,8X
MDWH$<AIO=_]DC[. UO;%BW1K >,N$TN()_[0I [9EP__,3Y,<WPJ:!F";C:M
MZG^,[+782H.?4(OD>Y2S'X&O5,3::+1/;PZYZ]"P*C/FT-;'];$F\6V^4N1@
MEJRONX] U/F9(M)0&IZ-P9;;701^C%(.>^_]=SC2VQQ3WIT3(L!Y8S!HP/?Z
M"^.7(3.9DGSJDY*L ]"9H1F+0][P@>?*&Y]ID1]QL18>4Z$;/V\MZ:JF&JZ-
M?@ZEX0 ,23G6A9LR6Q13IQ:AZD"MB*_5T3A56]4]9O_[$)F>'YNL\B\MGF8J
MY Y6S(CV-].SK61P')3K":P)SDFU'%2HP7BZ2AP&403?>LIF[P ,M[WH,:U#
MN?FQ1ZA/*4[^:D<O&VO-85>HB@NZ%\*^DF<NG0-C\WZ\N6'_*M_LH[FNY=."
M)_HGT9+@9'U6G *IIR'WEKC,Z*5@V,?^4%ULP>FO'PI5L2&JS][86AJ(P^@/
M#T>TIC:Z*#D0/B\T.*LW%_Q^YJ<YXN!M'BID0/7Q&7/5:OGBP$3S<R(=4B!+
MY!$H/A(Q1'"8[\*.'H&ZE/.A%MX0,C/I5.&AR=D"@/V'UB)>8?P(Y#,D_L=%
M$/ I_?WT'AKBF":.L#D41@P&SI.%T6^RXF85Z_E8XCB:>.-M0@V0FIB+$WJG
MT,-%'"B-B-I?AZ-Z8E2!HI)IB\!]D^J%< 5GO3W)E+0LQ0PS<<W^<XJX9^NC
M4;I#-%VJ>LDB;/HN<1)3-6L94?G(1>QC:UO+:ZRY&N9TCH?N5ZD=EPPGOPTJ
M*4E9A,%*":E_M\8#H+ONC=3ZUN[^3#<5B]:YT2E]&W2Z]<L74>[LZ=NL\8<_
MYYO 2?J>"D6L!. N<0S8W^J9VJJ0\'ET25[$.]HW1=B>/S?HE7]Q1F;+5REF
MXGRC)SF);K:F?P)E'Q! UQU<^(1LG$[.V]#3JF_-,G?&_:A_>\KULW\%=$._
M.3<>9TR"G$%*$MOC_!A7B3/M(A;!3PX^UZQ]?2_S9M(KR^02>>F\5*N2=6Y
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M7+\QKA?.Z8U6;#BH"-(],=6=<_O1'6^"<M<,QX'>H'L*?"":Y'WS8Z]J5^L
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M0"/#3RK?XK'53[%;"J2M%X>LP C=&"FO+(S47]2/.>3[72C1VMH*X_(ZY&K
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M R<NA&4*AO'B1UHCPYK\_?5<$8(TNX.WAV* ;+>+%(56B7GD I[0<:X9Q#@
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M_%>)6ZD1<O2WUOD6-1 +FO>7)UF5SWH_-%DU2KK;+([X!@(8;<;AB0P-Q '
MBIY(39))!5W&4C\7E!((WC/XH#JH*D=C:\Y7,9[*XWK9;=ZR7K++.L,.B :2
M%>47M8"A.MBO#TW *R?]L"H?V[.\8_:!XT_(*2E%F,/5=Z 6]F[9E._E^]D1
M' NLST"NATQ0*&:4G#P<UM8VA+T [\?E6@4\5EZI/W))82CZ\G>IKL\GV2>J
M_E,LNH5!H_RLI'P*Y7%4]_Q^3,J3-BO!M42R/=.R[$>@+SXX#WXU-,-ED#>T
MLO[*]DEX@<G&]V^*D8; O:#]G$X/L#QTT=6>J4;CCD-ZD.;MIL=BF6XJ^S4;
MS\LH]04^98C5V*1EI:<ID5VB28QS1+4^,Y8&4I2*3E*<FC5/[Y.VP?YU "6*
MCYM+OT\Y"Q#Z,/!(_XG8]TXA))BZL\>@>\D-QC+ONVF\*\L)5^O3%\.;A[UQ
M-D3&Q#R7DCQV LEU)YJ;XRFX"Q-G2NSL3N>A&V,Z&PMZ'5TZ\OV8&!!%]>2A
M6QJ:?^4E=7[,$;"VWHWRWY)"ZD^R)+_^@ @9"M8B3:'"SMJVTER)9=B]4M ;
M4>7Q6 ]O9J.:%N@4VWM!G2V;'7\*A ;K[>3O]!'DHL?T]?9WB#90G<\9(*(:
M3X$;U:\L[3P$^^Y<L9__J"RL^\?FTOR"#@ Q=N@<8CH;!'M1<84J]'?$L3B]
MV_1F4GO&%["A#MF@ZF.0NH9+]#51IP5<4LK3DBA[=X^;IL!0G__#\&, ^V\A
MGEM<+ )*X " -51;!KE ;//Q+OJ"(C_NF")RQ:OG/1M?WXX>/:; 3 E,8^,0
M>KSU-ZA\+P+M[]\6DB4]^"JHJQ]@Z<K+0"&&23.YU('!R_0H8OACLCX]B?3F
M_;BVI0X&>\I%Z*7J,Q#(]%OQA0P',_[(4,Q33 '*Y]_G#')T.,,,H=<GKRJO
M3GV-CB:]G._C+S8/+_85_UUP/\PN7V1@Z;)"8O.G2JXE4@7[0(0$4VX_+T*&
MJ4T#]UMQ(35;T_L[^3?2BD-)&.%%UZOO? (W1!3RE[ZMW'6;5N;I53H=>)XQ
M;(ECC4_5;.IN["P[Z'XW"&3K1W!3I!AZ"+W#:1"R_XX$D7+\^;=Q9O+G."+W
M2KY!7PO6<UZG9"U%W-N<>\7MQ:.C"C%HU%0-I&&7$18^C\N;,5RNY3IYQ/</
MA,6CYE^&]*")9U%7P9'OF4$SE.J;'PRU$-% P=<"T]^V,R9I"<^UZZ]=3I4*
M.7/M5532WYX.?WK\\OH!(!:"/5.H35/K!0)[RYSFT@6<$,D]&/%VMXHY,\N/
MF:Q/VA+CDLJF/!.FBC&@Z#ZM<>XTI@H]B*JWAVANHGGU^L<V=0C3LTL1Y2;4
MS]@21*%%U:A%[WHX2JQA6"B'],4_R9Q/[ZRFN8328\ /HVU,H1\.1#5E\:A4
MT>\,1,C33-"U,'G>MOKI^[CQH*/+'4DJ+_T>8-L3HM=YAX_ZGW:WY9<"U47I
M[.H Q+91S.,W"3?HPV1U-=((E.T^?;UFWOYU(,*=QF$$U)>K&OZF5+HLK.#C
MGA CK;5IGWB!7>Q7+)) $QR</0#PH'P=#'W(5G%&D/@;S0WRLDTTB5A7]:>#
MM^N?%V2H[+_P!A>=-4L3>Y-FS&7'F>!1)"A'MZ"N$_TW:/YP\E@<@1>.5**!
MKM-NII)>P\QHAKEV^;GQ,W]9(*^<$^J]%83CF9)^]QYD:IBLLHV'?X,:+B+L
MB.G,XQ9VU/(4YD5R*L1YQE BQ*.R-[1H37@P_+B%UD(_+$R8<T8B1VCI[L=J
M:2T[MR.P'[X T#)J?MZ6?H*F1%XLCT,&4-,'42+85/&3KHP[U([T ,B>K+7?
MR=QS\Q\SX7C'R\ 1P!"[:L='M2,=#E1NR@FB5>PARZ1N,6TJ86@!#4,?+9,G
M8^(_+>_# @(\)!-K:[9^ZS0,*ILH"!D%?MA* E0Q#.FB1.@&H19I-!TA2+>S
M:&^DUZ!T\_,7GCZ;/>=0$MQPLTO[VV+@_:^T(\_TEJ2<[6;$2-+Q&PYOUJ"-
MF+@.582_:X%9?5U[@<V772</D9_X_B\Y]9>:K[.S'9_W,'A]>0?@G)(ZO;D+
ML.N!8$M_;Q!HR<M[)1WGZ<;+8T) P4\S3V=3GX2KTK3#3@FS!00%P!0;\EZ<
MSCDYSRW5=9Z!OM,6QJ]/1E!6VS(EYV:.-OW)$M(2"Q'2>LKW7.MITI_D_PWZ
M7)*!-OC'&(FS1E&BNV!.I@:U-A=>0B=<^D"3G%7'Y%-JW>+LA45'GK=]3-U+
M'6:,5L5$[8A"C>WBF.#]Q,;.9YV-C86&U,T/0?ZD.>VVJO.&YQK"7S_[?<[X
MS.2\[M:BDF24)EOS8TW)SZ"%"@#F&0IFL377N2PQ2#$_?*')@X4*1L#LZE\8
MZ1]_+<G>>]:*1\AKY!EC+\V3-F=N-PF<BPSX;?3?LJ78CL3_!GXB=3L]"5Q(
M]?U\EMH/5UZZ"\E%8]Z<UA'UF*Q9ZP35F7<>Y'NOJ/;R1$B&#$4F]W>!'3?[
MJFI'$H:?#F6(^J".H7Q\#$-)BX%KA-YZGQ#;1P@O3X;!L4W/)(?2)CBAU43S
MR -VO]4'FJ_L/MP"C B;&[(-J6$C0IG&C?LO(B!,WR_8=(G#=53[LFQA\6)C
MX87,GM\WJ*/,I9#<59D$E;M_5LX8SAISI+]LE68,DB&)Z.X.CFFLV6ZX$Q0F
MX_7BY]\'RKFYEP1L53QOC:80_:1^7.C"'-E/-]) :J:37D&.E=,,0Z1CRU_Z
M=LC23/+^FI3+-9+*+<S5-\]ZG1*E:!1D1Z]&ZA/^0\1JK\79[7GOI]5T>F(2
M(S1FM G":XYE\61>)X.+8 N<_/UQ"F5D1"'M07^A@B<\J?=DD889N_ST)7;=
MB:QQN]4#0%J$_&'(BYE![Y"W:.4;Z&I4#_9+H?E86B-*1 \=*OC*CK+S4S=P
M4'=@^.-V;*9EY 6^"\!BH)".I9LQU?9=*&E??KY/>AK;9NY5M@ -CS/X"?B8
M,'*[+ZSUR-V4Y?-22M\AD83&K:A.C[%C7Q&B W_M4B.$JO72Q1)H+X1UT]+U
MV^>PV&GX;X=&3:XG5KHV63S'4WL![&_WTZN9,M1A,CCQ\ 'UQIF:I71N\W%M
M?R&?9D<'G](O2_M;5RW4APT*(JWQZFGF\'*9!+S$#^EMZ-S@WGTJ=_<!0!R1
M.[#$]OHSFB8BXY3A#PO.^BEL$N=CLQ&=HARH,Y(I5'TK]U,LQ_>9"G:UP0C-
M]_008JI;G_3;QJ>>\1XZ^_-1+=6WE0R>&S K83N58WM/Z'IDC+!><L=9UM L
MFH>I1'8HAEF)."):+5)U!<]'4+;4'Y:E^$R\_\J;Q\2&]-:'+_].IRCJO&3Q
MPVQ;P3'J+ 7+BJZ'M8VG@MRG^']5%PV>-7>WM21)/J^])1_Q* "M0O=@.#/!
M5'!T(R&NPZB5!HS2J'ZH,FD[2PYZ8<MMU]3$R]Z,[V)P3K[W +9F-\>\NK<:
M:0">$]BQG"#3OD?ORG%?IF[%'<I-BK>C<6VNWWW;R*\.BU(JPW+;C;E:XA&\
MCVXZG0E/PLWN>>WG,,&,TX@PYTFFBNJ[_5R,;TU5J$0NU-M)\7Z26+1XUWT>
M4S[?I/X$=IFZR(NG_U\\<_7_^=M!BT1\A1PSE,.X_'0<[ ?'Z]N^*_]TK[4!
M1U-Y(2$^*<"CKQV5'?_HDF([^ZW6,'6CT+?_M:]S6CDOZGF2?>7F1:Y5=K5,
M;AT:M)=7<*ZA'PUD6@:0#P#\=%CODBIM][GOVQZT"$Z""UTYOX1+]U>:=W8Y
M9?&LQ?V*8M3*D4L; NX> )F9"'$Z&PV]5XB=,I)8<PS.(B^:FGR8\6=:4&?[
M)N8:8?[AWDN6"[K5]UK.X3;L%TS^W+T_U W%@#XR)1A2B',DK\%]@T%YP7&<
M)NDHY0EH5'S]YD3C^3,YS+&+C57G<$Z!;HP+MTIO(B<#-6/67P#.P9T+ 2OH
MZU14,E0.Y=F9',Q?0I\:0'%C/]:4/+S\#B8N@L7EG;R^B7P;:?:Q6VR=(&QX
M1RW:4+C2=^+'W_($&:MFG\Z&QJ^3%FWON4])MYUN^*]*]@ID+HR4N]%; _L[
M%K<ZCA/4[0Q_IT/!Q#.=2&:-^R$6H@-JNL^<B\(BG[6!5*^\X\T\+@W [[]L
M1 L2F(@OVI#H3C'L!Z8<2?(P<^QKKTT@LJX5+LZ0P77SAK&K34'"()$&(2VN
MD0<=. R(#F:HT6%$O?ZQXXBLGAQ]C9A2>H%572/KX^3NUPUB+ 4?Z+F_Q'XN
M,9+Q5H9;S?!I*8!OWDXM\H+:) Y(GAV$SF'(BS$^1MHT=#<E$.0C(^3KV/^L
MQE^51Z0-?9(HHG76^.GO/JOC0\1T#M_\QJ=&[\A<4Q2\_P9%5SMS<X/MDTGM
MI^K_:F+X([CG>KB"SJX[LAI('QK![*,8@J]E&(QTJ 1T:W6(RV0?+7&T6.*D
M//&$QJ>AYY575F*Y_N4<N%KO[P. O Z_(!'3#_=#<2-,^#76#@"6^HVNRA-J
MS4$MR1O!8R=":UY?N]Y7W<<7U2")P8 ^L7A90RQI.C_M<;^\,K4T+;GH9X3J
MU 8<4J_=KFMP_D18\*N7G2&1(^1[1C\&NH?&Y-]=$OOE8CM[94H#[.]WHJ&A
M,;6L,/25J>S)MV=&!B,!')D(L9W! 70BH;Z9PEN&Q:0P[U-#G.=%>V5WUILL
M@AYBHI?N#BMD:IEQG^RB@J8[O;?$'.@6)*X:W5(21 @Q=1V7OF'WUS79NSG$
MNAN\N9"0?"J([0-OSN EV'?4')"(V>@GC_$,DIS4P:3T9-SE-Q8!_LJ.F%C*
M1E!CVJGKL2W-KSE&:''7?*ZGKGB]TV:;8 V<[CA-CR);;+$QK6G A$-E>>S0
M,N4Q]<OB:]!\V/<P6.AM"KAS=E#6\H0+1KF(N*NS^RNT>8/"T/$!-CQAG8V_
MG&[5,(FTJD'!YG_.Z(*\_,O8_?E4E6T,;MXPKC^RO7]^:#<?@*E<:VH5?QD0
M%A; __IU"5Q[9X1\GF0LY>EI"  H9W5A"HVTF3?WLSN]771JD%[+@C&MJU\+
M);^C7>J=JCR0XMME#AP9F9<NF'!'N=8P3!&58SW0HSH^6/ Q>LQ OLT*ZD'G
MY*Z3<5MKSC%4\,HU!XL*_H_.3?KL4 /6QP, )\H3+(ZPA?#,^:#XD"YD?A&G
MY%#%:238WZVF).#Z7?5^W ]5KQ0MI>MW_94NFA<)I.]IVM#L^@1%H A!<FX"
MTY2ZU9L_.E"@@:YT[:V=)QC,.WU*]PEG=9PG^_!00E6XN8LQY56CG5[^<U5F
M^P7EM&?Z?$_#"[/(X3"&*^%F79V30?A9&<1]3<5W^, 'ZL\E<G\.6)6,<_DG
MXSQ*D!#JMYDZC&^K7V+)UXJP@G7&BZ:F9NM+G"N!8B9F4LJ!QJ'@=(@O<&Z8
MC(Y7GF!:T42)Z(3=EZ_=P]3O0*? ZHLOOMD/*L>:<S\/Z*XB-#7\D![K+DCG
MI3=TL\[1[.*0#PAS=MN($'.XM8N"WDBN]56I<Q236]UOTJY4OP5]'"MD#4.Y
M#P">T+1#1=V=^M=FB>2G[967?^W2,:@"'_/9:U97Y?G3X/!""Y_K[E;7-7B>
M>(OK^X8P$<J!YFQ.[I!=1!3<H(:O$[SWC(!9?=9K^<HP6,6""5C=VA:E//R^
M23% ?@9X2BG@KT@+>*Z*:(G96*26@8]]77!:L)_WU8^EM$2/.!K[RTVOS(*.
MF%1WVVJ>3+D7><6+]Y7 WK^C29G_CB9UX?#M.$T3B">]/O/I/>^H(PL$>JSD
M7NF?D1TB*\NW0IQ-0<+H#,99IA_U(1Z5:@BGVO7CPW&!YG+8S?:R!7.9XZ<=
M1=P796/-V<:K^*C&=P\ T2F6)* (\GPSE9"&-"#'C<\'?^!.@AMJ(*^6(OS6
MQGXGJWS#A:UL?_IFK^UZ9V ;I)^2X4\:VUAGZ+#&C8[D'P"Z.WCI2F20@^*V
M/,.,NE>@C_\T$=?+><7MD923FU"OTOE_S8U*5,_T$J;H!-.<M$Z0-"VBSUZ?
MPCK)"3K->DZ3J;MPF+PZI>158Y7\416'N4"C6S'?, ]J[Q"M>H%T:S0'4XFX
MU?QOIZ ']!;O X%M(]'84*'J",_1T>;@!<I"P"OW7[6UD6<[3B M#\.4RLZP
MZG?<2R8MJI<([5?=P:7-'*&\TOAS5.J\H5<=)M_HW#JJ'M57,(P6'EW&Q.O;
M)=7,."5@QP00E?,W9CC*1.5)AB)59O,(MM_@F_Q/.JFW'0YMD!7@D&8&Y>5I
MH!^9HM57R4Y0P=<PRW$-]8@@6(7; H-G1>B.&^CLF0M]G8(H+^!<\_+WR-46
M:OJS"('U9&TN+MR4MH$4?V.-I&&1R\1[/IG#V"0!?G8^L#>\7(&4F?RU?V?
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M,<>3%3H&S>^G:M72EF ?3J2^OI?L_U*3_81= +M:T1"[6D61H"J]G<8@&K6
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M59II0H?PHJ\C,!ZIB7'QR;+W-E*$H7GIT0X;%+6P[$:^/9HDWB5Y#P7FE+G
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M=>\,JH^DC57E@JAV(AQ(F9AQR!BV:BU[VCJW1\0\YI]:+$J":\;TWWN$H<W
M'1F:#!%GGX0*%)%Z.W1*7E-E70;*(+B-.S6Y^B936ZO5LZ< !*5"RN3;0X;Y
M*IT/!*)+UM>?,UTL7D_DN9[]8I0_<Y, G]4EYDY1@:0JFJ05P***"!8]88YA
MQ,JA]^(%X*(9AY_O;QEX'-L!);P>8*7N/PX4?;W+FKDSN0JLU]X9K(+>)!BC
M$]N8"$SW2.XK\4J@.H^)Y7'_(PNG;9#&3<G\J<"&?JU#D7)%N3PY)<%$P)^D
M3E?ZO"X0C\; [HOEN&20IRV!O<R]V(F4],U O:9UO*KJ4*(1B:Z)8:M^NT=F
MR' R8_V>B+GN<=*.1QM.0Y67V52M"-KQ AC'W0\&+NM5C<P/B<=]W;$,,IPK
M0BR!;\P HASY_NC'M"SJ9#<:8I4*K.<[3M-3+]Y^#IT-S12(>5(O+S?)UB\#
M_X '9]SG:?-T/VL',7ETWZRZ3!Y0+7)2#'H2P4-\/EU_"N#H6UZ*=^/4K'0=
ML^@=@TI]%G/$S8Y<2A[4V;.N17Q\F1$4I.;:YZRQQ.@(FM4!QFNU%#B];S,(
M9C.U\M;#M-WX, Q60!'6ZI\<1FDU$E3QNT* /WG=D:RDJ\ HC:7X)288$DI?
MYD9"F.*G"O/9409B+YQBVRWNGJ6^5[KL)'1!6V;VXFY83>\/OBY@I8' +^']
MF#:ZHDVJ+.$,J=P%$3?0-CG5H62P^.?*FV^OOXBZ7[A]F1E _VH%V #?:<"Z
M\4&VN\1U\C \$ 'KN&Y'R:VT\[).8-X_VOB&CY7=AB\]>7;,-LBCY4U7KQG^
MY7_)0@#.NA$'2'+XM.ZG)!Z<5[R&]U[#+T"$%K'3XKNK$'O'QF[**!=Z\S,]
M(#]:<W=RW8".)!.!!<XRX8#Q5;??1WR&S.H*%3C0^96'8U]_(W#:^;PNM05J
MA:D3AKSIOT-]R/HT"^M-:),)Q%=C#!1(@:50T_9F2Q4W5N=>6K3+B_882]BH
M?=?0:KK6T1%S+S/5U.:(*:X2K!0L(A_"6HA&QS)8Y+V-ZW-*./-RB$?.V_W?
MZC*_C4 R^U8^PTE!&U<%1-N^=IPJ_.MYY10B!)LP$3,>4-20RSUUUHA9-$5K
MX_6;1"//'ISBYDV XAHL%8V_ YI)M71RQ%NE->QJW\LT;_.SO'X;C5]8^*TV
MS/K&Z!1@ZB'C I&2DI*8GN1;=>.!>;*ZN/7P0+J^_:W(IR-T[U2'1/@\R738
M=GIVX.;X06F%(66YHIRBHF/-] -86Y)"%:5$$I2/XKZYQ>=?(H$K-NN<;RT*
MSP5^_75YI@CO'KCJTLW-HU/SYT*&EI6ZH*YE!*F-_?GT6VK//X]WS?%>R]L^
MBY<R#?.Z<UH:/Y<M&B1+D\4# CS>G:-\$P6(GA==F3BJMOUTIBUNQ0VS'ZMS
M"N@ \?HN2H_[0]VQ2^Q+C7EA#_[:S3GN42_R\<\*%CI;7'SW5651.[^ 2;S=
M38HZBJX3Z &T9,/Q):YX5E*8$T$T4B%CH)LXS:R5'B%*<'Z\:!_&E&K^!J&4
MD#5OZ)X/N+HTDV,X GV!T]T&Q@A7]W"\?+Z>FQ0*!>+RSOR-6"B?_Y,Q;^P9
M-';6Y!$A.\JLG_O*JM=NT3^OLH'$")(JX1H9UT\Q)+5_):E8PJS&UD<U%G0[
M&X]9/<]S#XC664AG?MR7$ASQ_W:?-=]<<Y\7D-S!BWCZ];+YKILL],9)/96)
MXEL_5;\D3@(ZMHP&-[[]==RR']LV8,7=7]AIDB/WP_-M]NSGT%JV]&_2$>Z!
M+/-S?2(1,[QEO9]Q* VKGR <L=GG,\G=FA 7K;'$!%5!"2-?K=76YOIMMS:]
M3T$2$P?>'HPZ1)^+5_ZPRF4H#*LM?N6%:[?Q(@7BP$DP]@H]W3#?7/1+O<#'
M ;8B%T0J_,[,"^0N2-,K$'[8R1O=[MIN(;C->&$YNH$<I%:,N :I*!Q[L>TA
MSJPRF!:+23YR+@:+4W,_U [5%CT>YUY[<?Z\78,U8+#>XS<? 8VI3G-5."FO
M%YSK.@741:![..+4S:4V':OC*:9%F^@GGJJLSAW^3ZNE?;O"<B[.[B0+GF6P
MFV'PL/OA"-^Q(#AUJ,,>0Y5./H=8T9$4YEOM?VFC.,:/AG<6#O1BY:MD+LIE
MM#9^,< E?@[C!  $8;73+QN<8#Q:.9^W@=P&W%OB['FWQ25(8)SR30X^'[7-
MW8!MELWC(('<*QZSW\QYL?>7@[TCK9FF-5= "-7.7P;\I T,)R2Z=WJ)R^#B
MTL_-8_$+$U5/<+4SWFS]#H6V(Z6)@G4Y3-Y*F"2$Z.57.Q-T5MW"1_"88)&%
MN]9-J=-6XP]>E+]?VNOBONCEOL/+0[+K^YNVRXS7)JY.:)PPX>PZX7R_IG)'
MA6&Q1]6B))OZ.?_[)6>S]0TH:MZ%638.AI"/5.OF *8)-VXHLQ?!%+O>COUH
M\8,Z3&"'!Q;/OYOSBR].*7@BWGL^T%X'W*&H#R;"$'B.E-SA'EO8C)J/X]M,
MQW"N+2-.U7?NBSU:NM<]KBIT240Q O3*B?;XV.82Z&-"0U7FRKZPY?(IX"PI
M<<.L943/%)*[/YMKH:C[KA#9EL6_MR"IGG50E+U\2:@_P^_7+ 'TLW5Y+:[C
M'%72FXC2F= +#UV\J.XZ[\L%;_39)[)J)D[Y!$6.2LY5, R\=(+]T&:4FZ.E
MG?\XMUQQOKPK\M(IH,]D K:;0TV\"?@]'+UT<#MXG^QW"BAP;?%=C_Q?YYJ7
M KXDRO]OJ$X_ I'D3@%)*$DHE'!$;"?DK.PE??(5*"OSO@P)Z_G2WR-8S/2C
MCJQFZCTK<#=6T"35OG?1;GB:EQ:[0/2@1\KN1.A)M0::VWC%+6&)4X-9[V+I
MYK'VHAJ!VS>MQ+E],@G#J]@@=B.!MZ+[HMM"E=D5ILVM_V*>^G\".P<QG^13
M#7U 8L*EL4/<NG-S7D.-RQRRQFD2+1:9.Q7R8).,^9-E7]6C.#3UY)DK_3*<
M)!M94 T!6;1/4G6HDS0=3=-=R-QG%./4T-IWI:H"[T5E@'X> 7>CDZ>G[UDS
MI5$[T4R::2]AB")X3,-XJ3FL9.MO6]0+<GUK2VNLR\UU>Z_L>](:&3=^[4"N
M/GO#;DADD?_$(7;23.6 M*Y8?4N@.2L#*0TC+C8=3/ZER2?,6'F2%?ZU2\C
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M?P#MRW6K!R]JNX=J/? 2FM>QM<TA2\$>0_5(<I]. 9U&Z[#.CTT(^#"9'=1
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MA91@\XOP&QAAJS@>+#Q.!:KIXU_Y*VB;:Z%#>^9@YU%KXT.) [HA,YEA^B)
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M%,H#Q9/-9GHOGKZ1=:!T/Y3WC;]Y_CG)T+.-X>&8Y\CHWR=./;"SA6,A[8Q
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M=>3&76/7)O'\MS:&P-.9_P-02P,$%     @ :$!<5)?H*./($@$ [3@! !0
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MQ,K.S2 R)PNYEKHB:+]BOS/=B/6DCJ7348<I=/8WR-E_5_<%*_MDA ";P&5
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MPSC9DK?C49K#4-8#SP=_TY[I\Z_?J-"\>?]%^?>.6;S3%<^4^S>L7/XJ/I^
M+A;@.?:$>**$S.#<\[=F$6=%LOCFU@^HY9[O?(E.&D3#+\$BB_&]K\XE>K_.
M8?"DD'5"DC(6/QGQ-OJ"R<^%)"RS:O MDU/5[(_#]49+2*(0I= T):_5RB.=
MDC:'Y<@3FU Q);)Q219=-'S)LBQ;E4PW6'Y?\,;(UVUBEFO7Y"9'ZNPS-M7'
MCG0+FC-"DQS9&P*8[J'2W-G&Z&ZKID&':=%$&4L][?-W,OE1/GY'"\L$DYR#
M;QDL7127FQ5O?+#33F."%G.WUG:\9BOG?.BVAYD8*;HO4!^P%"(.V ZX4\2+
M,Z$I2P6__<H>OU?!KWRFTNAI[-%9@Z4>Q=R?!U3)FPR>7+(S(1A-D"%I=[?E
M]D1Q6I3T..'JT\+=7 <N/_^K W.=GQL\:O>1D_\=MY?3T3-'(QF0PW<,*83:
M1/U[NCU%\G.Q3,>XJWA'@N,T2>-7LZZZD8)9MMFI>S<CW'[.":=^X6S61AH"
M8!O@%L;@(R4_29,N,EKVME?'?VJS7"SZJ"7>3WO9H\SK4N2=!M"#4*N;O:?*
M7M6B83%(:-KMYL+V?W>.*%*3#W,1[#0G/P/9K*QF,&D3+K#Q?-/U05PK<7IK
M/S3Y9LZ9+TD?I#!.RK;1XH/T6ZQB&4-7!B8IZC!*\B<"Z094&"B\*JW2%%T&
MY-P<G;W5R(?^\@EFF)K]4.W(\Y.!U=6ODJX;[J24R'7P42)[)'&KB70_ E3,
MMPW6')E_8%L?$AO@^^WQS+UL?:_+QY+E4S^?_%,/;6:=)I,N/ U1]$4*_T J
M^&)T*)*I&7R&4%ZE!04OWINZWZ=.Z\R^7N")3C_%5GC!Z60%1=TRS ]W$(XL
MO*V\Y=[8BBG(;R[YJ4_02E@22HG92TD("@R')E)O^#'$8P/:__,<*WWN<@^N
M>4_XVRU#D;&:!F\-VZ6"/_4R4:J60 Y!UOK2])]98T^S*<V%,>JW;7DE_;,7
M>A1/+\:K9XQA TL2#7:>>I([L_K@R?O%RGE;/U5RN-+>EV%B'_5=4Q"6#SMY
MQ_R[C^+QRJ@4:A=@19#U:#Z$$?-[BK2O6Z\_;&UMIRB_TM6<@QD-/L@\"?&/
M?KY]+1A^]@$GX65VO<JG.KS-(>ILW[BU->S7?0P_RQ8P.A_Y>,Z6.]_'CTQ0
M.G*U^X.L=:]T<1DNXN7]ISDP5YG"-('J1FNU'*Z\SY:+PA]7 ]Q9J^+H\A3H
M9VU>NC:&G%6R".> FU7YMOE0RS<.GQ)U3UOL.GFH+PZI"FX);IM\'O H0XYA
M!1$F%(.0HS]9K+Q+?T$'G6U9_B-H;]!%S[+XC*M9@%?8*;77>1P/0$K$)H09
M[1Y=GIR2Z4U>J*4X$S#Y1/7HJ2DWM9W>J>ON?2RRU*QY\OZJ(J^YK1F\N<]J
M8SGNX) )(EO^>I,WB+;[N(CP8"6V*H!OJ3.@=[H@__&*%Z5HAYKWR3.D?B.B
M+;@RO.51L?6I.HF?W_2;N'[OJS?<-Y6='$6<8R%#(10!Z%()%Y#?@Q$-@KJ2
M!3-44YIE<JH7AJA\7-%EOA%?=35>^BT;EO'W1+"!0 9P6>0D$\2'E/0O2,I*
MPRA'L?>@VZ[]F(7#-I#RS4UYWUS>Z)J>J%%Z]-;JF%;U3XW7'[ZL=,Q2TUGG
M*D=('Q;HC:10#0;2F^<=&!)ZR^\E]*6=*CW/29Q'\TL87UTN>/A[*R;'(/FV
MHO KQ_Y;;<7$!Y&[<=A!LEB>G-RN5=P\$_1]%SKKS. Q$>H=47<!;F# 8^%!
MUOU3"SJ4B 2BX>!,,UAV4*R47C/)>?V=X&]%RR=!'?%OX\\\9(( 9<W]+&P
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MMB_ ?E+R[[ UUWO/+'TM0?@FGLXF'K_[_1PL#;M-JB>:+<Y"L,FEA0OS $*
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MSRO^P1=KWR"LM6?6Q$JF+%CDEK$F?7 ]F)4?-*ZP$FJ_OR[JE3/KA*-(-6J
MC@NF\6M=0UPO2Y%2Z,%P+B.^D=EA=T:"& @^E4T2JVTFQB4R3\'F$[M_BF+[
M #?U_&7+0X_5;\C_]GQ \:45%[(P&(:\!%4DTY\!J-914^:JC76H/94AL3,
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MPJ\]6230A4Z_80@A&^:8*7)=P3BQ_;Y_)'_P$ZW3_B7D8O\C#' R"P-_6WQ
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MC-WT7.FX9/098'F>?)DD##@#O$>1,\X >T)G /-X@LX98'W^#, +_U/$$@5
M_W<;E:!F+X6/M?,%O#/.P8V-9A@9D%:^4H-QJ6> $13Y\1E@\_DYYX"3%,\
M2WKD*O5,A@^D]5S@ UTO('?I#IF52(=/C2RVGH/LTJ[YU6<T>K69L_,'7TU^
M%/I"._$KUPV/&>./3MHEFB-QVWG(%[/) P@RPQG@Q.\,T)5%<@9A_OI 'DZ,
M/ .,(]IF)<FT6H0?#>;[O\X =-\L+SZ6FM/(&O MG6C)PGGNY'-MU*^V!+#G
MDH7*)GAX5:)P-?N(85'HHS:<22RSI%;K'T>,6>C5"1P(#/^'Y^;^XPN)*P2/
M,\!5)B(77BF:-4(6R %]I=ZQ3M-H\D$2&P?<TSXQ65@E,EDLQ'>FAH%HB)JX
MT2.O1?O\V<Y)UT\GE 64?4%O)WI7E( 9"XPIHM1W\R>2JXZ*$&UK8;P?D>Q\
M:WK_X-OO_\+K9?3CCZ_G2?_LNHE3$X=-E57]HUN!_^!O8W&F"_]G\/^O07<4
M,\II,!Q^R?85/CR6*(D9?YYU^_1YE$@Z:;)[;OZM7-5U9?/]0V_;9:$AP?F9
M]TN)#<H&_S1D(X)NG0&:?4$.\(N]_+Y(WG&8CAB,>;CRLW;2UHB_<]#7B7A"
M*IGV*0'NN"4+#P^21#V#*J0:'Z:C=I,$ E\QMN[PM16-- ^2YRQ1)P;J#.U#
M%MW @OE_EGU!6AM G!>3\QE@#75U*A6T-]&6_A1$;:=3 &_N>U9Q!LB' 1-,
ME(ZM^6<\"-/7#E!8)KPNX@^8F)EU!N!W^',"["?(_/GG&=BG=QW>W)U%N\M]
MI0QWU,$!M0N33V4Y"H#OYG('T+6B"!+A6]N+4W9QBVUH1-A*4HXSVK#GPA'T
M?02(!2')BCD#T&.2-UZLG@%<2]U(@BL)[4,IPQK3_[2:^,>W#*)!OX!<XN-Z
M5PDCK2K\,PI,(W_8"I+A<VHNO81W5OFPDM?*YC+>FVH=.KFZH+KT0L'26,0_
M3S+'8G47> OXG(V> 8X9SP E&D2!,\#![AD@ 70R%JT&^*\:-:[,\#O5Q^3N
M-385-2A6S 0$3"B89YZ/?#A'D@D98CO F^FY&N"_BS%'8\\G=AXS[^#:Z&(P
MZQF@%T6D/GEV1?Q?=*H-$CA,KOTP2_]ZJ00@GU=3E;A]V!&S.FE<FHX)G(2$
MQ!]>_2-7<9W*A6=RS"@0\/6Z!>B:#&Q$JX:4O'D\GE$=[^9T9&MY4B-8//3W
M!_I/;,// (*I> UR.[?%&4!S&:&&N$]"G(?/,%GX##"96P1?YZJ:3CD#- V?
M 9C@LD_(+'"Q9V> '^"O!0;G_,\0I?H4<7#]^,97KO-I!+#^HIO>/Y_*5K<2
M"!=.V+0L*W]_GJ*#"NAB4]JYQPT?'$8!@9L'EPXMSW5'K(O;RYJ1( FHWM;K
M2?7Q2H"Y%'DT94#GPLQ'ST &E) C(FD0"A3H'X'V4'\F?3\M/QT_ R@B^')2
M;I> 0K-&.IN!:+YF8&5X**LY#A19B6!P(KI!M"KX*?983 =XY,\ ]J- YVW1
M8W^"+CZ]'7RQT<8-00"!QY04BRV B2L]7ISTI'%N=CV?%X9'5U &<!LZPEWJ
MI_B7U4'LA FW*_$P0I0DP]1CM;S.KZ=/'GWJWEG_N)K\0 ;\UL,AI"[L@I*Z
M\>P;2'[301-+XC&$-#+>NG(GJT$9N!#T9<C(6]FWL^U$N33[VYSY!D?@%D2N
MJ;^R2$PF]WJ8L?XC$6[*NT5&A)F<D8J9@^ HX;S_-6LR&9.SL*+3K6ULJJVI
MJ*B*S4_S7Z+OO";<_<KN[5=:+:5KQ"52/6H!A002W,17PU5HI\T)1:;Q4EJ(
M61%R?[5K>/=3#D]0HV_!0X6HHUIXF!?7!NIG[WJ="L*QL[\I=>5$T-Z\4J2H
M/^LKB$E%@@!>* @5G%"R0JRK< ^_.)U0.**^QD@:Z^Z5VBI*#+A&)),*4 O8
MK*M0:8M818Q;V$ZCE>]GHS$YY7'?<_KFSW<&L+AYZ":!NHV\%S1D+4_*(]H(
M-BS&,SAG\HYF*9IO6'9>S/1M9VM11VU]O82NK2>'808O>VY)&WDYW1\A&T&;
MX=O#?^JM->(MI+]4%A2L!'+C3\G7.O'3AQ&)CG] 7,X<$ND*P"DT/7F@YM)I
M7F<D5X!B%6S3+T".U):D)Y:D(^KJYRLV$*BEK*NA%M3TMO<.E".H]ZJV["):
M1++7:R!92VON*4:-R<3CUO_M8HIQCN2.9#_N]N)]BT%JUSC-+T6W_E!XT@0*
MX"Z1KVWB5P_?)%(6-[KX8[DEN.BVS@ WZ+;9S#1PX5XKWP\US(\SHQ;ZI!MY
M[F>5=PS':AXFZNT@YWDQ^L_\HLM.14[OP)O;K"_CMU)._-JV+^XWFPS;T.;;
MU9\^M=OHN9K.=GCQB9_<T41K5A0/%P&%@01ZM:!74K$TO&NO%!NHDS-Y Z7S
M,.'N[AH>X-Y8ORS .<#R!/62)73=?B$%1QM! 0DKQ0ROJ+^"PDS317A/[_"B
M;F)!EZ6)VCZ>D?4R9!-_5;)G_+SDHZ'<S_U.!N ^\A=AQ !JTH!,O8J!1U>8
M$=RP8TT%(3!50=YXL_=96^G5ZZ>_/,>W K5>;N@(740]%D/8C!9C:VO2%*/]
M?VLQE?U\F:#9]4*#@GY #:ZT.J/P:6F,C/ADX!'(@T]-@V@<EQ;R--W^_1UQ
M1>O<QV'._Z/(%6) QY0HDA>HS]C*&:I'?GB.C9:#^TP7?O][.B;_G\TRK@B_
MVF(NF._AX%.L1M->',OTW>;#EOU=OEL>S<Q@,H=",_R *YQ,/(>_MC'/<O]4
MK^J<GT0@'JB&Q]>2.Y$Z\^7;TMOJ5ND5\8U7+8$]-;>U9_ZCISY$6=O/P?4<
MYBZ2DZM,D><>28436 ^^7C?_'[?"%)D;?SSY,@D4@QRE#[]EMRGH_MY?+7=2
MME8UM%[_Q-P9ENN=,?-'3JZDV/=9Q*+5#Y!YXK^\4V8?<:Y0R+J2V'A2U/T:
M<D*O=;2US^DYFG;G$\\)0YF&\1E@^!ZD1OP,$)!/%B8[?B:*D4VS_U[=O[62
M"X.",\!K['NW_J$H71TY ^#T!@FW3>)0-BY!G&PKJ6U!EVI3?79"O*2F>?3Z
M!2JXCO7]%I?=L!0+\3-94TF'^3CPM@^N8[K=FFK,;E3,OL7R 4&G1,7R9;NL
M?\]=HBI7X<T0<%_3&\16R*DM=/!0E%#FAD50@ID&^$9ECR/ET_+8NZ.,=K=:
M5PRZ>%&BB_/7<76C M'-^7J,\_8@$?_#%-).]6Z+7;[N7J\I6>, H>8/W+(Y
M?075.)PE*)\_BGIPN9_GUNA!MR5GQNU%=JG:G8+$TKLV:ZJ7)D2/%=A#$.\1
M8O*"$C+1%7K>@T'2^I9#D^=+M/ROGL$3'00Y9:%3F^'E"JV*\<S0:>/XIS_C
M1=RN87;<ECL>/^O\TI#UZT+WS8N02X>3I&H8WRDMC"^]#2GX12_PKF-EAJ#0
MQ56C+W2UJ%G5#V9=+2$SR08$NE,+\L2<+*F"+&H)+>K@"-$5DIJ<;--&.[FO
M\@H;*-'I>_;Y\Z>1%%K/ +0>["2]8JSD=5EK1'&6([E\RK\BG#7&,#FE^ ^8
M( PD,CMT9M7PE'E\*ZZ VOV2TDFWHAVW(W^X<&R]WJ$TL>9+:E^\=,]NKYW)
MY$^F2;*-]):2^Z?;SC?BNH/<BMR*WE3\*M0W@ W[V9RG\-<'_[1[.3Z/TY,D
MB/K%@6RMM*?51E_6XAU:.]P%AX52I2<O^@=H@-R/]@:[9G!Y.T#^(6M7EX\O
M]L5D?W[:<'8/!*YDKI?&.CL]S<N6<&S26Q\Y]"?E-@)/]8FR%7B'8)\('Q?!
M+9M?QZ\JDP"5!D*&"5Y=*FTO;^AY@/OCMYQ.(="10UY" 5VDDA#4?$Z_L'#=
M0.I4L(A2*2]Z*NSI!% ZJ9,BY'3_E(<\:4U'JD+>,"=4M/A9)SC?]RY6&<NW
MM!,4>4 <"[]^C_L766=QEQ9_[S+837V_M7M=H@S>*SFT1<P,1[WON-TSZ#7F
MF!-%'-W^6S*-XK*([\'DNJP548DJI7-6?.N<K94Z'$<!UOY=>=__MY:="9CJ
MX QPK0I9AX%?;T5 ''3KQV"J5"D]/5+V?NY4%Z%75A+G9"FZKN[>9WQGG6!*
M%L3I(J*J$+3SEEKN25"'9X':H^J_Q!+E2MH+Z3YH@256'KU5G6%:!00O(O-Z
M#G_O986!JDC(,LRL4U7#J\;:W]XD/5..N"2 %<BLK.)+^V'TB[TRTHKT#ZO4
MD$C*9JGUK&KY7>Z--W90N.'8^.;SLK+?XK*UMJQ)QR?ZSG2K[ 6:86/2L.;@
MMXVKNR96^-S#U\-!\O,E8^,E6'$63.5Q972A;'K5^_DI[9Y!-\$#C\KRD(_H
M17[7YIL3N-6M$LSN=>BN'IZF::7RJ-YG1B$A+['#UB'ZR7W;8(H7"RU^7#?\
M]C^@Q*TP=2R9'8(AIYY0$_/?.W(BWBC&]6I(+K?KV$Z)[>SWQQ7Y%9T,_,5S
MMC/WV\,IV2/L7SWDFD:2$)7;,N8U0ZY*?(N/\<H=>?4OAE@XM5S'-:H2-Q0D
M4J_0B2_&DCU$KAG5; $^6)#;YQBC6ZO1%K.0) NT8RH'DUHIO95=VHXB2N%V
MR%&AK*9A_,<+/55.:\ *GN0\PJH>7FVE"DL#:3.^_VZ4A_QG>VPG?<MS*L_U
M0RN7K6R4$R5]#G>GF,67S(6 566LWO3\KR#FWXT*A=9:WQ\Y815!-2%W@\>V
M;!C\GUH))G,X:-!RB-K(9MVZ1?E2O,[MU-#Q",@@B,,/P;2XY.LG<5OHQ@\/
MZV%^_:SI7(J-\W=VK;XRQ[P=>!>UPSRXD?4S*]R-R.>5W8P%L:ZC?;/SN3E(
MXM\JZ0)=#J/3DTU\:UY9E5OID(N_VE3>=9<RSV( .125/&HF\PXU*O(60:>M
M=2'/4(VC/%253B9;IPZ5IMF*<_+5L4/<(ZOLTG9O X*/3M)X) FX<3B=+)#5
M21Y_!FA1]BI5L__>Z\].*_8R8UNMS\(B5/K32XI5*2D!PZS4Y F42ZP0AIS[
M WB#^CE-1YW_-T?C(4OT9+_'Y0^:I:7\F8=8-DI6ZY<V1B$WKC ?UH'U\70M
M_9QMX&L[C1R'*_,/:T>>?BQ[& 2!PE#BOBQ7KX=<UAJX%H*N,SB5<+H/#VU4
MM,G9S!3 ;1^%;0N6A9N,K(1L3]P9>&0IAGRMQ^B?^*-',X;9Y_*UZ\%"//DJ
M0>$@MU-G1X/9?KD,) )+K?QP5[MBV&:D\L#L6R*Y?\?F\E+MM5];-RO$'DH_
M>/W=@><SK@:K%M^.NCBY>0)3J*X^"C.\8_V8K[8Z1<1:Q#9!]::T9EP!1;#)
MS800RS1R#Q((9GI4Q/VHC6%6]?LZ^I/,'%5OKYWSX9";GP'?CH9 K]0K5S]:
MU4TD!TRQG&"&4<U=WYO5=9:4V/6SE*Y,WW&UK_M@;Z3^>^\GUTMA=OZE9 D+
M1_H5Y+<_3,^?.?ZOM"), U] UAZ,0&WQ@<@QSLN;WPGG6"S@T 8^I,\Z ZC+
M>?Z9K+XK4'<@M"5S!%,[J"%[3OQFWC\79?_PL]\ >W^=^!>RA3S(B5K$DK)A
MEQ1:HU'L0G%*/'/T/S^V>I5*5+SVGO:_%-&CW'$&$#=5O+WP4_$3;0%S_GTY
M(9Q:D_X0V*3\3Z!BZ+#B-5%>8 0'39LY9V?).H-0%&CI^GF4<-3LF,,/O++F
M@Y9Y])) O#+>%.--3[*%B=KS8Z@[Y\4T[]_]D4@9[)RU2)PS#\EU"Z-_T,R
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M2;G<;KA<[I6:>$?G>Q<[KR0MN>]2JPD:EG*RR/\&'BL!LXRHSG/5*A&J/I6
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M;^EA!,X8*;C5_<ME:WMVY;[9[!Q>'Q6>WS%W0>CWMO"NE+*<0D(M2#KP<5G
M(T42H!*OYQM"9CW$\<#%#MZ7E\<]K*HC&]A=&^AM( ]FE"Q=!LW)X1S'#5P#
MXS;XS'H1+<OC/G_Z@9DG,3S _.V_G5\!IZ+Q;H@MU5EFHAD6\?&M?V>R)ZX@
M&EDH^@58=G\\C*F\/^GXIPITKS"+&$M2@@,7.@/'- F='_: ;.-U\4O.IMJ@
M) ./ESR?2 7GFR(^[/K)FZ4.=N(*ZF+S=NR'O*MB; >L((73G<SZ3_*PG-",
MGG9VDC?I\8FU5=( ] '7_;-(6%1H94S(<=!27,^*8GJJP;,S/U(NH#^/4[<"
MW@8,@_#J!I,7#AQ)ZB.SS*Y<3I_L3T IW"'J^".P[?<S_0;/&S(7D C+Q0!!
M>Z[<;(VZ#W,3&74GINN)UAC(* HJ,O \!(H,&M15Q76LZ_HLQ'%A7\2I"R3"
MQSW/&5PC<3OX=_?\=\A@0/^)Z V("I+?(TI&Y4#P9%2K]G<XQZ+U^(57Y>;3
M=^0'-\J>'>VQ?$,-<E/]3@PH!@B<.D!0&OUXE(>/%!W#A57YFWJ?6[AHF>_N
M?7XXAV<%_W9  (FUL<5HU41GY]_%M6-%0^#P91J@.B:K=WUWJ'SMFVG^!QI@
M48 &V.^C :0M//\]@VNVM.+VWTK;F@:48Z%,5YP5]6:6T%_=,F<J]R-V'/[<
M<!*NEGAWWW7&0!1;IOIJX1ISIK5FYP _-/T\WJ:.:/MKV)"@7^G/\36GV2L2
MLR7F$CNI5YSOK,8[T,I4<^],*M1-5_W[P)6 ?BH302[(:AIR6(J:<MD_%S=L
M4E^>>D\R3.&Z<+B)1[BI<+KP<QZ%OJ?5LAN(B<YFKP"1X4JH/S/,1?;[UD)U
M(%U*5AD-H*G&5]]86!.H+6!\6FOUU_LG$!Y.?E]'$J3;'><+#<(V/F@0G3T;
MWZ&@<%NN(?Z^H2N<"AGY6N.D\[G5I^;7E3L,$ 1TBD>*6<W5+1L>?&.DHI>N
M44H'>I7C>'][.R^05_L@FWN'.7CB6DROH6Z-4!98O&OY?6,^M;OIU+!'4?W5
MO7LY%0WA/ A)F,[V<QC]$W%"Z_DC@PDL2Z%",F.;$AO[]?L\"'R.GQ0E^P"]
MB=Z+V9HC:GM3\L!'%WV CKNE]<#U)IL,]Z;I76MDQI8_MDQ.>$3<LY]C0:L,
M7=<0>'!3K54X-F:@ZIRPO4^@+GTX<XJ%L/'5KS_M+:FSU NUA%S,A[E7@7_Z
M2Z[%VM>5LD2DP6TMD%$U-0J7-Y:Z^0]"'_WZ;,&X*&[Y'"[XHY*2TL#L^.V$
MKG=FP4JI/]-:^<VF))G(NGGWXNAW!D2(NPU>SY^HG]BN*I"SM40R\5I#=:WN
M2,36&-".I*,A8!4/7?9AN'L?D)#I5L$W 8B1(J"VYH.PL(-2[,XE>(J<%K)B
M1@,S9UH1S%Y3UE!S)?<$.&@!;SWK.O4,F\(#>?QCS14!%?-%0HIA%2!F2%YK
MFSP_L*FNH300ZE%7$\=\X'#+(Z?&(B&%3?':"J-.$6\YIRQC$G BYN>/5:]C
MUP-ZF!TD6_N;&NMT'TY))%;8J5E2?T=&]KG(G/&W8':-J0--O,3G%.SP?NB.
MI&0[.360&&+$':$OX%1-00WL'D5-7)P+K#E[)9O].@4IF^*G(%_CIX0;P9-D
M*"%/Y7_PV!A9_A&[3XB5MC^WK$&GV/;K?0I[597 & CRT2#"4N-]_D07S&X,
M5:'R?+D*<D/"-2?JOEQ91UN5=T>-J#GYI^1K[9V8:=GA QT\/;=$^E?&"#>H
MG4/^S)IT,ZS0YF<,Q*-ON/F:MN;GR%]]9[;'M<0JWD<<(S:7YF>DVDV/V[B?
M#LY8Z2<;M1Z0XE]*LER_/,UC)_+)D;D0E6K8_5.I[(ZU9,@)D@#@S4+)2OX(
M.V@Q6-M!+E+7\<6!]Q@G\%5:=[6HQ+:0R<M/S]H%A8HZ#.T=JXA1A,P ?M"'
MQ:;*AC(;GY+'!S 8[R'SD:)_^Y2&C>,E'E2<QM*N2>CD;9Z^)W/KEUH]G(A2
M\S$?J?PVD#M.Q^#QI=][U8/%:5LRW8N6RF%BFKO2,\E1C,N];I'SL38V/J!P
MQ"L#>J*F5O3!@@'A[&!W)H1Z[6EU9;0V/6>U+HSE'(M]%U^S ]?55?-Y+B3(
MN5_A22!F=J#55K2>(-R1ZYV+#AE2>MI4E31JLNSH_156=19N+M/7_*'KO/Y\
M>:]($5#6-'1?5*S98V?RT'C$#X&$'/+SC<K:W!AX^EO\U4K#\,*=C"TN 0-)
MIZ:1,HVMY<!+C]O8J[/O,E>5($DN<.C#WR>$M9&S_<HJV@[=..S:Q[$L 1/?
M7;G(IK<L!CN7/& >)!IW*7]SD7](I&S0&M$R$(D!LTO)I=W=:W15'ZFX=5VW
M2,)XYGF*L=.''UWRY25C:H?:C+D6-D;!8CUD&U* DT+3.<+(++M)FBT^+UD^
M%\9."#??7@@W"9O("K:35;+XY.--1Y\/;_F*JKQ9_6T:ESBQ)\R^8#FW922;
MNOP^SW+U;7!(H0T\KE5GI%BNZXJU)L3[7%OI %>PF<'GGSTR;051K=?NEMAU
MT !X0R0'XA0Q:Z,9<\=Y$O/QK-GK=O&JN$Z)^E\_CH:$O 6T7EL\"$:(>LI(
MON !0P_>V).T,C2,;#5I  9=AHQH.2FFJA"4L^+Q;#,4FF4Y9=GIR0535>I6
MZSL,4#MR[G3?B7KS\&9\B+/W23R1^OBJO3@BAUBX/+C7Y1FQ\;DX6WJ-8\!;
M."?JKLSY&?I!F3J-DO&SWUX7F[R1)FFE#ZJS/4WZ_ZKC24VJDU]A*(";J/"4
MP-CH[YJ[6B=<G%P]YLZK":-WMI@^G#\-7SQ \1(]_\4^!MK!@5?@P^KX@:@2
MH28"6Q-[*9Y<A?GA/#;Y07]#2*?,^N(5T4[Q#[TR@%+5UZ]S:8 JSA9$: 8G
M^<%\F@'#VBP#ALR9 _YJUL:M6ETRO>9HE2J!=*23-373P:Q)[7SETCB(OMX2
MS+ [L*F4G<%,[0&Q5!H G3E C'L#Y\DZ8WYJCC@;H(55&E+@C]A41J7\5!%(
ML%?=*TPWI^G-XZ/P&Y>9QI9J55E\W-N?^@TOAY?%#6IW"^$:EZ>TZ\7^3"5;
M3:5["N7WQ!21Z4@F<'><^DX@S,/7YL7Z;D=5L@)NKDL]_E'@W*T[LX$T0#W=
MZW-5K#X0*[H$,\^].C(>+U<=AG!H?&* CF]+3?[@IX[3DS)HP*\$5RKI^D;L
ML(>,\#%&R<9U6/?3NTB^U#40QJR8U\1&J+.(4D/&+EQQ\/CA*8#?QB=N[F,&
MAGZ-Z1!@\ND%,Z+91MW0OYC"[O)_^SSSOS?)(PO;"0AR/0WP$YT+>#'ZE9^I
M8MT0!9L A<A95BK?XB"MN&Z+['YC_*?7*#5L'*!I@'A=8C8-\"(:20/DO!G+
M&OL:,'9".B (-L2FT2AZ+]IRJQ<QNX8(!Z7>0-"!DFXB1J5^/RGXUY3V\7F_
M4"-U;] EM"."U>_%5RN]<I)JQA<5RB^[]_Y>Z27^"<"66L+=PKMO79 ^-]L]
MWS*H-S*W.K*O9UR@ >P1K.0G?TKR0U??JLU3\M88CS0I=V**_/4OU**R59D"
MNF:YB!9+-M:/Y/J?WPX8]@BRUZ,!'B\L2HTLDL+W'X\MUXZ%*@WUFE$:QA;1
M9H=\MUOW8UO(PI2O#=)X+W9_Q8$M[NC;AX=WX[SV)]]>.S $<6]_+ZI3"-X'
M,D>@-TET4SL_K%26QB;F(0']I^W\4!5\WVNY[-[)W$/U2YOW5"YOO!!:$ADM
M+Y2N"LU5A\#!S<?5T7+@'ZMUMKG%8#89.E\QQYJ$[^M>WT3.C+'?J)V7<&]5
MO1ZA/5)A8V4PFG=3L*RV/(XG3.&+I."SJ]O*](S0M$D-<O6(^*&,$]+&]V?=
MRL=*XM[7)QJC'C/&L'KQ;:10,/:05Y+YG5W\SX74S.^00VX]\D&UH1[4$RJH
M+BN3J2W@>=?!03GX[)4'B\R/[-/[+D(U6[C)LVP$T[2"J96!X6V[VI@+0)G;
MSX_#?WWCY8;=*/Y)>3TD=[<2*8KYPS'#,*TMZSAJ?AJD9BHV@'!@ND(#M!B0
M%(DZJ]6?!\<E2H7^/'[4/D AV'X$1[VXY:M8EG<LW[3L:Y0XVA)^LUCG+SXI
M7!:TI>#625D&C-F>/^<>P!W1-_J4!GC-0<W U.G\2W/W'^"DT@$]48UD,=G5
MI(SG_XBTE=FRN:]VX/\0=.@B."7%GU:Z!4ZG 2HZR3Q 1_>#B)T/ <I)_;7V
M0\IZP#0@J<B399L_R .V/7K<K^YOJMDQ@7GB$(@29C\ -P+)YV:D$C-2/EI+
MB&:P@#[3 )-/J)<:">4'CWUR"/GO/"/\)5E_(5]DN R'[M]1K[GA+S3I7]0Z
M&A09%+L%QI"R>B*+,Q.#+PI>"S]*.TBE 0+OD\]0"OK;,:7S$2I,5C7=BM4A
M7<,NU0B?0"9)M1T!N8#V6.+*!6>?1CK$V_0B&N!4/#F'PJ188H9)(PTL+X=3
M%"EYH/D)&H /KK;%.4>G#,XEMO2_Z<[;N"Q+(B,\';B"U;9GS5'O A2IO1G,
MB)=ZCINJJGAPJ+*8/*Y >"M;HF&%FM)WAS<#SR%'XM!MK]5XA1X7ZS X<H4@
MYB4'\*7+(ZTC^83LH*S(0?"C%_\54;(<]/2-.F->V529^*VN/$4D6'V#I^"<
MUO$5!H0^#7 Z0+B5D#:?_\'/RN5I)TZ/?\R8Y^VM).$WH--:9+&C -3< %'
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M1FV#8#%M2LH#&F"Q.R#?ZR1L!S0YKO7_AV,@[,G_,,()P9_QZ!^F.+&'+?"
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MD/F(^GZWYOU]VV:921HYQXT'*)A$Y4%^H8W65'X23G?<T0RBKR#_LQ5PRQ"
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MM+&_O?UGN*/Z _'[HFJ"=[3. WH9Y0<.YD90UT>5Y6<9RJN)R!QXUE1+/#$
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MVL#^Y==_C$O$9GI#\C7R.%J/9Y@".^<R$J^4SJ7;MOW<M8NUDL,S\1P["P2
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M[>2.LWZA_4,"X,=!R10S<)W5$&Y&'+AQZ_[U!>E_HHIC97B]Z,!-ONMBZR8
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M6'*V$1LD5!XT2K%5AV?V&YEY,\F%NMIP'B*CK-06N/G"ITKF-.%JW1%]:/!
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M]G"=Q:;_R4(9)U!&00#\\%#ZM\I\*].?UO46^K#B1/ZO1E$8 Q.VB^<1'4$
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M#V36H)9\D=H*/D[AF=>WW<.#C:?#6;0P_>>&&O&L.NR&RQN2]]Q.L JJ+M!
M8,CLNQEQ0(CHT:G+=/A!FQ/F1J"&+7TAH&*&VRK7A<6+[W4S9P0TN,L'BO!;
M3[R^,W4V06"EA9RV(JR6OFHW88TA[NRN/GI@V'1=L2"]'^==@QQ=H:];)@+
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M%LMI^ WI7B_M6VM+&1_?1$_VBPI0>%9(D00H7H;L3IT4UR5$;5&DQ(^/[-)
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M6T85/]X/*P3$*T_R.V376:6>P;<^TUB0]''J/T1!9G.)%!="1GLVE"M$P)[
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M@G5G)85*)9FK?[;ZN;+\-2>?2SZM(C1EU=(FLXMLX:GIW8F%S7,(M.OR_*!
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MED<[^@6R33DYH\7UGFB=W::D!%4D[,0=.F==_/;D_P4^ D?10$?5AS$"E'.
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MNPJYE Y9QPME\2'-"E-S0KFG.$7X3EQY(Q!*UFX81CAD$7K)9"U(H!*CF!>
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M>^XP$2M* J1UD0 V9B 28,9QF@0(R\.?(0&R-D@ OH8P$H#Y9Z(7HQT6"Q;
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M?*DG*;ZLI&UO?M/B:K2\:VDD\:CE<.IS4ZE)S\2W<>F:+#)S^J?47O\#P&@
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MV_F[T7/CZP)U+93924J'\16O:$:?O' Z.-_\6"BL:_[TD->&S8Q;Z2,E".W
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M?#R]$\^,E7'[?9>[G_HFX>S<@=)YE6AEL=0]0P:]1W\L_?X_EU+_9S[_R'6
MV9'$/D5GPK/?7[KW\[[[7QWRP@UV0 [Y*T#856+ZR[U?G1S]5<3_3<9 X ?K
M[PJ5W7$F[YMN["J^S([DI_ZG)QC_=A*T^&]G4D&L^Q3W(OE*FO_96=P_G.W=
M 1(OII.GC9&L/[+6.HW_/='XESL>]*UQA_R?X%@RL$I/[7H'.0D2Z>>(W]-3
MA=AR2 7507Z3E?R9;_K5W<%X.R2<C+S*CSW)R*OYZ/Y_?DKOMRK<HP83CD]
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M$WOR;))!3?6;/<7G</9V29B+%[!GEE_Q\\\F+6U_]5BO-/?OD(CX]5(9%?;
M:Q>\5W]PNS))VZ1='1"\R:Y2#+Z2,=4V'06E ' =T2JC;"2]1 M"40U&A,,]
MP(SW!4G>JW#^EI8!:YK.H!Q8HC5U*7#2VYIG0C&-EV$0J.V?J1ZO!2;T8[W+
M,9]5RZL!BA%^\CHXBR.Z^OKAJ9;7JZX@N>-\#<N/,;?#N&3KU)<[*X+-]A\1
MGJ9C0#&.@O5X"@"UPVU#/#)O[= LJBL=!OM1,V^.1 YMW6O0UH3@#:N[!^:G
MHT=I?%'P$S 7O(%CXAU\_'H4UBY;#Y7&KU8C_,%?-;JYI39N(/+ \7(Q)(,I
M*CHT]U6,TADJ"46",P\I -!L\B<BZWX*P:VOS;*+S/BWU59(3XI163\V_N;$
MB%H*Z]:W&7J>3YJMGI-7I"7&NZ7OTS\V0)!.$$,K/865";-A)+V@X\I2J"3Y
MQ)FB!X:%[74M<2//!VK*^K\HCKPTYS;MO/8R<Q5I-F=L3W1MYR#P1E4C@\WZ
M^>5F?X#E0R;0:##N=OI("]VX,S3V(W>!5V(W0'?$(!!OAGE:BA&"]#I*$+A:
M8#D2A-<;]@[Z][<E*N-;+T57;H_/F1>BGZ<EY7M["*S1<"$&O4XGJNZ1D12
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MK]PMYL07]NK/@BL_QZ6;X&EV,1XWZ"77-NHVZ#]+!&>!%Q$#E0]3.G;AIA3
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MJLF<Q;15A#FHF[PZNTI0+MT(JBP12]L\+V# IWH45_2MX5 M&^+F!F&I1%2
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M)()7OZTB[@#L?S0TOW!N0/7F_K?>2E!A=#7-.5"]>?Z)8_F74PG*"45"Y:]
M*/[:/\PY43[NW?^3#]9>'YWYA:PYBBBJ:93VYHM 965SSICY"/#5 ^-_6-_O
M=3^\Q:E 9?8Q*K-%*"=%N8"F.X"@@^@69^3OYF+H:OT:*N&B=\!O*_#%)/47
MHB+;BN0[8+7^SSR(J=]0$B$%(3="&Z;-U-O(M3^1-?O;K]Y$7(8BJ=SIKAXL
M_[._:N([(%7RGY%@MA6H!*[6,: B_</\]$:H!GS""D;B0^Z 1WF)(2>+9,<H
MXQ?S?S/"H-_MY%!T/Z+H=OV5*15-<WY4%OZ=6?/:]CET2Q-Z0X'*%(0#M.O'
ML95[;?,,NJ6%LJ%&K4979V)^PH:*BH6*6F"-->:I/]3V>U83.HJ:VPN>OTV;
M8U';SM_]Y8*OE"(N&X)FB>DN$_[0 OTABTI8[,-;7!=4PM#^Y+$:M/N(8PO5
MWO%UVX[V7RV5P(X&,3?],?_P0>6:3BY@$]4T'-7TW\QWP+OO'Y%A*(X=P:B%
MI7-I0"?_PUP,^OW%'UZE*%ZO46;/J.L7\B7J-PS1;B,WT!BD,(K;3C][>;KO
M;2[,:/'MT<U%DFGC\&([M<UAJ2X]J:8<\)^#HC2>(D3 8T\:3XY4 ^W_X\#Z
M$#3]L-CB][)JDDSL;04VEBO%[4+S\?2NF>ZJ;_JOCM#@7/E?%8,B*_'1'*C5
M\.;=3_-9,*AF/L/&N<51S 9IJ#K?\MJEHX*Z["S>WH=4SHR6G J;QH?0U6'%
MH];1]";V2DB1UO%>YNQ^P.6'HR;*UR\\DBU^8HU?3F[&>]HQ=YFV$S0%>9R<
M"H:>]22IR.#'XG]:%F:1C($IC2KH&2IM)KJ#>!WQMPL=NEM&Y#[/*S#%=KYD
M95P-%Q5I'UF?RN3[%2(SH_+>58[NDU3*@;;"#_A]7LB']E7OF*YLS0PW78D>
M.YK\A29%+4-YWGDDAKJ+C*PISL>&G=5+G4VK@'T[,3:II?:@ "T%!>*OXMHL
M83252"BC4K9$ZO6@])/63&36TL3I,N,K"/WO^<HX_M@#W?NI,@F7[77CG YA
M,94=B-,2;48XKS5[>Z6&4H;5V2Z<DK*,XZU<[*S^ ,>Q\WS\2$!0=I2,YX_>
M[G;=.5=9,,$.T?H-PE1!WI.UE&1O9=MNP96H0;+M5E=<.)4.5+?2<-ER? =,
M%>76^RPS&Y*UZKT]#KTQ7V/_Y1;0? /'R-5>\+J7/YEQUGC_HWU%@@+5\]A(
MJVCHR%2)H36%JS$E#6K#F5ZJ];)=K)K7@=2S#W1NT\#'#[\XZ!W)8!I\H_8<
M$5@KCY!P6>=^XW1JZZ4PZNM1WN<V"U<?A+(?UU9\#C#-ZUY3Y596!# G/BW^
M>"]Z-3VB3WYDN*#HPO<K38@5L<^Q[YZA7I?W:^GP)B9LF*<\RL6^+GE+N$U)
M,VLBLT%@\P!AMKJ"UV'T<#F-/*FT%\LZ>&DBE(8-L2>-*Z:=@&1(@PGL\TH3
M%I NV0VH JO=DG*0"^M\(R!6+W-7U0QZ=;(JC9=F))*#"Y@[(DDWSPI7HNWF
M&[H!2;NU/.VLA$-IHL4AL3P8K@^ZG+-=.ZTJKU&F--$.FQSS@9F=S'P<&[ Z
M3UJ3<5I .P'\]#L[4*&\L1M( Y)/"DA_[*FM!5/7'(X+="A?:*'+J)N7R;-]
MOXEXH4"@TH(I7<M0RPS:[4Q5IUXGHQ>U"_1=B\N4)C"K.2W,KA#81&3H!M^,
M(1,&QXO1&*Y&U\]=3@2XA-1/G9"[A5@[T'?0#>.Q-L38TUM +]'ZP@8I-\2!
M;$'=ST<Q[?3^"[>>__\@(/T.P.0^?GCF5QDGN+B).!ML]X(GBHC<(#9B9M=U
M0W5>3WNZ+O6$Y'ZCU(7NAV/O[C9$7TCHS[;]UBAZGHU&'SOMR8,0.E("SQQM
M:KDM4U5?Z&]7O-UC_EU>:E=L-TY4:1*W9#$\;T-0FX023!)]C-EG(141PWE#
MQFJ]MW3O3SO=+ZOW,X56"QC$:QS\&PY3,J(#>T1><+B+)HE,^RZ4*%"YZF1L
M6'G!!;?-0(<"1F?17TI(]A=\?<B'?034>&1[EA<9?Y=O$3,LR/%_I[#J43&<
MCW%#^AV:"^_X545EIGYVKC?I,EPX<*:R@X]&+RT6KQVF[,L<%SU)]3_NW6Y3
M*C\F/HH/EP;S90Y*U6KF,_!%XF +@^XC?0\NM1H2G*.,*?-TK3G5*&A3^D[/
M0&EID/GSWY;:61"IX%##I'/UFMY?Z#S]*Y:,N:#EB%JW@&-#WO<)(X/4AR%1
MI=D51V4O!VUH%$X)9/+/<+U!L9]\UVD4AVP6A9,J2W.6EH6&OH-:)7L\]"B;
MSWR>#_!@845>OW"5C'K>B[L?Y<$(4.'U@I?(G!8T:V1RXT1FS0<O4TATUE'W
M%J5,M<4F-69IM5]6W.(3KL6QS^.HA5X#&75$)H'^_I.1-*TN _6^G<5]-] 1
M/[.PY4:UHR&K>DY#_:;*%9M6\(C?9J2[K!O/X@ FRW)#^=@K<\ZX^7N*PV*'
M8XT$BL]]2EZ_G-V=*V?0Y]V/_;7!%#>\UR@C.O\3C'L\\L&,R+CGH?</IU;*
M8^^,+UGO9R(?G03**/<QQ48F L[.,)AZ3^7^NTVGH22)^Q!M4QT'M;<3NRV*
M9<\H(IPSY3Q?@Y[][M628T=TW,NHW4$R_![45V:\+QQZGESKJG]E,N=OT:,O
M(5)1TVE->FB&&#-MZ[V0<#;4QSG@LER^Z9]H39C<RNSV@T6+!J7"_+3%M*N/
MQM$&$,K=])0%)6@3+2V[;+9HG5F-W;Q^VNO=@$+C*:P<(EG">P+CHF?*5:61
MO-V!T]BBW?R ^]DR^8^?O=L*IBYM@BE!00C5Q>BLA+S30E"QG%"BGP8H*1\1
M$?G(-0?K2CN,-Y#M9V 1VL1FX7@8.=KZ:<%B:(0M8X62)D(%!](B?JEC;Z\F
M-H9F]UU@3E.:Z.1 S<SN8[>D+;H<C&W#I_!IBX@6NC2FI+\V6?'W,@6B$YAU
M6FO-3X!7J?E0%?;4[RMU2[%,_GD!72*@T!RAR+_9-O;ID9[+8OWH:/ MX>^1
MFX]^^K=^*,F5@SO^900?5?/5%T"G\\VO@#*Q+O0(UIQ_X=^#**/-^5=%A[$^
M<?BDUVOE9W"TB6X>1K#L\E@K]F_R7+KW-DXLFC%.&<F:_<F$C7A4Y0O$MSW7
ML#IY28X#]?G.U3(I(CL/[BF<<FDS(9'CAWW9[K=NV?VM[*,GX8*]GI^CR!:C
M!@GPS;RE#IDDN'XMB&6E8A4$Z+DA#X\@.ZEDK<45WG[Z[U#%SULAA*<FSI?U
M3/HXTXLXDF4?T9_-D38P1I$*H_']0G>DB3I1?WX/41_#=A'M6Z^3"IS1 !FR
MFCX7WZV>4<B90QZ#,PEL49&H&#_'I@V8KKJP=_BH+-(;6U@S\R0LKX=<:!LD
M$;M#I*(_V$)YHCWW:]=G/THB19JKW<0C?L9O+$]BAJ2.\OUP>W8'JER59$\X
M[\[GO<\4RZ>4(^YQNPE?U508JV.RTWH6BDXZ?(\(%E28QL,EV=GG.58Y2R2=
MXY;U_C>R-C#_'H^E7L]B@78Y\%.R6Z,^5B%VI)?,O41-?)UR!WJKZT[-W\!G
M=0H*B=_AT'GUN,[B<]VUA!K^6_1R$9:89DB%??: M6GO@I5%^&8PXF+,-Z*2
MYH.2%-^@C.B(2,%U9.4>BRA!-8PE1"?2P!C>-!#85+?Q^5X/EOK@^"R9JX9%
M=<?\FWN^5^M7$TF';TW00LXI;(IWP$EL52J&Z9LZ8"_]!MHW*>9:XC'+6+$9
MW,.X>Z=W@.B- TB_WIPS<4XI-#1BA]MII#^D>3PR\K!F^^:TY&%22:-5>+VE
MA$=(9/;(E6X95B"ACG%J;K1PP)'K+3:-'](KK(3-,(&H,3O5./)*;S^7;M9%
M(N]\X:;QYLC^7C"K:S=3>X_;\@1NGL[P\^]'R:G53.^IB7KUA4MV=SEX6+Q7
M1VA$RZLU8@:LG+H[(S-+(VVF3[]PO.6>#]JQZA,9V=;VM_]8.WSO'/(\3ITM
M?+\U,>5W']Z>U>,6COJ&>C4A$H,LJOH[H*2*N6JN@@/4E%-A@Y>N6[ _<9Z\
M]MJ@.2L*ZD>+.)K?%UV!HJEM2WB5\L]0Z#R8; 1-E9*]<B0VUW_?\Z,K@,@,
MWOO2_>K"U(:J'&'Q_53@<_J(LQW$_H1XFY"F^/M<&@&W7?"5WPD9Q6Z$3P&@
M5'-:%.I9K!=,GB&ZHNUV.99QB) F%"TP3TJ-/X'MCR@!KT=6E:,#=Q\6/%6;
M:'<EO7)1\2G(1X_P\;.!*D'7I8E $4:V(K"0@ZM1T(1-K<CXO:"$O,8<K""!
MU;GT-/,* 32&B0A[07B!*)1=6E&)K70N4YJ0 L8%43=Z(8$+5=$FSZH!-A%[
M6L5%R2>P/*_B%TKBWJ0UDS M-+=N4!FUS5Q\6GY[4"";G'":.^HFW<V4(;]P
M)E!BQW0'Z-T!LM)TGVDI[X!8%]12KU!H.T$S\DI=S;XD/\F^.D$5X-)D,(-@
M33E2X#\'P7R#'L,W,7Z %]DS)S/6HX?;]B/I!@WQ^V@4.01K[5XB15E'V,B3
M$O"C;5K%@NM]^&$AIV6%R2B6M)>R1<]-MH6"H(/' E+W W!C)]U[=J5Q;W2R
MK#KJYI9MM\BX35$GT %D:Y:0<MI^ED.8^4I^IQTI<+7IPW<$P[C2^;%L(GMN
MU7LB@#:F:? ;D;*F>Z-7\Z(I8E4&<B^8Y;]TEIEVQ&G)V0%IT6R8>OQQ?W.D
M%C#__-5Z"N;^C#WGYF?UB,1RD!XX"O LXWOZ9")(D&Z>GN[HAT.&[NGV-'-6
MB7@0*5K;62]XNV0\:9]\1:&P<8OJO9'UC_9Y:9IGW^KEL7;L)@?V7^THB/RR
M5SC89]B![]B"\C]76DQENFT50DHF+P19N;&(:JY',;^Q@1.Y_MNE[K])WM-K
M-PAU&Y;CE-50XY135YS32 *N$ADR) *),=U%2VY572-$<:2U9.'KW+YG)?H=
MDI72BQ$(*:YH@3HT/@*'U0TU8 _#<)4*/!HIF?3H8D=6'-9.WXA8-=BM$\^&
MZ[3JOPZ?W_" ZT@0_U(-D$=M"Q5606&Q;6?JZ4R37 =.7I2"JO2!Y9)9'C.J
M. 0X8,XBF9]1TYO#A$1*!S<<4#X[(01UG%3R8SZ98_2IV>O>P.H;EFE&T7)S
MM6KD0"1DZZ7"!N^\*?\^<:7V4?89-K7?R_IF*>6 W_="1E.<RT:&\ZAC:VY7
MHV5H8NK!DEPC!6W?O+WG/]NZ^QPW>"_"11@C+2^]R_P5&3N3 KO>E+:%QAPC
M#,@K>V.;8TL)^I5*;_H)15:"_,/L=MGO !OU&IHFI U5"*[?6III)-.X8!++
M0F5VJD=F(S+Q)>N8;$-<D"-^5M8=H#*AYQLG'_MNTJQLF<8?FI7H]MCI)^[>
MQZ+YG_*B);R.(58<HEY:/V$>@"3:"&W;JA[GLMLQ3YNPI/I8?IK@*R_.>TM-
M?L1PE_Z2+J3:1."/DLA-/YL974I)B*([HU,(CL>(B4?6Q+/A*JO$),-[\L8A
M>]F.DU3O^53@@WJ9[_34,FC;"I[7XT7MYQ#W+':Q1\/!8T7RG:QVA H:1(/+
M>]#L;=V"U&D'CE+Z;<DJOV#;8^5B=CW;MCDDG[_-H2!^!%>2KO9FH5"87"_M
MVP=+Q221@?*/!4;$GUZU BN>>R=?!,V%T,M7-4B4<BX_C%SNF6)N-L<;?!YJ
M?8*%/S.LL._ K-)-UP_(Q/ VU?ES:9;,M#?+?C,4>D_9\5+88]= _].!W1/\
M?'%+!RL;NHUI;0_Z;RD,/:JM^U:ZG2L>H4M57D[QX*2JA]N,FR)7>HYSG)O<
MS&&ZDQJ\(X/PG"_(V-X]<F"GX=9^JV$ ]QN,(Z1A&R3UIFJCP:(RR':"< 8Q
M?5AD.Y^TH36;+&X(PJ1!0QB>"\GD6VO0N-U(MI3JR;_H'HS:\<'W."D1QE6S
M_!"YGK1W,1Z9H>C6F##5E,#WVZ/]7NXK#F;L,J%ZCF _GG5;I*Z90J@SN[O.
MRB=1LOW5:J,)S_@M,YO0B+Z=Z2F.Q$MHK+:+!T*!O]OPFFT63G%KS_;8M@\K
MNR#0C(H&\B#?--LZ((B#NR)L2@GQ[9&DFQKIG/OT9]^WV=_5AX'3PB"!?5MT
MM9-],9L"7O6@B?T3(#-P=P IQU+(+LV_IX!I$B1PH/1*W$>@/5 LI2U1O P0
MCW1E@SB.RXDCI/&NQB?N@*O=O),"(R#9K>"TD$LLF$:-M-]5D@V-87QZ+@46
M 17YH^,9?F1$ ($BM G]?AH8'Y6OM.6>JFB PI1I9)?RS<NX@U78)B;WE+L5
M"*^\"O)[;,D4L+0J[)W04TB0 G'0$I?<W+_O+DK +<G?9+CZ_PT9SL:*9E?>
M05I]OT0L7F/1[$G)S4+C3EX%:J>OY"[?^.;8N%X5_298@-LKN/FY,+0&6O!J
MP62 _]5"FK7X65ZY+5KV<.:%F\SZKG*]VXK5*#IA \SM#I@J.!JA:J ]I3<.
M;!ZZQ 4^O$QVZUL_@KG4W %9Y>K7-4[UCFM..3ZOD#7 PDWS&&WVNM8E\0;&
MM[!6&&EACVLCFHE?*4CZOM.(Z%;:0#"[XN,XWNO>6? 21:&KW^DI*1H547H9
M'J-\>W$'3-C57P=:!MC-(5QHR2T:H2W&/&K)>(T4/.6JD!8IO' N*R(JI[/3
M',)O$;D6Q04S<\M,V8N2R,2@8%S6S_][L!%H-4_H49<$C'F>D:+9V\5A+OPB
MU7O54SGQG'??;Q*GT#=_X9?!!'0XF-PXG-FQMVO\'IO;4J0&_7J:YI5F73:U
M^+>JHE-[P"5 :R)+)<!Z34RBX:M"@\DM 8AQ,4,# A-D-TR]MY'$WQ-TQA;T
M'?R* (D 29,-,2]!"A1&^^B6HN 3CZ*#*;Y'GA4>-9](?BBFBK:+FD!QMY_7
M25L&B2>/3K64%Y/!,?8$AZ%7N[Y:V"*,A:R@"BS&"*/VRLE(1Q+MV'$O)SA#
M?Z-VK#3)?UYE_#\&M%7S.L'BY@M5#$4)5P4OD3I*0C0IDSRZX5;)K,4ILK#X
M0<XFVOM!=L0A?5I^G]Q.VBO*VYP42>C>UJG]TB$P(UQFNUUH%J[CO]*'C[(O
MR:(_Z0N??V#<N\$3(\FWZ)81:DZ0 6V^B;TBAR!WCRV<2LSFRHJN^1;S<^2W
MT)H&Y]RKGI;N240WT]9.[NQ10<Z:F.T8-6(7GU?$4\+[VT_AY^HK#FDU88Q-
M)#VTS)'.69QW0.F+9<2#0]&;:[T;[UC#G\_DY=Z(\K?D[6R^\ZB_+5?CGXXU
MHY**3]E[T1!;3:U6!L+G'.@AHH96QSE\KC3]%+8]B.7PE,8_;,\D*)W3S^F;
M2#;^S3W+HP8X5<L=H'8Z;I>LR$3_.3$S6C?FA0ABF31^6C;+V-9SZL(@4=@R
M6WT<=MEM%F725-7*R!&3ZM&T7'&OR*YR+R;HU&X^B<;/1]!9X3MVQD.-1A&9
M[[RG-_;#/@TJ>0/J @%-'C6TDI6&<0US0V%'$%R3WU3'J/*C=(AY-TU"N&\Q
MVF^[HDPOVWN63%<;KXG3[91V!J&2&2D^_S9"=8Q[0W0I DIT!YAJUDQ8-*0/
M>J0;+-#D>SS&HCA'SSU\,JC9PTCEP^%LIZXE=!AY*^8_I5K[(TZ.&+(A$[;,
M&8I[CR>'[6=0PLU'9>7,LK*.N-4(OLKX W9/4).5)USFM$RQ@I9U0Q;G6@3^
M)&1!W:6<(T6=Q,A(%C-#<W5+B]G9\ -%GPA"_:-!DO%KFLUCP[9)&7*>]R'S
M47!!Q7R;_EGO(^\4EPC].,W.<D :0C%D^9/\^R#>UI8/!<ZD;E.VHUY8UROB
M'/Y+E0PG/7SA!\-$!=H3%+,]5N9+?3\809B!UX<R^9K#]OH5UJ5X['(]AB%S
M.$@80]4I1Y^Q*G=<@O5+'#LTF_6M]:_%I]/I!"D)Y#$A38]]KV>0B5T_*UQ+
MGNCC#3^,M/(+&2NH_LS+DK1$T)<JL?LQH-DJ"'1C'R]33_3]PU%7+&*>YE"C
MH-.7&?*].CAB_L-LC/-6;MH&7VIS-<5BC:^CO/I4E7 E]:">L#[@,2SN/ZD0
MT-.9M'G9(Z4A:>]K8V>IE2Z-%UG/*%6K9GW4#.-[LS?M A 9M88>/84TIGR"
MY%Q68=T!9I]?RS@+5;HTMWN<Y$?_E+BT[U)04]SA\1]_G";HPH6#Z9&UV*1C
MKQIN52]OI0]]RN[>,G('&'T6VB<-=M79<--;_41F^@/+Q,)W,Q!9PY>9+CJ;
M96#)-,G6\,MZ+37MS#BTZC ZT+XRLL=UT2UMUO8-KVX'O57DH0;?@?6E/)'1
M%2>SBU9BGOZ2>?CQZ\&L1(?^Y*:G[4-&?NM.4@8W=?-O<';82H^]A@*=\'6I
MG[6(!GS+IOG0,=79I!.=>87[.?.D\(UO@7:LJ0U%(ZS4N= S1[.!I PT]<E[
M1,D+ &.5L8(_Y(\,0)0 O]-SF'6>MCI2I]V\,ZO-?RFE,*O%%NT.Z$^N%<HH
M#*9)TU3,JB&L"8[UPXU59Z0HNCJ!<6A@!'L5W-J5JN5@FA=(VD78=08S(=E-
MQB'V/N-E@*C'5$;KY_3YN:QF_%&,_MFK\3:CE]L5]C[.[(#/KK("P5,N54#K
M6%%Y5P?CHVK\K?$M ?N8(K(,F8!VQ;(:\U<%]_YO%9QAUO^APON 2:HI_1\!
M1^>@%LTE03W-_$=0C?W#Y5>FX<B::/ L;>W'B8TC=5&6-$#?.O8C[P*\6&#9
MS^SF/'\MF$I1:?!A<7O1^<,8?W \\4Z'^] )W<0H1N2/3KZ]^%DY28SUK;5)
M; 0+UF\:^_JY+DKRW4W:+$OW[<.]"UU(;&J]^$.I$S1O^?I(FF-5M^5-- AB
M2'C/%?(IJ7+E_%,RN$QS<5Q""ZJ6$-SZK6;@_+D"T;DE>ORU5H#ET(T0-SA1
M:\0B5):GCW)[+.6AU"('-\6S.^"@$W:EQ34UGE2O<M4Y1(E\79)>Q2?:S<KB
M*G'+"M*2M,!]RS>$FJ;""";S00]U.XR(84O#^] !9<LF.LV)(-V8R89;N_X.
M [XDV=M-$0&T@DT<4HI,*[-K57GY*7JWTZ*D$\50L:23-' B?+I:]YU+_*#W
M<>X.<TQ]->$$&JW0"9.V6Y98VJ=R>>D%7I6.!74EP/[F2P.39:N?WE9J*0X0
M;?ENAVJJ4LT[]ED%XU2PV*&RH9A>C@&V]; ?!RURLO1__1.NHMPK>^&NI A^
MN+S+#BN:2RWG?@1C=/<=T%DM5=/\,J8,>"*4J=E''Q/G^ZL&.#7)L-(V4EA_
MD=$<U:Y+N;VK&H\+R=H4O^2]/>@Z0WI1F4O8ZP%U._[T&[?JVM(/B>;(P:EC
MDQ#5[:V;]X*&:3/"0P+C0F+T<V#^M((MVFWF-(,L#^F'K;/..4ZU>K\"X,RA
MQ<X4Y&>(.P 8TD!TT[B[23]4/71\@-ED&7/Z&EF#UZW76R<-W<V(;ILJ+B4R
M$B9NESC+(1#QLGC@\630LM6[%YQ;C)RH9V%]W#CR.W<&M5@1EU/<!PDV%6.?
MV+/R=J4?-40K4I+5*32G;% P'A=*.(I8O+'_XA--IMF;"=[.^"YR1?NY3)8U
MV[W]EW%+<Y<-$GUQ!ZU-#5.P1"7/QEGVQ,H9NY!O/9)Z%,1[J=M$M5UMT<>V
MJ]LBR7H]-$Z*-C%OPM6/9=X/*S<;WMVSTC/3.<5J\=0PX>JRF#B\*4*W_X]D
MV/\+D. X@YLNXUCTO0#7?+YN&%F(KT288\]#<U4%,W\LVOM(\,N.TC;"G?TB
MKI?/ZL:,C2_TR;ZX4Q2*O947N@-LF5)&:@,HO?),NXNH_(>FSBT)\ =Z?E'?
MEY2!HV[1K8PB=X#O)>,)9_@=4'4SVX8YU%GT[,O1<[579AZT8N2TF3+EY7!=
M/,!03\CZ4BFFD7T;5HD5NYOMMX'2RO7SE0W1-%7PMPGP7E&*RP2D5P'LIY,E
MS7B-,=,B2MF:$;H=ET/H;H-J5XTK3XBT2ZOKL]4;B9R-$.JQRA"J&![,$Y$-
M/WW5PDMM^C@V7?0C7?D5V->1MDT3YW"__G WVTMGJ+<:U8+-]/Q<G>-!7N96
M$DY <3V(7@2(OQ$Y&)(+G\Q*MWEMJ1?E_=7$R<K<!&K4G$QK%/=*C]V5[$/'
M'8!:E&&N8E*E#$H?EL5"!G@Z</W](W8M6H6/'3]@O!.DWKO$.95J+/THNDGU
MZ' PMM.2&"LQFC2.9^%ZBF9CE)_R5?P(M@QQ#U_%*<T=<*NCBF<R*$MNF_!K
MCLH^=+K0MZ2>/&DJ_W*?*7.>O42&&!!E\CKM-OORD6-AI+FJSH[6<#25E*:R
M;WA**L=SQ?(WPB0Y7+"8J2F-@L*W7%AQBZVSAX?_ET>/@]ZZ7M,12TW=(C5)
MEZPJJWB^6>JP*->P5&+/@MVY7M(TV"$U#D*/YVD1IL6#)BHJ:6=J+&L+-Z[:
M3_0;<AUX,K:G>53488=S/4OSGB[*2^CKT!?61O_\<<=0-M,&[G77)Q"+;!.W
MM-4O<W-R/+*X+=]6"]/4$TA$>@*!O<MI&1@BJ<[[*%$^-I]QX,4,X(,++GNJ
M5;#A)Q%EB<$K.8!9VS&7/GQ&_\*2IBW3/8CQD&B.EHJ#]9G*4"QNJT%(=LH9
M#8($T?7 W!2E?QRH[O.YE\]2$TT7X+T."$$)%(O,TF_REC-TZO;NR<]9QS<G
M4Y-_2)2=0>G[K<#N).XS-,JT*:?E1L@^YD^4Y1(Y? 6ZRK3BM,N)+O887>_T
MO8Y3*+H8HYK/RZ%:<5,4'R5&F +(K"@6W';\<8=H-/DJ,"HVA38_5;:;88&F
MQW+B5JU>$0IC,94PXK[7:K)+$V5.?"D=02:T$AM=^][-QP4CCL<:@_HI8T6
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MQ2CHW!N^+N,XH0*?+A#H)UW)8ON0:,)"Y7:@9BAF$V-?/N[D#)'D55O"L]+
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M_C6J-#&9#!>LJ''$+JM5D*[,0M8^DV3Q?*8XLWF)*Q[QXUV/=33KJCJ]Z#I
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M^:2,9\;!&O4\M$S[_J6<YJY,Z5@+)1L 2U1"0.*H\U9C7&5</^Z5E>I>8A<
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M4J52RASGS&QTO.)C-1K)VN"MU3/D<6%\^TY$RXUT.-!CI!U_VGTZ4B)(08)
MCOVRVLB59(O5"9VR YFB,VN(E(T%@;<]2 &6S,=NI W0@YZ5"/=+817AEYZ9
MHRZ'3[BYJ*2O8@]9=PORZ*<W<_$"0?="1]X740>!+;M.ZSSVBS*L(>UH9@Q+
M] W!-9//UREN@P6RB4T/Z%RYI?F;Y6D;WJ8H(CWGZ5<!]PWY:4?JQ'M7DT*W
M/T_+<5&TB0?OXP9I29)<Q!5$Z=?B8?:B)F(9!'2;MGC1&>,3=,&H4@0'>QKR
M7QF9K?S1FU>&3NL94M!FZB1[3Q*?QM?+<I%*C'1'7&I")YD0\>QA#<!4CMS]
M9A3OU62O9;6RY>LFP"AUELM;C@KR8;U^YK9OG2/X5>7_U5#@_[<WUG V8R]9
MGQ >BHU^'5MR0)U,WFE/7RV='\3KCKJ0F@'(KVD> (_Q-5>PG;&S&/8J0N[(
M!8/=ZXMTR7ZN@>E_<O]?6%3YZ0ZY.:JW3Y=<H$_>;?0,S\2#S]YY/;B0S6DU
MK.L!L#/->@)CEIO<V K3930G>B,(L8L=$:H>49]IU]K2$LAO7V@SX(^@@6(K
MH+4$3X=J#F*:U@&*JP1%M&5O?MW].:.3_O<-2'A,'U?;>:=S^T=)?GW^=\89
M5YMA6H-ZTY'=6MV"FDI O?':%*L!:P3M=$H#R,CA"7$OUSA/"-&T$M/3,E=V
M-02<(PPBG:[\BXJ,6V2W8!R2_-F??30Y-G_!/?>^@[-=E3G3J#8!3 X6.5NK
M])P1N:AP\U^_64L>=&>'5X"9WXX,B1$]CS^#!X%&/SM4YJT_X<^BA5CI RV9
M*PM\L4&7YW"[-Z;)/%C]:NA!@T?UP@)M$.OW0D_,I$U$ST:]6S4[>A4M8Z2)
M\%%*."N2R,M9.L<R>=>/W<JP*-P0'&.2S#6 BN3P+A')'!H'2^'/;;EBDC%L
M:!E%E"=O1L-".'B._*<#SB*3+?%/*@GRVHC"+@-"XHU8;M_$7YD[.8=WK^+Z
M,)*:X(7 G?6V&[5XGHW\)BE2QP&M:V&,Q_RU4K6]A5J[;X"O:Q)M0OQ95/OH
M14_/2P:AY2-S?"K]+TMQCN^DQ#8WCR3+E>,-Q8VX_GQN>CS ,GOKJ#@P08Y+
M+H^S_T6493FWOODNEPO^'.G-5U=./*:F_-$S-\0H&,*P,"5TTJBN64AV->W:
M /0/BXQ/3'YWSR ;9#_>^TH13/5%D_*?*-[24Y8OO1 03O\-P8\1Z:GP0%1O
M*-<&_OK]HLJ]X:>%NAH;TY<1;:)P2%(Q?A?R['HFB:>21^SQ"MM-98<"G22[
M"TM^KL-BBS;ZLE!D;\= Z'=U$HV3OPON)/+J 4#M,Q>AQ=GFNJ0U.U-R?%Z^
MRB9A%GZ@?#[WI73V<R_#B)"5%;?ZR#1-66.-W7FI27E>O &_4PQDOHD!?4K?
M7(GDAM:MAZ_N]?L&J3ND_"(/TOO:;PVQUENSK#_IB8K7X?"[(/X5"F10=X D
MZ*?K ]G&G=%X.0UO!YP##N)JAMDD2)TF6_B,B0*&(V!D%^G,IF@1D<J=@("O
MSD.HPO?SKR6^*^)(>!^<PBN^3C=)?&O0]N9<J#!R:8KU%Y>AQ,F*OR=G;*/\
M;5@?TS+K9-_%''3@H,2)>A^LZ<;S\I;]=AP[E,U"ES/Z^>U]_5]S5\Z7HRO'
MQPJ/ FS@).IE*3.;&LT5+DN?<I(?C^!*$!&WC$'C#>J %7Q.."R7K=X#F"T(
MLWI6\4K6/T58(EBIR%=E#K+ &K+=CXK<12RH<#AKBCU?F:FJM$+9VN.5#$\N
M'N;O?CO$\\SI^"*83_1)E#V\"=U9I.[PR]+E1<L^=/VB8! 2#WC,XQ'4L?TA
MS*CF3RL)*7UQ>E*CB.DW?5-"5'87KUSTM>XF(JI Z)XU<@"SQS#3"0[F,Q*W
M\P@7->4&T*>=5H^M?"7<<,"6ZQ^\<_Q[7#(,H:<WIW>2&%-F#8S1L?LZJ)2N
MCC$U"B2HX[<7\BA%"3O3>797)W%K5W^M0FA.X/X#VIF?O^ZRX/?3JWYZ/#0L
MUHR^6_]R<K6CX / YRI7*BFD74K]6!(.8=;MGVQP1VCE;NEROL7O"DG^,M*+
M<TCNJC0IT>9K,?\VQ*#3V6F"%_A:':NY/R@$"0^4LUUD$KBDH"#2\G3I.KC2
M69,=IJZ:W+3"YHV&NE_=6^3#N)/(/ZB_K\8KYN&09:57(LO"LZ):^ 24V@O0
MWB?ZMAMFJ_E+T2A<+D&=[FLE7$:OGI/ZQ]5)#R96FG2BZ9&)53AD3.ANU^NV
M@FM;E/3Z>]<71I(]!,X<=2'^YMGK9RX0SE11,P3S#?58"DM2?51SI*FKR'!N
M2;&CRQKJ,8%>=1DB1'WX:B8D8?1">G"[#4H"A63T1="$G%E*X/::K6/*6&Z/
M#"C.;](_\.@RUP GFP52W#(=W7KSI;BE FX?  93M0TQ5C@ 2P8A4LFNVW+9
MM<7Y"EXF#W*/_&:<J7N(#XVWRWK  X ]0^K,S-]J=75/%'FU<S4]ET\#/I;S
M7E@/MEU9R(\4XBRJ=1EVZ:*D$D7,3L"#LCAP%SMQ1-R[#K)"V'/&!(Z/Y]73
M0BD/Q4_I[@)TX)6O9-MQ;21PNT&8<>J(;YM\NJHZL9)/LZJ@# 81JJ^;R%'Y
MH2CE?[MN VMB](!<(C?MYWOO,P:48%T> ,2._EP@ NB.EY)?BXOKB=J,D9W:
M7C#I45A@HBFX0,=?SNSMIY!X-#^&5COY5 YB-<4YT1!<T($:IL.KWTK*BYSR
M52N+1+ED-=H2CSUF[QPU #'6433=6X5LE]!;H&N0P)-[[PQ^TQ*-,NJI:<5=
MY B'9C)U0@GG;[Z+[^IGSJ>%)F[0WRS7Q9@&_<AKX3\A5Q1>L=<G_\L*LTP_
M^.4#(-Y6\1]8BH2<8ADD_[<>,^39%;TM%-*@K>YKAOL.NRE?LJOQUA _BU!1
M.NWD'Q9B%65WCKP 2)?$S4QQE=2:H9NZ:EOLJB-3;.<+P&8W"-T@G+?W3S-3
M;H%WB0AD7[I?1\'4[B-R_-=#Q")_#)_>V8?A$*U./1,V53?([A"?<H8A8&<X
M;+59="C:V>Q CT-41M,7LYF\^)^3%N_X^N?9+5F8:CX-2.Y,,B,D[M^4;5,;
M.!J BDJ&?EH8&]9;0T^B8: \S81-'6H?7Y#-I+?XEX8HVYCX)25-6B[HH0?H
M2PF<;(0J@W)Q,R8$FM"LV]V%>,^ )$\L-%9Q;:4BI)2S4)QB2#WPHA(1W1GW
MJ> 3&R2*VM9FCS#3*W/*7=W).HJU-$H5YE[D5_).")Q:-L*U'MOKB)6;:"4-
M;?4_HB@IN^SQ0_ND9\Q,O*.D>7'LOI-UHYMSV;,=8$J\U.UTK.!=JD*7Q&+^
M>B3Z)7/.ZO.MB9\QEP%YB#^=Q%OG3UF2XM_AHJZ//0\,)@U08X9ZV_E."@E\
M[-=D]?0.669F)Q<Q1C%"%Z,N-EQ_<I(."7V[!9">:F"B]@\X/7MC(6+@@SWP
MT;A7X9CB* ^V F"2TG-GWUZ_;CSX348EB8*#+'V:D>U1Q8)CQ9)_B-?[&"K0
MNOOU6JF;^Z<HZ.#&0 +.QVB:XSR2&#VQ_M5]5&CB/BXQNU53 Y\"T3$[$?N
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M/"H]V2P:&Q)U89*#^O#8S^O$U>6$5^-33$46ID%XM[+-L_X9GW;TR<Z!%H=
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MP=$W"!FF2HHSI,7D6RY4+48TZTW:D/C6V7[:EE*.^#^(>:N@N*)N;;<)P2U
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M 5%E8%OB:8RXRXA'0#/D. %-@6G AA+[=\6Y/0)"[4485L'1FQ4$ V^"D8/
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MHEK3SWS@!!Q ;X!#T8C10BA4<*,@Y()WOJ2'"O3,C]7F*H"T-59Q T32<64
M&9O&_#V(8^"_/ML:<JV%X!$QRGH[6QU5W3)QX06;/R*_3@Q[*_V--%CB17B7
MH+Y7P8>&"=YOGL^H(U0\L:.A;R_H@J5BO*@Z=<M;,>ZUI]$,RDPOL&;Z9]YH
MNW83CB3)',;B;' D;%4W$DM?9J@V6]N(FI'+Q?-R#E('"+%:*?Q7:\U4ZGK
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M63ZX-_'W9;\R> U#M6UT1WF*A ;P7Q??K!&6F6[PL$UNEI@RDMX52)IF%XN
MJ%MY[H42&$114EE1=LS_<*7(2\M,O_JSDUZI!<&K/HVM-QE[#H.&HW=W%J>]
MNY17G^)9=UZ7+2EA/@(:]YP"TDF7=#S7#;410V>F/[^9=L[AH<XVPH/0W-9C
MWNLM*FQG:68G(;7OG6=88L+6Y-V=XXRB<G:V.Q"1"MWO'R8+PAX!^QO?!.#1
M]^3Y7K<#9(:W'@5XJ[;>CDS?-R#'S-#/Z/#ZE\U]RB=R=6L0,OT=:4Y(U9Y
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MS( *7.GTHVUHR7"7(O(SBO+JCR;#;^9^U "=VU>*!A(.ND6:4C[C)IK=>=_
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MCY<3P-?G_]TIUJ!0=DUV\P/J08!1?,;]'R;U_P9/C</7/M-M) S, MX11>O
M8DQ@JTJ+P6567'+GC:K5[9/F15*? ( XQ%@'9=/@(S>',L@KCUBCI=6<8= V
MO//Z3T$1.,2G.>;W\IM&MK0T/9Z1Q3YASRJ%=\ <3"+PLK?>?NW,V0QF.C,?
M"$W*KZ8VY,ERI^KU_00AQNLI0TNOIR421NS:@MV<%+M-X15TCA<0AJ3/NCO
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MU:W/7)WIO.B2&)39!RKSRB1>IF]DDJX*E%D>K*2Q>N=OZ*!LJ0U"Q2@7,W5
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MC^_8OBRORG)N]@G Q4<J'/D4M]7L_9FXL.JQ DH<'M],9V2,SAMWFIR2+*?
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MGDD)[FRZZ+:G?N$L+&_/#61[)]CK*RO)MD-(#U0XN:@YML8M3[.]VG+X;/%
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MF*\]YMI6+S?ON^^IG:[[=(4K'1^)M;_76F)XK=?$D]K4>#83D89AA9BS@.M
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M8U=97K2"[^5A2<ZT.&#KIH6+HRO[U>NQFDT^>;#3:QK6R;%D'T=02_WUX\0
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M!3LKT:MR519U= FQJ!Z"?VIN^1&:8.=&C?H%HC,1#NP7F1K^.)W)97FO*^P
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M7+CWD0C+]@N(XH<'SL;"8M8XL. EZ%..B!7!)H51)SNM64GD7857'1)C_^3
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M^2K+SNB\@G6N>@3T-.VMG\ZTH@3&3CA,PM$+E]A89094%6W_M3><1>GC)50
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M=]J\TK-:"(]C%Q$MJP_P57"K0-]<P*AI3F>VZ1\1RWE9X2>$X:9=8N?TG%<
M7]@8@5!\:74YE*A7RAMW[!QU/$QOCW,U0B.O0P.,&*7=J*N%G3)NU?N2/-7
M3_:U;KY.''(P?F3(>HRC?"MRZH?C91'0QFVX=U-8> S)Q_ CL]O2L?5E").<
M>W.DY\JJD[]$L]0K#Q>J:Z/C\XM&KKL5_[:)H$,_>XAA5T^9V++;G\]_QSV
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MBMF]!N!4^&I$.'4G/^W$EB)W:_WR=&A;O"J]N6&-2WY-6BL90Q7Y\2O]YWF
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M?6O\X).>0+-YB__9L.VDJ] A1UW>MQ U+2O=,E9;$M"6NE"EAN"F,Z)G?+
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M&))OL7[G-7T005^9AEN_*.AC#GV&A[<I@>GCT)A*2IBX20G[+5<6ED#;"8;
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M%W8G*D>7^:M29R\ C>=N([VVY3](>1HA<01KIVNI!>-,RJX X_B O(Q7LTS
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MPA -PFOXRA<VWW/:\3.LWM]$D2IOU+46W4<^D6P9U42G]R:"W:"V%UQ?+[0
M\ ]K?9NGC\G>.DV/BM%<2J#CRY_VQ/L*>0"ZS9&C^!VY_3.3\Y-,;@QQR8NB
MY6>4P %"  <A478Y,.-T(*R').;#"C[?(\+$ZH;"%W2FDGP_^26@>%@=J-:
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M=2N\9H<[KKK&M;X]_3F]P-,9%-J-MFZI<["_]:WJW(]O;W*<BU4T) Q^PX/
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M<O+?5F3PCV*#"QQ@=[17P[OGZ9B??_>.[[+C:DGU$5R'V71+E0,(Y.4YW>$
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MG_^[_#_W:;[3^?I>YSK7OIQE: .T,6#G*1U]'8".C@YX /T#:#A@K[:/HQT
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MW4U6I,!#UJ/F="%GESA@6EU57S9,\:ZD8TR@43,Q#ZQY0 .^G?2D>%BLR=,
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M"2=_-/]AO<<]]+!E6,$: [AL_/VK1;C!2:I]@)_<IOO]2]+C[\/_/SQ<+G3
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M^ZIX2=*X4=BW_-324F)26$J1IW%GBU;Y[4_NZ ]5D&)KG#54G,JN1L1;U-.
MSZXU<U;R24K.3OJZ*2_CU0+<T40KD-_U3O;-/D6#2).K"-_S0Y.K]*YJY$ZF
M^2("I-W@E-"Z>;?"YX(R=Q.J(IJ.OH1]9D:,O445*G2&T("0$.H+&@!C_(19
M6X+*)5@ -1D[C4/8)U'$[&G 1 O%"8)9(]A@)DRAHI?.E.( +RF!'&;ZERG]
MFA4H2B9K83IKP78$20<**LV/,76C& ?7S:.HSU,T8,M"-XY@=V%PE150?7;B
M.>106V%"N>0.Y*5[G]^D 7EGH3@'4)_0@- JL&-TY7I203O(64 #EJ["">NC
M@T)@%/<:!%>KA %/YS7FD5Q=&<9![:/+-,!FRV/K_'SDP."C6VZ.:+R%N(K!
M+6(+E:G"$G,0Q-UK-(#R3)>BOKX&,9QZEYJ((41"O,9($[- H:&:\U#[< 9!
M8=R*0-#TYD]3!B01DA2*Y+<XSTX#=%G(:E![)X2@ ?N-_U1,/XHEYO=2@J;T
MJZ9KKZCOJ^0"!Q#T_IJ$Y49$H40UEJ3K;^C4YXV]2'C^X,*&<_^52/<AI,AU
M]/*(*TDLJ6[VOK+R/ ,N<H >5*<RJJ,_0B3\N0PQ)+:D\>.BD  YG$D0![H,
MN"0RM-*?"@H/$9;!J!UUB'4HG.;90-4L^_Q8!>9#.AS<ED[JP$"BA*+'SS.F
MF<6Y;V1__RO4V"I&$@HW&HQQ0-Z&$Z)()VK559%DU[MI\>,MFK<K&[I"7 -2
M%0<Q=<,(!^3F4>1/FL9NR&*%L%M$)FWP0.>K_I[ ?B-ZBTKX.P1A'3G(_8M.
MC[B"!J_"0=9QLF;=]26Y>4C4"P\ ##X\H:1K49$T^A/!-&"+8OKOT?YW###-
MY?VC:B7_Q)("%;_;"7SI )20;F7^;#:_3>G(TG^B6<0_FA(J$D48&=G11 F#
MPO*8%)1GMZ;MOTZ!P!8:\+,'_"27SUL>D%P%)?0ZL*/O@3RF3BOP4U8$E&.8
MSC"!L1;CH5N:7/Y5D[H_3%FW1%8BNATZ>,3?O:M"AFG(WY$L2QHR<CS.I?7&
M,$VQ6N+N4D1T4;FG6G^NCQ:XHV!\D:U!(5&5Q"FS6J'Z](N//"K(A.[X!^J7
M8(&D2ZCV:Z/%%G58+@-AT^D<!Z'=[S0G,C8?JW5HR)/LID,Z%,G#XB!AI_41
MRNC()V]Z2,"K"+(TIN:2QO; /LM[73>P?)C:P_@B-R&27SU!Z6&FJ]A1O:_5
MCS%%@I=0R,99*6EI1G/![:+,>1,2U:.BX'Z?U+J#W9BK_E:$X=N?U4-2=R:8
MO#OS*8;M]$NO/=%'\[(Q%UU)LK!ZU\\M# 6=_A9X%(\/-U+?</W.:D/(ND6G
M%GMRMDN:T(3>A^W'YW2.BCYF Q].YX5H0%UNC9,"ZMZR WLRR?0L43?X:@!K
MG1GQ-/_;D\5QONG-7 FNV-*K#!=@99HY4#M(.)L5R8]'15;0OR8%CK2;YW<4
M56J=Z,/UX'IDOL89AOO?<7A,+WA,P 1Y@GV;QJ>4*B5J#N8:3-3_,"3Y0']9
M8E]T)@VP)R4TK)>QYZ9Z.Z?DIDH:5%>YA?00%INE4JL8;O;7PDG2J'L5G(3T
ML[UJ5K8WQVVS?3HI!\:>3;U%PFS0,CQ6"U6]+ S.$0=9EXY\<3L.3^ZQ:*Q2
M@4Y0HI],XM?K7T$$:XCWY]@1GK1'*MZ+!W<<NV$EY/A1?O**X,,:D[.RRFRB
MJT5O(,[/*E"5FS)2:W;5)]*!O84=5XB:%??-%'=D830$&DHV&T]HF%#I=P&;
MM6&DF'H,P01*6HG[29Z$Q89$;M*)XDV)J HKQ^1S5:EY0S=+",UJ#ZHX=2Y=
MMMW'UPZW7,%"_0;!*"-0"NS=+*D[4"'AAAN=V\C->5G>4R207%KU:%1H4-5$
MN= YZ4G/\]O/W27IO_VK'M.37Z4!E5=I  IJO36=)/O!U3BJ/XS*D)'YT%BM
M::T?\FT54AH-N%R<3 ->+:(^!H12?*!2Z4+_!BOX'.&,V9#/"T.M23O!-\^L
M4IH&,$UW$:MMF =Y'>_E2+P!%A.!\OAH<B^,@&WCHHST^/_\Z5T+G<0M^QG_
M\C&B^V<3$^["*RMI&Y59W1H<_CP$Y7HL$\J:E(IOC!Y3_?#*P:1ET2#Q6YIA
MZ3*];J-*A">^(-/DT(4N"C?F8=JN(UFR>I:@LUQ#8;1ZWXT=BQS6,E6I5[W3
MOZBACS2Y<9^<BSB23<\V+_; E],LT-6)/ 6RGB=K4(X184UHU7F#<9V@9%0-
MCGVO9.&&0OA]T1L&VBR[KXZQ,#*+Z-S,N[6J1!;V9E3B.FA5K'%(F"-4I.#<
M1:(!IZ&AM$.9XD::1X%\ZV10GI3AZQA'U?22&PDE'S%M\[IM\RA/"M2-W+GF
M(U>-8/7,.=4HXJ$;@^Q8R:I4-B_K&8]GMS>IT/N0OZ2Q<F7Q,DR8=5D&";(8
MC+<IH[JN65@2ON 7]%-Z[;B>6#,DAWYZW)(>IWV:TG)(;^^[]/A+Z:(N:-_-
M"]]R'MAFML8\ A.=TRK+\LZ4PP]]5T#OBO_H6_'&<%PT-ZHIS\%&LJ"$T)MT
M[\:+,[63R26/#BSR#9\+F>V9$'V!?DV0H'"M8G#7K7SL&T2/=N\I*>U8%3%<
MR-[C;:#O?''9JT X*UWLJ^D')EZ3CV^_*;=MK%@<B3*(B#$V&AFV,._J=^Y<
MLOC.KPT9ZF!J5-4N95(X2H@5EL5W.H<M9=,Y$KMXWB<VI"TUM'!=]U@O#I@O
M^D#QI":DD!C&AU7K2FQD._RUL_1OR!0)61_2F)=Y5W',A65/^8W=4;V%AV_8
MRYYK6435>22^1MU/ASF:\%FZNI1CK!(O?3<<BT%$8?_<CC%4:+S<?9F5OEZ*
M7+;#^F9 ;,1FU,NX<+QKX;7E4R>>/51[VU#&P>#FBZ5PN[O2M7HB[JNA7UE-
MKXORE1,98S(:7/?F?(E=NC?"%%EU=??#YMGW%NIJ[3#)911&+LE@'<SV[/M
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MA%474M^JV=M3G[TS5 ;%86_T71C>&J4;1;>^']MYN&3A=H1?%]2N_MOV?VI
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M)W%:F3Q,-'L%X:APY>UX!\?@5=(<Y"UE2-JZQA/\N2R8&INFD"1Z%ZW'"%X
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MV&]])7ZC4%C+<*L]G5]^@3-P,(TMO'WM]-X55BM!!N>"YZ?XOR!38E./L%>
MO"9M%\B;E8"][R8:S5LANE40I%4:*.S1'F)-;9JB ZOKOVUH6U?J=CR_HS=*
MA"">X0&.@7O[S4(C_.]ZEYA,,><H_ERJO?SV^:Q@D@&9B4'XZ=&'])E_+=DD
MO$$[[##QHEE#_S:;QA6?/+%C73S-56+=I7R^,2-,0F=4T&-,39X"%:FIW]YQ
M%PY__G#9;I<C5-L&?&%V71(2G'ZDX._D@+[P@5+1(.S(,=YQI&Q>RX?>HFE&
M74SK<$OPVUF6FV[17D77,(XR3!U^N>8I2QS;3W6EGQO>??VV+>_$VQ_!Q^VG
MN.@F?MLHG=_M'[<C<&A^)QCAW^1U]SUPP/]ZJXT+4HE(_)5K1&B.ID_AC9Y6
MCTN5SR3XO91.''ZA(KQ%5_K7%*&\18']5JPX:AY;S%#98:]^O;,BWX_V2VD'
M3ST.?7$@KH-/'N5.LO0^W6<<LS&_Z=\6<[N3/R G6#0MZ-U*["NZQ;2_V4UE
MV!IT>LWSV\^9II\S>X+<VB\:>>9WB8:\*M7J@[W>\)G)B)GQ@--Z@KEQ'AF*
MHX^?\IPO-=7<.O,I1$T+Y/(WDFFV".RG<H:89I&T9O6/OSML)%W&6RLCJIU[
MDJQ14])=83"#'%-L%N9(H*ITH-5[<Y9ZERL?Y93))1 VWEYD=SH>FQFD(O.7
MNEOU'.* 9-5Y7.(SG&M+EQ=M+C3T[)'B9TC88XWN(D?_2T0L%A4E6:LY\)+$
M)GO^[AFCS(#80VKGW;89@Y0AOU.X<R,=-!#SN8QY!N.?F:0\46*![Q^O$MA<
M_G>R ]YA9?;O$MS^>9? 00.]J/WC70+B9S0-% $AL/SCV@#:AL!I0G:U(YI1
MI(/FOSSH*:7D<JK$2(M;]/_MER?_9S^0-#!1*NE+X.@4X9(#(#:#@]X0,B\G
M]48[%D7Q'D$L9EAMT$ 'W6R] ;BR5E@(P5[H;]/L)M<V6G'\U>U (A"5Y'-.
MM@(ARXO^NL2/)ABL&(:T[#X +:>.@W$W:""NP'$$Q_R0/"I&(!>9V58@%!MA
MRS.N=U7X$_F;@;'J<-0^!=3/9T4R4RT[4WL"P\O3?46>R"UX(&KS*R+,\[[;
M[6:]L5N].[U4>\;[B3UM?81+K[TWX!4[HP6H> 3^R"":PN-LO>^2"7<0+2K&
MF"W3"N2^@QN%KH@3]-%DTK[V9%"Y$#9C-%!W/8:R!\9:(?<Z8JF(1D0<E@9Z
M9ZI(!C!#1P[5?FZ*?*4"3@-II9C\XE-?@_\PP=V]#DH\\&]U F"R%A%AX%$%
MS.8&8+("(XA&U _6&!0.-@=>-M8'NB!^.B"2=A5IH*-K9H#2V U!]@&LK<Z?
M)@C\\'N^=/[ <.&;C04R[R[3WNMX1#>*G R;#P0H_V&-1G^F#RM$_9ZI/[*[
M<EH%6.A!JB8UQV9J$\ )IQ-W__>%J/,/&;Y _'<DB$'DZ!#XU;N=X0O.*HK:
M%Y+G6U'/7DI"28JZ#K+^E8>J1#]J_36CJ9A#D.EG L.?T,=-B*%--)!PG6;.
M,L]%L4_MX,YS_:G%M25??(\&P+<8NV\/O.P[5=70;Y=JR"S&6OG5Z?%(-[_J
MT&!%0HE=I6DYY?RYC<F:S.D8S*S^RW&SR #,J*]%9/J/02@JUX_B9L'WM:E8
M,@]F7,\[A[26_G*^VM_B4=P/ P_/X9G11$H!8#0A9H@5JAS"<1+1/80"XJL8
MN.4(G&.\Q;JT7RRQZ[36H0Q/3U :#82]03I74GD8,_K162 Z8A3<%1R/1-^$
M(R=6?;WL[ E%"V0*< [1Q-[?J,I7.%N_:W@;<QIUKU+PDZU$%6M:]9XQ<"HT
M=HN* %,] KA*M<E&3S?(6"5J<SN/BIG5^8W0L//?:^@Z@;7L.740\+FH(LCV
M?K'G"E?(PHH!!=%6Z[J: MO= 7P-Y@I9@MI1 ?3Q0Y"V($U(KQ++MP9_S>GX
MW^JN7WW(Z@SB/\@CU\R[=_?Z:2 8OGB<='J8&K#O='KVGUGZX(Q8F)RB4MAQ
M61.KO/:<?RU>SZF_U6KAC7NUEUX/R@#ZUOX-M0O&HUO 1#4%\W?J@N0CI"L:
MG825F0:S.++P-FFTT.$C?LGK\$><U*$.!FTU*1R4RJX'Q,V6.'$J1@:QQ2(M
M:,E"84^A_BE([@$31=%DU :@="31" #+-L-04\R('PQ6XC10R1/8WB7H(A.9
M SL(<=T((SV#$<ORT!2/\.P ]I$ODJB'2*JO.&5;9TP40#O/ 8!C>')[DXHA
MG2@NP"?.$*H^*KL2$"U(5JWLSX5K#?,_C.].B&>2.Z-]H0V43,CN(FIG$/P/
M&AK"'-/LHPC#,%6A7&*(('\YY!#Q(HGYGBXSIT6G0*LD7R.+Z*WT.7#*6!VL
M&5$2$:UZ:EHF5/UH?-,DQZ <[.#W[Q;+PU&7S%<\>-G.'C6KE5GOF>/G#[3[
M!#,C(=8 &]]]%8 ;^:2KB,U>R,9[$'%A%K*J.X,\3F35+:W&347X:P7,L',9
MS(!YOG=XS'UOXV]/%'H;9O#ZI\ZQ!(OS+"-M[B:3C#10R"-BVG +F#?1M!Q'
M3D9$E<-3%;Y=34W6-]-UM:V)U$NCH_35M,GJ[@9( 9I0KD,#J7%2][)^XX!^
M=@1S'\*G0WI,AA##YAT0(U3^WK-G[=W4Q:(;X6=EVSA=;L['73L9,GT\Q WV
MH%^]%TS>,B M(_])*YVI]\8_E_'/?P:!M2[^Q2(#_&^3/*FMZI>(>)+QDOH9
M' 6=9.V:-3*JZ4XH?^Y4+-+@D^U I]+T9@1D/9?&SDU _<=.&A&>T4 +F8BI
M.W18< 5T=4I\30NW\LG-T4JPWV[@"8S+P3=FK7ZV,.UNMN(9E[L6 =/XT)^
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M#W^>9XGF^HBHT9W>0:/43R(:[='4P]Z5[0J!(D3HC/2MX69U46I+F3,+?[$
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MV0C_R$^QVAV-2? NEUTM\0+-]),I2U A$F+0.3B?UI^@ MA".=G2_[X&!IK
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MY0OSB(4_9N[HJB.>K?LO_"GK)@U'30*^=N//DX#/ZJ'@_1HV;"]"%)\900:
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MBIJ@=. T^L@ \IYS=E']QS+-@DC QI;@PMGI=;:/27&\(79/=UE"N1U_P8R
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MUEH00A'=#<(-+$I#9#&BW%3HW)].N&'*,;SMZ@8I7ZH]!%7EAS0Q9_/%(TC
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M WM84;LLH6A1K+WMZ!>J\"#=B/M5L >U5>%3R"VC5XE&1YACOJ!!XRO7.<D
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M/\S!N/7>$Q[^"T-;* Z"\Z!3<<:;<BAK\Y:E/<Y[16.UX@UE281I ;<9,$[
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MEPDGW/J$>T++51QI^A5,Y\\<6/<^ $GW/1R O[RZ)7QQKUOD>>[C].3 0!V
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M-;1?-2H+^@S/( &Q3ZV,$-J-H.OC!]$,7Z1-T1Y!1(#HT-N6\[VRBR$Q!TZ
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M&!W![/?U7/85PE@0PVZ)D_;SF52UCY9JA0K)TS5JDOV55KQ2B^(WKE[.$C>
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M\[6H[U5=;7_;P!%<GM<!KH%$XH%R4N\FD[HYBR1MH_H;N9)4N6;:HD-&ZUZ
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M(7<)PNSC1.?K3,-)7SFR!*TV4;\FP#W)-NEF<X,&P/WX15Z*8MB,9N-6M>F
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M3/XVZOW+%-$0-6Y_BMITCWDEI,AT2[80OC)7ZC1GF;Q.8KK7?I_4M )" .P
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M)/!6V'F(A%,\U\"BOVV,XG;MF86'%^9[SOM--BCGHZPVY,N9>K)L(]#D4G4
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M8G^,'#UL&CV85F*;,?VV9_PI5V6TD^/D\SU;S_EPL/"(ALU$E6" [N(.L+S
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MKZ>DI*0L#/"85L6![JB(;"Q;N@[TQP<@Q/<'JO\%["G^\>U_X(*%#HILJR!
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M"D&XI&'#T:CS X4^>B=:C[K3F$Z2ZJ5%RUY,'.;SO^GUV5NSP<%E:,@DR'Y
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MB7<&][U;95SSJCW7.%"4ZTP_5_4%*\XJWKBT0;+N:5;'B@+AXYS;0PSV]+&
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M)4V&KR.9L0*/3/R2\@%$XZC)2$.ZR,?^=OKV&Q(49<N0L%T'?HKM0S/XZUA
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MH"+P#14+D&)DA10RNZ$ %K 2$5>.Z8_FM4B +['QU41F:P(IPDW:X'N9?UF
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M5P28MA1< N.,-&WM!-K'CV:]H1>?D"KF'RG>0HS'!V2P?:\;$0GXYLF[D(1
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MG?V?]KXSJHFM;31*4Q 04#I$#PHV1%%$::,'$3T<B J(BA(5I0H1&R"003V
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MU_^$YCH+Z@'6H(3(A-L:*+/9NP V$9RGE)EF(/J0/5:.'*<@\]Y$H>Q</G
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M6B@28+;/H-_GC# \=)O,7!UD1@9Q%@MDO"/%+8&_[^+*8#O$F1,+E".,+<W
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MA_J=[9U'8=/B,T%5.ZG52>9'.[O";CV\:KRLZQVO-U7!#E,RM/Y(0![E[X.
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MU;.-WL':)<D!(3UA,IA2F/[$S7R5X1.'JY8=EWU6<.+%\-Z=^_J2!+;8XH?
MF-RX@6-W\NT#>CKK&\PKN=^*KE"K+??47;-:Q%)-7O+ ^_2(H%9+^LJ=G6K
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MY1LUXUI&0<Q13U/_)]BL\/?X>_P]_AY_C[_'W^/O\3\Y1%__#5!+ P04
M" !H0%Q4<"J,MB]#  "090  %    &ER=&,M,C R,3$R,S%?9S8N:G!G[+L%
M5!W+UB[:N&MP#^[N3@@>W-W=+3@+2"#!+4 @N+N[NQ."!'=W=WWDR/ZSS]O_
M'<_&O7>,M^<:O:BJKIKSF]^L7C6KZ7Z>>5X!4*7%I<0!,# PP.#E SROHMZ(
MN5N: 8"L+$ +   L  G&!X"_E%!>*M*?+ '(ES+82UDK.>777X ( %#']P@
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MSY] V$\/D:?ID*WW5VF7)VW]/QMSKQ+DZWS&.2<:G&%7[B[S/+#3SF_:KC=
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M)KJ12A#VJT?/DJFO-*C1.@BP<@N<"5@K^?'?]R:5A=%[B[+[$JG%3]P+>2"
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M'9=90'.?S-QM#(^<17")]>!7:']$]E\+[.7_H\C^"NP?<<T"!!AHJ,7#( 9
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MZ+?14&*.@IE<J=-\'N.J^K**Y.5*2T"$'1#F?R]P%IIRQ![PR:XV+%F&)3-
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M-.F^#7YAZME8S0;.VH:Y,A'TEO#P5&3)+=!'*WT0+2LXOW:B"2_H5[<06[7
MHJG/SASXV!^(^;=!!)/0P) XU/!#^/9W5,/N1W&<-8*Y]=3A$@DC)(9#9#]
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M"?P4 KEX\2(Q$3$M"0FMP#7&:P+_Y0O;") 3 '&0&"CD.H!##H&20["M  P
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M ]M?9D,?(1>U]9S;OH6/+TI7M+60A<B^%OM\-3]8*9[;M^G4PVZ*@=&4N"%
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M8<B0TYG%N38'G5$8$K [DS"]S4YCZH76]5>B+N7_#YDM2?FB.?Q9/%)13DC
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MS4KR4535W\%7;0*<*QNNP$POYR0H5W;4WN+S.DL%69MBXR#CO)]/2]XK]MU
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M_T>GZ;^>\3NE&[\H)6EK1" I@SS,*90YT;GT\ACF>E.>!2((.6.9)';1KAY
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MR:R"V#Z_?7/O4CSJ I(6^X+;\0G,JG7CI%K"NZ@!JA+R=GP<;/S;<1K)I!^
MEYO]WH]$K[E^X=;QK/-^V0^,\2N7#J"[RJQO"+5V?]XO12?.N*E8G*2%(D6&
M0<9,*AY&,2"<%'H]+ H60Y&JPJJRL\.84Z/#-DV\.>\P)=*=DT!<(+?@2?]
MAK9&JQU]BV0M<M40H"/T]=K2@R%UH%;_T(Y$M37$J]Z7U9?7Q VD7A:V?-1X
MK.RFVP%+.][J?LST?KDQ[G,A](M3&D_ZI_6WU>_ZC<XYQ]I !510!)"2!+!$
MY0!QI J(BT)DR/;$Z<(84V/E6LRHD?,NJHYC5NO(R&I_%'4)T.NG4AY@"NVR
M'H*0TW'5%0P&GUQ=>NYHAUA7%.N>9UV[=%A9Z7.]ANOVUI^4:46UK?I\_+\K
M5MZ;7T%MCLU$2AB32H 4(PQ0SDQ_.ZYWJHS3),LS I%5?[L;9)@:27Q8K>7\
M85DW 7\W-XYKO1#/Z<*M%/*0V;"PXL)C')AANFW6#U2(:AVB3ZKZHU&CLO:,
M(J9T0E2K$GX6W&I3!YZ-\<I4FUG9:.#7A[,BZUE9J>J/?-OT?_H_9E9H_0>C
MDR\K\39$K]6P'O+H4<M9WZ#[<67K6QXU-!+R0K/6UOV@Y"RA*E94<5!4H160
M8L!0;BI@0QACG@K'4G068TYM@?E\M@?T723+S?RQ2D+8MLY4):NXBQ=)U^Z1
MDM<GP^[HRS/$@=>7HQ[0ARV@.^Y$Y?$4R@$ASP&5U\<=.;+2&HC3$$O[6WWE
MX>Y;6TF!%%)$$U(JM1DL&<!Q$FNK.%,%D9E4J5.;Y\M#38V,NI(>9N3^[=;,
M1\<$,C^8C>&3M,N$#)(^=AVDP,F1KY,F=EWMZ\F2/IHW?9;Z/=+&^(/\I#J.
MNX/2AY_4!SI?_T+7_Y2;ZH2YZC#5)IYH XA) =,8*&(ZRD/, "U(#'B,8M..
M&4F16.^X;Y=G:GRTU\CL+'@GV2Q26HTVI&@9";,]UY=4A7@=-H4>IM!BFS[N
MQ(0VJ?9SHC?GW6.9HS*VYL]&IZA6J@[V,;_LYK^-.U<.F_EQYVRDC?WA]U1V
MSGO:8#P9/55SI_]<?6&/]=SM8O>ZWZ"O7;X_J'MW_!Z&&6_W[P^3 T^ Q\?>
MVF'G^]+XEAZ6\_^6XAO]XXU<2C7?E%]6B\6'U;JJK7]8C"J32.6*IR#1+[>I
M0<( 2V0,6":+C.G)YMBM*N5@4::V3':KAW5UJ5RGC39#>^\X3Y.E?3\*^*'M
M?PO<R\AH$C6JC-2N9RBF@=KW.(OS2NU\AL)VN;W/X"<.V(YHDEFMS2OR<K\4
MO]#E5NG]S=;D6>R\)TTP"Y-)(1*4@X+*%* 84L"(0B#F"--,%8JF]IUDK8>=
M&FON!:_<@H]=T?>>6 <#U7X"+/8,06 -S(<=1,U9W8'4>[?KD"@M>V@=3/P@
M$(]DR=N]O+XL=&>D>@UQ^Z>-9V\[:WA@5KO?/;3ZT-*8[^NZ._F\_.?;M13S
MC?EI)CA#T!05B9-8F\<$9H#%609HD5(8TPR3S,EKW3/6U)C\0%1CC-6B1D96
MU])#EP&V,VP]P1:8J0\1,\+==4&[BSZO%G/^$OW6_#>(O6H!E><J19?'&[E2
MT57%3ZL57;]EY#82QDM0^0?NRW+[6,>L&GD^K*7)JI+Z?=V8L*E?YLOYX_9Q
MEO"<85ID@!2< 021 "1/">"\D'E!,Z[LHLO&%GQJ;&=$!4K+:G)K*V$C_5K(
MN^BQEC?ZB981-5GNYHWQW8'.U]M@Z2:8X!R'=BK<GG9;>=UK=WM'_;N*VB.#
M0-1"4,4UWD4-"A-H2C%PWJ;1H\)5^#]'RXJ!4^*M@\70\8>DM.T<-V]_&+$^
M+O6Z6YT3;^GB?K%8_6XJC-8NFT.O)V)0JBPU751-.WA!": LHR!1J6!9IG+!
MK.I_WB;&U):JKH.T5J7J@]G1)MJIXY*S-7B:+!POHX _EF/Z4XN[9OSSL$>U
M0]K!+^US/ES2ZL:8EY&\-UK [8*N([&K3UR=K>Z_$-Z9*MKJYBWW[E8D^]/Q
M!C]]Q R]6Q$X3-J[^6D#EJJWTBQ]Y8?5^A>]$>1ZX32NI^K'N6A\H3GE>E5B
M&&2Q\?/S@@.6809229B4G$">6"7UV0XXM>6G$3E2JW74"AW]&WU\^GO4"N[
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M8^C1^Q?Y,#=TN-S\JE^SF>8DR@3F0!0( P33#&"(<X +'HN<)3*5B=O9^^$
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M.1C%_M:3[H\=L=OD8)T/&TP.?TS8JKLFQ>+;[W+Q+)M$)<X4YG&F@! < ;W
M9 ##7 )L>E%@#A/%G:J2#15D:NN-?F]AF*J[)U-@9[". 6S@E<6U]FY5=??3
M\A6*[EX"\57J[IX(,\G2NY<@&UI]]^+S1O9LUTV!ZV;!NY;92J6(YZD$:4IS
M@+B2@ JH %2I(BJ35*96Z=5!I)L:E6J5'K5Q7@=TS.M.V_HSE\V):.G>FC[,
MI ;V+=\Z5=/W'-<:MLW4Y_[:H@?%?AK>WK,2_CE\N7W@>O/4]@XR\I)@RG[\
MLA)S->?5+54%U6I'>!*M,:,JC5&:4*#BS'0#C1' Q&32Q=K63GE.,6.CK!0.
M0D]M >F(>AI=:&(&MXO*FC3O=/38T7&DU<3E?0B\R 2:Y1'7GK.N#J-6U-6K
M*5O<O!1&G0FL,@/ G\;BXR+XGV--&C 5WI:J(6,/JA+U^+35]+LK/G6_%%]7
M:J-%D$V8F>!)"AEF("$FZEU!DR\L,4!,) D4G.48.U2!NC;>U-:-5N)(MB)7
M)>K*1FBGBD!7L;8X%O"+8&!.WH&WDS:Z-T4L&WFOA_H->V-=ZB;Y1'.TNDB]
MKZ2O!B'VV%PI973U,6.6*K+5Z:@4D?5MP[81NV/B\I,ZKK1?[AH/TU1@A*4
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M>;68\Y=9420$2J5 &IM>*(4L]&=?(-,5Y?\G[UV7Y,:5-,%7H?6:[=0Q2\R
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M0P!BF@"$L#()?0I(4E3I_9 )I\/?GK&F9JVZHM9MKIT3RZP0EH0DBB @**<
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M=/CB<"-7#5]3^[1@^.H= SH';.A&'C.5W_\JM3N1T8P0J@&$:68:B22 D)B
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M@*E7FWV+/*.:: _ '5MD'X\<6@BQ>EJNZ$::@^SOIN5BTY6QXB5-8!ZS7.4
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MP;G?E(1$+[!=T5)'K=A1(_<^A;"1O$+V^@[T;1 [%*0&@GJDBE0#^::%?-U
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M!&:Q$"HVE1^F]ES;#,)E J L,(T%SY,B=VY(4S][:MY+[;'0 7OF7<#LC,!
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M2ZEC#<,)IX[]G0-\]?>/3_/EBY15U<E7_4+]I.MN"R7(N';&"P52+ V7JX*
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M-T.9 )(A"?0'E289QR2%3G[SA7&F9OV-F-%>SAO:%UT"UL[N>H KL.4<A-0
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MQ-@[]X,@.K.7/^PYK]Y3^=]D^?#3&.YGN:(/\OTOTP!Z+;^N2BYG##,F(26
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M@+WE=K_T!_UUOU[+S?J?=+[=<=16E<7?EO/YA^7*R#B+)62%% *(C"F D,*
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M I H$D!-MP25*Z;_BU"ND'M7IYMD<OG"Q^O59(2LOFEN?I![<>\BMFOCI V
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M"*>T\[$$GYIM-*("I66-RD;8JB;E+GJLY9T.Q4S?VV#I+DYPCD.[FN'H90P
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M<B//[5X52$F%"P9P'.< P4P!EN44I$FN*.4XR7*G@P'KD2=G@3N"_[>H%GU
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MP48-+J^I?!P87KU^F%W8\9!],E3EHD[3_+1KHYQ*C(BD#&C?#@,D4PA8EC*
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M'BS.D>'PC&ZW7&^XC6LM>;*;MB#D2K-J2W-P9$-#<%%GE9)7Y?!BDQM+;@>
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M5C,++DCG/%@I&$(V6,<1,@8N: X!;12&ZU+R8]TC]T?4-2+&C0PU LZ^0NX
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MLCHSL88"UF":&#D@_KX63YP=X"B3R=(#9FWJ<*$,7A=.,N&6J8"^B*W@LU4
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M#X'N0+WT!+'GWZ^);7-/;/:F5I%)Y3($]'460**]F0NO.=M*,.."8VTR,W]
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M;&\6F^KP- +F6[=[7CXLYM^F2WI\F2_N_,H!][;V>U&#P'M?-H\1G,<B+)H
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M=I-L"4O>(,3$$C ;D^<L&)';7(\:V.JD+Y@OS_!]60GSA^]OS\)R>0MKY;S
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M9)H<,XV"X,P,^"PC)*X49RPF5K;*$]-3[_@E]*^'/LF]UW93*36"@[N__'L
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MBJG-G-+#:1^W1V0?7N21$= +YN/+',>''/_TU]?I8O7+5\/*)B;K8EATA,R
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MICHQ.@=+L5L4P(0I3#'T/H]THC8HGR.>6YS.HFJ'G->PKIY(B3\O'V$\<Z&
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MG1&U[YHK;<9 _[M-?-P)-3M-?-Q%A5VDV^\5+JR9D/0F7HJ$$C766-="U$:
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M+;G5@L :[*VZT FLBMQL=_G*Q;KBK[OFAQ<.+WX%4$L#!!0    ( &A 7%1
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M 066 :(T4M*FU(*J9<B@Q*+T+*2-E;8EMB-N-5H%Y!1&QR#PM65["!0!B+R
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M$64^U6H*E!9S/JE.\TW%DI 52L\!2V>I#KS(U]"+:'NA0FANAX&M$E_GT&/
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M+7];&;:0_FLY\T_NSO\/4$L! A0#%     @ :$!<5 )%PXMA#0  [TT  !X
M             ( !     &9I<G-T86UE;F1M96YT=&]D979E;&]P;65N+FAT
M;5!+ 0(4 Q0    ( &A 7%3?DGXZ"1T$ 'UI)  1              "  9T-
M  !I<G1C+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( &A 7%3NHMU!R!<  #+Z
M   1              "  =4J! !I<G1C+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0
M   ( &A 7%2ZBN2PG2(   A6 0 5              "  <Q"! !I<G1C+3(P
M,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !H0%Q4)'J[3X->   4-P0 %0
M            @ &<900 :7)T8RTR,#(Q,3(S,5]D968N>&UL4$L! A0#%
M  @ :$!<5/R=E!.S\P$ ;U$" !0              ( !4L0$ &ER=&,M,C R
M,3$R,S%?9S$N:G!G4$L! A0#%     @ :$!<5,QP4.J2+0  @T\  !4
M         ( !-[@& &ER=&,M,C R,3$R,S%?9S$P+FIP9U!+ 0(4 Q0    (
M &A 7%3>^J0:RI,  -V?   5              "  ?SE!@!I<G1C+3(P,C$Q
M,C,Q7V<Q,2YJ<&=02P$"% ,4    " !H0%Q4A$=V@J?B   P3P$ %0
M        @ 'Y>0< :7)T8RTR,#(Q,3(S,5]G,3(N:G!G4$L! A0#%     @
M:$!<5%2$@2<;;0  SX   !4              ( !TUP( &ER=&,M,C R,3$R
M,S%?9S$S+FIP9U!+ 0(4 Q0    ( &A 7%3FQP7/C'H! ,CU 0 5
M      "  2'*" !I<G1C+3(P,C$Q,C,Q7V<Q-"YJ<&=02P$"% ,4    " !H
M0%Q4E^@HX\@2 0#M. $ %               @ '@1 H :7)T8RTR,#(Q,3(S
M,5]G,BYJ<&=02P$"% ,4    " !H0%Q4]W\QGJRQ  !V[   %
M    @ ':5PL :7)T8RTR,#(Q,3(S,5]G,RYJ<&=02P$"% ,4    " !H0%Q4
M*S[?8G&X 0!;YP$ %               @ &X"0P :7)T8RTR,#(Q,3(S,5]G
M-"YJ<&=02P$"% ,4    " !H0%Q4#GWPHLV\ 0"=40( %
M@ %;P@T :7)T8RTR,#(Q,3(S,5]G-2YJ<&=02P$"% ,4    " !H0%Q4<"J,
MMB]#  "090  %               @ %:?P\ :7)T8RTR,#(Q,3(S,5]G-BYJ
M<&=02P$"% ,4    " !H0%Q4"_*VDI(Q   Q40  %               @ &[
MP@\ :7)T8RTR,#(Q,3(S,5]G-RYJ<&=02P$"% ,4    " !H0%Q4,GQPK%XN
M   '-@  %               @ %_] \ :7)T8RTR,#(Q,3(S,5]G."YJ<&=0
M2P$"% ,4    " !H0%Q4ZZE:]\0K  !*-@  %               @ $/(Q
M:7)T8RTR,#(Q,3(S,5]G.2YJ<&=02P$"% ,4    " !H0%Q482[9#; E 0#8
M5PP %0              @ $%3Q  :7)T8RTR,#(Q,3(S,5]L86(N>&UL4$L!
M A0#%     @ :$!<5$,SN=$<J@  B>L' !4              ( !Z'01 &ER
M=&,M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( &A 7%3:W?/6K0,  ,<*
M   7              "  3<?$@!I<G1C+3(P,C$Q,C,Q>&5X,C,Q+FAT;5!+
M 0(4 Q0    ( &A 7%1#F+',@P@  ,LH   7              "  1DC$@!I
M<G1C+3(P,C$Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( &A 7%1 Z/^150@
M !TJ   7              "  =$K$@!I<G1C+3(P,C$Q,C,Q>&5X,S$R+FAT
M;5!+ 0(4 Q0    ( &A 7%02KD0:9@4  '87   7              "  5LT
M$@!I<G1C+3(P,C$Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( &A 7%3/C4_3
M9PL  #]/   >              "  ?8Y$@!S96-O;F1A;65N9&UE;G1T;V1E
A=F5L;W!M92YH=&U02P4&     !H &@#7!@  F442

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
